O	O	Also	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	hepatic	no
O	O	injury	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
B-brand	B-brand	Rebif	yes
O	O	is	yes
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	products	no
O	O	associated	no
O	O	with	yes
O	O	hepatic	no
O	O	injury	no
O	O	,	no
O	O	or	no
O	O	when	no
O	O	new	no
O	O	agents	yes
O	O	are	no
O	O	added	no
O	O	to	no
O	O	the	no
O	O	regimen	no
O	O	of	yes
O	O	patients	no
O	O	already	no
O	O	on	no
B-brand	B-brand	Rebif	yes
O	O	.	no

O	O	-	yes
O	O	a	yes
B-group	B-group	steroid	no
O	I-group	medicine	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	prednisone	yes
O	O	(	no
B-drug	B-brand	Deltasone	yes
O	O	,	no
B-brand	B-brand	Orasone	yes
O	O	,	no
O	O	others	no
O	O	)	no
O	O	,	no
B-drug	B-drug	methylprednisolone	yes
O	O	(	no
B-brand	B-brand	Medrol	yes
O	O	,	no
O	O	others	no
O	O	)	no
O	O	,	no
B-drug	B-drug	prednisolone	yes
O	O	(	no
B-brand	B-brand	Prelone	yes
O	O	,	no
B-brand	B-brand	Pediapred	yes
O	O	,	no
O	O	others	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	;	no

O	O	also	no
O	O	,	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	medication	no
O	O	may	no
O	O	antagonise	no
O	O	the	no
O	O	anti-glaucoma	no
O	O	and	yes
O	O	miotic	no
O	O	actions	no
O	O	of	yes
B-group	O	ophthalmic	no
I-group	B-group	cholinesterase	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	If	no
O	O	any	no
O	O	signs	no
O	O	or	no
O	O	symptoms	no
O	O	occur	no
O	O	physicians	no
O	O	should	no
O	O	consider	no
O	O	discontinuation	no
O	O	of	yes
O	O	either	no
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	(	no
B-brand	B-brand	ZYVOX	yes
O	O	or	no
O	O	concomitant	no
B-group	B-group	serotonergic	no
I-group	I-group	agents	yes
O	O	)	no
O	O	.	no

O	O	This	no
O	O	time	no
O	O	window	no
O	O	is	yes
O	O	different	no
O	O	than	no
O	O	for	yes
O	O	other	no
O	O	oral	yes
O	O	formulations	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	which	no
O	O	are	no
O	O	usually	no
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	6	yes
O	O	hours	no
O	O	after	no
B-group	B-group	antacids	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-group	B-group	NSAIDs	no
O	O	have	no
O	O	produced	no
O	O	an	no
O	O	elevation	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	.	no

O	O	No	yes
O	O	pharmacokinetic	no
O	O	data	no
O	O	are	no
O	O	available	no
O	O	.	no

O	O	pregnancies	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	the	no
O	O	estimated	no
O	O	number	no
O	O	of	yes
O	O	regular	yes
O	O	users	no
O	O	of	yes
O	O	intravenous	yes
B-drug	B-drug	amphetamine	yes
O	O	in	yes
O	O	Ontario	no
O	O	,	no
O	O	the	no
O	O	mortality	no
O	O	rate	no
O	O	in	yes
O	O	such	no
O	O	users	no
O	O	is	yes
O	O	at	yes
O	O	least	no
O	O	four	no
O	O	times	no
O	O	as	yes
O	O	high	yes
O	O	as	yes
O	O	in	yes
O	O	the	no
O	O	general	no
O	O	population	no
O	O	of	yes
O	O	the	no
O	O	same	yes
O	O	age	no
O	O	,	no
O	O	and	yes
O	O	is	yes
O	O	comparable	no
O	O	to	no
O	O	that	no
O	O	in	yes
B-group	O	alcoholics	no
O	O	and	yes
B-drug	B-drug_n	heroin	yes
O	O	addicts	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	L-CCG-1	no
O	O	were	no
O	O	not	no
O	O	so	no
O	O	strong	no
O	O	.	no

O	O	A	yes
O	O	400	yes
O	O	mg	yes
O	O	once-daily	no
O	O	dose	no
O	O	was	no
O	O	not	no
O	O	studied	no
O	O	but	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
B-drug	B-drug	aliskiren	yes
O	O	blood	yes
O	O	levels	no
O	O	further	no
O	O	.	no

B-group	B-group	SSRIs	no
O	O	:	no
O	O	Weakness	no
O	O	hyperreflexia	no
O	O	,	no
O	O	and	yes
O	O	incoordination	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	rarely	no
O	O	when	no
B-group	B-group	5-HT1	no
I-group	I-group	agonists	no
O	O	have	no
O	O	been	no
O	O	co-administered	no
O	O	with	yes
B-group	B-group	SSRIs	no
O	O	(	no
O	O	e.	no
O	O	g	yes
O	O	.	no

O	O	Because	no
O	O	moderate	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	)	no
O	O	result	no
O	O	in	yes
O	O	2-fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	should	no
O	O	also	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

B-drug	B-drug	Exemestane	yes
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	3A4	no
O	O	,	no
O	O	but	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP	no
O	O	3A4	no
O	O	,	no
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	exemestane	yes
O	O	pharmacokinetics	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	Altered	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	(	no
O	O	increased	no
O	O	and	yes
O	O	decreased	no
O	O	)	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	ciprofloxacin	yes
O	O	.	no

O	O	Since	no
B-drug	B-drug	iloprost	yes
O	O	inhibits	no
O	O	platelet	yes
O	O	function	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	potential	no
O	O	for	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	patients	no
O	O	maintained	no
O	O	on	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	if	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	loxapine	yes
O	O	and	yes
O	O	CNS-active	no
O	O	drugs	no
O	O	is	yes
O	O	required	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	drugs	no
O	O	with	yes
O	O	a	yes
O	O	low	yes
O	O	therapeutic	no
O	O	margin	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
I-group	I-group	antagonists	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	could	no
O	O	have	no
O	O	a	yes
O	O	delayed	no
O	O	elimination	no
O	O	and	yes
O	O	increases	no
O	O	in	yes
O	O	their	no
O	O	serum	yes
O	O	half-life	no
O	O	leading	no
O	O	to	no
O	O	a	yes
O	O	toxic	no
O	O	level	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	using	no
O	O	these	no
O	O	drugs	no
O	O	together	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	;	no

B-group	B-group	Anticoagulants	no
O	O	:	no
B-drug	B-drug	Flurbiprofen	yes
O	O	like	yes
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	affect	no
O	O	bleeding	no
O	O	parameters	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	anti-coagulants	no
O	O	,	no
O	O	and	yes
O	O	serious	no
O	O	clinical	no
O	O	bleeding	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

B-drug	B-drug	propranolol	yes
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	under	no
O	O	steady-state	no
O	O	conditions	no
O	O	had	no
O	O	no	yes
O	O	relevant	no
O	O	effect	no
O	O	on	no
O	O	either	no
O	O	drug	yes
O	O	s	yes
O	O	bioavailability	no
O	O	,	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	differences	no
O	O	were	no
O	O	20	yes
O	O	%	no
O	O	between	yes
B-drug	B-drug	isradipine	yes
O	O	given	no
O	O	singly	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	and	yes
O	O	between	yes
B-drug	B-drug	propranolol	yes
O	O	given	no
O	O	singly	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	isradipine	yes
O	O	.	no

O	O	ocular	no
O	O	effects	no
O	O	;	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	I-drug	A	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	This	no
O	O	oxidation	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	catalyzed	no
O	O	by	no
O	O	xanthine	yes
O	O	oxidase	yes
O	O	,	no
O	O	inactivates	no
B-drug	B-drug	mercaptopurine	yes
O	O	.	no

B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	:	no
O	O	Substrate	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
O	O	major	no
O	O	)	no
O	O	,	no
O	O	3A5-7	no
O	O	(	no
O	O	minor	no
O	O	)	no
O	O	;	no

O	O	4	yes
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	clearances	no
O	O	of	yes
B-drug	B-drug	dofetilide	yes
O	O	were	no
O	O	16	yes
O	O	%	no
O	O	and	yes
O	O	15	yes
O	O	%	no
O	O	lower	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	and	yes
O	O	inhibitors	no
O	O	of	yes
O	O	tubular	no
O	O	organic	no
O	O	cation	yes
O	O	transport	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	B-drug	levetiracetam	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	glucuronidation	no
O	O	of	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	Specifically	no
O	O	,	no
O	O	they	no
O	O	have	no
O	O	focused	no
O	O	on	no
O	O	aspects	no
O	O	of	yes
O	O	learning	no
O	O	and	yes
O	O	memory	no
O	O	that	no
O	O	are	no
O	O	impaired	no
O	O	(	no
O	O	vs.	no
O	O	spared	no
O	O	)	no
O	O	by	no
O	O	lesions	no
O	O	of	yes
O	O	the	no
O	O	hippocampal	no
O	O	formation	no
O	O	.	no

O	O	The	no
O	O	concentrations	no
O	O	of	yes
B-drug_n	B-drug_n	SN38	no
O	O	,	no
O	O	the	no
O	O	active	no
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	irinotecan	yes
O	O	,	no
O	O	were	no
O	O	on	no
O	O	average	no
O	O	33	no
O	O	%	no
O	O	higher	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	bolus-IFL	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	AVASTIN	yes
O	O	when	no
O	O	compared	no
O	O	with	yes
O	O	bolus-IFL	no
O	O	alone	no
O	O	.	no

O	O	All	yes
B-group	B-group	vasopressors	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	If	no
O	O	an	no
O	O	alternative	no
O	O	treatment	no
O	O	is	yes
O	O	unavailable	no
O	O	,	no
O	O	a	yes
B-brand	B-brand	TARCEVA	yes
O	O	dose	no
O	O	greater	no
O	O	than	no
O	O	150	yes
O	O	mg	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	for	yes
O	O	NSCLC	no
O	O	patients	no
O	O	,	no
O	O	and	yes
O	O	greater	no
O	O	than	no
O	O	100	yes
O	O	mg	yes
O	O	considered	no
O	O	for	yes
O	O	pancreatic	yes
O	O	cancer	no
O	O	patients	no
O	O	.	no

B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	as	yes
O	O	this	no
O	O	could	no
O	O	create	no
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	hypercalcemia	no
O	O	.	no

O	O	Check	no
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	at	yes
O	O	frequent	no
O	O	intervals	no
O	O	;	no

O	O	Twenty-four	no
O	O	healthy	no
O	O	male	no
O	O	subjects	no
O	O	were	no
O	O	randomized	no
O	O	to	no
O	O	one	no
O	O	of	yes
O	O	two	no
O	O	cohorts	no
O	O	.	no

B-group	B-group	Androgens	no
O	O	may	no
O	O	increase	no
O	O	sensitivity	no
O	O	to	no
O	O	oral	yes
O	O	anticoagulahts	no
O	O	.	no

O	O	The	no
O	O	serum	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	increased	no
O	O	dramatically	no
O	O	from	no
O	O	16.6	no
O	O	to	no
O	O	49.1	no
O	O	microg/mL	no
O	O	when	no
B-drug	B-drug	fluvoxamine	yes
O	O	was	no
O	O	coadministered	no
O	O	,	no
O	O	although	no
O	O	the	no
O	O	daily	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	and	yes
O	O	other	no
O	B-drug	drugs	no
O	O	had	no
O	O	not	no
O	O	changed	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	other	no
B-group	B-group	folic	yes
I-group	I-group	acid	yes
I-group	I-group	antagonists	no
O	O	.	no

O	O	If	no
O	O	replacing	no
B-drug	B-drug	clonidine	yes
O	O	by	no
B-group	B-group	beta-blocker	no
O	O	therapy	no
O	O	,	no
O	O	the	no
O	O	introduction	no
O	O	of	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	should	no
O	O	be	no
O	O	delayed	no
O	O	for	yes
O	O	several	no
O	O	days	no
O	O	after	no
B-drug	B-drug	clonidine	yes
O	O	administration	no
O	O	has	no
O	O	stopped	no
O	O	.	no

O	O	Grapefruit	no
O	O	juice	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	with	yes
O	O	grapefruit	no
O	O	juice	no
O	O	resulted	no
O	O	in	yes
O	O	more	no
O	O	than	no
O	O	2-fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	but	no
O	O	no	yes
O	O	prolongation	no
O	O	in	yes
O	O	the	no
O	O	half-	no
O	O	life	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

O	O	Renal	no
O	O	clearance	no
O	O	measurements	no
O	O	of	yes
B-drug	B-drug	PAH	yes
O	O	can	no
O	O	not	no
O	O	be	no
O	O	made	no
O	O	with	yes
O	O	any	no
O	O	significant	no
O	O	accuracy	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-drug	B-drug	procaine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	thiazolesulfone	no
O	O	.	no

O	O	Co-administration	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	3A4	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	their	no
O	O	clearance	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	decreased	no
O	O	plasma	yes
O	O	concentration	no
O	O	.	no

O	O	Drug	yes
O	O	/	no
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	As	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Keflex	yes
O	O	,	no
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Marked	no
O	O	symptomatic	no
O	O	orthostatic	no
O	O	hypotension	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	and	yes
B-group	O	organic	no
I-group	B-group	nitrates	no
O	O	were	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	alterations	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	:	no
B-group	B-group	MAOI	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	a	yes
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	furazolidone	yes
O	O	,	no
O	O	slow	yes
B-drug	B-group	amphetamine	yes
O	O	metabolism	no
O	O	.	no

O	O	A	yes
O	O	host	no
O	O	of	yes
O	O	other	no
O	O	medical	yes
O	O	considerations	no
O	O	are	no
O	O	discussed	no
O	O	in	yes
O	O	chapter	no
O	O	8	yes
O	O	,	no
O	O	including	no
O	O	persistent	no
O	O	ovarian	no
O	O	follicles	no
O	O	;	no

B-drug	B-drug	Aprepitant	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	by	no
O	O	25	yes
O	O	%	no
O	O	on	no
O	O	Day	no
O	O	4	yes
O	O	and	yes
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	by	no
O	O	19	yes
O	O	%	no
O	O	on	no
O	O	Day	no
O	O	8	yes
O	O	relative	no
O	O	to	no
O	O	the	no
O	O	dosing	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	on	no
O	O	Days	no
O	O	1	yes
O	O	through	no
O	O	3	yes
O	O	.	no

O	O	1	yes
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	a	yes
O	O	.	no
O	O	Drugs	no
O	O	Enhancing	no
B-drug	B-drug	Heparin	yes
O	O	Effect	no
O	O	:	no
O	O	Oral	yes
B-group	B-group	anticoagulants	no
O	O	:	no
B-drug	B-drug	Heparin	yes
I-drug	I-drug	sodium	yes
O	O	may	no
O	O	prolong	no
O	O	the	no
O	O	one-stage	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Seventeen	no
O	O	percent	no
O	O	of	yes
O	O	CHOP-HAART	no
O	O	patients	no
O	O	developed	no
O	O	severe	no
O	O	autonomic	no
O	O	neurotoxicity	no
O	O	,	no
O	O	whereas	no
O	O	none	no
O	O	of	yes
O	O	the	no
O	O	CHOP	no
O	O	patients	no
O	O	developed	no
O	O	neurotoxicity	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	0.002	no
O	O	)	no
O	O	.	no

O	O	metabolic	no
O	O	interference	no
O	O	has	no
O	O	sometimes	no
O	O	been	no
O	O	observed	no
O	O	and	yes
O	O	the	no
O	O	behaviour	no
O	O	of	yes
O	O	the	no
O	O	biological	no
O	O	indicators	no
O	O	differs	no
O	O	from	no
O	O	what	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	.	no

O	O	The	no
O	O	different	no
O	O	responses	no
O	O	in	yes
O	O	locomotor	no
O	O	activity	yes
O	O	induced	no
O	O	by	no
B-drug	B-drug	cocaine	yes
O	O	suggest	no
O	O	that	no
O	O	genetic	no
O	O	factors	no
O	O	may	no
O	O	play	no
O	O	a	yes
O	O	role	no
O	O	in	yes
O	O	determining	no
O	O	the	no
O	O	magnitude	no
O	O	of	yes
O	O	response	no
O	O	to	no
O	O	this	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Acetylcysteine	yes
O	O	interference	no
O	O	with	yes
O	O	urine	no
O	O	ketone	yes
O	O	test	yes
O	O	.	no

O	O	Patients	no
O	O	with	yes
O	O	renal	no
O	O	insufficiency	no
O	O	or	no
O	O	renal	no
O	O	failure	no
O	O	may	no
O	O	be	no
O	O	at	yes
O	O	risk	no
O	O	for	yes
O	O	further	no
O	O	kidney	yes
O	O	damage	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	complications	no
O	O	related	yes
O	O	to	no
O	O	interactions	no
O	O	of	yes
O	O	herbal	no
O	O	remedies	no
O	O	with	yes
O	O	complex	yes
O	O	renal	no
O	O	therapy	no
O	O	regimens	no
O	O	.	no

B-group	B-group	nitrosourea	yes
O	O	AUC	no
O	O	,	no
O	O	with	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	the	no
O	O	reduction	yes
O	O	depending	no
O	O	on	no
O	O	the	no
O	O	minimum	no
O	O	effective	no
O	O	concentration	no
O	O	(	no
O	O	MEC	no
O	O	)	no
O	O	chosen	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	interferes	no
O	O	with	yes
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	and	yes
O	O	produces	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	level	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	in	yes
O	O	serum	yes
O	O	.	no

B-group	B-group	Cholinesterase	no
I-group	I-group	Inhibitors	no
O	O	:	no
B-drug	B-drug	Dipyridamole	yes
O	O	may	no
O	O	counteract	no
O	O	the	no
O	O	anticholinesterase	no
O	O	effect	no
O	O	of	yes
B-group	B-group	cholinesterase	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	thereby	no
O	O	potentially	no
O	O	aggravating	no
O	O	myasthenia	no
O	O	gravis	no
O	O	.	no

O	O	At	yes
O	O	steady	no
O	O	state	no
O	O	,	no
B-brand	B-brand	VIOXX	yes
O	O	50	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	anti-platelet	no
O	O	activity	yes
O	O	of	yes
O	O	low-dose	no
O	O	(	no
O	O	81	no
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	as	yes
O	O	assessed	no
O	O	by	no
O	O	ex	no
O	O	vivo	no
O	O	platelet	yes
O	O	aggregation	no
O	O	and	yes
O	O	serum	yes
O	O	TXB2	no
O	O	generation	no
O	O	in	yes
O	O	clotting	no
O	O	blood	yes
O	O	.	no

O	O	Cardiovascular	no
O	O	:	no
O	O	Hypotension	no
O	O	(	no
O	O	0-9	no
O	O	%	no
O	O	)	no
O	O	.	no

B-group	B-group	antihistamines	no
O	O	;	no

O	O	No	yes
O	O	significant	no
O	O	drug-drug	no
O	O	pharmacokinetic	no
O	O	(	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	)	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	in	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	.	no

B-brand	B-brand	WelChol	yes
O	O	decreased	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
O	O	sustained-release	no
B-drug	B-drug	verapamil	yes
O	O	(	no
B-brand	B-brand	Calan	yes
O	I-brand	SR	yes
O	O	)	no
O	O	by	no
O	O	approximately	no
O	O	31	yes
O	O	%	no
O	O	and	yes
O	O	11	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	etodolac	yes
O	O	in	yes
O	O	special	yes
O	O	populations	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Lithium	yes
O	O	should	no
O	O	generally	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	bumetanide	yes
O	O	)	no
O	O	because	no
O	O	they	no
O	O	reduce	no
O	O	its	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	Alternatives	no
O	O	to	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	azithromycin	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	with	yes
O	O	other	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	500	yes
O	O	mg	yes
O	O	BID	no
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	240	yes
O	O	mg	yes
O	O	QD	no
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	1200	no
O	O	mg	yes
O	O	TID	no
O	O	,	no
B-drug	B-drug	fluconazole	yes
O	O	200	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	increases	no
O	O	in	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	ranging	no
O	O	from	no
O	O	1.4-	no
O	O	to	no
O	O	1.6-	no
O	O	fold	no
O	O	and	yes
O	O	AUC	no
O	O	from	no
O	O	2.0-	no
O	O	to	no
O	O	2.9-	no
O	O	fold	no
O	O	.	no

O	O	These	no
O	O	alterations	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	pharmacokinetics	no
O	O	produced	no
O	O	by	no
B-drug	B-drug	amiodarone	yes
O	O	explain	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	level	no
O	O	that	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	when	no
O	O	this	no
O	O	drug	yes
O	O	combination	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	clinically	no
O	O	.	no

O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	synergistic	no
O	O	anticonvulsant	no
O	O	action	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
O	O	Steady-state	no
O	O	trough	no
O	O	plasma	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
B-drug	B-drug_n	carbamazepine	yes
O	I-drug_n	10	yes
O	I-drug_n	,	no
O	I-drug_n	11	yes
O	I-drug_n	epoxide	no
O	O	concentrations	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	gabapentin	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	TID	no
O	O	;	no

O	O	Restoration	no
O	O	of	yes
O	O	female	no
O	O	fertility	no
O	O	to	no
O	O	values	no
O	O	similar	no
O	O	to	no
O	O	controls	no
O	O	was	no
O	O	evident	no
O	O	following	no
O	O	a	yes
O	O	29-day	no
O	O	withdrawal	no
O	O	period	no
O	O	after	no
O	O	dosing	no
O	O	at	yes
O	O	2	yes
O	O	mg/kg/day	no
O	O	(	no
O	O	twice	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	based	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	.	no

B-group	B-group	Cardiac	no
I-group	I-group	glycosides	yes
O	O	could	no
O	O	exaggerate	no
O	O	the	no
O	O	depression	no
O	O	of	yes
O	O	AV	no
O	O	nodal	no
O	O	conduction	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

O	O	The	no
O	O	harmonic	no
O	O	mean	no
O	O	elimination	no
O	O	half-life	no
O	O	was	no
O	O	45.7	no
O	O	and	yes
O	O	43.4	no
O	O	hours	no
O	O	for	yes
B-drug	B-drug	rofecoxib	yes
O	O	+	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
O	O	placebo	no
O	O	+	no
B-drug	B-drug	digoxin	yes
O	O	treatments	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Most	no
O	O	who	no
O	O	take	no
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	and	yes
O	O	the	no
O	O	above	no
O	O	drugs	no
O	O	or	no
O	O	herbs	no
O	O	do	no
O	O	not	no
O	O	suffer	no
O	O	from	no
O	O	these	no
O	O	problems	no
O	O	and	yes
O	O	if	no
O	O	they	no
O	O	occur	no
O	O	,	no
O	O	they	no
O	O	are	no
O	O	rare	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	82	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	Animal	no
O	O	studies	no
O	O	also	no
O	O	suggest	no
O	O	an	no
O	O	increased	no
O	O	potential	no
O	O	for	yes
O	O	seizures	no
O	O	when	no
O	O	these	no
O	O	two	no
O	O	drugs	no
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	and	yes
O	O	overdose	no
O	O	.	no

B-drug	B-drug	Tadalafil	yes
O	O	dose	no
O	O	should	no
O	O	not	no
O	O	exceed	no
O	O	a	yes
O	O	maximum	no
O	O	of	yes
O	O	10	yes
O	O	mg	yes
O	O	in	yes
O	O	a	yes
O	O	72-	no
O	O	hour	yes
O	O	period	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	indinavir	yes
O	O	therapy	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	reactions	no
O	O	be	no
O	O	used	no
O	O	.	no

O	O	The	no
O	O	uptake	no
O	O	inhibitors	no
B-drug	B-drug	cocaine	yes
O	O	and	yes
B-drug	B-drug	desipramine	yes
O	O	(	no
O	O	3	yes
O	O	mumol/liter	no
O	O	)	no
O	O	potentiated	no
O	O	the	no
O	O	positive	no
O	O	inotropic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	in	yes
O	O	nonfailing	no
O	O	myocardium	no
O	O	(	no
O	O	p	yes
O	O	<	no
O	O	0.05	no
O	O	)	no
O	O	but	no
O	O	not	no
O	O	in	yes
O	O	functional	no
O	O	class	no
O	O	IV	yes
O	O	myocardium	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	performed	no
O	O	with	yes
B-drug	B-drug	Fondaparinux	yes
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	(	no
B-drug	B-drug	warfarin	yes
O	O	)	no
O	O	,	no
B-group	B-group	platelet	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	)	no
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	(	no
B-drug	B-drug	piroxicam	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics/pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	fondaparinux	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	The	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	in	yes
O	O	plasma	yes
O	O	and	yes
O	O	brain	yes
O	O	was	no
O	O	longer	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	halothane	yes
O	O	than	no
O	O	when	no
B-drug	B-drug	ketamine	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	B-drug	Tacrolimus	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	tacrolimus	yes
O	O	and	yes
B-drug	B-drug	bosentan	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	man	no
O	O	.	no

O	O	Animal	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	dobutamine	yes
O	O	may	no
O	O	be	no
O	O	ineffective	no
O	O	if	no
O	O	the	no
O	O	patient	no
O	O	has	no
O	O	recently	no
O	O	received	no
O	O	a	yes
B-group	B-group	b-blocking	no
I-group	I-group	drug	yes
O	O	.	no

O	O	Avoid	no
O	O	dong	no
O	O	quai	no
O	O	and	yes
O	O	black	yes
O	O	cohosh	no
O	O	(	no
O	O	have	no
O	O	estrogen	no
O	O	activity	yes
O	O	)	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	reserpine	yes
O	O	during	no
O	O	therapy	no
O	O	with	yes
O	O	a	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	produce	no
O	O	a	yes
O	O	stimulating	yes
O	O	effect	no
O	O	in	yes
O	O	some	no
O	O	depressed	no
O	O	patients	no
O	O	.	no

O	O	Nonetheless	no
O	O	,	no
O	O	they	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
B-group	B-group	macrolide	no
I-group	I-group	products	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Should	no
O	O	Not	no
O	O	Be	no
O	O	Coadministered	no
O	O	with	yes
B-brand	B-brand	CRIXIVAN	yes

O	O	Nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	other	no
B-group	B-group	cephalosporins	no
I-group	O	with	yes
I-group	O	potent	no
I-group	B-group	diuretics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Interactions	no
O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	Campath	yes
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	.	no

O	O	No	yes
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
B-drug	B-drug	azithromycin	yes
O	O	is	yes
O	O	co	yes
O	O	administered	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	above	no
O	O	agents	yes
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	,	no
B-drug	B-drug	naproxen	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	in	yes
O	O	an	no
O	O	animal	no
O	O	model	no
O	O	,	no
O	O	possibly	no
O	O	increasing	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

B-group	B-group	Adrenergic	no
I-group	I-group	blockers	no
O	O	:	no
B-group	B-group	Adrenergic	no
I-group	I-group	blockers	no
O	O	are	no
O	O	inhibited	no
O	O	by	no
B-group	B-group	amphetamines	no
O	O	.	no

O	O	+109	no
O	O	%	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	A	yes
O	O	single	yes
O	O	125-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	80	yes
O	O	mg/day	no
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	and	yes
O	O	3	yes
O	O	to	no
O	O	healthy	no
O	O	subjects	no
O	O	who	no
O	O	were	no
O	O	stabilized	no
O	O	on	no
O	O	chronic	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
B-brand	B-drug_n	Bombesin	yes
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	intestinal	no
O	O	tumors	no
O	O	and	yes
O	O	cancer	no
O	O	metastasis	no
O	O	to	no
O	O	the	no
O	O	peritoneum	no
O	O	.	no

O	O	The	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	also	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	inhibited	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	physician	no
O	O	should	no
O	O	be	no
O	O	cautious	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	flurbiprofen	yes
O	O	to	no
O	O	patients	no
O	O	taking	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	Interactions	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-group	O	adrenocorticoids	no
O	O	(	no
B-group	O	cortisone-like	no
O	O	medicine	no
O	O	)	no
O	O	,	no
B-group	B-group	anticoagulants	no
O	O	(	no
B-group	B-group	blood	yes
I-group	O	thinners	no
O	O	)	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	corticotropin	yes
O	O	(	no
B-group	B-group	barbiturates	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	medicines	no
O	O	)	no
O	O	,	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	(	no
I-group	I-group	CNS	no
I-group	I-group	)	no
I-group	I-group	depressants	no
O	O	(	no
O	O	using	no
O	O	these	no
O	O	medicines	no
O	O	with	yes
B-group	B-group	barbiturates	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	)	no
O	O	,	no
B-drug	B-drug	divalproex	yes
I-drug	I-drug	sodium	yes
O	O	,	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	(	no
O	O	using	no
O	O	these	no
O	O	medicines	no
O	O	with	yes
B-group	B-group	barbiturates	no
O	O	may	no
O	O	change	no
O	O	the	no
O	O	amount	no
O	O	of	yes
O	O	either	no
O	O	medicine	no
O	O	that	no
O	O	you	no
O	O	need	no
O	O	to	no
O	O	take	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	containing	yes
B-group	B-group	estrogens	yes
O	O	(	no
B-group	B-group	barbiturates	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
O	O	these	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
O	O	and	yes
O	O	you	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	change	no
O	O	to	no
O	O	a	yes
O	O	different	no
O	O	type	yes
O	O	of	yes
O	O	birth	no
O	O	control	no
O	O	)	no
O	O	.	no

O	O	Other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	opioids	no
O	O	and	yes
O	O	general	no
B-group	B-group	anesthetics	no
O	O	)	no
O	O	have	no
O	O	additive	no
O	O	or	no
O	O	potentiating	no
O	O	effects	no
O	O	with	yes
B-brand	B-brand	INAPSINE	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	small	no
O	O	effect	no
O	O	on	no
O	O	half-life	no
O	O	,	no
O	O	the	no
O	O	coadministration	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	to	no
O	O	extend	no
O	O	the	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	ertapenem	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	[	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug_n	B-brand	sandimmune	yes
O	O	on	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	mixed-function	no
O	O	mono-oxidases	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	microsomes	no
O	O	]	no
O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	B-group	immunodepressant	no
O	O	--	no
O	O	the	no
O	O	drug	yes
B-drug	B-brand	sandimmune	yes
O	O	--	no
O	O	on	no
O	O	hepatic	no
O	O	microsomal	no
O	O	monooxygenase	no
O	O	activities	no
O	O	were	no
O	O	studied	no
O	O	.	no

O	O	In	yes
O	O	large	no
O	O	,	no
O	O	well	no
O	O	controlled	no
O	O	trials	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	schizophrenia	no
O	O	or	no
O	O	related	yes
O	O	psychoses	no
O	O	,	no
B-drug	B-drug	olanzapine	yes
O	O	5	yes
O	O	to	no
O	O	20	yes
O	O	mg/day	no
O	O	was	no
O	O	significantly	no
O	O	superior	no
O	O	to	no
B-drug	B-drug	haloperidol	yes
O	O	5	yes
O	O	to	no
O	O	20	yes
O	O	mg/day	no
O	O	in	yes
O	O	overall	no
O	O	improvements	no
O	O	in	yes
O	O	psychopathology	no
O	O	rating	no
O	O	scales	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	depressive	no
O	O	and	yes
O	O	negative	no
O	O	symptoms	no
O	O	,	no
O	O	and	yes
O	O	was	no
O	O	comparable	no
O	O	in	yes
O	O	effects	no
O	O	on	no
O	O	positive	no
O	O	psychotic	no
O	O	symptoms	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	docetaxel	yes
O	O	may	no
O	O	be	no
O	O	modified	yes
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	compounds	no
O	O	that	no
O	O	induce	no
O	O	,	no
O	O	inhibit	no
O	O	,	no
O	O	or	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	terfenadine	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	troleandomycin	yes
O	O	.	no

O	O	Maximal	no
O	O	exercise	no
O	O	testing	no
O	O	,	no
O	O	a	yes
O	O	maneuver	no
O	O	often	no
O	O	applied	no
O	O	to	no
O	O	cardiac	no
O	O	patients	no
O	O	,	no
O	O	does	no
O	O	not	no
O	O	significantly	no
O	O	alter	no
O	O	the	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	level	no
O	O	.	no

O	O	Potential	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	TAXOL	yes
O	O	,	no
O	O	a	yes
O	O	substrate	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	and	yes
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	nelfinavir	yes
O	O	)	no
O	O	,	no
O	O	which	no
O	O	are	no
O	O	substrates	no
O	O	and/or	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	(	no
O	O	41	yes
O	O	)	no
O	O	but	no
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	levels	no
O	O	when	no
O	O	the	no
O	O	nerves	no
O	O	were	no
O	O	rewarmed	no
O	O	.	no

O	O	Animal	no
O	O	experience	no
O	O	indicates	no
O	O	that	no
B-drug	B-drug	clorazepate	yes
I-drug	I-drug	dipotassium	yes
O	O	prolongs	no
O	O	the	no
O	O	sleeping	no
O	O	time	no
O	O	after	no
B-drug	B-drug	hexobarbital	yes
O	O	or	no
O	O	after	no
B-drug	B-drug	ethyl	yes
I-drug	I-drug	alcohol	yes
O	O	,	no
O	O	increases	no
O	O	the	no
O	O	inhibitory	yes
O	O	effects	no
O	O	of	yes
B-drug	B-drug	chlorpromazine	yes
O	O	,	no
O	O	but	no
O	O	does	no
O	O	not	no
O	O	exhibit	no
O	O	monoamine	no
O	O	oxidase	yes
O	O	inhibition	no
O	O	.	no

O	O	and	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	antagonists	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	)	no
O	O	,	no
O	O	CYP1A2	no
O	O	inducers	no
O	O	(	no
B-drug	B-drug	omeprazole	yes
O	O	)	no
O	O	and	yes
B-group	O	CYP1A2	no
I-group	O	inhibitors	no
O	O	(	no
B-drug	B-drug	furafylline	no
O	O	and	yes
B-drug	B-drug	clarithromycin	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	use	no
O	O	may	no
O	O	be	no
O	O	rarely	no
O	O	associated	no
O	O	with	yes
O	O	ventricular	no
O	O	fibrillation	no
O	O	when	no
O	O	combined	no
O	O	with	yes
B-brand	B-brand	Adenocard	yes
O	O	.	no

B-drug	B-drug	Nelfinavir	yes
O	O	steady-state	no
O	O	Cmax	no
O	O	,	no
O	O	A.C.	no
O	O	and	yes
O	O	Cmin	no
O	O	were	no
O	O	increased	no
O	O	by	no
O	O	12	yes
O	O	%	no
O	O	,	no
O	O	15	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	14	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	amprenavir	yes
O	O	.	no

O	O	Phase	no
O	O	II	yes
O	O	clinical	no
O	O	trial	no
O	O	data	no
O	O	,	no
O	O	where	no
B-brand	B-brand	IRESSA	yes
O	O	and	yes
B-drug	B-drug	vinorelbine	yes
O	O	have	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	indicate	no
O	O	that	no
B-brand	B-brand	IRESSA	yes
O	O	may	no
O	O	exacerbate	no
O	O	the	no
O	O	neutropenic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	vinorelbine	yes
O	O	.	no

O	O	Weak	no
O	O	inhibitory	yes
O	O	effects	no
O	O	toward	no
O	O	other	no
O	O	isoforms	no
O	O	(	no
O	O	CYP2C8	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	3A4	no
O	O	)	no
O	O	were	no
O	O	found	no
O	O	,	no
O	O	but	no
O	O	Ki	yes
O	O	values	no
O	O	were	no
O	O	in	yes
O	O	excess	no
O	O	of	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	achieved	no
O	O	following	no
O	O	dosing	no
O	O	.	no

O	O	-	yes
O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	decrease	no
O	O	plasma	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	include	no
O	O	:	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	chronic	no
B-drug	B-drug	alcohol	yes
O	O	abuse	no
O	O	,	no
B-drug	B-drug	reserpine	yes

O	O	The	no
O	O	majority	no
O	O	of	yes
O	O	patients	no
O	O	in	yes
O	O	RA	yes
O	O	clinical	no
O	O	studies	no
O	O	received	no
O	O	one	no
O	O	or	no
O	O	more	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	concomitant	no
O	O	medications	no
O	O	with	yes
B-brand	B-brand	ORENCIA	yes
O	O	:	no
B-drug	B-drug	MTX	yes
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	TNF	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	azathioprine	yes
O	O	,	no
B-drug	B-drug	chloroquine	yes
O	O	,	no
B-drug	B-drug	gold	yes
O	O	,	no
B-drug	B-drug	hydroxychloroquine	yes
O	O	,	no
B-drug	B-drug	leflunomide	yes
O	O	,	no
B-drug	B-drug	sulfasalazine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	anakinra	yes
O	O	.	no

B-drug	B-drug	Indinavir	yes
O	O	steady-state	no
O	O	Cmax	no
O	O	,	no
O	O	A.C.	no
O	O	and	yes
O	O	Cmin	no
O	O	were	no
O	O	decreased	no
O	O	by	no
O	O	22	no
O	O	%	no
O	O	,	no
O	O	38	no
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	27	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	amprenavir	yes
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	the	no
O	O	potency	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	was	no
O	O	increased	no
O	O	in	yes
O	O	failing	no
O	O	hearts	no
O	O	(	no
O	O	New	no
O	O	York	no
O	O	Heart	no
O	O	Association	no
O	O	functional	no
O	O	class	no
O	O	IV	yes
O	O	)	no
O	O	in	yes
O	O	relation	no
O	O	to	no
O	O	the	no
O	O	concentrations	no
O	O	producing	no
O	O	50	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	maximal	no
O	O	effect	no
O	O	(	no
O	O	EC50	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	with	yes
O	O	commonly	no
O	O	used	no
B-group	O	preanesthetic	no
I-group	O	drugs	no
O	O	,	no
O	O	or	no
O	O	drugs	no
O	O	used	no
O	O	during	no
O	O	anesthesia	yes
O	O	(	no
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	intravenous	yes
O	O	agents	yes
O	O	,	no
O	O	and	yes
O	O	local	no
B-group	B-group	anesthetic	no
I-group	I-group	agents	yes
O	O	)	no
O	O	were	no
O	O	reported	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	Monitor	no
O	O	prothrombin	yes
O	O	levels	no
O	O	and	yes
O	O	adjust	no
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	accordingly	no
O	O	.	no

O	O	Further	no
O	O	,	no
O	O	if	no
B-drug	B-drug	guanfacine	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	discontinued	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	,	no
O	O	careful	no
O	O	tapering	no
O	O	of	yes
O	O	the	no
O	O	dosage	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
O	O	rebound	no
O	O	phenomena	no
O	O	.	no

O	O	Activation	no
O	O	of	yes
O	O	an	no
O	O	effector	no
O	O	immediate-early	no
O	O	gene	yes
O	O	arc	no
O	O	by	no
B-drug	B-drug	methamphetamine	yes
O	O	.	no

O	O	CYP450	no
O	O	Metabolized	no
O	O	Drugs	no
O	O	Results	no
O	O	from	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	studies	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	enfuvirtide	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	have	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
O	O	concomitantly	no
O	O	administered	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP450	no
O	O	enzymes	yes
O	O	.	no

O	O	The	no
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	methyldopa	yes
O	O	,	no
B-drug	B-drug	mecamylamine	yes
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	and	yes
B-group	B-drug	veratrum	no
I-group	I-drug	alkaloids	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
B-group	B-group	sympathomimetics	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	these	no
O	O	increases	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Omeprazole	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	as	yes
O	O	directed	no
O	O	and	yes
B-brand	B-brand	Proquin	yes
I-brand	I-brand	XR	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	with	yes
O	O	a	yes
O	O	main	no
O	O	meal	no
O	O	of	yes
O	O	the	no
O	O	day	no
O	O	,	no
O	O	preferably	no
O	O	the	no
O	O	evening	no
O	O	meal..	no

O	O	Certain	no
O	O	drugs	no
O	O	,	no
O	O	including	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
B-group	B-group	non-selective	no
I-group	I-group	beta-adrenergic-blocking	no
I-group	I-group	agents	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	Starlix	yes
O	O	and	yes
O	O	other	no
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	drugs	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	with	yes
B-brand	B-brand	aspirin	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	gastrointestinal	no
O	O	ulceration	no
O	O	and	yes
O	O	may	no
O	O	reduce	no
O	O	serum	yes
B-group	O	salicylate	yes
O	O	levels	no
O	O	.	no

O	O	Of	yes
O	O	particular	no
O	O	importance	no
O	O	,	no
O	O	sufficient	no
O	O	time	no
O	O	must	no
O	O	elapse	no
O	O	before	no
O	O	initiating	no
B-group	O	TCA	no
O	O	treatment	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	being	no
O	O	withdrawn	no
O	O	from	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	given	no
O	O	the	no
O	O	long	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	parent	no
O	O	and	yes
O	O	active	no
O	O	metabolite	yes
O	O	(	no
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	weeks	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	)	no
O	O	.	no

O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	500	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	did	no
O	O	not	no
O	O	modify	no
O	O	the	no
O	O	rate	no
O	O	or	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	absorption	no
O	O	or	no
O	O	its	no
O	O	plasma	yes
O	O	clearance	no
O	O	or	no
O	O	urinary	yes
O	O	excretion	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	follow-up	no
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	subjects	no
O	O	,	no
O	O	single-dose	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	and	yes
O	O	twice-a-day	no
O	O	administration	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	of	yes
O	O	both	no
O	O	agents	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	absorption	no
O	O	,	no
O	O	but	no
O	O	had	no
O	O	a	yes
O	O	small	no
O	O	yet	no
O	O	statistically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	its	no
O	O	rate	no
O	O	of	yes
O	O	absorption	no
O	O	;	no

O	O	Sexual	no
O	O	intercourse	no
O	O	with	yes
O	O	a	yes
O	O	steady	no
O	O	partner	no
O	O	causes	no
O	O	no	yes
O	O	more	no
O	O	cardiovascular	no
O	O	risk	no
O	O	than	no
O	O	normal	yes
O	O	daily	no
O	O	activities	no
O	O	such	no
O	O	as	yes
B-drug	O	ironing	no
O	O	,	no
O	O	2	yes
O	O	kilometers	no
O	O	of	yes
O	O	walking	no
O	O	without	no
O	O	climbing	no
O	O	,	no
O	O	paperhanging	no
O	O	,	no
O	O	playing	no
O	O	golf	no
O	O	or	no
O	O	gardening	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	may	no
O	O	decrease	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-group	B-group	cephalosporins	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	increased	no
O	O	and	yes
O	O	more	no
O	O	prolonged	no
B-group	B-group	cephalosporin	yes
O	O	blood	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	In	yes
O	O	subjects	no
O	O	receiving	no
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	no	yes
O	O	significant	no
O	O	change	no
O	O	in	yes
O	O	clotting	no
O	O	time	no
O	O	was	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	grepafloxacin	yes
O	O	was	no
O	O	coadministered	no
O	O	.	no

B-drug	B-drug	Bismuth	yes
O	O	:	no
B-drug	B-drug	Bismuth	yes
I-drug	I-drug	subsalicylate	yes
O	O	,	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	enoxacin	yes
O	O	or	no
O	O	60	no
O	O	minutes	no
O	O	following	no
B-drug	B-drug	enoxacin	yes
O	O	administration	no
O	O	,	no
O	O	decreased	no
B-drug	B-drug	enoxacin	yes
O	O	bioavailability	no
O	O	by	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	.	no

O	O	hepatotoxic	no
O	O	drugs	no
O	O	;	no

O	O	For	yes
O	O	the	no
B-group	B-group	calcium-entry	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	now	no
O	O	available	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	States	no
O	O	(	no
B-drug	B-drug	verapamil	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	and	yes
B-drug	B-drug	diltiazem	yes
O	O	)	no
O	O	,	no
O	O	these	no
O	O	data	no
O	O	appeared	no
O	O	well	no
O	O	after	no
O	O	clinical	no
O	O	patterns	no
O	O	of	yes
O	O	use	no
O	O	evolved	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	prudent	no
O	O	evaluation	no
O	O	of	yes
O	O	individual	no
O	O	cases	no
O	O	is	yes
O	O	warranted	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	setting	no
O	O	.	no

O	O	When	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
O	O	such	no
O	O	drugs	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	should	no
O	O	be	no
O	O	the	no
O	O	smallest	no
O	O	effective	no
O	O	dose	no
O	O	and	yes
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	dosing	no
O	O	reduced	yes
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	possible	no
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	potentiate	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	opioids	no
O	O	.	no

O	O	Most	no
O	O	events	no
O	O	were	no
O	O	reported	no
O	O	to	no
O	O	occur	no
O	O	when	no
O	O	contrast	no
O	O	media	no
O	O	was	no
O	O	given	no
O	O	within	no
O	O	4	yes
O	O	weeks	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	interleukin-2	yes
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	fosfomycin	yes
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	MONUROL	yes
O	O	.	no

O	O	C57BL/6N	no
O	O	demonstrated	no
O	O	large	no
O	O	numbers	no
O	O	of	yes
O	O	two	no
O	O	of	yes
O	O	the	no
O	O	three	no
O	O	types	no
O	O	of	yes
O	O	liver	yes
O	O	tumors	no
O	O	seen	no
O	O	in	yes
O	O	livers	no
O	O	of	yes
O	O	genetically	no
O	O	predisposed	no
O	O	mice	no
O	O	,	no
O	O	one	no
O	O	of	yes
O	O	which	no
O	O	required	no
O	O	the	no
O	O	additional	no
O	O	stimulus	no
O	O	of	yes
O	O	dietary	no
B-drug	B-drug	phenobarbital	yes
O	O	for	yes
O	O	growth	yes
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
B-group	O	thyroid	yes
I-group	O	medication	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	levothyroxine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	iodine-containing	no
O	O	products	no
O	O	,	no
B-group	B-group	antacids	no
O	O	,	no
B-group	B-group	H2-antagonists	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	famotidine	yes
O	O	,	no
B-drug	B-drug	ranitidine	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	lansoprazole	yes
O	O	,	no
B-drug	B-drug	omeprazole	yes
O	O	)	no
O	O	.	no

O	O	Photic	no
O	O	evoked	no
O	O	potentials	no
O	O	were	no
O	O	recorded	no
O	O	from	no
O	O	the	no
O	O	visual	no
O	O	cortex	no
O	O	of	yes
O	O	chronically	no
O	O	implanted	no
O	O	albino	no
O	O	rats	no
O	O	.	no

O	O	SETTING	no
O	O	:	no
O	O	Clinical	no
O	O	research	no
O	O	center	no
O	O	.	no

O	O	Concomitant	no
O	O	medications	no
O	O	were	no
O	O	grouped	no
O	O	as	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	,	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	substrates	no
O	O	and	yes
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	substrates	no
O	O	and	yes
O	O	inhibitors	no
O	O	of	yes
O	O	P-glycoprotein	no
O	O	,	no
B-group	B-group	nitrates	no
O	O	,	no
B-group	B-group	sulphonylureas	no
O	O	,	no
B-group	B-group	loop	no
I-group	I-group	diuretics	no
O	O	,	no
B-group	B-group	potassium	yes
I-group	I-group	sparing	no
I-group	I-group	diuretics	no
O	O	,	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	,	no
O	O	substrates	no
O	O	and	yes
O	O	inhibitors	no
O	O	of	yes
O	O	tubular	no
O	O	organic	no
O	O	cation	yes
O	O	transport	no
O	O	,	no
O	O	and	yes
O	O	QTc-prolonging	no
O	O	drugs	no
O	O	.	no

O	O	Recombinant	yes
O	O	shuttle	no
O	O	vectors	no
O	O	containing	yes
O	O	a	yes
O	O	vanH	no
O	O	promoter-vanA	no
O	O	antisense	no
O	O	gene	yes
O	O	cassette	no
O	O	fully	no
O	O	restored	no
B-drug	B-drug	vancomycin	yes
O	O	susceptibility	no
O	O	through	no
O	O	a	yes
O	O	combined	no
O	O	transcriptional	no
O	O	activator	yes
O	O	binding	no
O	O	domain	no
O	O	decoy	no
O	O	and	yes
O	O	inducible	no
O	O	vanA	no
O	O	antisense	no
O	O	RNA	yes
O	O	effect	no
O	O	.	no

O	O	3	yes
O	O	.	no

O	O	A	yes
O	O	single	yes
O	O	tonic	no
O	O	convulsion	no
O	O	was	no
O	O	seen	no
O	O	in	yes
O	O	each	no
O	O	of	yes
O	O	2	yes
O	O	male	no
O	O	dogs	no
O	O	(	no
O	O	one	no
O	O	treated	no
O	O	at	yes
O	O	10	yes
O	O	mg/kg/day	no
O	O	and	yes
O	O	one	no
O	O	at	yes
O	O	120	no
O	O	mg/kg/day	no
O	O	)	no
O	O	in	yes
O	O	a	yes
O	O	2-year	no
O	O	study	no
O	O	.	no

O	O	+82	no
O	O	%	no

B-drug	B-drug	Gemfibrozil	yes
O	O	Other	no
B-group	B-group	fibrates	no
B-drug	B-drug	Niacin	yes
O	O	(	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	)	no
O	O	(	no
O	O	=1	no
O	O	g/day	no
O	O	)	no

B-brand	B-brand	Angiomax	yes
O	O	does	no
O	O	not	no
O	O	exhibit	no
O	O	binding	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	(	no
O	O	other	no
O	O	than	no
O	O	thrombin	no
O	O	)	no
O	O	or	no
O	O	red	yes
O	O	blood	yes
O	O	cells	yes
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	doses	no
O	O	greater	no
O	O	than	no
O	O	the	no
O	O	normal	yes
O	O	antiasthmatic	no
O	O	dose	no
O	O	of	yes
B-group	B-group	beta-agonist	no
I-group	I-group	bronchodilator	no
I-group	I-group	drugs	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	strong	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	increased	no
B-drug	B-drug	cinacalcet	yes
O	O	exposure	yes
O	O	following	no
O	O	a	yes
O	O	single	yes
O	O	90	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Sensipar	yes
O	O	by	no
O	O	2.3	no
O	O	fold	no
O	O	.	no

O	O	If	no
O	O	resumed	no
O	O	during	no
B-drug	B-drug	captopril	yes
O	O	therapy	no
O	O	,	no
O	O	such	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	cautiously	no
O	O	,	no
O	O	and	yes
O	O	perhaps	no
O	O	at	yes
O	O	lower	no
O	O	dosage	no
O	O	.	no

B-drug	B-drug	allopurinol	yes
O	O	;	no

O	O	Certain	no
B-group	B-group	antibiotic	yes
O	O	,	no
B-drug	B-drug	cisplatin	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-group	B-group	diuretic	no
O	O	,	no
B-drug	B-drug	foscarnet	yes
O	O	,	no
O	O	and	yes
B-group	B-group	vaccines	no
O	O	.	no

O	O	With	yes
O	O	some	no
O	O	agents	yes
O	O	,	no
O	O	the	no
O	O	metabolism	no
O	O	may	no
O	O	be	no
O	O	induced	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	decreased	no
O	O	concentrations	no
O	O	.	no

B-group	B-group	Beta-blockers	no
O	O	,	no
B-drug	B-drug	clonidine	yes
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	salts	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	either	no
O	O	potentiate	no
O	O	or	no
O	O	weaken	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	.	no

O	O	Antimicrobial	no
O	O	activity	yes
O	O	of	yes
O	B-drug_n	Ganoderma	no
O	I-drug_n	lucidum	no
O	I-drug_n	extract	yes
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	some	no
B-group	B-group	antibiotics	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	,	no
O	O	in	yes
O	O	particular	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	exhibit	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	this	no
O	O	variety	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	antagonism	no
O	O	in	yes
O	O	vivo	no
O	O	,	no
O	O	particularly	no
O	O	when	no
O	O	bactericidal	no
O	O	activity	yes
O	O	is	yes
O	O	desired	no
O	O	,	no
O	O	this	no
O	O	drug	yes
O	O	combination	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	If	no
O	O	this	no
O	O	is	yes
O	O	not	no
O	O	possible	no
O	O	,	no
O	O	the	no
O	O	starting	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	and	yes
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	several	no
O	O	hours	no
O	O	following	no
O	O	an	no
O	O	initial	no
O	O	dose	no
O	O	and	yes
O	O	until	no
O	O	blood	yes
O	O	pressure	no
O	O	has	no
O	O	stabilized	no
O	O	(	no
O	O	see	no
O	O	DOSAGE	no
O	O	AND	yes
O	O	ADMINISTRATION	no
O	O	.	no
O	O	)	no

B-drug	B-drug	Cyclosporin	yes
O	O	:	no
O	O	Reports	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	cyclosporine	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	during	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	allopurinol	yes
I-drug	I-drug	sodium	yes
O	O	for	yes
O	O	injection	yes
O	O	.	no

O	O	Adequate	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	VIOXX	yes
O	O	is	yes
O	O	initiated	no
O	O	or	no
O	O	changed	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	midazolam	yes
O	O	is	yes
O	O	administered	no
O	O	parenterally	no
O	O	,	no
O	O	special	yes
O	O	precaution	no
O	O	is	yes
O	O	required	no
O	O	since	no
O	O	the	no
O	O	sedative	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	prolonged	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	Keppra	yes
O	O	on	no
B-drug	B-drug	probenecid	yes
O	O	was	no
O	O	not	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	Lopinavir/ritonavir	no

O	O	It	no
O	O	is	yes
O	O	structurally	no
O	O	distinct	no
O	O	from	no
O	O	the	no
O	O	other	no
O	O	currently	no
O	O	available	no
B-group	B-group	HMGCoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	(	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	simvastatin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	pravastatin	yes
O	O	)	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	unique	no
O	O	biopharmaceutical	no
O	O	properties	no
O	O	relative	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	agents	yes
O	O	of	yes
O	O	this	no
O	O	class	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	In	yes
O	O	patients	no
O	O	with	yes
O	O	hypercholesterolemia	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	resulted	no
O	O	in	yes
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	digoxin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	isolated	no
O	O	reports	no
O	O	of	yes
O	O	patients	no
O	O	experiencing	no
O	O	increases	no
O	O	in	yes
O	O	their	no
O	O	prothrombin	yes
O	O	times	no
O	O	when	no
B-drug	B-drug	etidronate	yes
O	O	was	no
O	O	added	no
O	O	to	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	.	no

O	O	ulcerans	no
O	O	infection	no
O	O	.	no

B-drug	B-drug	isoflurane	yes
O	O	;	no

B-brand	B-brand	INDOCIN	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	and	yes
O	O	to	no
O	O	potentiate	no
O	O	its	no
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	minimum	no
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	increased	no
O	O	15	yes
O	O	%	no
O	O	and	yes
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	was	no
O	O	decreased	no
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	behavioral	no
O	O	changes	no
O	O	of	yes
O	O	mice	no
O	O	induced	no
O	O	by	no
O	O	acute	no
O	O	and	yes
O	O	repeated	no
O	O	i.p	no
O	O	.	no

O	O	An	no
O	O	intravenous	yes
O	O	injection	yes
O	O	of	yes
B-drug	B-drug_n	perchlorate	yes
O	O	given	no
O	O	later	no
O	O	also	no
O	O	produces	no
O	O	a	yes
O	O	complete	yes
O	O	and	yes
O	O	immediately	no
O	O	beginning	no
O	O	depletion	no
O	O	of	yes
B-drug	B-drug	pertechnetate	yes
O	O	already	no
O	O	accumulated	no
O	O	in	yes
O	O	the	no
O	O	thyroid	yes
O	O	,	no
O	O	within	no
O	O	a	yes
O	O	period	no
O	O	of	yes
O	O	195	no
O	O	min	no
O	O	after	no
B-drug	O	99m-TcO-4-injection	no
O	O	with	yes
O	O	a	yes
O	O	corresponding	no
O	O	increase	no
O	O	in	yes
O	O	blood	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	development	no
O	O	of	yes
O	O	clinical	no
O	O	vancomycin-resistant	no
O	O	strains	no
O	O	of	yes
O	O	enterococci	no
O	O	(	no
O	O	VRE	no
O	O	)	no
O	O	is	yes
O	O	a	yes
O	O	major	no
O	O	cause	no
O	O	for	yes
O	O	concern	no
O	O	.	no

O	O	In	yes
O	O	human	yes
O	O	heart	no
O	O	failure	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	presynaptic	no
O	O	defect	no
O	O	in	yes
O	O	the	no
O	O	sympathetic	no
O	O	nervous	no
O	O	system	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	reduced	yes
O	O	uptake-1	no
O	O	activity	yes
O	O	.	no

O	O	Administering	no
B-drug_n	B-drug_n	InsP	no
O	I-drug_n	(	no
O	I-drug_n	3	yes
O	I-drug_n	)	no
O	O	together	no
O	O	with	yes
B-drug_n	B-drug_n	RR	no
O	O	(	no
O	O	100-500	no
O	O	microM	no
O	O	)	no
O	O	inhibited	no
B-drug_n	O	InsP	no
I-drug_n	O	(	no
I-drug_n	O	3	yes
I-drug_n	O	)	no
O	O	-induced	no
O	O	responses	no
O	O	(	no
O	O	both	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	and	yes
O	O	current	no
O	O	responses	no
O	O	)	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	fashion	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	exists	no
O	O	for	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
O	O	any	no
O	O	agent	yes
O	O	metabolized	no
O	O	by	no
O	O	one	no
O	O	(	no
O	O	or	no
O	O	more	no
O	O	)	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	.	no

O	O	Seizure	no
O	O	,	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
B-drug	B-drug	lidocaine	yes
O	O	concentrations	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	intravenous	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	Evaluation	no
O	O	of	yes
O	O	its	no
O	O	efficacy	no
O	O	and	yes
O	O	toxicity	no
O	O	.	no

B-drug	B-drug	Azithromycin	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	response	no
O	O	to	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Preliminary	no
O	O	investigations	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	icodextrin	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	interfere	no
O	O	with	yes
O	O	enzymatic-based	no
O	O	amylase	no
O	O	assays	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	inaccurately	no
O	O	low	yes
O	O	values	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Inhibit	no
O	O	CYP3A4	no
O	O	CYP3A4	no
O	O	is	yes
O	O	a	yes
O	O	minor	no
O	O	metabolic	no
O	O	pathway	no
O	O	for	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	because	no
O	O	the	no
O	O	sum	no
O	O	of	yes
B-drug	O	desethylzaleplon	no
O	O	(	no
O	O	formed	no
O	O	via	no
O	O	CYP3A4	no
O	O	in	yes
O	O	vitro	no
O	O	)	no
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	,	no
B-drug_n	B-drug_n	5-oxo-desethylzaleplon	no
O	O	and	yes
B-drug_n	B-drug_n	5-oxo-desethylzaleplon	no
I-drug_n	I-drug_n	glucuronide	no
O	O	,	no
O	O	account	no
O	O	for	yes
O	O	only	no
O	O	9	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	urinary	yes
O	O	recovery	no
O	O	of	yes
O	O	a	yes
B-drug	B-drug	zaleplon	yes
O	O	dose	no
O	O	.	no

O	O	Blood	yes
O	O	samples	no
O	O	also	no
O	O	were	no
O	O	taken	no
O	O	before	no
O	O	morning	no
O	O	doses	no
O	O	on	no
O	O	the	no
O	O	3rd	no
O	O	,	no
O	O	4th	no
O	O	,	no
O	O	and	yes
O	O	5th	no
O	O	days	no
O	O	of	yes
O	O	phases	no
O	O	1	yes
O	O	and	yes
O	O	3	yes
O	O	.	no

O	O	Elevated	no
O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	and	yes
O	O	Potential	no
O	O	Bleeding	no
O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	(	no
O	O	INR	no
O	O	)	no
O	O	elevations	no
O	O	and	yes
O	O	infrequent	no
O	O	reports	no
O	O	of	yes
O	O	bleeding	no
O	O	events	no
O	O	including	no
O	O	gastrointestinal	no
O	O	and	yes
O	O	non-gastrointestinal	no
O	O	bleedings	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
O	O	some	no
O	O	associated	no
O	O	with	yes
O	O	concomitant	no
B-drug	B-drug	warfarin	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	.	no

B-drug	B-drug	indomethacin	yes
O	O	;	no

O	O	-	yes
O	O	In	yes
O	O	isolated	no
O	O	cases	no
O	O	,	no
O	O	a	yes
O	O	pronounced	no
O	O	though	no
O	O	reversible	no
O	O	,	no
O	O	impairment	no
O	O	of	yes
O	O	renal	no
O	O	function	no
O	O	(	no
O	O	accompanied	no
O	O	by	no
O	O	a	yes
O	O	corresponding	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	serum	yes
O	O	creatinine	yes
O	O	level	no
O	O	)	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	organ	no
O	O	transplant	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	immuno-suppressant	no
O	O	therapy	no
O	O	and	yes
O	O	concomitant	no
B-drug	B-drug	bezafibrate	yes
O	O	.	no

O	O	Methadonea	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	disopyramide	yes
I-drug	I-drug	phosphate	yes
O	O	and	yes
O	O	hepatic	no
O	O	enzyme	no
O	O	inhibitors	no
O	O	concomitantly	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

O	O	Observe	no
O	O	the	no
O	O	patient	no
O	O	for	yes
O	O	possible	no
O	O	diminished	no
O	O	effect	no
O	O	of	yes
B-group	B-group	steroid	no
O	O	and	yes
O	O	increase	no
O	O	the	no
B-group	B-group	steroid	no
O	O	dosage	no
O	O	accordingly	no
O	O	.	no

O	O	This	no
O	O	defect	no
O	O	is	yes
O	O	not	no
O	O	related	yes
O	O	to	no
O	O	acute	no
B-drug	O	insulin	yes
O	O	release	yes
O	O	or	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	B-drug	glucose	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	efavirenz	yes
O	O	inhibits	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	and	yes
O	O	3A4	no
O	O	isozymes	no
O	O	in	yes
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	observed	no
B-drug	B-drug	efavirenz	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	At	yes
O	O	a	yes
O	O	higher	no
O	O	dose	no
O	O	and	yes
O	O	a	yes
O	O	shorter	no
O	O	withdrawal	no
O	O	period	no
O	O	(	no
O	O	20	yes
O	O	mg/kg	no
O	O	,	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	3-day	no
O	O	withdrawal	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	SST	no
O	O	mice	no
O	O	showed	no
O	O	behavioral	no
O	O	sensitization	no
O	O	similar	no
O	O	to	no
O	O	the	no
O	O	RBC	no
O	O	mice	no
O	O	,	no
O	O	but	no
O	O	the	no
O	O	LST	no
O	O	mice	no
O	O	did	no
O	O	not	no
O	O	develop	no
O	O	sensitization	no
O	O	.	no

O	O	the	no
O	O	fourth	no
O	O	group	yes
O	O	served	no
O	O	as	yes
O	O	control	no
O	O	and	yes
O	O	received	no
O	O	an	no
O	O	equivalent	no
O	O	volume	no
O	O	of	yes
O	O	an	no
O	O	isocaloric	no
O	O	solution	yes
O	O	of	yes
B-drug	B-drug	dextrose	yes
O	O	.	no

O	O	When	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug_n	B-drug_n	picrotoxin	yes
O	O	is	yes
O	O	minimized	no
O	O	to	no
O	O	0.5	yes
O	O	mg/kg	no
O	O	such	no
O	O	an	no
O	O	effect	no
O	O	is	yes
O	O	not	no
O	O	observed	no
O	O	.	no

O	O	They	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	,	no
O	O	particularly	no
O	O	if	no
O	O	renal	no
O	O	function	no
O	O	is	yes
O	O	impaired	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	monitoring	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	should	no
O	O	be	no
O	O	increased	no
O	O	at	yes
O	O	the	no
O	O	outset	no
O	O	of	yes
O	O	such	no
O	O	combination	yes
O	O	drug	yes
O	O	treatment	no
O	O	.	no

O	O	Dose-response	no
O	O	curves	no
O	O	(	no
O	O	derived	yes
O	O	from	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	using	no
O	O	the	no
O	O	tablets	yes
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	pure	yes
O	O	powders	no
O	O	)	no
O	O	showed	no
O	O	that	no
B-drug	B-drug	tripelennamine	yes
O	O	was	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	inhibitory	yes
O	O	activity	yes
O	O	,	no
O	O	which	no
O	O	was	no
O	O	partially	no
O	O	antagonized	no
O	O	by	no
B-drug	B-drug	pentazocine	yes
O	O	.	no

O	O	When	no
B-brand	B-brand	CANCIDAS	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
O	O	inducers	no
O	O	of	yes
O	O	drug	yes
O	O	clearance	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	efavirenz	yes
O	O	,	no
B-drug	B-drug	nevirapine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	use	no
O	O	of	yes
O	O	a	yes
O	O	daily	no
O	O	dose	no
O	O	of	yes
O	O	70	yes
O	O	mg	yes
O	O	of	yes
B-brand	B-brand	CANCIDAS	yes
O	O	should	no
O	O	be	no
O	O	considered	no

B-group	B-group	Antidiabetics	no
O	O	:	no
O	O	Because	no
B-group	B-group	corticosteroids	no
O	O	may	no
O	O	increase	no
O	O	blood	yes
O	O	glucose	yes
O	O	concentrations	no
O	O	,	no
O	O	dosage	no
O	O	adjustments	no
O	O	of	yes
B-group	B-group	antidiabetic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

B-drug	B-drug	Sulfapyridine	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	:	no
O	O	-	yes
B-drug	B-drug	Acetaminophen	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Tylenol	yes
O	O	)	no
O	O	(	no
O	O	with	yes
O	O	long-term	no
O	O	,	no
O	O	high-dose	no
O	O	use	no
O	O	)	no
O	O	or	no

O	O	Patients	no
O	O	receiving	no
B-group	B-group	beta-blockers	no
O	O	should	no
O	O	be	no
O	O	warned	no
O	O	of	yes
O	O	this	no
O	O	potential	no
O	O	hazard	no
O	O	.	no

B-drug	B-drug	Diltiazem	yes
O	O	is	yes
O	O	both	no
O	O	a	yes
O	O	substrate	yes
O	O	and	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P-450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	Recommendations	no
O	O	were	no
O	O	to	no
O	O	avoid	no
O	O	administration	no
O	O	of	yes
O	O	diffusible	no
O	B-group	anti-helminthic	no
O	O	treatment	no
O	O	during	no
O	O	the	no
O	O	cure	no
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	improve	no
O	O	the	no
O	O	general	no
O	O	conditions	no
O	O	of	yes
O	O	patients	no
O	O	before	no
O	O	the	no
O	O	cure	no
O	O	of	yes
B-drug	B-drug	melarsoprol	yes
O	O	.	no

B-group	B-group	Estrogen-containing	no
O	O	therapies	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
B-brand	B-brand	ARIMIDEX	yes
O	O	as	yes
O	O	they	no
O	O	may	no
O	O	diminish	no
O	O	its	no
O	O	pharmacologic	no
O	O	action	no
O	O	.	no

O	O	If	no
B-brand	B-brand	CEFOTAN	yes
O	O	and	yes
O	O	an	no
B-group	B-group	aminoglycoside	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	,	no
O	O	because	no
O	O	nephrotoxicity	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	Coagulation	yes
O	O	parameters	no
O	O	should	no
O	O	be	no
O	O	tested	no
O	O	more	no
O	O	frequently	no
O	O	and	yes
O	O	monitored	no
O	O	regularly	no
O	O	during	no
O	O	simultaneous	no
O	O	administration	no
O	O	of	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	may	no
O	O	affect	no
O	O	the	no
O	O	blood	yes
O	O	coagulation	yes
O	O	system	yes
O	O	or	no
O	O	the	no
O	O	thrombocyte	no
O	O	function	no
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	curve	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	(	no
O	O	AUC	no
O	O	(	no
O	O	ss	yes
O	O	)	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	by	no
O	O	2.93-fold	no
O	O	and	yes
O	O	the	no
O	O	AUC	no
O	O	(	no
O	O	ss	yes
O	O	)	no
O	O	of	yes
B-drug_n	B-drug_n	25-O-desacetylrifabutin	no
O	O	by	no
O	O	13.3-fold	no
O	O	.	no

O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Exjade	yes
O	O	and	yes
B-drug	B-drug	aluminum-containing	no
B-group	B-group	antacid	no
I-group	I-group	preparations	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

O	O	Clinical	no
O	O	experience	no
O	O	in	yes
O	O	the	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
O	O	ECT	no
O	O	and	yes
B-group	B-group	antidepressant	no
I-group	I-group	drugs	no
O	O	is	yes
O	O	limited	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	Interaction	no
O	O	between	yes
B-drug	B-drug	amprenavir	yes
O	O	and	yes
B-drug	B-drug	rifabutin	yes
O	O	or	no
B-drug	B-drug	rifampin	yes
O	O	in	yes
O	O	healthy	no
O	O	males	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	we	no
O	O	investigated	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	biocytin	no
O	O	inclusion	no
O	O	on	no
O	B-group	opioid	no
O	O	responses	no
O	O	and	yes
O	O	other	no
O	O	membrane	yes
O	O	properties	no
O	O	during	no
O	O	whole-cell	no
O	O	,	no
O	O	tight	no
O	O	seal	no
O	O	recordings	no
O	O	of	yes
O	O	these	no
O	O	neurons	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	May	no
O	O	decrease	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	ampicillin	yes
O	O	resulting	no
O	O	in	yes
O	O	increased	no
O	O	blood	yes
O	O	levels	no
O	O	and/or	no
B-drug	B-drug	ampicillin	yes
O	O	toxicity	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	cardiovascular	no
O	O	effects	no
O	O	of	yes
B-group	O	adreneric	no
I-group	O	agents	yes
O	O	.	no

O	O	4	yes
O	O	.	no

O	O	Many	no
O	O	drugs	no
O	O	used	no
O	O	in	yes
O	O	dentistry	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
O	O	these	no
O	O	medications	no
O	O	.	no

B-drug	B-drug	Fluvastatin	yes
O	O	is	yes
O	O	the	no
O	O	first	no
O	B-group	synthetic	yes
O	I-group	3-hydroxy-3-methylglutaryl	no
O	I-group	coenzyme	yes
O	I-group	A	yes
O	I-group	(	no
B-group	I-group	HMGCoA	no
I-group	I-group	)	no
I-group	I-group	reductase	no
I-group	I-group	inhibitor	yes
O	O	to	no
O	O	be	no
O	O	approved	no
O	O	for	yes
O	O	clinical	no
O	O	use	no
O	O	,	no
O	O	and	yes
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	extensively	no
O	O	in	yes
O	O	humans	no
O	O	since	no
O	O	1986	no
O	O	.	no

O	O	Endogenous	no
O	O	respiration	no
O	O	was	no
O	O	unaffected	no
O	O	by	no
O	O	the	no
O	O	drug	yes
O	O	at	yes
O	O	a	yes
O	O	concentration	no
O	O	as	yes
O	O	high	yes
O	O	as	yes
O	O	100	yes
O	O	mug/ml	no
O	O	,	no
O	O	whereas	no
O	O	exogenous	no
O	O	respiration	no
O	O	was	no
O	O	markedly	no
O	O	sensitive	no
O	O	and	yes
O	O	inhibited	no
O	O	to	no
O	O	an	no
O	O	extent	no
O	O	of	yes
O	O	85	no
O	O	%	no
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	Anti-Inflammatory	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	to	no
O	O	normal	yes
O	O	volunteers	no
O	O	receiving	no
B-drug	B-drug	indomethacin	yes
O	O	decreased	no
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	.	no

O	B-group	Analgesic/anti-inflammatory	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	acetaminophen	yes
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	,	no
B-drug	B-drug	codeine	yes
O	O	and	yes
B-drug	B-drug	codeine	yes
O	O	combinations	no
O	O	,	no
B-drug	B-drug	ibuprofen	yes
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	)	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	induce	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	rifabutin	yes
O	O	)	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	efavirenz	yes
O	O	resulting	no
O	O	in	yes
O	O	lowered	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	increases	no
O	O	the	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentration	no
O	O	by	no
O	O	70	yes
O	O	%	no
O	O	after	no
O	O	one	no
O	O	day	no
O	O	.	no

B-drug	B-drug	Haloperidol	yes
O	O	reduced	yes
O	O	or	no
O	O	eliminated	no
O	O	the	no
O	O	increases	no
O	O	in	yes
O	O	FI	no
O	O	responding	no
O	O	produced	no
O	O	by	no
O	O	intermediate	yes
O	O	doses	no
O	O	of	yes
O	O	either	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	or	no
B-drug_n	B-drug_n	PCP	yes
O	O	in	yes
O	O	pigeons	no
O	O	,	no
O	O	but	no
O	O	did	no
O	O	not	no
O	O	antagonize	no
O	O	the	no
O	O	decreases	no
O	O	in	yes
O	O	FI	no
O	O	or	no
O	O	FR	no
O	O	responding	no
O	O	produced	no
O	O	by	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug_n	O	PCP	yes
O	O	or	no
O	O	either	no
O	O	stereoisomer	no
O	O	of	yes
B-drug_n	B-drug_n	NANM	no
O	O	.	no

B-brand	B-brand	WelChol	yes
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	several	no
O	O	human	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	in	yes
O	O	which	no
O	O	it	no
O	O	was	no
O	O	administered	no
O	O	with	yes
O	O	a	yes
O	O	meal	no
O	O	and	yes
O	O	the	no
O	O	test	yes
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Propoxyphene	yes
O	O	:	no
O	O	In	yes
O	O	cases	no
O	O	of	yes
B-drug	B-drug	propoxyphene	yes
O	O	overdosage	no
O	O	,	no
B-drug	B-group	amphetamine	yes
O	O	CNS	no
O	O	stimulation	no
O	O	is	yes
O	O	potentiated	no
O	O	and	yes
O	O	fatal	no
O	O	convulsions	no
O	O	can	no
O	O	occur	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	for	yes
B-brand	B-brand	COLAZAL	yes
O	O	,	no
O	O	however	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	orally	no
O	O	administered	no
B-group	B-group	antibiotics	no
O	O	could	no
O	O	,	no
O	O	theoretically	no
O	O	,	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	release	yes
O	O	of	yes
B-drug	B-drug	mesalamine	yes
O	O	in	yes
O	O	the	no
O	O	colon	no
O	O	.	no

O	O	T3	yes
O	O	resin	yes
O	O	uptake	no
O	O	is	yes
O	O	decreased	no
O	O	,	no
O	O	reflecting	no
O	O	the	no
O	O	elevated	no
O	O	TBG	no
O	O	.	no

O	O	Local	no
O	O	and	yes
O	O	some	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	antiarrhythmic	no
I-group	I-group	agents	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	interfere	no
O	O	with	yes
O	O	neuromuscular	no
O	O	transmission	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	,	no
O	O	if	no
O	O	at	yes
O	O	all	yes
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	myasthenia	no
O	O	gravis	no
O	O	;	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	not	no
O	O	clear	no
O	O	.	no

O	O	If	no
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	is	yes
O	O	required	no
O	O	to	no
O	O	treat	no
O	O	Pneumocystis	no
O	O	carinii	no
O	O	pneumonia	no
O	O	,	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	HIVID	yes
O	O	should	no
O	O	be	no
O	O	interrupted	no
O	O	.	no

O	O	Both	no
B-drug_n	B-drug_n	ibogaine	no
O	O	and	yes
B-drug_n	B-drug_n	18-MC	no
O	O	block	yes
B-drug	B-drug	morphine-induced	no
O	O	and	yes
B-drug	B-drug	nicotine-induced	no
I-drug	O	dopamine	yes
O	O	release	yes
O	O	in	yes
O	O	the	no
O	O	nucleus	no
O	O	accumbens	no
O	O	;	no

B-group	B-group	Tetracyclines	no
O	O	:	no
O	O	Since	no
O	O	both	no
B-drug	B-drug	acitretin	yes
O	O	and	yes
B-group	B-group	tetracyclines	no
O	O	can	no
O	O	cause	no
O	O	increased	no
O	O	intracranial	no
O	O	pressure	no
O	O	,	no
O	O	their	no
O	O	combined	no
O	O	use	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	buspirone	yes
O	O	may	no
O	O	displace	no
O	O	less	no
O	O	firmly	no
O	O	bound	no
O	O	drugs	no
O	O	like	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Death	no
O	O	in	yes
B-drug	B-drug	amphetamine	yes
O	O	users	no
O	O	:	no
O	O	causes	no
O	O	and	yes
O	O	rates	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	products	no
O	O	.	no

O	O	The	no
O	O	goal	no
O	O	of	yes
O	O	enhancing	no
O	O	selective	no
O	O	tumor	yes
O	O	cell	yes
O	O	killing	no
O	O	relative	no
O	O	to	no
O	O	the	no
O	O	normal	yes
O	O	cells	yes
O	O	that	no
O	O	are	no
O	O	dose	no
O	O	limiting	no
O	O	may	no
O	O	be	no
O	O	achieved	no
O	O	either	no
O	O	by	no
O	O	overcoming	no
O	O	tumor	yes
O	O	cell	yes
O	O	resistance	no
O	O	or	no
O	O	by	no
O	O	protecting	no
O	O	normal	yes
O	O	cells	yes
O	O	.	no

O	O	this	no
O	O	phenomenon	no
O	O	was	no
O	O	not	no
O	O	observed	no
O	O	in	yes
O	O	North	no
O	O	American	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	reduces	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	quinidine	yes
O	O	and	yes
O	O	may	no
O	O	enhance	no
O	O	its	no
O	O	effect	no
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hemorrhage	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	Fondaparinux	yes
O	O	therapy	no
O	O	.	no

O	O	The	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	lymecycline	yes
O	O	may	no
O	O	be	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	simultaneous	no
O	O	administration	no
O	O	of	yes
O	O	indigestion	no
O	O	remedies	no
O	O	,	no
B-drug	B-drug	iron	yes
O	O	or	no
B-drug	B-drug	zinc	yes
O	O	supplements	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
B-drug	B-drug	Sildenafil	yes
O	O	has	no
O	O	demonstrated	no
O	O	effectiveness	no
O	O	in	yes
O	O	men	no
O	O	with	yes
O	O	erectile	no
O	O	dysfunction	no
O	O	associated	no
O	O	with	yes
O	O	prostatectomy	no
O	O	,	no
O	O	radiation	no
O	O	therapy	no
O	O	,	no
O	O	diabetes	no
O	O	mellitus	no
O	O	,	no
O	O	certain	no
O	O	neurologic	no
O	O	disorders	no
O	O	,	no
O	O	and	yes
O	O	drug	yes
O	O	therapy	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	[	no
B-group	B-group	SSRIs	no
O	O	]	no
O	O	)	no
O	O	.	no

B-group	B-group	Beta-Blockers	no
O	O	:	no
O	O	In	yes
O	O	controlled	no
O	O	clinical	no
O	O	studies	no
O	O	,	no
B-group	B-group	adrenergic	no
I-group	I-group	beta-receptor	no
I-group	I-group	blockers	no
O	O	have	no
O	O	been	no
O	O	frequently	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	.	no

B-drug	B-drug	Metoprolol	yes
O	O	-	yes
O	O	Administration	no
O	O	of	yes
O	O	20	yes
O	O	mg/day	no
B-brand	B-brand	LEXAPRO	yes
O	O	for	yes
O	O	21	yes
O	O	days	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	50	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	and	yes
O	O	82	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocker	no
B-drug	B-drug	metoprolol	yes
O	O	(	no
O	O	given	no
O	O	in	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	100	yes
O	O	mg	yes
O	O	)	no
O	O	.	no

B-group	B-group	Histamine	yes
I-group	I-group	H2-receptor	no
I-group	I-group	antagonists	no
O	O	:	no
B-group	B-group	Histamine	yes
I-group	I-group	H2-receptor	no
I-group	I-group	antagonists	no
O	O	appear	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	.	no

O	O	(	no
O	O	200	yes
O	O	mg	yes
O	O	Q12h	no
O	O	)	no

O	O	Usually	no
O	O	,	no
O	O	such	no
O	O	inactivation	no
O	O	of	yes
O	O	the	no
B-group	B-group	aminoglycoside	no
O	O	is	yes
O	O	clinically	no
O	O	significant	no
O	O	only	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	severely	no
O	O	impaired	no
O	O	renal	no
O	O	function..	no

O	O	Liver	yes
O	O	Function	no
O	O	Tests	no
O	O	:	no
O	O	Elevations	no
O	O	of	yes
O	O	AST	no
O	O	(	no
O	O	SGOT	no
O	O	)	no
O	O	,	no
O	O	ALT	no
O	O	(	no
O	O	SGPT	no
O	O	)	no
O	O	or	no
O	O	LDH	no
O	O	were	no
O	O	experienced	no
O	O	by	no
O	O	approximately	no
O	O	1	yes
O	O	in	yes
O	O	3	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-brand	Soriatane	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Robinul	yes
O	O	Injection	yes
O	O	and	yes
B-drug	B-drug	potassium	yes
I-drug	I-drug	chloride	yes
O	O	in	yes
O	O	a	yes
O	O	wax	yes
O	O	matrix	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	severity	no
O	O	of	yes
B-drug	O	potassium	yes
I-drug	O	chloride-induced	no
O	O	gastrointestinal	no
O	O	lesions	no
O	O	as	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	a	yes
O	O	slower	no
O	O	gastrointestinal	no
O	O	transit	no
O	O	time	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	significant	no
O	O	effects	no
O	O	on	no
B-drug	B-drug	cefdinir	yes
O	O	pharmacokinetics	no
O	O	if	no
O	O	the	no
B-group	B-group	antacid	no
O	O	is	yes
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	2	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	cefdinir	yes
O	O	.	no

B-drug	B-drug	Acarbose	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	change	no
O	O	the	no
O	O	bioavailabillty	no
B-drug	B-drug	digoxin	yes
O	O	when	no
O	O	they	no
O	O	are	no
O	O	co-administered	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	require	no
B-drug	B-drug	digoxin	yes
O	O	dose	no
O	O	adjustment	no
O	O	.	no

O	O	In	yes
O	O	such	no
O	O	cases	no
O	O	,	no
O	O	the	no
O	O	unbound	no
O	O	(	no
O	O	free	yes
O	O	)	no
O	O	hormone	yes
O	O	should	no
O	O	be	no
O	O	measured	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Procainamide	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Pronestyl	yes
O	O	)	no
O	O	or	no

O	O	4	yes
O	O	microg	no
O	O	mL	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	galangin	no
O	O	(	no
O	O	12.5	yes
O	O	microg	no
O	O	mL	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	)	no
O	O	or	no
O	O	3,7-dihydroxyflavone	no
O	O	(	no
O	O	6.25	no
O	O	microg	no
O	O	mL	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	)	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
B-brand	B-brand	CELEBREX	yes
O	O	can	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	low	yes
O	O	dose	no
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	however	no
O	O	,	no
O	O	no	yes
O	O	deleterious	no
O	O	interactions	no
O	O	were	no
O	O	seen	no
O	O	when	no
B-brand	B-brand	ROMAZICON	yes
O	O	was	no
O	O	administered	no
O	O	after	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	O	inhalational	no
I-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	and	yes
B-group	O	muscle	no
I-group	O	relaxant	no
I-group	O	antagonists	no
O	O	administered	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
O	O	sedation	no
O	O	or	no
O	O	anesthesia	yes
O	O	.	no

B-group	B-group	Opioid	no
I-group	I-group	analgesics	no
O	O	Decreased	no
O	O	antinociceptive	no
O	O	action	no

O	O	Both	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-brand	B-brand	COREG	yes
O	O	slow	yes
O	O	AV	no
O	O	conduction	no
O	O	.	no

O	O	Patients	no
O	O	with	yes
B-drug	O	HACA	no
O	O	titers	no
O	O	may	no
O	O	have	no
O	O	allergic	no
O	O	or	no
O	O	hypersensitivity	no
O	O	reactions	no
O	O	when	no
O	O	treated	no
O	O	with	yes
O	O	other	no
O	B-group	diagnostic	yes
O	O	or	no
O	B-group	therapeutic	no
O	I-group	monoclonal	yes
O	I-group	antibodies	no
O	O	.	no

O	O	Acute	no
O	O	dosing	no
O	O	with	yes
B-drug	B-drug	clozapine	yes
O	O	failed	no
O	O	to	no
O	O	alter	no
O	O	the	no
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	PCP	yes
O	O	in	yes
O	O	either	no
O	O	procedure	no
O	O	even	no
O	O	when	no
O	O	tested	no
O	O	up	no
O	O	to	no
O	O	doses	no
O	O	that	no
O	O	produced	no
O	O	pharmacological	no
O	O	effects	no
O	O	alone	no
O	O	.	no

O	O	Pharmacodynamic	no
O	O	Interactions	no
O	O	:	no
O	O	The	no
O	O	CNS-depressant	no
O	O	action	no
O	O	of	yes
O	O	the	no
B-group	B-group	benzodiazepine	yes
I-group	I-group	class	no
O	O	of	yes
O	O	drugs	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	nonbarbiturate	no
I-group	I-group	hypnotics	no
O	O	,	no
B-group	B-group	antianxiety	no
I-group	I-group	agents	yes
O	O	,	no
O	O	the	no
B-group	O	phenothiazines	no
O	O	,	no
B-drug	O	thioxanthene	no
O	O	and	yes
B-drug	B-group	butyrophenone	no
O	I-group	classes	no
O	I-group	of	yes
B-group	I-group	antipsychotic	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	and	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	and	yes
O	O	by	no
O	O	other	no
B-group	B-group	anticonvulsant	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Massive	no
O	O	seizures	no
O	O	may	no
O	O	be	no
O	O	encountered	no
O	O	with	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

O	O	This	no
O	O	article	no
O	O	reviews	no
O	O	the	no
O	O	impact	no
O	O	of	yes
O	O	renal	no
O	O	disease	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	cardiovascular	no
O	O	drugs	no
O	O	and	yes
O	O	identifies	no
O	O	clinically	no
O	O	important	no
O	O	interactions	no
O	O	between	yes
O	O	these	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	commonly	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	chronic	no
O	O	renal	no
O	O	disease	no
O	O	.	no

O	O	In	yes
O	O	diabetic	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	metabolic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	androgens	no
O	O	may	no
O	O	decrease	no
O	O	blood	yes
O	O	glucose	yes
O	O	and	yes
O	O	therefore	no
O	O	,	no
B-drug	B-drug	insulin	yes
O	O	requirements	no
O	O	.	no

O	O	Some	no
O	O	early	no
O	O	studies	no
O	O	indicated	no
O	O	that	no
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	might	no
O	O	have	no
O	O	detrimental	no
O	O	effects	no
O	O	in	yes
O	O	those	no
O	O	groups	no
O	O	.	no

O	O	Exacerbation	no
O	O	or	no
O	O	the	no
O	O	initial	no
O	O	presentation	no
O	O	of	yes
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	autoimmune	no
O	O	and	yes
O	O	inflammatory	no
O	O	disorders	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	following	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	interferon-alfa	no
O	O	and	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	,	no
O	O	including	no
O	O	crescentic	no
O	O	IgA	no
O	O	glomerulonephritis	no
O	O	,	no
O	O	oculo-bulbar	no
O	O	myasthenia	no
O	O	gravis	no
O	O	,	no
O	O	inflammatory	no
O	O	arthritis	no
O	O	,	no
O	O	thyroiditis	no
O	O	,	no
O	O	bullous	no
O	O	pemphigoid	no
O	O	,	no
O	O	and	yes
O	O	Stevens-Johnson	no
O	O	syndrome	no
O	O	.	no

O	O	3	yes
O	O	.	no

O	O	In	yes
O	O	female	no
O	O	rats	no
O	O	,	no
B-drug	B-drug	fulvestrant	yes
O	O	administered	no
O	O	at	yes
O	O	doses	no
O	O	0.01	no
O	O	mg/kg/day	no
O	O	(	no
O	O	approximately	no
O	O	one-hundredth	no
O	O	of	yes
O	O	the	no
O	O	human	yes
O	O	recommended	no
O	O	dose	no
O	O	based	no
O	O	on	no
O	O	body	no
O	O	surface	yes
O	O	area	no
O	O	[	no
O	O	BSA	no
O	O	]	no
O	O	,	no
O	O	for	yes
O	O	2	yes
O	O	weeks	no
O	O	prior	no
O	O	to	no
O	O	and	yes
O	O	for	yes
O	O	1	yes
O	O	week	no
O	O	following	no
O	O	mating	no
O	O	,	no
O	O	caused	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	fertility	no
O	O	and	yes
O	O	embryonic	no
O	O	survival	no
O	O	.	no

I-drug	I-drug	indinavir	yes
O	O	concentration	no

B-brand	B-brand	DOXIL	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	conventional	no
O	O	formulation	no
O	O	of	yes
B-drug	B-drug	doxorubicin	yes
I-drug	I-drug	HCl	yes
O	O	.	no

B-drug	B-drug	Ethosuximide	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ethosuximide	yes
O	O	.	no

O	O	In	yes
O	O	situations	no
O	O	in	yes
O	O	which	no
O	O	concurrent	no
O	O	therapy	no
O	O	is	yes
O	O	necessary	no
O	O	,	no
O	O	careful	no
O	O	patient	no
O	O	monitoring	no
O	O	is	yes
O	O	essential	yes
O	O	.	no

O	O	This	no
O	O	interference	no
O	O	has	no
O	O	resulted	no
O	O	in	yes
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	half-life	no
O	O	and	yes
O	O	AUC	no
O	O	.	no

O	O	suppression	no
O	O	of	yes
O	O	midcycle	no
O	O	gonadotropin	yes
O	O	peaks	no
O	O	;	no

O	O	However	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	CELEBREX	yes
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	since	no
O	O	these	no
O	O	patients	no
O	O	are	no
O	O	at	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	complications	no
O	O	.	no

B-drug	B-drug	Gentamicin	yes
O	O	-	yes
B-drug	B-drug	Methionine	yes
O	O	may	no
O	O	protect	no
O	O	against	yes
O	O	the	no
O	O	ototoxic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	gentamicin	yes
O	O	.	no

B-drug	B-drug	Atracurium	yes
O	O	was	no
O	O	again	no
O	O	given	no
O	O	by	no
O	O	infusion	no
O	O	to	no
O	O	maintain	no
O	O	40	yes
O	O	%	no
O	O	twitch	no
O	O	for	yes
O	O	a	yes
O	O	second	no
O	O	hour	yes
O	O	,	no
O	O	then	no
O	O	2	yes
O	O	mg	yes
B-drug	B-drug	gentamycin/kg	no
O	O	bwt	no
O	O	were	no
O	O	given	no
O	O	i.v	no
O	O	.	no

O	O	conversely	no
O	O	,	no
O	B-drug	diethylpropion	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
B-drug	B-drug	a-methyldopa	no
O	O	)	no
O	O	.	no

O	O	Co-treatment	no
O	O	with	yes
O	O	the	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitor	yes
B-drug	B-drug	ketoconazole	yes
O	O	increases	no
B-drug	B-drug	erlotinib	yes
O	O	AUC	no
O	O	by	no
O	O	2/3	no
O	O	.	no

B-group	B-group	Platelet	yes
I-group	I-group	inhibitors	no
O	O	:	no
O	O	Drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	dextran	yes
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	ibuprofen	yes
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	,	no
B-drug	B-drug	dipyridamole	yes
O	O	,	no
B-drug	B-drug	hydroxychloroquine	yes
O	O	and	yes
O	O	others	no
O	O	that	no
O	O	interfere	no
O	O	with	yes
O	O	platelet-aggregation	no
O	O	reactions	no
O	O	(	no
O	O	the	no
O	O	main	no
O	O	hemostatic	no
O	O	defense	no
O	O	of	yes
O	O	heparinized	no
O	O	patients	no
O	O	)	no
O	O	may	no
O	O	induce	no
O	O	bleeding	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	heparin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	the	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	with	yes
B-drug	B-drug	apraclonidine	yes
O	O	can	no
O	O	lead	no
O	O	to	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	IOP	no
O	O	lowering	no
O	O	effect	no
O	O	.	no

O	O	The	no
O	O	approach	no
O	O	is	yes
O	O	applicable	no
O	O	across	no
O	O	a	yes
O	O	wide	no
O	O	variety	no
O	O	of	yes
O	O	settings	no
O	O	commonly	no
O	O	associated	no
O	O	with	yes
O	O	joint	no
O	O	action	no
O	O	data	no
O	O	,	no
O	O	including	no
O	O	continuous	no
O	O	and	yes
O	O	discrete	no
O	O	responses	no
O	O	,	no
O	O	alternative	no
O	O	error	no
O	O	structures	no
O	O	,	no
O	O	and	yes
O	O	nonzero	no
O	O	background	no
O	O	response	no
O	O	.	no

O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-drug	B-drug	Ibuprofen	yes
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
O	O	probably	no
O	O	reduces	no
O	O	the	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	based	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	rabbit	yes
O	O	kidney	yes
O	O	slices	no
O	O	.	no

O	O	Inducers	no
O	O	of	yes
O	O	CYP3A4	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	additive	no
O	O	or	no
O	O	synergistic	no
O	O	depressant	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	SA	yes
O	O	and	yes
O	O	AV	no
O	O	nodes	no
O	O	,	no
O	O	however	no
O	O	,	no
B-brand	B-brand	Adenocard	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	Food	no
O	O	:	no
B-drug	B-drug	Isoniazid	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	food	no
O	O	.	no

O	O	Postoperatively	no
O	O	,	no
O	O	45	yes
O	O	patients	no
O	O	were	no
O	O	randomly	no
O	O	assigned	no
O	O	in	yes
O	O	a	yes
O	O	double-blind	no
O	O	fashion	no
O	O	to	no
O	O	receive	no
B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	(	no
O	O	4	yes
O	O	mg	yes
O	O	)	no
O	O	or	no
O	O	placebo	no
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	0.15	yes
O	O	mg/kg	no
O	O	)	no
O	O	or	no
O	O	to	no
O	O	receive	no
O	O	oral	yes
O	O	and	yes
O	O	intravenous	yes
O	O	placebo	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	available	no
O	O	.	no

O	O	An	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	benign	no
O	O	ovarian	no
O	O	granulosa	no
O	O	cell	yes
O	O	tumors	no
O	O	and	yes
O	O	testicular	no
O	O	Leydig	no
O	O	cell	yes
O	O	tumors	no
O	O	was	no
O	O	evident	no
O	O	,	no
O	O	in	yes
O	O	females	no
O	O	dosed	no
O	O	at	yes
O	O	10	yes
O	O	mg/rat/15	no
O	O	days	no
O	O	and	yes
O	O	males	no
O	O	dosed	no
O	O	at	yes
O	O	15	yes
O	O	mg/rat/30	no
O	O	days	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Behavioral	no
O	O	responses	no
O	O	to	no
O	O	repeated	no
B-drug	B-drug	cocaine	yes
O	O	exposure	yes
O	O	in	yes
O	O	mice	no
O	O	selectively	no
O	O	bred	no
O	O	for	yes
O	O	differential	no
O	O	sensitivity	no
O	O	to	no
B-drug	B-drug	pentobarbital	yes
O	O	.	no

O	O	Such	no
O	O	individuals	no
O	O	are	no
O	O	referred	no
O	O	to	no
O	O	as	yes
O	O	poor	no
O	O	metabolizers	no
O	O	of	yes
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	debrisoquin	yes
O	O	,	no
B-drug	B-drug	dextromethorphan	yes
O	O	,	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	clozapine	yes
O	O	.	no

O	O	Steady-state	no
O	O	plasma	yes
B-drug	B-drug	felbamate	yes
O	O	concentrations	no
O	O	were	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	29	yes
O	O	%	no
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	mean	no
O	O	concentrations	no
O	O	of	yes
O	O	a	yes
O	O	group	yes
O	O	of	yes
O	O	newly	no
O	O	diagnosed	no
O	O	subjects	no
O	O	with	yes
O	O	epilepsy	no
O	O	also	no
O	O	receiving	no
O	O	2400	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	a	yes
O	O	day	no
O	O	.	no

B-drug	B-drug	Cevimeline	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	individuals	no
O	O	known	no
O	O	or	no
O	O	suspected	no
O	O	to	no
O	O	be	no
O	O	deficient	no
O	O	in	yes
O	O	CYP2D6	no
O	O	activity	yes
O	O	,	no
O	O	based	no
O	O	on	no
O	O	previous	no
O	O	experience	no
O	O	,	no
O	O	as	yes
O	O	they	no
O	O	may	no
O	O	be	no
O	O	at	yes
O	O	a	yes
O	O	higher	no
O	O	risk	no
O	O	of	yes
O	O	adverse	no
O	O	events	no
O	O	.	no

O	O	see	no
O	O	DOSAGE	no
O	O	AND	yes
O	O	ADMINISTRATION	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Dasatinib	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	are	no
O	O	minimally	no
O	O	excreted	no
O	O	via	no
O	O	the	no
O	O	kidney	yes
O	O	.	no

O	O	Other	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	include	no
O	O	,	no
O	O	but	no
O	O	are	no
O	O	not	no
O	O	limited	no
O	O	to	no
O	O	,	no
B-drug	B-drug	rifabutin	yes
O	O	,	no
B-drug	B-drug	rifapentine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	and	yes
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	.	no

O	O	.	no

O	O	Co-medications	no
O	O	that	no
O	O	induce	no
O	O	CYP	no
O	O	3A4	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	rifampicin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	or	no
O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	wort	yes
O	O	)	no
O	O	may	no
O	O	significantly	no
O	O	decrease	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	exemestane	yes
O	O	.	no

O	O	Among	no
O	O	the	no
O	O	risk	no
O	O	factors	no
O	O	studied	no
O	O	,	no
O	O	two	no
O	O	appear	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	ARE	no
O	O	:	no
O	O	the	no
O	O	prescription	no
O	O	of	yes
B-drug	B-drug	thiabendazole	yes
O	O	to	no
O	O	treat	no
O	O	strongyloidiasis	no
O	O	during	no
O	O	the	no
B-drug	B-drug	melarsoprol	yes
O	O	cure	no
O	O	and	yes
O	O	the	no
O	O	bad	no
O	O	general	no
O	O	clinical	no
O	O	conditions	no
O	O	of	yes
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-group	O	nonbenzodiazepine	no
I-group	O	agonists	no
O	O	at	yes
B-group	O	benzodiazepine	yes
O	O	receptors	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	zopiclone	yes
O	O	,	no
B-group	O	triazolopyridazines	no
O	O	and	yes
O	O	others	no
O	O	,	no
O	O	are	no
O	O	also	no
O	O	blocked	no
O	O	by	no
B-brand	B-brand	ROMAZICON	yes
O	O	.	no

O	O	.	no

O	O	When	no
O	O	administered	no
O	O	with	yes
O	O	food	no
O	O	or	no
O	O	milk	yes
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	more	no
O	O	rapid	no
O	O	absorption	no
O	O	;	no

O	O	Read	no
O	O	circulars	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparations	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

I-drug	I-drug	indinavir	yes
O	O	concentration	no

O	O	=	no
O	O	decrease	no

O	O	No	yes
O	O	change	no
O	O	in	yes
O	O	dose	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	B-drug	INH	yes
O	O	(	no
B-drug	B-drug	Isoniazid	yes
O	O	)	no
O	O	is	yes
O	O	also	no
O	O	reported	no
O	O	to	no
O	O	affect	no
B-drug	B-drug	ketoconazole	yes
O	O	concentrations	no
O	O	adversely	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	demonstrated	no
O	O	that	no
O	O	the	no
O	O	plasma	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	des-ciclesonide	no
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	warfarin	yes
O	O	or	no
B-drug	B-drug	salicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	indicating	no
O	O	no	yes
O	O	potential	no
O	O	for	yes
O	O	protein	yes
O	O	binding-based	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	identified	no
O	O	involving	no
B-brand	B-brand	NIZORAL	yes
O	O	Tablets	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	tablets	yes
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	an	no
O	O	increased	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	and	yes
O	O	a	yes
O	O	delay	no
O	O	in	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
O	O	its	no
O	O	acid	yes
O	O	metabolite	yes
O	O	.	no

O	O	Cmax	no
O	O	and	yes
B-drug	O	t1/2	no
O	O	were	no
O	O	increased	no
O	O	1.4-fold	no
O	O	and	yes
O	O	1.3-fold	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	nisoldipine	yes
O	O	and	yes
B-group	B-group	beta-blockers	no
O	O	(	no
B-drug	B-drug	atenolol	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	were	no
O	O	variable	no
O	O	and	yes
O	O	not	no
O	O	significant	no
O	O	.	no

O	B-drug	Theophylline-related	no
O	O	adverse	no
O	O	effects	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	patients	no
O	O	when	no
B-drug	B-drug	theophylline	yes
O	O	and	yes
B-drug	B-drug	enoxacin	yes
O	O	were	no
O	O	coadministered	no
O	O	.	no

O	O	Certain	no
O	O	drugs	no
O	O	tend	no
O	O	to	no
O	O	produce	no
O	O	hyperglycemia	no
O	O	and	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	Example	no
B-group	O	inhibitors	no
O	O	include	no
B-group	B-group	azole	no
I-group	I-group	antifungals	no
O	O	,	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	diclofenac	yes
O	O	,	no
B-drug	B-drug	doxycycline	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	imatinib	yes
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	nicardipine	yes
O	O	,	no
B-drug	B-drug	propofol	yes
O	O	,	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	and	yes
B-drug	B-drug	midazolam	yes
O	O	on	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	,	no
B-drug	B-drug	metamizol	no
O	O	and	yes
B-drug	B-drug	indomethacin	yes
O	O	in	yes
O	O	mice	no
O	O	.	no

O	O	When	no
O	O	encountered	no
O	O	,	no
O	O	such	no
O	O	arrhythmias	no
O	O	may	no
O	O	respond	no
O	O	to	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	drug	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Cytochrome	no
O	O	P-450	no
O	O	inducers	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	induce	no
B-drug	B-drug	clonazepam	yes
O	O	metabolism	no
O	O	,	no
O	O	causing	no
O	O	an	no
O	O	approximately	no
O	O	30	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	clonazepam	yes
O	O	levels	no
O	O	.	no

O	O	Binding	no
O	O	to	no
O	O	plasma	yes
O	O	protein	yes
O	O	is	yes
O	O	not	no
O	O	significantly	no
O	O	altered	no
O	O	by	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	diphenylhydantoin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	phenylbutazone	yes
O	O	.	no

O	O	Immunogenicity/Re-exposure	no
O	O	:	no
O	O	In	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	,	no
B-brand	B-brand	Angiomax	yes
O	O	exhibited	no
O	O	no	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	response	no
O	O	against	yes
O	O	sera	no
O	O	from	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	HIT/HITTS	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	other	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	undesirable	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	FORADIL	yes
O	O	.	no

B-drug	B-drug	Doxylamine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	.	no

O	O	Rare	no
O	O	instances	no
O	O	of	yes
O	O	dyspnea	no
O	O	,	no
O	O	palpitation	no
O	O	,	no
O	O	chest	no
O	O	pain	yes
O	O	,	no
O	O	syncope	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	when	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	and	yes
B-drug	B-drug	enoxacin	yes
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	within	no
O	O	4	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	4	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	grepafloxacin	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	quinidine	yes
O	O	increases	no
B-drug	B-drug	quinidine	yes
O	O	serum	yes
O	O	concentration	no
O	O	by	no
O	O	33	no
O	O	%	no
O	O	after	no
O	O	two	no
O	O	days	no
O	O	.	no

O	O	If	no
B-group	B-group	antacid	no
O	O	therapy	no
O	O	is	yes
O	O	needed	no
O	O	,	no
O	O	the	no
B-group	O	antacid	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	or	no
O	O	2	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	SPRYCEL	yes
O	O	.	no

O	O	Although	no
O	O	17-hydroxy-corticosteroid	no
O	O	measurements	no
O	O	(	no
O	O	Porter-Silber	no
O	O	test	yes
O	O	)	no
O	O	do	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	artifactually	no
O	O	altered	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	naproxen	yes
O	O	be	no
O	O	temporarily	no
O	O	discontinued	no
O	O	72	no
O	O	hours	no
O	O	before	no
O	O	adrenal	no
O	O	function	no
O	O	tests	no
O	O	are	no
O	O	performed	no
O	O	if	no
O	O	the	no
O	O	Porter-Silber	no
O	O	test	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	used	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	,	no
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	drug	yes
O	O	metabolism	no
O	O	,	no
O	O	decreased	no
O	O	the	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	.	no

O	O	Drugs	no
O	O	Whose	no
O	O	Absorption	no
O	O	Can	no
O	O	Be	no
O	O	Affected	no
O	O	by	no
O	O	the	no
O	O	Level	no
O	O	of	yes
O	O	Acidity	no
O	O	in	yes
O	O	the	no
O	O	Stomach	no
O	O	:	no
O	O	Drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	itraconazole	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	dosing	no
O	O	with	yes
B-brand	B-brand	VIDEX	yes
O	O	.	no

O	O	Vaccinations	no
O	O	with	yes
O	O	attenuated	yes
O	O	live	yes
O	O	bacteria	no
O	O	should	no
O	O	therefore	no
O	O	be	no
O	O	completed	no
O	O	at	yes
O	O	least	no
O	O	3	yes
O	O	days	no
O	O	before	no
O	O	the	no
O	O	first	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Mefloquine	yes
O	O	.	no

O	O	Additional	no
O	O	reductions	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-brand	B-brand	FLOLAN	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	,	no
O	O	or	no
O	O	other	no
B-group	B-group	vasodilators	no
O	O	.	no

O	O	The	no
O	O	inhibitor	yes
O	O	,	no
O	O	on	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	promoted	no
O	O	significant	no
O	O	decrease	no
O	O	of	yes
O	O	nucleolin/C23	no
O	O	in	yes
O	O	NIH-3T3	no
O	O	cells	yes
O	O	during	no
O	O	serum	yes
O	O	deprivation	no
O	O	.	no

O	O	Candida	no
O	O	albicans	no
O	O	,	no
O	O	one	no
O	O	of	yes
O	O	the	no
O	O	pathogenic	no
O	O	species	no
O	O	,	no
O	O	was	no
O	O	totally	no
O	O	inhibited	no
O	O	at	yes
O	O	a	yes
O	O	concentration	no
O	O	of	yes
O	O	approximately	no
O	O	10	yes
O	O	mug/ml	no
O	O	.	no

O	O	certain	no
B-group	B-group	antibiotics	no
O	O	,	no
O	O	especially	no
O	O	the	no
B-group	B-group	aminoglycosides	no
O	O	and	yes
B-group	B-group	polymyxins	no
O	O	;	no

O	O	The	no
O	O	extent	no
O	O	to	no
O	O	which	no
B-group	B-group	SSRI-TCA	no
O	O	interactions	no
O	O	may	no
O	O	pose	no
O	O	clinical	no
O	O	problems	no
O	O	will	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	and	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRI	no
O	O	involved	no
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	was	no
O	O	increased	no
O	O	2.2-fold	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	.	no

B-drug	I-drug	Lopinavir	yes

O	O	Particular	no
O	O	caution	no
O	O	is	yes
O	O	necessary	no
O	O	when	no
O	O	using	no
B-brand	B-brand	ROMAZICON	yes
O	O	in	yes
O	O	cases	no
O	O	of	yes
O	O	mixed	yes
O	O	drug	yes
O	O	overdosage	no
O	O	since	no
O	O	the	no
O	O	toxic	no
O	O	effects	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	convulsions	no
O	O	and	yes
O	O	cardiac	no
O	O	dysrhythmias	no
O	O	)	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	taken	no
O	O	in	yes
O	O	overdose	no
O	O	(	no
O	O	especially	no
B-group	B-group	cyclic	yes
I-group	I-group	antidepressants	no
O	O	)	no
O	O	may	no
O	O	emerge	no
O	O	with	yes
O	O	the	no
O	O	reversal	no
O	O	of	yes
O	O	the	no
B-group	B-group	benzodiazepine	yes
O	O	effect	no
O	O	by	no
B-drug	B-drug	flumazenil	yes
O	O	.	no

O	O	The	no
O	O	second	no
O	O	response	no
O	O	is	yes
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	release	yes
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	from	no
O	O	nerves	no
O	O	and	yes
O	O	was	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	ouabain	yes
O	O	through	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	norepinephrine	yes
O	O	release	yes
O	O	,	no
O	O	whereas	no
O	O	the	no
O	O	first	no
O	O	response	no
O	O	was	no
O	O	not	no
O	O	due	no
O	O	to	no
O	O	the	no
B-drug	O	norepinephrine	yes
O	O	release	yes
O	O	but	no
O	O	presumably	no
O	O	to	no
O	O	a	yes
O	O	direct	no
O	O	action	no
O	O	on	no
O	O	smooth	no
O	O	muscle	no
O	O	cell	yes
O	O	and	yes
O	O	was	no
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	ouabain	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	contraceptives	no
O	O	and	yes
O	O	other	no
O	O	hormonalmethods	no
O	O	of	yes
O	O	birth	no
O	O	control	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	usedas	no
O	O	the	no
O	O	sole	no
O	O	method	yes
O	O	of	yes
O	O	contraception	no
O	O	inwomen	no
O	O	taking	no
B-drug	B-drug	nevirapine	yes
O	O	,	no
O	O	since	no
O	O	nevirapinemay	no
O	O	lower	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	thesemedications	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	such	no
O	O	drug	yes
O	O	interactions	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	dorzolamide	yes
O	O	.	no

O	I-drug	Human	yes
O	I-drug	growth	yes
O	I-drug	hormone	yes
O	O	-	yes
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	L-glutamine	yes
O	O	and	yes
O	B-drug	human	yes
O	I-drug	growth	yes
O	I-drug	hormone	yes
O	O	may	no
O	O	enhance	no
O	O	nutrient	no
O	O	absorption	no
O	O	in	yes
O	O	those	no
O	O	with	yes
O	O	severe	no
O	O	short	no
O	O	bowel	yes
O	O	syndrome	no
O	O	.	no

O	O	No	yes
O	O	effects	no
O	O	on	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	or	no
B-drug	B-drug	ketoconazole	yes
O	O	were	no
O	O	observed	no
O	O	.	no

B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	useful	no
O	O	in	yes
O	O	therapy	no
O	O	of	yes
O	O	human	yes
O	O	fungal	no
O	O	infections	no
O	O	because	no
O	O	it	no
O	O	is	yes
O	O	less	no
O	O	toxic	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	cyclosporine-induced	no
O	O	toxicity	no
O	O	,	no
O	O	possibly	no
O	O	due	no
O	O	to	no
O	O	decreased	no
O	O	synthesis	no
O	O	of	yes
O	O	renal	no
O	O	prostacyclin	yes
O	O	.	no

O	O	No	yes
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
O	O	other	no
B-group	B-group	NNRTIs	no
O	O	.	no

B-drug	B-drug	Nicotine	yes
O	O	:	no
B-drug	B-drug	Nicotine	yes
O	O	may	no
O	O	provoke	no
O	O	vasoconstriction	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	predisposing	no
O	O	to	no
O	O	a	yes
O	O	greater	no
O	O	ischemic	no
O	O	response	no
O	O	to	no
B-group	B-drug	ergot	yes
O	O	therapy	no
O	O	.	no

O	O	8	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	broadening	no
O	O	indications	no
O	O	for	yes
B-group	B-group	immunosuppressive	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	prolonged	no
O	O	survival	no
O	O	in	yes
O	O	conditions	no
O	O	for	yes
O	O	which	no
O	O	they	no
O	O	are	no
O	O	being	no
O	O	used	no
O	O	,	no
O	O	many	no
O	O	patients	no
O	O	on	no
O	O	immunosuppression	no
O	O	are	no
O	O	now	no
O	O	cared	no
O	O	for	yes
O	O	in	yes
O	O	the	no
O	O	community	no
O	O	or	no
O	O	seen	no
O	O	in	yes
O	O	non-specialist	no
O	O	hospitals	no
O	O	,	no
O	O	usually	no
O	O	in	yes
O	O	close	no
O	O	collaboration	no
O	O	with	yes
O	O	a	yes
O	O	specialist	no
O	O	.	no

O	O	A	yes
O	O	causal	no
O	O	relationship	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no

O	O	Therefore	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	potential	no
O	O	for	yes
O	O	an	no
O	O	in	yes
O	O	vivo	no
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	.	no

B-drug	B-drug	Verapamil	yes
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	verapamil	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	Q8h	no
O	O	)	no

B-drug	B-drug	Duloxetine	yes
O	O	May	no
O	O	Have	no
O	O	a	yes
O	O	Clinically	no
O	O	Important	no
O	O	Interaction	no
O	O	with	yes
O	O	the	no
O	O	Following	no
O	O	Other	no
O	O	Drugs	no
O	O	:	no
B-drug	B-drug	Alcohol	yes
O	O	:	no
O	O	When	no
B-drug	B-drug	Duloxetine	yes
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	were	no
O	O	administered	no
O	O	several	no
O	O	hours	no
O	O	apart	no
O	O	so	no
O	O	that	no
O	O	peak	no
O	O	concentrations	no
O	O	of	yes
O	O	each	no
O	O	would	no
O	O	coincide	no
O	O	,	no
B-drug	B-drug	Duloxetine	yes
O	O	did	no
O	O	not	no
O	O	increase	no
O	O	the	no
O	O	impairment	no
O	O	of	yes
O	O	mental	no
O	O	and	yes
O	O	motor	no
O	O	skills	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	On	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	bexarotene	yes
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	gemfibrozil	yes
O	O	,	no
O	O	grapefruit	no
O	O	juice	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	inhibitors	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	lead	no
O	O	to	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	bexarotene	yes
O	O	concentrations	no
O	O	.	no

O	O	-	yes
O	O	Decreased	no
B-drug	O	pregnanediol	no
O	O	excretion	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	upper	no
O	O	gastrointestinal	no
O	O	events	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	taking	no
B-brand	B-brand	aspirin	yes
O	O	or	no
B-group	B-group	NSAIDs	no
O	O	was	no
O	O	similar	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	ibandronate	yes
O	O	2.5	yes
O	O	mg	yes
O	O	daily	no
O	O	(	no
O	O	21.7	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	150	yes
O	O	mg	yes
O	O	once	no
O	O	monthly	no
O	O	(	no
O	O	22.0	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptive	yes
O	O	:	no
O	O	Based	no
O	O	on	no
O	O	AUC	no
O	O	and	yes
O	O	half-life	no
O	O	,	no
O	O	multiple-dose	no
O	O	pharmacokinetic	no
O	O	profiles	no
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	following	no
O	O	administration	no
O	O	of	yes
O	O	tablets	yes
O	O	containing	yes
O	O	2.5	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	norethindrone	yes
I-drug	I-drug	acetate	yes
O	O	and	yes
O	O	50	yes
O	O	mcg	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	were	no
O	O	similar	no
O	O	with	yes
O	O	and	yes
O	O	without	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	TID	no
O	O	;	no

O	O	Drugs	no
O	O	That	no
O	O	Are	no
O	O	Mainly	no
O	O	Metabolized	no
O	O	by	no
O	O	CYP3A4	no

O	O	Elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
B-group	B-group	quinolone	no
O	O	use	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	lithium	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	serotonergic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-brand	B-brand	LEXAPRO	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Should	no
O	O	Not	no
O	O	Be	no
O	O	Coadministered	no
O	O	With	yes
B-brand	B-brand	VIRACEPT	yes
B-group	B-group	Antiarrhythmics	no
O	O	:	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
B-group	B-group	Antihistamines	no
O	O	:	no
B-drug	B-drug	astemizole	yes
O	O	,	no
B-drug	B-drug	terfenadine	yes
I-drug	O	Antimigraine	no
O	O	:	no
B-group	B-group	ergot	yes
I-group	I-group	derivatives	no
I-group	I-group	Antimycobacterial	no
I-group	I-group	agents	yes
O	O	:	no
B-drug	B-drug	rifampin	yes
B-group	B-group	Benzodiazepines	no
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	triazolam	yes
O	O	GI	no
O	O	motility	no
O	O	agents	yes
O	O	:	no
B-drug	B-drug	cisapride	yes

O	O	Poor	no
O	O	metabolizers	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-group	B-group	TCAs	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

B-brand	O	Cercarial	no
O	O	encystment	no
O	O	at	yes
O	O	concentrations	no
O	O	of	yes
O	O	25000	no
O	O	microg/l	no
O	O	or	no
O	O	higher	no
O	O	was	no
O	O	significantly	no
O	O	impaired	no
O	O	by	no
O	O	all	yes
O	O	test	yes
O	O	metals	no
O	O	;	no

O	O	Hyperpyrexia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-drug	B-drug	amitriptyline	yes
I-drug	I-drug	HCl	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-group	B-drug	anticholinergic	no
I-group	O	agents	yes
O	O	or	no
O	O	with	yes
B-group	B-drug	neuroleptic	no
I-group	O	drugs	no
O	O	,	no
O	O	particularly	no
O	O	during	no
O	O	hot	no
O	O	weather	no
O	O	.	no

O	O	Some	no
O	O	clinicians	no
O	O	have	no
O	O	noted	no
O	O	that	no
O	O	these	no
O	O	reactions	no
O	O	resemble	no
O	O	the	no
O	O	immediate	no
O	O	side	no
O	O	effects	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	interleukin-2	yes
O	O	administration	no
O	O	,	no
O	O	however	no
O	O	the	no
O	O	cause	no
O	O	of	yes
O	O	contrast	no
O	O	reactions	no
O	O	after	no
B-drug	O	interleukin-2	yes
O	O	therapy	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	The	no
O	O	anxiogenic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	were	no
O	O	reduced	yes
O	O	by	no
O	O	pretreatment	no
O	O	with	yes
B-drug	B-drug_n	CGS	no
I-drug	I-drug_n	21680	no
O	O	,	no
O	O	an	no
O	O	A2-selective	no
O	O	agonist	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	by	no
B-drug_n	B-drug_n	N6-cyclopentyladenosine	no
O	O	(	no
B-drug_n	B-drug_n	CPA	no
O	O	)	no
O	O	,	no
O	O	an	no
B-group	O	A1-selective	no
I-group	O	agonist	no
O	O	.	no

O	O	CNS	no
O	O	vascular	no
O	O	lesions	no
O	O	,	no
O	O	characterized	no
O	O	by	no
O	O	perivascular	no
O	O	hemorrhages	no
O	O	,	no
O	O	edema	no
O	O	,	no
O	O	and	yes
O	O	mononuclear	no
O	O	cell	yes
O	O	infiltration	no
O	O	of	yes
O	O	perivascular	no
O	O	spaces	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	dogs	no
O	O	treated	no
O	O	with	yes
O	O	other	no
O	O	members	no
O	O	of	yes
O	O	this	no
O	O	class	no
O	O	.	no

B-drug	B-drug	Ketamine	yes
O	O	is	yes
O	O	clinically	no
O	O	compatible	no
O	O	with	yes
O	O	the	no
O	O	commonly	no
O	O	used	no
O	O	general	no
O	O	and	yes
O	O	local	no
B-group	B-group	anesthetic	no
I-group	I-group	agents	yes
O	O	when	no
O	O	an	no
O	O	adequate	no
O	O	respiratory	no
O	O	exchange	no
O	O	is	yes
O	O	maintained	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes

O	O	increased	no
O	O	plasminogen	yes
O	O	antigen	yes
O	O	and	yes
O	O	activity	yes
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	clinical	no
O	O	evidence	no
O	O	in	yes
O	O	the	no
O	O	vehicle-controlled	no
O	O	studies	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-group	O	systemic	no
I-group	B-group	antiretroviral	no
I-group	I-group	agents	yes
O	O	,	no
O	O	including	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	and	yes
B-group	B-group	azole	no
I-group	I-group	antifungals	no
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	Panretin	yes
O	O	gel	yes
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	concentrations	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	acute	no
O	O	toxicity	no
O	O	tests	no
O	O	showed	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	was	no
O	O	1.45	no
O	O	times	no
O	O	less	no
O	O	toxic	no
O	O	to	no
O	O	normal	yes
O	O	tissue	yes
O	O	,	no
O	O	although	no
O	O	the	no
O	O	dose-limiting	no
O	O	organ	no
O	O	may	no
O	O	be	no
O	O	different	no
O	O	for	yes
O	O	the	no
O	O	two	no
O	O	routes	no
O	O	.	no

B-drug	B-drug	Levodopa	yes
O	O	and	yes
B-drug	B-drug	Amantadine	yes
O	O	:	no
O	O	Limited	no
O	O	clinical	no
O	O	data	no
O	O	suggest	no
O	O	a	yes
O	O	higher	no
O	O	incidence	no
O	O	of	yes
O	O	adverse	no
O	O	experiences	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	bupropion	yes
O	O	concurrently	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	levodopa	yes
O	O	or	no
B-drug	B-drug	amantadine	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
O	O	another	no
B-group	B-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitor	yes
I-group	I-group	drug	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	MAOI	no
O	O	)	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	serious	no
O	O	,	no
O	O	sometimes	no
O	O	fatal	no
O	O	,	no
O	O	reactions	no
O	O	including	no
O	O	hyperthermia	no
O	O	,	no
O	O	rigidity	no
O	O	,	no
O	O	myoclonus	no
O	O	,	no
O	O	autonomic	no
O	O	instability	no
O	O	with	yes
O	O	possible	no
O	O	rapid	no
O	O	fluctuations	no
O	O	of	yes
O	O	vital	no
O	O	signs	no
O	O	,	no
O	O	and	yes
O	O	mental	no
O	O	status	no
O	O	changes	no
O	O	that	no
O	O	include	no
O	O	extreme	no
O	O	agitation	no
O	O	progressing	no
O	O	to	no
O	O	delirium	no
O	O	and	yes
O	O	coma	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	several	no
B-group	B-group	AED	no
O	O	s	yes
O	O	that	no
O	O	are	no
O	O	cytochrome	no
O	O	P450	no
O	O	inducers	no
O	O	can	no
O	O	decrease	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	oxcarbazepine	yes
O	O	and	yes
B-drug_n	B-drug_n	MHD	no
O	O	.	no

O	O	Administer	no
B-brand	B-brand	LEVSIN	no
O	O	before	no
O	O	meals	no
O	O	;	no

O	O	No	yes
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	at	yes
O	O	intermediate	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	Inhibition	no
O	O	of	yes
O	O	metabolism	no
O	O	may	no
O	O	produce	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	circulating	no
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	and	yes
O	O	enhance	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	drug	yes
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	for	yes
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	In	yes
O	O	ewes	no
O	O	given	no
O	O	40	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
I-drug	O	sodium/kg	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	intraperitoneally	no
O	O	(	no
O	O	IP	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	anticholinesterase	no
O	O	effect	no
O	O	of	yes
O	O	4	yes
O	O	mg	yes
O	O	of	yes
B-drug_n	B-drug_n	coumaphos/kg	no
O	O	was	no
O	O	significantly	no
O	O	reduced	yes
O	O	and	yes
O	O	signs	no
O	O	of	yes
O	O	toxicity	no
O	O	were	no
O	O	not	no
O	O	present	no
O	O	.	no

O	O	There	no
O	O	also	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	exposure	yes
O	O	to	no
O	O	and	yes
O	O	the	no
O	O	excretion	no
O	O	of	yes
O	O	the	no
O	O	primary	no
O	O	metabolite	yes
O	O	,	no
O	O	ucb	no
O	O	L057	no
O	O	.	no

B-drug	B-drug	Chlorthalidone	yes
O	O	may	no
O	O	add	no
O	O	to	no
O	O	or	no
O	O	potentiate	no
O	O	the	no
O	O	action	no
O	O	of	yes
O	O	other	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	OBJECTIVE	no
O	O	:	no
O	O	Our	no
O	O	objective	no
O	O	was	no
O	O	to	no
O	O	characterize	no
O	O	the	no
O	O	steady-state	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	(	no
O	O	INN	no
O	O	,	no
B-drug	B-drug	ciclosporin	yes
O	O	)	no
O	O	when	no
O	O	coadministered	no
O	O	in	yes
O	O	de	yes
O	O	novo	yes
O	O	kidney	yes
O	O	allograft	no
O	O	recipients	no
O	O	during	no
O	O	the	no
O	O	first	no
O	O	year	no
O	O	after	no
O	O	transplantation	no
O	O	.	no

B-group	O	Adrenocorticoids	no
O	O	:	no
O	O	Metabolic	no
O	O	clearance	no
O	O	of	yes
B-group	O	adrenocorticoids	no
O	O	is	yes
O	O	decreased	no
O	O	in	yes
O	O	hypothyroid	no
O	O	patients	no
O	O	and	yes
O	O	increased	no
O	O	in	yes
O	O	hyperthyroid	no
O	O	patients	no
O	O	,	no
O	O	and	yes
O	O	may	no
O	O	therefore	no
O	O	change	no
O	O	with	yes
O	O	changing	no
O	O	thyroid	yes
O	O	status	no
O	O	.	no

O	O	The	no
O	O	physician	no
O	O	should	no
O	O	be	no
O	O	notified	no
O	O	immediately	no
O	O	if	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	situations	no
O	O	occur	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	be	no
O	O	a	yes
O	O	sign	no
O	O	of	yes
O	O	seriously	no
O	O	worsening	no
O	O	asthma	no
O	O	:	no
O	O	Decreased	no
O	O	effectiveness	no
O	O	of	yes
O	B-group	short-acting	no
O	I-group	,	no
O	I-group	inhaled	no
B-group	I-group	beta2-agonists	no
O	O	;	no

B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	and	yes
O	O	many	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	many	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
B-drug	B-drug	propafenone	yes
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	steady-state	no
O	O	Cmin	no
O	O	concentration	no
O	O	increased	no
O	O	to	no
O	O	17.8	no
O	O	micrograms/mL	no
O	O	when	no
O	O	2400	no
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	was	no
O	O	coadministered	no
O	O	for	yes
O	O	one	no
O	O	week	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	-	yes
O	O	Coadministration	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
O	O	40	yes
O	O	mg/day	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	(	no
O	O	30	yes
O	O	mmol/day	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	citalopram	yes
O	O	or	no
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Avoid	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	preparations	no
O	O	such	no
O	O	as	yes
B-group	B-group	decongestants	no
O	O	and	yes
O	O	local	no
B-group	B-group	anesthetics	no
O	O	which	no
O	O	contain	no
O	O	any	no
B-group	B-group	sympathomimetic	no
I-group	I-group	amine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	epinephrine	yes
O	O	,	no
B-drug	B-drug	norepinephrine	yes
O	O	)	no
O	O	,	no
O	O	since	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	can	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	O	catecholamines	no
O	O	.	no

O	O	The	no
O	O	para-aminobenzoic	no
O	O	acid	yes
O	O	metabolite	yes
O	O	of	yes
B-drug	O	chloroprocaine	yes
O	O	inhibits	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	sulfonamides	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	Increased	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Use	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	be	no
O	O	prepared	no
O	O	to	no
O	O	treat	no
O	O	hypertension	no
O	O	,	no
O	O	if	no
O	O	necessary	no
O	O	.	no

B-group	O	Gastrointestinal	no
I-group	O	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	antacids	no
O	O	)	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Daunorubicin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Cerubidine	yes
O	O	)	no
O	O	or	no

O	O	Pediatric	yes
O	O	Use	no
O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	effectiveness	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	,	no
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	COPEGUS	yes
O	O	in	yes
O	O	patients	no
O	O	below	no
O	O	the	no
O	O	age	no
O	O	of	yes
O	O	18	yes
O	O	years	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Prolonged	no
O	O	menstrual	no
O	O	cycles	no
O	O	and/or	no
O	O	amenorrhea	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	female	no
O	O	cynomolgus	no
O	O	monkeys	no
O	O	given	no
O	O	sc	no
O	O	injections	no
O	O	of	yes
O	O	600	yes
O	O	m	yes
O	O	g/kg/dose	no
O	O	(	no
O	O	7200	no
O	O	m	yes
O	O	g/m2/dose	no
O	O	)	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	every	no
O	O	other	no
O	O	day	no
O	O	for	yes
O	O	one	no
O	O	month	no
O	O	,	no
O	O	at	yes
O	O	approximately	no
O	O	180	yes
O	O	times	no
O	O	the	no
O	O	recommended	no
O	O	weekly	yes
O	O	human	yes
O	O	dose	no
O	O	for	yes
O	O	a	yes
O	O	60	no
O	O	kg	no
O	O	person	no
O	O	(	no
O	O	based	no
O	O	on	no
O	O	body	no
O	O	surface	yes
O	O	area	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	using	no
O	O	these	no
O	O	drugs	no
O	O	together	no
O	O	.	no

O	O	Alternatives	no
O	O	to	no
B-drug	B-drug	rifampin	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	during	no
O	O	the	no
O	O	course	no
O	O	of	yes
B-drug_n	O	PCP	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	MEPRON	yes
O	O	.	no

O	O	Component	yes
O	O	P2	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	was	no
O	O	increased	no
O	O	in	yes
O	O	amplitude	no
O	O	.	no

O	O	In	yes
O	O	utero	no
O	O	,	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
O	O	exposure	yes
O	O	in	yes
O	O	these	no
O	O	monkeys	no
O	O	were	no
O	O	23	no
O	O	%	no
O	O	of	yes
O	O	maternal	no
O	O	serum	yes
O	O	levels	no
O	O	.	no

O	O	Patients	no
O	O	on	no
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	may	no
O	O	require	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-group	B-group	thyroid	yes
I-group	I-group	hormone	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	LEXAPRO	yes
O	O	and	yes
B-drug	B-drug	metoprolol	yes
O	O	had	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effects	no
O	O	on	no
O	O	blood	yes
O	O	pressure	no
O	O	or	no
O	O	heart	no
O	O	rate	no
O	O	.	no

B-drug_n	B-drug_n	NaCMC	no
O	O	at	yes
O	O	1	yes
O	O	%	no
O	O	(	no
O	O	m/v	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	free	yes
B-drug	B-drug	cysteine	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	R-value	no
O	O	of	yes
B-drug	B-drug	NaFlu	no
O	O	compared	no
O	O	to	no
B-drug_n	B-drug_n	NaCMC	no
O	O	alone	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	these	no
O	O	tests	no
O	O	be	no
O	O	performed	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
B-brand	B-brand	Soriatane	yes
O	O	therapy	no
O	O	,	no
O	O	at	yes
O	O	1-	no
O	O	to	no
O	O	2-week	no
O	O	intervals	no
O	O	until	no
O	O	stable	no
O	O	and	yes
O	O	thereafter	no
O	O	at	yes
O	O	intervals	no
O	O	as	yes
O	O	clinically	no
O	O	indicated	no
O	O	.	no

O	O	24.9	no
O	O	%	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	4.5	no
O	O	)	no
O	O	were	no
O	O	PICR	no
O	O	,	no
O	O	detected	no
O	O	in	yes
O	O	11.7	no
O	O	%	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	2.5	yes
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	MAC	no
O	O	.	no

O	O	Data	no
O	O	beyond	no
O	O	10	yes
O	O	days	no
O	O	are	no
O	O	not	no
O	O	available	no
O	O	.	no

O	O	Each	no
O	O	month	no
O	O	of	yes
O	O	therapy	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	must	no
O	O	have	no
O	O	a	yes
O	O	negative	no
O	O	result	no
O	O	from	no
O	O	a	yes
O	O	urine	no
O	O	or	no
O	O	serum	yes
O	O	pregnancy	no
O	O	test	yes
O	O	.	no

O	O	When	no
O	O	intravenous	yes
B-drug	B-drug	morphine	yes
O	O	and	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	were	no
O	O	concomitantly	no
O	O	administered	no
O	O	in	yes
O	O	normal	yes
O	O	subjects	no
O	O	,	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	morphine	yes
O	O	blood	yes
O	O	levels	no
O	O	was	no
O	O	seen	no
O	O	,	no
O	O	but	no
B-brand	B-brand	BREVIBLOC	yes
O	O	steady-state	no
O	O	blood	yes
O	O	levels	no
O	O	were	no
O	O	increased	no
O	O	by	no
O	O	46	no
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	pronounced	no
O	O	intersubject	no
O	O	variability	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	sirolimus-diltiazem	no
O	O	interaction	no
O	O	,	no
O	O	whole	yes
O	O	blood	yes
B-drug	B-drug	sirolimus	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	.	no

O	O	Effect	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	probenecid	yes
O	O	will	no
O	O	have	no
O	O	erroneously	no
O	O	low	yes
O	O	ERPF	no
O	O	and	yes
O	O	Tm	no
O	B-drug	PAH	yes
O	O	values	no
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
O	O	:	no
O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	at	yes
O	O	a	yes
O	O	low	yes
O	O	dose	no
O	O	,	no
B-drug	B-drug	azithromycin	yes
O	O	,	no
B-drug	B-drug	pseudoephedrine	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	Drug	yes
O	O	and	yes
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	1	yes
O	O	.	no

O	O	Drug	yes
O	O	interactions	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	are	no
O	O	summarized	no
O	O	in	yes
O	O	Table	no
O	O	5	yes
O	O	.	no

O	O	Since	no
O	O	blood	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	will	no
O	O	be	no
O	O	reduced	yes
O	O	,	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Rocaltrol	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	if	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	simultaneously	no
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	the	no
O	O	CYP3A4	no
O	O	isoenzyme	no
O	O	could	no
O	O	increase	no
O	O	systemic	no
B-drug	B-drug	dofetilide	yes
O	O	exposure	yes
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	has	no
O	O	a	yes
O	O	tendency	no
O	O	to	no
O	O	antagonize	no
O	O	the	no
O	O	skeletal	no
O	O	muscle	no
O	O	relaxing	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	tubocurarine	yes
O	O	and	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	tablets	yes
O	O	and	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	increased	no
O	O	possibility	no
O	O	of	yes
O	O	gastrointestinal	no
O	O	toxicity	no
O	O	,	no
O	O	with	yes
O	O	little	no
O	O	or	no
O	O	no	yes
O	O	increase	no
O	O	in	yes
O	O	efficacy	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	a	yes
O	O	slower	no
O	O	onset	no
O	O	can	no
O	O	be	no
O	O	anticipated	no
O	O	if	no
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	,	no
O	O	or	no
O	O	immediately	no
O	O	following	no
O	O	,	no
O	O	a	yes
B-group	B-group	nasal	no
I-group	I-group	vasoconstrictor	no
O	O	.	no

O	O	Smokers	no
O	O	have	no
O	O	an	no
O	O	increased	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	nonsmokers	no
O	O	;	no

O	O	In	yes
O	O	post-marketing	no
O	O	experience	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	increases	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	.	no

O	O	periodic	no
O	O	monitoring	no
O	O	of	yes
B-group	B-group	anticonvulsant	no
O	O	plasma	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	conducted	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-drug	B-drug	azathioprine	yes
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	concomitantly	no
O	O	should	no
O	O	have	no
O	O	a	yes
O	O	dose	no
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	azathioprine	yes
O	O	,	no
O	O	to	no
O	O	approximately	no
O	O	1/3	no
O	O	to	no
O	O	1/4	no
O	O	the	no
O	O	usual	no
O	O	dose	no
O	O	.	no

O	O	These	no
O	O	stimulants	no
O	O	are	no
O	O	commonly	no
O	O	found	no
O	O	in	yes
O	O	coffee	no
O	O	and	yes
B-drug	O	tea	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	The	no
O	O	pharmacodynamic	no
O	O	effects	no
O	O	can	no
O	O	be	no
O	O	explained	no
O	O	by	no
O	O	a	yes
O	O	combination	yes
O	O	of	yes
O	O	the	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	dofetilide	yes
O	O	exposure	yes
O	O	and	yes
O	O	the	no
O	O	reductions	no
O	O	in	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

O	O	In	yes
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	had	no
O	O	to	no
O	O	be	no
O	O	reduced	yes
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	maintain	no
B-drug	B-drug	cyclosporine	yes
O	O	concentrations	no
O	O	within	no
O	O	the	no
O	O	therapeutic	no
O	O	range	no
O	O	,	no
O	O	while	no
O	O	in	yes
O	O	the	no
O	O	remainder	no
O	O	no	yes
O	O	adjustment	no
O	O	was	no
O	O	needed	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	have	no
O	O	also	no
O	O	been	no
O	O	assessed	no
O	O	in	yes
O	O	various	no
O	O	demographic	no
O	O	groups	no
O	O	.	no

O	O	Potential	no
O	O	drug	yes
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	Mentax	yes
O	O	(	no
B-drug	B-drug	butenafine	yes
I-drug	I-drug	HCl	yes
O	O	cream	no
O	O	)	no
O	O	Cream	no
O	O	,	no
O	O	1	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	.	no

O	O	(	no
B-group	B-group	Thiazides	no
O	O	may	no
O	O	decrease	no
O	O	arterial	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	norepinephrine	yes
O	O	.	no

O	O	Nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	cephalosporins	no
O	O	with	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	or	no
O	O	potent	no
B-group	B-group	diuretics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	.	no

O	B-drug	Lithium-A	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	The	no
O	O	acid-catalyzed	no
O	B-drug	ethanol-drug	no
O	O	reaction	no
O	O	is	yes
O	O	a	yes
O	O	relatively	no
O	O	unexplored	no
O	O	area	no
O	O	and	yes
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	pharmacological	no
O	O	action	no
O	O	of	yes
O	O	some	no
O	O	drugs	no
O	O	.	no

B-group	B-group	Immunosuppressants	no

O	B-group	Intestinal	no
O	I-group	adsorbents	no
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-drug	B-drug	charcoal	yes
O	O	)	no
O	O	and	yes
O	B-group	digestive	no
O	I-group	enzyme	no
O	I-group	preparations	no
O	O	containing	yes
O	O	carbohydrate-splitting	no
O	O	enzymes	yes
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
O	B-drug	amylase	no
O	O	,	no
O	B-drug	pancreatin	yes
O	O	)	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	Acarbose	yes
O	O	and	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	concomitantly	no
O	O	.	no

O	O	The	no
O	O	augmentation	no
O	O	persisted	no
O	O	even	no
O	O	after	no
B-drug	B-drug	carbachol	yes
O	O	was	no
O	O	washed	no
O	O	out	no
O	O	and	yes
O	O	was	no
O	O	resistant	no
O	O	to	no
O	O	chelated	no
O	O	extracellular	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	and	yes
O	O	to	no
O	O	inhibitors	no
O	O	of	yes
O	O	either	no
O	O	protein	yes
O	O	kinase	yes
O	O	C	yes
O	O	or	no
B-drug	O	calmodulin	no
I-drug	O	kinase	yes
I-drug	O	II	yes
O	O	.	no

O	O	Much	no
O	O	higher	no
O	O	changes	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	liver	yes
O	O	,	no
O	O	increasing	no
O	O	from	no
O	O	a	yes
O	O	level	no
O	O	of	yes
O	O	60	no
O	O	%	no
O	O	at	yes
O	O	4	yes
O	O	h	yes
O	O	up	no
O	O	to	no
O	O	nearly	no
O	O	4	yes
O	O	times	no
O	O	the	no
O	O	control	no
O	O	at	yes
O	O	24	yes
O	O	h	yes
O	O	for	yes
O	O	single	yes
O	O	dose	no
O	O	.	no

O	O	BACKGROUND	no
O	O	:	no
O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	combined	no
O	O	administration	no
O	O	of	yes
B-drug_n	B-drug_n	bombesin	yes
O	O	and	yes
B-drug	B-drug	verapamil	yes
I-drug	I-drug	hydrochloride	yes
O	O	(	no
B-drug	B-drug	verapamil	yes
O	O	)	no
O	O	,	no
O	O	a	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocker	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	peritoneal	no
O	O	metastasis	no
O	O	of	yes
O	O	intestinal	no
O	O	adenocarcinomas	no
O	O	induced	no
O	O	by	no
B-drug_n	B-drug_n	azoxymethane	no
O	O	(	no
B-drug_n	B-drug_n	AOM	no
O	O	)	no
O	O	and	yes
O	O	the	no
O	O	labeling	no
O	O	index	no
O	O	of	yes
O	O	intestinal	no
O	O	cancers	no
O	O	were	no
O	O	investigated	no
O	O	in	yes
O	O	male	no
O	O	Wistar	no
O	O	rats	no
O	O	.	no

B-brand	B-brand	Exjade	yes
O	O	tablets	yes
O	O	for	yes
O	O	oral	yes
O	O	suspension	yes
O	O	can	no
O	O	be	no
O	O	dispersed	no
O	O	in	yes
O	O	water	yes
O	O	,	no
O	O	orange	no
O	O	juice	no
O	O	,	no
O	O	or	no
O	O	apple	no
O	O	juice	no
O	O	.	no

O	O	Since	no
B-drug	B-drug	apraclonidine	yes
O	O	may	no
O	O	reduce	no
O	O	pulse	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	,	no
O	O	caution	no
O	O	in	yes
O	O	using	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	beta-blockers	no
O	O	(	no
O	O	ophthalmic	no
O	O	and	yes
O	O	systemic	no
O	O	)	no
O	O	,	no
B-group	B-group	antihypertensives	no
O	O	,	no
O	O	and	yes
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	is	yes
O	O	advised	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
O	O	lower	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	with	yes
B-group	B-group	alpha-blockers	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	completely	no
O	O	evaluated	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	they	no
O	O	can	no
O	O	be	no
O	O	safely	no
O	O	administered	no
O	O	together	no
O	O	.	no

B-drug	B-drug	Ascorbic	yes
I-drug	I-drug	acid	yes
O	O	:	no
O	O	Doses	no
O	O	of	yes
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	(	no
B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	)	no
O	O	1	yes
O	O	g/day	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-group	B-group	synthetic	yes
I-group	I-group	estrogens	yes
O	O	by	no
O	O	~47	no
O	O	%	no
O	O	,	no
O	O	possibly	no
O	O	by	no
O	O	inhibiting	no
O	O	conjugation	no
O	O	;	no

O	O	In	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	cardiac	no
O	O	function	no
O	O	,	no
O	O	simultaneous	no
O	O	use	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	altogether	no
O	O	.	no

O	O	Investigations	no
O	O	into	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	acitretin	yes
O	O	on	no
O	O	the	no
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-group	B-group	anticoagulants	no
O	I-group	of	yes
O	I-group	the	no
B-group	I-group	coumarin	yes
I-group	I-group	type	yes
O	O	(	no
B-drug	B-drug	warfarin	yes
O	O	)	no
O	O	revealed	no
O	O	no	yes
O	O	interaction	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
B-drug	B-drug	lithium	yes
O	O	intoxication	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	plasma	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	.	no

O	O	2	yes
O	O	.	no

O	O	THE	no
O	O	DOSAGE	no
O	O	OF	yes
O	O	THE	no
B-group	B-group	ANTICOAGULANTS	no
O	O	SHOULD	no
O	O	BE	no
O	O	REDUCED	yes
O	O	TO	no
O	O	MAINTAIN	no
O	O	THE	no
O	O	PROTHROMBIN	yes
O	O	TIME/INR	no
O	O	AT	yes
O	O	THE	no
O	O	DESIRED	no
O	O	LEVEL	no
O	O	TO	no
O	O	PREVENT	no
O	O	BLEEDING	no
O	O	COMPLICATIONS	no
O	O	.	no

O	O	The	no
O	O	literature	no
O	O	provides	no
O	O	considerable	no
O	O	evidence	no
O	O	indicating	no
O	O	that	no
O	O	several	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	all	yes
B-group	B-group	antihistaminics	no
O	O	,	no
O	O	are	no
O	O	indeed	no
B-group	B-group	analgesic	no
I-group	I-group	agents	yes
O	O	and	yes
O	O	some	no
O	O	are	no
B-group	B-group	analgesic	no
I-group	I-group	adjuvants	no
O	O	as	yes
O	O	well	no
O	O	.	no

O	O	Two	no
O	O	of	yes
O	O	16	yes
O	O	subjects	no
O	O	dosed	no
O	O	simultaneously	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	10	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	tamsulosin	yes
O	O	0.4	no
O	O	mg	yes
O	O	experienced	no
O	O	a	yes
O	O	standing	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	below	no
O	O	85	no
O	O	mm	yes
O	O	Hg	yes
O	O	.	no

O	O	Thirty	no
O	O	male	no
O	O	rats	no
O	O	of	yes
O	O	the	no
O	O	Fischer-344	no
O	O	strain	no
O	O	were	no
O	O	divided	no
O	O	into	no
O	O	three	no
O	O	equal	no
O	O	groups	no
O	O	and	yes
O	O	were	no
O	O	given	no
O	O	injections	no
O	O	of	yes
B-drug	B-drug_n	trimethyl	no
I-drug	I-drug_n	lead	no
O	O	(	no
B-drug_n	B-drug_n	TML	no
O	O	)	no
O	O	(	no
O	O	8.0	no
O	O	or	no
O	O	17.0	no
O	O	mg/kg/ml	no
O	O	SC	no
O	O	)	no
O	O	or	no
O	O	the	no
O	O	saline	yes
O	O	vehicle	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	and	yes
B-drug	B-drug	sucralfate	yes
O	O	:	no
B-drug	B-drug	Sucralfate	yes
O	O	and	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
O	O	or	no
B-drug	B-drug	aluminum	yes
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	formulations	no
O	O	containing	yes
O	O	divalent	no
O	O	and	yes
O	O	trivalent	no
O	O	cations	no
O	O	such	no
O	O	as	yes
B-brand	B-brand	Videx	yes
O	O	(	no
B-drug	B-drug	didanosine	yes
O	O	)	no
O	O	,	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	can	no
O	O	form	yes
O	O	chelation	no
O	O	complexes	no
O	O	with	yes
B-drug	B-drug	lomefloxacin	yes
O	O	and	yes
O	O	interfere	no
O	O	with	yes
O	O	its	no
O	O	bioavailability	no
O	O	.	no

B-drug	B-drug	Flecainide	yes
O	O	is	yes
O	O	not	no
O	O	extensively	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	.	no

O	O	In	yes
O	O	well-controlled	no
O	O	patients	no
O	O	undergoing	no
O	O	concurrent	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-drug	O	cime-tidine	no
O	O	therapy	no
O	O	is	yes
O	O	discontinued	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	combined	no
O	O	therapy	no
O	O	is	yes
O	O	contemplated	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	Other	no
O	O	:	no
O	O	Concomitant	no
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	hot	no
O	O	drinks	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
O	O	flushing	no
O	O	and	yes
O	O	pruritus	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	at	yes
O	O	the	no
O	O	time	no
O	O	of	yes
O	O	drug	yes
O	O	ingestion	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
B-brand	B-brand	TORADOL	yes
O	O	IV/IM	no
O	O	reduced	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	response	no
O	O	to	no
B-drug	B-drug	furosemide	yes
O	O	in	yes
B-drug	O	normovolemic	no
O	O	healthy	no
O	O	subjects	no
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	(	no
O	O	mean	no
O	O	sodium	yes
O	O	and	yes
O	O	urinary	yes
O	O	output	no
O	O	decreased	no
O	O	17	yes
O	O	%	no
O	O	)	no
O	O	.	no

O	O	After	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	200	yes
O	O	mg	yes
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	twice	no
O	O	daily	no
O	O	and	yes
O	O	one	no
O	O	20	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	to	no
O	O	11	yes
O	O	subjects	no
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	averaged	no
O	O	302	no
O	O	%	no
O	O	(	no
O	O	142	no
O	O	S.D	no
O	O	.	no
O	O	)	no
O	O	and	yes
O	O	251	no
O	O	%	no
O	O	(	no
O	O	68	no
O	O	S.D	no
O	O	.	no
O	O	)	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	of	yes
O	O	those	no
O	O	obtained	no
O	O	after	no
O	O	co-treatment	no
O	O	with	yes
O	O	placebo	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-drug	B-drug	Atorvastatin	yes
O	O	had	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	prothrombin	yes
O	O	time	no
O	O	when	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
O	O	chronic	no
B-drug	B-drug	warfarin	yes
O	O	treatment	no
O	O	.	no

O	O	The	no
O	O	combination	yes
O	O	is	yes
O	O	well	no
O	O	tolerated	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	decreases	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	amphetamine	yes
O	O	and	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	magnitude	no
O	O	and	yes
O	O	duration	no
O	O	of	yes
O	O	their	no
O	O	effect	no
O	O	.	no

O	O	Theoretically	no
O	O	,	no
B-drug	B-drug	fenoprofen	yes
O	O	could	no
O	O	likewise	no
O	O	be	no
O	O	displaced	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no

O	O	It	no
O	O	is	yes
O	O	concluded	no
O	O	that	no
B-drug	B-drug	ketamine	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	short-acting	no
O	O	drug	yes
O	O	and	yes
O	O	that	no
O	O	concomitant	no
O	O	use	no
O	O	with	yes
B-drug	B-drug	halothane	yes
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	prolong	no
O	O	further	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	its	no
O	O	action	no
O	O	on	no
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	.	no

O	O	therefore	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	affect	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	since	no
B-brand	B-brand	aspirin	yes
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	and	yes
B-group	B-group	bisphosphonates	no
O	O	are	no
O	O	all	yes
O	O	associated	no
O	O	with	yes
O	O	gastrointestinal	no
O	O	irritation	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	in	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	or	no
B-group	B-group	NSAIDs	no
O	O	with	yes
B-drug	B-drug	Ibandronate	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-group	B-group	Quinolones	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	famotidine	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	lithium	yes
O	O	was	no
O	O	seen	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	(	no
O	O	see	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	:	no
O	O	Drug-	no
O	O	Drug	yes
O	O	Interactions	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	(	no
O	O	200	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	,	no
O	O	with	yes
B-drug	B-drug	aripiprazole	yes
O	O	(	no
O	O	30	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	70	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	aripiprazole	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	,	no
B-drug_n	B-drug_n	dehydro-aripiprazole	no
O	O	.	no

O	O	Certain	no
B-group	B-group	antibiotics	no
O	O	,	no
O	O	especially	no
B-drug	B-drug	neomycin	yes
O	O	,	no
B-drug	B-drug	streptomycin	yes
O	O	and	yes
B-drug	B-drug	kanamycin	yes
O	O	,	no
O	O	have	no
O	O	a	yes
O	O	mild	yes
O	O	but	no
O	O	definite	no
O	O	nondepolarizing	no
O	O	blocking	no
O	O	action	no
O	O	which	no
O	O	may	no
O	O	accentuate	no
O	O	neuromuscular	no
O	O	block	yes
O	O	.	no

B-drug	B-drug	Loratadine	yes
I-drug	I-drug	Descarboethoxyloratadine	yes

O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	APOKYN	yes
O	O	and	yes
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	as	yes
O	O	such	no
O	O	it	no
O	O	may	no
O	O	impair	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
O	O	any	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	In	yes
O	O	one	no
O	O	study	no
O	O	,	no
O	O	following	no
O	O	chronic	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	,	no
O	O	100	yes
O	O	mg	yes
O	O	3	yes
O	O	times	no
O	O	daily	no
O	O	to	no
O	O	8	yes
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	induction	no
O	O	of	yes
O	O	its	no
O	O	own	no
O	O	metabolism	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-drug	B-brand	Cetrotide	yes
O	O	.	no

O	O	Since	no
B-drug	B-drug	hydroxyurea	yes
O	O	may	no
O	O	raise	no
O	O	the	no
O	O	serum	yes
O	O	uric	yes
O	O	acid	yes
O	O	level	no
O	O	,	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	B-group	uricosuric	no
O	I-group	medication	no
O	O	may	no
O	O	be	no
O	O	necessary	no

O	O	Physiological	no
O	O	changes	no
O	O	resulting	no
O	O	from	no
O	O	smoking	no
O	O	cessation	no
O	O	,	no
O	O	with	yes
O	O	or	no
O	O	without	no
B-drug	B-drug	nicotine	yes
O	O	replacement	no
O	O	,	no
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	certain	no
O	O	concomitant	no
O	O	medications	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	administering	no
O	O	different	no
B-group	B-group	botulinum	yes
I-group	I-group	neurotoxin	yes
O	O	serotypes	no
O	O	at	yes
O	O	the	no
O	O	same	yes
O	O	time	no
O	O	or	no
O	O	within	no
O	O	less	no
O	O	than	no
O	O	4	yes
O	O	months	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Established	no
O	O	Drug	yes
O	O	Interactions	no

B-group	B-group	Non-nucleoside	no
I-group	I-group	reverse	no
I-group	I-group	transcriptase	no
I-group	I-group	inhibitors	no

B-drug	B-drug	Lithium	yes
O	O	toxicity	no
O	O	was	no
O	O	usually	no
O	O	reversible	no
O	O	upon	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	and	yes
O	O	the	no
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	The	no
O	O	in	yes
O	O	vitro	no
O	O	anti-cryptosporidial	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	buforin	no
I-drug_n	I-drug_n	II	yes
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	and	yes
B-drug	B-drug	minocycline	yes
O	O	was	no
O	O	investigated	no
O	O	.	no

O	O	Although	no
O	O	this	no
O	O	effect	no
O	O	was	no
O	O	noted	no
O	O	even	no
O	O	when	no
B-drug	B-drug	cholestyramine	yes
O	O	was	no
O	O	given	no
O	O	4	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
B-drug	B-drug	fluvastatin	yes
O	O	,	no
O	O	this	no
O	O	regimen	no
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	diminished	no
O	O	efficacy	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-group	B-group	Cephalosporins	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	occasionally	no
O	O	induce	no
O	O	a	yes
O	O	positive	no
O	O	direct	no
O	O	Coombs	no
O	O	test	yes
O	O	.	no

O	O	Perioperative	no
O	O	administration	no
O	O	of	yes
O	O	drugs	no
O	O	affecting	no
O	O	hepatic	no
O	O	blood	yes
O	O	flow	no
O	O	or	no
O	O	enzyme	no
O	O	function	no
O	O	may	no
O	O	reduce	no
O	O	plasma	yes
O	O	clearance	no
O	O	and	yes
O	O	prolong	no
O	O	recovery	no
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
B-group	B-group	Macrolide	no
I-group	I-group	antibiotics	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	atorvastatin	yes
O	O	,	no
B-drug	B-drug	cerivastatin	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	simvastatin	yes
O	O	)	no
O	O	.	no

O	O	CNS	no
O	O	depression	no
O	O	producing	no
O	O	medications	no
O	O	-	yes
O	O	concurrent	no
O	O	use	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-drug	B-drug	diphenidol	yes
O	O	;	no

B-drug	B-drug	Nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	usually	no
O	O	does	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	evaluated	no
O	O	after	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	is	yes
O	O	initiated	no
O	O	.	no

B-drug	B-drug	Sirolimus	yes
O	O	works	no
O	O	differently	no
O	O	from	no
O	O	the	no
B-group	B-group	immunosuppressants	no
O	O	currently	no
O	O	available	no
O	O	,	no
O	O	and	yes
O	O	except	no
O	O	for	yes
O	O	increased	no
O	O	lipid	no
O	O	levels	no
O	O	,	no
O	O	the	no
O	O	adverse	no
O	O	reaction	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	overlap	no
O	O	to	no
O	O	any	no
O	O	great	no
O	O	extent	no
O	O	with	yes
O	O	that	no
O	O	associated	no
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	or	no
B-drug	B-drug	tacrolimus	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	carbamazepine	yes
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	the	no
O	O	combination	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	then	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	A	yes
O	O	common	yes
O	O	phenotypic	no
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	serotype	no
O	O	O11	no
O	O	strains	no
O	O	from	no
O	O	drug	yes
O	O	addicts	no
O	O	was	no
O	O	especially	no
O	O	resistant	no
O	O	to	no
O	O	the	no
O	O	inhibitory	yes
O	O	effects	no
O	O	.	no

O	O	Because	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	data	no
O	O	on	no
O	O	the	no
O	O	compatibility	no
O	O	of	yes
B-brand	B-brand	NovoLog	yes
O	O	and	yes
O	O	crystalline	no
B-drug	B-drug	zinc	yes
I-drug	I-drug	insulin	yes
O	O	preparations	no
O	O	,	no
B-brand	B-brand	NovoLog	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	mixed	yes
O	O	with	yes
O	O	these	no
O	O	preparations	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	paper	no
O	O	lists	no
O	O	of	yes
O	O	multiple	no
O	O	exposure	yes
O	O	in	yes
O	O	which	no
O	O	the	no
O	O	doses	no
O	O	of	yes
O	O	the	no
O	O	substances	no
O	O	,	no
O	O	the	no
O	O	types	no
O	O	of	yes
O	O	interferences	no
O	O	and	yes
O	O	the	no
O	O	behaviour	no
O	O	of	yes
O	O	the	no
O	O	biological	no
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	drawn	no
O	O	up	no
O	O	and	yes
O	O	proposed	no
O	O	as	yes
O	O	a	yes
O	O	tool	no
O	O	for	yes
O	O	easy	no
O	O	consultation	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	Tablets	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
O	O	either	no
B-drug	B-drug	levodopa	yes
O	O	or	no
B-drug	B-drug	amantadine	yes
O	O	concurrently	no
O	O	should	no
O	O	be	no
O	O	undertaken	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	using	no
O	O	small	no
O	O	initial	no
O	O	doses	no
O	O	and	yes
O	O	small	no
O	O	gradual	no
O	O	dose	no
O	O	increases	no
O	O	.	no

O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	possible	no
O	O	CNS	no
O	O	and	yes
O	O	other	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	Agents	yes
O	O	Causing	no
O	O	Renin	no
O	O	Release	yes
O	O	:	no
O	O	The	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	enalapril	yes
O	O	and	yes
B-drug	B-drug	enalapril	yes
O	O	IV	yes
O	O	is	yes
O	O	augmented	no
O	O	by	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	that	no
O	O	cause	no
O	O	renin	no
O	O	release	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	)	no
O	O	.	no

O	O	Serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	if	no
B-brand	B-brand	INSPRA	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Increased	no
O	O	hepatotoxicity	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	in	yes
O	O	the	no
O	O	rat	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Supraventricular	no
O	O	arrhythmias	no
O	O	may	no
O	O	mask	no
O	O	the	no
O	O	cardiotoxicity	no
O	O	associated	no
O	O	with	yes
O	O	excessive	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	.	no

O	O	Since	no
O	O	falsely	no
O	O	elevated	no
O	O	glucose	yes
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	blood	yes
O	O	glucose	yes
O	O	monitoring	no
O	O	devices	no
O	O	and	yes
O	O	test	yes
O	O	strips	no
O	O	that	no
O	O	use	no
O	O	glucose	yes
O	O	dehydrogenase	no
B-drug_n	O	pyrroloquinolinequinone	no
O	O	(	no
O	O	GDH	no
O	O	PQQ	no
O	O	)	no
O	O	-based	no
O	O	methods	no
O	O	,	no
O	O	GDH	no
O	O	PQQ-based	no
O	O	methods	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	measure	no
O	O	glucose	yes
O	O	levels	no
O	O	in	yes
O	O	patients	no
O	O	administered	no
B-brand	B-brand	EXTRANEAL..	no

O	O	Both	no
O	O	the	no
O	O	magnitude	no
O	O	and	yes
O	O	duration	no
O	O	of	yes
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	and	yes
O	O	cardiovascular	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	when	no
B-brand	B-brand	ALFENTA	yes
O	O	is	yes
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	such	no
O	O	as	yes
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	opioids	no
O	O	,	no
O	O	or	no
O	O	inhalation	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	co	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	with	yes
O	O	either	no
B-drug	B-drug	ketoconazole	yes
O	O	or	no
B-drug	B-drug	erythromycin	yes
O	O	led	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
O	O	.	no

O	O	A	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	pravastatin	yes
O	O	had	no
O	O	no	yes
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug_n	B-drug_n	fenofibric	yes
I-drug_n	I-drug_n	acid	yes
O	O	.	no

O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	were	no
O	O	performed	no
O	O	both	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	and	yes
O	O	a	yes
O	O	rapidly	yes
O	O	hydrolyzed	yes
O	O	intravenous	yes
O	O	prodrug	no
O	O	form	yes
O	O	.	no

O	O	Usually	no
O	O	,	no
O	O	severe	no
O	O	abdominal	no
O	O	symptoms	no
O	O	appear	no
O	O	before	no
O	O	there	no
O	O	is	yes
O	O	such	no
O	O	a	yes
O	O	fall	no
O	O	in	yes
O	O	the	no
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	Determinations	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	utilizing	no
O	O	commercially	no
O	O	available	no
O	O	kits	no
O	O	with	yes
O	O	an	no
O	O	125I-labelled	no
O	O	antigen	yes
O	O	were	no
O	O	precise	no
O	O	and	yes
O	O	not	no
O	O	materially	no
O	O	different	no
O	O	from	no
O	O	results	no
O	O	obtained	no
O	O	with	yes
O	O	a	yes
O	O	3H-labelled	no
O	O	antigen	yes
O	O	.	no

O	O	At	yes
O	O	least	no
O	O	3	yes
O	O	weeks	no
O	O	should	no
O	O	elapse	no
O	O	between	yes
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	dexfenfluramine	yes
O	O	and	yes
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
O	O	a	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	The	no
O	O	lower	no
O	O	rate	no
O	O	of	yes
O	O	absorption	no
O	O	in	yes
O	O	the	no
O	O	groups	no
O	O	receiving	no
O	O	446	no
O	O	mg	yes
B-drug	B-drug	Fe	yes
O	O	instead	no
O	O	of	yes
O	O	48	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	Fe	yes
O	O	per	no
O	O	kg	no
O	O	diet	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	decreased	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	cobalt	yes
O	O	.	no

B-drug	B-drug	Etofibrate	yes
O	O	elicited	no
O	O	62	no
O	O	%	no
O	O	enhancement	no
O	O	of	yes
O	B-drug	post-heparin	no
O	O	lipolytic	no
O	O	activity	yes
O	O	and	yes
O	O	100	yes
O	O	%	no
O	O	increase	no
O	O	of	yes
B-drug_n	O	3H-triglyceride	no
O	O	fractional	no
O	O	clearance	no
O	O	rate	no
O	O	compared	no
O	O	with	yes
O	O	placebo	no
O	O	treatment	no
O	O	.	no

O	O	Recovery	no
O	O	from	no
O	O	50	yes
O	O	%	no
O	O	twitch	no
O	O	to	no
O	O	75	yes
O	O	%	no
O	O	fade	no
O	O	recovery	no
O	O	took	no
O	O	13.8	no
O	O	+/-	no
O	O	0.8	no
O	O	min	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	alone	no
O	O	and	yes
O	O	13.7	no
O	O	+/-	no
O	O	1.2	no
O	O	min	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	plus	yes
B-drug	B-drug	gentamycin	no
O	O	.	no

O	O	This	no
O	O	increase	no
O	O	is	yes
O	O	due	no
O	O	to	no
O	O	the	no
O	O	inhibition	no
O	O	of	yes
B-drug	B-drug	celecoxib	yes
O	O	metabolism	no
O	O	via	no
O	O	P450	no
O	O	2C9	no
O	O	by	no
B-drug	B-drug	fluconazole	yes
O	O	(	no
O	O	see	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	-	yes
O	O	Pharmacokinetics	no
O	O	:	no
O	O	Metabolism	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Non-pegylated	no
I-drug	I-drug	interferon	yes
I-drug	I-drug	alfa-2a	yes
O	O	treatment	no
O	O	of	yes
O	O	pregnant	no
O	O	Rhesus	no
O	O	monkeys	no
O	O	at	yes
O	O	approximately	no
O	O	20	yes
O	O	to	no
O	O	500	yes
O	O	times	no
O	O	the	no
O	O	human	yes
O	O	weekly	yes
O	O	dose	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	statistically	no
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	abortions	no
O	O	.	no

O	O	In	yes
O	O	monkeys	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	,	no
O	O	but	no
O	O	not	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	or	no
B-drug_n	B-drug_n	PCP	yes
O	O	,	no
O	O	were	no
O	O	antagonized	no
O	O	by	no
B-drug	B-drug	naloxone	yes
O	O	;	no

O	O	In	yes
O	O	monkeys	no
O	O	,	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	was	no
O	O	about	no
O	O	10	yes
O	O	times	no
O	O	more	no
O	O	potent	no
O	O	than	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	in	yes
O	O	decreasing	no
O	O	responding	no
O	O	,	no
O	O	whereas	no
O	O	in	yes
O	O	pigeons	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	was	no
O	O	about	no
O	O	equipotent	no
O	O	with	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	.	no

O	O	Increased	no
O	O	toxicity	no
O	O	(	no
O	O	CNS	no
O	O	depression	no
O	O	)	no
O	O	:	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	,	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	.	no

O	O	Transient	no
O	O	delirium	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	treated	no
O	O	with	yes
O	O	one	no
O	O	gram	no
O	O	of	yes
B-drug	B-drug	ethchlorvynol	yes
O	O	and	yes
O	O	75	yes
O	O	-	yes
O	O	150	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	amitriptyline	yes
I-drug	I-drug	HCl	yes
O	O	.	no

O	O	In	yes
O	O	such	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	mean	no
O	O	area	no
O	O	under	no
O	O	the	no
B-drug	B-drug	felodipine	yes
O	O	plasma	yes
O	O	concentration-time	no
O	O	curve	no
O	O	was	no
O	O	also	no
O	O	reduced	yes
O	O	to	no
O	O	approximately	no
O	O	6	yes
O	O	%	no
O	O	of	yes
O	O	that	no
O	O	observed	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	Several	no
O	O	clinically	no
O	O	important	no
O	O	interactions	no
O	O	have	no
O	O	previously	no
O	O	been	no
O	O	reported	no
O	O	for	yes
O	O	other	no
B-group	B-group	immunosuppressive	no
I-group	I-group	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	same	yes
O	O	enzyme	no
O	O	and	yes
O	O	for	yes
B-group	B-group	calcium	yes
I-group	I-group	antagonists	no
O	O	.	no

B-drug	B-drug	Clarithromycin	yes

O	O	Alteration	no
O	O	of	yes
O	O	pH	yes
O	O	may	no
O	O	affect	no
O	O	absorption	no
O	O	of	yes
O	O	certain	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	)	no
O	O	.	no

O	O	Both	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug_n	B-drug_n	filipin	no
O	O	and	yes
O	O	the	no
O	O	therapeutic	no
O	O	value	no
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	can	no
O	O	be	no
O	O	rationalized	no
O	O	at	yes
O	O	the	no
O	O	cellular	no
O	O	and	yes
O	O	molecular	yes
O	O	level	no
O	O	by	no
O	O	the	no
O	O	following	no
O	O	observations	no
O	O	:	no
O	O	(	no
O	O	i	yes
O	O	)	no
O	O	these	no
B-group	B-group	polyene	no
I-group	I-group	antibiotics	no
O	O	showed	no
O	O	differential	no
O	O	effects	no
O	O	on	no
O	O	cells	yes
O	O	;	no

B-group	B-group	Multivitamins	no
O	O	,	no
O	O	or	no
O	O	other	no
O	O	products	no
O	O	containing	yes
B-drug	B-drug	iron	yes
O	O	or	no
B-drug	B-drug	zinc	yes
O	O	,	no
B-group	B-group	antacids	no
O	O	or	no
B-drug	B-drug	sucralfate	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	,	no
O	O	or	no
O	O	within	no
O	O	2	yes
O	O	hours	no
O	O	of	yes
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	norfloxacin	yes
O	O	,	no
O	O	because	no
O	O	they	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	absorption	no
O	O	resulting	no
O	O	in	yes
O	O	lower	no
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	norfloxacin	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	under	no
O	O	the	no
O	O	influence	no
O	O	of	yes
B-group	O	sympatholytic	no
O	O	medicinal	yes
O	O	products	no
O	O	such	no
O	O	as	yes
B-group	B-group	beta-blockers	no
O	O	,	no
B-drug	B-drug	clonidine	yes
O	O	,	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	the	no
O	O	signs	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	or	no
O	O	absent	no
O	O	.	no

B-drug	B-drug	Valproic	yes
I-drug	I-drug	acid	yes

O	O	May	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	virologic	no
O	O	response	no
O	O	and	yes
O	O	possible	no
O	O	resistance	no
O	O	to	no
B-brand	B-brand	CRIXIVAN	yes
O	O	or	no
O	O	to	no
O	O	the	no
O	O	class	no
O	O	of	yes
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	or	no
O	O	other	no
O	O	coadministered	no
B-group	B-group	antiretroviral	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	myopathy	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	drugs	no
O	O	of	yes
O	O	this	no
O	O	class	no
O	O	is	yes
O	O	increased	no
O	O	with	yes
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-group	B-group	fibric	no
I-group	I-group	acid	yes
I-group	I-group	derivatives	no
O	O	,	no
B-drug	B-drug	niacin	yes
O	O	(	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-group	B-group	azole	no
I-group	I-group	antifungals	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	formal	no
O	O	interaction	no
O	O	study	no
O	O	,	no
B-brand	B-brand	TAMBOCOR	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	were	no
O	O	each	no
O	O	found	no
O	O	to	no
O	O	have	no
O	O	negative	no
O	O	inotropic	no
O	O	effects	no
O	O	;	no

O	O	This	no
O	O	slowing	no
O	O	potentiates	no
B-group	B-group	amphetamines	no
O	O	,	no
O	O	increasing	no
O	O	their	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	release	yes
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	and	yes
O	O	other	no
O	O	monoamines	no
O	O	from	no
O	O	adrenergic	no
O	O	nerve	yes
O	O	endings	no
O	O	;	no

O	O	Physiological	no
O	O	oral	yes
B-drug	B-drug	magnesium	yes
O	O	supplementation	no
O	O	(	no
O	O	5	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	is	yes
O	O	easy	no
O	O	and	yes
O	O	can	no
O	O	be	no
O	O	carried	no
O	O	out	no
O	O	in	yes
O	O	the	no
O	O	diet	no
O	O	or	no
O	O	with	yes
B-drug	B-drug	magnesium	yes
O	O	salts	no
O	O	,	no
O	O	with	yes
O	O	practically	no
O	O	only	no
O	O	one	no
O	O	contra-indication	no
O	O	:	no
O	O	overt	no
O	O	renal	no
O	O	failure	no
O	O	.	no

B-drug	B-drug	Rifampin	yes

O	O	Influence	no
O	O	of	yes
B-group	B-group	AED	no
O	O	On	no
B-drug_n	B-drug_n	MHD	no
O	O	Concentration	no
O	O	(	no
O	O	Mean	no
O	O	change	no
O	O	,	no
O	O	90	yes
O	O	%	no
O	O	Confidence	no
O	O	Interval	no
O	O	)	no

O	O	-	yes
O	O	Drugs	no
O	O	with	yes
O	O	nephrotoxic	no
O	O	potential	no
O	O	:	no
O	O	There	no
O	O	has	no
O	O	been	no
O	O	no	yes
O	O	experience	no
O	O	on	no
O	O	the	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	bumetanide	yes
O	O	with	yes
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	nephrotoxic	no
O	O	potential	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	setting	no
O	O	,	no
B-group	B-group	cardioselective	no
I-group	I-group	beta-blockers	no
O	O	could	no
O	O	be	no
O	O	considered	no
O	O	,	no
O	O	although	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	Before	no
O	O	taking	no
B-drug	B-drug	glimepiride	yes
O	O	,	no
O	O	tell	no
O	O	your	no
O	O	doctor	no
O	O	if	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	medicines	no
O	O	:	no
O	O	-	yes
B-brand	B-brand	aspirin	yes
O	O	or	no
O	O	another	no
B-group	B-group	salicylate	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	magnesium/choline	no
B-group	I-drug	salicylate	yes
O	O	(	no
B-brand	B-brand	Trilisate	yes
O	O	)	no
O	O	,	no
B-group	B-drug	salsalate	yes
O	O	(	no
B-brand	B-brand	Disalcid	yes
O	O	,	no
O	O	others	no
O	O	)	no
O	O	,	no
B-drug	B-drug	choline	yes
I-drug	I-drug	salicylate	yes
O	O	(	no
B-brand	B-drug	Arthropan	no
O	O	)	no
O	O	,	no
B-drug	B-drug	magnesium	yes
I-drug	I-drug	salicylate	yes
O	O	(	no
B-drug	B-brand	Magan	no
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-drug	bismuth	yes
I-drug	I-drug	subsalicylate	yes
O	O	(	no
B-drug	B-brand	Pepto-Bismol	no
O	O	)	no
O	O	;	no

O	O	It	no
O	O	is	yes
O	O	postulated	no
O	O	that	no
O	O	some	no
O	O	of	yes
O	O	the	no
O	O	observed	no
O	O	training-induced	no
O	O	neurobiological	no
O	O	alterations	no
O	O	might	no
O	O	reflect	no
O	O	the	no
O	O	interaction	no
O	O	between	yes
O	O	two	no
O	O	(	no
O	O	or	no
O	O	more	no
O	O	)	no
O	O	competing	no
O	O	memory	no
O	O	systems	no
O	O	at	yes
O	O	the	no
O	O	hippocampal	no
O	O	level	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	by	no
O	O	the	no
B-group	B-group	NSAID	no
O	O	.	no

O	O	Many	no
O	O	people	no
O	O	use	no
O	O	both	no
B-drug	B-drug	alcohol	yes
O	O	and	yes
B-drug	B-drug	nicotine	yes
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	cigarettes	no
O	O	and	yes
O	O	other	no
O	O	tobacco	no
O	O	products	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	reduced	yes
O	O	kidney	yes
O	O	and	yes
O	O	liver	yes
O	O	function	no
O	O	secondary	yes
O	O	to	no
B-brand	B-brand	PROLEUKIN	yes
O	O	treatment	no
O	O	may	no
O	O	delay	no
O	O	elimination	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	adverse	no
O	O	events	no
O	O	from	no
O	O	those	no
O	O	drugs	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Induce	no
O	O	CYP3A4	no
B-drug	B-drug	Rifampin	yes
O	O	:	no
B-drug	O	CYP3A4	no
O	O	is	yes
O	O	ordinarily	no
O	O	a	yes
O	O	minor	no
O	O	metabolizing	no
O	O	enzyme	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	.	no

B-drug	B-drug	Atovaquone	yes
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	protein	yes
O	O	(	no
O	O	99.9	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	and	yes
B-brand	B-brand	Videx	yes
O	O	,	no
O	O	(	no
B-drug	B-drug	Didanosine	yes
O	O	)	no
O	O	,	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	may	no
O	O	substantially	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	systemic	no
O	O	levels	no
O	O	considerably	no
O	O	lower	no
O	O	than	no
O	O	desired	no
O	O	.	no

O	O	No	yes
O	O	specific	no
O	O	pharmacokinetic	no
O	O	or	no
O	O	other	no
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Methylprednisolone	yes

B-group	B-group	Vaccines	no
O	O	neurological	no
O	O	complications	no
O	O	and	yes
O	O	lack	no
O	O	of	yes
O	O	antibody	yes
O	O	response	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	reports	no
O	O	of	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	beyond	no
O	O	the	no
O	O	therapeutic	no
O	O	range	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	concurrent	no
B-drug	B-drug	levamisole	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
I-drug	I-drug	sodium	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	be	no
O	O	monitored	no
O	O	carefully	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
I-drug	I-drug	sodium	yes
O	O	or	no
O	O	other	no
B-group	B-group	coumarin-like	no
I-group	O	drugs	no
O	O	should	no
O	O	be	no
O	O	adjusted	yes
O	O	accordingly	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	can	no
O	O	prolong	no
O	O	bleeding	no
O	O	time	no
O	O	by	no
O	O	approximately	no
O	O	3	yes
O	O	to	no
O	O	4	yes
O	O	minutes	no
O	O	from	no
O	O	baseline	no
O	O	values	no
O	O	.	no

O	O	Time	no
O	O	to	no
O	O	reach	no
O	O	Cmax	no
O	O	is	yes
O	O	also	no
O	O	prolonged	no
O	O	by	no
O	O	1	yes
O	O	hour	yes
O	O	.	no

O	O	There	no
O	O	may	no
O	O	remain	no
O	O	some	no
O	O	indications	no
O	O	of	yes
O	O	the	no
B-group	O	laxative	no
O	O	and	yes
B-group	O	antacid	no
O	O	properties	no
O	O	of	yes
O	O	non	no
O	O	soluble	no
B-drug	B-drug	magnesium	yes
O	O	,	no
O	O	particularly	no
O	O	during	no
O	O	intermittent	no
O	O	haemodialysis	no
O	O	.	no

O	O	Increased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	were	no
O	O	observed	no
O	O	12	yes
O	O	hours	no
O	O	after	no
O	O	dosing	no
O	O	and	yes
O	O	onwards	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	possible	no
O	O	clinical	no
O	O	significance	no
O	O	,	no
O	O	these	no
O	O	two	no
O	O	drugs	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

O	O	increased	no
O	O	thyroid	yes
O	O	binding	no
O	O	globulin	yes
O	O	(	no
O	O	TBG	no
O	O	)	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	circulating	no
O	O	total	yes
O	O	thyroid	yes
O	O	hormone	yes
O	O	,	no
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	PBI	no
O	O	,	no
O	O	T4	yes
O	O	by	no
O	O	column	no
O	O	,	no
O	O	or	no
O	O	T4	yes
O	O	by	no
O	O	radioimmunoassay	no
O	O	.	no

O	O	Whether	no
O	O	an	no
O	O	alteration	no
O	O	in	yes
B-drug	B-drug	norepinephrine	yes
O	O	uptake-1	no
O	O	occurs	no
O	O	is	yes
O	O	still	no
O	O	unresolved	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	altered	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
B-brand	B-brand	Ponstel	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	Interactions	no
O	O	for	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	(	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D2	yes
O	O	,	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D3	yes
O	O	,	no
B-drug	B-drug	Calcitriol	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Calcidiol	yes
O	O	)	no
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	fat	yes
I-group	I-group	soluble	no
I-group	I-group	vitamins	no
O	O	;	no

O	O	Reported	no
O	O	examples	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	include	no
O	O	the	no
O	O	following	no
O	O	:	no
B-group	B-drug	Immunosuppressives	no
O	O	:	no
B-drug	B-drug	Cyclosporine	yes
O	O	(	no
B-drug	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	produce	no
O	O	persistently	no
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	resulting	no
O	O	in	yes
O	O	elevated	no
O	O	creatinine	yes
O	O	,	no
O	O	despite	no
O	O	reduction	yes
O	O	in	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	results	no
O	O	from	no
O	O	regression	no
O	O	analyses	no
O	O	of	yes
O	O	patient	no
O	O	pharmacokinetic	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	co-administration	no
O	O	of	yes
O	O	other	no
O	O	inducers	no
O	O	of	yes
O	O	drug	yes
O	O	clearance	no
O	O	(	no
B-drug	B-drug	efavirenz	yes
O	O	,	no
B-drug	B-drug	nevirapine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	carbamazepine	yes
O	O	)	no
O	O	with	yes
B-brand	B-brand	CANCIDAS	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	clinically	no
O	O	meaningful	no
O	O	reductions	no
O	O	in	yes
B-drug	B-drug	caspofungin	yes
O	O	concentrations	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	isozymes	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	.	no

B-drug	O	Insulin	yes
O	O	parameters	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	.	no

O	O	Specific	no
O	O	and	yes
O	O	aspecific	no
O	O	treatments	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	depletion	no
O	O	are	no
O	O	tricky	no
O	O	using	no
O	O	for	yes
O	O	example	no
B-drug	B-group	magnesium	yes
O	I-group	sparing	no
B-group	I-group	diuretics	no
O	O	,	no
O	O	pharmacological	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B6	yes
O	O	,	no
O	O	physiological	no
O	O	doses	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	and	yes
O	O	of	yes
B-drug	B-drug	selenium	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	precaution	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
O	O	coadministration	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	O	Mefloquineuine	no
O	O	on	no
O	O	the	no
O	O	compromised	no
O	O	cardiovascular	no
O	O	system	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	this	no
O	O	difference	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	therefore	no
O	O	advised	no
O	O	in	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	ATROVENT	yes
O	O	Inhalation	no
O	O	Aerosol	no
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinergic-containing	no
I-group	O	drugs	no
O	O	.	no

B-drug	B-drug	Amphotericin	yes
I-drug	I-drug	B	yes
O	O	injection	yes
O	O	and	yes
B-group	O	potassium-depleting	no
I-group	O	agents	yes
O	O	:	no
O	O	When	no
B-group	B-group	corticosteroids	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-group	O	potassium-depleting	no
I-group	O	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
B-group	B-group	diuretics	no
O	O	)	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	development	no
O	O	of	yes
O	O	hypokalemia	no
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	relevant	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	anagrelide	yes
O	O	and	yes
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	were	no
O	O	observed	no
O	O	.	no

O	O	SETTING	no
O	O	:	no
O	O	Rural	no
O	O	primary	no
O	O	care	yes
O	O	centre	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	with	yes
O	O	other	no
O	O	members	no
O	O	of	yes
O	O	the	no
B-group	B-group	quinolone	no
I-group	I-group	class	no
O	O	.	no

O	O	Wait	no
O	O	2	yes
O	O	weeks	no
O	O	after	no
O	O	stopping	no
O	O	an	no
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	before	no
O	O	starting	no
B-drug	B-drug	escitalopram	yes
O	O	.	no

B-drug	B-drug	Tolbutamide	yes
O	O	:	no
B-drug	B-drug	Aprepitant	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	as	yes
O	O	125	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	80	yes
O	O	mg/day	no
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	and	yes
O	O	3	yes
O	O	,	no
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	(	no
O	O	a	yes
O	O	CYP2C9	no
O	O	substrate	yes
O	O	)	no
O	O	by	no
O	O	23	no
O	O	%	no
O	O	on	no
O	O	Day	no
O	O	4	yes
O	O	,	no
O	O	28	yes
O	O	%	no
O	O	on	no
O	O	Day	no
O	O	8	yes
O	O	,	no
O	O	and	yes
O	O	15	yes
O	O	%	no
O	O	on	no
O	O	Day	no
O	O	15	yes
O	O	,	no
O	O	when	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	500	yes
O	O	mg	yes
O	O	was	no
O	O	admini	no
O	O	,	no
O	O	stered	no
O	O	orally	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	the	no
O	O	3-day	no
O	O	regimen	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	and	yes
O	O	on	no
O	O	Days	no
O	O	4,8	no
O	O	,	no
O	O	and	yes
O	O	15	yes
O	O	.	no

O	O	increased	no
O	O	factors	no
O	O	II	yes
O	O	,	no
O	O	VII	yes
O	O	antigen	yes
O	O	,	no
O	O	VIII	yes
O	O	antigen	yes
O	O	,	no
O	O	VIII	yes
O	O	coagulant	yes
O	O	activity	yes
O	O	,	no
O	O	IX	yes
O	O	,	no
O	O	X	yes
O	O	,	no
O	O	XII	no
O	O	,	no
O	O	VII-X	no
O	O	complex	yes
O	O	,	no
O	O	II-VII-X	no
O	O	complex	yes
O	O	,	no
O	O	and	yes
O	O	beta-thromboglobulin	no
O	O	;	no

O	O	There	no
O	O	is	yes
O	O	one	no
O	O	report	no
O	O	of	yes
O	O	cardiopulmonary	no
O	O	arrest	no
O	O	,	no
O	O	with	yes
O	O	full	no
O	O	recovery	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	who	no
O	O	was	no
O	O	taking	no
O	O	a	yes
B-group	B-group	beta	yes
I-group	I-group	blocker	no
O	O	(	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	.	no

O	O	Such	no
O	O	agents	yes
O	O	must	no
O	O	be	no
O	O	discontinued	no
O	O	at	yes
O	O	least	no
O	O	seven	no
O	O	days	no
O	O	prior	no
O	O	to	no
O	O	starting	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	VISTIDE	yes
O	O	.	no

B-drug	B-drug	Ephedrine	yes
O	O	:	no
B-drug	B-drug	Ephedrine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	decreased	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	lessened	no
O	O	physiologic	no
O	O	activity	yes
O	O	,	no
O	O	thus	no
O	O	requiring	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-group	B-group	corticosteroid	no
O	O	dosage	no
O	O	.	no

O	O	-	yes
B-group	B-group	Anabolic	no
I-group	I-group	steroids	no
O	O	(	no
B-drug	B-drug	nandrolone	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Anabolin	no
O	O	]	no
O	O	,	no
B-drug	B-drug	oxandrolone	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Anavar	no
O	O	]	no
O	O	,	no
B-drug	B-drug	oxymetholone	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Anadrol	no
O	O	]	no
O	O	,	no
B-drug	B-drug	stanozolol	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Winstrol	yes
O	O	]	no
O	O	)	no
O	O	or	no

O	O	When	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	felodipine	yes
O	O	,	no
O	O	the	no
B-drug	B-drug	tacrolimus	yes
O	O	blood	yes
O	O	concentration	no
O	O	should	no
O	O	be	no
O	O	followed	no
O	O	and	yes
O	O	the	no
B-drug	O	tacrolimus	yes
O	O	dose	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	adjusted	yes
O	O	.	no

O	O	Increased	no
O	O	anticoagulation	no
O	O	effects	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	may	no
O	O	be	no
O	O	more	no
O	O	pronounced	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	.	no

O	O	A	yes
O	O	specific	no
O	O	treatment	no
O	O	for	yes
O	O	extravasation	no
O	O	reactions	no
O	O	is	yes
O	O	unknown	no
O	O	at	yes
O	O	this	no
O	O	time	no
O	O	.	no

O	O	An	no
O	O	interval	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	two	no
O	O	hours	no
O	O	between	yes
O	O	intake	no
O	O	of	yes
O	O	this	no
O	O	agent	yes
O	O	and	yes
B-drug	B-drug	chloroquine	yes
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	.	no

B-group	B-group	Amphetamines	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	antihypertensives	no
O	O	.	no

O	O	Although	no
O	O	one	no
O	O	study	no
O	O	tentatively	no
O	O	supports	no
O	O	the	no
O	O	hypothesis	no
O	O	that	no
O	O	such	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	may	no
O	O	be	no
O	O	efficacious	no
O	O	,	no
O	O	a	yes
O	O	second	no
O	O	study	no
O	O	by	no
O	O	the	no
O	O	same	yes
O	O	group	yes
O	O	did	no
O	O	not	no
O	O	confirm	no
O	O	the	no
O	O	significant	no
O	O	findings	no
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	clear	no
O	O	,	no
O	O	reproducible	no
O	O	pattern	no
O	O	of	yes
O	O	efficacy	no
O	O	has	no
O	O	emerged	no
O	O	from	no
O	O	the	no
O	O	review	no
O	O	of	yes
O	O	all	yes
O	O	the	no
O	O	evidence	no
O	O	.	no

O	O	This	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	Benedict	no
O	O	s	yes
O	O	and	yes
O	O	Fehling	no
O	O	s	yes
O	O	solutions	no
O	O	and	yes
O	O	also	no
O	O	with	yes
O	O	Clinitest	no
O	O	tablets	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	dose	no
O	O	adjustments	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	that	no
O	O	are	no
O	O	predominantly	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	and	yes
O	O	have	no
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	index	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	,	no
B-drug	B-drug	vinblastine	yes
O	O	,	no
B-drug	B-drug	thioridazine	yes
O	O	and	yes
O	O	most	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	)	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	quinolone	no
I-group	I-group	antibiotics	no
O	O	are	no
O	O	decreased	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
O	O	,	no
B-drug	B-drug	calcium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	aluminum	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	patients	no
O	O	receiving	no
O	O	infusions	no
O	O	of	yes
B-brand	B-brand	FLOLAN	yes
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	were	no
O	O	maintained	no
O	O	on	no
B-group	B-group	anticoagulants	no
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	increased	no
O	O	bleeding	no
O	O	.	no

O	O	Monitoring	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	levels	no
O	O	and	yes
O	O	possible	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	dosage	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	co-administered	no
O	O	.	no

O	O	Since	no
B-drug	B-drug	amiodarone	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	B-drug	CYP3A4	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	the	no
O	O	potential	no
O	O	that	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	Wort	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	amiodarone	yes
O	O	could	no
O	O	result	no
O	O	in	yes
O	O	reduced	yes
B-drug	B-drug	amiodarone	yes
O	O	levels	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	decreases	no
O	O	in	yes
O	O	exposure	yes
O	O	were	no
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	56	yes
O	O	%	no
O	O	and	yes
O	O	66	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	in	yes
O	O	individual	no
O	O	subjects	no
O	O	.	no

O	O	Drug	yes
O	O	Class	no

O	O	High	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cefoxitin	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	measurement	no
O	O	of	yes
O	O	urinary	yes
O	O	17-hydroxy-corticosteroids	no
O	O	by	no
O	O	the	no
O	O	Porter-Silber	no
O	O	reaction	no
O	O	,	no
O	O	and	yes
O	O	produce	no
O	O	false	no
O	O	increases	no
O	O	of	yes
O	O	modest	no
O	O	degree	no
O	O	in	yes
O	O	the	no
O	O	levels	no
O	O	reported	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	total	yes
B-drug	B-drug	ertapenem	yes
O	O	concentrations	no
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	by	no
O	O	25	yes
O	O	%	no
O	O	and	yes
O	O	reduced	yes
O	O	the	no
O	O	plasma	yes
O	O	and	yes
O	O	renal	no
O	O	clearances	no
O	O	by	no
O	O	20	yes
O	O	%	no
O	O	and	yes
O	O	35	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	CASE	no
O	O	SUMMARY	no
O	O	:	no
O	O	A	yes
O	O	64-year-old	no
O	O	African-American	no
O	O	man	no
O	O	was	no
O	O	admitted	no
O	O	to	no
O	O	the	no
O	O	hospital	no
O	O	for	yes
O	O	worsening	no
O	O	renal	no
O	O	failure	no
O	O	,	no
O	O	elevated	no
O	O	creatine	yes
O	O	phosphokinase	no
O	O	,	no
O	O	diffuse	no
O	O	muscle	no
O	O	pain	yes
O	O	,	no
O	O	and	yes
O	O	severe	no
O	O	muscle	no
O	O	weakness	no
O	O	.	no

B-drug	B-drug	Allopurinol	yes
O	O	:	no
O	O	Increased	no
O	O	possibility	no
O	O	of	yes
O	O	skin	yes
O	O	rash	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	hyperuricemic	no
O	O	patients	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
O	B-group	xanthine	yes
O	I-group	derivatives	no
O	O	in	yes
O	O	a	yes
O	O	light/dark	no
O	O	test	yes
O	O	in	yes
O	O	mice	no
O	O	and	yes
O	O	the	no
O	O	contribution	no
O	O	of	yes
O	O	adenosine	yes
O	O	receptors	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	on	no
B-drug	B-drug	propranolol	yes
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	when	no
B-brand	B-brand	COLESTID	yes
O	O	Tablets	yes
O	O	are	no
O	O	either	no
O	O	added	no
O	O	or	no
O	O	deleted	no
O	O	from	no
O	O	a	yes
O	O	therapeutic	no
O	O	regimen	no
O	O	.	no

B-group	B-group	Phenothiazines	no
O	O	and	yes
B-group	B-group	butyrophenones	no
O	O	may	no
O	O	reduce	no
O	O	or	no
O	O	reverse	no
O	O	the	no
O	O	pressor	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	reports	no
O	O	of	yes
O	O	skeletal	no
O	O	myopathy	no
O	O	in	yes
O	O	a	yes
O	O	placebo-controlled	no
O	O	Phase	no
O	O	I	yes
O	O	trial	no
O	O	in	yes
O	O	which	no
O	O	10	yes
O	O	healthy	no
O	O	subjects	no
O	O	on	no
O	O	stable	no
B-drug	B-drug	simvastatin	yes
O	O	therapy	no
O	O	were	no
O	O	treated	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	daptomycin	yes
O	O	(	no
O	O	4	yes
O	O	mg/kg	no
O	O	once	no
O	O	every	no
O	O	24	yes
O	O	hours	no
O	O	)	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	.	no

O	O	METHODS	no
O	O	:	no
O	O	We	no
O	O	carried	no
O	O	out	no
O	O	two	no
O	O	different	no
O	O	3-way	no
O	O	crossover	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	(	no
O	O	each	no
O	O	,	no
O	O	n	yes
O	O	=	no
O	O	9	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	under	no
O	O	the	no
O	O	influence	no
O	O	of	yes
B-group	O	sympatholytic	no
O	O	medicinal	yes
O	O	products	no
O	O	such	no
O	O	as	yes
B-group	B-group	beta-blockers	no
O	O	,	no
B-drug	B-drug	clonidine	yes
O	O	,	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	the	no
O	O	signs	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	or	no
O	O	absent	no
O	O	.	no

O	O	Since	no
B-group	B-group	barbiturates	no
O	O	are	no
O	O	potentiated	no
O	O	by	no
O	O	the	no
B-group	B-group	anticholinesterases	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	convulsions	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	medications	no
O	O	that	no
O	O	interfere	no
O	O	with	yes
O	O	platelet	yes
O	O	function	no
O	O	or	no
O	O	coagulation	yes
O	O	should	no
O	O	have	no
O	O	more	no
O	O	frequent	no
O	O	laboratory	no
O	O	monitoring	no
O	O	for	yes
O	O	thrombocytopenia	no
O	O	.	no

O	O	Pre-treatment	no
O	O	with	yes
O	O	the	no
O	O	CYP3A4	no
O	O	inducer	no
B-drug	B-drug	rifampicin	yes
O	O	decreased	no
B-drug	B-drug	erlotinib	yes
O	O	AUC	no
O	O	by	no
O	O	about	no
O	O	2/3	no
O	O	.	no

O	O	These	no
O	O	doses	no
O	O	are	no
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	therapeutic	no
O	O	doses	no
O	O	for	yes
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	as	yes
B-group	O	sole	no
I-group	B-group	protease	yes
I-group	I-group	inhibitor	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	:	no
O	O	Studies	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	showed	no
O	O	that	no
B-drug	B-drug	vardenafil	yes
O	O	is	yes
O	O	metabolized	no
O	O	primarily	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	isoforms	no
O	O	3A4/5	no
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	a	yes
O	O	lesser	no
O	O	degree	no
O	O	by	no
B-drug	O	CYP2C9	no
O	O	.	no

O	O	Careful	no
O	O	observation	no
O	O	is	yes
O	O	required	no
O	O	when	no
B-drug	B-drug	amantadine	yes
O	O	is	yes
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	stimulants	no
O	O	.	no

B-brand	B-brand	Accutane	yes
O	O	use	no
O	O	is	yes
O	O	associated	no
O	O	with	yes
O	O	depression	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-group	B-group	Antiretroviral	no
O	O	regimens	no
O	O	consisted	no
O	O	of	yes
O	O	two	no
B-group	B-group	reverse	no
I-group	I-group	transcriptase	no
I-group	I-group	inhibitors	no
O	O	and	yes
O	O	one	no
B-group	B-group	protease	yes
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	If	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	AXERT	yes
O	O	and	yes
O	O	an	no
B-group	B-group	SSRI	no
O	O	is	yes
O	O	clinically	no
O	O	warranted	no
O	O	,	no
O	O	appropriate	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	advised	no
O	O	.	no

B-drug	B-drug	Fenbufen	yes
O	O	is	yes
O	O	not	no
O	O	approved	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	States	no
O	O	at	yes
O	O	this	no
O	O	time	no
O	O	.	no

B-group	O	weaker	no
I-group	O	inhibitors	no
O	O	(	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	grapefruit	no
O	O	juice	no
O	O	)	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	using	no
B-drug	B-drug	loxapine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	CNS-active	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	.	no

O	O	In	yes
O	O	practice	no
O	O	,	no
O	O	the	no
O	O	greatest	no
O	O	value	no
O	O	of	yes
O	O	the	no
O	O	thioether	no
O	O	assay	no
O	O	appears	no
O	O	to	no
O	O	lie	no
O	O	in	yes
O	O	its	no
O	O	signal	no
O	O	function	no
O	O	.	no

O	O	Renal	no
O	O	clearance	no
O	O	of	yes
O	O	ucb	no
O	O	L057	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	decreased	no
O	O	60	no
O	O	%	no
O	O	,	no
O	O	probably	no
O	O	related	yes
O	O	to	no
O	O	competitive	no
O	O	inhibition	no
O	O	of	yes
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
O	O	ucb	no
O	O	L057	no
O	O	.	no

O	O	Fat	yes
O	O	redistribution	no
O	O	:	no
O	O	Redistribution/accumulation	no
O	O	of	yes
O	O	body	no
O	O	fat	yes
O	O	including	no
O	O	central	no
O	O	obesity	no
O	O	,	no
O	O	dorsocervical	no
O	O	fat	yes
O	O	enlargement	no
O	O	(	no
O	O	buffalo	no
O	O	hump	no
O	O	)	no
O	O	,	no
O	O	peripheral	no
O	O	wasting	no
O	O	,	no
O	O	facial	no
O	O	wasting	no
O	O	,	no
O	O	breast	no
O	O	enlargement	no
O	O	,	no
O	O	and	yes
O	O	cushingoid	no
O	O	appearance	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	antiretroviral	no
O	O	therapy	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	with	yes
O	O	chronic	no
O	O	hepatitis	yes
O	O	C	yes
O	O	treated	no
O	O	with	yes
B-brand	B-brand	PEGASYS	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	COPEGUS	yes
O	O	,	no
B-brand	B-brand	PEGASYS	yes
O	O	treatment	no
O	O	did	no
O	O	not	no
O	O	affect	no
B-drug	B-drug	ribavirin	yes
O	O	distribution	no
O	O	or	no
O	O	clearance	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	several	no
O	O	cardiovascular	no
O	O	drugs	no
O	O	directly	no
O	O	affect	no
O	O	renal	no
O	O	function	no
O	O	and	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	disease	no
O	O	.	no

O	O	FREQUENT	no
O	O	PROTHROMBIN	yes
O	O	TIME/INR	no
O	O	DETERMINATIONS	no
O	O	ARE	no
O	O	ADVISABLE	no
O	O	UNTIL	no
O	O	IT	no
O	O	HAS	no
O	O	BEEN	no
O	O	DEFINITELY	no
O	O	DETERMINED	no
O	O	THAT	no
O	O	THE	no
O	O	PROTHROMBIN	yes
O	O	TIME/INR	no
O	O	HAS	no
O	O	STABILIZED	no
O	O	.	no

B-brand	B-brand	PEGASYS	yes
O	O	and	yes
B-brand	B-brand	COPEGUS	yes
O	O	are	no
O	O	excreted	no
O	O	by	no
O	O	the	no
O	O	kidney	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	toxic	no
O	O	reactions	no
O	O	to	no
O	O	this	no
O	O	therapy	no
O	O	may	no
O	O	be	no
O	O	greater	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	.	no

B-group	O	Volatile	no
I-group	B-drug	Anesthetic	no
I-group	O	Agents	yes
O	O	:	no
O	O	.	no

B-drug	B-drug	Lansoprazole	yes
O	O	is	yes
O	O	metabolized	no
O	O	through	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	,	no
O	O	specifically	no
O	O	through	no
O	O	the	no
O	O	CYP3A	no
O	O	and	yes
O	O	CYP2C19	no
O	O	isozymes	no
O	O	.	no

O	O	Cholinergic	no
O	O	role	no
O	O	in	yes
B-drug	B-drug	alcohol	yes
O	O	's	no
O	O	effects	no
O	O	on	no
O	O	evoked	no
O	O	potentials	no
O	O	in	yes
O	O	visual	no
O	O	cortex	no
O	O	of	yes
O	O	the	no
O	O	albino	no
O	O	rat	yes
O	O	.	no

O	O	alopecia	no

O	O	Use	no
O	O	in	yes
O	O	Ambulatory	no
O	O	Patients	no
O	O	The	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	ROMAZICON	yes
O	O	may	no
O	O	wear	no
O	O	off	no
O	O	before	no
O	O	a	yes
O	B-group	long-acting	no
B-group	I-group	benzodiazepine	yes
O	O	is	yes
O	O	completely	no
O	O	cleared	no
O	O	from	no
O	O	the	no
O	O	body	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	critically	no
O	O	important	no
O	O	for	yes
O	O	women	yes
O	O	of	yes
O	O	childbearing	no
O	O	potential	no
O	O	to	no
O	O	select	no
O	O	and	yes
O	O	commit	yes
O	O	to	no
O	O	use	no
O	O	2	yes
O	O	forms	no
O	O	of	yes
O	O	effective	no
O	O	contraception	no
O	O	simultaneously	no
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	1	yes
O	O	of	yes
O	O	which	no
O	O	must	no
O	O	be	no
O	O	a	yes
O	O	primary	no
O	O	form	yes
O	O	,	no
O	O	unless	no
O	O	absolute	yes
O	O	abstinence	no
O	O	is	yes
O	O	the	no
O	O	chosen	no
O	O	method	yes
O	O	,	no
O	O	or	no
O	O	the	no
O	O	patient	no
O	O	has	no
O	O	undergone	no
O	O	a	yes
O	O	hysterectomy	no

O	O	Pharmacokinetics	no
O	O	were	no
O	O	assessed	no
O	O	in	yes
O	O	two	no
O	O	of	yes
O	O	these	no
O	O	trials	no
O	O	.	no

O	O	increased	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	may	no
O	O	result	no
O	O	.	no

B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	;	no

O	O	There	no
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	adverse	no
O	O	events	no
O	O	in	yes
O	O	subjects	no
O	O	who	no
O	O	received	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	and	yes
B-drug	B-drug	loratadine	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	numerous	no
O	O	potentiation	no
O	O	effects	no
O	O	have	no
O	O	frequently	no
O	O	been	no
O	O	reported	no
O	O	for	yes
O	O	combined	no
O	O	exposure	yes
O	O	to	no
O	O	substances	no
O	O	of	yes
O	O	widespread	no
O	O	use	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	its	no
O	O	lack	no
O	O	of	yes
O	O	platelet	yes
O	O	effects	no
O	O	,	no
B-brand	B-brand	VIOXX	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substitute	no
O	O	for	yes
B-brand	B-brand	aspirin	yes
O	O	for	yes
O	O	cardiovascular	no
O	O	prophylaxis	no
O	O	.	no

B-group	B-drug	Monoamine	no
I-group	I-drug	Oxidase	yes
I-group	I-drug	Inhibitors	no
O	O	:	no
B-drug	B-drug	Guanethidine	yes
O	O	or	no
O	O	similarly	no
O	O	acting	yes
O	O	compounds	no
O	O	;	no

O	O	Since	no
O	O	blood	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	will	no
O	O	be	no
O	O	reduced	yes
O	O	,	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Rocaltrol	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	if	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	simultaneously	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	post-marketing	no
O	O	observations	no
O	O	,	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	taking	no
O	O	this	no
O	O	medicine	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	azithromycin	yes
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	Cytochrome	no
O	O	P450IID6	no
O	O	(	no
O	O	CYP2D6	no
O	O	)	no
O	O	:	no
O	O	Many	no
O	O	drugs	no
O	O	,	no
O	O	including	no
O	O	most	no
B-group	B-group	antidepressants	no
O	O	(	no
B-group	O	SSRIs	no
O	O	,	no
O	O	many	no
B-group	B-group	tricyclics	no
O	O	)	no
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	,	no
B-group	B-drug	antiarrhythmics	no
O	O	,	no
O	O	and	yes
B-group	B-group	antipsychotics	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	CYP2D6	no
O	O	isoenzyme	no
O	O	.	no

O	O	Moreover	no
O	O	,	no
O	O	each	no
O	O	task	no
O	O	induced	no
O	O	significant	no
O	O	alterations	no
O	O	in	yes
O	O	hippocampal	no
O	O	adenylate	yes
O	O	cyclase	no
O	O	activity	yes
O	O	but	no
O	O	in	yes
O	O	opposite	no
O	O	directions	no
O	O	.	no

O	O	Registered	no
O	O	trademark	no
O	O	of	yes
O	O	Ames	no
O	O	Company	no
O	O	,	no
O	O	Division	no
O	O	of	yes
O	O	Miles	no
O	O	Laboratories	no
O	O	,	no
O	O	Inc	no
O	O	.	no

O	O	Twenty	no
O	O	four	no
O	O	male	no
O	O	Wistar	no
O	O	rats	no
O	O	were	no
O	O	divided	no
O	O	into	no
O	O	four	no
O	O	groups	no
O	O	.	no

B-drug	B-drug	Quinidine	yes
O	O	:	no
O	O	Immediate	no
O	O	Release	yes
O	O	Capsules	no
O	O	:	no
O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	reports	no
O	O	of	yes
O	O	an	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	quinidine	yes
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	(	no
O	O	with	yes
O	O	a	yes
O	O	decreased	no
O	O	plasma	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	known	no
O	O	drug	yes
O	O	interference	no
O	O	with	yes
O	O	standard	yes
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	The	no
O	O	absorption	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	gemifloxacin	yes
O	O	is	yes
O	O	significantly	no
O	O	reduced	yes
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	an	no
B-group	B-group	antacid	no
O	O	containing	yes
B-drug	B-drug	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Phenytoin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Dilantin	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	with	yes
B-drug	B-drug	sulfapyridine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	liver	yes
O	O	and/or	no
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes

O	O	Multivalent	no
O	O	Cation-Containing	no
O	O	Products	no
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	quinolone	no
O	O	,	no
O	O	including	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	with	yes
B-group	O	multivalent	no
I-group	O	cation-containing	no
I-group	O	products	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	magnesium	yes
O	O	or	no
B-drug	B-drug	aluminum	yes
B-group	B-group	antacids	no
O	O	,	no
B-drug	B-drug	sucralfate	yes
O	O	,	no
B-brand	B-brand	VIDEX	yes
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	pediatric	yes
O	O	powder	yes
O	O	,	no
O	O	or	no
O	O	products	no
O	O	containing	yes
B-drug	B-drug	calcium	yes
O	O	,	no
B-drug	B-drug	iron	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	zinc	yes
O	O	may	no
O	O	substantially	no
O	O	decrease	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	levels	no
O	O	considerably	no
O	O	lower	no
O	O	than	no
O	O	desired	no
O	O	.	no

O	O	Compounds	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	tested	no
O	O	in	yes
O	O	man	no
O	O	include	no
B-drug	B-drug	antipyrine	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
O	O	no	yes
O	O	clinically	no
O	O	meaningful	no
O	O	interactions	no
O	O	were	no
O	O	found	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	adequate	no
O	O	and	yes
O	O	well-controlled	no
O	O	studies	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	in	yes
O	O	pregnant	no
O	O	women	yes
O	O	.	no

B-drug	B-drug	cholestyramine	yes
O	O	;	no

O	O	cases	no
O	O	of	yes
O	O	rhabdomyolysis	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	seriously	no
O	O	ill	no
O	O	patients	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
B-drug	B-drug	theophylline-related	no
O	O	side	no
O	O	effects	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-group	B-group	quinolones	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	.	no

O	O	Use	no
O	O	with	yes
O	O	Other	no
O	O	Agents	yes
O	O	Affecting	no
O	O	Myelopoesis	no
O	O	:	no
O	O	Drugs	no
O	O	which	no
O	O	may	no
O	O	affect	no
O	O	leukocyte	no
O	O	production	no
O	O	,	no
O	O	including	no
B-drug	B-brand	co-trimoxazole	no
O	O	,	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	exaggerated	no
O	O	leukopenia	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	renal	no
O	O	transplant	no
O	O	recipients	no
O	O	.	no

O	O	Together	no
O	O	with	yes
O	O	previous	no
O	O	findings	no
O	O	,	no
O	O	these	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	hippocampus	no
O	O	is	yes
O	O	involved	no
O	O	in	yes
O	O	both	no
O	O	the	no
O	O	so-called	no
O	O	"	no
O	O	hippocampal-dependent	no
O	O	"	no

O	O	A	yes
O	O	clinical	no
O	O	interaction	no
O	O	study	no
O	O	was	no
O	O	also	no
O	O	conducted	no
O	O	with	yes
B-drug	B-drug	alosetron	yes
O	O	and	yes
O	O	the	no
O	O	CYP3A4	no
O	O	substrate	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	actively	no
O	O	secreted	no
O	O	via	no
O	O	this	no
O	O	route	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
B-drug	B-drug	metformin	yes
O	O	and	yes
B-drug	B-drug	amiloride	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
O	O	care	yes
O	O	as	yes
O	O	they	no
O	O	might	no
O	O	increase	no
B-drug	B-drug	dofetilide	yes
O	O	levels	no
O	O	.	no

O	O	Endothelium-intact	no
O	O	aortic	no
O	O	rings	no
O	O	from	no
O	B-drug	high-estradiol	no
O	O	rats	no
O	O	were	no
O	O	supersensitive	no
O	O	to	no
B-drug	B-drug	noradrenaline	yes
O	O	when	no
O	O	compared	no
O	O	to	no
O	O	vehicle-	no
O	O	,	no
O	B-drug	progesterone-	no
O	O	and	yes
B-drug	B-drug	progesterone	yes
O	O	+	no
O	O	high-estradiol-treated	no
O	O	rats	no
O	O	(	no
O	O	pD2	no
O	O	values	no
O	O	=	no
O	O	7.77+/-0.12	no
O	O	,	no
O	O	7.21+/-0.13	no
O	O	,	no
O	O	6.93+/-0.04	no
O	O	and	yes
O	O	7.22+/-0.18	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	.	no

O	O	A	yes
O	O	potential	no
O	O	interaction	no
O	O	between	yes
O	O	oral	yes
B-drug	B-drug	miconazole	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	leading	no
O	O	to	no
O	O	severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	as	yes
O	O	such	no
O	O	it	no
O	O	may	no
O	O	impair	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
O	O	any	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	Elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	some	no
B-group	B-group	quinolones	no
O	O	.	no

O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	data	no
O	O	described	no
O	O	in	yes
O	O	this	no
O	O	section	no
O	O	were	no
O	O	obtained	no
O	O	from	no
O	O	controlled	no
O	O	clinical	no
O	O	trials	no
O	O	and	yes
O	O	studies	no
O	O	involving	no
O	O	otherwise	no
O	O	healthy	no
O	O	adults	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	decreased	no
B-drug	B-drug	antithrombin	yes
O	I-drug	3	yes
O	O	;	no

O	O	The	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-group	B-group	sulfonylureas	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	certain	no
O	O	drugs	no
O	O	including	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-drug	B-drug	chloramphenicol	yes
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	,	no
B-group	B-group	coumarins	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
O	O	both	no
O	O	the	no
O	O	(	no
O	O	R	yes
O	O	)	no
O	O	and	yes
O	O	(	no
O	O	S	yes
O	O	)	no
O	O	isomers	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	were	no
O	O	unaffected	no
O	O	by	no
O	O	concurrent	no
O	O	dosing	no
O	O	of	yes
O	O	0.3	yes
O	O	mg	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	celecoxib	yes
O	O	have	no
O	O	identified	no
O	O	potentially	no
O	O	significant	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	fluconazole	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	.	no

B-drug	B-drug	Rifabutin	yes

B-group	B-group	Digitalis	yes

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	and	yes
O	O	long-term	no
O	O	consequences	no
O	O	of	yes
O	O	these	no
O	O	events	no
O	O	are	no
O	O	currently	no
O	O	unknown	no
O	O	.	no

O	O	-	yes
B-group	B-group	Estrogens	yes
O	O	(	no
O	O	female	no
B-group	O	hormones	no
O	O	)	no
O	O	or	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	lead	no
O	O	to	no
O	O	hypotension	no
O	O	and	yes
O	O	bradycardia	no
O	O	.	no

O	O	As	yes
O	O	immediate-early	no
O	O	genes	no
O	O	(	no
O	O	IEGs	no
O	O	)	no
O	O	are	no
O	O	thought	no
O	O	to	no
O	O	play	no
O	O	a	yes
O	O	critical	no
O	O	role	no
O	O	in	yes
O	O	mediating	no
O	O	stimulus-induced	no
O	O	neural	no
O	O	plasticity	no
O	O	,	no
O	O	IEG	no
O	O	response	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	methamphetamine	yes
O	O	(	no
B-drug	B-drug	METH	no
O	O	)	no
O	O	has	no
O	O	been	no
O	O	characterized	no
O	O	to	no
O	O	define	no
O	O	the	no
O	O	changes	no
O	O	in	yes
O	O	gene	yes
O	O	expression	no
O	O	that	no
O	O	may	no
O	O	underlie	no
O	O	its	no
O	O	long-lasting	no
O	O	behavioral	no
O	O	effects	no
O	O	.	no

O	O	In	yes
O	O	seven	no
O	O	experiments	no
O	O	reactions	no
O	O	to	no
B-drug	B-drug	norepinephrine	yes
O	O	and	yes
B-drug	B-drug	oxytocin	yes
O	O	were	no
B-drug	B-drug	PGF2alpha	yes
O	O	.	no

O	O	Both	no
B-drug	B-drug	itraconazole	yes
O	O	and	yes
O	O	its	no
O	O	major	no
O	O	metabolite	yes
O	O	,	no
B-drug_n	B-drug_n	hydroxyitraconazole	no
O	O	,	no
O	O	are	no
O	O	inhibitors	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	Prothrombin	yes
O	O	times	no
O	O	were	no
O	O	measured	no
O	O	four	no
O	O	times	no
O	O	weekly	yes
O	O	during	no
O	O	five	no
O	O	long-term	no
O	O	experiments	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
B-drug	B-drug	alosetron	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	therefore	no
O	O	advised	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	PEGANONE	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	CYP3A4	no
O	O	isoform	yes
O	O	and	yes
O	O	CYP1A2	no
O	O	isoform	yes
O	O	mediate	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	levobupivacaine	yes
O	O	to	no
O	B-drug_n	desbutyl	no
B-drug	I-drug_n	levobupivacaine	yes
O	O	and	yes
O	B-drug_n	3-hydroxy	no
B-drug	I-drug_n	levobupivacaine	yes
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	3	yes
O	O	.	no

B-drug	B-drug	Venlafaxine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	10	yes
O	O	mg	yes
O	O	and	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	venlafaxine	yes
O	O	ER	yes
O	O	(	no
O	O	extended	yes
O	O	release	yes
O	O	)	no
O	O	150	yes
O	O	mg	yes
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	any	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	zaleplon	yes
O	O	or	no
B-drug	B-drug	venlafaxine	yes
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP1A2	no
O	O	,	no
B-drug	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	or	no
O	O	uridine	yes
O	O	glucuronosyltransferase	no
O	O	(	no
O	O	UDPGT	no
O	O	)	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
O	O	single	yes
O	O	25-mg	no
O	O	dose	no
B-drug	B-drug	warfarin	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	total	yes
B-drug	B-drug	lenalidomide	yes
O	O	.	no

O	O	Advantages	no
O	O	offered	no
O	O	by	no
O	O	this	no
O	O	class	no
O	O	of	yes
B-group	B-group	antibiotics	no
O	O	include	no
O	O	optimal	no
O	O	pharmacokinetics	no
O	O	,	no
O	O	effectiveness	no
O	O	against	yes
O	O	multidrug-resistant	no
O	O	organisms	no
O	O	,	no
O	O	and	yes
O	O	oral	yes
O	O	administration	no
O	O	even	no
O	O	when	no
B-group	O	parenteral	no
I-group	B-drug	antibiotics	no
O	O	are	no
O	O	generally	no
O	O	used	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Amiodarone	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Cordarone	yes
O	O	)	no
O	O	or	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	midazolam	yes
O	O	or	no
B-drug	B-drug	triazolam	yes
O	O	has	no
O	O	resulted	no
O	O	in	yes
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	two	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Ritonavir	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	)	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	5	yes
O	O	mg	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	49-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	13-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	Cmax	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ceftazidime	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	when	no
O	O	using	no
O	O	CLINITEST	no
O	O	tablets	yes
O	O	,	no
O	O	Benedicts	no
O	O	solution	yes
O	O	,	no
O	O	or	no
O	O	Fehlings	no
O	O	solution	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	B-drug	olanzapine	yes
O	O	is	yes
O	O	not	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	risk	no
O	O	of	yes
O	O	agranulocytosis	no
O	O	as	yes
O	O	seen	no
O	O	with	yes
B-drug	B-drug	clozapine	yes
O	O	or	no
O	O	clinically	no
O	O	significant	no
O	O	hyperprolactinaemia	no
O	O	as	yes
O	O	seen	no
O	O	with	yes
B-drug	B-drug	risperidone	yes
O	O	or	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	.	no

B-drug	I-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes
I-drug	I-drug	Norethindrone	yes

O	O	Clinical	no
O	O	trials	no
O	O	have	no
O	O	indicated	no
O	O	that	no
B-brand	B-brand	Pulmozyme	yes
O	O	can	no
O	O	be	no
O	O	effectively	no
O	O	and	yes
O	O	safely	no
O	O	used	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-group	O	standard	yes
I-group	O	cystic	no
I-group	O	fibrosis	no
O	O	therapies	no
O	O	including	no
O	O	oral	yes
O	O	,	no
O	O	inhaled	no
O	O	and/or	no
O	O	parenteral	no
B-group	B-group	antibiotics	no
O	O	,	no
B-group	B-group	bronchodilators	no
O	O	,	no
O	O	enzyme	no
O	O	supplements	no
O	O	,	no
B-group	B-group	vitamins	no
O	O	,	no
O	O	oral	yes
O	O	or	no
O	O	inhaled	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	and	yes
B-group	B-group	analgesics	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interaction	no
B-drug	B-drug	Captopril	yes
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	false-positive	no
O	O	urine	no
O	O	test	yes
O	O	for	yes
B-drug	O	acetone	yes
O	O	.	no

B-drug	B-drug	Tolbutamide	yes
O	O	:	no
O	O	In	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	,	no
O	O	M1	yes
O	O	was	no
O	O	shown	no
O	O	to	no
O	O	cause	no
O	O	increases	no
O	O	ranging	no
O	O	from	no
O	O	13	yes
O	O	-	yes
O	O	50	yes
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	free	yes
O	O	fraction	yes
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	at	yes
O	O	concentrations	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	range	no
O	O	.	no

O	O	Interactions	no
O	O	between	yes
B-brand	B-brand	COPAXONE	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	fully	no
O	O	evaluated	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	without	no
O	O	a	yes
O	O	functioning	no
O	B-group	thyroid	yes
O	O	gland	no
O	O	who	no
O	O	are	no
O	O	on	no
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	increase	no
O	O	their	no
B-group	O	thyroid	yes
O	O	dose	no
O	O	if	no
B-group	B-group	estrogens	yes
O	O	or	no
B-group	B-group	estrogen-containing	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	are	no
O	O	given	no
O	O	.	no

O	O	These	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	coadministered	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	and	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Serum	yes
O	O	samples	no
O	O	from	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	cefoxitin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	analyzed	no
O	O	for	yes
O	O	creatinine	yes
O	O	if	no
O	O	withdrawn	no
O	O	within	no
O	O	2	yes
O	O	hours	no
O	O	of	yes
O	O	drug	yes
O	O	administration	no
O	O	.	no

O	O	-	yes
B-group	B-drug	Gold	yes
I-group	O	salts	no
O	O	(	no
O	O	medicine	no
O	O	for	yes
O	O	arthritis	no
O	O	)	no
O	O	or	no

B-group	B-group	Calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	may	no
O	O	also	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-brand	B-brand	TENORMIN	yes
O	O	.	no

B-drug	B-drug	Fluvoxamine	yes
O	O	has	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	inhibit	no
O	O	P450	no
O	O	1A2	no
O	O	,	no
O	O	an	no
O	O	isoform	yes
O	O	also	no
O	O	involved	no
O	O	in	yes
O	B-group	TCAmetabolism	no
O	O	.	no

O	O	Coadminstration	no
O	O	with	yes
O	O	agents	yes
O	O	that	no
O	O	induce	no
O	O	3A4	no
O	O	activity	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	DURAGESIC	no
O	O	.	no

O	O	1	yes
O	O	.	no

B-group	B-group	Antiarrhythmics	no
O	O	:	no
B-drug	B-drug	amiodarone	yes

B-group	B-group	Digitalis	yes
O	O	:	no
B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	dosage	no
O	O	must	no
O	O	be	no
O	O	determined	no
O	O	with	yes
O	O	care	yes
O	O	in	yes
O	O	patients	no
O	O	undergoing	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	,	no
O	O	as	yes
O	O	hypercalcemia	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	may	no
O	O	precipitate	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
O	O	0.1-mg/kg	no
O	O	(	no
O	O	2	yes
O	O	x	yes
O	O	ED95	no
O	O	)	no
B-brand	B-brand	NIMBEX	yes
O	O	at	yes
O	O	10	yes
O	O	%	no
O	O	or	no
O	O	95	no
O	O	%	no
O	O	recovery	no
O	O	following	no
O	O	an	no
O	O	intubating	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	(	no
O	O	1	yes
O	O	mg/kg	no
O	O	)	no
O	O	produced	no
O	O	95	no
O	O	%	no
O	O	neuromuscular	no
O	O	block	yes
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	interactions	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	with	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
B-drug	B-drug	hexobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	alfentanil	yes
O	O	,	no
B-drug	B-drug	cisapride	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	bromocriptine	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
B-drug	B-drug	terfenadine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	astemizole	yes
O	O	.	no

O	O	(	no
O	O	SGOT	no
O	O	)	no
O	O	,	no
O	O	ALT	no
O	O	(	no
O	O	SGPT	no
O	O	)	no

O	O	However	no
O	O	,	no
O	O	10	yes
O	O	patients	no
O	O	who	no
O	O	switched	no
O	O	from	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	Interferon	yes
I-drug	I-drug	beta	yes
O	O	to	no
B-brand	B-brand	COPAXONE	yes
O	O	did	no
O	O	not	no
O	O	report	no
O	O	any	no
O	O	serious	no
O	O	and	yes
O	O	unexpected	no
O	O	adverse	no
O	O	reactions	no
O	O	thought	no
O	O	to	no
O	O	be	no
O	O	related	yes
O	O	to	no
O	O	treatment	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	esomeprazole	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	drugs	no
O	O	where	no
O	O	gastric	yes
O	O	pH	yes
O	O	is	yes
O	O	an	no
O	O	important	no
O	O	determinant	no
O	O	of	yes
O	O	bioavailability	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	iron	yes
O	O	salts	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	similar	no
O	O	study	no
O	O	,	no
O	O	attempting	no
O	O	to	no
O	O	replicate	no
O	O	this	no
O	O	finding	no
O	O	,	no
O	O	no	yes
O	O	interactive	no
O	O	effect	no
O	O	on	no
O	O	hepatic	no
O	O	transaminases	no
O	O	was	no
O	O	identified	no
O	O	.	no

O	O	inhalation	no
B-group	B-group	anesthetics	no
O	O	;	no

O	O	Because	no
O	O	of	yes
O	O	its	no
O	O	lack	no
O	O	of	yes
O	O	platelet	yes
O	O	effects	no
O	O	,	no
B-brand	B-brand	CELEBREX	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substitute	no
O	O	for	yes
B-brand	B-brand	aspirin	yes
O	O	for	yes
O	O	cardiovascular	no
O	O	prophylaxis	no
O	O	.	no

B-drug	B-drug	Paroxetine	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	increased	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	by	no
O	O	about	no
O	O	60	no
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	greater	no
O	O	degrees	no
O	O	of	yes
O	O	inhibition	no
O	O	are	no
O	O	expected	no
O	O	with	yes
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	paroxetine	yes
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	when	no
B-group	B-group	NSAIDs	no
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	subjects	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	carefully	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	These	no
O	O	findings	no
O	O	suggest	no
O	O	that	no
O	O	intracellular	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	release	yes
O	O	by	no
O	O	cholinergic	no
O	O	stimulation	no
O	O	is	yes
O	O	critical	no
O	O	for	yes
O	O	determining	no
O	O	synergism	no
O	O	with	yes
O	O	cAMP	yes
O	O	in	yes
O	O	parietal	no
O	O	cell	yes
O	O	activation	no
O	O	and	yes
O	O	that	no
O	O	functional	no
O	O	coupling	no
O	O	between	yes
O	O	the	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	store	no
O	O	and	yes
O	O	the	no
O	O	receptor	yes
O	O	is	yes
O	O	maintained	no
O	O	by	no
O	O	actin	no
O	O	microfilaments	no
O	O	.	no

O	O	Dose	no
O	O	adjustments	no
O	O	of	yes
O	O	either	no
O	O	class	no
O	O	of	yes
O	O	agents	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Serum	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	digitoxin	yes
O	O	may	no
O	O	increase	no
O	O	when	no
O	O	patients	no
O	O	take	no
B-group	B-group	antithyroid	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	naratriptan	yes
O	O	with	yes
O	O	other	no
B-group	B-group	5-HT1	no
I-group	I-group	agonists	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	in	yes
O	O	migraine	yes
O	O	patients	no
O	O	.	no

O	O	Molecular	yes
O	O	basis	no
O	O	for	yes
O	O	the	no
O	O	selective	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	for	yes
O	O	yeast	no
O	O	and	yes
B-drug_n	B-drug_n	filipin	no
O	O	for	yes
O	O	animal	no
O	O	cells	yes
O	O	.	no

B-drug	B-drug	Estazolam	yes
O	O	:	no
O	O	Interaction	no
O	O	with	yes
O	O	Other	no
O	O	Drugs	no
O	O	that	no
O	O	are	no
O	O	Metabolized	no
O	O	by	no
O	O	Cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	:	no
O	O	At	yes
O	O	clinically	no
O	O	relevant	no
O	O	concentrations	no
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	estazolam	yes
O	O	(	no
O	O	0.6	no
O	O	M	yes
O	O	)	no
O	O	was	no
O	O	not	no
O	O	inhibitory	yes
O	O	towards	no
O	O	the	no
O	O	major	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoforms	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2A6	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	and	yes
O	O	CYP3A	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	when	no
O	O	the	no
O	O	thioether	no
O	O	concentration	no
O	O	ranges	no
O	O	within	no
O	O	the	no
O	O	limits	no
O	O	of	yes
O	O	the	no
O	O	normal	yes
O	O	value	no
O	O	,	no
O	O	one	no
O	O	must	no
O	O	not	no
O	O	conclude	no
O	O	that	no
O	O	there	no
O	O	is	yes
O	O	no	yes
O	O	,	no
O	O	or	no
O	O	negligible	no
O	O	,	no
O	O	exposure	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Naltrexone	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Trexan	no
O	O	)	no
O	O	(	no
O	O	with	yes
O	O	long-term	no
O	O	,	no
O	O	high-dose	no
O	O	use	no
O	O	)	no
O	O	or	no

O	O	Drugs	no
O	O	that	no
O	O	reportedly	no
O	O	may	no
O	O	increase	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	response	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	increased	no
O	O	prothrombin	yes
O	O	response	no
O	O	,	no
O	O	in	yes
O	O	man	no
O	O	include	no
O	O	:	no
B-drug	B-drug	alcohol*	no
O	O	;	no

O	O	Again	no
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	neutralized	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	glycemia	no
O	O	after	no
O	B-drug	glucose	yes
O	O	overload	no
O	O	both	no
O	O	in	yes
O	O	diabetic	no
O	O	and	yes
O	O	non-diabetic	no
O	O	rats	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	with	yes
O	O	40	yes
O	O	mg	yes
B-brand	B-brand	SULAR	yes
O	O	tablets	yes
O	O	in	yes
O	O	epileptic	no
O	O	patients	no
O	O	lowered	no
O	O	the	no
B-drug	B-drug	nisoldipine	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	to	no
O	O	undetectable	no
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	BARACLUDE	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	renally	no
O	O	eliminated	no
O	O	or	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	affect	no
O	O	renal	no
O	O	function	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	,	no
O	O	and	yes
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	for	yes
O	O	adverse	no
O	O	events	no
O	O	when	no
B-brand	B-brand	BARACLUDE	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
O	O	such	no
O	O	drugs	no
O	O	.	no

O	O	Garlic	no
O	O	Capsules	no
O	O	Garlic	no
O	O	capsules	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	while	no
O	O	taking	no
B-drug	B-drug	saquinavir	yes
O	O	(	no
B-brand	B-brand	FORTOVASE	yes
O	O	)	no
O	O	as	yes
O	O	the	no
B-group	O	sole	no
I-group	B-group	protease	yes
I-group	I-group	inhibitor	yes
O	O	due	no
O	O	to	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	decreased	no
B-drug	B-drug	saquinavir	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	poor	no
O	O	metabolizers	no
O	O	.	no

B-brand	B-brand	Mylotarg	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	any	no
O	O	routine	no
O	O	diagnostic	yes
O	O	tests	no
O	O	.	no

B-group	B-group	pyrazolones	no
O	O	;	no

O	O	.	no

O	O	Oral	yes
B-group	B-group	Hypoglycemics	no
O	O	:	no
B-drug	B-drug	Bepridil	yes
O	O	has	no
O	O	been	no
O	O	safely	no
O	O	used	no
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	without	no
O	O	significantly	no
O	O	lowering	no
O	O	their	no
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	or	no
O	O	altering	no
O	O	their	no
O	O	need	no
O	O	for	yes
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	.	no

O	O	however	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	moderate	no
O	O	to	no
O	O	severe	no
O	O	cardiovascular	no
O	O	disease	no
O	O	or	no
O	O	those	no
O	O	taking	no
B-drug	B-group	nitrate	yes
O	O	therapy	no
O	O	are	no
O	O	at	yes
O	O	increased	no
O	O	risk	no
O	O	for	yes
O	O	potentially	no
O	O	serious	no
O	O	cardiovascular	no
O	O	adverse	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	sildenafil	yes
O	O	therapy	no
O	O	.	no

O	O	A	yes
O	O	dose	no
O	O	increase	no
O	O	of	yes
B-drug	B-drug	lopinavir/ritonavir	no
O	O	to	no
O	O	533/133	no
O	O	mg	yes
O	O	(	no
O	O	4	yes
O	O	capsules	no
O	O	or	no
O	O	6.5	no
O	O	mL	no
O	O	)	no
O	O	twice	no
O	O	daily	no
O	O	taken	no
O	O	with	yes
O	O	food	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

B-group	O	Systemic	no
I-group	B-group	antibiotic	yes
I-group	I-group	agents	yes
O	O	.	no

O	O	Currently	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	conceived	no
O	O	that	no
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	events	no
O	O	,	no
O	O	or	no
O	O	hits	no
O	O	,	no
O	O	are	no
O	O	required	no
O	O	for	yes
O	O	the	no
O	O	induction	no
O	O	of	yes
O	O	tumors	no
O	O	by	no
O	O	chemical	yes
O	O	agents	yes
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	in	yes
O	O	Ontario	no
O	O	alone	no
O	O	,	no
O	O	in	yes
O	O	1972	no
O	O	and	yes
O	O	1973	no
O	O	there	no
O	O	were	no
O	O	26	yes
O	O	deaths	no
O	O	in	yes
B-drug	B-drug	amphetamine	yes
O	O	users	no
O	O	,	no
O	O	of	yes
O	O	which	no
O	O	16	yes
O	O	were	no
O	O	due	no
O	O	to	no
O	O	accident	no
O	O	suicide	no
O	O	or	no
O	O	homicide	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	(	no
O	O	a	yes
O	O	potent	no
O	B-drug	CYP3A4	no
O	O	inhibitor	yes
O	O	)	no
O	O	.	no

O	O	Thus	no
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	and	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	should	no
O	O	have	no
O	O	their	no
O	O	prothrombin	yes
O	O	time	no
O	O	monitored	no
O	O	and	yes
O	O	their	no
B-group	B-group	anticoagulant	no
O	O	dose	no
O	O	adjusted	yes
O	O	accordingly	no
O	O	.	no

O	O	We	no
O	O	compared	no
B-drug	B-drug	indinavir	yes
O	O	pharmacokinetics	no
O	O	and	yes
O	O	gastric	yes
O	O	pH	yes
O	O	in	yes
O	O	12	yes
O	O	human	yes
O	O	immunodeficiency	no
O	O	virus-positive	no
O	O	patients	no
O	O	by	no
O	O	use	no
O	O	of	yes
O	O	800	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	alone	no
O	O	versus	no
O	O	800	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	administered	no
O	O	1	yes
O	O	h	yes
O	O	after	no
B-drug	B-drug	didanosine	yes
O	O	administration	no
O	O	.	no

O	O	3	yes
O	O	.	no

O	O	The	no
O	O	possible	no
O	O	adverse	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	ZINECARD	yes
O	O	on	no
O	O	the	no
O	O	fertility	no
O	O	of	yes
O	O	humans	no
O	O	and	yes
O	O	experimental	no
O	O	animals	no
O	O	,	no
O	O	male	no
O	O	or	no
O	O	female	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	adequately	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	Terfenadine	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	and	yes
B-drug	B-drug	cisapride	yes
O	O	are	no
O	O	all	yes
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450IIIA4	no
O	O	isozyme	no
O	O	,	no
O	O	and	yes
O	O	it	no
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	IIIA4	no
O	O	,	no
O	O	blocks	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	parent	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Loperamide	yes
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	0.1	no
O	O	and	yes
O	O	1.0	no
O	O	mg/kg	no
O	O	,	no
O	O	s.c.	no
O	O	)	no
O	O	inhibited	no
O	O	the	no
B-drug_n	B-drug_n	dmPGE2	no
O	O	(	no
O	O	0.3	yes
O	O	mg/kg	no
O	O	,	no
O	O	p.o	no
O	O	.	no
O	O	)	no
O	O	-induced	no
O	O	diarrhea	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	.	no

O	O	In	yes
O	O	geriatric	no
O	O	subjects	no
O	O	(	no
O	O	n=7	no
O	O	)	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	the	no
O	O	rate	no
O	O	but	no
O	O	not	no
O	O	the	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	absorption	no
O	O	.	no

O	O	Influence	no
O	O	of	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	on	no
B-drug	B-drug	cisapride	yes
O	O	pharmacokinetics	no
O	O	and	yes
O	O	QTc	no
O	O	intervals	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	esomeprazole	yes
O	O	30	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	,	no
O	O	a	yes
O	O	CYP2C19	no
O	O	substrate	yes
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	45	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	.	no

O	O	.	no

O	O	SIDE	no
O	O	EFFECTS	no
O	O	(	no
B-brand	B-brand	KEMSTRO	yes
O	O	)	no
O	O	The	no
O	O	most	no
O	O	common	yes
O	O	adverse	no
O	O	reaction	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	baclofen	yes
O	O	is	yes
O	O	transient	no
O	O	drowsiness	no
O	O	(	no
O	O	10-63	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	and	yes
O	O	drugs	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	,	no
O	O	which	no
O	O	could	no
O	O	increase	no
O	O	or	no
O	O	prolong	no
O	O	its	no
O	O	therapeutic	no
O	O	and	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	The	no
O	O	relevance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	to	no
O	O	humans	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	at	yes
O	O	this	no
O	O	time	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-brand	B-brand	Sensipar	yes
O	O	on	no
O	O	other	no
O	O	drugs	no
O	O	:	no
O	O	Drugs	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	CYP2D6	no
O	O	)	no
O	O	:	no
B-brand	B-brand	Sensipar	yes
O	O	is	yes
O	O	a	yes
O	O	strong	no
O	O	in	yes
O	O	vitro	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP2D6	no
O	O	.	no

O	O	This	no
O	O	study	no
O	O	was	no
O	O	designed	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	basis	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	in	yes
O	O	10	yes
O	O	normal	yes
O	O	subjects	no
O	O	.	no

O	O	In	yes
O	O	uninfected	no
O	O	volunteers	no
O	O	,	no
O	O	46	no
O	O	%	no
O	O	developed	no
O	O	rash	no
O	O	while	no
O	O	receiving	no
B-brand	B-brand	SUSTIVA	yes
O	O	and	yes
B-drug	B-drug	clarithromycin	yes
O	O	.	no

O	O	Interactions	no
O	O	for	yes
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	B3	yes
O	O	(	no
B-drug	B-drug	Niacin	yes
O	O	)	no
O	O	:	no
B-group	B-group	Antihypertensive	no
O	O	Therapy	no
O	O	:	no
B-drug	B-drug	Nicotinic	yes
I-drug	I-drug	acid	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	ganglionic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	and	yes
B-group	O	vasoactive	no
I-group	O	drugs	no
O	O	resulting	no
O	O	in	yes
O	O	postural	no
O	O	hypotension	no
O	O	.	no

O	O	Of	yes
O	O	particular	no
O	O	importance	no
O	O	,	no
O	O	sufficient	no
O	O	time	no
O	O	must	no
O	O	elapse	no
O	O	before	no
O	O	initiating	no
B-group	O	TCA	no
O	O	treatment	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	being	no
O	O	withdrawn	no
O	O	from	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	given	no
O	O	the	no
O	O	long	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	parent	no
O	O	and	yes
O	O	active	no
O	O	metabolite	yes
O	O	(	no
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	weeks	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	)	no
O	O	.	no

O	O	Following	no
O	O	oral	yes
O	O	administration	no
O	O	of	yes
O	O	two	no
O	O	150-mg	no
O	O	sustained-release	no
O	O	tablets	yes
O	O	with	yes
O	O	and	yes
O	O	without	no
O	O	800	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	and	yes
B-drug_n	B-drug_n	hydroxybupropion	no
O	O	were	no
O	O	unaffected	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	most	no
B-group	B-group	macrolides	no
O	O	are	no
O	O	contraindicated	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	terfenadine	yes
O	O	therapy	no
O	O	who	no
O	O	have	no
O	O	pre-existing	no
O	O	cardiac	no
O	O	abnormalities	no
O	O	(	no
O	O	arrhythmia	no
O	O	,	no
O	O	bradycardia	no
O	O	,	no
O	O	QT	no
O	O	c	yes
O	O	interval	no
O	O	prolongation	no
O	O	,	no
O	O	ischemic	no
O	O	heart	no
O	O	disease	no
O	O	,	no
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	or	no
O	O	electrolyte	yes
O	O	disturbances	no
O	O	.	no

O	O	OBJECTIVE	no
O	O	:	no
O	O	This	no
O	O	paper	no
O	O	reviews	no
O	O	recent	no
O	O	studies	no
O	O	of	yes
O	O	the	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	sildenafil	yes
O	O	,	no
O	O	its	no
O	O	adverse	no
O	O	effects	no
O	O	and	yes
O	O	drug	yes
O	O	interactions	no
O	O	,	no
O	O	and	yes
O	O	socioeconomic	no
O	O	factors	no
O	O	involved	no
O	O	in	yes
O	O	its	no
O	O	use	no
O	O	,	no
O	O	with	yes
O	O	a	yes
O	O	focus	no
O	O	on	no
O	O	specific	no
O	O	patient	no
O	O	populations	no
O	O	(	no
O	O	prostate	no
O	O	cancer	no
O	O	,	no
O	O	diabetes	no
O	O	mellitus	no
O	O	,	no
O	O	ischemic	no
O	O	heart	no
O	O	disease	no
O	O	,	no
O	O	spinal	no
O	O	cord	no
O	O	injuries	no
O	O	,	no
O	O	neurologic	no
O	O	disorders	no
O	O	)	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	Measurement	no
O	O	of	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	determined	no
O	O	by	no
O	O	the	no
O	O	Jaffe	no
O	O	reaction	no
O	O	,	no
O	O	since	no
B-brand	B-brand	Ancobon	yes
O	O	does	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	determination	no
O	O	of	yes
O	O	creatinine	yes
O	O	values	no
O	O	by	no
O	O	this	no
O	O	method	yes
O	O	.	no

O	O	Other	no
O	O	strong	no
O	O	selective	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	can	no
O	O	also	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	;	no

O	O	In	yes
O	O	two	no
O	O	combined	no
O	O	12-week	no
O	O	placebo	no
O	O	controlled	no
O	O	trials	no
O	O	that	no
O	O	included	no
B-brand	B-brand	BROVANA	yes
O	O	doses	no
O	O	of	yes
O	O	15	yes
O	O	mcg	no
O	O	twice	no
O	O	daily	no
O	O	,	no
O	O	25	yes
O	O	mcg	no
O	O	twice	no
O	O	daily	no
O	O	,	no
O	O	and	yes
O	O	50	yes
O	O	mcg	no
O	O	once	no
O	O	daily	no
O	O	,	no
O	O	54	no
O	O	of	yes
O	O	873	no
B-brand	B-brand	BROVANA	yes
O	O	-treated	no
O	O	subjects	no
O	O	received	no
O	O	concomitant	no
B-drug	B-drug	theophylline	yes
O	O	at	yes
O	O	study	no
O	O	entry	no
O	O	.	no

O	O	Limited	no
O	O	comparative	no
O	O	data	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	high	yes
O	O	viral	no
O	O	loads	no
O	O	treated	no
O	O	with	yes
O	B-drug	nevirapine-	no
O	O	or	no
O	B-drug	delavirdine-based	no
O	O	regimens	no
O	O	currently	no
O	O	exist	no
O	O	.	no

B-drug	B-drug	Norepinephrine	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	enhance	no
O	O	the	no
O	O	adrenergic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	did	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	rofecoxib	yes
O	O	.	no

O	O	)	no

B-drug	B-drug	paraldehyde	yes
O	O	;	no

O	O	*Not	no
O	O	administered	no
O	O	,	no
O	O	but	no
O	O	an	no
O	O	active	no
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	increased	no
O	O	sedation	no
O	O	with	yes
O	O	concurrent	no
B-group	B-group	hypnotic	no
I-group	I-group	medications	no
O	O	.	no

O	O	The	no
B-drug	B-drug	digoxin	yes
O	O	median	no
O	O	tmax	no
O	O	was	no
O	O	0.5	yes
O	O	hours	no
O	O	for	yes
O	O	both	no
O	O	treatments	no
O	O	.	no

O	O	No	yes
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	dexmedetomidine	yes
O	O	and	yes
B-drug	B-drug	isoflurane	yes
O	O	,	no
B-drug	B-drug	propofol	yes
O	O	,	no
B-drug	B-drug	alfentanil	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	midazolam	yes
O	O	have	no
O	O	been	no
O	O	demonstrated	no
O	O	.	no

O	O	Close	no
O	O	supervision	no
O	O	and	yes
O	O	careful	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
O	O	dosage	no
O	O	are	no
O	O	required	no
O	O	when	no
B-drug	B-drug	nortriptyline	yes
I-drug	I-drug	hydrochloride	yes
O	O	is	yes
O	O	used	no
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	or	no
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Also	no
B-drug	B-drug	flucytosine	yes
O	O	.	no

O	O	An	no
O	O	individual	no
O	O	who	no
O	O	is	yes
O	O	stable	no
O	O	on	no
O	O	a	yes
O	O	given	no
O	O	dose	no
O	O	of	yes
B-group	B-group	TCA	no
O	O	may	no
O	O	become	no
O	O	abruptly	no
O	O	toxic	no
O	O	when	no
O	O	given	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	inhibiting	no
O	O	drugs	no
O	O	as	yes
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	appropriate	no
O	O	dose	no
O	O	adjustments	no
O	O	considered	no
O	O	for	yes
O	O	patients	no
O	O	given	no
O	O	both	no
B-drug	B-drug	theophylline	yes
O	O	and	yes
B-brand	B-brand	PEGASYS	yes
O	O	.	no

B-brand	B-brand	AXERT	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	commonly	no
O	O	employed	no
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

B-drug	B-drug	Bosentan	yes
O	O	is	yes
O	O	also	no
O	O	expected	no
O	O	to	no
O	O	reduce	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
B-group	B-group	statins	no
O	O	that	no
O	O	have	no
O	O	significant	no
O	O	metabolism	no
O	O	by	no
O	O	CYP3A4	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	lovastatin	yes
O	O	and	yes
B-drug	B-drug	atorvastatin	yes
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	relevant	no
O	O	interactions	no
O	O	with	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	CYP	no
O	O	enzymes	yes
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	.	no

O	O	therefore	no
O	O	,	no
B-drug	B-drug	nitroglycerin	yes
O	O	or	no
O	O	other	no
B-group	B-group	nitrates	no
O	O	(	no
O	O	as	yes
O	O	used	no
O	O	for	yes
O	O	management	no
O	O	of	yes
O	O	angina	no
O	O	)	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	having	no
O	O	vasodilator	no
O	O	activity	yes
O	O	should	no
O	O	,	no
O	O	if	no
O	O	possible	no
O	O	,	no
O	O	be	no
O	O	discontinued	no
O	O	before	no
O	O	starting	no
B-drug	B-drug	captopril	yes
O	O	.	no

O	O	(	no
B-group	B-group	Thiazide	no
I-group	I-group	drugs	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	tubocurarine	yes
O	O	.	no
O	O	)	no

B-drug	B-drug	DISULFIRAM	yes
O	O	SHOULD	no
O	O	BE	no
O	O	USED	no
O	O	WITH	yes
O	O	CAUTION	no
O	O	IN	yes
O	O	THOSE	no
O	O	PATIENTS	no
B-brand	O	REVEIVING	no
B-drug	B-drug	PHENYTOIN	yes
O	O	AND	yes
O	O	ITS	no
O	O	CONGENERS	no
O	O	.	no

O	O	These	no
O	O	increased	no
O	O	exposures	no
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	consideration	no
O	O	when	no
O	O	selecting	no
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	for	yes
O	O	women	yes
O	O	taking	no
B-drug	B-drug	valdecoxib	yes
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	narrow	no
O	O	therapeutic	no
O	O	ratio	no
O	O	drugs	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	require	no
O	O	careful	no
O	O	titration	yes
O	O	should	no
O	O	be	no
O	O	followed	no
O	O	closely	no
O	O	;	no

O	O	Evidence	no
O	O	supporting	no
O	O	the	no
O	O	conclusion	no
O	O	that	no
O	O	it	no
O	O	is	yes
O	O	inadvisable	no
O	O	to	no
O	O	co-administer	no
B-drug	B-drug	fluvoxamine	yes
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	is	yes
O	O	derived	yes
O	O	from	no
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	which	no
O	O	healthy	no
O	O	volunteers	no
O	O	taking	no
O	O	150	yes
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	were	no
O	O	administered	no
O	O	a	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
O	O	10	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	.	no

O	O	Inhibition	no
O	O	of	yes
O	O	these	no
O	O	isoenzymes	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	.	no

O	O	These	no
O	O	results	no
O	O	are	no
O	O	consistent	no
O	O	with	yes
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	finding	no
O	O	that	no
O	O	neither	no
B-drug	B-drug	isotretinoin	yes
O	O	nor	yes
O	O	its	no
O	O	metabolites	no
O	O	induce	no
O	O	or	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	CYP	no
O	O	2C9	no
O	O	human	yes
O	O	hepatic	no
O	O	P450	no
O	O	enzyme	no
O	O	.	no

O	O	Although	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	iloprost	yes
O	O	indicate	no
O	O	that	no
O	O	no	yes
O	O	relevant	no
O	O	inhibition	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	drug	yes
O	O	metabolism	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	.	no

B-group	B-group	Quinolone	no
I-group	O	Antibiotics	no
O	O	:	no
B-brand	B-brand	VIDEX	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	after	no
O	O	or	no
O	O	6	yes
O	O	hours	no
O	O	before	no
O	O	dosing	no
O	O	with	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	because	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	are	no
O	O	decreased	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
O	O	,	no
B-drug	B-drug	calcium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	aluminum	yes
O	O	.	no

B-group	B-group	Thyroid	yes
O	O	administration	no
O	O	to	no
O	O	a	yes
O	O	digitalized	no
O	O	,	no
O	O	hypothyroid	no
O	O	patient	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	dose	no
O	O	requirement	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Similarly	no
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	decreased	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	metamizol	no
O	O	(	no
O	O	only	no
O	O	in	yes
O	O	the	no
O	O	tail-flick	no
O	O	test	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	indomethacin	yes
O	O	.	no

O	O	The	no
O	O	following	no
O	O	are	no
O	O	examples	no
O	O	of	yes
O	O	substances	no
O	O	that	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	and	yes
O	O	susceptibility	no
O	O	to	no
O	O	hypoglycemia	no
O	O	:	no
O	O	oral	yes
B-group	O	antidiabetes	no
I-group	O	products	no
O	O	,	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-group	B-group	fibrates	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	propoxyphene	yes
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	somatostatin	yes
I-group	I-group	analog	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	octreotide	yes
O	O	)	no
O	O	,	no
B-group	B-group	sulfonamide	yes
I-group	I-group	antibiotics	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	withdrawal	no
O	O	and	yes
O	O	their	no
B-drug	B-drug	methadone	yes
O	O	dose	no
O	O	increased	no
O	O	as	yes
O	O	required	no
O	O	to	no
O	O	alleviate	no
O	O	withdrawal	no
O	O	symptoms	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	positive	no
O	O	test	yes
O	O	results	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	piperacillin	yes
O	O	should	no
O	O	be	no
O	O	interpreted	no
O	O	cautiously	no
O	O	and	yes
O	O	confirmed	no
O	O	by	no
O	O	other	no
O	O	diagnostic	yes
O	O	methods	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	may	no
O	O	reduce	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	well	no
O	O	controlled	no
O	O	on	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	receiving	no
O	O	concurrent	no
B-drug	B-drug	cimetidine	yes
O	O	therapy	no
O	O	,	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	established	no
O	O	steady-state	no
O	O	serum	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	levels	no
O	O	and	yes
O	O	compromise	no
O	O	their	no
O	O	therapeutic	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Insulin	yes
O	O	requirements	no
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	,	no
O	O	decreased	no
O	O	,	no
O	O	or	no
O	O	unchanged	no
O	O	.	no

O	O	at	yes
O	O	high	yes
O	O	doses	no
O	O	,	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	decreased	no
O	O	FI	no
O	O	and	yes
O	O	FR	no
O	O	responding	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	and	yes
O	O	its	no
O	O	acid	yes
O	O	metabolite	yes
O	O	and	yes
O	O	the	no
O	O	electrocardiographic	no
O	O	QT	no
O	O	c	yes
O	O	interval	no
O	O	were	no
O	O	measured	no
O	O	during	no
O	O	both	no
O	O	periods	no
O	O	:	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	alone	no
O	O	,	no
O	O	and	yes
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	plus	yes
B-drug	B-drug	dirithromycin	yes
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	if	no
O	O	such	no
O	O	treatment	no
O	O	is	yes
O	O	essential	yes
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	increased	no
O	O	risk	no
O	O	relative	no
O	O	to	no
O	O	benefits	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	In	yes
O	O	10	yes
O	O	otherwise	no
O	O	healthy	no
O	O	subjects	no
O	O	with	yes
O	O	epilepsy	no
O	O	ingesting	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	the	no
O	O	steadystate	no
O	O	trough	no
O	O	(	no
O	O	Cmin	no
O	O	)	no
B-drug	B-drug	phenytoin	yes
O	O	plasma	yes
O	O	concentration	no
O	O	was	no
O	O	17	yes
O	O	5	yes
O	O	micrograms/mL	no
O	O	.	no

B-group	B-group	Antiretroviral	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
O	O	other	no
B-group	B-group	antiretroviral	no
I-group	I-group	medications	no
O	O	have	no
O	O	been	no
O	O	identified	no
O	O	that	no
O	O	would	no
O	O	warrant	no
O	O	alteration	no
O	O	of	yes
O	O	either	no
O	O	the	no
B-drug	B-drug	enfuvirtide	yes
O	O	dose	no
O	O	or	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
O	O	other	no
B-group	B-group	antiretroviral	no
I-group	I-group	medication	no
O	O	.	no

O	O	Toxicology	no
O	O	studies	no
O	O	of	yes
B-drug_n	B-drug_n	heroin-related	no
O	O	deaths	no
O	O	reveal	no
O	O	frequent	no
O	O	involvement	no
O	O	of	yes
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	,	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	diazepam	yes
O	O	(	no
B-brand	B-brand	Valium	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	,	no
O	O	to	no
O	O	a	yes
O	O	rising	no
O	O	degree	no
O	O	,	no
B-drug	B-drug	methadone	yes
O	O	.	no

B-drug	B-drug	Aprepitant	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	induce	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	S	yes
I-drug	I-drug	(	no
I-drug	I-drug	-	yes
I-drug	I-drug	)	no
I-drug	I-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	which	no
O	O	are	no
O	O	metabolized	no
O	O	through	no
O	O	CYP2C9	no
O	O	.	no

O	O	5	yes
O	O	.	no

O	O	Although	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	C	yes
O	O	max	no
O	O	and	yes
O	O	AUC	no
O	O	0-24	no
O	O	hrs	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	desloratadine	yes
O	O	and	yes
B-drug_n	B-drug_n	3-hydroxydesloratadine	no
O	O	were	no
O	O	observed	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	safety	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	desloratadine	yes
O	O	,	no
O	O	as	yes
O	O	assessed	no
O	O	by	no
O	O	electrocardiographic	no
O	O	parameters	no
O	O	(	no
O	O	including	no
O	O	the	no
O	O	corrected	no
O	O	QT	no
O	O	interval	no
O	O	)	no
O	O	,	no
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	,	no
O	O	vital	no
O	O	signs	no
O	O	,	no
O	O	and	yes
O	O	adverse	no
O	O	events	no
O	O	.	no

O	O	Plasma	yes
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	was	no
O	O	increased	no
O	O	by	no
O	O	28	yes
O	O	%	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	for	yes
O	O	12	yes
O	O	days	no
O	O	,	no
O	O	while	no
O	O	plasma	yes
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	was	no
O	O	not	no
O	O	substantially	no
O	O	increased	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	for	yes
O	O	12	yes
O	O	days	no
O	O	.	no

O	O	When	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	ampicillin	yes
O	O	.	no

O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	methylxanthines	no
O	O	(	no
B-drug	B-drug	aminophylline	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	)	no
O	O	,	no
B-group	B-group	steroids	no
O	O	,	no
O	O	or	no
B-group	B-group	diuretics	no
O	O	may	no
O	O	potentiate	no
O	O	any	no
O	O	hypokalemic	no
O	O	effect	no
O	O	of	yes
B-group	B-group	adrenergic	no
I-group	I-group	agonists	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	glipizide	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Drug/LaboratoryTest	no
O	O	Interactions	no
B-drug	B-drug	Dactinomycin	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	bioassay	no
O	O	procedures	no
O	O	for	yes
O	O	the	no
O	O	determination	no
O	O	of	yes
B-group	B-group	antibacterial	no
I-group	I-group	drug	yes
O	O	levels	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	p.o	no
O	O	.	no

O	O	Intravenous	yes
B-brand	B-brand	Adenocard	yes
O	O	(	no
B-drug	B-drug	adenosine	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	effectively	no
O	O	administered	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	other	no
B-group	O	cardioactive	no
I-group	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
O	O	and	yes
B-group	B-group	angiotensin	yes
I-group	I-group	converting	no
I-group	I-group	enzyme	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	without	no
O	O	any	no
O	O	change	no
O	O	in	yes
O	O	the	no
O	O	adverse	no
O	O	reaction	no
O	O	profile	no
O	O	.	no

O	O	8	yes
O	O	.	no

O	O	At	yes
O	O	24	yes
O	O	hours	no
O	O	postdose	no
O	O	,	no
O	O	a	yes
O	O	similar	no
O	O	proportion	no
O	O	of	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	alone	no
O	O	(	no
O	O	94	yes
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	subsequently	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	co-administered	no
O	O	with	yes
O	O	75	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	rofecoxib	yes
O	O	(	no
O	O	88	no
O	O	%	no
O	O	)	no
O	O	had	no
B-drug	B-drug	methotrexate	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	below	no
O	O	the	no
O	O	measurable	no
O	O	limit	no
O	O	(	no
O	O	5	yes
O	O	ng/mL	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	p53	no
O	O	(	no
O	O	+/-	no
O	O	)	no
O	O	mouse	yes
O	O	carcinogenicity	no
O	O	study	no
O	O	at	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	the	no
O	O	maximum	no
O	O	tolerated	no
O	O	dose	no
O	O	of	yes
O	O	100	yes
O	O	mg/kg/day	no
B-drug	B-drug	ribavirin	yes
O	O	was	no
O	O	not	no
O	O	oncogenic	no
O	O	.	no

O	O	Results	no
O	O	of	yes
O	O	studies	no
O	O	in	yes
O	O	multiple	no
O	O	sclerosis	no
O	O	patients	no
O	O	taking	no
B-brand	B-brand	TYSABRI	yes
O	O	and	yes
O	O	concomitant	no
B-drug	B-drug	interferon	yes
I-drug	I-drug	beta-1a	yes
O	O	(	no
B-brand	B-brand	AVONEX	yes
O	O	30	yes
O	O	mcg	no
O	O	IM	yes
O	O	once	no
O	O	weekly	yes
O	O	)	no
O	O	or	no
O	B-drug	glatiramer	yes
B-drug	I-drug	acetate	yes
O	O	were	no
O	O	inconclusive	no
O	O	with	yes
O	O	regard	no
O	O	to	no
O	O	the	no
O	O	need	no
O	O	for	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	beta-interferon	no
O	O	or	no
O	B-drug	glatiramer	yes
B-drug	I-drug	acetate	yes
O	O	.	no

O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	:	no
O	O	The	no
O	O	biochemical	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	metabolizing	no
O	O	isozyme	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	debrisoquin	yes
O	O	hydroxylase	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	Caucasian	no
O	O	population	no
O	O	(	no
O	O	about	no
O	O	7-10	no
O	O	%	no
O	O	of	yes
O	O	Caucasians	no
O	O	are	no
O	O	so-called	no
O	O	poor	no
O	O	metabolizers	no
O	O	)	no
O	O	;	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P450IID6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	In	yes
O	O	general	no
O	O	,	no
O	O	any	no
O	O	added	no
B-group	B-drug	antiarrhythmic	no
I-group	I-drug	drug	yes
O	O	should	no
O	O	be	no
O	O	initiated	no
O	O	at	yes
O	O	a	yes
O	O	lower	no
O	O	than	no
O	O	usual	no
O	O	dose	no
O	O	with	yes
O	O	careful	no
O	O	monitoring	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	postmarketing	no
O	O	reports	no
O	O	of	yes
O	O	rhabdomyolysis	no
O	O	,	no
O	O	some	no
O	O	associated	no
O	O	with	yes
O	O	strenuous	no
O	O	physical	no
O	O	activity	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	on	no
O	O	the	no
O	O	PR	no
O	O	interval	no
O	O	were	no
O	O	less	no
O	O	than	no
O	O	additive	no
O	O	.	no

O	O	Influence	no
O	O	of	yes
B-group	B-group	calcium-channel	no
I-group	I-group	blockers	no
O	O	on	no
O	O	platelet	yes
O	O	function	no
O	O	and	yes
O	O	arachidonic	yes
O	O	acid	yes
O	O	metabolism	no
O	O	.	no

B-group	B-group	Amphetamines	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	urinary	yes
O	O	steroid	no
O	O	determinations	no
O	O	.	no

O	O	Studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	lansoprazole	yes
O	O	does	no
O	O	not	no
O	O	have	no
O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	antipyrine	yes
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	,	no
B-drug	B-drug	ibuprofen	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	prednisone	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	terfenadine	yes
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

O	O	We	no
O	O	report	no
O	O	the	no
O	O	case	no
O	O	of	yes
O	O	an	no
O	O	adolescent	no
O	O	with	yes
O	O	altered	no
O	O	consciousness	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	carbamazepine	yes
O	O	overdose	no
O	O	with	yes
O	O	a	yes
O	O	positive	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	level	no
O	O	to	no
O	O	alert	no
O	O	clinicians	no
O	O	to	no
O	O	the	no
O	O	cross-reactivity	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	with	yes
O	O	a	yes
O	O	toxicology	no
O	O	screen	no
O	O	for	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	nc1	no
O	O	18	yes
O	O	%	no
O	O	decrease	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	13	yes
O	O	%	no
O	O	decrease	no
O	O	,	no
O	O	40	yes
O	O	%	no
O	O	decrease	no
O	O	]	no

O	O	Trough	no
O	O	plasma	yes
B-drug	B-drug	enoxacin	yes
O	O	levels	no
O	O	were	no
O	O	also	no
O	O	20	yes
O	O	%	no
O	O	higher	no
O	O	when	no
B-drug	B-drug	caffeine	yes
O	O	and	yes
B-drug	B-drug	enoxacin	yes
O	O	were	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	preliminary	no
O	O	results	no
O	O	from	no
O	O	an	no
O	O	8-week	no
O	O	controlled	no
O	O	study	no
O	O	suggested	no
B-drug	B-drug	risperidone	yes
O	O	2	yes
O	O	to	no
O	O	6	yes
O	O	mg/day	no
O	O	was	no
O	O	superior	no
O	O	to	no
B-drug	B-drug	olanzapine	yes
O	O	5	yes
O	O	to	no
O	O	20	yes
O	O	mg/day	no
O	O	against	yes
O	O	positive	no
O	O	and	yes
O	O	anxiety/depressive	no
O	O	symptoms	no
O	O	(	no
O	O	p	yes
O	O	<	no
O	O	0.05	no
O	O	)	no
O	O	,	no
O	O	although	no
O	O	consistent	no
O	O	with	yes
O	O	the	no
O	O	first	no
O	O	study	no
O	O	,	no
O	O	both	no
O	O	agents	yes
O	O	demonstrated	no
O	O	similar	no
O	O	efficacy	no
O	O	on	no
O	O	measures	no
O	O	of	yes
O	O	overall	no
O	O	psychopathology	no
O	O	.	no

O	O	The	no
O	O	goal	no
O	O	of	yes
O	O	this	no
O	O	review	no
O	O	was	no
O	O	to	no
O	O	cite	no
O	O	primary	no
O	O	sources	no
O	O	for	yes
O	O	virtually	no
O	O	all	yes
O	O	research	no
O	O	specific	no
O	O	to	no
O	O	POPs	no
O	O	since	no
O	O	1975	no
O	O	.	no

O	O	Then	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	metabotropic	no
O	O	glutamate	yes
O	O	receptor	yes
O	O	(	no
O	O	mGluR	no
O	O	)	no
O	O	agonists	no
O	O	,	no
B-drug_n	B-drug_n	DCG-IV	no
O	O	and	yes
B-drug_n	B-drug_n	L-CCG-1	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	above	no
O	O	behavioral	no
O	O	changes	no
O	O	induced	no
O	O	by	no
B-drug_n	B-drug_n	PCP	yes
O	O	were	no
O	O	found	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	desirable	no
O	O	to	no
O	O	monitor	no
B-group	B-group	TCA	no
O	O	plasma	yes
O	O	levels	no
O	O	whenever	no
O	O	a	yes
B-group	B-group	TCA	no
O	O	is	yes
O	O	going	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	with	yes
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	concomitantly	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	monitored	no
O	O	for	yes
O	O	increases	no
O	O	in	yes
O	O	INR	no
O	O	and	yes
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Both	no
O	O	hypo-	no
O	O	and	yes
O	O	hyperglycemic	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	corrected	no
O	O	QT	no
O	O	intervals	no
O	O	during	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	alone	no
O	O	or	no
O	O	with	yes
B-drug	B-drug	fluoxetine	yes
O	O	.	no

O	O	A	yes
O	O	rare	no
O	O	,	no
O	O	but	no
O	O	serious	no
O	O	,	no
O	O	constellation	no
O	O	of	yes
O	O	symptoms	no
O	O	,	no
O	O	termed	no
O	O	serotonin	yes
O	O	syndrome	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	and	yes
O	O	agents	yes
O	O	for	yes
O	O	migraine	yes
O	O	therapy	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-brand	B-brand	Imitrex	yes
O	O	(	no
B-drug	B-drug	sumatriptan	yes
I-drug	I-drug	succinate	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	dihydroergotamine	yes
O	O	.	no

O	O	Concomitant	no
B-drug	B-drug	cyclophosphamide	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	vincristine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	prednisone	yes
O	O	chemotherapy	no
O	O	plus	yes
O	B-group	highly	no
O	I-group	active	no
B-group	I-group	antiretroviral	no
O	O	therapy	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	human	yes
O	O	immunodeficiency	no
O	O	virus-related	no
O	O	,	no
O	O	non-Hodgkin	no
O	O	lymphoma	no
O	O	.	no

O	O	Most	no
O	O	automated	no
O	O	equipment	no
O	O	for	yes
O	O	measurement	no
O	O	of	yes
O	O	creatinine	yes
O	O	makes	no
O	O	use	no
O	O	of	yes
O	O	the	no
O	O	Jaffe	no
O	O	reaction	no
O	O	.	no

O	O	Some	no
B-group	B-group	quinolones	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	vii	yes
O	O	.	no

O	O	No	yes
O	O	inhibition	no
O	O	of	yes
B-drug	B-drug	deferasirox	yes
O	O	metabolism	no
O	O	by	no
B-drug	B-drug	hydroxyurea	yes
O	O	is	yes
O	O	expected	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	an	no
O	O	in	yes
O	O	vitro	no
O	O	study	no
O	O	.	no

O	O	Since	no
O	O	aminotransferase	no
O	O	determinations	no
O	O	are	no
O	O	important	no
O	O	in	yes
O	O	the	no
O	O	differential	no
O	O	diagnosis	no
O	O	of	yes
O	O	myocardial	no
O	O	infarction	no
O	O	,	no
O	O	liver	yes
O	O	disease	no
O	O	and	yes
O	O	pulmonary	no
O	O	emboli	no
O	O	,	no
O	O	rises	no
O	O	that	no
O	O	might	no
O	O	be	no
O	O	caused	no
O	O	by	no
O	O	drugs	no
O	O	(	no
B-drug	B-drug	heparin	yes
I-drug	I-drug	sodium	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	interpreted	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	This	no
O	O	product	no
O	O	can	no
O	O	affect	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	certain	no
O	O	lab	no
O	O	tests	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	QT	no
O	O	c	yes
O	O	interval	no
O	O	(	no
O	O	msec	no
O	O	)	no
O	O	was	no
O	O	369	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	alone	no
O	O	and	yes
O	O	367	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	plus	yes
B-drug	B-drug	dirithromycin	yes
O	O	.	no

O	O	Therefore	no
O	O	you	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	take	no
O	O	a	yes
B-group	B-drug	vitamin	yes
I-group	I-drug	B12	yes
O	O	supplement	yes
O	O	while	no
O	O	taking	no
B-drug	B-drug	aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	.	no

B-group	B-group	Beta	yes
I-group	I-group	Blockers	no

B-drug	B-drug	Atorvastatin	yes
O	O	:	no
B-drug	B-drug	Atorvastatin	yes
O	O	increases	no
O	O	the	no
O	O	AUC	no
O	O	for	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	.	no

O	O	Combinations	no
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	were	no
O	O	indifferent	no
O	O	for	yes
O	O	29	yes
O	O	strains	no
O	O	and	yes
O	O	synergistic	no
O	O	for	yes
O	O	33	no
O	O	strains	no
O	O	.	no

O	O	Agents	yes
O	O	Causing	no
O	O	Renin	no
O	O	Release	yes
B-drug	B-drug	Captopril	yes
O	O	's	no
O	O	effect	no
O	O	will	no
O	O	be	no
O	O	augmented	no
O	O	by	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	that	no
O	O	cause	no
O	O	renin	no
O	O	release	yes
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	inhibits	no
O	O	the	no
O	O	ERMBT	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
B-drug	B-drug	rifabutin	yes
O	O	are	no
O	O	equipotent	no
O	O	inducers	no
O	O	of	yes
O	O	the	no
O	O	ERMBT	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	and	yes
B-drug	B-drug	lamivudine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Although	no
O	O	activation	no
O	O	of	yes
O	O	several	no
O	O	transcription	no
O	O	factor	yes
O	O	IEGs	no
O	O	has	no
O	O	been	no
O	O	described	no
O	O	,	no
O	O	little	no
O	O	is	yes
O	O	known	no
O	O	about	no
O	O	effector	no
O	O	IEGs	no
O	O	.	no

B-drug_n	B-drug_n	Clostridium	yes
I-drug_n	I-drug_n	difficile	no
I-drug_n	I-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	displays	no
O	O	both	no
O	O	cytotoxic	yes
O	O	and	yes
O	O	enterotoxic	no
O	O	activities	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	likely	no
O	O	that	no
O	O	experience	no
O	O	significantly	no
O	O	underestimates	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	accumulation	no
O	O	that	no
O	O	might	no
O	O	occur	no
O	O	with	yes
O	O	repealed	no
B-drug	B-drug	diazepam	yes
O	O	administration	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	dexfenfluramine	yes
O	O	with	yes
O	O	other	no
O	O	CNS-active	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	;	no

B-group	B-group	NSAIDs	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	hemodynamic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	hydralazine	yes
O	O	;	no

O	O	therefore	no
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	is	yes
O	O	recommended	no
O	O	,	no
O	O	and	yes
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	when	no
B-brand	B-brand	Tagamet	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Genetic	no
O	O	variation	no
O	O	also	no
O	O	occurs	no
O	O	in	yes
O	O	proteins	no
O	O	interacting	no
O	O	with	yes
O	O	drugs	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	change	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	e.g	no
O	O	.	no

O	O	Before	no
O	O	using	no
O	O	this	no
O	O	medication	no
O	O	,	no
O	O	tell	no
O	O	your	no
O	O	doctor	no
O	O	or	no
O	O	pharmacist	no
O	O	of	yes
O	O	all	yes
O	O	prescription	no
O	O	and	yes
O	O	nonprescription	no
O	O	products	no
O	O	you	no
O	O	may	no
O	O	use	no
O	O	,	no
O	O	especially	no
O	O	of	yes
O	O	:	no
B-group	B-group	aminoglycosides	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	gentamicin	yes
O	O	,	no
B-drug	B-drug	amikacin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ibuprofen	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
B-drug	B-drug	vancomycin	yes
O	O	.	no

O	O	-	yes
O	O	a	yes
B-group	B-group	diuretic	no
O	O	(	no
O	O	water	yes
O	O	pill	no
O	O	)	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	(	no
B-drug	B-drug	HCTZ	yes
O	O	,	no
B-drug	B-brand	Hydrodiuril	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	chlorothiazide	yes
O	O	(	no
B-brand	B-brand	Diuril	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	;	no

B-group	B-group	Diuretics	no
O	O	:	no
B-drug	O	Etodolac	yes
O	O	has	no
O	O	no	yes
O	O	apparent	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	furosemide	yes
O	O	or	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	Interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-drug	B-drug	fluvastatin	yes
O	O	and	yes
O	O	several	no
O	O	drugs	no
O	O	with	yes
O	O	which	no
O	O	it	no
O	O	might	no
O	O	be	no
O	O	coadministered	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	,	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	may	no
O	O	be	no
O	O	blunted	no
O	O	by	no
O	O	the	no
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drug	yes
B-drug	B-drug	indomethacin	yes

B-drug	O	Erythromycin	yes
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	(	no
B-brand	B-drug	PLENDIL	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	resulted	no
O	O	in	yes
O	O	approximately	no
O	O	2.5-	no
O	O	fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	and	yes
O	O	about	no
O	O	2-	no
O	O	fold	no
O	O	prolongation	no
O	O	in	yes
O	O	the	no
O	O	half-	no
O	O	life	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	VELCADE	yes
O	O	.	no

O	O	If	no
B-brand	B-brand	SPRYCEL	yes
O	O	must	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	a	yes
O	O	CYP3A4	no
O	O	inducer	no
O	O	,	no
O	O	a	yes
O	O	dose	no
O	O	increase	no
O	O	in	yes
B-brand	B-brand	SPRYCEL	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	multiple-dose	no
O	O	study	no
O	O	,	no
B-drug	B-drug	enoxacin	yes
O	O	caused	no
O	O	a	yes
O	O	dose-related	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	mean	no
O	O	elimination	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	,	no
O	O	thereby	no
O	O	decreasing	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	by	no
O	O	up	no
O	O	to	no
O	O	80	yes
O	O	%	no
O	O	and	yes
O	O	leading	no
O	O	to	no
O	O	a	yes
O	O	five-fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	the	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Interaction	no
O	O	between	yes
O	O	exogenous	no
O	O	and	yes
O	O	endogenous	no
B-drug	B-drug	oxytocin	yes
O	O	and	yes
B-drug	O	vasopressin	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	affect	no
O	O	the	no
O	O	mechanism	no
O	O	of	yes
O	O	milk	yes
O	O	ejection	no
O	O	by	no
O	O	the	no
O	O	alveoli	no
O	O	of	yes
O	O	the	no
O	O	mammary	no
O	O	gland	no
O	O	in	yes
O	O	lactating	no
O	O	rats	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-brand	B-brand	ELLENCE	yes
O	O	after	no
O	O	previous	no
O	O	radiation	no
O	O	therapy	no
O	O	may	no
O	O	induce	no
O	O	an	no
O	O	inflammatory	no
O	O	recall	no
O	O	reaction	no
O	O	at	yes
O	O	the	no
O	O	site	no
O	O	of	yes
O	O	the	no
O	O	irradiation	no
O	O	.	no

O	O	[	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	on	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	verografin	no
O	O	and	yes
B-drug	B-drug	iodamide	yes
O	O	in	yes
O	O	dogs	no
O	O	]	no
O	O	The	no
O	O	intravenous	yes
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	in	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	20	yes
O	O	mg/kg	no
O	O	enhanced	no
B-drug	B-drug	verografine	no
O	O	and	yes
B-drug	B-drug	iodamide	yes
O	O	excretion	no
O	O	in	yes
O	O	chronic	no
O	O	canine	no
O	O	experiments	no
O	O	.	no

O	O	An	no
O	O	adjustment	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	diltiazem	yes
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	warranted	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	or	no
B-brand	B-brand	aspirin	yes
O	O	during	no
O	O	the	no
O	O	first	no
O	O	24	yes
O	O	hours	no
O	O	following	no
O	O	symptom	no
O	O	onset	no
O	O	were	no
O	O	prohibited	no
O	O	in	yes
O	O	The	no
O	O	NINDS	no
O	O	t-PA	yes
O	O	Stroke	no
O	O	Trial	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolites	no
O	O	were	no
O	O	studied	no
O	O	in	yes
O	O	24	yes
O	O	healthy	no
O	O	young	no
O	O	male	no
O	O	volunteers	no
O	O	.	no

B-brand	B-brand	Gleevec	yes
O	O	will	no
O	O	increase	no
O	O	plasmaconcentration	no
O	O	of	yes
O	O	other	no
O	O	CYP3A4	no
O	O	metabolized	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	triazolo-benzodiazepines	no
O	O	,	no
B-group	B-group	dihydropyridine	no
I-group	I-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
O	O	certain	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	.	no

O	O	Pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	were	no
O	O	also	no
O	O	not	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	phenytoin	yes
O	O	.	no

B-drug	B-drug	Fulvestrant	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	3A4	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	of	yes
O	O	assays	no
O	O	using	no
O	O	red	yes
O	O	cells	yes
O	O	from	no
O	O	healthy	no
O	O	subjects	no
O	O	to	no
O	O	determine	no
O	O	whether	no
B-drug	B-drug	ceftibuten	yes
O	O	would	no
O	O	cause	no
O	O	direct	no
O	O	Coombs	no
O	O	reactions	no
O	O	in	yes
O	O	vitro	no
O	O	showed	no
O	O	no	yes
O	O	positive	no
O	O	reaction	no
O	O	at	yes
B-drug	B-drug	ceftibuten	yes
O	O	concentrations	no
O	O	as	yes
O	O	high	yes
O	O	as	yes
O	O	40	yes
O	O	g/mL	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
B-drug	B-drug	Enoxacin	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P-450	no
O	O	isozymes	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	methylxanthines	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	Reversible	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	concentrations	no
O	O	and	yes
O	O	toxicity	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
O	O	with	yes
O	O	some	no
B-group	B-group	angiotensin	yes
I-group	I-group	II	yes
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	.	no

O	O	Adjustment	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	dosage	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	The	no
O	O	proposed	no
O	O	mechanisms	no
O	O	of	yes
O	O	analgesic	no
O	O	action	no
O	O	of	yes
B-group	B-group	antihistaminics	no
O	O	are	no
O	O	reviewed	no
O	O	and	yes
O	O	discussed	no
O	O	.	no

B-drug	B-drug	PGF2alpha	yes
O	O	produced	no
O	O	significantly	no
O	O	increased	no
O	O	vasoconstriction	no
O	O	after	no
O	O	a	yes
O	O	single	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	oxytocin	yes
O	O	.	no

O	O	For	yes
O	O	these	no
O	O	reasons	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	felt	no
O	O	that	no
O	O	,	no
O	O	in	yes
O	O	most	no
O	O	subjects	no
O	O	who	no
O	O	have	no
O	O	had	no
O	O	an	no
O	O	unsatisfactory	no
O	O	lipid	no
O	O	response	no
O	O	to	no
O	O	either	no
O	O	drug	yes
O	O	alone	no
O	O	,	no
O	O	the	no
O	O	possible	no
O	O	benefits	no
O	O	of	yes
O	O	combined	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	lovastatin	yes
O	O	and	yes
O	O	a	yes
B-group	B-group	fibrate	no
O	O	do	no
O	O	not	no
O	O	outweigh	no
O	O	the	no
O	O	risks	no
O	O	of	yes
O	O	severe	no
O	O	myopathy	no
O	O	,	no
O	O	rhabdomyolysis	no
O	O	,	no
O	O	and	yes
O	O	acute	no
O	O	renal	no
O	O	failure	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	secondary	yes
O	O	to	no
O	O	this	no
O	O	mechanism	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	if	no
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-drug	B-drug	chlorpropamide	yes
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	renal	no
O	O	insufficiency	no
O	O	.	no

O	O	When	no
O	O	combined	no
O	O	therapy	no
O	O	is	yes
O	O	contemplated	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	As	yes
O	O	noted	no
O	O	below	no
O	O	,	no
O	O	a	yes
O	O	sub-	no
O	O	for	yes
B-drug	B-drug	fluvoxamine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	,	no
O	O	a	yes
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	IIIA4	no
O	O	isozyme	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	clinical	no
O	O	pharmacology	no
O	O	study	no
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	or	no
B-drug	B-drug	sulindac	yes
O	O	was	no
O	O	administered	no
O	O	to	no
O	O	hypertensive	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	VASOTEC	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	and	yes
O	O	moderate	no
B-group	O	CYP1A2	no
I-group	O	inhibitors	no
O	O	,	no
O	O	including	no
B-group	B-group	quinolone	no
I-group	I-group	antibiotics	no
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	,	no
O	O	but	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	unless	no
O	O	clinically	no
O	O	necessary	no
O	O	because	no
O	O	of	yes
O	O	similar	no
O	O	potential	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	This	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	mediated	no
O	O	by	no
O	O	the	no
O	O	ability	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	to	no
O	O	induce	no
O	O	microsomal	no
O	O	enzymes	yes
O	O	and	yes
O	O	,	no
O	O	thus	no
O	O	,	no
O	O	the	no
O	O	catabolism	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

B-group	B-group	NSAIDs	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
O	O	and	yes
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	.	no

O	O	The	no
O	O	reddish	no
O	O	color	no
O	O	is	yes
O	O	due	no
O	O	to	no
O	O	the	no
O	O	formation	no
O	O	of	yes
O	O	a	yes
O	O	nonabsorbable	no
O	O	complex	yes
O	O	between	yes
B-drug	B-drug	cefdinir	yes
O	O	or	no
O	O	its	no
O	O	breakdown	no
O	O	products	no
O	O	and	yes
B-drug	B-drug	iron	yes
O	O	in	yes
O	O	the	no
O	O	gastrointestinal	no
O	O	tract	no
O	O	.	no

O	O	On	no
O	O	administration	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	,	no
O	O	the	no
O	O	need	no
O	O	for	yes
B-group	B-group	digitalis	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	reviewed	no
O	O	and	yes
O	O	the	no
O	O	dose	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	or	no
O	O	discontinued	no
O	O	.	no

B-drug	B-drug	Anagrelide	yes
O	O	demonstrates	no
O	O	some	no
O	O	limited	no
O	O	inhibitory	yes
O	O	activity	yes
O	O	towards	no
O	O	CYP1A2	no
O	O	which	no
O	O	may	no
O	O	present	no
O	O	a	yes
O	O	theoretical	no
O	O	potential	no
O	O	for	yes
O	O	interaction	no
O	O	with	yes
O	O	other	no
O	O	coadministered	no
O	O	medicinal	yes
O	O	products	no
O	O	sharing	no
O	O	that	no
O	O	clearance	no
O	O	mechanism	no
O	O	e.g	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	celecoxib	yes
O	O	is	yes
O	O	not	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	or	no
O	O	3A4	no
O	O	.	no

O	O	The	no
O	O	metabolism	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	is	yes
O	O	catalyzed	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoen-zymes	no
O	O	CYP2C8	no
O	O	and	yes
O	O	CYP3A4	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	maintain	no
B-drug	B-drug	phenytoin	yes
O	O	levels	no
O	O	,	no
O	O	limit	no
O	O	adverse	no
O	O	experiences	no
O	O	,	no
O	O	and	yes
O	O	achieve	no
O	O	the	no
B-drug	B-drug	felbamate	yes
O	O	dose	no
O	O	of	yes
O	O	3600	no
O	O	mg/day	no
O	O	,	no
O	O	a	yes
B-drug	B-drug	phenytoin	yes
O	O	dose	no
O	O	reduction	yes
O	O	of	yes
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	was	no
O	O	necessary	no
O	O	for	yes
O	O	eight	no
O	O	of	yes
O	O	these	no
O	O	10	yes
O	O	subjects	no
O	O	.	no

O	O	Rare	no
O	O	cases	no
O	O	of	yes
O	O	a	yes
B-drug	O	disulfiram-like	no
O	O	reaction	no
O	O	to	no
B-drug	B-drug	alcohol	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Because	no
O	O	elderly	no
O	O	patients	no
O	O	are	no
O	O	more	no
O	O	likely	no
O	O	to	no
O	O	have	no
O	O	decreased	no
O	O	renal	no
O	O	function	no
O	O	,	no
O	O	care	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	in	yes
O	O	dose	no
O	O	selection	no
O	O	and	yes
O	O	it	no
O	O	may	no
O	O	be	no
O	O	useful	no
O	O	to	no
O	O	monitor	no
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	diet	no
O	O	high	yes
O	O	in	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	;	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
B-drug	B-drug	Valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	induce	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	the	no
O	O	combination	yes
O	O	oral	yes
B-group	B-group	contraceptive	yes
B-drug	B-drug	norethindrone/ethinyl	no
I-drug	I-drug	estradiol	yes
O	O	(	no
O	O	1	yes
O	O	mg	yes
O	O	/35	no
O	O	mcg	no
O	O	combination	yes
O	O	,	no
B-brand	B-brand	Ortho-Novum	yes
O	O	1/35	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	:	no
B-drug	B-drug	Vardenafil	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	CYP1A2	no
O	O	,	no
O	O	2A6	no
O	O	,	no
O	O	and	yes
O	O	2E1	no
O	O	(	no
O	O	Ki	yes
O	O	100uM	no
O	O	)	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
I-group	I-group	MAOI	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	a	yes
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	furazolidone	yes
O	O	,	no
O	O	slow	yes
B-drug	B-drug	amphetamine	yes
O	O	metabolism	no
O	O	.	no

O	O	Occasionally	no
B-brand	B-brand	TAXOL	yes
O	O	infusions	no
O	O	must	no
O	O	be	no
O	O	interrupted	no
O	O	or	no
O	O	discontinued	no
O	O	because	no
O	O	of	yes
O	O	initial	no
O	O	or	no
O	O	recurrent	no
O	O	hypertension	no
O	O	.	no

O	O	Because	no
O	O	their	no
O	O	vasospastic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	naratriptan	yes
O	O	and	yes
O	O	other	no
B-group	B-group	5-HT1	no
I-group	I-group	agonists	no
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	are	no
O	O	contraindicated	no
O	O	specifically	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	expected	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	and	yes
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	adverse	no
O	O	events	no
O	O	are	no
O	O	listed	no
O	O	CONTRAINDICATIONS	no
O	O	.	no

O	O	It	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	as	yes
O	O	effective	no
O	O	in	yes
O	O	women	yes
O	O	with	yes
O	O	sexual	no
O	O	dysfunction	no
O	O	,	no
O	O	with	yes
O	O	the	no
O	O	exception	no
O	O	of	yes
B-group	B-group	SSRI-associated	no
O	O	sexual	no
O	O	dysfunction	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	.	no

B-drug	B-drug	Ethopropazine	yes
O	O	can	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	chlorpromazine	yes
O	O	,	no
O	O	increasing	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	chlorpromazine	yes
O	O	.	no

O	O	In	yes
O	O	1992	no
O	O	and	yes
O	O	1993	no
O	O	,	no
O	O	two	no
O	O	outbreaks	no
O	O	of	yes
O	O	arsenical	no
O	O	reactive	yes
O	O	encephalopathy	no
O	O	(	no
O	O	ARE	no
O	O	)	no
O	O	occurred	no
O	O	in	yes
O	O	the	no
O	O	sleeping	no
O	O	sickness	no
O	O	center	no
O	O	of	yes
B-brand	O	Adjumani	no
O	O	.	no

O	O	Herbal	no
O	O	products	no
O	O	:	no
O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	wort	yes
O	O	(	no
O	O	Hypericum	yes
O	O	perforatum	yes
O	O	)	no

B-drug	B-drug	Selegiline	yes
O	O	:	no
O	B-group	Combination	yes
B-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	serum	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	selegiline	yes
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-brand	B-brand	BEXTRA	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE-inhibitors	no
O	O	.	no

O	O	Ventricular	no
O	O	tachycardia	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	ouabain	yes
O	O	was	no
O	O	generally	no
O	O	converted	no
O	O	to	no
O	O	sinus	yes
O	O	rhythm	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Innovar	yes
O	O	,	no
B-drug	B-drug	ketamine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	droperidol	yes
O	O	but	no
O	O	not	no
O	O	after	no
O	O	administration	no
O	O	of	yes
B-brand	B-drug	fentayl	no
O	O	alone	no
O	O	or	no
O	O	after	no
B-drug	B-drug	pentobarbital	yes
O	O	.	no

O	O	The	no
O	O	most	no
O	O	common	yes
O	O	adverse	no
O	O	effects	no
O	O	reported	no
O	O	with	yes
B-drug	B-drug	olanzapine	yes
O	O	are	no
O	O	bodyweight	no
O	O	gain	no
O	O	,	no
O	O	somnolence	no
O	O	,	no
O	O	dizziness	no
O	O	,	no
O	O	anticholinergic	no
O	O	effects	no
O	O	(	no
O	O	constipation	no
O	O	and	yes
O	O	dry	no
O	O	mouth	no
O	O	)	no
O	O	and	yes
O	O	transient	no
O	O	asymptomatic	no
O	O	liver	yes
O	O	enzyme	no
O	O	elevations	no
O	O	.	no

O	O	Lymphocytopenia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	CAMPTOSAR	yes
O	O	,	no
O	O	and	yes
O	O	it	no
O	O	is	yes
O	O	possible	no
O	O	that	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	as	yes
B-group	O	antiemetic	no
I-group	O	prophylaxis	no
O	O	may	no
O	O	have	no
O	O	enhanced	no
O	O	the	no
O	O	likelihood	no
O	O	of	yes
O	O	this	no
O	O	effect	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	alosetron	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	hepatic	no
O	O	CYP	no
O	O	drug-metabolizing	no
O	O	enzymes	yes
O	O	,	no
O	O	inducers	no
O	O	or	no
O	O	inhibitors	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	may	no
O	O	change	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	.	no

O	O	Dual	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	ouabain	yes
O	O	on	no
O	O	the	no
O	B-drug_n	palytoxin-induced	no
O	O	contraction	no
O	O	and	yes
B-drug	O	norepinephrine	yes
O	O	release	yes
O	O	in	yes
O	O	the	no
O	O	guinea-pig	no
O	O	vas	no
O	O	deferens	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-group	B-group	corticosteroids	no
O	O	in	yes
O	O	hypoprothrombinemia	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
I-drug	I-drug	hydroxide	yes
O	O	and	yes
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydroxide	yes
O	O	does	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	rate	no
O	O	or	no
O	O	extent	no
O	O	of	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ketoprofen	yes
O	O	administered	no
O	O	as	yes
B-brand	B-brand	Orudis	yes
O	O	.	no

O	O	Clinically	no
O	O	significant	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	when	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

B-drug	B-drug	Sildenafil	yes
I-drug	I-drug	citrate	yes
O	O	:	no
O	O	a	yes
O	O	therapeutic	no
O	O	update	no
O	O	.	no

O	O	Oral	yes
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Antizol	yes
O	O	(	no
O	O	10-20	no
O	O	mg/kg	no
O	O	)	no
O	O	,	no
O	O	via	no
B-drug	O	alcohol	yes
O	O	dehydrogenase	no
O	O	inhibition	no
O	O	,	no
O	O	significantly	no
O	O	reduced	yes
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	(	no
O	O	by	no
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	)	no
O	O	given	no
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	in	yes
O	O	moderate	no
O	O	doses	no
O	O	.	no

O	O	Monitor	no
B-group	B-group	salicylate	yes
O	O	levels	no
O	O	or	no
O	O	the	no
O	O	therapeutic	no
O	O	effect	no
O	O	for	yes
O	O	which	no
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	given	no
O	O	;	no

O	O	The	no
O	O	interaction	no
O	O	was	no
O	O	pharmacodynamic	no
O	O	with	yes
O	O	no	yes
O	O	alteration	no
O	O	of	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

B-drug	O	Cyclosporine	yes
O	O	,	no
B-drug	O	Digoxin	yes
O	O	,	no
B-drug	O	Methotrexate	yes
B-brand	B-brand	Lodine	yes
O	O	,	no
O	O	like	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	through	no
O	O	effects	no
O	O	on	no
O	O	renal	no
O	O	prostaglandins	no
O	O	,	no
O	O	may	no
O	O	cause	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	leading	no
O	O	to	no
O	O	elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
O	O	and	yes
O	O	increased	no
O	O	toxicity	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
B-group	B-group	NSAIDs	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	If	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	is	yes
O	O	changed	no
O	O	,	no
O	O	the	no
O	O	same	yes
O	O	procedure	no
O	O	should	no
O	O	be	no
O	O	repeated	no
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	likely	no
O	O	that	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	levobupivacaine	yes
O	O	may	no
O	O	be	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	known	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	)	no
O	O	,	no
B-drug	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
B-group	O	azole	no
I-group	O	antimycotics	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	;	no

B-drug	B-drug	Salicylic	yes
I-drug	I-drug	acid	yes
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	salicylic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	Acarbose	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	sulfonylureas	no
O	O	or	no
B-drug	B-drug	insulin	yes
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	any	no
O	O	evidence	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Only	no
O	O	with	yes
O	O	knowledge	no
O	O	of	yes
O	O	the	no
O	O	interaction	no
O	O	can	no
O	O	the	no
O	O	therapeutic	no
O	O	regimen	no
O	O	be	no
O	O	altered	no
O	O	so	no
O	O	as	yes
O	O	to	no
O	O	provide	no
O	O	therapeutic	no
O	O	levels	no
O	O	of	yes
O	O	necessary	no
O	O	drugs	no
O	O	while	no
O	O	avoiding	no
O	O	toxicity	no
O	O	.	no

O	O	Reduced	yes
O	O	efficacy	no
O	O	and	yes
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	breakthrough	no
O	O	bleeding	no
O	O	and	yes
O	O	menstrual	no
O	O	irregularities	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	.	no

O	O	Additionally	no
O	O	,	no
B-group	B-group	anti-malarial	no
I-group	I-group	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	chloroquine	yes
O	O	and	yes
B-drug	B-drug	mefloquine	yes
O	O	,	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	.	no

O	O	Whether	no
O	O	this	no
O	O	interaction	no
O	O	also	no
O	O	occurs	no
O	O	with	yes
O	O	the	no
O	O	intravenous	yes
O	O	,	no
O	O	topical	yes
O	O	,	no
O	O	or	no
O	O	vaginal	no
O	O	preparations	no
O	O	of	yes
B-drug	B-drug	miconazole	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	.	no

O	O	Agents	yes
O	O	Increasing	no
O	O	Serum	yes
O	O	Potassium	yes
O	O	Since	no
B-drug	B-drug	captopril	yes
O	O	decreases	no
O	O	aldosterone	yes
O	O	production	no
O	O	,	no
O	O	elevation	no
O	O	of	yes
O	O	serum	yes
O	O	potassium	yes
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	first	no
O	O	double-blind	no
O	O	comparative	no
O	O	study	no
O	O	(	no
O	O	28-week	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	olanzapine	yes
O	O	and	yes
B-drug	B-drug	risperidone	yes
O	O	,	no
B-drug	B-drug	olanzapine	yes
O	O	10	yes
O	O	to	no
O	O	20	yes
O	O	mg/day	no
O	O	proved	no
O	O	to	no
O	O	be	no
O	O	significantly	no
O	O	more	no
O	O	effective	no
O	O	than	no
B-drug	B-drug	risperidone	yes
O	O	4	yes
O	O	to	no
O	O	12	yes
O	O	mg/day	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	negative	no
O	O	and	yes
O	O	depressive	no
O	O	symptoms	no
O	O	but	no
O	O	not	no
O	O	on	no
O	O	overall	no
O	O	psychopathology	no
O	O	symptoms	no
O	O	.	no

O	O	Secondary	yes
O	O	prevention	no
O	O	of	yes
O	O	atherosclerotic	no
O	O	risk	no
O	O	factors	no
O	O	is	yes
O	O	also	no
O	O	important	no
O	O	:	no
O	O	regulation	no
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	and	yes
O	O	blood	yes
O	O	sugar	yes
O	O	level	no
O	O	,	no
O	O	hyperlipidaemia	no
O	O	and	yes
O	O	obesity	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	a	yes
O	O	change	no
O	O	of	yes
O	O	lifestyle	no
O	O	(	no
O	O	giving	no
O	O	up	no
O	O	smoking	no
O	O	,	no
O	O	adapting	no
O	O	of	yes
O	O	diet	no
O	O	and	yes
O	O	more	no
O	O	physical	no
O	O	exertion	no
O	O	)	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-brand	B-brand	FROVA	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	commonly	no
O	O	employed	no
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	By	no
O	O	decreasing	no
O	O	the	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	primidone	yes
O	O	,	no
B-brand	B-brand	DIAMOX	yes
O	O	may	no
O	O	decrease	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	primidone	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	,	no
O	O	with	yes
O	O	a	yes
O	O	consequent	no
O	O	possible	no
O	O	decrease	no
O	O	in	yes
O	O	anticonvulsant	no
O	O	effect	no
O	O	.	no

O	O	Other	no
O	O	plasma	yes
O	O	proteins	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	(	no
O	O	angiotensinogen/renin	no
O	O	substrate	yes
O	O	,	no
O	O	alpha-1-antitrypsin	yes
O	O	,	no
O	O	ceruloplasmin	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	models	no
O	O	are	no
O	O	typically	no
O	O	nonlinear	no
O	O	in	yes
O	O	the	no
O	O	parameters	no
O	O	,	no
O	O	and	yes
O	O	as	yes
O	O	such	no
O	O	,	no
O	O	a	yes
O	O	nonlinear	no
O	O	weighted	no
O	O	least	no
O	O	squares	no
O	O	approach	no
O	O	can	no
O	O	be	no
O	O	employed	no
O	O	for	yes
O	O	the	no
O	O	purpose	no
O	O	of	yes
O	O	designing	no
O	O	experiments	no
O	O	.	no

B-drug	B-drug	Fluvoxamine	yes
O	O	inhibits	no
O	O	the	no
O	O	CYP2C9	no
O	O	catalyzed	no
O	O	biotransformation	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	.	no

B-drug	B-drug	Norepinephrine	yes

O	O	Oral	yes
B-group	B-group	anticoagulants	no
O	O	decreased	no
O	O	prothrombin	yes
O	O	time	no
O	O	response	no
O	O	.	no

O	O	No	yes
O	O	adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	is	yes
O	O	recommended	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	placebo-controlled	no
O	O	trial	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	1	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	doxazosin	yes
O	O	on	no
O	O	day	no
O	O	1	yes
O	O	of	yes
O	O	a	yes
O	O	four-day	no
O	O	regimen	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	10	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	doxazosin	yes
O	O	(	no
O	O	p=0.006	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	slight	no
O	O	but	no
O	O	not	no
O	O	statistically	no
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	Cmax	no
O	O	and	yes
O	O	mean	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	doxazosin	yes
O	O	.	no

O	O	RESULTS	no
O	O	.	no

O	O	Similar	no
O	O	decreases	no
O	O	in	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	were	no
O	O	seen	no
O	O	after	no
O	O	the	no
O	O	first	no
O	O	dose	no
O	O	.	no

O	O	No	yes
O	O	in	yes
O	O	vitro	no
O	O	metabolism	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	.	no

O	O	If	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	naratriptan	yes
O	O	and	yes
O	O	an	no
B-group	B-group	SSRI	no
O	O	is	yes
O	O	clinically	no
O	O	warranted	no
O	O	,	no
O	O	appropriate	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	advised	no
O	O	.	no

O	O	-	yes
O	O	Other	no
B-group	B-group	anti-infectives	no
O	O	by	no
O	O	mouth	no
O	O	or	no
O	O	by	no
O	O	injection	yes
O	O	(	no
O	O	medicine	no
O	O	for	yes
O	O	infection	no
O	O	)	no
O	O	or	no

O	O	[	no
O	O	Multiple	no
O	O	occupational	no
O	O	exposure	yes
O	O	to	no
B-group	O	solvents	no
O	O	]	no
O	O	This	no
O	O	article	no
O	O	review	no
O	O	papers	no
O	O	published	no
O	O	over	no
O	O	the	no
O	O	last	no
O	O	20	yes
O	O	years	no
O	O	on	no
O	O	multiple	no
O	O	occupational	no
O	O	exposure	yes
O	O	to	no
B-group	O	solvents	no
O	O	.	no

O	O	Drug	yes
O	O	exposure	yes
O	O	in	yes
O	O	rodent	no
O	O	pups	no
O	O	from	no
B-drug	B-drug	fulvestrant-treated	no
O	O	lactating	no
O	O	dams	no
O	O	was	no
O	O	estimated	no
O	O	as	yes
O	O	10	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	administered	no
O	O	dose	no
O	O	.	no

O	O	If	no
B-drug	B-drug	rifampicin	yes
O	O	therapy	no
O	O	is	yes
O	O	required	no
O	O	,	no
B-drug	B-drug	isradipine	yes
O	O	concentrations	no
O	O	and	yes
O	O	therapeutic	no
O	O	effects	no
O	O	are	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	markedly	no
O	O	reduced	yes
O	O	or	no
O	O	abolished	no
O	O	as	yes
O	O	a	yes
O	O	consequence	no
O	O	of	yes
O	O	increased	no
O	O	metabolism	no
O	O	and	yes
O	O	higher	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	isradipine	yes
O	O	.	no

O	O	Use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Subsequent	no
O	O	adjustment	no
O	O	of	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	mercaptopurine	yes
O	O	or	no
B-drug	B-drug	azathioprine	yes
O	O	should	no
O	O	be	no
O	O	made	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	therapeutic	no
O	O	response	no
O	O	and	yes
O	O	the	no
O	O	appearance	no
O	O	of	yes
O	O	toxic	no
O	O	effects	no
O	O	.	no

O	O	All	yes
O	O	drugs	no
O	O	were	no
O	O	injected	no
O	O	intraperitoneally	no
O	O	.	no

B-drug	B-drug	Glyburide	yes
O	O	:	no
B-drug	B-drug	Etodolac	yes
O	O	has	no
O	O	no	yes
O	O	apparent	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fenofibrate	yes
O	O	(	no
O	O	equivalent	no
O	O	to	no
O	O	145	no
O	O	mg	yes
B-brand	B-brand	TRICOR	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	atorvastatin	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	resulted	no
O	O	in	yes
O	O	approximately	no
O	O	17	yes
O	O	%	no
O	O	decrease	no
O	O	(	no
O	O	range	no
O	O	from	no
O	O	67	yes
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	44	yes
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	in	yes
B-drug	B-drug	atorvastatin	yes
O	O	AUC	no
O	O	values	no
O	O	in	yes
O	O	22	no
O	O	healthy	no
O	O	males	no
O	O	.	no

O	O	Drug/Food	no
O	O	Interactions	no
O	O	The	no
O	O	bioavailability	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	deferasirox	yes
O	O	was	no
O	O	variably	no
O	O	increased	no
O	O	when	no
O	O	taken	no
O	O	with	yes
O	O	a	yes
O	O	meal	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	data	no
O	O	from	no
O	O	these	no
O	O	patients	no
O	O	demonstrated	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	paclitaxel	yes
O	O	clearance	no
O	O	of	yes
O	O	approximately	no
O	O	33	no
O	O	%	no
O	O	when	no
B-brand	B-brand	TAXOL	yes
O	O	was	no
O	O	administered	no
O	O	following	no
B-drug	B-drug	cisplatin	yes
O	O	.	no

O	O	In	yes
O	O	secretions	no
O	O	such	no
O	O	as	yes
O	O	colostrum	no
O	O	,	no
O	O	IgA	no
O	O	is	yes
O	O	the	no
O	O	only	no
O	O	protein	yes
O	O	precipitated	yes
O	O	by	no
B-drug_n	B-drug_n	jacalin	no
O	O	.	no

B-brand	B-brand	Trecator	yes
O	O	has	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	temporarily	no
O	O	raise	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-brand	B-brand	MIDAMOR	yes
O	O	and	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

B-drug	B-drug	Omeprazole	yes
O	O	:	no
O	O	The	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	was	no
O	O	bioequivalent	no
O	O	when	no
B-brand	B-brand	Proquin	yes
I-brand	I-brand	XR	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	or	no
O	O	when	no
B-brand	B-brand	Proquin	yes
I-brand	I-brand	XR	yes
O	O	was	no
O	O	given	no
O	O	2	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	omeprazole	yes
O	O	at	yes
O	O	the	no
O	O	dose	no
O	O	that	no
O	O	maximally	no
O	O	suppresses	no
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	.	no

B-drug	B-drug	Chlorotrianisene	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	antidepressants	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	bromocriptine	yes
O	O	,	no
B-drug	B-drug	calcium	yes
O	O	supplements	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-drug	B-drug	corticotropin	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	dantrolene	yes
O	O	,	no
B-drug	B-drug	nicotine	yes
O	O	,	no
B-drug	B-drug	somatropin	yes
O	O	,	no
B-drug	B-drug	tamoxifen	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isozyme	no
O	O	,	no
O	O	including	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	and	yes
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	and	yes
B-drug	B-drug	encainide	yes
O	O	)	no
O	O	,	no
O	O	or	no
O	O	that	no
O	O	inhibit	no
O	O	this	no
O	O	enzyme	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	imatinib	yes
O	O	when	no
B-brand	B-brand	Gleevec	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	)	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	one	no
O	O	report	no
O	O	suggesting	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	trazodone	yes
I-drug	I-drug	hydrochloride	yes
O	O	(	no
B-brand	B-brand	Desyrel	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	buspirone	yes
I-drug	I-drug	HCl	yes
O	O	may	no
O	O	have	no
O	O	caused	no
O	O	3-	no
O	O	to	no
O	O	6-fold	no
O	O	elevations	no
O	O	on	no
O	O	SGPT	no
O	O	(	no
O	O	ALT	no
O	O	)	no
O	O	in	yes
O	O	a	yes
O	O	few	no
O	O	patients	no
O	O	.	no

O	O	An	no
O	O	alternative	no
O	O	or	no
O	O	additional	no
O	O	method	yes
O	O	of	yes
O	O	contraception	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	rifampin	yes
O	O	(	no
B-brand	B-brand	Rifadin	yes
O	O	,	no
B-brand	B-brand	Rifamate	yes
O	O	)	no
O	O	;	no

B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	:	no
O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	Angiotensin	yes
I-group	I-group	Converting	no
I-group	I-group	Enzyme	no
I-group	I-group	(	no
I-group	I-group	ACE	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Atorvastatin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	LDL-C	no
O	O	reduction	yes
O	O	were	no
O	O	not	no
O	O	altered	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	In	yes
O	O	vivo	no
O	O	studies	no
O	O	:	no
B-group	B-group	Nitrates	no
O	O	:	no
O	O	The	no
O	O	blood	yes
O	O	pressure	no
O	O	lowering	no
O	O	effects	no
O	O	of	yes
O	O	sublingual	no
B-group	B-group	nitrates	no
O	O	(	no
O	O	0.4	no
O	O	mg	yes
O	O	)	no
O	O	taken	no
O	O	1	yes
O	O	and	yes
O	O	4	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	vardenafil	yes
O	O	and	yes
O	O	increases	no
O	O	in	yes
O	O	heart	no
O	O	rate	no
O	O	when	no
O	O	taken	no
O	O	at	yes
O	O	1	yes
O	O	,	no
O	O	4	yes
O	O	and	yes
O	O	8	yes
O	O	hours	no
O	O	were	no
O	O	potentiated	no
O	O	by	no
O	O	a	yes
O	O	20	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	in	yes
O	O	healthy	no
O	O	middle-aged	no
O	O	subjects	no
O	O	.	no

O	O	aeruginosa	no
O	O	serotype	no
O	O	O11	no
O	O	strains	no
O	O	,	no
O	O	but	no
O	O	not	no
B-drug	O	S	yes
O	O	.	no

B-drug	B-drug	Eprosartan	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	Neither	no
O	O	subject	no
O	O	demonstrated	no
O	O	clinical	no
O	O	evidence	no
O	O	of	yes
O	O	allergic	no
O	O	or	no
O	O	anaphylactic	no
O	O	reactions	no
O	O	and	yes
O	O	repeat	no
O	O	testing	no
O	O	was	no
O	O	not	no
O	O	performed	no
O	O	.	no

O	O	No	yes
O	O	specific	no
O	O	information	no
O	O	available	no

O	O	METHODS	no
O	O	:	no
O	O	Healthy	no
O	O	subjects	no
O	O	who	no
O	O	were	no
O	O	20	yes
O	O	to	no
O	O	43	yes
O	O	years	no
O	O	old	no
O	O	participated	no
O	O	in	yes
O	O	an	no
O	O	open	yes
O	O	,	no
O	O	three-period	no
O	O	,	no
O	O	randomized	no
O	O	,	no
O	O	crossover	no
O	O	study	no
O	O	of	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	10-mg	no
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	,	no
O	O	a	yes
O	O	single	yes
O	O	oral	yes
O	O	120-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	given	no
O	O	together	no
O	O	.	no

O	O	These	no
O	O	lines	no
O	O	showed	no
O	O	variable	no
O	O	degrees	no
O	O	of	yes
O	O	locomotor	no
O	O	activities	no
O	O	in	yes
O	O	response	no
O	O	to	no
B-drug	B-drug	cocaine	yes
O	O	.	no

O	O	An	no
O	O	adequate	no
O	O	period	no
O	O	of	yes
O	O	observation	no
O	O	must	no
O	O	be	no
O	O	provided	no
O	O	for	yes
O	O	any	no
O	O	patient	no
O	O	in	yes
O	O	whom	no
O	O	either	no
O	B-group	long-acting	no
B-group	I-group	benzodiazepines	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	diazepam	yes
O	O	)	no
O	O	or	no
O	O	large	no
O	O	doses	no
O	O	of	yes
B-group	B-group	short-acting	no
I-group	I-group	benzodiazepines	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	10	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	)	no
O	O	have	no
O	O	been	no
O	O	used	no
O	O	.	no

O	O	The	no
O	O	vasodilating	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	isosorbide	yes
I-drug	I-drug	dinitrate	yes
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	with	yes
O	O	those	no
O	O	of	yes
O	O	other	no
B-group	B-group	vasodilators	no
O	O	.	no

O	O	In	yes
O	O	the	no
B-drug	B-drug	Duloxetine	yes
O	O	clinical	no
O	O	trials	no
O	O	database	no
O	O	,	no
O	O	three	no
B-drug	B-drug	Duloxetine-treated	no
O	O	patients	no
O	O	had	no
O	O	liver	yes
O	O	injury	no
O	O	as	yes
O	O	manifested	no
O	O	by	no
O	O	ALT	no
O	O	and	yes
O	O	total	yes
O	O	bilirubin	no
O	O	elevations	no
O	O	,	no
O	O	with	yes
O	O	evidence	no
O	O	of	yes
O	O	obstruction	no
O	O	.	no

B-drug	B-drug	Stavudine	yes
O	O	and	yes
B-drug	B-drug	Zidovudine	yes
I-drug	I-drug	Ribavirin	yes
O	O	can	no
O	O	antagonize	no
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	antiviral	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	stavudine	yes
O	O	and	yes
B-drug	B-drug	zidovudine	yes
O	O	against	yes
O	O	HIV	no
O	O	.	no

O	O	No	yes
O	O	reported	no
O	O	interactions	no
O	O	.	no

O	O	The	no
O	O	aim	yes
O	O	of	yes
O	O	this	no
O	O	study	no
O	O	was	no
O	O	to	no
O	O	investigate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	low	yes
O	O	and	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	,	no
O	O	and	yes
O	O	of	yes
B-drug	B-drug	progesterone	yes
O	O	on	no
O	O	the	no
O	O	response	no
O	O	to	no
B-drug	B-drug	noradrenaline	yes
O	O	in	yes
O	O	rat	yes
O	O	thoracic	no
O	O	aorta	no
O	O	.	no

O	O	The	no
O	O	similarity	no
O	O	of	yes
O	O	the	no
B-brand	B-brand	TYSABRI	yes
O	O	-associated	no
O	O	adverse	no
O	O	event	no
O	O	profile	no
O	O	between	yes
O	O	Study	no
O	O	1	yes
O	O	(	no
O	O	without	no
O	O	co-administered	no
B-brand	B-brand	AVONEX	yes
O	O	)	no
O	O	and	yes
O	O	Study	no
O	O	2	yes
O	O	(	no
O	O	with	yes
O	O	co-administered	no
B-brand	B-brand	AVONEX	yes
O	O	)	no
O	O	indicates	no
O	O	that	no
O	O	this	no
O	O	alteration	no
O	O	in	yes
O	O	clearance	no
O	O	does	no
O	O	not	no
O	O	necessitate	no
O	O	reduction	yes
O	O	of	yes
O	O	the	no
B-brand	B-brand	TYSABRI	yes
O	O	dose	no
O	O	to	no
O	O	maintain	no
O	O	safety	no
O	O	,	no
O	O	General	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Haloperidol	yes
O	O	:	no
B-drug	B-drug	Haloperidol	yes
O	O	blocks	no
O	O	dopamine	yes
O	O	and	yes
O	O	norepinephrine	yes
O	O	reuptake	no
O	O	,	no
O	O	thus	no
O	O	inhibiting	no
O	O	the	no
O	O	central	no
O	O	stimulant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	Patients	no
O	O	on	no
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	agents	yes
O	O	receiving	no
B-brand	B-brand	VELCADE	yes
O	O	treatment	no
O	O	may	no
O	O	require	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	their	no
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	and	yes
O	O	adjustment	no
O	O	of	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	their	no
B-group	B-group	antidiabetic	no
I-group	I-group	medication	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	can	no
O	O	produce	no
O	O	clinically	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	Haemodynamic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	glucose	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	were	no
O	O	additive	no
O	O	when	no
B-drug	B-drug	somatostatin	yes
O	O	was	no
O	O	co-administered	no
O	O	but	no
O	O	not	no
O	O	under	no
O	O	basal	no
O	O	conditions	no
O	O	.	no

O	O	Inhibits	no
O	O	CYP1A2	no
O	O	(	no
O	O	weak	no
O	O	)	no
O	O	,	no
O	O	2B6	no
O	O	(	no
O	O	weak	no
O	O	)	no
O	O	,	no
O	O	2C19	no
O	O	(	no
O	O	weak	no
O	O	)	no
O	O	,	no
O	O	3A4	no
O	O	(	no
O	O	weak	no
O	O	)	no
O	O	.	no

O	O	Subjects	no
O	O	who	no
O	O	do	no
O	O	not	no
O	O	metabolize	no
B-drug	B-drug	losartan	yes
O	O	to	no
O	O	active	no
O	O	metabolite	yes
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	specific	no
O	O	,	no
O	O	rare	no
O	O	defect	no
O	O	in	yes
O	O	cytochrome	no
O	O	P450	no
O	O	2C9	no
O	O	.	no

O	O	This	no
O	O	diminution	no
O	O	is	yes
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	preclude	no
O	O	effectiveness	no
O	O	of	yes
O	O	the	no
O	O	pressor	no
O	O	agent	yes
O	O	for	yes
O	O	therapeutic	no
O	O	use	no
O	O	.	no

O	O	Thus	no
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	bumetanide	yes
O	O	.	no

O	O	A	yes
O	O	3-fold	no
O	O	increase	no
O	O	was	no
O	O	seen	no
O	O	in	yes
O	O	another	no
O	O	5	yes
O	O	patients	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	systemic	no
O	O	administration	no
O	O	of	yes
O	O	some	no
B-group	B-group	quinolones	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	elevate	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	,	no
O	O	and	yes
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
B-drug	B-drug	warfarin	yes
O	O	and	yes
O	O	its	no
O	O	derivatives	no
O	O	,	no
O	O	and	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	transient	no
O	O	elevations	no
O	O	in	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	systemic	no
B-drug	B-drug	cyclosporine	yes
O	O	concomitantly	no
O	O	.	no

O	O	Other	no
O	O	Agents	yes

B-group	B-group	Coumarin	yes
I-group	I-group	Anticoagulants	no
O	O	:	no
O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	reports	no
O	O	of	yes
O	O	increased	no
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	to	no
O	O	whom	no
B-drug	B-drug	nifedipine	yes
O	O	was	no
O	O	administered	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	study	no
O	O	,	no
O	O	40	yes
O	O	healthy	no
O	O	female	no
O	O	subjects	no
O	O	received	no
B-drug	B-drug	fluvoxamine	yes
O	O	in	yes
O	O	escalating	no
O	O	doses	no
O	O	from	no
O	O	50	yes
O	O	to	no
O	O	200	yes
O	O	mg	yes
O	O	per	no
O	O	day	no
O	O	for	yes
O	O	16	yes
O	O	days	no
O	O	,	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	1	yes
O	O	mg	yes
O	O	on	no
O	O	the	no
O	O	last	no
O	O	day	no
O	O	.	no

B-drug	B-drug	Anakinra	yes
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	anakinra	yes
O	O	(	no
O	O	an	no
B-group	B-group	interleukin-1	yes
I-group	I-group	antagonist	yes
O	O	)	no
O	O	and	yes
O	O	another	no
B-group	B-group	TNF-blocking	no
I-group	I-group	agent	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	infections	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	neutropenia	no
O	O	and	yes
O	O	no	yes
O	O	additional	no
O	O	benefit	no
O	O	compared	no
O	O	to	no
O	O	these	no
O	O	medicinal	yes
O	O	products	no
O	O	alone	no
O	O	.	no

O	O	Some	no
O	O	of	yes
O	O	the	no
O	O	CNS	no
O	O	and	yes
O	O	genitourinary	no
O	O	symptoms	no
O	O	may	no
O	O	be	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	underlying	no
O	O	disease	no
O	O	rather	no
O	O	than	no
O	O	to	no
O	O	drug	yes
O	O	therapy	no
O	O	.	no

O	O	This	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	Benedict	no
O	O	s	yes
O	O	and	yes
O	O	Fehling	no
O	O	s	yes
O	O	solutions	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	the	no
O	O	glucose	yes
O	O	enzymatic	no
O	O	test	yes
O	O	.	no

O	O	If	no
O	O	co-administration	no
O	O	is	yes
O	O	essential	yes
O	O	,	no
O	O	conduct	no
O	O	close	no
O	O	clinical	no
O	O	and	yes
O	O	laboratory	no
O	O	monitoring	no

O	O	Using	no
O	O	this	no
O	O	technique	no
O	O	,	no
O	O	it	no
O	O	was	no
O	O	possible	no
O	O	to	no
O	O	escalate	no
O	O	the	no
B-drug	B-drug	cisplatin	yes
O	O	dose	no
O	O	to	no
O	O	225	yes
O	O	mg/m2	no
O	O	before	no
O	O	dose-limiting	no
O	O	toxicities	no
O	O	were	no
O	O	encountered	no
O	O	.	no

O	O	Close	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	a	yes
B-group	B-group	beta-blocker	no
O	O	is	yes
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
O	O	catecholamine-depleting	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	the	no
O	O	production	no
O	O	of	yes
O	O	hypotension	no
O	O	and/or	no
O	O	marked	no
O	O	bradycardia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	produce	no
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	or	no
O	O	postural	no
O	O	hypotension	no
O	O	.	no

B-drug	B-drug	primidone	yes
O	O	;	no

O	O	Physiological	no
O	O	oral	yes
B-drug	B-drug	magnesium	yes
O	O	load	no
O	O	constitutes	no
O	O	the	no
O	O	best	no
O	O	tool	no
O	O	for	yes
O	O	diagnosis	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	deficiency	no
O	O	and	yes
O	O	the	no
O	O	first	no
O	O	step	no
O	O	of	yes
O	O	its	no
O	O	treatment	no
O	O	.	no

B-drug	I-drug	sildenafil	yes
O	O	concentration	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Kerlone	yes
O	O	with	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
B-drug	B-drug	warfarin	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	not	no
O	O	to	no
O	O	potentiate	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Free	yes
O	O	hormone	yes
O	O	concentrations	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	.	no

O	O	2	yes
O	O	.	no

B-drug	B-drug	Diazepam	yes
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	0.25	no
O	O	mg/kg	no
O	O	and	yes
O	O	2.5	yes
O	O	mg/kg	no
O	O	injected	no
O	O	with	yes
B-drug	B-drug	morphine	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	Mutagenesis	no
O	O	Impairment	no
O	O	of	yes
O	O	Fertility	no
B-brand	B-brand	PEGASYS	yes
O	O	may	no
O	O	impair	no
O	O	fertility	no
O	O	in	yes
O	O	women	yes
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
B-drug	B-drug	ibuprofen	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	However	no
O	O	,	no
B-group	B-group	antacids	no
O	O	can	no
O	O	decrease	no
O	O	the	no
O	O	peak	no
O	O	concentration	no
O	O	reached	no
O	O	by	no
O	O	15	yes
O	O	%	no
O	O	to	no
O	O	20	yes
O	O	%	no
O	O	but	no
O	O	have	no
O	O	no	yes
O	O	detectable	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	time-to-peak	no
O	O	.	no

O	O	The	no
O	O	anesthesiologist	no
O	O	should	no
O	O	be	no
O	O	informed	no
O	O	when	no
O	O	a	yes
O	O	patient	no
O	O	is	yes
O	O	receiving	no
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	Other	no
B-group	B-group	Antiretroviral	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	Significant	no
O	O	decreases	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	delavirdine	yes
O	O	(	no
O	O	20	yes
O	O	%	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	indinavir	yes
O	O	(	no
O	O	84	no
O	O	%	no
O	O	)	no
O	O	occurred	no
O	O	following	no
O	O	simultaneous	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	with	yes
B-brand	B-brand	VIDEX	yes
O	O	.	no

O	O	Other	no
O	O	Drugs	no
O	O	:	no
O	O	Drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	antihistamines	no
O	O	,	no
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	QT-interval	no
O	O	prolongation	no
O	O	and	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	ventricular	no
O	O	arrhythmia	no
O	O	.	no

B-drug	B-drug	Cyclophosphamide	yes
O	O	treatment	no
O	O	,	no
O	O	which	no
O	O	causes	no
O	O	a	yes
O	O	marked	no
O	O	and	yes
O	O	persistent	no
O	O	inhibition	no
O	O	of	yes
O	O	cholinesterase	no
O	O	activity	yes
O	O	,	no
O	O	potentiates	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
I-drug	I-drug	chloride	yes
O	O	.	no

B-drug	B-drug	Chloral	yes
I-drug	I-drug	hydrate	yes
O	O	may	no
O	O	cause	no
O	O	an	no
O	O	increased	no
O	O	prothrombin	yes
O	O	response	no
O	O	by	no
O	O	displacing	no
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	from	no
O	O	protein	yes
O	O	binding	no
O	O	sites	no
O	O	or	no
O	O	a	yes
O	O	diminished	no
O	O	prothrombin	yes
O	O	response	no
O	O	through	no
O	O	increased	no
O	O	metabolism	no
O	O	of	yes
O	O	the	no
O	O	unbound	no
O	O	drug	yes
O	O	by	no
O	O	hepatic	no
O	O	enzyme	no
O	O	induction	no
O	O	,	no
O	O	thus	no
O	O	leading	no
O	O	to	no
O	O	inter-patient	no
O	O	variation	no
O	O	in	yes
O	O	ultimate	no
O	O	prothrombin	yes
O	O	effect	no
O	O	.	no

O	O	The	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	imipramine	yes
O	O	may	no
O	O	increase	no
O	O	when	no
O	O	the	no
O	O	drug	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	hepatic	no
O	O	enzyme	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	)	no
O	O	and	yes
O	O	decrease	no
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	hepatic	no
O	O	enzyme	no
O	O	inducers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	adjustment	no
O	O	of	yes
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	imipramine	yes
O	O	may	no
O	O	therefore	no
O	O	be	no
O	O	necessary	no
O	O	.	no

B-drug	B-drug	Lomefloxacin	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	phenytoin	yes
O	O	metabolism	no
O	O	.	no

O	O	Hemodynamic	no
O	O	and	yes
O	O	electrophysiologic	no
O	O	interactions	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	observed	no
O	O	after	no
O	O	concomitant	no
O	O	administration	no
O	O	with	yes
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	appropriate	no
O	O	dose	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	for	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Perhexiline	yes
I-drug	I-drug	hydrogen	yes
I-drug	I-drug	maleate	yes
O	O	or	no
B-group	B-group	MAO-inhibitors	no
O	O	(	no
O	O	with	yes
O	O	hepatotoxic	no
O	O	potential	no
O	O	)	no
O	O	must	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	together	no
O	O	with	yes
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	.	no

O	O	These	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	conversion	yes
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	to	no
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	is	yes
O	O	mediated	no
O	O	primarily	no
O	O	by	no
O	O	P450	no
O	O	2C9	no
O	O	and	yes
O	O	not	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	Analgesia	no
O	O	and	yes
O	O	pupil	no
O	O	constriction	no
O	O	were	no
O	O	measured	no
O	O	.	no

O	O	Effects	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	O	excystment	no
O	O	rates	no
O	O	over	no
O	O	a	yes
O	O	2	yes
O	O	h	yes
O	O	period	no
O	O	demonstrated	no
O	O	widespread	no
O	O	effects	no
O	O	for	yes
O	O	cercariae-exposed	no
O	O	P	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	single	yes
O	O	subject	no
O	O	given	no
O	O	one	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	2	yes
O	O	hours	no
O	O	after	no
O	O	a	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	didanosine-placebo	no
O	O	tablets	yes
O	O	,	no
O	O	a	yes
O	O	greater	no
O	O	than	no
O	O	50	yes
O	O	%	no
O	O	reduction	yes
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	was	no
O	O	observed	no
O	O	.	no

O	O	If	no
O	O	you	no
O	O	are	no
O	O	also	no
O	O	using	no
O	O	a	yes
B-group	B-group	steroid	no
I-group	O	inhaler	no
O	O	,	no
O	O	take	no
B-drug	B-drug	bitolterol	yes
O	O	first	no
O	O	and	yes
O	O	then	no
O	O	wait	no
O	O	about	no
O	O	15	yes
O	O	minutes	no
O	O	before	no
O	O	using	no
O	O	the	no
B-group	B-group	steroid	no
I-group	O	inhaler	no
O	O	.	no

B-group	O	Urinary	yes
I-group	O	acidifying	no
I-group	O	agents	yes
O	O	These	no
O	O	agents	yes
O	O	(	no
B-drug	B-drug	ammonium	yes
I-drug	I-drug	chloride	yes
O	O	,	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	acid	yes
I-drug	I-drug	phosphate	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	increase	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
O	O	the	no
O	O	ionized	no
O	O	species	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	amphetamine	yes
O	O	molecule	yes
O	O	,	no
O	O	thereby	no
O	O	increasing	no
O	O	urinary	yes
O	O	excretion	no
O	O	.	no

O	O	6	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	nilutamide	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	liver	yes
O	O	cytochrome	no
O	O	P-450	no
O	O	isoenzymes	no
O	O	and	yes
O	O	therefore	no
O	O	,	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	compounds	no
O	O	requiring	no
O	O	these	no
O	O	systems	no
O	O	.	no

O	O	Both	no
O	O	of	yes
O	O	these	no
O	O	effects	no
O	O	were	no
B-drug_n	O	endothelium-dependent	no
O	O	.	no

O	O	Although	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	established	no
O	O	a	yes
O	O	cause	no
O	O	and	yes
O	O	effect	no
O	O	relationship	no
O	O	,	no
O	O	physicians	no
O	O	should	no
O	O	be	no
O	O	aware	no
O	O	that	no
O	O	variable	no
O	O	effects	no
O	O	an	no
O	O	blood	yes
O	O	coagulation	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	very	no
O	O	rarely	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	and	yes
B-drug	B-drug	chlordiazepoxide	yes
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
O	O	concurrent	no
O	O	medications	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	use	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	receiving	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	theophylline	yes
O	O	levels	no
O	O	and	yes
O	O	potential	no
B-drug	B-drug	theophylline	yes
O	O	toxicity	no
O	O	.	no

O	O	If	no
O	O	concomitant	no
O	O	use	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	avoided	no
O	O	,	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	dosage	no
O	O	adjustments	no
O	O	made	no
O	O	as	yes
O	O	appropriate	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	it	no
O	O	was	no
O	O	found	no
O	O	that	no
O	O	chronic	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
O	O	3.6	no
O	O	g	yes
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	per	no
O	O	day	no
O	O	decreases	no
B-drug	B-drug	indomethacin	yes
O	O	blood	yes
O	O	levels	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	REVIA	yes
O	O	and	yes
B-drug	B-drug	disulfiram	yes
O	O	is	yes
O	O	unknown	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	two	no
O	O	potentially	no
O	O	hepatotoxic	no
O	O	medications	no
O	O	is	yes
O	O	not	no
O	O	ordinarily	no
O	O	recommended	no
O	O	unless	no
O	O	the	no
O	O	probable	no
O	O	benefits	no
O	O	outweigh	no
O	O	the	no
O	O	known	no
O	O	risks	no
O	O	.	no

B-drug	B-drug	Propranolol	yes
O	O	increases	no
B-group	B-drug	hydralazines	no
O	O	serum	yes
O	O	concentrations	no
O	O	.	no

B-group	B-group	Uricosuric	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Since	no
O	O	the	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	oxipurinol	yes
O	O	is	yes
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	of	yes
B-drug	O	urate	yes
O	O	,	no
O	B-group	uricosuric	no
O	I-group	agents	yes
O	O	,	no
O	O	which	no
O	O	increase	no
O	O	the	no
O	O	excretion	no
O	O	of	yes
O	O	urate	yes
O	O	,	no
O	O	are	no
O	O	also	no
O	O	likely	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	oxipurinol	yes
O	O	and	yes
O	O	thus	no
O	O	lower	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	of	yes
O	O	xanthine	yes
O	O	oxidase	yes
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	for	yes
B-drug	B-drug	delavirdine	yes
O	O	;	no

O	O	All	yes
O	O	elevations	no
O	O	resolved	no
O	O	,	no
O	O	2	yes
O	O	with	yes
O	O	continuation	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	and	yes
O	O	3	yes
O	O	after	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	leflunomide	yes
O	O	.	no

O	O	Reports	no
O	O	of	yes
O	O	fatal	no
O	O	hepatic	no
O	O	failure	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	peripheral	no
O	O	neuropathy	no
O	O	,	no
O	O	pancreatitis	no
O	O	,	no
O	O	and	yes
O	O	symptomatic	no
O	O	hyperlactatemia/lactic	no
O	O	acidosis	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	thus	no
O	O	an	no
O	O	enhancement	no
O	O	effect	no

O	O	Systemic	no
O	O	exposure	yes
O	O	to	no
O	O	substrates	no
O	O	of	yes
O	O	CYP2D6	no
O	O	is	yes
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-brand	O	Gleevec	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	chlorprothixene	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	opioids	no
O	O	,	no
O	O	the	no
B-group	B-group	opioid	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	(	no
O	O	by	no
O	O	approx	no
O	O	.	no
O	O	50	yes
O	O	%	no
O	O	)	no
O	O	,	no
O	O	because	no
B-drug	B-drug	chlorprothixene	yes
I-drug	O	amplifies	no
O	O	the	no
O	O	therapeutic	no
O	O	actions	no
O	O	and	yes
O	O	side-effects	no
O	O	of	yes
B-group	B-group	opioids	no
O	O	massively	no
O	O	.	no

O	O	Close	no
O	O	supervision	no
O	O	and	yes
O	O	careful	no
O	O	adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	is	yes
O	O	required	no
O	O	when	no
O	O	this	no
O	O	drug	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	.	no

B-drug	B-drug	Sucralfate	yes
O	O	and	yes
B-group	B-group	antacids	no
O	O	:	no
B-group	B-group	Quinolones	no
O	O	form	yes
O	O	chelates	no
O	O	with	yes
O	O	metal	no
O	O	cations	no
O	O	.	no

O	O	These	no
O	O	doses	no
O	O	correspond	no
O	O	to	no
O	O	approximately	no
O	O	1-	no
O	O	,	no
O	O	3-	no
O	O	,	no
O	O	and	yes
O	O	5-fold	no
O	O	(	no
O	O	in	yes
O	O	females	no
O	O	)	no
O	O	and	yes
O	O	1.3-	no
O	O	,	no
O	O	1.3-	no
O	O	,	no
O	O	and	yes
O	O	1.6-fold	no
O	O	(	no
O	O	in	yes
O	O	males	no
O	O	)	no
O	O	the	no
O	O	systemic	no
O	O	exposure	yes
O	O	[	no
O	O	AUC0-30	no
O	O	days	no
O	O	]	no
O	O	]	no
O	O	achieved	no
O	O	in	yes
O	O	women	yes
O	O	receiving	no
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	of	yes
O	O	250	yes
O	O	mg/month	no
O	O	.	no

B-group	B-group	Antibiotics	no
O	O	:	no
B-group	B-group	Macrolide	no
I-group	I-group	antibiotics	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	a	yes
O	O	significant	no
O	O	decrease	no
O	O	in	yes
B-group	B-group	corticosteroid	no
O	O	clearance	no
O	O	.	no

B-drug	O	Digoxin	yes
O	O	When	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-brand	B-drug	PLENDIL	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	heart	no
O	O	failure	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	altered	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	reactions	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	Clinistix	no
O	O	or	no
O	O	Tes-Tape	no
O	O	)	no
O	O	be	no
O	O	used	no
O	O	.	no

B-group	B-group	Potassium-sparing	no
I-group	I-group	diuretics	no
O	O	(	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	amiloride	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	)	no
O	O	or	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	can	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hyperkalemia	no
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	:	no
O	O	Available	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	there	no
O	O	is	yes
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	valproate	yes
O	O	on	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	,	no
O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	valproate	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	cause	no
O	O	a	yes
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
B-brand	B-brand	Felbatol	yes
O	O	(	no
B-drug	B-drug	felbamate	yes
O	O	)	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

B-drug	B-drug	Ascorbic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
O	O	the	no
O	O	common	yes
O	O	cold	yes
O	O	.	no

O	O	CYP3A4	no
O	O	Interactions	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-drug	B-drug	Ketoprofen	yes
O	O	,	no
O	O	like	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	may	no
O	O	cause	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	leading	no
O	O	to	no
O	O	elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	and	yes
O	O	increased	no
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	observations	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
O	O	,	no
B-drug	B-drug	aluminum	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	calcium	yes
O	O	;	no

O	O	Tinnitus	no
O	O	and	yes
O	O	decreased	no
O	O	hearing	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	receiving	no
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	effects	no
O	O	were	no
O	O	noted	no
O	O	with	yes
O	O	other	no
O	O	drug	yes
O	O	combinations	no
O	O	or	no
O	O	with	yes
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Tests	no
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	of	yes
B-brand	B-brand	CLOLAR	yes
O	O	with	yes
O	O	other	no
O	O	medications	no
O	O	or	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

B-drug	B-drug	Dicumarol	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	may	no
O	O	decrease	no
O	O	hypoprothrombinemic	no
O	O	effect	no
O	O	.	no

B-drug	B-drug	apomorphine	yes
O	O	-	yes
O	O	prior	no
O	O	ingestion	no
O	O	of	yes
B-drug	B-drug	diphenidol	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	B-group	emetic	no
O	O	response	no
O	O	to	no
B-drug	B-drug	apomorphine	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	poisoning	no
O	O	.	no

O	O	Dosing	no
O	O	recommendations	no
O	O	for	yes
B-brand	B-brand	SUSTIVA	yes
O	O	and	yes
B-drug	B-drug	atazanavir	yes
O	O	in	yes
O	O	treatment-experienced	no
O	O	patients	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Toxicity	no
O	O	associated	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	aerosolized	no
B-drug	B-drug	pentamidine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	reported	no
O	O	.	no

B-drug	B-drug	Lithium	yes
I-drug	I-drug	carbonate	yes
O	O	:	no
O	O	The	no
O	O	stimulatory	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	may	no
O	O	be	no
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	lithium	yes
I-drug	I-drug	carbonate	yes
O	O	.	no

O	O	The	no
O	O	treatment	no
O	O	of	yes
O	O	depression	no
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	must	no
O	O	take	no
O	O	into	no
O	O	account	no
O	O	variations	no
O	O	of	yes
O	O	glycemic	no
O	O	levels	no
O	O	at	yes
O	O	different	no
O	O	times	no
O	O	and	yes
O	O	a	yes
O	O	comparison	no
O	O	of	yes
O	O	the	no
O	O	available	no
B-group	B-group	antidepressant	no
I-group	I-group	agents	yes
O	O	is	yes
O	O	important	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	ETOPOPHOS	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	inhibit	no
O	O	phosphatase	yes
O	O	activities	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	levamisole	yes
I-drug	I-drug	hydrochloride	yes
O	O	)	no
O	O	.	no

O	O	Because	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	theoretical	no
O	O	basis	no
O	O	that	no
O	O	these	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	,	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ergotamine-containing	no
O	O	or	no
B-group	B-group	ergot-type	no
I-group	I-group	medications	no
O	O	(	no
O	O	like	yes
B-drug	B-drug	dihydroergotamine	yes
O	O	or	no
B-drug	B-drug	methysergide	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	naratriptan	yes
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	This	no
O	O	suggests	no
O	O	that	no
O	O	interactions	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	elements	no
O	O	only	no
O	O	take	no
O	O	place	no
O	O	at	yes
O	O	the	no
O	O	site	no
O	O	of	yes
O	O	absorption	no
O	O	.	no

B-group	B-group	Aminoglycosides	no
O	O	:	no
O	O	The	no
O	O	mixing	no
O	O	of	yes
B-drug	B-drug	piperacillin	yes
O	O	with	yes
O	O	an	no
B-group	B-group	aminoglycoside	no
O	O	in	yes
O	O	vitro	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	substantial	no
O	O	inactivation	no
O	O	of	yes
O	O	the	no
B-group	B-group	aminoglycoside	no
O	O	.	no

O	O	A	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	not	no
O	O	needed	no
O	O	when	no
B-drug	B-drug	zidovudine	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	.	no

B-group	B-group	HIV	no
I-group	I-group	Protease	yes
I-group	I-group	Inhibitors	no
O	O	:	no
B-drug	B-drug	Indinavir	yes
O	O	(	no
O	O	800	no
O	O	mg	yes
O	O	t.i.d	no
O	O	.	no
O	O	)	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	10	yes
O	O	mg	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	16-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	AUC	no
O	O	,	no
O	O	a	yes
O	O	7-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	Cmax	no
O	O	and	yes
O	O	a	yes
O	O	2-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	half-life	no
O	O	.	no

B-group	B-group	AED	no
O	O	Co-administered	no

B-group	B-drug	Antiarrhythmic	no
I-group	I-drug	agents	yes
O	I-drug	,	no
O	I-drug	class	no
O	I-drug	I	yes
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	flecainide	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	:	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-drug	B-drug	arbutamine	yes
O	O	may	no
O	O	have	no
O	O	a	yes
O	O	proarrhythmic	no
O	O	effect	no
O	O	.	no

B-group	O	Antitubercular	no
I-group	O	drugs	no
O	O	:	no
O	O	Serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	isoniazid	yes
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	available	no
O	O	.	no

O	O	Other	no
O	O	Potentially	no
O	O	Important	no
O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
B-group	B-group	Benzodiazepines	no
O	O	:	no
B-group	B-group	Benzodiazepines	no
O	O	metabolized	no
O	O	by	no
O	O	hepatic	no
O	O	oxidation	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	triazolam	yes
O	O	elc	no
O	O	.	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	because	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
B-drug	B-drug	fluvoxamine	yes
O	O	.	no

B-drug	B-drug	Fluoxetine	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	clonazepam	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
O	O	orally	no
O	O	inhaled	no
B-drug	B-drug	ciclesonide	yes
O	O	and	yes
O	O	oral	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	,	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	des-ciclesonide	no
O	O	or	no
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	in	yes
O	O	human	yes
O	O	plasma	yes
O	O	indicate	no
O	O	that	no
B-drug	B-drug	doxazosin	yes
I-drug	I-drug	mesylate	yes
O	O	has	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	indomethacin	yes
O	O	.	no

O	O	Herbal	no
O	O	Products	no
O	O	:	no
O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	wort	yes
O	O	(	no
O	O	hypericum	yes
O	O	perforatum	yes
O	O	)	no
O	O	WARNING	no
O	O	coadministration	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	virologic	no
O	O	response	no
O	O	and	yes
O	O	possible	no
O	O	resistance	no
O	O	to	no
B-brand	B-brand	INVIRASE	yes
O	O	or	no
O	O	to	no
O	O	the	no
O	O	class	no
O	O	of	yes
B-group	O	protease	yes
I-group	O	inhibitors	no
O	O	.	no

O	O	The	no
O	O	action	no
O	O	of	yes
B-group	O	nondepolarizing	no
I-group	O	relaxants	no
O	O	is	yes
O	O	augmented	no
O	O	by	no
B-drug	B-drug	Enflurane	yes
O	O	.	no

B-drug	B-drug	Theophylline	yes
B-brand	B-brand	VIOXX	yes
O	O	12.5	yes
O	O	,	no
O	O	25	yes
O	O	,	no
O	O	and	yes
O	O	50	yes
O	O	mg	yes
O	O	administered	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	increased	no
O	O	plasma	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	(	no
O	O	AUC	no
O	O	(	no
O	O	0-	no
O	O	)	no
O	O	)	no
O	O	by	no
O	O	38	no
O	O	to	no
O	O	60	no
O	O	%	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	administered	no
O	O	a	yes
O	O	single	yes
O	O	300-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	bupropion	yes
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	the	no
O	O	treatment	no
O	O	regimen	no
O	O	of	yes
O	O	a	yes
O	O	patient	no
O	O	already	no
O	O	receiving	no
O	O	a	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	,	no
O	O	the	no
O	O	need	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
O	O	original	no
O	O	medication	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	,	no
O	O	particularly	no
O	O	for	yes
O	O	those	no
O	O	concomitant	no
O	O	medications	no
O	O	with	yes
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	index	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
B-brand	B-brand	TRACLEER	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	enzymes	yes
O	O	.	no

O	O	Each	no
O	O	subject	no
O	O	received	no
O	O	an	no
O	O	individualized	no
O	O	fixed	no
O	O	daily	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
O	O	served	no
O	O	as	yes
O	O	his	yes
O	O	own	no
O	O	pre-	no
O	O	and	yes
O	O	postsedative	no
O	O	treatment	no
O	O	control	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	Multiple	no
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	q24h	no
O	O	for	yes
O	O	13	yes
O	O	days	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	R+	no
O	O	)	no
O	O	-	yes
O	O	or	no
O	O	(	no
B-drug	O	S-	no
O	O	)	no
O	O	-enantiomers	no
O	O	or	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	(	no
O	O	prothrombin	yes
O	O	time	no
O	O	)	no
O	O	following	no
O	O	a	yes
O	O	single	yes
O	O	25-mg	no
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	The	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-group	B-group	sulfonylurea	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	certain	no
O	O	drugs	no
O	O	including	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-drug	B-drug	chloramphenicol	yes
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	,	no
B-group	B-group	coumarins	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Rates	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	maximum	no
O	O	potassium	yes
O	O	levels	no
O	O	5.5	no
O	O	mEq/L	no
O	O	were	no
O	O	similar	no
O	O	regardless	no
O	O	of	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-group	B-group	ACEI/ARB	no
O	O	.	no

O	O	SUBSEQUENT	no
O	O	TO	no
O	O	INITIATION	no
O	O	OF	yes
B-drug	B-drug	DISULFIRAM	yes
O	O	THERAPY	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	Increased	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	cause	no
O	O	osteomalacia	no
O	O	.	no

O	O	The	no
O	O	beneficial	no
O	O	effects	no
O	O	on	no
O	O	arterial	no
O	O	thrombus	no
O	O	formation	no
O	O	from	no
O	O	combined	no
O	O	therapy	no
O	O	with	yes
B-group	O	antiplatelet	no
O	O	and	yes
B-group	B-group	anticoagulant	no
O	I-group	medication	no
O	O	must	no
O	O	be	no
O	O	weighed	no
O	O	against	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	inducing	no
O	O	hemorrhage	no
O	O	.	no

B-drug	B-drug	Sulfacetamide	yes
O	O	preparations	no
O	O	are	no
O	O	incompatible	no
O	O	with	yes
O	B-drug	silver	yes
O	O	preparations	no
O	O	.	no

O	O	antibody	yes

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Albendazole	yes
I-drug	I-drug	sulfoxide	yes
O	O	concentrations	no
O	O	in	yes
O	O	bile	no
O	O	and	yes
O	O	cystic	no
O	O	fluid	no
O	O	were	no
O	O	increased	no
O	O	(	no
O	O	about	no
O	O	2-fold	no
O	O	)	no
O	O	in	yes
O	O	hydatid	no
O	O	cyst	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	10	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	(	no
O	O	n=7	no
O	O	)	no
O	O	compared	no
O	O	with	yes
B-drug	B-drug	albendazole	yes
O	O	(	no
O	O	20	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	alone	no
O	O	(	no
O	O	n=12	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Omeprazole	yes
O	O	:	no
B-drug	B-drug	Omeprazole	yes
O	O	is	yes
O	O	a	yes
O	O	CYP	no
O	O	3A4	no
O	O	substrate	yes
O	O	and	yes
O	O	CYP	no
O	O	2C19	no
O	O	substrate	yes
O	O	and	yes
O	O	inhibitor	yes
O	O	.	no

O	O	It	no
O	O	was	no
O	O	observed	no
O	O	that	no
B-drug_n	B-drug_n	MPTP	no
O	O	induced	no
O	O	long	yes
O	O	lasting	no
O	O	depletions	no
O	O	of	yes
O	O	striatal	no
O	O	dopamine	yes
O	O	concentrations	no
O	O	and	yes
O	O	this	no
O	O	neurotoxic	no
O	O	effect	no
O	O	could	no
O	O	be	no
O	O	prevented	no
O	O	by	no
B-drug	B-drug	pargyline	yes
O	O	pretreatment	no
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	(	no
B-drug	B-drug	esmolol	yes
I-drug	I-drug	HCl	yes
O	O	)	no
O	O	and	yes
O	O	a	yes
O	O	catecholamine	no
O	O	depletor	no
O	O	should	no
O	O	therefore	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	evidence	no
O	O	of	yes
O	O	hypotension	no
O	O	or	no
O	O	marked	no
O	O	bradycardia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	,	no
O	O	or	no
O	O	postural	no
O	O	hypotension	no
O	O	.	no

O	O	Other	no
O	O	Concomitant	no
O	O	Therapy	no
O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	when	no
B-drug	B-drug	felodipine	yes
O	O	was	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	indomethacin	yes
O	O	or	no
B-drug	B-drug	spironolactone	yes
O	O	.	no

B-group	B-group	vasopressors	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dopamine	yes
O	O	and	yes
B-drug	B-drug	isoproterenol	yes
O	O	;	no

O	O	Decreasing	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-drug_n	B-drug_n	CMC-Cys	no
O	O	,	no
O	O	exhibiting	no
O	O	7.3	no
O	O	%	no
O	O	(	no
O	O	m/m	no
O	O	)	no
O	O	of	yes
O	O	immobilised	no
B-drug	B-drug	cysteine	yes
O	O	(	no
B-brand	O	CMC-Cys7.3	no
O	O	)	no
O	O	from	no
O	O	1	yes
O	O	%	no
O	O	(	no
O	O	m/v	no
O	O	)	no
O	O	to	no
O	O	0.5	yes
O	O	%	no
O	O	(	no
O	O	m/v	no
O	O	)	no
O	O	decreased	no
O	O	the	no
O	O	R-value	no
O	O	of	yes
B-drug	B-drug	NaFlu	no
O	O	from	no
O	O	1.8	no
O	O	to	no
O	O	1.2	no
O	O	.	no

B-group	B-group	Antidepressants	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	Amphetamines	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	or	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	;	no

O	O	.	no

O	O	However	no
O	O	,	no
O	O	modification	no
O	O	abolished	no
O	O	the	no
O	O	'cold	no
O	O	'	no
O	O	binding	no
O	O	of	yes
B-drug_n	O	toxin	yes
O	O	to	no
O	O	bovine	yes
O	O	thyroglobulin	yes
O	O	in	yes
O	O	an	no
O	O	ELISA	no
O	O	and	yes
O	O	reduced	yes
O	O	ligand	no
O	O	binding	no
O	O	activity	yes
O	O	in	yes
O	O	a	yes
O	O	rabbit	yes
O	O	erythrocyte	no
O	O	haemagglutination	no
O	O	assay	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	at	yes
O	O	that	no
O	O	time	no
O	O	,	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	were	no
O	O	below	no
O	O	the	no
O	O	therapeutic	no
O	O	interval	no
O	O	,	no
O	O	and	yes
O	O	thus	no
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	clinical	no
O	O	relevance	no
O	O	.	no

O	O	In	yes
O	O	simultaneous	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	imidazole	yes
I-group	I-group	drugs	no
O	O	and	yes
B-group	B-group	coumarin	yes
I-group	I-group	drugs	no
O	O	,	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	titrated	no
O	O	and	yes
O	O	monitored	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	in	yes
O	O	which	no
B-drug	B-drug	dobutamine	yes
O	O	was	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	including	no
B-group	B-group	digitalis	yes
I-group	I-group	preparations	no
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	glyceryl	yes
I-drug	I-drug	trinitrate	yes
O	O	,	no
B-drug	B-drug	isosorbide	yes
I-drug	I-drug	dinitrate	yes
O	O	,	no
B-drug	B-drug	morphine	yes
O	O	,	no
B-drug	B-drug	atropine	yes
O	O	,	no
B-drug	B-drug	heparin	yes
O	O	,	no
B-drug	B-drug	protamine	yes
O	O	,	no
B-drug	B-drug	potassium	yes
I-drug	I-drug	chloride	yes
O	O	,	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	.	no

B-drug	B-drug	halothane	yes
O	O	;	no

B-drug	B-drug	Olanzapine	yes
O	O	:	no
O	O	an	no
O	O	updated	no
O	O	review	no
O	O	of	yes
O	O	its	no
O	O	use	no
O	O	in	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	schizophrenia	no
O	O	.	no

O	O	We	no
O	O	assessed	no
O	O	the	no
O	O	ability	no
O	O	of	yes
O	O	gene	yes
O	O	transfer	no
O	O	to	no
O	O	reverse	no
O	B-drug	vancomycin	yes
O	O	resistance	no
O	O	in	yes
O	O	class	no
O	O	A	yes
O	O	(	no
O	O	VanA	no
O	O	)	no
O	O	glycopeptide-resistant	no
O	O	Enterococcus	no
O	O	faecalis	no
O	O	.	no

O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	reported	no
O	O	laboratory	no
O	O	test	yes
O	O	interactions	no
O	O	.	no

O	O	Cell	yes
O	O	permeable	no
O	O	caspase-3	no
O	O	inhibitor	yes
O	O	added	no
O	O	in	yes
O	O	the	no
O	O	medium	no
O	O	blocked	no
O	O	the	no
O	O	decrease	no
O	O	of	yes
O	O	nucleophosmin/B23	no
O	O	and	yes
O	O	apoptosis	no
O	O	induced	no
O	O	by	no
O	O	serum	yes
O	O	deprivation	no
O	O	in	yes
O	O	NIH-3T3	no
O	O	cells	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	Duloxetine	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	extensively	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	which	no
O	O	have	no
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	index	no
O	O	,	no
O	O	including	no
O	O	certain	no
B-group	B-group	antidepressants	no
O	O	(	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	[	no
B-group	B-group	TCAs	no
O	O	]	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	nortriptyline	yes
O	O	,	no
B-drug	B-drug	amitriptyline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	imipramine	yes
O	O	)	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	and	yes
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	aureus	no
O	O	to	no
O	O	P	yes
O	O	.	no

O	O	gestational	no
O	O	trophoblastic	no
O	O	disease	no
O	O	;	no

O	O	While	no
O	O	only	no
O	O	a	yes
O	O	limited	no
O	O	number	no
O	O	of	yes
O	O	in	yes
O	O	vivo	no
O	O	drug-drug	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	chiefly	no
O	O	with	yes
O	O	the	no
O	O	oral	yes
O	O	formulation	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	other	no
O	O	interactions	no
O	O	should	no
O	O	be	no
O	O	anticipated	no
O	O	.	no

O	O	Discontinuing	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	could	no
O	O	pose	no
O	O	a	yes
O	O	hazard	no
O	O	to	no
O	O	health	no
O	O	if	no
O	O	a	yes
O	O	potentially	no
O	O	toxic	no
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	significantly	no
O	O	bound	no
O	O	to	no
O	O	the	no
B-group	B-group	resin	yes
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	maintenance	no
O	O	level	no
O	O	while	no
O	O	the	no
O	O	patient	no
O	O	was	no
O	O	taking	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

O	O	DEA	no
O	O	concentrations	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	.	no

O	O	thrombocytopenia	no

O	O	Since	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	high	yes
O	O	degree	no
O	O	of	yes
O	O	variability	no
O	O	in	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	verapamil	yes
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	unclear	no
O	O	.	no

I-drug	B-drug	Nevirapine	yes

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	caffeine	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	CYP1A2	no
O	O	,	no
O	O	inhibit	no
O	O	CYP1A2	no
O	O	,	no
O	O	or	no
O	O	induce	no
O	O	CYP1A2	no
O	O	.	no

O	O	Conversely	no
O	O	,	no
O	O	decreases	no
O	O	in	yes
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	upon	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	which	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	the	no
O	O	loss	no
O	O	of	yes
O	O	the	no
O	O	therapeutic	no
O	O	efficacy	no
O	O	of	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	6	yes
O	O	.	no

O	O	Prothrombin	yes
O	O	time	no
O	O	was	no
O	O	increased	no
O	O	by	no
O	O	5	yes
O	O	%	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	which	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-drug	B-drug	Iron	yes
O	O	salts	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	carbidopa	yes
O	O	and	yes
B-drug	B-drug	levodopa	yes
O	O	.	no

B-group	O	Monoamine	no
I-group	O	Oxidase	yes
O	O	Inhibition	no
O	O	:	no
B-drug	B-drug	Linezolid	yes
O	O	is	yes
O	O	a	yes
O	O	reversible	no
O	O	,	no
O	O	nonselective	no
O	O	inhibitor	yes
O	O	of	yes
B-group	O	monoamine	no
I-group	O	oxidase	yes
O	O	.	no

O	O	Patients	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	were	no
O	O	prohibited	no
O	O	from	no
O	O	receiving	no
O	O	growth	yes
O	O	factor	yes
O	O	treatment	no
O	O	for	yes
O	O	2	yes
O	O	weeks	no
O	O	prior	no
O	O	to	no
O	O	the	no
B-brand	B-brand	ZEVALIN	yes
O	O	therapeutic	no
O	O	regimen	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	for	yes
O	O	2	yes
O	O	weeks	no
O	O	following	no
O	O	completion	no
O	O	of	yes
O	O	the	no
O	O	regimen	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	believed	no
O	O	that	no
O	O	the	no
O	O	toxicity	no
O	O	may	no
O	O	have	no
O	O	resulted	no
O	O	from	no
O	O	a	yes
O	O	previously	no
O	O	unrecognized	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	isoniazid	yes
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	and	yes
O	O	a	yes
O	O	molecular	yes
O	O	basis	no
O	O	for	yes
O	O	this	no
O	O	interaction	no
O	O	has	no
O	O	been	no
O	O	proposed	no
O	O	.	no

O	O	Vesselinovitch	no
O	O	et	no
O	O	al	yes
O	O	.	no

O	O	Patients	no
O	O	taking	no
O	O	these	no
O	O	drugs	no
O	O	with	yes
B-brand	B-brand	LODOSYN	yes
O	O	and	yes
B-drug	B-drug	levodopa	yes
O	O	or	no
B-drug	B-drug	carbidopa-levodopa	no
O	O	combination	yes
O	O	products	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	observed	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	therapeutic	no
O	O	response	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	p.o	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	precaution	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
O	O	coadministration	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

O	O	-	yes
O	O	Drugs	no
O	O	with	yes
O	O	ototoxic	no
O	O	potential	no
O	O	:	no
O	O	Especially	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	parenterally	no
O	O	administered	no
B-drug	B-drug	bumetanide	yes
O	O	in	yes
O	O	patients	no
O	O	to	no
O	O	whom	no
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	are	no
O	O	also	no
O	O	being	no
O	O	given	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	,	no
O	O	except	no
O	O	in	yes
O	O	life-threatening	no
O	O	conditions	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	severe	no
O	O	reactions	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	hypotension	no
O	O	requiring	no
O	O	treatment	no
O	O	,	no
O	O	dyspnea	no
O	O	requiring	no
B-group	B-group	bronchodilators	no
O	O	,	no
O	O	angioedema	no
O	O	,	no
O	O	or	no
O	O	generalized	no
O	O	urticaria	no
O	O	require	no
O	O	immediate	no
O	O	discontinuation	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	and	yes
O	O	aggressive	no
O	O	symptomatic	no
O	O	therapy	no
O	O	.	no

O	O	A	yes
O	O	30	yes
O	O	to	no
O	O	45	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	nisoldipine	yes
O	O	was	no
O	O	observed	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	I-drug	400	yes
O	I-drug	mg	yes
O	O	twice	no
O	O	daily	no
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
O	O	other	no
B-group	B-group	anticonvulsants	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	same	yes
O	O	study	no
O	O	it	no
O	O	was	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	didanosine	yes
O	O	and	yes
B-drug	B-drug	stavudine	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	intracellular	no
O	O	phosphorylation	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	in	yes
O	O	peripheral	no
O	O	blood	yes
O	O	mononuclear	no
O	O	cells	yes
O	O	.	no

O	O	A	yes
O	O	study	no
O	O	of	yes
O	O	interaction	no
O	O	between	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	showed	no
O	O	that	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	does	no
O	O	not	no
O	O	alter	no
B-drug	B-drug	warfarin	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	involving	no
O	O	12	yes
O	O	adult	yes
O	O	volunteers	no
O	O	,	no
B-brand	O	TORADOLORAL	no
O	O	was	no
O	O	coadministered	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	25	yes
O	O	mg	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	causing	no
O	O	no	yes
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	pharmacokinetics	no
O	O	or	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	both	no
B-drug	B-drug	indomethacin	yes
O	O	and	yes
B-drug	B-drug	furosemide	yes
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
B-group	O	diuretic	no
O	O	and/or	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	is	yes
O	O	achieved	no
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	Anti-inflammatory	no
I-group	I-group	Drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti	yes
I-group	I-group	inflammatory	no
I-group	I-group	drug	yes
O	O	with	yes
O	O	a	yes
B-group	B-group	quinolone	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risks	no
O	O	of	yes
O	O	CNS	no
O	O	stimulation	no
O	O	and	yes
O	O	convulsions	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	induction	no
O	O	or	no
O	O	inhibition	no
O	O	of	yes
O	O	other	no
O	O	pathways	no
O	O	on	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	alosetron	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	troleandomycin	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	and	yes
O	O	thus	no
O	O	decrease	no
O	O	their	no
O	O	clearance	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	this	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	reduced	yes
O	O	clearance	no
O	O	,	no
O	O	prolongation	no
O	O	of	yes
O	O	plasma	yes
O	O	half-life	no
O	O	,	no
O	O	and	yes
O	O	enhanced	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
B-drug	B-drug	theobromine	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	other	no
O	O	agents	yes

B-drug	B-drug	Hydrochlorothiazide	yes
O	O	(	no
B-drug	B-drug	HCTZ	yes
O	O	)	no
O	O	Alone	no
O	O	or	no
O	O	in	yes
O	O	Combination	yes
O	O	with	yes
B-drug	B-drug	Triamterene	yes
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	HCTZ	yes
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	triamterene	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

B-group	B-group	Salicylate	yes
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	falsely	no
O	O	elevated	no
O	O	with	yes
O	O	some	no
O	O	assay	no
O	O	methods	no
O	O	.	no

O	O	Little	no
O	O	or	no
O	O	no	yes
O	O	change	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	was	no
O	O	observed	no
O	O	when	no
B-brand	B-brand	VIRACEPT	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	lamivudine	yes
O	O	or	no
B-drug	B-drug	stavudine	yes
O	O	.	no

O	O	Each	no
O	O	group	yes
O	O	took	no
O	O	either	no
O	O	150	yes
O	O	mg	yes
O	O	or	no
O	O	75	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	a	yes
O	O	day	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	(	no
O	O	day	no
O	O	-3	no
O	O	to	no
O	O	day	no
O	O	2	yes
O	O	)	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Chloroquine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Aralen	yes
O	O	)	no
O	O	or	no

B-drug	B-drug	Indinavir	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	.	no

O	O	In	yes
O	O	one	no
O	O	controlled	no
O	O	clinical	no
O	O	study	no
O	O	,	no
O	O	the	no
B-group	O	ureidopenicillins	no
O	O	,	no
O	O	including	no
B-drug	B-drug	piperacillin	yes
O	O	,	no
O	O	were	no
O	O	reported	no
O	O	to	no
O	O	prolong	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	vecuronium	yes
O	O	.	no

O	O	Of	yes
O	O	particular	no
O	O	importance	no
O	O	,	no
O	O	sufficient	no
O	O	time	no
O	O	must	no
O	O	elapse	no
O	O	before	no
O	O	initiating	no
B-group	O	TCA	no
O	O	treatment	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	being	no
O	O	withdrawn	no
O	O	from	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	given	no
O	O	the	no
O	O	long	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	parent	no
O	O	and	yes
O	O	active	no
O	O	metabolite	yes
O	O	(	no
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	weeks	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Thalidomide	yes
O	O	:	no
O	O	Co-administration	no
O	O	with	yes
B-drug	B-drug	thalidomide	yes
O	O	should	no
O	O	be	no
O	O	employed	no
O	O	cautiously	no
O	O	,	no
O	O	as	yes
O	O	toxic	no
O	O	epidermal	yes
O	O	necrolysis	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-brand	B-brand	TIKOSYN	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	or	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	or	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	or	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	.	no

O	O	-	yes
O	O	Medicinal	yes
O	O	or	no
O	O	dietary	no
B-drug	B-group	iodine	yes
O	O	interferes	no
O	O	with	yes
O	O	all	yes
O	O	in	yes
O	O	vivo	no
O	O	tests	no
O	O	of	yes
B-drug	O	radio-iodine	no
O	O	uptake	no
O	O	producing	no
O	O	low	yes
O	O	uptakes	no
O	O	which	no
O	O	may	no
O	O	not	no
O	O	be	no
O	O	reflective	no
O	O	of	yes
O	O	a	yes
O	O	true	yes
O	O	decrease	no
O	O	in	yes
O	O	hormone	yes
O	O	synthesis	no

O	O	The	no
O	O	pressor	no
O	O	effects	no
O	O	of	yes
O	B-drug	diethylpropion	yes
O	O	and	yes
O	O	those	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	when	no
O	O	the	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	;	no

O	O	Previous	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	a	yes
O	O	significant	no
O	O	reduction	yes
O	O	in	yes
O	O	the	no
O	O	oral	yes
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	trovafloxacin	yes
O	O	and	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	an	no
O	O	intravenous	yes
B-group	B-group	opiate	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	morphine	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	was	no
O	O	not	no
O	O	significantly	no
O	O	changed	no
O	O	.	no

O	O	free	yes
O	O	T4	yes
O	O	concentration	no
O	O	is	yes
O	O	unaltered	no

O	O	Serious	no
O	O	anticholinergic	no
O	O	symptoms	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	severe	no
O	O	dry	no
O	O	mouth	no
O	O	,	no
O	O	urinary	yes
O	O	retention	no
O	O	and	yes
O	O	blurred	no
O	O	vision	no
O	O	)	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	elevations	no
O	O	in	yes
O	O	the	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	when	no
B-drug	B-drug	cimetidine	yes
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	.	no

O	O	there	no
O	O	was	no
O	O	no	yes
O	O	alteration	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	disopyramide	yes
I-drug	I-drug	phosphate	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	concomitantly	no
O	O	may	no
O	O	develop	no
O	O	increased	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	disopyramide	yes
O	O	resulting	no
O	O	in	yes
O	O	excessive	no
O	O	widening	no
O	O	of	yes
O	O	the	no
O	O	QRS	no
O	O	complex	yes
O	O	and/or	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	Q-T	no
O	O	interval	no
O	O	.	no

O	O	Since	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	isolated	no
O	O	reports	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	elevated	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	when	no
O	O	initiating	no
O	O	,	no
O	O	adjusting	no
O	O	,	no
O	O	and	yes
O	O	discontinuing	no
B-drug	B-drug	nifedipine	yes
O	O	to	no
O	O	avoid	no
O	O	possible	no
O	O	over-	no
O	O	or	no
O	O	under-digitalization	no
O	O	.	no

B-drug	B-drug	Valdecoxib	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	a	yes
O	O	statistically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	(	no
O	O	a	yes
O	O	CYP	no
O	O	2C9	no
O	O	and	yes
O	O	CYP	no
O	O	2C19	no
O	O	substrate	yes
O	O	)	no
O	O	.	no

O	O	certain	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	e.g.	no
O	O	,	no
B-drug	O	ritanovir	no
O	O	;	no

O	O	Three	no
O	O	clinical	no
O	O	trials	no
O	O	have	no
O	O	investigated	no
B-brand	B-brand	Simulect	yes
O	O	use	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	triple-therapy	no
O	O	regimens	no
O	O	.	no

O	O	adjust	no
O	O	dosage	no
O	O	of	yes
B-group	B-group	antidiabetic	no
I-group	I-group	drug	yes
O	O	accordingly	no
O	O	.	no

O	O	Potent	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
O	O	below	no
O	O	)	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	myopathy	no
O	O	by	no
O	O	reducing	no
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	inconsistent	no
O	O	reports	no
O	O	regarding	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	penicillamine	yes
O	O	)	no
O	O	on	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentration	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	appropriate	no
B-drug	B-drug	cyclosporine	yes
O	O	dosage	no
O	O	adjustments	no
O	O	made	no
O	O	when	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	These	no
O	O	include	no
B-drug	B-drug	probenecid	yes
O	O	,	no
B-drug	B-drug	cholestyramine	yes
O	O	,	no
O	O	and	yes
O	O	some	no
B-group	B-group	antibiotics	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	O	rifamipicin	no
O	O	,	no
B-drug	B-drug	ampicillin	yes
O	O	and	yes
B-drug	B-drug	chloramphenicol	yes
O	O	)	no
O	O	.	no

B-group	O	Thyroid	yes
O	O	Physiology	no
O	O	:	no
O	O	The	no
O	O	following	no
O	O	agents	yes
O	O	may	no
O	O	alter	no
O	O	thyroid	yes
O	O	hormone	yes
O	O	or	no
O	O	TSH	yes
O	O	levels	no
O	O	,	no
O	O	generally	no
O	O	by	no
O	O	effects	no
O	O	on	no
O	O	thyroid	yes
O	O	hormone	yes
O	O	synthesis	no
O	O	,	no
O	O	secretion	no
O	O	,	no
O	O	distribution	no
O	O	,	no
O	O	metabolism	no
O	O	,	no
O	O	hormone	yes
O	O	action	no
O	O	,	no
O	O	or	no
O	O	elimination	no
O	O	,	no
O	O	or	no
O	O	altered	no
O	O	TSH	yes
O	O	secretion	no
O	O	:	no
B-drug	B-drug	aminoglutethimide	yes
O	O	,	no
O	B-drug	p-aminosalicylic	yes
O	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-group	B-group	androgens	no
O	O	and	yes
O	O	related	yes
B-group	O	anabolic	no
I-group	O	hormones	no
O	O	,	no
O	O	complex	yes
O	O	anions	no
O	O	(	no
O	B-drug	thiocyanate	no
O	O	,	no
B-drug	B-drug	perchlorate	yes
O	O	,	no
B-drug	B-drug	pertechnetate	yes
O	O	)	no
O	O	,	no
B-group	B-group	antithyroid	no
I-group	I-group	drugs	no
O	O	,	no
B-group	B-group	b-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	chloral	yes
I-drug	I-drug	hydrate	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	dopamine	yes
O	O	and	yes
B-group	B-group	dopamine	yes
I-group	I-group	agonists	no
O	O	,	no
B-drug	B-drug	ethionamide	yes
O	O	,	no
B-group	B-group	glucocorticoids	no
O	O	,	no
B-drug	B-drug	heparin	yes
O	O	,	no
O	O	hepatic	no
O	O	enzyme	no
O	O	inducers	no
O	O	,	no
B-drug	B-drug	insulin	yes
O	O	,	no
B-group	O	iodinated	no
I-group	O	cholestographic	no
I-group	O	agents	yes
O	O	,	no
B-drug	B-group	iodine-containing	no
I-drug	I-group	compounds	no
O	O	,	no
B-drug	B-drug	levodopa	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
B-drug	B-drug	6-mercaptopurine	yes
O	O	,	no
B-drug	B-drug	metoclopramide	yes
O	O	,	no
B-drug	B-drug	mitotane	yes
O	O	,	no
B-drug	B-drug	nitroprusside	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	resorcinol	no
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-group	somatostatin	yes
O	I-group	analogs	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-group	B-group	sulfonylureas	no
O	O	,	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Given	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	extravasation	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	advisable	no
O	O	to	no
O	O	closely	no
O	O	monitor	no
O	O	the	no
O	O	infusion	no
O	O	site	no
O	O	for	yes
O	O	possible	no
O	O	infiltration	no
O	O	during	no
O	O	drug	yes
O	O	administration	no
O	O	.	no

O	O	Since	no
B-brand	B-brand	INVIRASE	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	,	no
O	O	the	no
B-drug	B-drug	ritonavir	yes
O	O	label	no
O	O	should	no
O	O	be	no
O	O	reviewed	no
O	O	for	yes
O	O	additional	no
O	O	drugs	no
O	O	that	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	coadministered	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	desirable	no
O	O	to	no
O	O	monitor	no
B-group	B-group	TCA	no
O	O	plasma	yes
O	O	levels	no
O	O	whenever	no
O	O	a	yes
B-group	B-group	TCA	no
O	O	is	yes
O	O	going	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	PBI	no
O	O	,	no
O	O	T4	yes
O	O	by	no
O	O	column	no
O	O	,	no
O	O	or	no
O	O	T4	yes
O	O	by	no
O	O	radioimmunoassay	no
O	O	.	no

O	O	Sixty-two	no
O	O	(	no
O	O	94	yes
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	66	no
O	O	strains	no
O	O	of	yes
O	O	Enterobacteriaceae	no
O	O	and	yes
O	O	Pseudomonas	no
O	O	aeruginosa	no
O	O	were	no
O	O	inhibited	no
O	O	by	no
O	O	6.2	no
O	O	mug	no
O	O	or	no
O	O	less	no
O	O	of	yes
B-drug	B-drug	gentamicin	yes
O	O	per	no
O	O	ml	no
O	O	.	no

B-group	B-group	Anticonvulsants	no
O	O	:	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes

B-drug	B-drug_n	Resveratrol	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	induce	no
O	O	vasorelaxation	no
O	O	.	no

O	B-group	prolonged	no
B-group	I-group	narcotics	no
O	O	;	no

O	O	Risk	no
O	O	of	yes
O	O	Anaphylactic	no
O	O	Reaction	no
O	O	:	no
O	O	While	no
O	O	taking	no
B-group	B-group	beta-blockers	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	severe	no
O	O	anaphylactic	no
O	O	reaction	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	reactive	yes
O	O	to	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	either	no
O	O	accidental	no
O	O	,	no
O	O	diagnostic	yes
O	O	,	no
O	O	or	no
O	O	therapeutic	no
O	O	.	no

B-drug	B-drug	Epinephrine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	isoproterenol	yes
O	O	)	no
O	O	because	no
O	O	of	yes
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	increased	no
O	O	toxicity	no
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-brand	B-brand	INDOCIN	yes
O	O	does	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	hypoprothrombinemia	no
O	O	produced	no
O	O	by	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	on	no
B-brand	B-brand	Sensipar	yes
O	O	:	no
B-brand	B-brand	Sensipar	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	multiple	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	,	no
O	O	primarily	no
O	O	CYP3A4	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	and	yes
O	O	CYP1A2	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	drug	yes
O	O	interactions	no
O	O	mediated	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	hepatic	no
O	O	metabolism	no
O	O	are	no
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	occur	no
O	O	.	no

O	O	In	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	,	no
O	O	concomitant	no
O	O	medications	no
O	O	besides	no
B-drug	B-drug	MTX	yes
O	O	were	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	and/or	no
B-group	B-group	narcotics	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-drug	B-drug	Hydrochlorothiazide	yes
O	O	and	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	steady	no
O	O	state	no
O	O	levels	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	different	no
O	O	in	yes
O	O	poor	no
O	O	metabolizers	no
O	O	and	yes
O	O	extensive	no
O	O	CYP2D6	no
O	O	metabolizers	no
O	O	after	no
O	O	multiple-dose	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	citalopram	yes
O	O	,	no
O	O	suggesting	no
O	O	that	no
O	O	coadministration	no
O	O	,	no
O	O	with	yes
B-drug	B-drug	escitalopram	yes
O	O	,	no
O	O	of	yes
O	O	a	yes
O	O	drug	yes
O	O	that	no
O	O	inhibits	no
O	O	CYP2D6	no
O	O	,	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	have	no
O	O	clinically	no
O	O	significant	no
O	O	effects	no
O	O	on	no
B-drug	B-drug	escitalopram	yes
O	O	metabolism	no
O	O	.	no

O	O	May	no
O	O	interact	no
B-group	B-group	anticoagulants	no
O	O	(	no
O	O	altered	no
O	O	hypo-prothrombinemic	no
O	O	effect	no
O	O	)	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	and	yes
O	O	other	no
O	O	inducers	no
O	O	of	yes
O	O	hepatic	no
O	O	microsomal	no
O	O	enzyme	no
O	O	oxidation	no
O	O	system	yes
O	O	(	no
O	O	decreased	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	diethylstilbestrol	yes
O	O	)	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	(	no
O	O	increased	no
O	O	effect	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	)	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
O	O	other	no
O	O	Antiepilepsy	no
O	O	Drugs	no
O	O	(	no
B-group	B-group	AEDs	no
O	O	)	no
O	O	on	no
B-brand	B-brand	GABITRIL	yes
O	O	:	no
B-drug	B-drug	Carbamazepine	yes
O	O	:	no
O	O	Population	no
O	O	pharmacokinetic	no
O	O	analyses	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	tiagabine	yes
O	O	clearance	no
O	O	is	yes
O	O	60	no
O	O	%	no
O	O	greater	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	carbamazepine	yes
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	other	no
O	O	enzyme-	no
O	O	inducing	no
B-group	B-group	AEDs	no
O	O	.	no

B-drug	B-drug	Diphenhydramine	yes
O	O	:	no
B-drug	B-drug	Diphenhydramine	yes
O	O	is	yes
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	a	yes
O	O	weak	no
O	O	inhibitor	yes
O	O	of	yes
O	O	aldehyde	yes
O	O	oxidase	yes
O	O	in	yes
O	O	rat	yes
O	O	liver	yes
O	O	,	no
O	O	but	no
O	O	its	no
O	O	inhibitory	yes
O	O	effects	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	are	no
O	O	not	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Verapamil	yes
O	O	produced	no
O	O	a	yes
O	O	decrease	no
O	O	of	yes
O	O	20	yes
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	18-27	no
O	O	]	no
O	O	of	yes
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug_n	B-drug_n	MHD	no
O	O	.	no

O	O	serum	yes
B-drug	O	magnesium	yes
O	O	levels	no
O	O	may	no
O	O	increase	no
O	O	in	yes
O	O	uremic	no
O	O	patients	no
O	O	)	no
O	O	Serum	yes
O	O	protein-bound	no
O	O	iodine	yes
O	O	(	no
O	O	PBI	no
O	O	)	no
O	O	levels	no
O	O	(	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	)	no
B-group	B-group	Thiazides	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	before	no
O	O	carrying	no
O	O	out	no
O	O	tests	no
O	O	for	yes
O	O	parathyroid	yes
O	O	function	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
B-drug	B-drug	fulvestrant	yes
O	O	is	yes
O	O	excreted	no
O	O	in	yes
O	O	human	yes
O	O	milk	yes
O	O	.	no

O	O	Doses	no
O	O	of	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	up	no
O	O	to	no
O	O	200	yes
O	O	mg	yes
O	O	were	no
O	O	allowed	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	without	no
O	O	negative	no
O	O	consequences	no
O	O	.	no

O	O	-	yes
O	O	Drugs	no
O	O	whose	no
O	O	efficacy	no
O	O	is	yes
O	O	impaired	no
O	O	by	no
B-drug	B-drug	phenytoin	yes
O	O	include	no
O	O	:	no
B-group	B-group	anticoagulants	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	coumarin	yes
O	O	,	no
B-drug	B-drug	digitoxin	yes
O	O	,	no
B-drug	B-drug	doxycycline	yes
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	Here	no
O	O	we	no
O	O	show	no
O	O	that	no
O	O	a	yes
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	galangin	no
O	O	or	no
B-drug_n	O	3,7-dihydroxyflavone	no
O	O	with	yes
B-drug	B-drug	vancomycin	yes
O	O	may	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	sensitize	no
O	O	resistant	no
O	O	strains	no
O	O	of	yes
O	O	Enterococcus	no
O	O	faecalis	no
O	O	and	yes
O	O	Enterococcus	no
O	O	faecium	no
O	O	to	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	vancomycin-sensitive	no
O	O	strains	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	with	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	bortezomib	yes
O	O	is	yes
O	O	primarily	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	and	yes
O	O	1A2	no
O	O	.	no

O	O	Additionally	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	circulating	no
O	O	active	no
O	O	metabolites	no
O	O	or	no
O	O	accumulation	no
O	O	during	no
O	O	chronic	no
O	O	dosing	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	potential	no
O	O	for	yes
O	O	an	no
O	O	interaction	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	1A2	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	amitriptyline	yes
O	O	,	no
B-drug	B-drug	tacrine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	zileuton	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	KRM-1648	no
O	O	,	no
O	O	either	no
O	O	singly	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ofloxacin	yes
O	O	,	no
O	O	against	yes
O	O	Mycobacterium	yes
O	O	ulcerans	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	ethoxzolamide	yes
O	O	with	yes
O	O	other	no
B-group	B-group	diuretics	no
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	may	no
O	O	cause	no
O	O	hypokalemia	no
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	norepinephrine	yes
O	O	may	no
O	O	still	no
O	O	be	no
O	O	used	no
O	O	effectively	no
O	O	.	no

B-drug	B-drug	haloperidol	yes
O	O	;	no

O	O	Absorption	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	is	yes
O	O	virtually	no
O	O	complete	yes
O	O	across	no
O	O	all	yes
O	O	species	no
O	O	,	no
O	O	including	no
O	O	man	no
O	O	,	no
O	O	and	yes
O	O	is	yes
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	food	no
O	O	.	no

O	O	.	no

O	O	decreased	no
B-drug	O	pregnanediol	no
O	O	excretion	no
O	O	;	no

O	O	Use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

B-drug	I-drug	ritonavir	yes
O	O	concentration	no

O	O	Patients	no
O	O	on	no
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	may	no
O	O	require	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-group	B-group	thyroid	yes
I-group	I-group	hormone	yes
O	O	.	no

B-drug	B-drug	Enoxacin	yes
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	42	no
O	O	%	no
O	O	to	no
O	O	74	no
O	O	%	no
O	O	dose-related	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	and	yes
O	O	a	yes
O	O	subsequent	no
O	O	260	no
O	O	%	no
O	O	to	no
O	O	350	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	O	theophylline	yes
O	O	levels	no
O	O	.	no

O	O	Prostatic	no
O	O	epithelium	no
O	O	proliferates	no
O	O	in	yes
O	O	a	yes
O	O	defined	no
O	O	medium	no
O	O	consisting	no
O	O	of	yes
O	O	basal	no
O	O	medium	no
O	O	RPMI1640	no
O	O	containing	yes
B-drug	B-drug_n	transferrin	no
O	O	(	no
O	O	1	yes
O	O	microgram/ml	no
O	O	)	no
O	O	,	no
B-drug_n	B-drug_n	EGF	no
O	O	(	no
O	O	10	yes
O	O	ng/ml	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	(	no
O	O	3.7	no
O	O	micrograms/ml	no
O	O	or	no
O	O	0.1	no
O	O	IU/ml	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Amantadine	yes
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	and	yes
B-group	B-group	MAOIs	no
O	O	may	no
O	O	increase	no
O	O	anticholinergic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	clidinium	yes
O	O	.	no

O	O	In	yes
O	O	these	no
O	O	patients	no
O	O	whose	no
O	O	hypertension	no
O	O	was	no
O	O	controlled	no
O	O	with	yes
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	Vardenafil	yes
O	O	20	yes
O	O	mg	yes
O	O	produced	no
O	O	mean	no
O	O	additional	no
O	O	supine	no
O	O	systolic/diastolic	no
O	O	blood	yes
O	O	pressure	no
O	O	reductions	no
O	O	of	yes
O	O	6/5	no
O	O	mm	yes
O	O	Hg	yes
O	O	compared	no
O	O	to	no
O	O	placebo	no
O	O	.	no

O	O	-	yes
O	O	Oral	yes
B-group	B-group	contraceptives	no
O	O	(	no
O	O	birth	no
O	O	control	no
O	O	pills	no
O	O	)	no
O	O	containing	yes
B-group	B-group	estrogen	no
O	O	or	no

B-drug	B-drug	meprobamate	yes
O	O	;	no

B-drug	B-drug	Morphine	yes
O	O	prolonged	no
O	O	gastrointestinal	no
O	O	transit	no
O	O	time	no
O	O	from	no
O	O	69	no
O	O	to	no
O	O	103	no
O	O	minutes	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	.005	no
O	O	)	no
O	O	;	no

O	O	Hematopoietic	no

O	O	It	no
O	O	is	yes
O	O	unknown	no
O	O	how	no
O	O	the	no
O	O	effect	no
O	O	seen	no
O	O	in	yes
O	O	these	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	translates	no
O	O	into	no
O	O	clinical	no
O	O	consequences	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	:	no
B-drug	B-drug	Dexamethasone	yes
O	O	:	no
B-drug	B-drug	Aprepitant	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	as	yes
O	O	a	yes
O	O	regimen	no
O	O	of	yes
O	O	125mg	no
O	O	with	yes
B-drug	B-drug	dexamethasone	yes
O	O	coadministered	no
O	O	orally	no
O	O	as	yes
O	O	20	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Aprepitant	yes
O	O	when	no
O	O	given	no
O	O	as	yes
O	O	80	yes
O	O	mg/day	no
O	O	with	yes
B-drug	B-drug	dexamethasone	yes
O	O	coadministered	no
O	O	orally	no
O	O	as	yes
O	O	8	yes
O	O	mg	yes
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	through	no
O	O	5	yes
O	O	,	no
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	,	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	by	no
O	O	2.2-fold	no
O	O	,	no
O	O	on	no
O	O	Days	no
O	O	1	yes
O	O	and	yes
O	O	5	yes
O	O	.	no

O	O	ii	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	The	no
O	O	following	no
O	O	drugs	no
O	O	or	no
O	O	moieties	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	laboratory	no
O	O	tests	no
O	O	performed	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-group	B-group	thyroid	yes
I-group	I-group	hormone	yes
O	O	therapy	no
O	O	:	no
B-group	B-group	androgens	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	containing	yes
B-group	B-group	estrogens	yes
O	O	,	no
B-drug	B-group	iodine-containing	no
O	O	preparations	no
O	O	and	yes
O	O	the	no
O	O	numerous	no
O	O	preparations	no
O	O	containing	yes
B-group	B-group	salicylates	no
O	O	.	no

B-drug	B-drug	Ketamine	yes
O	O	:	no
O	O	Marked	no
O	O	hypertension	no
O	O	and	yes
O	O	tachycardia	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	association	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	levothyroxine	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
B-drug	B-drug	ketamine	yes
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	NSAIDs	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	greater	no
O	O	than	no
O	O	2-fold	no
O	O	increases	no
O	O	in	yes
O	O	previously	no
O	O	stable	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
O	O	including	no
B-drug	B-drug	nortriptyline	yes
O	O	,	no
O	O	when	no
B-drug	B-drug	fluoxetine	yes
I-drug	I-drug	hydrochloride	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	No	yes
O	O	confirmed	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	between	yes
B-brand	B-brand	ZOLADEX	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no

O	O	Strong	no
O	O	inducers	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	(	no
O	O	i.e	no
O	O	.	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
O	O	)	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug_n	B-drug_n	MHD	no
O	O	(	no
O	O	29-40	no
O	O	%	no
O	O	)	no
O	O	.	no

B-group	B-drug	Tolbutamides	no
O	O	conversion	yes
O	O	to	no
O	O	inactive	no
O	O	metabolites	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	be	no
O	O	catalyzed	no
O	O	by	no
O	O	xanthine	yes
O	O	oxidase	yes
O	O	from	no
O	O	rat	yes
O	O	liver	yes
O	O	.	no

O	O	For	yes
O	O	example	no
O	O	,	no
O	O	since	no
B-drug	B-drug	cholestyramine	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
O	O	both	no
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	and	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	,	no
O	O	the	no
O	O	net	no
O	O	effects	no
O	O	are	no
O	O	unpredictable	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	if	no
B-brand	B-brand	CASODEX	yes
O	O	is	yes
O	O	started	no
O	O	in	yes
O	O	patients	no
O	O	already	no
O	O	receiving	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	,	no
O	O	prothrombin	yes
O	O	times	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	and	yes
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

B-group	B-group	Anticonvulsants	no
O	O	(	no
B-drug	B-drug	Phenytoin	yes
O	O	)	no
O	O	:	no
O	O	Steady	no
O	O	state	no
O	O	plasma	yes
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	12	yes
O	O	days	no
O	O	)	no
O	O	was	no
O	O	decreased	no
O	O	by	no
O	O	27	yes
O	O	%	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
O	O	multiple	no
O	O	doses	no
O	O	(	no
O	O	300	yes
O	O	mg	yes
O	O	QD	no
O	O	for	yes
O	O	12	yes
O	O	days	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	(	no
O	O	a	yes
O	O	CYP	no
O	O	3A4	no
O	O	inducer	no
O	O	)	no
O	O	.	no

B-group	B-group	Quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	norfloxacin	yes
O	O	,	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	including	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	or	no
O	O	similar	no
O	O	agents	yes
O	O	.	no

B-brand	B-drug	Felbamate	yes
O	O	treatment	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	42	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	gestodene	yes
O	O	AUC	no
O	O	0-24	no
O	O	,	no
O	O	but	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	effect	no
O	O	was	no
O	O	observed	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	As	yes
O	O	with	yes
B-drug	B-drug	cephalothin	yes
O	O	,	no
O	O	high	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cefoxitin	yes
O	O	(	no
O	O	100	yes
O	O	micrograms/mL	no
O	O	)	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	measurement	no
O	O	of	yes
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	creatinine	yes
O	O	levels	no
O	O	by	no
O	O	the	no
O	O	Jaff	no
O	O	reaction	no
O	O	,	no
O	O	and	yes
O	O	produce	no
O	O	false	no
O	O	increases	no
O	O	of	yes
O	O	modest	no
O	O	degree	no
O	O	in	yes
O	O	the	no
O	O	levels	no
O	O	of	yes
O	O	creatinine	yes
O	O	reported	no
O	O	.	no

O	O	aureus	no
O	O	,	no
O	O	to	no
O	O	survive	no
O	O	in	yes
B-drug	B-drug	pentazocine	yes
O	O	and	yes
B-drug	B-drug	tripelennamine	yes
O	O	may	no
O	O	explain	no
O	O	in	yes
O	O	part	no
O	O	a	yes
O	O	shift	no
O	O	from	no
B-drug	O	S	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	to	no
O	O	the	no
O	O	interactions	no
O	O	noted	no
O	O	above	no
O	O	,	no
O	O	chronic	no
O	O	(	no
O	O	2	yes
O	O	weeks	no
O	O	)	no
O	O	oral	yes
B-drug	B-drug	Cordarone	yes
O	O	administration	no
O	O	impairs	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	dextromethorphan	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	.	no

O	O	A	yes
O	O	review	no
O	O	is	yes
O	O	presented	no
O	O	of	yes
O	O	some	no
O	O	of	yes
O	O	the	no
O	O	problems	no
O	O	that	no
O	O	may	no
O	O	arise	no
O	O	in	yes
O	O	association	no
O	O	with	yes
O	O	anaesthesia	no
O	O	for	yes
O	O	epileptic	no
O	O	patients	no
O	O	.	no

O	O	Special	yes
O	O	care	yes
O	O	is	yes
O	O	required	no
O	O	if	no
O	O	this	no
O	O	drug	yes
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	ganglion	no
I-group	I-group	blocking	no
I-group	I-group	compounds	no
O	O	because	no
O	O	a	yes
O	O	critical	no
O	O	fall	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	may	no
O	O	occur	no
O	O	.	no

B-group	B-group	Tetracyclines	no
O	O	:	no
O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	Accutane	yes
O	O	and	yes
B-group	B-group	tetracyclines	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	because	no
B-brand	B-brand	Accutane	yes
O	O	use	no
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	cases	no
O	O	of	yes
O	O	pseudotumor	no
O	O	cerebri	no
O	O	(	no
O	O	benign	no
O	O	intracranial	no
O	O	hypertension	no
O	O	)	no
O	O	,	no
O	O	some	no
O	O	of	yes
O	O	which	no
O	O	involved	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tetracyclines	no

O	O	No	yes
O	O	drug	yes
O	O	interaction	no
O	O	data	no
O	O	are	no
O	O	available	no
O	O	on	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Panretin	yes
O	O	gel	yes
O	O	and	yes
B-group	O	systemic	no
I-group	O	anti-KS	no
I-group	O	agents	yes
O	O	.	no

O	O	A	yes
O	O	drug-drug	no
O	O	interaction	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	rifampin	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	has	no
O	O	shown	no
O	O	a	yes
O	O	30	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	caspofungin	yes
O	O	trough	no
O	O	concentrations	no
O	O	.	no

O	O	To	no
O	O	find	no
O	O	out	no
O	O	whether	no
O	O	this	no
O	O	observation	no
O	O	is	yes
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	increased	no
O	O	regional	no
O	O	perfusion	no
O	O	in	yes
O	O	diabetes	no
O	O	longitudinal	no
O	O	studies	no
O	O	on	no
O	O	patients	no
O	O	with	yes
O	O	Type	yes
O	O	I	yes
O	O	(	no
O	O	insulin-dependent	no
O	O	)	no
O	O	diabetes	no
O	O	mellitus	no
O	O	are	no
O	O	needed	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	-	yes
O	O	Combined	no
O	O	administration	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
O	O	40	yes
O	O	mg/day	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	carbamazepine	yes
O	O	(	no
O	O	titrated	no
O	O	to	no
O	O	400	yes
O	O	mg/day	no
O	O	for	yes
O	O	35	yes
O	O	days	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	.	no

B-drug	B-drug	Levetiracetam	yes
O	O	circulates	no
O	O	largely	no
O	O	unbound	no
O	O	(	no
O	O	10	yes
O	O	%	no
O	O	bound	no
O	O	)	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	;	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-brand	B-brand	INSPRA	yes
O	O	and	yes
B-group	B-group	NSAIDs	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	to	no
O	O	determine	no
O	O	whether	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	on	no
O	O	blood	yes
O	O	pressure	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	treating	no
O	O	patients	no
O	O	with	yes
O	O	either	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	or	no
O	O	other	no
O	O	highly	no
O	O	protein-bound	no
O	O	drugs	no
O	O	and	yes
B-brand	B-brand	Atromid-S	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	unclear	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
B-drug	B-drug	Carbamazepine	yes
O	O	causes	no
O	O	an	no
O	O	approximate	no
O	O	50	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	and	yes
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	results	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	40	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	the	no
O	O	same	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	given	no
O	O	as	yes
O	O	monotherapy	no
O	O	.	no

B-drug	B-drug	Saquinavir	yes

O	O	Less	no
O	O	than	no
O	O	the	no
O	O	usual	no
O	O	amounts	no
O	O	of	yes
O	O	these	no
O	O	medicines	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
B-brand	B-brand	Tilade	yes
O	O	has	no
O	O	been	no
O	O	co-administered	no
O	O	with	yes
O	O	other	no
B-group	O	anti-asthma	no
I-group	O	medications	no
O	O	,	no
O	O	including	no
O	O	inhaled	no
O	O	and	yes
O	O	oral	yes
B-group	B-group	bronchodilators	no
O	O	,	no
O	O	and	yes
O	O	inhaled	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	with	yes
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	increased	no
O	O	frequency	no
O	O	of	yes
O	O	adverse	no
O	O	events	no
O	O	or	no
O	O	laboratory	no
O	O	abnormalities	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Methyldopa	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Aldomet	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	methyldopa	yes
O	O	with	yes
B-drug	B-drug	sulfapyridine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	liver	yes
O	O	and/or	no
O	O	the	no
O	O	blood	yes

O	O	Consideration	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-group	B-drug	antidiabetic	no
I-group	O	agents	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	pharmacodynamic	no
O	O	effect	no
O	O	increased	no
O	O	by	no
O	O	197	yes
O	O	%	no
O	O	(	no
O	O	QTc	no
O	O	increase	no
O	O	over	no
O	O	time	no
O	O	)	no
O	O	and	yes
O	O	by	no
O	O	95	no
O	O	%	no
O	O	(	no
O	O	maximum	no
O	O	QTc	no
O	O	increase	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	drug/drug	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

B-drug	B-drug	Insulin	yes
O	O	or	no
O	O	Oral	yes
B-group	B-group	Hypoglycemics	no
O	O	:	no
O	O	Initiating	no
B-group	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	may	no
O	O	cause	no
O	O	increases	no
O	O	in	yes
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemic	no
O	O	requirements	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	occurrence	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	reported	no
O	O	with	yes
B-brand	B-brand	Cefizox	yes
O	O	,	no
O	O	nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	other	no
B-group	B-group	cephalosporins	no
O	O	and	yes
B-group	B-group	aminoglycosides	no
O	O	.	no

O	O	Serotonin	yes
O	O	release	yes
O	O	by	no
O	O	platelets	no
O	O	plays	no
O	O	an	no
O	O	important	no
O	O	role	no
O	O	in	yes
O	O	hemostasis	no
O	O	.	no

O	O	.	no

B-drug	B-drug	Sumatriptan	yes
O	O	-	yes
O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	postmarketing	no
O	O	reports	no
O	O	describing	no
O	O	patients	no
O	O	with	yes
O	O	weakness	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	and	yes
O	O	incoordination	no
O	O	following	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitor	yes
O	O	(	no
B-group	B-group	SSRI	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	sumatriptan	yes
O	O	.	no

O	O	reliable	no
O	O	estimates	no
O	O	of	yes
O	O	the	no
O	O	prevalence	no
O	O	of	yes
O	O	reduced	yes
O	O	P450	no
O	O	2D6	no
O	O	isozyme	no
O	O	activity	yes
O	O	among	no
O	O	Asian	yes
O	O	,	no
O	O	African	no
O	O	and	yes
O	O	other	no
O	O	populations	no
O	O	are	no
O	O	not	no
O	O	yet	no
O	O	available	no
O	O	.	no

O	O	.	no

O	O	An	no
O	O	individual	no
O	O	who	no
O	O	is	yes
O	O	stable	no
O	O	on	no
O	O	a	yes
O	O	given	no
O	O	dose	no
O	O	of	yes
B-group	B-group	TCA	no
O	O	may	no
O	O	become	no
O	O	abruptly	no
O	O	toxic	no
O	O	when	no
O	O	given	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	inhibiting	no
O	O	drugs	no
O	O	as	yes
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Fluoxetine	yes
O	O	and	yes
B-drug	B-drug	moclobemide	yes
O	O	increased	no
O	O	blood	yes
O	B-drug	glucose	yes
O	O	at	yes
O	O	different	no
O	O	times	no
O	O	after	no
O	O	the	no
O	O	glucose	yes
O	O	overload	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	at	yes
O	O	the	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	therapy	no
O	O	and	yes
O	O	frequently	no
O	O	thereafter	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	these	no
O	O	three	no
O	O	drug	yes
O	O	products	no
O	O	adjusted	yes
O	O	appropriately	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	ORAL	yes
O	O	and	yes
B-drug	B-drug	probenecid	yes
O	O	resulted	no
O	O	in	yes
O	O	decreased	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	ketorolac	yes
O	O	and	yes
O	O	significant	no
O	O	increases	no
O	O	in	yes
B-drug	B-drug	ketorolac	yes
O	O	plasma	yes
O	O	levels	no
O	O	(	no
O	O	total	yes
O	O	AUC	no
O	O	increased	no
O	O	approximately	no
O	O	threefold	no
O	O	from	no
O	O	5.4	no
O	O	to	no
O	O	17.8	no
O	O	m	yes
O	O	g/h/mL	no
O	O	)	no
O	O	and	yes
O	O	terminal	no
O	O	half-life	no
O	O	increased	no
O	O	approximately	no
O	O	twofold	no
O	O	from	no
O	O	6.6	no
O	O	to	no
O	O	15.1	no
O	O	hours	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	advisable	no
O	O	to	no
O	O	be	no
O	O	particularly	no
O	O	cautious	no
O	O	in	yes
O	O	patients	no
O	O	whose	no
O	O	plasma	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	are	no
O	O	above	no
O	O	or	no
O	O	suspected	no
O	O	to	no
O	O	be	no
O	O	above	no
O	O	the	no
O	O	usual	no
O	O	therapeutic	no
O	O	range	no
O	O	.	no

O	O	Pediatric	yes
O	O	Use	no

O	O	Thus	no
O	O	,	no
O	O	the	no
O	O	interaction	no
O	O	observed	no
O	O	between	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	terfenadine	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	for	yes
B-drug	B-drug	dirithromycin	yes
O	O	.	no

O	O	The	no
O	O	reported	no
O	O	dose	no
O	O	used	no
O	O	for	yes
B-drug	B-drug	L-glutamine	yes
O	O	was	no
O	O	21	yes
O	O	grams	no
O	O	daily	no
O	O	taken	no
O	O	in	yes
O	O	divided	no
O	O	doses	no
O	O	three	no
O	O	times	no
O	O	a	yes
O	O	day	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	its	no
O	O	potential	no
O	O	to	no
O	O	cause	no
O	O	neutropenia	no
O	O	and	yes
O	O	lymphopenia	no
O	O	,	no
O	O	proper	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	is	yes
O	O	required	no
O	O	if	no
B-brand	B-brand	Rebif	yes
O	O	is	yes
O	O	given	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	myelosuppressive	no
O	O	agents	yes
O	O	.	no

O	O	Since	no
O	O	blood	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	will	no
O	O	be	no
O	O	reduced	yes
O	O	,	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Rocaltrol	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	if	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	simultaneously	no
O	O	.	no

O	O	Most	no
O	O	of	yes
O	O	the	no
O	O	above	no
O	O	effects	no
O	O	concerning	no
B-group	B-group	diuretics	no
O	O	have	no
O	O	been	no
O	O	attributed	no
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	in	yes
O	O	part	no
O	O	,	no
O	O	to	no
O	O	mechanisms	no
O	O	involving	no
O	O	inhibition	no
O	O	of	yes
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	by	no
B-brand	B-brand	INDOCIN	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	-	yes
O	O	Administration	no
O	O	of	yes
O	O	40	yes
O	O	mg/day	no
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	for	yes
O	O	21	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	bromocriptine	yes
I-drug	I-drug	mesylate	yes
O	O	with	yes
O	O	other	no
B-group	B-group	ergot	yes
I-group	I-group	alkaloids	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-group	B-group	Antifungals	no
O	O	:	no
B-drug	B-drug	Itraconazole	yes
I-drug	I-drug	Ketoconazole	yes

O	O	Blood	yes
O	O	samples	no
O	O	were	no
O	O	drawn	no
O	O	at	yes
O	O	0	no
O	O	,	no
O	O	0.5	yes
O	O	,	no
O	O	1	yes
O	O	,	no
O	O	1.5	yes
O	O	,	no
O	O	2	yes
O	O	,	no
O	O	3	yes
O	O	,	no
O	O	4	yes
O	O	,	no
O	O	6	yes
O	O	,	no
O	O	8	yes
O	O	,	no
O	O	12	yes
O	O	,	no
O	O	18	yes
O	O	,	no
O	O	and	yes
O	O	24	yes
O	O	hours	no
O	O	for	yes
O	O	Cmax	no
O	O	,	no
O	O	tmax	no
O	O	,	no
O	O	and	yes
O	O	AUC	no
O	O	determinations	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agent	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	B-group	diuretic	no
O	I-group	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
O	O	potassium-sparing	no
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	These	no
O	O	facts	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	evaluating	no
O	O	plasma	yes
O	O	renin	no
O	O	activity	yes
O	O	in	yes
O	O	hypertensive	no
O	O	patients	no
O	O	.	no

O	O	Onset	no
O	O	of	yes
O	O	the	no
O	O	interaction	no
O	O	began	no
O	O	within	no
O	O	five	no
O	O	days	no
O	O	of	yes
O	O	beginning	no
O	O	concurrent	no
O	O	therapy	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Enteric	no
O	O	Coated	no
B-brand	B-brand	Aspirin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	,	no
O	O	since	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	pH	yes
O	O	of	yes
O	O	the	no
O	O	stomach	no
O	O	may	no
O	O	effect	no
O	O	the	no
O	O	enteric	no
O	O	coating	no
O	O	of	yes
O	O	the	no
O	O	tablets	yes
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	desirable	no
O	O	to	no
O	O	monitor	no
B-group	B-group	TCA	no
O	O	plasma	yes
O	O	levels	no
O	O	whenever	no
O	O	a	yes
B-group	B-group	TCA	no
O	O	is	yes
O	O	going	no
O	O	to	no
O	O	be	no
O	O	coadministered	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	To	no
O	O	study	no
O	O	the	no
O	O	pancreatic	yes
O	O	effects	no
O	O	of	yes
O	O	other	no
O	O	agents	yes
O	O	,	no
O	O	dynamic	no
B-drug	O	insulin	yes
O	O	and	yes
O	O	glucagon	yes
O	O	release	yes
O	O	was	no
O	O	measured	no
O	O	from	no
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	perfused	no
O	O	pancreases	no
O	O	of	yes
O	O	normal	yes
O	O	and	yes
O	O	diabetic	no
O	O	Chinese	yes
O	O	hamsters	no
O	O	in	yes
O	O	response	no
O	O	to	no
O	O	various	no
O	O	combinations	no
O	O	of	yes
B-drug	B-drug	arginine	yes
O	O	(	no
O	O	20mM	no
O	O	)	no
O	O	,	no
B-drug	B-drug	glucose	yes
O	O	(	no
O	O	100	yes
O	O	or	no
O	O	150	yes
O	O	mg.	no
O	O	per	no
O	O	100	yes
O	O	ml	no
O	O	.	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	10	yes
O	O	mM	yes
O	O	)	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	Studies	no
O	O	in	yes
O	O	animals	no
O	O	demonstrate	no
O	O	that	no
O	O	the	no
O	O	acute	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	is	yes
O	O	enhanced	no
O	O	by	no
O	O	the	no
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
B-drug	B-drug	phenelzine	yes
O	O	.	no

B-drug	B-drug	Ethopropazine	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	,	no
O	O	causing	no
O	O	increased	no
O	O	sedative	no
O	O	effects	no
O	O	.	no

O	O	The	no
O	O	blood	yes
O	O	pressure	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	SULAR	yes
O	O	tended	no
O	O	to	no
O	O	be	no
O	O	greater	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-drug	B-drug	atenolol	yes
O	O	than	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	no	yes
O	O	other	no
B-group	B-group	antihypertensive	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	In	yes
O	O	controlled	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	either	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	(	no
O	O	one	no
O	O	study	no
O	O	)	no
O	O	or	no
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	modest	no
O	O	increases	no
O	O	,	no
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	(	no
O	O	two	no
O	O	studies	no
O	O	)	no
O	O	in	yes
O	O	steady-state	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	.	no

O	O	Four	no
O	O	educational	no
O	O	messages	no
O	O	advise	no
O	O	on	no
O	O	over	no
O	O	60	no
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	PICR	no
O	O	detected	no
O	O	.	no

O	O	Racemic	yes
B-drug	B-drug	citalopram	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	mean	no
O	O	AUC	no
O	O	or	no
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	pimozide	yes
O	O	.	no

B-group	B-group	Antigout	no
I-group	I-group	medications	no

O	O	Because	no
B-drug	B-drug	warfarin	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
B-drug	O	CYP2C9	no
O	O	and	yes
O	O	CYP3A4	no
O	O	,	no
O	O	patients	no
O	O	who	no
O	O	require	no
O	O	anticoagulation	no
O	O	should	no
O	O	receive	no
O	O	low-molecular	no
O	O	weight	yes
O	O	or	no
O	O	standard	yes
B-drug	B-drug	heparin	yes
O	O	.	no

O	O	Lupus-like	no
O	O	syndrome	no

O	O	Other	no
O	O	binding	no
O	O	proteins	no
O	O	may	no
O	O	be	no
O	O	elevated	no
O	O	in	yes
O	O	serum	yes
O	O	,	no
O	O	i.e.	no
O	O	,	no
O	O	corticosteroid	no
O	O	binding	no
O	O	globulin	yes
O	O	(	no
O	O	CBG	no
O	O	)	no
O	O	,	no
O	O	sex	no
O	O	hormone-binding	no
O	O	globulin	yes
O	O	(	no
O	O	SHBG	no
O	O	)	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	total	yes
O	O	circulating	no
B-group	B-group	corticosteroids	no
O	O	and	yes
B-group	B-group	sex	no
I-group	I-group	steroids	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Toxicity	no
O	O	of	yes
O	O	cadmium	no
O	O	and	yes
B-drug	B-drug	zinc	yes
O	O	to	no
O	O	encystment	no
O	O	and	yes
O	O	in	yes
O	O	vitro	no
O	O	excystment	no
O	O	of	yes
O	O	Parorchis	no
O	O	acanthus	no
O	O	(	no
O	O	Digenea	no
O	O	:	no
O	O	Philophthalmidae	no
O	O	)	no
O	O	.	no

O	O	Although	no
O	O	clinical	no
O	O	evidence	no
O	O	to	no
O	O	date	no
O	O	has	no
O	O	not	no
O	O	demonstrated	no
O	O	renal	no
O	O	precipitation	no
O	O	of	yes
B-drug	O	oxypurines	no
O	O	in	yes
O	O	patients	no
O	O	either	no
O	O	on	no
B-drug	B-drug	allopurinol	yes
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	B-group	uricosuric	no
O	I-group	agents	yes
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	should	no
O	O	be	no
O	O	kept	no
O	O	in	yes
O	O	mind	no
O	O	.	no

O	O	(	no
O	O	Concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	intensify	no
O	O	electrolyte	yes
O	O	imbalance	no
O	O	,	no
O	O	particularly	no
O	O	hypokalemia	no
O	O	.	no
O	O	)	no

B-drug	B-drug	Diphenoxylate	yes
I-drug	I-drug	HCl	yes
O	O	and	yes
B-drug	B-drug	atropine	yes
I-drug	I-drug	sulfate	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	In	yes
O	O	studies	no
O	O	with	yes
O	O	male	no
O	O	rats	no
O	O	,	no
B-drug	B-drug	diphenoxylate	yes
I-drug	I-drug	hydrochloride	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	hepatic	no
O	O	microsomal	no
O	O	enzyme	no
O	O	system	yes
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	2	yes
O	O	mg/kg/day	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	similar	no
O	O	changes	no
O	O	may	no
O	O	be	no
O	O	expected	no
O	O	with	yes
O	O	larger	no
O	O	doses	no
O	O	of	yes
B-group	B-group	estrogen	no
O	O	:	no
O	O	-	yes
O	O	Increased	no
O	O	sulfobromophthalein	no
O	O	retention	no

B-group	B-group	Corticosteroids	no
O	O	,	no
B-drug	B-drug	ACTH	yes
O	O	:	no
O	O	intensified	no
O	O	electrolyte	yes
O	O	depletion	no
O	O	,	no
O	O	particularly	no
O	O	hypokalemia	no
O	O	.	no

B-drug	B-drug	Flucytosine	yes
O	O	:	no
O	O	while	no
O	O	a	yes
O	O	synergistic	no
O	O	relationship	no
O	O	with	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	flucytosine	yes
O	O	by	no
O	O	possibly	no
O	O	increasing	no
O	O	its	no
O	O	cellular	no
O	O	uptake	no
O	O	and/or	no
O	O	impairing	no
O	O	its	no
O	O	renal	no
O	O	excretion	no
O	O	.	no

O	O	reduced	yes
O	O	response	no
O	O	to	no
O	O	metyrapone	yes
O	O	test	yes
O	O	;	no

B-drug	B-drug	Quinidine	yes
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	spironolactone	yes
O	O	raise	no
O	O	the	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentration	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	clearance	no
O	O	and/or	no
O	O	in	yes
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	,	no
O	O	with	yes
O	O	the	no
O	O	implication	no
O	O	that	no
B-group	B-group	digitalis	yes
O	O	intoxication	no
O	O	may	no
O	O	result	no
O	O	.	no

B-drug	B-drug	Aminoglutethimide	yes
O	O	:	no
O	O	May	no
O	O	increase	no
O	O	CYP	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	progestins	no
O	O	leading	no
O	O	to	no
O	O	possible	no
O	O	decrease	no
O	O	in	yes
O	O	contraceptive	yes
O	O	effectiveness	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	case	no
O	O	reports	no
O	O	of	yes
O	O	patients	no
O	O	who	no
O	O	developed	no
O	O	increased	no
O	O	BUN	no
O	O	,	no
O	O	serum	yes
O	O	creatinine	yes
O	O	and	yes
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	,	no
O	O	and	yes
O	O	weight	yes
O	O	gain	no
O	O	when	no
B-drug	B-drug	furosemide	yes
O	O	was	no
O	O	used	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-group	B-group	NSAIDs	no
O	O	.	no

O	O	A	yes
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	was	no
O	O	performed	no
O	O	in	yes
O	O	which	no
B-brand	B-brand	ERBITUX	yes
O	O	was	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	irinotecan	yes
O	O	.	no

O	O	Clinically	no
O	O	significant	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
B-group	B-group	warfarin	yes
I-group	I-group	anticoagulants	no
O	O	;	no

B-drug	B-drug	Phenobarbital	yes
O	O	or	no
B-drug	B-drug	Primidone	yes
O	O	:	no
O	O	No	yes
O	O	formal	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	examining	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	to	no
O	O	regimens	no
O	O	containing	yes
B-drug	B-drug	phenobarbital	yes
O	O	or	no
B-drug	B-drug	primidone	yes
O	O	.	no

O	O	.	no

O	O	Interconversion	no
O	O	between	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	preterm	no
O	O	neonates	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	dofetilide	yes
O	O	does	no
O	O	not	no
O	O	necessitate	no
O	O	an	no
O	O	adjustment	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	dose	no
O	O	to	no
O	O	maintain	no
O	O	therapeutic	no
B-drug	O	digoxin	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Spermine	yes
O	O	promotes	no
O	O	the	no
O	O	translocation	no
O	O	of	yes
O	O	phosphatidate	no
O	O	phosphohydrolase	no
O	O	from	no
O	O	the	no
O	O	cytosol	no
O	O	to	no
O	O	the	no
O	O	microsomal	no
O	O	fraction	yes
O	O	of	yes
O	O	rat	yes
O	O	liver	yes
O	O	and	yes
O	O	it	no
O	O	enhances	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	oleate	yes
O	O	in	yes
O	O	this	no
O	O	respect	no
O	O	.	no

O	O	The	no
O	O	steady	no
O	O	state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	imipramine	yes
O	O	and	yes
B-drug	B-drug	desipramine	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	an	no
O	O	average	no
O	O	of	yes
O	O	31	yes
O	O	%	no
O	O	and	yes
O	O	20	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	tablets	yes
O	O	in	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	4	yes
O	O	mg/day	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	insufficient	no
O	O	experience	no
O	O	to	no
O	O	assess	no
O	O	the	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	ORENCIA	yes
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	anakinra	yes
O	O	,	no
O	O	and	yes
O	O	therefore	no
O	O	such	no
O	O	use	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	it	no
O	O	adversely	no
O	O	affected	no
O	O	response	no
O	O	duration	no
O	O	suggesting	no
O	O	that	no
B-drug	B-drug	pyridoxine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	with	yes
B-brand	B-brand	HEXALEN	yes
O	O	and/or	no
B-drug	B-drug	cisplatin.1	no

O	O	Nursing	no
O	O	Mothers	no
O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
B-drug	B-drug	peginterferon	yes
O	O	or	no
B-drug	B-drug	ribavirin	yes
O	O	or	no
O	O	its	no
O	O	components	no
O	O	are	no
O	O	excreted	no
O	O	in	yes
O	O	human	yes
O	O	milk	yes
O	O	.	no

B-drug	B-group	Antiretroviral	no
O	O	plasma	yes
O	O	and	yes
O	O	urine	no
O	O	sampling	no
O	O	were	no
O	O	conducted	no
O	O	on	no
O	O	Days	no
O	O	1	yes
O	O	,	no
O	O	7	yes
O	O	,	no
O	O	and	yes
O	O	21	yes
O	O	for	yes
B-drug	B-drug	zidovudine	yes
O	O	and	yes
O	O	on	no
O	O	Days	no
O	O	7	yes
O	O	and	yes
O	O	21	yes
O	O	for	yes
B-drug	B-drug	dideoxyinosine	yes
O	O	.	no

O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	provide	no
O	O	information	no
O	O	for	yes
O	O	the	no
O	O	appropriate	no
O	O	package	no
O	O	insert	no
O	O	labeling	no
O	O	of	yes
B-group	B-group	progestin-only	no
O	I-group	oral	yes
B-group	I-group	contraceptives	no
O	O	(	no
B-group	B-group	POC	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	US	no
O	O	,	no
O	O	a	yes
O	O	comprehensive	no
O	O	review	no
O	O	was	no
O	O	made	no
O	O	of	yes
B-drug	B-drug	norgestrel	yes
O	O	(	no
O	O	0.075	no
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	norethindrone	yes
O	O	(	no
O	O	0.35	no
O	O	mg	yes
O	O	)	no
O	O	,	no
O	O	with	yes
O	O	the	no
O	O	clinical	no
O	O	differences	no
O	O	indicated	no
O	O	where	no
O	O	applicable	no
O	O	.	no

O	O	Drug-Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	ELLENCE	yes
O	O	and	yes
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	None	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	:	no
O	O	The	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	to	no
O	O	patients	no
O	O	taking	no
B-drug	B-drug	valproate	yes
O	O	chronically	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	tiagabine	yes
O	O	pharmacokinetics	no
O	O	,	no
O	O	but	no
B-drug	B-drug	valproate	yes
O	O	significantly	no
O	O	decreased	no
B-drug	B-drug	tiagabine	yes
O	O	binding	no
O	O	in	yes
O	O	vitro	no
O	O	from	no
O	O	96.3	no
O	O	to	no
O	O	94.8	no
O	O	%	no
O	O	,	no
O	O	which	no
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	of	yes
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	free	yes
B-drug	O	tiagabine	yes
O	O	concentration	no
O	O	.	no

O	O	The	no
O	O	successive	no
O	O	application	no
O	O	of	yes
B-drug	B-drug	glycine	yes
O	O	(	no
O	O	5	yes
O	O	or	no
O	O	10	yes
O	O	mg/kg	no
O	O	egg	no
O	O	weight	yes
O	O	(	no
O	O	e.w	no
O	O	.	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	glutamate	yes
O	O	(	no
O	O	15	yes
O	O	mg/kg	no
O	O	e.w	no
O	O	.	no
O	O	)	no
O	O	in	yes
O	O	a	yes
O	O	10	yes
O	O	min	no
O	O	interval	no
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	activation	no
O	O	of	yes
O	O	spontaneous	no
O	O	motility	no
O	O	of	yes
O	O	17-day-old	no
O	O	chick	no
O	O	embryos	no
O	O	in	yes
O	O	comparison	no
O	O	with	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	glutamate	yes
O	O	alone	no
O	O	.	no

B-drug	B-drug	Propranolol	yes
O	O	:	no
O	O	May	no
O	O	decrease	no
B-group	B-brand	aspirins	no
I-group	O	anti-inflammatory	no
O	O	action	no
O	O	by	no
O	O	competing	no
O	O	for	yes
O	O	the	no
O	O	same	yes
O	O	receptors	no
O	O	.	no

O	O	with	yes
B-drug	B-drug	sucralfate	yes
O	O	;	no

O	O	Some	no
B-group	B-group	quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	transient	no
O	O	elevations	no
O	O	in	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	cyclosporine	yes
O	O	concomitantly	no
O	O	.	no

O	O	twice	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	and	yes
O	O	non-ossification	no
O	O	of	yes
O	O	the	no
O	O	odontoid	no
O	O	and	yes
O	O	ventral	no
O	O	tubercle	no
O	O	of	yes
O	O	the	no
O	O	first	no
O	O	cervical	no
O	O	vertebra	no
O	O	at	yes
O	O	doses	no
O	O	0.1	no
O	O	mg/kg/day	no
O	O	IM	yes
O	O	(	no
O	O	approximately	no
O	O	one-tenth	no
O	O	of	yes
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	when	no
O	O	administered	no
O	O	during	no
O	O	the	no
O	O	period	no
O	O	of	yes
O	O	organogenesis	no
O	O	.	no

O	O	Thus	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	tendency	no
O	O	toward	no
O	O	a	yes
O	O	more	no
O	O	pronounced	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	4-hydroxylation	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	150	yes
O	O	mg/d	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	compared	no
O	O	with	yes
O	O	75	yes
O	O	mg/d	no
O	O	,	no
O	O	but	no
O	O	the	no
O	O	difference	no
O	O	was	no
O	O	not	no
O	O	statistically	no
O	O	significant	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	is	yes
O	O	also	no
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Mefloquine	yes
O	O	and	yes
O	O	other	no
O	O	related	yes
O	O	compounds	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	and	yes
B-drug	B-drug	chloroquine	yes
O	O	)	no
O	O	may	no
O	O	produce	no
O	O	electrocardiographic	no
O	O	abnormalities	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	convulsions	no
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	of	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	strong	no
O	O	CYP	no
O	O	3A4	no
O	O	inhibitors	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	fulvestrant	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	The	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	inhibited	no
O	O	by	no
O	O	some	no
O	O	drugs	no
O	O	of	yes
O	O	this	no
O	O	class	no
O	O	.	no

O	O	Interference	no
O	O	of	yes
O	O	biocytin	no
O	O	with	yes
B-drug_n	B-group	opioid-evoked	no
O	O	hyperpolarization	no
O	O	and	yes
O	O	membrane	yes
O	O	properties	no
O	O	of	yes
O	O	rat	yes
O	O	spinal	no
O	O	substantia	no
O	O	gelatinosa	no
O	O	neurons	no
O	O	.	no

B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	effects	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	safety	no
O	O	or	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	ibutilide	yes
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	reliable	no
O	O	estimates	no
O	O	of	yes
O	O	the	no
O	O	prevalence	no
O	O	of	yes
O	O	reduced	yes
O	O	P450	no
O	O	2D6	no
O	O	isozyme	no
O	O	activity	yes
O	O	among	no
O	O	Asian	yes
O	O	,	no
O	O	African	no
O	O	and	yes
O	O	other	no
O	O	populations	no
O	O	are	no
O	O	not	no
O	O	yet	no
O	O	available	no
O	O	.	no

O	O	In	yes
O	O	an	no
O	O	effort	no
O	O	to	no
O	O	screen	no
O	O	compounds	no
O	O	for	yes
O	O	antipsychotic	no
O	O	activity	yes
O	O	,	no
O	O	preclinical	no
O	O	researchers	no
O	O	have	no
O	O	investigated	no
O	O	whether	no
O	O	these	no
O	O	compounds	no
O	O	block	yes
B-drug_n	B-drug_n	PCP-induced	no
O	O	behaviors	no
O	O	in	yes
O	O	animals	no
O	O	.	no

O	O	Other	no
O	O	compounds	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	of	yes
O	O	CYP3A4	no
O	O	may	no
O	O	have	no
O	O	decreased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	(	no
B-drug	B-drug	efavirenz	yes
O	O	)	no
O	O	.	no

O	O	Only	no
O	O	at	yes
O	O	the	no
O	O	highest	no
O	O	concentration	no
O	O	tested	no
O	O	(	no
O	O	171	no

O	O	No	yes
O	O	carcinogenicity	no
O	O	or	no
O	O	fertility	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Estazolam	yes
O	O	:	no
O	O	Interaction	no
O	O	with	yes
O	O	Drugs	no
O	O	that	no
O	O	Inhibit	no
O	O	Metabolism	no
O	O	via	no
O	O	Cytochrome	no
O	O	P450	no
O	O	3A	yes
O	O	(	no
O	O	CYP3A	no
O	O	)	no
O	O	:	no
O	O	The	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	estazolam	yes
O	O	to	no
O	O	the	no
O	O	major	no
O	O	circulating	no
O	O	metabolite	yes
B-drug_n	B-drug_n	4-hydroxy-estazolam	no
O	O	and	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
B-group	B-group	triazolobenzodiazepines	no
O	O	is	yes
O	O	catalyzed	no
O	O	by	no
O	O	CYP3A	no
O	O	.	no

O	O	A	yes
O	O	daily	no
O	O	dose	no
O	O	of	yes
O	O	2	yes
O	O	mg	yes
O	O	of	yes
B-drug_n	B-drug_n	coumaphos/kg	no
O	O	of	yes
O	O	body	no
O	O	weight	yes
O	O	for	yes
O	O	6	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	plasma	yes
O	O	enzymes	yes
O	O	or	no
O	O	the	no
O	O	antiprothrombinemic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	bishydroxy-coumarin	no
O	O	in	yes
O	O	wethers	no
O	O	.	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	cardiovascular	no
O	O	morbidity	no
O	O	and	yes
O	O	mortality	no
O	O	is	yes
O	O	not	no
O	O	higher	no
O	O	among	no
O	O	users	no
O	O	of	yes
B-drug	B-drug	sildenafil	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Primaquine	yes
O	O	or	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
B-drug	B-drug	theophylline-related	no
O	O	side	no
O	O	effects	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	norfloxacin	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	Since	no
B-drug	B-drug	entecavir	yes
O	O	is	yes
O	O	primarily	no
O	O	eliminated	no
O	O	by	no
O	O	the	no
O	O	kidneys	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	BARACLUDE	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	reduce	no
O	O	renal	no
O	O	function	no
O	O	or	no
O	O	compete	no
O	O	for	yes
O	O	active	no
O	O	tubular	no
O	O	secretion	no
O	O	may	no
O	O	increase	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	entecavir	yes
O	O	or	no
O	O	the	no
O	O	coadministered	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	:	no
O	O	Coadministration	no
O	O	(	no
O	O	N=18	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	naproxen	yes
I-drug	I-drug	sodium	yes
O	O	capsules	no
O	O	(	no
O	O	250	yes
O	O	mg	yes
O	O	)	no
O	O	with	yes
B-brand	B-brand	Neurontin	yes
O	O	(	no
O	O	125	yes
O	O	mg	yes
O	O	)	no
O	O	appears	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	amount	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	absorbed	no
O	O	by	no
O	O	12	yes
O	O	%	no
O	O	to	no
O	O	15	yes
O	O	%	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-brand	B-brand	COLESTlD	no
O	O	Tablets	yes
O	O	may	no
O	O	delay	no
O	O	or	no
O	O	reduce	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	concomitant	no
O	O	oral	yes
O	O	medication	no
O	O	.	no

B-brand	B-brand	PEGANONE	yes
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	adversely	no
O	O	affect	no
O	O	the	no
O	O	hematopoietic	no
O	O	system	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	if	no
O	O	possible	no
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	with	yes
B-group	B-group	Antacids	no
O	O	Administration	no
O	O	of	yes
O	O	120	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	(	no
O	O	2	yes
O	O	x	yes
O	O	60	no
O	O	mg	yes
O	O	capsule	yes
O	O	)	no
O	O	within	no
O	O	15	yes
O	O	minutes	no
O	O	of	yes
O	O	an	no
B-drug	B-drug	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	containing	yes
B-group	B-group	antacid	no
O	O	(	no
B-brand	B-brand	Maalox	no
O	O	)	no
O	O	decreased	no
B-drug	B-drug	fexofenadine	yes
O	O	AUC	no
O	O	by	no
O	O	41	yes
O	O	%	no
O	O	and	yes
O	O	cmax	no
O	O	by	no
O	O	43	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Somatrem/Somatropin	no
O	O	:	no
O	O	Excessive	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	thyroid	yes
I-group	I-group	hormone	yes
O	O	may	no
O	O	accelerate	no
O	O	epiphyseal	no
O	O	closure	no
O	O	.	no

O	O	Drugs	no
O	O	whose	no
O	O	absorption	no
O	O	is	yes
O	O	sensitive	no
O	O	to	no
O	O	pH	yes
O	O	may	no
O	O	be	no
O	O	negatively	no
O	O	impacted	no
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	omeprazole	yes
O	O	and	yes
B-drug	B-drug	valdecoxib	yes
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	available	no
O	O	.	no

B-drug	B-drug	Arginine	yes
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
B-drug	B-drug	glucose	yes
O	O	or	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	caused	no
O	O	excessive	no
O	O	glucagon	yes
O	O	release	yes
O	O	in	yes
O	O	the	no
O	O	diabetics	no
O	O	and	yes
O	O	undetectable	no
O	O	insulin	yes
O	O	release	yes
O	O	in	yes
O	O	either	no
O	O	diabetics	no
O	O	or	no
O	O	normals	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	for	yes
O	O	8	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	for	yes
O	O	2	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	enoxacin	yes
O	O	administration	no
O	O	.	no

O	O	During	no
B-drug	B-drug	amiodarone	yes
O	O	administration	no
O	O	,	no
O	O	systemic	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	was	no
O	O	reduced	yes
O	O	from	no
O	O	234	no
O	O	+/-	no
O	O	72	no
O	O	ml/min	no
O	O	(	no
O	O	mean	no
O	O	+/-	no
O	O	standard	yes
O	O	deviation	no
O	O	)	no
O	O	to	no
O	O	172	no
O	O	+/-	no
O	O	33	no
O	O	ml/min	no
O	O	(	no
O	O	p	yes
O	O	less	no
O	O	than	no
O	O	0.01	no
O	O	)	no
O	O	.	no

O	O	Drug	yes
O	O	interactions	no
O	O	:	no
O	O	How	no
O	O	to	no
O	O	identify	no
O	O	them	no
O	O	.	no

O	O	.	no

O	O	injection	yes
O	O	of	yes
O	O	vehicle	no
O	O	(	no
O	O	corn	no
B-drug	O	oil	yes
O	O	,	no
O	O	0.1	no
O	O	mL/day	no
O	O	)	no
O	O	,	no
B-drug	B-drug	estradiol	yes
O	O	(	no
O	O	10	yes
O	O	microg/kg/day	no
O	O	or	no
O	O	4	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	and/or	no
B-drug	B-drug	progesterone	yes
O	O	(	no
O	O	20	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	,	no
O	O	for	yes
O	O	eight	no
O	O	days	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	indicate	no
O	O	that	no
O	O	they	no
O	O	could	no
O	O	enhance	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	)	no
O	O	or	no
B-drug	O	CYP2D6	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	paroxetine	yes
O	O	)	no
O	O	can	no
O	O	inhibit	no
B-drug	B-drug	aripiprazole	yes
O	O	elimination	no
O	O	and	yes
O	O	cause	no
O	O	increased	no
O	O	blood	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	underlying	no
O	O	many	no
O	O	of	yes
O	O	these	no
O	O	events	no
O	O	is	yes
O	O	unknown	no
O	O	,	no
O	O	but	no
O	O	may	no
O	O	represent	no
O	O	increased	no
O	O	hypotension	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	therefore	no
O	O	necessary	no
O	O	to	no
O	O	be	no
O	O	well	no
O	O	acquainted	no
O	O	with	yes
O	O	the	no
O	O	clinical	no
O	O	and	yes
O	O	paraclinical	no
O	O	pattern	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	deficit	no
O	O	and	yes
O	O	to	no
O	O	discriminate	no
O	O	between	yes
B-drug	B-drug	magnesium	yes
O	O	deficiency	no
O	O	due	no
O	O	to	no
O	O	an	no
O	O	insufficient	no
B-drug	B-drug	magnesium	yes
O	O	intake	no
O	O	which	no
O	O	only	no
O	O	requires	no
O	O	oral	yes
O	O	physiological	no
O	O	supplementation	no
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	depletion	no
O	O	related	yes
O	O	to	no
O	O	a	yes
O	O	dysregulation	no
O	O	of	yes
O	O	the	no
O	O	control	no
O	O	mechanisms	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	status	no
O	O	which	no
O	O	requires	no
O	O	more	no
O	O	or	no
O	O	less	no
O	O	specific	no
O	O	regulation	no
O	O	of	yes
O	O	its	no
O	O	causal	no
O	O	dysregulation	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TRACLEER	yes
O	O	and	yes
B-drug	B-drug	glyburide	yes
O	O	is	yes
O	O	contraindicated	no
O	O	,	no
O	O	and	yes
O	O	alternative	no
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	Serum	yes
B-drug	B-drug	phenytoin	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	by	no
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	Pharmacologic	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	effects	no
O	O	in	yes
O	O	prolonging	no
O	O	AV	no
O	O	conduction	no
O	O	when	no
O	O	using	no
B-group	B-group	beta-blockers	no
O	O	or	no
B-group	B-group	digitalis	yes
O	O	concomitantly	no
O	O	with	yes
B-brand	B-brand	Tiazac	yes
O	O	.	no

B-drug	B-drug	Amprenavir	yes

O	O	No	yes
O	O	abortifacient	no
O	O	or	no
O	O	teratogenic	no
O	O	effects	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	cynomolgus	no
O	O	monkeys	no
O	O	following	no
O	O	intravenous	yes
O	O	bolus	no
O	O	injections	no
O	O	of	yes
B-brand	B-brand	AMEVIVE	no
O	O	administered	no
O	O	weekly	yes
O	O	during	no
O	O	the	no
O	O	period	no
O	O	of	yes
O	O	organogenesis	no
O	O	to	no
O	O	gestation	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	and	yes
B-drug	B-drug	probenecid	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	(	no
O	O	54	no
O	O	)	no
O	O	microtubules	no
O	O	per	no
O	O	axon	no
O	O	.	no

O	O	Primary	no
O	O	and	yes
O	O	secondary	yes
B-drug	B-drug	magnesium	yes
O	O	deficiencies	no
O	O	constitute	no
O	O	the	no
O	O	sole	no
O	O	indication	no
O	O	of	yes
O	O	physiological	no
O	O	oral	yes
B-drug	B-drug	magnesium	yes
O	O	therapy	no
O	O	.	no

B-group	B-group	Antacid	no
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	an	no
B-drug	B-drug	aluminum	yes
O	O	hydroxide-	no
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	hydroxide-containing	no
B-group	B-group	antacid	no
O	O	(	no
B-brand	B-brand	Maalox	no
O	O	)	no
O	O	*	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	capecitabine	yes
O	O	was	no
O	O	investigated	no
O	O	in	yes
O	O	12	yes
O	O	cancer	no
O	O	patients	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	,	no
B-drug	B-drug	kaolin-pectin	no
O	O	,	no
B-drug	B-drug	sulfasalazine	yes
O	O	,	no
B-drug	B-drug	neomycin	yes
O	O	,	no
B-drug	B-drug	cholestyramine	yes
O	O	,	no
O	O	certain	no
B-group	O	anticancer	no
I-group	O	drugs	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	metoclopramide	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	intestinal	no
B-drug	B-drug	digoxin	yes
O	O	absorption	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	unexpectedly	no
O	O	low	yes
O	O	serum	yes
O	O	concentrations	no
O	O	.	no

O	O	Close	no
O	O	supervision	no
O	O	and	yes
O	O	careful	no
O	O	adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	are	no
O	O	required	no
O	O	when	no
O	O	this	no
O	O	drug	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	anticholinergic	no
O	O	or	no
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	.	no

B-drug	B-drug	Acetaminophen	yes
O	O	diminished	no
O	O	the	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	to	no
O	O	human	yes
O	O	serum	yes
O	O	by	no
O	O	a	yes
O	O	net	no
O	O	change	no
O	O	of	yes
O	O	5.7	no
O	O	%	no
O	O	(	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	free	yes
O	O	drug	yes
O	O	fraction	yes
O	O	[	no
O	O	FDF	no
O	O	]	no
O	O	,	no
O	O	11.0	no
O	O	%	no
O	O	)	no
O	O	at	yes
O	O	662	no
O	O	micromol/L	no
O	O	and	yes
O	O	by	no
O	O	a	yes
O	O	net	no
O	O	change	no
O	O	of	yes
O	O	7.1	no
O	O	%	no
O	O	(	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	FDF	no
O	O	,	no
O	O	13.7	no
O	O	%	no
O	O	)	no
O	O	at	yes
O	O	1324	no
O	O	micromol/L	no
O	O	.	no

O	O	This	no
O	O	paper	no
O	O	attempts	no
O	O	to	no
O	O	provide	no
O	O	a	yes
O	O	basis	no
O	O	for	yes
O	O	the	no
O	O	understanding	no
O	O	and	yes
O	O	identifications	no
O	O	of	yes
O	O	important	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-drug	B-drug	etofibrate	yes
O	O	upon	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	chylomicron-like	no
O	O	emulsions	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	.	no

O	O	Hypersensitivity	no
O	O	Reactions	no
O	O	:	no
O	O	Patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	severe	no
O	O	hypersensitivity	no
O	O	reactions	no
O	O	to	no
O	O	products	no
O	O	containing	yes
O	O	Cremophor	no
O	O	EL	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	cyclosporin	yes
O	O	for	yes
O	O	injection	yes
O	O	concentrate	yes
O	O	and	yes
B-drug	B-drug	teniposide	yes
O	O	for	yes
O	O	injection	yes
O	O	concentrate	yes
O	O	)	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	TAXOL	yes
O	O	.	no

O	O	Rare	no
O	O	reports	no
O	O	of	yes
O	O	more	no
O	O	severe	no
O	O	events	no
O	O	such	no
O	O	as	yes
O	O	phlebitis	no
O	O	,	no
O	O	cellulitis	no
O	O	,	no
O	O	induration	no
O	O	,	no
O	O	skin	yes
O	O	exfoliation	no
O	O	,	no
O	O	necrosis	yes
O	O	,	no
O	O	and	yes
O	O	fibrosis	no
O	O	have	no
O	O	been	no
O	O	received	no
O	O	as	yes
O	O	part	no
O	O	of	yes
O	O	the	no
O	O	continuing	no
O	O	surveillance	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	safety	no
O	O	.	no

B-drug	B-drug	Cocaine	yes
O	O	sometimes	no
O	O	proves	no
O	O	to	no
O	O	be	no
O	O	fatal	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug_n	B-drug_n	heroin	yes
O	O	.	no

O	O	Nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	and	yes
B-group	B-group	cephalosporin	yes
I-group	I-group	antibiotics	no
O	O	.	no

O	O	Of	yes
O	O	the	no
O	O	229	no
O	O	patients	no
O	O	who	no
O	O	had	no
B-group	B-group	potassium	yes
I-group	I-group	depleting	no
I-group	I-group	diuretics	no
O	O	added	no
O	O	to	no
O	O	their	no
O	O	concomitant	no
O	O	medications	no
O	O	in	yes
O	O	the	no
O	O	DIAMOND	no
O	O	trials	no
O	O	,	no
O	O	the	no
O	O	patients	no
O	O	on	no
B-brand	B-brand	TIKOSYN	yes
O	O	had	no
O	O	a	yes
O	O	non-significantly	no
O	O	reduced	yes
O	O	relative	no
O	O	risk	no
O	O	for	yes
O	O	death	no
O	O	of	yes
O	O	0.68	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	0.376	no
O	O	,	no
O	O	1.230	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Azlocillin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	amikacin	yes
O	O	,	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
B-drug	B-drug	gentamicin	yes
O	O	,	no
B-drug	B-drug	netilmicin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	tobramycin	yes
O	O	.	no

B-drug	B-drug	Itraconazole	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	when	no
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	Moreover	no
O	O	,	no
O	O	its	no
O	O	activity	yes
O	O	was	no
O	O	enhanced	no
O	O	when	no
O	O	it	no
O	O	was	no
O	O	combined	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	azithromycin	yes
O	O	or	no
B-drug	B-drug	minocycline	yes
O	O	with	yes
O	O	90	yes
O	O	%	no
O	O	parasite	no
O	O	reduction	yes
O	O	at	yes
O	O	the	no
O	O	highest	no
O	O	concentration	no
O	O	tested	no
O	O	.	no

O	O	Whether	no
O	O	abnormal	no
O	O	topoisomerase	no
O	O	quantity	no
O	O	and	yes
O	O	specific	no
O	O	activity	yes
O	O	are	no
O	O	associated	no
O	O	with	yes
O	O	resistance	no
O	O	or	no
O	O	sensitivity	no
O	O	to	no
O	O	topoisomerase-targeted	no
O	O	chemotherapy	no
O	O	in	yes
O	O	the	no
O	O	clinic	no
O	O	is	yes
O	O	now	no
O	O	being	no
O	O	studied	no
O	O	.	no

B-group	B-group	Cardiac	no
I-group	I-group	glycosides	yes

O	O	The	no
O	O	color	no
O	O	reverses	no
O	O	when	no
O	O	the	no
O	O	test	yes
O	O	sample	no
O	O	is	yes
O	O	acidified	no
O	O	in	yes
O	O	vitro	no
O	O	to	no
O	O	a	yes
O	O	pH	yes
O	O	below	no
O	O	4	yes
O	O	.	no

B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	and	yes
O	O	many	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	many	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
B-drug	B-drug	propafenone	yes
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	or	no
B-drug	B-drug	Verapamil	yes
O	O	:	no
O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	myopathy/rhabdomyolysis	no
O	O	is	yes
O	O	increased	no
O	O	when	no
O	O	either	no
B-drug	B-drug	amiodarone	yes
O	O	or	no
B-drug	B-drug	verapamil	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
O	O	closely	no
O	O	related	yes
O	O	member	yes
O	O	of	yes
O	O	the	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitor	yes
I-group	I-group	class	no
O	O	(	no
O	O	see	no
O	O	WARNINGS	no
O	O	,	no
O	O	Myopathy/Rhabdomyolysis	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Diclofenac	yes
O	O	decreases	no
B-drug	B-drug	lithium	yes
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	increases	no
B-drug	B-drug	lithium	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	Pretreatment	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	reduces	no
O	O	both	no
O	O	the	no
O	O	natriuresis	no
O	O	and	yes
O	O	hyperreninemia	no
O	O	produced	no
O	O	by	no
B-drug	B-drug	bumetanide	yes
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	was	no
O	O	pharmacodynamic	no
O	O	;	no

O	O	Dose	no
O	O	of	yes
B-group	B-group	AED	no
O	O	(	no
O	O	mg/day	no
O	O	)	no

O	O	Concomitantly	no
O	O	administered	no
B-drug_n	B-drug_n	iron-fortified	no
O	O	infant	no
O	O	formula	yes
O	O	(	no
O	O	2.2	no
O	O	mg	yes
O	O	elemental	yes
B-drug_n	B-drug_n	iron/6	no
O	O	oz	no
O	O	)	no
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	cefdinir	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	No	yes
O	O	dosage	no
O	O	adjustment	no
O	O	is	yes
O	O	required	no
O	O	for	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
O	O	drugs	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	that	no
O	O	could	no
O	O	increase	no
O	O	or	no
O	O	prolong	no
O	O	both	no
O	O	therapeutic	no
O	O	and	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

B-drug_n	B-drug_n	Buforin	no
I-drug_n	I-drug_n	II	yes
O	O	may	no
O	O	be	no
O	O	active	no
O	O	in	yes
O	O	inhibiting	no
O	O	Cryptosporidium	no
O	O	parvum	no
O	O	growth	yes
O	O	in	yes
O	O	vitro	no
O	O	upon	no
O	O	combination	yes
O	O	with	yes
O	O	either	no
B-drug	B-drug	azithromycin	yes
O	O	or	no
B-drug	B-drug	minocycline	yes
O	O	.	no

B-drug	B-drug	Lovastatin	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	but	no
O	O	has	no
O	O	no	yes
O	O	CYP3A4	no
O	O	inhibitory	yes
O	O	activity	yes
O	O	;	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-drug	B-drug	amphetamine	yes
O	O	and	yes
B-drug	B-drug	cocaine	yes
O	O	on	no
O	O	bar-press	no
O	O	behavior	no
O	O	in	yes
O	O	normal	yes
O	O	and	yes
O	O	genetically	no
O	O	nervous	no
O	O	dogs	no
O	O	.	no

B-drug	B-drug	Hydrocodone	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	Neurontin	yes
O	O	(	no
O	O	125	yes
O	O	to	no
O	O	500	yes
O	O	mg	yes
O	O	;	no

O	O	There	no
O	O	are	no
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	steps	no
O	O	physicians	no
O	O	can	no
O	O	take	no
O	O	to	no
O	O	ensure	no
O	O	that	no
O	O	their	no
O	O	patients	no
O	O	are	no
O	O	not	no
O	O	being	no
O	O	undertreated	no
O	O	.	no

B-group	B-group	Digitalis	yes
O	O	:	no
B-group	B-group	Thyroid	yes
I-group	I-group	preparations	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	toxic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	digitalis	yes
O	O	.	no

O	O	Studies	no
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	diuretics	no
O	O	indicate	no
O	O	that	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
O	O	can	no
O	O	be	no
O	O	reduced	yes
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	given	no
O	O	with	yes
O	O	a	yes
B-group	B-group	diuretic	no
O	O	.	no

O	O	Monitoring	no
O	O	of	yes
O	O	liver	yes
O	O	enzymes	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
B-brand	B-brand	SUSTIVA	yes
O	O	is	yes
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	.	no

O	O	Severe	no
O	O	allergic	no
O	O	reactions	no
O	O	including	no
O	O	anaphylaxis	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	exposed	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	either	no
O	O	by	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	or	no
O	O	accidental	no
O	O	contact	no
O	O	,	no
O	O	and	yes
O	O	with	yes
O	O	diagnostic	yes
O	O	or	no
O	O	therapeutic	no
O	O	agents	yes
O	O	while	no
O	O	receiving	no
B-group	B-group	beta-blockers	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-brand	B-brand	Sensipar	yes
O	O	is	yes
O	O	metabolized	no
O	O	in	yes
O	O	part	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hrs	no
O	O	)	no

O	O	In	yes
O	O	the	no
O	O	present	no
O	O	study	no
O	O	,	no
O	O	evoked	no
O	O	potentials	no
O	O	were	no
O	O	recorded	no
O	O	at	yes
O	O	5	yes
O	O	,	no
O	O	20	yes
O	O	,	no
O	O	and	yes
O	O	40	yes
O	O	min	no
O	O	following	no
O	O	IP	no
O	O	injections	no
O	O	of	yes
O	O	saline	yes
O	O	,	no
B-drug	B-drug	ethanol	yes
O	O	(	no
O	O	2.0	no
O	O	g/kg	no
O	O	)	no
O	O	,	no
B-drug	B-drug	physostigmine	yes
O	O	(	no
O	O	0.6	no
O	O	mg/kg	no
O	O	)	no
O	O	or	no
B-drug	B-drug	atropine	yes
O	O	(	no
O	O	15.0	no
O	O	mg/kg	no
O	O	)	no
O	O	on	no
O	O	separate	no
O	O	days	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	little	no
O	O	if	no
O	O	any	no
O	O	clinically	no
O	O	significant	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	Acarbose	yes
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	.	no

O	O	Edema	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	receiving	no
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-group	B-group	dihydropyridine	no
I-group	I-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	.	no

O	O	Thyroid	yes
O	O	hormonal	no
O	O	replacement	no
O	O	increases	no
O	O	metabolic	no
O	O	rate	no
O	O	,	no
O	O	which	no
O	O	requires	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-group	B-group	digitalis	yes
O	O	dosage	no
O	O	.	no

O	O	No	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

B-group	B-group	Antihypertensives	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihypertensives	no
O	O	.	no

O	O	reliable	no
O	O	estimates	no
O	O	of	yes
O	O	the	no
O	O	prevalence	no
O	O	of	yes
O	O	reduced	yes
O	O	P450	no
O	O	2D6	no
O	O	isozyme	no
O	O	activity	yes
O	O	among	no
O	O	Asian	yes
O	O	,	no
O	O	African	no
O	O	and	yes
O	O	other	no
O	O	populations	no
O	O	are	no
O	O	not	no
O	O	yet	no
O	O	available	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	if	no
B-brand	B-brand	LEUSTATIN	yes
O	O	Injection	yes
O	O	is	yes
O	O	administered	no
O	O	before	no
O	O	,	no
O	O	after	no
O	O	,	no
O	O	or	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	cause	no
O	O	immunosuppression	no
O	O	or	no
O	O	myelosuppression	no
O	O	.	no

O	O	As	yes
O	O	a	yes
O	O	false-negative	no
O	O	result	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	the	no
O	O	ferricyanide	no
O	O	test	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	either	no
O	O	the	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	or	no
O	O	hexokinase	no
O	O	method	yes
O	O	be	no
O	O	used	no
O	O	to	no
O	O	determine	no
O	O	blood/plasma	no
O	O	glucose	yes
O	O	levels	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	hydralazine	yes
O	O	,	no
B-drug	B-drug	sulfinpyrazone	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	.	no

O	O	The	no
O	O	high	yes
O	O	acquisition	no
O	O	cost	no
O	O	of	yes
B-drug	B-drug	olanzapine	yes
O	O	is	yes
O	O	offset	no
O	O	by	no
O	O	reductions	no
O	O	in	yes
O	O	other	no
O	O	treatment	no
O	O	costs	no
O	O	(	no
O	O	inpatient	no
O	O	and/or	no
O	O	outpatient	no
O	O	services	no
O	O	)	no
O	O	of	yes
O	O	schizophrenia	no
O	O	.	no

O	O	The	no
O	O	daily	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	ENABLEX	yes
O	O	should	no
O	O	not	no
O	O	exceed	no
O	O	7.5	yes
O	O	mg	yes
O	O	when	no
O	O	coadministered	no
O	O	with	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	and	yes
O	O	nefazadone	no
O	O	)	no
O	O	.	no

O	O	Treatment	no
O	O	of	yes
O	O	the	no
O	O	glands	no
O	O	with	yes
B-drug_n	B-drug_n	cytochalasin	no
I-drug_n	I-drug_n	D	yes
O	O	redistributed	no
O	O	type	yes
O	O	3	yes
O	O	inositol	yes
O	O	1,4,5-trisphosphate	yes
O	O	receptor	yes
O	O	(	no
O	O	the	no
O	O	major	no
O	O	subtype	no
O	O	in	yes
O	O	the	no
O	O	parietal	no
O	O	cell	yes
O	O	)	no
O	O	from	no
O	O	the	no
O	O	fraction	yes
O	O	containing	yes
O	O	membranes	no
O	O	of	yes
O	O	large	no
O	O	size	no
O	O	to	no
O	O	the	no
O	O	microsomal	no
O	O	fraction	yes
O	O	,	no
O	O	suggesting	no
O	O	a	yes
O	O	dissociation	no
O	O	of	yes
O	O	the	no
O	O	store	no
O	O	from	no
O	O	the	no
O	O	plasma	yes
O	O	membrane	yes
O	O	.	no

B-group	B-group	diuretics*	no
O	O	;	no

O	O	It	no
O	O	is	yes
O	O	presently	no
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	these	no
O	O	same	yes
O	O	drug	yes
O	O	interactions	no
O	O	occur	no
O	O	with	yes
B-drug	B-drug	dirithromycin	yes
O	O	.	no

B-drug	B-drug	Doxazosin	yes
I-drug	I-drug	mesylate	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	without	no
O	O	any	no
O	O	evidence	no
O	O	of	yes
O	O	an	no
O	O	adverse	no
O	O	drug	yes
O	O	interaction	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	,	no
B-group	B-group	beta-blocking	no
I-group	O	agents	yes
O	O	,	no
O	O	and	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Viable	no
O	O	counts	no
O	O	for	yes
O	O	type	yes
O	O	culture	no
O	O	E	yes
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	drugs	no
O	O	from	no
O	O	these	no
O	O	groups	no
O	O	is	yes
O	O	decreasing	no
O	O	according	no
O	O	to	no
O	O	a	yes
O	O	survey	no
O	O	of	yes
O	O	200	yes
O	O	hospital	no
O	O	medical	yes
O	O	records	no
O	O	.	no

O	O	Nephrotoxicity	no
O	O	associated	no
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	may	no
O	O	also	no
O	O	be	no
O	O	enhanced	no
O	O	.	no

O	O	Pretreatment	no
O	O	of	yes
O	O	megakaryocytes	no
O	O	with	yes
O	O	extracellular	no
B-drug_n	B-drug_n	RR	no
O	O	(	no
O	O	50	yes
O	O	microM	no
O	O	)	no
O	O	also	no
O	O	inhibited	no
B-drug_n	B-drug_n	InsP	no
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	3	yes
I-drug_n	I-drug_n	)	no
O	O	-induced	no
O	O	responses	no
O	O	.	no

B-group	B-group	Dopamine	yes
I-group	I-group	Antagonists	no
O	O	:	no
O	O	Since	no
B-drug	B-drug	apomorphine	yes
O	O	is	yes
O	O	a	yes
B-group	B-group	dopamine	yes
I-group	I-group	agonist	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	possible	no
O	O	that	no
B-group	B-group	dopamine	yes
I-group	I-group	antagonists	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	the	no
B-group	B-group	neuroleptics	no
O	O	(	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	butyrophenones	no
O	O	,	no
B-group	B-group	thioxanthenes	no
O	O	)	no
O	O	or	no
B-drug	B-drug	metoclopramide	yes
O	O	,	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
B-brand	B-brand	APOKYN	yes
O	O	.	no

O	O	If	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	needed	no
O	O	,	no
O	O	their	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reassessed	no
O	O	and	yes
O	O	,	no
O	O	where	no
O	O	appropriate	no
O	O	,	no
O	O	plasma	yes
O	O	concentration	no
O	O	measured	no
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	on	no
O	O	Day	no
O	O	15	yes
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	observed	no
O	O	at	yes
O	O	baseline	no
O	O	.	no

O	O	5	yes
O	O	.	no

O	O	Appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	arenot	no
O	O	established	no
O	O	,	no
O	O	but	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	thedosage	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	They	no
O	O	are	no
O	O	part	no
O	O	of	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	organ	no
O	O	transplants	no
O	O	,	no
O	O	malignancy	no
O	O	,	no
O	O	and	yes
O	O	increasingly	no
O	O	those	no
O	O	with	yes
O	O	conditions	no
O	O	such	no
O	O	as	yes
O	O	psoriasis	no
O	O	,	no
O	O	rheumatoid	no
O	O	arthritis	no
O	O	,	no
O	O	and	yes
O	O	liver	yes
O	O	and	yes
O	O	bowel	yes
O	O	disease	no
O	O	in	yes
O	O	which	no
O	O	inflammation	no
O	O	is	yes
O	O	an	no
O	O	aetiological	no
O	O	factor	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-drug	B-drug	Etodolac	yes
O	O	has	no
O	O	no	yes
O	O	apparent	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	HIVID	yes
O	O	with	yes
B-drug	B-drug	didanosine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Under	no
O	O	similar	no
O	O	conditions	no
O	O	,	no
B-drug	B-drug	bexarotene	yes
O	O	concentrations	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	atorvastatin	yes
O	O	administration	no
O	O	.	no

O	O	Increased	no
O	O	stability	no
O	O	of	yes
O	O	nucleophosmin/B23	no
O	O	in	yes
O	O	anti-apoptotic	no
O	O	effect	no
O	O	of	yes
O	O	ras	yes
O	O	during	no
O	O	serum	yes
O	O	deprivation	no
O	O	.	no

B-group	B-group	H2	no
I-group	I-group	Receptor	yes
I-group	I-group	Antagonists	no
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	coadministration	no
O	O	leads	no
O	O	to	no
O	O	an	no
O	O	increased	no
O	O	peak	no
O	O	plasma	yes
O	O	concentration	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	cisapride	yes
O	O	absorption	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ranitidine	yes
O	O	.	no

B-drug	B-drug	Pentamidine	yes
O	O	may	no
O	O	cause	no
O	O	hypoglycemia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	sometimes	no
O	O	be	no
O	O	followed	no
O	O	by	no
O	O	hyperglycemia	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	with	yes
B-brand	B-brand	CELEBREX	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increased	no
O	O	rate	no
O	O	of	yes
O	O	GI	no
O	O	ulceration	no
O	O	or	no
O	O	other	no
O	O	complications	no
O	O	,	no
O	O	compared	no
O	O	to	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	CELEBREX	yes
O	O	alone	no
O	O	.	no

O	O	Another	no
O	O	investigator	no
O	O	found	no
O	O	no	yes
O	O	increase	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	in	yes
O	O	13	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	.	no

O	O	If	no
O	O	additional	no
B-group	B-group	adrenergic	no
I-group	I-group	drugs	no
O	O	are	no
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	by	no
O	O	any	no
O	O	route	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	because	no
O	O	the	no
O	O	pharmacologically	no
O	O	predictable	no
O	O	sympathetic	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	BROVANA	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	this	no
O	O	reported	no
O	O	activity	yes
O	O	,	no
O	O	they	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-brand	B-brand	Coly-Mycin	yes
I-brand	I-brand	M	yes
O	O	Parenteral	no
O	O	except	no
O	O	with	yes
O	O	the	no
O	O	greatest	no
O	O	caution	no
O	O	.	no

O	O	No	yes
O	O	changes	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	anticoagulation	no
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	include	no
O	O	some	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	enzyme	no
O	O	(	no
B-drug	B-drug	quinidine	yes
O	O	;	no

O	O	However	no
O	O	,	no
O	O	because	no
O	O	higher	no
O	O	doses	no
O	O	(	no
O	O	up	no
O	O	to	no
O	O	360	no
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	omeprazole	yes
O	O	are	no
O	O	tolerated	no
O	O	in	yes
O	O	Zollinger-Ellison	no
O	O	(	no
O	O	ZE	no
O	O	)	no
O	O	patients	no
O	O	,	no
O	O	no	yes
O	O	dose	no
O	O	adjustment	no
O	O	for	yes
B-drug	B-drug	omeprazole	yes
O	O	is	yes
O	O	recommended	no
O	O	at	yes
O	O	current	no
O	O	doses	no
O	O	.	no

O	O	After	no
O	O	14	yes
O	O	days	no
O	O	of	yes
O	O	co-administration	no
O	O	,	no
O	O	mean	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	,	no
B-drug_n	B-drug_n	N-desmethylclozapine	no
O	O	and	yes
B-drug_n	B-drug_n	clozapine	yes
I-drug_n	I-drug_n	N-oxide	yes
O	O	,	no
O	O	were	no
O	O	elevated	no
O	O	with	yes
B-drug	B-drug	fluvoxamine	yes
O	O	by	no
O	O	about	no
O	O	three-fold	no
O	O	compared	no
O	O	to	no
O	O	baseline	no
O	O	concentrations	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	involving	no
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
B-brand	B-brand	TAMBOCOR	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	concurrently	no
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	flecainide	yes
O	O	levels	no
O	O	were	no
O	O	increased	no
O	O	about	no
O	O	20	yes
O	O	%	no
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	levels	no
O	O	were	no
O	O	increased	no
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	compared	no
O	O	to	no
O	O	control	no
O	O	values	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	its	no
O	O	lack	no
O	O	of	yes
O	O	anti-platelet	no
O	O	effect	no
B-drug	B-drug	valdecoxib	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substitute	no
O	O	for	yes
B-brand	B-brand	aspirin	yes
O	O	for	yes
O	O	cardiovascular	no
O	O	prophylaxis	no
O	O	.	no

O	O	The	no
O	O	management	no
O	O	of	yes
O	O	infection	no
O	O	is	yes
O	O	dealt	no
O	O	with	yes
O	O	as	yes
O	O	a	yes
O	O	separate	no
O	O	section	no
O	O	.	no

B-group	B-group	diuretics*	no
O	O	;	no

O	O	Patients	no
O	O	should	no
O	O	be	no
O	O	advised	no
O	O	against	yes
O	O	the	no
O	O	simultaneous	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
O	O	cautioned	no
O	O	that	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	.	no

O	O	OTHER	no
O	O	CONCOMITANT	no
O	O	THERAPY	no
O	O	:	no
O	O	Although	no
O	O	specific	no
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	not	no
O	O	performed	no
O	O	,	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	was	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	angiotensin-	no
I-group	I-group	converting	no
I-group	I-group	enzyme	no
I-group	I-group	(	no
I-group	I-group	ACE	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	betablockers	no
O	O	,	no
B-group	B-group	calcium-channel	no
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
O	O	and	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	Known	no
O	O	drug	yes
O	O	interactions	no
O	O	include	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	drugs	no
O	O	possessing	no
O	O	nephrotoxic	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	aminoglycosides	no
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	)	no
O	O	,	no
O	O	myelotoxic	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	B-group	cytotoxic	yes
O	O	chemotherapy	no
O	O	)	no
O	O	,	no
O	O	cardiotoxic	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	)	no
O	O	or	no
O	O	hepatotoxic	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
B-brand	B-drug	asparaginase	yes
O	O	)	no
O	O	effects	no
O	O	with	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	may	no
O	O	increase	no
O	O	toxicity	no
O	O	in	yes
O	O	these	no
O	O	organ	no
O	O	systems	no
O	O	.	no

B-drug_n	B-drug_n	PCP	yes
O	O	produced	no
O	O	distinctive	no
O	O	effects	no
O	O	in	yes
O	O	each	no
O	O	task	no
O	O	:	no
O	O	it	no
O	O	substituted	yes
O	O	for	yes
O	O	the	no
O	O	training	no
O	O	dose	no
O	O	in	yes
B-drug_n	B-drug_n	PCP	yes
O	O	discrimination	no
O	O	and	yes
O	O	it	no
O	O	increased	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	responses	no
O	O	with	yes
O	O	short	no
O	O	(	no
O	O	<	no
O	O	3	yes
O	O	s	yes
O	O	)	no
O	O	interresponse	no
O	O	times	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	increasing	no
O	O	overall	no
O	O	response	no
O	O	rates	no
O	O	in	yes
O	O	the	no
O	O	DRL	no
O	O	schedule	no
O	O	.	no

B-drug	B-drug	Eprosartan	yes
O	O	(	no
O	O	up	no
O	O	to	no
O	O	400	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	or	no
O	O	800	no
O	O	mg	yes
O	O	q.d	no
O	O	.	no
O	O	)	no
O	O	doses	no
O	O	have	no
O	O	been	no
O	O	safely	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretic	no
O	O	(	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	)	no
O	O	.	no

O	O	clinical	no
O	O	significance	no
O	O	unknown	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	candesartan	yes
O	O	is	yes
O	O	not	no
O	O	significantly	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	and	yes
O	O	at	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	has	no
O	O	no	yes
O	O	effects	no
O	O	on	no
O	O	P450	no
O	O	enzymes	yes
O	O	,	no
O	O	interactions	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	or	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	those	no
O	O	enzymes	yes
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
B-drug_n	B-drug_n	descarboethoxyloratadine	yes
O	O	,	no
O	O	an	no
O	O	active	no
O	O	metabolite	yes
O	O	,	no
O	O	averaged	no
O	O	155	no
O	O	%	no
O	O	(	no
O	O	27	yes
O	O	S.D	no
O	O	.	no
O	O	)	no
O	O	and	yes
O	O	141	no
O	O	%	no
O	O	(	no
O	O	35	yes
O	O	S.D	no
O	O	.	no
O	O	)	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	difference	no
O	O	was	no
O	O	found	no
O	O	between	yes
O	O	the	no
O	O	mean	no
O	O	values	no
O	O	of	yes
O	O	the	no
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	cloxacillin	yes
O	O	with	yes
O	O	and	yes
O	O	without	no
B-drug	B-drug	probenecid	yes
O	O	(	no
O	O	13.0	no
O	O	and	yes
O	O	12.6	no
O	O	liters	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	.	no

O	O	Toxicity	no
O	O	of	yes
O	O	cadmium	no
O	O	and	yes
B-drug	B-drug	zinc	yes
O	O	to	no
O	O	miracidia	no
O	O	of	yes
O	O	Schistosoma	no
O	O	mansoni	no
O	O	.	no

B-drug	B-drug	Rifampicin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	a	yes
O	O	six-day	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	rifampicin	yes
O	O	at	yes
O	O	600	yes
O	O	mg/day	no
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	single	yes
O	O	5	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	isradipine	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
B-drug	B-drug	isradipine	yes
O	O	levels	no
O	O	to	no
O	O	below	no
O	O	detectable	no
O	O	limits	no
O	O	.	no

O	O	and	yes
O	O	,	no
O	O	rarely	no
O	O	,	no
O	O	euphoria	no
O	O	,	no
O	O	excitement	no
O	O	,	no
O	O	depression	no
O	O	,	no
O	O	hallucinations	no
O	O	,	no
O	O	paresthesia	no
O	O	,	no
O	O	muscle	no
O	O	pain	yes
O	O	,	no
O	O	tinnitus	no
O	O	,	no
O	O	slurred	no
O	O	speech	no
O	O	,	no
O	O	coordination	no
O	O	disorder	no
O	O	,	no
O	O	tremor	no
O	O	,	no
O	O	rigidity	no
O	O	,	no
O	O	dystonia	no
O	O	,	no
O	O	ataxia	no
O	O	,	no
O	O	blurred	no
O	O	vision	no
O	O	,	no
O	O	nystagmus	no
O	O	,	no
O	O	strabismus	no
O	O	,	no
O	O	miosis	no
O	O	,	no
O	O	mydriasis	no
O	O	,	no
O	O	diplopia	no
O	O	,	no
O	O	dysarthria	no
O	O	,	no
O	O	epileptic	no
O	O	seizure	no
O	O	.	no

O	O	Cholecystokinin	yes
O	O	octapeptide	yes
O	O	is	yes
O	O	a	yes
O	O	necessary	no
O	O	factor	yes
O	O	for	yes
O	O	realization	no
O	O	of	yes
O	O	this	no
O	O	action	no
O	O	of	yes
B-group	B-group	neuroleptics	no
O	O	.	no

O	O	Menstrual	no
O	O	cycle	no
O	O	irregularities	no
O	O	were	no
O	O	accompanied	no
O	O	by	no
O	O	both	no
O	O	a	yes
O	O	decrease	no
O	O	and	yes
O	O	delay	no
O	O	in	yes
O	O	the	no
O	O	peak	no
O	O	17b	no
O	O	-estradiol	no
O	O	and	yes
O	O	progesterone	yes
O	O	levels	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	to	no
O	O	female	no
O	O	monkeys	no
O	O	.	no

B-group	B-group	HMG-CoA	no
I-group	I-group	Reductase	no
I-group	I-group	Inhibitors	no
O	O	:	no
B-group	B-group	Inhibitors	no
I-group	I-group	of	yes
I-group	I-group	HMG-CoA	no
I-group	I-group	reductase	no
O	O	may	no
O	O	cause	no
O	O	myopathy	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	manifested	no
O	O	as	yes
O	O	muscle	no
O	O	pain	yes
O	O	or	no
O	O	weakness	no
O	O	associated	no
O	O	with	yes
O	O	elevated	no
O	O	levels	no
O	O	of	yes
O	O	CPK	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	effects	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	beta-agonists	no
O	O	with	yes
B-group	B-group	non-potassium	no
I-group	I-group	sparing	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Since	no
O	O	animal	no
O	O	studies	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	barbiturates	no
O	O	may	no
O	O	be	no
O	O	prolonged	no
O	O	by	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	chlorpropamide	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	should	no
O	O	be	no
O	O	employed	no
O	O	with	yes
O	O	caution	no
O	O	.	no

B-group	B-group	Antihistamines	no
O	O	may	no
O	O	have	no
O	O	additive	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	and	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	antianxiety	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Upon	no
O	O	administration	no
O	O	of	yes
O	O	10	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	with	yes
O	O	800	no
O	O	mg	yes
O	O	TID	no
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	were	no
O	O	reduced	yes
O	O	by	no
O	O	40	yes
O	O	%	no
O	O	and	yes
O	O	30	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Interaction	no
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

B-brand	B-brand	Anafranil	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Respiratory	no
O	O	depression	no
O	O	,	no
O	O	hypotension	no
O	O	,	no
O	O	and	yes
O	O	profound	no
O	O	sedation	no
O	O	or	no
O	O	coma	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	and	yes
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	adjusted	yes
O	O	as	yes
O	O	required	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	oral	yes
O	O	administration	no
O	O	of	yes
B-drug_n	B-drug_n	dmPGE2	no
O	O	induces	no
O	O	a	yes
O	O	more	no
O	O	pronounced	no
O	O	secretory	no
O	O	diarrhea	no
O	O	in	yes
O	O	cecectomized	no
O	O	than	no
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	,	no
O	O	probably	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	lack	no
O	O	of	yes
O	O	the	no
O	O	reservoir	no
O	O	function	no
O	O	of	yes
O	O	the	no
O	O	cecum	no
O	O	in	yes
O	O	the	no
O	O	operated	no
O	O	animals	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	B-drug	CYP3A4	no
O	O	inhibitors	no
O	O	are	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

O	O	The	no
O	O	actions	no
O	O	of	yes
O	O	the	no
B-group	B-group	benzodiazepines	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	or	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-drug	B-drug	Erythromycin	yes
O	O	on	no
B-brand	B-brand	Felbatol	yes
O	O	The	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	(	no
O	O	1000	yes
O	O	mg/day	no
O	O	)	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	of	yes
O	O	Cmax	no
O	O	,	no
O	O	Cmin	no
O	O	,	no
O	O	AUC	no
O	O	,	no
O	O	CI/kg	no
O	O	or	no
O	O	tmax	no
O	O	at	yes
B-drug	B-drug	felbamate	yes
O	O	daily	no
O	O	doses	no
O	O	of	yes
O	O	3000	no
O	O	or	no
O	O	3600	no
O	O	mg/day	no
O	O	in	yes
O	O	10	yes
O	O	otherwise	no
O	O	healthy	no
O	O	subjects	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	Small	no
O	O	differences	no
O	O	in	yes
O	O	sensitivity	no
O	O	to	no
O	O	chemotherapy	no
O	O	can	no
O	O	have	no
O	O	a	yes
O	O	dramatic	no
O	O	effect	no
O	O	on	no
O	O	cure	no
O	O	rates	no
O	O	,	no
O	O	and	yes
O	O	therefore	no
O	O	subtle	no
O	O	cell	yes
O	O	type-specific	no
O	O	differences	no
O	O	may	no
O	O	be	no
O	O	important	no
O	O	determinants	no
O	O	of	yes
O	O	drug	yes
O	O	sensitivity	no
O	O	.	no

B-group	O	Potassium	yes
I-group	O	sparing	no
I-group	O	agents	yes
O	O	should	no
O	O	generally	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	heart	no
O	O	failure	no
O	O	who	no
O	O	are	no
O	O	receiving	no
B-brand	B-brand	PRINIVIL	yes
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-drug	B-drug	Valdecoxib	yes
O	I-drug	10	yes
O	I-drug	mg	yes
O	O	BID	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	a	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	plasma	yes
O	O	exposure	yes
O	O	or	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	Medications	no
O	O	that	no
O	O	interfere	no
O	O	with	yes
O	O	your	no
O	O	bodys	no
O	O	ability	no
O	O	to	no
O	O	use	no
O	O	folate	yes
O	O	may	no
O	O	also	no
O	O	increase	no
O	O	the	no
O	O	need	no
O	O	for	yes
O	O	this	no
O	B-group	vitamin	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	on	no
B-drug_n	B-drug_n	endotoxin-induced	no
O	O	changes	no
O	O	in	yes
O	O	steroid	no
O	O	hormone	yes
O	O	levels	no
O	O	and	yes
O	O	lethality	no
O	O	in	yes
O	O	male	no
O	O	rats	no
O	O	.	no

O	O	In	yes
B-drug	B-drug	noradrenaline-precontracted	no
O	O	arteries	no
O	O	from	no
O	O	dietary-obese	no
O	O	rats	no
O	O	,	no
O	O	responses	no
O	O	to	no
B-drug_n	B-drug_n	resveratrol	yes
O	O	were	no
O	O	not	no
O	O	attenuated	yes
O	O	by	no
O	O	endothelial	no
O	O	denudation	no
O	O	,	no
O	O	indicating	no
O	O	an	no
O	O	action	no
O	O	independent	no
O	O	of	yes
O	O	the	no
O	O	endothelium	no
O	O	.	no

B-drug	I-drug	Nelfinavir	yes
O	O	M8	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no

B-drug	B-drug	d-amphetamine	yes
O	O	with	yes
B-drug	B-drug	desipramine	yes
O	O	or	no
B-drug	B-drug	protriptyline	yes
O	O	and	yes
O	O	possibly	no
O	O	other	no
B-group	B-group	tricyclics	no
O	O	cause	no
O	O	striking	no
O	O	and	yes
O	O	sustained	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	d-amphetamine	yes
O	O	in	yes
O	O	the	no
O	O	brain	yes
O	O	;	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	to	no
O	O	investigate	no
O	O	the	no
O	O	potential	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	major	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2A6	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	and	yes
O	O	CYP3A4	no
O	O	)	no
O	O	that	no
O	O	mediate	no
O	O	drug	yes
O	O	and	yes
O	O	xenobiotic	no
O	O	metabolism	no
O	O	using	no
O	O	isoform	yes
O	O	selective	no
O	O	marker	no
O	O	substrates	no
O	O	and	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomal	no
O	O	preparations	no
O	O	.	no

O	O	Careful	no
O	O	supervision	no
O	O	of	yes
O	O	diabetic	no
O	O	patients	no
O	O	under	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	Soriatane	yes
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	clinically	no
O	O	significant	no
O	O	drug-drug	no
O	O	interactions	no
O	O	posed	no
O	O	by	no
B-drug	B-drug	dolasetron	yes
O	O	and	yes
B-drug_n	B-drug_n	hydrodolasetron	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	low	yes
O	O	for	yes
O	O	drugs	no
O	O	commonly	no
O	O	used	no
O	O	in	yes
O	O	chemotherapy	no
O	O	or	no
O	O	surgery	no
O	O	,	no
O	O	because	no
B-drug_n	B-drug_n	hydrodolasetron	no
O	O	is	yes
O	O	eliminated	no
O	O	by	no
O	O	multiple	no
O	O	routes	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concomitant	no
B-brand	B-brand	aspirin	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	During	no
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	hypoglycemia	no
O	O	and	yes
O	O	hyperglycemia	no
O	O	were	no
O	O	reported	no
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	hypoglycemics	no
O	O	.	no

O	O	use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
O	O	a	yes
O	O	5	yes
O	O	g	yes
O	O	bolus	no
O	O	followed	no
O	O	by	no
O	O	1	yes
O	O	to	no
O	O	1.25	yes
O	O	g/hr	no
O	O	should	no
O	O	achieve	no
O	O	and	yes
O	O	sustain	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	0.13	no
O	O	mg/mL	no
O	O	.	no

O	O	Dose	no
O	O	reduction	yes
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	to	no
O	O	600	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	a	yes
O	O	starting	no
O	O	daily	no
O	O	dose	no
O	O	of	yes
O	O	25	yes
O	O	mg	yes
O	O	of	yes
B-brand	B-brand	VIOXX	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	osteoarthritis	no
O	O	when	no
B-brand	B-brand	VIOXX	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
O	O	potent	no
O	O	inducers	no
O	O	of	yes
O	O	hepatic	no
O	O	metabolism	no
O	O	.	no

O	O	Influence	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	on	no
B-group	B-group	AED	no
O	O	Concentration	no
O	O	(	no
O	O	Mean	no
O	O	change	no
O	O	,	no
O	O	90	yes
O	O	%	no
O	O	Confidence	no
O	O	Interval	no
O	O	)	no

O	O	Although	no
O	O	these	no
O	O	results	no
O	O	do	no
O	O	not	no
O	O	indicate	no
O	O	a	yes
O	O	significant	no
O	O	interaction	no
O	O	between	yes
B-brand	B-brand	TORADOL	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
B-drug	B-drug	heparin	yes
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	to	no
O	O	patients	no
O	O	taking	no
B-group	B-group	anticoagulants	no
O	O	should	no
O	O	be	no
O	O	done	no
O	O	extremely	no
O	O	cautiously	no
O	O	,	no
O	O	and	yes
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

O	O	The	no
O	O	decision	no
O	O	to	no
O	O	prescribe	no
O	O	this	no
O	O	agent	yes
O	O	should	no
O	O	include	no
O	O	such	no
O	O	considerations	no
O	O	as	yes
O	O	the	no
O	O	cost-risk-benefit	no
O	O	balance	yes
O	O	,	no
O	O	patient	no
O	O	access	no
O	O	,	no
O	O	drug	yes
O	O	distribution	no
O	O	pathways	no
O	O	,	no
O	O	and	yes
O	O	prescription	no
O	O	drug	yes
O	O	coverage	no
O	O	.	no

B-brand	B-brand	Aspirin/Acetaminophen	no
O	O	:	no
O	O	Pharmacokinetic	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	drug-drug	no
O	O	interactions	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	demonstrated	no
O	O	between	yes
B-drug	B-drug	Argatroban	yes
O	O	and	yes
O	O	concomitantly	no
O	O	administered	no
B-brand	B-brand	aspirin	yes
O	O	(	no
O	O	162.5	no
O	O	mg	yes
O	O	orally	no
O	O	given	no
O	O	26	yes
O	O	and	yes
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	1	yes
O	O	g/kg/min	no
O	O	.	no
O	O	over	no
O	O	4	yes
O	O	hours	no
O	O	)	no
O	O	or	no
B-drug	B-drug	acetaminophen	yes
O	O	(	no
O	O	1000	yes
O	O	mg	yes
O	O	orally	no
O	O	given	no
O	O	12	yes
O	O	,	no
O	O	6	yes
O	O	and	yes
O	O	0	no
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	,	no
O	O	and	yes
O	O	6	yes
O	O	and	yes
O	O	12	yes
O	O	hours	no
O	O	subsequent	no
O	O	to	no
O	O	,	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	1.5	yes
O	O	g/kg/min	no
O	O	.	no
O	O	over	no
O	O	18	yes
O	O	hours	no
O	O	)	no
O	O	.	no

O	O	Pregnancy	no
O	O	Pregnancy	no
O	O	:	no
O	O	Category	no
O	O	C	yes
B-brand	B-brand	PEGASYS	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	for	yes
O	O	its	no
O	O	teratogenic	no
O	O	effect	no
O	O	.	no

O	O	Intravenous	yes
B-drug	B-drug	ranitidine	yes
O	O	was	no
O	O	shown	no
O	O	to	no
O	O	double	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	alendronate	yes
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	if	no
O	O	patients	no
O	O	receive	no
O	O	large	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ethchlorvynol	yes
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Chlorprothixene	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	plasma-level	no
O	O	of	yes
O	O	concomitantly	no
O	O	given	no
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Genetic	no
O	O	variation	no
O	O	in	yes
O	O	metabolism	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	high	yes
O	O	concentrations	no
O	O	of	yes
O	O	drugs	no
O	O	and	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	adverse	no
O	O	effects	no
O	O	in	yes
O	O	slow	yes
O	O	metabolizers	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	important	no
O	O	when	no
O	O	using	no
O	O	for	yes
O	O	example	no
B-group	B-group	antidepressants	no
O	O	or	no
O	O	chemotherapy	no
O	O	.	no

B-drug	B-drug	Ampicillin/Amoxicillin	no
O	O	:	no
O	O	An	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	skin	yes
O	O	rash	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	among	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	ampicillin	yes
O	O	or	no
B-drug	B-drug	amoxicillin	yes
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	allopurinol	yes
O	O	compared	no
O	O	to	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	not	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Hyperglycemia	no
O	O	has	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	CAMPTOSAR	yes
O	O	.	no

O	O	Until	no
O	O	further	no
O	O	data	no
O	O	are	no
O	O	developed	no
O	O	regarding	no
O	O	drug	yes
O	O	interactions	no
O	O	when	no
B-drug	B-drug	azithromycin	yes
O	O	and	yes
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	is	yes
O	O	advised	no
O	O	:	no
B-drug	B-drug	Digoxin	yes
O	O	elevated	no
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	Multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	,	no
O	O	the	no
O	O	estrogenic	yes
O	O	component	yes
O	O	in	yes
O	O	most	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	.	no

O	O	When	no
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	is	yes
O	O	used	no
O	O	at	yes
O	O	the	no
O	O	same	yes
O	O	time	no
O	O	as	yes
O	O	other	no
O	O	medicines	no
O	O	or	no
O	O	substances	no
O	O	the	no
O	O	following	no
O	O	interactions	no
O	O	must	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	account	no
O	O	:	no
O	O	-	yes
B-brand	B-brand	Bezalip	yes
O	O	and	yes
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	anticoagulants	no
I-group	I-group	of	yes
I-group	I-group	the	no
I-group	I-group	coumarin	yes
I-group	I-group	type	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	D.H.E	no
I-brand	I-brand	.	no
I-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Reduced	yes
O	O	response	no
O	O	to	no
O	O	metyrapone	yes
O	O	test	yes
O	O	.	no

O	O	About	no
O	O	three	no
O	O	weeks	no
O	O	prior	no
O	O	to	no
O	O	admission	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	was	no
O	O	started	no
O	O	on	no
B-drug	B-drug	clarithromycin	yes
O	O	for	yes
O	O	sinusitis	no
O	O	.	no

O	O	The	no
O	O	unrestricted	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	for	yes
O	O	these	no
O	O	purposes	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	advocated	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	the	no
O	O	evidence	no
O	O	currently	no
O	O	available	no
O	O	.	no

B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	and	yes
O	O	many	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	many	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
B-drug	B-drug	propafenone	yes
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes

O	O	Drugs	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	diminish	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	response	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	decreased	no
O	O	prothrom-bin	no
O	O	time	no
O	O	response	no
O	O	,	no
O	O	in	yes
O	O	man	no
O	O	significantly	no
O	O	include	no
O	O	:	no
B-group	B-group	adrenocortical	no
I-group	I-group	steroids	no
O	O	;	no
B-drug	B-drug	alcohol*	no
O	O	;	no
B-group	B-group	antacids	no
O	O	;	no
B-group	B-group	antihistamines	no
O	O	;	no
B-group	B-group	barbiturates	no
O	O	;	no
B-drug	B-drug	carbamazepine	yes
O	O	;	no
B-drug	B-drug	chloral	yes
O	O	hydrate*	no
O	O	;	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	;	no
B-drug	B-drug	cholestyramine	yes
O	O	;	no
O	O	diet	no
O	O	high	yes
O	O	in	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	;	no
B-group	B-group	diuretics*	no
O	O	;	no
B-drug	B-drug	ethchlorvynol	yes
O	O	;	no
B-drug	B-drug	glutethimide	yes
O	O	;	no
B-drug	B-drug	griseofulvin	yes
O	O	;	no
B-drug	B-drug	haloperidol	yes
O	O	;	no
B-drug	B-drug	meprobamate	yes
O	O	;	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	;	no
B-drug	B-drug	paraldehyde	yes
O	O	;	no
B-drug	B-drug	primidone	yes
O	O	;	no
B-drug	B-drug	ranitidine*	no
O	O	;	no
B-drug	B-drug	rifampin	yes
O	O	;	no
O	O	unreliable	no
O	O	prothrombin	yes
O	O	time	no
O	O	determinations	no
O	O	;	no
B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	;	no
B-drug	B-drug	warfarin	yes
I-drug	I-drug	sodium	yes
O	O	under-dosage	no
O	O	.	no

O	O	This	no
O	O	transient	no
O	O	hypotensive	no
O	O	response	no
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	contraindication	no
O	O	to	no
O	O	further	no
O	O	doses	no
O	O	which	no
O	O	can	no
O	O	be	no
O	O	given	no
O	O	without	no
O	O	difficulty	no
O	O	once	no
O	O	the	no
O	O	blood	yes
O	O	pressure	no
O	O	has	no
O	O	increased	no
O	O	after	no
O	O	volume	no
O	O	expansion	no
O	O	.	no

O	O	Human	yes
O	O	pharmacokinetics	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	potently	no
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	resulting	no
O	O	in	yes
O	O	an	no
O	O	eight-fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	mean	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

O	O	Increasing	no
O	O	the	no
B-drug	B-drug	felbamate	yes
O	O	dose	no
O	O	to	no
O	O	1800	no
O	O	mg/day	no
O	O	in	yes
O	O	six	no
O	O	of	yes
O	O	these	no
O	O	subjects	no
O	O	increased	no
O	O	the	no
O	O	steady-state	no
B-drug	B-drug	phenytoin	yes
O	O	Cmin	no
O	O	to	no
O	O	25	yes
O	O	7	yes
O	O	micrograms/mL	no
O	O	.	no

O	O	Literature	no
O	O	reports	no
O	O	suggest	no
O	O	that	no
O	O	oral	yes
B-group	B-group	calcium	yes
I-group	I-group	antagonists	no
O	O	may	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	when	no
O	O	heart	no
O	O	function	no
O	O	is	yes
O	O	normal	yes
O	O	,	no
O	O	but	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	cardiac	no
O	O	function	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	temperature	no
O	O	changes	no
O	O	on	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	microtubules	no
O	O	in	yes
O	O	non-myelinated	no
O	O	axons	no
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	cat	no
O	O	inferior	no
O	O	mesenteric	no
O	O	ganglion/hypogastric	no
O	O	nerve	yes
O	O	preparations	no
O	O	incubated	no
O	O	at	yes
O	O	various	no
O	O	temperatures	no
O	O	in	yes
O	O	Eagles	no
O	O	minimal	no
O	O	essential	yes
O	O	tissue	yes
O	O	culture	no
O	O	medium	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	to	no
O	O	hypoparathyroid	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	concurrently	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	ergocalciferol	yes
O	O	may	no
O	O	cause	no
O	O	hypercalcemia	no
O	O	.	no

O	O	Until	no
O	O	further	no
O	O	data	no
O	O	are	no
O	O	available	no
O	O	regarding	no
O	O	the	no
O	O	potential	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	dirithromycin	yes
O	O	with	yes
O	O	these	no
O	O	compounds	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	during	no
O	O	coadministration	no
O	O	.	no

O	O	Restoration	no
O	O	of	yes
B-drug	B-drug	vancomycin	yes
O	O	susceptibility	no
O	O	in	yes
O	O	Enterococcus	no
O	O	faecalis	no
O	O	by	no
O	O	antiresistance	no
O	O	determinant	no
O	O	gene	yes
O	O	transfer	no
O	O	.	no

O	O	Other	no
O	O	common	yes
O	O	adverse	no
O	O	reactions	no
O	O	are	no
O	O	dizziness	no
O	O	(	no
O	O	5-15	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	weakness	no
O	O	(	no
O	O	5-15	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	fatigue	no
O	O	(	no
O	O	2-4	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	enzyme	no
O	O	could	no
O	O	potentially	no
O	O	occur	no
O	O	.	no

O	O	Further	no
O	O	,	no
O	O	designs	no
O	O	can	no
O	O	be	no
O	O	expressed	yes
O	O	in	yes
O	O	terms	no
O	O	of	yes
O	O	proportionate	no
O	O	responses	no
O	O	associated	no
O	O	with	yes
O	O	the	no
O	O	individual	no
O	O	compounds	no
O	O	rather	no
O	O	than	no
O	O	dose	no
O	O	levels	no
O	O	,	no
O	O	thereby	no
O	O	providing	no
O	O	for	yes
O	O	results	no
O	O	that	no
O	O	are	no
O	O	applicable	no
O	O	across	no
O	O	compounds	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	disposition	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	sensitive	no
O	O	to	no
O	O	alterations	no
O	O	in	yes
O	O	protein	yes
O	O	binding	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	drug-drug	no
O	O	interaction	no
O	O	with	yes
O	O	drugs	no
O	O	affected	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	may	no
O	O	not	no
O	O	be	no
O	O	ruled	no
O	O	out	no
O	O	.	no

O	O	dermatitis	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	conducted	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	,	no
O	O	mean	no
O	O	steady-state	no
B-drug	B-drug	lithium	yes
O	O	plasma	yes
O	O	levels	no
O	O	increased	no
O	O	approximately	no
O	O	17	yes
O	O	%	no
O	O	in	yes
O	O	subjects	no
O	O	receiving	no
B-drug	B-drug	lithium	yes
O	O	450	yes
O	O	mg	yes
O	O	BID	no
O	O	with	yes
B-brand	B-brand	CELEBREX	yes
O	O	200	yes
O	O	mg	yes
O	O	BID	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	subjects	no
O	O	receiving	no
B-drug	B-drug	lithium	yes
O	O	alone	no
O	O	.	no

O	O	In	yes
O	O	situations	no
O	O	when	no
O	O	concurrent	no
O	O	therapy	no
O	O	is	yes
O	O	necessary	no
O	O	,	no
O	O	careful	no
O	O	patient	no
O	O	monitoring	no
O	O	is	yes
O	O	essential	yes
O	O	.	no

O	O	Phosphate-Binding	no
O	O	Agents	yes
O	O	:	no
O	O	Since	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	also	no
O	O	has	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	phosphate	yes
O	O	transport	no
O	O	in	yes
O	O	the	no
O	O	intestine	no
O	O	,	no
O	O	kidneys	no
O	O	and	yes
O	O	bones	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	phosphate-binding	no
O	O	agents	yes
O	O	must	no
O	O	be	no
O	O	adjusted	yes
O	O	in	yes
O	O	accordance	no
O	O	with	yes
O	O	the	no
O	O	serum	yes
O	O	phosphate	yes
O	O	concentration	no
O	O	.	no

O	O	or	no
O	O	with	yes
B-group	B-group	multivitamins	no
O	O	containing	yes
B-drug	B-drug	zinc	yes
O	O	may	no
O	O	substantially	no
O	O	interfere	no
O	O	with	yes
O	O	drug	yes
O	O	absorption	no
O	O	and	yes
O	O	result	no
O	O	in	yes
O	O	insufficient	no
O	O	plasma	yes
O	O	and	yes
O	O	tissue	yes
B-group	B-group	quinolone	no
O	O	concentrations	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	patients	no
O	O	receiving	no
O	O	the	no
O	O	drug	yes
O	O	and	yes
O	O	a	yes
B-drug	B-group	hydantoin	no
O	O	,	no
B-group	B-group	sulfonamide	yes
O	O	or	no
B-group	B-group	sulfonylurea	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	toxicity	no
O	O	to	no
O	O	these	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Antipyrine	yes
O	O	:	no
B-drug	B-drug	Antipyrine	yes
O	O	pharmacokinetics	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	different	no
O	O	before	no
O	O	and	yes
O	O	after	no
B-drug	B-drug	tiagabine	yes
O	O	multiple-dose	no
O	O	regimens	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	single	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
O	O	multiple	no
O	O	dose	no
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	TID	no
O	O	)	no
O	O	study	no
O	O	of	yes
B-brand	B-brand	Neurontin	yes
O	O	in	yes
O	O	epileptic	no
O	O	patients	no
O	O	(	no
O	O	N=8	no
O	O	)	no
O	O	maintained	no
O	O	on	no
B-drug	B-drug	phenytoin	yes
O	O	monotherapy	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	months	no
O	O	,	no
B-drug	B-drug	gabapentin	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	gabapentin	yes
O	O	pharmacokinetics	no
O	O	.	no

B-drug	B-drug	Zidovudine	yes
O	O	should	no
O	O	either	no
O	O	be	no
O	O	temporarily	no
O	O	discontinued	no
O	O	or	no
O	O	decreased	no
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	on	no
O	O	the	no
O	O	day	no
O	O	of	yes
B-brand	B-brand	VISTIDE	yes
O	O	infusion	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	related	yes
O	O	both	no
O	O	to	no
O	O	pressor	no
O	O	activity	yes
O	O	and	yes
O	O	to	no
O	O	beta-adrenergic	no
O	O	stimulating	yes
O	O	properties	no
O	O	of	yes
O	O	these	no
O	B-group	catecholamines	no
O	O	and	yes
O	O	may	no
O	O	produce	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	and	yes
O	O	hypertension	no
O	O	.	no

B-drug_n	B-drug_n	Jacalin	no
O	O	:	no
O	O	an	no
O	O	IgA-binding	no
O	O	lectin	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	desirable	no
O	O	to	no
O	O	monitor	no
B-group	B-group	TCAplasma	no
O	O	levels	no
O	O	whenever	no
O	O	an	no
O	O	agent	yes
O	O	of	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
I-group	I-group	class	no
O	O	including	no
B-brand	B-brand	Anafranil	yes
O	O	is	yes
O	O	going	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	and/or	no
O	O	P450	no
O	O	1A2	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	on	no
B-drug	B-drug	diltiazem	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	.	no

B-brand	B-brand	ERGAMISOL	yes
O	O	(	no
B-drug	B-drug	levamisole	yes
I-drug	I-drug	hydrochloride	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	produce	no
O	O	ANTABUSE-like	no
O	O	side	no
O	O	effects	no
O	O	when	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	During	no
O	O	the	no
O	O	above	no
O	O	experiments	no
O	O	we	no
O	O	noted	no
O	O	a	yes
O	O	massive	no
O	O	precipitation	no
O	O	in	yes
O	O	cell	yes
O	O	cultures	no
O	O	stimulated	no
O	O	with	yes
O	O	greater	no
O	O	than	no
O	O	or	no
O	O	equal	no
O	O	to	no
O	O	100	yes
O	O	micrograms	no
O	O	of	yes
O	O	lectin	yes
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	C.P.A	no
O	O	.	no

B-drug_n	B-drug_n	Cytochalasin	no
I-drug_n	I-drug_n	D	yes
O	O	inhibited	no
O	O	the	no
B-drug	B-drug	carbachol-stimulated	no
O	O	intracellular	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	concentration	no
O	O	(	no
O	O	[	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	]	no
O	O	(	no
O	O	i	yes
O	O	)	no
O	O	)	no
O	O	increase	no
O	O	due	no
O	O	to	no
O	O	release	yes
O	O	from	no
O	O	the	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	store	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	a	yes
O	O	reduction	yes
O	O	that	no
O	O	reached	no
O	O	borderline	no
O	O	statistical	no
O	O	significance	no
O	O	in	yes
O	O	the	no
O	O	group	yes
O	O	that	no
O	O	received	no
O	O	150	yes
O	O	mg/d	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	.	no

O	O	Currently	no
O	O	,	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	data	no
O	O	available	no
O	O	from	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

B-drug	B-drug	glutethimide	yes
O	O	;	no

O	O	For	yes
O	O	patients	no
O	O	receiving	no
O	O	both	no
O	O	therapies	no
O	O	,	no
O	O	standard	yes
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	tacrolimus	yes
O	O	blood	yes
O	O	concentrations	no
O	O	and	yes
O	O	appropriate	no
B-drug	B-drug	tacrolimus	yes
O	O	dosage	no
O	O	adjustments	no
O	O	are	no
O	O	recommended	no
O	O	.	no

O	O	Patients	no
O	O	on	no
B-drug	B-drug	rifampin	yes
O	O	should	no
O	O	receive	no
O	O	70	yes
O	O	mg	yes
O	O	of	yes
B-brand	B-brand	CANCIDAS	yes
O	O	daily	no
O	O	.	no

B-drug	B-drug	Sodium	yes
I-drug	I-drug	Iodide	yes
O	O	(	no
O	O	123I	no
O	O	and	yes
O	O	131I	no
O	O	)	no
O	O	,	no
B-drug	B-drug	Sodium	yes
I-drug	I-drug	Pertechnetate	yes
I-drug	I-drug	Tc99m	no
O	O	:	no
O	O	Uptake	no
O	O	of	yes
O	O	radiolabeled	no
O	O	ions	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	.	no

B-drug	B-drug	Nevirapine	yes
O	O	is	yes
O	O	principally	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	liver	yes
O	O	via	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzymes	no
O	O	,	no
O	O	3A4	no
O	O	and	yes
O	O	2B6	no
O	O	.	no

O	O	CNS	no
O	O	Toxicity	no
O	O	Brain	yes
O	O	hemorrhage	no
O	O	was	no
O	O	seen	no
O	O	in	yes
O	O	a	yes
O	O	female	no
O	O	dog	no
O	O	treated	no
O	O	for	yes
O	O	3	yes
O	O	months	no
O	O	at	yes
O	O	120	no
O	O	mg/kg/day	no
O	O	.	no

O	O	This	no
O	O	allows	no
B-drug	B-drug	bitolterol	yes
O	O	to	no
O	O	open	yes
O	O	air	yes
O	O	passages	no
O	O	,	no
O	O	increasing	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
O	O	the	no
B-group	B-group	steroid	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	known	no
O	O	that	no
O	O	CYP1A2	no
O	O	is	yes
O	O	inhibited	no
O	O	by	no
O	O	several	no
O	O	medicinal	yes
O	O	products	no
O	O	,	no
O	O	including	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	and	yes
O	O	such	no
O	O	medicinal	yes
O	O	products	no
O	O	could	no
O	O	theoretically	no
O	O	adversely	no
O	O	influence	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	anagrelide	yes
O	O	.	no

O	O	The	no
O	O	present	no
O	O	work	no
O	O	involved	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	ethynyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
B-drug	B-drug	levonorgestrel	yes
O	O	to	no
O	O	groups	no
O	O	of	yes
O	O	rats	no
O	O	,	no
O	O	followed	no
O	O	by	no
O	O	determination	no
O	O	of	yes
O	O	the	no
O	O	homocysteine	no
O	O	excretion	no
O	O	rate	no
O	O	in	yes
O	O	urine	no
O	O	.	no

O	O	Theoretically	no
O	O	,	no
O	O	the	no
B-drug	B-drug	naproxen	yes
O	O	anion	yes
O	O	itself	no
O	O	could	no
O	O	likewise	no
O	O	be	no
O	O	displaced	no
O	O	.	no

B-drug	B-drug	Indinavir	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	83	no
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	51	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	indinavir	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	Pharmacokinetics	no
O	O	of	yes
B-group	B-group	calcium-entry	no
I-group	I-group	blockers	no
O	O	.	no

B-group	B-group	Coumarin-Type	no
I-group	I-group	Anticoagulants	no
O	O	:	no
O	O	Several	no
O	O	short-term	no
O	O	controlled	no
O	O	studies	no
O	O	failed	no
O	O	to	no
O	O	wshow	no
O	O	that	no
B-drug	B-drug	ibuprofen	yes
O	O	significantly	no
O	O	affected	no
O	O	prothrombin	yes
O	O	times	no
O	O	or	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	other	no
O	O	clotting	no
O	O	factors	no
O	O	when	no
O	O	administered	no
O	O	to	no
O	O	individuals	no
O	O	on	no
B-group	B-group	coumarin-type	no
I-group	I-group	anticoagulants	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	glipizide	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

B-drug_n	B-drug_n	Flavoridin	no
O	O	alone	no
O	O	was	no
O	O	found	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	CAS	no
O	O	,	no
O	O	but	no
O	O	can	no
O	O	completely	no
O	O	block	yes
O	B-drug_n	contortrostatin-induced	no
O	O	phosphorylation	no
O	O	of	yes
O	O	this	no
O	O	protein	yes
O	O	in	yes
O	O	MDA-MB-435	no
O	O	cells	yes
O	O	.	no

O	O	If	no
O	O	a	yes
O	O	patient	no
O	O	is	yes
O	O	truly	no
O	O	hypothyroid	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	likely	no
O	O	that	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	will	no
O	O	be	no
O	O	required	no
O	O	.	no

B-drug	B-drug	Methenamine	yes

O	O	Therefore	no
O	O	,	no
B-brand	B-brand	OMNICEF	yes
O	O	for	yes
O	O	Oral	yes
O	O	Suspension	yes
O	O	can	no
O	O	be	no
O	O	administered	no
O	O	with	yes
B-drug_n	B-drug_n	iron-fortified	no
O	O	infant	no
O	O	formula	yes
O	O	.	no

O	O	Both	no
B-brand	B-brand	CRIXIVAN	yes
O	O	and	yes
B-drug	B-drug	atazanavir	yes
O	O	are	no
O	O	associated	no
O	O	with	yes
O	O	indirect	no
O	O	(	no
O	O	unconjugated	no
O	O	)	no
O	O	hyperbilirubinemia	no
O	O	.	no

O	O	Alkalinizing	no
O	O	agents	yes
O	O	:	no
O	O	Gastrointestinal	no
O	O	alkalinizing	no
O	O	agents	yes
O	O	(	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	bicarbonate	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	increase	no
O	O	absorption	no
O	O	of	yes
B-group	B-drug	amphetamines	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-brand	B-brand	REVIA	yes
O	O	may	no
O	O	not	no
O	O	benefit	no
O	O	from	no
B-group	B-group	opioid	no
O	O	containing	yes
O	O	medicines	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	cough	no
O	O	and	yes
O	O	cold	yes
O	O	preparations	no
O	O	,	no
O	O	antidiarrheal	no
O	O	preparations	no
O	O	,	no
O	O	and	yes
B-group	B-group	opioid	no
I-group	I-group	analgesics	no
O	O	.	no

B-group	B-group	Hormonal	no
I-group	I-group	Contraceptives	no
O	O	,	no
O	O	Including	no
O	O	Oral	yes
O	O	,	no
O	O	Injectable	no
O	O	,	no
O	O	Transdermal	no
O	O	,	no
O	O	and	yes
O	O	Implantable	no
B-group	B-group	Contraceptives	no
O	O	:	no
O	O	An	no
O	O	interaction	no
O	O	study	no
O	O	demonstrated	no
O	O	that	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	and	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptive	yes
B-brand	B-brand	Ortho-Novum	yes
O	O	produced	no
O	O	average	no
O	O	decreases	no
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	levels	no
O	O	of	yes
O	O	14	yes
O	O	%	no
O	O	and	yes
O	O	31	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	;	no

O	O	Radioligand	no
O	O	binding	no
O	O	experiments	no
O	O	using	no
O	O	the	no
O	O	uptake	no
O	O	inhibitor	yes
O	O	hydrogen-3	no
B-drug	B-drug	mazindol	yes
O	O	revealed	no
O	O	a	yes
O	O	significant	no
O	O	decrease	no
O	O	by	no
O	O	approximately	no
O	O	30	yes
O	O	%	no
O	O	in	yes
B-drug	B-drug	norepinephrine	yes
O	O	uptake-1	no
O	O	carrier	no
O	O	density	no
O	O	in	yes
O	O	functional	no
O	O	classes	no
O	O	II	yes
O	O	to	no
O	O	III	yes
O	O	and	yes
O	O	IV	yes
O	O	myocardium	no
O	O	versus	no
O	O	nonfailing	no
O	O	myocardium	no
O	O	(	no
O	O	p	yes
O	O	<	no
O	O	0.05	no
O	O	)	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	and	yes
B-drug	B-drug	promethazine	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	.	no

O	O	AIM	yes
O	O	AND	yes
O	O	BACKGROUND	no
O	O	:	no
O	O	The	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	sirolimus	yes
O	O	,	no
O	O	a	yes
B-group	B-group	macrolide	no
I-group	I-group	immunosuppressant	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocker	no
B-drug	B-drug	diltiazem	yes
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	18	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

O	O	only	no
B-drug_n	B-drug_n	ibogaine	no
O	O	enhances	no
B-drug	B-drug	cocaine-induced	no
O	O	increases	no
O	O	in	yes
O	O	accumbal	no
O	O	dopamine	yes
O	O	.	no

O	O	Behavioral	no
O	O	mechanisms	no
O	O	underlying	no
O	O	the	no
O	O	link	no
O	O	between	yes
O	O	smoking	no
O	O	and	yes
O	O	drinking	no
O	O	.	no

O	O	John	no
O	O	s	yes
O	O	wort	yes
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	formation	no
O	O	of	yes
B-drug_n	B-drug_n	dapsone	yes
I-drug_n	I-drug_n	hydroxylamine	no
O	O	,	no
O	O	a	yes
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	dapsone	yes
O	O	associated	no
O	O	with	yes
O	O	hemolysis	no
O	O	.	no

O	O	Like	yes
B-drug_n	B-drug_n	ibogaine	no
O	O	(	no
O	O	40	yes
O	O	mg/kg	no
O	O	)	no
O	O	,	no
B-drug_n	B-drug_n	18-MC	no
O	O	(	no
O	O	40	yes
O	O	mg/kg	no
O	O	)	no
O	O	decreases	no
O	O	the	no
O	O	intravenous	yes
O	O	self-administration	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	and	yes
B-drug	B-drug	cocaine	yes
O	O	and	yes
O	O	the	no
O	O	oral	yes
O	O	self-administration	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	and	yes
B-drug	B-drug	nicotine	yes
O	O	in	yes
O	O	rats	no
O	O	;	no

O	O	increased	no
O	O	plasminogen	yes
O	O	antigen	yes
O	O	and	yes
O	O	activity	yes
O	O	.	no

O	O	Permeation	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	on	no
O	O	guinea	no
O	O	pig	yes
O	O	small	no
O	O	intestinal	no
O	O	mucosa	no
O	O	mounted	no
O	O	in	yes
O	O	Ussing-type	no
O	O	chamber	no
O	O	.	no

O	O	Other	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

O	O	Compounds	no
O	O	tested	no
O	O	in	yes
O	O	man	no
O	O	include	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	aminopyrine	yes
O	O	and	yes
B-drug	B-drug	antipyrine	yes
O	O	.	no

O	O	Reported	no
O	O	examples	no
O	O	include	no
O	O	the	no
O	O	following	no
O	O	:	no
B-group	B-group	Protease	yes
I-group	I-group	Inhibitors	no
O	O	:	no
B-group	B-group	Protease	yes
I-group	I-group	inhibitors	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	inhibit	no
O	O	CYP3A4	no
O	O	to	no
O	O	varying	no
O	O	degrees	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	patients	no
O	O	who	no
O	O	may	no
O	O	be	no
O	O	adversely	no
O	O	affected	no
O	O	by	no
O	O	such	no
O	O	an	no
O	O	action	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	observed	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	given	no
O	O	very	no
O	O	high	yes
O	O	doses	no
O	O	(	no
O	O	3900	no
O	O	mg	yes
O	O	)	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	daily	no
O	O	,	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
O	B-group	salicylate	yes
O	O	levels	no
O	O	were	no
O	O	seen	no
O	O	when	no
B-drug	B-drug	nizatidine	yes
O	O	,	no
O	O	150	yes
O	O	mg	yes
O	O	b.i.d.	no
O	O	,	no
O	O	was	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Nicotine	yes
O	O	Transdermal	no
O	O	System	yes
O	O	:	no
O	O	.	no

O	O	Rabbits	no
O	O	failed	no
O	O	to	no
O	O	maintain	no
O	O	pregnancy	no
O	O	when	no
O	O	dosed	no
O	O	with	yes
O	O	1	yes
O	O	mg/kg/day	no
B-drug	B-drug	fulvestrant	yes
O	O	IM	yes
O	O	(	no
O	O	twice	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	during	no
O	O	the	no
O	O	period	no
O	O	of	yes
O	O	organogenesis	no
O	O	.	no

O	O	-	yes
O	O	Other	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	:	no
O	O	Additive	no
O	O	effect	no
O	O	or	no
O	O	potentiation	no

O	O	The	no
O	O	physician	no
O	O	is	yes
O	O	advised	no
O	O	to	no
O	O	monitor	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	when	no
O	O	any	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	is	yes
O	O	taken	no
O	O	concurrently	no
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	if	no
O	O	necessary	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	with	yes
O	O	irradiation	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	adequately	no
O	O	studied	no
O	O	and	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Indomethacin	yes
O	O	-	yes
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	L-glutamine	yes
O	O	and	yes
B-drug	B-drug	indomethacin	yes
O	O	may	no
O	O	ameliorate	no
O	O	increased	no
O	O	intestinal	no
O	O	permeability	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	indomethacin	yes
O	O	.	no

O	O	Prospective	no
O	O	studies	no
O	O	on	no
O	O	the	no
O	O	potential	no
O	O	for	yes
B-drug	B-drug	hydroxyurea	yes
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	currently	no
O	O	no	yes
O	O	data	no
O	O	on	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	combined	no
O	O	hyperglycaemia	no
O	O	and	yes
O	O	hyperinsulinaemia	no
O	O	on	no
O	O	the	no
O	O	renal	no
O	O	and	yes
O	O	ocular	no
O	O	blood	yes
O	O	flow	no
O	O	seen	no
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	on	no
B-drug	O	insulin	yes
O	O	therapy	no
O	O	.	no

O	O	Animals	no
O	O	dosed	no
O	O	with	yes
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	did	no
O	O	not	no
O	O	display	no
O	O	the	no
O	O	2-3	no
O	O	hour	yes
O	O	lag	no
O	O	phase	no
O	O	in	yes
O	O	either	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	synthesis	no
O	O	or	no
O	O	in	yes
O	O	citrate	yes
O	O	and	yes
O	O	fluoride	yes
O	O	accumulation	no
O	O	characteristic	no
O	O	of	yes
O	O	animals	no
O	O	dosed	no
O	O	with	yes
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
B-group	B-group	antacids	no
O	O	were	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lansoprazole	yes
O	O	delayed-release	no
O	O	capsules	no
O	O	;	no

O	O	DISCUSSION	no
O	O	:	no
B-drug	B-drug	Clarithromycin	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	the	no
O	O	major	no
O	O	enzyme	no
O	O	responsible	no
O	O	for	yes
B-drug	B-drug	simvastatin	yes
O	O	metabolism	no
O	O	.	no

B-drug	B-drug	Sodium	yes
I-drug	I-drug	thiosulfate	yes
O	O	is	yes
O	O	a	yes
O	O	neutralizing	no
O	O	agent	yes
O	O	for	yes
B-drug	B-drug	cisplatin	yes
O	O	that	no
O	O	protects	no
O	O	against	yes
O	O	renal	no
O	O	damage	no
O	O	.	no

B-group	B-group	Digitalis	yes
I-group	I-group	glycosides	yes
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	digitalis	yes
I-group	I-group	glycosides	yes
O	O	may	no
O	O	be	no
O	O	at	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	arrhythmias	no
O	O	due	no
O	O	to	no
O	O	hypokalemia	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-brand	B-brand	Accutane	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	in	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	seven	no
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	The	no
O	O	average	no
O	O	increase	no
O	O	was	no
O	O	45	yes
O	O	%	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	an	no
O	O	increasing	no
O	O	incidence	no
O	O	of	yes
O	O	transient	no
O	O	thrombocytopenia	no
O	O	(	no
O	O	or	no
O	O	=100	no
O	O	x	yes
O	O	10	yes
O	O	(	no
O	O	9	yes
O	O	)	no
O	O	/L	no
O	O	)	no
O	O	with	yes
O	O	increasing	no
B-drug	B-drug	everolimus	yes
O	O	AUC	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	.03	no
O	O	)	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	Serious	no
O	O	side	no
O	O	effects	no
O	O	and	yes
O	O	even	no
O	O	death	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	certain	no
O	O	drugs	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	This	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	account	no
O	O	when	no
O	O	evaluating	no
O	O	serum	yes
O	O	amylase	no
O	O	levels	no
O	O	for	yes
O	O	diagnosis	no
O	O	or	no
O	O	monitoring	no
O	O	of	yes
O	O	pancreatitis	no
O	O	in	yes
O	O	patients	no
O	O	using	no
B-brand	B-brand	EXTRANEAL	yes
O	O	.	no

O	O	No	yes
O	O	change	no
O	O	in	yes
O	O	phase	no
O	O	was	no
O	O	detected	no
O	O	,	no
O	O	although	no
O	O	the	no
O	O	aerosol	no
O	O	particles	no
O	O	appeared	no
O	O	to	no
O	O	contain	no
O	O	residual	no
O	B-group	solvent	yes
O	O	.	no

B-group	B-group	Sympathomimetic	no
I-group	I-group	amines	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
B-group	B-group	veratrum	no
I-group	I-group	alkaloids	yes
O	O	,	no
B-drug	B-drug	methyldopa	yes
O	O	and	yes
B-drug	B-drug	mecamylamine	yes
O	O	.	no

O	O	CYP3A4	no
O	O	and	yes
O	O	-2C19	no
O	O	Inhibitors	no
O	O	-	yes
O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicated	no
O	O	that	no
O	O	CYP3A4	no
O	O	and	yes
O	O	-2C19	no
O	O	are	no
O	O	the	no
O	O	primary	no
O	O	enzymes	yes
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	.	no

O	O	this	no
O	O	can	no
O	O	cause	no
O	O	headaches	no
O	O	and	yes
O	O	other	no
O	O	signs	no
O	O	of	yes
O	O	hypertensive	no
O	O	crisis	no
O	O	.	no

B-drug	B-drug	Celecoxib	yes
O	O	metabolism	no
O	O	is	yes
O	O	predominantly	no
O	O	mediated	no
O	O	via	no
O	O	cytochrome	no
O	O	P450	no
O	O	2C9	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	.	no

B-group	B-group	Digitalis	yes
I-group	I-group	glycosides	yes
O	O	:	no
B-drug	B-drug	amphotericin	yes
O	O	B-induced	no
O	O	hypokalemia	no
O	O	may	no
O	O	potentiate	no
B-group	B-group	digitalis	yes
O	O	toxicity	no
O	O	.	no

O	O	Potential	no
O	O	effect	no
O	O	on	no
O	O	anticoagulation	no
O	O	.	no

B-group	B-group	Androgens	no
O	O	may	no
O	O	increase	no
O	O	sensitivity	no
O	O	to	no
O	O	oral	yes
O	O	anticoagulahts	no
O	O	.	no

O	O	SERUM	yes
O	O	LEVELS	no
O	O	OF	yes
B-drug	B-drug	PHENYTOIN	yes
O	O	SHOULD	no
O	O	BE	no
O	O	DETERMINED	no
O	O	ON	no
O	O	DIFFERENT	no
O	O	DAYS	no
O	O	FOR	yes
O	O	EVIDENCE	no
O	O	OF	yes
O	O	AN	no
O	O	INCREASE	no
O	O	OR	no
O	O	FOR	yes
O	O	A	yes
O	O	CONTINUING	no
O	O	RISE	no
O	O	IN	yes
O	O	LEVELS	no
O	O	.	no

O	O	Absorption	no
O	O	of	yes
B-group	B-group	tetracyclines	no
O	O	is	yes
O	O	impaired	no
O	O	by	no
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	aluminum	yes
O	O	,	no
B-drug	B-drug	calcium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	magnesium	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	iron-containing	no
O	O	preparations	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	are	no
O	O	antagonized	no
O	O	by	no
B-group	B-group	methylxanthines	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	contraceptives	no
O	O	:	no
B-drug	B-drug	Aprepitant	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	as	yes
O	O	a	yes
O	O	100-mg	no
O	O	capsule	yes
O	O	with	yes
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	containing	yes
O	O	35	yes
O	O	mcg	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
O	O	1	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	,	no
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	by	no
O	O	43	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	by	no
O	O	8	yes
O	O	%	no
O	O	;	no

O	O	Particular	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	in	yes
O	O	using	no
O	O	preparations	no
O	O	containing	yes
B-drug	B-drug	sulfur	yes
O	O	,	no
B-drug	B-drug	resorcinol	no
O	O	,	no
O	O	or	no
B-drug	B-drug	salicylic	yes
I-drug	I-drug	acid	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	DIFFERIN	yes
O	O	Gel	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	-	yes
O	O	Combined	no
O	O	administration	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	200	yes
O	O	mg	yes
O	O	)	no
O	O	decreased	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	by	no
O	O	21	yes
O	O	%	no
O	O	and	yes
O	O	10	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	and	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	citalopram	yes
O	O	.	no

B-drug	B-drug	Terfenadine	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	prospective	no
O	O	study	no
O	O	involving	no
O	O	six-healthy-male	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	dirithromycin	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	.	no

O	O	The	no
O	O	existence	no
O	O	of	yes
O	O	PI	no
O	O	was	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	drugs	no
O	O	prescribed	no
O	O	to	no
O	O	each	no
O	O	patient	no
O	O	(	no
O	O	p	yes
O	O	<	no
O	O	0.01	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	Information	no
O	O	Provided	no

O	O	.	no

O	O	Certain	no
O	O	other	no
B-group	B-group	antibiotics	no
O	O	(	no
B-group	B-group	aminoglycosides	no
O	O	and	yes
B-group	B-group	polymyxin	yes
O	O	)	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	nerve	yes
O	O	transmission	no
O	O	at	yes
O	O	the	no
O	O	neuromuscular	no
O	O	junction	no
O	O	.	no

O	O	Likewise	no
O	O	,	no
B-drug	B-drug	gabapentin	yes
O	O	pharmacokinetics	no
O	O	were	no
O	O	unaltered	no
O	O	by	no
B-drug	B-drug	carbamazepine	yes
O	O	administration	no
O	O	.	no

B-drug	I-drug	atorvastatin	yes
O	O	concentration	no

O	O	Controlled	no
O	O	and	yes
O	O	uncontrolled	no
O	O	domestic	no
O	O	studies	no
O	O	suggest	no
O	O	that	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
I-drug	I-drug	hydrochloride	yes
O	O	and	yes
B-group	B-group	beta-blockers	no
O	O	is	yes
O	O	usually	no
O	O	well	no
O	O	tolerated	no
O	O	,	no
O	O	but	no
O	O	available	no
O	O	data	no
O	O	are	no
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	predict	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	treatment	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	left	no
O	O	ventricular	no
O	O	dysfunction	no
O	O	or	no
O	O	cardiac	no
O	O	conduction	no
O	O	abnormalities	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	buspirone	yes
I-drug	I-drug	hydrochloride	yes
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	Because	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	buspirone	yes
I-drug	I-drug	HCl	yes
O	O	with	yes
O	O	most	no
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	buspirone	yes
I-drug	I-drug	HCl	yes
O	O	with	yes
O	O	other	no
O	O	CNS-active	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	No	yes
O	O	interaction	no
O	O	trials	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	MEPRON	yes
O	O	and	yes
B-drug	B-drug	rifabutin	yes
O	O	.	no

B-drug	B-drug	Fluconazole	yes
O	O	and	yes
B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	and	yes
B-drug	B-drug	fluconazole	yes
O	O	are	no
O	O	predominantly	no
O	O	CYP	no
O	O	3A4	no
O	O	and	yes
O	O	2C9	no
O	O	inhibitors	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	These	no
O	O	observations	no
O	O	strongly	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	homodimeric	no
O	O	structure	no
O	O	of	yes
B-drug_n	B-drug_n	contortrostatin	no
O	O	functionally	no
O	O	distinguishes	no
O	O	it	no
O	O	from	no
O	O	other	no
O	O	monomeric	no
O	O	members	no
O	O	of	yes
O	O	the	no
O	O	disintegrin	no
O	O	family	yes
O	O	.	no

O	O	-	yes
O	O	Impaired	no
O	O	glucose	yes
O	O	tolerance	no

O	O	If	no
O	O	a	yes
B-group	B-group	diuretic	no
O	O	is	yes
O	O	also	no
O	O	used	no
O	O	,	no
O	O	it	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	most	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Cerebyx	yes
O	O	are	no
O	O	expected	no
O	O	to	no
O	O	occur	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	:	no
O	O	A	yes
O	O	relationship	no
O	O	of	yes
O	O	functional	no
O	O	antagonism	no
O	O	exists	no
O	O	between	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	,	no
O	O	which	no
O	O	promote	no
O	O	calcium	yes
O	O	absorption	no
O	O	,	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	which	no
O	O	inhibit	no
O	O	calcium	yes
O	O	absorption	no
O	O	.	no

O	O	Keys	no
O	O	to	no
O	O	maximizing	no
O	O	benefit	no
O	O	while	no
O	O	avoiding	no
O	O	adverse	no
O	O	drug	yes
O	O	effects	no
O	O	.	no

O	O	When	no
O	O	given	no
O	O	concurrently	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Other	no
O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	No	yes
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	were	no
O	O	observed	no
O	O	between	yes
B-drug	B-drug	vardenafil	yes
O	O	and	yes
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	:	no
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-brand	B-brand	Maalox	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	ranitidine	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	can	no
O	O	cause	no
O	O	a	yes
O	O	significant	no
O	O	elevation	no
O	O	in	yes
O	O	plasma	yes
B-group	B-group	corticosteroid	no
O	O	levels	no
O	O	.	no

O	O	When	no
B-drug	B-drug	cocaine	yes
O	O	is	yes
O	O	the	no
O	O	primary	no
O	O	addiction	no
O	O	,	no
O	O	after	no
O	O	withdrawal	no
O	O	the	no
O	O	most	no
O	O	effective	no
O	O	treatment	no
O	O	is	yes
O	O	group	yes
O	O	therapy	no
O	O	with	yes
O	O	other	no
O	O	recovering	no
B-drug	O	cocaine	yes
O	O	abusers	no
O	O	.	no

O	O	Today	yes
O	O	pharmacological	no
B-drug	B-drug	magnesium	yes
O	O	therapy	no
O	O	mainly	no
O	O	concerns	no
O	O	the	no
O	O	obstetrical	no
O	O	,	no
O	O	cardiological	no
O	O	and	yes
O	O	anaesthesiological	no
O	O	fields	no
O	O	.	no

O	O	Compared	no
O	O	with	yes
B-group	B-group	conventional	no
I-group	I-group	antipsychotics	no
O	O	,	no
O	O	it	no
O	O	has	no
O	O	greater	no
O	O	affinity	no
O	O	for	yes
O	O	serotonin	yes
O	O	5-HT2A	no
O	O	than	no
O	O	for	yes
O	O	dopamine	yes
O	O	D2	yes
O	O	receptors	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	a	yes
O	O	theoretical	no
O	O	risk	no
O	O	of	yes
O	O	a	yes
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	,	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ergotamine-containing	no
O	O	or	no
B-group	B-group	ergot-type	no
I-group	I-group	medications	no
O	O	(	no
O	O	like	yes
B-drug	B-drug	dihydroergotamine	yes
O	O	or	no
B-drug	B-drug	methysergide	yes
O	O	)	no
O	O	and	yes
B-brand	B-brand	FROVA	yes
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	(	no
O	O	see	no
O	O	a	yes
O	O	href=	no
O	O	frova_od.htm	no
O	O	#	no
O	O	CI	yes
O	O	CONTRAINDICATIONS	no
O	O	)	no
O	O	.	no

O	O	Drug	yes
O	O	Name	no

O	O	The	no
O	O	following	no
O	O	similar	no
O	O	changes	no
O	O	may	no
O	O	be	no
O	O	expected	no
O	O	with	yes
O	O	larger	no
O	O	doses	no
O	O	of	yes
B-group	B-group	estrogen	no
O	O	:	no
O	O	Increased	no
O	O	sulfobromophthalein	no
O	O	retention	no
O	O	;	no

O	O	Due	no
O	O	to	no
O	O	high	yes
O	O	inter-patient	no
O	O	variability	no
O	O	and	yes
O	O	limited	no
O	O	sampling	no
O	O	,	no
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	the	no
O	O	increase	no
O	O	in	yes
B-drug_n	B-drug_n	SN38	no
O	O	levels	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concurrent	no
B-drug	B-drug	irinotecan	yes
O	O	and	yes
B-brand	B-brand	AVASTIN	yes
O	O	is	yes
O	O	uncertain	no
O	O	.	no

B-group	B-group	Hypoglycemics	no

O	O	http	no
O	O	:	no
O	O	//www.rxlist.com/cgi/generic3/guanethidine_od.htm	no

O	O	The	no
O	O	authors	no
O	O	examined	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	the	no
O	O	cyclooxygenase-2	no
O	O	(	no
O	O	COX-2	no
O	O	)	no
O	O	inhibitor	yes
O	O	,	no
B-drug	B-drug	rofecoxib	yes
O	O	,	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	following	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

B-brand	B-brand	WelChol	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	metoprolol	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Such	no
O	O	interactions	no
O	O	might	no
O	O	be	no
O	O	manifested	no
O	O	by	no
O	O	increased	no
O	O	susceptibility	no
O	O	to	no
O	O	bruising	no
O	O	,	no
O	O	nosebleeds	no
O	O	,	no
O	O	hemoptysis	no
O	O	,	no
O	O	hematemesis	no
O	O	,	no
O	O	hematuria	no
O	O	and	yes
O	O	blood	yes
O	O	in	yes
O	O	the	no
O	O	stool	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	a	yes
O	O	single	yes
O	O	case	no
O	O	report	no
O	O	,	no
O	O	which	no
O	O	suggests	no
O	O	that	no
B-drug	B-drug	sucralfate	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
B-drug	B-drug	anagrelide	yes
O	O	absorption	no
O	O	.	no

O	O	Spontaneous	no
O	O	reports	no
O	O	of	yes
O	O	serotonin	yes
O	O	syndrome	no
O	O	associated	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-brand	B-brand	ZYVOX	yes
O	O	and	yes
B-group	B-group	serotonergic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	including	no
B-group	B-group	antidepressants	no
O	O	such	no
O	O	as	yes
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	4	yes
O	O	to	no
O	O	5	yes
O	O	hours	no
O	O	should	no
O	O	elapse	no
O	O	between	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cholestyramine	yes
O	O	and	yes
B-group	B-group	thyroid	yes
I-group	I-group	hormones	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
B-drug	B-drug	alosetron	yes
O	O	might	no
O	O	induce	no
O	O	other	no
O	O	enzymes	yes
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	ROMAZICON	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	in	yes
O	O	epileptic	no
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	been	no
O	O	receiving	no
B-group	O	benzodiazepine	yes
O	O	treatment	no
O	O	for	yes
O	O	a	yes
O	O	prolonged	no
O	O	period	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	administering	no
O	O	or	no
O	O	taking	no
B-brand	B-brand	TARCEVA	yes
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
O	O	other	no
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	such	no
O	O	as	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	limited	no
O	O	to	no
O	O	,	no
B-drug	B-drug	atazanavir	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	,	no
B-drug	B-drug	telithromycin	yes
O	O	,	no
B-drug	B-drug	troleandomycin	yes
O	O	(	no
B-drug	B-drug	TAO	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	voriconazole	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	,	no
O	O	if	no
O	O	any	no
O	O	,	no
O	O	of	yes
O	O	these	no
O	O	observations	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Anticoagulants	no
O	O	:	no
B-group	B-group	Thyroid	yes
I-group	I-group	hormones	no
O	O	appear	no
O	O	to	no
O	O	increase	no
O	O	catabolism	no
O	O	of	yes
O	O	vitamin	yes
O	O	K-dependent	yes
O	O	clotting	no
O	O	factors	no
O	O	.	no

B-drug	B-drug	Medroxyprogesterone	yes
I-drug	I-drug	Acetate	yes
O	O	-	yes
B-drug	B-drug	L-histidine	yes
O	O	was	no
O	O	observed	no
O	O	to	no
O	O	enhance	no
O	O	(	no
O	O	in	yes
O	O	tissue	yes
O	O	culture	no
O	O	)	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	medroxyprogesterone	yes
I-drug	I-drug	acetate	yes
O	O	in	yes
O	O	reducing	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	human	yes
O	O	breast	no
O	O	cancer	no
O	O	cells	yes
O	O	that	no
O	O	were	no
O	O	in	yes
O	O	the	no
O	O	S	yes
O	O	phase	no
O	O	.	no

O	O	Other	no
O	O	Drugs	no
O	O	:	no
O	O	Based	no
O	O	on	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	,	no
O	O	no	yes
O	O	dosage	no
O	O	adjustment	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
B-brand	B-brand	SUSTIVA	yes
O	O	(	no
B-drug	B-drug	efavirenz	yes
O	O	)	no
O	O	is	yes
O	O	given	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-group	aluminum/magnesium	no
B-group	I-group	hydroxide	yes
I-group	I-group	antacids	no
O	O	,	no
B-drug	B-drug	azithromycin	yes
O	O	,	no
B-drug	B-drug	cetirizine	yes
O	O	,	no
B-drug	B-drug	famotidine	yes
O	O	,	no
B-drug	B-drug	fluconazole	yes
O	O	,	no
B-drug	B-drug	lamivudine	yes
O	O	,	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	zidovudine	yes
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	intravenously	no
O	O	or	no
O	O	orally	no
O	O	administered	no
B-group	B-group	methylxanthines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	aminophylline	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	)	no
O	O	by	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	BROVANA	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	completely	no
O	O	evaluated	no
O	O	.	no

O	O	74.1	no
O	O	%	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	9.3	no
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	total	yes
O	O	PICR	no
O	O	could	no
O	O	be	no
O	O	avoided	no
O	O	by	no
O	O	simple	no
O	O	recommendations	no
O	O	;	no

O	O	The	no
O	O	data	no
O	O	do	no
O	O	not	no
O	O	suggest	no
O	O	the	no
O	O	need	no
O	O	for	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
O	O	either	no
B-brand	B-brand	HUMIRA	yes
O	O	or	no
B-drug	B-drug	MTX	yes
O	O	.	no

B-drug	B-drug	Diphenhydramine	yes
I-drug	I-drug	hydrochloride	yes
O	O	has	no
O	O	additive	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	and	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
B-group	B-group	hypnotics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
O	O	etc	no
O	O	)	no
O	O	.	no

O	O	g/mL	no
O	O	;	no

O	O	If	no
O	O	the	no
O	O	treatment	no
O	O	is	yes
O	O	continued	no
O	O	,	no
O	O	these	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	particularly	no
O	O	carefully	no
O	O	monitored	no
O	O	for	yes
O	O	adverse	no
O	O	effects	no
O	O	,	no
O	O	especially	no
O	O	conduction	no
O	O	disturbances	no
O	O	and	yes
O	O	exacerbation	no
O	O	of	yes
O	O	tachyarrhythmias	no
O	O	,	no
O	O	as	yes
B-drug	B-drug	amiodarone	yes
O	O	is	yes
O	O	continued	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	Prolonged	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	etomidate	yes

O	O	The	no
O	O	first	no
O	O	phase	no
O	O	of	yes
O	O	this	no
O	O	sequence	yes
O	O	,	no
O	O	initiation	no
O	O	,	no
O	O	is	yes
O	O	considered	no
O	O	to	no
O	O	result	no
O	O	from	no
O	O	at	yes
O	O	least	no
O	O	one	no
O	O	event	no
O	O	in	yes
O	O	the	no
O	O	genetic	no
O	O	apparatus	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
O	O	prophylactic	no
O	O	low	yes
O	O	dose	no
B-drug	B-drug	heparin	yes
O	O	did	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	affect	no
O	O	safety	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	its	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	Xigris	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	in	yes
O	O	an	no
O	O	adequate	no
O	O	and	yes
O	O	well-controlled	no
O	O	clinical	no
O	O	trial	no
O	O	.	no

B-drug	B-drug	Amphotericin	yes
I-drug	I-drug	B	yes
O	O	or	no
B-group	B-group	potassium-depleting	no
I-group	I-group	diuretics	no
O	O	(	no
B-group	B-group	benzothiadiazines	no
O	O	and	yes
O	O	related	yes
O	O	drugs	no
O	O	,	no
B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
B-drug	B-drug	furosemide	yes
O	O	)	no
O	O	enhanced	no
O	O	hypokalemia	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Ponstel	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	not	no
O	O	generally	no
O	O	recommended	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	of	yes
O	O	increased	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

B-group	B-group	Calcium	yes
I-group	O	Antagonists	no
O	O	:	no
O	O	After	no
O	O	repeated	no
O	O	co-administration	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	was	no
O	O	lowered	no
O	O	by	no
O	O	28	yes
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	20-33	no
O	O	]	no
O	O	.	no

O	O	Patients	no
O	O	with	yes
O	O	Crohn	no
O	O	s	yes
O	O	disease	no
O	O	who	no
O	O	received	no
B-group	B-group	immunosuppressants	no
O	O	tended	no
O	O	to	no
O	O	experience	no
O	O	fewer	no
O	O	infusion	no
O	O	reactions	no
O	O	compared	no
O	O	to	no
O	O	patients	no
O	O	on	no
O	O	no	yes
B-group	B-group	immunosuppressants	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	reports	no
O	O	in	yes
O	O	the	no
O	O	post-marketing	no
O	O	experience	no
O	O	of	yes
O	O	coma	no
O	O	and	yes
O	O	death	no
O	O	associated	no
O	O	with	yes
O	O	the	no
O	O	concomitant	no
O	O	intravenous	yes
O	O	misuse	no
O	O	of	yes
B-drug	B-drug	buprenorphine	yes
O	O	and	yes
B-group	B-drug	benzodiazepines	no
O	O	by	no
O	O	addicts	no
O	O	.	no

O	O	The	no
O	O	regulation	no
O	O	of	yes
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	the	no
O	O	glucocorticoid-induced	no
O	O	gene	yes
O	O	expression	no
O	O	by	no
O	O	the	no
O	O	antioxidative	no
O	O	gallates	no
O	O	is	yes
O	O	of	yes
O	O	great	no
O	O	interest	no
O	O	from	no
O	O	a	yes
O	O	therapeutic	no
O	O	point	no
O	O	of	yes
O	O	view	no
O	O	.	no

O	O	If	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	frovatriptan	yes
O	O	and	yes
O	O	an	no
B-group	B-group	SSRI	no
O	O	is	yes
O	O	clinically	no
O	O	warranted	no
O	O	,	no
O	O	appropriate	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	advised	no
O	O	.	no

B-group	B-group	Quinolones	no
O	O	form	yes
O	O	chelates	no
O	O	with	yes
O	O	alkaline	yes
O	O	earth	no
O	O	and	yes
O	O	transition	no
O	O	metals	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	Blocking	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Experience	no
O	O	in	yes
O	O	over	no
O	O	1400	no
O	O	patients	no
O	O	in	yes
O	O	a	yes
O	O	non-comparative	no
O	O	clinical	no
O	O	trial	no
O	O	has	no
O	O	shown	no
O	O	that	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	nifedipine	yes
O	O	and	yes
B-group	B-group	beta-blocking	no
I-group	I-group	agents	yes
O	O	is	yes
O	O	usually	no
O	O	well	no
O	O	tolerated	no
O	O	,	no
O	O	but	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	occasional	no
O	O	literature	no
O	O	reports	no
O	O	suggesting	no
O	O	that	no
O	O	the	no
O	O	combination	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	likelihood	no
O	O	of	yes
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	,	no
O	O	severe	no
O	O	hypotension	no
O	O	or	no
O	O	exacerbation	no
O	O	of	yes
O	O	angina	no
O	O	.	no

O	O	Moreover	no
O	O	,	no
O	O	as	yes
O	O	noted	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	may	no
O	O	even	no
O	O	be	no
O	O	more	no
O	O	pronounced	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	administered	no
O	O	at	yes
O	O	higher	no
O	O	doses	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	ertapenem	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	P-glycoprotein-mediated	no
O	O	transport	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	or	no
B-drug	B-drug	vinblastine	yes
O	O	and	yes
O	O	that	no
B-drug	B-drug	ertapenem	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	P-glycoprotein-mediated	no
O	O	transport	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-group	B-group	vasopressor	no
I-group	I-group	drugs	no
O	O	(	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	hypotension	no
O	O	related	yes
O	O	to	no
O	O	obstetric	no
O	O	blocks	no
O	O	)	no
O	O	and	yes
B-group	B-group	ergot-type	no
I-group	I-group	oxytocic	no
I-group	I-group	drugs	no
O	O	may	no
O	O	cause	no
O	O	severe	no
O	O	,	no
O	O	persistent	no
O	O	hypertension	no
O	O	or	no
O	O	cerebrovascular	no
O	O	accidents	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	when	no
B-group	B-group	NSAIDs	no
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	subjects	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	carefully	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	(	no
O	O	Read	no
O	O	circulars	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparation	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	concurrent	no
O	O	therapy	no
O	O	)	no
O	O	.	no

O	O	When	no
B-drug	B-drug	atropine	yes
O	O	and	yes
B-drug	B-drug	pralidoxime	yes
O	O	are	no
O	O	used	no
O	O	together	no
O	O	,	no
O	O	the	no
O	O	signs	no
O	O	of	yes
O	O	atropinization	no
O	O	(	no
O	O	flushing	no
O	O	,	no
O	O	mydriasis	no
O	O	,	no
O	O	tachycardia	no
O	O	,	no
O	O	dryness	no
O	O	of	yes
O	O	the	no
O	O	mouth	no
O	O	and	yes
O	O	nose	no
O	O	)	no
O	O	may	no
O	O	occur	no
O	O	earlier	no
O	O	than	no
O	O	might	no
O	O	be	no
O	O	expected	no
O	O	than	no
O	O	when	no
B-drug	B-drug	atropine	yes
O	O	is	yes
O	O	used	no
O	O	alone	no
O	O	because	no
B-drug	B-drug	pralidoxime	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	atropine	yes
O	O	.	no

B-group	B-group	Diuretic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	decrease	no
O	O	vascular	no
O	O	response	no
O	O	to	no
O	O	pressor	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	epinephrine	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Nitrofurantoin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Furadantin	yes
O	O	)	no
O	O	or	no

O	O	Effect	no
O	O	of	yes
B-group	B-group	AEDs	no
O	O	in	yes
O	O	Pediatric	yes
O	O	Patients	no
O	O	There	no
O	O	was	no
O	O	about	no
O	O	a	yes
O	O	22	no
O	O	%	no
O	O	increase	no
O	O	of	yes
O	O	apparent	no
O	O	total	yes
O	O	body	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	when	no
O	O	it	no
O	O	was	no
O	O	co-administered	no
O	O	with	yes
O	O	enzyme-inducing	no
B-group	B-group	AEDs	no
O	O	.	no

B-drug	B-drug	Disulfiram	yes
O	O	appears	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	rate	no
O	O	at	yes
O	O	which	no
O	O	certain	no
O	O	drugs	no
O	O	are	no
O	O	metabolized	no
O	O	and	yes
O	O	therefore	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	clinical	no
O	O	toxicity	no
O	O	of	yes
O	O	drugs	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	thioridazine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	worsen	no
O	O	the	no
O	O	tremor	no
O	O	in	yes
O	O	elderly	no
O	O	patients	no
O	O	with	yes
O	O	Parkinsons	no
O	O	disease	no
O	O	;	no

B-group	B-group	Antihistamines	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	counteract	no
O	O	the	no
O	O	sedative	no
O	O	effect	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Changes	no
O	O	in	yes
O	O	urinary	yes
O	O	homocysteine	no
O	O	following	no
B-group	B-group	synthetic	yes
I-group	I-group	steroidal	no
I-group	I-group	estrogen	no
O	O	and	yes
O	O	progestogen	no
O	O	administration	no
O	O	to	no
O	O	rats	no
O	O	.	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	azole	no
I-group	I-group	antifungal	no
I-group	I-group	agents	yes
O	O	are	no
O	O	reduced	yes
O	O	when	no
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	Hitherto	no
O	O	unrecognized	no
O	O	interactions	no
O	O	between	yes
O	O	homopolyribonucleotides	no
O	O	and	yes
O	O	complexes	no
O	O	thereof	no
O	O	are	no
O	O	suggested	no
O	O	by	no
O	O	interferon	yes
O	O	induction	no
O	O	data	no
O	O	obtained	no
O	O	in	yes
O	O	a	yes
O	O	highly	no
O	O	sensitive	no
O	O	assay	no
O	O	system	yes
O	O	of	yes
O	O	primary	no
O	O	rabbit	yes
O	O	kidney	yes
O	O	cell	yes
O	O	cultures	no
O	O	superinduced	no
O	O	by	no
O	O	metabolic	no
O	O	inhibitors	no
O	O	.	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	allergic	no
O	O	reaction	no
O	O	.	no

B-drug	B-drug	Isoflurane	yes
O	O	potentiates	no
O	O	the	no
O	O	muscle	no
O	O	relaxant	no
O	O	effect	no
O	O	of	yes
O	O	all	yes
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	most	no
O	O	notably	no
B-group	B-group	nondepolarizing	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	and	yes
O	O	MAC	no
O	O	(	no
O	O	minimum	no
O	O	alveolar	no
O	O	concentration	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	N	yes
O	O	2O	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	etanercept	yes
O	O	(	no
O	O	another	no
O	O	TNF	no
O	O	-blocking	no
O	O	agent	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	anakinra	yes
O	O	(	no
O	O	an	no
B-group	B-group	interleukin-1	yes
I-group	I-group	antagonist	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	infections	no
O	O	,	no
O	O	and	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	neutropenia	no
O	O	and	yes
O	O	no	yes
O	O	additional	no
O	O	benefit	no
O	O	compared	no
O	O	to	no
O	O	these	no
O	O	medicinal	yes
O	O	products	no
O	O	alone	no
O	O	.	no

O	O	The	no
O	O	conversion	yes
O	O	of	yes
B-drug_n	B-drug_n	6-deoxy	no
I-drug_n	I-drug_n	penciclovir	yes
O	O	to	no
B-drug	B-drug	penciclovir	yes
O	O	is	yes
O	O	catalyzed	no
O	O	by	no
O	O	aldehyde	yes
O	O	oxidase	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	coumarin-type	no
I-group	I-group	anticoagulants	no
O	O	,	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-brand	B-brand	Nalfon	yes
O	O	to	no
O	O	therapy	no
O	O	could	no
O	O	prolong	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	5	yes
O	O	.	no

O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
O	O	high-dose	no
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-group	B-group	carbonic	yes
I-group	I-group	anhydrase	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	as	yes
O	O	anorexia	no
O	O	,	no
O	O	tachypnea	no
O	O	,	no
O	O	lethargy	no
O	O	and	yes
O	O	coma	no
O	O	have	no
O	O	been	no
O	O	rarely	no
O	O	reported	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	block	yes
O	O	the	no
O	O	antihypertensive	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	guanethidine	yes
O	O	and	yes
O	O	similarly	no
O	O	acting	yes
O	O	compounds	no
O	O	.	no

O	O	The	no
O	O	rats	no
O	O	treated	no
O	O	with	yes
O	O	the	no
O	O	highest	no
O	O	dose	no
O	O	of	yes
B-drug_n	B-drug_n	TML	no
O	O	manifested	no
O	O	significantly	no
O	O	longer	no
O	O	latencies	no
O	O	to	no
O	O	lose	no
O	O	the	no
O	O	righting	no
O	O	reflex	no
O	O	and	yes
O	O	shorter	no
O	O	durations	no
O	O	of	yes
O	O	sleep	no
O	O	than	no
O	O	did	no
O	O	controls	no
O	O	.	no

O	O	High-dose	no
B-drug	B-drug	cyclosporin	yes
O	I-drug	A	yes
O	O	resulting	no
O	O	in	yes
O	O	concentrations	no
O	O	above	no
O	O	2000	yes
O	O	ng/mL	no
O	O	administered	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	etoposide	yes
O	O	has	no
O	O	led	no
O	O	to	no
O	O	an	no
O	O	80	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	etoposide	yes
O	O	exposure	yes
O	O	with	yes
O	O	a	yes
O	O	38	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	total	yes
O	O	body	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	etoposide	yes
O	O	compared	no
O	O	to	no
B-drug	B-drug	etoposide	yes
O	O	alone	no
O	O	.	no

O	O	Since	no
O	O	a	yes
O	O	clinically	no
O	O	significant	no
O	O	interaction	no
O	O	may	no
O	O	be	no
O	O	anticipated	no
O	O	,	no
O	O	alternative	no
B-group	B-drug	antihypertensive	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	changes	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	adequately	no
O	O	studied	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	minor	no
O	O	contribution	no
O	O	of	yes
O	O	adenosine	yes
O	O	receptors	no
O	O	to	no
O	O	these	no
O	O	effects	no
O	O	,	no
O	O	although	no
B-drug	B-drug	theophylline-induced	no
O	O	anxiogenic	no
O	O	effects	no
O	O	were	no
O	O	antagonized	no
O	O	by	no
O	O	an	no
O	O	A2	yes
O	O	receptor	yes
O	O	agonist	no
O	O	.	no

O	O	Drug/	no
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
B-brand	B-brand	MEPRON	yes
O	O	interferes	no
O	O	with	yes
O	O	clinical	no
O	O	laboratory	no
O	O	test	yes
O	O	or	no
O	O	assay	no
O	O	results	no
O	O	.	no

O	O	These	no
O	O	levels	no
O	O	then	no
O	O	remained	no
O	O	stable	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	1	yes
O	O	year	no
O	O	of	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Indomethacin	yes
O	O	may	no
O	O	also	no
O	O	affect	no
O	O	plasma	yes
O	O	renin	no
O	O	levels	no
O	O	,	no
O	O	aldosterone	yes
O	O	excretion	no
O	O	,	no
O	O	and	yes
O	O	renin	no
O	O	profile	no
O	O	evaluation	no
O	O	.	no

O	O	The	no
O	O	extent	no
O	O	of	yes
O	O	interaction	no
O	O	depends	no
O	O	on	no
O	O	the	no
O	O	variability	no
O	O	of	yes
O	O	effect	no
O	O	on	no
O	O	CYP2D6	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	Inhibit	no
O	O	Drug	yes
O	O	Transport	no
O	O	Systems	no
B-drug	B-drug	Lapatinib	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	of	yes
O	O	the	no
O	O	efflux	no
O	O	transporter	no
O	O	P-glycoprotein	no
O	O	(	no
O	O	Pgp	no
O	O	,	no
O	O	ABCB1	no
O	O	)	no
O	O	.	no

O	O	Ultimately	no
O	O	however	no
O	O	,	no
O	O	up	no
O	O	to	no
O	O	80	yes
O	O	%	no
O	O	of	yes
O	O	type	yes
O	O	2	yes
O	O	diabetics	no
O	O	die	no
O	O	from	no
O	O	macrovascular	no
O	O	cardiovascular	no
O	O	disease	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	combining	no
B-drug	B-drug	digoxin	yes
O	O	with	yes
O	O	any	no
O	O	drug	yes
O	O	that	no
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	significant	no
O	O	deterioration	no
O	O	in	yes
O	O	renal	no
O	O	function	no
O	O	,	no
O	O	since	no
O	O	a	yes
O	O	decline	no
O	O	in	yes
O	O	glomerular	no
O	O	filtration	no
O	O	or	no
O	O	tubular	no
O	O	secretion	no
O	O	may	no
O	O	impair	no
O	O	the	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Effect	no

O	O	CONCLUSION	no
O	O	:	no
B-drug	B-drug	Cisapride	yes
O	O	can	no
O	O	be	no
O	O	administered	no
O	O	safely	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
O	O	low	yes
O	O	therapeutic	no
O	O	dosages	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	.	no

O	O	The	no
O	O	optimal	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	,	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-group	B-group	Cephalosporins	no
O	O	,	no
O	O	including	no
B-drug	B-drug	cefotaxime	yes
I-drug	I-drug	sodium	yes
O	O	,	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	occasionally	no
O	O	induce	no
O	O	a	yes
O	O	positive	no
O	O	direct	no
O	O	Coombs	no
O	O	test	yes
O	O	.	no

O	O	OBJECTIVES	no
O	O	.	no

B-drug	B-drug	Metoclopramide	yes
O	O	:	no
O	O	Bioavailability	no
O	O	is	yes
O	O	mildly	no
O	O	reduced	yes
O	O	(	no
O	O	approximately	no
O	O	10	yes
O	O	%	no
O	O	)	no
O	O	when	no
B-drug	B-drug	zalcitabine	yes
O	O	and	yes
B-drug	B-drug	metoclopramide	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	In	yes
O	O	our	no
O	O	laboratory	no
O	O	,	no
O	O	preliminary	no
O	O	whole-cell	no
O	O	,	no
O	O	tight	no
O	O	seal	no
O	O	recordings	no
O	O	of	yes
O	O	rat	yes
O	O	spinal	no
O	O	substantia	no
O	O	gelatinosa	no
O	O	neurons	no
O	O	including	no
O	O	biocytin	no
O	O	in	yes
O	O	the	no
O	O	patch	no
O	O	pipette	no
O	O	yielded	no
O	O	a	yes
O	O	significantly	no
O	O	smaller	no
O	O	proportion	no
O	O	of	yes
O	O	neurons	no
O	O	hyperpolarized	no
O	O	by	no
B-group	B-group	selective	no
I-group	I-group	opioid	no
I-group	I-group	agonists	no
O	O	compared	no
O	O	with	yes
O	O	recordings	no
O	O	without	no
O	O	biocytin	no
O	O	.	no

O	O	Nonetheless	no
O	O	,	no
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	individual	no
B-brand	B-brand	Simulect	yes
O	O	clearance	no
O	O	values	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	azathioprine	yes
O	O	(	no
O	O	12-57	no
O	O	mL/h	no
O	O	)	no
O	O	or	no
B-drug	B-drug	mycophenolate	yes
I-drug	I-drug	mofetil	yes
O	O	(	no
O	O	7-54	no
O	O	mL/h	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	extend	no
O	O	outside	no
O	O	the	no
O	O	range	no
O	O	observed	no
O	O	with	yes
O	O	dual	yes
O	O	therapy	no
O	O	(	no
O	O	10-78	no
O	O	mL/h	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	vivo	no
O	O	interaction	no
O	O	studies	no
O	O	in	yes
O	O	humans	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	do	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	PK	no
O	O	properties	no
O	O	of	yes
B-drug	B-drug	anagrelide	yes
O	O	,	no
O	O	nor	yes
O	O	does	no
B-drug	B-drug	anagrelide	yes
O	O	affect	no
O	O	the	no
O	O	PK	no
O	O	properties	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	.	no

B-drug	B-drug	Diltiazem	yes
O	O	plasma	yes
O	O	levels	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	lovastatin	yes
O	O	or	no
B-drug	B-drug	pravastatin	yes
O	O	.	no

O	O	Metabolism	no
O	O	of	yes
B-drug	B-drug	dasatinib	yes
O	O	is	yes
O	O	mainly	no
O	O	hepatic	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	,	no
B-drug	B-drug	Ranitidine	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	(	no
O	O	n=9	no
O	O	)	no
O	O	,	no
O	O	pretreatment	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	or	no
B-drug	B-drug	ranitidine	yes
O	O	did	no
O	O	not	no
O	O	affect	no
B-drug	B-drug	flurbiprofen	yes
O	O	pharmacokinetics	no
O	O	except	no
O	O	that	no
O	O	a	yes
O	O	small	no
O	O	(	no
O	O	13	yes
O	O	%	no
O	O	)	no
O	O	but	no
O	O	statistically	no
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	serum	yes
O	O	concentration	no
O	O	curve	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	resulted	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	Using	no
O	O	in	yes
O	O	situ	no
O	O	hybridization	no
O	O	,	no
O	O	we	no
O	O	observed	no
O	O	that	no
B-drug	B-drug	METH	no
O	O	caused	no
O	O	a	yes
O	O	rapid	no
O	O	and	yes
O	O	transient	no
O	O	dose-dependent	no
O	O	increase	no
O	O	in	yes
O	O	arc	no
O	O	mRNA	yes
O	O	level	no
O	O	in	yes
O	O	the	no
O	O	striatum	no
O	O	and	yes
O	O	cortex	no
O	O	that	no
O	O	was	no
O	O	abolished	no
O	O	by	no
O	O	pretreatment	no
O	O	with	yes
O	O	the	no
O	O	specific	no
O	O	dopamine	yes
O	O	D1	no
O	O	receptor	yes
O	O	antagonist	yes
B-drug_n	B-drug_n	SCH-23390	no
O	O	but	no
O	O	not	no
O	O	by	no
O	O	an	no
B-group	B-group	atypical	no
I-group	I-group	neuroleptic	no
B-drug	B-drug	clozapine	yes
O	O	.	no

O	O	Consider	no
O	O	additive	no
O	O	sedative	no
O	O	effects	no
O	O	and	yes
O	O	confusional	no
O	O	states	no
O	O	to	no
O	O	emerge	no
O	O	,	no
O	O	if	no
B-drug	B-drug	chlorprothixene	yes
O	O	is	yes
O	O	given	no
O	O	with	yes
B-group	B-group	benzodiazepines	no
O	O	or	no
B-group	B-group	barbituates	no
O	O	.	no

B-drug	B-drug	Aminophylline	yes
I-drug	I-drug	Etomidate	yes
O	O	antagonism	no

B-group	B-group	Coumarin	yes
I-group	O	Anticoagulants	no
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	small	no
O	O	clinical	no
O	O	trial	no
O	O	in	yes
O	O	which	no
B-drug	B-drug	lovastatin	yes
O	O	was	no
O	O	administered	no
O	O	to	no
B-drug	B-drug	warfarin	yes
O	O	treated	no
O	O	patients	no
O	O	,	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	prothrombin	yes
O	O	time	no
O	O	was	no
O	O	detected	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
O	O	single	yes
O	O	,	no
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	and	yes
O	O	800	no
O	O	mg	yes
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	strong	no
O	O	,	no
O	O	selective	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	produced	no
O	O	a	yes
O	O	34	no
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	zaleplons	no
O	O	maximal	no
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	a	yes
O	O	20	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	plasma	yes
O	O	concentration-time	no
O	O	curve	no
O	O	.	no

O	O	Other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	)	no
O	O	may	no
O	O	also	no
O	O	have	no
O	O	this	no
O	O	effect	no
O	O	.	no

O	O	iii	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	is	yes
O	O	unclear	no
O	O	.	no

B-drug	B-drug	alcohol*	no
O	O	;	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	fenoprofen	yes
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	its	no
O	O	affinity	no
O	O	for	yes
O	O	albumin	yes
O	O	,	no
O	O	may	no
O	O	displace	no
O	O	from	no
O	O	their	no
O	O	binding	no
O	O	sites	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	also	no
O	O	albumin	yes
O	O	bound	no
O	O	,	no
O	O	and	yes
O	O	this	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	drug	yes
O	O	interaction	no
O	O	.	no

O	O	[	no
O	O	A	yes
O	O	pharmacological	no
O	O	analysis	no
O	O	of	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug_n	B-drug_n	angiotensin	yes
O	O	on	no
O	O	stimulated	no
O	O	gastric	yes
O	O	secretion	no
O	O	]	no
O	O	Chronic	no
O	O	experiments	no
O	O	on	no
O	O	dogs	no
O	O	with	yes
O	O	gastric	yes
O	O	fistulas	no
O	O	were	no
O	O	carried	no
O	O	out	no
O	O	to	no
O	O	study	no
O	O	the	no
O	O	influence	no
O	O	of	yes
B-drug_n	B-drug_n	angiotensin	yes
I-drug_n	I-drug_n	1	yes
O	O	and	yes
B-drug_n	B-drug_n	angiotensin	yes
I-drug_n	I-drug_n	2	yes
O	O	on	no
B-drug	B-drug	pentagastrin-	no
O	O	and	yes
B-drug	B-drug	histamine-induced	no
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	.	no

O	O	changes	no
O	O	in	yes
O	O	cervical	no
O	O	mucus	no
O	O	,	no
O	O	the	no
O	O	endometrium	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	fallopian	no
O	O	tubes	no
O	O	;	no

B-group	B-group	Anticoagulants	no
O	O	including	no
B-group	O	coumarin	yes
I-group	O	derivatives	no
O	O	,	no
O	O	indandione	yes
O	O	derivatives	no
O	O	,	no
O	O	and	yes
B-group	B-group	platelet	yes
I-group	I-group	aggregation	no
I-group	I-group	inhibitors	no
O	O	such	no
O	O	as	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	ardeparin	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	)	no
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	5	yes
O	O	mg	yes
O	O	QD	no
O	O	or	no
O	O	10	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	(	no
O	O	exposure	yes
O	O	)	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	Protein	yes
O	O	Binding	no
O	O	In	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	diclofenac	yes
O	O	interferes	no
O	O	minimally	no
O	O	or	no
O	O	not	no
O	O	at	yes
O	O	all	yes
O	O	with	yes
O	O	the	no
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	salicylic	yes
I-drug	I-drug	acid	yes
O	O	(	no
O	O	20	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	binding	no
O	O	)	no
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
B-drug	B-drug	prednisolone	yes
O	O	(	no
O	O	10	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	binding	no
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	injection	yes
O	O	of	yes
B-drug_n	B-drug_n	phencyclidine	yes
O	O	(	no
B-drug_n	B-drug_n	PCP	yes
O	O	)	no
O	O	were	no
O	O	observed	no
O	O	by	no
O	O	measuring	no
O	O	locomotor	no
O	O	activity	yes
O	O	and	yes
O	O	stereotyped	no
O	O	behavior	no
O	O	.	no

O	O	Thus	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	stable	no
O	O	dosage	no
O	O	on	no
O	O	one	no
O	O	of	yes
O	O	the	no
O	O	agents	yes
O	O	in	yes
O	O	this	no
O	O	category	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	begins	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	EQUETROTM	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	reasonable	no
O	O	to	no
O	O	expect	no
O	O	that	no
O	O	a	yes
O	O	dose	no
O	O	adjustment	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Repeated	no
O	O	injection	yes
O	O	of	yes
B-drug_n	B-drug_n	PCP	yes
O	O	for	yes
O	O	20	yes
O	O	days	no
O	O	into	no
O	O	mice	no
O	O	induced	no
O	O	lower	no
O	O	locomotor	no
O	O	activity	yes
O	O	than	no
O	O	that	no
O	O	in	yes
O	O	acutely	no
O	O	injected	no
O	O	mice	no
O	O	.	no

B-drug_n	B-drug_n	Ibogaine	no
O	O	,	no
O	O	but	no
O	O	not	no
B-drug_n	B-drug_n	18-MC	no
O	O	,	no
O	O	decreases	no
O	O	heart	no
O	O	rate	no
O	O	at	yes
O	O	high	yes
O	O	doses	no
O	O	.	no

O	O	Similar	no
O	O	effects	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	with	yes
O	O	other	no
O	O	potent	no
O	O	CYP2D6	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	medications	no
O	O	have	no
O	O	been	no
O	O	administered	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	with	yes
B-brand	B-brand	Simulect	yes
O	O	with	yes
O	O	no	yes
O	O	increase	no
O	O	in	yes
O	O	adverse	no
O	O	reactions	no
O	O	:	no
O	O	ATG/ALG	no
O	O	,	no
B-drug	B-drug	azathioprine	yes
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	mycophenolate	yes
I-drug	I-drug	mofetil	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	muromonab-CD3	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	MAOIs	no
O	O	,	no
O	O	or	no
O	O	within	no
O	O	14	yes
O	O	days	no
O	O	of	yes
O	O	discontinuing	no
O	O	treatment	no
O	O	with	yes
O	O	a	yes
B-group	B-group	MAOI	no
O	O	.	no

B-drug	B-drug	Midazolam	yes
O	O	used	no
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	1.25	yes
O	O	mg/kg	no
O	O	and	yes
O	O	2.5	yes
O	O	mg/kg	no
O	O	decreased	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	,	no
B-drug	B-drug	metamizol	no
O	O	(	no
O	O	only	no
O	O	in	yes
O	O	the	no
O	O	tail-flick	no
O	O	test	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	indomethacin	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
B-drug	B-drug	Rofecoxib	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
B-drug	B-drug	norethindrone	yes
O	O	.	no

O	O	The	no
O	O	continued	no
O	O	need	no
O	O	for	yes
O	O	the	no
O	O	other	no
B-group	B-drug	antiarrhythmic	no
I-group	O	agent	yes
O	O	should	no
O	O	be	no
O	O	reviewed	no
O	O	after	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	have	no
O	O	been	no
O	O	established	no
O	O	,	no
O	O	and	yes
O	O	discontinuation	no
O	O	ordinarily	no
O	O	should	no
O	O	be	no
O	O	attempted	no
O	O	.	no

O	O	Drug-lab	no
O	O	interactions	no
O	O	:	no
O	O	implications	no
O	O	for	yes
O	O	nutrition	no
O	O	support	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	careful	no
O	O	attention	no
O	O	must	no
O	O	be	no
O	O	directed	no
O	B-group	to	no
O	O	cross	no
O	O	toxicity	no
O	O	and	yes
O	O	possible	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-group	O	antiretroviral	no
O	O	and	yes
B-group	B-group	antineoplastic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
O	O	other	no
O	O	agents	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinefics	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes

O	O	Patients	no
O	O	who	no
O	O	require	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	with	yes
B-drug	B-drug	HIVID	yes
O	O	should	no
O	O	have	no
O	O	frequent	no
O	O	clinical	no
O	O	and	yes
O	O	laboratory	no
O	O	monitoring	no
O	O	with	yes
O	O	dosage	no
O	O	adjustment	no
O	O	for	yes
O	O	any	no
O	O	significant	no
O	O	change	no
O	O	in	yes
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	150	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	ranitidine	yes
O	O	q12h	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	increased	no
O	O	the	no
B-drug	B-drug	ceftibuten	yes
O	O	C	yes
O	O	max	no
O	O	by	no
O	O	23	no
O	O	%	no
O	O	and	yes
B-drug	B-drug	ceftibuten	yes
O	O	AUC	no
O	O	by	no
O	O	16	yes
O	O	%	no
O	O	.	no

B-group	B-group	Antacid	no
O	O	(	no
B-brand	B-brand	Maalox	no
O	O	)	no
O	O	:	no
B-brand	B-brand	Maalox	no
O	O	reduced	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	(	no
O	O	N=16	no
O	O	)	no
O	O	by	no
O	O	about	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	intensity	no
O	O	,	no
O	O	uniformity	no
O	O	and	yes
O	O	time	no
O	O	course	no
O	O	of	yes
B-group	B-group	anticoagulant	no
O	O	interference	no
O	O	by	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	secobarbital	yes
O	O	,	no
B-drug	B-drug	glutethimide	yes
O	O	,	no
B-drug	B-drug	chloral	yes
I-drug	I-drug	hydrate	yes
O	O	and	yes
B-drug	B-drug	methaqualone	yes
O	O	were	no
O	O	systematically	no
O	O	investigated	no
O	O	in	yes
O	O	16	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	coumarin	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Warfarin-Vitamin	no
I-drug	B-group	K	yes
O	O	can	no
O	O	antagonize	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes

O	O	If	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	cyclophosphamide	yes
O	O	within	no
O	O	10	yes
O	O	days	no
O	O	of	yes
O	O	general	no
O	O	anesthesia	yes
O	O	,	no
O	O	the	no
O	O	anesthesiologist	no
O	O	should	no
O	O	be	no
O	O	alerted	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	on	no
O	O	monoamine	no
O	O	oxidases	no
O	O	and	yes
O	O	on	no
O	O	intestinal	no
O	O	first	no
O	O	pass	no
O	O	secondary	yes
O	O	to	no
O	O	high	yes
O	O	intraluminal	no
O	O	concentrations	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	examined	no
O	O	.	no

O	O	2	yes
O	O	.	no

O	O	Clinical	no
O	O	implications	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	interactions	no
O	O	with	yes
O	O	five	no
B-group	B-group	sedatives	no
O	O	.	no

O	O	Table	no
O	O	5a	no
O	O	:	no
O	O	Drugs	no
O	O	That	no
O	O	Should	no
O	O	Not	no
O	O	Be	no
O	O	Coadministered	no
O	O	With	yes
B-brand	B-brand	SUSTIVA	yes

B-drug	B-drug	Clonidine	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	with	yes
O	B-group	agents	yes
O	I-group	with	yes
B-group	I-group	b-blocking	no
I-group	I-group	properties	no
O	O	may	no
O	O	potentiate	no
O	O	blood-pressure-	no
O	O	and	yes
O	O	heart-rate-lowering	no
O	O	effects	no
O	O	.	no

O	O	Steady	no
O	O	state	no
O	O	plasma	yes
B-drug	B-drug	digitoxin	yes
O	O	concentrations	no
O	O	did	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	change	no
O	O	.	no

O	O	CFUs	no
O	O	were	no
O	O	maintained	no
O	O	at	yes
O	O	low	yes
O	O	levels	no
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	3	yes
O	O	)	no
O	O	CFU	no
O	O	mL	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	)	no
O	O	for	yes
O	O	24	yes
O	O	h	yes
O	O	by	no
B-drug	B-drug	vancomycin/flavone	no
O	O	combinations	no
O	O	.	no

O	O	Appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	are	no
O	O	not	no
O	O	established	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	whenever	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	other	no
O	O	drugs	no
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	cotherapy	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

B-drug	B-drug	Olanzapine	yes
O	O	treatment	no
O	O	improves	no
O	O	quality	no
O	O	of	yes
O	O	life	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	schizophrenia	no
O	O	and	yes
O	O	related	yes
O	O	psychoses	no
O	O	to	no
O	O	a	yes
O	O	greater	no
O	O	extent	no
O	O	than	no
B-drug	B-drug	haloperidol	yes
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	broadly	no
O	O	the	no
O	O	same	yes
O	O	extent	no
O	O	as	yes
B-drug	B-drug	risperidone	yes
O	O	.	no

O	O	Since	no
B-brand	B-brand	PLETAL	yes
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P-450	no
O	O	isoenzymes	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-brand	B-brand	PLETAL	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
O	O	inhibitors	no
O	O	of	yes
O	O	C.P.A	no
O	O	.	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	or	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2C19	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	omeprazole	yes
O	O	.	no

O	O	On	no
O	O	the	no
O	O	average	no
O	O	for	yes
O	O	the	no
O	O	group	yes
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	was	no
O	O	reduced	yes
O	O	about	no
O	O	20	yes
O	O	%	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	evaluating	no
O	O	the	no
O	O	minimum	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	(	no
O	O	MIC	yes
O	O	)	no
O	O	of	yes
B-drug	B-drug	vancomycin	yes
O	O	,	no
B-drug	B-drug	cefazolin	yes
O	O	,	no
B-drug	B-drug	ampicillin	yes
O	O	,	no
B-drug	B-drug	ampicillin/flucoxacillin	no
O	O	,	no
B-drug	B-drug	ceftazidime	yes
O	O	,	no
B-drug	B-drug	gentamicin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	amphotericin	yes
O	O	demonstrated	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	incompatibility	no
O	O	of	yes
O	O	these	no
B-group	B-group	antibiotics	no
O	O	with	yes
B-brand	B-brand	EXTRANEAL	yes
O	O	.	no

O	O	Fulminant	no
O	O	rhabdomyolysis	no
O	O	has	no
O	O	been	no
O	O	seen	no
O	O	as	yes
O	O	early	no
O	O	as	yes
O	O	three	no
O	O	weeks	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	combined	no
O	O	therapy	no
O	O	with	yes
O	O	another	no
B-group	B-group	fibrate	no
O	O	and	yes
B-drug	B-drug	lovastatin	yes
O	O	but	no
O	O	may	no
O	O	be	no
O	O	seen	no
O	O	after	no
O	O	several	no
O	O	months	no
O	O	.	no

O	O	Although	no
O	O	it	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	definitively	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	fluvoxamine	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	IIIA4	no
O	O	inhibitor	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	,	no
O	O	given	no
O	O	the	no
O	O	substantial	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	that	no
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	be	no
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	H2	no
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	guanfacine	yes
O	O	concomitantly	no
O	O	with	yes
O	O	known	no
O	O	microsomal	no
O	O	enzyme	no
O	O	inducer	no
O	O	(	no
B-drug	B-drug	phenobarbital	yes
O	O	or	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	to	no
O	O	two	no
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	impairment	no
O	O	reportedly	no
O	O	resulted	no
O	O	in	yes
O	O	significant	no
O	O	reductions	no
O	O	in	yes
O	O	elimination	no
O	O	half-life	no
O	O	and	yes
O	O	plasma	yes
O	O	concentration	no
O	O	.	no

O	O	These	no
B-group	B-group	antibiotics	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	myasthenic	no
O	O	patient	no
O	O	only	no
O	O	where	no
O	O	definitely	no
O	O	indicated	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	careful	no
O	O	adjustment	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	of	yes
O	O	adjunctive	no
B-group	B-group	anticholinesterase	no
O	O	dosage	no
O	O	.	no

O	O	Both	no
B-drug_n	B-drug_n	18-MC	no
O	O	and	yes
B-drug_n	B-drug_n	ibogaine	no
O	O	are	no
O	O	sequestered	no
O	O	in	yes
O	O	fat	yes
O	O	and	yes
O	O	,	no
O	O	like	yes
B-drug_n	B-drug_n	ibogaine	no
O	O	,	no
B-drug_n	B-drug_n	18-MC	no
O	O	probably	no
O	O	has	no
O	O	an	no
O	O	active	no
O	O	metabolite	yes
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	-	yes
O	O	Combined	no
O	O	administration	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
O	O	40	yes
O	O	mg/day	no
O	O	for	yes
O	O	21	yes
O	O	days	no
O	O	)	no
O	O	and	yes
O	O	the	no
O	O	CYP1A2	no
O	O	substrate	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	300	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

B-group	B-group	Digitalis	yes
I-group	I-group	Glycosides	yes
O	O	:	no
O	O	Therapeutic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	digitalis	yes
I-group	I-group	glycosides	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	other	no
O	O	published	no
O	O	reports	no
O	O	describe	no
O	O	modest	no
O	O	elevations	no
O	O	(	no
O	O	less	no
O	O	than	no
O	O	two-fold	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	and	yes
O	O	metabolite	yes
O	O	concentrations	no
O	O	when	no
B-drug	B-drug	clozapine	yes
O	O	was	no
O	O	taken	no
O	O	with	yes
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	sertraline	yes
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	D1	no
O	O	receptors	no
O	O	are	no
O	O	coupled	no
O	O	to	no
O	O	activation	no
O	O	of	yes
O	O	arc	no
O	O	gene	yes
O	O	,	no
O	O	which	no
O	O	may	no
O	O	be	no
O	O	involved	no
O	O	in	yes
O	O	functional	no
O	O	or	no
O	O	structural	no
O	O	alterations	no
O	O	underlying	no
O	O	neural	no
O	O	plasticity	no
O	O	triggered	no
O	O	by	no
B-drug	B-drug	METH	no
O	O	.	no

O	O	.	no

O	O	Close	no
O	O	monitoring	no
O	O	allows	no
O	O	physicians	no
O	O	to	no
O	O	minimize	no
O	O	risks	no
O	O	,	no
O	O	maximize	no
O	O	benefits	no
O	O	,	no
O	O	and	yes
O	O	get	no
O	O	the	no
O	O	most	no
O	O	out	no
O	O	of	yes
O	O	what	no
O	O	modern	no
O	O	medications	no
O	O	can	no
O	O	do	no
O	O	to	no
O	O	help	no
O	O	older	no
O	O	patients	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	ritonavir	yes
O	O	is	yes
O	O	coadministered	no
O	O	,	no
O	O	prescribers	no
O	O	should	no
O	O	also	no
O	O	refer	no
O	O	to	no
O	O	the	no
O	O	prescribing	no
O	O	information	no
O	O	for	yes
B-drug	B-drug	ritonavir	yes
O	O	regarding	no
O	O	drug	yes
O	O	interactions	no
O	O	associated	no
O	O	with	yes
O	O	this	no
O	O	agent	yes
O	O	.	no

O	O	Exogenous	no
B-drug	B-drug	estradiol	yes
O	O	also	no
O	O	appeared	no
O	O	to	no
O	O	influence	no
O	O	the	no
O	O	percentage	no
O	O	of	yes
B-drug_n	B-drug_n	endotoxin-induced	no
O	O	deaths	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	manner	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	MEPRON	yes
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	highly	no
O	O	plasma	yes
O	O	protein-	no
O	O	bound	no
O	O	drugs	no
O	O	with	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	indices	no
O	O	,	no
O	O	as	yes
O	O	competition	no
O	O	for	yes
O	O	binding	no
O	O	sites	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	such	no
O	O	drug	yes
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	AZOPT	yes
O	O	(	no
B-drug	B-drug	brinzolamide	yes
O	O	ophthalmic	no
O	O	suspension	yes
O	O	)	no
O	O	1	yes
O	O	%	no
O	O	.	no

O	O	When	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	adrenal	no
I-group	I-group	corticosteroids	no
O	O	.	no

O	O	forms	no
O	O	of	yes
O	O	memory	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	,	no
B-drug	B-drug	Digoxin	yes
O	O	,	no
B-group	B-group	Salicylate	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Heparin	yes
O	O	The	no
O	O	in	yes
O	O	vitro	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	is	yes
O	O	only	no
O	O	slightly	no
O	O	reduced	yes
O	O	by	no
B-drug	B-drug	ketorolac	yes
I-drug	I-drug	tromethamine	yes
O	O	(	no
O	O	99.5	no
O	O	%	no
O	O	control	no
O	O	vs	no
O	O	99.3	no
O	O	%	no
O	O	)	no
O	O	when	no
B-drug	B-drug	ketorolac	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	reach	no
O	O	5	yes
O	O	to10	no
O	O	m	yes
O	O	g/mL	no
O	O	.	no

O	O	Conversely	no
O	O	,	no
O	O	at	yes
O	O	exposure	yes
O	O	levels	no
O	O	close	no
O	O	to	no
O	O	the	no
O	O	"	no
O	O	limit	no
O	O	values	no
O	O	"	no

O	O	Reduced	yes
O	O	response	no
O	O	to	no
O	O	metyrapone	yes
O	O	test	yes
O	O	.	no

O	O	Subjects	no
O	O	treated	no
O	O	with	yes
O	O	200	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	dideoxyinosine	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	21	yes
O	O	days	no
O	O	received	no
O	O	1200	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	or	no
O	O	an	no
O	O	equivalent	no
O	O	amount	no
O	O	of	yes
O	O	placebo/day	no
O	O	for	yes
O	O	Days	no
O	O	8	yes
O	O	to	no
O	O	21	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	concomitant	no
O	O	administration	no
O	O	.	no

O	O	Use	no
O	O	of	yes
O	O	barrier	no
O	O	form	yes
O	O	of	yes
O	O	contraception	no
O	O	is	yes
O	O	suggested	no
O	O	while	no
O	O	on	no
B-drug	B-drug	griseofulvin	yes
O	O	therapy	no
O	O	.	no

O	O	With	yes
O	O	drugs	no
O	O	inhibiting	no
O	O	CYP3A	no
O	O	to	no
O	O	a	yes
O	O	lesser	no
O	O	,	no
O	O	but	no
O	O	still	no
O	O	significant	no
O	O	degree	no
O	O	,	no
B-drug	B-drug	estazolam	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	only	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	consideration	no
O	O	of	yes
O	O	appropriate	no
O	O	dosage	no
O	O	reduction	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	because	no
O	O	some	no
B-group	B-group	quinolones	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	enhance	no
O	O	the	no
O	O	anticoagulant	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	in	yes
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	if	no
O	O	a	yes
B-group	B-group	quinolone	no
I-group	I-group	antimicrobial	no
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	Clinically	no
O	O	meaningful	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	occurred	no
O	O	with	yes
O	O	concomitant	no
O	O	medications	no
O	O	and	yes
O	O	include	no
O	O	,	no
O	O	but	no
O	O	are	no
O	O	not	no
O	O	limited	no
O	O	to	no
O	O	the	no
O	O	following	no
O	O	:	no
O	O	Agents	yes
O	O	Highly	no
O	O	Bound	no
O	O	to	no
O	O	Plasma	yes
O	O	Protein	yes
B-drug	B-drug	Carbamazepine	yes
O	O	is	yes
O	O	not	no
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	;	no

O	O	Clinical	no
O	O	Laboratory	no

O	O	Geriatric	no
O	O	Use	no
O	O	When	no
O	O	tumor	yes
O	O	response	no
O	O	was	no
O	O	considered	no
O	O	by	no
O	O	age	no
O	O	,	no
O	O	objective	no
O	O	responses	no
O	O	were	no
O	O	seen	no
O	O	in	yes
O	O	24	yes
O	O	%	no
O	O	and	yes
O	O	22	no
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	under	no
O	O	65	yes
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	and	yes
O	O	in	yes
O	O	16	yes
O	O	%	no
O	O	and	yes
O	O	11	yes
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	65	yes
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	and	yes
O	O	older	no
O	O	,	no
O	O	who	no
O	O	were	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	FASLODEX	yes
O	O	in	yes
O	O	the	no
O	O	European	yes
O	O	and	yes
O	O	North	no
O	O	American	yes
O	O	trials	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	etodolac	yes
O	O	can	no
O	O	generally	no
O	O	be	no
O	O	given	no
O	O	without	no
O	O	the	no
O	O	need	no
O	O	for	yes
O	O	dosage	no
O	O	modifications	no
O	O	in	yes
O	O	special	yes
O	O	populations	no
O	O	such	no
O	O	as	yes
O	O	uncompromised	no
O	O	elderly	no
O	O	patients	no
O	O	,	no
O	O	those	no
O	O	with	yes
O	O	moderate	no
O	O	renal	no
O	O	impairment	no
O	O	,	no
O	O	and	yes
O	O	patients	no
O	O	with	yes
O	O	stable	no
O	O	hepatic	no
O	O	disease	no
O	O	.	no

O	O	Studies	no
O	O	of	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	food	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	have	no
O	O	demonstrated	no
O	O	marked	no
O	O	reductions	no
O	O	in	yes
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	bioavailability	no
O	O	--	no
O	O	from	no
O	O	40	yes
O	O	%	no
O	O	to	no
O	O	60	no
O	O	%	no
O	O	;	no

O	O	In	yes
O	O	a	yes
O	O	patient	no
O	O	with	yes
O	O	a	yes
O	O	nonfunctioning	no
O	O	thyroid	yes
O	O	gland	no
O	O	who	no
O	O	is	yes
O	O	receiving	no
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	,	no
O	O	free	yes
B-drug	B-drug	levothyroxine	yes
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	when	no
B-group	B-group	estrogens	yes
O	O	are	no
O	O	started	no
O	O	thus	no
O	O	increasing	no
O	B-group	thyroid	yes
O	O	requirements	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	Nalfon	yes
O	O	and	yes
O	O	a	yes
B-group	B-group	steroid	no
O	O	concomitantly	no
O	O	,	no
O	O	any	no
O	O	reduction	yes
O	O	in	yes
B-group	B-group	steroid	no
O	O	dosage	no
O	O	should	no
O	O	be	no
O	O	gradual	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
O	O	the	no
O	O	possible	no
O	O	complications	no
O	O	of	yes
O	O	sudden	no
O	B-group	steroid	no
O	O	withdrawal	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	foods	no
O	O	highly	no
O	O	fortified	no
O	O	with	yes
O	O	elemental	yes
B-drug_n	B-drug_n	iron	yes
O	O	(	no
O	O	primarily	no
B-drug_n	B-drug_n	iron-fortified	no
O	O	breakfast	no
O	O	cereals	no
O	O	)	no
O	O	on	no
B-drug	B-drug	cefdinir	yes
O	O	absorption	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	As	yes
O	O	plasma	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	decitabine	yes
O	O	is	yes
O	O	negligible	no
O	O	(	no
O	O	1	yes
O	O	%	no
O	O	)	no
O	O	,	no
O	O	interactions	no
O	O	due	no
O	O	to	no
O	O	displacement	no
O	O	of	yes
O	O	more	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	drugs	no
O	O	from	no
O	O	plasma	yes
O	O	proteins	no
O	O	are	no
O	O	not	no
O	O	expected	no
O	O	.	no

O	O	Although	no
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	ALPHAGAN	yes
I-brand	I-brand	P	yes
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	an	no
O	O	additive	no
O	O	or	no
O	O	potentiating	no
O	O	effect	no
O	O	with	yes
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	opiates	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
O	O	or	no
B-group	B-group	anesthetics	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

B-drug	B-drug	Gabapentin	yes
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	without	no
O	O	and	yes
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	were	no
O	O	comparable	no
O	O	.	no

O	O	and	yes
O	O	,	no
O	O	rarely	no
O	O	,	no
O	O	dry	no
O	O	mouth	no
O	O	,	no
O	O	anorexia	no
O	O	,	no
O	O	taste	no
O	O	disorder	no
O	O	,	no
O	O	abdominal	no
O	O	pain	yes
O	O	,	no
O	O	vomiting	no
O	O	,	no
O	O	diarrhea	no
O	O	,	no
O	O	and	yes
O	O	positive	no
O	O	test	yes
O	O	for	yes
O	O	occult	no
O	O	blood	yes
O	O	in	yes
O	O	stool	no
O	O	.	no

O	O	Plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	anticonvulsant	no
I-group	I-group	agents	yes
O	O	may	no
O	O	become	no
O	O	subtherapeutic	no
O	O	during	no
B-drug	B-drug	cisplatin	yes
O	O	therapy	no
O	O	.	no

O	O	Cardiovascular	no
O	O	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	.	no

O	O	+164	no
O	O	%	no

O	O	vi	no
O	O	.	no

O	O	A	yes
O	O	possible	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	glyburide	yes
O	O	and	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	a	yes
B-group	B-group	fluoroquinolone	no
I-group	I-group	antibiotic	yes
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	potentiation	no
O	O	of	yes
O	O	the	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	allergic	no
O	O	reaction	no
O	O	.	no

O	O	These	no
O	O	above	no
O	O	findings	no
O	O	are	no
O	O	summarized	no
O	O	in	yes
O	O	TABLE	no
O	O	1	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	its	no
O	O	affinity	no
O	O	for	yes
O	O	protein	yes
O	O	,	no
B-drug_n	B-drug_n	6MNA	no
O	O	may	no
O	O	displace	no
O	O	other	no
O	O	protein-bound	no
O	O	drugs	no
O	O	from	no
O	O	their	no
O	O	binding	no
O	O	site	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	on	no
O	O	male	no
O	O	fertility	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	pressor	no
O	O	effects	no
O	O	of	yes
O	B-group	catecholamines	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dopamine	yes
O	O	or	no
B-drug	B-drug	norepinephrine	yes
O	O	are	no
O	O	enhanced	no
O	O	by	no
B-drug	B-drug	Bretylium	yes
I-drug	I-drug	Tosylate	yes
O	O	.	no

O	O	Because	no
B-drug	B-drug	dexfenfluramine	yes
O	O	is	yes
O	O	a	yes
O	O	serotonin	yes
O	O	releaser	no
O	O	and	yes
O	O	reuptake	no
O	O	inhibitor	yes
O	O	,	no
B-drug	B-drug	dexfenfluramine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	CONCLUSIONS/INTERPRETATION	no
O	O	:	no
B-drug	B-drug	Glucose	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	can	no
O	O	exert	no
O	O	additive	no
O	O	vasodilator	no
O	O	properties	no
O	O	on	no
O	O	renal	no
O	O	and	yes
O	O	ocular	no
O	O	circulation	no
O	O	.	no

B-drug	B-drug	Dexamethasone	yes
O	O	at	yes
O	O	10	yes
O	O	(	no
O	O	-10	no
O	O	)	no
O	O	M	yes
O	O	or	no
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	at	yes
O	O	about	no
O	O	3	yes
O	O	X	yes
O	O	10	yes
O	O	(	no
O	O	-9	no
O	O	)	no
O	O	M	yes
O	O	inhibits	no
O	O	proliferation	no
O	O	stimulated	no
O	O	by	no
B-drug_n	B-drug_n	EGF	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
O	O	drugs	no
O	O	that	no
O	O	induce	no
O	O	or	no
O	O	inhibit	no
O	O	this	no
O	O	enzyme	no
O	O	may	no
O	O	affect	no
B-drug	B-drug	quetiapine	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	Our	no
O	O	results	no
O	O	indicate	no
O	O	important	no
O	O	relationships	no
O	O	among	no
O	O	ras	yes
O	O	,	no
O	O	nucleophosmin/B23	no
O	O	,	no
O	O	activation	no
O	O	of	yes
O	O	caspase-3	no
O	O	,	no
O	O	and	yes
O	O	induction	no
O	O	of	yes
O	O	apoptosis	no
O	O	.	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	increased	no
O	O	by	no
B-brand	B-brand	SUSTIVA	yes
O	O	(	no
B-drug	B-drug	efavirenz	yes
O	O	)	no
O	O	;	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	with	yes
B-drug	B-drug	Itraconazole	yes
O	O	has	no
O	O	led	no
O	O	to	no
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	rare	no
O	O	instances	no
O	O	of	yes
O	O	life-	no
O	O	threatening	no
O	O	cardiac	no
O	O	dysrhythmias	no
O	O	and	yes
O	O	one	no
O	O	death	no
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	are	no
O	O	CYP	no
O	O	inducers	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	,	no
O	O	or	no
O	O	are	no
O	O	expected	no
O	O	,	no
O	O	to	no
O	O	decrease	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-brand	B-brand	EQUETROTM	no
O	O	are	no
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	Cisplatin	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
I-drug	I-drug	HCL	yes
O	O	,	no
B-drug	B-drug	felbamate	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	Phenytoin	yes
O	O	(	no
O	O	2	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	primidone	yes
O	O	,	no
B-drug	B-drug	methsuximide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	Thus	no
O	O	,	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	stable	no
O	O	dosage	no
O	O	on	no
B-brand	B-brand	EQUETROTM	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	begins	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	reasonable	no
O	O	to	no
O	O	expect	no
O	O	that	no
O	O	a	yes
O	O	dose	no
O	O	increase	no
O	O	for	yes
B-brand	B-brand	EQUETROTM	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	The	no
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	was	no
O	O	13	yes
O	O	%	no
O	O	higher	no
O	O	when	no
O	O	it	no
O	O	was	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	gabapentin	yes
O	O	;	no

O	O	The	no
O	O	effectiveness	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	in	yes
O	O	increasing	no
O	O	the	no
O	O	force	no
O	O	of	yes
O	O	contraction	no
O	O	was	no
O	O	decreased	no
O	O	in	yes
O	O	relation	no
O	O	to	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	heart	no
O	O	failure	no
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
B-group	B-group	resin	yes
O	O	may	no
O	O	delay	no
O	O	or	no
O	O	reduce	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	concomitant	no
O	O	oral	yes
O	O	medication	no
O	O	such	no
O	O	as	yes
B-drug	B-group	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	acidic	no
O	O	)	no
O	O	or	no
B-drug	B-drug	propranolol	yes
O	O	(	no
O	O	basic	yes
O	O	)	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
B-drug	B-drug	tetracycline	yes
I-drug	I-drug	penicillin	yes
I-drug	I-drug	G	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	thyroid	yes
O	O	and	yes
B-group	B-drug	thyroxine	no
I-group	O	preparations	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	and	yes
B-group	B-group	progestins	no
O	O	,	no
O	O	and	yes
B-group	B-group	digitalis	yes
O	O	.	no

O	O	-	yes
O	O	Changes	no
O	O	in	yes
O	O	TBg	no
O	O	concentration	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	consideration	no
O	O	in	yes
O	O	the	no
O	O	interpretation	no
O	O	of	yes
O	O	T4	yes
O	O	and	yes
O	O	T3	yes
O	O	values	no
O	O	.	no

O	O	14-OH	no
O	O	metabolite	yes
O	O	concentration	no

O	O	No	yes
O	O	data	no
O	O	from	no
O	O	prospective	no
O	O	clinical	no
O	O	trials	no
O	O	currently	no
O	O	exist	no
O	O	comparing	no
O	O	the	no
O	O	3	yes
O	O	approved	no
O	O	agents	yes
O	O	(	no
B-drug	B-drug	efavirenz	yes
O	O	,	no
B-drug	B-drug	nevirapine	yes
O	O	or	no
B-drug	B-drug	delavirdine	yes
O	O	)	no
O	O	.	no

O	O	A	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Intracellular	no
O	O	and	yes
O	O	extracellular	no
O	O	application	no
O	O	of	yes
B-drug_n	B-drug_n	RR	no
O	O	reduced	yes
O	O	ADP-induced	no
O	O	increases	no
O	O	in	yes
O	O	[	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	]	no
O	O	(	no
O	O	i	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Imipramine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	single	yes
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	20	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	imipramine	yes
O	O	75	yes
O	O	mg	yes
O	O	produced	no
O	O	additive	no
O	O	effects	no
O	O	on	no
O	O	decreased	no
O	O	alertness	no
O	O	and	yes
O	O	impaired	no
O	O	psychomotor	no
O	O	performance	no
O	O	for	yes
O	O	2	yes
O	O	to	no
O	O	4	yes
O	O	hours	no
O	O	after	no
O	O	administration	no
O	O	.	no

O	O	Total	yes
O	O	body	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	Simulect	yes
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	an	no
O	O	average	no
O	O	22	no
O	O	%	no
O	O	and	yes
O	O	51	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	azathioprine	yes
O	O	and	yes
B-drug	B-drug	mycophenolate	yes
I-drug	I-drug	mofetil	yes
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	were	no
O	O	added	no
O	O	to	no
O	O	a	yes
O	O	regimen	no
O	O	consisting	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
O	O	USP	yes
O	O	(	no
O	O	MODIFIED	yes
O	O	)	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	Of	yes
O	O	the	no
O	O	1357	no
O	O	patients	no
O	O	who	no
O	O	received	no
B-brand	B-brand	AMEVIVE	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	a	yes
O	O	total	yes
O	O	of	yes
O	O	100	yes
O	O	patients	no
O	O	were	no

B-drug	B-drug	Ibandronate	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	60	no
O	O	minutes	no
O	O	before	no
O	O	any	no
O	O	oral	yes
O	O	medications	no
O	O	containing	yes
O	O	multivalent	no
O	O	cations	no
O	O	(	no
O	O	including	no
B-group	B-group	antacids	no
O	O	,	no
O	O	supplements	no
O	O	or	no
B-group	B-group	vitamins	no
O	O	)	no
O	O	.	no

O	O	Frequent	no
O	O	prothrombin	yes
O	O	determinations	no
O	O	are	no
O	O	advisable	no
O	O	until	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	determined	no
O	O	definitely	no
O	O	that	no
O	O	the	no
O	O	prothrombin	yes
O	O	level	no
O	O	has	no
O	O	been	no
O	O	stabilized	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	a	yes
O	O	potential	no
O	O	interaction	no
O	O	between	yes
B-brand	B-brand	NovoSeven	no
O	O	and	yes
B-group	B-group	coagulation	yes
I-group	I-group	factor	yes
I-group	O	concentrates	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	adequately	no
O	O	evaluated	no
O	O	in	yes
O	O	preclinical	no
O	O	or	no
O	O	clinical	no
O	O	studies	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	slows	no
O	O	the	no
O	O	renal	no
O	O	elimination	no
O	O	of	yes
B-drug	O	lome-floxacin	no
O	O	.	no

O	O	Among	no
O	O	the	no
B-group	B-group	polyene	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	many	no
O	O	,	no
O	O	like	yes
B-drug_n	B-drug_n	filipin	no
O	O	,	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	clinically	no
O	O	because	no
O	O	they	no
O	O	are	no
O	O	toxic	no
O	O	;	no

O	O	Patients	no
O	O	'	no
O	O	mean	no
O	O	age	no
O	O	was	no
O	O	69.1	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	1.2	no
O	O	)	no
O	O	.	no

O	O	Plasma	yes
B-drug	B-drug	valproate	yes
O	O	concentration	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	when	no
B-drug	B-drug	isoniazid	yes
O	O	and	yes
B-drug	B-drug	valproate	yes
O	O	are	no
O	O	co	yes
O	O	administered	no
O	O	,	no
O	O	and	yes
O	O	appropriate	no
O	O	dosage	no
O	O	adjustments	no
O	O	of	yes
B-drug	B-drug	valproate	yes
O	O	should	no
O	O	be	no
O	O	made	no
O	O	.	no

O	O	Effective	no
O	O	use	no
O	O	of	yes
O	O	drugs	no
O	O	in	yes
O	O	therapy	no
O	O	depends	no
O	O	not	no
O	O	only	no
O	O	on	no
O	O	clinical	no
O	O	acumen	no
O	O	but	no
O	O	also	no
O	O	on	no
O	O	the	no
O	O	availability	no
O	O	of	yes
O	O	relevant	no
O	O	pharmacokinetic	no
O	O	and	yes
O	O	pharmacodynamic	no
O	O	data	no
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	.	no

B-group	B-group	salicylates	no
O	O	;	no
B-drug	B-drug	sulfinpyrazone	yes
O	O	;	no

O	O	No	yes
O	O	adverse	no
O	O	effects	no
O	O	on	no
O	O	female	no
O	O	fertility	no
O	O	and	yes
O	O	embryonic	no
O	O	survival	no
O	O	were	no
O	O	evident	no
O	O	in	yes
O	O	female	no
O	O	animals	no
O	O	dosed	no
O	O	at	yes
O	O	0.001	no
O	O	mg/kg/day	no
O	O	(	no
O	O	approximately	no
O	O	one-thousandth	no
O	O	of	yes
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	based	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	have	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	decrease	no
O	O	platelet	yes
O	O	nucleotide	no
O	O	release	yes
O	O	and	yes
O	O	thromboxane	no
O	O	A2	yes
O	O	generation	no
O	O	.	no

O	O	Do	no
O	O	not	no
O	O	start	no
O	O	or	no
O	O	stop	no
O	O	any	no
O	O	medicine	no
O	O	without	no
O	O	doctor	no
O	O	or	no
O	O	pharmacist	no
O	O	approval	no
O	O	.	no

B-group	B-group	Psychoactive	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	Hallucinations	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-brand	B-brand	TORADOL	yes
O	O	was	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	psychoactive	no
I-group	I-group	drugs	no
O	O	(	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	thiothixene	yes
O	O	,	no
B-drug	B-drug	alprazolam	yes
O	O	)	no
O	O	.	no

O	O	Use	no
O	O	caution	no
O	O	when	no
O	O	giving	no
O	O	these	no
O	O	drugs	no
O	O	together	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	hepatic	no
O	O	or	no
O	O	cardiac	no
O	O	disease	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	B-drug	Fondaparinux	yes
O	O	neither	no
O	O	influenced	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	piroxicam	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	nor	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	.	no

B-drug	B-drug	Cypermethrin-induced	no
O	O	oxidative	no
O	O	stress	no
O	O	in	yes
O	O	rat	yes
O	O	brain	yes
O	O	and	yes
O	O	liver	yes
O	O	is	yes
O	O	prevented	no
O	O	by	no
B-drug	B-drug	vitamin	yes
I-drug	I-drug	E	yes
O	O	or	no
B-drug	B-drug	allopurinol	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	diclofenac	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	concomitantly	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	may	no
O	O	develop	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	present	no
O	O	study	no
O	O	,	no
O	O	the	no
B-group	B-group	atypical	no
I-group	I-group	antipsychotic	no
B-drug	B-drug	clozapine	yes
O	O	was	no
O	O	tested	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	an	no
O	O	active	no
O	O	dose	no
O	O	of	yes
B-drug_n	B-drug_n	PCP	yes
O	O	in	yes
O	O	two-lever	no
O	O	drug	yes
O	O	discrimination	no
O	O	and	yes
O	O	mixed	yes
O	O	signalled-unsignalled	no
O	O	differential-reinforcement-of-low-rates	no
O	O	(	no
O	O	DRL	no
O	O	)	no
O	O	procedures	no
O	O	.	no

O	O	The	no
O	O	vasodilating	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	isosorbide	yes
I-drug	I-drug	mononitrate	yes
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	with	yes
O	O	those	no
O	O	of	yes
O	O	other	no
B-group	B-group	vasodilators	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	buspirone	yes
O	O	does	no
O	O	not	no
O	O	displace	no
O	O	tightly	no
O	O	bound	no
O	O	drugs	no
O	O	like	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	from	no
O	O	serum	yes
O	O	proteins	no
O	O	.	no

O	O	No	yes
O	O	evidence	no
O	O	of	yes
O	O	fetal	no
O	O	toxicity	no
O	O	including	no
O	O	adverse	no
O	O	effects	no
O	O	on	no
O	O	immune	yes
O	O	system	yes
O	O	development	no
O	O	was	no
O	O	observed	no
O	O	in	yes
O	O	any	no
O	O	of	yes
O	O	these	no
O	O	animals	no
O	O	.	no

B-drug	B-drug	Efavirenz	yes
O	O	has	no
O	O	demonstrated	no
O	O	superiority	no
O	O	over	no
B-drug	B-drug	nelfinavir	yes
O	O	in	yes
O	O	nucleoside-experienced	no
O	O	patients	no
O	O	,	no
O	O	although	no
O	O	combining	no
O	O	these	no
O	O	2	yes
O	O	agents	yes
O	O	may	no
O	O	represent	no
O	O	the	no
O	O	best	no
O	O	approach	no
O	O	in	yes
O	O	these	no
O	O	circumstances	no
O	O	.	no

B-drug	B-group	Gold	yes
O	O	is	yes
O	O	excreted	no
O	O	slowly	no
O	O	from	no
O	O	the	no
O	O	body	no
O	O	.	no

O	O	When	no
B-drug	B-drug	ertapenem	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	p.o	no
O	O	.	no
O	O	every	no
O	O	6	yes
O	O	hours	no
O	O	)	no
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	competes	no
O	O	for	yes
O	O	active	no
O	O	tubular	no
O	O	secretion	no
O	O	and	yes
O	O	reduces	no
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	ertapenem	yes
O	O	.	no

O	O	METHODS	no
O	O	:	no
O	O	All	yes
O	O	patients	no
O	O	were	no
O	O	enrolled	no
O	O	in	yes
O	O	two	no
O	O	sequential	no
O	O	trials	no
O	O	performed	no
O	O	at	yes
O	O	the	no
O	O	Aviano	no
O	O	Cancer	no
O	O	Center	no
O	O	,	no
O	O	Italy	no
O	O	,	no
O	O	from	no
O	O	April	no
O	O	1988	no
O	O	to	no
O	O	December	no
O	O	1998	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	bleeding	no
O	O	time	no
O	O	,	no
O	O	PT	no
O	O	or	no
O	O	aPTT	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-brand	B-brand	EMTRIVA	yes
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	stavudine	yes
O	O	,	no
B-drug	B-drug	famciclovir	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	tenofovir	yes
I-drug	I-drug	disoproxil	yes
I-drug	I-drug	fumarate	yes
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	should	no
O	O	precede	no
B-drug	B-drug	lomefloxacin	yes
O	O	dosing	no
O	O	by	no
O	O	4	yes
O	O	hours	no
O	O	or	no
O	O	follow	no
B-drug	B-drug	lomefloxacin	yes
O	O	dosing	no
O	O	by	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	.	no

O	O	As	yes
O	O	a	yes
O	O	moderate	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
B-drug	B-drug	aprepitant	yes
O	O	can	no
O	O	increase	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	coadministered	no
O	O	medicinal	yes
O	O	products	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	through	no
O	O	CYP3A4	no
O	O	.	no

O	O	Medications	no
O	O	can	no
O	O	interfere	no
O	O	with	yes
O	O	folate	yes
O	O	utilization	no
O	O	,	no
O	O	including	no
O	O	:	no
B-group	B-group	anticonvulsant	no
I-group	I-group	medications	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	primidone	yes
O	O	)	no
B-drug	B-drug	metformin	yes
O	O	(	no
O	O	sometimes	no
O	O	prescribed	no
O	O	to	no
O	O	control	no
O	O	blood	yes
O	O	sugar	yes
O	O	in	yes
O	O	type	yes
O	O	2	yes
O	O	diabetes	no
O	O	)	no
B-drug	B-drug	sulfasalazine	yes
O	O	(	no
O	O	used	no
O	O	to	no
O	O	control	no
O	O	inflammation	no
O	O	associated	no
O	O	with	yes
O	O	Crohns	no
O	O	disease	no
O	O	and	yes
O	O	ulcerative	no
O	O	colitis	no
O	O	)	no
B-drug	B-drug	triamterene	yes
O	O	(	no
O	O	a	yes
B-group	B-group	diuretic	no
O	O	)	no
B-drug	B-drug	Methotrexate	yes
O	O	There	no
O	O	has	no
O	O	been	no
O	O	concern	no
O	O	about	no
O	O	the	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B12	yes
O	O	and	yes
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Some	no
B-group	B-group	calcium	yes
I-group	I-group	blockers	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-group	B-group	digitalis	yes
I-group	I-group	preparations	no
O	O	in	yes
O	O	the	no
O	O	blood	yes
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	of	yes
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug_n	B-drug_n	PTX	no
O	O	was	no
O	O	discussed	no
O	O	in	yes
O	O	the	no
O	O	relation	no
O	O	with	yes
O	O	Na	no
O	O	,	no
O	O	K-ATPase	no
O	O	.	no

O	O	Pregnancy	no
B-group	B-group	estrogens	yes
O	O	and	yes
B-group	B-group	estrogen-containing	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	increase	no
O	O	TBg	no
O	O	concentrations	no
O	O	.	no

O	O	Reformed	no
O	O	microtubules	no
O	O	appeared	no
O	O	to	no
O	O	function	no
O	O	normally	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	their	no
O	O	possible	no
O	O	role	no
O	O	in	yes
O	O	the	no
O	O	transport	no
O	O	of	yes
O	O	noradrenaline	yes
O	O	storage	no
O	O	vesicles	no
O	O	along	no
O	O	the	no
O	O	axons	no
O	O	.	no

O	O	Free	yes
O	O	hormone	yes
O	O	concentrations	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	.	no

O	O	Exposed	no
O	O	histidines	no
O	O	on	no
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	are	no
O	O	available	no
O	O	for	yes
B-drug	B-drug	zinc	yes
O	O	chelation	no
O	O	,	no
O	O	and	yes
O	O	these	no
O	O	have	no
O	O	been	no
O	O	exploited	no
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	a	yes
O	O	novel	no
O	O	purification	no
O	O	protocol	no
O	O	for	yes
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	using	no
B-drug	B-drug	zinc-chelating	no
O	O	chromatography	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	it	no
O	O	was	no
O	O	observed	no
O	O	that	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	ENBREL	yes
O	O	was	no
O	O	unaltered	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	methotrexate	yes
O	O	in	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Ketamine	yes
O	O	:	no
O	O	When	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	on	no
O	O	a	yes
O	B-group	thyroid	yes
O	I-group	preparation	no
O	O	,	no
O	O	this	no
O	O	parenteral	no
B-group	B-group	anesthetic	no
O	O	may	no
O	O	cause	no
O	O	hypertension	no
O	O	and	yes
O	O	tachycardia	no
O	O	.	no

B-drug	B-drug	Acetaminophen	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	were	no
O	O	added	no
O	O	to	no
O	O	pooled	no
O	O	human	yes
O	O	serum	yes
O	O	at	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	.	no

B-drug	B-drug	Metformin	yes
O	O	:	no
O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	given	no
O	O	single	yes
O	O	500	yes
O	O	mg	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cephalexin	yes
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	metformin	yes
O	O	mean	no
O	O	cmax	no
O	O	and	yes
O	O	AUC	no
O	O	increased	no
O	O	by	no
O	O	an	no
O	O	average	no
O	O	of	yes
O	O	34	no
O	O	%	no
O	O	and	yes
O	O	24	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	mean	no
O	O	renal	no
O	O	clearance	no
O	O	decreased	no
O	O	by	no
O	O	14	yes
O	O	%	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	a	yes
O	O	possible	no
O	O	lack	no
O	O	of	yes
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	treatment	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	consideration	no
O	O	before	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lactulose	yes
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	postmarketing	no
O	O	observations	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-brand	B-brand	Lodine	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	narcotic	no
I-group	I-group	analgesics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	meperidine	yes
O	O	)	no
O	O	,	no
B-group	B-group	nitrates	no
O	O	and	yes
B-group	B-group	nitrites	no
O	O	,	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	having	no
O	O	anticholinergic	no
O	O	activity	yes
O	O	.	no

O	O	consequently	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	if	no
B-drug	B-drug	dexfenfluramine	yes
O	O	and	yes
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	prescribed	no
O	O	concurrently	no
O	O	.	no

O	O	(	no
O	O	Effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	;	no

O	O	The	no
O	O	effectiveness	no
O	O	of	yes
B-group	B-group	progestin-only	no
O	O	pills	no
O	O	is	yes
O	O	reduced	yes
O	O	by	no
O	O	hepatic	no
O	O	enzyme-inducing	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
O	O	the	no
B-group	B-group	anticonvulsants	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	and	yes
B-group	B-group	barbiturates	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	antituberculosis	no
I-group	I-group	drug	yes
B-drug	B-drug	rifampin	yes
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	and	yes
B-drug	B-drug	didanosine	yes
O	O	significantly	no
O	O	reduces	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	but	no
O	O	it	no
O	O	is	yes
O	O	unclear	no
O	O	how	no
O	O	soon	no
O	O	after	no
B-drug	B-drug	didanosine	yes
O	O	administration	no
B-drug	B-drug	indinavir	yes
O	O	may	no
O	O	be	no
O	O	given	no
O	O	safely	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	DIABINESE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	Xigris	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	severe	no
O	O	sepsis	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	,	no
B-drug	B-drug	nicotine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	may	no
O	O	decrease	no
B-drug	B-drug	Clozapine	yes
O	O	plasma	yes
O	O	levels	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	effectiveness	no
O	O	of	yes
O	O	a	yes
O	O	previously	no
O	O	effective	no
B-drug	B-drug	Clozapine	yes
O	O	dose	no
O	O	.	no

O	O	Concomitant	no
O	O	treatment	no
O	O	of	yes
O	O	four	no
O	O	patients	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	Kingdom	no
O	O	with	yes
B-brand	B-brand	FOSCAVIR	yes
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	may	no
O	O	have	no
O	O	caused	no
O	O	hypocalcemia	no
O	O	;	no

O	O	Tablets	yes
O	O	Simultaneous	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	sucralfate	yes
O	O	and	yes
B-drug	B-drug	furosemide	yes
O	O	tablets	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	(	no
O	O	day	no
O	O	1	yes
O	O	)	no
O	O	and	yes
O	O	40	yes
O	O	mg	yes
O	O	QD	no
O	O	(	no
O	O	days	no
O	O	2-7	no
O	O	)	no
O	O	)	no
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	5	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	either	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	(	no
O	O	exposure	yes
O	O	)	no
O	O	or	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	(	no
O	O	blood	yes
O	O	glucose	yes
O	O	and	yes
O	O	insulin	yes
O	O	levels	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	effects	no
O	O	on	no
B-drug	B-drug	cisapride	yes
O	O	metabolism	no
O	O	or	no
O	O	QT	no
O	O	interval	no
O	O	were	no
O	O	noted	no
O	O	.	no

O	O	This	no
O	O	study	no
O	O	demonstrates	no
O	O	that	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	thiosulfate	yes
O	O	permits	no
O	O	at	yes
O	O	least	no
O	O	a	yes
O	O	twofold	no
O	O	increase	no
O	O	in	yes
O	O	dose	no
O	O	and	yes
O	O	total	yes
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	cisplatin	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	such	no
O	O	combined	no
O	O	treatment	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	when	no
B-drug	B-drug	Clozapine	yes
O	O	is	yes
O	O	combined	no
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	,	no
O	O	particularly	no
O	O	with	yes
B-drug	B-drug	fluvoxamine	yes
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	long-term	no
O	O	safety	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	guanfacine	yes
O	O	was	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	many	no
O	O	drugs	no
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	any	no
O	O	interactions	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Robinul	yes
O	O	Injection	yes
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinergics	no
O	O	or	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	antiparkinson	no
I-group	I-group	drugs	no
O	O	,	no
O	O	or	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	may	no
O	O	intensify	no
O	O	the	no
O	O	antimuscarinic	no
O	O	effects	no
O	O	and	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	anticholinergic	no
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	They	no
O	O	are	no
O	O	weak	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2C19	no
O	O	and	yes
O	O	CYP2A6	no
O	O	,	no
O	O	and	yes
O	O	mild-to-moderate	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2C9	no
O	O	at	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	fluvoxamine	yes
O	O	reduces	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	diazepam	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	,	no
B-drug_n	B-drug_n	N-desmethyldiazepam	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	strong	no
O	O	likelihood	no
O	O	of	yes
O	O	substantial	no
O	O	accumulation	no
O	O	of	yes
O	O	both	no
O	O	species	no
O	O	during	no
O	O	chronic	no
O	O	co-administration	no
O	O	.	no

B-group	B-group	Antibiotics	no
O	O	:	no
O	O	No	yes
O	O	human	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-group	B-group	antibiotics	no
O	O	were	no
O	O	conducted	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	greater	no
O	O	than	no
O	O	two-fold	no
O	O	increases	no
O	O	of	yes
O	O	previously	no
O	O	stable	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	when	no
B-drug	B-drug	fluoxetine	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug/laboratory	no
O	O	test	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	CLOLAR	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	where	no
B-drug	B-drug	rifampin	yes
O	O	or	no
O	O	other	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	are	no
O	O	indicated	no
O	O	,	no
O	O	alternative	no
O	O	therapeutic	no
O	O	agents	yes
O	O	with	yes
O	O	less	no
O	O	enzyme	no
O	O	induction	no
O	O	potential	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	all	yes
O	O	drugs	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	exists	no
O	O	for	yes
O	O	interaction	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	by	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	mechanisms	no
O	O	.	no

O	O	The	no
O	O	amount	no
O	O	of	yes
B-drug	B-drug	metformin	yes
O	O	absorbed	no
O	O	while	no
O	O	taking	no
B-drug	B-drug	Acarbose	yes
O	O	was	no
O	O	bioequivalent	no
O	O	to	no
O	O	the	no
O	O	amount	no
O	O	absorbed	no
O	O	when	no
O	O	taking	no
O	O	placebo	no
O	O	,	no
O	O	as	yes
O	O	indicated	no
O	O	by	no
O	O	the	no
O	O	plasma	yes
O	O	AUC	no
O	O	values	no
O	O	.	no

O	O	All	yes
O	O	the	no
O	O	animals	no
O	O	were	no
O	O	killed	no
O	O	at	yes
O	O	the	no
O	O	end	no
O	O	of	yes
O	O	the	no
O	O	9th	no
O	O	week	no
O	O	of	yes
O	O	the	no
O	O	experiment	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	etodolac	yes
O	O	in	yes
O	O	healthy	no
O	O	normal	yes
O	O	volunteers	no
O	O	has	no
O	O	been	no
O	O	extensively	no
O	O	studied	no
O	O	and	yes
O	O	is	yes
O	O	well	no
O	O	described	no
O	O	.	no

O	O	Patients	no
O	O	on	no
B-drug	B-drug	lithium	yes
O	O	treatment	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	when	no
B-brand	B-brand	CELEBREX	yes
O	O	is	yes
O	O	introduced	no
O	O	or	no
O	O	withdrawn	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	administration	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	population	no
O	O	with	yes
O	O	hepatic	no
O	O	insufficiency	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	2.5-fold	no
O	O	increase	no
O	O	in	yes
O	O	both	no
O	O	the	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
O	O	bioavailability	no
O	O	relative	no
O	O	to	no
O	O	controls	no
O	O	.	no

B-drug	B-drug	Hydrocodone	yes
O	O	increases	no
B-drug	B-drug	gabapentin	yes
O	O	AUC	no
O	O	values	no
O	O	by	no
O	O	14	yes
O	O	%	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	Clozapine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	other	no
O	O	agents	yes
O	O	having	no
O	O	a	yes
O	O	well-known	no
O	O	potential	no
O	O	to	no
O	O	suppress	no
O	O	bone	no
O	O	marrow	no
O	O	function	no
O	O	.	no

O	O	We	no
O	O	could	no
O	O	observe	no
O	O	that	no
B-drug_n	B-drug_n	ginsenosides	no
O	O	inhibited	no
O	O	high	yes
O	O	threshold	no
O	O	voltage-dependent	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	currents	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	manner	no
O	O	.	no

B-drug	B-drug	Selegiline	yes
O	O	-	yes
B-drug	B-drug	L-phenylalanine	yes
O	O	and	yes
O	O	the	no
B-group	B-group	selective	no
I-group	I-group	MAO	no
I-group	I-group	inhibitor	yes
B-drug	B-drug	selegiline	yes
O	O	may	no
O	O	have	no
O	O	synergistic	no
O	O	antidepressant	no
O	O	activity	yes
O	O	if	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	As	yes
O	O	the	no
O	O	primary	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	is	yes
O	O	to	no
O	O	decrease	no
O	O	conduction	no
O	O	through	no
O	O	the	no
O	O	A-V	no
O	O	node	no
O	O	,	no
O	O	higher	no
O	O	degrees	no
O	O	of	yes
O	O	heart	no
O	O	block	yes
O	O	may	no
O	O	be	no
O	O	produced	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	these	no
O	O	interactions	no
O	O	on	no
O	O	mean	no
O	O	AUCs	no
O	O	and	yes
O	O	Cmin	no
O	O	are	no
O	O	summarized	no
O	O	in	yes
O	O	Table	no
O	O	2	yes
O	O	:	no
O	O	Table	no
O	O	2	yes
O	O	:	no
O	O	Summary	no
O	O	of	yes
O	O	AED	no
O	O	interactions	no
O	O	with	yes
B-brand	B-brand	Trileptal	yes

O	O	Drugs	no
O	O	and	yes
O	O	other	no
O	O	substances	no
O	O	demonstrated	no
O	O	to	no
O	O	be	no
O	O	CYP	no
O	O	3A	yes
O	O	inhibitors	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	clinical	no
O	O	studies	no
O	O	involving	no
B-group	B-group	benzodiazepines	no
O	O	metabolized	no
O	O	similarly	no
O	O	to	no
B-drug	B-drug	alprazolam	yes
O	O	or	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	or	no
O	O	other	no
B-group	B-group	benzodiazepines	no
O	O	(	no
O	O	caution	no
O	O	is	yes
O	O	recommended	no
O	O	during	no
O	O	coadministration	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	)	no
O	O	:	no
O	O	Available	no
O	O	data	no
O	O	from	no
O	O	clinical	no
O	O	studies	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	other	no
O	O	than	no
B-drug	B-drug	alprazolam	yes
O	O	suggest	no
O	O	a	yes
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	for	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	clarithromycin	yes
O	O	,	no
O	O	and	yes
O	O	grapefruit	no
O	O	juice	no
O	O	.	no

B-drug	B-drug	Ketorolac	yes
O	O	does	no
O	O	not	no
O	O	alter	no
B-drug	B-drug	digoxin	yes
O	O	protein	yes
O	O	binding	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	seizure	no
O	O	risk	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	tramadol	yes

O	O	Since	no
O	O	the	no
O	O	therapeutic	no
O	O	range	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	is	yes
O	O	narrow	no
B-drug	B-drug	theophylline	yes
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	,	no
O	O	and	yes
O	O	appropriate	no
O	O	dosage	no
O	O	adjustments	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	should	no
O	O	be	no
O	O	made	no
O	O	.	no

O	O	Combination	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	higher	no
O	O	frequency	no
O	O	of	yes
O	O	adverse	no
O	O	clinical	no
O	O	experiences	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	O	dizziness	no
O	O	,	no
O	O	nausea	no
O	O	,	no
O	O	paresthesia	no
O	O	)	no
O	O	and	yes
O	O	laboratory	no
O	O	abnormalities	no
O	O	(	no
O	O	elevated	no
O	O	liver	yes
O	O	enzymes	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
O	O	other	no
B-group	B-group	quinolones	no
O	O	.	no

B-drug	B-drug	Antipyrine	yes
O	O	:	no
O	O	Because	no
B-drug	B-drug	atorvastatin	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	antipyrine	yes
O	O	,	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	B-drug	drugs	no
O	O	metabolized	no
O	O	via	no
O	O	the	no
O	O	same	yes
O	O	cytochrome	no
O	O	isozymes	no
O	O	are	no
O	O	not	no
O	O	expected	no
O	O	.	no

O	O	Because	no
O	O	a	yes
O	O	similar	no
O	O	interaction	no
O	O	is	yes
O	O	likely	no
O	O	,	no
B-brand	B-brand	VIRACEPT	yes
O	O	should	no
O	O	also	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	astemizole	yes
O	O	.	no

B-group	B-group	Calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	did	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	effect	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	safety	no
O	O	or	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	ibutilide	yes
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	trials	no
O	O	.	no

B-group	B-drug	Anticoagulants	no
O	O	:	no
O	O	Potentiation	no
O	O	of	yes
B-drug	B-drug	warfarin-type	no
O	O	(	no
O	B-drug	CYP2C9	no
O	O	and	yes
O	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	)	no
B-group	B-drug	anticoagulant	no
O	O	response	no
O	O	is	yes
O	O	almost	no
O	O	always	no
O	O	seen	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	amiodarone	yes
O	O	and	yes
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	serious	no
O	O	or	no
O	O	fatal	no
O	O	bleeding	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	or	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
B-drug	B-drug	hydrocodone	yes
O	O	preparations	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	either	no
O	O	the	no
B-group	B-group	antidepressant	no
O	O	or	no
B-drug	B-drug	hydrocodone	yes
O	O	.	no

O	O	It	no
O	O	has	no
O	O	recently	no
O	O	been	no
O	O	demonstrated	no
O	O	that	no
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	exerts	no
O	O	its	no
O	O	cytotoxic	yes
O	O	effect	no
O	O	by	no
O	O	the	no
O	O	glucosylation	no
O	O	of	yes
O	O	the	no
O	O	small	no
O	O	GTP-binding	no
O	O	proteins	no
O	O	of	yes
O	O	the	no
O	O	Rho	yes
O	O	family	yes
O	O	.	no

O	O	Potentiation	no
O	O	occurs	no
O	O	with	yes
B-group	B-group	ganglionic	no
I-group	I-group	peripheral	no
I-group	I-group	adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Also	no
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	experiments	no
O	O	demonstrated	no
O	O	a	yes
O	O	lack	no
O	O	of	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	dirithromycin	yes
O	O	and	yes
B-drug	B-drug	terfenadine	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	The	no
O	O	main	no
O	O	indications	no
O	O	are	no
O	O	eclampsia	no
O	O	,	no
O	O	some	no
O	O	dysrhythmias	no
O	O	(	no
O	O	torsades	no
O	O	de	yes
O	O	pointe	no
O	O	particularly	no
O	O	)	no
O	O	and	yes
O	O	myocardial	no
O	O	ischaemias	no
O	O	.	no

O	O	Also	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	differences	no
O	O	in	yes
O	O	adverse	no
O	O	events	no
O	O	when	no
B-drug	B-drug	loratadine	yes
O	O	was	no
O	O	administered	no
O	O	with	yes
O	O	or	no
O	O	without	no
B-drug	B-drug	ketoconazole	yes
O	O	.	no

O	O	To	no
O	O	determine	no
O	O	whether	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	thiosulfate	yes
O	O	would	no
O	O	permit	no
O	O	larger	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cisplatin	yes
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	,	no
O	O	a	yes
O	O	fixed	no
O	O	9.9-g/m2	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	thiosulfate	yes
O	O	was	no
O	O	given	no
O	O	intravenously	no
O	O	over	no
O	O	three	no
O	O	hours	no
O	O	concurrently	no
O	O	with	yes
O	O	escalating	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cisplatin	yes
O	O	.	no

B-drug_n	B-drug_n	Cytochalasin	no
I-drug_n	I-drug_n	D	yes
O	O	at	yes
O	O	10	yes
O	O	microM	no
O	O	preferentially	no
O	O	blocked	no
O	O	the	no
O	O	secretory	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	carbachol	yes
O	O	and	yes
O	O	its	no
O	O	synergism	no
O	O	with	yes
O	O	cAMP	yes
O	O	,	no
O	O	whereas	no
O	O	it	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	histamine-	no
O	O	or	no
O	O	cAMP-stimulated	no
O	O	acid	yes
O	O	secretion	no
O	O	within	no
O	O	15	yes
O	O	min	no
O	O	.	no

B-drug	B-drug	Omeprazole	yes
O	O	:	no
O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
B-drug	B-drug	lomefloxacin	yes
O	O	pharmacokinetics	no
O	O	(	no
O	O	AUC	no
O	O	,	no
O	O	C	yes
O	O	max	no
O	O	,	no
O	O	or	no
O	O	T	yes
O	O	max	no
O	O	)	no
O	O	were	no
O	O	observed	no
O	O	when	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	lomefloxacin	yes
O	O	400	yes
O	O	mg	yes
O	O	was	no
O	O	given	no
O	O	after	no
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	omeprazole	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	qd	no
O	O	)	no
O	O	in	yes
O	O	13	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	indicated	no
O	O	when	no
B-drug	B-drug	piperacillin	yes
O	O	is	yes
O	O	used	no
O	O	perioperatively	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	phentolamine	yes
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	-6	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	second	no
O	O	contraction	no
O	O	was	no
O	O	inhibited	no
O	O	selectively	no
O	O	.	no

B-drug	B-drug	Heparin	yes
I-drug	I-drug	Sodium	yes
O	O	Injection	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	mixed	yes
O	O	with	yes
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	droperidol	yes
O	O	,	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	mitoxantrone	yes
O	O	,	no
O	O	since	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	incompatible	no
O	O	with	yes
B-drug	B-drug	heparin	yes
O	O	and	yes
O	O	a	yes
O	O	precipitate	no
O	O	may	no
O	O	form	yes
O	O	.	no

O	O	The	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug_n	B-drug_n	arsenate	no
O	O	(	no
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	)	no
O	O	has	no
O	O	been	no
O	O	investigated	no
O	O	in	yes
O	O	the	no
O	O	chick	no
O	O	by	no
O	O	means	no
O	O	of	yes
O	O	the	no
O	O	in	yes
O	O	situ	no
O	O	ligated	no
O	O	duodenal	no
O	O	loop	no
O	O	technique	no
O	O	.	no

O	O	If	no
O	O	leprosy-associated	no
O	O	inflammatory	no
O	O	reactions	no
O	O	develop	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	dapsone	yes
O	O	and	yes
B-drug	B-drug	clofazimine	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	still	no
O	O	advisable	no
O	O	to	no
O	O	continue	no
O	O	treatment	no
O	O	with	yes
O	O	both	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Fexofenadine	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	erythromycin	yes
O	O	or	no
B-drug	B-drug	ketoconazole	yes
O	O	.	no

B-drug	B-drug	Dofetilide	yes
O	O	is	yes
O	O	metabolized	no
O	O	to	no
O	O	a	yes
O	O	small	no
O	O	extent	no
O	O	by	no
O	O	the	no
O	O	CYP3A4	no
O	O	isoenzyme	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	.	no

O	O	Because	no
O	O	the	no
O	O	risk	no
O	O	to	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	the	no
O	O	fetal	no
O	O	immune	yes
O	O	system	yes
O	O	and	yes
O	O	postnatal	no
O	O	immune	yes
O	O	function	no
O	O	in	yes
O	O	humans	no
O	O	is	yes
O	O	unknown	no
O	O	,	no
B-brand	B-brand	AMEVIVE	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	during	no
O	O	pregnancy	no
O	O	only	no
O	O	if	no
O	O	clearly	no
O	O	needed	no
O	O	.	no

O	O	Significant	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	mediated	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	CYP	no
O	O	isoenzymes	no
O	O	therefore	no
O	O	appear	no
O	O	unlikely	no
O	O	.	no

B-drug	B-drug	Tiagabine	yes
O	O	has	no
O	O	shown	no
O	O	no	yes
O	O	clinically	no
O	O	important	no
O	O	potentiation	no
O	O	of	yes
O	O	the	no
O	O	pharmacodynamic	no
O	O	effects	no
O	O	of	yes
O	O	triazo	no
O	O	lam	no
O	O	or	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	metabolizers	no
O	O	.	no

O	O	Population	no
O	O	pharmacokinetic	no
O	O	analyses	no
O	O	were	no
O	O	conducted	no
O	O	on	no
O	O	plasma	yes
O	O	concentration	no
O	O	data	no
O	O	from	no
O	O	1445	no
O	O	patients	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	to	no
O	O	examine	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	on	no
O	O	clearance	no
O	O	or	no
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	dofetilide	yes
O	O	.	no

B-drug	B-drug	Isoproterenol	yes
I-drug	I-drug	hydrochloride	yes
O	O	injection	yes
O	O	and	yes
B-drug	B-drug	epinephrine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	simultaneously	no
O	O	because	no
O	O	both	no
O	O	drugs	no
O	O	are	no
O	O	direct	no
O	O	cardiac	no
O	O	stimulants	no
O	O	and	yes
O	O	their	no
O	O	combined	no
O	O	effects	no
O	O	may	no
O	O	induce	no
O	O	serious	no
O	O	arrhythmias	no
O	O	.	no

O	O	Compared	no
O	O	with	yes
O	O	lean	no
O	O	rats	no
O	O	,	no
O	O	arteries	no
O	O	from	no
O	O	dietary-obese	no
O	O	rats	no
O	O	showed	no
O	O	significant	no
O	O	(	no
O	O	P	yes
O	O	<	no
O	O	0.001	no
O	O	)	no
O	O	endothelial	no
O	O	dysfunction	no
O	O	,	no
O	O	as	yes
O	O	indicated	no
O	O	by	no
O	O	a	yes
O	O	decrease	no
O	O	(	no
O	O	>	no
O	O	20	yes
O	O	%	no
O	O	)	no
O	O	in	yes
O	O	maximal	no
O	O	acetylcholine-induced	no
O	O	vasorelaxation	no
O	O	.	no

O	O	Suppression	no
O	O	by	no
B-drug	B-drug	verapamil	yes
O	O	of	yes
B-drug_n	B-drug_n	bombesin-enhanced	no
O	O	peritoneal	no
O	O	metastasis	no
O	O	of	yes
O	O	intestinal	no
O	O	adenocarcinomas	no
O	O	induced	no
O	O	by	no
B-drug_n	B-drug_n	azoxymethane	no
O	O	in	yes
O	O	wistar	no
O	O	rats	no
O	O	.	no

B-drug	B-drug	Glyburide	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	randomized	no
O	O	,	no
O	O	multiple-dose	no
O	O	crossover	no
O	O	study	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	Type	yes
O	O	2	yes
O	O	diabetes	no
O	O	were	no
O	O	administered	no
O	O	120	no
O	O	mg	yes
B-brand	B-brand	Starlix	yes
O	O	three	no
O	O	times	no
O	O	a	yes
O	O	day	no
O	O	before	no
O	O	meals	no
O	O	for	yes
O	O	1	yes
O	O	day	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	10	yes
O	O	mg	yes
O	O	daily	no
O	O	.	no

O	O	This	no
O	O	might	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	toxic	no
O	O	reactions	no
O	O	.	no

O	O	Since	no
O	O	the	no
O	O	arrival	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	erection-supporting	no
I-group	I-group	medication	no
O	O	,	no
O	O	patients	no
O	O	want	no
O	O	to	no
O	O	know	no
O	O	how	no
O	O	safe	no
O	O	sexual	no
O	O	activity	yes
O	O	is	yes
O	O	in	yes
O	O	cardiovascular	no
O	O	disease	no
O	O	in	yes
O	O	general	no
O	O	and	yes
O	O	during	no
O	O	use	no
O	O	of	yes
B-group	B-group	erection-supporting	no
I-group	I-group	medication	no
O	O	in	yes
O	O	particular	no
O	O	.	no

B-group	B-group	Bile	no
I-group	I-group	acid	yes
I-group	I-group	sequestrants	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	bind	no
O	O	other	no
O	O	drugs	no
O	O	given	no
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Allopurinol	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	no	yes
O	O	significant	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	occurred	no
O	O	when	no
B-drug	B-drug	captopril	yes
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	were	no
O	O	administered	no
O	O	concomitantly	no
O	O	for	yes
O	O	6	yes
O	O	days	no
O	O	.	no

O	O	See	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	.	no

O	O	Inhibitory	yes
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	ruthenium	yes
O	I-drug_n	red	yes
O	O	on	no
O	O	inositol	yes
O	O	1,4	no
O	O	,	no
O	O	5-trisphosphate-induced	no
O	O	responses	no
O	O	in	yes
O	O	rat	yes
O	O	megakaryocytes	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Inhibit	no
O	O	Both	no
O	O	Aldehyde	yes
O	O	Oxidase	yes
O	O	and	yes
O	O	CYP3A4	no
B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	inhibits	no
O	O	both	no
O	O	aldehyde	yes
O	O	oxidase	yes
O	O	(	no
O	O	in	yes
O	O	vitro	no
O	O	)	no
O	O	and	yes
O	O	CYP3A4	no
O	O	(	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	primary	no
O	O	and	yes
O	O	secondary	yes
O	O	enzymes	yes
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	responsible	no
O	O	for	yes
B-drug	B-drug	zaleplon	yes
O	O	metabolism	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	No	yes
O	O	laboratory	no
O	O	test	yes
O	O	abnormalities	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	guanfacine	yes
O	O	have	no
O	O	been	no
O	O	identified	no
O	O	.	no

O	O	These	no
O	O	increases	no
O	O	in	yes
O	O	concentration	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	increased	no
O	O	effects	no
O	O	,	no
O	O	(	no
O	O	lower	no
O	O	blood	yes
O	O	pressure	no
O	O	and	yes
O	O	increased	no
O	O	heart	no
O	O	rate	no
O	O	)	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	postmarketing	no
O	O	reports	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	when	no
B-drug	B-drug	erythromycin	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	QT	no
O	O	prolongation	no
O	O	,	no
O	O	cardiac	no
O	O	arrythmias	no
O	O	,	no
O	O	ventricular	no
O	O	tachycardia	no
O	O	,	no
O	O	ventricular	no
O	O	fibrulation	no
O	O	,	no
O	O	and	yes
O	O	torsades	no
O	O	de	yes
O	O	pointes	no
O	O	,	no
O	O	most	no
O	O	like	yes
O	O	due	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	by	no
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	There	no
O	O	are	no
O	O	3	yes
O	O	types	no
O	O	of	yes
O	O	indications	no
O	O	:	no
O	O	specific	no
O	O	(	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	some	no
O	O	forms	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	deficit	no
O	O	i.e	no
O	O	.	no
O	O	acute	no
O	O	)	no
O	O	,	no
O	O	pharmacological	no
O	O	(	no
O	O	i.e	no
O	O	.	no
O	O	without	no
O	O	alterations	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	status	no
O	O	)	no
O	O	and	yes
O	O	mixed	yes
O	O	--	no
O	O	pharmacological	no
O	O	and	yes
O	O	aetiopathogenic	no
O	O	--	no
O	O	(	no
O	O	for	yes
O	O	example	no
O	O	complications	no
O	O	of	yes
O	O	chronic	no
O	O	alcoholism	no
O	O	)	no
O	O	.	no

O	O	decreased	no
B-drug	O	antithrombin	yes
I-drug	O	3	yes
O	O	;	no

O	O	Two	no
O	O	percent	no
O	O	of	yes
O	O	patients	no
O	O	treated	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	ENBREL	yes
O	O	and	yes
B-drug	B-drug	anakinra	yes
O	O	developed	no
O	O	neutropenia	no
O	O	(	no
O	O	ANC	no
O	O	1	yes
O	O	x	yes
O	O	109/L	no
O	O	)	no
O	O	.	no

O	O	Reported	no
O	O	examples	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	include	no
O	O	the	no
O	O	following	no
O	O	:	no
B-group	B-drug	Antibiotics	no
O	O	:	no
B-drug	B-drug	Rifampin	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inducer	no
O	O	of	yes
O	B-drug	CYP3A4	no
O	O	.	no

O	O	The	no
O	O	resulting	no
O	O	increase	no
O	O	in	yes
O	O	free	yes
O	O	drug	yes
O	O	concentration	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	enhanced	no
O	O	drug	yes
O	O	effect	no
O	O	in	yes
O	O	vivo	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	raise	no
O	O	the	no
O	O	possibility	no
O	O	that	no
O	O	the	no
O	O	ethanolysis	no
O	O	reaction	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	the	no
O	O	stomach	no
O	O	of	yes
O	O	people	no
O	O	who	no
O	O	consume	no
B-drug	B-drug	alcohol	yes
O	O	and	yes
B-drug_n	B-group	3-hydroxy-1,4-benzodiazepine	no
O	O	on	no
O	O	a	yes
O	O	regular	yes
O	O	basis	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	be	no
O	O	warned	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	danger	no
O	O	of	yes
O	O	the	no
O	O	intravenous	yes
O	O	self-administration	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	while	no
O	O	under	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	SUBOXONE	yes
O	O	or	no
B-brand	B-brand	SUBUTEX	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	also	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	celecoxib	yes
O	O	,	no
O	O	although	no
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	,	no
O	O	is	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	Acute	no
O	O	symptoms	no
O	O	should	no
O	O	be	no
O	O	treated	no
O	O	with	yes
O	O	a	yes
O	O	short-acting	no
O	O	,	no
O	O	inhaled	no
B-group	B-group	beta2-agonist	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	salbutamol	yes
O	O	(	no
O	O	the	no
O	O	physician	no
O	O	should	no
O	O	provide	no
O	O	the	no
O	O	patient	no
O	O	with	yes
O	O	such	no
O	O	medication	no
O	O	and	yes
O	O	instruct	no
O	O	the	no
O	O	patient	no
O	O	in	yes
O	O	how	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	)	no
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
O	O	these	no
O	O	compounds	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	is	yes
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
O	O	certain	no
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	,	no
O	O	thereby	no
O	O	delaying	no
O	O	elimination	no
O	O	and	yes
O	O	increasing	no
O	O	steady-state	no
O	O	concentrations	no
O	O	of	yes
O	O	these	no
O	B-drug	drugs	no
O	O	.	no

O	O	This	no
O	O	indicates	no
O	O	that	no
B-drug	B-drug	gabapentin	yes
O	O	does	no
O	O	not	no
O	O	undergo	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	by	no
O	O	the	no
O	O	pathway	no
O	O	that	no
O	O	is	yes
O	O	blocked	no
O	O	by	no
B-drug	B-drug	probenecid	yes
O	O	.	no

O	O	Induction	no
O	O	of	yes
O	O	such	no
O	O	tumors	no
O	O	is	yes
O	O	consistent	no
O	O	with	yes
O	O	the	no
O	O	pharmacology-related	no
O	O	endocrine	no
O	O	feedback	no
O	O	alterations	no
O	O	in	yes
O	O	gonadotropin	yes
O	O	levels	no
O	O	caused	no
O	O	by	no
O	O	an	no
B-group	B-group	antiestrogen	no
O	O	.	no

O	O	Acid-catalyzed	no
O	O	ethanolysis	no
O	O	of	yes
B-drug	B-drug	temazepam	yes
O	O	in	yes
O	O	anhydrous	yes
O	O	and	yes
O	O	aqueous	yes
B-drug	B-drug	ethanol	yes
O	O	solutions	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	calcium	yes
O	O	supplements	no
O	O	and	yes
B-drug	B-drug	L-lysine	yes
O	O	may	no
O	O	increase	no
B-drug	B-drug	calcium	yes
O	O	absorption	no

O	O	Monitor	no
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	;	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	12	yes
O	O	patients	no
O	O	with	yes
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	where	no
B-drug	B-drug	ketoprofen	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	were	no
O	O	concomitantly	no
O	O	administered	no
O	O	,	no
B-drug	B-drug	ketoprofen	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

B-drug	B-drug	Valproate	yes
B-brand	B-brand	Keppra	yes
O	O	(	no
O	O	1500	no
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	valproate	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	If	no
O	O	you	no
O	O	are	no
O	O	50	yes
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	or	no
O	O	older	no
O	O	,	no
O	O	ask	no
O	O	your	no
O	O	physician	no
O	O	to	no
O	O	check	no
O	O	your	no
O	O	B12	yes
O	O	status	no
O	O	before	no
O	O	you	no
O	O	take	no
O	O	a	yes
O	O	supplement	yes
O	O	that	no
O	O	contains	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	Vancomycin	yes
O	O	resistance	no
O	O	reversal	no
O	O	in	yes
O	O	enterococci	no
O	O	by	no
O	O	flavonoids	no
O	O	.	no

O	O	route	no
O	O	.	no

B-drug_n	B-drug_n	Jacalin	no
O	O	is	yes
O	O	a	yes
O	O	D-Gal	no
O	O	binding	no
O	O	lectin	yes
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	a	yes
O	O	useful	no
O	O	tool	no
O	O	for	yes
O	O	studying	no
O	O	of	yes
O	O	serum	yes
O	O	and	yes
O	O	secretory	no
O	O	IgA	no
O	O	.	no

O	O	The	no
O	O	increase	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	level	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	small	no
O	O	(	no
O	O	15	yes
O	O	%	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-brand	B-brand	Trileptal	yes
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	periodic	no
O	O	liver	yes
O	O	function	no
O	O	testing	no
O	O	(	no
O	O	transaminases	no
O	O	,	no
O	O	bilirubin	no
O	O	,	no
O	O	and	yes
O	O	alkaline	yes
O	O	phosphatase	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Until	no
O	O	specific	no
O	O	compatibility	no
O	O	data	no
O	O	are	no
O	O	available	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	that	no
B-brand	B-brand	DOXIL	yes
O	O	be	no
O	O	mixed	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

B-group	B-group	Anticonvulsants	no

O	O	Pharmacokinetic-related	no
O	O	Interactions	no
O	O	:	no
B-drug	B-drug	Clozapine	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	many	no
O	O	CYP	no
O	O	450	yes
O	O	isozymes	no
O	O	,	no
O	O	in	yes
O	O	particular	no
O	O	1A2	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	and	yes
O	O	3A4	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Isocarboxazid	yes
O	O	and	yes
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	agents	yes
O	O	is	yes
O	O	generally	no
O	O	not	no
O	O	recommended	no
O	O	because	no
O	O	of	yes
O	O	possible	no
O	O	potentiating	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Methadone	yes

O	O	Table	no
O	O	9	yes

O	O	The	no
O	O	majority	no
O	O	of	yes
O	O	adverse	no
O	O	events	no
O	O	with	yes
B-group	B-group	NNRTIs	no
O	O	occur	no
O	O	within	no
O	O	the	no
O	O	first	no
O	O	month	no
O	O	,	no
O	O	and	yes
O	O	are	no
O	O	predictable	no
O	O	and	yes
O	O	manageable	no
O	O	without	no
O	O	therapy	no
O	O	interruption	no
O	O	.	no

O	O	administration	no
O	O	1	yes
O	O	hour	yes
O	O	before	no
O	O	or	no
O	O	4	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	colestipol	yes
O	O	is	yes
O	O	recommended	no
O	O	.	no
O	O	)	no

O	O	Failure	no
O	O	of	yes
B-drug	B-drug	neomycin	yes
O	O	to	no
O	O	modify	no
B-group	B-group	ACTH	yes
O	O	induced	no
O	O	hypertension	no
O	O	in	yes
O	O	sheep	yes
O	O	.	no

O	O	PATIENTS	no
O	O	:	no
O	O	Random	no
O	O	sample	no
O	O	of	yes
O	O	626	no
O	O	MAC	no
O	O	out	no
O	O	of	yes
O	O	a	yes
O	O	total	yes
O	O	of	yes
O	O	1306	no
O	O	.	no

O	O	Monitor	no
O	O	for	yes
O	O	symptoms	no
O	O	of	yes
O	O	hyperglycemia	no
O	O	;	no

O	O	At	yes
O	O	higher	no
O	O	than	no
O	O	recommended	no
O	O	doses	no
O	O	,	no
B-brand	B-brand	VIOXX	yes
O	O	75	yes
O	O	mg	yes
O	O	administered	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	by	no
O	O	23	no
O	O	%	no
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	AUC0-24hr	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	methotrexate	yes
O	O	7.5	yes
O	O	to	no
O	O	15	yes
O	O	mg/week	no
O	O	for	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	.	no

B-drug	B-drug	Acitretin	yes
O	O	:	no
O	O	Interferes	no
O	O	with	yes
O	O	the	no
O	O	contraceptive	yes
O	O	effect	no
O	O	of	yes
O	O	microdosed	no
O	B-group	progestin-containing	no
O	O	minipill	no
O	O	preparations	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	grapefruit	no
O	O	juice	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	felodipine	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	several-	no
O	O	fold	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	,	no
O	O	either	no
O	O	due	no
O	O	to	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	bioavailability	no
O	O	or	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	metabolism	no
O	O	.	no

O	O	Differences	no
O	O	can	no
O	O	occur	no
O	O	in	yes
O	O	therapeutic	no
O	O	effect	no
O	O	and	yes
O	O	in	yes
O	O	adverse	no
O	O	events	no
O	O	.	no

O	O	Conversely	no
O	O	,	no
O	O	adverse	no
O	O	effects	no
O	O	may	no
O	O	result	no
O	O	from	no
O	O	displacement	no
O	O	of	yes
O	O	protein-bound	no
B-brand	B-brand	Anafranil	yes
O	O	by	no
O	O	other	no
O	O	highly	no
O	O	bound	no
O	O	drugs	no
O	O	.	no

O	O	The	no
O	O	recommended	no
O	O	dosage	no
O	O	(	no
O	O	one	no
O	O	or	no
O	O	two	no
O	O	capsules	no
O	O	twice	no
O	O	daily	no
O	O	,	no
O	O	morning	no
O	O	and	yes
O	O	evening	no
O	O	)	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	exceeded	no
O	O	.	no

O	O	Increases	no
O	O	in	yes
B-drug	B-drug	sertraline	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	guided	no
O	O	by	no
O	O	clinical	no
O	O	response	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	omeprazole	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	systemic	no
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	cilostazol	yes
O	O	and/or	no
O	O	its	no
O	O	major	no
O	O	metabolites	no
O	O	.	no

O	O	Brain	yes
O	O	hemorrhage	no
O	O	and	yes
O	O	optic	no
O	O	nerve	yes
O	O	vacuolation	no
O	O	were	no
O	O	seen	no
O	O	in	yes
O	O	another	no
O	O	female	no
O	O	dog	no
O	O	that	no
O	O	was	no
O	O	sacrificed	no
O	O	in	yes
O	O	moribund	no
O	O	condition	no
O	O	after	no
O	O	11	yes
O	O	weeks	no
O	O	of	yes
O	O	escalating	no
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	280	yes
O	O	mg/kg/day	no
O	O	.	no

O	O	Warning	no
O	O	signs	no
O	O	,	no
O	O	irrespective	no
O	O	of	yes
O	O	cause	no
O	O	,	no
O	O	are	no
O	O	:	no
O	O	dryness	no
O	O	of	yes
O	O	mouth	no
O	O	,	no
O	O	thirst	no
O	O	,	no
O	O	weakness	no
O	O	,	no
O	O	lethargy	no
O	O	,	no
O	O	drowsiness	no
O	O	,	no
O	O	restlessness	no
O	O	,	no
O	O	muscle	no
O	O	pains	no
O	O	or	no
O	O	cramps	no
O	O	,	no
O	O	muscular	no
O	O	fatigue	no
O	O	,	no
O	O	hypotension	no
O	O	,	no
O	O	oliguria	no
O	O	,	no
O	O	tachycardia	no
O	O	,	no
O	O	and	yes
O	O	gastrointestinal	no
O	O	disturbances	no
O	O	such	no
O	O	as	yes
O	O	nausea	no
O	O	and	yes
O	O	vomiting	no
O	O	.	no

O	O	In	yes
O	O	studies	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	between	yes
O	O	intravenous	yes
B-drug	B-drug	iloprost	yes
O	O	and	yes
O	O	either	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	captopril	yes
O	O	.	no

O	O	Expected	no
O	O	to	no
O	O	substantially	no
O	O	decrease	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	efavirenz	yes
O	O	;	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	some	no
O	O	other	no
B-group	B-group	nondepolarizing	no
I-group	I-group	neuromuscular	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
O	O	the	no
O	O	time	no
O	O	of	yes
O	O	onset	no
O	O	of	yes
O	O	neuromuscular	no
O	O	block	yes
O	O	induced	no
O	O	by	no
B-brand	B-brand	NUROMAX	yes
O	O	is	yes
O	O	lengthened	no
O	O	and	yes
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	block	yes
O	O	is	yes
O	O	shortened	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	carbamazepine	yes
O	O	.	no

B-group	B-group	Uricosuric	no
I-group	I-group	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	probenecid	yes
O	O	and	yes
B-drug	B-drug	sulfinpyrazone	yes
O	O	,	no
O	O	can	no
O	O	inhibit	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	.	no

O	O	Potential	no
O	O	for	yes
B-brand	B-brand	ABILIFY	yes
O	O	to	no
O	O	Affect	no
O	O	Other	no
O	O	Drugs	no
B-drug	B-drug	Aripiprazole	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	cause	no
O	O	clinically	no
O	O	important	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	with	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

B-group	B-group	Antifungals	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	and/or	no
O	O	in	yes
O	O	vivo	no
O	O	data	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	fluconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
O	O	and	yes
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	markedly	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	which	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	cisapride	yes
O	O	levels	no
O	O	and	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	This	no
O	O	medicine	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450IID6	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
O	O	might	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	flecainide	yes
O	O	in	yes
O	O	patients	no
O	O	that	no
O	O	are	no
O	O	on	no
O	O	chronic	no
B-drug	B-drug	flecainide	yes
O	O	therapy	no
O	O	;	no

B-drug	B-drug	Methotrexate	yes
B-brand	B-brand	VIOXX	yes
O	O	12.5	yes
O	O	,	no
O	O	25	yes
O	O	,	no
O	O	and	yes
O	O	50	yes
O	O	mg	yes
O	O	,	no
O	O	each	no
O	O	dose	no
O	O	administered	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	,	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	AUC0-24hr	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	single	yes
O	O	weekly	yes
B-drug	B-drug	methotrexate	yes
O	O	doses	no
O	O	of	yes
O	O	7.5	yes
O	O	to	no
O	O	20	yes
O	O	mg	yes
O	O	for	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	.	no

B-group	I-group	Antacids	no
O	O	:	no
O	O	Administration	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	to	no
O	O	volunteers	no
O	O	under	no
O	O	fasting	no
O	O	conditions	no
O	O	,	no
O	O	or	no
O	O	with	yes
B-group	B-group	antacid	no
O	O	suspension	yes
O	O	yielded	no
O	O	similar	no
O	O	serum	yes
B-drug	B-drug	flurbiprofen	yes
O	O	time	no
O	O	profiles	no
O	O	in	yes
O	O	young	no
O	O	subjects	no
O	O	(	no
O	O	n=12	no
O	O	)	no
O	O	.	no

O	O	Effects	no
O	O	on	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	other	no
B-group	B-group	beta-blockers	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	determined	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	EXTREME	no
O	O	CAUTION	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	cyclopropane	no
O	O	or	no
B-group	B-group	halogenated	no
I-group	I-group	hydrocarbon	no
I-group	I-group	anesthetics	no
O	O	.	no

O	O	Another	no
O	O	investigator	no
O	O	found	no
O	O	no	yes
O	O	increase	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	in	yes
O	O	12	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	.	no

B-brand	B-brand	PEGASYS	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	used	no
O	O	during	no
O	O	pregnancy	no
O	O	only	no
O	O	if	no
O	O	the	no
O	O	potential	no
O	O	benefit	no
O	O	justifies	no
O	O	the	no
O	O	potential	no
O	O	risk	no
O	O	to	no
O	O	the	no
O	O	fetus	no
O	O	.	no

O	O	In	yes
O	O	hematologic	no
O	O	studies	no
O	O	or	no
O	O	in	yes
O	O	transfusion	no
O	O	cross-matching	no
O	O	procedures	no
O	O	when	no
O	O	anti-globulin	no
O	O	tests	no
O	O	are	no
O	O	performed	no
O	O	on	no
O	O	the	no
O	O	minor	no
O	O	side	no
O	O	or	no
O	O	in	yes
O	O	Coombs	no
O	O	testing	no
O	O	of	yes
O	O	newborns	no
O	O	whose	no
O	O	mothers	no
O	O	have	no
O	O	received	no
B-group	B-group	cephalosporin	yes
I-group	I-group	antibiotics	no
O	O	before	no
O	O	parturition	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	recognized	no
O	O	that	no
O	O	a	yes
O	O	positive	no
O	O	Coombs	no
O	O	test	yes
O	O	may	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	.	no

B-drug	B-drug	Tolbutamide	yes
O	O	:	no
O	O	In	yes
O	O	diabetic	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	no	yes
O	O	significant	no
O	O	effects	no
O	O	were	no
O	O	seen	no
O	O	on	no
B-drug	B-drug	tolbutamide	yes
O	O	plasma	yes
O	O	levels	no
O	O	or	no
O	O	fasting	no
O	O	blood	yes
O	O	glucose	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	limited	no
O	O	experience	no
O	O	with	yes
O	O	concomitant	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-group	B-group	alpha-blockers	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel-blockers	no
O	O	,	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
B-group	B-group	diuretics	no
O	O	(	no
O	O	both	no
B-group	B-group	thiazide-like	no
O	O	and	yes
O	O	loop	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	,	no
O	O	nutritional	no
O	O	supplement	yes
O	O	,	no
O	O	food	no
O	O	or	no
O	O	herb	yes
O	O	interactions	no
O	O	have	no
O	O	yet	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Note	no
O	O	:	no
O	O	dissolution	no
O	O	of	yes
O	O	aerosol	no
O	O	particles	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	in	yes
B-brand	B-brand	Survanta	yes
O	O	,	no
O	O	a	yes
O	O	model	no
B-group	B-group	lung	yes
I-group	I-group	surfactant	yes
O	O	.	no

O	O	If	no
B-brand	B-brand	TYKERB	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	of	yes
O	O	Pgp	no
O	O	,	no
O	O	increased	no
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	substrate	yes
O	O	drug	yes
O	O	are	no
O	O	likely	no
O	O	,	no
O	O	and	yes
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	.	no

B-drug	B-drug	ETHANOL	yes
O	O	/	no
O	O	NUTRITION	no
O	O	/	no
O	O	HERB	yes
O	O	INTERACTIONS	no
O	O	:	no
O	O	Food	no
O	O	:	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	if	no
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	If	no
B-group	B-group	antacids	no
O	O	are	no
O	O	required	no
O	O	during	no
B-brand	B-brand	OMNICEF	yes
O	O	therapy	no
O	O	,	no
B-brand	B-brand	OMNICEF	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	after	no
O	O	the	no
B-group	B-group	antacid	no
O	O	.	no

O	O	Of	yes
O	O	particular	no
O	O	importance	no
O	O	,	no
O	O	sufficient	no
O	O	time	no
O	O	must	no
O	O	elapse	no
O	O	before	no
O	O	initiating	no
O	O	TCA	no
O	O	treatment	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	being	no
O	O	withdrawn	no
O	O	from	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	given	no
O	O	the	no
O	O	long	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	parent	no
O	O	and	yes
O	O	active	no
O	O	metabolite	yes
O	O	(	no
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	weeks	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	)	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	are	no
O	O	altered	no
O	O	by	no
O	O	concomitant	no
O	O	medications	no
O	O	that	no
O	O	affect	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
O	O	drugs	no
O	O	(	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	,	no
O	O	but	no
O	O	physicians	no
O	O	should	no
O	O	be	no
O	O	alert	no
O	O	to	no
O	O	the	no
O	O	possibility	no
O	O	that	no
O	O	a	yes
O	O	smaller	no
O	O	initial	no
O	O	dose	no
O	O	and	yes
O	O	longer	no
O	O	intervals	no
O	O	between	yes
O	O	doses	no
O	O	may	no
O	O	be	no
O	O	needed	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	C	yes
O	O	max	no
O	O	,	no
O	O	T	yes
O	O	max	no
O	O	,	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
O	O	acid	yes
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	changed	no
O	O	.	no

B-group	B-group	Beta-blocking	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Bepridil	yes
O	O	and	yes
B-group	B-group	beta-blocking	no
I-group	I-group	agents	yes
O	O	has	no
O	O	been	no
O	O	well	no
O	O	tolerated	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	stable	no
O	O	angina	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	increased	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	kept	no
O	O	in	yes
O	O	mind	no
O	O	when	no
B-brand	B-brand	Orudis	yes
O	O	doses	no
O	O	greater	no
O	O	than	no
O	O	50	yes
O	O	mg	yes
O	O	as	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	or	no
O	O	200	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	ketoprofen	yes
O	O	per	no
O	O	day	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	highly	no
O	O	bound	no
O	O	drugs	no
O	O	.	no

O	O	Results	no
O	O	showed	no
O	O	that	no
O	O	,	no
O	O	depending	no
O	O	on	no
O	O	the	no
O	O	task	no
O	O	considered	no
O	O	,	no
O	O	the	no
O	O	same	yes
O	O	pharmacological	no
O	O	treatment	no
O	O	produced	no
O	O	either	no
O	O	a	yes
O	O	facilitation	no
O	O	or	no
O	O	an	no
O	O	impairment	no
O	O	of	yes
O	O	acquisition	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	nelfinavir	yes
O	O	at	yes
O	O	steady-state	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	.	no

O	O	TABLE	no
O	O	1	yes
O	O	Effects	no
O	O	on	no
O	O	Plasma	yes
O	O	Concentrations	no
O	O	(	no
O	O	AUC	no
O	O	0-24	no
O	O	hrs	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	Loratadine	yes
O	O	and	yes
B-drug	B-drug	Descarboethoxyloratadine	yes
O	O	After	no
O	O	10	yes
O	O	Days	no
O	O	of	yes
O	O	Coadministration	no
O	O	(	no
B-drug	B-drug	Loratadine	yes
O	O	10	yes
O	O	mg	yes
O	O	)	no
O	O	in	yes
O	O	Normal	yes
O	O	Volunteers	no

O	O	Serum	yes
B-drug	B-drug	infliximab	yes
O	O	concentrations	no
O	O	appeared	no
O	O	to	no
O	O	be	no
O	O	unaffected	no
O	O	by	no
O	O	baseline	no
O	O	use	no
O	O	of	yes
O	O	medications	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	Crohn	no
O	O	s	yes
O	O	disease	no
O	O	including	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	antibiotics	no
O	O	(	no
B-drug	B-drug	metronidazole	yes
O	O	or	no
B-drug	B-drug	ciprofloxacin	yes
O	O	)	no
O	O	and	yes
O	O	aminosalicylates	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	triazolam	yes
O	O	and	yes
B-drug	B-drug	midazolam	yes
O	O	and	yes
O	O	thus	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	pharmacologic	no
O	O	effect	no
O	O	of	yes
O	O	these	no
B-group	B-group	benzodiazepines	no
O	O	.	no

O	O	Drugs	no
O	O	Associated	no
O	O	With	yes
O	O	Peripheral	no
O	O	Neuropathy	no
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	HIVID	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	have	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	cause	no
O	O	peripheral	no
O	O	neuropathy	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	where	no
O	O	possible	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	Elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
B-group	B-group	quinolone	no
O	O	use	no
O	O	.	no

O	O	HAART	no
O	O	was	no
O	O	included	no
O	O	with	yes
O	O	combination	yes
O	O	therapy	no
O	O	from	no
O	O	January	no
O	O	1997	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
B-drug	B-drug	estazolam	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	itraconazole	yes
O	O	,	no
O	O	which	no
O	O	are	no
O	O	very	no
O	O	potent	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A	no
O	O	.	no

B-drug	B-drug	trimethoprim/sulfamethoxazole	no
O	O	;	no

O	O	We	no
O	O	conclude	no
O	O	that	no
O	O	an	no
O	O	ability	no
O	O	of	yes
O	O	some	no
O	O	P	yes
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	Drug	yes
O	O	interactions	no
O	O	caused	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	P-glycoprotein-mediated	no
O	O	drug	yes
O	O	clearance	no
O	O	or	no
O	O	CYP-mediated	no
O	O	drug	yes
O	O	clearance	no
O	O	with	yes
O	O	the	no
O	O	listed	no
O	O	isoforms	no
O	O	are	no
O	O	unlikely	no
O	O	.	no

O	O	Drugs	no
O	O	other	no
O	O	than	no
O	O	those	no
O	O	listed	no
O	O	here	no
O	O	may	no
O	O	also	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	glimepiride	yes
O	O	or	no
O	O	affect	no
O	O	your	no
O	O	condition	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	clinical	no
O	O	trial	no
O	O	of	yes
O	O	217	no
O	O	pediatric	yes
O	O	patients	no
O	O	(	no
O	O	12	yes
O	O	to	no
O	O	17	yes
O	O	years	no
O	O	)	no
O	O	with	yes
O	O	severe	no
O	O	recalcitrant	no
O	O	nodular	no
O	O	acne	no
O	O	,	no
O	O	transient	no
O	O	elevations	no
O	O	in	yes
O	O	CPK	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	12	yes
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	,	no
O	O	including	no
O	O	those	no
O	O	undergoing	no
O	O	strenuous	no
O	O	physical	no
O	O	activity	yes
O	O	in	yes
O	O	association	no
O	O	with	yes
O	O	reported	no
O	O	musculoskeletal	no
O	O	adverse	no
O	O	events	no
O	O	such	no
O	O	as	yes
O	O	back	no
O	O	pain	yes
O	O	,	no
O	O	arthralgia	no
O	O	,	no
O	O	limb	no
O	O	injury	no
O	O	,	no
O	O	or	no
O	O	muscle	no
O	O	sprain	no
O	O	.	no

O	O	Recent	no
O	O	,	no
O	O	better	no
O	O	designed	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	reported	no
O	O	these	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	doxapram	yes
O	O	to	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	receiving	no
B-group	B-group	sympathomimetic	no
O	O	or	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibiting	no
I-group	I-group	drugs	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	additive	no
O	O	pressor	no
O	O	effect	no
O	O	.	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	allergic	no
O	O	reactions	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	30	yes
O	O	minutes	no
O	O	prior	no
O	O	to	no
B-drug	B-drug	sucralfate	yes
O	O	.	no

O	O	Potential	no
O	O	for	yes
O	O	Interaction	no
O	O	with	yes
O	O	Drugs	no
O	O	that	no
O	O	Affect	no
O	O	Gastric	yes
O	O	Acidity	no
O	O	:	no
B-drug	B-drug	Duloxetine	yes
O	O	has	no
O	O	an	no
O	O	enteric	no
O	O	coating	no
O	O	that	no
O	O	resists	no
O	O	dissolution	no
O	O	until	no
O	O	reaching	no
O	O	a	yes
O	O	segment	no
O	O	of	yes
O	O	the	no
O	O	gastrointestinal	no
O	O	tract	no
O	O	where	no
O	O	the	no
O	O	pH	yes
O	O	exceeds	no
O	O	5.5	no
O	O	.	no

B-group	B-group	Non-steroidal	no
I-group	I-group	Anti-inflammatory	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agent	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	O	diuretic	no
O	O	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
O	O	potassium-sparing	no
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	bupropion	yes
O	O	is	yes
O	O	primarily	no
O	O	metabolized	no
O	O	to	no
B-drug_n	B-drug_n	hydroxybupropion	no
O	O	by	no
O	O	the	no
O	O	CYP2B6	no
O	O	isoenzyme	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
O	O	the	no
O	O	UDP-glucuronyl	no
O	O	transferase	no
O	O	level	no
O	O	was	no
O	O	increased	no
O	O	,	no
O	O	indicating	no
O	O	induction	no
O	O	of	yes
O	O	this	no
O	O	enzyme	no
O	O	.	no

O	O	In	yes
O	O	Study	no
O	O	1	yes
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	colorectal	no
O	O	cancer	no
O	O	were	no
O	O	given	no
B-drug	B-drug	irinotecan/5-FU/leucovorin	no
O	O	(	no
O	O	bolus-IFL	no
O	O	)	no
O	O	with	yes
O	O	or	no
O	O	without	no
B-brand	B-brand	AVASTIN	yes
O	O	.	no

O	O	Avoid	no
O	O	saw	no
O	O	palmetto	no
O	O	,	no
O	O	red	yes
O	O	clover	no
O	O	,	no
O	O	ginseng	yes
O	O	.	no

O	O	.	no

O	O	phase	no
O	O	2	yes
O	O	(	no
O	O	days	no
O	O	14-44	no
O	O	)	no
O	O	:	no
B-drug	B-drug	fluoxetine	yes
O	O	20	yes
O	O	mg/day	no
O	O	;	no

O	O	In	yes
O	O	study	no
O	O	one	no
O	O	,	no
O	O	hyperglycaemic	no
O	O	clamps	no
O	O	(	no
O	O	5.6	no
O	O	mmol/l	no
O	O	,	no
O	O	11.1	no
O	O	mmol/	no
O	O	1	yes
O	O	,	no
O	O	16.7	no
O	O	mmol/l	no
O	O	)	no
O	O	were	no
O	O	carried	no
O	O	out	no
O	O	during	no
O	O	placebo	no
O	O	or	no
B-drug	B-drug	insulin	yes
O	O	(	no
O	O	dose	no
O	O	1	yes
O	O	:	no
O	O	1	yes
O	O	mU/kg/min	no
O	O	;	no
O	O	dose	no
O	O	2	yes
O	O	:	no
O	O	2	yes
O	O	mU/kg/min	no
O	O	)	no
O	O	infusion	no
O	O	.	no

B-brand	B-brand	Omniscan	yes
O	O	interferes	no
O	O	with	yes
O	O	serum	yes
O	O	calcium	yes
O	O	measurements	no
O	O	with	yes
O	O	some	no
O	O	colorimetric	no
O	O	(	no
O	O	complexometric	no
O	O	)	no
O	O	methods	no
O	O	commonly	no
O	O	used	no
O	O	in	yes
O	O	hospitals	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	serum	yes
O	O	calcium	yes
O	O	concentrations	no
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	true	yes
O	O	values	no
O	O	.	no

O	O	Appropriate	no
O	O	dosage	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Drug/	no
O	O	Laboratory	no
O	O	Tests	no
O	O	Interactions	no
O	O	Hyperaminotransferasemia	no
O	O	:	no
O	O	Significant	no
O	O	elevations	no
O	O	of	yes
O	O	aminotransferase	no
O	O	(	no
O	O	SGOT	no
O	O	[	no
O	O	S-AST	no
O	O	]	no
O	O	and	yes
O	O	SGPT	no
O	O	[	no
O	O	S-ALT	no
O	O	]	no
O	O	)	no
O	O	levels	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	a	yes
O	O	high	yes
O	O	percentage	no
O	O	of	yes
O	O	patients	no
O	O	(	no
O	O	and	yes
O	O	healthy	no
O	O	subjects	no
O	O	)	no
O	O	who	no
O	O	have	no
O	O	received	no
B-drug	B-drug	heparin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	clofarabine	yes
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	cytochrome	no
O	O	p450	no
O	O	substrates	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	natural	yes
O	O	and	yes
O	O	synthetic	yes
O	O	galloyl	no
O	O	esters	yes
O	O	on	no
O	O	glucocorticoid-induced	no
O	O	gene	yes
O	O	expression	no
O	O	was	no
O	O	evaluated	no
O	O	by	no
O	O	using	no
O	O	rat	yes
O	O	fibroblast	yes
O	O	3Y1	no
O	O	cells	yes
O	O	stably	no
O	O	transfected	no
O	O	with	yes
O	O	a	yes
O	O	luciferase	no
O	O	reporter	no
O	O	gene	yes
O	O	under	no
O	O	the	no
O	O	transcriptional	no
O	O	regulation	no
O	O	of	yes
O	O	the	no
O	O	mouse	yes
O	O	mammary	no
O	O	tumor	yes
O	O	virus	yes
O	B-drug	promoter	no
O	O	.	no

O	O	The	no
O	O	ECG	no
O	O	changes	no
O	O	and/or	no
O	O	hypokalemia	no
O	O	that	no
O	O	may	no
O	O	result	no
O	O	from	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-group	B-group	non-potassium	no
I-group	I-group	sparing	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	loop	no
O	O	or	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	)	no
O	O	can	no
O	O	be	no
O	O	acutely	no
O	O	worsened	no
O	O	by	no
B-group	B-group	beta-agonists	no
O	O	,	no
O	O	especially	no
O	O	when	no
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	of	yes
O	O	the	no
B-group	B-group	beta-agonist	no
O	O	is	yes
O	O	exceeded	no
O	O	.	no

B-drug	B-drug	Corticotropin	yes
O	O	may	no
O	O	accentuate	no
O	O	the	no
O	O	electrolyte	yes
O	O	loss	no
O	O	associated	no
O	O	with	yes
B-group	B-group	diuretic	no
O	O	therapy	no
O	O	.	no

O	O	Given	no
O	O	the	no
O	O	anticonvulsant	no
O	O	properties	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-brand	B-brand	EQUETROTM	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	thyroid	yes
O	O	function	no
O	O	as	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	other	no
B-group	B-group	anticonvulsants	no
O	O	.	no

O	O	Concomitant	no
O	O	single	yes
O	O	dose	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	20	yes
O	O	mg	yes
O	O	with	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	fluconazole	yes
O	O	produced	no
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	.	no

O	O	Both	no
B-drug_n	B-drug_n	ibogaine	no
O	O	and	yes
B-drug_n	B-drug_n	18-MC	no
O	O	enhance	no
O	O	the	no
O	O	locomotor	no
O	O	and/or	no
O	O	stereotypic	no
O	O	effects	no
O	O	of	yes
O	O	stimulants	no
O	O	.	no

B-group	B-group	Protease	yes
I-group	I-group	inhibitor	yes
O	O	:	no
B-drug	B-drug	atazanavir	yes

O	O	T3	yes
O	O	resin	yes
O	O	uptake	no
O	O	is	yes
O	O	decreased	no
O	O	,	no
O	O	reflecting	no
O	O	the	no
O	O	elevated	no
O	O	TBG	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	COPD	no
O	O	should	no
O	O	not	no
O	O	normally	no
O	O	be	no
O	O	treated	no
O	O	with	yes
B-group	B-group	beta-blockers	no
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	of	yes
O	O	intramuscularly	no
O	O	injected	no
B-drug	B-drug	ketamine	yes
O	O	and	yes
O	O	its	no
O	O	N-demethylated	no
O	O	metabolite	yes
O	O	(	no
O	O	metabolite	yes
O	O	I	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	halothane	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	rats	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	be	no
O	O	reduced	yes
O	O	to	no
O	O	one-half	no
O	O	the	no
O	O	usual	no
O	O	dose	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	.	no

O	O	however	no
O	O	,	no
O	O	patients	no
O	O	receiving	no
O	O	such	no
O	O	combined	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	for	yes
O	O	early	no
O	O	evidence	no
O	O	of	yes
O	O	neurological	no
O	O	toxicity	no
O	O	and	yes
O	O	treatment	no
O	O	discontinued	no
O	O	promptly	no
O	O	if	no
O	O	such	no
O	O	signs	no
O	O	appear	no
O	O	.	no

O	O	During	no
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	O	fluvoxamine	yes
O	O	treatment	no
O	O	,	no
O	O	ataxia	no
O	O	,	no
O	O	a	yes
O	O	typical	no
O	O	side	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	was	no
O	O	observed	no
O	O	.	no

O	O	1	yes
O	O	.	no

O	O	The	no
O	O	increased	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	or	no
O	O	its	no
O	O	metabolite	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	prolonged	no
O	O	QT	no
O	O	intervals	no
O	O	.	no

B-drug	O	Phenytoin	yes
O	O	intoxication	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	fluvoxamine	yes
O	O	.	no

O	O	Clinically	no
O	O	significant	no
O	O	interactions	no
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	since	no
O	O	the	no
B-group	B-group	NRTIs	no
O	O	are	no
O	O	metabolized	no
O	O	via	no
O	O	a	yes
O	O	different	no
O	O	route	no
O	O	than	no
B-drug	B-drug	efavirenz	yes
O	O	and	yes
O	O	would	no
O	O	be	no
O	O	unlikely	no
O	O	to	no
O	O	compete	no
O	O	for	yes
O	O	the	no
O	O	same	yes
O	O	metabolic	no
O	O	enzymes	yes
O	O	and	yes
O	O	elimination	no
O	O	pathways	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	bioavailability	no
O	O	parameters	no
O	O	,	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	protein	yes
O	O	binding	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	(	no
O	O	measured	no
O	O	by	no
O	O	prothrombin	yes
O	O	time	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	changed	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	poor	no
O	O	metabolizers	no
O	O	.	no

O	O	A	yes
O	O	method	yes
O	O	to	no
O	O	maximize	no
O	O	the	no
O	O	therapeutic	no
O	O	benefit	no
O	O	of	yes
B-drug	B-drug	gentamicin	yes
O	O	while	no
O	O	minimizing	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	nephrotoxicity	no
O	O	and	yes
O	O	the	no
O	O	appearance	no
O	O	of	yes
O	O	a	yes
O	O	hot	no
O	O	kidney	yes
O	O	on	no
O	O	scintigraphy	no
O	O	is	yes
O	O	desirable	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	TRACRIUM	yes
O	O	include	no
O	O	:	no
B-drug	B-drug	enflurane	yes
O	O	;	no

O	O	Patients	no
O	O	stabilized	no
O	O	on	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	who	no
O	O	are	no
O	O	found	no
O	O	to	no
O	O	require	no
O	B-group	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	watched	no
O	O	very	no
O	O	closely	no
O	O	when	no
O	O	thyroid	yes
O	O	is	yes
O	O	started	no
O	O	.	no

O	O	The	no
O	O	second	no
O	O	study	no
O	O	was	no
O	O	identical	no
O	O	but	no
O	O	endogenous	no
O	O	insulin	yes
O	O	secretion	no
O	O	was	no
O	O	blocked	no
O	O	with	yes
B-drug	B-drug	somatostatin	yes
O	O	.	no

O	O	If	no
O	O	other	no
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	are	no
O	O	used	no
O	O	during	no
O	O	the	no
O	O	same	yes
O	O	procedure	no
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	a	yes
O	O	synergistic	no
O	O	or	no
O	O	antagonist	yes
O	O	effect	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

B-drug	B-drug	Magnesium-	no
O	O	and/or	no
B-drug	B-drug	aluminum-containing	no
B-group	B-group	antacids	no
O	O	,	no
O	O	products	no
O	O	containing	yes
B-drug	B-drug	ferrous	yes
I-drug	I-drug	sulfate	yes
O	O	(	no
B-drug	B-drug	iron	yes
O	O	)	no
O	O	,	no
B-group	B-group	multivitamin	no
I-group	I-group	preparations	no
O	O	containing	yes
B-drug	B-drug	zinc	yes
O	O	or	no
O	O	other	no
O	O	metal	no
O	O	cations	no
O	O	,	no
O	O	or	no
B-brand	B-brand	Videx	yes
O	O	(	no
B-drug	B-drug	didanosine	yes
O	O	)	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	within	no
O	O	3	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	2	yes
O	O	hours	no
O	O	after	no
B-brand	B-brand	FACTIVE	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	cocaine	yes
O	O	or	no
B-drug	B-drug	amphetamine	yes
O	O	,	no
O	O	compounds	no
O	O	which	no
O	O	inhibit	no
O	O	neuronal	no
O	O	reuptake	no
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	,	no
O	O	disrupts	no
O	O	the	no
O	O	behavioral	no
O	O	response	no
O	O	of	yes
O	O	the	no
O	O	genetically	no
O	O	nervous	no
O	O	E-strain	no
O	O	subjects	no
O	O	to	no
O	O	a	yes
O	O	far	no
O	O	greater	no
O	O	extent	no
O	O	than	no
O	O	the	no
O	O	stable	no
O	O	A-strain	no
O	O	subjects	no
O	O	.	no

O	O	If	no
B-brand	B-brand	TYKERB	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	Pgp	no
O	O	,	no
O	O	increased	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	lapatinib	yes
O	O	are	no
O	O	likely	no
O	O	,	no
O	O	and	yes
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	.	no

O	O	Because	no
O	O	changes	no
O	O	in	yes
O	O	glucose	yes
O	O	concentrations	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	coadministration	no
O	O	were	no
O	O	within	no
O	O	the	no
O	O	normal	yes
O	O	variability	no
O	O	and	yes
O	O	individual	no
O	O	glucose	yes
O	O	concentrations	no
O	O	were	no
O	O	above	no
O	O	or	no
O	O	near	no
O	O	70	yes
O	O	mg/dL	no
O	O	,	no
O	O	dose	no
O	O	adjustment	no
O	O	for	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	5	yes
O	O	mg	yes
O	O	QD	no
O	O	and	yes
O	O	10	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	coadministration	no
O	O	(	no
O	O	up	no
O	O	to	no
O	O	40	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	is	yes
O	O	not	no
O	O	indicated	no
O	O	.	no

O	O	False-positive	no
O	O	direct	no
O	O	Coombs	no
O	O	tests	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	other	no
B-group	B-group	cephalosporins	no
O	O	.	no

O	O	Impaired	no
O	O	glucose	yes
O	O	tolerance	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	When	no
O	O	a	yes
O	O	single	yes
O	O	125-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	Day5	no
O	O	of	yes
O	O	a	yes

O	O	In	yes
O	O	four	no
O	O	subjects	no
O	O	with	yes
O	O	epilepsy	no
O	O	ingesting	no
B-drug	B-drug	valproate	yes
O	O	,	no
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	(	no
O	O	Cmin	no
O	O	)	no
B-drug	B-drug	valproate	yes
O	O	plasma	yes
O	O	concentration	no
O	O	was	no
O	O	63	no
O	O	16	yes
O	O	micrograms/mL	no
O	O	.	no

B-group	B-group	Anti-HIV	no
I-group	I-group	Reverse	no
I-group	I-group	Transcriptase	no
I-group	I-group	Inhibitors	no

B-drug_n	B-drug_n	Clofibric	no
I-drug_n	I-drug_n	acid	yes
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug_n	B-drug_n	clofibric	no
I-drug_n	I-drug_n	acid	yes
O	O	.	no

O	O	No	yes
O	O	specific	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	and	yes
O	O	caution	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	rash	no

O	O	Frequent	no
O	O	determination	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	and	yes
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	essential	yes
O	O	to	no
O	O	ascertain	no
O	O	when	no
O	O	adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	of	yes
B-group	B-group	anticoagulant	no
O	O	may	no
O	O	be	no
O	O	needed	no
O	O	.	no

O	O	A	yes
O	O	21	yes
O	O	(	no
O	O	17	yes
O	O	)	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ganciclovir	yes
O	O	was	no
O	O	observed	no
O	O	when	no
B-brand	B-brand	VIDEX	yes
O	O	was	no
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
B-drug	B-drug	ganciclovir	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	when	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	were	no
O	O	administered	no
O	O	simultaneously	no
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	12	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Cevimeline	yes
O	O	might	no
O	O	interfere	no
O	O	with	yes
O	O	desirable	no
O	O	antimuscarinic	no
O	O	effects	no
O	O	of	yes
O	O	drugs	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	Statistical	no
O	O	analysis	no
O	O	:	no
O	O	Mantel-Haenszel	no
O	O	(	no
O	O	alpha	yes
O	O	=	no
O	O	0.05	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	doses	no
O	O	,	no
O	O	trough	no
O	O	concentrations	no
O	O	,	no
O	O	and	yes
O	O	AUC	no
O	O	exhibited	no
O	O	similar	no
O	O	temporal	no
O	O	patterns	no
O	O	during	no
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	the	no
O	O	study	no
O	O	regardless	no
O	O	of	yes
O	O	the	no
O	O	co-administered	no
B-drug	B-drug	everolimus	yes
O	O	dose	no
O	O	level	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	.13	no
O	O	,	no
O	O	.82	no
O	O	,	no
O	O	and	yes
O	O	.76	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	the	no
B-brand	B-brand	Vitrasert	yes
O	O	Implant	no
O	O	.	no

O	O	No	yes
O	O	interactions	no
O	O	were	no
O	O	observed	no
O	O	.	no

O	O	An	no
O	O	interaction	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	showed	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	anastrozole	yes
O	O	on	no
B-drug	B-drug	warfarin	yes
O	O	pharmacokinetics	no
O	O	or	no
B-group	O	anticoagulant	no
O	O	activity	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-drug	B-drug	Naproxen	yes
O	O	may	no
O	O	decrease	no
O	O	platelet	yes
O	O	aggregation	no
O	O	and	yes
O	O	prolong	no
O	O	bleeding	no
O	O	time	no
O	O	.	no

O	O	Intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug_n	B-drug_n	arsenate	no
O	O	in	yes
O	O	the	no
O	O	chick	no
O	O	.	no

B-drug	B-drug	Ethanol	yes
O	O	depressed	no
O	O	the	no
O	O	amplitudes	no
O	O	of	yes
O	O	most	no
O	O	evoked	no
O	O	potential	no
O	O	components	no
O	O	in	yes
O	O	comparison	no
O	O	to	no
O	O	saline	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-drug	barbiturates	no
O	O	and	yes
O	O	other	no
B-group	B-drug	CNS	no
I-group	I-drug	depressants	no
O	O	;	no

O	O	An	no
O	O	immune	yes
O	O	response	no
O	O	to	no
B-brand	B-brand	Campath	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	subsequent	no
O	O	diagnostic	yes
O	O	serum	yes
O	O	tests	no
O	O	that	no
O	O	utilize	no
O	B-group	antibodies	no

O	O	After	no
O	O	one	no
O	O	day	no
O	O	,	no
O	O	fecal	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
O	O	both	no
O	O	elements	no
O	O	had	no
O	O	already	no
O	O	responded	no
O	O	to	no
O	O	the	no
O	O	dietary	no
O	O	treatments	no
O	O	,	no
O	O	with	yes
O	O	constant	no
O	O	values	no
O	O	being	no
O	O	reached	no
O	O	after	no
O	O	approximately	no
O	O	three	no
O	O	days	no
O	O	.	no

B-drug	B-drug	Epinephrine	yes
O	O	also	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	digitalis	yes
O	O	,	no
B-group	B-group	glycosides	yes
O	O	)	no
O	O	that	no
O	O	sensitize	no
O	O	the	no
O	O	myocardium	no
O	O	to	no
O	O	the	no
O	O	actions	no
O	O	of	yes
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Significant	no
O	O	increases	no
O	O	In	yes
O	O	AUC	no
O	O	(	no
O	O	27	yes
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	Cmax	no
O	O	(	no
O	O	58	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	decreases	no
O	O	in	yes
O	O	tmax	no
O	O	(	no
O	O	23	no
O	O	%	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	were	no
O	O	noted	no
O	O	in	yes
O	O	this	no
O	O	study	no
O	O	.	no

O	O	Treatment	no
O	O	with	yes
B-brand	B-brand	PEGASYS	yes
O	O	once	no
O	O	weekly	yes
O	O	for	yes
O	O	4	yes
O	O	weeks	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	inhibition	no
O	O	of	yes
O	O	P450	no
O	O	1A2	no
O	O	and	yes
O	O	a	yes
O	O	25	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	theophylline	yes
O	O	AUC	no
O	O	.	no

B-drug	B-drug	Itraconazole	yes

O	O	Clinical	no
O	O	Comment	no

O	O	The	no
O	O	risks	no
O	O	of	yes
O	O	using	no
B-brand	B-brand	Anafranil	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Quinidine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Quinidex	yes
O	O	)	no
O	O	or	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Increases	no
O	O	in	yes
O	O	lymphocyte	yes
O	O	counts	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	pharmacologic	no
O	O	mechanism	no
O	O	of	yes
O	O	action	no
O	O	are	no
O	O	frequently	no
O	O	observed	no
O	O	during	no
B-brand	B-brand	RAPTIVA	yes
O	O	treatment	no
O	O	.	no

O	O	Because	no
O	O	many	no
O	O	drugs	no
O	O	are	no
O	O	excreted	no
O	O	in	yes
O	O	human	yes
O	O	milk	yes
O	O	,	no
O	O	and	yes
O	O	because	no
O	O	there	no
O	O	exists	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	adverse	no
O	O	reactions	no
O	O	in	yes
O	O	nursing	no
O	O	infants	no
O	O	from	no
B-brand	B-brand	AMEVIVE	no
O	O	,	no
O	O	a	yes
O	O	decision	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	whether	no
O	O	to	no
O	O	discontinue	no
O	O	nursing	no
O	O	while	no
O	O	taking	no
O	O	the	no
O	O	drug	yes
O	O	or	no
O	O	to	no
O	O	discontinue	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	,	no
O	O	taking	no
O	O	into	no
O	O	account	no
O	O	the	no
O	O	importance	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	to	no
O	O	the	no
O	O	mother	no
O	O	.	no

O	O	Both	no
B-drug	B-drug	efavirenz	yes
O	O	and	yes
B-drug	B-drug	nevirapine	yes
O	O	have	no
O	O	been	no
O	O	compared	no
O	O	to	no
O	O	triple	yes
O	O	therapy	no
O	O	with	yes
O	O	the	no
O	B-group	PI	no
B-drug	B-drug	indinavir	yes
O	O	over	no
O	O	48	yes
O	O	weeks	no
O	O	as	yes
O	O	initial	no
O	O	therapy	no
O	O	,	no
O	O	with	yes
O	O	similar	no
O	O	responses	no
O	O	being	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	regimens	no
O	O	and	yes
O	O	superiority	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	efavirenz	yes
O	O	.	no

O	O	Several	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	completed	no
O	O	with	yes
O	O	both	no
B-brand	B-brand	INVIRASE	yes
O	O	and	yes
B-brand	B-brand	FORTOVASE	yes
O	O	.	no

B-drug	B-drug	Bexarotene	yes
O	O	oxidative	no
O	O	metabolites	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	formed	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	If	no
O	O	you	no
O	O	think	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	an	no
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	talk	no
O	O	to	no
O	O	your	no
O	O	doctor	no
O	O	or	no
O	O	pharmacist	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
B-group	B-group	pulmonary	no
I-group	I-group	surfactant	yes
O	O	extract	yes
O	O	from	no
O	O	bovine	yes
O	O	lung	yes
O	O	,	no
B-brand	B-brand	Survanta	yes
O	O	,	no
O	O	on	no
O	O	the	no
O	O	dissolution	no
O	O	rate	no
O	O	of	yes
O	O	aerosol	no
O	O	particles	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	was	no
O	O	determined	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	single	yes
O	O	study	no
O	O	,	no
O	O	rats	no
O	O	given	no
O	O	high	yes
O	O	intraperitoneal	no
O	O	doses	no
O	O	of	yes
O	O	an	no
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	plus	yes
B-drug	B-drug	disulfiram	yes
O	O	experienced	no
O	O	severe	no
O	O	toxicity	no
O	O	,	no
O	O	including	no
O	O	convulsions	no
O	O	and	yes
O	O	death	no
O	O	.	no

B-brand	B-brand	FACTIVE	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	on	no
O	O	stable	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	.	no

O	O	The	no
O	O	interindividual	no
O	O	pharmacokinetic	no
O	O	variability	no
O	O	for	yes
O	O	AUC	no
O	O	was	no
O	O	85.4	no
O	O	%	no
O	O	and	yes
O	O	intraindividual	no
O	O	,	no
O	O	interoccasion	no
O	O	variability	no
O	O	was	no
O	O	40.8	no
O	O	%	no
O	O	.	no

O	O	Excretion	no
O	O	of	yes
O	O	thioethers	no
O	O	in	yes
O	O	urine	no
O	O	after	no
O	O	exposure	yes
O	O	to	no
O	O	electrophilic	no
O	O	chemicals	no
O	O	.	no

O	O	Expected	no
O	O	changes	no
O	O	in	yes
O	O	laboratory	no
O	O	assessments	no
O	O	of	yes
O	O	PT	no
O	O	and	yes
O	O	INR	no
O	O	were	no
O	O	observed	no
O	O	after	no
B-drug	B-drug	warfarin	yes
O	O	administration	no
O	O	,	no
O	O	but	no
O	O	these	no
O	O	changes	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	lenalidomide	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Propoxyphene	yes
O	O	:	no
O	O	In	yes
O	O	cases	no
O	O	of	yes
B-drug	B-drug	propoxyphene	yes
O	O	overdosage	no
O	O	,	no
B-drug	B-drug	amphetamine	yes
O	O	CNS	no
O	O	stimulation	no
O	O	is	yes
O	O	potentiated	no
O	O	and	yes
O	O	fatal	no
O	O	convulsions	no
O	O	can	no
O	O	occur	no
O	O	.	no

B-group	B-group	Quinolones	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	when	no
O	O	treating	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	TAXOTERE	yes
O	O	as	yes
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	potential	no
O	O	for	yes
O	O	a	yes
O	O	significant	no
O	O	interaction	no
O	O	.	no

O	O	Except	no
O	O	for	yes
B-drug	B-drug	clindamycin-sensitive	no
O	O	isolates	no
O	O	,	no
O	O	synergy	no
O	O	was	no
O	O	usually	no
O	O	observed	no
O	O	only	no
O	O	at	yes
O	O	concentrations	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	drugs	no
O	O	which	no
O	O	are	no
O	O	not	no
O	O	readily	no
O	O	obtainable	no
O	O	in	yes
O	O	vivo	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Cholestyramine	yes
O	O	and	yes
B-drug	B-drug	colestipol	yes
B-group	B-group	resins	no
O	O	:	no
B-drug	B-drug	Cholestytamine	no
O	O	and	yes
B-drug	B-drug	colestipol	yes
B-group	B-group	resins	no
O	O	have	no
O	O	the	no
O	O	potential	no
O	O	of	yes
O	O	binding	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	and	yes
O	O	reducing	no
B-group	B-group	diuretic	no
O	O	absorption	no
O	O	from	no
O	O	the	no
O	O	gastrointestinal	no
O	O	tract	no

O	O	This	no
O	O	medicine	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Patients	no
O	O	with	yes
O	O	a	yes
O	O	very	no
O	O	low	yes
O	O	cardiac	no
O	O	capacity	no
O	O	should	no
O	O	be	no
O	O	advised	no
O	O	to	no
O	O	refrain	no
O	O	from	no
O	O	treatment	no
O	O	of	yes
O	O	the	no
O	O	erection	no
O	O	disorder	no
O	O	.	no

O	O	As	yes
O	O	binding	no
O	O	of	yes
B-drug_n	B-drug_n	MHD	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	is	yes
O	O	low	yes
O	O	(	no
O	O	40	yes
O	O	%	no
O	O	)	no
O	O	,	no
O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	through	no
O	O	competition	no
O	O	for	yes
O	O	protein	yes
O	O	binding	no
O	O	sites	no
O	O	are	no
O	O	unlikely	no
O	O	.	no

O	O	Adverse	no
O	O	reactions	no
O	O	related	yes
O	O	to	no
O	B-drug	alpha	yes
O	O	interferons	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	CNS	no
O	O	,	no
O	O	cardiac	no
O	O	,	no
O	O	and	yes
O	O	systemic	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	O	flu-like	no
O	O	)	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	severe	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	and	yes
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	in	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	in	yes
O	O	this	no
O	O	population	no
O	O	.	no

O	O	In	yes
B-group	B-group	opioid-dependent	no
O	O	patients	no
O	O	,	no
B-group	B-group	mixed	yes
I-group	I-group	agonist/antagonist	no
I-group	I-group	analgesics	no
O	O	may	no
O	O	precipitate	no
O	O	withdrawal	no
O	O	symptoms	no
O	O	.	no

B-drug	B-brand	Chirocaine	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	other	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	or	no
O	O	agents	yes
O	O	structurally	no
O	O	related	yes
O	O	to	no
O	O	amide-type	no
O	O	local	no
B-group	O	anesthetics	no
O	O	since	no
O	O	the	no
O	O	toxic	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	could	no
O	O	be	no
O	O	additive	no
O	O	.	no

B-drug_n	B-drug_n	Misonidazole	yes
O	O	reduced	yes
O	O	the	no
O	O	antitumour	no
O	O	activity	yes
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	by	no
O	O	dose	no
O	O	modifying	no
O	O	factors	no
O	O	(	no
O	O	DMF	no
O	O	)	no
O	O	of	yes
O	O	0.58-0.71	no
O	O	.	no

O	O	An	no
O	O	association	no
O	O	between	yes
B-drug	B-drug	prilocaine	yes
O	O	and	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	methaemoglobinaemia	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	infants	no
O	O	,	no
O	O	has	no
O	O	specifically	no
O	O	been	no
O	O	described	no
O	O	in	yes
O	O	a	yes
O	O	literature	no
O	O	case	no
O	O	report	no
O	O	.	no

B-drug	B-drug	Fenfluramine	yes
O	O	may	no
O	O	increase	no
O	O	slightly	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
B-drug	B-drug	methyldopa	yes
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	.	no

O	O	Cytochrome	no
O	O	P450	no
O	O	1A2	no
O	O	(	no
O	O	CYP1A2	no
O	O	)	no
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	the	no
O	O	major	no
O	O	enzyme	no
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Exposure	yes
O	O	of	yes
O	O	the	no
O	O	muscle	no
O	O	to	no
B-drug	B-drug	ouabain	yes
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	-5	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	markedly	no
O	O	increased	no
O	O	the	no
B-drug_n	B-drug_n	PTX-induced	no
O	O	release	yes
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	hypotensive	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	enalapril	yes
O	O	or	no
B-drug	B-drug	enalaprilat	yes
O	O	can	no
O	O	be	no
O	O	minimized	no
O	O	by	no
O	O	either	no
O	O	discontinuing	no
O	O	the	no
B-group	B-drug	diuretic	no
O	O	or	no
O	O	increasing	no
O	O	the	no
O	O	salt	yes
O	O	intake	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	enalapril	yes
O	O	or	no
B-drug	B-drug	enalaprilat	yes
O	O	.	no

O	O	+15	no
O	O	%	no
O	O	+0	no
O	O	%	no
O	O	+17	no
O	O	%	no
O	O	+13	no
O	O	%	no

O	O	When	no
B-drug	B-drug	phenobarbital	yes
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	or	no
O	O	withdrawn	no
O	O	from	no
O	O	treatment	no
O	O	,	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
B-brand	B-brand	Nalfon	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

B-group	B-group	Digitalis	yes
O	O	:	no
O	O	Immediate	no
O	O	Release	yes
O	O	Capsules	no
O	O	:	no
O	O	Since	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	isolated	no
O	O	reports	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	elevated	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	,	no
O	O	and	yes
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	possible	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	when	no
O	O	initiating	no
O	O	,	no
O	O	adjusting	no
O	O	,	no
O	O	and	yes
O	O	discontinuing	no
B-drug	B-drug	nifedipine	yes
O	O	to	no
O	O	avoid	no
O	O	possible	no
O	O	over-	no
O	O	or	no
O	O	under-digitalization	no
O	O	.	no

B-drug	B-drug	Cyclosporin	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
B-drug	B-drug	sirolimus	yes

O	O	Thus	no
O	O	,	no
O	O	the	no
O	O	selective	no
O	O	regulation	no
O	O	of	yes
O	O	voltage-dependent	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	subtypes	no
O	O	by	no
B-drug_n	B-drug_n	ginsenosides	no
O	O	in	yes
O	O	bovine	yes
O	O	chromaffin	no
O	O	cell	yes
O	O	could	no
O	O	be	no
O	O	the	no
O	O	cellular	no
O	O	basis	no
O	O	of	yes
O	O	antistress	no
O	O	effects	no
O	O	induced	no
O	O	by	no
B-drug_n	B-drug	ginseng	yes
O	O	.	no

O	O	It	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	triamterene	yes
O	O	to	no
O	O	a	yes
O	O	maintenance	no
O	O	schedule	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	resulted	no
O	O	in	yes
O	O	reversible	no
O	O	acute	no
O	O	renal	no
O	O	failure	no
O	O	in	yes
O	O	two	no
O	O	of	yes
O	O	four	no
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	primarily	no
O	O	being	no
O	O	metabolized	no
O	O	through	no
O	O	CYP3A4	no
O	O	,	no
O	O	ingestion	no
O	O	of	yes
O	O	grapefruit	no
O	O	or	no
O	O	grapefruit	no
O	O	juice	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	connection	no
O	O	with	yes
B-drug	B-drug	budesonide	yes
O	O	administration	no
O	O	.	no

O	O	.	no

B-drug	B-drug	Dexamethasone	yes
O	O	had	no
O	O	a	yes
O	O	similar	no
O	O	effect	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	limited	no
O	O	experience	no
O	O	with	yes
O	O	use	no
O	O	of	yes
O	O	retinal	no
O	O	tamponades	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
O	O	the	no
B-brand	B-brand	Vitrasert	yes
O	O	Implant	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	inhibit	no
O	O	CYP2D6	no
O	O	and	yes
O	O	CYP3A3/4	no
O	O	also	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cevimeline	yes
O	O	.	no

B-drug	B-drug	Tubocurarine	yes

B-drug	B-drug_n	Benzyl	yes
I-drug	I-drug_n	alcohol	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	neurological	no
O	O	and	yes
O	O	other	no
O	O	complications	no
O	O	in	yes
O	O	neonates	no
O	O	and	yes
O	O	infants	no
O	O	,	no
O	O	which	no
O	O	are	no
O	O	sometimes	no
O	O	fatal	no
O	O	.	no

O	O	+135	no
O	O	%	no

O	O	these	no
O	O	may	no
O	O	also	no
O	O	occur	no
O	O	in	yes
O	O	neonates	no
O	O	whose	no
O	O	mothers	no
O	O	received	no
B-group	B-group	cephalosporins	no
O	O	before	no
O	O	delivery	no
O	O	.	no

O	O	Blood	yes
O	O	glucose	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	when	no
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

B-drug	B-drug	Prednisolone	yes
O	O	:	no
B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	prednisolone	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	induce	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	reduced	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	decreased	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	.	no

O	O	Diagnostic	yes
O	O	dip-stick	no
O	O	methodology	no
O	O	,	no
O	O	used	no
O	O	to	no
O	O	detect	no
O	O	ketone	yes
O	O	bodies	no
O	O	in	yes
O	O	urine	no
O	O	,	no
O	O	has	no
O	O	resulted	no
O	O	in	yes
O	O	false-positive	no
O	O	findings	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	Lodine	yes
O	O	.	no

O	O	Concomitant	no
O	O	Administration	no
O	O	with	yes
O	O	Racemic	yes
B-drug	B-drug	Citalopram	yes
I-drug	I-drug	Citalopram	yes
O	O	-	yes
O	O	Since	no
B-drug	B-drug	escitalopram	yes
O	O	is	yes
O	O	the	no
O	O	active	no
O	O	isomer	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
B-brand	B-brand	Celexa	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	two	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	coadministered	no
O	O	.	no

B-group	B-group	Calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no

B-group	B-group	Antihypertensive	no
I-group	I-group	medications	no
O	O	,	no
O	O	other	no
O	O	,	no
O	O	especially	no
B-drug	B-drug	diazoxide	yes
O	O	,	no
O	O	or	no
O	B-group	preanesthetic	no
O	O	and	yes
B-group	O	anesthetic	no
I-group	O	agents	yes
O	O	used	no
O	O	in	yes
O	O	surgery	no
O	O	or	no
B-group	B-group	skeletal-muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	nondepolarizing	no
O	O	,	no
O	O	used	no
O	O	in	yes
O	O	surgery	no

O	O	Clinical	no
O	O	Comment	no

B-drug	B-drug	Glyburide	yes
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	with	yes
O	O	the	no
B-group	B-group	sulfonylurea	no
B-drug	B-drug	glyburide	yes
O	O	has	no
O	O	,	no
O	O	on	no
O	O	rare	no
O	O	occasions	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	severe	no
O	O	hypoglycemia	no
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	,	no
O	O	with	yes
O	O	dosage	no
O	O	adjustment	no
O	O	as	yes
O	O	appropriate	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	whose	no
O	O	pulmonary	no
O	O	disease	no
O	O	requires	no
O	O	maintaining	no
O	O	a	yes
O	O	given	no
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	concentration	no
O	O	for	yes
O	O	optimal	no
O	O	pulmonary	no
O	O	function	no
O	O	or	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	at	yes
O	O	the	no
O	O	higher	no
O	O	end	no
O	O	of	yes
O	O	the	no
O	O	therapeutic	no
O	O	range	no
O	O	.	no

O	O	Chronic	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	a	yes
O	O	known	no
O	O	enzyme	no
O	O	inducer	no
O	O	,	no
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	fenoprofen	yes
O	O	.	no

O	O	Similarly	no
O	O	dialyzed	no
O	O	were	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	both	no
O	O	alone	no
O	O	at	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	in	yes
O	O	serum	yes
O	O	and	yes
O	O	with	yes
B-drug	B-drug	ethanol	yes
O	O	at	yes
O	O	three	no
O	O	different	no
O	O	concentrations	no
O	O	in	yes
O	O	serum	yes
O	O	.	no

O	O	Do	no
O	O	not	no
O	O	take	no
O	O	this	no
O	O	medicine	no
O	O	with	yes
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	sertonin	no
O	O	.	no

B-brand	B-brand	ATROVENT	yes
O	O	Inhalation	no
O	O	Aerosol	no
O	O	has	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	including	no
B-group	B-group	sympathomimetic	no
I-group	I-group	bronchodilators	no
O	O	,	no
B-group	B-group	methylxanthines	no
O	O	,	no
O	O	and	yes
B-group	B-group	steroids	no
O	O	,	no
O	O	commonly	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	chronic	no
O	O	obstructive	no
O	O	pulmonary	no
O	O	disease	no
O	O	.	no

O	O	This	no
O	O	drug	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
B-group	B-group	anticholinergics	no
O	O	or	no
O	O	other	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	(	no
O	O	anticholinergic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	these	no
O	O	medications	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-drug	antihistamines	no
O	O	may	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	and	yes
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
B-group	B-drug	antihistamines	no
O	O	)	no
O	O	.	no

O	O	This	no
O	O	could	no
O	O	lead	no
O	O	to	no
O	O	decreased	no
B-group	B-group	salicylate	yes
O	O	serum	yes
O	O	levels	no
O	O	or	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
B-group	B-group	salicylate	yes
O	O	toxicity	no
O	O	when	no
B-group	B-drug	corticosteroid	no
O	O	is	yes
O	O	withdrawn	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Hypoglycemics	no
O	O	:	no
B-drug	B-drug	Diclofenac	yes
O	O	does	no
O	O	not	no
O	O	alter	no
O	O	glucose	yes
O	O	metabolism	no
O	O	in	yes
O	O	normal	yes
O	O	subjects	no
O	O	nor	yes
O	O	does	no
O	O	it	no
O	O	alter	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	.	no

O	O	After	no
O	O	extensive	no
O	O	intake	no
O	O	of	yes
O	O	grapefruit	no
O	O	juice	no
O	O	(	no
O	O	which	no
O	O	inhibits	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	predominantly	no
O	O	in	yes
O	O	the	no
O	O	intestinal	no
O	O	mucosa	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	systemic	no
O	O	exposure	yes
O	O	for	yes
O	O	oral	yes
B-drug	B-drug	budesonide	yes
O	O	increased	no
O	O	about	no
O	O	two	no
O	O	times	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Blood	yes
O	O	Glucose	yes
O	O	Blood	yes
O	O	glucose	yes
O	O	measurement	no
O	O	must	no
O	O	be	no
O	O	done	no
O	O	with	yes
O	O	a	yes
O	O	glucose-specific	no
O	O	method	yes
O	O	to	no
O	O	prevent	no
O	O	maltose	yes
O	O	interference	no
O	O	with	yes
O	O	test	yes
O	O	results	no
O	O	.	no

O	O	Interaction	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	has	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	produce	no
O	O	adverse	no
O	O	clinical	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
O	O	Elevated	no
B-drug	B-drug	carbamazepine	yes
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	postmarketing	no
O	O	experience	no
O	O	when	no
B-brand	B-brand	SUPRAX	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	increased	no
O	O	ulcerogenic	no
O	O	effect	no
O	O	;	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	tetracycline	yes
O	O	may	no
O	O	render	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	less	no
O	O	effective	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
B-drug_n	B-drug_n	KRM-1648	no
O	O	has	no
O	O	a	yes
O	O	great	no
O	O	potential	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	M	yes
O	O	.	no

O	O	Two	no
O	O	different	no
O	O	types	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	magnesium	yes
O	O	are	no
O	O	used	no
O	O	:	no
O	O	physiological	no
O	O	oral	yes
B-drug	B-drug	magnesium	yes
O	O	supplementation	no
O	O	which	no
O	O	is	yes
O	O	totally	no
O	O	atoxic	no
O	O	since	no
O	O	it	no
O	O	palliates	no
B-drug	B-drug	magnesium	yes
O	O	deficiencies	no
O	O	by	no
O	O	simply	no
O	O	normalizing	no
O	O	the	no
B-drug	B-drug	magnesium	yes
O	O	intake	no
O	O	and	yes
O	O	pharmacological	no
B-drug	B-drug	magnesium	yes
O	O	therapy	no
O	O	which	no
O	O	may	no
O	O	induce	no
O	O	toxicity	no
O	O	since	no
O	O	it	no
O	O	creates	no
O	O	iatrogenic	no
B-drug	B-drug	magnesium	yes
O	O	overload	no
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	are	no
O	O	available	no
O	O	on	no
O	O	potential	no
O	O	interactions	no
O	O	in	yes
O	O	individuals	no
O	O	who	no
O	O	consume	no
O	O	greater	no
O	O	than	no
O	O	200	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	per	no
O	O	day	no
O	O	or	no
O	O	in	yes
O	O	those	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	the	no
O	O	geriatric	no
O	O	population	no
O	O	,	no
O	O	who	no
O	O	are	no
O	O	generally	no
O	O	believed	no
O	O	to	no
O	O	be	no
O	O	more	no
O	O	susceptible	no
O	O	to	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	drug-induced	no
O	O	CNS-related	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	Twelve	no
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	were	no
O	O	administered	no
O	O	one	no
O	O	200-mg	no
B-drug	B-drug	ceftibuten	yes
O	O	capsule	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	6	yes
O	O	days	no
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	interactions	no
O	O	were	no
O	O	found	no
O	O	between	yes
B-drug	B-drug	nisoldipine	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	It	no
O	O	was	no
O	O	concluded	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	oxycodone	yes
O	O	and	yes
B-drug	B-drug	levofloxacin	yes
O	O	can	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	without	no
O	O	a	yes
O	O	significant	no
O	O	decrease	no
O	O	in	yes
O	O	AUC	no
O	O	,	no
O	O	Cmax	no
O	O	,	no
O	O	or	no
O	O	tmax	no
O	O	.	no

O	O	The	no
O	O	cause	no
O	O	of	yes
O	O	the	no
O	O	reported	no
O	O	association	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Phosphate-Binding	no
O	O	Agents	yes
O	O	:	no
O	O	Since	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	also	no
O	O	has	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	phosphate	yes
O	O	transport	no
O	O	in	yes
O	O	the	no
O	O	intestine	no
O	O	,	no
O	O	kidneys	no
O	O	and	yes
O	O	bones	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	phosphate-binding	no
O	O	agents	yes
O	O	must	no
O	O	be	no
O	O	adjusted	yes
O	O	in	yes
O	O	accordance	no
O	O	with	yes
O	O	the	no
O	O	serum	yes
O	O	phosphate	yes
O	O	concentration	no
O	O	.	no

O	O	vasculitis	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	allergic	no
O	O	reaction	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Nonclinical	no
O	O	data	no
O	O	demonstrate	no
O	O	that	no
O	O	the	no
O	O	solubility	no
O	O	of	yes
B-drug	B-drug	dasatinib	yes
O	O	is	yes
O	O	pH	yes
O	O	dependent	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	which	no
O	O	drug	yes
O	O	clearance	no
O	O	mechanism	no
O	O	involved	no
O	O	in	yes
B-drug	B-drug	caspofungin	yes
O	O	disposition	no
O	O	may	no
O	O	be	no
O	O	inducible	no
O	O	.	no

O	O	Laboratory	no
O	O	Tests	no
O	O	Response	no
O	O	to	no
B-brand	B-brand	Plenaxis	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	by	no
O	O	measuring	no
O	O	serum	yes
O	O	total	yes
O	B-drug	testosterone	yes
O	O	concentrations	no
O	O	just	no
O	O	prior	no
O	O	to	no
O	O	administration	no
O	O	on	no
O	O	Day	no
O	O	29	yes
O	O	and	yes
O	O	every	no
O	O	8	yes
O	O	weeks	no
O	O	thereafter	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	present	no
O	O	study	no
O	O	we	no
O	O	evaluated	no
O	O	the	no
O	O	interference	no
O	O	of	yes
B-group	B-group	antidepressants	no
O	O	with	yes
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	of	yes
O	O	diabetic	no
O	O	and	yes
O	O	non-diabetic	no
O	O	rats	no
O	O	.	no

O	O	In	yes
O	O	two	no
O	O	clinical	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	(	no
O	O	one	no
O	O	4	yes
O	O	mg/kg	no
O	O	dose	no
O	O	or	no
O	O	two	no
O	O	3	yes
O	O	mg/kg	no
O	O	doses	no
O	O	)	no
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	caspofungin	yes
O	O	by	no
O	O	approximately	no
O	O	35	yes
O	O	%	no
O	O	.	no

O	O	dietary	no
O	O	deficiencies	no
O	O	;	no

O	O	Women	yes
O	O	should	no
O	O	practice	no
O	O	additional	no
O	O	methods	no
O	O	of	yes
O	O	contraception	no
O	O	and	yes
O	O	not	no
O	O	rely	no
O	O	on	no
O	O	hormonal	no
O	O	contraception	no
O	O	alone	no
O	O	when	no
O	O	taking	no
B-brand	B-brand	TRACLEER	yes
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	barbiturates	no
O	O	usually	no
O	O	depresses	no
B-drug	B-drug	griseofulvin	yes
O	O	activity	yes
O	O	and	yes
O	O	may	no
O	O	necessitate	no
O	O	raising	no
O	O	the	no
O	O	dosage	no
O	O	.	no

B-drug	B-drug	Tetracycline	yes
O	O	,	no
O	O	a	yes
B-group	B-group	bacteriostatic	yes
I-group	I-group	antibiotic	yes
O	O	,	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	bactericidal	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	penicillin	yes
O	O	and	yes
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	formal	no
O	O	clinical	no
O	O	studies	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	drug	yes
O	O	interactions	no
O	O	of	yes
B-brand	B-brand	TAXOTERE	yes
O	O	with	yes
O	O	other	no
O	O	medications	no
O	O	.	no

B-group	B-group	Amphetamines	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	Immunologic	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	sulfadoxine	yes
O	O	and	yes
B-drug	B-drug	pyrimethamine	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	adverse	no
O	O	reaction	no
O	O	profile	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	VIRACEPT	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	induce	no
O	O	CYP3A	no
O	O	may	no
O	O	decrease	no
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	reduce	no
O	O	its	no
O	O	therapeutic	no
O	O	effect	no
O	O	.	no

O	O	CYP3A4	no
O	O	inhibitors	no
O	O	:	no
O	O	May	no
O	O	increase	no
O	O	the	no
O	O	levels/effects	no
O	O	of	yes
B-drug	B-drug	chlorpheniramine	yes
O	O	.	no

O	O	Results	no
O	O	from	no
O	O	human	yes
O	O	in	yes
O	O	vitro	no
O	O	metabolism	no
O	O	studies	no
O	O	and	yes
O	O	nonclinical	no
O	O	studies	no
O	O	show	no
O	O	that	no
B-brand	B-brand	REVLIMID	yes
O	O	(	no
B-drug	B-drug	lenalidomide	yes
O	O	)	no
O	O	is	yes
O	O	neither	no
O	O	metabolized	no
O	O	by	no
O	O	nor	yes
O	O	inhibits	no
O	O	or	no
O	O	induces	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	pathway	no
O	O	suggesting	no
O	O	that	no
B-drug	B-drug	lenalidomide	yes
O	O	is	yes
O	O	not	no
O	O	likely	no
O	O	to	no
O	O	cause	no
O	O	or	no
O	O	be	no
O	O	subject	no
O	O	to	no
O	O	P450-based	no
O	O	metabolic	no
O	O	drug	yes
O	O	interactions	no
O	O	in	yes
O	O	man	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	and	yes
O	O	of	yes
B-brand	B-brand	Innovar	yes
O	O	anesthesia	yes
O	O	on	no
B-group	B-group	digitalis	yes
O	O	tolerance	no
O	O	in	yes
O	O	dogs	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	fulvestrant	yes
O	O	on	no
O	O	the	no
O	O	fertility	no
O	O	of	yes
O	O	male	no
O	O	animals	no
O	O	were	no
O	O	not	no
O	O	studied	no
O	O	but	no
O	O	in	yes
O	O	a	yes
O	O	6-month	no
O	O	toxicology	no
O	O	study	no
O	O	,	no
O	O	male	no
O	O	rats	no
O	O	treated	no
O	O	with	yes
O	O	intramuscular	no
O	O	doses	no
O	O	of	yes
O	O	15	yes
O	O	mg/kg/30	no
O	O	days	no
O	O	,	no
O	O	10	yes
O	O	mg/rat/30	no
O	O	days	no
O	O	,	no
O	O	or	no
O	O	10	yes
O	O	mg/rat/15	no
O	O	days	no
B-drug	B-drug	fulvestrant	yes
O	O	showed	no
O	O	a	yes
O	O	loss	no
O	O	of	yes
O	O	spermatozoa	no
O	O	from	no
O	O	the	no
O	O	seminiferous	no
O	O	tubules	no
O	O	,	no
O	O	seminiferous	no
O	O	tubular	no
O	O	atrophy	no
O	O	,	no
O	O	and	yes
O	O	degenerative	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	epididymides	no
O	O	.	no

O	O	Talk	no
O	O	to	no
O	O	your	no
O	O	doctor	no
O	O	and	yes
O	O	pharmacist	no
O	O	before	no
O	O	taking	no
O	O	any	no
O	O	prescription	no
O	O	or	no
O	O	over-the-counter	no
O	O	medicines	no
O	O	,	no
O	O	including	no
O	O	herbal	no
O	O	products	no
O	O	.	no

O	O	If	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	medications	no
O	O	for	yes
O	O	migraines	no
O	O	such	no
O	O	as	yes
B-brand	B-brand	Imitrex	yes
O	O	,	no
O	O	talk	no
O	O	to	no
O	O	your	no
O	O	doctor	no
O	O	before	no
O	O	starting	no
O	O	this	no
O	O	medicine	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	fluvoxamine	yes
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	either	no
B-drug	B-drug	terbinafine	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	cisapride	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	similar	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	tamsulosin	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	1	yes
O	O	of	yes
O	O	24	yes
O	O	subjects	no
O	O	dosed	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	20	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	tamsulosin	yes
O	O	0.4	no
O	O	mg	yes
O	O	separated	no
O	O	by	no
O	O	6	yes
O	O	hours	no
O	O	experienced	no
O	O	a	yes
O	O	standing	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	below	no
O	O	85	no
O	O	mm	yes
O	O	Hg	yes
O	O	.	no

O	O	Doses	no
O	O	of	yes
O	O	these	no
O	O	and	yes
O	O	perhaps	no
O	O	other	no
O	O	medications	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	adjusted	yes
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	successfully	no
O	O	quit	no
O	O	smoking	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	no	yes
O	O	related	yes
O	O	changes	no
O	O	were	no
O	O	noted	no
O	O	in	yes
O	O	the	no
O	O	QT0	no
O	O	on	no
O	O	ECG	no
O	O	taken	no
O	O	at	yes
O	O	2	yes
O	O	,	no
O	O	6	yes
O	O	,	no
O	O	and	yes
O	O	24	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	coadministration	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	on	no
B-drug	B-drug	cimetidine	yes
O	O	was	no
O	O	not	no
O	O	evaluated	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	the	no
O	O	consequences	no
O	O	of	yes
O	O	concomitant	no
B-drug	B-drug	irbesartan	yes
O	O	on	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	were	no
O	O	negligible	no
O	O	.	no

O	O	When	no
O	O	patients	no
O	O	have	no
O	O	received	no
O	O	such	no
O	O	drugs	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	INAPSINE	yes
O	O	required	no
O	O	will	no
O	O	be	no
O	O	less	no
O	O	than	no
O	O	usual	no
O	O	.	no

B-drug	B-drug	Pyrantel	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-drug	Antiminth	no
O	O	)	no
O	O	-	yes
O	O	Taking	no
B-drug	B-drug	piperazine	yes
O	O	and	yes
B-drug	B-drug	pyrantel	no
O	O	together	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	piperazine	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	observation	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	The	no
O	O	administrative	no
O	O	arrangements	no
O	O	in	yes
O	O	an	no
O	O	area	no
O	O	of	yes
O	O	Scotland	no
O	O	were	no
O	O	accompanied	no
O	O	by	no
O	O	a	yes
O	O	300	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	admissions	no
O	O	for	yes
O	O	mania	no
O	O	,	no
O	O	whereas	no
O	O	in	yes
O	O	an	no
O	O	area	no
O	O	of	yes
O	O	the	no
O	O	West	no
O	O	Midlands	no
O	O	,	no
O	O	a	yes
O	O	large	no
O	O	decrease	no
O	O	was	no
O	O	achieved	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	noted	no
O	O	that	no
O	O	both	no
O	O	products	no
O	O	are	no
O	O	capable	no
O	O	of	yes
O	O	producing	no
O	O	transient	no
O	O	increases	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	given	no
O	O	concurrently	no
O	O	increases	no
B-drug	B-drug	naproxen	yes
O	O	anion	yes
O	O	plasma	yes
O	O	levels	no
O	O	and	yes
O	O	extends	no
O	O	its	no
O	O	plasma	yes
O	O	half-life	no
O	O	significantly	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	tablets	yes
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	.	no

B-group	B-group	Adrenergic	no
I-group	I-group	blockers	no
I-group	I-group	Adrenergic	no
I-group	I-group	blockers	no
O	O	are	no
O	O	inhibited	no
O	O	by	no
B-group	B-group	amphetamines	no
O	O	.	no

O	O	Since	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	conflicting	no
O	O	results	no
O	O	regarding	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	when	no
O	O	initiating	no
O	O	,	no
O	O	adjusting	no
O	O	,	no
O	O	and	yes
O	O	discontinuing	no
B-drug	B-drug	diltiazem	yes
I-drug	I-drug	hydrochloride	yes
O	O	therapy	no
O	O	to	no
O	O	avoid	no
O	O	possible	no
O	O	over-	no
O	O	or	no
O	O	under-digitalization	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	caution	no
O	O	must	no
O	O	be	no
O	O	exercised	no
O	O	in	yes
O	O	extrapolating	no
O	O	these	no
O	O	findings	no
O	O	to	no
O	O	the	no
O	O	clinical	no
O	O	situation	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	glipizide	yes
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	The	no
O	O	daily	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	administered	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	Aprepitant	yes
O	O	reflects	no
O	O	an	no
O	O	approximate	no
O	O	50	yes
O	O	%	no
O	O	reduction	yes
O	O	of	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	.	no

O	O	During	no
O	O	controlled	no
O	O	hypotensive	no
O	O	anesthesia	yes
O	O	using	no
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	in	yes
O	O	association	no
O	O	with	yes
B-drug	B-drug	halothane	yes
O	O	,	no
O	O	high	yes
O	O	concentrations	no
O	O	(	no
O	O	3	yes
O	O	%	no
O	O	or	no
O	O	above	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	halothane	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	because	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	hypotension	no
O	O	will	no
O	O	be	no
O	O	increased	no
O	O	and	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	a	yes
O	O	large	no
O	O	reduction	yes
O	O	in	yes
O	O	cardiac	no
O	O	output	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	central	no
O	O	venous	no
O	O	pressure	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	desirable	no
O	O	to	no
O	O	monitor	no
B-group	B-group	TCA	no
O	O	plasma	yes
O	O	levels	no
O	O	whenever	no
O	O	a	yes
B-group	B-group	TCA	no
O	O	is	yes
O	O	going	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	Formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	Abciximab	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Bosentan	yes
O	O	had	no
O	O	no	yes
O	O	relevant	no
O	O	inhibitory	yes
O	O	effect	no
O	O	on	no
O	O	any	no
O	O	CYP	no
O	O	isoenzymes	no
O	O	tested	no
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP3A4	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	coagulation	yes
O	O	indices	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	to	no
O	O	maintain	no
O	O	the	no
O	O	desired	no
O	O	anticoagulant	no
O	O	effect	no
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

O	O	-	yes
B-drug	B-drug	Lofexidine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	CNS	no
O	O	depressive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	and	yes
O	O	other	no
B-group	B-group	sedatives	no

O	O	When	no
O	O	s.c	no
O	O	.	no

O	O	Population	no
O	O	pharmacokinetic	no
O	O	analyses	no
O	O	revealed	no
O	O	that	no
B-drug	B-drug	MTX	yes
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	and	yes
B-group	B-group	TNF	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	did	no
O	O	not	no
O	O	influence	no
B-drug	B-drug	abatacept	yes
O	O	clearance	no
O	O	.	no

O	O	Carcinogenesis	no
O	O	,	no
O	O	Mutagenesis	no
O	O	,	no
O	O	Impairment	no
O	O	of	yes
O	O	Fertility	no
O	O	Carcinogenesis	no
B-brand	B-brand	PEGASYS	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	tested	no
O	O	for	yes
O	O	its	no
O	O	carcinogenic	no
O	O	potential	no
O	O	.	no

B-drug	B-drug	Alosetron	yes
O	O	also	no
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	induce	no
O	O	CYP	no
O	O	enzymes	yes
O	O	2E1	no
O	O	or	no
O	O	2C19	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	now	no
O	O	strong	no
O	O	evidence	no
O	O	that	no
O	O	intensive	no
O	O	control	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	can	no
O	O	significantly	no
O	O	reduce	no
O	O	and	yes
O	O	retard	yes
O	O	the	no
O	O	microvascular	no
O	O	complications	no
O	O	of	yes
O	O	retinopathy	no
O	O	,	no
O	O	nephropathy	no
O	O	,	no
O	O	and	yes
O	O	neuropathy	no
O	O	.	no

O	O	20	yes
O	O	mg	yes
O	O	result	no
O	O	in	yes
O	O	incomplete	no
O	O	depletion	no
O	O	which	no
O	O	becomes	no
O	O	complete	yes
O	O	after	no
O	O	a	yes
O	O	second	no
O	O	additional	no
O	O	dose	no
O	O	.	no

O	O	Excessive	no
O	O	widening	no
O	O	of	yes
O	O	the	no
O	O	QRS	no
O	O	complex	yes
O	O	and/or	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	Q-T	no
O	O	interval	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	these	no
O	O	situations	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	of	yes
B-group	B-group	calcium	yes
I-group	I-group	blockers	no
O	O	on	no
O	O	platelet	yes
O	O	function	no
O	O	and	yes
O	O	arachidonic	yes
O	O	acid	yes
O	O	metabolism	no
O	O	could	no
O	O	contribute	no
O	O	in	yes
O	O	part	no
O	O	to	no
O	O	their	no
O	O	efficacy	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	ischemic	no
O	O	heart	no
O	O	disease	no
O	O	.	no

B-group	B-group	Antithrombotics	no

O	O	pruritus	no

B-drug	B-drug	Lovastatin	yes

B-drug_n	B-drug_n	Palytoxin	no
O	O	(	no
B-drug_n	B-drug_n	PTX	no
O	O	)	no
O	O	,	no
O	O	C129H223N3O54	no
O	O	,	no
O	O	isolated	no
O	O	from	no
O	O	marine	no
O	O	coelenterates	no
O	O	of	yes
O	O	Palythoa	no
O	O	tuberculosa	no
O	O	,	no
O	O	caused	no
O	O	a	yes
O	O	first	no
O	O	rapid	no
O	O	contraction	no
O	O	followed	no
O	O	by	no
O	O	the	no
O	O	slow	yes
O	O	phasic	no
O	O	contraction	no
O	O	of	yes
O	O	guinea-pig	no
O	O	vas	no
O	O	deferens	no
O	O	.	no

O	O	If	no
B-brand	B-brand	TRANXENE	yes
O	O	tablets	yes
O	O	are	no
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	anxiety	no
O	O	associated	no
O	O	with	yes
O	O	somatic	no
O	O	disease	no
O	O	states	no
O	O	,	no
O	O	careful	no
O	O	attention	no
O	O	must	no
O	O	be	no
O	O	paid	no
O	O	to	no
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
O	O	concomitant	no
O	O	medication	no
O	O	.	no

O	O	Cancer	no
O	O	chemotherapy	no

O	O	Drugs	no
O	O	Within	no
O	O	Class	no
O	O	Not	no
O	O	To	no
O	O	Be	no
O	O	Coadministered	no
O	O	With	yes
B-brand	B-brand	SUSTIVA	yes

O	O	Every	no
O	O	other	no
O	O	day	no
O	O	dosing	no
O	O	with	yes
O	O	100m	no
O	O	g/kg	no
O	O	(	no
O	O	1200m	no
O	O	g/m2	no
O	O	)	no
B-brand	B-brand	PEGASYS	yes
O	O	(	no
O	O	equivalent	no
O	O	to	no
O	O	approximately	no
O	O	30	yes
O	O	times	no
O	O	the	no
O	O	recommended	no
O	O	human	yes
O	O	dose	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	effects	no
O	O	on	no
O	O	cycle	no
O	O	duration	no
O	O	or	no
O	O	reproductive	no
O	O	hormone	yes
O	O	status	no
O	O	.	no

O	O	Symptoms	no
O	O	resolved	no
O	O	when	no
B-drug	B-drug	clonidine	yes
O	O	was	no
O	O	withdrawn	no
O	O	and	yes
O	O	recurred	no
O	O	when	no
O	O	the	no
O	O	patient	no
O	O	was	no
O	O	rechallenged	no
O	O	with	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Rearrangements	no
O	O	of	yes
O	O	genomes	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	accompany	no
O	O	cellular	no
O	O	aging	no
O	O	.	no

B-drug	B-drug	Anagrelide	yes
O	O	demonstrates	no
O	O	some	no
O	O	limited	no
O	O	inhibitory	yes
O	O	activity	yes
O	O	towards	no
O	O	CYP1A2	no
O	O	which	no
O	O	may	no
O	O	present	no
O	O	a	yes
O	O	theoretical	no
O	O	potential	no
O	O	for	yes
O	O	interaction	no
O	O	with	yes
O	O	other	no
O	O	coadministered	no
O	O	medicinal	yes
O	O	products	no
O	O	sharing	no
O	O	that	no
O	O	clearance	no
O	O	mechanism	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	theophylline	yes
O	O	.	no

B-drug	B-drug	Cefuroxime	yes
O	O	does	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	assay	no
O	O	of	yes
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	creatinine	yes
O	O	by	no
O	O	the	no
O	O	alkaline	yes
O	O	picrate	no
O	O	method	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	danger	no
O	O	of	yes
O	O	a	yes
O	O	potentially	no
O	O	fatal	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QTc	no
O	O	interval	no
O	O	,	no
B-drug	B-drug	halofantrine	yes
O	O	must	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	simultaneously	no
O	O	with	yes
O	O	or	no
O	O	subsequent	no
O	O	to	no
B-drug	B-drug	Mefloquine	yes
O	O	.	no

O	O	He	no
O	O	was	no
O	O	treated	no
O	O	aggressively	no
O	O	with	yes
O	O	intravenous	yes
O	O	hydration	no
O	O	,	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	bicarbonate	yes
O	O	,	no
O	O	and	yes
O	O	hemodialysis	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	,	no
O	O	in	yes
O	O	particular	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	exhibit	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	this	no
O	O	variety	no
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

O	O	Since	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	BUSULFEX	yes
O	O	were	no
O	O	studied	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	BUSULFEX	yes
O	O	at	yes
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	lower	no
O	O	and	yes
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	higher	no
O	O	in	yes
O	O	patients	no
O	O	not	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	Effects	no
O	O	of	yes
O	O	Other	no
B-group	B-group	Antiepileptic	no
I-group	I-group	Drugs	no
O	O	on	no
B-brand	B-brand	Felbatol	yes
B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-drug	B-drug	Phenytoin	yes
O	O	causes	no
O	O	an	no
O	O	approximate	no
O	O	doubling	no
O	O	of	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	(	no
B-drug	B-drug	felbamate	yes
O	O	)	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	and	yes
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	causes	no
O	O	an	no
O	O	approximate	no
O	O	45	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	the	no
O	O	same	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	given	no
O	O	as	yes
O	O	monotherapy	no
O	O	.	no

O	O	[	no
O	O	Pharmacologic	no
O	O	interactions	no
O	O	in	yes
O	O	chronic	no
O	O	treatments	no
O	O	:	no
O	O	corrective	no
O	O	measures	no
O	O	for	yes
O	O	its	no
O	O	prevention	no
O	O	in	yes
O	O	a	yes
O	O	basic	yes
O	O	area	no
O	O	of	yes
O	O	rural	no
O	O	health	no
O	O	]	no
O	O	OBJECTIVES	no
O	O	:	no
O	O	To	no
O	O	identify	no
O	O	the	no
O	O	pharmacological	no
O	O	interactions	no
O	O	of	yes
O	O	clinical	no
O	O	relevance	no
O	O	(	no
O	O	PICR	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	medication	no
O	O	authorization	no
O	O	cards	no
O	O	(	no
O	O	MAC	no
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	chronically	no
O	O	ill	no
O	O	and	yes
O	O	to	no
O	O	establish	no
O	O	strategies	no
O	O	to	no
O	O	minimise	no
O	O	their	no
O	O	appearance	no
O	O	.	no

O	O	As	yes
O	O	a	yes
O	O	result	no
O	O	,	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	enzyme	no
O	O	systems	no
O	O	may	no
O	O	have	no
O	O	lower	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	levels	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	.	no

O	O	General	no
O	O	:	no
O	O	In	yes
O	O	humans	no
O	O	,	no
B-drug	B-drug	valdecoxib	yes
O	O	metabolism	no
O	O	is	yes
O	O	predominantly	no
O	O	mediated	no
O	O	via	no
O	O	CYP	no
O	O	3A4	no
O	O	and	yes
O	O	2C9	no
O	O	with	yes
O	O	glucuronidation	no
O	O	being	no
O	O	a	yes
O	O	further	no
O	O	(	no
O	O	20	yes
O	O	%	no
O	O	)	no
O	O	route	no
O	O	of	yes
O	O	metabolism	no
O	O	.	no

O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	(	no
O	O	INR	no
O	O	)	no
O	O	elevations	no
O	O	and/or	no
O	O	bleeding	no
O	O	events	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	taking	no
B-drug	B-drug	warfarin	yes
O	O	while	no
O	O	on	no
B-brand	B-brand	IRESSA	yes
O	O	therapy	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	case	no
O	O	reports	no
O	O	of	yes
O	O	increased	no
O	O	steady-state	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	during	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	Since	no
O	O	1988	no
O	O	,	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	noted	no
O	O	that	no
O	O	incidence	no
O	O	of	yes
B-drug	B-drug	melarsoprol	yes
O	O	reaction	no
O	O	had	no
O	O	increased	no
O	O	systematically	no
O	O	between	yes
O	O	June	no
O	O	and	yes
O	O	October	no
O	O	of	yes
O	O	each	no
O	O	year	no
O	O	,	no
O	O	indicating	no
O	O	strong	no
O	O	seasonal	no
O	O	variation	no
O	O	.	no

O	O	Treatment	no
O	O	plans	no
O	O	for	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	anticoagulants	no
O	O	can	no
O	O	become	no
O	O	complicated	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	reactions	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	CLINISTIX	no
O	O	or	no
O	O	TES-TAPE	no
O	O	)	no
O	O	be	no
O	O	used	no
O	O	.	no

B-drug	I-drug	Saquinavir	yes

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	evidence	no
O	O	in	yes
O	O	animal	no
O	O	or	no
O	O	human	yes
O	O	studies	no
O	O	that	no
B-brand	B-brand	TORADOL	yes
O	O	induces	no
O	O	or	no
O	O	inhibits	no
O	O	hepatic	no
O	O	enzymes	yes
O	O	capable	no
O	O	of	yes
O	O	metabolizing	no
O	O	itself	no
O	O	or	no
O	O	other	no
O	O	drugs	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	propoxyphene	yes
O	O	decreased	no
O	O	the	no
O	O	maximum	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	by	no
O	O	6	yes
O	O	%	no
O	O	,	no
O	O	decreased	no
O	O	clearance	no
O	O	by	no
O	O	38	no
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	increased	no
O	O	half-life	no
O	O	by	no
O	O	58	no
O	O	%	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	A	yes
O	O	similar	no
O	O	association	no
O	O	,	no
O	O	though	no
O	O	less	no
O	O	marked	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	suggested	no
O	O	with	yes
B-group	B-group	barbiturates	no
O	O	,	no
O	O	phenyl-butazone	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
I-drug	I-drug	sodium	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
O	O	possibly	no
O	O	with	yes
B-drug	B-drug	griseofulvin	yes
O	O	,	no
B-drug	B-drug	ampicillin	yes
O	O	,	no
O	O	and	yes
B-group	B-group	tetracyclines	no
O	O	(	no
O	O	72	no
O	O	)	no

O	O	Pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
O	O	single	yes
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	and	yes
B-drug	B-drug	sirolimus	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

B-drug_n	B-drug_n	Resveratrol	yes
O	O	(	no
O	O	5-35	no
O	O	micromol/l	no
O	O	)	no
O	O	induced	no
O	O	concentration-dependent	no
O	O	relaxation	no
O	O	of	yes
O	O	mesenteric	no
O	O	arteries	no
O	O	preconstricted	no
O	O	with	yes
B-drug	B-drug	noradrenaline	yes
O	O	(	no
O	O	8	yes
O	O	micromol/l	no
O	O	)	no
O	O	or	no
B-drug	B-drug	KCl	yes
O	O	(	no
O	O	125	yes
O	O	mmol/l	no
O	O	)	no
O	O	from	no
O	O	both	no
O	O	lean	no
O	O	and	yes
O	O	dietary-obese	no
O	O	rats	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	combined	no
O	O	therapy	no
O	O	is	yes
O	O	contemplated	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	significantly	no
O	O	reduced	yes
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	atorvastatin	yes
O	O	does	no
O	O	not	no
O	O	reduce	no
O	O	basal	no
O	O	plasma	yes
O	O	cortisol	yes
O	O	concentration	no
O	O	or	no
O	O	impair	no
O	O	adrenal	no
O	O	reserve	no
O	O	.	no

O	O	CNS-Active	no
O	O	Drugs	no
B-drug	B-drug	Ethanol	yes
O	O	An	no
O	O	additive	no
O	O	effect	no
O	O	on	no
O	O	psychomotor	no
O	O	performance	no
O	O	was	no
O	O	seen	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	0.70	no
O	O	g/kg	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	4	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	administration	no
O	O	.	no

O	O	In	yes
O	O	response	no
O	O	to	no
B-drug	B-drug	cocaine	yes
O	O	,	no
O	O	the	no
O	O	locomotor	no
O	O	activities	no
O	O	of	yes
O	O	the	no
O	O	SST	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	different	no
O	O	from	no
O	O	the	no
O	O	RBC	no
O	O	group	yes
O	O	.	no

O	O	In	yes
O	O	previous	no
O	O	reports	no
O	O	we	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug_n	B-drug_n	ginsenosides	no
O	O	inhibit	no
O	O	high	yes
O	O	threshold	no
O	O	voltage-dependent	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	channels	no
O	O	in	yes
O	O	neuronal	no
O	O	cells	yes
O	O	.	no

B-drug	B-drug	oxyphenbutazone	yes
O	O	;	no

O	O	The	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	.	no

B-group	B-group	Hypoglycemics	no
O	O	and	yes
O	O	endocrine	no
O	O	drugs	no
O	O	.	no

B-group	B-group	Antiarrhythmics	no
O	O	:	no
B-drug	B-drug	Amiodarone	yes
O	O	,	no
B-drug	B-drug	bepridil	yes
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	.	no

B-group	B-group	H2-Receptor	no
I-group	I-group	Antagonists	no
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	intravenously	no
O	O	administered	no
B-drug	B-drug	famotidine	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	reduced	yes
O	O	the	no
O	O	oral	yes
O	O	absorption	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	400	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	administered	no
O	O	following	no
O	O	a	yes
O	O	meal	no
O	O	,	no
O	O	as	yes
O	O	evidenced	no
O	O	by	no
O	O	a	yes
O	O	27	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	mean	no
O	O	Cmax	no
O	O	and	yes
O	O	a	yes
O	O	22	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	mean	no
O	O	AUC	no
O	O	.	no

B-drug	B-drug	Everolimus	yes
O	O	exposure-response	no
O	O	relationships	no
O	O	between	yes
O	O	area	no
O	O	under	no
O	O	the	no
O	O	blood	yes
O	O	concentration-time	no
O	O	curve	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	and	yes
O	O	changes	no
O	O	in	yes
O	O	platelets	no
O	O	,	no
O	O	leukocytes	no
O	O	,	no
O	O	and	yes
O	O	lipids	no
O	O	were	no
O	O	explored	no
O	O	with	yes
O	O	the	no
O	O	median-effect	no
O	O	model	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	cautioned	no
O	O	about	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	drugs	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	LEXAPRO	yes
O	O	.	no

O	O	Oils	no
O	O	may	no
O	O	enhance	no
O	O	absorption	no
O	O	.	no

O	O	Drugs	no
O	O	Highly	no
O	O	Bound	no
O	O	To	no
O	O	Plasma	yes
O	O	Protein	yes
B-drug	B-drug	Eszopiclone	yes
O	O	is	yes
O	O	not	no
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	(	no
O	O	52-59	no
O	O	%	no
O	O	bound	no
O	O	)	no
O	O	;	no

O	O	however	no
O	O	,	no
O	O	a	yes
O	O	comparison	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	administration	no
O	O	with	yes
O	O	the	no
O	O	evening	no
O	O	meal	no
O	O	or	no
O	O	at	yes
O	O	bedtime	no
O	O	has	no
O	O	revealed	no
O	O	no	yes
O	O	significant	no
O	O	differences	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	bioavailability	no
O	O	(	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	curve	no
O	O	)	no
O	O	of	yes
O	O	these	no
O	O	two	no
O	O	regimens	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	catecholamine-depleting	no
O	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	reserpine	yes
O	O	or	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	,	no
O	O	because	no
O	O	the	no
O	O	added	no
O	O	beta-adrenergic	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	ZEBETA	yes
O	O	may	no
O	O	produce	no
O	O	excessive	no
O	O	reduction	yes
O	O	of	yes
O	O	sympathetic	no
O	O	activity	yes
O	O	.	no

O	O	The	no
O	O	benefits	no
O	O	and	yes
O	O	risks	no
O	O	of	yes
O	O	using	no
B-brand	B-brand	TRICOR	yes
O	O	with	yes
B-group	B-group	immunosuppressants	no
O	O	and	yes
O	O	other	no
O	O	potentially	no
O	O	nephrotoxic	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	considered	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	lowest	no
O	O	effective	no
O	O	dose	no
O	O	employed	no

O	O	The	no
B-drug_n	B-drug_n	16,16-dimethylprostaglandin	no
I-drug_n	I-drug_n	E2	yes
O	O	(	no
B-drug_n	B-drug_n	dmPGE2	no
O	O	)	no
O	O	-induced	no
O	O	diarrhea	no
O	O	was	no
O	O	analyzed	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	prepared	no
O	O	by	no
O	O	resecting	no
O	O	the	no
O	O	cecum	no
O	O	and	yes
O	O	its	no
O	O	vasculature	no
O	O	without	no
O	O	disturbing	no
O	O	the	no
O	O	ileocecal	no
O	O	junction	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	decitabine	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	inhibit	no
O	O	or	no
O	O	induce	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

O	O	In	yes
O	O	one	no
O	O	controlled	no
O	O	study	no
O	O	of	yes
O	O	175	no
O	O	patients	no
O	O	,	no
O	O	transient	no
O	O	drowsiness	no
O	O	was	no
O	O	observed	no
O	O	in	yes
O	O	63	no
O	O	%	no
O	O	of	yes
O	O	those	no
O	O	receiving	no
B-drug	B-drug	baclofen	yes
O	O	tablets	yes
O	O	compared	no
O	O	to	no
O	O	36	no
O	O	%	no
O	O	of	yes
O	O	those	no
O	O	in	yes
O	O	the	no
O	O	placebo	no
O	O	group	yes
O	O	.	no

B-group	B-drug	HMG-CoA	no
I-group	I-drug	Reductase	no
I-group	I-drug	Inhibitors	no
O	O	:	no
B-drug	B-drug	Simvastatin	yes
O	O	(	no
O	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	reports	no
O	O	of	yes
O	O	myopathy/rhabdomyolysis	no
O	O	.	no

O	O	The	no
O	O	majority	no
O	O	of	yes
O	O	patients	no
O	O	in	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	or	no
O	O	Crohn	no
O	O	s	yes
O	O	disease	no
O	O	clinical	no
O	O	studies	no
O	O	received	no
O	O	one	no
O	O	or	no
O	O	more	no
O	O	concomitant	no
O	O	medications	no
O	O	.	no

B-drug	B-drug	Danazol	yes
O	O	:	no
O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	myopathy/rhabdomyolysis	no
O	O	is	yes
O	O	increased	no
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	danazol	yes
O	O	particularly	no
O	O	with	yes
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	(	no
O	O	see	no
O	O	WARNINGS	no
O	O	,	no
O	O	Myopathy/Rhabdomyolysis	no
O	O	)	no
O	O	.	no

O	O	one-half	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	when	no
O	O	administered	no
O	O	during	no
O	O	the	no
O	O	period	no
O	O	of	yes
O	O	organogenesis	no
O	O	.	no

O	O	Close	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	a	yes
B-group	B-group	beta-blocker	no
O	O	is	yes
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
O	O	catecholamine-depleting	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	the	no
O	O	production	no
O	O	of	yes
O	O	hypotension	no
O	O	and/or	no
O	O	marked	no
O	O	bradycardia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	produce	no
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	,	no
O	O	or	no
O	O	postural	no
O	O	hypotension	no
O	O	.	no

O	O	These	no
O	O	findings	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	phenotype	no
O	O	of	yes
O	O	a	yes
O	O	tumor	yes
O	O	that	no
O	O	results	no
O	O	from	no
O	O	a	yes
O	O	pulse	no
O	O	of	yes
O	O	a	yes
O	O	chemical	yes
O	O	carcinogen	no
O	O	may	no
O	O	depend	no
O	O	upon	no
O	O	the	no
O	O	target	no
O	O	cell	yes
O	O	.	no

B-group	B-group	Ergot	yes
I-group	I-group	Derivatives	no
O	O	:	no
B-drug	B-drug	Dihydroergotamine	yes
O	O	,	no
B-drug	B-drug	ergonovine	yes
O	O	,	no
B-drug	B-drug	ergotamine	yes
O	O	,	no
B-drug	B-drug	methylergonovine	yes
O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and	yes
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	acute	no
O	B-group	ergot	yes
O	O	toxicity	no
O	O	characterized	no
O	O	by	no
O	O	peripheral	no
O	O	vasospasm	no
O	O	and	yes
O	O	ischemia	no
O	O	of	yes
O	O	the	no
O	O	extremities	no
O	O	and	yes
O	O	other	no
O	O	tissues	no
O	O	.	no

O	O	Measurement	no
O	O	of	yes
O	O	nociception	no
O	O	was	no
O	O	performed	no
O	O	within	no
O	O	2	yes
O	O	h	yes
O	O	after	no
B-group	B-group	benzodiazepine	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Epirubicin	yes
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	liver	yes
O	O	.	no

O	O	After	no
O	O	consumption	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	36	no
O	O	hours	no
O	O	should	no
O	O	elapse	no
O	O	before	no
O	O	these	no
O	O	determinations	no
O	O	are	no
O	O	made	no
O	O	.	no

O	O	If	no
O	O	it	no
O	O	is	yes
O	O	necessary	no
O	O	to	no
O	O	continue	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	,	no
O	O	provide	no
O	O	close	no
O	O	medical	yes
O	O	supervision	no
O	O	after	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	two	no
O	O	hours	no
O	O	and	yes
O	O	until	no
O	O	blood	yes
O	O	pressure	no
O	O	has	no
O	O	stabilized	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	an	no
O	O	additional	no
O	O	hour..	no

O	O	The	no
O	O	magnitude	no
O	O	of	yes
O	O	these	no
O	O	effects	no
O	O	may	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	administration	no
O	O	of	yes
O	O	the	no
O	O	volatile	no
O	O	agents	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	Population	no
O	O	pharmacokinetic	no
O	O	analyses	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	tiagabine	yes
O	O	clearance	no
O	O	is	yes
O	O	60	no
O	O	%	no
O	O	greater	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	phenytoin	yes
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	other	no
O	O	enzyme-	no
O	O	inducing	no
B-group	B-group	AEDs	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	we	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug_n	B-drug_n	RR	no
O	O	is	yes
O	O	a	yes
O	O	useful	no
O	O	pharmacological	no
O	O	tool	no
O	O	with	yes
O	O	which	no
O	O	to	no
O	O	examine	no
O	O	the	no
B-drug_n	B-drug_n	InsP	no
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	3	yes
I-drug_n	I-drug_n	)	no
O	O	-mediated	no
O	O	responses	no
O	O	of	yes
O	O	megakaryocytes	no
O	O	.	no

O	O	Conversely	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	(	no
O	O	1	yes
O	O	mg	yes
B-drug	B-drug	butorphanol	yes
O	O	QID	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	a	yes
O	O	300-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

B-drug	B-drug	Rifabutin	yes

O	O	The	no
O	O	clinical	no
O	O	effects	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	The	no
O	O	next	yes
O	O	chapter	no
O	O	presents	no
O	O	information	no
O	O	on	no
O	O	efficacy	no
O	O	and	yes
O	O	pregnancy	no
O	O	outcomes	no
O	O	in	yes
O	O	terms	no
O	O	of	yes
O	O	pregnancy	no
O	O	rates	no
O	O	,	no
O	O	compliance	yes
O	O	and	yes
O	O	efficacy	no
O	O	,	no
O	O	ectopic	no
O	O	pregnancies	no
O	O	,	no
O	O	the	no
O	O	outcome	no
O	O	of	yes
O	O	pregnancies	no
O	O	conceived	no
O	O	while	no
O	O	using	no
B-group	B-group	POCs	no
O	O	,	no
O	O	and	yes
O	O	fertility	no
O	O	following	no
O	O	discontinuation	no
O	O	.	no

O	O	Interactions	no
O	O	between	yes
B-brand	B-brand	Betaseron	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	fully	no
O	O	evaluated	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	reported	no
O	O	cases	no
O	O	from	no
O	O	spontaneous	no
O	O	reports	no
O	O	of	yes
O	O	drug	yes
O	O	interaction	no
O	O	between	yes
B-group	B-group	SSRIs	no
O	O	and	yes
B-brand	B-brand	D.H.E	no
I-brand	I-brand	.	no
I-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	.	no

O	O	increased	no
O	O	bilirubin	no

O	O	A	yes
O	O	small	no
O	O	number	no
O	O	of	yes
O	O	patients	no
O	O	received	no
B-drug	B-drug	epirubicin-based	no
O	O	chemotherapy	no
O	O	concomitantly	no
O	O	with	yes
O	O	radiation	no
O	O	therapy	no
O	O	but	no
O	O	had	no
O	O	chemotherapy	no
O	O	interrupted	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
O	O	potential	no
O	O	overlapping	no
O	O	toxicities	no
O	O	.	no

O	O	Laboratory	no
O	O	Test	yes
O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	laboratory	no
O	O	test	yes
O	O	abnormalities	no
O	O	were	no
O	O	identified	no
O	O	as	yes
O	O	causally	no
O	O	related	yes
O	O	to	no
O	O	drug	yes
O	O	during	no
O	O	short-term	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	guanfacine	yes
O	O	.	no

O	O	These	no
O	O	reactions	no
O	O	consisted	no
O	O	of	yes
O	O	erythema	no
O	O	,	no
O	O	pruritus	no
O	O	,	no
O	O	and	yes
O	O	hypotension	no
O	O	and	yes
O	O	occurred	no
O	O	within	no
O	O	hours	no
O	O	of	yes
O	O	administration	no
O	O	of	yes
O	O	chemotherapy	no
O	O	.	no

O	O	Although	no
O	O	much	no
O	O	statistical	no
O	O	work	no
O	O	has	no
O	O	focused	no
O	O	on	no
O	O	developing	no
O	O	mathematical	no
O	O	functions	no
O	O	to	no
O	O	model	no
O	O	the	no
O	O	joint	no
O	O	dose-response	no
O	O	curves	no
O	O	,	no
O	O	relatively	no
O	O	little	no
O	O	work	no
O	O	exists	no
O	O	in	yes
O	O	regard	no
O	O	to	no
O	O	designing	no
O	O	experiments	no
O	O	for	yes
O	O	assessing	no
O	O	joint	no
O	O	action	no
O	O	.	no

B-brand	B-brand	PEGASYS	yes
O	O	is	yes
O	O	recommended	no
O	O	for	yes
O	O	use	no
O	O	in	yes
O	O	women	yes
O	O	of	yes
O	O	childbearing	no
O	O	potential	no
O	O	only	no
O	O	when	no
O	O	they	no
O	O	are	no
O	O	using	no
O	O	effective	no
O	O	contraception	no
O	O	during	no
O	O	therapy	no
O	O	.	no

O	O	The	no
O	O	extent	no
O	O	to	no
O	O	which	no
B-group	B-group	SSRI-TCA	no
O	O	interactions	no
O	O	may	no
O	O	pose	no
O	O	clinical	no
O	O	problems	no
O	O	will	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	and	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRI	no
O	O	involved	no
O	O	.	no

B-drug	B-drug	Lithium	yes
I-drug	I-drug	carbonate	yes
O	O	(	no
O	O	450	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	valdecoxib	yes
O	O	pharmacokinetics	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	salts	no

O	O	therefore	no
O	O	,	no
O	O	these	no
O	O	combinations	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes

O	O	Vasospastic	no
O	O	reactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	therapeutic	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ergotamine-containing	no
O	O	drugs	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
O	O	these	no
B-group	B-group	antibiotics	no
O	O	.	no

O	O	Apparent	no
O	O	oral	yes
O	O	clearance	no
O	O	and	yes
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	decreased	no
O	O	with	yes
O	O	38	no
O	O	%	no
O	O	and	yes
O	O	45	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	when	no
B-drug	B-drug	sirolimus	yes
O	O	was	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	prostaglandin	yes
I-drug	I-drug	F2alpha	yes
O	O	and	yes
O	O	synthetic	yes
B-drug	B-drug	oxytocin	yes
O	O	on	no
O	O	placental	no
O	O	vessels	no
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	Urinary	yes
O	O	alkalinizing	no
O	O	agents	yes
O	O	increase	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	decrease	no
O	O	excretion	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	day	no
O	O	1	yes
O	O	,	no
O	O	250	yes
O	O	mg	yes
O	O	QD	no
O	O	4	yes
O	O	days	no
O	O	)	no

O	O	METHODS	no
O	O	:	no
B-drug	B-drug	Hydrocortisone	yes
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	d-amphetamine	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	were	no
O	O	administered	no
O	O	orally	no
O	O	to	no
O	O	16	yes
O	O	healthy	no
O	O	male	no
O	O	and	yes
O	O	female	no
O	O	volunteers	no
O	O	in	yes
O	O	a	yes
O	O	four-session	no
O	O	,	no
O	O	placebo-controlled	no
O	O	,	no
O	O	within-subject	no
O	O	,	no
O	O	crossover	no
O	O	design	no
O	O	.	no

O	O	The	no
O	O	world	no
O	O	medical	yes
O	O	literature	no
O	O	contains	no
O	O	43	yes
O	O	reports	no
O	O	of	yes
O	O	deaths	no
O	O	associated	no
O	O	with	yes
B-group	B-drug	amphetamines	no
O	O	in	yes
O	O	a	yes
O	O	35-year	no
O	O	period	no
O	O	.	no

O	O	Cardiovasculars	no
O	O	:	no
B-group	B-drug	Cardiac	no
I-group	I-drug	glycosides	yes
O	O	:	no
O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	digoxin	yes
O	O	therapy	no
O	O	,	no
O	O	administration	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	regularly	no
O	O	results	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentration	no
O	O	that	no
O	O	may	no
O	O	reach	no
O	O	toxic	no
O	O	levels	no
O	O	with	yes
O	O	resultant	no
O	O	clinical	no
O	O	toxicity	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	:	no
O	O	The	no
O	O	biochemical	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	metabolizing	no
O	O	isozyme	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	debrisoquin	yes
O	O	hydroxylase	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	caucasian	no
O	O	population	no
O	O	(	no
O	O	about	no
O	O	7	yes
O	O	to	no
O	O	10	yes
O	O	%	no
O	O	of	yes
O	O	caucasians	no
O	O	are	no
O	O	so	no
O	O	called	no
O	O	poor	no
O	O	metabolizers	no
O	O	)	no
O	O	;	no

O	O	New	no
O	O	oral	yes
O	O	therapies	no
O	O	for	yes
O	O	type	yes
O	O	2	yes
O	O	diabetes	no
O	O	mellitus	no
O	O	:	no
O	O	The	no
B-group	B-group	glitazones	no
O	O	or	no
B-drug	O	insulin	yes
O	O	sensitizers	no
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
O	O	In	yes
O	O	contrast	no
O	O	to	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	glucocorticoids	no
O	O	in	yes
O	O	rodent	no
O	O	studies	no
O	O	,	no
O	O	these	no
O	O	results	no
O	O	indicate	no
O	O	that	no
O	O	an	no
O	O	acute	no
O	O	increase	no
O	O	in	yes
O	O	cortisol	yes
O	O	does	no
O	O	not	no
O	O	enhance	no
O	O	the	no
O	O	psychostimulant	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	d-amphetamine	yes
O	O	in	yes
O	O	humans	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	alone	no
O	O	can	no
O	O	inhibit	no
O	O	adrenal	no
O	B-drug	corticosteroid	no
O	O	synthesis	no
O	O	and	yes
O	O	may	no
O	O	cause	no
O	O	adrenal	no
O	O	insufficiency	no
O	O	during	no
O	O	corticosteroid	no
O	O	withdrawal	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	because	no
B-drug	B-drug	diclofenac	yes
O	O	is	yes
O	O	displaced	no
O	O	from	no
O	O	its	no
O	O	binding	no
O	O	sites	no
O	O	during	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	lower	no
O	O	plasma	yes
O	O	concentrations	no
O	O	,	no
O	O	peak	no
O	O	plasma	yes
O	O	levels	no
O	O	,	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	.	no

O	O	The	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	metabolized	no
O	O	by	no
O	O	glucuronidation	no
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
B-drug	B-drug	oxazepam	yes
O	O	,	no
B-drug	B-drug	temazepam	yes
O	O	)	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	be	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	fluvoxamine	yes
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	are	no
O	O	unaltered	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	flumazenil	yes
O	O	and	yes
O	O	vice	no
O	O	versa	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Other	no
O	O	:	no
O	O	Neither	no
B-drug	B-drug	fosinopril	yes
I-drug	I-drug	sodium	yes
O	O	nor	yes
O	O	its	no
O	O	metabolites	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	food	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	this	no
O	O	specificity	no
O	O	we	no
O	O	describe	no
O	O	a	yes
O	O	simple	no
O	O	and	yes
O	O	reliable	no
O	O	affinity	no
O	O	chromatography	no
O	O	procedure	no
O	O	for	yes
O	O	the	no
O	O	purification	no
O	O	of	yes
O	O	both	no
O	O	human	yes
O	O	serum	yes
O	O	and	yes
O	O	colostrum	no
O	O	IgA	no
O	O	.	no

O	O	and	yes
B-drug	B-drug	disulfiram	yes
O	O	When	no
B-drug	B-drug	amitriptyline	yes
I-drug	I-drug	HCl	yes
O	O	is	yes
O	O	given	no
O	O	with	yes
B-group	B-drug	anticholinergic	no
I-group	O	agents	yes
O	O	or	no
B-group	B-drug	sympathomimetic	no
I-group	O	drugs	no
O	O	,	no
O	O	including	no
B-drug	B-drug	epinephrine	yes
O	O	combined	no
O	O	with	yes
O	O	local	no
B-group	B-drug	anesthetics	no
O	O	,	no
O	O	close	no
O	O	supervision	no
O	O	and	yes
O	O	careful	no
O	O	adjustment	no
O	O	of	yes
O	O	dosages	no
O	O	are	no
O	O	required	no
O	O	.	no

B-drug	B-drug	Rifabutin	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	and	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	32	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	207	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	rifabutin	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	while	no
O	O	no	yes
O	O	formal	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	,	no
O	O	no	yes
O	O	interactions	no
O	O	were	no
O	O	observed	no
O	O	.	no

O	O	Food	no
O	O	has	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	anagrelide	yes
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	;	no

O	O	Established	no
O	O	Drug	yes
O	O	Interactions	no
O	O	(	no
O	O	continued	no
O	O	)	no

B-group	B-group	Potassium-sparing	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	amiloride	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	,	no
O	O	or	no
O	B-drug	potassium-containing	no
O	O	salt	yes
O	O	substitutes	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

O	O	This	no
O	O	observed	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
O	O	may	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	transport-related	no
O	O	effects	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	p-glycoprotein	no
O	O	.	no
O	O	in	yes
O	O	vivo	no
O	O	animal	no
O	O	studies	no
O	O	also	no
O	O	suggest	no
O	O	that	no
O	O	in	yes
O	O	addition	no
O	O	to	no
O	O	enhancing	no
O	O	absorption	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	decreases	no
B-drug	B-drug	fexofenadine	yes
O	O	gastrointestinal	no
O	O	secretion	no
O	O	,	no
O	O	while	no
B-drug	B-drug	erythromycin	yes
O	O	may	no
O	O	also	no
O	O	decrease	no
O	O	biliary	no
O	O	excretion	no
O	O	.	no

O	O	No	yes
O	O	pharmacokinetic	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	PERSANTINE	yes
O	O	(	no
B-drug	B-drug	dipyridamole	yes
O	O	USP	yes
O	O	)	no
O	O	Tablets	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	experience	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-brand	B-brand	Angiomax	yes
O	O	and	yes
O	O	plasma	yes
O	O	expanders	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dextran	yes
O	O	.	no

O	O	On	no
O	O	the	no
O	O	ninth	no
O	O	day	no
O	O	,	no
O	O	the	no
O	O	rats	no
O	O	were	no
O	O	sacrificed	no
O	O	and	yes
O	O	aortic	no
O	O	rings	no
O	O	,	no
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	endothelium	no
O	O	,	no
O	O	were	no
O	O	used	no
O	O	to	no
O	O	generate	no
O	O	concentration-response	no
O	O	curves	no
O	O	to	no
B-drug	B-drug	noradrenaline	yes
O	O	.	no

O	O	At	yes
O	O	stable	no
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
O	O	concentrations	no
O	O	greater	no
O	O	than	no
O	O	1	yes
O	O	mM	yes
O	O	,	no
O	O	fractional	no
O	O	mucosal	no
O	O	cell	yes
O	O	accumulation	no
O	O	of	yes
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
O	O	remains	no
O	O	constant	no
O	O	,	no
O	O	while	no
O	O	fractional	no
O	O	transfer	no
O	O	to	no
O	O	the	no
O	O	body	no
O	O	declines	no
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	is	yes
O	O	little	no
O	O	published	no
O	O	information	no
O	O	on	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lidocaine	yes
O	O	and	yes
B-drug	B-drug	Bretylium	yes
I-drug	I-drug	Tosylate	yes
O	O	,	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	often	no
O	O	administered	no
O	O	concurrently	no
O	O	without	no
O	O	any	no
O	O	evidence	no
O	O	of	yes
O	O	interactions	no
O	O	resulting	no
O	O	in	yes
O	O	adverse	no
O	O	effects	no
O	O	or	no
O	O	diminished	no
O	O	efficacy	no
O	O	.	no

B-brand	B-brand	Plenaxis	yes
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	(	no
O	O	96	no
O	O	to	no
O	O	99	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	tetracycline	yes
O	O	and	yes
B-brand	B-brand	Penthrane	yes
O	O	(	no
B-drug	B-drug	methoxyflurane	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	fatal	no
O	O	renal	no
O	O	toxicity	no
O	O	.	no

O	O	Increased	no
O	O	nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	cephalosporins	no
O	O	and	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	.	no

O	O	with	yes
O	O	divalent	no
O	O	or	no
O	O	trivalent	no
O	O	cations	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	iron	yes
O	O	;	no

O	O	Patients	no
O	O	response	no
O	O	to	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	be	no
O	O	affected	no
O	O	by	no
O	O	his/her	no
O	O	thyroid	yes
O	O	and	yes
O	O	metabolic	no
O	O	status	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	relationship	no
O	O	to	no
B-drug	B-drug	nifedipine	yes
O	O	therapy	no
O	O	is	yes
O	O	uncertain	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	increased	no
O	O	AUC	no
O	O	by	no
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	but	no
O	O	caused	no
O	O	no	yes
O	O	change	no
O	O	in	yes
O	O	Cmax	no
O	O	.	no

O	O	Clinically	no
O	O	significant	no
O	O	QTc	no
O	O	prolongation	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	found	no
O	O	with	yes
O	O	Mefloquineuine	no
O	O	alone	no
O	O	.	no

O	O	Acute	no
O	O	effect	no
O	O	of	yes
O	O	different	no
B-group	B-group	antidepressants	no
O	O	on	no
O	O	glycemia	no
O	O	in	yes
O	O	diabetic	no
O	O	and	yes
O	O	non-diabetic	no
O	O	rats	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	separate	no
O	O	study	no
O	O	,	no
O	O	baboons	no
O	O	given	no
O	O	3	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	alefacept	yes
O	O	at	yes
O	O	1	yes
O	O	mg/kg	no
O	O	every	no
O	O	8	yes
O	O	weeks	no
O	O	were	no
O	O	found	no
O	O	to	no
O	O	have	no
O	O	centroblast	no
O	O	proliferation	no
O	O	in	yes
O	O	B-cell	no
O	O	dependent	no
O	O	areas	no
O	O	in	yes
O	O	the	no
O	O	germinal	no
O	O	centers	no
O	O	of	yes
O	O	the	no
O	O	spleen	no
O	O	following	no
O	O	a	yes
O	O	116-day	no
O	O	washout	no
O	O	period	no
O	O	.	no

B-drug	I-drug	Nevirapine	yes

O	O	Although	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	on	no
O	O	the	no
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	R	yes
O	O	(	no
I-drug	O	+	no
I-drug	O	)	no
I-drug	O	or	no
I-drug	B-drug	S	yes
I-drug	I-drug	(	no
I-drug	I-drug	-	yes
I-drug	I-drug	)	no
I-drug	I-drug	warfarin	yes
O	O	determined	no
O	O	on	no
O	B-drug	Day	no
O	I-drug	3	yes
O	I-drug	,	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	34	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	S	yes
I-drug	I-drug	(	no
I-drug	I-drug	-	yes
I-drug	I-drug	)	no
I-drug	I-drug	warfarin	yes
O	O	(	no
O	O	a	yes
O	O	CYP2C9	no
O	O	substrate	yes
O	O	)	no
O	O	trough	no
O	O	concentration	no
O	O	accompanied	no
O	O	by	no
O	O	a	yes
O	O	14	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	(	no
O	O	reported	no
O	O	as	yes
O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	or	no
O	O	INR	no
O	O	)	no
O	O	5	yes
O	O	days	no
O	O	after	no
O	O	completion	no
O	O	of	yes
O	O	dosing	no
O	O	with	yes
B-drug	B-drug	Aprepitant	yes
O	O	.	no

B-group	B-group	influenza	no
I-group	I-group	virus	yes
I-group	I-group	vaccine	yes
O	O	;	no

O	O	This	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	reduced	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
O	O	a	yes
O	O	prolongation	no
O	O	of	yes
O	O	its	no
O	O	plasma	yes
O	O	half-life	no
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	and	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	and	yes
O	O	other	no
B-group	B-group	beta-blockers	no
O	O	.	no

O	O	Routine	no
O	O	monitoring	no
O	O	should	no
O	O	be	no
O	O	performed	no
O	O	when	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	BEXTRA	yes
O	O	is	yes
O	O	either	no
O	O	initiated	no
O	O	or	no
O	O	discontinued	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-group	O	anticonvulsant	no
O	O	therapy	no
O	O	.	no

O	O	These	no
B-group	B-group	cephalosporins	no
O	O	are	no
O	O	inhibitors	no
O	O	of	yes
O	O	hepatic	no
O	O	vitamin	yes
O	O	K	yes
O	O	epoxide	no
O	O	reductase	no
O	O	.	no

O	O	CONCLUSION	no
O	O	:	no
B-drug	B-drug	Fluvoxamine	yes
O	O	is	yes
O	O	a	yes
O	O	moderate	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP2C9	no
O	O	in	yes
O	O	vivo	no
O	O	.	no

B-drug	B-drug	Calcium	yes
O	O	,	no
O	O	particularly	no
O	O	if	no
O	O	administered	no
O	O	rapidly	yes
O	O	by	no
O	O	the	no
O	O	intravenous	yes
O	O	route	no
O	O	,	no
O	O	may	no
O	O	produce	no
O	O	serious	no
O	O	arrhythmias	no
O	O	in	yes
O	O	digitalized	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Dextromethorphan	yes
O	O	:	no
B-drug	B-drug	Dextromethorphan	yes
O	O	is	yes
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	2D6	no
O	O	and	yes
O	O	to	no
O	O	a	yes
O	O	lesser	no
O	O	extent	no
O	O	by	no
O	O	3A4	no
O	O	.	no

B-drug	B-drug	Didanosine	yes

O	O	However	no
O	O	,	no
O	O	preliminary	no
O	O	results	no
O	O	from	no
O	O	an	no
O	O	8-week	no
O	O	trial	no
O	O	showed	no
O	O	comparable	no
O	O	cognitive	no
O	O	enhancing	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	olanzapine	yes
O	O	and	yes
B-drug	B-drug	risperidone	yes
O	O	treatment	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	schizophrenia	no
O	O	or	no
O	O	schizoaffective	no
O	O	disorder	no
O	O	.	no

O	O	The	no
O	O	physician	no
O	O	should	no
O	O	be	no
O	O	alert	no
O	O	for	yes
O	O	possible	no
O	O	combined	no
O	O	drug	yes
O	O	actions	no
O	O	,	no
O	O	desirable	no
O	O	or	no
O	O	undesirable	no
O	O	,	no
O	O	involving	no
B-drug	B-drug	ifosfamide	yes
O	O	even	no
O	O	though	no
B-drug	B-drug	ifosfamide	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	successfully	no
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	including	no
O	O	other	no
B-group	O	cytotoxic	yes
I-group	O	drugs	no
O	O	.	no

O	O	Population	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	showed	no
O	O	higher	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cilostazol	yes
O	O	among	no
O	O	patients	no
O	O	concurrently	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	C.P.A..	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	generally	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	.	no

B-group	B-group	Antihistamines	no
O	O	:	no
B-group	B-group	Benzodiazepines	no
O	O	GI	no
O	O	Motility	no
O	O	Agents	yes
B-group	B-group	Anti-Migraine	no
I-group	I-group	Antifungal	no

B-drug	B-drug	Cimetidine	yes
O	O	treatment	no
O	O	should	no
O	O	be	no
O	O	stopped	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	ELLENCE	yes
O	O	.	no

B-drug	B-drug	Propoxyphene	yes
O	O	:	no
O	O	The	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	propoxyphene	yes
I-drug	I-drug	hydrochloride	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
O	O	or	no
B-group	B-group	narcotics	no
O	O	:	no
O	O	potentiation	no
O	O	of	yes
O	O	orthostatic	no
O	O	hypotension	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	120	no
O	O	mg/kg	no
O	O	dose	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	systemic	no
O	O	exposure	yes
O	O	approximately	no
O	O	16	yes
O	O	times	no
O	O	the	no
O	O	human	yes
O	O	plasma	yes
O	O	area-under-the-curve	no
O	O	(	no
O	O	AUC	no
O	O	,	no
O	O	0-24	no
O	O	hours	no
O	O	)	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	maximum	no
O	O	human	yes
O	O	dose	no
O	O	of	yes
O	O	80	yes
O	O	mg/day	no
O	O	.	no

O	O	This	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	whenever	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	prescribed	no
O	O	concomitantly	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	rofecoxib	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	b-lactam	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	loracarbef	yes
O	O	is	yes
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	probenecid	yes
O	O	and	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	80	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	for	yes
B-drug	B-drug	loracarbef	yes
O	O	.	no

O	O	Plasma	yes
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	to	no
B-drug	B-drug	valdecoxib	yes
O	O	was	no
O	O	increased	no
O	O	62	no
O	O	%	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	fluconazole	yes
O	O	and	yes
O	O	38	no
O	O	%	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	.	no

B-drug	B-drug	Cyclosporine	yes

B-drug	I-drug	vardenafil	yes
O	O	concentration	no

O	O	Interaction	no
O	O	with	yes
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	other	no
O	O	than	no
B-group	B-group	benzodiazepines	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	specifically	no
O	O	studied	no
O	O	;	no

B-drug	B-drug	Ketoconazole	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	conversion	yes
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	to	no
O	O	the	no
O	O	active	no
O	O	metabolite	yes
O	O	after	no
O	O	intravenous	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	had	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	after	no
O	O	oral	yes
O	O	administration	no
O	O	.	no

B-group	B-group	Antidepressants	no
O	O	,	no
B-group	B-group	tricyclic	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-group	B-group	tricyclic	no
O	O	or	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	;	no

B-drug	B-drug	Anagrelide	yes
O	O	alone	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	platelet	yes
O	O	aggregation	no
O	O	,	no
O	O	but	no
O	O	did	no
O	O	slightly	no
O	O	enhance	no
O	O	the	no
O	O	inhibition	no
O	O	of	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	by	no
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	Substantial	no
O	O	intercurrent	no
B-drug	B-drug	ethanol	yes
O	O	use	no
O	O	was	no
O	O	present	no
O	O	in	yes
O	O	each	no
O	O	of	yes
O	O	these	no
O	O	cases	no
O	O	,	no
O	O	and	yes
O	O	this	no
O	O	may	no
O	O	have	no
O	O	contributed	no
O	O	to	no
O	O	the	no
O	O	abnormalities	no
O	O	seen	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-drug	B-drug	ketoprofen	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Tablets	yes
O	O	:	no
O	O	The	no
B-group	B-group	benzodiazepines	no
O	O	,	no
O	O	including	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
O	O	produce	no
O	O	CNS-depressant	no
O	O	effects	no
O	O	when	no
O	O	administered	no
O	O	with	yes
O	O	such	no
O	O	medications	no
O	O	as	yes
B-group	B-group	barbiturates	no
O	O	or	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	The	no
O	O	first	no
O	O	test	yes
O	O	is	yes
O	O	obtained	no
O	O	by	no
O	O	the	no
O	O	prescriber	no
O	O	when	no
O	O	the	no
O	O	decision	no
O	O	is	yes
O	O	made	no
O	O	to	no
O	O	pursue	no
O	O	qualification	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	for	yes
B-brand	B-brand	Accutane	yes
O	O	(	no
O	O	a	yes
O	O	screening	no
O	O	test	yes
O	O	)	no
O	O	.	no

O	O	High	yes
O	O	oral	yes
B-drug	B-drug	magnesium	yes
O	O	doses	no
O	O	besides	no
O	O	their	no
O	O	laxative	no
O	O	action	no
O	O	may	no
O	O	bring	no
O	O	latent	no
O	O	complications	no
O	O	which	no
O	O	may	no
O	O	reduce	no
O	O	lifespan	no
O	O	.	no

B-drug	B-drug	phenylbutazone	yes
O	O	;	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interaction	no
O	O	Because	no
B-brand	B-brand	Xigris	no
O	O	may	no
O	O	affect	no
O	O	the	no
O	O	APTT	no
O	O	assay	no
O	O	,	no
B-brand	B-brand	Xigris	no
O	O	present	no
O	O	in	yes
O	O	plasma	yes
O	O	samples	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	one-stage	no
O	O	coagulation	yes
O	O	assays	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	APTT	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	factor	yes
O	O	VIII	yes
O	O	,	no
O	O	IX	yes
O	O	,	no
O	O	and	yes
O	O	XI	no
O	O	assays	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Methenamine	yes
O	O	therapy	no
O	O	:	no
O	O	Urinary	yes
O	O	excretion	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	is	yes
O	O	increased	no
O	O	,	no
O	O	and	yes
O	O	efficacy	no
O	O	is	yes
O	O	reduced	yes
O	O	,	no
O	O	by	no
B-group	B-group	acidifying	no
I-group	I-group	agents	yes
O	O	used	no
O	O	in	yes
B-drug	B-drug	methenamine	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
B-drug	B-drug	Rifampin	yes
O	O	increases	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
O	O	some	no
B-group	B-group	progestins	no
O	O	(	no
B-drug	B-drug	norethindrone	yes
O	O	)	no
O	O	resulting	no
O	O	in	yes
O	O	decreased	no
O	O	contraceptive	yes
O	O	effectiveness	no
O	O	and	yes
O	O	increased	no
O	O	menstrual	no
O	O	irregularities	no
O	O	.	no

O	O	Potentiation	no
O	O	of	yes
B-group	B-group	coumarin-type	no
I-group	I-group	anticoagulants	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time/INR	no
O	O	.	no

O	O	Further	no
O	O	,	no
B-drug	B-drug	misoprostol	yes
O	O	is	yes
O	O	reported	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	synergistic	no
O	O	effect	no
O	O	with	yes
O	O	this	no
O	O	combination	yes
O	O	in	yes
O	O	ameliorating	no
O	O	intestinal	no
O	O	permeability	no
O	O	.	no

B-group	B-group	Phenothiazines	no
O	O	-	yes
O	O	Taking	no
B-drug	B-drug	piperazine	yes
O	O	and	yes
O	O	a	yes
B-group	B-group	phenothiazine	yes
O	O	together	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	convulsions	no
O	O	(	no
O	O	seizures	no
O	O	)	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	cohort	no
O	O	data	no
O	O	and	yes
O	O	selected	no
O	O	patient	no
O	O	data	no
O	O	from	no
O	O	clinical	no
O	O	trials	no
O	O	suggest	no
O	O	comparable	no
O	O	activity	yes
O	O	to	no
B-group	B-group	PI-based	no
O	O	regimens	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Dicumarol	yes
O	O	:	no
O	O	It	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
B-drug	B-drug	allopurinol	yes
O	O	prolongs	no
O	O	the	no
O	O	half-life	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	,	no
B-drug	B-drug	dicumarol	yes
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	GI	no
O	O	ulceration	no
O	O	and	yes
O	O	complications	no
O	O	compared	no
O	O	to	no
B-drug	B-drug	valdecoxib	yes
O	O	alone	no
O	O	.	no

O	O	as	yes
O	O	such	no
O	O	it	no
O	O	may	no
O	O	impair	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
O	O	any	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	Taken	no
O	O	together	no
O	O	,	no
O	O	these	no
O	O	findings	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	Kd	no
O	O	of	yes
O	O	D2	yes
O	O	in	yes
O	O	the	no
O	O	NAC	yes
O	O	and	yes
O	O	the	no
O	O	Bmax	no
O	O	of	yes
O	O	D2	yes
O	O	in	yes
O	O	the	no
O	O	STR	no
O	O	may	no
O	O	contribute	no
O	O	to	no
O	O	the	no
O	O	differences	no
O	O	in	yes
O	O	locomotor	no
O	O	responses	no
O	O	to	no
B-drug	B-drug	cocaine	yes
O	O	exposure	yes
O	O	in	yes
O	O	these	no
O	O	mouse	yes
O	O	lines	no
O	O	.	no

B-group	B-group	Barbiturates	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	.	no

B-drug	B-drug	Glucose	yes
O	O	,	no
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	caused	no
O	O	subnormal	no
O	O	insulin	yes
O	O	release	yes
O	O	and	yes
O	O	less	no
O	O	suppression	no
O	O	of	yes
O	O	glucagon	yes
O	O	release	yes
O	O	in	yes
O	O	the	no
O	O	diabectics	no
O	O	than	no
O	O	in	yes
O	O	the	no
O	O	normals	no
O	O	.	no

O	O	Nucleophosmin/B23	no
O	O	in	yes
O	O	serum-deprived	no
O	O	(	no
O	O	0	no
O	O	%	no
O	O	serum	yes
O	O	)	no
O	O	NIH-3T3	no
O	O	cells	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	highly	no
O	O	unstable	no
O	O	with	yes
O	O	a	yes
O	O	half-life	no
O	O	less	no
O	O	than	no
O	O	4	yes
O	O	h	yes
O	O	.	no

O	O	Although	no
B-drug	B-drug	deferasirox	yes
O	O	has	no
O	O	a	yes
O	O	lower	no
O	O	affinity	no
O	O	for	yes
B-drug	B-drug	aluminum	yes
O	O	than	no
O	O	for	yes
B-drug	B-drug	iron	yes
O	O	,	no
B-brand	B-brand	Exjade	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	with	yes
B-drug	B-drug	aluminum-containing	no
B-group	B-group	antacid	no
I-group	I-group	preparations	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	under	no
O	O	certain	no
O	O	circumstances	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
O	O	as	yes
O	O	prophylaxis	no
O	O	after	no
O	O	myocardial	no
O	O	infarction	no
O	O	,	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	no	yes
O	O	acceptable	no
O	O	alternatives	no
O	O	to	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-group	B-group	beta-blockers	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	COPD	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
B-drug	B-drug	clozapine	yes
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	increased	no
O	O	serum	yes
O	O	triglyceride	yes
O	O	and	yes
O	O	phospholipid	no
O	O	concentration	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
B-drug	B-drug	Digoxin	yes
O	O	concentrations	no
O	O	are	no
O	O	increased	no
O	O	by	no
O	O	about	no
O	O	15	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	carvedilol	yes
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	This	no
O	O	drug	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
B-group	B-group	anticholinergics	no
O	O	or	no
O	O	other	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	(	no
O	O	anticholinergic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	these	no
O	O	medications	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	may	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	and	yes
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	diuretic	no
O	O	and/or	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	is	yes
O	O	achieved	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	re-treated	no
O	O	with	yes
O	O	subsequent	no
O	O	cycles	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	until	no
O	O	neutrophils	no
O	O	recover	no
O	O	to	no
O	O	a	yes
O	O	level	no
O	O	1500	no
O	O	cells/mm3	no
O	O	and	yes
O	O	platelets	no
O	O	recover	no
O	O	to	no
O	O	a	yes
O	O	level	no
O	O	100,000	no
O	O	cells/mm3	no
O	O	.	no

B-group	B-group	Anabolic	no
I-group	I-group	steroids	no
O	O	(	no
O	O	particularly	no
O	O	C-17	no
O	O	alkylated	no
B-group	B-group	androgens	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	oxymetholone	yes
O	O	,	no
B-drug	B-drug	methandrostenolone	no
O	O	,	no
B-drug	B-drug	norethandrolone	yes
O	O	,	no
O	O	and	yes
O	O	similar	no
O	O	compounds	no
O	O	)	no
O	O	enhanced	no
O	O	tendency	no
O	O	toward	no
O	O	edema	no
O	O	.	no

O	O	Physicians	no
O	O	are	no
O	O	provided	no
O	O	this	no
O	O	information	no
O	O	to	no
O	O	increase	no
O	O	awareness	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	interactions	no
O	O	when	no
B-drug	B-drug	cinoxacin	yes
O	O	and	yes
O	O	certain	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	no	yes
O	O	significant	no
O	O	difference	no
O	O	in	yes
O	O	pharmacodynamic	no
O	O	effect	no
O	O	(	no
O	O	reduction	yes
O	O	in	yes
O	O	low-density	no
O	O	lipoprotein	yes
O	O	cholesterol	yes
O	O	levels	no
O	O	)	no
O	O	could	no
O	O	be	no
O	O	ascertained	no
O	O	between	yes
O	O	mealtime	no
O	O	dosing	no
O	O	and	yes
O	O	bedtime	no
O	O	dosing	no
O	O	.	no

O	O	5	yes
O	O	.	no

O	O	In	yes
O	O	diabetic	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	metabolic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	androgens	no
O	O	may	no
O	O	decrease	no
O	O	blood	yes
O	O	glucose	yes
O	O	and	yes
O	O	therefore	no
O	O	,	no
B-drug	B-drug	insulin	yes
O	O	requirements	no
O	O	.	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	hypertriglyceridemia	no
O	O	is	yes
O	O	1	yes
O	O	patient	no
O	O	in	yes
O	O	4	yes
O	O	on	no
B-brand	B-brand	Accutane	yes
O	O	therapy	no

B-drug	B-drug	Dexamethasone	yes
O	O	and	yes
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	similarly	no
O	O	inhibit	no
O	O	and	yes
O	O	stimulate	no
B-drug_n	B-drug_n	EGF-	no
O	O	or	no
B-drug	B-drug	insulin-induced	no
O	O	proliferation	no
O	O	of	yes
O	O	prostatic	no
O	O	epithelium	no
O	O	.	no

O	O	Cold	yes
O	O	and	yes
O	O	flu	no
O	O	remedies	no
O	O	.	no

B-drug	B-drug	Diflunisal	yes
O	O	decreased	no
O	O	the	no
O	O	hyperuricemic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	No	yes
O	O	other	no
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	were	no
O	O	changed	no
O	O	.	no

O	O	Use	no
O	O	of	yes
B-group	B-group	Antithrombotics	no
B-brand	B-brand	Aspirin	yes
O	O	and	yes
B-drug	B-drug	heparin	yes
O	O	have	no
O	O	been	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	and	yes
O	O	following	no
O	O	infusions	no
O	O	of	yes
B-brand	B-brand	Activase	yes
O	O	in	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	acute	no
O	O	myocardial	no
O	O	infarction	no
O	O	or	no
O	O	pulmonary	no
O	O	embolism	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	from	no
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	which	no
O	O	eight	no
O	O	HIV-infected	no
O	O	individuals	no
O	O	were	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	zidovudine	yes
O	O	,	no
O	O	8	yes
O	O	+/-	no
O	O	0.4	no
O	O	mg/kg/day	no
O	O	,	no
O	O	showed	no
O	O	that	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	zidovudine	yes
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	during	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	,	no
O	O	100	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	including	no
B-drug	B-drug	norfloxacin	yes
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	a	yes
B-group	B-group	sulfonylurea	no
I-group	I-group	agent	yes
O	O	)	no
O	O	has	no
O	O	,	no
O	O	on	no
O	O	rare	no
O	O	occasions	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	severe	no
O	O	hypoglycemia	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	may	no
O	O	also	no
O	O	cause	no
O	O	increased	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	O	glucose	yes
O	O	,	no
O	O	alkaline	yes
O	O	phosphatase	yes
O	O	,	no
O	O	and	yes
O	O	gamma	yes
O	O	glutamyl	yes
O	O	transpeptidase	no
O	O	(	no
O	O	GGT	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	metabolic	no
O	O	interactions	no
O	O	caused	no
O	O	by	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	an	no
O	O	individual	no
O	O	isoform	yes
O	O	is	yes
O	O	therefore	no
O	O	minimized	no
O	O	.	no

O	O	"	no
O	O	hippocampal-independent	no
O	O	"	no

O	O	Repeated	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	given	no
O	O	prior	no
O	O	to	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	in	yes
O	O	human	yes
O	O	trials	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
B-drug	B-drug	propranolol	yes
O	O	absorption	no
O	O	.	no

B-drug	B-drug	Acetaminophen	yes
O	O	and	yes
B-drug	B-drug	methotrexate	yes
O	O	-	yes
B-drug	B-drug	L-methionine	yes
O	O	may	no
O	O	decrease	no
O	O	hepatic	no
O	O	toxicity	no
O	O	in	yes
O	O	those	no
O	O	with	yes
B-drug	B-drug	acetaminophen	yes
O	O	overdosage	no
O	O	or	no
O	O	in	yes
O	O	those	no
O	O	taking	no
B-drug	B-drug	methotrexate	yes
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	and	yes
B-drug	B-drug	Charcoal	yes
O	O	Administration	no
O	O	of	yes
B-drug	B-drug	cholestyramine	yes
O	O	or	no
B-drug	B-drug	activated	yes
I-drug	I-drug	charcoal	yes
O	O	in	yes
O	O	patients	no
O	O	(	no
O	O	n=13	no
O	O	)	no
O	O	and	yes
O	O	volunteers	no
O	O	(	no
O	O	n=96	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	rapid	no
O	O	and	yes
O	O	significant	no
O	O	decrease	no
O	O	in	yes
O	O	plasma	yes
O	O	M1	yes
O	O	(	no
O	O	the	no
O	O	active	no
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	leflunomide	yes
O	O	)	no
O	O	concentration	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-drug	B-drug	diflunisal	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	fatal	no
O	O	gastrointestinal	no
O	O	hemorrhage	no
O	O	.	no

O	O	-	yes
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	lofexidine	yes
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	may	no
O	O	add	no
O	O	to	no
O	O	or	no
O	O	potentiate	no
O	O	the	no
O	O	therapeutic	no
O	O	effect	no
O	O	of	yes
O	O	other	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	.	no

O	O	dosage	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no
O	O	)	no

O	O	Synergism	no
O	O	was	no
O	O	observed	no
O	O	when	no
B-drug_n	B-drug_n	GL	no
O	O	was	no
O	O	combined	no
O	O	with	yes
B-drug	B-drug	cefazolin	yes
O	O	against	yes
O	O	Bacillus	yes
O	O	subtilis	no
O	O	and	yes
O	O	Klebsiella	no
O	O	oxytoca	no
O	O	.	no

B-drug	B-drug	Etonogestrel	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	medications	no
O	O	:	no
B-drug	B-drug	acetaminophen	yes
O	O	(	no
B-brand	B-brand	Tylenol	yes
O	O	)	no
O	O	,	no
B-group	B-group	antibiotics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ampicillin	yes
O	O	and	yes
B-drug	B-drug	tetracycline	yes
O	O	,	no
B-group	B-group	anticonvulsants	no
O	O	(	no
B-brand	B-brand	Dilantin	yes
O	O	,	no
B-drug	B-drug	Phenobarbital	yes
O	O	,	no
B-brand	B-brand	Tegretol	yes
O	O	,	no
B-brand	B-brand	Trileptal	yes
O	O	,	no
B-brand	B-brand	Topamax	yes
O	O	,	no
B-brand	B-brand	Felbatol	yes
O	O	)	no
O	O	,	no
B-group	B-group	antifungals	no
O	O	(	no
B-brand	B-brand	Gris-PEG	yes
O	O	,	no
B-brand	B-brand	Nizoral	yes
O	O	,	no
B-brand	B-brand	Sporanox	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	atorvastatin	yes
O	O	(	no
B-brand	B-brand	Lipitor	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	clofibrate	yes
O	O	(	no
B-brand	B-brand	Atromid-S	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	(	no
B-brand	B-brand	Neoral	yes
O	O	,	no
B-brand	B-brand	Sandimmune	yes
O	O	)	no
O	O	,	no
O	O	HIV	no
O	O	drugs	no
O	O	classified	no
O	O	as	yes
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-brand	B-brand	Agenerase	yes
O	O	,	no
B-brand	B-brand	Crixivan	yes
O	O	,	no
B-brand	B-brand	Fortovase	yes
O	O	,	no
B-brand	B-brand	Invirase	yes
O	O	,	no
B-brand	B-brand	Kaletra	yes
O	O	,	no
B-brand	B-brand	Norvir	yes
O	O	,	no
B-brand	B-brand	Viracept	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	morphine	yes
O	O	(	no
B-brand	B-brand	Astramorph	yes
O	O	,	no
B-brand	B-brand	Kadian	yes
O	O	,	no
B-brand	B-brand	MS	yes
I-brand	I-brand	Contin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	prednisolone	yes
O	O	(	no
B-brand	B-brand	Prelone	yes
O	O	)	no
O	O	,	no
B-brand	B-brand	rifadin	yes
O	O	(	no
B-drug	B-drug	rifampin	yes
O	O	)	no
O	O	,	no
O	O	St.	yes
O	O	Johns	yes
O	O	wort	yes
O	O	,	no
B-drug	B-drug	temazepam	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	(	no
B-brand	B-brand	Theo-Dur	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	.	no

O	O	The	no
O	O	three	no
O	O	study	no
O	O	periods	no
O	O	were	no
O	O	separated	no
O	O	by	no
O	O	a	yes
O	O	21-day	yes
O	O	washout	no
O	O	phase	no
O	O	.	no

O	O	Nephrotoxic	no
O	O	agents	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	VISTIDE	yes
O	O	and	yes
O	O	agents	yes
O	O	with	yes
O	O	nephrotoxic	no
O	O	potential	no
O	O	[	no
O	O	e.g.	no
O	O	,	no
O	O	intravenous	yes
B-group	B-group	aminoglycosides	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	tobramycin	yes
O	O	,	no
B-drug	B-drug	gentamicin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	amikacin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
B-drug	B-drug	foscarnet	yes
O	O	,	no
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	,	no
B-drug	B-drug	vancomycin	yes
O	O	,	no
O	O	and	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	]	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	O	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	hydroxides	no
O	O	does	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	B-drug	absorption	no
O	O	of	yes
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Tell	no
O	O	your	no
O	O	doctor	no
O	O	if	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	:	no
B-group	B-group	blood	yes
I-group	O	thinners	no
O	O	(	no
B-brand	B-brand	Coumadin	yes
O	O	)	no
O	O	other	no
B-group	B-group	antidepressants	no
B-drug	B-drug	metoprolol	yes
B-group	B-group	antihistamines	no
B-drug	B-drug	carbamazepine	yes
O	O	(	no
B-brand	B-brand	Tegretol	yes
O	O	)	no
B-drug	B-drug	cimetidine	yes
O	O	(	no
B-brand	B-brand	Tagamet	yes
O	O	)	no
B-group	B-group	estrogens	yes
B-drug	B-drug	fluoxetine	yes
O	O	(	no
B-brand	B-brand	Prozac	yes
O	O	)	no
O	O	intraconazole	no
O	O	(	no
B-brand	B-brand	Sporanox	yes
O	O	)	no
B-drug	B-drug	ketoconazole	yes
O	O	(	no
B-brand	B-brand	Nizoral	yes
O	O	)	no
B-drug	B-drug	levodopa	yes
I-drug	I-drug	lithium	yes
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	birth	no
O	O	control	no
O	O	pills	no
O	O	sleeping	no
O	O	pills	no
O	O	thyroid	yes
O	O	medications	no

O	O	and/or	no
O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	See	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	,	no
O	O	Pharmacokinetics	no
O	O	and	yes
O	O	Drug	yes
O	O	Interactions	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	ototoxicity	no
O	O	.	no

B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	as	yes
O	O	this	no
O	O	could	no
O	O	create	no
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	hypercalcemia	no
O	O	.	no

O	O	A	yes
O	O	variety	no
O	O	of	yes
O	O	neurological	no
O	O	toxic	no
O	O	effects	no
O	O	and	yes
O	O	malignant	no
O	O	hyperpyrexia	no
O	O	can	no
O	O	occur	no
O	O	,	no
O	O	sometimes	no
O	O	with	yes
O	O	fatal	no
O	O	results	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	is	yes
O	O	available	no
O	O	about	no
O	O	the	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	cephalexin	yes
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	following	no
O	O	multiple	no
O	O	doses	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	The	no
O	O	groups	no
O	O	then	no
O	O	took	no
O	O	500	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	as	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	(	no
O	O	day	no
O	O	0	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Indinavir	yes

O	O	When	no
O	O	other	no
O	O	potent	no
O	O	parental	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	diazoxide	yes
O	O	,	no
O	O	are	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	hydralazine	yes
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	continuously	no
O	O	observed	no
O	O	for	yes
O	O	several	no
O	O	hours	no
O	O	for	yes
O	O	any	no
O	O	excessive	no
O	O	fall	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	Agents	yes
O	O	Increasing	no
O	O	Serum	yes
O	O	Potassium	yes
O	O	:	no
B-brand	B-brand	PRINIVIL	yes
O	O	attenuates	no
O	O	potassium	yes
O	O	loss	no
O	O	caused	no
O	O	by	no
B-group	B-group	thiazide-type	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Effects	no
O	O	were	no
O	O	already	no
O	O	seen	no
O	O	with	yes
O	O	doses	no
O	O	corresponding	no
O	O	to	no
O	O	relevant	no
O	O	plasma	yes
O	O	levels	no
O	O	in	yes
O	O	humans	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	intracellular	no
O	O	phosphorylation	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	to	no
O	O	its	no
O	O	three	no
O	O	metabolites	no
O	O	(	no
O	O	including	no
O	O	the	no
O	O	active	no
O	O	zalcitabine	yes
O	O	triphosphate	yes
O	O	metabolite	yes
O	O	)	no
O	O	was	no
O	O	significantly	no
O	O	inhibited	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	large	no
O	O	,	no
O	O	placebo-controlled	no
O	O	osteoporosis	no
O	O	Treatment	no
O	O	Study	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	were	no
O	O	taken	no
O	O	by	no
O	O	62	no
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	2946	no
O	O	patients	no
O	O	.	no

O	O	Certain	no
O	O	drugs	no
O	O	including	no
B-group	B-group	thiazides	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	products	no
O	O	,	no
O	O	and	yes
B-group	B-group	sympathomimetics	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	Starlix	yes
O	O	and	yes
O	O	other	no
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	drugs	no
O	O	.	no

B-group	B-group	Neuromuscular	no
I-group	I-group	Blockers	no
O	O	:	no
O	O	In	yes
O	O	one	no
O	O	study	no
O	O	of	yes
O	O	10	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	PRECEDEX	yes
O	O	for	yes
O	O	45	yes
O	O	minutes	no
O	O	at	yes
O	O	a	yes
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
O	O	1	yes
O	O	(	no
O	O	one	no
O	O	)	no
O	O	ng/mL	no
O	O	resulted	no
O	O	in	yes
O	O	no	yes
O	O	clinically	no
O	O	meaningful	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	magnitude	no
O	O	or	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	associated	no
O	O	with	yes
B-drug	B-drug	rocuronium	yes
O	O	administration	no
O	O	.	no

O	O	A	yes
O	O	variety	no
O	O	of	yes
O	O	parametric	no
O	O	dose-response	no
O	O	models	no
O	O	based	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	normal	yes
O	O	or	no
O	O	logistic	no
O	O	probability	no
O	O	distribution	no
O	O	have	no
O	O	been	no
O	O	proposed	no
O	O	in	yes
O	O	the	no
O	O	literature	no
O	O	.	no

O	O	Drugs	no
O	O	with	yes
O	O	parasympathomimetic	no
O	O	effects	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	cevimeline	yes
O	O	can	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	have	no
O	O	additive	no
O	O	effects	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-brand	B-brand	Lodine	yes
O	O	should	no
O	O	not	no
O	O	require	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	14	yes
O	O	normal	yes
O	O	male	no
O	O	and	yes
O	O	female	no
O	O	volunteers	no
O	O	suggests	no
O	O	that	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	The	no
O	O	IC	no
O	O	(	no
O	O	50	yes
O	O	)	no
O	O	was	no
O	O	about	no
O	O	120	no
O	O	microgram/ml	no
O	O	.	no

O	O	-	yes
B-group	B-group	Phenothiazines	no
O	O	(	no
B-drug	B-drug	acetophenazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Tindal	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	chlorpromazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Thorazine	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	fluphenazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Prolixin	yes
O	O	]	no
O	O	,	no
B-brand	B-brand	mesoridazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Serentil	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	perphenazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Trilafon	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	prochlorperazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Compazine	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	promazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Sparine	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	promethazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Phenergan	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	thioridazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Mellaril	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	trifluoperazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Stelazine	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	triflupromazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Vesprin	yes
O	O	]	no
O	O	,	no
B-drug	B-drug	trimeprazine	yes
O	O	[	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Temaril	yes
O	O	]	no
O	O	)	no
O	O	or	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-drug	B-drug	Finasteride	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	circulating	no
O	O	levels	no
O	O	of	yes
O	O	cortisol	yes
O	O	,	no
O	O	thyroid-stimulating	no
O	O	hormone	yes
O	O	,	no
O	O	or	no
O	O	thyroxine	no
O	O	,	no
O	O	nor	yes
O	O	did	no
O	O	it	no
O	O	affect	no
O	O	the	no
O	O	plasma	yes
O	O	lipid	no
O	O	profile	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	total	yes
O	O	cholesterol	yes
O	O	,	no
O	O	low-density	no
O	O	lipoproteins	no
O	O	,	no
O	O	high-density	no
O	O	lipoproteins	no
O	O	and	yes
O	O	triglycerides	yes
O	O	)	no
O	O	or	no
O	O	bone	no
O	O	mineral	no
O	O	density	no
O	O	.	no

O	O	Some	no
B-group	B-group	quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Simultaneous	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	SPRYCEL	yes
O	O	with	yes
B-group	B-group	antacids	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	procainamide	yes
O	O	;	no

O	O	Your	no
O	O	doctor	no
O	O	or	no
O	O	pharmacist	no
O	O	can	no
O	O	give	no
O	O	you	no
O	O	more	no
O	O	information	no
O	O	on	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

B-drug	B-drug	Clonidine	yes
I-drug	I-drug	hydrochloride	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	CNS-depressive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	or	no
O	O	other	no
B-group	B-group	sedatives	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	pharmacokinetic	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	isradipine	yes
O	O	and	yes
O	O	racemic	yes
B-drug	B-drug	warfarin	yes
O	O	was	no
O	O	seen	no
O	O	when	no
O	O	two	no
O	O	single	yes
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	0.7	no
O	O	mg/kg	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	were	no
O	O	administered	no
O	O	during	no
O	O	11	yes
O	O	days	no
O	O	of	yes
O	O	multipledose	no
O	O	treatment	no
O	O	with	yes
O	O	5	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
B-drug	B-drug	isradipine	yes
O	O	.	no

O	O	These	no
O	O	events	no
O	O	were	no
O	O	also	no
O	O	reported	no
O	O	to	no
O	O	occur	no
O	O	when	no
O	O	contrast	no
O	O	media	no
O	O	was	no
O	O	given	no
O	O	several	no
O	O	months	no
O	O	after	no
O	B-drug	interleukin-2	yes
O	O	treatment	no
O	O	.	no

O	O	reliable	no
O	O	estimates	no
O	O	of	yes
O	O	the	no
O	O	prevalence	no
O	O	of	yes
O	O	reduced	yes
O	O	P450	no
O	O	2D6	no
O	O	isozyme	no
O	O	activity	yes
O	O	among	no
O	O	Asian	yes
O	O	,	no
O	O	African	no
O	O	and	yes
O	O	other	no
O	O	populations	no
O	O	are	no
O	O	not	no
O	O	yet	no
O	O	available	no
O	O	.	no

O	O	Established	no
O	O	and	yes
O	O	Other	no
O	O	Potentially	no
O	O	Significant	no
O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	Alteration	no
O	O	in	yes
O	O	Dose	no
O	O	or	no
O	O	Regimen	no
O	O	May	no
O	O	Be	no
O	O	Recommended	no
O	O	Based	no
O	O	on	no
O	O	Drug	yes
O	O	Interaction	no
O	O	Studies	no
O	O	or	no
O	O	Predicted	no
O	O	Interaction	no

O	O	.	no

O	O	In	yes
O	O	an	no
O	O	in	yes
O	O	vivo	no
O	O	metabolic	no
O	O	probe	no
O	O	study	no
O	O	,	no
B-drug	B-drug	alosetron	yes
O	O	did	no
O	O	not	no
O	O	inhibit	no
O	O	CYP2E1	no
O	O	but	no
O	O	did	no
O	O	produce	no
O	O	30	yes
O	O	%	no
O	O	inhibition	no
O	O	of	yes
O	O	both	no
O	O	CYP1A2	no
O	O	and	yes
O	O	N-acetyltransferase	no
O	O	.	no

O	O	2	yes
O	O	.	no

B-drug	B-drug	Saquinavir	yes
O	O	:	no
O	O	The	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	HIVID	yes
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	ZDV	yes
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	(	no
O	O	as	yes
O	O	triple	yes
O	O	combination	yes
O	O	)	no
O	O	in	yes
O	O	adults	no
O	O	.	no

B-group	B-group	Serotonergic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	linezolid	yes
O	O	and	yes
B-group	B-group	serotonergic	no
I-group	I-group	agents	yes
O	O	was	no
O	O	not	no
O	O	associated	no
O	O	with	yes
O	O	serotonin	yes
O	O	syndrome	no
O	O	in	yes
O	O	Phase	no
O	O	1	yes
O	O	,	no
O	O	2	yes
O	O	or	no
O	O	3	yes
O	O	studies	no
O	O	.	no

O	O	In	yes
O	O	an	no
O	O	analysis	no
O	O	of	yes
O	O	the	no
O	O	supraventricular	no
O	O	arrhythmia	no
O	O	and	yes
O	O	DIAMOND	no
O	O	patient	no
O	O	populations	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	verapamil	yes
O	O	with	yes
B-drug	B-drug	dofetilide	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	higher	no
O	O	occurrence	no
O	O	of	yes
O	O	torsade	no
O	O	de	yes
O	O	pointes	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	,	no
B-drug	B-drug	Nimodipine	yes
O	O	and	yes
B-drug	B-drug	Losartan	yes
O	O	:	no
B-drug	B-drug	Bosentan	yes
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	nimodipine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	losartan	yes
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	.	no

O	O	In	yes
O	O	general	no
O	O	,	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	shows	no
O	O	no	yes
O	O	signs	no
O	O	of	yes
O	O	sedation	no
O	O	within	no
O	O	2	yes
O	O	hours	no
O	O	after	no
O	O	a	yes
O	O	1-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	flumazenil	yes
O	O	,	no
O	O	serious	no
O	O	resedation	no
O	O	at	yes
O	O	a	yes
O	O	later	no
O	O	time	no
O	O	is	yes
O	O	unlikely	no
O	O	.	no

O	O	Mice	no
O	O	from	no
O	O	the	no
O	O	20th	no
O	O	generation	no
O	O	of	yes
O	O	three	no
O	O	lines	no
O	O	divergently	no
O	O	selected	no
O	O	for	yes
O	O	response	no
O	O	to	no
B-drug	B-drug	pentobarbital-induced	no
O	O	sedation	no
O	O	times	no
O	O	[	no
O	O	long-sedation	no
O	O	time	no
O	O	(	no
O	O	LST	no
O	O	)	no
O	O	,	no
O	O	short	no
O	O	sedation	no
O	O	time	no
O	O	(	no
O	O	SST	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	randomly	no
O	O	bred	no
O	O	control	no
O	O	(	no
O	O	RBC	no
O	O	)	no
O	O	]	no
O	O	were	no
O	O	used	no
O	O	to	no
O	O	study	no
B-drug	B-drug	cocaine-induced	no
O	O	behavioral	no
O	O	sensitization	no
O	O	.	no

B-drug	B-drug	Bosentan	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP2C9	no
O	O	and	yes
O	O	CYP3A4	no
O	O	.	no

O	O	No	yes
O	O	teratogenic	no
O	O	effects	no
O	O	were	no
O	O	seen	no
O	O	in	yes
O	O	the	no
O	O	offspring	no
O	O	delivered	no
O	O	at	yes
O	O	term	no
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	:	no
B-drug	B-drug	Tiagabine	yes
O	O	causes	no
O	O	a	yes
O	O	slight	no
O	O	decrease	no
O	O	(	no
O	O	about	no
O	O	10	yes
O	O	%	no
O	O	)	no
O	O	in	yes
O	O	steady-state	no
B-drug	B-drug	valproate	yes
O	O	concentrations	no
O	O	.	no

O	O	The	no
O	O	risks	no
O	O	of	yes
O	O	using	no
B-drug	B-drug	Clozapine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	.	no

O	O	when	no
O	O	the	no
O	O	drugs	no
O	O	were	no
O	O	administered	no
O	O	together	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	were	no
O	O	additive	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	suggested	no
O	O	to	no
O	O	monitor	no
O	O	both	no
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	synergistic	no
O	O	anticonvulsant	no
O	O	action	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	Since	no
B-drug	B-drug	caffeine	yes
O	O	is	yes
O	O	frequently	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	acetaminophen	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	of	yes
O	O	clinical	no
O	O	interest	no
O	O	to	no
O	O	study	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	on	no
O	O	the	no
O	O	hepatotoxicity	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	No	yes
O	O	significant	no
O	O	differences	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	mean	no
B-drug	B-drug	phenytoin	yes
O	O	AUC	no
O	O	,	no
O	O	C	yes
O	O	max	no
O	O	,	no
O	O	C	yes
O	O	min	no
O	O	or	no
O	O	T	yes
O	O	max	no
O	O	(	no
O	O	although	no
O	O	C	yes
O	O	max	no
O	O	increased	no
O	O	by	no
O	O	11	yes
O	O	%	no
O	O	)	no
O	O	when	no
O	O	extended	yes
B-drug	B-drug	phenytoin	yes
I-drug	I-drug	sodium	yes
O	O	capsules	no
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	tid	no
O	O	)	no
O	O	were	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	lomefloxacin	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	qd	no
O	O	)	no
O	O	for	yes
O	O	five	no
O	O	days	no
O	O	in	yes
O	O	15	yes
O	O	healthy	no
O	O	males	no
O	O	.	no

O	O	These	no
O	O	precautions	no
O	O	probably	no
O	O	should	no
O	O	apply	no
O	O	to	no
B-drug	B-drug	digitoxin	yes
O	O	administration	no
O	O	as	yes
O	O	well	no
O	O	.	no

B-drug	B-drug	Phospholine	yes
I-drug	I-drug	Iodide	yes
O	O	potentiates	no
O	O	other	no
B-group	B-group	cholinesterase	no
I-group	I-group	inhibitors	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	succinylcholine	yes
O	O	or	no
B-drug_n	B-drug_n	organophosphate	no
O	O	and	yes
B-group	B-drug_n	carbamate	yes
I-group	O	insecticides	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	heart	no
O	O	block	yes
O	O	produced	no
O	O	by	no
O	O	other	no
O	O	agents	yes
O	O	.	no

O	O	Avoid	no
O	O	concomitant	no
O	O	use	no
O	O	unless	no
O	O	necessary	no
O	O	to	no
O	O	control	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	.	no

B-group	B-group	Monoamine	no
I-group	I-group	Oxidase	yes
I-group	I-group	Inhibitors	no
O	O	(	no
B-group	B-group	MAOIs	no
O	O	)	no

B-drug	B-drug	Fluoxetine	yes
O	O	,	no
B-group	B-group	OCs	no
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	(	no
O	O	exercise	no
O	O	caution	no
O	O	)	no
O	O	.	no

O	O	Powder	yes
O	O	x-ray	no
O	O	diffraction	no
O	O	,	no
O	O	differential	no
O	O	scanning	no
O	O	calorimetry	no
O	O	,	no
O	O	differential	no
O	O	thermal	no
O	O	analysis	no
O	O	,	no
O	O	and	yes
O	O	scanning	no
O	O	electron	no
O	O	microscopy	no
O	O	were	no
O	O	used	no
O	O	to	no
O	O	characterize	no
O	O	the	no
O	O	aerosol	no
O	O	particles	no
O	O	and	yes
O	O	starting	no
O	O	material	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	b-lactam	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	with	yes
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	cefditoren	yes
O	O	,	no
O	O	with	yes
O	O	a	yes
O	O	49	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	Cmax	no
O	O	,	no
O	O	a	yes
O	O	122	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	AUC	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	53	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	half-life	no
O	O	.	no

O	O	The	no
O	O	hypoglycemic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	when	no
B-brand	B-brand	Atromid-S	yes
O	O	is	yes
O	O	given	no
O	O	concurrently	no
O	O	.	no

O	O	Hepatotoxic	no
O	O	medications	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	high-dose	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
O	O	may	no
O	O	impair	no
O	O	liver	yes
O	O	function	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	toxicity	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	clear	no
O	O	whether	no
O	O	this	no
O	O	represents	no
O	O	an	no
O	O	interaction	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	or	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	more	no
O	O	severe	no
O	O	structural	no
O	O	heart	no
O	O	disease	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-drug	B-drug	digoxin	yes
O	O	;	no

O	O	Some	no
O	O	reports	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	thiazides	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	causes	no
O	O	hypercalcemia	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	paper	no
O	O	,	no
O	O	we	no
O	O	show	no
O	O	that	no
O	O	the	no
O	O	precipitate	no
O	O	is	yes
O	O	formed	no
O	O	after	no
O	O	the	no
O	O	interaction	no
O	O	of	yes
B-drug_n	B-drug_n	jacalin	no
O	O	and	yes
O	O	the	no
O	O	serum	yes
O	O	protein	yes
O	O	added	no
O	O	to	no
O	O	the	no
O	O	culture	no
O	O	medium	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	hypotensive	no
O	O	effects	no
O	O	can	no
O	O	be	no
O	O	minimized	no
O	O	by	no
O	O	either	no
O	O	discontinuing	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	or	no
O	O	increasing	no
O	O	salt	yes
O	O	intake	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	fosinopril	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Several	no
O	O	beta-adrenergic	no
O	O	neuroeffector	no
O	O	defects	no
O	O	occur	no
O	O	in	yes
O	O	heart	no
O	O	failure	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	basis	no
O	O	of	yes
O	O	this	no
O	O	drug	yes
O	O	interaction	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	but	no
O	O	should	no
O	O	be	no
O	O	noted	no
O	O	when	no
B-drug	B-drug	allopurinol	yes
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	already	no
O	O	on	no
B-drug	B-drug	dicumarol	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-drug	B-drug	Piperacillin	yes
I-drug	I-drug	sodium	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	The	no
O	O	onset	no
O	O	of	yes
O	O	80	yes
O	O	%	no
O	O	of	yes
O	O	those	no
O	O	"	no
O	O	epidemic	no
O	O	"	no

O	O	Testicular	no
O	O	atrophy	no
O	O	was	no
O	O	seen	no
O	O	with	yes
B-drug	B-drug	dexrazoxane	yes
O	O	administration	no
O	O	at	yes
O	O	doses	no
O	O	as	yes
O	O	low	yes
O	O	as	yes
O	O	30	yes
O	O	mg/kg	no
O	O	weekly	yes
O	O	for	yes
O	O	6	yes
O	O	weeks	no
O	O	in	yes
O	O	rats	no
O	O	(	no
O	O	1/3	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	a	yes
O	O	mg/m	no
O	O	2	yes
O	O	basis	no
O	O	)	no
O	O	and	yes
O	O	as	yes
O	O	low	yes
O	O	as	yes
O	O	20	yes
O	O	mg/kg	no
O	O	weekly	yes
O	O	for	yes
O	O	13	yes
O	O	weeks	no
O	O	in	yes
O	O	dogs	no
O	O	(	no
O	O	approximately	no
O	O	equal	no
O	O	to	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	a	yes
O	O	mg/m	no
O	O	2	yes
O	O	basis	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	generally	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	because	no
O	O	they	no
O	O	reduce	no
O	O	its	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	O	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	Co-medications	no
O	O	that	no
O	O	induce	no
O	O	CYP3A4	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	or	no
O	O	St	yes
O	O	.	no

O	O	We	no
O	O	propose	no
O	O	these	no
O	O	pharmacokinetic	no
O	O	changes	no
O	O	to	no
O	O	be	no
O	O	the	no
O	O	underlying	no
O	O	mechanism	no
O	O	for	yes
O	O	the	no
O	O	reduction	yes
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	cytotoxicity	no
O	O	by	no
B-drug_n	B-drug_n	misonidazole	yes
O	O	.	no

O	O	General	no
O	O	Interactions	no
O	O	:	no
O	O	Certain	no
O	O	drugs	no
O	O	could	no
O	O	increase	no
O	O	the	no
O	O	likelihood	no
O	O	of	yes
O	O	potentially	no
O	O	serious	no
O	O	adverse	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

O	O	The	no
O	O	response	no
O	O	to	no
B-brand	B-brand	Factrel	yes
O	O	may	no
O	O	be	no
O	O	blunted	no
O	O	by	no
B-group	B-group	phenothiazines	no
O	O	and	yes
B-group	B-group	dopamine	yes
I-group	I-group	antagonists	no
O	O	which	no
O	O	cause	no
O	O	a	yes
O	O	rise	no
O	O	in	yes
O	O	prolactin	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	when	no
O	O	beginning	no
O	O	,	no
O	O	discontinuing	no
O	O	,	no
O	O	or	no
O	O	changing	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	DIAMOX	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	primidone	yes
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	have	no
O	O	their	no
O	O	plasma	yes
O	O	concentration	no
O	O	altered	no
O	O	by	no
B-brand	B-brand	Gleevec	yes
I-brand	I-brand	Gleevec	yes
O	O	increases	no
O	O	the	no
O	O	mean	no
O	O	cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	simvastatin	yes
O	O	(	no
O	O	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	2-	no
O	O	and	yes
O	O	3.5-fold	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	suggesting	no
O	O	an	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	CYP3A4	no
O	O	by	no
B-brand	B-brand	Gleevec	yes
O	O	.	no

O	O	While	no
O	O	all	yes
O	O	the	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	citalopram	yes
O	O	,	no
B-drug	B-drug	escitalopram	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	inhibit	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	they	no
O	O	may	no
O	O	vary	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	inhibition	no
O	O	.	no

O	O	During	no
O	O	clinical	no
O	O	trials	no
O	O	,	no
B-drug	B-drug	iloprost	yes
O	O	was	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	anticoagulants	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	analgesics	no
O	O	,	no
B-group	B-group	antipyretics	no
O	O	,	no
B-group	B-group	nonsteroidal	no
I-group	I-group	antiinflammatories	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	medications	no
O	O	.	no

O	O	Prolonged	no
O	O	daily	no
O	O	administration	no
O	O	of	yes
B-drug_n	B-drug_n	picrotoxin	yes
O	O	in	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	1	yes
O	O	mg/kg	no
O	O	results	no
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	brain	yes
O	O	edema	no
O	O	.	no

O	O	The	no
O	O	superiority	no
O	O	of	yes
B-drug	B-drug	efavirenz	yes
O	O	over	no
B-drug	B-drug	indinavir-based	no
O	O	regimens	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	comparative	no
O	O	data	no
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	high	yes
O	O	viral	no
O	O	loads	no
O	O	.	no

O	O	and	yes
O	O	by	no
O	O	observations	no
O	O	now	no
O	O	appearing	no
O	O	on	no
O	O	the	no
O	O	relation	no
O	O	between	yes
O	O	plasma	yes
O	O	drug	yes
O	O	levels	no
O	O	and	yes
O	O	drug	yes
O	O	effects	no
O	O	,	no
O	O	both	no
O	O	therapeutic	no
O	O	and	yes
O	O	toxic	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	not	no
O	O	to	no
O	O	use	no
O	O	such	no
O	O	methods	no
O	O	for	yes
O	O	12-24	no
O	O	hours	no
O	O	after	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Omniscan	yes
O	O	.	no

O	O	Cardiovascular	no
O	O	:	no
O	O	Hypotension	no
O	O	,	no
O	O	bradycardia	no
O	O	,	no
O	O	and	yes
O	O	hypertension	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	during	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	,	no
O	O	but	no
O	O	generally	no
O	O	do	no
O	O	not	no
O	O	require	no
O	O	treatment	no
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	oral	yes
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	)	no
O	O	diminished	no
O	O	antidiabetic	no
O	O	effect	no
O	O	.	no

B-group	B-group	Digitalis	yes
O	O	toxicity	no
O	O	may	no
O	O	be	no
O	O	aggravated	no
O	O	by	no
O	O	the	no
O	O	initial	no
O	O	release	yes
O	O	of	yes
O	O	norepinephrine	yes
O	O	caused	no
O	O	by	no
B-drug	B-drug	Bretylium	yes
I-drug	I-drug	Tosylate	yes
O	O	Injection	yes
O	O	.	no

O	O	The	no
O	O	dissolution	no
O	O	rate	no
O	O	of	yes
O	O	the	no
O	O	aerosol	no
O	O	particles	no
O	O	in	yes
O	O	saline	yes
O	O	was	no
O	O	low	yes
O	O	and	yes
O	O	variable	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	because	no
O	O	both	no
O	O	of	yes
O	O	these	no
O	O	compounds	no
O	O	have	no
O	O	CNS	no
O	O	effects	no
O	O	,	no
O	O	an	no
O	O	additive	no
O	O	pharmacodynamic	no
O	O	effect	no
O	O	is	yes
O	O	possible	no
O	O	.	no

O	O	Pediatric	yes
O	O	Use	no
O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	FASLODEX	yes
O	O	in	yes
O	O	pediatric	yes
O	O	patients	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	The	no
O	O	steady-state	no
O	O	Cmin	no
O	O	increased	no
O	O	to	no
O	O	78	no
O	O	14	yes
O	O	micrograms/mL	no
O	O	when	no
O	O	1200	no
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	was	no
O	O	coadministered	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	examine	no
O	O	some	no
O	O	molecular	yes
O	O	mechanisms	no
O	O	of	yes
B-drug_n	B-drug_n	PCP-induced	no
O	O	behavioral	no
O	O	changes	no
O	O	,	no
O	O	Northern	no
O	O	blot	no
O	O	analysis	no
O	O	of	yes
O	O	total	yes
O	O	RNA	yes
O	O	from	no
O	O	prefrontal	no
O	O	cortical	no
O	O	tissues	no
O	O	of	yes
O	O	mice	no
O	O	treated	no
O	O	with	yes
B-drug_n	B-drug_n	PCP	yes
O	O	,	no
B-drug_n	B-drug_n	DCG-IV	no
O	O	,	no
O	O	and	yes
B-drug_n	B-drug_n	L-CCG-1	no
O	O	was	no
O	O	carried	no
O	O	out	no
O	O	.	no

B-drug	B-drug	Clonidine	yes
O	O	therapy	no
O	O	can	no
O	O	then	no
O	O	be	no
O	O	discontinued	no
O	O	several	no
O	O	days	no
O	O	later	no
O	O	by	no
O	O	gradually	no
O	O	decreasing	no
O	O	the	no
O	O	dosage	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	4-methylpyrazole	yes
O	O	(	no
O	O	90	yes
O	O	mg	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	to	no
O	O	rats	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	was	no
O	O	ineffective	no
O	O	in	yes
O	O	preventing	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	synthesis	no
O	O	and	yes
O	O	did	no
O	O	not	no
O	O	diminish	no
O	O	fluoride	yes
O	O	or	no
O	O	citrate	yes
O	O	accumulation	no
O	O	in	yes
O	O	vivo	no
O	O	.	no

O	O	When	no
B-drug	B-drug	Mefloquine	yes
O	O	is	yes
O	O	taken	no
O	O	concurrently	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	live	yes
I-group	I-group	typhoid	no
I-group	I-group	vaccines	no
O	O	,	no
O	O	attenuation	no
O	O	of	yes
O	O	immunization	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	excluded	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	fenofibrate	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	1	yes
O	O	hour	yes
O	O	before	no
O	O	or	no
O	O	4-6	no
O	O	hours	no
O	O	after	no
O	O	a	yes
B-group	B-group	bile	no
I-group	I-group	acid	yes
I-group	I-group	binding	no
I-group	I-group	resin	yes
O	O	to	no
O	O	avoid	no
O	O	impeding	no
O	O	its	no
O	O	absorption	no
O	O	.	no

O	O	no	yes
O	O	change	no
O	O	in	yes
B-drug	B-drug	pravastatin	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	was	no
O	O	observed	no
O	O	during	no
B-drug	B-drug	diltiazem	yes
O	O	coadministration	no
O	O	.	no

O	O	The	no
O	O	extent	no
O	O	to	no
O	O	which	no
B-group	B-group	SSRI-TCA	no
O	O	interactions	no
O	O	may	no
O	O	pose	no
O	O	clinical	no
O	O	problems	no
O	O	will	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRI	no
O	O	involved	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	clinical	no
O	O	evidence	no
O	O	to	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	anagrelide	yes
O	O	interacts	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	these	no
O	O	compounds	no
O	O	.	no

O	O	The	no
O	O	affinity	no
O	O	(	no
O	O	Kd	no
O	O	)	no
O	O	of	yes
O	O	D2	yes
O	O	in	yes
O	O	the	no
O	O	NAC	yes
O	O	decreased	no
O	O	significantly	no
O	O	,	no
O	O	without	no
O	O	changes	no
O	O	in	yes
O	O	density	no
O	O	(	no
O	O	Bmax	no
O	O	)	no
O	O	,	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	cocaine-treated	no
O	O	SST	no
O	O	and	yes
O	O	RBC	no
O	O	mice	no
O	O	.	no

O	O	angioedema	no

O	O	Nonetheless	no
O	O	,	no
O	O	individual	no
O	O	patients	no
O	O	may	no
O	O	require	no
O	O	additional	no
O	O	titration	yes
O	O	of	yes
O	O	their	no
B-drug	B-drug	theophylline	yes
O	O	dosage	no
O	O	when	no
B-drug	B-drug	lansoprazole	yes
O	O	is	yes
O	O	started	no
O	O	or	no
O	O	stopped	no
O	O	to	no
O	O	ensure	no
O	O	clinically	no
O	O	effective	no
O	O	blood	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Chloramphenicol	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	be	no
O	O	antagonistic	no
O	O	to	no
B-group	B-group	beta-lactam	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	including	no
B-drug	B-drug	ceftazidime	yes
O	O	,	no
O	O	based	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	and	yes
O	O	time	no
O	O	kill	no
O	O	curves	no
O	O	with	yes
O	O	enteric	no
O	O	gram-negative	no
O	O	bacilli	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isoenzyme	no
O	O	,	no
O	O	including	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	and	yes
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	encainide	yes
O	O	)	no
O	O	,	no
O	O	or	no
O	O	that	no
O	O	inhibit	no
O	O	this	no
O	O	enzyme	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	In	yes
O	O	another	no
O	O	study	no
O	O	,	no
O	O	TORADOLIV/IM	no
O	O	was	no
O	O	given	no
O	O	with	yes
O	O	two	no
O	O	doses	no
O	O	of	yes
O	O	5000	no
O	O	U	yes
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	to	no
O	O	11	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	mean	no
O	O	template	no
O	O	bleeding	no
O	O	time	no
O	O	of	yes
O	O	6.4	no
O	O	minutes	no
O	O	(	no
O	O	3.2	no
O	O	to	no
O	O	11.4	no
O	O	min	no
O	O	)	no
O	O	compared	no
O	O	to	no
O	O	a	yes
O	O	mean	no
O	O	of	yes
O	O	6.0	no
O	O	minutes	no
O	O	(	no
O	O	3.4	no
O	O	to	no
O	O	7.5	yes
O	O	min	no
O	O	)	no
O	O	for	yes
B-drug	B-drug	heparin	yes
O	O	alone	no
O	O	and	yes
O	O	5.1	no
O	O	minutes	no
O	O	(	no
O	O	3.5	no
O	O	to	no
O	O	8.5	no
O	O	min	no
O	O	)	no
O	O	for	yes
O	O	placebo	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	and	yes
B-brand	B-brand	Ortho-Novum	yes
O	O	1/35	yes
O	O	increased	no
O	O	the	no
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	by	no
O	O	20	yes
O	O	%	no
O	O	and	yes
O	O	34	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-group	B-group	Corticosteroids	no
O	O	may	no
O	O	affect	no
O	O	the	no
O	O	nitrobluetetrazolium	no
O	O	test	yes
O	O	for	yes
O	O	bacterial	no
O	O	infection	no
O	O	and	yes
O	O	produce	no
O	O	false-negative	no
O	O	results	no

B-drug	B-drug	Ketoconazole	yes
O	O	is	yes
O	O	a	yes
O	O	known	no
O	O	strong	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	generally	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	because	no
O	O	they	no
O	O	reduce	no
B-drug	B-drug	lithiums	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	clinical	no
O	O	status	no
O	O	is	yes
O	O	warranted	no
O	O	when	no
B-drug	B-drug	rifampin	yes
O	O	is	yes
O	O	administered	no
O	O	or	no
O	O	discontinued	no
O	O	in	yes
B-drug	B-drug	haloperidol-treated	no
O	O	patients	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	intrathecal	no
B-drug	B-drug	naloxone	yes
O	O	(	no
O	O	12-120	no
O	O	micrograms	no
O	O	)	no
O	O	had	no
O	O	only	no
O	O	a	yes
O	O	very	no
O	O	weak	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	tail-flick	no
O	O	inhibition	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	40	yes
O	O	micrograms	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	data	no
O	O	described	no
O	O	in	yes
O	O	this	no
O	O	section	no
O	O	were	no
O	O	obtained	no
O	O	from	no
O	O	studies	no
O	O	involving	no
O	O	either	no
O	O	healthy	no
O	O	subjects	no
O	O	or	no
O	O	patients	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	in	yes
O	O	dogs	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	in	yes
O	O	rats	no
O	O	,	no
O	O	at	yes
O	O	approximately	no
O	O	2	yes
O	O	times	no
O	O	the	no
O	O	recommended	no
O	O	maximum	no
O	O	human	yes
O	O	therapeutic	no
O	O	dose	no
O	O	of	yes
O	O	each	no
O	O	(	no
O	O	40	yes
O	O	to	no
O	O	52	no
O	O	mg/kg/day	no
O	O	of	yes
B-drug	B-drug	diflunisal/acetaminophen	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	greater	no
O	O	gastrointestinal	no
O	O	toxicity	no
O	O	than	no
O	O	when	no
O	O	either	no
O	O	drug	yes
O	O	was	no
O	O	administered	no
O	O	alone	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	naltrexone	yes
O	O	with	yes
B-drug	B-drug	Acamprosate	yes
O	O	produced	no
O	O	a	yes
O	O	25	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	33	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	acamprosate	yes
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
B-drug	B-drug	Everolimus	yes
O	O	exhibited	no
O	O	dose-proportional	no
O	O	,	no
O	O	stable	no
O	O	exposure	yes
O	O	during	no
O	O	the	no
O	O	first	no
O	O	post-transplant	no
O	O	year	no
O	O	.	no

B-drug	B-drug	Cholestyramine-Concomitant	no
O	O	intake	no
O	O	of	yes
B-drug	B-drug	cholestyramine	yes
O	O	and	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	.	no

B-drug	B-drug	Morphine	yes
O	O	:	no
O	O	TORADOLIV/IM	no
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	morphine	yes
O	O	in	yes
O	O	several	no
O	O	clinical	no
O	O	trials	no
O	O	of	yes
O	O	postoperative	no
O	O	pain	yes
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	At	yes
O	O	low-levels	no
O	O	of	yes
O	O	exposure	yes
O	O	the	no
O	O	toxicokinetic	no
O	O	interferences	no
O	O	between	yes
O	O	solvents	no
O	O	have	no
O	O	generally	no
O	O	not	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	man	no
O	O	and	yes
O	O	presumably	no
O	O	a	yes
O	O	threshold	no
O	O	limit	no
O	O	exists	no
O	O	.	no

B-group	O	Antiacid	no
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	Didanosine	yes
O	O	,	no
B-drug	B-drug	Fluconazole	yes
O	O	,	no
B-drug	B-drug	Fluoxetine	yes
O	O	,	no
O	O	Indanavir	no
O	O	,	no
B-drug	B-drug	Ketoconazole	yes
O	O	,	no
B-drug	B-drug	Phenytoin	yes
O	O	,	no
O	O	Phenobarbitol	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	Rifabutin	yes
O	O	,	no
B-drug	B-drug	Rifampin	yes
O	O	,	no
O	O	Ritanovir	no
O	O	,	no
B-drug	B-drug	Saquinavir	yes
O	O	.	no

B-drug	B-drug	disulfiram	yes
O	O	;	no

B-drug	B-drug	Bentiromide	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	acetaminophen	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Tylenol	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	chloramphenicol	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Chloromycetin	yes
O	O	)	no
O	O	,	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	benzocaine	yes
O	O	and	yes
B-drug	B-drug	lidocaine	yes
O	O	)	no
O	O	,	no
B-drug_n	B-drug_n	para-aminobenzoic	no
I-drug_n	I-drug_n	acid	yes
O	O	(	no
B-drug_n	B-drug_n	PABA	no
O	O	)	no
O	O	-containing	no
O	O	preparations	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	sunscreens	no
O	O	and	yes
O	O	some	no
B-group	B-group	multivitamins	no
O	O	)	no
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Pronestyl	yes
O	O	)	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	(	no
B-group	O	sulfa	yes
I-group	O	medicines	no
O	O	)	no
O	O	,	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	medicines	no
O	O	during	no
O	O	the	no
O	O	test	yes
O	O	period	no
O	O	will	no
O	O	affect	no
O	O	the	no
O	O	test	yes
O	O	results	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	pancreatic	yes
O	O	supplements	no
O	O	(	no
O	O	use	no
O	O	of	yes
O	O	pancreatic	yes
O	O	supplements	no
O	O	may	no
O	O	give	no
O	O	false	no
O	O	test	yes
O	O	results	no
O	O	)	no
O	O	.	no

O	O	When	no
O	O	used	no
O	O	in	yes
O	O	external	no
O	O	subcutaneous	yes
O	O	infusion	no
O	O	pumps	no
O	O	for	yes
B-drug	B-drug	insulin	yes
O	O	,	no
B-brand	B-brand	NovoLog	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	mixed	yes
O	O	with	yes
O	O	any	no
O	O	other	no
B-group	B-group	insulins	no
O	O	or	no
O	O	diluent	no
O	O	.	no

B-group	B-group	Digitalis	yes
O	O	:	no
B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	dosage	no
O	O	must	no
O	O	be	no
O	O	determined	no
O	O	with	yes
O	O	care	yes
O	O	in	yes
O	O	patients	no
O	O	undergoing	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	,	no
O	O	as	yes
O	O	hypercalcemia	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	may	no
O	O	precipitate	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

B-group	B-group	Anticholinergic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	potentially	no
O	O	alter	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	some	no
O	O	concomitantly	no
O	O	administered	no
O	O	drugs	no
O	O	due	no
O	O	to	no
O	O	effects	no
O	O	on	no
O	O	gastrointestinal	no
O	O	motility	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	or	no
B-group	B-group	H	yes
I-group	I-group	2	yes
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	:	no
O	O	When	no
B-drug	B-drug	dirithromycin	yes
O	O	is	yes
O	O	administered	no
O	O	immediately	no
O	O	following	no
B-group	B-group	antacids	no
O	O	or	no
B-group	B-group	H	yes
I-group	I-group	2	yes
I-group	I-group	-receptor	no
I-group	I-group	antagonists	no
O	O	,	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	dirithromycin	yes
O	O	is	yes
O	O	slightly	no
O	O	enhanced	no
O	O	.	no

O	O	In	yes
O	O	particular	no
O	O	,	no
O	O	convulsions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-drug	B-drug	ethionamide	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-drug	B-drug	cycloserine	yes
O	O	and	yes
O	O	special	yes
O	O	care	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
O	O	the	no
O	O	treatment	no
O	O	regimen	no
O	O	includes	no
O	O	both	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	dopamine	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	monoamine	no
O	O	oxidase	yes
O	O	(	no
O	O	MAO	no
O	O	)	no
O	O	,	no
O	O	inhibition	no
O	O	of	yes
O	O	this	no
O	O	enzyme	no
O	O	prolongs	no
O	O	and	yes
O	O	potentiates	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	dopamine	yes
O	O	.	no

O	O	Also	no
O	O	included	no
O	O	in	yes
O	O	this	no
O	O	paper	no
O	O	is	yes
O	O	a	yes
O	O	study	no
O	O	which	no
O	O	confirms	no
O	O	the	no
O	O	identity	no
O	O	of	yes
O	O	the	no
O	O	HPLC	no
O	O	peak	no
O	O	as	yes
O	O	being	no
O	O	homocysteine	no
O	O	by	no
O	O	forming	no
O	O	a	yes
O	O	radioactive	no
O	O	derivative	yes
O	O	of	yes
O	O	this	no
O	O	particular	no
O	O	sulphydryl-containing	no
O	O	amino	yes
O	O	acid	yes
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	analysing	no
O	O	the	no
O	O	resulting	no
O	O	mixture	no
O	O	by	no
O	O	TLC	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
B-brand	B-brand	Keppra	yes
O	O	(	no
O	O	1000	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	and	yes
O	O	pharmacodynamics	no
O	O	(	no
O	O	ECG	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	given	no
O	O	as	yes
O	O	a	yes
O	O	0.25	no
O	O	mg	yes
O	O	dose	no
O	O	every	no
O	O	day	no
O	O	.	no

B-drug	B-drug	Azithromycin	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	dideoxyinosine	yes
O	O	pharmacokinetics	no
O	O	.	no

B-group	B-group	Macrolide	no
I-group	I-group	Antibiotics	no
O	O	(	no
O	O	e.	no
O	O	g.	no
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	troleandomycin	yes
O	O	)	no
O	O	:	no
O	O	Agents	yes
O	O	of	yes
O	O	the	no
B-group	B-group	ergot	yes
I-group	I-group	alkaloid	no
I-group	I-group	class	no
O	O	,	no
O	O	of	yes
O	O	which	no
B-brand	B-brand	D.H.E	no
I-brand	I-brand	.	no
I-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	is	yes
O	O	a	yes
O	O	member	yes
O	O	,	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interact	no
O	O	with	yes
B-group	B-group	antibiotics	no
O	O	of	yes
O	O	the	no
B-group	B-group	macrolide	no
I-group	I-group	class	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	unchanged	no
O	O	alkaloids	yes
O	O	and	yes
O	O	peripheral	no
O	O	vasoconstriction	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	their	no
O	O	similar	no
O	O	mechanism	no
O	O	of	yes
O	O	action	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	expected	no
O	O	that	no
O	O	the	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	produced	no
O	O	by	no
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	non-depolarizing	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	could	no
O	O	be	no
O	O	prolonged	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	piperacillin	yes
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	DIAMOND	no
O	O	trials	no
O	O	,	no
O	O	1252	no
O	O	patients	no
O	O	were	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	and	yes
B-group	B-group	diuretics	no
O	O	concomitantly	no
O	O	of	yes
O	O	whom	no
O	O	493	no
O	O	died	no
O	O	compared	no
O	O	to	no
O	O	508	no
O	O	deaths	no
O	O	among	no
O	O	the	no
O	O	1248	no
O	O	patients	no
O	O	receiving	no
O	O	placebo	no
O	O	and	yes
B-group	B-group	diuretics	no
O	O	.	no

O	O	7	yes
O	O	.	no

O	O	Increased	no
O	O	nephrotoxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	cephalosporins	no
O	O	and	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	;	no

O	O	Co-administration	no
O	O	of	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
O	O	10	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	lenalidomide	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	single	yes
O	O	dose	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	R-	no
O	O	and	yes
O	B-drug	S-	no
B-drug	I-drug	warfarin	yes
O	O	.	no

B-drug	B-drug	Nimodipine	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug_n	B-drug_n	ginsenosides	no
O	O	response	no
O	O	.	no

O	O	Specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	,	no
O	O	including	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	MTX	yes
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	these	no
O	O	data	no
O	O	,	no
B-drug	B-drug	Vardenafil	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-group	B-group	alpha-blocker	no
O	O	therapy	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	12-month	no
O	O	controlled	no
O	O	trial	no
O	O	that	no
O	O	included	no
O	O	a	yes
O	O	50	yes
O	O	mcg	no
O	O	once	no
O	O	daily	no
B-brand	B-brand	BROVANA	yes
O	O	dose	no
O	O	,	no
O	O	30	yes
O	O	of	yes
O	O	the	no
O	O	528	no
B-brand	B-brand	BROVANA	yes
O	O	-treated	no
O	O	subjects	no
O	O	received	no
O	O	concomitant	no
B-drug	B-drug	theophylline	yes
O	O	at	yes
O	O	study	no
O	O	entry	no
O	O	.	no

B-drug	B-drug	Fentanyl	yes

B-drug	B-drug	Phenytoin	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	hepatic	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	and	yes
O	O	is	yes
O	O	particularly	no
O	O	susceptible	no
O	O	to	no
O	O	inhibitory	yes
O	O	drug	yes
O	O	interactions	no
O	O	because	no
O	O	it	no
O	O	is	yes
O	O	subject	no
O	O	to	no
O	O	saturable	no
O	O	metabolism	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	provided	no

O	O	The	no
O	O	literature	no
O	O	suggests	no
O	O	that	no
O	O	more	no
O	O	than	no
O	O	one	no
O	O	mechanism	no
O	O	of	yes
O	O	action	no
O	O	exists	no
O	O	for	yes
O	O	them	no
O	O	.	no

O	O	In	yes
O	O	view	no
O	O	of	yes
O	O	the	no
O	O	long	yes
O	O	and	yes
O	O	variable	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	,	no
O	O	potential	no
O	O	for	yes
O	O	drug	yes
O	O	interactions	no
O	O	exists	no
O	O	not	no
O	O	only	no
O	O	with	yes
O	O	concomitant	no
O	O	medication	no
O	O	but	no
O	O	also	no
O	O	with	yes
O	O	drugs	no
O	O	administered	no
O	O	after	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	FACTIVE	yes
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	45	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	systemic	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	gemifloxacin	yes
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	Catechol-O-methyltransferase	no
O	O	(	no
O	O	COMT	no
O	O	)	no
O	O	:	no
O	O	Hormone	yes
O	O	levels	no
O	O	:	no
B-drug	B-drug	Levodopa	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	depress	no
O	O	prolactin	no
O	O	secretion	no
O	O	and	yes
O	O	increase	no
O	O	growth	yes
O	O	hormone	yes
O	O	levels	no
O	O	.	no

O	O	Hepatic	no
O	O	:	no
O	O	There	no
O	O	is	yes
O	O	limited	no
O	O	evidence	no
O	O	that	no
O	O	the	no
O	O	myelotoxicity	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	may	no
O	O	be	no
O	O	exacerbated	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	serum	yes
O	O	total	yes
O	O	bilirubin	no
O	O	2	yes
O	O	times	no
O	O	ULN	no
O	O	.	no

O	O	Other	no
B-group	B-group	antiarrhythmic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	have	no
O	O	occasionally	no
O	O	been	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	Norpace	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	exists	no
O	O	for	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
O	O	any	no
O	O	agent	yes
O	O	that	no
O	O	inhibits	no
O	O	CYP3A4	no
O	O	and/or	no
O	O	epoxide	no
O	O	hydrolase	yes
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	MYOBLOC	yes
O	O	and	yes
B-group	B-group	aminoglycosides	no
O	O	or	no
O	O	other	no
O	O	agents	yes
O	O	interfering	yes
O	O	with	yes
O	O	neuromuscular	no
O	O	transmission	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	curare-like	no
I-group	I-group	compounds	no
O	O	)	no
O	O	should	no
O	O	only	no
O	O	be	no
O	O	performed	no
O	O	with	yes
O	O	caution	no
O	O	as	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	the	no
O	B-drug	toxin	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

O	O	1	yes
O	O	mM	yes
O	O	)	no
O	O	was	no
O	O	a	yes
O	O	slight	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	(	no
O	O	14	yes
O	O	%	no
O	O	-30	no
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	isoform	yes
O	O	CYP2A6	no
O	O	observed	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	6	yes
O	O	healthy	no
O	O	volunteers	no
O	O	has	no
O	O	shown	no
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	peak	no
B-drug	B-drug	nifedipine	yes
O	O	plasma	yes
O	O	levels	no
O	O	(	no
O	O	80	yes
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	area-under-the-curve	no
O	O	(	no
O	O	74	no
O	O	%	no
O	O	)	no
O	O	after	no
O	O	a	yes
O	O	1	yes
O	O	week	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	at	yes
O	O	1000	yes
O	O	mg	yes
O	O	per	no
O	O	day	no
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	at	yes
O	O	40	yes
O	O	mg	yes
O	O	per	no
O	O	day	no
O	O	.	no

O	O	Lipids	no
O	O	:	no
O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	hypertriglyceridemia	no
O	O	was	no
O	O	66	no
O	O	%	no
O	O	,	no
O	O	hypercholesterolemia	no
O	O	was	no
O	O	33	no
O	O	%	no
O	O	and	yes
O	O	that	no
O	O	of	yes
O	O	decreased	no
O	O	HDL	no
O	O	was	no
O	O	40	yes
O	O	%	no
O	O	.	no

B-group	B-group	Alpha-agonists	no
O	O	,	no
O	O	as	yes
O	O	a	yes
O	O	class	no
O	O	,	no
O	O	may	no
O	O	reduce	no
O	O	pulse	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	Experience	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	and	yes
B-drug	B-drug	Fentanyl	yes
O	O	in	yes
O	O	patients	no
O	O	is	yes
O	O	limited	no
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	temporarily	no
O	O	suspending	no
O	O	use	no
O	O	of	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	Fentanyl	yes
O	O	.	no

O	O	Resistance	no
O	O	to	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-group	B-group	nondepolarizing	no
I-group	I-group	neuromuscular	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	in	yes
O	O	patients	no
O	O	chronically	no
O	O	administered	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	carbamazepine	yes
O	O	.	no

O	O	Drug/	no
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-brand	B-brand	AMERGE	yes
O	O	Tablets	yes
O	O	are	no
O	O	not	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	commonly	no
O	O	employed	no
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	important	no
O	O	for	yes
O	O	older	no
O	O	adults	no
O	O	to	no
O	O	be	no
O	O	aware	no
O	O	of	yes
O	O	the	no
O	O	relationship	no
O	O	between	yes
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B12	yes
O	O	because	no
O	O	they	no
O	O	are	no
O	O	at	yes
O	O	greater	no
O	O	risk	no
O	O	of	yes
O	O	having	no
O	O	a	yes
O	O	vitamin	yes
O	O	B12	yes
O	O	deficiency	no
O	O	.	no

O	O	Much	no
O	O	less	no
O	O	caspase-3	no
O	O	activity	yes
O	O	was	no
O	O	noted	no
O	O	in	yes
O	O	the	no
O	O	lysate	no
O	O	derived	yes
O	O	from	no
O	O	serum-deprived	no
O	O	RAS-3T3	no
O	O	cells	yes
O	O	compared	no
O	O	with	yes
O	O	that	no
O	O	in	yes
O	O	the	no
O	O	lysate	no
O	O	of	yes
O	O	serum-deprived	no
O	O	NIH-3T3	no
O	O	cells	yes
O	O	.	no

B-brand	B-brand	FORADIL	yes
O	O	is	yes
O	O	not	no
O	O	meant	no
O	O	to	no
O	O	relieve	no
O	O	acute	no
O	O	asthma	no
O	O	or	no
O	O	COPD	no
O	O	symptoms	no
O	O	and	yes
O	O	extra	yes
O	O	doses	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	for	yes
O	O	that	no
O	O	purpose	no
O	O	.	no

B-drug	I-drug	Nevirapine	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	should	no
O	O	not	no
O	O	beadministered	no
O	O	concomitantly	no
O	O	becausedecreases	no
O	O	in	yes
B-drug	B-drug	ketoconazole	yes
O	O	plasmaconcentrations	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	A	yes
O	O	false	no
O	O	positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	Benedicts	no
O	O	solution	yes
O	O	,	no
O	O	Fehlings	no
O	O	solution	yes
O	O	or	no
O	O	with	yes
O	O	CLINITEST	no
O	O	tablets	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	enzyme-based	no
O	O	tests	no
O	O	such	no
O	O	as	yes
O	O	CLINISTIX	no
O	O	.	no

O	O	Examples	no
O	O	of	yes
O	O	Drugs	no
O	O	in	yes
O	O	Which	no
O	O	Plasma	yes
O	O	Concentrations	no
O	O	May	no
O	O	Be	no
O	O	Increased	no
O	O	By	no
O	O	Co-administration	no
O	O	With	yes
B-drug	B-drug	Nevirapine	yes

B-drug	B-drug	Alcohol	yes
O	O	:	no
O	O	There	no
O	O	was	no
O	O	no	yes
O	O	significant	no
O	O	difference	no
O	O	between	yes
B-drug	B-drug	aripiprazole	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ethanol	yes
O	O	and	yes
O	O	placebo	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	ethanol	yes
O	O	on	no
O	O	performance	no
O	O	of	yes
O	O	gross	no
O	O	motor	no
O	O	skills	no
O	O	or	no
O	O	stimulus	no
O	O	response	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

B-drug	B-drug	Aprepitant	yes
O	O	is	yes
O	O	also	no
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	CYP2C9	no
O	O	.	no

O	O	.	no

O	O	Drug	yes
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	None	no
O	O	known	no
O	O	.	no

O	O	Although	no
O	O	specific	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	,	no
O	O	coadministration	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	mainly	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
B-drug	B-drug	dapsone	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-group	B-group	ergot	yes
I-group	I-group	derivatives	no
O	O	,	no
B-drug	B-drug	pimozide	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	fentanyl	yes
O	O	,	no
B-drug	B-drug	alfentanyl	yes
O	O	,	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	triazolam	yes
O	O	)	no
O	O	may	no
O	O	have	no
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	saquinavir	yes
O	O	;	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interaction	no
B-drug	B-drug	Fosinopril	yes
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	false	no
O	O	low	yes
O	O	measurement	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	with	yes
O	O	the	no
O	O	Digi-	no
O	O	Tab	no
O	O	RIA	no
O	O	Kit	yes
O	O	for	yes
B-drug	B-drug	Digoxin	yes
O	O	.	no

O	O	An	no
O	O	encephalopathic	no
O	O	syndrome	no
O	O	(	no
O	O	characterized	no
O	O	by	no
O	O	weakness	no
O	O	,	no
O	O	lethargy	no
O	O	,	no
O	O	fever	no
O	O	,	no
O	O	tremulousness	no
O	O	and	yes
O	O	confusion	no
O	O	,	no
O	O	extrapyramidal	no
O	O	symptoms	no
O	O	,	no
O	O	leukocytosis	no
O	O	,	no
O	O	elevated	no
O	O	serum	yes
O	O	enzymes	yes
O	O	,	no
O	O	BUN	no
O	O	,	no
O	O	and	yes
O	O	FBS	no
O	O	)	no
O	O	followed	no
O	O	by	no
O	O	irreversible	no
O	O	brain	yes
O	O	damage	no
O	O	has	no
O	O	occurred	no
O	O	in	yes
O	O	a	yes
O	O	few	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	plus	yes
B-brand	B-brand	HALDOL	yes
O	O	.	no

O	O	InjectionSite	no
O	O	Reaction	no
O	O	:	no
O	O	Injection	yes
O	O	site	no
O	O	reactions	no
O	O	,	no
O	O	including	no
O	O	reactions	no
O	O	secondary	yes
O	O	to	no
O	O	extravasation	no
O	O	,	no
O	O	were	no
O	O	usually	no
O	O	mild	yes
O	O	and	yes
O	O	consisted	no
O	O	of	yes
O	O	erythema	no
O	O	,	no
O	O	tenderness	no
O	O	,	no
O	O	skin	yes
O	O	discoloration	no
O	O	,	no
O	O	or	no
O	O	swelling	no
O	O	at	yes
O	O	the	no
O	O	injection	yes
O	O	site	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	SPRYCEL	yes
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	for	yes
O	O	toxicity	no
O	O	and	yes
O	O	a	yes
B-brand	B-brand	SPRYCEL	yes
O	O	dose	no
O	O	reduction	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	if	no
O	O	systemic	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	can	no
O	O	not	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	Additional	no
O	O	dose	no
O	O	increases	no
O	O	should	no
O	O	be	no
O	O	based	no
O	O	on	no
O	O	clinical	no
O	O	evaluation	no
O	O	.	no

O	O	The	no
O	O	oral	yes
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	enoxacin	yes
O	O	is	yes
O	O	reduced	yes
O	O	by	no
O	O	60	no
O	O	%	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	ranitidine	yes
O	O	.	no

B-drug	B-drug	ranitidine*	no
O	O	;	no

O	O	Antimicrobial	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	GL	no
O	O	(	no
O	O	the	no
O	O	aqueous	yes
O	O	extract	yes
O	O	from	no
O	O	the	no
O	O	carpophores	no
O	O	of	yes
O	O	Ganoderma	no
O	O	lucidum	no
O	O	(	no
O	O	FR	no
O	O	)	no
O	O	KARST	no
O	O	)	no
O	O	was	no
O	O	tested	no
O	O	in	yes
O	O	vitro	no
O	O	against	yes
O	O	Gram	no
O	O	positive	no
O	O	and	yes
O	O	Gram	no
O	O	negative	no
O	O	bacteria	no
O	O	by	no
O	O	serial	no
O	O	broth	no
O	O	dilution	no
O	O	method	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	antimicrobial	no
O	O	activity	yes
O	O	was	no
O	O	expressed	yes
O	O	by	no
O	O	minimal	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	(	no
O	O	MIC	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Ethanol	yes
O	O	:	no
O	O	Clinical	no
O	O	evidence	no
O	O	has	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	etretinate	yes
O	O	can	no
O	O	be	no
O	O	formed	no
O	O	with	yes
O	O	concurrent	no
O	O	ingestion	no
O	O	of	yes
B-drug	B-drug	acitretin	yes
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	.	no

O	O	INTERVENTIONS	no
O	O	:	no
O	O	Each	no
O	O	subject	no
O	O	was	no
O	O	treated	no
O	O	according	no
O	O	to	no
O	O	the	no
O	O	following	no
O	O	sequence	yes
O	O	:	no
O	O	baseline	no
O	O	;	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Administration	no
O	O	of	yes
B-group	B-group	nonsteroial	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	cyclosporine-induced	no
O	O	toxicity	no
O	O	,	no
O	O	possibly	no
O	O	due	no
O	O	to	no
O	O	decreased	no
O	O	synthesis	no
O	O	of	yes
O	O	renal	no
O	O	prostacyclin	yes
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	BOTOX	yes
O	O	and	yes
B-group	B-group	aminoglycosides	no
O	O	or	no
O	O	other	no
O	O	agents	yes
O	O	interfering	yes
O	O	with	yes
O	O	neuromuscular	no
O	O	transmission	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	curare-like	no
I-group	I-group	compounds	no
O	O	)	no
O	O	should	no
O	O	only	no
O	O	be	no
O	O	performed	no
O	O	with	yes
O	O	caution	no
O	O	as	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	the	no
O	B-drug	toxin	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	no	yes
O	O	binding	no
O	O	displacement	no
O	O	between	yes
B-drug	B-drug	entacapone	yes
O	O	and	yes
O	O	other	no
O	O	highly	no
O	O	bound	no
O	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	salicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	.	no

O	O	Compromised	no
B-drug	B-drug	norepinephrine	yes
O	O	uptake-1	no
O	O	in	yes
O	O	functional	no
O	O	class	no
O	O	IV	yes
O	O	can	no
O	O	not	no
O	O	be	no
O	O	further	no
O	O	increased	no
O	O	by	no
B-drug	B-drug	cocaine	yes
O	O	and	yes
B-drug	B-drug	desipramine	yes
O	O	.	no

O	O	SINCE	no
B-drug	B-drug	CHOLESTYRAMINE	yes
B-group	B-group	RESIN	yes
O	O	MAY	no
O	O	BIND	no
O	O	OTHER	no
O	O	DRUGS	no
O	O	GIVEN	no
O	O	CONCURRENTLY	no
O	O	,	no
O	O	IT	no
O	O	IS	yes
O	O	RECOMMENDED	no
O	O	THAT	no
O	O	PATIENTS	no
O	O	TAKE	no
O	O	OTHER	no
O	O	DRUGS	no
O	O	AT	yes
O	O	LEAST	no
O	O	1	yes
O	O	HOUR	yes
O	O	BEFORE	no
O	O	OR	no
O	O	4	yes
O	O	TO	no
O	O	6	yes
O	O	HOURS	no
O	O	AFTER	no
B-drug	B-drug	CHOLESTYRAMINE	yes
B-group	B-group	RESIN	yes
O	O	(	no
O	O	OR	no
O	O	AT	yes
O	O	AS	yes
O	O	GREAT	no
O	O	AN	no
O	O	INTERVAL	no
O	O	AS	yes
O	O	POSSIBLE	no
O	O	)	no
O	O	TO	no
O	O	AVOID	no
O	O	IMPEDING	no
O	O	THEIR	no
O	O	ABSORPTION	no
O	O	.	no

B-drug	B-drug	Lansoprazole	yes
O	O	causes	no
O	O	a	yes
O	O	profound	no
O	O	and	yes
O	O	long	yes
O	O	lasting	no
O	O	inhibition	no
O	O	of	yes
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	;	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	recognized	no
O	O	that	no
O	O	a	yes
O	O	positive	no
O	O	Coombs	no
O	O	test	yes
O	O	could	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	.	no

B-brand	B-brand	Maalox	no
O	O	*	no
O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	Maalox	no
I-brand	I-brand	TC	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	absorption	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
O	O	or	no
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	.	no

O	O	Table	no
O	O	8	yes

B-group	B-group	anabolic	no
I-group	I-group	steroids	no
O	O	;	no

O	O	adjust	no
O	O	dosage	no
O	O	of	yes
B-group	B-group	antidiabetic	no
I-group	I-group	drug	yes
O	O	upward	no
O	O	if	no
O	O	necessary	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	(	no
B-drug	B-drug	CBZ	yes
O	O	)	no

O	O	Combinations	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	and	yes
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	and	yes
B-drug	B-drug	atazanavir	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Amphotericin	yes
O	O	,	no
B-drug	B-drug	Foscarnet	yes
O	O	,	no
O	O	and	yes
B-group	B-group	Aminoglycosides	no
O	O	:	no
O	O	Drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	amphotericin	yes
O	O	,	no
B-drug	B-drug	foscarnet	yes
O	O	,	no
O	O	and	yes
B-group	B-group	aminoglycosides	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	developing	no
O	O	peripheral	no
O	O	neuropathy	no
O	O	or	no
O	O	other	no
B-drug	B-drug	HIVID-associated	no
O	O	adverse	no
O	O	events	no
O	O	by	no
O	O	interfering	yes
O	O	with	yes
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	(	no
O	O	thereby	no
O	O	raising	no
O	O	systemic	no
O	O	exposure	yes
O	O	)	no
O	O	.	no

B-group	B-group	Antiepileptic	no
I-group	I-group	drugs	no
O	O	:	no
O	O	Potential	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	Trileptal	yes
O	O	and	yes
O	O	other	no
B-group	B-group	AEDs	no
O	O	were	no
O	O	assessed	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	.	no

B-group	B-group	Selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	)	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	rarely	no
O	O	,	no
O	O	to	no
O	O	cause	no
O	O	weakness	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	and	yes
O	O	incoordination	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-group	B-group	5-HT1	no
I-group	I-group	agonists	no
O	O	.	no

O	O	Short-term	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-brand	B-brand	Lodine	yes
O	O	(	no
B-drug	B-drug	etodolac	yes
O	O	capsules	no
O	O	and	yes
O	O	tablets	yes
O	O	)	no
O	O	results	no
O	O	in	yes
O	O	reduced	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	but	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	change	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	free	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

B-group	B-group	Antihistamines	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	and	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	.	no

B-group	B-group	Skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	nondepolarizing	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	tubocurarine	yes
O	O	)	no
O	O	:	no
O	O	possible	no
O	O	increased	no
O	O	responsiveness	no
O	O	to	no
O	O	the	no
B-group	B-group	muscle	no
I-group	I-group	relaxant	no
O	O	.	no

B-brand	B-brand	Videx	yes
O	O	(	no
B-drug	B-drug	Didanosine	yes
O	O	)	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	,	no
O	O	or	no
O	O	within	no
O	O	2	yes
O	O	hours	no
O	O	of	yes
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	norfloxacin	yes
O	O	,	no
O	O	because	no
O	O	these	no
O	O	products	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	absorption	no
O	O	resulting	no
O	O	in	yes
O	O	lower	no
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	norfloxacin	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	desipramine	yes
I-drug	I-drug	hydrochloride	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	combined	no
O	O	with	yes
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-group	B-group	tranquilizers	no
O	O	or	no
B-group	B-group	sedative/hypnotics	no
O	O	,	no
O	O	careful	no
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	the	no
O	O	pharmacology	no
O	O	of	yes
O	O	the	no
O	O	agents	yes
O	O	employed	no
O	O	since	no
O	O	the	no
O	O	sedative	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	and	yes
B-group	B-group	benzodiazepines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	or	no
B-drug	B-drug	diazepam	yes
O	O	)	no
O	O	are	no
O	O	additive	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	T.A	no
O	I-group	.	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRIs	no
O	O	and	yes
O	O	also	no
O	O	in	yes
O	O	switching	no
O	O	from	no
O	O	one	no
O	O	class	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	from	no
O	O	trials	no
O	O	using	no
O	O	the	no
O	O	intravenous	yes
O	O	prodrug	no
O	O	are	no
O	O	reported	no
O	O	in	yes
O	O	this	no
O	O	section	no
O	O	as	yes
O	O	they	no
O	O	relate	no
O	O	to	no
O	O	the	no
O	O	role	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	in	yes
O	O	drug	yes
O	O	interactions	no
O	O	.	no

B-group	B-group	ACE	no
I-group	I-group	Inhibitors	no
O	O	and	yes
B-group	B-group	Angiotensin	yes
I-group	I-group	II	yes
I-group	I-group	Receptor	yes
I-group	I-group	Antagonists	no
O	O	(	no
O	O	Congestive	no
O	O	Heart	no
O	O	Failure	no
O	O	Post-Myocardial	no
O	O	Infarction	no
O	O	)	no
O	O	-	yes
O	O	In	yes
O	O	EPHESUS	no
O	O	,	no
O	O	3020	no
O	O	(	no
O	O	91	no
O	O	%	no
O	O	)	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	INSPRA	yes
O	O	25	yes
O	O	to	no
O	O	50	yes
O	O	mg	yes
O	O	also	no
O	O	received	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	or	no
B-group	B-group	angiotensin	yes
I-group	I-group	II	yes
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	(	no
B-group	B-group	ACEI/ARB	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	ototoxic	no
O	O	potential	no
O	O	of	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	.	no

O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	should	no
O	O	generally	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-group	B-group	Thiazides	no
O	O	:	no
B-group	B-group	Thiazides	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	hypercalcemia	no
O	O	by	no
O	O	the	no
O	O	reduction	yes
O	O	of	yes
O	O	calcium	yes
O	O	excretion	no
O	O	in	yes
O	O	urine	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	prolong	no
O	O	the	no
O	O	QTc	no
O	O	interval	no
O	O	have	no
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	ventricular	no
O	O	arrhythmias	no
O	O	.	no

O	O	Exposure	yes
O	O	from	no
O	O	the	no
O	O	proposed	no
O	O	topical	yes
O	O	dose	no
O	O	is	yes
O	O	about	no
O	O	1	yes
O	O	%	no
O	O	of	yes
O	O	that	no
O	O	from	no
O	O	the	no
O	O	100	yes
O	O	mg	yes
O	O	oral	yes
O	O	dose	no
O	O	,	no
O	O	even	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	TMP/SMX	no
O	O	.	no

B-drug	B-drug	Morphine	yes
O	O	:	no
O	O	A	yes
O	O	literature	no
O	O	article	no
O	O	reported	no
O	O	that	no
O	O	when	no
O	O	a	yes
O	O	60-mg	no
O	O	controlled-release	no
B-drug	B-drug	morphine	yes
O	O	capsule	yes
O	O	was	no
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	a	yes
O	O	600-mg	no
B-brand	B-brand	Neurontin	yes
O	O	capsule	yes
O	O	(	no
O	O	N=12	no
O	O	)	no
O	O	,	no
O	O	mean	no
B-drug	B-drug	gabapentin	yes
O	O	AUC	no
O	O	increased	no
O	O	by	no
O	O	44	yes
O	O	%	no
O	O	compared	no
O	O	to	no
B-drug	B-drug	gabapentin	yes
O	O	administered	no
O	O	without	no
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	The	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	was	no
O	O	decreased	no
O	O	approximately	no
O	O	3-fold	no
O	O	.	no

B-drug	B-drug_n	phenyramidol	no
O	O	;	no

B-drug	B-drug	Auranofin	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	by	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	serious	no
O	O	reaction	no
O	O	to	no
O	O	any	no
B-group	B-group	gold	yes
I-group	I-group	medication	no
O	O	,	no
O	O	including	no
B-brand	B-brand	Solganal	no
O	O	and	yes
B-brand	B-brand	Myochrysine	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	on	no
O	O	a	yes
O	O	body	no
O	O	surface	yes
O	O	area	no
O	O	basis	no
O	O	,	no
O	O	this	no
O	O	dose	no
O	O	was	no
O	O	0.5	yes
O	O	times	no
O	O	maximum	no
O	O	recommended	no
O	O	human	yes
O	O	24-hour	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	ribavirin	yes
O	O	.	no

B-group	B-group	ANTACID	no
O	O	(	no
B-drug	B-drug	Magnesium-Aluminum	no
I-drug	I-drug	Hydroxide	yes
O	O	)	no
O	O	:	no
B-drug	B-drug	Cerivastatin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	antacid	no
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	interaction	no
O	O	between	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	and	yes
B-brand	B-brand	Levo-Dromoran	yes
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	for	yes
O	O	use	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Table	no
O	O	1	yes
O	O	Changes	no
O	O	in	yes
B-drug	B-drug	Desloratadine	yes
O	O	and	yes
B-drug_n	B-drug_n	3-Hydroxydesloratadine	no
O	O	Pharmacokinetics	no
O	O	in	yes
O	O	Healthy	no
O	O	Male	no
O	O	and	yes
O	O	Female	no
O	O	Volunteers	no

O	O	If	no
O	O	it	no
O	O	is	yes
O	O	necessary	no
O	O	to	no
O	O	continue	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	,	no
O	O	initiate	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	PRINIVIL	yes
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	5	yes
O	O	mg	yes
O	O	daily	no
O	O	,	no
O	O	and	yes
O	O	provide	no
O	O	close	no
O	O	medical	yes
O	O	supervision	no
O	O	after	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	until	no
O	O	blood	yes
O	O	pressure	no
O	O	has	no
O	O	stabilized	no
O	O	.	no

O	O	Diabetics	no
O	O	who	no
O	O	take	no
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	by	no
O	O	their	no
O	O	physicians	no
O	O	.	no

O	O	if	no
O	O	plasma	yes
O	O	levels	no
O	O	are	no
O	O	being	no
O	O	monitored	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	reassessed	no
O	O	.	no

O	O	In	yes
O	O	adjuvant	no
O	O	trials	no
O	O	of	yes
B-drug	B-drug	epirubicin-containing	no
O	O	CEF-120	no
O	O	or	no
O	O	FEC-100	no
O	O	chemotherapies	no
O	O	,	no
O	O	breast	no
O	O	irradiation	no
O	O	was	no
O	O	delayed	no
O	O	until	no
O	O	after	no
O	O	chemotherapy	no
O	O	was	no
O	O	completed	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inducer	no
O	O	of	yes
O	O	hepatic	no
O	O	drug-metabolizing	no
O	O	enzymes	yes
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	warranted	no
O	O	and	yes
O	O	clinical	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	In	yes
O	O	both	no
O	O	species	no
O	O	,	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	,	no
O	O	but	no
O	O	not	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	,	no
O	O	antagonized	no
O	O	the	no
O	O	rate-decreasing	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	on	no
O	O	FI	no
O	O	and	yes
O	O	FR	no
O	O	responding	no
O	O	.	no

B-drug	B-drug	Glibenclamide	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	7	yes
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	acitretin	yes
O	O	treatment	no
O	O	potentiated	no
O	O	the	no
O	O	blood	yes
O	O	glucose	yes
O	O	lowering	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	glibenclamide	yes
O	O	(	no
O	O	a	yes
B-group	B-group	sulfonylurea	no
O	O	similar	no
O	O	to	no
B-drug	B-drug	chlorpropamide	yes
O	O	)	no
O	O	in	yes
O	O	3	yes
O	O	of	yes
O	O	the	no
O	O	7	yes
O	O	subjects	no
O	O	.	no

O	O	By	no
O	O	this	no
O	O	procedure	no
O	O	,	no
O	O	it	no
O	O	was	no
O	O	observed	no
O	O	that	no
B-drug_n	B-drug_n	arsenate	no
O	O	is	yes
O	O	rapidly	yes
O	O	and	yes
O	O	essentially	no
O	O	completely	no
O	O	absorbed	no
O	O	(	no
O	O	80-95	no
O	O	%	no
O	O	)	no
O	O	from	no
O	O	the	no
O	O	lumen	no
O	O	at	yes
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
O	O	concentrations	no
O	O	up	no
O	O	to	no
O	O	5	yes
O	O	mM	yes
O	O	,	no
O	O	declining	no
O	O	to	no
O	O	about	no
O	O	50	yes
O	O	%	no
O	O	absorption	no
O	O	at	yes
O	O	50	yes
O	O	mM	yes
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	QTc	no
O	O	prolongation	no
O	O	,	no
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	TdP	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	amiodarone	yes
O	O	when	no
B-group	B-drug	fluoroquinolones	no
O	O	,	no
B-group	B-drug	macrolide	no
I-group	I-drug	antibiotics	no
O	O	,	no
O	O	or	no
O	O	azoles	no
O	O	were	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	cinchophen	no
O	O	;	no

B-drug	B-drug	Cholestyramine	yes
B-group	B-group	resin	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	drugs	no
O	O	that	no
O	O	undergo	no
O	O	enterohepatic	no
O	O	circulation	no
O	O	,	no
O	O	The	no
O	O	discontinuance	no
O	O	of	yes
B-drug	B-drug	cholestyramine	yes
B-group	B-group	resin	yes
O	O	could	no
O	O	pose	no
O	O	a	yes
O	O	hazard	no
O	O	to	no
O	O	health	no
O	O	if	no
O	O	a	yes
O	O	potentially	no
O	O	toxic	no
O	O	drug	yes
O	O	such	no
O	O	as	yes
B-group	B-group	digitalis	yes
O	O	has	no
O	O	been	no
O	O	filtrated	no
O	O	to	no
O	O	a	yes
O	O	maintenance	no
O	O	level	no
O	O	while	no
O	O	the	no
O	O	patient	no
O	O	was	no
O	O	taking	no
B-drug	B-drug	cholestyramine	yes
B-group	B-group	resin	yes
O	O	.	no

B-drug	B-drug	Ibuprofen	yes
O	O	-	yes
B-drug	B-drug	L-arginine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ibuprofen	yes
O	O	if	no
O	O	taken	no
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	Prednisone/prednisolone	no
O	O	:	no
B-drug	B-drug	Rofecoxib	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	prednisolone	yes
O	O	or	no
B-drug	B-drug	prednisone	yes
O	O	.	no

O	O	Therefore	no
O	O	smaller	no
B-brand	B-brand	ALFENTA	yes
O	O	doses	no
O	O	will	no
O	O	be	no
O	O	required	no
O	O	with	yes
O	O	prolonged	no
O	O	administration	no
O	O	and	yes
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	action	no
O	O	of	yes
B-brand	B-brand	ALFENTA	yes
O	O	my	no
O	O	be	no
O	O	extended	yes
O	O	.	no

O	O	Reductions	no
O	O	in	yes
O	O	serum	yes
O	O	endogenous	no
O	O	vitamin	yes
O	O	D	yes
O	O	concentrations	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	300	yes
O	O	mg/day	no
O	O	to	no
O	O	1200	no
O	O	mg/day	no
B-drug	B-drug	ketoconazole	yes
O	O	for	yes
O	O	a	yes
O	O	week	no
O	O	to	no
O	O	healthy	no
O	O	men	no
O	O	.	no

B-drug	B-drug	Methadone	yes
O	O	dose	no
O	O	was	no
O	O	increased	no
O	O	by	no
O	O	a	yes
O	O	mean	no
O	O	of	yes
O	O	22	no
O	O	%	no
O	O	to	no
O	O	alleviate	no
O	O	withdrawal	no
O	O	symptoms	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	ENABLEX	yes
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinergic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	frequency	no
O	O	and/or	no
O	O	severity	no
O	O	of	yes
O	O	dry	no
O	O	mouth	no
O	O	,	no
O	O	constipation	no
O	O	,	no
O	O	blurred	no
O	O	vision	no
O	O	and	yes
O	O	other	no
O	O	anticholinergic	no
O	O	pharmacological	no
O	O	effects	no
O	O	.	no

O	O	You	no
O	O	may	no
O	O	require	no
O	O	a	yes
O	O	dosage	no
O	O	adjustment	no
O	O	or	no
O	O	special	yes
O	O	monitoring	no
O	O	if	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	medicines	no
O	O	listed	no
O	O	above	no
O	O	.	no

B-drug	B-drug	Nateglinide	yes
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	(	no
O	O	98	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	mainly	no
O	O	albumin	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	Generally	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	some	no
O	O	other	no
B-group	B-group	quinolones	no
O	O	,	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	elevated	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	and	yes
O	O	prolongation	no
O	O	of	yes
O	O	its	no
O	O	elimination	no
O	O	half-life	no
O	O	.	no

O	O	This	no
O	O	problem	no
O	O	has	no
O	O	been	no
O	O	analysed	no
O	O	using	no
O	O	two	no
O	O	different	no
O	O	tasks	no
O	O	in	yes
O	O	mice	no
O	O	:	no
O	O	a	yes
O	O	bar-press	no
O	O	conditioning	no
O	O	and	yes
O	O	a	yes
O	O	spatial	no
O	O	discrimination	no
O	O	task	no
O	O	.	no

O	O	Patients	no
O	O	with	yes
O	O	Hepatic	no
O	O	Impairment	no
O	O	In	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	evidence	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	erlotinib	yes
O	O	is	yes
O	O	cleared	no
O	O	primarily	no
O	O	by	no
O	O	the	no
O	O	liver	yes
O	O	.	no

O	O	Of	yes
O	O	over	no
O	O	3500	no
O	O	patients	no
O	O	enrolled	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	Ibandronate	yes
O	O	osteoporosis	no
O	O	Treatment	no
O	O	and	yes
O	O	Prevention	no
O	O	Studies	no
O	O	,	no
O	O	15	yes
O	O	%	no
O	O	used	no
O	O	anti-peptic	no
O	O	agents	yes
O	O	(	no
O	O	primarily	no
B-group	B-group	H2	no
I-group	I-group	blockers	no
O	O	and	yes
B-group	B-group	PPIs	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Desloratadine	yes
I-drug	B-drug_n	3-Hydroxydesloratadine	no

O	O	More	no
O	O	importantly	no
O	O	,	no
O	O	we	no
O	O	demonstrate	no
O	O	that	no
O	O	IgA	no
O	O	is	yes
O	O	probably	no
O	O	the	no
O	O	major	no
O	O	serum	yes
O	O	constituent	no
O	O	precipitated	yes
O	O	by	no
O	O	the	no
O	O	lectin	yes
O	O	and	yes
O	O	that	no
O	O	no	yes
O	O	IgG	yes
O	O	or	no
O	O	IgM	no
O	O	can	no
O	O	be	no
O	O	detected	no
O	O	in	yes
O	O	the	no
O	O	precipitates	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	on	no
O	O	other	no
B-group	B-group	progestational	no
I-group	I-group	contraceptives	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	O	implants	no
O	O	,	no
O	O	injectables	no
O	O	)	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	These	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	coad-ministered	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
B-group	B-group	antigout	no
I-group	I-group	medications	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	to	no
O	O	control	no
O	O	hyperuricemia	no
O	O	and	yes
O	O	gout	no
O	O	.	no
O	O	)	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	False	no
O	O	elevations	no
O	O	of	yes
O	O	urinary	yes
O	O	catecholamine	no
O	O	levels	no
O	O	may	no
O	O	occur	no
O	O	due	no
O	O	to	no
O	O	interference	no
O	O	with	yes
O	O	the	no
O	O	fluorescence	no
O	O	test	yes
O	O	.	no

O	O	In	yes
O	O	these	no
O	O	six	no
O	O	cases	no
O	O	it	no
O	O	was	no
O	O	demonstrated	no
O	O	that	no
O	O	the	no
B-group	B-group	neuroleptics	no
O	O	dosage	no
O	O	was	no
O	O	inappropriate	no
O	O	,	no
O	O	being	no
O	O	either	no
O	O	too	no
O	O	high	yes
O	O	or	no
O	O	too	no
O	O	low	yes
O	O	as	yes
O	O	judged	no
O	O	from	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	low	yes
B-drug	B-drug	amiodarone	yes
O	O	serum	yes
O	O	levels	no
O	O	and	yes
O	O	potential	no
O	O	decrease	no
O	O	in	yes
O	O	efficacy	no
O	O	.	no

B-group	B-group	Vasopressors	no
O	O	:	no
B-drug	B-drug	Thyroxine	no
O	O	increases	no
O	O	the	no
O	O	adrenergic	no
O	O	effect	no
O	O	of	yes
B-group	O	catecholamines	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	epinephrine	yes
O	O	and	yes
B-drug	B-drug	norepinephrine	yes
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	TRACRIUM	yes
O	O	include	no
O	O	:	no
B-drug	B-drug	enflurane	yes
O	O	;	no
B-drug	B-drug	isoflurane	yes
O	O	;	no
B-drug	B-drug	halothane	yes
O	O	;	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	,	no
O	O	especially	no
O	O	the	no
B-group	B-group	aminoglycosides	no
O	O	and	yes
B-group	B-group	polymyxins	no
O	O	;	no
B-drug	B-drug	lithium	yes
O	O	;	no
B-drug	B-drug	magnesium	yes
O	O	salts	no
O	O	;	no
B-drug	B-drug	procainamide	yes
O	O	;	no
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	whenever	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	other	no
O	O	drugs	no
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	co-therapy	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

B-group	B-group	ACE	no
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	renal	no
O	O	impairment	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	volume-depleted	no
O	O	patients	no
O	O	.	no

B-group	B-group	barbiturates	no
O	O	;	no

O	O	b	yes
O	O	.	no

B-drug	B-drug	Paroxetine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	20	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	20	yes
O	O	mg	yes
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	produce	no
O	O	any	no
O	O	interaction	no
O	O	on	no
O	O	psychomotor	no
O	O	performance	no
O	O	.	no

O	O	ulcerans	no
O	O	was	no
O	O	measured	no
O	O	by	no
O	O	plate	no
O	O	counts	no
O	O	and	yes
O	O	the	no
O	O	BACTEC	no
O	O	radiometric	no
O	O	method	yes
O	O	.	no

O	O	The	no
O	O	objective	no
O	O	of	yes
O	O	this	no
O	O	study	no
O	O	was	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	when	no
B-drug	B-drug	amprenavir	yes
O	O	is	yes
O	O	given	no
O	O	with	yes
B-drug	B-drug	rifabutin	yes
O	O	or	no
B-drug	B-drug	rifampin	yes
O	O	and	yes
O	O	to	no
O	O	determine	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	on	no
O	O	the	no
O	O	erythromycin	yes
O	O	breath	yes
O	O	test	yes
O	O	(	no
O	O	ERMBT	no
O	O	)	no
O	O	.	no

O	O	Stereoselective	no
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	N-allylnormetazocine	no
O	O	in	yes
O	O	pigeons	no
O	O	and	yes
O	O	squirrel	no
O	O	monkeys	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	on	no
O	O	CYP1A2	no
O	O	was	no
O	O	explored	no
O	O	further	no
O	O	in	yes
O	O	a	yes
O	O	clinical	no
O	O	interaction	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	and	yes
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	metabolism	no
O	O	was	no
O	O	observed	no
O	O	.	no

B-drug	I-drug	Nabilone	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	taking	no
O	O	other	no
B-group	B-group	psychoactive	no
I-group	I-group	drugs	no
O	O	or	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	,	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	and	yes
B-group	B-group	narcotic	no
I-group	I-group	analgesics	no
O	O	,	no
O	O	or	no
O	O	to	no
O	O	those	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	psychiatric	no
O	O	disorder	no
O	O	(	no
O	O	including	no
O	O	manic-depressive	no
O	O	illness	no
O	O	and	yes
O	O	schizophrenia	no
O	O	)	no
O	O	.	no

O	O	Drug-Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	and	yes
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	prophylaxis	no
O	O	.	no

B-group	B-group	Sedatives/Hypnotics	no
O	O	:	no
B-drug	B-drug	triazolam	yes
O	O	,	no
B-drug	B-drug	midazolam	yes
O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	prolonged	no
O	O	or	no
O	O	increased	no
O	O	sedation	no
O	O	or	no
O	O	respiratory	no
O	O	depression	no
O	O	.	no

O	O	Drug	yes
O	O	Class	no
O	O	Examples	no
O	O	of	yes
O	O	Drugs	no

O	O	Dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	current	no
O	O	study	no
O	O	,	no
O	O	the	no
O	O	nonpredisposed	no
O	O	strain	no
O	O	C57BL/6N	no
O	O	was	no
O	O	also	no
O	O	shown	no
O	O	to	no
O	O	be	no
O	O	highly	no
O	O	susceptible	no
O	O	to	no
O	O	diethylnitrosamine	no
O	O	during	no
O	O	the	no
O	O	neonatal	yes
O	O	period	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	(	no
B-drug	B-drug	Primidone	yes
O	O	)	no
O	O	:	no
O	O	Population	no
O	O	pharmacokinetic	no
O	O	analyses	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	tiagabine	yes
O	O	clearance	no
O	O	is	yes
O	O	60	no
O	O	%	no
O	O	greater	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	phenobarbital	yes
O	O	(	no
B-drug	B-drug	primidone	yes
O	O	)	no
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	other	no
O	O	enzyme-inducing	no
B-group	B-group	AEDs	no
O	O	.	no

O	O	BACKGROUND	no
O	O	:	no
O	O	Since	no
O	O	its	no
O	O	approval	no
O	O	by	no
O	O	the	no
O	O	US	no
O	O	Food	no
O	O	and	yes
O	O	Drug	yes
O	O	Administration	no
O	O	in	yes
O	O	March	no
O	O	1998	no
O	O	,	no
B-drug	B-drug	sildenafil	yes
I-drug	I-drug	citrate	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	by	no
O	O	millions	no
O	O	of	yes
O	O	men	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	erectile	no
O	O	dysfunction	no
O	O	.	no

O	O	unreliable	no
O	O	prothrombin	yes
O	O	time	no
O	O	determinations	no
O	O	;	no

O	O	Additional	no
B-drug	B-drug	iron	yes
O	O	significantly	no
O	O	inhibited	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	cobalt	yes
O	O	in	yes
O	O	both	no
O	O	dietary	no
B-drug	B-drug	cobalt	yes
O	O	treatments	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	clear	no
O	O	whether	no
O	O	this	no
O	O	was	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
O	O	therapy	no
O	O	.	no

O	O	increased	no
O	O	creatine	yes

O	O	A	yes
O	O	number	no
O	O	of	yes
O	O	substances	no
O	O	affect	no
O	O	glucose	yes
O	O	metabolism	no
O	O	and	yes
O	O	may	no
O	O	require	no
O	B-drug	insulin	yes
O	O	dose	no
O	O	adjustment	no
O	O	and	yes
O	O	particularly	no
O	O	close	no
O	O	monitoring	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	(	no
B-group	B-group	beta-blockers	no
O	O	)	no
O	O	and	yes
B-brand	B-brand	BROVANA	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	when	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	the	no
O	O	chemical	yes
O	O	resemblance	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	with	yes
B-drug	B-drug	itraconazole	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	Unless	no
O	O	really	no
O	O	needed	no
O	O	,	no
O	O	agents	yes
O	O	which	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hemorrhage	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
B-brand	B-brand	Lovenox	yes
O	O	Injection	yes
O	O	therapy	no
O	O	.	no

O	O	With	yes
O	O	the	no
O	O	morning	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	ceftibuten	yes
O	O	on	no
O	O	day	no
O	O	6	yes
O	O	,	no
O	O	each	no
O	O	volunteer	no
O	O	received	no
O	O	a	yes
O	O	single	yes
O	O	intravenous	yes
O	O	infusion	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	4	yes
O	O	mg/kg	no
O	O	)	no
O	O	.	no

O	O	Ways	no
O	O	of	yes
O	O	improving	no
O	O	the	no
O	O	adequacy	no
O	O	of	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	psychotic	no
O	O	patients	no
O	O	with	yes
B-group	B-group	neuroleptics	no
O	O	are	no
O	O	discussed	no
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
B-drug	O	wthionamide	no
O	O	(	no
B-brand	B-brand	Trecator-SC	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	(	no
B-brand	B-brand	Nydrazid	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	include	no
O	O	some	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	enzyme	no
O	O	(	no
B-drug	B-drug	quinidine	yes
O	O	;	no

B-drug	B-drug	Methadone	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	and	yes
B-drug	B-drug	methadone	yes
O	O	can	no
O	O	decrease	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	methadone	yes
O	O	.	no

B-drug_n	B-drug_n	N-methyllevallorphan	no
O	O	(	no
O	O	5	yes
O	O	mg/kg	no
O	O	,	no
O	O	s.c	no
O	O	.	no
O	O	)	no

O	O	Studies	no
O	O	showed	no
O	O	that	no
B-drug	B-drug	diltiazem	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	and	yes
B-drug	B-drug	triazolam	yes
O	O	by	no
O	O	3-4	no
O	O	fold	no
O	O	and	yes
O	O	the	no
O	O	Cmax	no
O	O	by	no
O	O	2-fold	no
O	O	,	no
O	O	compared	no
O	O	to	no
O	O	placebo	no
O	O	.	no

B-brand	B-brand	AMEVIVE	no
O	O	is	yes
O	O	not	no
O	O	indicated	no
O	O	for	yes
O	O	pediatric	yes
O	O	patients	no
O	O	.	no

O	O	If	no
O	O	pregnancy	no
O	O	occurs	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	or	no
O	O	partner	no
O	O	of	yes
O	O	a	yes
O	O	patient	no
O	O	during	no
O	O	treatment	no
O	O	or	no
O	O	during	no
O	O	the	no
O	O	6	yes
O	O	months	no
O	O	after	no
O	O	treatment	no
O	O	cessation	no
O	O	,	no
O	O	such	no
O	O	cases	no
O	O	should	no
O	O	be	no
O	O	reported	no
O	O	to	no
O	O	the	no
B-brand	B-brand	COPEGUS	yes
O	O	Pregnancy	no
O	O	Registry	no
O	O	at	yes
O	O	1-800-526-6367	no
O	O	.	no

O	O	.	no

O	O	Steady-state	no
B-drug	B-drug	bosentan	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	were	no
O	O	3-	no
O	O	to	no
O	O	4-fold	no
O	O	higher	no
O	O	than	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	I-drug	A	yes
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	such	no
O	O	agents	yes
O	O	.	no

O	O	this	no
O	O	did	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	its	no
O	O	effect	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	these	no
O	O	studies	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	concluded	no
O	O	that	no
B-drug	B-drug	azithromycin	yes
O	O	may	no
O	O	be	no
O	O	safely	no
O	O	coadministered	no
O	O	with	yes
O	O	both	no
B-drug	B-drug	zidovudine	yes
O	O	and	yes
B-drug	B-drug	dideoxyinosine	yes
O	O	.	no

O	O	Hypotension	no
O	O	-	yes
O	O	Patients	no
O	O	on	no
B-group	O	Diuretic	no
O	O	Therapy	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	diuretics	no
O	O	,	no
O	O	and	yes
O	O	especially	no
O	O	those	no
O	O	in	yes
O	O	whom	no
B-group	O	diuretic	no
O	O	therapy	no
O	O	was	no
O	O	recently	no
O	O	instituted	no
O	O	,	no
O	O	may	no
O	O	occasionally	no
O	O	experience	no
O	O	an	no
O	O	excessive	no
O	O	reduction	yes
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	PRINIVIL	yes
O	O	.	no

B-drug	B-drug	Metformin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	single-dose	no
O	O	interaction	no
O	O	study	no
O	O	in	yes
O	O	NIDDM	no
O	O	subjects	no
O	O	,	no
O	O	decreases	no
O	O	in	yes
B-drug	B-drug	glyburide	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	were	no
O	O	observed	no
O	O	,	no
O	O	but	no
O	O	were	no
O	O	highly	no
O	O	variable	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	bioavailability	no
O	O	of	yes
O	O	the	no
O	O	capsule	yes
O	O	formulation	no
O	O	of	yes
B-drug	B-drug	cefprozil	yes
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	when	no
O	O	administered	no
O	O	5	yes
O	O	minutes	no
O	O	following	no
O	O	an	no
B-group	B-group	antacid	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
O	O	using	no
O	O	these	no
B-group	O	blocking	no
I-group	O	agents	yes
O	O	to	no
O	O	treat	no
O	O	hypertension	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	carefully	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	confirm	no
O	O	that	no
O	O	the	no
O	O	desired	no
O	O	therapeutic	no
O	O	effect	no
O	O	has	no
O	O	been	no
O	O	obtained	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	was	no
O	O	not	no
O	O	accompanied	no
O	O	by	no
O	O	ECG	no
O	O	changes	no
O	O	and	yes
O	O	its	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

B-group	B-group	Veratrum	no
I-group	I-group	alkaloids	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	inhibit	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	veratrum	no
I-group	I-group	alkaloids	yes
O	O	.	no

O	O	aBased	no
O	O	on	no
O	O	reports	no
O	O	of	yes
B-group	O	narcotic	no
O	O	withdrawal	no
O	O	syndrome	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	and	yes
B-drug	B-drug	methadone	yes
O	O	concurrently	no
O	O	,	no
O	O	and	yes
O	O	evidence	no
O	O	of	yes
O	O	decreased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	methadone	yes
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	naproxen	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	urinary	yes
O	O	values	no
O	O	for	yes
O	O	17-ketogenic	no
O	O	steroids	no
O	O	because	no
O	O	of	yes
O	O	an	no
O	O	interaction	no
O	O	between	yes
O	O	the	no
O	O	drug	yes
O	O	and/or	no
O	O	its	no
O	O	metabolites	no
O	O	with	yes
B-drug_n	O	m-dinitrobenzene	no
O	O	used	no
O	O	in	yes
O	O	this	no
O	O	assay	no
O	O	.	no

O	O	these	no
O	O	enzymes	yes
O	O	would	no
O	O	therefore	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	inhibited	no
O	O	in	yes
O	O	clinical	no
O	O	use	no
O	O	.	no

O	O	The	no
O	O	reduced	yes
O	O	risk	no
O	O	of	yes
O	O	adverse	no
O	O	events	no
O	O	and	yes
O	O	therapeutic	no
O	O	superiority	no
O	O	compared	no
O	O	with	yes
B-drug	B-drug	haloperidol	yes
O	O	and	yes
B-drug	B-drug	risperidone	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	negative	no
O	O	and	yes
O	O	depressive	no
O	O	symptoms	no
O	O	support	no
O	O	the	no
O	O	choice	no
O	O	of	yes
B-drug	B-drug	olanzapine	yes
O	O	as	yes
O	O	a	yes
O	O	first-line	no
O	O	option	no
O	O	in	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	schizophrenia	no
O	O	in	yes
O	O	the	no
O	O	acute	no
O	O	phase	no
O	O	and	yes
O	O	for	yes
O	O	the	no
O	O	maintenance	no
O	O	of	yes
O	O	treatment	no
O	O	response	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	12	yes
O	O	schizophrenic	no
O	O	patients	no
O	O	coadministered	no
O	O	oral	yes
B-drug	B-drug	haloperidol	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	haloperidol	yes
O	O	levels	no
O	O	were	no
O	O	decreased	no
O	O	by	no
O	O	a	yes
O	O	mean	no
O	O	of	yes
O	O	70	yes
O	O	%	no
O	O	and	yes
O	O	mean	no
O	O	scores	no
O	O	on	no
O	O	the	no
O	O	Brief	no
O	O	Psychiatric	no
O	O	Rating	no
O	O	Scale	no
O	O	were	no
O	O	increased	no
O	O	from	no
O	O	baseline	no
O	O	.	no

O	O	Co-administration	no
O	O	with	yes
B-group	B-group	antifungal	no
I-group	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	or	no
B-drug	B-drug	itraconazole	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Leucovorin	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
O	B-drug	5-fluorouracil	yes
O	O	.	no

O	O	Laboratory	no
O	O	Tests	no
O	O	Pregnancy	no
O	O	Test	yes
O	O	Female	no
O	O	patients	no
O	O	of	yes
O	O	childbearing	no
O	O	potential	no
O	O	must	no
O	O	have	no
O	O	negative	no
O	O	results	no
O	O	from	no
O	O	2	yes
O	O	urine	no
O	O	or	no
O	O	serum	yes
O	O	pregnancy	no
O	O	tests	no
O	O	with	yes
O	O	a	yes
O	O	sensitivity	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	25	yes
O	O	mIU/mL	no
O	O	before	no
O	O	receiving	no
O	O	the	no
O	O	initial	no
B-brand	B-brand	Accutane	yes
O	O	prescription	no
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	include	no
O	O	some	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	enzyme	no
O	O	(	no
B-drug	B-drug	quinidine	yes
O	O	;	no

O	B-drug	Mineral	no
O	I-drug	oil	yes
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	fat-soluble	no
I-group	I-group	vitamins	no
O	O	,	no
O	O	including	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	preparations	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	half-life	no
O	O	of	yes
O	O	elimination	no
O	O	was	no
O	O	prolonged	no
O	O	from	no
O	O	34	no
O	O	+/-	no
O	O	13	yes
O	O	to	no
O	O	40	yes
O	O	+/-	no
O	O	16	yes
O	O	hours	no
O	O	(	no
O	O	p	yes
O	O	less	no
O	O	than	no
O	O	0.05	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	based	no
O	O	on	no
O	O	these	no
O	O	in	yes
O	O	vitro	no
O	O	data	no
O	O	,	no
B-drug	B-drug	estazolam	yes
O	O	is	yes
O	O	very	no
O	O	unlikely	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	biotransformation	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	CYP	no
O	O	isoforms	no

O	O	The	no
O	O	biochemical	no
O	O	toxicology	no
O	O	of	yes
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	,	no
O	O	a	yes
O	O	known	no
O	O	metabolite	yes
O	O	of	yes
O	O	the	no
O	O	major	no
O	O	ingredient	no
O	O	of	yes
O	O	the	no
O	O	pesticide	no
B-brand	B-drug_n	Gliftor	no
O	O	(	no
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	)	no
O	O	,	no
O	O	was	no
O	O	investigated	no
O	O	in	yes
O	O	vivo	no
O	O	and	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	No	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	was	no
O	O	identified	no
O	O	.	no

B-drug	B-drug	Alprazolam	yes
O	O	:	no
O	O	When	no
B-drug	B-drug	fluvoxamine	yes
I-drug	I-drug	maleate	yes
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	qd	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	alprazolam	yes
O	O	(	no
O	O	1	yes
O	O	mg	yes
O	O	q.d	no
O	O	.	no
O	O	were	no
O	O	co-administered	no
O	O	to	no
O	O	steady	no
O	O	state	no
O	O	,	no
O	O	plasma	yes
O	O	concentration	no
O	O	and	yes
O	O	other	no
O	O	pharmacokinetics	no
O	O	parameters	no
O	O	(	no
O	O	AUC	no
O	O	,	no
O	O	Cmax	no
O	O	,	no
O	O	T1/2	no
O	O	,	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	were	no
O	O	approximately	no
O	O	twice	no
O	O	those	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	alprazolam	yes
O	O	was	no
O	O	administered	no
O	O	alone	no
O	O	;	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	have	no
O	O	been	no
O	O	observed	no

O	O	Certain	no
O	O	drugs	no
O	O	tend	no
O	O	to	no
O	O	produce	no
O	O	hyperglycemia	no
O	O	and	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	control	no
O	O	.	no

O	O	These	no
O	O	compounds	no
O	O	are	no
O	O	metabolized	no
O	O	through	no
O	O	various	no
O	O	cytochrome	no
O	O	P450	no
O	O	isozymes	no
O	O	including	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	and	yes
O	O	CYP3A	no
O	O	.	no

B-drug	B-drug	Efavirenz	yes

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug_n	fenofibric	yes
I-drug	I-drug_n	acid	yes
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	atorvastatin	yes

B-drug	B-drug	Acebutolol	yes
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	nadolol	yes
O	O	(	no
O	O	low	yes
O	O	hepatic	no
O	O	clearance	no
O	O	or	no
O	O	no	yes
O	O	first-pass	no
O	O	metabolism	no
O	O	)	no
O	O	are	no
O	O	unlikely	no
O	O	to	no
O	O	be	no
O	O	affected	no
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	include	no
O	O	some	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	enzyme	no
O	O	(	no
B-drug	B-drug	quinidine	yes
O	O	;	no

O	O	Drugs	no
O	O	Demonstrated	no
O	O	to	no
O	O	be	no
O	O	CYP	no
O	O	3A	yes
O	O	Inhibitors	no
O	O	of	yes
O	O	Possible	no
O	O	Clinical	no
O	O	Significance	no
O	O	on	no
O	O	the	no
O	O	Basis	no
O	O	of	yes
O	O	Clinical	no
O	O	Studies	no
O	O	Involving	no
B-drug	B-drug	Alprazolam	yes
O	O	(	no
O	O	caution	no
O	O	is	yes
O	O	recommended	no
O	O	during	no
O	O	coadministration	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	)	no
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	increased	no
O	O	the	no
O	O	maximum	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	by	no
O	O	46	no
O	O	%	no
O	O	,	no
O	O	decreased	no
O	O	clearance	no
O	O	by	no
O	O	21	yes
O	O	%	no
O	O	,	no
O	O	increased	no
O	O	half-life	no
O	O	by	no
O	O	17	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	decreased	no
O	O	measured	no
O	O	psychomotor	no
O	O	performance	no
O	O	.	no

O	O	The	no
O	O	serum	yes
O	O	androgen	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	+	no
O	B-drug_n	endotoxin-treated	no
O	O	rats	no
O	O	did	no
O	O	not	no
O	O	change	no
O	O	significantly	no
O	O	,	no
O	O	while	no
O	O	those	no
O	O	of	yes
O	B-drug_n	endotoxin-treated	no
O	O	rats	no
O	O	dropped	no
O	O	to	no
O	O	30-40	no
O	O	%	no

O	O	The	no
O	O	mechanism	no
O	O	for	yes
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-drug	B-drug	Sucralfate	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	within	no
O	O	2	yes
O	O	hours	no
O	O	of	yes
B-brand	B-brand	FACTIVE	yes
O	O	.	no

B-drug	B-drug	Diltiazem	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	verapamil	yes

O	O	In	yes
O	O	contrast	no
O	O	,	no
B-drug	B-drug	atropine	yes
O	O	increased	no
O	O	the	no
O	O	amplitudes	no
O	O	of	yes
O	O	components	no
O	O	P1	no
O	O	and	yes
O	O	P2	no
O	O	,	no
O	O	while	no
O	O	decreasing	no
O	O	components	no
O	O	N1	no
O	O	,	no
O	O	N2	no
O	O	and	yes
O	O	N3	no
O	O	for	yes
O	O	varying	no
O	O	durations	no
O	O	of	yes
O	O	time	no
O	O	.	no

B-drug	B-drug	Clindamycin	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	properties	no
O	O	that	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	action	no
O	O	of	yes
O	O	other	no
B-group	B-group	neuromuscular	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	of	yes
O	O	clinical	no
O	O	importance	no
O	O	have	no
O	O	been	no
O	O	identified	no
O	O	.	no

O	O	Prior	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	has	no
O	O	no	yes
O	O	clinically	no
O	O	important	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	NUROMAX	yes
O	O	.	no

B-drug	B-drug	Imipramine	yes
I-drug	I-drug	hydrochloride	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	.	no

B-brand	B-brand	SUSTIVA	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	decrease	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	.	no

O	O	Since	no
O	O	symptoms	no
O	O	of	yes
O	O	anticholinesterase	no
O	O	overdose	no
O	O	(	no
O	O	cholinergic	no
O	O	crisis	no
O	O	)	no
O	O	may	no
O	O	mimic	no
O	O	underdosage	no
O	O	(	no
O	O	myasthenic	no
O	O	weakness	no
O	O	)	no
O	O	,	no
O	O	their	no
O	O	condition	no
O	O	may	no
O	O	be	no
O	O	worsened	no
O	O	by	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	drug	yes
O	O	.	no

O	O	Since	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	AMEVIVE	no
O	O	on	no
O	O	pregnancy	no
O	O	and	yes
O	O	fetal	no
O	O	development	no
O	O	,	no
O	O	including	no
O	O	immune	yes
O	O	system	yes
O	O	development	no
O	O	,	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	,	no
O	O	health	no
O	O	care	yes
O	O	providers	no
O	O	are	no
O	O	encouraged	no
O	O	to	no
O	O	enroll	no
O	O	patients	no
O	O	currently	no
O	O	taking	no
B-brand	B-brand	AMEVIVE	no
O	O	who	no
O	O	become	no
O	O	pregnant	no
O	O	into	no
O	O	the	no
B-brand	O	Biogen	no
O	O	Pregnancy	no
O	O	Registry	no
O	O	by	no
O	O	calling	no
O	B-brand	1-866-AMEVIVE	no
O	O	(	no
O	O	1-866-263-8483	no
O	O	)	no
O	O	.	no

O	O	Myocardial	no
O	O	injury	no
O	O	,	no
O	O	including	no
O	O	myocardial	no
O	O	infarction	no
O	O	,	no
O	O	myocarditis	no
O	O	,	no
O	O	ventricular	no
O	O	hypokinesia	no
O	O	,	no
O	O	and	yes
O	O	severe	no
O	O	rhabdomyolysis	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	PROLEUKIN	yes
O	O	and	yes
B-drug	B-drug	interferon-alfa	no
O	O	concurrently	no
O	O	.	no

O	O	In	yes
O	O	comparison	no
O	O	to	no
O	O	saline	yes
O	O	values	no
O	O	,	no
O	O	all	yes
O	O	three	no
O	O	agents	yes
O	O	produced	no
O	O	reliable	no
O	O	increases	no
O	O	in	yes
O	O	peak	no
O	O	latency	no
O	O	for	yes
O	O	most	no
O	O	of	yes
O	O	the	no
O	O	components	no
O	O	,	no
O	O	with	yes
O	O	only	no
O	O	N3	no
O	O	showing	no
O	O	no	yes
O	O	effects	no
O	O	.	no

O	O	Understanding	no
O	O	the	no
O	O	breadth	no
O	O	of	yes
O	O	systemic	no
B-group	B-group	antimicrobial	no
I-group	I-group	agents	yes
O	O	available	no
O	O	for	yes
O	O	use	no
O	O	by	no
O	O	the	no
O	O	dermatologist	no
O	O	and	yes
O	O	their	no
O	O	associated	no
O	O	side-effect	no
O	O	profiles	no
O	O	and	yes
O	O	drug	yes
O	O	interactions	no
O	O	allows	no
O	O	the	no
O	O	clinician	no
O	O	to	no
O	O	offer	no
O	O	patients	no
O	O	optimal	no
O	O	care	yes
O	O	in	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	cutaneous	no
O	O	infectious	no
O	O	disease	no
O	O	.	no

O	O	Studies	no
O	O	in	yes
O	O	humans	no
O	O	show	no
O	O	that	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	chlorothiazide	yes
O	O	as	yes
O	O	reflected	no
O	O	in	yes
O	O	urinary	yes
O	O	excretion	no
O	O	is	yes
O	O	markedly	no
O	O	decreased	no
O	O	even	no
O	O	when	no
O	O	administered	no
O	O	one	no
O	O	hour	yes
O	O	before	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	(	no
O	O	Oral	yes
O	O	)	no
O	O	:	no
O	O	The	no
O	O	hypoprothrombinemic	no
O	O	effect	no
O	O	of	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	,	no
O	O	apparently	no
O	O	by	no
O	O	increased	no
O	O	catabloism	no
O	O	of	yes
O	O	vitamin	yes
O	O	K-dependent	yes
O	O	clotting	no
O	O	factors	no
O	O	.	no

B-drug	B-drug	Boric	no
I-drug	I-drug	acid	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	the	no
B-drug	B-drug	idoxuridine	yes
O	O	preparation	no
O	O	causing	no
O	O	a	yes
O	O	gritty	no
O	O	substance	yes
O	O	to	no
O	O	form	yes
O	O	or	no
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	preservative	yes
O	O	in	yes
O	O	the	no
B-drug	B-drug	idoxuridine	yes
O	O	preparation	no
O	O	causing	no
O	O	a	yes
O	O	toxic	no
O	O	effect	no
O	O	in	yes
O	O	the	no
O	O	eye	yes
O	O	.	no

O	O	Although	no
O	O	inhibition	no
O	O	of	yes
O	O	CYP	no
O	O	3A4/5	no
O	O	by	no
B-drug_n	B-drug	OXC	no
O	O	and	yes
B-drug_n	B-drug_n	MHD	no
O	O	did	no
O	O	occur	no
O	O	at	yes
O	O	high	yes
O	O	concentrations	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	clinical	no
O	O	significance	no
O	O	.	no

O	O	The	no
O	O	dosage	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	or	no
O	O	others	no
O	O	with	yes
O	O	a	yes
O	O	similar	no
O	O	metabolism	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	modified	yes
O	O	if	no
O	O	they	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	nilutamide	yes
O	O	.	no

O	O	Lastly	no
O	O	local	no
O	O	use	no
O	O	of	yes
O	O	the	no
O	O	mucocutaneous	no
O	O	and	yes
O	O	cytoprotective	no
O	O	properties	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	is	yes
O	O	still	no
O	O	valid	no
O	O	,	no
O	O	in	yes
O	B-drug	cardioplegic	yes
O	I-drug	solutions	no
O	O	and	yes
O	O	for	yes
O	O	preservation	no
O	O	of	yes
O	O	transplants	no
O	O	particularly	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	may	no
O	O	decrease	no
O	O	arterial	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	norepinephrine	yes
O	O	.	no

B-drug	I-drug	efavirenz	yes
O	O	concentration	no

O	O	In	yes
O	O	a	yes
O	O	Phase	no
O	O	I	yes
O	O	trial	no
O	O	using	no
O	O	escalating	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	(	no
O	O	110-200	no
O	O	mg/m2	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	cisplatin	yes
O	O	(	no
O	O	50	yes
O	O	or	no
O	O	75	yes
O	O	mg/m2	no
O	O	)	no
O	O	given	no
O	O	as	yes
O	O	sequential	no
O	O	infusions	no
O	O	,	no
O	O	myelosuppression	no
O	O	was	no
O	O	more	no
O	O	profound	no
O	O	when	no
B-brand	B-brand	TAXOL	yes
O	O	was	no
O	O	given	no
O	O	after	no
B-drug	B-drug	cisplatin	yes
O	O	than	no
O	O	with	yes
O	O	the	no
O	O	alternate	no
O	O	sequence	yes
O	O	(	no
O	O	ie	no
O	O	,	no
B-brand	B-brand	TAXOL	yes
O	O	before	no
B-drug	B-drug	cisplatin	yes
O	O	)	no
O	O	.	no

B-group	O	-adrenergic	no
I-group	O	Blockers	no
O	O	:	no
B-group	O	-adrenergic	no
I-group	O	blockers	no
O	O	may	no
O	O	weaken	no
O	O	or	no
O	O	antagonise	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	FORADIL	yes
O	O	.	no

O	O	The	no
O	O	key	no
O	O	to	no
O	O	maximizing	no
O	O	therapy	no
O	O	lies	no
O	O	in	yes
O	O	individualizing	no
O	O	it	no
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	possible	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	PROPECIA	yes
O	O	(	no
B-drug	B-drug	finasteride	yes
O	O	,	no
O	O	1	yes
O	O	mg	yes
O	O	)	no
O	O	in	yes
O	O	men	no
O	O	18-41	no
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	,	no
O	O	the	no
O	O	mean	no
O	O	value	no
O	O	of	yes
O	O	serum	yes
O	O	prostate-specific	no
O	O	antigen	yes
O	O	(	no
O	O	PSA	no
O	O	)	no
O	O	decreased	no
O	O	from	no
O	O	0.7	no
O	O	ng/mL	no
O	O	at	yes
O	O	baseline	no
O	O	to	no
O	O	0.5	yes
O	O	ng/mL	no
O	O	at	yes
O	O	Month	no
O	O	12	yes
O	O	.	no

O	O	The	no
O	O	patient	no
O	O	had	no
O	O	been	no
O	O	receiving	no
B-drug	B-drug	simvastatin	yes
O	O	for	yes
O	O	approximately	no
O	O	six	no
O	O	months	no
O	O	.	no

O	B-group	Ergot-containing	no
O	O	drugs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	prolonged	no
O	O	vasospastic	no
O	O	reactions	no
O	O	.	no

O	O	Poor	no
O	O	metabolizers	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	lasma	no
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-group	B-group	TCAs	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	.	no

B-group	B-drug	Antiarrhythmics	no
O	O	:	no
O	O	Other	no
B-group	B-drug	antiarrhythmic	no
I-group	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	have	no
O	O	been	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	because	no
B-drug	B-drug	nafarelin	yes
I-drug	I-drug	acetate	yes
O	O	is	yes
O	O	a	yes
O	O	peptide	yes
O	O	that	no
O	O	is	yes
O	O	primarily	no
O	O	degraded	yes
O	O	by	no
O	O	peptidase	no
O	O	and	yes
O	O	not	no
O	O	by	no
O	O	cytochrome	no
O	O	P-450	no
O	O	enzymes	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	drug	yes
O	O	is	yes
O	O	only	no
O	O	about	no
O	O	80	yes
O	O	%	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	at	yes
O	O	4	yes
O	O	C	yes
O	O	,	no
O	O	drug	yes
O	O	interactions	no
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	occur	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	since	no
O	O	there	no
O	O	is	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	with	yes
B-brand	B-brand	Xigris	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	employed	no
O	O	when	no
B-brand	B-brand	Xigris	no
O	O	is	yes
O	O	used	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	affect	no
O	O	hemostasis	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	new	no
O	O	cases	no
O	O	of	yes
O	O	diabetes	no
O	O	have	no
O	O	been	no
O	O	diagnosed	no
O	O	during	no
O	B-group	retinoid	yes
O	O	therapy	no
O	O	,	no
O	O	including	no
O	O	diabetic	no
O	O	ketoacidosis	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	contrary	no
O	O	,	no
B-drug_n	B-drug_n	neurotensin	no
O	O	and	yes
O	B-drug_n	tuftsin	no
O	O	were	no
O	O	agonists	no
O	O	in	yes
O	O	induction	no
O	O	of	yes
O	O	analgesia	no
O	O	.	no

O	O	A	yes
O	O	chemically	no
O	O	similar	no
O	O	drug	yes
O	O	in	yes
O	O	this	no
O	O	class	no
O	O	produced	no
O	O	optic	no
O	O	nerve	yes
O	O	degeneration	no
O	O	(	no
O	O	Wallerian	no
O	O	degeneration	no
O	O	of	yes
B-drug	O	retinogeniculate	no
O	O	fibers	no
O	O	)	no
O	O	in	yes
O	O	clinically	no
O	O	normal	yes
O	O	dogs	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	fashion	no
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	that	no
O	O	produced	no
O	O	plasma	yes
O	O	drug	yes
O	O	levels	no
O	O	about	no
O	O	30	yes
O	O	times	no
O	O	higher	no
O	O	than	no
O	O	the	no
O	O	mean	no
O	O	drug	yes
O	O	level	no
O	O	in	yes
O	O	humans	no
O	O	taking	no
O	O	the	no
O	O	highest	no
O	O	recommended	no
O	O	dose	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Furazolidone	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Furoxone	yes
O	O	)	no
O	O	or	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	with	yes
B-drug	B-drug	carbamazepine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	(	no
O	O	40	yes
O	O	%	no
O	O	to	no
O	O	72	no
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	toxicity	no
O	O	in	yes
O	O	some	no
O	O	cases	no
O	O	.	no

O	O	In	yes
O	O	single	yes
O	O	and	yes
O	O	multiple	no
O	O	dose	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
O	O	both	no
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	rofecoxib	yes
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	(	no
O	O	measured	no
O	O	as	yes
O	O	INR	no
O	O	)	no
O	O	was	no
O	O	increased	no
O	O	by	no
O	O	approximately	no
O	O	8	yes
O	O	%	no
O	O	to	no
O	O	11	yes
O	O	%	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	disulfiram	yes
O	O	or	no
B-drug	B-drug	diazepam	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	acamprosate	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	agents	yes
O	O	affecting	no
O	O	sympathetic	no
O	O	activity	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	ganglionic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	or	no
B-group	B-group	adrenergic	no
I-group	I-group	neuron	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	Reports	no
O	O	in	yes
O	O	the	no
O	O	literature	no
O	O	suggest	no
O	O	that	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	doxorubicin	yes
O	O	(	no
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
B-drug	B-drug_n	doxorubicinol	no
O	O	)	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	when	no
B-drug	B-drug	paclitaxel	yes
O	O	and	yes
B-drug	B-drug	doxorubicin	yes
O	O	are	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	H2	no
I-group	I-group	blockers	no
O	O	or	no
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	with	yes
B-brand	B-brand	SPRYCEL	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	indicate	no
O	O	that	no
O	O	a	yes
O	O	statistically	no
O	O	significant	no
O	O	difference	no
O	O	exists	no
O	O	between	yes
O	O	the	no
O	O	excreted	no
O	O	levels	no
O	O	of	yes
O	O	homocysteine	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	of	yes
O	O	both	no
O	O	control	no
O	O	and	yes
O	B-drug	levonorgestrel-treated	no
O	O	rats	no
O	O	and	yes
O	O	the	no
O	O	levels	no
O	O	shown	no
O	O	by	no
O	O	rats	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	ethynyl	yes
I-drug	I-drug	estradiol	yes
O	O	.	no

O	O	The	no
O	O	IV	yes
B-drug	B-drug	methylprednisolone	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	oral	yes
B-drug	B-drug	methylprednisolone	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	Aprepitant	yes
O	O	to	no
O	O	achieve	no
O	O	exposures	no
O	O	of	yes
B-drug	B-drug	methylprednisolone	yes
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	obtained	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	given	no
O	O	without	no
B-drug	B-drug	Aprepitant	yes
O	O	.	no

O	O	Simultaneous	no
O	O	use	no
O	O	of	yes
O	B-group	activated	yes
O	I-group	prothrombin	yes
O	I-group	complex	yes
O	I-group	concentrates	no
O	O	or	no
O	B-group	prothrombin	yes
O	I-group	complex	yes
O	I-group	concentrates	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	did	no
O	O	not	no
O	O	affect	no
B-brand	B-brand	BREVIBLOC	yes
O	O	pharmacokinetics	no
O	O	.	no

O	B-drug	Urinary	yes
O	I-drug	acidifying	no
O	O	agents	yes
O	O	decrease	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	increase	no
O	O	excretion	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

B-group	B-group	Antibiotics	no
O	O	(	no
B-drug	B-drug	ampicillin	yes
O	O	,	no
B-drug	B-drug	tetracycline	yes
O	O	)	no
O	O	:	no
O	O	Pregnancy	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	concomitant	no
O	O	use	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	shown	no
O	O	consistent	no
O	O	effects	no
O	O	with	yes
O	O	these	no
B-group	B-group	antibiotics	no
O	O	on	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	synthetic	yes
I-group	I-group	steroids	no
O	O	.	no

O	O	The	no
O	O	second	no
O	O	pregnancy	no
O	O	test	yes
O	O	(	no
O	O	a	yes
O	O	confirmation	no
O	O	test	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	done	no
O	O	during	no
O	O	the	no
O	O	first	no
O	O	5	yes
O	O	days	no
O	O	of	yes
O	O	the	no
O	O	menstrual	no
O	O	period	no
O	O	immediately	no
O	O	preceding	no
O	O	the	no
O	O	beginning	no
O	O	of	yes
B-brand	B-brand	Accutane	yes
O	O	therapy	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	total	yes
O	O	mucosal	no
O	O	accumulation	no
O	O	of	yes
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
O	I-drug_n	)	no
O	O	and	yes
O	O	that	no
O	O	transferred	no
O	O	to	no
O	O	the	no
O	O	body	no
O	O	increase	no
O	O	in	yes
O	O	a	yes
O	O	linear	yes
O	O	logarithmic	no
O	O	fashion	no
O	O	from	no
O	O	0.05	no
O	O	to	no
O	O	5	yes
O	O	mm	yes
O	B-drug_n	As	yes
B-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
O	I-drug_n	)	no
O	O	.	no

O	O	Information	no
O	O	on	no
O	O	concurrent	no
O	O	usage	no
O	O	of	yes
B-drug	B-drug	atenolol	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	limited	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	severe	no
O	O	hypersensitivity	no
O	O	reactions	no
O	O	,	no
O	O	all	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	TAXOL	yes
O	O	should	no
O	O	be	no
O	O	premedicated	no
O	O	with	yes
B-group	B-group	corticosteroids	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dexamethasone	yes
O	O	)	no
O	O	,	no
B-drug	O	diphen-hydramine	no
O	O	and	yes
B-group	B-group	H2	no
I-group	I-group	antagonists	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	cimetidine	yes
O	O	or	no
B-drug	B-drug	ranitidine	yes
O	O	)	no
O	O	.	no

O	O	Patients	no
O	O	in	yes
O	O	a	yes
O	O	clinical	no
O	O	study	no
O	O	who	no
O	O	were	no
O	O	on	no
O	O	established	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	sulfasalazine	yes
O	O	,	no
O	O	to	no
O	O	which	no
B-brand	B-brand	ENBREL	yes
O	O	was	no
O	O	added	no
O	O	,	no
O	O	were	no
O	O	noted	no
O	O	to	no
O	O	develop	no
O	O	a	yes
O	O	mild	yes
O	O	decrease	no
O	O	in	yes
O	O	mean	no
O	O	neutrophil	no
O	O	counts	no
O	O	in	yes
O	O	comparison	no
O	O	to	no
O	O	groups	no
O	O	treated	no
O	O	with	yes
O	O	either	no
B-brand	B-brand	ENBREL	yes
O	O	CI	yes
O	O	or	no
B-drug	B-drug	sulfasalazine	yes
O	O	alone	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	concluded	no
O	O	from	no
O	O	these	no
O	O	results	no
O	O	that	no
O	O	the	no
O	O	modulatory	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	glycine	yes
O	O	is	yes
O	O	evidently	no
O	O	a	yes
O	O	later	no
O	O	developmental	no
O	O	acquisition	no
O	O	(	no
O	O	after	no
O	O	day	no
O	O	15	yes
O	O	of	yes
O	O	incubation	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	embryogenesis	no
O	O	of	yes
O	O	NMDA-ergic	no
O	O	activation	no
O	O	of	yes
O	O	spontaneous	no
O	O	motility	no
O	O	in	yes
O	O	chick	no
O	O	embryos	no
O	O	similarly	no
O	O	as	yes
O	O	glycinergic	no
O	O	inhibition	no
O	O	.	no

O	O	If	no
B-brand	B-brand	TRANXENE	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	combined	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	acting	yes
O	O	on	no
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	,	no
O	O	careful	no
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	the	no
O	O	pharmacology	no
O	O	of	yes
O	O	the	no
O	O	agents	yes
O	O	to	no
O	O	be	no
O	O	employed	no
O	O	.	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	should	no
O	O	therefore	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	,	no
O	O	and	yes
O	O	its	no
O	O	dosage	no
O	O	reduced	yes
O	O	accordingly	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	nicardipine	yes
O	O	.	no

O	O	Excessive	no
B-drug	B-drug	ethanol	yes
O	O	ingestion	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	because	no
O	O	a	yes
O	O	psychotic	no
O	O	reaction	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	thus	no
O	O	an	no
O	O	enhancement	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	PGF2alpha	yes
O	O	upon	no
O	O	the	no
O	O	reaction	no
O	O	of	yes
O	O	placental	no
O	O	vessels	no
O	O	to	no
B-drug	B-drug	oxytocin	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

B-drug	B-drug	Azithromycin	yes

O	O	or	no
O	O	-	yes
O	O	over-the-counter	no
O	O	cough	no
O	O	,	no
O	O	cold	yes
O	O	,	no
O	O	allergy	yes
O	O	,	no
O	O	or	no
O	O	weight	yes
O	O	loss	no
O	O	medications	no
O	O	.	no

O	O	DESIGN	no
O	O	:	no
O	O	Open-label	no
O	O	,	no
O	O	three-phase	no
O	O	,	no
O	O	sequential	no
O	O	study	no
O	O	.	no

O	B-drug	Adenosine	yes
O	O	effects	no
O	O	are	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	dipyridamole	yes
O	O	.	no

O	O	Aerosol	no
O	O	particles	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	were	no
O	O	generated	no
O	O	from	no
O	O	an	no
B-drug	B-drug	ethanol	yes
O	O	solution	yes
O	O	,	no
O	O	dried	yes
O	O	,	no
O	O	and	yes
O	O	collected	no
O	O	by	no
O	O	a	yes
O	O	cascade	no
O	O	impactor	no
O	O	for	yes
O	O	characterization	no
O	O	or	no
O	O	by	no
O	O	a	yes
O	O	liquid	yes
O	O	impinger	no
O	O	for	yes
O	O	dissolution	no
O	O	experiments	no
O	O	.	no

B-drug	B-drug	Colestipol	yes

O	O	STUDY	no
O	O	OBJECTIVE	no
O	O	:	no
O	O	To	no
O	O	evaluate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	and	yes
O	O	cardiovascular	no
O	O	safety	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	in	yes
O	O	healthy	no
O	O	men	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	current	no
O	O	evidence	no
O	O	suggests	no
O	O	that	no
B-drug	B-drug	isoniazid	yes
O	O	does	no
O	O	induce	no
O	O	P-450IIE1	no
O	O	,	no
O	O	a	yes
O	O	mixed-function	no
O	O	oxidase	yes
O	O	enzyme	no
O	O	that	no
O	O	appears	no
O	O	to	no
O	O	generate	no
O	O	the	no
O	O	toxic	no
O	O	metabolites	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	.	no

B-drug	B-drug	Nelfinavir	yes
O	O	is	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A	no
O	O	(	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	vasodilating	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	nitroglycerin	yes
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	with	yes
O	O	those	no
O	O	of	yes
O	O	other	no
B-group	B-group	vasodilators	no
O	O	.	no

O	O	The	no
O	O	hatching	no
O	O	of	yes
O	O	miracidia	no
O	O	from	no
O	O	eggs	no
O	O	was	no
O	O	inhibited	no
O	O	by	no
O	O	concentrations	no
O	O	of	yes
O	O	1000-10000	no
O	O	microg/l	no
O	O	of	yes
O	O	single	yes
O	O	metals	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	decreases	no
O	O	serum	yes
B-drug	O	amiodarone	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	orally	no
O	O	ingested	no
B-drug	B-drug	peginterferon	yes
O	O	or	no
B-drug	B-drug	ribavirin	yes
O	O	from	no
O	O	breast	no
O	O	milk	yes
O	O	on	no
O	O	the	no
O	O	nursing	no
O	O	infant	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	.	no

B-drug	B-drug	Vardenafil	yes
O	O	dose	no
O	O	should	no
O	O	not	no
O	O	exceed	no
O	O	a	yes
O	O	maximum	no
O	O	of	yes
O	O	2.5	yes
O	O	mg	yes
O	O	in	yes
O	O	a	yes
O	O	24-hour	no
O	O	period	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	indinavir	yes
O	O	therapy	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	administering	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	with	yes
B-brand	B-brand	IRESSA	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	simultaneous	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-group	B-group	Non-selective	no
I-group	I-group	MAO	no
I-group	I-group	inhibitors	no
O	O	including	no
B-drug	B-drug	tranylcypromine	yes
I-drug	I-drug	sulfate	yes
O	O	,	no
B-drug	B-drug	phenelzine	yes
I-drug	I-drug	sulfate	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	pargyline	yes
O	O	HC1	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	L-tyrosine	yes
O	O	and	yes
B-group	O	non-selective	no
I-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	cause	no
O	O	hypertension	no
O	O	.	no

B-drug	B-drug	Acetaminophen	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	carbonic	yes
I-group	I-group	anhydrase	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	rare	no
O	O	instances	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	occurred	no
O	O	with	yes
O	O	high-dose	no
B-group	B-drug	salicylate	yes
O	O	therapy	no
O	O	.	no

B-group	B-group	Immunosuppressive	no
I-group	I-group	Drugs	no
O	O	,	no
B-group	B-group	Fibric	no
I-group	I-group	Acid	yes
I-group	I-group	Derivatives	no
O	O	,	no
B-drug	B-drug	Niacin	yes
O	O	(	no
B-drug	B-drug	Nicotinic	yes
I-drug	I-drug	Acid	yes
O	O	,	no
B-drug	B-drug	Erythromycin	yes
O	O	,	no
B-group	B-group	Azole	no
I-group	I-group	Antifungals	no
O	O	:	no
O	O	Skeletal	no
O	O	Muscle	no
O	O	.	no

O	O	Further	no
O	O	,	no
O	O	these	no
O	O	results	no
O	O	confirm	no
O	O	that	no
O	O	the	no
O	O	diabetic	no
O	O	Chinese	yes
O	O	hamster	no
O	O	's	no
B-drug	O	alpha	yes
O	O	and	yes
O	O	beta	yes
O	O	cells	yes
O	O	respond	no
O	O	normally	no
O	O	to	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	but	no
O	O	are	no
O	O	relatively	no
O	O	insensitive	no
O	O	to	no
O	B-drug	glucose	yes
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	acebutolol	yes
O	O	plus	yes
O	B-group	catecholamine	no
O	I-group	depletors	no
O	O	should	no
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	evidence	no
O	O	of	yes
O	O	marked	no
O	O	bradycardia	no
O	O	or	no
O	O	hypotension	no
O	O	which	no
O	O	may	no
O	O	present	no
O	O	as	yes
O	O	vertigo	no
O	O	,	no
O	O	syncope/presyncope	no
O	O	,	no
O	O	or	no
O	O	orthostatic	no
O	O	changes	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	without	no
O	O	compensatory	no
O	O	tachycardia	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	the	no
O	O	hypothesis	no
O	O	of	yes
B-brand	O	Gibaldi	no
O	O	et	no
O	O	al	yes
O	O	.	no

O	O	This	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	CLINITEST	no
O	O	reagent	yes
O	O	tablets	yes

O	O	For	yes
O	O	patients	no
O	O	with	yes
O	O	amenorrhea	no
O	O	,	no
O	O	the	no
O	O	second	no
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	done	no
O	O	at	yes
O	O	least	no
O	O	11	yes
O	O	days	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	act	no
O	O	of	yes
O	O	unprotected	no
O	O	sexual	no
O	O	intercourse	no
O	O	(	no
O	O	without	no
O	O	using	no
O	O	2	yes
O	O	effective	no
O	O	forms	no
O	O	of	yes
O	O	contraception	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
B-group	B-group	beta-receptor	no
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	antagonists	no
O	O	,	no
B-group	O	thiazide	no
O	O	and	yes
B-group	B-group	loop	no
I-group	I-group	diuretics	no
O	O	and	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	These	no
O	O	experiences	no
O	O	have	no
O	O	been	no
O	O	characterized	no
O	O	by	no
O	O	flushing	no
O	O	,	no
O	O	rash	no
O	O	,	no
O	O	peripheral	no
O	O	edema	no
O	O	,	no
O	O	nausea	no
O	O	,	no
O	O	and	yes
O	O	headache	no
O	O	.	no

O	O	Modification	no
O	O	of	yes
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	with	yes
B-drug	B-drug_n	diethyl	yes
I-drug	I-drug_n	pyrocarbonate	no
O	O	abolished	no
O	O	both	no
O	O	its	no
O	O	cytotoxic	yes
O	O	activity	yes
O	O	and	yes
O	O	the	no
O	O	ability	no
O	O	of	yes
O	O	the	no
O	O	toxin	yes
O	O	to	no
O	O	bind	no
O	O	Zn-Sepharose	no
O	O	gel	yes
O	O	.	no

B-drug	B-drug	Flurbiprofen	yes
O	O	pretreatment	no
O	O	attenuated	yes
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	but	no
O	O	not	no
B-drug	B-drug	atenolol	yes
O	O	.	no

O	O	Conclusions	no
O	O	and	yes
O	O	the	no
O	O	types	no
O	O	of	yes
O	O	studies	no
O	O	which	no
O	O	support	no
O	O	these	no
O	O	conclusions	no
O	O	are	no
O	O	given	no
O	O	for	yes
O	O	each	no
O	O	major	no
O	O	section	no
O	O	.	no

B-group	B-group	Thiazide	no
I-group	I-group	Diuretics	no
O	O	:	no
O	O	The	no
O	O	reports	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	contribute	no
O	O	to	no
O	O	the	no
O	O	enhancement	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	toxicity	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	have	no
O	O	been	no
O	O	reviewed	no
O	O	in	yes
O	O	an	no
O	O	attempt	no
O	O	to	no
O	O	establish	no
O	O	a	yes
O	O	cause-and-effect	no
O	O	relationship	no
O	O	and	yes
O	O	a	yes
O	O	mechanism	no
O	O	of	yes
O	O	causation	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-group	B-group	vasopressor	no
I-group	I-group	drugs	no
O	O	(	no
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	hypotension	no
O	O	related	yes
O	O	to	no
O	O	obstetric	no
O	O	blocks	no
O	O	)	no
O	O	and	yes
B-group	B-group	ergot-type	no
I-group	I-group	oxytocic	no
I-group	I-group	drugs	no
O	O	may	no
O	O	cause	no
O	O	severe	no
O	O	,	no
O	O	persistent	no
O	O	hypertension	no
O	O	or	no
O	O	cerebrovascular	no
O	O	accidents	no
O	O	.	no

O	O	For	yes
O	O	example	no
O	O	,	no
O	O	when	no
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
I-group	I-group	antagonists	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	nilutamide	yes
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	and	yes
O	O	if	no
O	O	necessary	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
I-group	I-group	antagonists	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
B-drug	B-drug	Grepafloxacin	yes
O	O	is	yes
O	O	a	yes
O	O	competitive	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	absolute	yes
O	O	number	no
O	O	of	yes
O	B-drug	alcohol-related	no
O	O	deaths	no
O	O	is	yes
O	O	far	no
O	O	greater	no
O	O	than	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	deaths	no
O	O	in	yes
B-drug	B-drug	amphetamine	yes
O	O	or	no
B-drug	B-drug_n	heroin	yes
O	O	users	no
O	O	.	no

O	B-drug	Phenytoin/Phenobarbital	no
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	phenobarbital	yes
O	O	will	no
O	O	not	no
O	O	affect	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	,	no
O	O	but	no
O	O	may	no
O	O	reduce	no
O	O	endogenous	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	by	no
O	O	accelerating	no
O	O	metabolism	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	these	no
B-group	B-group	methylxanthines	no
O	O	,	no
O	O	larger	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	or	no
B-drug	B-drug	adenosine	yes
O	O	may	no
O	O	not	no
O	O	be	no
O	O	effective	no
O	O	.	no

O	O	Gastrointestinal	no
O	O	:	no
O	O	Nausea	no
O	O	(	no
O	O	4-12	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	constipation	no
O	O	(	no
O	O	2-6	no
O	O	%	no
O	O	)	no
O	O	;	no

O	O	If	no
O	O	a	yes
B-group	B-group	diuretic	no
O	O	is	yes
O	O	also	no
O	O	used	no
O	O	,	no
O	O	the	no
O	O	risk	no
O	O	of	yes
B-drug	O	lithium	yes
O	O	toxicity	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	drug	yes
O	O	induced	no
O	O	hypotension	no
O	O	because	no
O	O	of	yes
O	O	a	yes
O	O	possible	no
O	O	reverse	no
O	B-drug	epinephrine	yes
O	O	effect	no
O	O	.	no

O	O	The	no
O	O	blood	yes
O	O	pressure	no
O	O	(	no
O	O	carotid	no
O	O	cannulation	no
O	O	)	no
O	O	decreased	no
O	O	along	no
O	O	with	yes
O	O	the	no
O	O	core	yes
O	O	temperature	no
O	O	.	no

O	O	The	no
O	O	decrease	no
O	O	in	yes
O	O	temperature	no
O	O	began	no
O	O	within	no
O	O	20	yes
O	O	minutes	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	administration	no
O	O	,	no
O	O	reaching	no
O	O	a	yes
O	O	maximal	no
O	O	decrease	no
O	O	between	yes
O	O	60	no
O	O	and	yes
O	O	120	no
O	O	minutes	no
O	O	post	no
B-drug	B-drug	ethanol	yes
O	O	.	no

B-drug	B-drug	Aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	to	no
O	O	one-half	no
O	O	of	yes
O	O	its	no
O	O	normal	yes
O	O	dose	no
O	O	when	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	quinidine	yes
O	O	with	yes
B-drug	B-drug	aripiprazole	yes
O	O	occurs	no
O	O	.	no

O	O	Dose	no
O	O	adjustment	no
O	O	is	yes
O	O	not	no
O	B-drug	recommended.Levetiracetam	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
B-drug	B-drug	topiramate	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	lamotrigine	yes
O	O	.	no

O	O	Peripheral	no
O	O	mononuclear	no
O	O	cells	yes
O	O	were	no
O	O	also	no
O	O	collected	no
O	O	for	yes
O	O	quantitation	no
O	O	of	yes
O	O	phosphorylated	yes
B-drug	B-drug	zidovudine	yes
O	O	.	no

O	O	Dose	no
O	O	adjustments	no
O	O	of	yes
O	O	either	no
O	O	class	no
O	O	of	yes
O	O	agents	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	present	no
O	O	study	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	proposed	no
O	O	that	no
O	O	the	no
B-group	B-group	opioids	no
O	O	applied	no
O	O	to	no
O	O	supraspinal	no
O	O	brain	yes
O	O	sites	no
O	O	produced	no
O	O	their	no
O	O	analgesic	no
O	O	effects	no
O	O	by	no
O	O	the	no
O	O	activation	no
O	O	of	yes
O	O	different	no
O	O	descending	no
O	O	pain	yes
O	O	inhibitory	yes
O	O	systems	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	on	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	1	yes
O	O	-	yes
O	O	8	yes
O	O	mg/day	no
O	O	)	no
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	BEXTRA	yes
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	.	no

O	O	While	no
O	O	mean	no
O	O	INR	no
O	O	values	no
O	O	were	no
O	O	only	no
O	O	slightly	no
O	O	increased	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	,	no
O	O	the	no
O	O	day-to-day	no
O	O	variability	no
O	O	in	yes
O	O	individual	no
O	O	INR	no
O	O	values	no
O	O	was	no
O	O	increased	no
O	O	.	no

O	O	The	no
O	O	preservation	no
O	O	of	yes
O	O	the	no
O	O	microtubules	no
O	O	was	no
O	O	improved	no
O	O	when	no
O	O	D2O	no
O	O	was	no
O	O	present	no
O	O	in	yes
O	O	the	no
O	O	incubation	no
O	O	medium	no
O	O	.	no

O	O	With	yes
O	O	simultaneous	no
O	O	dosing	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	10	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	terazosin	yes
O	O	10	yes
O	O	mg	yes
O	O	,	no
O	O	6	yes
O	O	of	yes
O	O	8	yes
O	O	subjects	no
O	O	experienced	no
O	O	a	yes
O	O	standing	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	of	yes
O	O	less	no
O	O	than	no
O	O	85	no
O	O	mm	yes
O	O	Hg	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	Inhibition	no
O	O	of	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	some	no
B-group	O	prostaglandin	yes
I-group	O	synthesis-inhibiting	no
I-group	O	drugs	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	reduce	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	blood	yes
O	O	platelets	no
O	O	by	no
O	O	causing	no
O	O	bone	no
O	O	marrow	no
O	O	depression	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-group	B-group	antineoplastic	no
I-group	I-group	agents	yes
O	O	)	no
O	O	or	no
O	O	drugs	no
O	O	which	no
O	O	inhibit	no
O	O	platelet	yes
O	O	function	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	and	yes
O	O	other	no
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
B-drug	B-drug	dipyridamole	yes
O	O	,	no
B-drug	B-drug	hydrochloroquine	no
O	O	,	no
B-drug	B-drug	clofibrate	yes
O	O	,	no
B-drug	B-drug	dextran	yes
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	bleeding	no
O	O	tendency	no
O	O	produced	no
O	O	by	no
B-group	B-group	anticoagulants	no
O	O	without	no
O	O	altering	no
O	O	prothrombin	yes
O	O	time	no
O	O	determinations	no
O	O	.	no

O	O	Monitoring	no
O	O	for	yes
B-drug	B-drug	amiodarone	yes
O	O	toxicity	no
O	O	and	yes
O	O	serial	no
O	O	measurement	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	serum	yes
O	O	concentration	no
O	O	during	no
O	O	concomitant	no
B-group	B-group	protease	yes
I-group	I-group	inhibitor	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	Fruit	no
O	O	Juices	no
O	O	Fruit	no
O	O	juices	no
O	O	such	no
O	O	as	yes
O	O	grapefruit	no
O	O	,	no
O	O	orange	no
O	O	and	yes
O	O	apple	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	bioavailability	no
O	O	and	yes
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	neomycin	yes
O	O	on	no
B-drug	B-group	ACTH	yes
O	O	induced	no
O	O	hypertension	no
O	O	were	no
O	O	examined	no
O	O	in	yes
O	O	conscious	no
O	O	sheep	yes
O	O	.	no

O	O	Cardiovascular	no
O	O	disease	no
O	O	is	yes
O	O	a	yes
O	O	common	yes
O	O	comorbidity	no
O	O	and	yes
O	O	a	yes
O	O	major	no
O	O	cause	no
O	O	of	yes
O	O	mortality	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	chronic	no
O	O	renal	no
O	O	disease	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	other	no
B-group	B-group	coumarin-derivative	no
I-group	I-group	anticoagulants	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	regularly	no
O	O	for	yes
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	INR	no

O	O	Risk	no
O	O	of	yes
O	O	Anaphylactic	no
O	O	Reaction	no
O	O	:	no
O	O	Although	no
O	O	it	no
O	O	is	yes
O	O	known	no
O	O	that	no
O	O	patients	no
O	O	on	no
B-group	B-group	beta-blockers	no
O	O	may	no
O	O	be	no
O	O	refractory	no
O	O	to	no
B-drug	B-drug	epinephrine	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	anaphylactic	no
O	O	shock	no
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	can	no
O	O	,	no
O	O	in	yes
O	O	addition	no
O	O	,	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	modulation	no
O	O	of	yes
O	O	allergic	no
O	O	reaction	no
O	O	and	yes
O	O	lead	no
O	O	to	no
O	O	an	no
O	O	increased	no
O	O	severity	no
O	O	and/or	no
O	O	frequency	no
O	O	of	yes
O	O	attacks	no
O	O	.	no

O	O	-	yes
O	O	Increased	no
O	O	thyroid-binding	no
O	O	globulin	yes
O	O	(	no
O	O	TBG	no
O	O	)	no
O	O	leading	no
O	O	to	no
O	O	in-creased	no
O	O	circulating	no
O	O	total	yes
O	O	thyroid	yes
O	O	hormone	yes
O	O	;	no

O	O	Serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	using	no
O	O	an	no
O	O	125I-labelled	no
O	O	antigen	yes
O	O	:	no
O	O	Validation	no
O	O	of	yes
O	O	method	yes
O	O	and	yes
O	O	observations	no
O	O	on	no
O	O	cardiac	no
O	O	patients	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-brand	B-brand	LEUSTATIN	yes
O	O	Injection	yes
O	O	.	no

O	O	This	no
O	O	cluster	no
O	O	of	yes
O	O	metabolic	no
O	O	abnormalities	no
O	O	has	no
O	O	been	no
O	O	termed	no
O	O	the	no
O	O	insulin	yes
O	O	resistance	no
O	O	or	no
O	O	cardiovascular	no
O	O	dysmetabolic	no
O	O	syndrome	no
O	O	.	no

B-drug	B-drug	Deferasirox	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	on	no
O	O	an	no
O	O	empty	no
O	O	stomach	no
O	O	30	yes
O	O	minutes	no
O	O	before	no
O	O	eating	no
O	O	.	no

O	O	As	yes
B-brand	B-brand	DIFFERIN	yes
O	O	Gel	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	produce	no
O	O	local	no
O	O	irritation	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
O	O	potentially	no
O	O	irritating	no
O	O	topical	yes
O	O	products	no
O	O	(	no
O	O	medicated	no
O	O	or	no
O	O	abrasive	no
O	O	soaps	no
O	O	and	yes
O	O	cleansers	no
O	O	,	no
O	O	soaps	no
O	O	and	yes
O	O	cosmetics	no
O	O	that	no
O	O	have	no
O	O	a	yes
O	O	strong	no
O	O	drying	no
O	O	effect	no
O	O	,	no
O	O	and	yes
O	O	products	no
O	O	with	yes
O	O	high	yes
O	O	concentrations	no
O	O	of	yes
B-drug	O	alcohol	yes
O	O	,	no
B-group	O	astringents	no
O	O	,	no
O	O	spices	no
O	O	or	no
O	O	lime	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	To	no
O	O	investigate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	antimicrobial	no
O	O	combinations	no
O	O	of	yes
B-drug_n	B-drug_n	GL	no
O	O	with	yes
O	O	four	no
O	O	kinds	no
O	O	of	yes
B-group	B-group	antibiotics	no
O	O	(	no
B-drug	B-drug	ampicillin	yes
O	O	,	no
B-drug	B-drug	cefazolin	yes
O	O	,	no
B-drug	B-drug	oxytetracycline	yes
O	O	and	yes
B-drug	B-drug	chloramphenicol	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	fractional	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	index	no
O	O	(	no
O	O	FICI	no
O	O	)	no
O	O	was	no
O	O	determined	no
O	O	by	no
O	O	checkerboard	no
O	O	assay	no
O	O	for	yes
O	O	each	no
O	O	strain	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	Clonazepam	yes
O	O	on	no
O	O	the	no
O	O	Pharmacokinetics	no
O	O	of	yes
O	O	Other	no
O	O	Drugs	no
O	O	:	no
B-drug	B-drug	Clonazepam	yes
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	phenobarbital	yes
O	O	.	no

O	O	Excystment	no
O	O	in	yes
O	O	vitro	no
O	O	was	no
O	O	only	no
O	O	significantly	no
O	O	affected	no
O	O	by	no
O	O	cercariae	no
O	O	exposed	no
O	O	to	no
O	O	cadmium/zinc	no
O	O	mixtures	no
O	O	whilst	no
O	O	encysting	no
O	O	.	no

O	O	Hypokalemia	no
O	O	may	no
O	O	increase	no
O	O	susceptibility	no
O	O	to	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	.	no

B-drug	B-drug	Lamivudine	yes
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	peripheral	no
O	O	blood	yes
O	O	mononuclear	no
O	O	cells	yes
O	O	,	no
O	O	U937	no
O	O	and	yes
O	O	Molt-4	no
O	O	cells	yes
O	O	revealed	no
O	O	that	no
B-drug	B-drug	lamivudine	yes
O	O	significantly	no
O	O	inhibited	no
B-drug	B-drug	zalcitabine	yes
O	O	phosphorylation	no
O	O	in	yes
O	O	a	yes
O	O	dose	no
O	O	dependent	no
O	O	manner	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	precaution	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
O	O	coadministration	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

O	O	as	yes
O	O	judged	no
O	O	by	no
O	O	increased	no
O	O	serum	yes
O	O	enzyme	no
O	O	activities	no
O	O	and	yes
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	hepatic	no
O	O	necrosis	yes
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	if	no
O	O	an	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitor	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	levels	no
O	O	or	no
O	O	activity	yes
O	O	of	yes
B-group	O	endogenous	no
I-group	O	steroid	no
I-group	O	hormones	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	:	no
O	O	Because	no
O	O	CYP2D6	no
O	O	is	yes
O	O	involved	no
O	O	in	yes
B-drug	B-drug	duloxetine	yes
O	O	metabolism	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	with	yes
O	O	potent	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	higher	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
O	O	200	yes
O	O	mg	yes
O	O	twice-daily	no
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-drug	B-drug	aliskiren	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	80	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	aliskiren	yes
O	O	.	no

O	O	The	no
O	O	pharmacokinetic	no
O	O	variables	no
O	O	for	yes
B-drug	B-drug	digoxin	yes
O	O	were	no
O	O	determined	no
O	O	after	no
O	O	a	yes
O	O	1.0	no
O	O	mg	yes
O	O	intravenous	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	each	no
O	O	subject	no
O	O	,	no
O	O	before	no
O	O	and	yes
O	O	after	no
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	,	no
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	for	yes
O	O	3	yes
O	O	weeks	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Interfere	no
O	O	With	yes
O	O	Hemostasis	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	,	no
B-brand	B-brand	Aspirin	yes
O	O	,	no
B-drug	B-drug	Warfarin	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no

O	O	Rat	yes
O	O	kidney	yes
O	O	homogenates	no
O	O	supplemented	no
O	O	with	yes
O	O	coenzyme	yes
O	O	A	yes
O	O	,	no
O	O	ATP	yes
O	O	,	no
B-drug	O	oxaloacetate	yes
O	O	,	no
O	O	and	yes
O	O	Mg2+	no
O	O	converted	no
B-drug_n	B-drug_n	1,3-difluoroacetone	no
I-drug_n	O	to	no
I-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	;	no

O	O	Genitourinary	no
O	O	:	no
O	O	Urinary	yes
O	O	frequency	no
O	O	(	no
O	O	2-6	no
O	O	%	no
O	O	)	no
O	O	;	no

O	O	Human	yes
O	O	pharmacokinetics	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	potently	no
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	mean	no
O	O	eight-fold	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	at	yes
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	(	no
O	O	the	no
O	O	maximum	no
O	O	approved	no
O	O	prescription	no
O	O	dose	no
O	O	)	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	(	no
O	O	500	yes
O	O	mcg	no
O	O	BID	no
O	O	)	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
B-drug	B-drug	dofetilide	yes
O	O	Cmax	no
O	O	by	no
O	O	53	no
O	O	%	no
O	O	in	yes
O	O	males	no
O	O	and	yes
O	O	97	no
O	O	%	no
O	O	in	yes
O	O	females	no
O	O	,	no
O	O	and	yes
O	O	AUC	no
O	O	by	no
O	O	41	yes
O	O	%	no
O	O	in	yes
O	O	males	no
O	O	and	yes
O	O	69	no
O	O	%	no
O	O	in	yes
O	O	females	no
O	O	.	no

O	O	Any	no
O	O	agent	yes
O	O	that	no
O	O	alters	no
O	O	thyroid	yes
O	O	hormone	yes
O	O	synthesis	no
O	O	,	no
O	O	secretion	no
O	O	,	no
O	O	distribution	no
O	O	,	no
O	O	effect	no
O	O	on	no
O	O	target	no
O	O	tissues	no
O	O	,	no
O	O	metabolism	no
O	O	,	no
O	O	or	no
O	O	elimination	no
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	optimal	no
O	O	therapeutic	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	levothyroxine	yes
I-drug	O	sodium	yes
O	O	.	no

B-drug	B-drug	Cysteine	yes
O	O	conjugation	no
O	O	at	yes
O	O	3.6	no
O	O	,	no
O	O	5.3	no
O	O	and	yes
O	O	7.3	no
O	O	%	no
O	O	(	no
O	O	m/m	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	R-values	no
O	O	of	yes
O	O	1.4	no
O	O	,	no
O	O	1.7	no
O	O	and	yes
O	O	1.8	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-group	B-group	Monoamine	no
I-group	I-group	Oxidase	yes
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	moclobemide	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	27	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	almotriptan	yes
O	O	clearance	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	of	yes
O	O	approximately	no
O	O	6	yes
O	O	%	no
O	O	.	no

O	O	GI	no
O	O	Motility	no
O	O	Agent	yes
O	O	:	no
B-drug	B-drug	cisapride*	no
O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	increasing	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	preparations	no
O	O	to	no
O	O	control	no
O	O	symptoms	no
O	O	indicates	no
O	O	deterioration	no
O	O	of	yes
O	O	asthma	no
O	O	control	no
O	O	and	yes
O	O	the	no
O	O	need	no
O	O	to	no
O	O	reassess	no
O	O	the	no
O	O	patient	no
O	O	s	yes
O	O	therapy	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	FACTIVE	yes
O	O	and	yes
B-drug	B-drug	calcium	yes
I-drug	I-drug	carbonate	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	omeprazole	yes
O	O	,	no
O	O	or	no
O	O	an	no
B-drug	B-group	estrogen/progesterone	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	produced	no
O	O	minor	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	gemifloxacin	yes
O	O	,	no
O	O	which	no
O	O	were	no
O	O	considered	no
O	O	to	no
O	O	be	no
O	O	without	no
O	O	clinical	no
O	O	significance	no
O	O	.	no

O	O	Interaction	no
O	O	with	yes
O	O	Food	no
O	O	See	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	,	no
O	O	Pharmacokinetics	no
O	O	and	yes
O	O	Metabolism	no
O	O	.	no

B-group	B-group	5-HT3	no
I-group	I-group	antagonists	no
O	O	:	no
O	O	In	yes
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	aprepitant	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	clinically	no
O	O	important	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	ondansetron	yes
O	O	or	no
B-drug	B-drug	granisetron	yes
O	O	.	no

O	O	Use	no
O	O	lowest	no
O	O	possible	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	with	yes
O	O	careful	no
O	O	monitoring	no
O	O	,	no
O	O	or	no
O	O	consider	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	pravastatin	yes
O	O	,	no
B-drug	B-drug	fluvastatin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	rosuvastatin	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	have	no
O	O	been	no
O	O	treated	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	within	no
O	O	two	no
O	O	to	no
O	O	three	no
O	O	weeks	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	should	no
O	O	receive	no
O	O	initial	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	no	yes
O	O	greater	no
O	O	than	no
O	O	one-tenth	no
O	O	(	no
O	O	1/10	no
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	usual	no
O	O	dose	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	considerable	no
O	O	evidence	no
O	O	suggesting	no
O	O	that	no
O	O	histaminergic	no
O	O	and	yes
O	O	serotoninergic	no
O	O	central	no
O	O	pathways	no
O	O	are	no
O	O	involved	no
O	O	in	yes
O	O	nociception	no
O	O	and	yes
O	O	that	no
B-group	B-group	antihistaminic	no
I-group	O	drugs	no
O	O	can	no
O	O	modulate	no
O	O	their	no
O	O	responses	no
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Glyburide	yes
O	O	:	no
B-drug	B-drug	Glyburide	yes
O	O	is	yes
O	O	a	yes
O	O	CYP	no
O	O	2C9	no
O	O	substrate	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	since	no
B-drug	B-drug	nitrofurantoin	yes
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	antibacterial	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	Norfloxacin	yes
O	O	in	yes
O	O	the	no
O	O	urinary	yes
O	O	tract	no
O	O	.	no

O	O	Use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	The	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	nitroprusside	yes
O	O	is	yes
O	O	augmented	no
O	O	by	no
O	O	that	no
O	O	of	yes
O	O	most	no
O	O	other	no
O	B-group	hypotensive	no
O	I-group	drugs	no
O	O	,	no
O	O	including	no
B-group	B-group	ganglionic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
O	O	negative	no
B-group	O	inotropic	no
I-group	O	agents	yes
O	O	,	no
O	O	and	yes
O	O	inhaled	no
B-group	B-group	anesthetics	no
O	O	.	no

B-brand	B-brand	GABITRIL	yes
O	O	is	yes
O	O	considered	no
O	O	to	no
O	O	be	no
O	O	a	yes
O	O	non-enzyme	no
O	O	inducing	no
B-group	B-group	AED	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drugs	no
O	O	have	no
O	O	been	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	Kerlone	yes
O	O	and	yes
O	O	have	no
O	O	not	no
O	O	altered	no
O	O	its	no
O	O	pharmacokinetics	no
O	O	:	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	chlorthalidone	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	AUCss	no
O	O	(	no
O	O	0-12h	no
O	O	)	no
O	O	(	no
O	O	Extent	no
O	O	of	yes
O	O	systemic	no
O	O	exposure	yes
O	O	)	no

O	O	Although	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Clozapine	yes
O	O	and	yes
B-drug	B-drug	carbamazepine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	noted	no
O	O	that	no
O	O	discontinuation	no
O	O	of	yes
O	O	concomitant	no
B-drug	B-drug	carbamazepine	yes
O	O	administration	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	Clozapine	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Sildenafil	yes

O	O	Therefore	no
O	O	,	no
O	O	coagulation	yes
O	O	indices	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	to	no
O	O	maintain	no
O	O	the	no
O	O	desired	no
O	O	anticoagulant	no
O	O	effect	no
O	O	.	no

O	O	Data	no
O	O	from	no
O	O	studies	no
O	O	to	no
O	O	date	no
O	O	show	no
O	O	that	no
O	O	disease	no
O	O	states	no
O	O	,	no
O	O	underlying	no
O	O	conditions	no
O	O	,	no
O	O	and	yes
O	O	concomitantly	no
O	O	administered	no
O	O	highly	no
O	O	protein-bound	no
O	O	drugs	no
O	O	have	no
O	O	essentially	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	etodolac	yes
O	O	pharmacokinetics	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	Increased	no
O	O	INR	no
O	O	(	no
O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	)	no
O	O	when	no
B-brand	B-brand	ARAVA	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	were	no
O	O	co-administered	no
O	O	has	no
O	O	been	no
O	O	rarely	no
O	O	reported	no
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	for	yes
O	O	this	no
O	O	interaction	no
O	O	probably	no
O	O	is	yes
O	O	adsorption	no
O	O	of	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	onto	no
O	O	the	no
O	O	surface	yes
O	O	of	yes
B-drug	B-drug	magnesium	yes
I-drug	I-drug	trisilicate	yes
O	O	.	no

O	O	An	no
O	O	oral	yes
O	B-drug	glucose	yes
O	O	overload	no
O	O	of	yes
O	O	1	yes
O	O	ml	no
O	O	of	yes
O	O	a	yes
O	O	50	yes
O	O	%	no
O	B-drug	glucose	yes
O	O	solution	yes
O	O	was	no
O	O	given	no
O	O	to	no
O	O	rats	no
O	O	and	yes
O	O	blood	yes
O	O	glucose	yes
O	O	was	no
O	O	determined	no
O	O	after	no
O	O	30	yes
O	O	,	no
O	O	60	no
O	O	and	yes
O	O	90	yes
O	O	min	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-drug	B-drug	imipramine	yes
I-drug	I-drug	hydrochloride	yes
O	O	is	yes
O	O	used	no
O	O	with	yes
O	O	agents	yes
O	O	that	no
O	O	lower	no
O	O	blood	yes
O	O	pressure	no
O	O	.	no

B-drug	B-drug	Rifampin	yes

O	O	There	no
O	O	is	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
B-group	O	precipitating	no
I-group	O	anticonvulsant	no
I-group	O	drug	yes
O	O	toxicity	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	with	yes
O	O	other	no
B-group	B-group	carbonic	yes
I-group	I-group	anhydrase	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	is	yes
O	O	not	no
O	O	advisable	no
O	O	.	no

O	O	certain	no
B-group	B-group	tetracyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	maprotiline	yes
O	O	)	no
O	O	;	no

B-group	B-drug	Nonsteroidal	no
I-group	I-drug	Antiinflammatory	no
I-group	O	Agents	yes
O	O	:	no
B-brand	B-drug	Aspirin	yes
O	O	is	yes
O	O	contraindicated	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	hypersensitive	no
O	O	to	no
B-group	B-drug	nonsteroidal	no
I-group	I-drug	anti-inflammatory	no
I-group	O	agents	yes
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	data	no
O	O	that	no
O	O	conclusively	no
O	O	establish	no
O	O	whether	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	Mefloquineuine	no
O	O	and	yes
O	O	the	no
O	O	above	no
O	O	listed	no
O	O	agents	yes
O	O	has	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	cardiac	no
O	O	function	no
O	O	.	no

O	O	especially	no
O	O	if	no
O	O	these	no
O	O	patients	no
O	O	are	no
O	O	extensive	no
O	O	metabolizers	no
O	O	.	no

O	O	These	no
O	O	drugs	no
O	O	include	no
O	O	the	no
B-group	B-group	thiazides	no
O	O	and	yes
O	O	other	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	products	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	B-group	sympathomimetics	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel-blocking	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	concentrations	no
O	O	which	no
O	O	have	no
O	O	been	no
O	O	obtained	no
O	O	in	yes
O	O	vivo	no
O	O	clinically	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	normal	yes
O	O	renal	no
O	O	function	no
O	O	are	no
O	O	considerably	no
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	concentrations	no
O	O	found	no
O	O	to	no
O	O	induce	no
O	O	abnormalities	no
O	O	in	yes
O	O	platelet	yes
O	O	function	no
O	O	tests	no
O	O	.	no

O	O	In	yes
O	O	psoriatic	no
O	O	arthritis	no
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	concomitant	no
O	O	medications	no
O	O	included	no
B-drug	B-drug	MTX	yes
O	O	in	yes
O	O	approximately	no
O	O	half	no
O	O	of	yes
O	O	the	no
O	O	patients	no
O	O	as	yes
O	O	well	no
O	O	as	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	Coadministration	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	increased	no
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	omeprazole	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	by	no
O	O	46	no
O	O	%	no
O	O	.	no

O	O	Coadministration	no
O	O	in	yes
O	O	HIV-infected	no
O	O	individuals	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	injection	yes
O	O	drug	yes
O	O	use	no
O	O	resulted	no
O	O	in	yes
O	O	decreased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	methadone	yes
O	O	and	yes
O	O	signs	no
O	O	of	yes
B-group	B-group	opiate	no
O	O	withdrawal	no
O	O	.	no

B-drug	B-drug	Saquinavir	yes

O	O	The	no
O	O	appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	,	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Dose	no
O	O	reduction	yes
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	to	no
O	O	600	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	itraconazole	yes
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
B-brand	B-brand	Felbatol	yes
O	O	causes	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
B-drug	B-drug	carbamazepine	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
B-drug	B-drug_n	carbamazepine	yes
O	I-drug_n	epoxide	no
O	O	plasma	yes
O	O	concentration	no
O	O	.	no

B-drug	O	Glucose	yes
O	O	:	no
O	O	Some	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	Accutane	yes
O	O	have	no
O	O	experienced	no
O	O	problems	no
O	O	in	yes
O	O	the	no
O	O	control	no
O	O	of	yes
O	O	their	no
O	O	blood	yes
O	O	sugar	yes
O	O	.	no

O	O	Products	no
O	O	containing	yes
B-drug	B-drug	calcium	yes
O	O	and	yes
O	O	other	no
O	O	multivalent	no
O	O	cations	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	aluminum	yes
O	O	,	no
B-drug	B-drug	magnesium	yes
O	O	,	no
B-drug	B-drug	iron	yes
O	O	)	no
O	O	are	no
O	O	likely	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	Ibandronate	yes
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	has	no
O	O	no	yes
O	O	apparent	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	of	yes
B-brand	B-brand	Lodine	yes
O	O	.	no

B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-drug	B-drug	triamterene	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	together	no
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	hydrocortisone	yes
O	O	pretreatment	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	physiological	no
O	O	,	no
O	O	behavioral	no
O	O	,	no
O	O	or	no
O	O	subjective	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	d-amphetamine	yes
O	O	.	no

O	O	Depending	no
O	O	on	no
O	O	the	no
O	O	fraction	yes
O	O	of	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentration	no
O	O	may	no
O	O	be	no
O	O	small	no
O	O	,	no
O	O	or	no
O	O	quite	no
O	O	large	no
O	O	(	no
O	O	8-fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	O	TCA	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	resulting	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	serum	yes
O	O	levels	no
O	O	may	no
O	O	increase	no
O	O	toxicity	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	decreased	no
O	O	urinary	yes
O	O	levels	no
O	O	could	no
O	O	lessen	no
O	O	its	no
O	O	efficacy	no
O	O	as	yes
O	O	a	yes
O	O	urinary	yes
O	O	tract	no
B-group	B-group	antibacterial	no
O	O	.	no

O	O	In	yes
O	O	pigeons	no
O	O	,	no
B-drug	B-drug	naloxone	yes
O	O	did	no
O	O	not	no
O	O	systematically	no
O	O	alter	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
I-drug_n	O	,	no
I-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	or	no
B-drug_n	B-drug_n	PCP	yes
O	O	.	no

O	O	A	yes
O	O	group	yes
O	O	of	yes
O	O	patients	no
O	O	who	no
O	O	had	no
O	O	had	no
O	O	a	yes
O	O	new	no
O	O	acute	no
O	O	episode	no
O	O	despite	no
O	O	seemingly	no
O	O	adequate	no
O	O	treatment	no
O	O	were	no
O	O	selected	no
O	O	.	no

O	O	Hypotension	no
O	O	was	no
O	O	more	no
O	O	likely	no
O	O	to	no
O	O	occur	no
O	O	if	no
O	O	the	no
B-group	B-group	calcium	yes
I-group	I-group	antagonist	yes
O	O	were	no
O	O	a	yes
O	B-group	dihydropyridine	no
O	I-group	derivative	yes
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
O	O	while	no
O	O	left	no
O	O	ventricular	no
O	O	failure	no
O	O	and	yes
O	O	AV	no
O	O	conduction	no
O	O	disturbances	no
O	O	,	no
O	O	including	no
O	O	complete	yes
O	O	heart	no
O	O	block	yes
O	O	,	no
O	O	were	no
O	O	more	no
O	O	likely	no
O	O	to	no
O	O	occur	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	verapamil	yes
O	O	or	no
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	In	yes
O	O	the	no
B-drug	B-drug	warfarin	yes
O	O	study	no
O	O	,	no
B-drug	B-drug	vardenafil	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	pharmacodynamic	no
O	O	parameters	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	chronic	no
O	O	toxicity	no
O	O	study	no
O	O	,	no
O	O	cynomolgus	no
O	O	monkeys	no
O	O	were	no
O	O	dosed	no
O	O	weekly	yes
O	O	for	yes
O	O	52	no
O	O	weeks	no
O	O	with	yes
O	O	intravenous	yes
B-drug	B-drug	alefacept	yes
O	O	at	yes
O	O	1	yes
O	O	mg/kg/dose	no
O	O	or	no
O	O	20	yes
O	O	mg/kg/dose	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	serious	no
O	O	opportunistic	no
O	O	infections	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	observed	no
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	complications	no
O	O	have	no
O	O	specifically	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	lymphocytopenia	no
O	O	.	no

B-drug	O	Adenosine	yes
I-drug	O	3':5'-cyclic	no
I-drug	O	phosphate	yes
O	O	in	yes
O	O	turn	no
O	O	controls	no
O	O	levels	no
O	O	of	yes
O	O	free	yes
O	O	calcium	yes
O	O	ions	no
O	O	in	yes
O	O	platelets	no
O	O	and	yes
O	O	regulates	no
O	O	calcium-dependent	no
O	O	reactions	no
O	O	.	no

O	O	Accordingly	no
O	O	,	no
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	and	yes
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	event	no
O	O	of	yes
O	O	relevant	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	laboratory	no
O	O	parameters	no
O	O	,	no
B-drug	B-drug	bezafibrate	yes
O	O	should	no
O	O	,	no
O	O	if	no
O	O	necessary	no
O	O	,	no
O	O	be	no
O	O	discontinued	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	a	yes
O	O	small	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	diflunisal	yes
O	O	levels	no
O	O	was	no
O	O	observed	no
O	O	when	no
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	were	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	Clonazepam	yes
O	O	would	no
O	O	be	no
O	O	useful	no
O	O	in	yes
O	O	cases	no
O	O	with	yes
O	O	potential	no
O	O	risk	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	6	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	metabolism	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	tizoxanide	no
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	inhibitory	yes
O	O	effect	no
O	O	on	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

O	O	This	no
O	O	may	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	ibuprofen	yes
O	O	could	no
O	O	enhance	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

B-brand	B-brand	FLEXERIL	yes
O	O	may	no
O	O	have	no
O	O	life-threatening	no
O	O	interactions	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	acanthus	no
O	O	.	no

O	O	0.001	no
O	O	.	no

O	O	In	yes
O	O	an	no
O	O	in	yes
O	O	vitro	no
O	O	study	no
O	O	,	no
O	O	cytochrome	no
O	O	P450	no
O	O	isozymes	no
O	O	1A2	no
O	O	,	no
O	O	2A6	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	2E1	no
O	O	,	no
O	O	and	yes
O	O	3A4	no
O	O	were	no
O	O	not	no
O	O	inhibited	no
O	O	by	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	cevimeline	yes
O	O	.	no

B-brand	B-brand	ZEBETA	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	combined	no
O	O	with	yes
O	O	other	no
B-group	B-group	beta-blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	any	no
B-group	B-group	antineoplastic	no
I-group	I-group	agents	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	Mefloquine	yes
O	O	on	no
O	O	travelers	no
O	O	receiving	no
O	O	comedication	no
O	O	,	no
O	O	particularly	no
O	O	diabetics	no
O	O	or	no
O	O	patients	no
O	O	using	no
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	checked	no
O	O	before	no
O	O	departure	no
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	nucleophosmin/B23	no
O	O	in	yes
O	O	serum-deprived	no
O	O	ras-transformed	no
O	O	(	no
O	O	RAS-3T3	no
O	O	)	no
O	O	cells	yes
O	O	was	no
O	O	as	yes
O	O	stable	no
O	O	as	yes
O	O	that	no
O	O	in	yes
O	O	serum-supplemented	no
O	O	NIH-3T3	no
O	O	or	no
O	O	RAS-3T3	no
O	O	cells	yes
O	O	.	no

O	O	Patients	no
O	O	using	no
O	O	CYP3A4	no
O	O	metabolized	no
O	B-group	statins	no
O	O	should	no
O	O	have	no
O	O	cholesterol	yes
O	O	levels	no
O	O	monitored	no
O	O	after	no
B-brand	B-brand	TRACLEER	yes
O	O	is	yes
O	O	initiated	no
O	O	to	no
O	O	see	no
O	O	whether	no
O	O	the	no
O	B-group	statin	no
O	O	dose	no
O	O	needs	no
O	O	adjustment	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	its	no
O	O	nephrotoxicity	no
O	O	,	no
B-drug	B-drug	gentamicin	yes
O	O	may	no
O	O	cause	no
O	O	abnormal	no
O	O	renal	no
O	O	uptake	no
O	O	to	no
O	O	be	no
O	O	seen	no
O	O	on	no
O	B-drug	99mTc-MDP	no
O	O	bone	no
O	O	scintigraphy	no
O	O	.	no

B-drug	B-drug	Paroxetine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	single	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
I-drug	O	3	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	20	yes
O	O	mg	yes
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	produced	no
O	O	no	yes
O	O	pharmacokinetic	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	.	no

O	O	More	no
O	O	than	no
O	O	600	yes
O	O	Parkinsons	no
O	O	disease	no
O	O	patients	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	have	no
O	O	used	no
B-drug	B-drug	selegiline	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	entacapone	yes
O	O	and	yes
B-group	B-drug	levodopa/dopa	no
I-group	B-group	decarboxylase	no
I-group	I-group	inhibitor	yes
O	O	.	no

B-drug	B-drug	Lincomycin	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	properties	no
O	O	that	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	action	no
O	O	of	yes
O	O	other	no
B-group	B-group	neuromuscular	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

B-group	B-group	Antacids	no
O	O	,	no
B-drug	B-drug	Sucralfate	yes
O	O	,	no
O	O	Metal	no
O	O	Cations	no
O	O	,	no
B-group	B-group	Multivitamins	no
I-group	I-group	Quinolones	no
O	O	form	yes
O	O	chelates	no
O	O	with	yes
O	O	alkaline	yes
O	O	earth	no
O	O	and	yes
O	O	transition	no
O	O	metal	no
O	O	cations	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	mixing	no
O	O	of	yes
O	O	an	no
B-group	B-group	aminoglycoside	no
O	O	with	yes
B-group	O	beta-lactamtype	no
I-group	B-group	antibiotics	no
O	O	(	no
B-group	B-group	penicillins	no
O	O	or	no
B-group	B-group	cephalosporins	no
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	significant	no
O	O	mutual	no
O	O	inactivation	no
O	O	.	no

O	O	When	no
O	O	given	no
O	O	in	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	50	yes
O	O	mg/kg	no
O	O	,	no
B-brand	B-brand	sandimmune	yes
O	O	produced	no
O	O	no	yes
O	O	statistically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
B-drug	O	hexanal-induced	no
O	O	sleep	no
O	O	in	yes
O	O	mice	no
O	O	.	no

O	O	Although	no
O	O	trough	no
B-drug	B-drug	citalopram	yes
O	O	plasma	yes
O	O	levels	no
O	O	were	no
O	O	unaffected	no
O	O	,	no
O	O	given	no
O	O	the	no
O	O	enzyme-inducing	no
O	O	properties	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	that	no
B-drug	B-drug	carbamazepine	yes
O	O	might	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	if	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	are	no
O	O	coadministered	no
O	O	.	no

B-brand	B-brand	BREVIBLOC	yes
O	O	concentrations	no
O	O	were	no
O	O	equivocally	no
O	O	higher	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	but	no
O	O	this	no
O	O	is	yes
O	O	not	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	clinically	no
O	O	important	no
O	O	.	no

B-drug	B-drug	Propranolol	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	had	no
O	O	a	yes
O	O	small	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	rate	no
O	O	but	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	isradipine	yes
O	O	bioavailability	no
O	O	.	no

B-group	B-group	Antipsychotic	no
I-group	I-group	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	phenothiazines	no
O	O	or	no
B-drug	B-drug	haloperidol	yes
O	O	;	no

B-drug	B-drug	Sumatriptan	yes
O	O	and	yes
B-brand	B-brand	D.H.E	no
O	I-brand	.	no
B-drug	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
O	O	each	no
O	O	other..	no

O	O	Use	no
O	O	With	yes
B-drug	B-drug	Ribavirin	yes
I-drug	I-drug	Ribavirin	yes
O	O	is	yes
O	O	genotoxic	no
O	O	and	yes
O	O	mutagenic	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	may	no
O	O	also	no
O	O	potentiate	no
O	O	the	no
O	O	replication	no
O	O	of	yes
O	O	some	no
O	O	organisms	no
O	O	contained	no
O	O	in	yes
O	B-group	live	yes
B-group	I-group	attenuated	yes
I-group	I-group	vaccines	no
O	O	.	no

O	O	If	no
O	O	the	no
B-brand	B-brand	TARCEVA	yes
O	O	dose	no
O	O	is	yes
O	O	adjusted	yes
O	O	upward	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	will	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	reduced	yes
O	O	upon	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	rifampicin	yes
O	O	or	no
O	O	other	no
O	O	inducers	no
O	O	.	no

B-drug	B-drug	Dexamethasone	yes
O	O	:	no
O	O	Steady-state	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	albendazole	yes
I-drug	I-drug	sulfoxide	yes
O	O	were	no
O	O	about	no
O	O	56	yes
O	O	%	no
O	O	higher	no
O	O	when	no
O	O	8	yes
O	O	mg	yes
B-drug	B-drug	dexamethasone	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
O	O	each	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	albendazole	yes
O	O	(	no
O	O	15	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	in	yes
O	O	eight	no
O	O	neurocysticercosis	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Dexbrompheniramine	yes
O	O	can	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
B-group	B-group	anticholinergics	no
O	O	or	no
O	O	other	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	(	no
O	O	anticholinergic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	these	no
O	O	medications	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	may	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	and	yes
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	.	no

B-brand	B-brand	COPEGUS	yes
O	O	therapy	no
O	O	is	yes
O	O	contraindicated	no
O	O	in	yes
O	O	women	yes
O	O	who	no
O	O	are	no
O	O	pregnant	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	male	no
O	O	partners	no
O	O	of	yes
O	O	women	yes
O	O	who	no
O	O	are	no
O	O	pregnant	no
O	O	.	no

O	O	A	yes
O	O	similar	no
O	O	association	no
O	O	,	no
O	O	though	no
O	O	less	no
O	O	marked	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	suggested	no
O	O	with	yes
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
I-drug	I-drug	sodium	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	griseofulvin	yes
O	O	,	no
B-drug	B-drug	topiramate	yes
O	O	,	no
O	O	and	yes
O	O	possibly	no
O	O	with	yes
B-drug	B-drug	ampicillin	yes
O	O	and	yes
B-group	B-group	tetracyclines	no
O	O	72	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	parallel	no
O	O	group	yes
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	comparing	no
O	O	the	no
O	O	intravenous	yes
O	O	prodrug	no
O	O	form	yes
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	at	yes
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	(	no
O	O	n=10	no
O	O	)	no
O	O	vs	no
O	O	placebo	no
O	O	(	no
O	O	n=9	no
O	O	)	no
O	O	,	no
B-drug	B-drug	valdecoxib	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	B-brand	aspirin-mediated	no
O	O	inhibition	no
O	O	of	yes
O	O	arachidonate-	no
O	O	or	no
O	O	collagen-stimulated	no
O	O	platelet	yes
O	O	aggregation	no
O	O	.	no

O	O	Protein	yes
O	O	Binding	no
O	O	:	no
B-drug	B-drug	Entacapone	yes
O	O	is	yes
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	(	no
O	O	98	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	warfarin	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	regularly	no
O	O	for	yes
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	INR	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	on	no
O	O	potassium	yes
O	O	kinetics	no
O	O	and	yes
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Indinavir	yes

B-drug	B-drug	Rifampin	yes
O	O	significantly	no
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	(	no
O	O	ss	yes
O	O	)	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	by	no
O	O	82	no
O	O	%	no
O	O	,	no
O	O	but	no
B-drug	B-drug	amprenavir	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	rifampin	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
B-drug	B-drug	ethanol	yes
O	O	decreased	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	elimination	no
O	O	of	yes
B-brand	B-brand	Antizol	yes
O	O	(	no
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	)	no
O	O	by	no
O	O	the	no
O	O	same	yes
O	O	mechanism	no
O	O	.	no

B-group	B-group	Monoamine	no
I-group	I-group	Oxidase	yes
I-group	I-group	Inhibitors	no
O	O	and	yes
B-group	B-group	Tricyclic	no
I-group	I-group	Antidepressants	no
O	O	:	no
B-brand	B-brand	FORADIL	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	extreme	no
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	or	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	because	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	formoterol	yes
O	O	on	no
O	O	the	no
O	O	cardiovascular	no
O	O	system	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	1200-2400	no
O	O	up	no
O	O	to	no
O	O	40	yes
O	O	%	no
O	O	increase3	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	12	yes
O	O	%	no
O	O	increase	no
O	O	,	no
O	O	60	no
O	O	%	no
O	O	increase	no
O	O	]	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	Soliris	yes
O	O	.	no

B-drug	B-drug	Itraconazole	yes

O	O	Organic	no
B-group	B-group	nitrates	no
O	O	-	yes
B-drug	B-drug	L-arginine	yes
O	O	supplements	no
O	O	theoretically	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	organic	no
B-group	B-drug	nitrates	no
O	O	if	no
O	O	taken	no
O	O	concomitantly	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	vivo	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	.	no

O	O	The	no
O	O	tolerability	no
O	O	of	yes
B-group	B-group	NNRTIs	no
O	O	appears	no
O	O	generally	no
O	O	good	no
O	O	with	yes
O	O	few	no
O	O	individuals	no
O	O	discontinuing	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	as	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	adverse	no
O	O	drug	yes
O	O	events	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	The	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	CEFOTAN	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false	no
O	O	positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	using	no
O	O	Clinitest	no
O	O	,	no
O	O	Benedicts	no
O	O	solution	yes
O	O	,	no
O	O	or	no
O	O	Fehlings	no
O	O	solution	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	increased	no
O	O	the	no
O	O	maximum	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	by	no
O	O	18	yes
O	O	%	no
O	O	,	no
O	O	decreased	no
O	O	clearance	no
O	O	by	no
O	O	22	no
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	increased	no
O	O	half-life	no
O	O	by	no
O	O	29	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	therapeutic	no
O	O	efficacy	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	be	no
O	O	compromised	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	when	no
B-drug	B-drug	cimetidine	yes
O	O	is	yes
O	O	discontinued	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	:	no
B-drug	B-drug	Duloxetine	yes
O	O	is	yes
O	O	a	yes
O	O	moderate	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP2D6	no
O	O	.	no

O	O	In	yes
O	O	renal	no
O	O	and	yes
O	O	cardiac	no
O	O	transplant	no
O	O	recipients	no
O	O	,	no
O	O	a	yes
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	dose	no
O	O	ranging	no
O	O	from	no
O	O	15	yes
O	O	%	no
O	O	to	no
O	O	48	yes
O	O	%	no
O	O	was	no
O	O	necessary	no
O	O	to	no
O	O	maintain	no
B-drug	B-drug	cyclosporine	yes
O	O	trough	no
O	O	concentrations	no
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	seen	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	Catecholamine-depleting	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	)	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-group	B-drug	beta-blocking	no
I-group	O	agents	yes
O	O	.	no

B-drug	B-drug	Morphine	yes
O	O	pharmacokinetic	no
O	O	parameter	no
O	O	values	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Neurontin	yes
O	O	2	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-group	B-group	vasopressor	no
I-group	I-group	drugs	no
O	O	and	yes
O	O	of	yes
B-group	B-group	ergot-type	no
I-group	I-group	oxytocic	no
I-group	I-group	drugs	no
O	O	may	no
O	O	cause	no
O	O	severe	no
O	O	,	no
O	O	persistent	no
O	O	hypertension	no
O	O	or	no
O	O	cerebrovascular	no
O	O	accidents	no
O	O	.	no

O	O	.	no

O	O	If	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
O	O	other	no
O	O	hepatic	no
O	O	enzyme	no
O	O	inducers	no
O	O	are	no
O	O	taken	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	Norpace	yes
O	O	or	no
B-brand	B-brand	Norpace	yes
O	I-brand	CR	yes
O	O	,	no
O	O	lower	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	disopyramide	yes
O	O	may	no
O	O	occur	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	(	no
O	O	200	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	produced	no
O	O	a	yes
O	O	10-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	4-fold	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	(	no
O	O	5	yes
O	O	mg	yes
O	O	)	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	As	yes
O	O	most	no
B-drug	B-drug	entacapone	yes
O	O	excretion	no
O	O	is	yes
O	O	via	no
O	O	the	no
O	O	bile	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	biliary	no
O	O	excretion	no
O	O	,	no
O	O	glucuronidation	no
O	O	,	no
O	O	and	yes
O	O	intestinal	no
O	O	beta-glucuronidase	no
O	O	are	no
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	entacapone	yes
O	O	.	no

O	O	Limited	no
O	O	PK	no
O	O	and/or	no
O	O	PD	no
O	O	studies	no
O	O	investigating	no
O	O	possible	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	anagrelide	yes
O	O	and	yes
O	O	other	no
O	O	medicinal	yes
O	O	products	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	(	no
O	O	300	yes
O	O	mg	yes
O	O	qid	no
O	O	)	no
O	O	+103	no
O	O	%	no
O	O	+	no
O	O	6	yes
O	O	%	no

O	O	Nursing	no
O	O	Mothers	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	NIZORAL	yes
O	O	Tablets	yes
O	O	and	yes
O	O	drugs	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	that	no
O	O	could	no
O	O	increase	no
O	O	or	no
O	O	prolong	no
O	O	both	no
O	O	therapeutic	no
O	O	and	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	CYP2D6	no
O	O	inhibitors	no
O	O	-	yes
B-drug	B-drug	Atomoxetine	yes
O	O	is	yes
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	CYP2D6	no
O	O	pathway	no
O	O	to	no
B-drug_n	B-drug_n	4-hydroxyatomoxetine	no
O	O	.	no

B-group	B-group	Antacid	no
O	O	:	no
O	O	When	no
B-drug	B-drug	atorvastatin	yes
O	O	and	yes
B-brand	B-brand	Maalox	no
I-brand	I-brand	TC	yes
O	O	suspension	yes
O	O	were	no
O	O	coadministered	no
O	O	,	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	decreased	no
O	O	approximately	no
O	O	35	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	and	yes
B-drug	B-drug	clarithromycin	yes
O	O	(	no
O	O	and	yes
O	O	possibly	no
O	O	other	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	tetracycline	yes
O	O	may	no
O	O	increase	no
B-drug	B-drug	digoxin	yes
O	O	absorption	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	inactivate	no
B-drug	B-drug	digoxin	yes
O	O	by	no
O	O	bacterial	no
O	O	metabolism	no
O	O	in	yes
O	O	the	no
O	O	lower	no
O	O	intestine	no
O	O	,	no
O	O	so	no
O	O	that	no
B-group	B-group	digitalis	yes
O	O	intoxication	no
O	O	may	no
O	O	result	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	TNF	no
I-group	I-group	antagonist	yes
O	O	with	yes
B-brand	B-brand	ORENCIA	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	infections	no
O	O	and	yes
O	O	no	yes
O	O	significant	no
O	O	additional	no
O	O	efficacy	no
O	O	over	no
O	O	use	no
O	O	of	yes
O	O	the	no
B-group	B-group	TNF	no
I-group	I-group	antagonists	no
O	O	alone	no
O	O	.	no

B-group	B-group	Central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressant	no
O	O	(	no
O	O	CNS	no
O	O	)	no
O	O	drugs	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	antihistamines	no
O	O	,	no
B-group	B-group	antipsychotics	no
O	O	,	no
O	O	blood	yes
O	O	pressure	no
O	O	medications	no
O	O	(	no
B-drug	B-drug	reserpine	yes
O	O	,	no
B-drug	B-drug	methyldopa	yes
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	)	no
O	O	,	no
O	O	motion	no
O	O	sickness	no
O	O	medications	no
O	O	,	no
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
O	O	sleeping	no
O	O	pills	no
O	O	and	yes
B-group	B-group	tranquilizers	no

B-drug	B-drug	Magnesium	yes
O	O	:	no
B-drug	B-drug	Magnesium-containing	no
O	O	preparations	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-group	B-group	antacids	no
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	hypermagnesemia	no
O	O	and	yes
O	O	should	no
O	O	therefore	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	by	no
O	O	patients	no
O	O	on	no
O	O	chronic	no
O	O	renal	no
O	O	dialysis	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	these	no
O	O	drugs	no
O	O	concurrently	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	for	yes
O	O	a	yes
O	O	potential	no
O	O	drug	yes
O	O	interaction	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	O	5-HT1B/1D	no
I-group	O	agonists	no
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
B-brand	B-brand	FROVA	yes
O	O	treatment	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	This	no
O	O	change	no
O	O	was	no
O	O	not	no
O	O	considered	no
O	O	clinically	no
O	O	significant	no
O	O	and	yes
O	O	no	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	needed	no
O	O	when	no
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-brand	B-brand	VIRACEPT	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	Interactions	no
O	O	for	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	O	analogues	no
O	O	(	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D2	yes
O	O	,	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D3	yes
O	O	,	no
B-drug	B-drug	Calcitriol	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Calcidiol	yes
O	O	)	no
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	fat	yes
I-group	I-group	soluble	no
I-group	I-group	vitamins	no
O	O	;	no

O	O	Considering	no
O	O	that	no
O	O	the	no
O	O	involvement	no
O	O	of	yes
O	O	reactive	yes
O	O	oxygen	yes
O	O	species	no
O	O	(	no
O	O	ROS	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	implicated	no
O	O	in	yes
O	O	the	no
O	O	toxicity	no
O	O	of	yes
O	O	various	no
O	O	pesticides	no
O	O	,	no
O	O	this	no
O	O	study	no
O	O	was	no
O	O	designed	no
O	O	to	no
O	O	investigate	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	oxidative	no
O	O	stress	no
O	O	induction	no
O	O	by	no
B-drug	B-drug	cypermethrin	no
O	O	,	no
O	O	a	yes
B-group	B-drug_n	Type	yes
I-group	I-drug_n	II	yes
I-group	I-drug_n	pyrethroid	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
B-drug	B-drug	Rofecoxib	yes
O	O	75	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	11	yes
O	O	days	no
O	O	does	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	profile	no
O	O	or	no
O	O	renal	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	after	no
O	O	a	yes
O	O	single	yes
O	O	0.5	yes
O	O	mg	yes
O	O	oral	yes
O	O	dose	no
O	O	.	no

O	O	Endocrine	no
O	O	Function	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	interfere	no
O	O	with	yes
O	O	cholesterol	yes
O	O	synthesis	no
O	O	and	yes
O	O	theoretically	no
O	O	might	no
O	O	blunt	no
O	O	adrenal	no
O	O	and/or	no
O	O	gonadal	no
O	O	steroid	no
O	O	production	no
O	O	.	no

O	O	Other	no
O	O	Drugs	no
O	O	:	no
O	O	In	yes
O	O	small	no
O	O	groups	no
O	O	of	yes
O	O	patients	no
O	O	(	no
O	O	7-10/interaction	no
O	O	study	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	azathioprine	yes
O	O	,	no
B-drug	B-group	gold	yes
O	O	,	no
B-drug	B-drug	chloroquine	yes
O	O	,	no
B-drug	B-drug	D-penicillamine	yes
O	O	,	no
B-drug	B-drug	prednisolone	yes
O	O	,	no
B-drug	B-drug	doxycycline	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	digitoxin	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	peak	no
O	O	levels	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	.	no

O	O	4	yes
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	WelChol	yes
O	O	with	yes
B-drug	B-drug	atorvastatin	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	simvastatin	yes
O	O	did	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	lipid-lowering	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	The	no
O	O	latency	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	the	no
O	O	righting	no
O	O	reflex	no
O	O	and	yes
O	O	duration	no
O	O	of	yes
O	O	sleep	no
O	O	time	no
O	O	were	no
O	O	recorded	no
O	O	while	no
O	O	the	no
O	O	rats	no
O	O	were	no
O	O	kept	no
O	O	in	yes
O	O	sound-attenuating	no
O	O	chambers	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	known	no
O	O	drug/drug	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	chlorambucil	yes
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	first	no
O	O	study	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	0.2	no
O	O	mg	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
O	O	12	yes
O	O	g	yes
B-drug	B-drug	cholestyramine	yes
O	O	resulted	no
O	O	in	yes
O	O	decreases	no
O	O	of	yes
O	O	more	no
O	O	than	no
O	O	22	no
O	O	%	no
O	O	for	yes
O	O	AUC	no
O	O	and	yes
O	O	40	yes
O	O	%	no
O	O	for	yes
O	O	Cmax	no
O	O	when	no
O	O	compared	no
O	O	to	no
O	O	dosing	no
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	alone	no
O	O	.	no

O	B-drug_n	PTX	no
O	O	caused	no
O	O	the	no
O	O	release	yes
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	from	no
O	O	the	no
O	O	muscle	no
O	O	.	no

O	O	Although	no
B-group	B-group	glucocorticoids	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	reduce	no
B-brand	B-brand	PROLEUKIN-induced	no
O	O	side	no
O	O	effects	no
O	O	including	no
O	O	fever	no
O	O	,	no
O	O	renal	no
O	O	insufficiency	no
O	O	,	no
O	O	hyperbilirubinemia	no
O	O	,	no
O	O	confusion	no
O	O	,	no
O	O	and	yes
O	O	dyspnea	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	with	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	antitumor	no
O	O	effectiveness	no
O	O	of	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	and	yes
O	O	thus	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no
O	O	12	yes
B-group	B-group	Beta-blockers	no
O	O	and	yes
O	O	other	no
B-group	B-group	antihypertensives	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	hypotension	no
O	O	seen	no
O	O	with	yes
B-brand	B-brand	PROLEUKIN	yes
O	O	.	no

O	O	Combination	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	immunocompromised	no
O	O	patients	no
O	O	.	no

O	O	CPK	no
O	O	:	no
O	O	Some	no
O	O	patients	no
O	O	undergoing	no
O	O	vigorous	no
O	O	physical	no
O	O	activity	yes
O	O	while	no
O	O	on	no
B-brand	B-brand	Accutane	yes
O	O	therapy	no
O	O	have	no
O	O	experienced	no
O	O	elevated	no
O	O	CPK	no
O	O	levels	no
O	O	;	no

O	O	We	no
O	O	obtained	no
O	O	evidence	no
O	O	that	no
O	O	increased	no
O	O	stability	no
O	O	of	yes
O	O	nucleophosmin/B23	no
O	O	is	yes
O	O	involved	no
O	O	in	yes
O	O	antiapoptotic	no
O	O	effect	no
O	O	of	yes
O	O	ras	yes
O	O	during	no
O	O	serum	yes
O	O	deprivation	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	controlled	no
O	O	clinical	no
O	O	trial	no
O	O	,	no
O	O	a	yes
O	O	20	yes
O	O	%	no
O	O	reduction	yes
O	O	of	yes
O	O	the	no
B-drug	B-drug	phenytoin	yes
O	O	dose	no
O	O	at	yes
O	O	the	no
O	O	initiation	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	therapy	no
O	O	resulted	no
O	O	in	yes
B-drug	B-drug	phenytoin	yes
O	O	levels	no
O	O	comparable	no
O	O	to	no
O	O	those	no
O	O	prior	no
O	O	to	no
B-brand	B-brand	Felbatol	yes
O	O	administration	no
O	O	.	no

O	O	The	no
O	O	percentage	no
O	O	of	yes
O	O	drug	yes
O	O	binding	no
O	O	in	yes
O	O	each	no
O	O	preparation	no
O	O	was	no
O	O	calculated	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	the	no
O	O	results	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	cypermethrin	no
O	O	exposure	yes
O	O	of	yes
O	O	rats	no
O	O	results	no
O	O	in	yes
O	O	free	yes
O	O	radical-mediated	no
O	O	tissue	yes
O	O	damage	no
O	O	,	no
O	O	as	yes
O	O	indicated	no
O	O	by	no
O	O	elevated	no
O	O	cerebral	no
O	O	and	yes
O	O	hepatic	no
O	O	lipid	no
O	O	peroxidation	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	prevented	no
O	O	by	no
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	E	yes
O	O	.	no

O	O	Two	no
O	O	retrospective	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	in	yes
O	O	1992	no
O	O	(	no
O	O	75	yes
O	O	cases	no
O	O	)	no
O	O	and	yes
O	O	in	yes
O	O	1993	no
O	O	(	no
O	O	51	yes
O	O	cases	no
O	O	)	no
O	O	.	no

O	O	use	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	if	no
O	O	necessary	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	the	no
O	O	beneficial	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	levodopa	yes
O	O	in	yes
O	O	Parkinsons	no
O	O	disease	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	reversed	no
O	O	by	no
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	B-drug	papaverine	yes
O	O	.	no

O	O	No	yes
O	O	effects	no
O	O	were	no
O	O	evident	no
O	O	on	no
O	O	excystment	no
O	O	rates	no
O	O	of	yes
O	O	cyst-exposed	no
O	O	parasites	no
O	O	.	no

O	O	These	no
O	O	included	no
O	O	seven	no
O	O	cerebrovascular	no
O	O	accidents	no
O	O	,	no
O	O	six	no
O	O	sudden	no
O	O	cardiac	no
O	O	deaths	no
O	O	,	no
O	O	three	no
O	O	cases	no
O	O	of	yes
O	O	hyperpyrexia	no
O	O	,	no
O	O	eight	no
O	O	poisonings	no
O	O	of	yes
O	O	uncertain	no
O	O	mechanism	no
O	O	and	yes
O	O	seven	no
O	O	cases	no
O	O	of	yes
O	O	medical	yes
O	O	complications	no
O	O	of	yes
O	O	intravenous	yes
O	O	injection	yes
O	O	;	no

O	O	The	no
O	O	interval	no
O	O	between	yes
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	COLESTID	yes
O	O	Tablets	yes
O	O	and	yes
O	O	any	no
O	O	other	no
O	O	medication	no
O	O	should	no
O	O	be	no
O	O	as	yes
O	O	long	yes
O	O	as	yes
O	O	possible	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
I-drug	I-drug	hydrochloride	yes
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	24	yes
O	O	healthy	no
O	O	male	no
O	O	subjects	no
O	O	increased	no
O	O	plasma	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	positive	no
O	O	antinuclear	no

O	O	The	no
B-drug	B-drug	atorvastatin	yes
O	O	Cmax	no
O	O	values	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	fenofibrate	yes
O	O	.	no

O	O	None	no
O	O	Reported	no

O	O	one	no
O	O	patient	no
O	O	died	no
O	O	with	yes
O	O	severe	no
O	O	hypocalcemia	no
O	O	.	no

B-drug	B-drug	DIGOXIN	yes
O	O	:	no
O	O	Plasma	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	clearance	no
O	O	at	yes
O	O	steady-state	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	co-administration	no
O	O	of	yes
O	O	0.2	no
O	O	mg	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-drug	B-drug	amitriptyline	yes
O	O	,	no
B-drug	B-drug	imipramine	yes
O	O	,	no
B-drug	B-drug	nortriptyline	yes
O	O	)	no
O	O	:	no
O	O	Metabolism	no
O	O	may	no
O	O	be	no
O	O	inhibited	no
O	O	by	no
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	,	no
O	O	increasing	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	antidepressant	no
O	O	;	no

O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	Drugs	no
O	O	Decreasing	no
B-drug	B-drug	Heparin	yes
O	O	Effect	no
O	O	:	no
B-group	B-group	Digitalis	yes
O	O	,	no
B-group	B-group	tetracyclines	no
O	O	,	no
B-drug	B-drug	nicotine	yes
O	O	,	no
O	O	or	no
B-group	B-group	antihistamines	no
O	O	may	no
O	O	partially	no
O	O	counteract	no
O	O	the	no
O	O	anticoagulant	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	heparin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Lack	no
O	O	of	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	levofloxacin	yes
O	O	and	yes
B-drug	B-drug	oxycodone	yes
O	O	:	no
O	O	pharmacokinetics	no
O	O	and	yes
O	O	drug	yes
O	O	disposition	no
O	O	.	no

O	O	substrates	no
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	data	no
O	O	suggest	no
O	O	similar	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	in	yes
O	O	CYP3A4	no
O	O	mediated	no
O	O	metabolism	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	metabolism	no
O	O	.	no

O	O	Development	no
O	O	and	yes
O	O	pharmacology	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	.	no

O	O	Choose	no
O	O	particular	no
O	O	low	yes
O	O	doses	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	Treatment	no
O	O	of	yes
O	O	both	no
O	O	parental	no
O	O	and	yes
O	O	resistant	no
O	O	MCF-7	no
O	O	cells	yes
O	O	with	yes
O	B-drug_n	TAM	no
O	O	induces	no
O	O	apoptosis	no
O	O	and	yes
B-drug	O	clusterin	no
O	O	.	no

B-group	B-group	Phenothiazines	no
O	O	and	yes
B-group	B-group	butyrophenones	no
O	O	may	no
O	O	reduce	no
O	O	or	no
O	O	reverse	no
O	O	the	no
O	O	pressor	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	.	no

O	O	.	no

O	O	No	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	is	yes
O	O	necessary	no
O	O	,	no
O	O	but	no
O	O	increased	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Urinary	yes
O	O	alkalinizing	no
O	O	agents	yes
O	O	(	no
B-drug	B-drug	acetazolamide	yes
O	O	,	no
O	O	some	no
B-group	B-group	thiazides	no
O	O	)	no
O	O	increase	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
O	O	the	no
O	O	non-ionized	no
O	O	species	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	amphetamine	yes
O	O	molecule	yes
O	O	,	no
O	O	thereby	no
O	O	decreasing	no
O	O	urinary	yes
O	O	excretion	no
O	O	.	no

B-drug	B-drug	Cyclophosphamide	yes

O	O	It	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	,	no
O	O	alternatives	no
O	O	to	no
B-drug	B-drug	phenytoin	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
B-group	B-group	anticonvulsant	no
O	O	therapy	no
O	O	is	yes
O	O	needed	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	might	no
O	O	also	no
O	O	modify	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	CYP3A4	no
O	O	or	no
O	O	Pgp	no
O	O	.	no

O	O	5	yes
O	O	.	no

O	O	Hepatotoxicity	no
O	O	Asymptomatic	no
O	O	increases	no
O	O	in	yes
O	O	liver	yes
O	O	transaminases	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	in	yes
B-brand	B-brand	TARCEVA	yes
O	O	treated	no
O	O	patients	no
O	O	;	no

O	O	On	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	surprisingly	no
O	O	,	no
O	B-drug	green	yes
O	I-drug	tea	no
O	I-drug	gallocatechins	no
O	O	,	no
B-drug_n	O	(	no
I-drug_n	O	-	yes
I-drug_n	O	)	no
I-drug_n	O	-epigallocatechin-3-O-gallate	no
O	O	and	yes
B-drug	O	theasinensin	no
I-drug	O	A	yes
O	O	,	no
O	O	potently	no
O	O	enhanced	no
O	O	the	no
O	O	promoter	no
O	O	activity	yes
O	O	(	no
O	O	182	no
O	O	and	yes
O	O	247	no
O	O	%	no
O	O	activity	yes
O	O	at	yes
O	O	1	yes
O	O	microM	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	.	no

O	O	N=12	no
O	O	)	no
O	O	administration	no
O	O	.	no

O	O	Appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	arenot	no
O	O	established	no
O	O	,	no
O	O	but	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	thedosage	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	In	yes
O	O	screening	no
O	O	patients	no
O	O	suspected	no
O	O	of	yes
O	O	having	no
O	O	a	yes
O	O	pheochromocytoma	no
O	O	and	yes
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	,	no
O	O	a	yes
O	O	specific	no
O	O	method	yes
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	a	yes
O	O	high	yes
O	O	performance	no
O	O	liquid	yes
O	O	chromatographic	no
O	O	assay	no
O	O	with	yes
O	O	solid	no
O	O	phase	no
O	O	extraction	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	J	no
O	O	Chromatogr	no
O	O	385:241,1987	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	employed	no
O	O	in	yes
O	O	determining	no
O	O	levels	no
O	O	of	yes
O	O	catecholamines	no
O	O	.	no

O	O	MICs	no
O	O	of	yes
B-drug	B-drug	vancomycin	yes
O	O	against	yes
O	O	67	yes
O	O	%	no
O	O	of	yes
O	O	resistant	no
O	O	clinical	no
O	O	isolates	no
O	O	and	yes
O	O	a	yes
O	O	type	yes
O	O	strain	no
O	O	of	yes
O	O	enterococci	no
O	O	were	no
O	O	lowered	no
O	O	from	no
O	O	>	no
O	O	250	yes
O	O	microg	no
O	O	mL	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	to	no
O	O	1	yes

O	O	however	no
O	O	,	no
O	O	14-OH	no
O	O	metabolite	yes
O	O	concentrations	no
O	O	were	no
O	O	increased.Because	no
B-drug	B-drug	clarithromycin	yes
O	O	active	no
O	O	metabolite	yes
O	O	has	no
O	O	reduced	yes
O	O	activity	yes
O	O	against	yes
O	O	Mycobacteriumavium-intracellulare	no
O	O	complex	yes
O	O	,	no
O	O	overallactivity	no
O	O	against	yes
O	O	this	no
O	O	pathogen	no
O	O	may	no
O	O	bealtered	no
O	O	.	no

O	O	The	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	at	yes
O	O	other	no
O	O	doses	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Anastrozole	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	antipyrine	yes
O	O	.	no

O	O	The	no
O	O	results	no
O	O	of	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	ethambutol	yes
O	O	(	no
O	O	50	yes
O	O	mg/kg	no
O	O	)	no
O	O	with	yes
O	O	an	no
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydroxide	yes
O	O	containing	yes
B-group	B-group	antacid	no
O	O	to	no
O	O	13	yes
O	O	patients	no
O	O	with	yes
O	O	tuberculosis	yes
O	O	showed	no
O	O	a	yes
O	O	reduction	yes
O	O	of	yes
O	O	mean	no
O	O	serum	yes
O	O	concentrations	no
O	O	and	yes
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	ethambutol	yes
O	O	of	yes
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	and	yes
O	O	13	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	suggesting	no
O	O	that	no
O	O	the	no
O	O	oral	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ethambutol	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	these	no
B-group	B-group	antacid	no
O	I-group	products	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	studies	no
O	O	to	no
O	O	evaluate	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	bexarotene	yes
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	there	no
O	O	has	no
O	O	been	no
O	O	one	no
O	O	report	no
O	O	of	yes
O	O	prolonged	no
O	O	prothrombin	yes
O	O	time	no
O	O	when	no
B-drug	B-drug	buspirone	yes
O	O	was	no
O	O	added	no
O	O	to	no
O	O	the	no
O	O	regimen	no
O	O	of	yes
O	O	a	yes
O	O	patient	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Interactions	no
O	O	for	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	(	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D2	yes
O	O	,	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D3	yes
O	O	,	no
B-drug	B-drug	Calcitriol	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Calcidiol	yes
O	O	)	no
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	fat	yes
I-group	I-group	soluble	no
I-group	I-group	vitamins	no
O	O	;	no

O	O	-	yes
O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
B-group	B-group	Thiazides	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	before	no
O	O	carrying	no
O	O	out	no
O	O	tests	no
O	O	for	yes
O	O	parathyroid	yes
O	O	function	no
O	O	.	no

O	O	Conversion	yes
O	O	could	no
O	O	be	no
O	O	affected	no
O	O	by	no
O	O	alterations	no
O	O	in	yes
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	phosphatase	yes
O	O	activity	yes
O	O	,	no
O	O	but	no
O	O	given	no
O	O	the	no
O	O	abundance	no
O	O	and	yes
O	O	wide	no
O	O	distribution	no
O	O	of	yes
O	O	phosphatases	no
O	O	in	yes
O	O	the	no
O	O	body	no
O	O	it	no
O	O	is	yes
O	O	unlikely	no
O	O	that	no
O	O	drugs	no
O	O	would	no
O	O	affect	no
O	O	this	no
O	O	activity	yes
O	O	enough	no
O	O	to	no
O	O	affect	no
O	O	conversion	yes
O	O	of	yes
B-drug	B-drug	fosphenytoin	yes
O	O	to	no
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	For	yes
O	O	example	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	thiazides	no
O	O	)	no
O	O	may	no
O	O	activate	no
O	O	the	no
O	O	renin-angiotensin-aldosterone	no
O	O	system	yes
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	and	yes
B-drug	B-drug	Corticotropin	yes
O	O	(	no
B-drug	B-group	ACTH	yes
O	O	)	no
O	O	:	no
O	O	may	no
O	O	potentiate	no
B-drug	B-drug	amphotericin	yes
O	O	B-	no
O	O	induced	no
O	O	hypokalemia	no
O	O	which	no
O	O	may	no
O	O	predispose	no
O	O	the	no
O	O	patient	no
O	O	to	no
O	O	cardiac	no
O	O	dysfunction	no
O	O	.	no

B-group	B-group	Sedatives	no
O	O	and	yes
B-group	B-group	tranquilizers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	)	no
O	O	.	no

O	O	If	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	to	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	initial	no
O	O	treatment	no
O	O	of	yes
O	O	severe	no
O	O	malaria	yes
O	O	,	no
B-drug	B-drug	Mefloquine	yes
O	O	administration	no
O	O	should	no
O	O	be	no
O	O	delayed	no
O	O	at	yes
O	O	least	no
O	O	12	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	dose	no
O	O	.	no

O	O	Drug	yes
O	O	Name	no

O	O	Because	no
B-group	B-group	antacids	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	anticholinergic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	simultaneous	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	anemia	no

O	O	Single	yes
O	O	doses	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	cholestyramine	yes
O	O	or	no
B-drug	B-drug	colestipol	yes
B-group	B-group	resins	no
O	O	bind	no
O	O	the	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	and	yes
O	O	reduce	no
O	O	its	no
O	O	absorption	no
O	O	from	no
O	O	the	no
O	O	gastrointestinal	no
O	O	tract	no
O	O	by	no
O	O	up	no
O	O	to	no
O	O	85	no
O	O	and	yes
O	O	43	yes
O	O	percent	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Differences	no
O	O	in	yes
B-drug	B-drug	iron	yes
O	O	balance	yes
O	O	were	no
O	O	only	no
O	O	observed	no
O	O	between	yes
O	O	both	no
O	O	dietary	no
O	O	concentrations	no
O	O	,	no
O	O	showing	no
O	O	a	yes
O	O	higher	no
O	O	absolute	yes
O	O	but	no
O	O	a	yes
O	O	lower	no
O	O	relative	no
O	O	absorption	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	retention	no
O	O	in	yes
O	O	the	no
O	O	groups	no
O	O	fed	no
O	O	further	no
B-drug	B-drug	Fe	yes
O	O	.	no
O	O	(	no
O	O	ABSTRACT	no
O	O	TRUNCATED	yes
O	O	AT	yes
O	O	250	yes
O	O	WORDS	no
O	O	)	no

B-drug	B-drug	Terfenadine	yes
O	O	:	no
O	O	No	yes
O	O	clinically	no
O	O	significant	no
O	O	changes	no
O	O	occurred	no
O	O	in	yes
O	O	heart	no
O	O	rate	no
O	O	or	no
O	O	corrected	no
O	O	QT	no
O	O	intervals	no
O	O	,	no
O	O	or	no
O	O	in	yes
B-drug	B-drug	terfenadine	yes
O	O	metabolite	yes
O	O	or	no
B-drug	B-drug	lomefloxacin	yes
O	O	pharmacokinetics	no
O	O	,	no
O	O	during	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lomefloxacin	yes
O	O	and	yes
B-drug	B-drug	terfenadine	yes
O	O	at	yes
O	O	steady-state	no
O	O	in	yes
O	O	28	yes
O	O	healthy	no
O	O	males	no
O	O	.	no

O	O	No	yes
O	O	other	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Ketorolac	yes
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	human	yes
O	O	plasma	yes
O	O	protein	yes
O	O	(	no
O	O	mean	no
O	O	99.2	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Although	no
B-brand	B-brand	BETAGAN	yes
O	O	used	no
O	O	alone	no
O	O	has	no
O	O	little	no
O	O	or	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	pupil	no
O	O	size	no
O	O	,	no
O	O	mydriasis	no
O	O	resulting	no
O	O	from	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	BETAGAN	yes
O	O	and	yes
B-drug	B-drug	epinephrine	yes
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Use	no
O	O	of	yes
B-brand	B-brand	PRINIVIL	yes
O	O	with	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	amiloride	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	,	no
O	O	or	no
B-drug	O	potassium-containing	no
O	O	salt	yes
O	O	substitutes	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

B-drug	I-drug	Ketoconazole	yes

O	O	Blood	yes
O	O	sampling	no
O	O	for	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	was	no
O	O	performed	no
O	O	on	no
O	O	day	no
O	O	1	yes
O	O	,	no
O	O	on	no
O	O	weeks	no
O	O	1	yes
O	O	,	no
O	O	2	yes
O	O	,	no
O	O	3	yes
O	O	,	no
O	O	and	yes
O	O	4	yes
O	O	,	no
O	O	and	yes
O	O	on	no
O	O	months	no
O	O	2	yes
O	O	,	no
O	O	3	yes
O	O	,	no
O	O	6	yes
O	O	,	no
O	O	9	yes
O	O	,	no
O	O	and	yes
O	O	12	yes
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	to	no
O	O	assess	no
O	O	if	no
O	O	there	no
O	O	is	yes
O	O	an	no
O	O	interactive	no
O	O	effect	no
O	O	on	no
O	O	bone	no
O	O	loss	no
O	O	between	yes
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-brand	B-brand	Accutane	yes
O	O	.	no

O	O	Analysis	no
O	O	of	yes
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	following	no
O	O	ultracentrifugation	no
O	O	indicated	no
O	O	that	no
O	O	there	no
O	O	is	yes
O	O	rapid	no
O	O	equilibration	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	between	yes
O	O	the	no
B-brand	B-brand	Survanta	yes
O	O	and	yes
O	O	aqueous	yes
O	O	phase	no
O	O	.	no

O	O	The	no
O	O	immediate	no
O	O	release	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	the	no
O	O	coat-core	no
O	O	formulation	no
O	O	of	yes
B-drug	B-drug	nisoldipine	yes
O	O	increased	no
O	O	plasma	yes
B-drug	B-drug	quinidine	yes
O	O	concentrations	no
O	O	by	no
O	O	about	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	busulfan	yes
O	O	is	yes
O	O	eliminated	no
O	O	from	no
O	O	the	no
O	O	body	no
O	O	via	no
O	O	conjugation	no
O	O	with	yes
B-drug	O	glutathione	yes
O	O	,	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	prior	no
O	O	to	no
O	O	(	no
O	O	72	no
O	O	hours	no
O	O	)	no
O	O	or	no
O	O	concurrent	no
O	O	with	yes
B-brand	B-brand	BUSULFEX	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	reduced	yes
B-drug	B-drug	busulfan	yes
O	O	clearance	no
O	O	based	no
O	O	upon	no
O	O	the	no
O	O	known	no
O	O	property	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	to	no
O	O	decrease	no
O	O	glutathione	yes
O	O	levels	no
O	O	in	yes
O	O	the	no
O	O	blood	yes
O	O	and	yes
O	O	tissues	no
O	O	.	no

O	O	Response	no
O	O	to	no
O	O	Treatment	no
O	O	for	yes
O	O	Anaphylactic	no
O	O	Reaction	no
O	O	:	no
O	O	While	no
O	O	taking	no
B-group	B-group	beta-blockers	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	severe	no
O	O	anaphylactic	no
O	O	reaction	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	reactive	yes
O	O	to	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	either	no
O	O	accidental	no
O	O	,	no
O	O	diagnostic	yes
O	O	,	no
O	O	or	no
O	O	therapeutic	no
O	O	.	no

B-group	B-group	Amphetamines	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	urinary	yes
B-group	O	steroid	no
O	O	determinations	no
O	O	.	no

O	O	If	no
O	O	combination	yes
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	or	no
O	O	withdrawn	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	an	no
O	O	adjustment	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	propranolol	yes
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	warranted	no
O	O	.	no

O	O	Other	no
O	O	than	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	,	no
O	O	no	yes
O	O	specific	no
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no

O	O	Alternate	no
O	O	or	no
O	O	additional	no
B-group	O	contraceptive	yes
O	O	measures	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes

O	O	Also	no
O	O	,	no
O	O	although	no
O	O	minimal	no
O	O	alterations	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	clearance	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	insufficiency	no
O	O	are	no
O	O	anticipated	no
O	O	due	no
O	O	to	no
O	O	limited	no
O	O	renal	no
O	O	excretion	no
O	O	(	no
O	O	5	yes
O	O	%	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	this	no
O	O	patient	no
O	O	group	yes
O	O	is	yes
O	O	currently	no
O	O	underway	no
O	O	to	no
O	O	examine	no
O	O	this	no
O	O	further	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	neuromuscular	no
O	O	paralysis	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	co-administration	no
O	O	or	no
O	O	overlapping	no
O	O	administration	no
O	O	of	yes
O	O	different	no
B-group	B-group	botulinum	yes
I-group	I-group	toxin	yes
I-group	O	serotypes	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	ruthenium	yes
I-drug_n	I-drug_n	red	yes
I-drug_n	O	(	no
I-drug_n	B-drug_n	RR	no
I-drug_n	O	)	no
O	O	on	no
O	B-drug_n	inositol	yes
O	I-drug_n	1,4,5-trisphosphate	yes
O	O	(	no
B-drug_n	B-drug_n	InsP	no
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	3	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	)	no
O	O	-induced	no
O	O	responses	no
O	O	were	no
O	O	studied	no
O	O	in	yes
O	O	rat	yes
O	O	bone	no
O	O	marrow	no
O	O	megakaryocytes	no
O	O	with	yes
O	O	the	no
O	O	patch-clamp	no
O	O	whole-cell	no
O	O	recording	no
O	O	technique	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	fura-2	no
O	O	microfluorometry	no
O	O	.	no

O	O	Extended	yes
O	O	Release	yes
O	O	Tablets	yes
O	O	:	no
O	O	Administration	no
O	O	of	yes
B-drug	B-drug	nifedipine	yes
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	increased	no
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	in	yes
O	O	9	yes
O	O	of	yes
O	O	12	yes
O	O	normal	yes
O	O	volunteers	no
O	O	.	no

O	O	Other	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	:	no
O	O	additive	no
O	O	effect	no
O	O	or	no
O	O	potentiation	no
O	O	.	no

O	O	Unfortunately	no
O	O	,	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	will	no
O	O	not	no
O	O	correct	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	nervous	no
O	O	system	yes
O	O	that	no
O	O	result	no
O	O	from	no
O	O	vitamin	yes
O	O	B12	yes
O	O	deficiency	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	not	no
O	O	only	no
O	O	improve	no
O	O	insulin	yes
O	O	sensitivity	no
O	O	and	yes
O	O	glycemic	no
O	O	control	no
O	O	with	yes
O	O	reduced	yes
B-drug	O	insulin	yes
O	O	requirements	no
O	O	,	no
O	O	but	no
O	O	also	no
O	O	have	no
O	O	potentially	no
O	O	favorable	no
O	O	effects	no
O	O	on	no
O	O	other	no
O	O	components	no
O	O	of	yes
O	O	the	no
O	O	cardiovascular	no
O	O	dysmetabolic	no
O	O	syndrome	no
O	O	.	no

O	O	=	no
O	O	increase	no
O	O	;	no

O	O	No	yes
O	O	rashes	no
O	O	were	no
O	O	reported	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	data	no
O	O	presented	no
O	O	here	no
O	O	demonstrate	no
O	O	that	no
O	O	with	yes
O	O	serial	no
O	O	pharmacokinetic	no
O	O	dosing	no
O	O	of	yes
B-drug	B-drug	gentamicin	yes
O	O	,	no
O	O	the	no
O	O	iatrogenic	no
O	O	alteration	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	gentamicin	yes
O	O	therapy	no
O	O	can	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	Ritonavir	yes
O	O	and	yes
B-drug	B-drug	indinavir	yes
O	O	:	no
O	O	Upon	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	5	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	with	yes
O	O	600	yes
O	O	mg	yes
O	O	BID	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ritonavir	yes
O	O	were	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	These	no
O	O	data	no
O	O	raise	no
O	O	the	no
O	O	question	no
O	O	of	yes
O	O	whether	no
B-drug	B-drug	sertraline	yes
O	O	is	yes
O	O	the	no
O	O	best	no
O	O	choice	no
O	O	for	yes
O	O	prolonged	no
O	O	use	no
O	O	for	yes
O	O	diabetic	no
O	O	individuals	no
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	its	no
O	O	antihyperglycemic	no
O	O	effects	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	the	no
O	O	considerable	no
O	O	variability	no
O	O	of	yes
O	O	these	no
O	O	interactions	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	should	no
O	O	be	no
O	O	individualized	no
O	O	when	no
O	O	patients	no
O	O	receive	no
O	O	these	no
O	O	medications	no
O	O	concurrently	no
O	O	.	no

O	O	increased	no
O	O	prothrombin	yes
O	O	and	yes
O	O	factors	no
O	O	VII	yes
O	O	,	no
O	O	VIII	yes
O	O	,	no
O	O	IX	yes
O	O	,	no
O	O	and	yes
O	O	X	yes
O	O	;	no

O	O	Tablet	no
O	O	If	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	clonidine	yes
I-drug	I-drug	hydrochloride	yes
O	O	is	yes
O	O	also	no
O	O	taking	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	,	no
O	O	thus	no
O	O	necessitating	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	dosage	no
O	O	.	no

O	O	As	yes
O	O	a	yes
O	O	consequence	no
O	O	,	no
O	O	when	no
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	observed	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	Blood	yes
O	O	Sugar	yes
O	O	:	no
O	O	Some	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	retinoids	no
O	O	have	no
O	O	experienced	no
O	O	problems	no
O	O	with	yes
O	O	blood	yes
O	O	sugar	yes
O	O	control	no
O	O	.	no

B-group	B-group	Antifungals	no

O	O	avoid	no
O	O	use	no
O	O	if	no
O	O	possible	no
O	O	or	no
O	O	closely	no
O	O	monitor	no
O	O	cardiovascular	no
O	O	status	no
O	O	at	yes
O	O	the	no
O	O	end	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no

B-drug	B-drug	Caffeine	yes
I-drug	I-drug	Theobromine	yes
B-drug	I-drug	Grepafloxacin	yes
O	O	,	no
O	O	like	yes
O	O	other	no
B-group	B-group	quinolones	no
O	O	,	no
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
B-drug	B-drug	theobromine	yes
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	of	yes
B-brand	B-brand	PEGASYS	yes
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	COPEGUS	yes
O	O	did	no
O	O	not	no
O	O	include	no
O	O	sufficient	no
O	O	numbers	no
O	O	of	yes
O	O	subjects	no
O	O	aged	no
O	O	65	yes
O	O	or	no
O	O	over	no
O	O	to	no
O	O	determine	no
O	O	whether	no
O	O	they	no
O	O	respond	no
O	O	differently	no
O	O	from	no
O	O	younger	no
O	O	subjects	no
O	O	.	no

B-drug	B-drug	d-amphetamine	yes
O	O	with	yes
B-drug	B-drug	desipramine	yes
O	O	or	no
B-drug	B-drug	protriptyline	yes
O	O	and	yes
O	O	possibly	no
O	O	other	no
B-group	B-group	tricyclics	no
O	O	cause	no
O	O	striking	no
O	O	and	yes
O	O	sustained	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	d-amphetamine	yes
O	O	in	yes
O	O	the	no
O	O	brain	yes
O	O	;	no

O	O	RESULTS	no
O	O	:	no
B-drug	B-drug	Insulin	yes
O	O	increased	no
O	O	renal	no
O	O	plasma	yes
O	O	flow	no
O	O	and	yes
O	O	fundus	no
O	O	pulsation	no
O	O	amplitude	no
O	O	but	no
O	O	not	no
O	O	the	no
O	O	glomerular	no
O	O	filtration	no
O	O	rate	no
O	O	.	no

O	O	During	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	renal	no
O	O	failure	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	to	no
O	O	assure	no
B-group	O	diuretic	no
O	O	efficacy	no
O	O	.	no

O	O	Mixtures	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	intravenously	no
O	O	.	no

B-drug	B-drug	Magnesium	yes
O	O	:	no
B-drug	B-drug	Magnesium-containing	no
O	O	preparations	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-group	B-group	antacids	no
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	hypermagnesemia	no
O	O	and	yes
O	O	should	no
O	O	therefore	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	by	no
O	O	patients	no
O	O	on	no
O	O	chronic	no
O	O	renal	no
O	O	dialysis	no
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	of	yes
O	O	using	no
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	and	yes
B-brand	B-brand	IMITREX	yes
O	O	(	no
B-drug	B-drug	sumatriptan	yes
O	O	)	no
O	O	Nasal	no
O	O	Spray	no
O	O	during	no
O	O	the	no
O	O	same	yes
O	O	episode	no
O	O	of	yes
O	O	migraine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

B-drug	B-drug	Cevimeline	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	taking	no
B-group	B-group	beta	yes
I-group	I-group	adrenergic	no
I-group	I-group	antagonists	no
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	conduction	no
O	O	disturbances	no
O	O	.	no

O	O	An	no
O	O	individual	no
O	O	who	no
O	O	is	yes
O	O	stable	no
O	O	on	no
O	O	a	yes
O	O	given	no
O	O	dose	no
O	O	of	yes
B-group	B-group	TCAmay	no
O	O	become	no
O	O	abruptly	no
O	O	toxic	no
O	O	when	no
O	O	given	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	inhibiting	no
O	O	drugs	no
O	O	as	yes
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

O	O	Depending	no
O	O	on	no
O	O	the	no
O	O	fraction	yes
O	O	of	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentration	no
O	O	may	no
O	O	be	no
O	O	small	no
O	O	,	no
O	O	or	no
O	O	quite	no
O	O	large	no
O	O	(	no
O	O	8	yes
O	O	fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	B-group	TCA	no
O	O	)	no
O	O	.	no

O	O	No	yes
O	O	interaction	no
O	O	with	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
B-drug	B-drug	imipramine	yes
O	O	was	no
O	O	shown	no
O	O	in	yes
O	O	a	yes
O	O	single-dose	no
O	O	study	no
O	O	with	yes
B-drug	B-drug	entacapone	yes
O	O	without	no
O	O	coadministered	no
O	B-drug	levodopa/dopa-decarboxylase	no
O	B-group	inhibitor	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Effect	no
O	O	on	no
O	O	Blood	yes
O	O	Coagulation	yes
O	O	:	no
B-drug	B-drug	Diclofenac	yes
O	O	increases	no
O	O	platelet	yes
O	O	aggregation	no
O	O	time	no
O	O	but	no
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	bleeding	no
O	O	time	no
O	O	,	no
O	O	plasma	yes
O	O	thrombin	no
O	O	clotting	no
O	O	time	no
O	O	,	no
O	O	plasma	yes
O	O	fibrinogen	yes
O	O	,	no
O	O	or	no
O	O	factors	no
O	O	V	yes
O	O	and	yes
O	O	VII	yes
O	O	to	no
O	O	XII	no
O	O	.	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	the	no
O	O	allergic	no
O	O	reaction	no
O	O	.	no

O	O	This	no
O	O	diminution	no
O	O	is	yes
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	preclude	no
O	O	effectiveness	no
O	O	of	yes
O	O	the	no
O	O	pressor	no
O	O	agent	yes
O	O	for	yes
O	O	therapeutic	no
O	O	use	no
O	O	.	no
O	O	)	no

B-drug	B-drug	Morphine	yes
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	This	no
O	O	may	no
O	O	potentiate	no
O	O	and	yes
O	O	prolong	no
O	O	hypnotic	no
O	O	and	yes
O	O	sedative	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	Each	no
O	O	healthy	no
O	O	subject	no
O	O	(	no
O	O	N	yes
O	O	=	no
O	O	10	yes
O	O	)	no
O	O	received	no
B-drug	B-drug	rofecoxib	yes
O	O	(	no
O	O	75	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	or	no
O	O	placebo	no
O	O	for	yes
O	O	11	yes
O	O	days	no
O	O	in	yes
O	O	a	yes
O	O	double-blind	no
O	O	,	no
O	O	randomized	no
O	O	,	no
O	O	balanced	yes
O	O	,	no
O	O	two-period	no
O	O	crossover	no
O	O	study	no
O	O	.	no

O	O	Since	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	is	yes
O	O	an	no
O	B-group	anion	yes
O	I-group	exchange	no
B-group	I-group	resin	yes
O	O	,	no
O	O	it	no
O	O	may	no
O	O	have	no
O	O	a	yes
O	O	strong	no
O	O	affinity	no
O	O	for	yes
O	O	anions	no
O	O	other	no
O	O	than	no
O	O	the	no
O	O	bile	no
O	O	acids	yes
O	O	.	no

O	O	In	yes
O	O	such	no
O	O	cases	no
O	O	of	yes
O	O	combined	no
O	O	treatment	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	Intracellular	no
O	O	resistance	no
O	O	to	no
B-group	B-group	thyroid	yes
I-group	I-group	hormone	yes
O	O	is	yes
O	O	quite	no
O	O	rare	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	suppress	no
O	O	the	no
O	O	immune	yes
O	O	system	yes
O	O	are	no
O	O	widely	no
O	O	used	no
O	O	.	no

B-drug	B-drug	Saquinavir	yes
O	O	steady-state	no
O	O	Cmax	no
O	O	,	no
O	O	A.C.	no
O	O	and	yes
O	O	Cmin	no
O	O	were	no
O	O	increased	no
O	O	21	yes
O	O	%	no
O	O	,	no
O	O	decreased	no
O	O	19	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	decreased	no
O	O	48	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	amprenavir	yes
O	O	.	no

B-group	B-group	Anticholinergics	no
O	O	antagonize	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antiglaucoma	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	intake	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-drug	B-drug	sucralfate	yes
O	O	should	no
O	O	be	no
O	O	separated	no
O	O	by	no
O	O	at	yes
O	O	least	no
O	O	two	no
O	O	hours	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	digoxin	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	appropriately	no
O	O	.	no

O	O	For	yes
O	O	this	no
O	O	reason	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	adrenaline	yes
O	O	should	no
O	O	be	no
O	O	restricted	no
O	O	and	yes
O	O	an	no
B-group	B-group	antiarrhythmic	no
I-group	I-group	agent	yes
O	O	administered	no
O	O	as	yes
O	O	appropriate	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	the	no
O	O	density	no
O	O	of	yes
O	O	D2	yes
O	O	binding	no
O	O	sites	no
O	O	in	yes
O	O	the	no
O	O	SST	no
O	O	and	yes
O	O	the	no
O	O	RBC	no
O	O	mice	no
O	O	in	yes
O	O	the	no
O	O	STR	no
O	O	was	no
O	O	significantly	no
O	O	increased	no
O	O	in	yes
B-drug	B-drug	cocaine-treated	no
O	O	groups	no
O	O	without	no
O	O	change	no
O	O	in	yes
O	O	Kd	no
O	O	.	no

O	O	This	no
O	O	study	no
O	O	investigated	no
O	O	the	no
O	O	role	no
O	O	of	yes
O	O	neuronal	no
O	O	uptake	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	(	no
O	O	uptake-1	no
O	O	)	no
O	O	in	yes
O	O	human	yes
O	O	heart	no
O	O	failure	no
O	O	as	yes
O	O	a	yes
O	O	local	no
O	O	factor	yes
O	O	for	yes
O	O	altering	no
O	O	concentrations	no
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	at	yes
O	O	the	no
O	O	cardiac	no
O	O	myocyte	no
O	O	membranes	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	mean	no
O	O	decreases	no
O	O	of	yes
O	O	1	yes
O	O	to	no
O	O	2	yes
O	O	mg/dL	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	arthritic	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	etodolac	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	to	no
O	O	1000	yes
O	O	mg/day	no
O	O	)	no
O	O	after	no
O	O	4	yes
O	O	weeks	no
O	O	of	yes
O	O	therapy	no
O	O	.	no

O	O	Breakthrough	no
O	O	bleeding	no
O	O	has	no
O	O	been	no
O	O	reported	no

O	O	The	no
O	O	appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	,	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	A	yes
O	O	variety	no
O	O	of	yes
O	O	toxic	no
O	O	neurological	no
O	O	effects	no
O	O	and	yes
O	O	malignant	no
O	O	hyperpyrexia	no
O	O	can	no
O	O	occur	no
O	O	,	no
O	O	sometimes	no
O	O	with	yes
O	O	fatal	no
O	O	results	no
O	O	.	no

O	O	Postoperative	no
O	O	respiratory	no
O	O	depression	no
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	or	no
O	O	prolonged	no
O	O	by	no
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	Both	no
O	O	groups	no
O	O	of	yes
O	O	agents	yes
O	O	increase	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	therefore	no
O	O	potentiate	no
O	O	the	no
O	O	actions	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	monitoring	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	co-administered	no
O	O	.	no

O	O	Hypersensitivity	no
O	O	reactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	combination	yes
O	O	regimens	no
O	O	containing	yes
O	O	sequential	no
O	O	high	yes
O	O	dose	no
B-brand	B-brand	PROLEUKIN	yes
O	O	and	yes
B-group	B-group	antineoplastic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	specifically	no
O	O	,	no
B-drug	B-drug	dacarbazine	yes
O	O	,	no
B-drug	B-drug	cis-platinum	no
O	O	,	no
B-drug	B-drug	tamoxifen	yes
O	O	and	yes
B-drug	B-drug	interferon-alfa	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	oxyphenbutazone	yes
O	O	and	yes
B-group	B-group	androgens	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	oxyphenbutazone	yes
O	O	.	no

O	O	Increased	no
O	O	ectopic	no
O	O	pacemaker	no
O	O	activity	yes
O	O	can	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	pseudoephedrine	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	.	no

O	O	When	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
O	B-group	agents	yes
O	I-group	with	yes
B-group	I-group	b-blocking	no
I-group	I-group	properties	no
O	O	and	yes
B-drug	B-drug	clonidine	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	terminated	no
O	O	,	no
O	O	the	no
B-group	B-group	b-blocking	no
I-group	I-group	agent	yes
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	first	no
O	O	.	no

O	O	Blunting	no
O	O	of	yes
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	beta-adrenoceptor	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	by	no
B-group	B-group	non-steroidal	no
I-group	I-group	antiinflammatory	no
I-group	I-group	drugs	no
O	O	including	no
B-brand	B-brand	INDOCIN	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Serious	no
O	O	cardiac	no
O	O	dysrhythmias	no
O	O	,	no
O	O	some	no
O	O	resulting	no
O	O	in	yes
O	O	death	no
O	O	,	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	terfenadine	yes
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	.	no

O	O	The	no
O	O	growth	yes
O	O	of	yes
O	O	Pseudomonas	no
O	O	aeruginosa	no
O	O	,	no
O	O	particularly	no
O	O	serotype	no
O	O	O11	no
O	O	,	no
O	O	in	yes
B-drug	B-drug	pentazocine	yes
O	O	and	yes
B-drug	B-drug	tripelennamine	yes

O	O	There	no
O	O	is	yes
O	O	strong	no
O	O	evidence	no
O	O	that	no
B-drug	O	insulin	yes
O	O	resistance	no
O	O	is	yes
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	not	no
O	O	only	no
O	O	hyperglycemia	no
O	O	,	no
O	O	but	no
O	O	also	no
O	O	dyslipidemia	no
O	O	,	no
O	O	hypertension	no
O	O	,	no
O	O	hypercoagulation	no
O	O	,	no
O	O	vasculopathy	no
O	O	,	no
O	O	and	yes
O	O	ultimately	no
O	O	atherosclerotic	no
O	O	cardiovascular	no
O	O	disease	no
O	O	.	no

B-group	B-group	Central	no
I-group	I-group	Nervous	no
I-group	I-group	System	yes
I-group	I-group	Depressants	no
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	DURAGESIC	no
O	O	(	no
B-drug	B-drug	fentanyl	yes
O	O	transdermal	no
O	O	system	yes
O	O	)	no
O	O	with	yes
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	,	no
O	O	including	no
O	O	but	no
O	O	not	no
O	O	limited	no
O	O	to	no
O	O	other	no
B-group	B-group	opioids	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	)	no
O	O	,	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	may	no
O	O	cause	no
O	O	respiratory	no
O	O	depression	no
O	O	,	no
O	O	hypotension	no
O	O	,	no
O	O	and	yes
O	O	profound	no
O	O	sedation	no
O	O	,	no
O	O	or	no
O	O	potentially	no
O	O	result	no
O	O	in	yes
O	O	coma	no
O	O	or	no
O	O	death	no
O	O	.	no

O	O	OBJECTIVE	no
O	O	:	no
O	O	Our	no
O	O	objective	no
O	O	was	no
O	O	to	no
O	O	examine	no
O	O	the	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	fluvoxamine	yes
O	O	and	yes
B-drug	B-drug	tolbutamide	yes
O	O	to	no
O	O	confirm	no
O	O	that	no
B-drug	B-drug	fluvoxamine	yes
O	O	inhibits	no
O	O	CYP2C9	no
O	O	.	no

B-drug	B-drug	Abciximab	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	ischemic	no
O	O	heart	no
O	O	disease	no
O	O	treated	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
O	O	broad	no
O	O	range	no
O	O	of	yes
O	O	medications	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	angina	no
O	O	myocardial	no
O	O	infarction	no
O	O	and	yes
O	O	hypertension	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemics	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	watched	no
O	O	during	no
O	O	initiation	no
O	O	of	yes
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	for	yes
B-drug	B-drug	saquinavir	yes
O	O	.	no

O	O	N=48	no
O	O	)	no
O	O	decreases	no
B-drug	B-drug	hydrocodone	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	;	no

O	O	Appropriate	no
O	O	laboratory	no
O	O	testing	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	prior	no
O	O	to	no
O	O	initiating	no
O	O	combination	yes
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	Amprenavir	yes
O	O	and	yes
B-drug	B-drug	ritonavir	yes
O	O	and	yes
O	O	at	yes
O	O	periodic	no
O	O	intervals	no
O	O	or	no
O	O	if	no
O	O	any	no
O	O	clinical	no
O	O	signs	no
O	O	or	no
O	O	symptoms	no
O	O	of	yes
O	O	hyperlipidemia	no
O	O	or	no
O	O	elevated	no
O	O	liver	yes
O	O	function	no
O	O	tests	no
O	O	occur	no
O	O	during	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Griseofulvin	yes
O	O	:	no
B-drug	B-drug	Griseofulvin	yes
O	O	may	no
O	O	induce	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	causing	no
O	O	menstrual	no
O	O	changes	no
O	O	;	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	other	no
B-group	B-group	progestational	no
I-group	I-group	contraceptives	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	implants	no
O	O	and	yes
O	O	injectables	no
O	O	,	no
O	O	are	no
O	O	adequate	no
O	O	methods	no
O	O	of	yes
O	O	contraception	no
O	O	during	no
B-drug	B-drug	acitretin	yes
O	O	therapy	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	heparin	yes
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	or	no
B-brand	B-brand	Activase	yes
O	O	may	no
O	O	cause	no
O	O	bleeding	no
O	O	complications	no
O	O	,	no
O	O	careful	no
O	O	monitoring	no
O	O	for	yes
O	O	bleeding	no
O	O	is	yes
O	O	advised	no
O	O	,	no
O	O	especially	no
O	O	at	yes
O	O	arterial	no
O	O	puncture	no
O	O	sites	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	ethanol	yes
O	O	and	yes
B-drug	B-drug	flumazenil	yes
O	O	.	no

O	O	This	no
O	O	is	yes
O	O	demonstrated	no
O	O	for	yes
O	O	cigarette	no
O	O	smokers	no
O	O	and	yes
O	O	industrial	no
O	O	workers	no
O	O	involved	no
O	O	in	yes
O	O	chemical	yes
O	O	waste	no
O	O	incineration	no
O	O	.	no

O	O	Differences	no
O	O	in	yes
O	O	clearance	no
O	O	between	yes
O	O	patients	no
O	O	on	no
O	O	these	no
O	O	medications	no
O	O	(	no
O	O	at	yes
O	O	any	no
O	O	occasion	no
O	O	in	yes
O	O	the	no
O	O	study	no
O	O	)	no
O	O	and	yes
O	O	those	no
O	O	off	no
O	O	medications	no
O	O	varied	no
O	O	between	yes
O	O	-16	no
O	O	%	no
O	O	and	yes
O	O	+3	no
O	O	%	no
O	O	.	no

O	O	The	no
O	O	adverse	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	myelosuppression	no
O	O	and	yes
O	O	diarrhea	no
O	O	,	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	exacerbated	no
O	O	by	no
O	O	other	no
B-group	B-group	antineoplastic	no
I-group	I-group	agents	yes
O	O	having	no
O	O	similar	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	possible	no
O	O	that	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
O	O	known	no
O	B-group	photosensitizing	no
O	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	griseofulvin	yes
O	O	,	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	,	no
B-group	B-group	sulfonylureas	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	and	yes
B-group	B-group	tetracyclines	no
O	O	might	no
O	O	increase	no
O	O	the	no
O	O	photosensitivity	no
O	O	reaction	no
O	O	of	yes
O	O	actinic	no
O	O	keratoses	no
O	O	treated	no
O	O	with	yes
O	O	the	no
B-brand	B-brand	LEVULAN	yes
B-brand	I-brand	KERASTICK	no
O	O	for	yes
O	O	Topical	yes
O	O	Solution	yes
O	O	.	no

O	O	No	yes
O	O	evaluation	no
O	O	of	yes
B-brand	B-brand	EXTRANEALs	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	was	no
O	O	conducted	no
O	O	.	no

O	O	These	no
O	O	increases	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	selecting	no
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	for	yes
O	O	a	yes
O	O	woman	no
O	O	taking	no
B-drug	B-drug	atorvastatin	yes
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	produce	no
O	O	clinically	no
O	O	significant	no
O	O	fluctuations	no
O	O	in	yes
O	O	steady-state	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	various	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	on	no
O	O	chronic	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	,	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	(	no
O	O	INR	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	in	yes
O	O	the	no
O	O	2-week	no
O	O	period	no
O	O	,	no
O	O	particularly	no
O	O	at	yes
O	O	7	yes
O	O	to	no
O	O	10	yes
O	O	days	no
O	O	,	no
O	O	following	no
O	O	initiation	no
O	O	of	yes
O	O	the	no
O	O	3-day	no
O	O	regimen	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	each	no
O	O	chemotherapy	no
O	O	cycle	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	etofibrate	yes
O	O	on	no
O	O	both	no
B-drug	O	chylomicron	no
O	O	lipolysis	no
O	O	and	yes
O	O	remnant	no
O	O	removal	no
O	O	was	no
O	O	achieved	no
O	O	,	no
O	O	indicating	no
O	O	that	no
O	O	this	no
O	O	drug	yes
O	O	can	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	improve	no
O	O	this	no
O	O	metabolism	no
O	O	in	yes
O	O	future	no
O	O	prospective	no
O	O	studies	no
O	O	.	no

O	B-group	Antimycobacterial	no
O	O	:	no
B-drug	B-drug	rifampin	yes

O	O	Patients	no
O	O	already	no
O	O	stabilized	no
O	O	on	no
B-drug	B-drug	valdecoxib	yes
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	symptom	no
O	O	control	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	coadministration	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	26	yes
O	O	PI	no
O	O	with	yes
O	O	drugs	no
O	O	of	yes
O	O	low	yes
O	O	intrinsic	yes
O	O	value	no
O	O	(	no
O	O	7.6	no
O	O	%	no
O	O	;	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	2.8	no
O	O	)	no
O	O	.	no

O	O	Seizures	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	another	no
B-group	B-group	quinolone	no
I-group	I-group	class	no
I-group	I-group	antimicrobial	no
O	O	and	yes
O	O	the	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drug	yes
B-drug	B-drug	fenbufen	yes
O	O	concurrently	no
O	O	.	no

O	O	Monitoring	no
O	O	of	yes
B-drug	B-drug	disopyramide	yes
O	O	plasma	yes
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	in	yes
O	O	such	no
O	O	concurrent	no
O	O	use	no
O	O	to	no
O	O	avoid	no
O	O	ineffective	no
O	O	therapy	no
O	O	.	no

O	O	Available	no
O	O	data	no
O	O	are	no
O	O	not	no
O	O	sufficient	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	to	no
O	O	predict	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
O	O	medication	no
O	O	on	no
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	ventricular	no
O	O	function	no
O	O	or	no
O	O	cardiac	no
O	O	conduction	no
O	O	abnormalities	no
O	O	.	no

O	O	Withdrawal	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	decreased	no
O	O	the	no
B-drug	B-drug	warfarin	yes
O	O	requirement	no
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	received	no
O	O	general	no
O	O	anesthesia	yes
O	O	utilizing	no
O	O	a	yes
O	O	volatile	no
O	O	agent	yes
O	O	known	no
O	O	to	no
O	O	sensitize	no
O	O	the	no
O	O	myocardium	no
O	O	to	no
O	O	catecholamines	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	doxapram	yes
O	O	should	no
O	O	be	no
O	O	delayed	no
O	O	until	no
O	O	the	no
O	O	volatile	no
O	O	agent	yes
O	O	has	no
O	O	been	no
O	O	excreted	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	lessen	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	arrhythmias	no
O	O	,	no
O	O	including	no
O	O	ventricular	no
O	O	tachycardia	no
O	O	and	yes
O	O	ventricular	no
O	O	fibrillation	no
O	O	.	no

O	O	This	no
O	O	defect	no
O	O	in	yes
O	O	the	no
O	O	failing	no
O	O	heart	no
O	O	can	no
O	O	be	no
O	O	mimicked	no
O	O	by	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	uptake	no
O	O	blocking	no
O	O	agents	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	cocaine	yes
O	O	and	yes
B-drug	B-drug	desipramine	yes
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	nonfailing	no
O	O	heart	no
O	O	only	no
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	Nalfon	yes
O	O	may	no
O	O	be	no
O	O	resistant	no
O	O	to	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	loop	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	In	yes
O	O	Europe	no
O	O	,	no
B-brand	B-brand	Nimotop	yes
O	O	was	no
O	O	observed	no
O	O	to	no
O	O	occasionally	no
O	O	intensify	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	antihypertensive	no
I-group	I-group	compounds	no
O	O	taken	no
O	O	concomitantly	no
O	O	by	no
O	O	patients	no
O	O	suffering	no
O	O	from	no
O	O	hypertension	no
O	O	;	no

O	O	Inhibits	no
O	O	CYP2D6	no
O	O	(	no
O	O	weak	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	,	no
O	O	an	no
O	O	anionic-binding	no
B-group	O	resin	yes
O	O	,	no
O	O	has	no
O	O	a	yes
O	O	considerable	no
O	O	effect	no
O	O	in	yes
O	O	lowering	no
O	O	the	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	bioavailability	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	diminish	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	response	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	decreased	no
O	O	prothrom-bin	no
O	O	time	no
O	O	response	no
O	O	,	no
O	O	in	yes
O	O	man	no
O	O	significantly	no
O	O	include	no
O	O	:	no
B-group	B-group	adrenocortical	no
I-group	I-group	steroids	no
O	O	;	no

O	O	Certain	no
O	O	concomitant	no
O	O	medications	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
B-group	B-group	anticonvulsants	no
O	O	,	no
O	O	St	yes
O	O	.	no

O	O	The	no
O	O	authors	no
O	O	investigated	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	a	yes
O	O	similar	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	oxycodone	yes
O	O	and	yes
B-drug	B-drug	levofloxacin	yes
O	O	.	no

O	O	The	no
O	O	successive	no
O	O	application	no
O	O	of	yes
B-drug	B-drug	glycine	yes
O	O	(	no
O	O	5	yes
O	O	or	no
O	O	10	yes
O	O	mg/kg	no
O	O	egg	no
O	O	weight	yes
O	O	(	no
O	O	e.w	no
O	O	.	no
O	O	)	no

O	O	Combinations	no
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	were	no
O	O	indifferent	no
O	O	for	yes
O	O	16	yes
O	O	and	yes
O	O	synergistic	no
O	O	for	yes
O	O	11	yes
O	O	of	yes
O	O	the	no
O	O	resistant	no
O	O	strains	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	ergotamine	yes
O	O	or	no
B-drug	B-drug	dihydroergotamine	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	acute	no
B-group	O	ergot	yes
O	O	toxicity	no
O	O	characterized	no
O	O	by	no
O	O	severe	no
O	O	peripheral	no
O	O	vasospasm	no
O	O	and	yes
O	O	dysesthesia	no
O	O	.	no

B-drug	B-drug	Triazolam	yes
O	O	-	yes
O	O	Combined	no
O	O	administration	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	(	no
O	O	titrated	no
O	O	to	no
O	O	40	yes
O	O	mg/day	no
O	O	for	yes
O	O	28	yes
O	O	days	no
O	O	)	no
O	O	and	yes
O	O	the	no
O	O	CYP3A4	no
O	O	substrate	yes
B-drug	B-drug	triazolam	yes
O	O	(	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	0.25	no
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	citalopram	yes
O	O	or	no
B-drug	B-drug	triazolam	yes
O	O	.	no

B-drug	B-drug	Aprepitant	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	,	no
O	O	a	yes
O	O	moderate	no
O	O	inhibitor	yes
O	O	,	no
O	O	and	yes
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	highintersubject	no
O	O	variability	no
O	O	,	no
O	O	however	no
O	O	,	no
B-group	O	somepatients	no
O	O	may	no
O	O	experience	no
O	O	large	no
O	O	increases	no
B-drug	B-drug	inrifabutin	no
O	O	exposure	yes
O	O	and	yes
O	O	may	no
O	O	be	no
O	O	at	yes
O	O	higher	no
O	O	riskfor	no
B-drug	O	rifabutin	yes
O	O	toxicity	no
O	O	.	no

O	O	In	yes
O	O	eight	no
O	O	experiments	no
O	O	the	no
O	O	perfusion	no
O	O	medium	no
O	O	contained	no
B-drug	B-drug	oxytocin	yes
O	O	.	no

O	O	The	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	is	yes
O	O	enhanced	no
O	O	by	no
O	O	concurrent	no
O	O	treatment	no
O	O	with	yes
O	B-drug	antithrombin	yes
O	I-drug	III	yes
O	O	(	no
O	O	human	yes
O	O	)	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	hereditary	no
O	O	antithrombin	yes
O	O	III	yes
O	O	deficiency	no
O	O	.	no

O	O	After	no
O	O	multiple	no
O	O	dosing	no
O	O	,	no
B-drug	B-drug	interferon	yes
I-drug	I-drug	beta-1a	yes
O	O	(	no
B-brand	B-brand	AVONEX	yes
O	O	30	yes
O	O	mcg	no
O	O	IM	yes
O	O	once	no
O	O	weekly	yes
O	O	)	no
O	O	reduced	yes
B-brand	B-brand	TYSABRI	yes
O	O	clearance	no
O	O	by	no
O	O	approximately	no
O	O	30	yes
O	O	%	no
O	O	.	no

O	O	Drug	yes
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	NEUPOGEN	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	fully	no
O	O	evaluated	no
O	O	.	no

B-drug	B-drug	Fluconazole	yes
O	O	,	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	P450	no
O	O	2C9	no
O	O	,	no
O	O	decreased	no
O	O	active	no
O	O	metabolite	yes
O	O	concentration	no
O	O	and	yes
O	O	increased	no
B-drug	B-drug	losartan	yes
O	O	concentration	no
O	O	.	no

O	O	A	yes
O	O	proposed	no
O	O	mechanism	no
O	O	for	yes
O	O	the	no
O	O	potentiation	no
O	O	of	yes
O	O	cAMP-mediated	no
O	O	acid	yes
O	O	secretion	no
O	O	by	no
B-drug	B-drug	carbachol	yes
O	O	.	no

O	O	Renal	no
O	O	Impairment	no
O	O	There	no
O	O	are	no
O	O	currently	no
O	O	no	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	SPRYCEL	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	(	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	excluded	no
O	O	patients	no
O	O	with	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	concentration	no
O	O	1.5	yes
O	O	times	no
O	O	the	no
O	O	upper	no
O	O	limit	no
O	O	of	yes
O	O	the	no
O	O	normal	yes
O	O	range	no
O	O	)	no
O	O	.	no

O	O	Limited	no
O	O	clinical	no
O	O	data	no
O	O	in	yes
O	O	angina	no
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	therapy	no
O	O	indicate	no
O	O	no	yes
O	O	discernible	no
O	O	changes	no
O	O	in	yes
O	O	serum	yes
B-drug	O	digoxin	yes
O	O	levels	no
O	O	.	no

B-brand	B-brand	FLEXERIL	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
O	O	and	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	.	no

O	O	Interactions	no
O	O	of	yes
B-drug	B-drug	cobalt	yes
O	O	and	yes
B-drug	B-drug	iron	yes
O	O	in	yes
O	O	absorption	no
O	O	and	yes
O	O	retention	no
O	O	.	no

B-drug	B-drug	Adenosine	yes
O	O	:	no
B-drug	B-drug	Dipyridamole	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	and	yes
O	O	cardiovascular	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	and	yes
B-drug	B-drug	colestipol	yes
B-group	B-group	resins	no
O	O	:	no
O	O	Absorption	no
O	O	of	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	is	yes
O	O	impaired	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	B-group	anionic	no
O	I-group	exchange	no
B-group	I-group	resins	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	Blocking	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	on	no
O	O	blood	yes
O	O	pressure	no
O	O	response	no
O	O	to	no
B-drug	B-drug	propranolol	yes
O	O	and	yes
B-drug	B-drug	atenolol	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	men	no
O	O	with	yes
O	O	mild	yes
O	O	uncomplicated	no
O	O	hypertension	no
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	10	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	methyldopa	yes
O	O	;	no

O	O	Because	no
O	O	the	no
B-group	B-group	nitrosourea	yes
B-drug	B-drug	CCNU	yes
O	O	is	yes
O	O	given	no
O	O	exclusively	no
O	O	by	no
O	O	the	no
O	O	oral	yes
O	O	route	no
O	O	in	yes
O	O	man	no
O	O	,	no
O	O	we	no
O	O	have	no
O	O	carried	no
O	O	out	no
O	O	studies	no
O	O	in	yes
O	O	mice	no
O	O	on	no
O	O	the	no
O	O	antitumour	no
O	O	activity	yes
O	O	,	no
O	O	acute	no
O	O	toxicity	no
O	O	and	yes
O	O	pharmacokinetics	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	,	no
O	O	either	no
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	the	no
O	O	chemosensitizer	no
O	B-drug_n	misonidazole	yes
O	O	.	no

O	O	Given	no
O	O	the	no
O	O	primary	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	Anafranil	yes
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	using	no
O	O	it	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	CNS-active	no
O	O	drugs	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	occur	no
O	O	because	no
B-drug	B-drug	diflunisal	yes
O	O	competitively	no
O	O	displaces	no
B-group	B-group	coumarins	no
O	O	from	no
O	O	protein	yes
O	O	binding	no
O	O	sites	no
O	O	.	no

O	O	In	yes
O	O	vivo	no
O	O	studies	no
O	O	:	no
O	O	Cytochrome	no
O	O	P450	no
O	O	Inhibitors	no

O	O	These	no
O	O	potential	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	listed	no
O	O	in	yes
O	O	Table	no
O	O	4	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	not	no
O	O	to	no
O	O	exceed	no
O	O	a	yes
O	O	single	yes
O	O	2.5	yes
O	O	mg	yes
B-drug	B-drug	Vardenafil	yes
O	O	dose	no
O	O	in	yes
O	O	a	yes
O	O	24-hour	no
O	O	period	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	indinavir	yes
O	O	.	no

O	O	Because	no
O	O	severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	receiving	no
O	O	oral	yes
B-drug	B-drug	miconazole	yes
O	O	(	no
O	O	an	no
B-group	B-group	imidazole	yes
O	O	)	no
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	such	no
O	O	a	yes
O	O	potential	no
O	O	interaction	no
O	O	involving	no
O	O	the	no
O	O	latter	no
O	O	agents	yes
O	O	when	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	tablets	yes
O	O	(	no
O	O	an	no
B-group	B-group	imidazole	yes
O	O	)	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	ruled	no
O	O	out	no
O	O	.	no

O	O	The	no
O	O	oral	yes
B-drug	B-drug	dexamethasone	yes
O	O	doses	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	Aprepitant	yes
O	O	,	no
O	O	to	no
O	O	achieve	no
O	O	exposures	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	obtained	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	given	no
O	O	without	no
B-drug	B-drug	Aprepitant	yes
O	O	.	no

B-group	O	Beta-Blocking	no
I-group	O	Agents	yes
O	O	A	yes
O	O	pharmacokinetic	no
O	O	study	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-drug	B-drug	metoprolol	yes
O	O	demonstrated	no
O	O	no	yes
O	O	significant	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

B-brand	B-brand	ROMAZICON	yes
O	O	blocks	no
O	O	the	no
O	O	central	no
O	O	effects	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	by	no
O	O	competitive	no
O	O	interaction	no
O	O	at	yes
O	O	the	no
O	O	receptor	yes
O	O	level	no
O	O	.	no

O	O	Serum	yes
O	O	Amylase	no
O	O	An	no
O	O	apparent	no
O	O	decrease	no
O	O	in	yes
O	O	serum	yes
O	O	amylase	no
O	O	activity	yes
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	administered	no
B-brand	B-brand	EXTRANEAL	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	patient	no
O	O	's	no
O	O	serum	yes
O	O	potassium	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isozyme	no
O	O	,	no
O	O	including	no
O	O	many	no
B-group	B-group	antidepressants	no
O	O	(	no
B-drug	B-drug	clozapine	yes
O	O	,	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	)	no
O	O	,	no
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	,	no
O	O	and	yes
O	O	thus	no
O	O	may	no
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	poor	no
O	O	metabolizers	no
O	O	with	yes
O	O	regard	no
O	O	to	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	enzyme	no
O	O	system	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	drug	yes
O	O	interaction	no
O	O	.	no

O	O	increased	no
O	O	alkaline	yes

B-drug	B-drug	Ethanol	yes
O	O	or	no
B-drug	B-drug	Triazolam	yes
O	O	:	no
O	O	No	yes
O	O	significant	no
O	O	differences	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	triazolam	yes
O	O	(	no
O	O	0.125	no
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	tiagabine	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	)	no
O	O	when	no
O	O	given	no
O	O	together	no
O	O	as	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	.	no

O	O	Studies	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
O	O	pretreatment	no
O	O	with	yes
B-drug	B-drug	isoniazid	yes
O	O	potentiates	no
O	O	a	yes
B-drug	O	cetaminophen	no
O	O	hepatoxicity	no
O	O	in	yes
O	O	rats	no
O	O	.	no

B-drug_n	B-drug_n	Ibogaine	no
O	O	attenuates	no
O	O	,	no
O	O	but	no
B-drug_n	B-drug_n	18-MC	no
O	O	potentiates	no
O	O	,	no
O	O	the	no
O	O	acute	no
O	O	locomotor	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	;	no

O	O	The	no
B-drug	B-drug	carbamazepine	yes
O	O	steady-state	no
O	O	Cmin	no
O	O	decreased	no
O	O	31	yes
O	O	%	no
O	O	to	no
O	O	5	yes
O	O	1	yes
O	O	micrograms/mL	no
O	O	when	no
B-drug	B-drug	felbamate	yes
O	O	(	no
O	O	3000	no
O	O	mg/day	no
O	O	,	no
O	O	divided	no
O	O	into	no
O	O	three	no
O	O	doses	no
O	O	)	no
O	O	was	no
O	O	coadministered	no
O	O	.	no

B-drug	B-drug	Sodium	yes
I-drug	I-drug	cephalothin	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	nephrotoxicity	no
O	O	of	yes
B-brand	B-brand	Coly-Mycin	yes
O	I-brand	M	yes
O	O	Parenteral	no
O	O	.	no

B-drug	B-drug	magnesium	yes
O	O	salts	no
O	O	;	no

O	O	The	no
O	O	gradual	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	guafacine	no
O	O	or	no
O	O	a	yes
B-group	B-group	cardioselective	no
I-group	I-group	beta-blocker	no
O	O	could	no
O	O	be	no
O	O	substituted	yes
O	O	.	no

O	O	Refer	no
O	O	to	no
O	O	the	no
O	O	package	no
O	O	insert	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparations	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	preparations	no
O	O	with	yes
B-drug	B-drug	Hydrochlorothiazide	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
B-drug	B-drug	theophylline	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	fluvoxamine	yes
I-drug	I-drug	maleate	yes
O	O	,	no
O	O	its	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	to	no
O	O	one	no
O	O	third	no
O	O	of	yes
O	O	the	no
O	O	usual	no
O	O	daily	no
O	O	maintenance	no
O	O	dose	no
O	O	and	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	should	no
O	O	to	no
O	O	monitored	no
O	O	.	no

O	O	Caution	no
O	O	in	yes
O	O	using	no
O	O	concomitant	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	beta-blockers	no
O	O	(	no
O	O	ophthalmic	no
O	O	and	yes
O	O	systemic	no
O	O	)	no
O	O	,	no
B-group	B-group	anti-hypertensives	no
O	O	and/or	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	is	yes
O	O	advised	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	may	no
O	O	also	no
O	O	interact	no
O	O	with	yes
B-group	B-group	sympathomimetics	no
O	O	.	no

B-brand	B-brand	EDECRIN	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	ototoxic	no
O	O	potential	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	aminoglycoside	no
O	O	and	yes
O	O	some	no
B-group	B-group	cephalosporin	yes
I-group	I-group	antibiotics	no
O	O	.	no

O	O	A	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	copper	yes
O	O	reduction	yes
O	O	tests	no
O	O	(	no
O	O	Benedicts	no
O	O	or	no
O	O	Fehlings	no
O	O	solution	yes
O	O	or	no
O	O	with	yes
O	O	CLINITEST	no
O	O	tablets	yes
O	O	)	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	enzyme-based	no
O	O	tests	no
O	O	for	yes
O	O	glycosuria	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	CLINISTIX	no
O	O	,	no
O	O	TES-TAPE	no
O	O	)	no
O	O	.	no

B-group	B-group	Immunosuppressants	no
O	O	:	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
B-drug	B-drug	sirolimus	yes

B-drug	B-drug	Pentamidine	yes
O	O	may	no
O	O	cause	no
O	O	hypoglycemia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	sometimes	no
O	O	be	no
O	O	followed	no
O	O	by	no
O	O	hyperglycemia	no
O	O	.	no

B-drug	B-drug	quinine	yes
O	O	;	no

O	O	This	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	mediated	no
O	O	by	no
O	O	the	no
O	O	known	no
O	O	inhibition	no
O	O	of	yes
O	O	hepatic	no
O	O	cytochrome	no
O	O	P-	no
O	O	450	yes
O	O	by	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	which	no
O	O	could	no
O	O	decrease	no
O	O	first	no
O	O	pass	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	nimodipine	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	this	no
O	O	potentiation	no
O	O	of	yes
B-drug	B-drug	ampicillin	yes
O	O	rashes	no
O	O	is	yes
O	O	due	no
O	O	to	no
B-drug	B-drug	allopurinol	yes
O	O	or	no
O	O	the	no
O	O	hyperuricemia	no
O	O	present	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	Following	no
O	O	co-administration	no
O	O	of	yes
O	O	two	no
O	O	250-mg	no
B-drug	B-drug	dirithromycin	yes
O	O	tablets	yes
O	O	administered	no
O	O	once	no
O	O	daily	no
O	O	with	yes
O	O	200-mg	no
B-drug	B-drug	theophylline	yes
O	O	tablets	yes
O	O	administered	no
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	to	no
O	O	14	yes
O	O	healthy	no
O	O	subjects	no
O	O	,	no
O	O	the	no
O	O	steady-state	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	was	no
O	O	not	no
O	O	significantly	no
O	O	altered	no
O	O	.	no

O	O	These	no
O	O	reactions	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	discontinued	no
O	O	that	no
O	O	drug	yes
O	O	and	yes
O	O	have	no
O	O	been	no
O	O	started	no
O	O	on	no
O	O	a	yes
B-group	B-group	MAOI	no
O	O	.	no

B-drug	B-drug	Zidovudine	yes
O	O	:	no
O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	significant	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	ZDV	yes
O	O	and	yes
B-drug	B-drug	zalcitabine	yes
O	O	which	no
O	O	has	no
O	O	been	no
O	O	confirmed	no
O	O	clinically	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	transdermal	no
B-drug	B-drug	fentanyl	yes
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	or	no
O	O	other	no
O	O	potent	no
O	O	3A4	no
O	O	inhibitors	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	troleandomycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
O	O	and	yes
B-drug	O	nefazadone	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	fentanyl	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	Most	no
O	O	(	no
O	O	98	no
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	doxazosin	yes
O	O	is	yes
O	O	protein	yes
O	O	bound	no
O	O	.	no

B-drug	B-drug	Tetracycline	yes
O	O	,	no
O	O	a	yes
B-group	B-group	bacteriostatic	yes
I-group	I-group	antibiotic	yes
O	O	,	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	bactercidal	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	penicillin	yes
O	O	and	yes
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	Specific	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	demonstrated	no
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	Cyclosporine	yes
O	I-drug	A	yes
O	O	:	no
O	O	During	no
O	O	the	no
O	O	first	no
O	O	day	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	,	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	were	no
O	O	increased	no
O	O	by	no
O	O	about	no
O	O	30-fold	no
O	O	.	no

O	O	This	no
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	in	yes
O	O	view	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	not	no
O	O	well	no
O	O	documented	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no

O	O	Conflicting	no
O	O	results	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	regarding	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	on	no
O	O	glycemic	no
O	O	control	no
O	O	in	yes
O	O	non-diabetics	no
O	O	with	yes
O	O	glucose	yes
O	O	intolerance	no
O	O	,	no
O	O	and	yes
O	O	those	no
O	O	with	yes
O	O	type	yes
O	O	2	yes
O	O	diabetes	no
O	O	.	no

O	O	Hematology	no
O	O	:	no
B-brand	B-brand	TAXOL	yes
O	O	therapy	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	baseline	no
O	O	neutrophil	no
O	O	counts	no
O	O	of	yes
O	O	less	no
O	O	than	no
O	O	1,500	no
O	O	cells/mm3	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	another	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitor	yes
O	O	has	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	produce	no
O	O	a	yes
O	O	less	no
O	O	than	no
O	O	two-second	no
O	O	increase	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	receiving	no
O	O	low	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	500	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	for	yes
O	O	6	yes
O	O	days	no
O	O	decreased	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	both	no
B-drug_n	B-drug	S-warfarin	no
O	O	(	no
O	O	a	yes
O	O	CYP2C9	no
O	O	substrate	yes
O	O	)	no
O	O	and	yes
B-drug_n	B-drug	R-warfarin	no
O	O	(	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	by	no
O	O	29	yes
O	O	and	yes
O	O	38	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
O	O	local	no
B-group	B-group	anesthetic	no
O	I-group	solutions	no
O	O	containing	yes
B-drug	B-drug	epinephrine	yes
O	O	or	no
B-drug	B-drug	norepinephrine	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	or	no
B-group	B-group	phenothiazines	no
O	O	may	no
O	O	produce	no
O	O	severe	no
O	O	,	no
O	O	prolonged	no
O	O	hypotension	no
O	O	or	no
O	O	hypertension	no
O	O	.	no

O	O	Acid	yes
O	O	secretion	no
O	O	in	yes
O	O	isolated	no
O	O	rabbit	yes
O	O	gastric	yes
O	O	glands	no
O	O	was	no
O	O	monitored	no
O	O	by	no
O	O	the	no
O	O	accumulation	no
O	O	of	yes
O	O	[	no
O	O	(	no
O	O	14	yes
O	O	)	no
O	O	C	yes
O	O	]	no
B-drug	B-drug	aminopyrine	yes
O	O	.	no

B-group	B-group	Antiarrhythmics	no
O	O	:	no
B-drug	B-drug	bepridil	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	(	no
O	O	systemic	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	quinidine	yes

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-brand	B-brand	INDOCIN	yes
O	O	.	no

O	O	decreased	no
O	O	levels	no
O	O	of	yes
O	O	anti-factor	no
O	O	Xa	no
O	O	and	yes
O	B-drug	antithrombin	yes
O	I-drug	III	yes
O	O	,	no
O	O	decreased	no
O	B-drug	antithrombin	yes
O	I-drug	III	yes
O	O	activity	yes
O	O	;	no

B-group	B-brand	Anticoagulant	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	,	no
O	O	particularly	no
O	O	during	no
O	O	the	no
O	O	first	no
O	O	few	no
O	O	weeks	no
O	O	,	no
O	O	after	no
O	O	initiating	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	BEXTRA	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	similar	no
O	O	agents	yes
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	O	data	no
O	O	,	no
O	O	no	yes
O	O	interaction	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	with	yes
O	O	drugs	no
O	O	whose	no
O	O	metabolism	no
O	O	is	yes
O	O	dependent	no
O	O	upon	no
O	O	cytochrome	no
O	O	P450	no
O	O	isozymes	no
O	O	1A1	no
O	O	,	no
O	O	1A2,2A6,2B6,2D6,2E1	no
O	O	,	no
O	O	or	no
O	O	3A4	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	35	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	Moreover	no
O	O	,	no
O	O	additional	no
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	niacin	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	have	no
O	O	not	no
O	O	demonstrated	no
O	O	any	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	fluvastatin	yes
O	O	plasma	yes
O	O	levels	no
O	O	,	no
O	O	and	yes
O	O	administration	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	population	no
O	O	chronically	no
O	O	receiving	no
B-drug	B-drug	digoxin	yes
O	O	resulted	no
O	O	in	yes
O	O	no	yes
O	O	difference	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	relative	no
O	O	to	no
O	O	control	no
O	O	data	no
O	O	.	no

O	O	The	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
B-drug	B-drug	nicotine	yes
O	O	use	no
O	O	may	no
O	O	be	no
O	O	precipitated	yes
O	O	by	no
O	O	similar	no
O	O	personality	no
O	O	characteristics	no
O	O	in	yes
O	O	the	no
O	O	user	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	impulsivity	no
O	O	and	yes
O	O	sensation	no
O	O	seeking	no
O	O	.	no

B-brand	B-brand	ZINECARD	yes
O	O	does	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	doxorubicin	yes
O	O	.	no

B-brand	B-brand	FORADIL	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	as	yes
O	O	a	yes
O	O	substitute	no
O	O	for	yes
O	O	oral	yes
O	O	or	no
O	O	inhaled	no
B-group	B-group	corticosteroids	no
O	O	.	no

B-drug_n	B-drug_n	dmPGE2	no
O	O	(	no
O	O	0.1-1.0	no
O	O	mg/kg	no
O	O	,	no
O	O	p.o	no
O	O	.	no
O	O	)	no

O	O	A	yes
O	O	subset	no
O	O	(	no
O	O	3	yes
O	O	%	no
O	O	-10	no
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	population	no
O	O	has	no
O	O	reduced	yes
O	O	activity	yes
O	O	of	yes
O	O	certain	no
O	O	drug	yes
O	O	metabolizing	no
O	O	enzymes	yes
O	O	such	no
O	O	as	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isozyme	no
O	O	P450	no
O	O	2D6	no
O	O	.	no

O	O	It	no
O	O	may	no
O	O	also	no
O	O	produce	no
O	O	artifactually	no
O	O	low	yes
O	O	results	no
O	O	in	yes
B-drug	O	dexamethasone	yes
O	O	or	no
O	O	metyrapone	yes
O	O	tests	no
O	O	.	no

O	O	-	yes
O	O	Reduced	yes
O	O	response	no
O	O	to	no
O	O	metyrapone	yes
O	O	test	yes

O	O	Potential	no
O	O	drug	yes
O	O	interactions	no
O	O	for	yes
B-drug	B-drug	doxylamine	yes
O	O	include	no
O	O	,	no
O	O	increased	no
O	O	sedation	no
O	O	if	no
B-drug	B-drug	doxylamine	yes
O	O	is	yes
O	O	combined	no
O	O	with	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	plus	yes
B-drug	B-drug	rifabutin	yes
O	O	was	no
O	O	poorly	no
O	O	tolerated	no
O	O	,	no
O	O	and	yes
O	O	5	yes
O	O	of	yes
O	O	11	yes
O	O	subjects	no
O	O	discontinued	no
O	O	therapy	no
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	HEXALEN	yes
O	O	and	yes
B-group	B-group	antidepressants	no
O	I-group	of	yes
O	I-group	the	no
B-group	I-group	MAO	no
I-group	I-group	inhibitor	yes
I-group	I-group	class	no
O	O	may	no
O	O	cause	no
O	O	severe	no
O	O	orthostatic	no
O	B-drug	hypotension.Cimetidine	no
O	O	,	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	microsomal	no
O	O	drug	yes
O	O	metabolism	no
O	O	,	no
O	O	increased	no
O	B-drug	altretamines	no
O	O	half-life	no
O	O	and	yes
O	O	toxicity	no
O	O	in	yes
O	O	a	yes
O	O	rat	yes
O	O	model	no
O	O	.	no

B-group	B-group	Anticholinesterases	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	anticholinesterase	no
I-group	I-group	agents	yes
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	may	no
O	O	produce	no
O	O	severe	no
O	O	weakness	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	myasthenia	no
O	O	gravis	no
O	O	.	no

O	O	Such	no
O	O	information	no
O	O	assists	no
O	O	in	yes
O	O	development	no
O	O	of	yes
O	O	safe	no
O	O	dosing	no
O	O	regimens	no
O	O	,	no
O	O	prediction	no
O	O	of	yes
O	O	abnormal	no
O	O	handling	no
O	O	of	yes
O	O	drugs	no
O	O	in	yes
O	O	states	no
O	O	of	yes
O	O	disease	no
O	O	and	yes
O	O	disorder	no
O	O	and	yes
O	O	anticipation	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	administering	no
O	O	different	no
B-group	B-group	botulinum	yes
I-group	I-group	neurotoxin	yes
O	O	serotypes	no
O	O	at	yes
O	O	the	no
O	O	same	yes
O	O	time	no
O	O	or	no
O	O	within	no
O	O	several	no
O	O	months	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	non-	no
I-group	I-group	steroidal	no
I-group	I-group	antiinflammatory	no
I-group	I-group	agent	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	B-group	diuretic	no
O	I-group	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
O	O	potassium-	no
O	O	sparing	no
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Given	no
O	O	the	no
O	O	primary	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	Clozapine	yes
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	using	no
O	O	it	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	CNS-active	no
O	O	drugs	no
O	O	or	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	This	no
O	O	suggests	no
O	O	that	no
O	O	an	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	with	yes
O	O	inhibitors	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	,	no
O	O	or	no
O	O	other	no
O	O	factors	no
O	O	,	no
O	O	like	yes
O	O	smoking	no
O	O	,	no
O	O	is	yes
O	O	unlikely	no
O	O	.	no

O	O	Animal	no
O	O	reproduction	no
O	O	studies	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	are	no
O	O	not	no
O	O	always	no
O	O	predictive	no
O	O	of	yes
O	O	human	yes
O	O	response	no
O	O	and	yes
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	adequate	no
O	O	and	yes
O	O	well-controlled	no
O	O	studies	no
O	O	in	yes
O	O	pregnant	no
O	O	women	yes
O	O	.	no

O	O	Increased	no
O	O	plasma	yes
O	O	HDL	no
O	O	and	yes
O	O	HDL2	no
O	O	cholesterol	yes
O	O	subfraction	no
O	O	concentrations	no
O	O	,	no
O	O	reduced	yes
O	O	LDL	no
O	O	cholesterol	yes
O	O	concentration	no
O	O	,	no
O	O	increased	no
O	O	triglyceride	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	is	yes
O	O	unaffected	no
O	O	by	no
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	indicating	no
O	O	no	yes
O	O	change	no
O	O	in	yes
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	absorption	no
O	O	.	no

O	O	Renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	carefully	no
O	O	if	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-group	B-group	aminoglycosides	no
O	O	are	no
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	with	yes
B-brand	B-brand	MAXIPIME	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	increased	no
O	O	potential	no
O	O	of	yes
O	O	nephrotoxicity	no
O	O	and	yes
O	O	ototoxicity	no
O	O	of	yes
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotics	no
O	O	.	no

B-drug	B-drug	Netilmicin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	potent	no
B-group	B-group	loop	no
I-group	I-group	diuretics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	as	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	ototoxicity	no
O	O	is	yes
O	O	enhanced	no
O	O	by	no
O	O	the	no
O	O	combination	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	warfarin	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	,	no
O	O	anticoagulation	no
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	.	no

B-drug	B-drug	Sucralfate	yes
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	before	no
B-drug	B-drug	lomefloxacin	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	slower	no
O	O	absorption	no
O	O	(	no
O	O	mean	no
O	O	C	yes
O	O	max	no
O	O	decreased	no
O	O	by	no
O	O	30	yes
O	O	%	no
O	O	and	yes
O	O	mean	no
O	O	T	yes
O	O	max	no
O	O	increased	no
O	O	by	no
O	O	1	yes
O	O	hour	yes
O	O	)	no
O	O	and	yes
O	O	a	yes
O	O	lesser	no
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	(	no
O	O	mean	no
O	O	AUC	no
O	O	decreased	no
O	O	by	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Medication	no
O	O	is	yes
O	O	rarely	no
O	O	needed	no
O	O	.	no

O	O	Liver	yes
O	O	Function	no
O	O	Tests	no
O	O	:	no
O	O	Since	no
O	O	elevations	no
O	O	of	yes
O	O	liver	yes
O	O	enzymes	yes
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	during	no
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	and	yes
O	O	hepatitis	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	pretreatment	no
O	O	and	yes
O	O	follow-up	no
O	O	liver	yes
O	O	function	no
O	O	tests	no
O	O	should	no
O	O	be	no
O	O	performed	no
O	O	at	yes
O	O	weekly	yes
O	O	or	no
O	O	biweekly	no
O	O	intervals	no
O	O	until	no
O	O	the	no
O	O	response	no
O	O	to	no
B-brand	B-brand	Accutane	yes
O	O	has	no
O	O	been	no
O	O	established	no

O	O	Renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	,	no
O	O	especially	no
O	O	if	no
O	O	higher	no
O	O	dosages	no
O	O	of	yes
O	O	the	no
B-group	B-group	aminoglycosides	no
O	O	are	no
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	or	no
O	O	if	no
O	O	therapy	no
O	O	is	yes
O	O	prolonged	no
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	nephrotoxicity	no
O	O	and	yes
O	O	ototoxicity	no
O	O	of	yes
B-group	B-group	aminoglycosidic	no
I-group	I-group	antibiotics	no
O	O	.	no

O	O	A	yes
O	O	case	no
O	O	report	no
O	O	of	yes
O	O	one	no
O	O	patient	no
O	O	taking	no
B-drug	B-drug	amiodarone	yes
O	O	200	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	indinavir	yes
O	O	800	no
O	O	mg	yes
O	O	three	no
O	O	times	no
O	O	a	yes
O	O	day	no
O	O	resulted	no
O	O	in	yes
O	O	increases	no
O	O	in	yes
B-drug	B-drug	amiodarone	yes
O	O	concentrations	no
O	O	from	no
O	O	0.9	no
O	O	mg/L	no
O	O	to	no
O	O	1.3	no
O	O	mg/L	no
O	O	.	no

O	O	The	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	in	yes
O	O	a	yes
O	O	limited	no
O	O	number	no
O	O	of	yes
O	O	patients	no
O	O	in	yes
O	O	three	no
O	O	well-controlled	no
O	O	studies	no
O	O	caused	no
O	O	no	yes
O	O	systematic	no
O	O	changes	no
O	O	in	yes
B-drug	B-drug	phenobarbital	yes
O	O	or	no
B-drug	B-drug	primidone	yes
O	O	concentrations	no
O	O	when	no
O	O	compared	no
O	O	to	no
O	O	placebo	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	injection	yes
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	into	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	thyroid	yes
I-group	I-group	preparations	no
O	O	increases	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	precipitating	no
O	O	coronary	no
O	O	insufficiency	no
O	O	especially	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	.	no

O	O	Here	no
O	O	,	no
O	O	we	no
O	O	have	no
O	O	examined	no
O	O	whether	no
B-drug	B-drug	METH	no
O	O	administration	no
O	O	affects	no
O	O	expression	no
O	O	of	yes
O	O	an	no
O	O	effector	no
O	O	IEG	no
O	O	arc	no
O	O	(	no
O	O	activity-regulated	no
O	O	,	no
B-drug_n	O	cytoskeleton-associated	no
O	O	)	no
O	O	that	no
O	O	encodes	no
O	O	a	yes
O	O	protein	yes
O	O	with	yes
O	O	homology	no
O	O	to	no
O	O	spectrin	no
O	O	.	no

B-brand	B-brand	Lotensin	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	beta-adrenergic-blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	calcium-channel-blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	hydralazine	yes
O	O	,	no
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	important	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	These	no
O	O	pharmacokinetic	no
O	O	effects	no
O	O	seen	no
O	O	during	no
B-drug	B-drug	diltiazem	yes
O	O	coadministration	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	clinical	no
O	O	effects	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	prolonged	no
O	O	sodation	no
O	O	)	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	midazolam	yes
O	O	and	yes
B-drug	B-drug	triazolam	yes
O	O	.	no

O	O	Combinations	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	and	yes
B-drug	B-drug_n	phencyclidine	yes
O	O	:	no
O	O	effects	no
O	O	on	no
O	O	drug	yes
O	O	discrimination	no
O	O	and	yes
O	O	behavioral	no
O	O	inhibition	no
O	O	in	yes
O	O	rats	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
B-drug	B-drug	Everolimus	yes
O	O	steady	no
O	O	state	no
O	O	was	no
O	O	reached	no
O	O	on	no
O	O	or	no
O	O	before	no
O	O	day	no
O	O	7	yes
O	O	,	no
O	O	with	yes
O	O	a	yes
O	O	median	no
O	O	3-fold	no
O	O	accumulation	no
O	O	of	yes
O	O	drug	yes
O	O	exposure	yes
O	O	compared	no
O	O	with	yes
O	O	that	no
O	O	after	no
O	O	the	no
O	O	first	no
O	O	postoperative	no
O	O	dose	no
O	O	.	no

O	O	The	no
O	O	binding	no
O	O	of	yes
O	O	thyroxine	no
O	O	by	no
O	O	thyroxine-binding	no
O	O	prealbumin	no
O	O	(	no
O	O	TBPA	no
O	O	)	no
O	O	is	yes
O	O	inhibited	no
O	O	by	no
B-group	B-group	salicylates	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-drug	B-drug	Eszopiclone	yes
I-drug	O	3	yes
O	O	mg	yes
O	O	administered	no
O	O	daily	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	(	no
O	O	R	yes
O	B-drug	)	no
O	I-drug	-	yes
O	I-drug	or	no
B-drug_n	I-drug	(	no
I-drug_n	I-drug	S	yes
I-drug_n	I-drug	)	no
I-drug_n	I-drug	-warfarin	no
O	O	,	no
O	O	nor	yes
O	O	were	no
O	O	there	no
O	O	any	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacodynamic	no
O	O	profile	no
O	O	(	no
O	O	prothrombin	yes
O	O	time	no
O	O	)	no
O	O	following	no
O	O	a	yes
O	O	single	yes
O	O	25	yes
O	O	mg	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes

O	O	The	no
O	O	patient	no
O	O	continued	no
O	O	to	no
O	O	receive	no
O	O	intermittent	no
O	O	hemodialysis	no
O	O	until	no
O	O	his	yes
O	O	death	no
O	O	from	no
O	O	infectious	no
O	O	complications	no
O	O	that	no
O	O	occurred	no
O	O	three	no
O	O	months	no
O	O	after	no
O	O	admission	no
O	O	.	no

O	O	Pharmacoeconomic	no
O	O	analyses	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	olanzapine	yes
O	O	does	no
O	O	not	no
O	O	significantly	no
O	O	increase	no
O	O	,	no
O	O	and	yes
O	O	may	no
O	O	even	no
O	O	decrease	no
O	O	,	no
O	O	the	no
O	O	overall	no
O	O	direct	no
O	O	treatment	no
O	O	costs	no
O	O	of	yes
O	O	schizophrenia	no
O	O	,	no
O	O	compared	no
O	O	with	yes
B-drug	B-drug	haloperidol	yes
O	O	.	no

O	O	In	yes
O	O	spite	no
O	O	of	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	kidney	yes
O	O	function	no
O	O	,	no
O	O	the	no
O	O	value	no
O	O	of	yes
O	O	the	no
O	O	elimination	no
O	O	rate	no
O	O	constant	no
O	O	was	no
O	O	significantly	no
O	O	decreased	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	(	no
O	O	from	no
O	O	0.326	no
O	O	to	no
O	O	0.263/h	no
O	O	)	no
O	O	.	no

O	O	Information	no
O	O	on	no
O	O	precautions	no
O	O	and	yes
O	O	contraindications	no
O	O	,	no
O	O	indications	no
O	O	,	no
O	O	use	no
O	O	instructions	no
O	O	,	no
O	O	and	yes
O	O	instructions	no
O	O	for	yes
O	O	appropriate	no
O	O	actions	no
O	O	after	no
O	O	missing	no
O	O	a	yes
O	O	pill	no
O	O	is	yes
O	O	appended	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	:	no
O	O	Has	no
O	O	a	yes
O	O	synergistic	no
O	O	effect	no
O	O	with	yes
B-brand	B-brand	aspirin	yes
O	O	in	yes
O	O	causing	no
O	O	gastrointestinal	no
O	O	bleeding	no
O	O	.	no

B-group	B-group	Immunosuppressive	no
I-group	I-group	drugs	no
O	O	and	yes
O	O	their	no
O	O	complications	no
O	O	.	no

O	O	Current	no
B-group	O	immunosuppressive	no
I-group	O	therapies	no
O	O	are	no
O	O	effective	no
O	O	but	no
O	O	can	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	significant	no
O	O	adverse	no
O	O	reactions	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	as	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	and	yes
B-drug	B-drug	venlafaxine	yes
O	O	ER	yes
O	O	.	no

O	O	Increases	no
O	O	in	yes
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	frequency	no
O	O	and	yes
O	O	severity	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	,	no
O	O	particularly	no
O	B-drug	anticholinergic	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-drug	B-drug	cimetidine	yes
O	O	was	no
O	O	added	no
O	O	to	no
O	O	the	no
O	B-drug	drug	yes
O	O	regimen	no
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	of	yes
B-drug	B-drug_n	resveratrol-induced	no
O	O	vasorelaxation	no
O	O	differs	no
O	O	in	yes
O	O	the	no
O	O	mesenteric	no
O	O	resistance	no
O	O	arteries	no
O	O	of	yes
O	O	lean	no
O	O	and	yes
O	O	obese	no
O	O	rats	no
O	O	.	no

O	O	clinical	no
O	O	implications	no
O	O	are	no
O	O	unclear	no
O	O	.	no

O	O	When	no
O	O	the	no
O	O	muscle	no
O	O	was	no
O	O	exposed	no
O	O	to	no
O	O	the	no
O	O	potassium-depleted	no
O	O	solution	yes
O	O	,	no
O	O	the	no
O	O	first	no
O	O	contractile	no
O	O	response	no
O	O	to	no
B-drug_n	B-drug_n	PTX	no
O	O	was	no
O	O	rather	no
O	O	potentiated	no
O	O	.	no

O	O	Addition	no
O	O	or	no
O	O	deletion	no
O	O	of	yes
O	O	any	no
O	O	drug	yes
O	O	from	no
O	O	the	no
O	O	therapeutic	no
O	O	regimen	no
O	O	of	yes
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	affect	no
O	O	patient	no
O	O	response	no
O	O	to	no
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
O	O	agents	yes
O	O	in	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
I-group	I-group	class	no
O	O	(	no
O	O	which	no
O	O	includes	no
B-brand	B-brand	Anafranil	yes
O	O	)	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
I-group	I-group	agent	yes
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	other	no
B-group	B-group	narcotic	no
I-group	O	analgesics	no
O	O	,	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	sedative-hypnotics	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	)	no
O	O	concomitantly	no
O	O	with	yes
B-brand	B-brand	DILAUDID	yes
O	O	may	no
O	O	exhibit	no
O	O	an	no
O	O	additive	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	of	yes
O	O	human	yes
O	O	CYP	no
O	O	enzymes	yes
O	O	showed	no
O	O	that	no
B-drug	B-drug	entacapone	yes
O	O	inhibited	no
O	O	the	no
O	O	CYP	no
O	O	enzymes	yes
O	O	1A2	no
O	O	,	no
O	O	2A6	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	2E1	no
O	O	and	yes
O	O	3A	yes
O	O	only	no
O	O	at	yes
O	O	very	no
O	O	high	yes
O	O	concentrations	no
O	O	(	no
O	O	IC50	no
O	O	from	no
O	O	200	yes
O	O	to	no
O	O	over	no
O	O	1000	yes
O	O	uM	no
O	O	;	no

O	O	900	no

B-group	B-group	NSAIDs	no
O	O	:	no
O	O	In	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	,	no
O	O	M1	yes
O	O	was	no
O	O	shown	no
O	O	to	no
O	O	cause	no
O	O	increases	no
O	O	ranging	no
O	O	from	no
O	O	13	yes
O	O	-	yes
O	O	50	yes
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	free	yes
O	O	fraction	yes
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	and	yes
B-drug	B-drug	ibuprofen	yes
O	O	at	yes
O	O	concentrations	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	range	no
O	O	.	no

O	O	The	no
O	O	appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	,	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

B-drug	B-drug	Hydrochlorothiazide	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	resulted	no
O	O	in	yes
O	O	significantly	no
O	O	increased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	Enhanced	no
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	secondary	yes
O	O	to	no
B-drug	B-drug	phenytoin	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Glyburide	yes
O	O	:	no
O	O	An	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	elevated	no
O	O	liver	yes
O	O	aminotransferases	no
O	O	was	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	an	no
B-group	B-drug	aluminum-containing	no
I-group	B-group	antacid	no
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	in	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug_n	B-drug_n	6MNA	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	MICRONASE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	almotriptan	yes
O	O	and	yes
O	O	other	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	)	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	,	no
O	O	increased	no
O	O	exposures	no
O	O	to	no
B-drug	B-drug	almotriptan	yes
O	O	may	no
O	O	be	no
O	O	expected	no
O	O	when	no
B-drug	B-drug	almotriptan	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	these	no
O	O	medications	no
O	O	.	no

O	O	Pretreatment	no
O	O	and	yes
O	O	follow-up	no
O	O	measurements	no
O	O	should	no
O	O	be	no
O	O	obtained	no
O	O	under	no
O	O	fasting	no
O	O	conditions	no
O	O	.	no

B-drug	B-drug	Ergotamine	yes
O	O	or	no
B-drug	B-drug	dihydroergotamine	yes
O	O	acute	no
B-group	O	ergot	yes
O	O	toxicity	no
O	O	characterized	no
O	O	by	no
O	O	severe	no
O	O	peripheral	no
O	O	vasospasm	no
O	O	and	yes
O	O	dysesthesia	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	Other	no
B-group	O	CNS	no
I-group	O	Agents	yes
O	O	:	no
O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Levo-Dromoran	yes
O	O	with	yes
O	O	all	yes
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	,	no
O	O	other	no
B-group	B-group	opioids	no
O	O	,	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	and	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	additive	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	depressant	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Propantheline	yes
O	O	and	yes
B-drug	B-drug	diphenoxylate	yes
O	O	,	no
O	O	by	no
O	O	decreasing	no
O	O	gut	no
O	O	motility	no
O	O	,	no
O	O	may	no
O	O	increase	no
B-drug	B-drug	digoxin	yes
O	O	absorption	no
O	O	.	no

O	O	If	no
O	O	taken	no
O	O	1	yes
O	O	hour	yes
O	O	before	no
B-drug	B-drug	indinavir	yes
O	O	(	no
O	B-drug	IDV	no
O	O	)	no
O	O	,	no
B-drug	B-drug	didanosine	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	B-drug	IDV	no
O	O	exposure	yes
O	O	,	no
O	O	despite	no
O	O	persistent	no
O	O	buffering	no
O	O	effects	no
O	O	.	no

O	O	5	yes
O	O	.	no

B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	and	yes
O	O	many	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	many	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
B-drug	B-drug	propafenone	yes
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fluconazole	yes
O	O	and	yes
B-drug	B-drug	glipizide	yes
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	in	yes
O	O	a	yes
O	O	placebo-controlled	no
O	O	crossover	no
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	second	no
O	O	study	no
O	O	,	no
O	O	administration	no
O	O	of	yes
O	O	12	yes
O	O	g	yes
B-drug	B-drug	cholestyramine	yes
O	O	1	yes
O	O	hour	yes
O	O	before	no
O	O	the	no
O	O	evening	no
O	O	meal	no
O	O	and	yes
O	O	0.3	yes
O	O	mg	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	approximately	no
O	O	4	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	same	yes
O	O	evening	no
O	O	meal	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	B-drug	cerivastatin	yes
O	O	AUC	no
O	O	of	yes
O	O	less	no
O	O	than	no
O	O	8	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	Cmax	no
O	O	of	yes
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	when	no
O	O	compared	no
O	O	to	no
O	O	dosing	no
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	alone	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	hepatoxicity	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	in	yes
B-drug	O	alcoholic	no
O	O	beverages	no
O	O	is	yes
O	O	enhanced	no
O	O	by	no
O	O	interaction	no
O	O	with	yes
O	O	its	no
O	O	congeners	no
O	O	and	yes
B-drug	B-drug_n	acetaldehyde	yes
O	O	;	no

O	O	It	no
O	O	is	yes
O	O	now	no
O	O	clear	no
O	O	that	no
O	O	topoisomerase	no
O	O	activity	yes
O	O	level	no
O	O	is	yes
O	O	an	no
O	O	important	no
O	O	determinant	no
O	O	of	yes
O	O	sensitivity	no
O	O	to	no
O	O	topo	no
O	O	drugs	no
O	O	.	no

O	O	(	no
O	O	See	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	)	no
O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	Femara	yes
O	O	and	yes
B-drug	B-drug	tamoxifen	yes
O	O	20	yes
O	O	mg	yes
O	O	daily	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	letrozole	yes
O	O	plasma	yes
O	O	levels	no
O	O	by	no
O	O	38	no
O	O	%	no
O	O	on	no
O	O	average	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	the	no
O	O	total	yes
O	O	amount	no
O	O	of	yes
B-drug_n	B-drug_n	6MNA	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	is	yes
O	O	unchanged	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	interactions	no
O	O	with	yes
O	O	drugs	no
O	O	or	no
O	O	substances	no
O	O	that	no
O	O	may	no
O	O	be	no
O	O	substrates	no
O	O	,	no
O	O	inhibitors	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Neither	no
O	O	racemic	yes
B-drug	B-drug	warfarin	yes
O	O	nor	yes
B-drug	B-drug	isradipine	yes
O	O	binding	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	in	yes
O	O	vitro	no
O	O	was	no
O	O	altered	no
O	O	by	no
O	O	the	no
O	O	addition	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	,	no
O	O	including	no
B-drug	B-drug	norfloxacin	yes
O	O	,	no
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
B-drug	B-drug	ofloxacin	yes
O	O	,	no
B-drug	B-drug	enoxacin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	lomefloxacin	yes
O	O	,	no
O	O	have	no
O	O	been	no
O	O	extensively	no
O	O	studied	no
O	O	and	yes
O	O	have	no
O	O	demonstrated	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	profiles	no
O	O	comparable	no
O	O	to	no
O	O	those	no
O	O	of	yes
O	O	other	no
O	O	traditional	no
O	O	agents	yes
O	O	for	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	complicated	no
O	O	or	no
O	O	uncomplicated	no
O	O	urinary	yes
O	O	tract	no
O	O	infections	no
O	O	and	yes
O	O	prostatitis	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	When	no
B-drug	B-drug	aliskiren	yes
O	O	was	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	furosemide	yes
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	were	no
O	O	reduced	yes
O	O	by	no
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	and	yes
O	O	50	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Treatment	no
O	O	with	yes
B-group	B-group	antidepressant	no
I-group	I-group	drugs	no
O	O	can	no
O	O	directly	no
O	O	interfere	no
O	O	with	yes
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	or	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	.	no

B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	Estradiol	yes
O	O	and	yes
B-drug	B-drug	Norethindrone	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	VIRACEPT	yes
O	O	with	yes
B-brand	B-brand	OVCON-35	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	47	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
O	O	an	no
O	O	18	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	norethindrone	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	-	yes
B-brand	B-drug	Sulfoxone	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Diasone	yes
O	O	)	no
O	O	or	no

O	O	The	no
O	O	8.5	no
O	O	%	no
O	O	incidence	no
O	O	of	yes
O	O	akathisia	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	within	no
O	O	the	no
O	O	range	no
O	O	reported	no
O	O	for	yes
O	O	use	no
O	O	of	yes
B-drug	B-drug	prochlorperazine	yes
O	O	when	no
O	O	given	no
O	O	as	yes
O	O	a	yes
O	O	premedication	no
O	O	for	yes
O	O	other	no
O	O	chemotherapies	no
O	O	.	no

O	O	-	yes
O	O	a	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drug	yes
O	O	(	no
B-group	B-group	NSAID	no
O	O	)	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ibuprofen	yes
O	O	(	no
B-brand	B-brand	Motrin	yes
O	O	,	no
B-brand	B-brand	Advil	yes
O	O	,	no
B-brand	B-brand	Nuprin	yes
O	O	,	no
O	O	others	no
O	O	)	no
O	O	,	no
B-drug	B-drug	ketoprofen	yes
O	O	(	no
B-brand	B-brand	Orudis	yes
O	O	,	no
B-brand	B-brand	Orudis	yes
O	I-brand	KT	yes
O	O	,	no
B-brand	B-brand	Oruvail	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	diclofenac	yes
O	O	(	no
B-brand	B-brand	Voltaren	yes
O	O	,	no
B-brand	B-brand	Cataflam	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	etodolac	yes
O	O	(	no
B-brand	B-brand	Lodine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	(	no
B-brand	B-brand	Indocin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	nabumetone	yes
O	O	(	no
B-brand	B-brand	Relafen	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	oxaprozin	yes
O	O	(	no
B-brand	B-brand	Daypro	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	naproxen	yes
O	O	(	no
B-brand	B-brand	Anaprox	yes
O	O	,	no
B-brand	B-brand	Naprosyn	yes
O	O	,	no
B-brand	B-brand	Aleve	yes
O	O	)	no
O	O	;	no

O	O	However	no
O	O	,	no
O	O	when	no
O	O	any	no
O	O	additional	no
O	O	drug	yes
O	O	,	no
O	O	including	no
B-brand	B-brand	INDOCIN	yes
O	O	,	no
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	patients	no
O	O	on	no
B-group	B-group	anticoagulant	no
O	O	therapy	no
O	O	,	no
O	O	the	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	for	yes
O	O	alterations	no
O	O	of	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

B-drug	B-drug	Lorazepam	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	single	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
I-drug	O	3	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	lorazepam	yes
O	O	2	yes
O	O	mg	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	clinically	no
O	O	relevant	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	or	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	Drug	yes
O	O	Interaction	no
O	O	During	no
O	O	Pregnancy	no
O	O	:	no
B-brand	B-drug	Cromolyn	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
B-drug	B-drug	isoproterenol	yes
O	O	were	no
O	O	studied	no
O	O	following	no
O	O	subcutaneous	yes
O	O	injections	no
O	O	in	yes
O	O	pregnant	no
O	O	mice	no
O	O	.	no

O	O	Symptoms	no
O	O	resolved	no
O	O	within	no
O	O	a	yes
O	O	few	no
O	O	hours	no
O	O	.	no

O	O	The	no
O	B-drug_n	threohydrobupropion	no
O	O	metabolite	yes
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	produced	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzymes	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	DIABINESE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	should	no
O	O	generally	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	case	no
O	O	that	no
O	O	you	no
O	O	are	no
O	O	taking	no
B-drug	B-drug	digoxin	yes
O	O	while	no
O	O	taking	no
B-drug	B-drug	aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	may	no
O	O	be	no
O	O	needed	no
O	O	.	no

O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	mutagenicity	no
O	O	was	no
O	O	observed	no
O	O	.	no

O	O	Further	no
O	O	,	no
O	O	in	yes
O	O	rabbits	no
O	O	dosed	no
O	O	at	yes
O	O	0.25	no
O	O	mg/kg/day	no
O	O	(	no
O	O	about	no
O	O	one-half	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	on	no
O	O	BSA	no
O	O	)	no
O	O	,	no
O	O	increases	no
O	O	in	yes
O	O	placental	no
O	O	weight	yes
O	O	and	yes
O	O	post-implantation	no
O	O	loss	no
O	O	were	no
O	O	observed	no
O	O	but	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	observed	no
O	O	effects	no
O	O	on	no
O	O	fetal	no
O	O	development	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	are	no
O	O	examples	no
O	O	of	yes
O	O	substances	no
O	O	that	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	:	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-drug	B-drug	danazol	yes
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	epinephrine	yes
O	O	,	no
B-drug	B-drug	albuterol	yes
O	O	,	no
B-drug	B-drug	terbutaline	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-group	B-group	phenothiazine	yes
I-group	I-group	derivatives	no
O	O	,	no
B-drug	B-drug	somatropin	yes
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	hormones	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
B-group	B-group	progestogens	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	in	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	monitor	no
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	myelotoxicity	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	frequent	no
O	O	peripheral	no
O	O	blood	yes
O	O	cell	yes
O	O	counts	no
O	O	be	no
O	O	performed	no
O	O	on	no
O	O	all	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	TAXOL	yes
O	O	.	no

O	O	Acid-base	no
O	O	and	yes
O	O	electrolyte	yes
O	O	alterations	no
O	O	were	no
O	O	not	no
O	O	reported	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	trials	no
O	O	with	yes
B-drug	B-drug	brinzolamide	yes
O	O	.	no

O	O	.	no

B-drug	B-drug	Albendazole	yes
I-drug	I-drug	sulfoxide	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	were	no
O	O	unchanged	no
O	O	4	yes
O	O	hours	no
O	O	after	no
O	O	dosing	no
O	O	.	no

B-group	B-group	HIV	no
I-group	I-group	Antiviral	no
I-group	I-group	Agents	yes

O	O	Drugs	no
O	O	that	no
O	O	inhibit	no
O	O	or	no
O	O	Induce	no
O	O	CYP	no
O	O	2D6	no
O	O	and	yes
O	O	CYP	no
O	O	3A4	no
O	O	may	no
O	O	affect	no
O	O	the	no
O	O	concentration	no
O	O	on	no
B-brand	B-brand	Aricept	yes
O	O	.	no

O	O	The	no
O	O	optimal	no
O	O	dosing	no
O	O	interval	no
O	O	for	yes
O	O	coadministration	no
O	O	with	yes
B-brand	B-brand	VIDEX	yes
O	O	should	no
O	O	be	no
O	O	determined	no
O	O	by	no
O	O	consulting	no
O	O	the	no
O	O	appropriate	no
B-group	B-group	quinolone	no
O	O	package	no
O	O	insert	no
O	O	.	no

B-drug	B-drug	Itraconazole	yes
O	O	decreases	no
B-drug	B-drug	busulfan	yes
O	O	clearance	no
O	O	by	no
O	O	up	no
O	O	to	no
O	O	25	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	may	no
O	O	produce	no
O	O	AUCs	no
O	O	1500	no
O	O	M	yes
O	O	min	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
O	O	or	no
B-drug	B-drug	aluminum	yes
O	O	with	yes
B-brand	B-brand	VIDEX	yes
O	O	Chewable/Dispersible	no
O	O	Buffered	no
O	O	Tablets	yes
O	O	or	no
O	O	Pediatric	yes
O	O	Powder	yes
O	O	for	yes
O	O	Oral	yes
O	O	Solution	yes
O	O	may	no
O	O	potentiate	no
O	O	adverse	no
O	O	events	no
O	O	associated	no
O	O	with	yes
O	O	the	no
B-group	B-group	antacid	no
I-group	O	components	no
O	O	.	no

O	O	This	no
O	O	article	no
O	O	will	no
O	O	describe	no
O	O	the	no
O	O	escalating	no
O	O	use	no
O	O	of	yes
O	O	herbal	no
O	O	therapy	no
O	O	and	yes
O	O	the	no
O	O	hazards	no
O	O	of	yes
O	O	herbal	no
O	O	remedy	no
O	O	use	no
O	O	among	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Nelfinavir	yes

B-drug	O	Interferon	yes
O	O	induction	no
O	O	:	no
O	O	tool	no
O	O	for	yes
O	O	establishing	no
O	O	interactions	no
O	O	among	no
O	O	homopolyribonucleotides	no
O	O	.	no

O	O	-	yes
B-group	O	Pressor	no
I-group	O	amines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	norepinephrine	yes
O	O	)	no
O	O	:	no
O	O	Possible	no
O	O	decreased	no
O	O	response	no
O	O	to	no
B-group	O	pressor	no
I-group	O	amines	no
O	O	but	no
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	preclude	no
O	O	their	no
O	O	use	no

O	O	This	no
O	O	study	no
O	O	demonstrated	no
O	O	that	no
O	O	the	no
O	O	potent	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzyme-inducer	no
B-drug	B-drug	phenytoin	yes
O	O	did	no
O	O	indeed	no
O	O	have	no
O	O	a	yes
O	O	marked	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	quetiapine	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	5-fold	no
O	O	increase	no
O	O	in	yes
O	O	clearance	no
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	DSM-IV-diagnosed	no
O	O	schizophrenia	no
O	O	,	no
O	O	schizoaffective	no
O	O	disorder	no
O	O	,	no
O	O	or	no
O	O	bipolar	no
O	O	disorder	no
O	O	.	no

O	O	Accordingly	no
O	O	,	no
O	O	when	no
B-drug	B-drug	diflunisal	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	during	no
O	O	and	yes
O	O	for	yes
O	O	several	no
O	O	days	no
O	O	after	no
O	O	concomitant	no
O	O	drug	yes
O	O	administration	no
O	O	.	no

O	B-group	Imidazoles	no
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	miconazole	yes
O	O	,	no
B-drug	B-drug	clotrimazole	yes
O	O	,	no
B-drug	B-drug	fluconazole	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	:	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	animal	no
O	O	studies	no
O	O	with	yes
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	and	yes
O	B-group	imidazoles	no
O	O	suggest	no
O	O	that	no
O	B-group	imidazoles	no
O	O	may	no
O	O	induce	no
O	O	fungal	no
O	O	resistance	no
O	O	to	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	;	no

B-group	B-group	Benzodiazepines	no

O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	rats	no
O	O	to	no
O	O	assess	no
O	O	the	no
O	O	carcinogenic	no
O	O	potential	no
O	O	of	yes
B-drug	B-drug	ribavirin	yes
O	O	is	yes
O	O	ongoing	no
O	O	.	no

O	O	Although	no
B-drug	B-drug	bupropion	yes
O	O	is	yes
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isoenzyme	no
O	O	,	no
B-drug	B-drug	bupropion	yes
O	O	and	yes
O	B-drug_n	hydroxybupropion	no
O	O	are	no
O	O	inhibitors	no
O	O	of	yes
O	O	the	no
O	O	CYP2D6	no
O	O	isoenzyme	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	formal	no
O	O	interaction	no
O	O	studies	no
O	O	other	no
O	O	than	no
O	O	with	yes
B-drug	B-drug	antipyrine	yes
O	O	,	no
O	O	based	no
O	O	on	no
O	O	these	no
O	O	in	yes
O	O	vivo	no
O	O	and	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	unlikely	no
O	O	that	no
O	O	co-administration	no
O	O	of	yes
O	O	a	yes
O	O	1	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	ARIMIDEX	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	will	no
O	O	result	no
O	O	in	yes
O	O	clinically	no
O	O	significant	no
O	O	drug	yes
O	O	inhibition	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450-mediated	no
O	O	metabolism	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	,	no
O	O	a	yes
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	blocking	no
O	O	agent	yes
O	O	,	no
O	O	administered	no
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	500	yes
O	O	mg	yes
O	O	four	no
O	O	times	no
O	O	a	yes
O	O	day	no
O	O	,	no
O	O	did	no
O	O	not	no
O	O	change	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	1000	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	.	no

B-drug_n	B-drug_n	18-MC	no
O	O	does	no
O	O	not	no
O	O	produce	no
O	O	these	no
O	O	effects	no
O	O	.	no

O	O	Plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	flecainide	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	;	no

O	O	No	yes
O	O	increase	no
O	O	in	yes
O	O	mortality	no
O	O	was	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	digoxin	yes
O	O	as	yes
O	O	concomitant	no
O	O	medication	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	if	no
O	O	the	no
O	O	patients	no
O	O	thyroid	yes
O	O	gland	no
O	O	has	no
O	O	sufficient	no
O	O	function	no
O	O	,	no
O	O	the	no
O	O	decreased	no
O	O	free	yes
B-drug	B-drug	thyroxine	no
O	O	will	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	compensatory	no
O	O	increase	no
O	O	in	yes
O	O	thyroxine	no
O	O	output	no
O	O	by	no
O	O	the	no
O	O	thyroid	yes
O	O	.	no

O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	data	no
O	O	described	no
O	O	in	yes
O	O	this	no
O	O	section	no
O	O	were	no
O	O	obtained	no
O	O	from	no
O	O	studies	no
O	O	involving	no
O	O	healthy	no
O	O	adults	no
O	O	and	yes
O	O	adult	yes
O	O	patients	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
O	O	repeat	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	FACTIVE	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	repeat	no
O	O	dose	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	or	no
O	O	an	no
B-drug	B-drug	ethinylestradiol/levonorgestrol	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
I-group	I-group	product	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	change	no
O	O	after	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	PGF2alpha	yes
O	O	.	no

O	O	Studies	no
O	O	in	yes
O	O	vitro	no
O	O	show	no
O	O	that	no
B-drug	B-drug	caspofungin	yes
I-drug	I-drug	acetate	yes
O	O	is	yes
O	O	not	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	any	no
O	O	enzyme	no
O	O	in	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	system	yes
O	O	.	no

B-group	B-group	Salicylates-Salicylates	no
O	O	in	yes
O	O	large	no
O	O	doses	no
O	O	may	no
O	O	inhibit	no
O	O	vitamin	yes
O	O	K	yes
O	O	epoxide	no
O	O	reductase	no
O	O	resulting	no
O	O	in	yes
B-group	O	vitamin	yes
I-group	O	K	yes
O	O	deficiency	no
O	O	.	no

O	O	During	no
O	O	co-administration	no
O	O	,	no
O	O	systemic	no
O	O	levels	no
O	O	of	yes
O	B-drug	TMP	yes
O	O	and	yes
B-drug_n	B-drug	SMX	yes
O	O	were	no
O	O	essentially	no
O	O	unchanged	no
O	O	.	no

O	O	After	no
O	O	incubation	no
O	O	at	yes
O	O	0	no
O	O	degrees	no
O	O	C	yes
O	O	for	yes
O	O	4	yes
O	O	h	yes
O	O	this	no
O	O	number	no
O	O	fell	no
O	O	to	no
O	O	2.3	no
O	O	plus	yes
O	O	or	no
O	O	minus	no
O	O	0.1	no
O	O	S.E.M	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Valproic	yes
I-drug	I-drug	acid	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Depakene	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	sulfapyridine	yes
O	O	with	yes
O	O	these	no
O	O	medicines	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	liver	yes

B-drug	B-drug	Ketoconazole	yes
O	O	tablets	yes
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	methylprednisolone	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	drugs	no
O	O	.	no

O	O	-	yes
O	O	The	no
O	O	action	no
O	O	of	yes
B-group	B-group	sulphonylureas	no
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	these	no
O	O	studies	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	whether	no
B-drug	B-drug_n	ginsenosides-induced	no
O	O	inhibition	no
O	O	of	yes
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	currents	no
O	O	discriminates	no
O	O	among	no
O	O	the	no
O	O	various	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	channel	no
O	O	subtypes	no
O	O	,	no
O	O	although	no
O	O	it	no
O	O	is	yes
O	O	known	no
O	O	that	no
O	O	there	no
O	O	are	no
O	O	at	yes
O	O	least	no
O	O	five	no
O	O	different	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	channel	no
O	O	subtypes	no
O	O	in	yes
O	O	neuronal	no
O	O	cells	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	elevated	no
B-drug	B-drug	digoxin	yes
O	O	serum	yes
O	O	levels	no
O	O	.	no

O	O	Differential	no
O	O	actions	no
O	O	of	yes
O	O	intrathecal	no
B-drug	B-drug	naloxone	yes
O	O	on	no
O	O	blocking	no
O	O	the	no
O	O	tail-flick	no
O	O	inhibition	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
B-drug	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	in	yes
O	O	rats	no
O	O	.	no

O	O	While	no
O	O	taking	no
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	anaphylactic	no
O	O	reaction	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	may	no
O	O	have	no
O	O	a	yes
O	O	more	no
O	O	severe	no
O	O	reaction	no
O	O	on	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	either	no
O	O	accidental	no
O	O	,	no
O	O	diagnostic	yes
O	O	or	no
O	O	therapeutic	no
O	O	.	no

O	O	Q4H	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	levofloxacin	yes
O	O	,	no
O	O	500	yes
O	O	mg	yes
O	O	p.o	no
O	O	.	no

O	O	Nonetheless	no
O	O	,	no
O	O	their	no
O	O	relevance	no
O	O	continues	no
O	O	to	no
O	O	be	no
O	O	demonstrated	no
O	O	by	no
O	O	the	no
O	O	dependence	no
O	O	of	yes
O	O	each	no
O	O	agent	yes
O	O	on	no
O	O	intact	no
O	O	liver	yes
O	O	blood	yes
O	O	flow	no
O	O	and	yes
O	O	function	no
O	O	for	yes
O	O	normal	yes
O	O	rates	no
O	O	of	yes
O	O	elimination	no
O	O	;	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	at	yes
O	O	high	yes
O	O	concentrations	no
O	O	(	no
O	O	7.4	yes
O	O	mMol/L	no
O	O	or	no
O	O	0.97	no
O	O	mg/mL	no
O	O	and	yes
O	O	greater	no
O	O	)	no
O	B-drug	EACA	yes
O	O	inhibits	no
O	O	ADP	no
O	O	and	yes
O	O	collagen-induced	no
O	O	platelet	yes
O	O	aggregation	no
O	O	,	no
O	O	the	no
O	O	release	yes
O	O	of	yes
O	O	ATP	yes
O	O	and	yes
O	O	serotonin	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	binding	no
O	O	of	yes
O	O	fibrinogen	yes
O	O	to	no
O	O	the	no
O	O	platelets	no
O	O	in	yes
O	O	a	yes
O	O	concentration-response	no
O	O	manner	no
O	O	.	no

O	O	Use	no
O	O	with	yes
B-drug	B-drug	Allopurinol	yes
O	O	:	no
O	O	The	no
O	O	principal	no
O	O	pathway	no
O	O	for	yes
O	O	detoxification	no
O	O	of	yes
B-drug	B-drug	azathioprine	yes
O	O	is	yes
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	allopurinol	yes
O	O	.	no

O	O	Familial	no
O	O	hyper-	no
O	O	or	no
O	O	hypo-thyroxine-binding-globulinemias	no
O	O	have	no
O	O	been	no
O	O	described	no
O	O	.	no

O	O	Talk	no
O	O	to	no
O	O	your	no
O	O	doctor	no
O	O	if	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	or	no
B-drug	B-drug	azithromycin	yes
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	Guardians	no
O	O	of	yes
O	O	children	no
O	O	who	no
O	O	have	no
O	O	been	no
O	O	prescribed	no
B-brand	B-brand	FORADIL	yes
O	O	should	no
O	O	be	no
O	O	alerted	no
O	O	to	no
O	O	the	no
O	O	general	no
O	O	concern	no
O	O	regarding	no
O	O	asthma	no
O	O	therapy	no
O	O	compliance	yes
O	O	,	no
O	O	especially	no
O	O	neglect	no
O	O	of	yes
O	O	anti-inflammatory	no
O	O	therapy	no
O	O	and	yes
O	O	overuse	no
O	O	of	yes
B-group	B-group	short-acting	no
I-group	I-group	beta2-agonists	no
O	O	.	no

O	O	Injection	yes
O	O	:	no
B-drug	B-drug	Lorazepam	yes
O	O	injection	yes
O	O	,	no
O	O	like	yes
O	O	other	no
O	O	injectable	no
B-group	B-group	benzodiazepines	no
O	O	,	no
O	O	produces	no
O	O	depression	no
O	O	of	yes
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	ethyl	yes
I-drug	I-drug	alcohol	yes
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
O	O	other	no
B-drug	B-group	antidepressants.When	no
I-drug	B-drug	scopolamine	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	injectable	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	sedation	no
O	O	,	no
O	O	hallucinations	no
O	O	,	no
O	O	and	yes
O	O	irrational	no
O	O	behavior	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	.	no

B-group	B-group	Acidifying	no
I-group	I-group	agents	yes
O	O	:	no
B-group	B-group	Gastrointestinal	no
I-group	I-group	acidifying	no
I-group	I-group	agents	yes
O	O	(	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	,	no
B-drug	B-drug	glutamic	yes
I-drug	I-drug	acid	yes
I-drug	I-drug	HCl	yes
O	O	,	no
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	fruit	no
O	O	juices	no
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	lower	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	Positive	no
O	O	direct	no
O	O	and	yes
O	O	indirect	no
B-drug	O	antiglobulin	no
O	O	(	no
O	O	Coombs	no
O	O	)	no
O	O	tests	no
O	O	have	no
O	O	occurred	no
O	O	;	no

O	O	Drugs	no
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	albumin	yes
O	O	could	no
O	O	increase	no
O	O	the	no
O	O	unbound	no
O	O	fraction	yes
O	O	of	yes
B-drug	B-drug	fosphenytoin	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	and	yes
B-group	B-group	calcium	yes
I-group	O	antagonists	no
O	O	may	no
O	O	have	no
O	O	additive	no
O	O	effects	no
O	O	on	no
O	O	prolonging	no
O	O	atrioventricular	no
O	O	conduction	no
O	O	time	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
O	O	The	no
O	O	two	no
O	O	treatment	no
O	O	groups	no
O	O	were	no
O	O	well	no
O	O	matched	no
O	O	with	yes
O	O	regard	no
O	O	to	no
O	O	patient	no
O	O	demographics	no
O	O	,	no
O	O	NHL	no
O	O	characteristics	no
O	O	,	no
O	O	HIV	no
O	O	status	no
O	O	,	no
O	O	and	yes
O	O	treatment	no
O	O	,	no
O	O	i.e.	no
O	O	,	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	cycles	no
O	O	and	yes
O	O	chemotherapy	no
O	O	dose	no
O	O	.	no

O	O	Avoid	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	chlorprothixene	yes
O	O	and	yes
B-drug	B-drug	tramadol	yes
O	O	(	no
B-brand	B-brand	Ultram	yes
O	O	)	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	NIZORAL	yes
O	O	Tablets	yes
O	O	with	yes
B-drug	B-drug	midazolam	yes
O	O	or	no
B-drug	B-drug	triazolam	yes
O	O	has	no
O	O	resulted	no
O	O	in	yes
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	two	no
O	O	drugs	no
O	O	.	no

O	O	This	no
O	O	treatment	no
O	O	arm	no
O	O	was	no
O	O	discontinued	no
O	O	from	no
O	O	the	no
O	O	trial	no
O	O	.	no

O	O	No	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

O	O	An	no
O	O	in	yes
O	O	vitro	no
O	O	effect	no
O	O	occurs	no
O	O	when	no
O	O	the	no
O	O	medication	no
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	assay	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	result	no
O	O	is	yes
O	O	erroneous	no
O	O	and	yes
O	O	can	no
O	O	not	no
O	O	be	no
O	O	interpreted	no
O	O	.	no

O	O	Ironically	no
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	are	no
O	O	often	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
B-drug	B-drug	heroin	yes
O	O	addiction	no
O	O	while	no
O	O	they	no
O	O	cause	no
O	O	much	no
O	O	more	no
O	O	severe	no
O	O	withdrawal	no
O	O	symptoms	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	a	yes
O	O	crossover	no
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
O	O	either	no
B-brand	B-brand	Tagamet	yes
O	O	300	yes
O	O	mg	yes
O	O	q.i.d	no
O	O	.	no
O	O	or	no
O	O	800	no
O	O	mg	yes
O	O	h.s	no
O	O	.	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
O	O	300	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
B-brand	B-brand	Theo-Dur	yes
O	O	,	no
O	O	Key	no
O	O	Pharmaceuticals	no
O	O	,	no
O	O	Inc.	no
O	O	)	no
O	O	demonstrated	no
O	O	less	no
O	O	alteration	no
O	O	in	yes
O	O	steady-state	no
B-drug	B-drug	theophylline	yes
O	O	peak	no
O	O	serum	yes
O	O	levels	no
O	O	with	yes
O	O	the	no
O	O	800	no
O	O	mg	yes
O	O	h.s	no
O	O	.	no
O	O	regimen	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	subjects	no
O	O	aged	no
O	O	54	no
O	O	years	no
O	O	and	yes
O	O	older	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	NSAIDs	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	;	no

O	O	Specific	no
O	O	studies	no
O	O	have	no
O	O	confirmed	no
O	O	these	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	sevoflurane	yes
O	O	,	no
B-drug	B-drug	isoflurane	yes
O	O	,	no
B-drug	B-drug	propofol	yes
O	O	,	no
B-drug	B-drug	alfentanil	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	midazolam	yes
O	O	.	no

B-group	B-group	Anti-arrhythmics	no
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	anti-depressants	no
O	O	could	no
O	O	exaggerate	no
O	O	the	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	assumed	no
O	O	that	no
O	O	increased	no
O	O	interaction	no
O	O	between	yes
O	B-drug_n	3H-spiroperidol	no
O	O	and	yes
O	O	high	yes
O	O	affinity	no
O	O	binding	no
O	O	sites	no
O	O	for	yes
B-drug	B-drug	apomorphine	yes
O	O	on	no
O	O	dopamine2-	no
O	O	and	yes
O	O	serotonin2-receptors	no
O	O	underlies	no
O	O	the	no
O	O	antipsychotic	no
O	O	action	no
O	O	of	yes
B-group	B-group	neuroleptics	no
O	O	after	no
O	O	their	no
O	O	prolonged	no
O	O	administration	no
O	O	.	no

O	O	The	no
O	O	most	no
O	O	commonly	no
O	O	occurring	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	listed	no
O	O	below	no
O	O	:	no
O	O	-	yes
O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	increase	no
O	O	plasma	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	include	no
O	O	:	no
O	O	acute	no
B-drug	B-drug	alcohol	yes
O	O	intake	no
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-drug	O	chboramphenicol	no
O	O	,	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	dicumarol	yes
O	O	,	no
B-drug	B-drug	disulfiram	yes
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
B-drug	B-drug	ethosuximide	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-group	B-group	H2-antagonists	no
O	O	,	no
B-drug	B-drug	halothane	yes
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-drug	B-drug	methylphenidate	yes
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	succinimides	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
B-drug	B-drug	trazodone	yes

O	O	If	no
O	O	they	no
O	O	do	no
O	O	occur	no
O	O	,	no
O	O	the	no
B-drug	B-drug	EPA	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	lowered	no
O	O	or	no
O	O	discontinued	no
O	O	.	no

O	O	For	yes
B-drug	B-drug	digoxin	yes
O	O	AUC	no
O	O	(	no
O	O	0-infinity	no
O	O	)	no
O	O	,	no
O	O	AUC	no
O	O	(	no
O	O	0-24	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	the	no
O	O	geometric	no
O	O	mean	no
O	O	ratios	no
O	O	(	no
O	O	90	yes
O	O	%	no
O	O	confidence	no
O	O	interval	no
O	O	)	no
O	O	for	yes
O	O	(	no
B-drug	B-drug	rofecoxib	yes
I-drug	O	+	no
I-drug	B-drug	digoxin/placebo	no
O	O	+	no
B-drug	B-drug	digoxin	yes
O	O	)	no
O	O	were	no
O	O	1.04	no
O	O	(	no
O	O	0.94	no
O	O	,	no
O	O	1.14	no
O	O	)	no
O	O	,	no
O	O	1.02	no
O	O	(	no
O	O	0.94	no
O	O	,	no
O	O	1.09	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	1.00	no
O	O	(	no
O	O	0.91	no
O	O	,	no
O	O	1.10	no
O	O	)	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	washout	no
O	O	(	no
O	O	days	no
O	O	7-13	no
O	O	)	no
O	O	;	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	which	no
O	O	patients	no
O	O	with	yes
O	O	active	no
O	O	RA	yes
O	O	were	no
O	O	treated	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	24	yes
O	O	weeks	no
O	O	with	yes
O	O	concurrent	no
B-brand	B-brand	Kineret	yes
O	O	and	yes
B-drug	B-drug	etanercept	yes
O	O	therapy	no
O	O	,	no
O	O	a	yes
O	O	7	yes
O	O	%	no
O	O	rate	no
O	O	of	yes
O	O	serious	no
O	O	infections	no
O	O	was	no
O	O	observed	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	higher	no
O	O	than	no
O	O	that	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	etanercept	yes
O	O	alone	no
O	O	(	no
O	O	0	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Because	no
B-brand	B-brand	Nalfon	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	produce	no
O	O	any	no
O	O	additional	no
O	O	effect	no
O	O	beyond	no
O	O	that	no
O	O	obtained	no
O	O	with	yes
B-brand	B-brand	aspirin	yes
O	O	alone	no
O	O	and	yes
O	O	because	no
B-brand	B-brand	aspirin	yes
O	O	increases	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	excretion	no
O	O	of	yes
B-brand	B-brand	Nalfon	yes
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Nalfon	yes
O	O	and	yes
B-group	B-group	salicylates	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	In	yes
O	O	that	no
O	O	same	yes
O	O	study	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	alone	no
O	O	produced	no
O	O	a	yes
O	O	marked	no
O	O	inhibition	no
O	O	in	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	ex	no
O	O	vivo	no
O	O	.	no

O	O	When	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
B-group	B-group	anesthetics	no
O	O	and	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	should	no
O	O	be	no
O	O	titrated	no
O	O	carefully	no
O	O	.	no

O	O	When	no
B-group	B-group	estrogen	no
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	,	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
B-group	B-group	corticosteroid	no
O	O	dosage	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	,	no
O	O	and	yes
O	O	increased	no
O	O	amounts	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	when	no
B-group	B-group	estrogen	no
O	O	is	yes
O	O	terminated	no
O	O	.	no

O	O	In	yes
O	O	neither	no
O	O	case	no
O	O	were	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	sumatriptan	yes
O	O	affected	no
O	O	by	no
O	O	coadministration	no
O	O	with	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	.	no

O	O	Some	no
O	O	cases	no
O	O	presented	no
O	O	with	yes
O	O	features	no
O	O	resembling	no
O	O	neuroleptic	no
O	O	malignant	no
O	O	syndrome	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	intake	no
O	O	of	yes
O	O	supplemental	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	should	no
O	O	not	no
O	O	exceed	no
O	O	1000	yes
O	O	micrograms	no
O	O	(	no
O	O	g	yes
O	O	,	no
O	O	sometimes	no
O	O	mcg	no
O	O	)	no
O	O	per	no
O	O	day	no
O	O	to	no
O	O	prevent	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	from	no
O	O	masking	no
O	O	symptoms	no
O	O	of	yes
O	O	vitamin	yes
O	O	B12	yes
O	O	deficiency	no
O	O	.	no

B-brand	B-brand	Xigris	no
O	O	present	no
O	O	in	yes
O	O	plasma	yes
O	O	samples	no
O	O	does	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	one-stage	no
O	O	factor	yes
O	O	assays	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	PT	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	factor	yes
O	O	II	yes
O	O	,	no
I-drug_n	O	V	yes
O	O	,	no
O	O	VII	yes
O	O	,	no
O	O	and	yes
O	O	X	yes
O	O	assays	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	compounds	no
O	O	interfere	no
O	O	with	yes
O	O	chemical	yes
O	O	color	no
O	O	development	no
O	O	essential	yes
O	O	to	no
O	O	the	no
O	O	analytical	no
O	O	procedures	no
O	O	.	no

O	O	GI	no
O	O	motility	no
O	O	agents	yes
O	O	:	no
B-drug	B-drug	cisapride	yes

B-drug	B-drug	Amprenavir	yes
O	O	is	yes
O	O	metabolized	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	At	yes
O	O	least	no
O	O	14	yes
O	O	days	no
O	O	should	no
O	O	elapse	no
O	O	between	yes
O	O	discontinuation	no
O	O	of	yes
O	O	a	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	and	yes
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	dexfenfluramine	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	is	yes
O	O	extensively	no
O	O	bound	no
O	O	to	no
O	O	serum	yes
O	O	plasma	yes
O	O	proteins	no
O	O	and	yes
O	O	is	yes
O	O	prone	no
O	O	to	no
O	O	competitive	no
O	O	displacement	no
O	O	.	no

O	O	the	no
O	O	third	no
O	O	group	yes
O	O	(	no
O	O	SH/EA	no
O	O	)	no
O	O	was	no
O	O	treated	no
O	O	with	yes
O	O	a	yes
B-drug	O	hydroalcoholic	no
O	O	solution	yes
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	;	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	concomitantly	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	decreases	no
O	O	in	yes
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	and	yes
B-drug	B-drug	desethylamiodarone	no
O	O	.	no

O	O	The	no
B-group	B-group	fluoroquinolones	no
O	O	are	no
O	O	also	no
O	O	extensively	no
O	O	used	no
O	O	in	yes
O	O	urologic	yes
O	O	surgery	no
O	O	.	no

O	O	Each	no
O	O	serum	yes
O	O	without	no
O	O	the	no
O	O	other	no
O	O	added	no
O	O	drug	yes
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	the	no
O	O	serum	yes
O	O	supplemented	no
O	O	with	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	at	yes
O	O	the	no
O	O	three	no
O	O	concentrations	no
O	O	was	no
O	O	dialyzed	no
O	O	against	yes
O	O	phosphate	yes
O	O	buffer	no
O	O	.	no

O	O	endocrine	no
O	O	dysfunction	no
O	O	;	no

B-group	B-group	Quinolones	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	with	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	render	no
O	O	these	no
B-group	B-group	contraceptives	no
O	O	less	no
O	O	effective	no
O	O	.	no

O	O	In	yes
O	O	controlled	no
O	O	clinical	no
O	O	trials	no
O	O	of	yes
B-brand	B-brand	AUGMENTIN	yes
I-brand	I-brand	XR	yes
O	O	,	no
O	O	22	no
O	O	patients	no
O	O	received	no
O	O	concomitant	no
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-brand	B-brand	AUGMENTIN	yes
I-brand	I-brand	XR	yes
O	O	.	no

O	O	Examples	no
O	O	of	yes
O	O	Drugs	no
O	O	in	yes
O	O	Which	no
O	O	Plasma	yes
O	O	Concentrations	no
O	O	May	no
O	O	Be	no
O	O	Decreased	no
O	O	By	no
O	O	Co-administration	no
O	O	With	yes
B-drug	B-drug	Nevirapine	yes

O	O	Using	no
B-drug	B-drug	calcium	yes
I-drug	I-drug	acetate	yes
O	O	with	yes
B-group	B-group	digitalis	yes
I-group	I-group	glycosides	yes
O	O	(	no
O	O	heart	no
O	O	medicine	no
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	hypercalcemia	no
O	O	(	no
O	O	too	no
O	O	much	no
B-drug	B-drug	calcium	yes
O	O	in	yes
O	O	the	no
O	O	blood	yes
O	O	)	no
O	O	,	no
O	O	which	no
O	O	could	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	developing	no
O	O	an	no
O	O	irregular	no
O	O	heartbeat	no
O	O	.	no

B-drug	B-drug	Fentanyl	yes
O	O	Anesthesia	yes
O	O	:	no
O	O	Severe	no
O	O	hypotension	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	during	no
B-drug	B-drug	fentanyl	yes
O	O	anesthesia	yes
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	beta	yes
I-group	I-group	blocker	no
O	O	and	yes
O	O	a	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocker	no
O	O	.	no

O	O	Laboratory	no
O	O	Tests	no
O	O	If	no
O	O	significant	no
O	O	abnormal	no
O	O	laboratory	no
O	O	results	no
O	O	are	no
O	O	obtained	no
O	O	,	no
O	O	either	no
O	O	dosage	no
O	O	reduction	yes
O	O	with	yes
O	O	careful	no
O	O	monitoring	no
O	O	or	no
O	O	treatment	no
O	O	discontinuation	no
O	O	is	yes
O	O	recommended	no
O	O	,	no
O	O	depending	no
O	O	on	no
O	O	clinical	no
O	O	judgement	no
O	O	.	no

O	O	reliable	no
O	O	estimates	no
O	O	of	yes
O	O	the	no
O	O	prevalence	no
O	O	of	yes
O	O	reduced	yes
O	O	P450	no
O	O	2D6	no
O	O	isozyme	no
O	O	activity	yes
O	O	among	no
O	O	Asian	yes
O	O	,	no
O	O	African	no
O	O	and	yes
O	O	other	no
O	O	populations	no
O	O	are	no
O	O	not	no
O	O	yet	no
O	O	available	no
O	O	.	no

O	O	Although	no
B-brand	B-brand	ROMAZICON	yes
O	O	exerts	no
O	O	a	yes
O	O	slight	no
O	O	intrinsic	yes
O	O	anticonvulsant	no
O	O	effect	no
O	O	,	no
O	O	its	no
O	O	abrupt	no
O	O	suppression	no
O	O	of	yes
O	O	the	no
O	O	protective	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
B-group	B-group	benzodiazepine	yes
I-group	O	agonist	no
O	O	can	no
O	O	give	no
O	O	rise	no
O	O	to	no
O	O	convulsions	no
O	O	in	yes
O	O	epileptic	no
O	O	patients	no
O	O	.	no

O	O	In	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	a	yes
O	O	1-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	administered	no
O	O	as	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	6-mg	no
O	O	subcutaneous	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	sumatriptan	yes
O	O	.	no

O	O	In	yes
O	O	post-marketing	no
O	O	experience	no
O	O	,	no
O	O	bleeding	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	anticoagulants	no
O	O	and	yes
B-brand	B-brand	INDOCIN	yes
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	low-dose	no
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	and	yes
B-group	B-group	diuretic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	produce	no
O	O	an	no
O	O	additive	no
O	O	or	no
O	O	potentiating	no
O	O	effect	no
O	O	on	no
O	O	urine	no
O	O	flow	no
O	O	.	no

O	O	Maximal	no
O	O	hypotension	no
O	O	was	no
O	O	found	no
O	O	120	no
O	O	minutes	no
O	O	post	no
B-drug	B-drug	ethanol	yes
O	O	,	no
O	O	and	yes
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	300	yes
O	O	minutes	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	.	no

O	O	Since	no
B-group	O	bacteriostatic	yes
I-group	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	the	no
B-group	B-group	tetracycline	yes
I-group	I-group	class	no
I-group	O	of	yes
I-group	B-group	antibiotics	no
O	O	,	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	bactericidal	no
O	O	action	no
O	O	of	yes
B-group	B-group	penicillins	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	advisable	no
O	O	to	no
O	O	administer	no
O	O	these	no
O	O	drugs	no
O	O	concomitantly	no
O	O	.	no

O	O	In	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
B-brand	B-brand	Exjade	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

B-drug	B-drug	Dexfenfluramine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	other	no
B-group	B-group	serotoninergic	no
I-group	I-group	agents	yes
O	O	.	no

B-drug	I-drug	Nevirapine	yes

O	O	To	no
O	O	prevent	no
O	O	stomach	no
O	O	irritation	no
O	O	,	no
O	O	subjects	no
O	O	received	no
B-drug	B-drug	rantidine	no
I-drug	I-drug	hydrochloride	yes
O	O	before	no
O	O	each	no
O	O	experimental	no
O	O	session	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	raise	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	of	yes
B-brand	B-brand	Aranesp	yes
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	Deaths	no
O	O	from	no
O	O	severe	no
O	O	enterocolitis	no
O	O	,	no
O	O	diarrhea	no
O	O	,	no
O	O	and	yes
O	O	dehydration	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	elderly	no
O	O	patients	no
O	O	receiving	no
O	O	weekly	yes
B-drug	B-drug	leucovorin	yes
O	O	and	yes
B-drug	B-drug	fluorouracil	yes
O	O	.	no

O	O	The	no
O	O	response	no
O	O	rates	no
O	O	were	no
O	O	similar	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	groups	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	and	yes
O	B-drug	kaolin	yes
O	O	:	no
B-group	B-group	Antacids	no
O	O	and	yes
O	B-drug	kaolin	yes
O	O	can	no
O	O	reduce	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	chloroquine	yes
O	O	;	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	stress	no
O	O	and	yes
B-group	B-group	glucocorticoids	no
O	O	on	no
O	O	the	no
O	O	subjective	no
O	O	and	yes
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
B-group	B-group	psychostimulants	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	well	no
O	O	studied	no
O	O	in	yes
O	O	humans	no
O	O	.	no

B-drug_n	B-drug_n	filipin	no
O	O	was	no
O	O	more	no
O	O	potent	no
O	O	in	yes
O	O	lysing	no
O	O	human	yes
O	O	red	yes
O	O	blood	yes
O	O	cells	yes
O	O	,	no
O	O	whereas	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	was	no
O	O	more	no
O	O	potent	no
O	O	in	yes
O	O	inhibiting	no
O	O	yeast	no
O	O	cell	yes
O	O	growth	yes
O	O	;	no

O	O	Oral	yes
B-group	B-group	contraceptives	no
O	O	may	no
O	O	be	no
O	O	less	no
O	O	effective	no
O	O	while	no
O	O	you	no
O	O	are	no
O	O	taking	no
B-drug	B-drug	lymecycline	yes
O	O	.	no

O	O	AIMS/HYPOTHESIS	no
O	O	:	no
O	O	There	no
O	O	is	yes
O	O	evidence	no
O	O	that	no
B-drug	B-drug	insulin	yes
O	O	and	yes
O	B-drug	glucose	yes
O	O	cause	no
O	O	renal	no
O	O	and	yes
O	O	ocular	no
O	O	vasodilation	no
O	O	.	no

O	O	Latent	no
O	O	LCV	no
O	O	infection	no
O	O	is	yes
O	O	generally	no
O	O	asymptomatic	no
O	O	,	no
O	O	but	no
O	O	can	no
O	O	lead	no
O	O	to	no
O	O	B-cell	no
O	O	lymphomas	no
O	O	when	no
O	O	animals	no
O	O	are	no
O	O	immune	yes
O	O	suppressed	no
O	O	.	no

B-brand	B-brand	PEGASYS	yes
O	O	should	no
O	O	be	no
O	O	assumed	no
O	O	to	no
O	O	have	no
O	O	abortifacient	no
O	O	potential	no
O	O	.	no

B-group	B-group	Adrenergic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Some	no
O	O	individuals	no
O	O	receiving	no
B-brand	B-brand	ZYVOX	yes
O	O	may	no
O	O	experience	no
O	O	a	yes
O	O	reversible	no
O	O	enhancement	no
O	O	of	yes
O	O	the	no
O	O	pressor	no
O	O	response	no
O	O	to	no
O	O	indirect-acting	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	,	no
O	B-group	vasopressor	no
O	O	or	no
B-group	B-group	dopaminergic	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
O	O	Other	no
O	O	Drugs	no
O	O	on	no
O	O	the	no
O	O	Pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	Clonazepam	yes
O	O	:	no
O	O	Literature	no
O	O	reports	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	ranitidine	yes
O	O	,	no
O	O	an	no
O	O	agent	yes
O	O	that	no
O	O	decreases	no
O	O	stomach	no
O	O	acidity	no
O	O	,	no
O	O	does	no
O	O	not	no
O	O	greatly	no
O	O	alter	no
B-drug	B-drug	clonazepam	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	Substances	no
O	O	that	no
O	O	inhibit	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzyme	no
O	O	(	no
O	O	CYP3A4	no
O	O	)	no
O	O	activity	yes
O	O	may	no
O	O	decrease	no
O	O	metabolism	no
O	O	and	yes
O	O	increase	no
B-drug	B-drug	imatinib	yes
O	O	concentrations	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	well-controlled	no
O	O	study	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	lymphoma	no
O	O	on	no
O	O	combination	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	allopurinol	yes
O	O	did	no
O	O	not	no
O	O	increase	no
O	O	the	no
O	O	marrow	no
O	O	toxicity	no
O	O	of	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	cyclophosphamide	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	bleomycin	yes
O	O	,	no
B-drug	B-drug	procarbazine	yes
O	O	and/or	no
B-drug	B-drug	mechlorethamine	yes
O	O	.	no

O	O	Diabetic	no
O	O	patients	no
O	O	have	no
O	O	a	yes
O	O	20	yes
O	O	%	no
O	O	higher	no
O	O	risk	no
O	O	of	yes
O	O	depression	no
O	O	than	no
O	O	the	no
O	O	general	no
O	O	population	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	A	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	ketones	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	tests	no
O	O	using	no
B-drug	B-drug	nitroprusside	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	those	no
O	O	using	no
B-drug	B-drug	nitroferricyanide	yes
O	O	.	no

O	O	General	no
O	O	No	yes
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	lomefloxacin	yes
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	tests	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

B-group	B-group	Beta	yes
I-group	I-group	blockers	no
O	O	may	no
O	O	exacerbate	no
O	O	the	no
O	O	hypertensive	no
O	O	response	no
O	O	seen	no
O	O	with	yes
B-drug	B-drug	clonidine	yes
O	O	withdrawl	no
O	O	.	no

O	O	Potential	no
O	O	for	yes
O	O	reduction	yes
O	O	in	yes
O	B-group	anticonvulsant	no
O	O	and/or	no
B-drug	B-drug	efavirenz	yes
O	O	plasma	yes
O	O	levels	no
O	O	;	no

B-group	B-group	Beta-blockers	no
O	O	(	no
B-drug	B-drug	metoprolol	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	serum	yes
O	O	concentrations	no
O	O	and	yes
O	O	pharmacologic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	.	no

B-drug	B-drug	Aprepitant	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	the	no
O	O	P-glycoprotein	no
O	O	transporter	no
O	O	,	no
O	O	as	yes
O	O	demonstrated	no
O	O	by	no
O	O	the	no
O	O	lack	no
O	O	of	yes
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	a	yes
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	.	no

O	O	Hypotension	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	O	Diuretic	no
O	O	Therapy	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-drug	diuretics	no
O	O	and	yes
O	O	especially	no
O	O	those	no
O	O	in	yes
O	O	whom	no
B-group	O	diuretic	no
O	O	therapy	no
O	O	was	no
O	O	recently	no
O	O	instituted	no
O	O	,	no
O	O	may	no
O	O	occasionally	no
O	O	experience	no
O	O	an	no
O	O	excessive	no
O	O	reduction	yes
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	enalapril	yes
O	O	or	no
B-drug	B-drug	enalaprilat	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	No	yes
O	O	significant	no
O	O	differences	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug_n	B-drug	R-warfarin	no
O	O	or	no
B-drug_n	B-drug	S-warfarin	no
O	O	with	yes
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	given	no
O	O	as	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	FORADIL	yes
O	O	,	no
O	O	other	no
O	O	inhaled	no
O	O	medications	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	only	no
O	O	as	yes
O	O	directed	no
O	O	by	no
O	O	the	no
O	O	physician	no
O	O	.	no

O	O	With	yes
O	O	the	no
O	O	exception	no
O	O	of	yes
B-drug	B-drug	albuterol	yes
O	O	,	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	formal	no
O	O	studies	no
O	O	fully	no
O	O	evaluating	no
O	O	the	no
O	O	interaction	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	ATROVENT	yes
O	O	Inhalation	no
O	O	Aerosol	no
O	O	and	yes
O	O	these	no
O	O	drugs	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	effectiveness	no
O	O	.	no

O	O	We	no
O	O	demonstrate	no
O	O	that	no
O	O	the	no
O	O	conversion	yes
O	O	of	yes
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	to	no
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	by	no
O	O	an	no
O	O	NAD+-dependent	no
O	O	oxidation	no
O	O	is	yes
O	O	the	no
O	O	rate-limiting	no
O	O	step	no
O	O	in	yes
O	O	the	no
O	O	synthesis	no
O	O	of	yes
O	O	the	no
O	O	toxic	no
O	O	product	no
O	O	,	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	from	no
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	exposure	yes
O	O	to	no
O	O	environmental	no
O	B-drug_n	lead	no
O	O	may	no
O	O	alter	no
O	O	the	no
O	O	biological	no
O	O	and	yes
O	O	behavioral	no
O	O	responsiveness	no
O	O	of	yes
O	O	an	no
O	O	animal	no
O	O	to	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	were	no
O	O	detected	no
O	O	except	no
O	O	for	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	symptomatic	no
O	O	hypotension	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Excessive	no
O	O	neuromuscular	no
O	O	weakness	no
O	O	may	no
O	O	be	no
O	O	exacerbated	no
O	O	by	no
O	O	administration	no
O	O	of	yes
O	O	another	no
B-group	B-group	botulinum	yes
I-group	I-group	toxin	yes
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	resolution	no
O	O	of	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	a	yes
O	O	previously	no
O	O	administered	no
B-group	B-group	botulinum	yes
I-group	I-group	toxin	yes
O	O	.	no

O	O	SINCE	no
O	O	THE	no
O	O	CONCOMITANT	no
O	O	ADMINISTRATION	no
O	O	OF	yes
O	O	THESE	no
O	O	TWO	no
O	O	DRUGS	no
O	O	CAN	no
O	O	LEAD	no
O	O	TO	no
B-drug	B-drug	PHENYTOIN	yes
O	O	INTOXICATION	no
O	O	,	no
O	O	PRIOR	no
O	O	TO	no
O	O	ADMINISTERING	no
B-drug	B-drug	DISULFIRAM	yes
O	O	TO	no
O	O	A	yes
O	O	PATIENT	no
O	O	ON	no
B-drug	B-drug	PHENYTOIN	yes
O	O	THERAPY	no
O	O	,	no
O	O	A	yes
O	O	BASELINE	no
B-drug	B-drug	PHENYTOIN	yes
O	O	SERUM	yes
O	O	LEVEL	no
O	O	SHOULD	no
O	O	BE	no
O	O	OBTAINED	no
O	O	.	no

O	O	Other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	fenfluramine	yes
O	O	,	no
O	O	since	no
O	O	the	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	.	no

O	O	When	no
O	O	taken	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	ethanol	yes
O	O	,	no
O	O	a	yes
O	O	pharmacological	no
O	O	interaction	no
O	O	may	no
O	O	occur	no
O	O	,	no
O	O	potentiating	no
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	depression	no
O	O	produced	no
O	O	by	no
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	Cytochrome	no
O	O	P-450	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	to	no
O	O	be	no
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-brand	B-brand	Plenaxis	yes
O	O	.	no

B-group	B-group	Diuretics	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	diuretics	no
O	O	,	no
O	O	especially	no
O	O	those	no
O	O	with	yes
O	O	intravascular	no
O	O	volume	no
O	O	depletion	no
O	O	,	no
O	O	may	no
O	O	occasionally	no
O	O	experience	no
O	O	an	no
O	O	excessive	no
O	O	reduction	yes
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	fosinopril	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-drug	B-drug	Acetaminophen	yes
O	O	may	no
O	O	produce	no
O	O	false-positive	no
O	O	test	yes
O	O	results	no
O	O	for	yes
O	O	urinary	yes
O	O	5-hydroxyindoleacetic	no
O	O	acid	yes
O	O	.	no

O	O	Some	no
B-group	B-group	quinolone	no
I-group	I-group	antibiotics	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	have	no
O	O	similar	no
O	O	effects	no
O	O	and	yes
O	O	these	no
O	O	combinations	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	B-drug	Colestipol-Concomitant	no
O	O	intake	no
O	O	of	yes
B-drug	B-drug	colestipol	yes
O	O	and	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	.	no

O	O	Since	no
B-drug	B-drug	fondaparinux	yes
O	O	does	no
O	O	not	no
O	O	markedly	no
O	O	inhibit	no
O	O	CYP450s	no
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2A6	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	or	no
O	O	CYP3A4	no
O	O	)	no
O	O	in	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	fondaparinux	yes
I-drug	I-drug	sodium	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	significantly	no
O	O	interact	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	in	yes
O	O	vivo	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	metabolism	no
O	O	mediated	no
O	O	by	no
O	O	these	no
O	O	isozymes	no
O	O	.	no

O	O	Several	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	olanzapine	yes
O	O	has	no
O	O	benefits	no
O	O	against	yes
O	O	symptoms	no
O	O	of	yes
O	O	aggression	no
O	O	and	yes
O	O	agitation	no
O	O	,	no
O	O	while	no
O	O	other	no
O	O	studies	no
O	O	strongly	no
O	O	support	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
B-drug	B-drug	olanzapine	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	depressive	no
O	O	symptomatology	no
O	O	.	no

O	O	In	yes
O	O	view	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	risk	no
O	O	of	yes
O	O	dehydration	no
O	O	secondary	yes
O	O	to	no
O	O	vomiting	no
O	O	and/or	no
O	O	diarrhea	no
O	O	induced	no
O	O	by	no
B-brand	B-brand	CAMPTOSAR	yes
O	O	,	no
O	O	the	no
O	O	physician	no
O	O	may	no
O	O	wish	no
O	O	to	no
O	O	withhold	no
B-group	B-group	diuretics	no
O	O	during	no
O	O	dosing	no
O	O	with	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	and	yes
O	O	,	no
O	O	certainly	no
O	O	,	no
O	O	during	no
O	O	periods	no
O	O	of	yes
O	O	active	no
O	O	vomiting	no
O	O	or	no
O	O	diarrhea	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	decreased	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	by	no
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Diltiazem	yes
O	O	:	no
O	O	In	yes
O	O	patients	no
O	O	with	yes
O	O	mild	yes
O	O	to	no
O	O	moderate	no
O	O	hypertension	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	once	no
O	O	daily	no
O	O	,	no
O	O	as	yes
O	O	a	yes
O	O	tablet	no
O	O	formulation	no
O	O	comparable	no
O	O	to	no
O	O	230	no
O	O	mg	yes
O	O	of	yes
O	O	the	no
O	O	capsule	yes
O	O	formulation	no
O	O	,	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	120	no
O	O	mg	yes
O	O	3	yes
O	O	times	no
O	O	daily	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	2-fold	no
O	O	increase	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	simultaneous	no
O	O	1.7-fold	no
O	O	increase	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	AUC	no
O	O	.	no

O	O	This	no
O	O	increase	no
O	O	is	yes
O	O	greatest	no
O	O	in	yes
O	O	the	no
O	O	evening	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Should	no
O	O	Not	no
O	O	Be	no
O	O	Coadministered	no
O	O	With	yes
B-drug_n	B-brand	INVIRASE/Ritonavir	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	is	yes
O	O	eliminated	no
O	O	renally	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	LDL-C	no
O	O	reduction	yes
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	apparent	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	zaleplon	yes
O	O	and	yes
B-drug	B-drug	ibuprofen	yes
O	O	following	no
O	O	single	yes
O	O	dose	no
O	O	administration	no
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	and	yes
O	O	600	yes
O	O	mg	yes
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	of	yes
O	O	each	no
O	O	drug	yes
O	O	.	no

O	O	In	yes
O	O	controlled	no
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	however	no
O	O	,	no
B-group	B-drug	beta	yes
I-group	I-drug	blockers	no
O	O	including	no
B-drug	B-drug	metoprolol	yes
O	O	were	no
O	O	concurrently	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	felodipine	yes
O	O	and	yes
O	O	were	no
O	O	well	no
O	O	tolerated	no
O	O	.	no

O	O	When	no
B-drug	B-drug	amiodarone	yes
O	O	is	yes
O	O	added	no
O	O	to	no
B-drug	B-drug	flecainide	yes
O	O	therapy	no
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	flecainide	yes
O	O	levels	no
O	O	may	no
O	O	increase	no
O	O	two-fold	no
O	O	or	no
O	O	more	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	if	no
B-drug	B-drug	flecainide	yes
O	O	dosage	no
O	O	is	yes
O	O	not	no
O	O	reduced	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
B-drug	B-drug	Enoxacin	yes
O	O	may	no
O	O	raise	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	in	yes
O	O	some	no
O	O	individuals	no
O	O	.	no

O	O	Cardiovascular	no
O	O	collapse	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	simultaneously	no
O	O	with	yes
B-drug	O	varapamil	no
O	O	and	yes
B-drug	B-drug	dantrolene	yes
I-drug	I-drug	sodium	yes
O	O	is	yes
O	O	rare	no
O	O	.	no

B-drug	B-drug	tolbutamide	yes
O	O	;	no

O	O	In	yes
O	O	such	no
O	O	a	yes
O	O	case	no
O	O	,	no
O	O	the	no
O	O	peripheral	no
O	O	vascular	no
O	O	resistance	no
O	O	may	no
O	O	increase	no
O	O	.	no

O	O	9	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug_n	diethyl	yes
I-drug	I-drug_n	pyrocarbonate	no
O	O	could	no
O	O	be	no
O	O	reversed	no
O	O	by	no
O	B-drug_n	hydroxylamine	no
O	O	treatment	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	both	no
O	O	compounds	no
O	O	attenuate	no
B-drug	B-drug	morphine-induced	no
O	O	locomotion	no
O	O	in	yes
B-drug	B-drug	morphine-experienced	no
O	O	rats	no
O	O	.	no

B-group	B-group	ACE	no
I-group	I-group	Inhibitors	no
O	O	and	yes
B-group	B-group	Angiotensin	yes
I-group	I-group	II	yes
I-group	I-group	Receptor	yes
I-group	I-group	Antagonists	no
O	O	(	no
O	O	Hypertension	no
O	O	)	no
O	O	-	yes
O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	hypertension	no
O	O	,	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-brand	B-brand	INSPRA	yes
O	O	50	yes
O	O	to	no
O	O	100	yes
O	O	mg	yes
O	O	to	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	and	yes
B-group	B-group	angiotensin	yes
I-group	I-group	II	yes
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	increased	no
O	O	mean	no
O	O	serum	yes
O	O	potassium	yes
O	O	slightly	no
O	O	(	no
O	O	about	no
O	O	0.09-0.13	no
O	O	mEq/L	no
O	O	)	no
O	O	.	no

O	O	Although	no
O	O	results	no
O	O	have	no
O	O	varied	no
O	O	from	no
O	O	study	no
O	O	to	no
O	O	study	no
O	O	,	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	on	no
B-drug	B-drug	furosemide-stimulated	no
O	O	diuresis	no
O	O	,	no
O	O	natriuresis	no
O	O	,	no
O	O	and	yes
O	O	kaliuresis	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	reduced	yes
O	B-group	statin	no
O	O	efficacy	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	These	no
O	O	data	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	levetiracetam	yes
O	O	does	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
O	O	other	no
B-group	B-group	AEDs	no
O	O	and	yes
O	O	that	no
O	O	these	no
B-group	B-group	AEDs	no
O	O	do	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	.	no

O	O	Multiple-dose	no
O	O	administration	no
O	O	of	yes
O	O	the	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inducer	no
B-drug	B-drug	rifampin	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	every	no
O	O	24	yes
O	O	hours	no
O	O	,	no
O	O	q24h	no
O	O	,	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	)	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	reduced	yes
B-drug	B-drug	zaleplon	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	by	no
O	O	approximately	no
O	O	80	yes
O	O	%	no
O	O	.	no

O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	indicated	no
O	O	that	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	binds	no
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	drugs	no
O	O	.	no

O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	also	no
O	O	increase	no
O	O	risk	no
O	O	of	yes
O	O	thromboembolic	no
O	O	disorders	no
O	O	.	no

O	O	(	no
O	O	1968	no
O	O	,	no
O	O	1970	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	higher	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	penicillins	no
O	O	and	yes
B-drug	B-drug	cephaloridine	yes
O	O	reached	no
O	O	after	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	are	no
O	O	due	no
O	O	not	no
O	O	only	no
O	O	to	no
O	O	slower	no
O	O	renal	no
O	O	elimination	no
O	O	but	no
O	O	also	no
O	O	to	no
O	O	an	no
O	O	altered	no
O	O	distribution	no
O	O	in	yes
O	O	the	no
O	O	body	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	also	no
O	O	be	no
O	O	applied	no
O	O	for	yes
O	O	other	no
B-group	B-group	sympathomimetics	no
O	O	,	no
O	O	and	yes
O	O	for	yes
B-drug	B-drug	aminophylline	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	also	no
O	O	precipitate	no
O	O	arrhythmias	no
O	O	.	no

O	O	CNS	no
O	O	Drugs	no
O	O	-	yes
O	O	Given	no
O	O	the	no
O	O	primary	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	taken	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	centrally	no
O	O	acting	yes
O	O	drugs	no
O	O	.	no

O	O	nc1	no
O	O	40	yes
O	O	%	no
O	O	decrease	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	17	yes
O	O	%	no
O	O	decrease	no
O	O	,	no
O	O	57	yes
O	O	%	no
O	O	decrease	no
O	O	]	no

O	O	approximately	no
O	O	one-hundredth	no
O	O	of	yes
O	O	the	no
O	O	human	yes
O	O	recommended	no
O	O	dose	no
O	O	based	no
O	O	on	no
O	O	body	no
O	O	surface	yes
O	O	area	no
O	O	[	no
O	O	BSA	no
O	O	]	no
O	O	)	no
O	O	,	no
B-drug	B-drug	fulvestrant	yes
O	O	caused	no
O	O	a	yes
O	O	reversible	no
O	O	reduction	yes
O	O	in	yes
O	O	female	no
O	O	fertility	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	effects	no
O	O	on	no
O	O	embryo/fetal	no
O	O	development	no
O	O	consistent	no
O	O	with	yes
O	O	its	no
O	O	anti-estrogenic	no
O	O	activity	yes
O	O	.	no

O	O	The	no
O	O	appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	,	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

B-drug	B-drug	Morphine	yes
O	O	analgesia	no
O	O	and	yes
O	O	pupil	no
O	O	constriction	no
O	O	were	no
O	O	unaffected	no
O	O	by	no
B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	and	yes
O	O	differed	no
O	O	from	no
O	O	placebo	no
O	O	(	no
O	O	P	yes
O	O	<	no
O	O	.002	no
O	O	)	no
O	O	.	no

B-brand	B-brand	Survanta	yes
O	O	increased	no
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	dissolution	no
O	O	of	yes
B-drug	B-drug	budesonide	yes
O	O	in	yes
O	O	proportion	no
O	O	to	no
O	O	the	no
O	O	added	no
O	O	concentration	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	also	no
O	O	verified	no
O	O	by	no
O	O	equilibrium	no
O	O	solubilization	no
O	O	studies	no
O	O	.	no

O	O	Each	no
O	O	volunteer	no
O	O	was	no
O	O	administered	no
O	O	one	no
O	O	400-mg	no
B-drug	B-drug	ceftibuten	yes
O	O	capsule	yes
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	Dimenhydrinate	yes
O	O	may	no
O	O	decrease	no
B-group	B-group	emetic	no
O	O	response	no
O	O	to	no
B-drug	B-drug	apomorphine	yes
O	O	.	no

O	O	Electrocardiograms	no
O	O	were	no
O	O	done	no
O	O	at	yes
O	O	baseline	no
O	O	and	yes
O	O	on	no
O	O	the	no
O	O	last	no
O	O	day	no
O	O	of	yes
O	O	the	no
O	O	washout	no
O	O	period	no
O	O	and	yes
O	O	phase	no
O	O	2	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	variability	no
O	O	of	yes
O	O	individual	no
O	O	patient	no
O	O	response	no
O	O	,	no
O	O	multiple	no
O	O	interacting	no
O	O	mechanisms	no
O	O	with	yes
O	O	some	no
O	O	drugs	no
O	O	,	no
O	O	the	no
O	O	dependency	no
O	O	of	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	the	no
O	O	interaction	no
O	O	on	no
O	O	the	no
O	O	dosage	no
O	O	and	yes
O	O	duration	no
O	O	of	yes
O	O	therapy	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	possible	no
O	O	administration	no
O	O	of	yes
O	O	several	no
O	O	interacting	no
O	O	drugs	no
O	O	simultaneously	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	difficult	no
O	O	to	no
O	O	predict	no
O	O	the	no
O	O	direction	no
O	O	and	yes
O	O	degree	no
O	O	of	yes
O	O	the	no
O	O	ultimate	no
O	O	effect	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	on	no
B-group	B-group	anticoagulant	no
O	O	response	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	because	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	a	yes
O	O	few	no
O	O	spontaneous	no
O	O	reports	no
O	O	of	yes
O	O	prolonged	no
O	O	prothrombin	yes
O	O	times	no
O	O	,	no
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	bleeding	no
O	O	,	no
O	O	in	yes
B-drug	B-drug	etodolac-treated	no
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Doxepin	yes
O	O	is	yes
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	(	no
O	O	with	yes
O	O	CYP1A2	no
O	O	and	yes
O	O	CYP3A4	no
O	O	as	yes
O	O	minor	no
O	O	pathways	no
O	O	)	no
O	O	.	no

O	O	Release	yes
O	O	of	yes
O	O	arachidonic	yes
O	O	acid	yes
O	O	from	no
O	O	membrane	yes
O	O	phospholipids	yes
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	subsequent	no
O	O	synthesis	no
O	O	and	yes
O	O	release	yes
O	O	of	yes
O	O	vasoconstrictor	no
O	O	thromboxane	no
O	O	A2	yes
O	O	are	no
O	O	also	no
O	O	regulated	no
O	O	by	no
O	O	movement	no
O	O	of	yes
O	O	calcium	yes
O	O	ions	no
O	O	.	no

O	O	DESIGN	no
O	O	:	no
O	O	Cross-sectional	no
O	O	descriptive	no
O	O	study	no
O	O	.	no

B-drug	B-drug	Finasteride	yes
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	affect	no
O	O	the	no
O	O	cytochrome	no
O	O	P450-linked	no
O	O	drug-metabolizing	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	We	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	MCF-7	no
O	O	cells	yes
O	O	treated	no
O	O	with	yes
O	O	100	yes
O	O	nM	no
O	B-drug	1,25	no
O	I-drug	(	no
O	I-drug	OH	no
O	I-drug	)	no
O	I-drug	2D3	no
O	O	exhibit	no
O	O	characteristic	no
O	O	apoptotic	no
O	O	morphology	no
O	O	(	no
O	O	pyknotic	no
O	O	nuclei	no
O	O	,	no
O	O	chromatin	no
O	O	and	yes
O	O	cytoplasmic	no
O	O	condensation	no
O	O	,	no
O	O	nuclear	no
O	O	matrix	no
O	O	protein	yes
O	O	reorganization	no
O	O	)	no
O	O	within	no
O	O	48	yes
O	O	h	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	exists	no
O	O	for	yes
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	between	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	affect	no
O	O	the	no
O	O	CYP2B6	no
O	O	isoenzyme	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	orphenadrine	yes
O	O	and	yes
B-drug	B-drug	cyclophosphamide	yes
O	O	)	no
O	O	.	no

O	O	Dose	no
O	O	adjustment	no
O	O	of	yes
B-brand	B-brand	Sensipar	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	and	yes
O	O	PTH	yes
O	O	and	yes
O	O	serum	yes
O	O	calcium	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	initiates	no
O	O	or	no
O	O	discontinues	no
O	O	therapy	no
O	O	with	yes
O	O	a	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	;	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	significant	no
O	O	differences	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	groups	no
O	O	,	no
O	O	achieving	no
O	O	a	yes
O	O	maximum	no
O	O	relaxation	no
O	O	of	yes
O	O	>	no
O	O	95	no
O	O	%	no
O	O	at	yes
O	O	a	yes
O	O	concentration	no
O	O	of	yes
O	O	35	yes
O	O	micromol/l	no
O	O	.	no

O	O	It	no
O	O	was	no
O	O	concluded	no
O	O	that	no
O	O	,	no
O	O	although	no
B-drug	B-drug	gentamycin	no
O	O	did	no
O	O	augment	no
O	O	the	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	of	yes
B-drug	B-drug	atracurium	yes
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	was	no
O	O	minimal	no
O	O	.	no

O	O	Whether	no
O	O	this	no
O	O	interaction	no
O	O	also	no
O	O	occurs	no
O	O	with	yes
O	O	the	no
O	O	intravenous	yes
O	O	,	no
O	O	topical	yes
O	O	or	no
O	O	vaginal	no
O	O	preparations	no
O	O	of	yes
B-drug	B-drug	miconazole	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	The	no
O	O	mode	no
O	O	of	yes
O	O	toxic	no
O	O	action	no
O	O	of	yes
O	O	the	no
B-group	O	pesticide	no
I-group	B-drug_n	gliftor	no
O	O	:	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug_n	B-drug_n	1,3-difluoroacetone	no
I-drug_n	O	to	no
I-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	.	no

O	O	.	no

O	O	Rare	no
O	O	cases	no
O	O	of	yes
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	At	yes
O	O	75	yes
O	O	%	no
O	O	recovery	no
O	O	of	yes
O	O	fade	no
O	O	,	no
O	O	hoof	no
O	O	twitch	no
O	O	was	no
O	O	87	no
O	O	+/-	no
O	O	3	yes
O	O	%	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	alone	no
O	O	and	yes
O	O	82	no
O	O	+/-	no
O	O	4	yes
O	O	%	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	plus	yes
B-drug	B-drug	gentamycin	no
O	O	.	no

B-drug	B-drug	CYP3A4	no
I-drug	O	Inhibitors	no
B-drug	O	Felodipine	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	B-drug	CYP3A4	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	if	no
B-group	B-group	glucocorticoid	no
O	O	replacement	no
O	O	is	yes
O	O	needed	no
O	O	,	no
B-drug	B-drug	hydrocortisone	yes
O	O	should	no
O	O	be	no
O	O	prescribed	no
O	O	.	no

O	O	Hepatic	no
O	O	Impairment	no
O	O	There	no
O	O	are	no
O	O	currently	no
O	O	no	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	SPRYCEL	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	liver	yes
O	O	function	no
O	O	(	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	excluded	no
O	O	patients	no
O	O	with	yes
O	O	ALT	no
O	O	and/or	no
O	O	AST	no
O	O	2.5	yes
O	O	times	no
O	O	the	no
O	O	upper	no
O	O	limit	no
O	O	of	yes
O	O	the	no
O	O	normal	yes
O	O	range	no
O	O	and/or	no
O	O	total	yes
O	O	bilirubin	no
O	O	2	yes
O	O	times	no
O	O	the	no
O	O	upper	no
O	O	limit	no
O	O	of	yes
O	O	the	no
O	O	normal	yes
O	O	range	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Studies	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	to	no
O	O	healthy	no
O	O	men	no
O	O	(	no
O	O	n=	no
O	O	14	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	a	yes
O	O	change	no
O	O	in	yes
O	O	the	no
O	O	steady	no
O	O	state	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	when	no
B-drug	B-drug	ibuprofen	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	subjects	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	carefully	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

B-drug	B-drug	Acarbose	yes
O	O	may	no
O	O	affect	no
B-drug	B-drug	digoxin	yes
O	O	bioavailabillty	no
O	O	and	yes
O	O	may	no
O	O	require	no
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	by	no
O	O	16	yes
O	O	%	no
O	O	(	no
O	O	90	yes
O	O	%	no
O	O	confidence	no
O	O	interval	no
O	O	:	no
O	O	8-23	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	decrease	no
O	O	mean	no
O	O	C	yes
O	O	max	no
B-drug	B-drug	digoxin	yes
O	O	by	no
O	O	26	yes
O	O	%	no
O	O	(	no
O	O	90	yes
O	O	%	no
O	O	confidence	no
O	O	interval	no
O	O	:	no
O	O	16-34	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	decrease	no
O	O	mean	no
O	O	trough	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	by	no
O	O	9	yes
O	O	%	no
O	O	(	no
O	O	90	yes
O	O	%	no
O	O	confidence	no
O	O	limit	no
O	O	:	no
O	O	19	yes
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	2	yes
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	.	no

O	O	According	no
O	O	to	no
O	O	Gibaldi	no
O	O	et	no
O	O	al	yes
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	hydroxyurea	yes
O	O	and	yes
O	O	other	no
B-group	O	myelosuppressive	no
I-group	O	agents	yes
O	O	or	no
O	O	radiation	no
O	O	therapy	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	likelihood	no
O	O	of	yes
O	O	bone	no
O	O	marrow	no
O	O	depression	no
O	O	or	no
O	O	other	no
O	O	adverse	no
O	O	events	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	may	no
O	O	inhibit	no
O	O	both	no
O	O	synthetic	yes
O	O	and	yes
O	O	catabolic	no
O	O	enzymes	yes
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	the	no
O	O	frequent	no
O	O	occurrence	no
O	O	of	yes
O	O	severe	no
O	O	and	yes
O	O	prolonged	no
O	O	thrombocytopenia	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	benefits	no
O	O	of	yes
O	O	medications	no
O	O	which	no
O	O	interfere	no
O	O	with	yes
O	O	platelet	yes
O	O	function	no
O	O	and/or	no
O	O	anticoagulation	no
O	O	should	no
O	O	be	no
O	O	weighed	no
O	O	against	yes
O	O	the	no
O	O	potential	no
O	O	increased	no
O	O	risks	no
O	O	of	yes
O	O	bleeding	no
O	O	and	yes
O	O	hemorrhage	no
O	O	.	no

B-drug	B-drug_n	Carbamazepine	yes
I-drug	I-drug_n	epoxide	no
O	O	steady-state	no
O	O	Cmin	no
O	O	concentrations	no
O	O	increased	no
O	O	57	yes
O	O	%	no
O	O	from	no
O	O	1.0	no
O	O	0.3	yes
O	O	to	no
O	O	1.6	no
O	O	0.4	no
O	O	micrograms/mL	no
O	O	with	yes
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	.	no

O	O	LABORATORY	no
O	O	TEST	yes
O	O	FINDINGS	no
O	O	Asymptomatic	no
O	O	,	no
O	O	transitory	no
O	O	changes	no
O	O	in	yes
O	O	serum	yes
B-drug	O	iron	yes
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	.	no

O	O	In	yes
O	O	separate	no
O	O	single	yes
O	O	or	no
O	O	multiple	no
O	O	dose	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	chlorthalidone	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	propanolol	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	metoclopramide	yes
O	O	,	no
B-drug	B-drug	propantheline	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug_n	fosinoprilat	no
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	fosinopril	yes
O	O	with	yes
O	O	any	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	Caution	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	which	no
O	O	can	no
O	O	affect	no
O	O	the	no
O	O	metabolism	no
O	O	and	yes
O	O	uptake	no
O	O	of	yes
O	O	circulating	no
O	O	amines	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	if	no
B-drug	B-drug	tacrolimus	yes
O	O	and	yes
B-drug	B-drug	bosentan	yes
O	O	are	no
O	O	used	no
O	O	together	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	isoniazid	yes
O	O	when	no
B-drug	B-drug	disulfiram	yes
O	O	is	yes
O	O	given	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	for	yes
O	O	the	no
O	O	appearance	no
O	O	of	yes
O	O	unsteady	no
O	O	gait	no
O	O	or	no
O	O	marked	no
O	O	changes	no
O	O	in	yes
O	O	mental	no
O	O	status	no
O	O	;	no

B-drug_n	B-drug	ADL-8-2698	no
O	O	is	yes
O	O	a	yes
O	O	novel	no
O	B-group	peripherally	no
O	I-group	restricted	no
B-group	I-group	opioid	no
I-group	I-group	antagonist	yes
O	O	that	no
O	O	may	no
O	O	selectively	no
O	O	prevent	no
B-group	B-group	opioid-induced	no
O	O	gastrointestinal	no
O	O	effects	no
O	O	without	no
O	O	reversing	no
O	O	analgesia	no
O	O	.	no

O	O	This	no
O	O	was	no
O	O	due	no
O	O	to	no
O	O	reductions	no
O	O	in	yes
O	O	both	no
O	O	renal	no
O	O	clearance	no
O	O	(	no
O	O	from	no
O	O	105	yes
O	O	+/-	no
O	O	39	no
O	O	to	no
O	O	84	no
O	O	+/-	no
O	O	15	yes
O	O	ml/min	no
O	O	)	no
O	O	(	no
O	O	p	yes
O	O	less	no
O	O	than	no
O	O	0.05	no
O	O	)	no
O	O	and	yes
O	O	nonrenal	no
O	O	clearance	no
O	O	(	no
O	O	from	no
O	O	130	no
O	O	+/-	no
O	O	38	no
O	O	to	no
O	O	88	no
O	O	+/-	no
O	O	20	yes
O	O	ml/min	no
O	O	)	no
O	O	(	no
O	O	p	yes
O	O	less	no
O	O	than	no
O	O	0.01	no
O	O	)	no
O	O	.	no

O	O	Use	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	Diabetics	no
O	O	should	no
O	O	discuss	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	supplements	no
O	O	with	yes
O	O	their	no
O	O	physicians	no
O	O	and	yes
O	O	note	no
O	O	if	no
O	O	the	no
O	O	supplements	no
O	O	affect	no
O	O	their	no
O	O	glycemic	no
O	O	control	no
O	O	.	no

O	O	Infusion	no
O	O	of	yes
B-drug	B-drug	arginine	yes
O	O	alone	no
O	O	markedly	no
O	O	decreased	no
O	O	the	no
O	O	amount	no
O	O	of	yes
O	O	extractable	no
O	O	pancreatic	yes
O	O	insulin	yes
O	O	and	yes
O	O	glucagon	yes
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
B-drug	B-drug	Vardenafil	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	and	yes
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	potentiate	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	bleeding	no
O	O	time	no
O	O	caused	no
O	O	by	no
B-brand	B-brand	aspirin	yes
O	O	(	no
O	O	two	no
O	O	81	no
O	O	mg	yes
O	O	tablets	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	12-week	no
O	O	endoscopy	no
O	O	study	no
O	O	conducted	no
O	O	in	yes
O	O	OA	no
O	O	patients	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	difference	no
O	O	in	yes
O	O	the	no
O	O	cumulative	no
O	O	incidence	no
O	O	of	yes
O	O	endoscopic	no
O	O	gastroduodenal	no
O	O	ulcers	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	low-dose	no
O	O	(	no
O	O	81	no
O	O	mg	yes
O	O	)	no
O	O	enteric	no
O	O	coated	no
B-brand	B-brand	aspirin	yes
O	O	plus	yes
B-brand	B-brand	VIOXX	yes
O	O	25	yes
O	O	mg	yes
O	O	daily	no
O	O	,	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	those	no
O	O	taking	no
B-drug	B-drug	ibuprofen	yes
O	O	2400	no
O	O	mg	yes
O	O	daily	no
O	O	alone	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	under	no
O	O	careful	no
O	O	observation	no
O	O	.	no

O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	are	no
O	O	3	yes
O	O	%	no
O	O	to	no
O	O	4	yes
O	O	%	no
O	O	lower	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	after	no
O	O	administration	no
O	O	of	yes
O	O	125	yes
O	O	mg	yes
B-brand	B-brand	Neurontin	yes
O	O	and	yes
O	O	21	yes
O	O	%	no
O	O	to	no
O	O	22	no
O	O	%	no
O	O	lower	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	after	no
O	O	administration	no
O	O	of	yes
O	O	500	yes
O	O	mg	yes
B-brand	B-brand	Neurontin	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	with	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	increased	no
O	O	possibility	no
O	O	of	yes
O	O	gastrointestinal	no
O	O	toxicity	no
O	O	,	no
O	O	with	yes
O	O	little	no
O	O	or	no
O	O	no	yes
O	O	increase	no
O	O	in	yes
O	O	efficacy	no
O	O	.	no

O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	coumarin	yes
I-group	I-group	derivatives	no
O	O	(	no
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
I-group	I-group	antagonists	no
O	O	)	no
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	affect	no
O	O	platelet	yes
O	O	function	no
O	O	may	no
O	O	also	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

B-drug_n	B-drug	1,25-Dihydroxycholecalciferol	yes
I-drug_n	I-drug	D3	yes
O	O	(	no
O	B-drug	1,25	no
O	I-drug	(	no
O	I-drug	OH	no
O	I-drug	)	no
O	I-drug	2D3	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	active	no
O	O	metabolite	yes
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	,	no
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	breast	no
O	O	cancer	no
O	O	cell	yes
O	O	growth	yes
O	O	both	no
O	O	in	yes
O	O	vivo	no
O	O	and	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	cmaxSS	no
O	O	(	no
O	O	Peak	no
O	O	plasma	yes
O	O	concentration	no
O	O	)	no

B-drug	B-drug	Dexbrompheniramine	yes
O	O	can	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
B-group	B-group	anticholinergics	no
O	O	or	no
O	O	other	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	(	no
O	O	anticholinergic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	these	no
O	O	medications	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	antihistamines	no
O	O	may	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	and	yes
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	reactions	no
O	O	include	no
O	O	fever	no
O	O	,	no
O	O	chills	no
O	O	,	no
O	O	nausea	no
O	O	,	no
O	O	vomiting	no
O	O	,	no
O	O	pruritus	no
O	O	,	no
O	O	rash	no
O	O	,	no
O	O	diarrhea	no
O	O	,	no
O	O	hypotension	no
O	O	,	no
O	O	edema	no
O	O	,	no
O	O	and	yes
O	O	oliguria	no
O	O	.	no

O	O	Increases	no
O	O	of	yes
O	O	22	no
O	O	%	no
O	O	with	yes
B-drug_n	B-drug_n	MHD	no
O	O	and	yes
O	O	47	no
O	O	%	no
O	O	with	yes
B-drug	B-drug	oxcarbazepine	yes
O	O	were	no
O	O	observed	no
O	O	.	no

O	O	Interaction	no
O	O	of	yes
O	O	the	no
O	O	constituents	no
O	O	of	yes
B-drug	O	alcoholic	no
O	O	beverages	no
O	O	in	yes
O	O	the	no
O	O	promotion	no
O	O	of	yes
O	O	liver	yes
O	O	damage	no
O	O	.	no

O	O	Resistance	no
O	O	was	no
O	O	measured	no
O	O	near	no
O	O	the	no
O	O	placental	no
O	O	margin	no
O	O	after	no
O	O	spontaneous	no
O	O	term	no
O	O	delivery	no
O	O	.	no

O	O	Elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	with	yes
B-drug	B-drug	norfloxacin	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes

O	O	Geriatric	no
O	O	Use	no
O	O	Younger	no
O	O	patients	no
O	O	have	no
O	O	higher	no
O	O	virologic	no
O	O	response	no
O	O	rates	no
O	O	than	no
O	O	older	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Rifampin	yes

O	O	The	no
O	O	magnitude	no
O	O	and	yes
O	O	relative	no
O	O	importance	no
O	O	of	yes
O	O	the	no
O	O	effects	no
O	O	noted	no
O	O	below	no
O	O	are	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	patient	no
O	O	specific	no
O	O	and	yes
O	O	may	no
O	O	vary	no
O	O	by	no
O	O	such	no
O	O	factors	no
O	O	as	yes
O	O	age	no
O	O	,	no
O	O	gender	no
O	O	,	no
O	O	race	no
O	O	,	no
O	O	intercurrent	no
O	O	illnesses	no
O	O	,	no
O	O	dose	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	,	no
O	O	additional	no
O	O	concomitant	no
O	O	medications	no
O	O	,	no
O	O	and	yes
O	O	timing	no
O	O	of	yes
O	O	drug	yes
O	O	administration	no
O	O	.	no

O	B-group	Phenothiazine-related	no
O	I-group	compounds	no
O	O	and	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	may	no
O	O	have	no
O	O	additive	no
O	O	hypotensite	no
O	O	effects	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	inhibition	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	s	yes
O	O	metabolism	no
O	O	.	no

O	O	Lethargy	no
O	O	and	yes
O	O	somnolence	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	following	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	REVIA	yes
O	O	and	yes
B-drug	B-drug	thioridazine	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	and	yes
B-drug	B-drug	methadone	yes
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	a	yes
O	O	non-matched	no
O	O	historicalcontrol	no
O	O	group	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	30	yes
O	O	%	no
O	O	,	no
O	O	27	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	25	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	amprenavir	yes
O	O	AUC	no
O	O	,	no
O	O	Cmax	no
O	O	,	no
O	O	andCmin	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	(	no
O	O	drying	no
O	O	)	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	metabolism	no
O	O	studies	no
O	O	have	no
O	O	suggested	no
O	O	that	no
B-drug	B-drug	decitabine	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	the	no
O	O	human	yes
O	O	liver	yes
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

O	O	For	yes
O	O	the	no
O	O	identification	no
O	O	of	yes
O	O	"	no
O	O	limit	no
O	O	values	no
O	O	"	no
O	O	,	no
O	O	it	no
O	O	has	no
O	O	generally	no
O	O	been	no
O	O	suggested	no
O	O	in	yes
O	O	the	no
O	O	literature	no
O	O	that	no
O	O	the	no
O	O	possible	no
O	O	effects	no
O	O	deriving	no
O	O	from	no
O	O	multiple	no
O	O	exposure	yes
O	O	be	no
O	O	considered	no
O	O	as	yes
O	O	additive	no
O	O	.	no

O	O	Cancer	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	:	no
O	O	basic	yes
O	O	science	no
O	O	and	yes
O	O	clinical	no
O	O	aspects	no
O	O	.	no

O	O	Rare	no
O	O	cases	no
O	O	of	yes
O	O	serious	no
O	O	cardiovascular	no
O	O	adverse	no
O	O	events	no
O	O	,	no
O	O	including	no
O	O	electrocardiographic	no
O	O	QT/QTc	no
O	O	interval	no
O	O	prolongation	no
O	O	,	no
O	O	cardiac	no
O	O	arrest	no
O	O	,	no
O	O	torsades	no
O	O	de	yes
O	O	pointes	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	.	no

O	O	Other	no
O	O	Agents	yes
O	O	:	no
B-brand	B-brand	PRINIVIL	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	nitrates	no
O	O	and/or	no
B-drug	B-drug	digoxin	yes
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	Animal	no
O	O	studies	no
O	O	also	no
O	O	suggest	no
O	O	an	no
O	O	increased	no
O	O	potential	no
O	O	for	yes
O	O	seizures	no
O	O	when	no
O	O	these	no
O	O	2	yes
O	O	drugs	no
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	important	no
O	O	that	no
O	O	patients	no
O	O	understand	no
O	O	how	no
O	O	to	no
O	O	use	no
B-brand	B-brand	FORADIL	yes
O	O	(	no
B-drug	B-drug	formoterol	yes
I-drug	I-drug	fumarate	yes
O	O	)	no
O	O	capsules	no
O	O	with	yes
O	O	the	no
O	O	supplied	no
O	O	AerolizerTM	no
O	O	inhalation	no
O	O	device	no
O	O	and	yes
O	O	how	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	relation	no
O	O	to	no
O	O	other	no
O	O	asthma	no
O	O	or	no
O	O	COPD	no
O	O	medications	no
O	O	they	no
O	O	are	no
O	O	taking	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	and	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	telithromycin	yes
O	O	,	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	voriconazole	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	itraconazole	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	but	no
O	O	should	no
O	O	be	no
O	O	undertaken	no
O	O	with	yes
O	O	caution	no
O	O	because	no
O	O	of	yes
O	O	similar	no
O	O	potential	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	suggest	no
O	O	that	no
O	O	coadministration	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	inhibitors	no
O	O	to	no
O	O	PMs	no
O	O	will	no
O	O	not	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	atomoxetine	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	dofetillide	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	.	no

B-drug	B-drug	miconazole	yes
O	O	;	no

O	O	An	no
O	O	individual	no
O	O	who	no
O	O	is	yes
O	O	stable	no
O	O	on	no
O	O	a	yes
O	O	given	no
O	O	dose	no
O	O	of	yes
B-group	B-group	TCA	no
O	O	may	no
O	O	become	no
O	O	abruptly	no
O	O	toxic	no
O	O	when	no
O	O	given	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	inhibiting	no
O	O	drugs	no
O	O	as	yes
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-group	B-group	anticoagulants	no
O	O	are	no
O	O	given	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-brand	B-brand	Atromid-S	yes
O	O	.	no

O	O	Because	no
B-group	B-group	tetracyclines	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	depress	no
O	O	plasma	yes
O	O	prothrombin	yes
O	O	activity	yes
O	O	,	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	on	no
B-group	B-group	anticoagulant	no
O	O	therapy	no
O	O	may	no
O	O	require	no
O	O	downward	no
O	O	adjustment	no
O	O	of	yes
O	O	their	no
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	.	no

B-drug	B-drug	Caspofungin	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	P-glycoprotein	no
O	O	and	yes
O	O	is	yes
O	O	a	yes
O	O	poor	no
O	O	substrate	yes
O	O	for	yes
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	Acarbose	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	control	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	containing	yes
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydroxide	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
I-drug	I-drug	hydroxide	yes
O	O	reduce	no
O	O	the	no
O	O	oral	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	enoxacin	yes
O	O	by	no
O	O	75	yes
O	O	%	no
O	O	.	no

O	B-drug	Green	yes
O	I-drug	tea	no
B-group	I-drug	polyphenols	no
O	O	as	yes
O	O	potent	no
O	B-drug	enhancers	no
O	O	of	yes
O	O	glucocorticoid-induced	no
O	O	mouse	yes
O	O	mammary	no
O	O	tumor	yes
O	O	virus	yes
O	O	gene	yes
O	O	expression	no
O	O	.	no

O	O	1-	no
O	O	nc	no
O	O	denotes	no
O	O	a	yes
O	O	mean	no
O	O	change	no
O	O	of	yes
O	O	less	no
O	O	than	no
O	O	10	yes
O	O	%	no
O	O	2-	no
O	O	Pediatrics	no
O	O	3-	no
O	O	Mean	no
O	O	increase	no
O	O	in	yes
O	O	adults	no
O	O	at	yes
O	O	high	yes
B-brand	B-brand	Trileptal	yes
O	O	doses	no
O	O	In	yes
O	O	vivo	no
O	O	,	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	increased	no
O	O	by	no
O	O	up	no
O	O	to	no
O	O	40	yes
O	O	%	no
O	O	,	no
O	O	when	no
B-brand	B-brand	Trileptal	yes
O	O	was	no
O	O	given	no
O	O	at	yes
O	O	doses	no
O	O	above	no
O	O	1200	no
O	O	mg/day	no
O	O	.	no

O	O	-	yes
B-group	B-group	Androgens	no
O	O	(	no
O	O	male	no
O	O	hormones	no
O	O	)	no
O	O	or	no

B-drug	B-drug	Cimetidine	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	vardenafil	yes
O	O	bioavailability	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	and	yes
O	O	maximum	no
O	O	concentration	no
O	O	(	no
O	O	Cmax	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	vardenafil	yes
O	O	when	no
O	O	co-administered	no
O	O	with	yes
O	O	20	yes
O	O	mg	yes
B-drug	B-drug	Vardenafil	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	furosemide	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	diuretic	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	While	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	chronic	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	carbamazepine	yes
O	O	therapy	no
O	O	on	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	are	no
O	O	unknown	no
O	O	,	no
O	O	slightly	no
O	O	shorter	no
O	O	durations	no
O	O	of	yes
O	O	neuromuscular	no
O	O	block	yes
O	O	may	no
O	O	be	no
O	O	anticipated	no
O	O	and	yes
O	O	infusion	no
O	O	rate	no
O	O	requirements	no
O	O	may	no
O	O	be	no
O	O	higher	no
O	O	.	no

O	O	Animal	no
O	O	toxicology	no
O	O	studies	no
O	O	showed	no
O	O	increased	no
O	B-drug	DEET	no
O	O	toxicity	no
O	O	when	no
O	B-drug	DEET	no
O	O	was	no
O	O	included	no
O	O	as	yes
O	O	proof	no
O	O	of	yes
O	O	the	no
O	O	formulation	no
O	O	.	no

B-drug	B-drug	Itraconazole	yes
B-drug	I-drug	Ketoconazole	yes
I-drug	I-drug	Erythromycin	yes
B-drug	I-drug	Clarithromycin	yes
I-drug	I-drug	Telithromycin	yes
B-group	B-group	HIV	no
I-group	I-group	protease	yes
I-group	I-group	inhibitors	no
B-drug	B-drug	Nefazodone	yes
I-drug	I-drug	Cyclosporine	yes
O	O	Large	no
O	O	quantities	no
O	O	of	yes
O	O	grapefruit	no
O	O	juice	no
O	O	(	no
O	O	1	yes
O	O	quart	no
O	O	daily	no
O	O	)	no

O	O	The	no
B-group	B-group	fluoroquinolones	no
O	O	for	yes
O	O	urinary	yes
O	O	tract	no
O	O	infections	no
O	O	:	no
O	O	a	yes
O	O	review	no
O	O	.	no

O	O	A	yes
O	O	clinical	no
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	(	no
O	O	n=24	no
O	O	)	no
O	O	demonstrated	no
O	O	that	no
O	O	mixing	no
B-brand	B-brand	NovoLog	yes
O	O	with	yes
O	B-drug	NPH	yes
O	I-drug	human	yes
B-drug	I-drug	insulin	yes
O	O	immediately	no
O	O	before	no
O	O	injection	yes
O	O	produced	no
O	O	some	no
O	O	attenuation	no
O	O	in	yes
O	O	the	no
O	O	peak	no
O	O	concentration	no
O	O	of	yes
B-brand	B-brand	NovoLog	yes
O	O	,	no
O	O	but	no
O	O	that	no
O	O	the	no
O	O	time	no
O	O	to	no
O	O	peak	no
O	O	and	yes
O	O	the	no
O	O	total	yes
O	O	bioavailability	no
O	O	of	yes
B-brand	B-brand	NovoLog	yes
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	affected	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

O	O	Hyperglycaemia	no
O	O	increased	no
O	O	all	yes
O	O	the	no
O	O	renal	no
O	O	and	yes
O	O	ocular	no
O	O	parameters	no
O	O	studied	no
O	O	.	no

O	O	Increase	no
O	O	daily	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	.	no

O	O	After	no
O	O	30	yes
O	O	min	no
O	O	,	no
O	O	fasting	no
O	O	glycemia	no
O	O	was	no
O	O	measured	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	celecoxib	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	inhibit	no
O	O	2C9	no
O	O	should	no
O	O	be	no
O	O	done	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	B-drug	Potassium	yes
O	O	Supplements	no
O	O	and	yes
B-group	B-group	Potassium-Sparing	no
I-group	I-group	Diuretics	no
B-brand	O	Lotensin	yes
O	O	can	no
O	O	attenuate	no
O	O	potassium	yes
O	O	loss	no
O	O	caused	no
O	O	by	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	In	yes
O	O	case	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	toxicity	no
O	O	and/or	no
O	O	elevated	no
O	O	serum	yes
B-drug	B-drug	theophylline	yes
O	O	levels	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	while	no
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	erythromycin	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	In	yes
O	O	post-marketing	no
O	O	experience	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	both	no
O	O	increases	no
O	O	and	yes
O	O	decreases	no
O	O	in	yes
B-drug	B-drug	phenytoin	yes
O	O	levels	no
O	O	with	yes
B-drug	B-drug	dexamethasone	yes
O	O	co-administration	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	alterations	no
O	O	in	yes
O	O	seizure	no
O	O	control	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	binding	no
O	O	studies	no
O	O	with	yes
O	O	human	yes
O	O	serum	yes
O	O	proteins	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	glipizide	yes
O	O	binds	no
O	O	differently	no
O	O	than	no
B-drug	B-drug	tolbutamide	yes
O	O	and	yes
O	O	does	no
O	O	not	no
O	O	interact	no
O	O	with	yes
B-group	B-group	salicylate	yes
O	O	or	no
B-drug	B-drug	dicumarol	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	differ	no
O	O	in	yes
O	O	their	no
O	O	effectiveness	no
O	O	when	no
O	O	used	no
O	O	with	yes
B-brand	B-brand	Accutane	yes
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	dantrolene	yes
O	O	may	no
O	O	potentiate	no
B-drug	B-drug	vecuronium-induced	no
O	O	neuromuscular	no
O	O	block	yes
O	O	.	no

O	O	This	no
O	O	decrease	no
O	O	in	yes
O	O	bioavailability	no
O	O	was	no
O	O	about	no
O	O	5	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	gabapentin	yes
O	O	was	no
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	after	no
B-brand	B-brand	Maalox	no
O	O	.	no

B-drug	B-drug	Folic	yes
I-drug	I-drug	acid	yes
O	O	supplements	no
O	O	can	no
O	O	correct	no
O	O	the	no
O	O	anemia	no
O	O	associated	no
O	O	with	yes
B-drug	O	vitamin	yes
O	O	B12	yes
O	O	deficiency	no
O	O	.	no

O	O	Taking	no
B-drug	B-drug	amyl	yes
I-drug	I-drug	nitrite	yes
O	O	after	no
O	O	drinking	no
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	worsen	no
O	O	side	no
O	O	effects	no
O	O	and	yes
O	O	may	no
O	O	cause	no
O	O	severe	no
O	O	hypotension	no
O	O	and	yes
O	O	cardiovascular	no
O	O	collapse	no
O	O	.	no

B-drug	B-drug	Indomethacin	yes
O	O	was	no
O	O	also	no
O	O	ineffective	no
O	O	in	yes
O	O	altering	no
O	B-drug_n	resveratrol	yes
O	O	activity	yes
O	O	in	yes
O	O	arteries	no
O	O	from	no
O	O	both	no
O	O	lean	no
O	O	and	yes
O	O	dietary-obese	no
O	O	rats	no
O	O	.	no

B-brand	B-brand	INDOCIN	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	serum	yes
O	O	concentration	no
O	O	and	yes
O	O	prolong	no
O	O	the	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Considerable	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	if	no
B-brand	B-brand	PEGANONE	yes
O	O	is	yes
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	Phenurone	yes
O	O	(	no
B-drug	B-drug	phenacemide	yes
O	O	)	no
O	O	since	no
O	O	paranoid	no
O	O	symptoms	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

B-drug	B-drug	Paroxetine	yes
O	O	produced	no
O	O	only	no
O	O	minor	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	.	no

O	O	Formulation	no
O	O	of	yes
O	O	fluorescence	no
O	O	labelled	no
B-drug	B-drug	bacitracin	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	in	yes
O	O	unconjugated	no
B-drug_n	B-drug_n	NaCMC	no
O	O	(	no
O	O	1	yes
O	O	%	no
O	O	m/v	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	improve	no
O	O	the	no
O	O	permeation	no
O	O	,	no
O	O	however	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	1	yes
O	O	%	no
O	O	(	no
O	O	m/v	no
O	O	)	no
O	B-drug_n	CMC-Cys7.3	no
O	O	a	yes
O	O	significantly	no
O	O	improved	no
O	O	permeation	no
O	O	was	no
O	O	observed	no
O	O	(	no
O	O	R=	no
O	O	1.3	no
O	O	)	no
O	O	.	no

O	O	Interaction	no
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	and	yes
B-drug	B-drug	halothane	yes
O	O	in	yes
O	O	rats	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	stable	no
O	O	dosage	no
O	O	on	no
O	O	one	no
O	O	of	yes
O	O	the	no
O	O	agents	yes
O	O	in	yes
O	O	this	no
O	O	category	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	begins	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	EQUETROTM	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	reasonable	no
O	O	to	no
O	O	expect	no
O	O	that	no
O	O	a	yes
O	O	dose	no
O	O	increase	no
O	O	for	yes
O	O	the	no
O	O	concomitant	no
O	O	agent	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

B-brand	B-brand	PEGASYS	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	creatinine	yes
O	O	clearance	no
O	O	50	yes
O	O	mL/min	no
O	O	and	yes
B-brand	B-brand	COPEGUS	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	creatinine	yes
O	O	clearance	no
O	O	50	yes
O	O	mL/min	no

O	O	Other	no
O	O	binding	no
O	O	proteins	no
O	O	may	no
O	O	be	no
O	O	elevated	no
O	O	in	yes
O	O	serum	yes
O	O	,	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	corticosteroid	no
O	O	binding	no
O	O	globulin	yes
O	O	(	no
O	O	CBG	no
O	O	)	no
O	O	,	no
O	O	sex	no
O	O	hormone	yes
O	O	binding	no
O	O	globulin	yes
O	O	(	no
O	O	SHBG	no
O	O	)	no
O	O	)	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	total	yes
O	O	circulating	no
B-group	B-group	corticosteroids	no
O	O	and	yes
B-group	B-group	sex	no
I-group	I-group	steroids	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Decreases	no
O	O	in	yes
O	O	TBg	no
O	O	concentrations	no
O	O	are	no
O	O	observed	no
O	O	in	yes
O	O	nephrosis	no
O	O	,	no
O	O	acromegaly	no
O	O	and	yes
O	O	after	no
O	B-group	androgen	no
O	O	or	no
B-group	B-group	corticosteroid	no
O	O	therapy	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	clarithromycin	yes
O	O	with	yes
B-drug	B-drug	pimozide	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	In	yes
O	O	comparison	no
O	O	with	yes
B-drug	B-drug	haloperidol	yes
O	O	,	no
O	O	the	no
O	O	adverse	no
O	O	events	no
O	O	reported	no
O	O	significantly	no
O	O	more	no
O	O	frequently	no
O	O	with	yes
B-drug	B-drug	olanzapine	yes
O	O	in	yes
O	O	>	no
O	O	or	no
O	O	=	no
O	O	3.5	no
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	were	no
O	O	dry	no
O	O	mouth	no
O	O	,	no
O	O	bodyweight	no
O	O	gain	no
O	O	and	yes
O	O	increased	no
O	O	appetite	no
O	O	and	yes
O	O	compared	no
O	O	with	yes
B-drug	B-drug	risperidone	yes
O	O	,	no
O	O	only	no
O	O	bodyweight	no
O	O	gain	no
O	O	occurred	no
O	O	significantly	no
O	O	more	no
O	O	frequently	no
O	O	with	yes
B-drug	B-drug	olanzapine	yes
O	O	.	no

O	O	These	no
O	O	medications	no
O	O	have	no
O	O	included	no
B-drug	B-drug	heparin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	receptor	yes
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	antagonists	no
O	O	,	no
B-group	B-group	angiotensin	yes
I-group	I-group	converting	no
I-group	I-group	enzyme	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	intravenous	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	nitrates	no
O	O	,	no
B-drug	B-drug	ticlopidine	yes
O	O	,	no
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	Pretreatment	no
O	O	of	yes
O	O	rats	no
O	O	with	yes
B-drug	B-drug	allopurinol	yes
O	O	(	no
O	O	100	yes
O	O	mg/kg	no
O	O	,	no
O	O	ip	no
O	O	)	no
O	O	or	no
B-drug	B-drug	Vitamin	yes
I-drug	I-drug	E	yes
O	O	(	no
O	O	100	yes
O	O	mg/kg	no
O	O	per	no
O	O	day	no
O	O	,	no
O	O	ig	no
O	O	,	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	and	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	40	yes
O	O	mg/kg	no
O	O	on	no
O	O	the	no
O	O	4th	no
O	O	day	no
O	O	)	no
O	O	provided	no
O	O	significant	no
O	O	protection	no
O	O	against	yes
O	O	the	no
O	O	elevation	no
O	O	of	yes
B-brand	O	TBARS	no
O	O	levels	no
O	O	in	yes
O	O	cerebral	no
O	O	and	yes
O	O	hepatic	no
O	O	tissues	no
O	O	,	no
O	O	induced	no
O	O	by	no
O	O	single	yes
O	O	high	yes
O	O	dose	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	cypermethrin	no
O	O	administration	no
O	O	within	no
O	O	4	yes
O	O	h	yes
O	O	.	no

O	O	These	no
O	O	would	no
O	O	include	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	preparations	no
O	O	which	no
O	O	contain	no
B-group	B-group	androgens	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
B-group	B-group	progestins	no
O	O	,	no
O	O	or	no
B-group	B-group	glucocorticoids	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
B-drug	B-drug	Theophylline	yes
O	O	clearance	no
O	O	may	no
O	O	decrease	no
O	O	in	yes
O	O	hypothyroid	no
O	O	patients	no
O	O	and	yes
O	O	return	no
O	O	toward	no
O	O	normal	yes
O	O	when	no
O	O	a	yes
O	O	euthyroid	no
O	O	state	no
O	O	is	yes
O	O	achieved	no
O	O	.	no

O	O	These	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	rofecoxib	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	modest	no
O	O	inhibition	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	1A2	no
O	O	.	no

O	O	Because	no
O	O	many	no
O	O	drugs	no
O	O	are	no
O	O	excreted	no
O	O	in	yes
O	O	human	yes
O	O	milk	yes
O	O	,	no
O	O	and	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	adverse	no
O	O	reactions	no
O	O	from	no
B-brand	B-brand	FASLODEX	yes
O	O	in	yes
O	O	nursing	no
O	O	infants	no
O	O	,	no
O	O	a	yes
O	O	decision	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	whether	no
O	O	to	no
O	O	discontinue	no
O	O	nursing	no
O	O	or	no
O	O	to	no
O	O	discontinue	no
O	O	the	no
O	O	drug	yes
O	O	taking	no
O	O	into	no
O	O	account	no
O	O	the	no
O	O	importance	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	to	no
O	O	the	no
O	O	mother	no
O	O	.	no

O	O	A	yes
O	O	return	no
O	O	to	no
O	O	normal	yes
O	O	menstrual	no
O	O	rhythm	no
O	O	followed	no
O	O	cessation	no
O	O	of	yes
O	O	treatment	no
O	O	.	no

O	O	The	no
O	O	higher	no
B-drug	B-drug	verografine	no
O	O	and	yes
B-drug	B-drug	iodamide	yes
O	O	excretion	no
O	O	was	no
O	O	due	no
O	O	to	no
O	O	their	no
O	O	increased	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	.	no

B-group	B-group	Opioids	no
O	O	are	no
O	O	strong	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	,	no
O	O	but	no
O	O	regular	yes
O	O	users	no
O	O	develop	no
O	O	physiological	no
O	O	tolerance	no
O	O	allowing	no
O	O	gradually	no
O	O	increased	no
O	O	dosages	no
O	O	.	no

B-group	B-group	Calcium	yes
I-group	I-group	Channel	no
I-group	I-group	Blockers	no
O	O	,	no
B-drug	B-group	Dihydropyridine	no
O	O	:	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	felodipine	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	nicardipine	yes

O	O	Additionally	no
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	,	no
O	O	reflecting	no
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	a	yes
O	O	role	no
O	O	of	yes
O	O	CYP2D6	no
O	O	in	yes
B-drug	B-drug	zaleplon	yes
O	O	s	yes
O	O	metabolism	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	monitoring	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	indicated	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	similar	no
O	O	combination	yes
O	O	chemotherapy	no
O	O	regimens	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	may	no
O	O	require	no
O	O	lower	no
O	O	doses	no
O	O	than	no
O	O	usually	no
O	O	prescribed	no
O	O	for	yes
O	O	either	no
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	or	no
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Dolasetron	yes
O	O	has	no
O	O	been	no
O	O	safely	no
O	O	coadministered	no
O	O	with	yes
O	O	drugs	no
O	O	used	no
O	O	in	yes
O	O	chemotherapy	no
O	O	and	yes
O	O	surgery	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	with	yes
B-drug	B-drug	phenobarbital	yes
O	O	causes	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	phenobarbital	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	,	no
O	O	In	yes
O	O	12	yes
O	O	otherwise	no
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	ingesting	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	(	no
O	O	Cmin	no
O	O	)	no
B-drug	B-drug	phenobarbital	yes
O	O	concentration	no
O	O	was	no
O	O	14.2	no
O	O	micrograms/mL	no
O	O	.	no

B-group	B-group	Antihypertensives	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-group	B-drug	antihypertensives	no
O	O	.	no

O	O	In	yes
O	O	these	no
O	O	subjects	no
O	O	,	no
B-drug	B-drug	celecoxib	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	as	yes
O	O	determined	no
O	O	by	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Repeating	no
O	O	the	no
O	O	study	no
O	O	with	yes
O	O	6	yes
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
B-drug	B-drug	glibenclamide	yes
O	O	did	no
O	O	not	no
O	O	detect	no
O	O	an	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	acitretin	yes
O	O	on	no
O	O	glucose	yes
O	O	tolerance	no
O	O	.	no

O	O	Two	no
O	O	weeks	no
O	O	after	no
O	O	bilateral	no
O	O	ovariectomy	no
O	O	,	no
O	O	female	no
O	O	rats	no
O	O	received	no
O	O	a	yes
O	O	s.c	no
O	O	.	no

O	O	(	no
O	O	Effectiveness	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	because	no
O	O	of	yes
O	O	alkalinization	no
O	O	of	yes
O	O	the	no
O	O	urine	no
O	O	.	no
O	O	)	no

O	O	Although	no
O	O	not	no
O	O	studied	no
O	O	with	yes
B-drug	B-drug	alosetron	yes
O	O	,	no
O	O	inhibition	no
O	O	of	yes
O	O	N-acetyltransferase	no
O	O	may	no
O	O	have	no
O	O	clinically	no
O	O	relevant	no
O	O	consequences	no
O	O	for	yes
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	hydralazine	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	if	no
B-drug	B-drug	Argatroban	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	initiated	no
O	O	after	no
O	O	cessation	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	therapy	no
O	O	,	no
O	O	allow	no
O	O	sufficient	no
O	O	time	no
O	O	for	yes
O	O	heparins	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	aPTT	no
O	O	to	no
O	O	decrease	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	therapy	no
O	O	.	no

O	O	-	yes
B-group	B-group	Antidiabetics	no
O	O	,	no
O	O	oral	yes
O	O	(	no
O	O	diabetes	no
O	O	medicine	no
O	O	you	no
O	O	take	no
O	O	by	no
O	O	mouth	no
O	O	)	no
O	O	Use	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	antidiabetics	no
O	O	with	yes
B-drug	B-drug	sulfapyridine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	blood	yes
O	O	and/or	no
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	or	no
O	O	oral	yes
B-group	B-group	antidiabetics	no

O	O	Data	no
O	O	suggest	no
O	O	that	no
O	O	coadministration	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	cisapride	yes
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	If	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	a	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	,	no
O	O	talk	no
O	O	to	no
O	O	your	no
O	O	doctor	no
O	O	before	no
O	O	taking	no
O	O	this	no
O	O	medicine	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
B-drug	B-drug	Isoniazid	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	slow	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
O	O	increase	no
O	O	its	no
O	O	serum	yes
O	O	levels	no
B-drug	B-drug	Carbamazepine	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	determined	no
O	O	prior	no
O	O	to	no
O	O	concurrent	no
O	O	administration	no
O	O	with	yes
B-drug	B-drug	isoniazid	yes
O	O	,	no
O	O	signs	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	toxicity	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	,	no
O	O	and	yes
O	O	appropriate	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticonvulsant	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	post	no
O	O	marketing	no
O	O	observations	no
O	O	,	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-group	B-group	Butyrophenones	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	haloperidol	yes
O	O	)	no
O	O	and	yes
B-group	B-group	phenothiazines	no
O	O	can	no
O	O	suppress	no
O	O	the	no
O	B-drug	dopaminergic	no
O	O	renal	no
O	O	and	yes
O	O	mesenteric	no
O	O	vasodilation	no
O	O	induced	no
O	O	with	yes
O	O	low	yes
O	O	dose	no
O	O	dopamine	yes
O	O	infusion	no
O	O	.	no

B-drug	I-drug	Erythromycin	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	q8h	no
O	O	)	no
O	O	+	no
O	O	40	yes
O	O	%	no
O	O	+46	no
O	O	%	no

O	O	Also	no
O	O	,	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	additive	no
O	O	effects	no
O	O	such	no
O	O	as	yes
O	O	bradycardia	no
O	O	and	yes
O	O	AV	no
O	O	block	yes
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	warranted	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	clonidine	yes
O	O	with	yes
O	O	agents	yes
O	O	known	no
O	O	to	no
O	O	affect	no
O	O	sinus	yes
O	O	node	no
O	O	function	no
O	O	or	no
O	O	AV	no
O	O	nodal	no
O	O	conduction	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	digitalis	yes
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta-blockers	no
O	O	.	no
O	O	)	no

O	O	The	no
O	O	size	no
O	O	of	yes
O	O	wheal	no
O	O	and	yes
O	O	flare	no
O	O	were	no
O	O	significantly	no
O	O	larger	no
O	O	when	no
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	was	no
O	O	administered	no
O	O	with	yes
O	O	either	no
O	O	grapefruit	no
O	O	or	no
O	O	orange	no
O	O	juices	no
O	O	compared	no
O	O	to	no
O	O	water	yes
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-drug	B-drug	Lapatinib	yes
O	O	on	no
O	O	Drug	yes
O	O	Metabolizing	no
O	O	Enzymes	yes
O	O	and	yes
O	O	Drug	yes
O	O	Transport	no
O	O	Systems	no
B-drug	B-drug	Lapatinib	yes
O	O	inhibits	no
O	O	CYP3A4	no
O	O	and	yes
O	O	CYP2C8	no
O	O	in	yes
O	O	vitro	no
O	O	at	yes
O	O	clinically	no
O	O	relevant	no
O	O	concentrations	no
O	O	.	no

O	O	Certain	no
O	O	drugs	no
O	O	tend	no
O	O	to	no
O	O	produce	no
O	O	hyperglycemia	no
O	O	and	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	cyclopropane	no
O	O	or	no
B-group	B-group	halogenated	no
I-group	I-group	hydrocarbon	no
O	I-group	general	no
B-group	I-group	anesthetics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	halothane	yes
O	O	which	no
O	O	sensitize	no
O	O	the	no
O	O	myocardium	no
O	O	,	no
O	O	may	no
O	O	induce	no
O	O	cardiac	no
O	O	arrhythmia..	no

B-brand	B-brand	AZOPT	yes
O	O	(	no
B-drug	B-drug	brinzolamide	yes
O	O	ophthalmic	no
O	O	suspension	yes
O	O	)	no
O	O	1	yes
O	O	%	no
O	O	contains	no
O	O	a	yes
B-group	B-group	carbonic	yes
I-group	I-group	anhydrase	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	All	yes
O	O	20	yes
O	O	strains	no
O	O	of	yes
O	O	enterococcus	no
O	O	,	no
O	O	three	no
O	O	strains	no
O	O	of	yes
B-drug_n	O	Clostridium	yes
O	O	,	no
O	O	three	no
O	O	strains	no
O	O	of	yes
O	O	Escherichia	yes
O	O	coli	yes
O	O	,	no
O	O	and	yes
O	O	one	no
O	O	strain	no
O	O	of	yes
O	O	Proteus	no
O	O	rettgeri	no
O	O	were	no
O	O	resistant	no
O	O	to	no
O	O	both	no
B-drug	B-drug	clindamycin	yes
O	O	(	no
O	O	minimal	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	greater	no
O	O	than	no
O	O	3.1	no
O	O	mug/ml	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	(	no
O	O	minimal	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	greater	no
O	O	than	no
O	O	6.2	no
O	O	mug/ml	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	,	no
B-drug	B-drug_n	heroin	yes
O	O	may	no
O	O	still	no
O	O	kill	no
O	O	even	no
O	O	experienced	no
O	O	users	no
O	O	,	no
O	O	particularly	no
O	O	if	no
O	O	their	no
O	O	tolerance	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	has	no
O	O	reduced	yes
O	O	or	no
O	O	the	no
O	O	strength	yes
O	O	of	yes
O	O	their	no
O	O	usual	no
O	O	dose	no
O	O	has	no
O	O	increased	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	when	no
B-brand	B-brand	TRISENOX	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
O	O	other	no
O	O	medications	no
O	O	that	no
O	O	can	no
O	O	prolong	no
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	(	no
O	O	e.g	no
O	O	.	no
O	O	certain	no
B-group	B-group	antiarrhythmics	no
O	O	or	no
B-drug	B-drug	thioridazine	yes
O	O	)	no
O	O	or	no
O	O	lead	no
O	O	to	no
O	O	electrolyte	yes
O	O	abnormalities	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-group	B-group	diuretics	no
O	O	or	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	)	no
O	O	.	no

O	O	Available	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	O	platelet	yes
O	O	function	no
O	O	and	yes
O	O	arachidonic	yes
O	O	acid	yes
O	O	metabolism	no
O	O	are	no
O	O	important	no
O	O	factors	no
O	O	in	yes
O	O	hemostasis	no
O	O	and	yes
O	O	regulation	no
O	O	of	yes
O	O	vascular	no
O	O	tone	no
O	O	.	no

O	O	All	yes
O	O	patients	no
O	O	in	yes
O	O	whom	no
O	O	this	no
O	O	effect	no
O	O	was	no
O	O	observed	no
O	O	remained	no
O	O	asymptomatic	no
O	O	.	no

O	O	Combination	yes
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	with	yes
O	O	other	no
B-drug	B-drug	antiarrhythmic	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	reserved	no
O	O	for	yes
O	O	patients	no
O	O	with	yes
O	O	life-threatening	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	who	no
O	O	are	no
O	O	incompletely	no
O	O	responsive	no
O	O	to	no
O	O	a	yes
O	O	single	yes
O	O	agent	yes
O	O	or	no
O	O	incompletely	no
O	O	responsive	no
O	O	to	no
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	RESULTS	no
O	O	:	no
O	O	During	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	statistically	no
O	O	significant	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	median	no
O	O	of	yes
O	O	the	no
O	O	total	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	from	no
O	O	845	no
O	O	mL/h	no
O	O	to	no
O	O	688	no
O	O	mL/h	no
O	O	,	no
O	O	among	no
O	O	the	no
O	O	volunteers	no
O	O	who	no
O	O	received	no
O	O	75	yes
O	O	mg/d	no
O	O	.	no

B-drug	B-drug	Disopyramide	yes
O	O	increases	no
O	O	QT	no
O	O	prolongation	no
O	O	which	no
O	O	could	no
O	O	cause	no
O	O	arrhythmia	no
O	O	.	no

O	O	When	no
O	O	combined	no
O	O	with	yes
B-drug	B-drug	ofloxacin	yes
O	O	,	no
B-drug_n	B-drug_n	KRM-1648	no
O	O	exhibited	no
O	O	strong	no
O	O	synergistic	no
O	O	activity	yes
O	O	while	no
O	O	only	no
O	O	additive	no
O	O	effects	no
O	O	were	no
O	O	observed	no
O	O	with	yes
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	rifampicin	yes
O	O	(	no
O	O	or	no
B-drug	B-drug	rifabutin	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	ofloxacin	yes
O	O	.	no

B-drug	B-drug	Clarithromycin	yes
O	O	exposure	yes
O	O	was	no
O	O	significantly	no
O	O	decreased	no
O	O	by	no
B-drug	B-drug	nevirapine	yes
O	O	;	no

O	O	Pregnancies	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	by	no
O	O	users	no
O	O	of	yes
O	B-group	combined	no
B-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	who	no
O	O	also	no
O	O	used	no
O	O	some	no
O	O	form	yes
O	O	of	yes
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	.	no

O	O	Patients	no
O	O	currently	no
O	O	receiving	no
B-drug	B-drug	diltiazem	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	for	yes
O	O	a	yes
O	O	change	no
O	O	in	yes
O	O	pharmacological	no
O	O	effect	no
O	O	when	no
O	O	initiating	no
O	O	and	yes
O	O	discontinuing	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	,	no
O	O	oral	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	usually	no
O	O	results	no
O	O	in	yes
O	O	inhibition	no
O	O	of	yes
O	O	response	no
O	O	to	no
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	although	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	some	no
O	O	conflicting	no
O	O	reports	no
O	O	.	no

O	O	-	yes
O	O	a	yes
B-group	B-group	phenothiazine	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	chlorpromazine	yes
O	O	(	no
B-brand	B-brand	Thorazine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	fluphenazine	yes
O	O	(	no
B-brand	B-brand	Prolixin	yes
O	O	,	no
B-brand	B-brand	Permitil	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	prochlorperazine	yes
O	O	(	no
B-brand	B-brand	Compazine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	promethazine	yes
O	O	(	no
B-brand	B-brand	Phenergan	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	;	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
O	O	Following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	ARAVA	yes
O	O	to	no
O	O	subjects	no
O	O	receiving	no
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	M1	yes
O	O	peak	no
O	O	levels	no
O	O	were	no
O	O	increased	no
O	O	(	no
O	O	~40	no
O	O	%	no
O	O	)	no
O	O	over	no
O	O	those	no
O	O	seen	no
O	O	when	no
B-brand	B-brand	ARAVA	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

B-group	B-group	sulfonamides	yes
O	O	,	no
O	O	long	yes
O	O	acting	yes
O	O	;	no

O	O	In	yes
O	O	both	no
O	O	plasma	yes
O	O	and	yes
O	O	KHT	no
O	O	tumour	no
O	O	the	no
O	O	peak	no
O	O	concentration	no
O	O	and	yes
O	O	"	no
O	O	early	no
O	O	"	no

O	O	The	no
O	O	monoamine	no
O	O	oxidase	yes
O	O	inhibitory	yes
O	O	effects	no
O	O	of	yes
B-drug	B-drug	Isocarboxazid	yes
O	O	may	no
O	O	persist	no
O	O	for	yes
O	O	a	yes
O	O	substantial	no
O	O	period	no
O	O	after	no
O	O	discontinuation	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	,	no
O	O	and	yes
O	O	this	no
O	O	should	no
O	O	be	no
O	O	borne	no
O	O	in	yes
O	O	mind	no
O	O	when	no
O	O	another	no
O	O	drug	yes
O	O	is	yes
O	O	prescribed	no
O	O	following	no
B-drug	B-drug	Isocarboxazid	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	cholestyramine	yes
B-group	B-group	resin	yes
O	O	is	yes
O	O	given	no
O	O	for	yes
O	O	long	yes
O	O	periods	no
O	O	of	yes
O	O	time	no
O	O	,	no
O	O	concomitant	no
O	O	supplementation	no
O	O	with	yes
O	O	water-miscible	no
O	O	(	no
O	O	or	no
O	O	parenteral	no
O	O	)	no
O	O	forms	no
O	O	of	yes
B-group	B-group	fat-soluble	no
I-group	I-group	vitamins	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Induce	no
O	O	CYP3A4	no
O	O	(	no
B-drug	B-drug	Rifampicin	yes
O	O	)	no
O	O	Racemic	yes
B-drug	B-drug	zopiclone	yes
O	O	exposure	yes
O	O	was	no
O	O	decreased	no
O	O	80	yes
O	O	%	no
O	O	by	no
O	O	concomitant	no
O	O	useof	no
B-drug	B-drug	rifampicin	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inducer	no
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Prothrombin	yes
O	O	time	no
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	.	no

O	O	400-2000	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	resulted	no
O	O	in	yes
O	O	the	no
O	O	need	no
O	O	for	yes
O	O	an	no
O	O	unusually	no
O	O	high	yes
O	O	maintenance	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	per	no
O	O	day	no
O	O	)	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	produce	no
O	O	a	yes
O	O	therapeutic	no
O	O	effect	no
O	O	.	no

B-drug	B-drug	Cyclosporin	yes
O	O	:	no
O	O	After	no
O	O	introduction	no
O	O	of	yes
B-drug	B-drug	chloroquine	yes
O	O	(	no
O	O	oral	yes
O	O	form	yes
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	sudden	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	cyclosporin	yes
O	O	level	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Although	no
O	O	a	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	when	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	nelfinavir	yes
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	for	yes
O	O	known	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	liver	yes
O	O	enzyme	no
O	O	abnormalities	no
O	O	and	yes
O	O	hearing	no
O	O	impairment	no
O	O	,	no
O	O	is	yes
O	O	warranted	no
O	O	.	no

O	O	Special	yes
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	ETHYOL	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	antihypertensive	no
I-group	I-group	medications	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	could	no
O	O	cause	no
O	O	or	no
O	O	potentiate	no
O	O	hypotension	no
O	O	.	no

O	O	Synergism	no
O	O	between	yes
B-group	B-group	xanthine	yes
I-group	I-group	bronchodilators	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	ephedrine	yes
O	O	,	no
O	O	and	yes
O	O	other	no
B-group	B-group	sympathomimetic	no
I-group	I-group	bronchodilators	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

B-drug	B-drug	Promethazine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	and	yes
B-drug	B-drug	promethazine	yes
O	O	(	no
O	O	10	yes
O	O	and	yes
O	O	25	yes
O	O	mg	yes
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	15	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	maximal	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	,	no
O	O	but	no
O	O	no	yes
O	O	change	no
O	O	in	yes
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	plasma	yes
O	O	concentration-time	no
O	O	curve	no
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	specific	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
O	O	topical	yes
O	O	glaucoma	no
O	O	drugs	no
O	O	or	no
O	O	systemic	no
O	O	medications	no
O	O	were	no
O	O	identified	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	of	yes
B-brand	B-brand	IOPIDINE	yes
O	O	0.5	yes
O	O	%	no
O	O	Ophthalmic	no
O	O	Solution	yes
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	an	no
O	O	additive	no
O	O	or	no
O	O	potentiating	no
O	O	effect	no
O	O	with	yes
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	opiates	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	anesthetics	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
O	O	It	no
O	O	is	yes
O	O	important	no
O	O	to	no
O	O	identify	no
O	O	the	no
O	O	medications	no
O	O	most	no
O	O	commonly	no
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	PICR	no
O	O	so	no
O	O	as	yes
O	O	to	no
O	O	establish	no
O	O	corrective	no
O	O	measures	no
O	O	to	no
O	O	minimise	no
O	O	the	no
O	O	risks	no
O	O	arising	no
O	O	from	no
O	O	multiple	no
O	O	medication	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Lithium	yes
O	O	toxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	lithium	yes
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	which	no
O	O	cause	no
O	O	elimination	no
O	O	of	yes
B-drug	O	sodium	yes
O	O	,	no
O	O	including	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Effect	no
O	O	on	no
O	O	Concentration	no
O	O	of	yes
B-drug	B-drug	Nevirapine	yes
O	O	or	no
O	O	Concomitant	no
O	O	Drug	yes

O	O	Additionally	no
O	O	,	no
O	O	higher	no
O	O	than	no
O	O	expected	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	when	no
O	O	they	no
O	O	are	no
O	O	begun	no
O	O	in	yes
O	O	patients	no
O	O	already	no
O	O	taking	no
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	Interactions	no
O	O	may	no
O	O	occur	no
O	O	between	yes
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	and	yes
O	O	other	no
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	and	yes
O	O	herbs	no
O	O	such	no
O	O	as	yes
O	O	garlic	no
O	O	(	no
B-brand	O	Allium	no
I-brand	O	sativum	no
O	O	)	no
O	O	and	yes
O	B-drug	ginkgo	yes
O	O	(	no
O	B-drug	Ginkgo	yes
O	I-drug	biloba	yes
O	O	)	no
O	O	.	no

O	O	Theoretically	no
O	O	,	no
O	O	it	no
O	O	may	no
O	O	decrease	no
O	O	hepatic	no
O	O	toxicity	no
O	O	in	yes
O	O	the	no
O	O	case	no
O	O	of	yes
O	O	other	no
O	O	potential	no
O	O	hepatotoxic	no
O	O	drugs	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	the	no
O	O	principles	no
O	O	observed	no
O	O	the	no
O	O	concentrations	no
O	O	fo	yes
O	O	these	no
O	O	hormones	no
O	O	were	no
O	O	investigated	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	of	yes
O	O	dogs	no
O	O	deprived	no
O	O	of	yes
O	O	water	yes
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	and	yes
O	O	then	no
O	O	allowed	no
O	O	to	no
O	O	drink	no
O	O	.	no

O	B-brand	Ocupress	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	receiving	no
O	O	a	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agent	yes
O	O	orally	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	additive	no
O	O	effects	no
O	O	on	no
O	O	systemic	no
O	O	beta-blockade	no
O	O	.	no

O	O	In	yes
O	O	diabetics	no
O	O	,	no
O	O	blood-sugar	no
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	very	no
O	O	carefully	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	125	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	,	no
O	O	increased	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	by	no
O	O	approximately	no
O	O	2-fold	no
O	O	.	no

B-drug	I-drug	clarithromycin	yes
O	O	concentration	no
B-drug	B-drug	indinavir	yes
O	O	concentration	no

O	O	Further	no
O	O	,	no
O	O	no	yes
O	O	effects	no
O	O	on	no
O	O	either	no
B-drug	B-drug	warfarin	yes
O	O	levels	no
O	O	or	no
O	O	prothrombin	yes
O	O	times	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	a	yes
O	O	study	no
O	O	involving	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	fluvastatin	yes
O	O	.	no

O	O	The	no
O	O	amplitude	no
O	O	data	no
O	O	from	no
O	O	this	no
O	O	study	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	ethanol	yes
O	O	's	no
O	O	augmentation	no
O	O	of	yes
O	O	component	yes
O	O	P2	no
O	O	may	no
O	O	result	no
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	in	yes
O	O	part	no
O	O	,	no
O	O	from	no
O	O	alterations	no
O	O	in	yes
O	O	cholinergic	no
O	O	functions	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	DOXIL	yes
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	mediated	no
O	O	by	no
O	B-drug	cimetidines	no
O	O	known	no
O	O	inhibition	no
O	O	of	yes
O	O	hepatic	no
O	O	cytochrome	no
O	O	P-450	no
O	O	,	no
O	O	the	no
O	O	enzyme	no
O	O	system	yes
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	first-pass	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	a	yes
O	O	lower	no
O	O	total	yes
O	O	daily	no
O	O	dosage	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	satisfactory	no
O	O	therapeutic	no
O	O	effect	no
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	decitabine	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	not	no
O	O	to	no
O	O	exceed	no
O	O	a	yes
O	O	single	yes
O	O	5	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	in	yes
O	O	a	yes
O	O	24-hour	no
O	O	period	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	griseofulvin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	and	yes
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	breakthrough	no
O	O	bleeding	no
O	O	.	no

B-drug	B-drug	Fluvoxamine	yes
O	O	is	yes
O	O	a	yes
O	O	known	no
O	O	strong	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP1A2	no
O	O	and	yes
O	O	also	no
O	O	inhibits	no
O	O	CYP3A4	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	and	yes
O	O	CYP2C19	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	is	yes
O	O	available	no
O	O	.	no

O	O	Greater	no
O	O	fecal	no
O	O	blood	yes
O	O	loss	no
O	O	results	no
O	O	from	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	than	no
O	O	from	no
O	O	either	no
O	O	drug	yes
O	O	alone	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	with	yes
O	O	other	no
B-group	B-group	oxytocic	no
I-group	I-group	agents	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no

O	O	Data	no
O	O	from	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	suggest	no
O	O	a	yes
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	for	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	sertraline	yes
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	increases	no
O	O	the	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	ZEBETA	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	shortened	no
O	O	elimination	no
O	O	half-life	no
O	O	of	yes
B-brand	B-brand	ZEBETA	yes
O	O	.	no

O	O	Urinary	yes
O	O	Alkalinizers	no
O	O	:	no
O	O	Decrease	no
B-brand	B-brand	aspirin	yes
O	O	effectiveness	no
O	O	by	no
O	O	increasing	no
O	O	the	no
O	O	rate	no
O	O	of	yes
B-group	B-group	salicylate	yes
O	O	renal	no
O	O	excretion	no
O	O	.	no

O	O	When	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-drug	B-drug	aripiprazole	yes
O	O	occurs	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	to	no
O	O	one-half	no
O	O	of	yes
O	O	its	no
O	O	normal	yes
O	O	dose	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-group	B-group	corticosteroid	no
O	O	should	no
O	O	be	no
O	O	titrated	no
O	O	to	no
O	O	avoid	no
B-group	O	steroid	no
O	O	toxicity	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	taking	no
O	O	an	no
B-group	B-group	anticonvulsant	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	or	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Mefloquine	yes
O	O	may	no
O	O	reduce	no
O	O	seizure	no
O	O	control	no
O	O	by	no
O	O	lowering	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticonvulsant	no
O	O	.	no

O	O	Moreover	no
O	O	,	no
O	O	the	no
O	O	mechanisms	no
O	O	underlying	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	dependence	no
O	O	may	no
O	O	be	no
O	O	similar	no
O	O	for	yes
B-drug	B-drug	alcohol	yes
O	O	and	yes
B-drug	B-drug	nicotine	yes
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	cefamandole	yes
I-drug	I-drug	naftate	no
O	O	,	no
B-drug	B-drug	cephalothin	yes
I-drug	I-drug	sodium	yes
O	O	,	no
B-drug	B-drug	magnesium	yes
I-drug	I-drug	sulfate	yes
O	O	,	no
B-drug	B-drug	prednisolone	yes
I-drug	I-drug	sodium	yes
I-drug	I-drug	succinate	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	prochlorperazine	yes
I-drug	I-drug	edisylate	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Etretinate	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Tegison	yes
O	O	)	no
O	O	or	no

O	O	In	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	,	no
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	and	yes
O	O	various	no
O	O	chemotherapy	no
O	O	agents	yes
O	O	,	no
O	O	no	yes
O	O	effect	no
O	O	was	no
O	O	shown	no
O	O	on	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug_n	B-drug_n	hydrodolasetron	no
O	O	.	no

O	O	The	no
O	O	depression	no
O	O	of	yes
O	O	cardiac	no
O	O	contractility	no
O	O	,	no
O	O	conductivity	no
O	O	,	no
O	O	and	yes
O	O	automaticity	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	the	no
O	O	vascular	no
O	O	dilation	no
O	O	associated	no
O	O	with	yes
B-group	B-group	anesthetics	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	.	no

B-drug	B-drug	Nifedipine	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	when	no
O	O	taken	no
O	O	in	yes
O	O	combination	yes
O	O	.	no

O	O	No	yes
O	O	evidence	no
O	O	of	yes
O	O	interaction	no
O	O	of	yes
B-brand	B-brand	PROCRIT	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	was	no
O	O	observed	no
O	O	in	yes
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	is	yes
O	O	not	no
O	O	well	no
O	O	known	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	due	no
O	O	to	no
O	O	possible	no
O	O	pharmacodynamic	no
O	O	interactions	no
O	O	,	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	PRECEDEX	yes
O	O	,	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	dosage	no
O	O	of	yes
B-brand	B-brand	PRECEDEX	yes
O	O	on	no
O	O	the	no
O	O	concomitant	no
B-group	B-group	anesthetic	no
O	O	,	no
B-group	B-group	sedative	no
O	O	,	no
B-group	B-group	hypnotic	no
O	O	or	no
B-group	B-group	opioid	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	inhibit	no
O	O	this	no
O	O	metabolic	no
O	O	pathway	no
O	O	may	no
O	O	have	no
O	O	a	yes
O	O	profound	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	alprazolam	yes
O	O	.	no

B-drug	B-drug	Enoxacin	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	the	no
O	O	active	no
O	O	S-isomer	yes
O	O	,	no
O	O	and	yes
O	O	changes	no
O	O	in	yes
O	O	clotting	no
O	O	time	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	enoxacin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	were	no
O	O	coadministered	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	(	no
O	O	Oral	yes
O	O	)	no
O	O	:	no
O	O	In	yes
O	O	patients	no
O	O	receiving	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	the	no
O	O	coagulation	yes
O	O	times	no
O	O	were	no
O	O	increased	no
O	O	in	yes
O	O	some	no
O	O	cases	no
O	O	.	no

O	O	AUC	no
O	O	for	yes
O	O	total	yes
B-group	B-group	nitrosoureas	no
O	O	were	no
O	O	about	no
O	O	1.4-1.5	no
O	O	fold	no
O	O	greater	no
O	O	for	yes
O	O	the	no
O	O	oral	yes
O	O	compared	no
O	O	to	no
O	O	the	no
O	O	i.p	no
O	O	.	no

O	O	Because	no
O	O	the	no
B-group	B-group	tetracyclines	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	depress	no
O	O	plasma	yes
O	O	prothrombin	yes
O	O	activity	yes
O	O	,	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	on	no
B-group	B-group	anticoagulant	no
O	O	therapy	no
O	O	may	no
O	O	require	no
O	O	downward	no
O	O	adjustment	no
O	O	of	yes
O	O	their	no
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	.	no

B-drug	B-drug	Oxytocin	yes
O	O	or	no
O	O	other	no
B-group	B-group	oxytocics	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-drug	B-drug	dinoprost	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	uterine	no
O	O	hypertonus	no
O	O	,	no
O	O	possibly	no
O	O	causing	no
O	O	uterine	no
O	O	rupture	no
O	O	or	no
O	O	cervical	no
O	O	laceration	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	adequate	no
O	O	cervical	no
O	O	dilatation	no
O	O	;	no

O	O	The	no
O	O	single-dose	no
O	O	nature	no
O	O	of	yes
O	O	this	no
O	O	study	no
O	O	and	yes
O	O	the	no
O	O	lack	no
O	O	of	yes
O	O	correlation	no
O	O	between	yes
B-drug	B-drug	glyburide	yes
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	pharmaco-dynamic	no
O	O	effects	no
O	O	,	no
O	O	makes	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	uncertain	no
O	O	.	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	TBg	no
O	O	deficiency	no
O	O	approximates	no
O	O	1	yes
O	O	in	yes
O	O	9000	no
O	O	.	no

O	O	If	no
B-drug	B-drug	midazolam	yes
O	O	is	yes
O	O	administered	no
O	O	parenterally	no
O	O	,	no
O	O	special	yes
O	O	precaution	no
O	O	is	yes
O	O	required	no
O	O	since	no
O	O	the	no
O	O	sedative	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	prolonged	no
O	O	.	no

B-drug	B-drug	Caffeine	yes
O	O	:	no
B-drug	B-drug	Enoxacin	yes
O	O	is	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P-450	no
O	O	isozymes	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	methylxanthines	no
O	O	.	no

O	O	Poor	no
O	O	metabolizers	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-group	B-group	TCAs	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

B-drug	O	Dexamethasone	yes
O	O	suppression	no
O	O	test	yes
O	O	(	no
O	O	DST	no
O	O	)	no
O	O	:	no
O	O	False-negative	no
O	O	results	no
O	O	in	yes
O	O	the	no
B-drug	O	dexamethasone	yes
O	O	suppression	no
O	O	test	yes
O	O	(	no
O	O	DST	no
O	O	)	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	indomethacin	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Use	no
O	O	with	yes
B-group	B-group	Angiotensln	no
I-group	I-group	Converting	no
I-group	I-group	Enzyme	no
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	The	no
O	O	use	no
O	O	of	yes
B-group	B-group	angiotensin	yes
I-group	I-group	converting	no
I-group	I-group	enzyme	no
I-group	I-group	inhibitors	no
O	O	to	no
O	O	control	no
O	O	hypertension	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-drug	B-drug	azathioprine	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	induce	no
O	O	severe	no
O	O	leukopenia	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	other	no
B-group	B-group	quinolones	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	CYP3A4-mediated	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	.	no

B-drug	B-drug	Imipramine	yes
O	O	and	yes
B-drug	B-drug	clonazepam	yes
O	O	did	no
O	O	not	no
O	O	change	no
O	O	fasting	no
O	O	or	no
O	O	overload	no
O	O	glycemia	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-drug	B-drug	ampicillin	yes
O	O	increases	no
O	O	substantially	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	rashes	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	ampicillin	yes
O	O	alone	no
O	O	.	no

O	O	The	no
O	O	initial	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	levorphanol	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	or	no
O	O	more	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	along	no
O	O	with	yes
O	O	another	no
O	O	drug	yes
O	O	affecting	no
O	O	respiration	no
O	O	.	no

B-drug	B-drug	Cerivastatin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	were	no
O	O	also	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

B-brand	B-brand	Betaseron	yes
O	O	administration	no
O	O	to	no
O	O	three	no
O	O	cancer	no
O	O	patients	no
O	O	over	no
O	O	a	yes
O	O	dose	no
O	O	range	no
O	O	of	yes
O	O	0.025	no
O	O	mg	yes
O	O	to	no
O	O	2.2	no
O	O	mg	yes
O	O	led	no
O	O	to	no
O	O	a	yes
O	O	dose-dependent	no
O	O	inhibition	no
O	O	of	yes
B-drug	B-drug	antipyrine	yes
O	O	elimination.14	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	alternate-day	no
O	O	administration	no
O	O	of	yes
O	O	0.25	no
O	O	mg	yes
O	O	of	yes
B-brand	B-brand	Betaseron	yes
O	O	on	no
O	O	drug	yes
O	O	metabolism	no
O	O	in	yes
O	O	MS	yes
O	O	patients	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Acetohydroxamic	yes
I-drug	I-drug	acid	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Lithostat	yes
O	O	)	no
O	O	or	no

B-drug	B-drug	Indinavir	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

O	O	Plasma	yes
O	O	was	no
O	O	analyzed	no
O	O	for	yes
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	and	yes
O	O	urine	no
O	O	was	no
O	O	analyzed	no
O	O	for	yes
B-drug	B-drug	tolbutamide	yes
O	O	and	yes
O	O	its	no
O	O	two	no
O	O	metabolites	no
O	O	,	no
B-drug_n	B-drug_n	4-hydroxytolbutamide	no
O	O	and	yes
B-drug	B-drug_n	carboxytolbutamide	no
O	O	by	no
O	O	means	no
O	O	of	yes
O	O	HPLC	no
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	relevant	no
O	O	drug-drug	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	drugs	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	anidulafungin	yes
O	O	.	no

B-drug	B-drug	Nelfinavir	yes
O	O	is	yes
O	O	metabolized	no
O	O	in	yes
O	O	proof	no
O	O	by	no
O	O	C.P.A	no
O	O	.	no

O	O	.	no

B-group	B-brand	Curariform	no
I-group	I-brand	muscle	no
I-group	I-brand	relaxants	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	tubocurarine	yes
O	O	)	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	including	no
B-drug	O	ether	yes
O	O	,	no
B-drug	B-drug	succinylcholine	yes
O	O	,	no
B-drug	B-drug	gallamine	yes
O	O	,	no
B-drug	B-drug	decamethonium	yes
O	O	and	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	citrate	yes
O	O	,	no
O	O	potentiate	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	effect	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	extreme	no
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	Coly-Mycin	yes
O	I-brand	M	yes
O	O	Parenteral	no
O	O	.	no

O	O	The	no
B-drug_n	B-drug	MPTP-induced	no
O	O	neuronal	no
O	O	damage	no
O	O	produced	no
O	O	a	yes
O	O	tolerance	no
O	O	to	no
O	O	the	no
O	O	disruptive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	amphetamine	yes
O	O	and	yes
O	O	a	yes
O	O	supersensitivity	no
O	O	to	no
O	O	the	no
O	O	disruptive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	apomorphine	yes
O	O	in	yes
O	O	rats	no
O	O	responding	no
O	O	in	yes
O	O	a	yes
O	O	schedule	no
O	O	controlled	no
O	O	paradigm	no
O	O	.	no

O	O	Since	no
O	O	chronic	no
O	O	dosing	no
O	O	is	yes
O	O	required	no
O	O	for	yes
O	O	therapeutic	no
O	O	efficacy	no
O	O	of	yes
B-group	B-group	antipsychotics	no
O	O	,	no
O	O	future	no
O	O	studies	no
O	O	should	no
O	O	focus	no
O	O	on	no
O	O	investigation	no
O	O	of	yes
O	O	chronic	no
O	O	dosing	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug_n	B-drug_n	PCP	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	carbamazepine	yes
O	O	is	yes
O	O	added	no
O	O	to	no
B-drug	B-drug	aripiprazole	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	doubled	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	is	yes
O	O	a	yes
O	O	blocker	no
O	O	of	yes
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	.	no

O	O	Post-marketing	no
O	O	reports	no
O	O	of	yes
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	measures	no
O	O	have	no
O	O	been	no
O	O	received	no
O	O	among	no
O	O	patients	no
O	O	on	no
O	O	concomitant	no
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	esomeprazole	yes
O	O	therapy	no
O	O	.	no

O	O	To	no
O	O	determine	no
O	O	whether	no
B-drug	B-drug	probenecid	yes
O	O	has	no
O	O	a	yes
O	O	direct	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	cloxacillin	yes
O	O	,	no
O	O	the	no
O	O	elimination	no
O	O	and	yes
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	cloxacillin	yes
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	six	no
O	O	patients	no
O	O	,	no
O	O	five	no
O	O	lacking	no
O	O	kidney	yes
O	O	function	no
O	O	and	yes
O	O	one	no
O	O	with	yes
O	O	a	yes
O	O	partially	no
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	or	no
O	O	absence	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	.	no

O	O	Accordingly	no
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	and	yes
B-drug	B-drug	fluvoxamine	yes
O	O	should	no
O	O	not	no
O	O	ordinarily	no
O	O	be	no
O	O	co-administered	no
O	O	.	no

O	O	A	yes
O	O	potential	no
O	O	interaction	no
O	O	between	yes
O	O	oral	yes
B-drug	B-drug	miconazole	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	leading	no
O	O	to	no
O	O	severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

B-group	B-drug	Calcium	yes
I-group	B-group	Supplements/Antacids	no

B-drug	B-drug	Fluoxetine	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	,	no
B-drug	O	norfluoxe-tine	no
O	O	,	no
O	O	have	no
O	O	long	yes
B-group	O	half-lives	no
O	O	(	no
O	O	4	yes
O	O	to	no
O	O	16	yes
O	O	days	no
O	O	for	yes
B-drug	B-drug_n	norfluoxetine	no
O	O	)	no
O	O	,	no
O	O	that	no
O	O	may	no
O	O	affect	no
O	O	strategies	no
O	O	during	no
O	O	conversion	yes
O	O	from	no
O	O	one	no
O	O	drug	yes
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	displacement	no
O	O	studies	no
O	O	with	yes
O	O	highly	no
O	O	protein-bound	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	captopril	yes
O	O	,	no
B-drug	B-drug	nicardipine	yes
O	O	,	no
B-drug	B-drug	pravastatin	yes
O	O	,	no
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	showed	no
O	O	no	yes
O	O	influence	no
O	O	on	no
O	O	the	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	nateglinide	yes
O	O	protein	yes
O	O	binding	no
O	O	.	no

O	O	In	yes
O	O	those	no
O	O	patients	no
O	O	in	yes
O	O	whom	no
O	O	renal	no
O	O	insufficiency	no
O	O	was	no
O	O	documented	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	the	no
O	O	recommendation	no
O	O	to	no
O	O	lower	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	was	no
O	O	not	no
O	O	followed	no
O	O	.	no

O	O	Serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	and	yes
O	O	cardiac	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	and	yes
O	O	any	no
O	O	deficit	no
O	O	promptly	no
O	O	corrected	no
O	O	.	no

O	O	More	no
O	O	specific	no
O	O	applications	no
O	O	of	yes
O	O	the	no
O	O	assay	no
O	O	of	yes
O	O	thio	no
O	O	compounds	no
O	O	in	yes
O	O	urine	no
O	O	allow	no
O	O	development	no
O	O	of	yes
O	O	selective	no
O	O	methods	no
O	O	that	no
O	O	may	no
O	O	be	no
O	O	useful	no
O	O	for	yes
O	O	biological	no
O	O	monitoring	no
O	O	.	no

O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	small	no
O	O	(	no
O	O	n=30	no
O	O	)	no
O	O	combination	yes
O	O	study	no
O	O	of	yes
B-brand	B-brand	ARAVA	yes
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	,	no
O	O	a	yes
O	O	2-	no
O	O	to	no
O	O	3-fold	no
O	O	elevation	no
O	O	in	yes
O	O	liver	yes
O	O	enzymes	yes
O	O	was	no
O	O	seen	no
O	O	in	yes
O	O	5	yes
O	O	of	yes
O	O	30	yes
O	O	patients	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	formal	no
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	TAXOL	yes
O	O	concomitantly	no
O	O	with	yes
O	O	known	no
O	O	substrates	no
O	O	or	no
O	O	inhibitors	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzymes	no
O	O	CYP2C8	no
O	O	and	yes
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	pentoxifylline	yes
O	O	;	no

O	O	and	yes
O	O	clinical	no
O	O	implications	no
O	O	.	no

B-group	B-group	Sedative/hypnotics	no
O	O	:	no
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	triazolam	yes

O	O	Other	no
O	O	kits	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	the	no
O	O	Coat-A-Count	no
O	O	RIA	no
O	O	Kit	yes
O	O	,	no
O	O	may	no
O	O	be	no
O	O	used	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	,	no
O	O	if	no
O	O	any	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	pituitary-gonadal	no
O	O	axis	no
O	O	in	yes
O	O	premenopausal	no
O	O	women	yes
O	O	are	no
O	O	unknown	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	doxazosin	yes
O	O	AUC	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Potential	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	Ketoconazole	yes
O	O	and	yes
B-drug	B-drug	Isoniazid	yes
O	O	may	no
O	O	exist	no
O	O	.	no

O	O	Close	no
O	O	supervision	no
O	O	and	yes
O	O	careful	no
O	O	adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	are	no
O	O	required	no
O	O	when	no
B-brand	B-brand	Anafranil	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-group	B-group	anticholinergic	no
O	O	or	no
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Prolonged	no
O	O	recovery	no
O	O	time	no
O	O	may	no
O	O	occur	no
O	O	if	no
B-group	B-group	barbiturates	no
O	O	and/or	no
B-group	B-group	narcotics	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	ketamine	yes
O	O	.	no

O	O	It	no
O	O	was	no
O	O	observed	no
O	O	that	no
B-drug_n	B-drug_n	contortrostatin	no
O	O	had	no
O	O	a	yes
O	O	dramatic	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	tyrosine	yes
O	O	phosphorylation	no
O	O	status	no
O	O	of	yes
O	O	several	no
O	O	proteins	no
O	O	in	yes
O	O	T24	no
O	O	human	yes
O	O	bladder	no
O	O	cancer	no
O	O	cells	yes
O	O	,	no
O	O	including	no
O	O	robust	no
O	O	induction	no
O	O	of	yes
O	O	phosphorylation	no
O	O	of	yes
O	O	proteins	no
O	O	in	yes
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	120-140	no
O	O	kDa	no
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-brand	B-brand	AMEVIVE	no
O	O	in	yes
O	O	pediatric	yes
O	O	patients	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	with	yes
O	O	doses	no
O	O	higher	no
O	O	than	no
O	O	40	yes
O	O	mg	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	dextrorotatory	no
O	O	isomer	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	had	no
O	O	effects	no
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	of	yes
B-drug_n	B-drug_n	PCP	yes
O	O	in	yes
O	O	both	no
O	O	species	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	increase	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	pseudoephedrine	yes
O	O	,	no
O	O	while	no
O	B-drug	kaolin	yes
O	O	decreases	no
O	O	it	no
O	O	.	no

O	B-group	Thyroid	yes
O	I-group	hormone	yes
O	O	activity	yes
O	O	may	no
O	O	also	no
O	O	be	no
O	O	enhanced	no
O	O	.	no

B-drug	B-drug	Ritonavir	yes

B-drug	B-drug	Methotrexate	yes
O	O	Renal	no
O	O	tubular	no
O	O	transport	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	may	no
O	O	be	no
O	O	inhibited	no
O	O	by	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	potentially	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	A	yes
O	O	number	no
O	O	of	yes
O	O	drugs	no
O	O	,	no
O	O	including	no
B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	displace	no
B-drug	B-drug	warfarin	yes
O	O	from	no
O	O	plasma	yes
O	O	protein	yes
O	O	;	no

O	O	Milk	yes
O	O	,	no
O	O	milk	yes
O	O	products	no
O	O	,	no
O	O	and	yes
O	B-drug	calcium-rich	no
O	O	foods	no
O	O	or	no
O	O	drugs	no
O	O	may	no
O	O	impair	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-brand	B-brand	EMCYT	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	increase	no
O	O	or	no
O	O	decrease	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	coumarin	yes
I-group	I-group	derivatives	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	gemfibrozil	yes
O	O	with	yes
B-drug	B-brand	Targretin	yes
O	O	capsules	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	and	yes
B-drug	B-drug	diflunisal	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	and	yes
O	O	these	no
B-group	O	imidazole	yes
O	O	and	yes
B-group	B-group	triazole	no
I-group	I-group	antifungals	no
O	O	have	no
O	O	not	no
O	O	been	no
O	B-group	conducted	no
O	I-group	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	taking	no
O	O	another	no
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	should	no
O	O	not	no
O	O	cause	no
O	O	transient	no
O	O	increase	no
O	O	in	yes
O	O	free	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	When	no
O	O	taken	no
O	O	orally	no
O	O	,	no
B-group	B-group	imidazole	yes
I-group	I-group	compounds	no
O	O	like	yes
B-drug	B-drug	ketoconazole	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-group	B-group	coumarin-like	no
I-group	O	drugs	no
O	O	.	no

B-group	B-group	Anticholinergic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	affect	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
O	O	various	no
O	O	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	slowly	no
O	O	dissolving	no
O	O	dosage	no
O	O	forms	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	;	no

O	O	However	no
O	O	,	no
O	O	no	yes
O	O	clinically	no
O	O	or	no
O	O	statistically	no
O	O	significant	no
O	O	differences	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	ratio	no
O	O	or	no
B-drug	B-drug	warfarin	yes
I-drug	O	enantiomer	no
O	O	pharmacokinetics	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	a	yes
O	O	small	no
O	O	study	no
O	O	of	yes
O	O	7	yes
O	O	healthy	no
O	O	males	no
O	O	who	no
O	O	received	no
O	O	both	no
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	lomefloxacin	yes
O	O	under	no
O	O	steady-state	no
O	O	conditions	no
O	O	.	no

O	O	All	yes
O	O	of	yes
O	O	these	no
O	O	also	no
O	O	resolved	no
O	O	,	no
O	O	2	yes
O	O	with	yes
O	O	continuation	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	and	yes
O	O	3	yes
O	O	after	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	leflunomide	yes
O	O	.	no

O	O	Optimal	no
O	O	designs	no
O	O	for	yes
O	O	the	no
O	O	individual	no
O	O	and	yes
O	O	joint	no
O	O	exposure	yes
O	O	general	no
O	O	logistic	no
O	O	regression	no
O	O	models	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
B-drug	B-drug	etomidate	yes
O	O	.	no

O	O	The	no
O	O	renal	no
O	O	plasma	yes
O	O	flow	no
O	O	,	no
O	O	glomerular	no
O	O	filtration	no
O	O	rate	no
O	O	and	yes
B-drug	O	pulsatile	no
O	O	choroidal	no
O	O	blood	yes
O	O	flow	no
O	O	were	no
O	O	measured	no
O	O	using	no
O	O	the	no
O	O	paraaminohippurate	no
O	O	method	yes
O	O	,	no
O	O	the	no
O	O	inulin	yes
O	O	method	yes
O	O	and	yes
O	O	a	yes
O	O	laser	no
O	O	interferometric	no
O	O	measurement	no
O	O	of	yes
O	O	fundus	no
O	O	pulsation	no
O	O	amplitude	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-group	B-group	Potassium-sparing	no
I-group	I-group	diuretics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	amiloride	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	only	no
O	O	for	yes
O	O	documented	no
O	O	hypokalemia	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	since	no
O	O	they	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	of	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

O	O	Optimal	no
O	O	conditions	no
O	O	,	no
O	O	kinetics	no
O	O	,	no
O	O	equilibrium	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	mechanism	no
O	O	of	yes
O	O	this	no
O	O	acid-catalyzed	no
O	O	ethanolysis	no
O	O	are	no
O	O	reported	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Dosage	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	may	no
O	O	require	no
O	O	reduction	yes
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	maintain	no
O	O	satisfactory	no
O	O	therapeutic	no
O	O	hypoprothrombinemia	no
O	O	.	no

O	O	The	no
O	O	histology	no
O	O	of	yes
O	O	the	no
O	O	liver	yes
O	O	was	no
O	O	altered	no
O	O	in	yes
O	O	the	no
O	O	three	no
O	O	groups	no
O	O	which	no
O	O	were	no
O	O	submitted	no
O	O	to	no
O	O	treatment	no
O	O	with	yes
O	O	the	no
B-drug	O	hydroalcoholic	no
O	O	solutions	no
O	O	,	no
O	O	with	yes
O	O	quantitative	no
O	O	and	yes
O	O	qualitative	no
O	O	differences	no
O	O	between	yes
O	O	the	no
O	O	groups	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	laboratory	no
O	O	tests	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	abnormal	no
O	O	in	yes
O	O	a	yes
O	O	few	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	baclofen	yes
O	O	:	no
O	O	increased	no
O	O	SGOT	no
O	O	,	no
O	O	elevated	no
O	O	alkaline	yes
O	O	phosphatase	yes
O	O	,	no
O	O	and	yes
O	O	elevation	no
O	O	of	yes
O	O	blood	yes
O	O	sugar	yes
O	O	.	no

O	O	Analgesic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistaminics	no
O	O	.	no

O	O	Combined	no
O	O	effects	no
O	O	may	no
O	O	induce	no
O	O	serious	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Hypoglycemic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	In	yes
O	O	one	no
O	O	study	no
O	O	,	no
B-drug	B-drug	flurbiprofen	yes
O	O	was	no
O	O	given	no
O	O	to	no
O	O	adult	yes
O	O	diabetics	no
O	O	who	no
O	O	were	no
O	O	already	no
O	O	receiving	no
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	n=4	no
O	O	)	no
O	O	,	no
B-drug	B-drug	metformin	yes
O	O	(	no
B-drug	O	n=2	no
O	O	)	no
B-drug	B-drug	chlorpropamide	yes
O	O	with	yes
B-drug	B-drug	phenformin	yes
O	O	(	no
B-brand	O	n=	no
I-brand	O	3	yes
O	O	)	no
O	O	or	no
B-drug	B-drug	glyburide	yes
O	O	with	yes
B-drug	B-drug	phenformin	yes
O	O	(	no
O	O	n=6	no
O	O	)	no
O	O	.	no

B-brand	B-brand	CELEBREX	yes
O	O	should	no
O	O	be	no
O	O	introduced	no
O	O	at	yes
O	O	the	no
O	O	lowest	no
O	O	recommended	no
O	O	dose	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	fluconazole	yes
O	O	.	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	akathisia	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	of	yes
O	O	the	no
O	O	weekly	yes
O	O	dosage	no
O	O	schedule	no
O	O	was	no
O	O	greater	no
O	O	(	no
O	O	8.5	no
O	O	%	no
O	O	,	no
O	O	4/47	no
O	O	patients	no
O	O	)	no
O	O	when	no
B-drug	B-drug	prochlorperazine	yes
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	the	no
O	O	same	yes
O	O	day	no
O	O	as	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	than	no
O	O	when	no
O	O	these	no
O	O	drugs	no
O	O	were	no
O	O	given	no
O	O	on	no
O	O	separate	no
O	O	days	no
O	O	(	no
O	O	1.3	no
O	O	%	no
O	O	,	no
O	O	1/80	yes
O	O	patients	no
O	O	)	no
O	O	.	no

O	O	To	no
O	O	avoid	no
B-drug	B-drug	phenytoin	yes
O	O	intoxication	no
O	O	,	no
O	O	appropriate	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticonvulsant	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	no	yes
O	O	significant	no
O	O	difference	no
O	O	in	yes
O	O	the	no
O	O	maximum	no
O	O	concentration	no
O	O	in	yes
O	O	plasma	yes
O	O	or	no
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	concentration-time	no
O	O	curve	no
O	O	from	no
O	O	time	no
O	O	zero	no
O	O	to	no
O	O	8	yes
O	O	h	yes
O	O	was	no
O	O	observed	no
O	O	.	no

O	B-drug	Orlistat-Orlistat	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	vivo	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	.	no

O	O	Clinical	no
O	O	Comment	no

O	O	When	no
O	O	used	no
O	O	in	yes
O	O	therapeutic	no
O	O	doses	no
O	O	,	no
B-drug	B-drug	azithromycin	yes
O	O	had	no
O	O	a	yes
O	O	modest	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	cetirizine	yes
O	O	,	no
B-drug	B-drug	didanosine	yes
O	O	,	no
B-drug	B-drug	efavirenz	yes
O	O	,	no
B-drug	B-drug	fluconazole	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	rifabutin	yes
O	O	,	no
B-drug	B-drug	sildenafil	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	intravenous	yes
O	O	and	yes
O	O	oral	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	triazolam	yes
O	O	,	no
B-drug	B-drug	trimethoprim/sulfamethoxazole	no
O	O	or	no
B-drug	B-drug	zidovudine	yes
O	O	.	no

B-group	B-group	HMG-CoA	no
I-group	I-group	Reductase	no
I-group	I-group	Inhibitors	no
O	O	:	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	simvastatin	yes
O	O	WARNING	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	risk	no
O	O	of	yes
O	O	myopathy	no
O	O	including	no
O	O	rhabdomyolysis	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	to	no
O	O	established	no
O	O	drug	yes
O	O	interactions	no
O	O	,	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	potential	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	nevirapine	yes
O	O	and	yes
O	O	other	no
O	O	drug	yes
O	O	classes	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interaction	no
O	O	After	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	ampicillin	yes
O	O	,	no
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	B-drug_n	copper	yes
O	I-drug_n	sulfate	yes
O	O	tests	no
O	O	(	no
O	O	Benedicts	no
O	O	solution	yes
O	O	,	no
O	O	Fehlings	no
O	O	solution	yes
O	O	,	no
O	O	or	no
O	O	Clinitest	no
O	O	tablets	yes
O	O	)	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	enzyme	no
O	O	based	no
O	O	tests	no
O	O	such	no
O	O	as	yes
O	O	Clinistix	no
O	O	and	yes
O	O	Glucose	yes
O	O	Enzymatic	no
O	O	Test	yes
O	O	Strip	no
O	O	USP	yes
O	O	.	no

B-drug	B-drug	Lovastatin	yes
O	O	therapy	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	bleeding	no
O	O	or	no
O	O	with	yes
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	patients	no
O	O	not	no
O	O	taking	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	.	no

O	O	Note	no
O	O	:	no

B-drug	B-drug	Olanzapine	yes
O	O	,	no
O	O	a	yes
O	B-group	thienobenzodiazepine	no
O	I-group	derivative	yes
O	O	,	no
O	O	is	yes
O	O	a	yes
O	B-group	second	no
O	I-group	generation	no
O	I-group	(	no
B-group	I-group	atypical	no
I-group	I-group	)	no
I-group	I-group	antipsychotic	no
I-group	I-group	agent	yes
O	O	which	no
O	O	has	no
O	O	proven	no
O	O	efficacy	no
O	O	against	yes
O	O	the	no
O	O	positive	no
O	O	and	yes
O	O	negative	no
O	O	symptoms	no
O	O	of	yes
O	O	schizophrenia	no
O	O	.	no

O	O	Other	no
O	O	Drug	yes
O	O	Interaction	no
O	O	Information	no
B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Studies	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-brand	B-brand	TIKOSYN	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Caution	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	which	no
O	O	can	no
O	O	affect	no
O	O	the	no
O	O	metabolism	no
O	O	and	yes
O	O	uptake	no
O	O	of	yes
O	O	circulating	no
O	O	amines	no
O	O	.	no

B-drug	B-drug	Propanolol	yes
O	O	:	no
O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	almotriptan	yes
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	.	no

O	O	phase	no
O	O	1	yes
O	O	(	no
O	O	days	no
O	O	1-6	no
O	O	)	no
O	O	:	no
B-drug	B-drug	cisapride	yes
O	O	10	yes
O	O	mg	yes
O	O	4	yes
O	O	times/day	no
O	O	;	no

O	O	Compared	no
O	O	with	yes
B-drug	B-drug	risperidone	yes
O	O	,	no
B-drug	B-drug	olanzapine	yes
O	O	has	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	overall	no
O	O	treatment	no
O	O	costs	no
O	O	,	no
O	O	despite	no
O	O	the	no
O	O	several-fold	no
O	O	higher	no
O	O	daily	no
O	O	acquisition	no
O	O	cost	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	-	yes
O	O	Although	no
B-brand	B-brand	LEXAPRO	yes
O	O	did	no
O	O	not	no
O	O	potentiate	no
O	O	the	no
O	O	cognitive	no
O	O	and	yes
O	O	motor	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	in	yes
O	O	a	yes
O	O	clinical	no
O	O	trial	no
O	O	,	no
O	O	as	yes
O	O	with	yes
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	medications	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	by	no
O	O	patients	no
O	O	taking	no
B-brand	B-brand	LEXAPRO	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	-	yes
O	O	When	no
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	is	yes
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	anion-exchange	no
I-group	I-group	resins	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	cholestryramine	no
O	O	)	no
O	O	,	no
O	O	an	no
O	O	interval	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	should	no
O	O	be	no
O	O	maintained	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	medicines	no
O	O	,	no
O	O	since	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	I-brand	retard	yes
O	O	is	yes
O	O	impaired	no

O	O	However	no
O	O	,	no
O	O	initial	no
O	O	dose	no
O	O	modification	no
O	O	is	yes
O	O	generally	no
O	O	not	no
O	O	necessary	no
O	O	.	no

O	O	4	yes
O	O	.	no

O	O	These	no
O	O	behavioral	no
O	O	changes	no
O	O	may	no
O	O	be	no
O	O	related	yes
O	O	with	yes
O	O	the	no
O	O	negative	no
O	O	symptoms	no
O	O	of	yes
O	O	schizophrenia	no
O	O	.	no

B-drug	B-drug	metronidazole	yes
O	O	;	no

O	O	Other	no
B-group	B-group	quinolones	no
O	O	have	no
O	O	demonstrated	no
O	O	moderate	no
O	O	to	no
O	O	marked	no
O	O	interference	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	reduced	yes
O	O	clearance	no
O	O	,	no
O	O	a	yes
O	O	prolongation	no
O	O	of	yes
O	O	plasma	yes
O	O	half-life	no
O	O	,	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	symptoms	no
O	O	that	no
O	O	accompany	no
O	O	high	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	METHODS	no
O	O	:	no
O	O	From	no
O	O	the	no
O	O	beginning	no
O	O	of	yes
O	O	the	no
O	O	experiment	no
O	O	,	no
O	O	rats	no
O	O	were	no
O	O	given	no
O	O	10	yes
O	O	weekly	yes
O	O	subcutaneous	yes
O	O	injections	no
O	O	of	yes
B-drug_n	B-drug_n	AOM	no
O	O	(	no
O	O	7.4	yes
O	O	mg/kg	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	and	yes
O	O	subcutaneous	yes
O	O	injections	no
O	O	of	yes
B-drug_n	B-drug_n	bombesin	yes
O	O	(	no
O	O	40	yes
O	O	microg/kg	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	every	no
O	O	other	no
O	O	day	no
O	O	,	no
O	O	and	yes
O	O	from	no
O	O	week	no
O	O	16	yes
O	O	,	no
O	O	intraperitoneal	no
O	O	injections	no
O	O	of	yes
B-drug	B-drug	verapamil	yes
O	O	(	no
O	O	10	yes
O	O	or	no
O	O	20	yes
O	O	mg/kg	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	every	no
O	O	other	no
O	O	day	no
O	O	until	no
O	O	the	no
O	O	end	no
O	O	fo	yes
O	O	the	no
O	O	experiment	no
O	O	in	yes
O	O	week	no
O	O	45	yes
O	O	.	no

O	O	The	no
O	O	exact	no
O	O	length	no
O	O	of	yes
O	O	time	no
O	O	may	no
O	O	vary	no
O	O	and	yes
O	O	is	yes
O	O	dependent	no
O	O	upon	no
O	O	the	no
O	O	particular	no
B-group	B-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	being	no
O	O	used	no
O	O	,	no
O	O	the	no
O	O	length	no
O	O	of	yes
O	O	time	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	dosage	no
O	O	involved	no
O	O	.	no

B-drug	B-drug	Saquinavir	yes

O	O	Interaction	no
O	O	between	yes
B-drug	B-drug	lomefloxacin	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	this	no
O	O	effect	no
O	O	is	yes
O	O	at	yes
O	O	least	no
O	O	balanced	yes
O	O	by	no
O	O	decreased	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	Although	no
B-drug	B-drug	metoclopramide	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	levodopa	yes
O	O	by	no
O	O	increasing	no
O	O	gastric	yes
O	O	emptying	no
O	O	,	no
B-drug	B-drug	metoclopramide	yes
O	O	may	no
O	O	also	no
O	O	adversely	no
O	O	affect	no
O	O	disease	no
O	O	control	no
O	O	by	no
O	O	its	no
O	O	dopamine	yes
O	O	receptor	yes
O	O	antagonistic	no
O	O	properties	no
O	O	.	no

O	O	This	no
O	O	increase	no
O	O	may	no
O	O	be	no
O	O	clinically	no
O	O	relevant	no
O	O	as	yes
O	O	adverse	no
O	O	experiences	no
O	O	are	no
O	O	related	yes
O	O	to	no
O	O	dose	no
O	O	and	yes
O	O	exposure	yes
O	O	;	no

O	O	Increasing	no
O	O	the	no
B-drug	B-drug	indinavir	yes
O	O	dose	no
O	O	to	no
O	O	1000	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	does	no
O	O	not	no
O	O	compensate	no
O	O	for	yes
O	O	the	no
O	O	increased	no
B-drug	B-drug	indinavir	yes
O	O	metabolism	no
O	O	due	no
O	O	to	no
B-drug	B-drug	efavirenz	yes
O	O	.	no

O	O	Internal	no
O	O	application	no
O	O	of	yes
B-drug_n	B-drug_n	InsP	no
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	3	yes
O	I-drug_n	)	no
O	O	(	no
O	O	100	yes
O	O	microM	no
O	O	)	no
O	O	increased	no
O	O	intracellular	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	concentration	no
O	O	(	no
O	O	[	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	]	no
O	O	(	no
O	O	i	yes
O	O	)	no
O	O	)	no
O	O	and	yes
O	O	activated	yes
O	O	the	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	-dependent	no
O	O	K	yes
O	O	(	no
O	O	+	no
O	O	)	no
O	O	current	no
O	O	.	no

O	O	If	no
O	O	treatment	no
O	O	with	yes
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	activity	yes
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	intraconazole	no
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	is	yes
O	O	indicated	no
O	O	,	no
O	O	reduction	yes
O	O	of	yes
O	O	the	no
B-drug	B-drug	budesonide	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	The	no
O	O	core	yes
O	O	temperature	no
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	300	yes
O	O	minutes	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	.	no

O	O	St.	yes
O	O	Johns	yes
O	O	wort	yes
O	O	(	no
O	O	Hypericum	yes
O	O	perforatum	yes
O	O	)	no
O	O	may	no
O	O	decrease	no
B-brand	B-brand	SPRYCEL	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	unpredictably	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	multiple	no
O	O	dose	no
O	O	study	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	cetirizine	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	16	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	cetirizine	yes
O	O	was	no
O	O	observed	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
O	O	low-dose	no
B-brand	B-brand	aspirin	yes
O	O	plus	yes
B-drug	B-drug	ibuprofen	yes
O	O	were	no
O	O	not	no
O	O	studied	no
O	O	.	no

O	O	These	no
O	O	drugs	no
O	O	include	no
O	O	the	no
B-group	B-group	thiazides	no
O	O	and	yes
O	O	other	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	products	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	B-group	sympathomimetics	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	iloprost	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	vasodilators	no
O	O	and	yes
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-drug	B-drug	Levofloxacin	yes
O	O	.	no

O	O	These	no
O	O	reports	no
O	O	are	no
O	O	more	no
O	O	frequent	no
O	O	for	yes
O	O	women	yes
O	O	who	no
O	O	use	no
O	O	only	no
O	O	a	yes
O	O	single	yes
O	O	method	yes
O	O	of	yes
O	O	contraception	no
O	O	.	no

O	O	Other	no
O	O	medicines	no
O	O	-	yes
O	O	Although	no
O	O	certain	no
O	O	medicines	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	together	no
O	O	at	yes
O	O	all	yes
O	O	,	no
O	O	in	yes
O	O	other	no
O	O	cases	no
O	O	two	no
O	O	different	no
O	O	medicines	no
O	O	may	no
O	O	be	no
O	O	used	no
O	O	together	no
O	O	even	no
O	O	if	no
O	O	an	no
O	O	interaction	no
O	O	might	no
O	O	occur	no
O	O	.	no

O	O	Most	no
O	O	cases	no
O	O	of	yes
O	O	serious	no
O	O	or	no
O	O	fatal	no
O	O	adverse	no
O	O	events	no
O	O	involving	no
B-brand	B-brand	Levo-Dromoran	yes
O	O	reported	no
O	O	to	no
O	O	the	no
O	O	manufacturer	no
O	O	or	no
O	O	the	no
O	O	FDA	no
O	O	have	no
O	O	involved	no
O	O	either	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	large	no
O	O	initial	no
O	O	doses	no
O	O	or	no
O	O	too	no
O	O	frequent	no
O	O	doses	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	to	no
O	O	nonopioid	no
O	O	tolerant	no
O	O	patients	no
O	O	,	no
O	O	or	no
O	O	the	no
O	O	simultaneous	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	levorphanol	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	affecting	no
O	O	respiration	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	demonstrate	no
O	O	a	yes
O	O	high	yes
O	O	degree	no
O	O	of	yes
O	O	stereoselectivity	no
O	O	in	yes
O	O	the	no
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	NANM	no
O	O	.	no

B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	and	yes
O	O	many	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	for	yes
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	many	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	O	Type	yes
I-group	O	1C	no
I-group	O	antiarrhythrnics	no
B-drug	O	propatenone	no
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	ceftibuten	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	administered	no
O	O	orally	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes

O	O	As	yes
O	O	a	yes
O	O	precursor	yes
O	O	to	no
O	O	this	no
O	O	effort	no
O	O	,	no
O	O	optimal	no
O	O	and	yes
O	O	minimal	no
O	O	experimental	no
O	O	designs	no
O	O	for	yes
O	O	the	no
O	O	case	no
O	O	in	yes
O	O	which	no
O	O	a	yes
O	O	single	yes
O	O	compound	yes
O	O	is	yes
O	O	administered	no
O	O	have	no
O	O	also	no
O	O	been	no
O	O	developed	no
O	O	.	no

O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	synergistic	no
O	O	anticonvulsant	no
O	O	action	no
O	O	.	no

O	O	If	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	saquinavir	yes
O	O	hard	no
B-drug	O	gelatin	no
O	O	capsules	no
O	O	at	yes
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	of	yes
O	O	600	yes
O	O	mg	yes
O	O	tid	no
O	O	,	no
O	O	no	yes
O	O	dose	no
O	O	adjustments	no
O	O	are	no
O	O	needed	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
B-brand	B-brand	REGRANEX	yes
O	O	Gel	yes
O	O	interacts	no
O	O	with	yes
O	O	other	no
O	O	topical	yes
O	O	medications	no
O	O	applied	no
O	O	to	no
O	O	the	no
O	O	ulcer	no
O	O	site	no
O	O	.	no

O	O	.	no

O	O	Possible	no
O	O	extrarenal	no
O	O	mechanisms	no
O	O	of	yes
O	O	action	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	on	no
B-drug	B-drug	verografine	no
O	O	and	yes
B-drug	B-drug	iodamide	yes
O	O	transport	no
O	O	were	no
O	O	also	no
O	O	examined	no
O	O	.	no

O	O	[	no
O	O	Hippocampus	no
O	O	as	yes
O	O	interaction	no
O	O	sites	no
O	O	between	yes
O	O	cerebral	no
O	O	memory	no
O	O	systems	no
O	O	]	no
O	O	Most	no
O	O	of	yes
O	O	the	no
O	O	current	no
O	O	theories	no
O	O	assume	no
O	O	that	no
O	O	there	no
O	O	are	no
O	O	multiple	no
O	O	forms	no
O	O	of	yes
O	O	memory	no
O	O	that	no
O	O	are	no
O	O	supported	no
O	O	by	no
O	O	separate	no
O	O	brain	yes
O	O	systems	no
O	O	and	yes
O	O	have	no
O	O	different	no
O	O	characteristics	no
O	O	.	no

O	O	Concomitant	no
O	O	medications	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	assessed	no
O	O	.	no

O	O	Periodic	no
O	O	measurement	no
O	O	of	yes
O	O	serum	yes
O	O	PSA	no
O	O	levels	no
O	O	may	no
O	O	also	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Recovery	no
O	O	of	yes
O	O	hoof	no
O	O	twitch	no
O	O	from	no
O	O	50	yes
O	O	%	no
O	O	to	no
O	O	75	yes
O	O	%	no
O	O	took	no
O	O	7.7	no
O	O	+/-	no
O	O	0.7	no
O	O	min	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	alone	no
O	O	and	yes
O	O	11.5	no
O	O	+/-	no
O	O	2.7	no
O	O	min	no
O	O	for	yes
B-drug	B-drug	atracurium	yes
O	O	plus	yes
B-drug	B-drug	gentamycin	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	0.03	no
O	O	)	no
O	O	.	no

O	O	Inducers	no
O	O	and	yes
O	O	Inhibitors	no
O	O	of	yes
O	O	Hepatic	no
O	O	Metabolism	no
O	O	:	no
B-drug	B-drug	Rifampin	yes
O	O	reduced	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	carvedilol	yes
O	O	by	no
O	O	about	no
O	O	70	yes
O	O	%	no
O	O	.	no

O	O	The	no
B-group	B-group	fluoroquinolones	no
O	O	are	no
O	O	a	yes
O	O	rapidly	yes
O	O	growing	no
O	O	class	no
O	O	of	yes
B-group	B-group	antibiotics	no
O	O	with	yes
O	O	a	yes
O	O	broad	no
O	O	spectrum	no
O	O	of	yes
O	O	activity	yes
O	O	against	yes
O	O	gram-negative	no
O	O	and	yes
O	O	some	no
O	O	gram-positive	no
O	O	aerobic	no
O	O	bacteria	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	minimum	no
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	increased	no
O	O	15	yes
O	O	%	no
O	O	and	yes
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	was	no
O	O	decreased	no
O	O	by	no
O	O	19	yes
O	O	%	no
O	O	during	no
O	O	this	no
O	O	period	no
O	O	of	yes
O	O	concomitant	no
O	O	drug	yes
O	O	administration	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	escitalopram	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	multiple	no
O	O	enzyme	no
O	O	systems	no
O	O	,	no
O	O	inhibition	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	enzyme	no
O	O	may	no
O	O	not	no
O	O	appreciably	no
O	O	decrease	no
B-drug	B-drug	escitalopram	yes
O	O	clearance	no
O	O	.	no

O	O	Some	no
O	B-drug	drugs/substances	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	accelerate	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	by	no
O	O	stimulating	yes
O	O	the	no
O	O	synthesis	no
O	O	of	yes
O	B-drug	CYP3A4	no
O	O	(	no
O	O	enzyme	no
O	O	induction	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-brand	B-brand	HUMIRA	yes
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	patients	no
O	O	taking	no
O	O	concomitant	no
B-drug	B-drug	MTX	yes
O	O	.	no

O	O	Some	no
O	O	disorders	no
O	O	unrelated	no
O	O	to	no
O	O	sexual	no
O	O	dysfunction	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	O	esophageal	no
O	O	motility	no
O	O	dysfunction	no
O	O	)	no
O	O	may	no
O	O	also	no
O	O	respond	no
O	O	to	no
B-drug	B-drug	sildenafil	yes
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	irbesartan	yes
O	O	reduced	yes
B-drug	B-drug	aliskiren	yes
O	O	Cmax	no
O	O	up	no
O	O	to	no
O	O	50	yes
O	O	%	no
O	O	after	no
O	O	multiple	no
O	O	dosing	no
O	O	.	no

B-drug	B-drug	Disulfiram	yes
O	O	alone	no
O	O	in	yes
O	O	the	no
O	O	rat	yes
O	O	s	yes
O	O	diet	no
O	O	did	no
O	O	not	no
O	O	lead	no
O	O	to	no
O	O	such	no
O	O	tumors	no
O	O	.	no

O	O	Platelet	yes
O	O	function	no
O	O	studies	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	have	no
O	O	not	no
O	O	demonstrated	no
O	O	any	no
O	O	significant	no
O	O	platelet	yes
O	O	dysfunction	no
O	O	.	no

B-drug	B-drug	Paclitaxel	yes
O	O	-	yes
O	O	In	yes
O	O	one	no
O	O	report	no
O	O	,	no
B-drug	B-drug	L-glutamine	yes
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	10	yes
O	O	grams	no
O	O	three	no
O	O	times	no
O	O	daily	no
O	O	,	no
O	O	given	no
O	O	24	yes
O	O	hours	no
O	O	after	no
O	O	receiving	no
B-drug	B-drug	paclitaxel	yes
O	O	,	no
O	O	appeared	no
O	O	to	no
O	O	prevent	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	myalgia	no
O	O	and	yes
O	O	arthralgia	no
O	O	,	no
O	O	adverse	no
O	O	reactions	no
O	O	of	yes
B-drug	B-drug	paclitaxel	yes
O	O	.	no

B-drug	B-drug	METH	no
O	O	induced	no
O	O	arc	no
O	O	mRNA	yes
O	O	in	yes
O	O	layers	no
O	O	IV	yes
O	O	and	yes
O	O	VI	no
O	O	of	yes
O	O	the	no
O	O	cortex	no
O	O	which	no
O	O	dopamine	yes
O	O	receptor	yes
O	O	are	no
O	O	localized	no
O	O	to	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
B-drug	B-drug	Tiagabine	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	or	no
O	O	its	no
O	O	epoxide	no
O	O	metabolite	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	Table	no
O	O	4	yes
O	O	Potential	no
O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	Use	no
O	O	With	yes
O	O	Caution	no
O	O	,	no
O	O	Dose	no
O	O	Adjustment	no
O	O	of	yes
O	O	Co-administered	no
O	O	Drug	yes
O	O	May	no
O	O	Be	no
O	O	Needed	no
O	O	due	no
O	O	to	no
O	O	Possible	no
O	O	Decrease	no
O	O	in	yes
O	O	Clinical	no
O	O	Effect	no

O	O	Other	no
O	O	concomitant	no
O	O	therapies	no
O	O	:	no
O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	the	no
O	O	safety	no
O	O	profile	no
O	O	in	yes
O	O	subjects	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	Acamprosate	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	anxiolytics	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	and	yes
B-group	B-group	sedatives	no
O	O	(	no
O	O	including	no
B-group	B-group	benzodiazepines	no
O	O	)	no
O	O	,	no
O	O	or	no
B-group	B-group	non-opioid	no
I-group	I-group	analgesics	no
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	of	yes
O	O	subjects	no
O	O	taking	no
O	O	placebo	no
O	O	with	yes
O	O	these	no
O	O	concomitant	no
O	O	medications	no
O	O	.	no

O	O	could	no
O	O	not	no
O	O	be	no
O	O	confirmed	no
O	O	for	yes
B-drug	B-drug	cloxacillin	yes
O	O	in	yes
O	O	patients	no
O	O	lacking	no
O	O	kidney	yes
O	O	function	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	-	yes
O	O	The	no
O	O	biochemical	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	metabolizing	no
O	O	isozyme	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	debrisoquin	yes
O	O	hydroxylase	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	caucasian	no
O	O	population	no
O	O	(	no
O	O	about	no
O	O	7-10	no
O	O	%	no
O	O	of	yes
O	O	caucasians	no
O	O	are	no
O	O	so	no
O	O	called	no
O	O	poor	no
O	O	metabolizers	no
O	O	)	no
O	O	;	no

O	O	Chapter	no
O	O	3	yes
O	O	covers	no
O	O	pharmacology	no
O	O	(	no
O	O	pharmacokinetics	no
O	O	,	no
O	O	pharmacodynamics	no
O	O	and	yes
O	O	potency	no
O	O	,	no
O	O	and	yes
O	O	clinical	no
O	O	implications	no
O	O	)	no
O	O	.	no

B-group	B-group	Slow-channel	no
I-group	I-group	calcium	yes
I-group	I-group	blockers	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	verapamil	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	,	no
O	O	inhibit	no
O	O	platelet	yes
O	O	activation	no
O	O	in	yes
O	O	vitro	no
O	O	,	no
O	O	and	yes
O	O	decrease	no
O	O	platelet	yes
O	O	adhesion	yes
O	O	intravascularly	no
O	O	.	no

B-drug	B-drug	Magnesium-	no
O	O	and	yes
B-drug	B-drug	aluminum-containing	no
B-group	B-group	antacids	no
O	O	,	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lomefloxacin	yes
O	O	,	no
O	O	significantly	no
O	O	decreased	no
O	O	the	no
O	O	bioavailability	no
O	O	(	no
O	O	48	yes
O	O	%	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	lomefloxacin	yes
O	O	.	no

O	O	The	no
O	O	regulation	no
O	O	of	yes
O	O	topoisomerases	no
O	O	is	yes
O	O	no	yes
O	O	doubt	no
O	O	complex	yes
O	O	and	yes
O	O	multifaceted	no
O	O	and	yes
O	O	is	yes
O	O	probably	no
O	O	accomplished	no
O	O	through	no
O	O	redundancy	no
O	O	at	yes
O	O	many	no
O	O	control	no
O	O	levels	no
O	O	.	no

O	O	clinical	no
O	O	significance	no
O	O	unknown	no
O	O	.	no

B-group	B-group	Narcotic	no
I-group	I-group	analgesics	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Valdecoxib	yes
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	produced	no
O	O	significant	no
O	O	decreases	no
O	O	in	yes
B-drug	B-drug	lithium	yes
O	O	serum	yes
O	O	clearance	no
O	O	(	no
O	O	25	yes
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	renal	no
O	O	clearance	no
O	O	(	no
O	O	30	yes
O	O	%	no
O	O	)	no
O	O	with	yes
O	O	a	yes
O	O	34	no
O	O	%	no
O	O	higher	no
O	O	serum	yes
O	O	exposure	yes
O	O	compared	no
O	O	to	no
B-drug	B-drug	lithium	yes
O	O	alone	no
O	O	.	no

B-drug	B-drug	Clidinium	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	phenothiazines	no
O	O	,	no
B-drug	B-drug	levodopa	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	(	no
O	O	day	no
O	O	1	yes
O	O	)	no
O	O	and	yes
O	O	40	yes
O	O	mg	yes
O	O	QD	no
O	O	(	no
O	O	days	no
O	O	2-7	no
O	O	)	no
O	O	)	no
O	O	with	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
B-drug	B-drug	glyburide	yes
O	O	BID	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	21	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	glyburide	yes
O	O	AUC0-12	no
O	O	and	yes
O	O	a	yes
O	O	16	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	glyburide	yes
O	O	Cmax	no
O	O	leading	no
O	O	to	no
O	O	a	yes
O	O	16	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	glucose	yes
O	O	AUC0-24	no
O	O	.	no

O	O	Nursing	no
O	O	Mothers	no
B-drug	B-drug	Fulvestrant	yes
O	O	is	yes
O	O	found	no
O	O	in	yes
O	O	rat	yes
O	O	milk	yes
O	O	at	yes
O	O	levels	no
O	O	significantly	no
O	O	higher	no
O	O	(	no
O	O	approximately	no
O	O	12-fold	no
O	O	)	no
O	O	than	no
O	O	plasma	yes
O	O	after	no
O	O	administration	no
O	O	of	yes
O	O	2	yes
O	O	mg/kg	no
O	O	.	no

O	O	dose-dependently	no
O	O	increased	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	defecation	no
O	O	episodes	no
O	O	and	yes
O	O	induced	no
O	O	a	yes
O	O	soft	yes
O	O	and	yes
O	O	watery	no
O	O	stool	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	.	no

O	O	Intermediate	yes
O	O	doses	no
O	O	of	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	+	no
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	or	no
B-drug_n	B-drug_n	PCP	yes
O	O	produced	no
O	O	transient	no
O	O	increases	no
O	O	in	yes
O	O	FI	no
O	O	responding	no
O	O	in	yes
O	O	monkeys	no
O	O	and	yes
O	O	sustained	no
O	O	increases	no
O	O	in	yes
O	O	FI	no
O	O	responding	no
O	O	in	yes
O	O	pigeons	no
O	O	;	no

O	O	The	no
O	O	basal	no
O	O	colonic	no
O	O	fluid	no
O	O	contents	no
O	O	and	yes
O	O	transits	no
O	O	were	no
O	O	the	no
O	O	same	yes
O	O	in	yes
O	O	cecectomized	no
O	O	and	yes
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	nelfinavir	yes
O	O	at	yes
O	O	steady-state	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	(	no
O	O	2	yes
O	O	x	yes
O	O	600	yes
O	O	mg	yes
O	O	tablets	yes
O	O	)	no
O	O	results	no
O	O	in	yes
O	O	increased	no
B-drug	B-drug	azithromycin	yes
O	O	serum	yes
O	O	concentrations	no
O	O	.	no

O	O	Drug	yes
O	O	monitoring	no
O	O	may	no
O	O	be	no
O	O	of	yes
O	O	assistance	no
O	O	in	yes
O	O	detecting	no
O	O	alterations	no
O	O	in	yes
B-drug	B-drug	carbamazepine	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	Pharmacological/Pharmacodynamic	no
O	O	Interactions	no
O	O	with	yes
B-drug	B-drug	Carbamazepine	yes
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	neurotoxic	no
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	The	no
O	O	reaction	no
O	O	after	no
B-drug	B-drug	norepinephrine	yes
O	O	remained	no
O	O	the	no
O	O	same	yes
O	O	in	yes
O	O	both	no
O	O	groups	no
O	O	of	yes
O	O	experiments	no
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
B-drug	B-drug	Olanzapine	yes
O	O	demonstrated	no
O	O	superior	no
O	O	antipsychotic	no
O	O	efficacy	no
O	O	compared	no
O	O	with	yes
B-drug	B-drug	haloperidol	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	acute	no
O	O	phase	no
O	O	schizophrenia	no
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	first-episode	no
O	O	or	no
O	O	treatment-resistant	no
O	O	schizophrenia	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	where	no
O	O	patients	no
O	O	were	no
O	O	on	no
O	O	chronic	no
B-drug	B-drug	theophylline	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	lomefloxacin	yes
O	O	had	no
O	O	no	yes
O	O	measurable	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	mean	no
O	O	distribution	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	or	no
O	O	the	no
O	O	mean	no
O	O	estimates	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	.	no

O	O	No	yes
O	O	cases	no
O	O	of	yes
O	O	rhabdomyolysis	no
O	O	were	no
O	O	reported	no
O	O	in	yes
O	O	this	no
O	O	trial	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	is	yes
O	O	available	no
O	O	about	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	concurrently	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

B-drug	B-drug	Cromolyn	yes
I-drug	I-drug	sodium	yes
O	O	alone	no
O	O	in	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	540	no
O	O	mg/kg/day	no
O	O	(	no
O	O	approximately	no
O	O	340	no
O	O	times	no
O	O	the	no
O	O	maximum	no
O	O	recommended	no
O	O	daily	no
O	O	inhalation	no
O	O	dose	no
O	O	in	yes
O	O	adults	no
O	O	on	no
O	O	a	yes
O	O	mg/m2	no
O	O	basis	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	cause	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
O	O	resorptions	no
O	O	or	no
O	O	major	no
O	O	malformations	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	chronic	no
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Methamphetamine	yes
O	O	,	no
O	O	like	yes
B-drug_n	B-drug_n	MPTP	no
O	O	,	no
O	O	produced	no
O	O	depletions	no
O	O	of	yes
O	O	striatal	no
O	O	dopamine	yes
O	O	but	no
O	O	these	no
O	O	actions	no
O	O	were	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	pargyline	yes
O	O	pretreatment	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	is	yes
O	O	metabolized	no
O	O	to	no
O	B-drug	desethylamiodarone	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP450	no
O	O	)	no
O	O	enzyme	no
O	O	group	yes
O	O	,	no
O	O	specifically	no
O	O	cytochromes	no
O	O	P450	no
O	O	3A4	no
O	O	(	no
O	O	CYP3A4	no
O	O	)	no
O	O	and	yes
O	O	CYP2C8	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	blunt	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
O	O	systemic	no
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Antagonism	no
O	O	was	no
O	O	never	no
O	O	observed	no
O	O	.	no

O	O	When	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	in	yes
O	O	treatment-naive	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	atazanavir	yes
O	O	is	yes
O	O	300	yes
O	O	mg	yes
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	100	yes
O	O	mg	yes
O	O	and	yes
B-brand	B-brand	SUSTIVA	yes
O	O	600	yes
O	O	mg	yes
O	O	(	no
O	O	all	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	.	no

B-group	B-group	Vaccines	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	corticosteroid	no
O	O	therapy	no
O	O	may	no
O	O	exhibit	no
O	O	a	yes
O	O	diminished	no
O	O	response	no
O	O	to	no
B-group	O	toxoids	no
O	O	and	yes
O	O	live	yes
O	B-group	or	no
B-group	I-group	inactivated	yes
I-group	I-group	vaccines	no
O	O	due	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	antibody	yes
O	O	response	no
O	O	.	no

O	O	In	yes
O	O	rats	no
O	O	,	no
O	O	simultaneous	no
O	O	ingestion	no
O	O	of	yes
B-drug	B-drug	disulfiram	yes
O	O	and	yes
O	B-drug	nitrite	yes
O	O	in	yes
O	O	the	no
O	O	diet	no
O	O	for	yes
O	O	78	no
O	O	weeks	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	tumors	no
O	O	,	no
O	O	and	yes
O	O	it	no
O	O	has	no
O	O	been	no
O	O	suggested	no
O	O	that	no
B-drug	B-drug	disulfiram	yes
O	O	may	no
O	O	react	no
O	O	with	yes
B-group	B-group	nitrites	no
O	O	in	yes
O	O	the	no
O	O	rat	yes
O	O	stomach	no
O	O	to	no
O	O	form	yes
O	O	a	yes
B-drug	O	nitrosamine	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	tumorigenic	no
O	O	.	no

B-drug	O	Therophylline	no
O	O	:	no
O	O	A	yes
O	O	recent	no
O	O	study	no
O	O	has	no
O	O	shown	no
O	O	that	no
B-drug	O	concomitan	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	isoniazid	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	may	no
O	O	cause	no
O	O	elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	some	no
O	O	instances	no
O	O	a	yes
O	O	slight	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	and	yes
O	O	(	no
O	O	ii	yes
O	O	)	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	filipin	no
O	O	were	no
O	O	more	no
O	O	efficiently	no
O	O	inhibited	no
O	O	by	no
O	O	added	no
O	O	cholesterol	yes
O	O	,	no
O	O	the	no
O	O	major	no
O	O	membrane	yes
O	O	sterol	no
O	O	in	yes
O	O	human	yes
O	O	cells	yes
O	O	,	no
O	O	whereas	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	were	no
O	O	more	no
O	O	efficiently	no
O	O	inhibited	no
O	O	by	no
B-drug	O	ergosterol	yes
O	O	,	no
O	O	the	no
O	O	major	no
O	O	membrane	yes
O	O	sterol	no
O	O	in	yes
O	O	yeast	no
O	O	.	no

O	O	Some	no
O	O	of	yes
O	O	the	no
O	O	cases	no
O	O	of	yes
O	O	collapse/respiratory	no
O	O	arrest/cardiac	no
O	O	arrest	no
O	O	during	no
O	O	initial	no
O	O	treatment	no
O	O	occurred	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	being	no
O	O	administered	no
B-group	B-group	benzodiazepines	no
O	O	;	no

O	O	For	yes
O	O	comprehensive	no
O	O	information	no
O	O	concerning	no
O	O	laboratory	no
O	O	test	yes
O	O	alterations	no
O	O	associated	no
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	,	no
O	O	physicians	no
O	O	should	no
O	O	refer	no
O	O	to	no
O	O	the	no
O	O	complete	yes
O	O	prescribing	no
O	O	information	no
O	O	for	yes
B-brand	B-brand	NORVIR	yes
O	O	(	no
B-drug	B-drug	ritonavir	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	ERGOMAR	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	triacetyloleandomycin	no
O	O	which	no
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	ergotamine	yes
O	O	.	no

O	O	In	yes
O	O	2	yes
O	O	separate	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	120	no
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	(	no
O	O	240	yes
O	O	mg	yes
O	O	total	yes
O	O	daily	no
O	O	dose	no
O	O	)	no
O	O	was	no
O	O	co-administered	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	erythromycin	yes
O	O	500	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	or	no
B-drug	B-drug	ketoconazole	yes
O	O	400	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	under	no
O	O	steady-state	no
O	O	conditions	no
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	(	no
O	O	n=24	no
O	O	,	no
O	O	each	no
O	O	study	no
O	O	)	no
O	O	.	no

B-group	B-group	HMG-CoA	no
I-group	I-group	Reductase	no
I-group	I-group	inhibitors	no
O	O	:	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	simvastatin	yes

O	O	Oral	yes
B-group	B-group	Anticoagulants	no
O	O	CAUTION	no
O	O	SHOULD	no
O	O	BE	no
O	O	EXERCISED	no
O	O	WHEN	no
B-brand	B-group	COUMARIN	yes
B-group	I-group	ANTICOAGULANTS	no
O	O	ARE	no
O	O	GIVEN	no
O	O	IN	yes
O	O	CONJUNCTION	no
O	O	WITH	yes
B-brand	B-brand	TRICOR	yes
O	O	.	no

O	O	High-dose	no
B-drug	B-drug	cisplatin	yes
O	O	with	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	thiosulfate	yes
O	O	protection	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	reports	no
O	O	of	yes
O	O	significant	no
O	O	respiratory	no
O	O	depression	no
O	O	,	no
O	O	stupor	no
O	O	and/or	no
O	O	hypotension	no
O	O	with	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	loxapine	yes
O	O	and	yes
B-drug	B-drug	lorazepam	yes
O	O	.	no

O	O	The	no
O	O	latter	no
O	O	might	no
O	O	arise	no
O	O	from	no
O	O	a	yes
O	O	hit	no
O	O	in	yes
O	O	a	yes
O	O	genetically	no
O	O	initiated	no
O	O	cell	yes
O	O	,	no
O	O	the	no
O	O	result	no
O	O	of	yes
O	O	which	no
O	O	is	yes
O	O	a	yes
O	O	more	no
O	O	rapid	no
O	O	progression	no
O	O	in	yes
O	O	tumor	yes
O	O	type	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	CYP3A4	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	and	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	other	no
O	B-group	b-lactams	no
O	O	,	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	cephalexin	yes
O	O	is	yes
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	probenecid	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
O	O	using	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	greater	no
O	O	than	no
O	O	1200	no
O	O	mg/day	no
O	O	during	no
O	O	adjunctive	no
O	O	therapy	no
O	O	,	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

B-drug	B-drug	oxolinic	no
I-drug	I-drug	acid	yes
O	O	;	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	In	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	at	yes
O	O	300	yes
O	O	mg	yes
O	O	QID	no
O	O	(	no
O	O	N=12	no
O	O	)	no
O	O	the	no
O	O	mean	no
O	O	apparent	no
O	O	oral	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	fell	no
O	O	by	no
O	O	14	yes
O	O	%	no
O	O	and	yes
O	O	creatinine	yes
O	O	clearance	no
O	O	fell	no
O	O	by	no
O	O	10	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	toxicity	no
O	O	of	yes
O	O	cadmium	no
O	O	,	no
B-drug	B-drug	zinc	yes
O	O	,	no
O	O	and	yes
O	O	cadmium/zinc	no
O	O	mixtures	no
O	O	at	yes
O	O	concentrations	no
O	O	ranging	no
O	O	from	no
O	O	10000	no
O	O	to	no
O	O	10	yes
O	O	microg/l	no
O	O	was	no
O	O	investigated	no
O	O	.	no

B-drug	B-drug	Vecuronium	yes
O	O	:	no
O	O	When	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	perioperative	no
O	O	period	no
O	O	,	no
B-drug	B-drug	piperacillin	yes
O	O	has	no
O	O	been	no
O	O	implicated	no
O	O	in	yes
O	O	the	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	of	yes
B-drug	B-drug	vecuronium	yes
O	O	.	no

O	O	The	no
O	O	agent	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	produce	no
O	O	some	no
O	O	inhibiting	no
O	O	activity	yes
O	O	against	yes
O	O	hepatic	no
O	O	microsomal	no
O	O	7-ethoxycoumarine	no
O	O	deethylase	no
O	O	in	yes
O	O	male	no
O	O	Wistar	no
O	O	rats	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	experiments	no
O	O	.	no

O	O	Other	no
O	O	strong	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
B-drug	B-drug	itraconazole	yes
O	O	)	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	have	no
O	O	similar	no
O	O	effects	no
O	O	and	yes
O	O	need	no
O	O	similar	no
O	O	dose	no
O	O	reductions	no
O	O	;	no

O	O	-	yes
O	O	a	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitor	yes
O	O	(	no
B-group	B-group	MAOI	no
O	O	)	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	isocarboxazid	yes
O	O	(	no
B-brand	B-brand	Marplan	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	tranylcypromine	yes
O	O	(	no
B-brand	B-brand	Parnate	yes
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-drug	phenelzine	yes
O	O	(	no
B-brand	B-brand	Nardil	yes
O	O	)	no
O	O	;	no

O	O	The	no
O	O	mean	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	the	no
B-drug	B-drug	glipizide	yes
O	O	AUC	no
O	O	after	no
B-drug	B-drug	fluconazole	yes
O	O	administration	no
O	O	was	no
O	O	56.9	no
O	O	%	no
O	O	(	no
O	O	range	no
O	O	:	no
O	O	35	yes
O	O	to	no
O	O	81	no
O	O	)	no
O	O	.	no

O	O	A	yes
O	O	potential	no
O	O	interaction	no
O	O	between	yes
O	O	oral	yes
B-drug	B-drug	miconazole	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	leading	no
O	O	to	no
O	O	severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Additive	no
O	O	adverse	no
O	O	effects	no
O	O	resulting	no
O	O	from	no
O	O	cholinergic	no
O	O	blockade	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-brand	B-brand	LEVSIN	no
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
B-group	B-group	antimuscarinics	no
O	O	,	no
B-drug	B-drug	amantadine	yes
O	O	,	no
B-drug	B-drug	haloperidol	yes
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	or	no
O	O	some	no
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Additional	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	recommended	no
O	O	for	yes
O	O	coadministration	no
O	O	with	yes
B-brand	B-brand	INVIRASE	yes
O	O	and	yes
B-drug	B-drug	ritonavir	yes
O	O	are	no
O	O	included	no
O	O	below	no
O	O	.	no

O	O	The	no
O	O	physician	no
O	O	is	yes
O	O	advised	no
O	O	to	no
O	O	monitor	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	and	yes
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	dose	no
O	O	if	no
O	O	necessary	no
O	O	.	no

B-drug	B-drug	Benazepril	yes
O	O	,	no
O	O	like	yes
O	O	other	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	has	no
O	O	had	no
O	O	less	no
O	O	than	no
O	O	additive	no
O	O	effects	no
O	O	with	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blockers	no
O	O	,	no
O	O	presumably	no
O	O	because	no
O	O	both	no
O	O	drugs	no
O	O	lower	no
O	O	blood	yes
O	O	pressure	no
O	O	by	no
O	O	inhibiting	no
O	O	parts	no
O	O	of	yes
O	O	the	no
O	O	renin-angiotensin	no
O	O	system	yes

O	O	Fifteen	no
O	O	to	no
O	O	30	yes
O	O	minutes	no
O	O	of	yes
O	O	exposure	yes
O	O	to	no
O	O	1.25	yes
O	O	MAC	no
B-drug	B-drug	isoflurane	yes
O	O	or	no
B-drug	B-drug	enflurane	yes
O	O	had	no
O	O	minimal	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	action	no
O	O	of	yes
O	O	initial	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	and	yes
O	O	therefore	no
O	O	,	no
O	O	no	yes
O	O	adjustment	no
O	O	to	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	necessary	no
O	O	when	no
B-brand	B-brand	NIMBEX	yes
O	O	is	yes
O	O	administered	no
O	O	shortly	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	volatile	no
O	O	agents	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	with	yes
O	O	several	no
O	O	drugs	no
O	O	which	no
O	O	may	no
O	O	be	no
O	O	administered	no
O	O	concomitantly	no
O	O	showed	no
O	O	that	no
O	O	the	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	flecainide	yes
O	O	binding	no
O	O	to	no
O	O	human	yes
O	O	plasma	yes
O	O	proteins	no
O	O	is	yes
O	O	either	no
O	O	unchanged	no
O	O	or	no
O	O	only	no
O	O	slightly	no
O	O	less	no
O	O	.	no

B-drug_n	B-drug_n	N-methyllevallorphan	no
O	O	(	no
O	O	5	yes
O	O	mg/kg	no
O	O	,	no
O	O	s.c.	no
O	O	)	no
O	O	completely	no
O	O	antagonized	no
O	O	the	no
O	O	inhibitory	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	loperamide	yes
O	O	and	yes
O	O	partly	no
O	O	antagonized	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	At	yes
O	O	a	yes
O	O	median	no
O	O	follow-up	no
O	O	of	yes
O	O	33	no
O	O	months	no
O	O	,	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-brand	B-brand	ARIMIDEX	yes
O	O	and	yes
B-drug	B-drug	tamoxifen	yes
O	O	did	no
O	O	not	no
O	O	demonstrate	no
O	O	any	no
O	O	efficacy	no
O	O	benefit	no
O	O	when	no
O	O	compared	no
O	O	with	yes
B-drug	B-drug	tamoxifen	yes
O	O	in	yes
O	O	all	yes
O	O	patients	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	in	yes
O	O	the	no
O	O	hormone	yes
O	O	receptor-positive	no
O	O	subpopulation	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	dofetilide	yes
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	a	yes
O	O	randomized	no
O	O	,	no
O	O	double-blind	no
O	O	study	no
O	O	.	no

O	O	increased	no
O	O	platelet	yes
O	O	count	no
O	O	;	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	DCG-IV	no
O	O	and	yes
B-drug_n	B-drug_n	L-CCG-1	no
O	O	upon	no
B-drug_n	B-drug_n	phencyclidine	yes
O	O	(	no
B-drug_n	B-drug_n	PCP	yes
O	O	)	no
O	O	-induced	no
O	O	locomotion	no
O	O	and	yes
O	O	behavioral	no
O	O	changes	no
O	O	in	yes
O	O	mice	no
O	O	.	no

O	O	Serious	no
O	O	anticholinergic	no
O	O	symptoms	no
O	O	(	no
O	O	severe	no
O	O	dry	no
O	O	mouth	no
O	O	,	no
O	O	urinary	yes
O	O	retention	no
O	O	,	no
O	O	blurred	no
O	O	vision	no
O	O	)	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	elevations	no
O	O	in	yes
O	O	the	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	when	no
B-drug	B-drug	cimetidine	yes
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	regimen	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	with	yes
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
O	O	and	yes
B-group	B-group	antihistamines	no
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	B-group	central	no
O	I-group	nervous	no
O	I-group	system	yes
O	I-group	depressant	no
O	O	effects	no
O	O	.	no

B-brand	B-brand	Atromid-S	yes
O	O	may	no
O	O	displace	no
O	O	acidic	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	tolbutamide	yes
O	O	from	no
O	O	their	no
O	O	binding	no
O	O	sites	no
O	O	.	no

O	O	-	yes
B-group	B-group	Corticosteroids	no
O	O	,	no
B-drug	B-drug	ACTH	yes
O	O	:	no
O	O	Intensified	no
O	O	electrolyte	yes
O	O	depletion	no
O	O	,	no
O	O	particularly	no
O	O	hypokalemia	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	and	yes
O	O	sudden	no
O	O	death	no
O	O	potentially	no
O	O	associated	no
O	O	with	yes
O	O	elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	thioridazine	yes
O	O	,	no
B-drug	B-drug	Duloxetine	yes
O	O	and	yes
B-drug	B-drug	thioridazine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	co-administered	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	essentially	no
O	O	completely	no
O	O	metabolised	no
O	O	,	no
O	O	therefore	no
O	O	little	no
O	O	is	yes
O	O	excreted	no
O	O	unchanged	no
O	O	.	no

B-drug	B-drug	Atazanavir	yes

B-drug	B-drug	Alcohol	yes
O	O	:	no
O	O	In	yes
O	O	post-marketing	no
O	O	experience	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	reports	no
O	O	of	yes
O	O	adverse	no
O	O	neuropsychiatric	no
O	O	events	no
O	O	or	no
O	O	reduced	yes
B-drug	B-drug	alcohol	yes
O	O	tolerance	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	drinking	no
B-drug	B-drug	alcohol	yes
O	O	during	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	.	no

O	O	Such	no
O	O	an	no
O	O	interaction	no
O	O	can	no
O	O	potentially	no
O	O	lead	no
O	O	to	no
O	O	higher	no
O	O	free	yes
O	O	fractions	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	tiagabine	yes
O	O	or	no
O	O	the	no
O	O	competing	no
O	O	drug	yes
O	O	.	no

B-brand	B-brand	PROSTIN	yes
I-brand	I-brand	E2	yes
O	O	may	no
O	O	augment	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	other	no
B-group	B-group	oxytocic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Single	yes
O	O	dose	no
O	O	bioavailability	no
O	O	studies	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	have	no
O	O	failed	no
O	O	to	no
O	O	wshow	no
O	O	an	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	on	no
B-drug	B-drug	ibuprofen	yes
O	O	blood	yes
O	O	levels	no
O	O	.	no

B-group	O	Ergot	yes
I-group	O	derivatives	no
O	O	:	no
B-drug	B-drug	dihydroergotamine	yes
O	O	,	no
B-drug	B-drug	ergonovine	yes
O	O	,	no
B-drug	B-drug	ergotamine	yes
O	O	,	no
B-drug	B-drug	methylergonovine	yes

B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	show	no
O	O	significant	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	formation	no
O	O	of	yes
O	O	oxidized	yes
B-drug	O	irbesartan	yes
O	O	metabolites	no
O	O	with	yes
O	O	the	no
O	O	known	no
O	O	cytochrome	no
O	O	CYP	no
O	O	2C9	no
O	O	substrates/inhibitors	no
B-drug	B-drug	sulphenazole	no
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	specific	no
O	O	substrates	no
O	O	,	no
O	O	inhibitors	no
O	O	,	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	the	no
O	O	enzyme	no
O	O	system	yes
O	O	may	no
O	O	have	no
O	O	a	yes
O	O	significant	no
O	O	impact	no
O	O	on	no
O	O	the	no
O	O	efficacy	no
O	O	and	yes
O	O	side	no
O	O	effect	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	[	no
O	O	Quantitative	no
O	O	approach	no
O	O	to	no
O	O	treatment	no
O	O	with	yes
O	O	incisive	no
B-group	B-group	neuroleptics	no
O	O	by	no
O	O	therapeutic	no
O	O	monitoring	no
O	O	]	no
O	O	;	no
O	O	The	no
O	O	problems	no
O	O	encountered	no
O	O	during	no
O	O	the	no
O	O	longterm	no
O	O	treatment	no
O	O	of	yes
O	O	psychotic	no
O	O	patients	no
O	O	with	yes
B-group	B-group	neuroleptics	no
O	O	are	no
O	O	illustrated	no
O	O	by	no
O	O	six	no
O	O	typical	no
O	O	case	no
O	O	reports	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-brand	B-drug	BREVIBLOC	yes
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
B-drug	B-drug	succinylcholine-induced	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	patients	no
O	O	undergoing	no
O	O	surgery	no
O	O	.	no

O	O	In	yes
O	O	treatment-experienced	no
O	O	patients	no
O	O	,	no
O	O	available	no
O	O	uncontrolled	no
O	O	data	no
O	O	suggest	no
O	O	these	no
O	O	agents	yes
O	O	contribute	no
O	O	to	no
O	O	regimen	no
O	O	efficacy	no
O	O	in	yes
O	B-group	NNRTI-na	no
O	O	ve	no
O	O	,	no
O	O	treatment-experienced	no
O	O	patients	no
O	O	.	no

O	O	While	no
O	O	all	yes
O	O	the	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	inhibit	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	they	no
O	O	may	no
O	O	vary	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	inhibition	no
O	O	.	no

B-drug	B-drug	Haloperidol	yes
O	O	:	no
B-drug	B-drug	Haloperidol	yes
O	O	blocks	no
O	O	dopamine	yes
O	O	receptors	no
O	O	,	no
O	O	thus	no
O	O	inhibiting	no
O	O	the	no
O	O	central	no
O	O	stimulant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	between	yes
B-brand	B-brand	Prostin	yes
I-brand	I-brand	VR	yes
O	I-brand	Pediatric	yes
O	O	and	yes
O	O	the	no
O	O	therapy	no
O	O	standard	yes
O	O	in	yes
O	O	neonates	no
O	O	with	yes
O	O	restricted	no
O	O	pulmonary	no
O	O	or	no
O	O	systemic	no
O	O	blood	yes
O	O	flow	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	procainamide	yes
O	O	for	yes
O	O	less	no
O	O	than	no
O	O	seven	no
O	O	days	no
O	O	increases	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	procainamide	yes
O	O	and	yes
B-drug_n	O	n-acetyl	yes
B-drug	B-drug	procainamide	yes
O	O	by	no
O	O	55	no
O	O	%	no
O	O	and	yes
O	O	33	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	O	diuretic	no
O	O	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	B-group	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
O	O	potassium-sparing	no
O	O	,	no
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Improvements	no
O	O	in	yes
O	O	general	no
O	O	cognitive	no
O	O	function	no
O	O	seen	no
O	O	with	yes
B-drug	B-drug	olanzapine	yes
O	O	treatment	no
O	O	in	yes
O	O	a	yes
O	O	1-year	no
O	O	controlled	no
O	O	study	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	early-phase	no
O	O	schizophrenia	no
O	O	,	no
O	O	were	no
O	O	significantly	no
O	O	greater	no
O	O	than	no
O	O	changes	no
O	O	seen	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	risperidone	yes
O	O	or	no
B-drug	B-drug	haloperidol	yes
O	O	.	no

O	O	Intravenous	yes
B-drug	B-drug	Pentamidine	yes
O	O	:	no
O	O	Treatment	no
O	O	with	yes
B-drug	B-drug	HIVID	yes
O	O	should	no
O	O	be	no
O	O	interrupted	no
O	O	when	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	a	yes
O	O	drug	yes
O	O	that	no
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	cause	no
O	O	pancreatitis	no
O	O	is	yes
O	O	required	no
O	O	.	no

O	O	Studies	no
O	O	to	no
O	O	evaluate	no
O	O	possible	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	REVIA	yes
O	O	and	yes
O	O	drugs	no
O	O	other	no
O	O	than	no
B-group	B-group	opiates	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	B-drug	nalidixic	yes
O	I-drug	acid	yes
O	O	;	no

O	O	The	no
O	O	findings	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	agent	yes
O	O	has	no
O	O	slight	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	tested	no
O	O	activities	no
O	O	.	no

O	O	Drug	yes
O	O	Effect	no

B-drug	B-drug	Aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	amount	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	(	no
B-brand	B-brand	Lanoxin	yes
O	O	,	no
B-drug	B-drug	Lanoxicaps	yes
O	O	)	no
O	O	that	no
O	O	gets	no
O	O	absorbed	no
O	O	into	no
O	O	your	no
O	O	body	no
O	O	.	no

O	O	Clinical	no
O	O	Comment	no

B-drug	B-drug	Quinidine	yes
O	O	and	yes
B-drug	O	procainamide	yes
O	O	doses	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	one-third	no
O	O	when	no
O	O	either	no
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	halothane	yes
O	O	anesthetic	no
O	O	requirement	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	MAC	no
O	O	)	no
O	O	was	no
O	O	depressed	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	fashion	no
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	56	yes
O	O	%	no
O	O	1-2	no
O	O	hours	no
O	O	and	yes
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	14	yes
O	O	%	no
O	O	5-6	no
O	O	hours	no
O	O	after	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	,	no
O	O	50	yes
O	O	mg/kg	no
O	O	,	no
O	O	im	yes
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
O	O	The	no
O	O	combination	yes
O	O	of	yes
O	O	CHOP	no
O	O	plus	yes
O	O	HAART	no
O	O	is	yes
O	O	feasible	no
O	O	and	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	morbidity	no
O	O	from	no
O	O	OIs	no
O	O	in	yes
O	O	HIV-NHL	no
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
O	O	local	no
B-group	B-group	anesthetic	no
O	I-group	solutions	no
O	O	containing	yes
B-drug	B-drug	epinephrine	yes
O	O	or	no
B-drug	B-drug	norepinephrine	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	or	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	produce	no
O	O	severe	no
O	O	,	no
O	O	prolonged	no
O	O	hypertension	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
O	O	Decreases	no
B-brand	B-brand	aspirin	yes
O	O	effectiveness	no
O	O	by	no
O	O	enzyme	no
O	O	induction	no
O	O	.	no

O	O	Orthostatic	no
O	O	hypotension	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	clozapine	yes
O	O	can	no
O	O	,	no
O	O	in	yes
O	O	rare	no
O	O	cases	no
O	O	(	no
O	O	approximately	no
O	O	1	yes
O	O	case	no
O	O	per	no
O	O	3,000	no
O	O	patients	no
O	O	)	no
O	O	,	no
O	O	be	no
O	O	accompanied	no
O	O	by	no
O	O	profound	no
O	O	collapse	no
O	O	and	yes
O	O	respiratory	no
O	O	and/or	no
O	O	cardiac	no
O	O	arrest	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	dextromethorphan	yes
I-drug	I-drug	hydrobromide	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	additive	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	antihistamines	no
O	O	,	no
B-group	B-group	psychotropics	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	produce	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	vivo	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	.	no

O	O	No	yes
O	O	inhibition	no
O	O	of	yes
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	isoforms	no
O	O	tested	no
O	O	was	no
O	O	observed	no
O	O	at	yes
B-drug	B-drug	gabapentin	yes
O	O	concentrations	no
O	O	up	no
O	O	to	no
O	O	171	no
O	O	mg/mL	no
O	O	(	no
O	O	approximately	no
O	O	15	yes
O	O	times	no
O	O	the	no
O	O	Cmax	no
O	O	at	yes
O	O	3600	no
O	O	mg/day	no
O	O	)	no
O	O	.	no

O	O	Dose	no
O	O	modification	no
O	O	is	yes
O	O	recommended	no
O	O	for	yes
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	also	no
O	O	receiving	no
O	O	a	yes
O	O	potent	no
O	O	CYP	no
O	O	3A4	no
O	O	inducer	no
O	O	.	no

O	O	Following	no
O	O	a	yes
O	O	10	yes
O	O	g	yes
O	O	bolus	no
O	O	of	yes
B-brand	B-brand	AMICAR	yes
O	O	,	no
O	O	transient	no
O	O	peak	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	4.6	no
O	O	mMol/L	no
O	O	or	no
O	O	0.60	no
O	O	mg/mL	no
O	O	have	no
O	O	been	no
O	O	obtained	no
O	O	.	no

B-drug	B-drug	Butalbital	yes
O	O	,	no
B-drug	B-drug	acetaminophen	yes
O	O	and	yes
B-drug	B-drug	caffeine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	:	no
O	O	other	no
B-group	B-group	narcotic	no
I-group	O	analgesics	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-group	B-group	sedative-hypnotics	no
O	O	,	no
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	,	no
O	O	causing	no
O	O	increased	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	Reduced	yes
O	O	efficacy	no
O	O	and	yes
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	breakthrough	no
O	O	bleeding	no
O	O	and	yes
O	O	menstrual	no
O	O	irregularities	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	.	no

O	O	Discontinuation	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	in	yes
O	O	well-controlled	no
O	O	patients	no
O	O	receiving	no
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
O	O	the	no
B-group	B-drug	antidepressants	no
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	and	yes
O	O	to	no
O	O	potentiate	no
O	O	its	no
O	O	toxicity	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	elevated	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	B-drug_n	desmethylastemizole	no
O	O	which	no
O	O	may	no
O	O	prolong	no
O	O	QT	no
O	O	intervals	no
O	O	.	no

B-drug	B-drug	Flurbiprofen	yes
O	O	did	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	affect	no
O	O	the	no
O	O	beta-blocker-mediated	no
O	O	reduction	yes
O	O	in	yes
O	O	heart	no
O	O	rate	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	HCTZ	yes
O	O	alone	no
O	O	,	no
B-drug	B-drug	dofetilide	yes
O	O	AUC	no
O	O	increased	no
O	O	by	no
O	O	27	yes
O	O	%	no
O	O	and	yes
O	O	Cmax	no
O	O	by	no
O	O	21	yes
O	O	%	no
O	O	.	no

O	O	descending	no
O	O	epsilon	yes
O	O	and	yes
O	O	mu	no
O	O	systems	no
O	O	for	yes
B-drug	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	are	no
O	O	proposed	no
O	O	.	no

O	O	Both	no
O	O	steady-state	no
O	O	maximum	no
O	O	concentration	no
O	O	and	yes
O	O	AUC	no
O	O	were	no
O	O	dose	no
O	O	proportional	no
O	O	over	no
O	O	the	no
O	O	full	no
O	O	dose	no
O	O	range	no
O	O	when	no
O	O	assessed	no
O	O	on	no
O	O	day	no
O	O	1	yes
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	for	yes
O	O	the	no
O	O	full	no
O	O	duration	no
O	O	of	yes
O	O	the	no
O	O	study	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	.	no

B-group	B-group	Non-steroidal	no
I-group	I-group	Anti-inflammatory	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	compromised	no
O	O	renal	no
O	O	function	no
O	O	who	no
O	O	are	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	lisinopril	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	further	no
O	O	deterioration	no
O	O	of	yes
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	release	yes
O	O	of	yes
O	O	neutrophils	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	lithium	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	bone	no
O	O	density	no
O	O	;	no

O	O	Treatment	no
O	O	with	yes
B-drug	B-drug	entacapone	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	levodopa/dopa	no
B-group	B-group	decarboxylase	no
I-group	I-group	inhibitor	yes
O	O	does	no
O	O	not	no
O	O	change	no
O	O	these	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Pimozide	yes
O	O	and	yes
B-brand	B-brand	Celexa	yes
O	O	-	yes
O	O	In	yes
O	O	a	yes
O	O	controlled	no
O	O	study	no
O	O	,	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	pimozide	yes
O	O	2	yes
O	O	mg	yes
O	O	co-administered	no
O	O	with	yes
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	40	yes
O	O	mg	yes
O	O	given	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	11	yes
O	O	days	no
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	mean	no
O	O	increase	no
O	O	in	yes
O	O	QTc	no
O	O	values	no
O	O	of	yes
O	O	approximately	no
O	O	10	yes
O	O	msec	no
O	O	compared	no
O	O	to	no
B-drug	B-drug	pimozide	yes
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
O	O	Multiple	no
O	O	dose	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	(	no
O	O	8	yes
O	O	mg/day	no
O	O	monotherapy	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	in	yes
O	O	healthy	no
O	O	women	yes
O	O	of	yes
O	O	childbearing	no
O	O	age	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	property	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-group	B-group	Cephalosporins	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	occasionally	no
O	O	induce	no
O	O	a	yes
O	O	positive	no
O	O	direct	no
O	O	Coombs	no
O	O	test	yes
O	O	.	no

B-drug	B-drug	Loperamide	yes
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	0.1	no
O	O	and	yes
O	O	1.0	no
O	O	mg/kg	no
O	O	,	no
O	O	s.c	no
O	O	.	no
O	O	)	no

O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	cephalosporins	no
O	O	,	no
O	O	high	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cefotetan	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	measurement	no
O	O	of	yes
O	O	serum	yes
O	O	and	yes
O	O	urine	no
O	O	creatinine	yes
O	O	levels	no
O	O	by	no
O	O	Jaffe	no
O	O	reaction	no
O	O	and	yes
O	O	produce	no
O	O	false	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	levels	no
O	O	of	yes
O	O	creatinine	yes
O	O	reported	no
O	O	.	no

O	O	Profound	no
O	O	hypotensive	no
O	O	episodes	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	diazoxide	yes
O	O	infection	no
O	O	and	yes
B-drug	B-drug	hydralazine	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	5	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
B-drug	B-drug	isradipine	yes
O	O	and	yes
O	O	40	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no

O	O	Two	no
O	O	groups	no
O	O	(	no
O	O	SH/DA	no
O	O	;	no
B-brand	O	SH/FA	no
O	O	)	no
O	O	were	no
O	O	submitted	no
O	O	to	no
O	O	daily	no
O	O	treatment	no
O	O	with	yes
B-group	O	synthetic	yes
B-drug	O	hydroalcoholic	no
O	O	solutions	no
O	O	containing	yes
B-drug	B-drug	ethanol	yes
O	O	,	no
B-drug	B-drug_n	methanol	no
O	O	,	no
O	O	higher	no
B-drug	B-drug_n	alcohols	no
O	O	and	yes
B-drug	B-drug_n	acetaldehyde	yes
O	O	in	yes
O	O	the	no
O	O	same	yes
O	O	proportions	no
O	O	as	yes
O	O	those	no
O	O	found	no
O	O	in	yes
O	O	most	no
O	O	common	yes
O	O	distilled	yes
O	O	and	yes
O	O	fermented	no
B-drug	O	alcoholic	no
O	O	beverages	no
O	O	;	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-brand	B-brand	VIOXX	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

B-drug	B-drug	Esomeprazole	yes
O	O	inhibits	no
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	.	no

B-group	B-group	Antihistamines	no

B-group	B-group	Anesthetics	no

B-drug	B-drug	Acetaminophen	yes
O	O	:	no
O	O	A	yes
O	O	report	no
O	O	of	yes
O	O	severe	no
B-drug	B-drug	acetaminophen	yes
O	O	toxicity	no
O	O	was	no
O	O	reported	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	Isoniazid	yes
O	O	.	no

O	O	Interaction	no
O	O	between	yes
B-drug	B-drug	glycine	yes
O	O	and	yes
B-drug	B-drug	glutamate	yes
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	spontaneous	no
O	O	motility	no
O	O	in	yes
O	O	chick	no
O	O	embryos	no
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	was	no
O	O	pharmacodynamic	no
O	O	with	yes
O	O	no	yes
O	O	alteration	no
O	O	of	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	were	no
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	b	yes
O	O	This	no
O	O	table	no
O	O	is	yes
O	O	not	no
O	O	all-inclusive	no
O	O	.	no

O	O	Wait	no
O	O	5	yes
O	O	weeks	no
O	O	after	no
O	O	stopping	no
B-drug	B-drug	escitalopram	yes
O	O	before	no
O	O	starting	no
O	O	a	yes
B-group	B-group	non-selective	no
I-group	I-group	MAO	no
I-group	I-group	inhibitor	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	ritonavir	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	.	no

O	O	This	no
O	O	loss	no
O	O	of	yes
O	O	microtubules	no
O	O	on	no
O	O	cooling	no
O	O	the	no
O	O	nerves	no
O	O	and	yes
O	O	their	no
O	O	reappearance	no
O	O	on	no
O	O	rewarming	no
O	O	was	no
O	O	a	yes
O	O	rapid	no
O	O	process	no
O	O	;	no

O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	increased	no
O	O	sedation	no
O	O	when	no
B-drug	B-drug	guanfacine	yes
O	O	is	yes
O	O	given	no
O	O	with	yes
O	O	other	no
O	B-group	CNS-depressant	no
O	I-group	drug	yes
O	O	should	no
O	O	be	no
O	O	appreciated	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	effects	no
O	O	of	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	or	no
O	O	other	no
B-group	B-group	benzodiazepines	no
O	O	metabolized	no
O	O	via	no
O	O	CYP3A4	no
O	O	(	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
B-drug	B-drug	triazolam	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	coadministering	no
O	O	these	no
O	O	agents	yes
O	O	with	yes
B-drug	B-drug	Aprepitant	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	anticoagulant	no
I-group	I-group	agents	yes
O	O	:	no
O	O	Pharmacokinetic	no
O	O	drug-drug	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	Argatroban	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	7.5	yes
O	O	mg	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	)	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	demonstrated	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test-Interactions	no
O	O	None	no
O	O	observed	no
O	O	.	no

O	O	The	no
O	O	ratios	no
O	O	of	yes
O	O	the	no
O	O	AUCs	no
O	O	of	yes
O	O	unbound	no
B-drug	B-drug	valproate	yes
O	O	to	no
O	O	the	no
O	O	AUCs	no
O	O	of	yes
O	O	the	no
O	O	total	yes
B-drug	B-drug	valproate	yes
O	O	were	no
O	O	11.1	no
O	O	%	no
O	O	,	no
O	O	13.0	no
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	11.5	no
O	O	%	no
O	O	,	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
O	O	0	no
O	O	,	no
O	O	1200	no
O	O	,	no
O	O	and	yes
O	O	2400	no
O	O	mg/day	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	of	yes
O	O	the	no
O	O	ERMBT	no
O	O	after	no
O	O	2	yes
O	O	weeks	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	therapy	no
O	O	were	no
O	O	increased	no
O	O	187	no
O	O	and	yes
O	O	156	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Interations	no

B-brand	B-brand	CANCIDAS	yes
O	O	reduced	yes
O	O	the	no
O	O	blood	yes
O	O	AUC0-12	no
O	O	of	yes
B-drug	B-drug	tacrolimus	yes
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	,	no
O	O	peak	no
O	O	blood	yes
O	O	concentration	no
O	O	(	no
O	O	Cmax	no
O	O	)	no
O	O	by	no
O	O	16	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	12-hour	no
O	O	blood	yes
O	O	concentration	no
O	O	(	no
O	O	C12hr	no
O	O	)	no
O	O	by	no
O	O	26	yes
O	O	%	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	when	no
B-drug	B-drug	tacrolimus	yes
O	O	(	no
O	O	2	yes
O	O	doses	no
O	O	of	yes
O	O	0.1	no
O	O	mg/kg	no
O	O	12	yes
O	O	hours	no
O	O	apart	no
O	O	)	no
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	the	no
O	O	10th	no
O	O	day	no
O	O	of	yes
B-brand	B-brand	CANCIDAS	yes
O	O	70	yes
O	O	mg	yes
O	O	daily	no
O	O	,	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	results	no
O	O	from	no
O	O	a	yes
O	O	control	no
O	O	period	no
O	O	in	yes
O	O	which	no
B-drug	B-drug	tacrolimus	yes
O	O	was	no
O	O	administered	no
O	O	alone	no
O	O	.	no

O	O	This	no
O	O	combinational	no
O	O	action	no
O	O	in	yes
O	O	reversing	no
B-drug	O	vancomycin	yes
O	O	resistance	no
O	O	of	yes
O	O	enterococci	no
O	O	highlights	no
O	O	novel	no
O	O	drug	yes
O	O	targets	no
O	O	and	yes
O	O	has	no
O	O	importance	no
O	O	in	yes
O	O	the	no
O	O	design	no
O	O	of	yes
O	O	new	no
O	O	therapeutic	no
O	O	regimes	no
O	O	against	yes
O	O	resistant	no
O	O	pathogens	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	macrolides	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	in	yes
O	O	clinical	no
O	O	practice	no
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
O	O	anticoagulant	no
O	O	effects	no
O	O	.	no

O	O	Serial	no
O	O	plasma	yes
O	O	and	yes
O	O	urine	no
O	O	samples	no
O	O	for	yes
O	O	measurement	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	,	no
B-drug	B-drug	rifabutin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
O	O	their	no
O	B-drug_n	25-O-desacetyl	no
O	I-drug_n	metabolites	no
O	O	,	no
O	O	were	no
O	O	measured	no
O	O	by	no
O	O	high-performance	no
O	O	liquid	yes
O	O	chromatography	no
O	O	.	no

B-drug	I-drug	Nevirapine	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	should	no
O	O	not	no
O	O	beadministered	no
O	O	concomitantly	no
O	O	becausedecreases	no
O	O	in	yes
B-drug	B-drug	nevirapine	yes
O	O	plasmaconcentrations	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	ofthe	no
O	O	drug	yes
O	O	.	no

B-group	B-group	Antibiotics	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	and/or	no
O	O	in	yes
O	O	vivo	no
O	O	data	no
O	O	show	no
O	O	that	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	troleandomycin	yes
O	O	markedly	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	which	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	cisapride	yes
O	O	levels	no
O	O	and	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	The	no
O	O	treatment	no
O	O	of	yes
O	O	ewes	no
O	O	with	yes
O	O	an	no
O	O	intravenous	yes
O	O	(	no
O	O	IV	yes
O	O	)	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug_n	trichlorfon	no
O	O	,	no
O	O	insufficient	no
O	O	to	no
O	O	produce	no
O	O	significant	no
O	O	inhibition	no
O	O	of	yes
O	O	erythrocyte	no
O	O	acetylcholinesterase	no
O	O	(	no
O	O	AChE	no
O	O	)	no
O	O	activity	yes
O	O	,	no
O	O	appeared	no
O	O	to	no
O	O	produce	no
O	O	additive	no
O	O	effects	no
O	O	with	yes
O	O	those	no
O	O	produced	no
O	O	by	no
O	O	subsequent	no
O	O	treatment	no
O	O	with	yes
O	O	4	yes
O	O	mg	yes
O	O	of	yes
O	B-drug_n	coumaphos/kg/day	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	not	no
O	O	to	no
O	O	exceed	no
O	O	a	yes
O	O	single	yes
O	O	2.5	yes
O	O	mg	yes
B-drug	B-drug	Vardenafil	yes
O	O	dose	no
O	O	in	yes
O	O	a	yes
O	O	72-hour	no
O	O	period	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	.	no

O	B-drug	Castor	no
O	I-drug	oil	yes
O	O	(	no
O	O	4	yes
O	O	ml/kg	no
O	O	,	no
O	O	p.o	no
O	O	.	no
O	O	)	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	increases	no
O	O	both	no
O	O	free	yes
O	O	and	yes
O	O	bound	no
B-drug	B-drug	ketoprofen	yes
O	O	by	no
O	O	reducing	no
O	O	the	no
O	O	plasma	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	ketoprofen	yes
O	O	to	no
O	O	about	no
O	O	one-third	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	decreasing	no
O	O	its	no
O	O	protein	yes
O	O	binding	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	and	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	.	no

O	O	Capsules	no
B-brand	B-brand	INDOCIN	yes
O	O	50	yes
O	O	mg	yes
O	O	t.i.d	no
O	O	.	no
O	O	produced	no
O	O	a	yes
O	O	clinically	no
O	O	relevant	no
O	O	elevation	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	and	yes
O	O	reduction	yes
O	O	in	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	in	yes
O	O	psychiatric	no
O	O	patients	no
O	O	and	yes
O	O	normal	yes
O	O	subjects	no
O	O	with	yes
O	O	steady	no
O	O	state	no
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	concentrations	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	increased	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	initiating	no
O	O	,	no
O	O	adjusting	no
O	O	,	no
O	O	or	no
O	O	discontinuing	no
B-brand	B-brand	COREG	yes
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	,	no
B-drug	B-drug	caffeine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	may	no
O	O	increase	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	Clozapine	yes
O	O	,	no
O	O	potentially	no
O	O	resulting	no
O	O	in	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	Analysis	no
O	O	of	yes
B-drug_n	B-drug_n	16,16-dimethylprostaglandin	no
I-drug_n	O	E2-induced	no
O	O	diarrhea	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	.	no

O	O	Response	no
O	O	to	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
B-drug	B-drug	colchicine	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	findings	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Increases	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	have	no
O	O	been	no
O	O	noted	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	O	long-	no
O	O	term	no
B-drug	B-drug	warfarin	yes
O	O	therapy	no
O	O	after	no
B-drug	B-drug	flutamide	yes
O	O	was	no
O	O	initiated	no
O	O	.	no

O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
B-drug	B-drug	diflunisal	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	dosage	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no
O	O	)	no

O	O	While	no
O	O	all	yes
O	O	the	no
B-group	O	selective	no
I-group	B-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	inhibit	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	they	no
O	O	may	no
O	O	vary	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	inhibition	no
O	O	.	no

B-drug	B-drug	Fulvestrant	yes
O	O	was	no
O	O	not	no
O	O	mutagenic	no
O	O	or	no
O	O	clastogenic	no
O	O	in	yes
O	O	multiple	no
O	O	in	yes
O	O	vitro	no
O	O	tests	no
O	O	with	yes
O	O	and	yes
O	O	without	no
O	O	the	no
O	O	addition	no
O	O	of	yes
O	O	a	yes
O	O	mammalian	no
O	O	liver	yes
O	O	metabolic	no
O	O	activation	no
O	O	factor	yes
O	O	(	no
O	O	bacterial	no
O	O	mutation	no
O	O	assay	no
O	O	in	yes
O	O	strains	no
O	O	of	yes
O	O	Salmonella	no
O	O	typhimurium	no
O	O	and	yes
O	O	Escherichia	yes
O	O	coli	yes
O	O	,	no
O	O	in	yes
O	O	vitro	no
O	O	cytogenetics	no
O	O	study	no
O	O	in	yes
O	O	human	yes
O	O	lymphocytes	no
O	O	,	no
O	O	mammalian	no
O	O	cell	yes
O	O	mutation	no
O	O	assay	no
O	O	in	yes
O	O	mouse	yes
O	O	lymphoma	no
O	O	cells	yes
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	micronucleus	no
O	O	test	yes
O	O	in	yes
O	O	rat	yes
O	O	.	no

O	O	Concomitantly	no
O	O	given	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	did	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	a	yes
O	O	tablet	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	After	no
O	O	1	yes
O	O	h	yes
O	O	,	no
B-drug	B-drug	atracurium	yes
O	O	was	no
O	O	discontinued	no
O	O	and	yes
O	O	hoof	no
O	O	twitch	no
O	O	allowed	no
O	O	to	no
O	O	recover	no
O	O	to	no
O	O	75	yes
O	O	%	no
O	O	.	no

O	O	Depression	no
O	O	is	yes
O	O	reaching	no
O	O	epidemic	no
O	O	proportions	no
O	O	in	yes
O	O	the	no
O	O	western	no
O	O	world	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	or	no
O	O	withdrawn	no
O	O	from	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	Starlix	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	changes	no
O	O	in	yes
O	O	glycemic	no
O	O	control	no
O	O	.	no

O	O	When	no
B-drug	B-drug	amiloride	yes
I-drug	O	HCl	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	an	no
B-group	B-group	angiotensin-converting	no
I-group	I-group	enzyme	no
I-group	I-group	inhibitor	yes
O	O	,	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hyperkalemia	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	.	no

O	O	No	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	between	yes
B-drug	B-drug	nizatidine	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	with	yes
O	O	doses	no
O	O	higher	no
O	O	than	no
O	O	40	yes
O	O	mg	yes
O	O	QD	no
B-drug	B-drug	omeprazole	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	second	no
O	O	experiment	no
O	O	,	no
O	O	non-diabetic	no
O	O	and	yes
O	O	streptozotocin-induced	no
O	O	diabetic	no
O	O	rats	no
O	O	were	no
O	O	fasted	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	same	yes
O	O	procedures	no
O	O	were	no
O	O	followed	no
O	O	for	yes
O	O	estimation	no
O	O	of	yes
O	B-drug	glucose	yes
O	O	tolerance	no
O	O	30	yes
O	O	min	no
O	O	after	no
O	B-drug	glucose	yes
O	O	overload	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	,	no
B-drug	B-drug	Methotrexate	yes
O	O	,	no
B-drug	B-drug	Cyclosporine	yes
O	O	:	no
B-drug	B-drug	Diclofenac	yes
O	O	,	no
O	O	like	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	may	no
O	O	affect	no
O	O	renal	no
O	O	prostaglandins	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
O	O	certain	no
O	O	drugs	no
O	O	.	no

O	O	Studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	isoniazid	yes
O	O	is	yes
O	O	reduced	yes
O	O	significantly	no
O	O	when	no
O	O	administered	no
O	O	with	yes
O	O	food	no
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
B-drug	B-drug	Albuterol	yes
O	O	-	yes
B-brand	B-brand	STRATTERA	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
O	O	systemically-administered	no
O	O	(	no
O	O	oral	yes
O	O	or	no
O	O	intravenous	yes
O	O	)	no
B-drug	B-drug	albuterol	yes
O	O	(	no
O	O	or	no
O	O	other	no
B-group	B-group	beta2	no
I-group	I-group	agonists	no
O	O	)	no
O	O	because	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	albuterol	yes
O	O	on	no
O	O	the	no
O	O	cardiovascular	no
O	O	system	yes
O	O	can	no
O	O	be	no
O	O	potentiated	no
O	O	resulting	no
O	O	in	yes
O	O	increases	no
O	O	in	yes
O	O	heart	no
O	O	rate	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	Drugs	no
O	O	Which	no
O	O	Require	no
O	O	a	yes
O	O	Dose	no
O	O	Reduction	yes
O	O	When	no
O	O	Coadminstered	no
O	O	With	yes
B-brand	B-brand	VIRACEPT	yes
B-group	B-group	Antimycobacterial	no
I-group	I-group	agents	yes
O	O	:	no
B-drug	B-drug	rifabutin	yes

O	O	phosphokinase	no

B-drug	B-drug	Acetaminophen	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	50	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	single-dose	no
O	O	crossover	no
O	O	study	no
O	O	examining	no
B-drug	B-drug	lansoprazole	yes
O	O	30	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	omeprazole	yes
O	O	20	yes
O	O	mg	yes
O	O	each	no
O	O	administered	no
O	O	alone	no
O	O	and	yes
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	sucralfate	yes
O	O	1	yes
O	O	gram	no
O	O	,	no
O	O	absorption	no
O	O	of	yes
O	O	the	no
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	was	no
O	O	delayed	no
O	O	and	yes
O	O	their	no
O	O	bioavailability	no
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	17	yes
O	O	%	no
O	O	and	yes
O	O	16	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	sucralfate	yes
O	O	.	no

O	O	Pharmacokinetics	no
O	O	.	no

B-drug	B-drug	Saquinavir	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	(	no
O	O	using	no
O	O	an	no
O	O	experimental	no
B-drug	O	soft-gelatin	no
O	O	capsule	yes
O	O	formulation	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	1200mg	no
O	O	)	no
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	18	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	4-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	saquinavir	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	This	no
O	O	is	yes
O	O	based	no
O	O	on	no
O	O	the	no
O	O	results	no
O	O	from	no
O	O	3	yes
O	O	clinical	no
O	O	studies	no
O	O	using	no
O	B-drug	histamine	yes
O	O	induced	no
O	O	skin	yes
O	O	wheals	no
O	O	and	yes
O	O	flares	no
O	O	coupled	no
O	O	with	yes
O	O	population	no
O	O	pharmacokinetic	no
O	O	analysis	no
O	O	.	no

O	O	CONCLUSIONS	no
O	O	.	no

O	O	Other	no
O	O	:	no
O	O	There	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	no	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	acitretin	yes
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	glyburide	yes
O	O	.	no

O	O	While	no
O	O	all	yes
O	O	the	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	inhibit	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	they	no
O	O	may	no
O	O	vary	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	inhibition	no
O	O	.	no

O	O	Substrate	yes
O	O	of	yes
O	O	CYP2D6	no
O	O	(	no
O	O	minor	no
O	O	)	no
O	O	,	no
O	O	3A4	no
O	O	(	no
O	O	major	no
O	O	)	no
O	O	;	no

O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	clinical	no
O	O	importance	no
O	O	.	no

O	O	Other	no
B-group	B-group	TNFa-blocking	no
I-group	I-group	agents	yes
O	O	(	no
O	O	including	no
B-brand	B-brand	REMICADE	yes
O	O	)	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	anakinra	yes
O	O	may	no
O	O	also	no
O	O	result	no
O	O	in	yes
O	O	similar	no
O	O	toxicities	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	positive	no
O	O	test	yes
O	O	results	no
O	O	using	no
O	O	the	no
O	O	Bio-Rad	no
O	O	Laboratories	no
O	O	Platelia	no
O	O	Aspergillus	no
O	O	EIA	no
O	O	test	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	piperacillin/tazobactam	no
O	O	injection	yes
O	O	who	no
O	O	were	no
O	O	subsequently	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	free	yes
O	O	of	yes
O	O	Aspergillus	no
O	O	infection	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	Inhibitors	no
O	O	:	no
B-brand	B-brand	DURAGESIC	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	for	yes
O	O	use	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	received	no
B-group	B-group	MAOI	no
O	O	within	no
O	O	14	yes
O	O	days	no
O	O	because	no
O	O	severe	no
O	O	and	yes
O	O	unpredictable	no
O	O	potentiation	no
O	O	by	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
B-group	B-group	opioid	no
I-group	I-group	analgesics	no

B-brand	B-brand	INDOCIN	yes
O	O	reduces	no
O	O	basal	no
O	O	plasma	yes
O	O	renin	no
O	O	activity	yes
O	O	(	no
O	O	PRA	no
O	O	)	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	those	no
O	O	elevations	no
O	O	of	yes
O	O	PRA	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	furosemide	yes
O	O	administration	no
O	O	,	no
O	O	or	no
O	O	salt	yes
O	O	or	no
O	O	volume	no
O	O	depletion	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	which	no
O	O	patients	no
O	O	with	yes
O	O	active	no
O	O	RA	yes
O	O	were	no
O	O	treated	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	24	yes
O	O	weeks	no
O	O	with	yes
O	O	concurrent	no
B-brand	B-brand	ENBREL	yes
O	O	and	yes
B-drug	B-drug	anakinra	yes
O	O	therapy	no
O	O	,	no
O	O	a	yes
O	O	7	yes
O	O	%	no
O	O	rate	no
O	O	of	yes
O	O	serious	no
O	O	infections	no
O	O	was	no
O	O	observed	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	higher	no
O	O	than	no
O	O	that	no
O	O	observed	no
O	O	with	yes
B-brand	B-brand	ENBREL	yes
O	O	alone	no
O	O	(	no
O	O	0	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	antimicrobial	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
B-drug	B-drug_n	benzoxazinorifamycin	no
O	O	,	no
B-drug_n	B-drug_n	KRM-1648	no
O	O	,	no
O	O	either	no
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ofloxacin	yes
O	O	,	no
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	vitro	no
O	O	against	yes
O	O	two	no
O	O	type	yes
O	O	strains	no
O	O	and	yes
O	O	six	no
O	O	clinical	no
O	O	isolates	no
O	O	of	yes
O	O	Mycobacterium	yes
O	O	ulcerans	no
O	O	.	no

O	O	The	no
O	O	combination	yes
O	O	of	yes
O	O	therapeutic	no
O	O	doses	no
O	O	of	yes
O	O	intravenous	yes
B-drug	B-drug	dantrolene	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	in	yes
B-drug	B-drug	halothane	yes
O	O	a-chloralose	no
O	O	anesthetized	no
O	O	swine	no
O	O	has	no
O	O	resulted	no
O	O	in	yes
O	O	ventricular	no
O	O	fibrillation	no
O	O	and	yes
O	O	cardiovascular	no
O	O	collapse	no
O	O	in	yes
O	O	association	no
O	O	with	yes
O	O	marked	no
O	O	hyperkalemia	no
O	O	.	no

B-drug	B-drug	Phenylbutazone	yes
O	O	:	no
B-drug	B-drug	Phenylbutazone	yes
O	O	causes	no
O	O	increase	no
O	O	(	no
O	O	by	no
O	O	about	no
O	O	80	yes
O	O	%	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	free	yes
O	O	fraction	yes
O	O	of	yes
B-drug	B-drug	etodolac	yes
O	O	.	no

O	O	These	no
O	O	drugs	no
O	O	include	no
O	O	the	no
B-group	B-group	thiazides	no
O	O	and	yes
O	O	other	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	O	phe-nothiazines	no
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	products	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	O	sympathomimet-ics	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

B-drug	B-drug	Fulvestrant	yes
O	O	caused	no
O	O	an	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	fetal	no
O	O	abnormalities	no
O	O	in	yes
O	O	rats	no
O	O	(	no
O	O	tarsal	no
O	O	flexure	no
O	O	of	yes
O	O	the	no
O	O	hind	no
O	O	paw	no
O	O	at	yes
O	O	2	yes
O	O	mg/kg/day	no
O	O	IM	yes
O	O	;	no

B-drug	B-drug	CIMETlDINE	no
O	O	:	no
B-drug	B-drug	Cerivastatin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

B-brand	B-brand	DIAMOX	yes
O	O	modifies	no
B-drug	B-drug	phenytoin	yes
O	O	metabolism	no
O	O	with	yes
O	O	increased	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
O	O	,	no
O	O	at	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-group	salicylate	yes
O	O	(	no
O	O	300	yes
O	O	m	yes
O	O	g/mL	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	ketorolac	yes
O	O	was	no
O	O	reduced	yes
O	O	from	no
O	O	approximately	no
O	O	99.2	no
O	O	%	no
O	O	to	no
O	O	97.5	no
O	O	%	no
O	O	,	no
O	O	representing	no
O	O	a	yes
O	O	potential	no
O	O	twofold	no
O	O	increase	no
O	O	in	yes
O	O	unbound	no
B-drug	B-drug	ketorolac	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	increased	no
O	O	norepinephrine-induced	no
O	O	platelet	yes
O	O	aggregability	no

O	O	Ergot-containing	no
O	O	drugs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	prolonged	no
O	O	vasospastic	no
O	O	reactions	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	to	no
O	O	assess	no
O	O	if	no
O	O	there	no
O	O	is	yes
O	O	an	no
O	O	interactive	no
O	O	effect	no
O	O	on	no
O	O	bone	no
O	O	loss	no
O	O	between	yes
O	B-group	systemic	no
B-group	I-group	corticosteroids	no
O	O	and	yes
B-brand	B-brand	Accutane	yes
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	:	no
O	O	In	yes
O	O	healthy	no
O	O	individuals	no
O	O	,	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	increased	no
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	a	yes
O	O	known	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	to	no
O	O	contend	no
O	O	with	yes
O	O	.	no

B-drug	B-drug	Cysteine	yes
O	O	was	no
O	O	covalently	no
O	O	linked	no
O	O	to	no
B-drug	O	carbodiimide	no
O	O	activated	yes
B-drug_n	B-drug_n	NaCMC	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-drug	B-drug	Meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	enhances	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	changes	no
O	O	were	no
O	O	observed	no
O	O	to	no
O	O	be	no
O	O	less	no
O	O	than	no
O	O	1	yes
O	O	second	no
O	O	in	yes
O	O	both	no
O	O	instances	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	and	yes
O	O	are	no
O	O	unlikely	no
O	O	to	no
O	O	be	no
O	O	clinically	no
O	O	important	no
O	O	.	no

O	O	SUBJECTS	no
O	O	:	no
O	O	Twelve	no
O	O	healthy	no
O	O	male	no
O	O	volunteers	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

B-brand	B-brand	Angiomax	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	disease	no
O	O	states	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

O	O	The	no
O	O	syndrome	no
O	O	requires	no
O	O	immediate	no
O	O	medical	yes
O	O	attention	no
O	O	and	yes
O	O	may	no
O	O	include	no
O	O	one	no
O	O	or	no
O	O	more	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	symptoms	no
O	O	:	no
O	O	excitement	no
O	O	,	no
O	O	hypomania	no
O	O	,	no
O	O	restlessness	no
O	O	,	no
O	O	loss	no
O	O	of	yes
O	O	consciousness	no
O	O	,	no
O	O	confusion	no
O	O	,	no
O	O	disorientation	no
O	O	,	no
O	O	anxiety	no
O	O	,	no
O	O	agitation	no
O	O	,	no
O	O	motor	no
O	O	weakness	no
O	O	,	no
O	O	myoclonus	no
O	O	,	no
O	O	tremor	no
O	O	,	no
O	O	hemiballismus	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	ataxia	no
O	O	,	no
O	O	dysarthria	no
O	O	,	no
O	O	incoordination	no
O	O	,	no
O	O	hyperthermia	no
O	O	,	no
O	O	shivering	no
O	O	,	no
O	O	pupillary	no
O	O	dilation	no
O	O	,	no
O	O	diaphoresis	no
O	O	,	no
O	O	emesis	no
O	O	,	no
O	O	and	yes
O	O	tachycardia	no
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	b-lactam	no
I-group	I-group	antibiotics	no
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	inhibits	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	cefdinir	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	an	no
O	O	approximate	no
O	O	doubling	no
O	O	in	yes
O	O	A.C.	no
O	O	a	yes
O	O	54	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	peak	no
B-drug	B-drug	cefdinir	yes
O	O	plasma	yes
O	O	levels	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	50	yes
O	O	%	no
O	O	prolongation	no
O	O	in	yes
O	O	the	no
O	O	apparent	no
O	O	elimination	no
O	O	half-life	no
O	O	.	no

O	O	Future	no
O	O	trends	no
O	O	are	no
O	O	also	no
O	O	predicted	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	be	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2C9	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	lower	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	efavirenz	yes
O	O	concentration	no

B-drug	I-drug	Indinavir	yes

O	O	Lack	no
O	O	of	yes
O	O	an	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	on	no
O	O	the	no
O	O	disposition	no
O	O	of	yes
B-drug	B-drug	zidovudine	yes
O	O	and	yes
B-drug	B-drug	dideoxyinosine	yes
O	O	in	yes
O	O	HIV-infected	no
O	O	patients	no
O	O	.	no

O	O	Although	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	AUC	no
O	O	0-24	no
O	O	hrs	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	and/or	no
B-drug	B-drug	descarboethoxyloratadine	yes
O	O	were	no
O	O	observed	no
O	O	following	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	with	yes
O	O	each	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	24	yes
O	O	in	yes
O	O	each	no
O	O	study	no
O	O	)	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	safety	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	,	no
O	O	as	yes
O	O	assessed	no
O	O	by	no
O	O	electrocardiographic	no
O	O	parameters	no
O	O	,	no
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	,	no
O	O	vital	no
O	O	signs	no
O	O	,	no
O	O	and	yes
O	O	adverse	no
O	O	events	no
O	O	.	no

O	O	The	no
O	O	conjugates	no
O	O	so	no
O	O	formed	no
O	O	often	no
O	O	appear	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	as	yes
O	O	mercapturic	yes
O	O	acids	yes
O	O	or	no
O	O	other	no
O	O	thioether	no
O	O	products	no
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	,	no
O	O	or	no
O	O	are	no
O	O	expected	no
O	O	to	no
O	O	have	no
O	O	decreased	no
O	O	plasma	yes
O	O	levels	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-brand	B-brand	EQUETROTM	no
O	O	due	no
O	O	to	no
O	O	induction	no
O	O	of	yes
O	O	CYP	no
O	O	enzymes	yes
O	O	are	no
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	Acetaminophen	yes
O	O	,	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
B-drug	B-drug	amitriptyline	yes
O	O	,	no
B-drug	B-drug	bupropion	yes
O	O	,	no
B-drug	B-drug	buspirone	yes
O	O	,	no
B-drug	B-drug	citalopram	yes
O	O	,	no
B-drug	B-drug	clobazam	yes
O	O	,	no
B-drug	B-drug	clonazepam	yes
O	O	,	no
B-drug	B-drug	clozapine	yes
O	O	,	no
B-drug	B-drug	cyclosporin	yes
O	O	,	no
B-drug	B-drug	delavirdine	yes
O	O	,	no
B-drug	B-drug	desipramine	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	dicumarol	yes
O	O	,	no
B-drug	B-drug	doxycycline	yes
O	O	,	no
B-drug	B-drug	ethosuximide	yes
O	O	,	no
B-drug	B-drug	felbamate	yes
O	O	,	no
B-drug	B-drug	felodipine	yes
O	O	,	no
B-group	B-group	glucocorticoids	no
O	O	,	no
B-drug	B-drug	haloperidol	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	lamotrigine	yes
O	O	,	no
B-drug	B-drug	levothyroxine	yes
O	O	,	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
B-drug	B-drug	methadone	yes
O	O	,	no
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	mirtazapine	yes
O	O	,	no
B-drug	B-drug	nortriptyline	yes
O	O	,	no
B-drug	B-drug	olanzapine	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	(	no
O	O	3	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	oxcarbazepine	yes
O	O	,	no
B-drug	B-drug	Phenytoin	yes
O	O	(	no
O	O	4	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	praziquantel	yes
O	O	,	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	quetiapine	yes
O	O	,	no
B-drug	B-drug	risperidone	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug	topiramate	yes
O	O	,	no
B-drug	B-drug	tiagabine	yes
O	O	,	no
B-drug	B-drug	tramadol	yes
O	O	,	no
B-drug	B-drug	triazolam	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	5	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	ziprasidone	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	zonisamide	yes
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	nelfinavir	yes
O	O	are	no
O	O	not	no
O	O	altered	no
O	O	to	no
O	O	a	yes
O	O	clinically	no
O	O	significant	no
O	O	degree	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	administered	no
O	O	with	yes
O	O	a	yes
O	O	light	yes
O	O	meal	no
O	O	1	yes
O	O	hour	yes
O	O	after	no
B-brand	B-brand	VIDEX	yes
O	O	.	no

O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
B-drug	B-drug	naproxen	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	to	no
O	O	avoid	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ethambutol	yes
O	O	with	yes
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydroxide	yes
O	O	containing	yes
B-group	B-group	antacids	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	4	yes
O	O	hours	no
O	O	following	no
B-drug	B-drug	ethambutol	yes
O	O	administration	no
O	O	.	no

O	O	*Increased	no
O	O	and	yes
O	O	decreased	no
O	O	prothrombin	yes
O	O	time	no
O	O	responses	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

B-drug	B-drug	Epinephrine	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	hyperthyroidism	no
O	O	,	no
O	O	hypertension	no
O	O	and	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

B-drug	B-drug	Atracurium	yes
O	O	infusion	no
O	O	was	no
O	O	continued	no
O	O	for	yes
O	O	a	yes
O	O	third	no
O	O	hour	yes
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	hoof	no
O	O	twitch	no
O	O	was	no
O	O	again	no
O	O	allowed	no
O	O	to	no
O	O	recover	no
O	O	spontaneously	no
O	O	to	no
O	O	75	yes
O	O	%	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	report	no
O	O	to	no
O	O	their	no
O	O	practitioners	no
O	O	any	no
O	O	new	no
O	O	rashes	no
O	O	,	no
O	O	itching	no
O	O	,	no
O	O	mouth	no
O	O	sores	no
O	O	,	no
O	O	or	no
O	O	unusual	no
O	O	taste	no
O	O	while	no
O	O	taking	no
B-drug	B-drug	auranofin	yes
O	O	.	no

O	O	and	yes
O	O	the	no
O	O	remaining	no
O	O	25.9	no
O	O	%	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	9.3	no
O	O	)	no
O	O	by	no
O	O	monitoring	no
O	O	and	yes
O	O	follow-up	no
O	O	of	yes
O	O	patients	no
O	O	.	no

B-group	B-group	immunosuppressant	no
I-group	I-group	agents	yes
O	O	concentration	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	hydralazine	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
B-brand	B-brand	CASODEX	yes
O	O	can	no
O	O	displace	no
B-group	B-group	coumarin	yes
I-group	O	anticoagulants	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	from	no
O	O	their	no
O	O	protein-binding	no
O	O	sites	no
O	O	.	no

B-drug	B-drug	chlorpropamide	yes
O	O	;	no

O	O	The	no
B-group	B-group	benzodiazepines	no
O	O	,	no
O	O	including	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
O	O	produce	no
O	O	additive	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	medications	no
O	O	,	no
B-group	B-group	anticonvulsants	no
O	O	,	no
B-group	B-group	antihistaminics	no
O	O	,	no
B-drug	B-drug	ethanol	yes
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	which	no
O	O	themselves	no
O	O	produce	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

B-group	B-group	Digitalis	yes
I-group	I-group	glycosides	yes
O	O	enhanced	no
O	O	possibility	no
O	O	of	yes
O	O	arrhythmias	no
O	O	or	no
B-group	B-group	digitalis	yes
O	O	toxicity	no
O	O	associated	no
O	O	with	yes
O	O	hypokalemia	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	ouabain	yes
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	-5	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	,	no
B-drug_n	B-drug_n	PTX	no
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	-8	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	failed	no
O	O	to	no
O	O	cause	no
O	O	the	no
O	O	first	no
O	O	contraction	no
O	O	;	no

O	O	no	yes
O	O	other	no
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	performed	no
O	O	.	no

O	O	INFORMATION	no
O	O	TO	no
O	O	BE	no
O	O	PROVIDED	no
O	O	TO	no
O	O	THE	no
O	O	PATIENT	no
O	O	OR	no
O	O	GUARDIAN	no
O	O	See	no
O	O	illustrated	no
O	O	Information	no
O	O	For	yes
O	O	The	no
O	O	Patient	no
O	O	or	no
O	O	Guardian	no
O	O	section	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	to	no
O	O	maximize	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-brand	B-brand	ALLEGRA	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	with	yes
O	O	water	yes

O	O	Patients	no
O	O	were	no
O	O	intravenously	no
O	O	injected	no
O	O	a	yes
O	O	chylomicron-like	no
O	O	emulsion	no
O	O	doubly	no
O	O	labeled	no
O	O	with	yes
O	O	14C-cholesteryl	no
O	O	oleate	yes
O	O	and	yes
O	O	3H-triolein	no
O	O	at	yes
O	O	baseline	no
O	O	and	yes
O	O	after	no
O	O	treatments	no
O	O	.	no

O	O	increased	no
O	O	levels	no
O	O	of	yes
O	B-drug	fibrinogen	yes
O	O	and	yes
O	B-drug	fibrinogen	yes
O	O	activity	yes
O	O	;	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-group	B-group	NSAIDs	no
O	O	on	no
O	O	GI	no
O	O	bleeding	no
O	O	are	no
O	O	synergistic	no
O	O	,	no
O	O	such	no
O	O	that	no
O	O	users	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	together	no
O	O	have	no
O	O	a	yes
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	GI	no
O	O	bleeding	no
O	O	higher	no
O	O	than	no
O	O	users	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	alone	no
O	O	.	no

O	O	A	yes
O	O	greater	no
O	O	understanding	no
O	O	of	yes
O	O	pain	yes
O	O	mechanisms	no
O	O	will	no
O	O	aid	no
O	O	in	yes
O	O	elucidating	no
O	O	the	no
O	O	role	no
O	O	of	yes
B-group	B-group	antihistaminics	no
O	O	in	yes
O	O	analgesia	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	displaced	no
O	O	from	no
O	O	its	no
O	O	binding	no
O	O	sites	no
O	O	by	no
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	For	yes
O	O	example	no
O	O	,	no
O	O	the	no
O	O	plasma	yes
B-group	B-group	nitrosourea	yes
O	O	AUC	no
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	factors	no
O	O	of	yes
O	O	1.05	no
O	O	and	yes
O	O	9.6	no
O	O	for	yes
O	O	MEC	no
O	O	values	no
O	O	of	yes
O	O	1	yes
O	O	and	yes
O	O	2	yes
O	O	micrograms	no
O	O	ml-1	no
O	O	respectively	no
O	O	.	no

B-brand	B-brand	Proquin	yes
I-brand	I-brand	XR	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	at	yes
O	O	least	no
O	O	4	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	2	yes
O	O	hours	no
O	O	after	no
O	O	these	no
O	O	products	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	markedly	no
O	O	increases	no
O	O	the	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	,	no
O	O	and	yes
O	O	coadministration	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	CNS-Active	no
O	O	Drugs	no
B-drug	B-drug	Ethanol	yes
O	O	:	no
B-brand	B-brand	Sonata	yes
O	O	10	yes
O	O	mg	yes
O	O	potentiated	no
O	O	the	no
O	O	CNS-impairing	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	0.75	yes
O	O	g/kg	no
O	O	on	no
O	O	balance	yes
O	O	testing	no
O	O	and	yes
O	O	reaction	no
O	O	time	no
O	O	for	yes
O	O	1	yes
O	O	hour	yes
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	administration	no
O	O	and	yes
O	O	on	no
O	O	the	no
O	O	digit	no
O	O	symbol	no
O	O	substitution	no
O	O	test	yes
O	O	(	no
O	O	DSST	no
O	O	)	no
O	O	,	no
O	O	symbol	no
O	O	copying	no
O	O	test	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	variability	no
O	O	component	yes
O	O	of	yes
O	O	the	no
O	O	divided	no
O	O	attention	no
O	O	test	yes
O	O	for	yes
O	O	2.5	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	administration	no
O	O	.	no

O	O	Additionally	no
O	O	,	no
B-brand	B-brand	BREVIBLOC	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	control	no
O	O	supraventricular	no
O	O	tachycardia	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	agents	yes
O	O	which	no
O	O	are	no
O	O	vasoconstrictive	no
O	O	and	yes
O	O	inotropic	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dopamine	yes
O	O	,	no
B-drug	B-drug	epinephrine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	norepinephrine	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	danger	no
O	O	of	yes
O	O	blocking	no
O	O	cardiac	no
O	O	contractility	no
O	O	when	no
O	O	systemic	no
O	O	vascular	no
O	O	resistance	no
O	O	is	yes
O	O	high	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	DynaCirc	yes
O	O	(	no
B-drug	B-drug	isradipine	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	a	yes
O	O	single-dose	no
O	O	pharmacokinetic	no
O	O	study	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	renal	no
O	O	,	no
O	O	nonrenal	no
O	O	and	yes
O	O	total	yes
O	O	body	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	valdecoxib	yes
O	O	is	yes
O	O	a	yes
O	O	moderate	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP	no
O	O	2C19	no
O	O	(	no
O	O	IC50	no
O	O	=	no
O	O	6	yes
O	O	g/mL	no
O	O	or	no
O	O	19	yes
O	O	M	yes
O	O	)	no
O	O	and	yes
O	O	2C9	no
O	O	(	no
O	O	IC50	no
O	O	=	no
O	O	13	yes
O	O	g/mL	no
O	O	or	no
O	O	41	yes
O	O	M	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	weak	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP	no
O	O	2D6	no
O	O	(	no
O	O	IC50	no
O	O	=	no
O	O	31	yes
O	O	g/mL	no
O	O	or	no
O	O	100	yes
O	O	M	yes
O	O	)	no
O	O	and	yes
O	O	3A4	no
O	O	(	no
O	O	IC50	no
O	O	=	no
O	O	44	yes
O	O	g/mL	no
O	O	or	no
O	O	141	no
O	O	M	yes
O	O	)	no
O	O	..	no

O	O	If	no
O	O	the	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	together	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	because	no
O	O	unexpected	no
O	O	hypotension	no
O	O	could	no
O	O	result	no
O	O	from	no
O	O	beta-blocker	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	sympathetic	no
O	O	reflex	no
O	O	response	no
O	O	to	no
B-drug	B-drug	fenoldopam	yes
O	O	.	no

O	O	Because	no
B-drug	B-drug	cholestyramine	yes
O	O	binds	no
O	O	bile	no
O	O	acids	yes
O	O	,	no
B-drug	B-drug	cholestyramine	yes
B-group	B-group	resin	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	normal	yes
O	O	fat	yes
O	O	digestion	no
O	O	and	yes
O	O	absorption	no
O	O	and	yes
O	O	thus	no
O	O	may	no
O	O	prevent	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	fat	yes
I-group	I-group	soluble	no
I-group	I-group	vitamins	no
O	O	such	no
O	O	as	yes
O	O	A	yes
O	O	,	no
O	O	D	yes
O	O	,	no
O	O	E	yes
O	O	,	no
O	O	and	yes
O	O	K	yes
O	O	.	no

O	O	.	no

O	O	Chapter	no
O	O	5	yes
O	O	focuses	no
O	O	on	no
O	O	metabolic	no
O	O	effects	no
O	O	,	no
O	O	specifically	no
O	O	lipid	no
O	O	metabolism	no
O	O	,	no
O	O	carbohydrate	no
O	O	metabolism	no
O	O	and	yes
O	O	diabetes	no
O	O	,	no
O	O	coagulation	yes
O	O	factors	no
O	O	,	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	Therapeutic	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	ibuprofen	yes
O	O	,	no
B-drug	B-drug	naproxen	yes
O	O	,	no
B-drug	B-drug	piroxicam	yes
O	O	,	no
B-drug	B-drug	acetaminophen	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
I-drug	O	andtolbutamide	no
O	O	did	no
O	O	not	no
O	O	alter	no
B-drug	B-drug	ketorolac	yes
I-drug	I-drug	tromethamine	yes
O	O	protein	yes
O	O	binding	no
O	O	.	no

O	O	6	yes
O	O	.	no

O	O	[	no
O	O	Importance	no
O	O	of	yes
O	O	pharmacogenetics	no
O	O	]	no
O	O	;	no
O	O	Pharmacogenetics	no
O	O	deals	no
O	O	with	yes
O	O	the	no
O	O	differences	no
O	O	in	yes
O	O	effect	no
O	O	of	yes
O	O	drugs	no
O	O	caused	no
O	O	by	no
O	O	genetic	no
O	O	variation	no
O	O	.	no

B-brand	B-brand	INSPRA	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	drugs	no
O	O	described	no
O	O	as	yes
O	O	strong	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	in	yes
O	O	their	no
O	O	labeling	no
O	O	.	no

O	O	*	no
O	O	No	yes
O	O	longer	no
O	O	marketed	no
O	O	in	yes
O	O	the	no
O	O	US	no
O	O	.	no

O	O	The	no
O	O	peripheral	no
O	O	vasoconstriction	no
O	O	caused	no
O	O	by	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	dopamine	yes
I-drug	I-drug	HCl	yes
O	O	is	yes
O	O	antagonized	no
O	O	by	no
B-group	B-group	alpha-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Dosage	no
O	O	reduction	yes
O	O	of	yes
B-drug	B-brand	Cerubidine	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	myelosuppressive	no
O	O	agents	yes
O	O	.	no

O	O	In	yes
O	B-drug	amiodarone-treated	no
O	O	patients	no
O	O	who	no
O	O	require	no
O	O	additional	no
B-drug	B-drug	antiarrhythmic	no
O	O	therapy	no
O	O	,	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	of	yes
O	O	such	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	approximately	no
O	O	half	no
O	O	of	yes
O	O	the	no
O	O	usual	no
O	O	recommended	no
O	O	dose	no
O	O	.	no

O	O	Increased	no
O	O	thyroid-binding	no
O	O	globulin	yes
O	O	(	no
O	O	TBG	no
O	O	)	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	circulating	no
O	O	total	yes
O	O	thyroid	yes
O	O	hormone	yes
O	O	levels	no
O	O	,	no
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	protein-bound	no
O	O	iodine	yes
O	O	(	no
O	O	PBI	no
O	O	)	no
O	O	,	no
O	O	T4	yes
O	O	levels	no
O	O	(	no
O	O	by	no
O	O	column	no
O	O	or	no
O	O	by	no
O	O	radioimmunoassay	no
O	O	)	no
O	O	or	no
O	O	T3	yes
O	O	levels	no
O	O	by	no
O	O	radioimmunoassay	no
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	,	no
O	O	General	no
O	O	:	no
O	O	Although	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	formal	no
O	O	interaction	no
O	O	studies	no
O	O	,	no
O	O	intravenous	yes
B-drug	B-drug	fenoldopam	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	safely	no
O	O	with	yes
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	digitalis	yes
O	O	and	yes
O	O	sublingual	no
B-drug	B-drug	nitroglycerin	yes
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	was	no
O	O	decreased	no
O	O	an	no
O	O	average	no
O	O	of	yes
O	O	15-fold	no
O	O	in	yes
O	O	12	yes
O	O	healthy	no
O	O	subjects	no
O	O	given	no
B-drug	B-drug	ciprofloxacin	yes
O	O	and	yes
B-drug	B-drug	didanosine-placebo	no
O	O	tablets	yes
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Allopurinol	yes
O	O	:	no
O	O	The	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	didanosine	yes
O	O	was	no
O	O	increased	no
O	O	about	no
O	O	4-fold	no
O	O	when	no
B-drug	B-drug	allopurinol	yes
O	O	at	yes
O	O	300	yes
O	O	mg/day	no
O	O	was	no
O	O	coadministered	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	200-mg	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	VIDEX	yes
O	O	to	no
O	O	two	no
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	impairment	no
O	O	(	no
O	O	CLcr=15	no
O	O	and	yes
O	O	18	yes
O	O	mL/min	no
O	O	)	no
O	O	.	no

O	O	ulcerans	no
O	O	was	no
O	O	between	yes
O	O	0.012	no
O	O	and	yes
O	O	0.025	no
O	O	mg/l	no
O	O	,	no
O	O	while	no
O	O	corresponding	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	rifampicin	yes
O	O	and	yes
B-drug	B-drug	rifabutin	yes
O	O	were	no
O	O	in	yes
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	0.1-0.8	no
O	O	mg/l	no
O	O	and	yes
O	O	0.1-0.4	no
O	O	mg/l	no
O	O	respectively	no
O	O	.	no

B-group	B-group	Antibiotics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	trimethoprim	yes
O	O	and	yes
B-drug	B-drug	sulfamethoxazole	yes
O	O	,	no
B-drug	B-drug	amoxicillin	yes
O	O	)	no
O	O	.	no

O	O	If	no
O	O	such	no
O	O	measurements	no
O	O	are	no
O	O	necessary	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	other	no
O	O	methods	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	information	no
O	O	was	no
O	O	obtained	no
O	O	from	no
O	O	studies	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	.	no

O	O	.	no

O	O	Few	no
O	O	systemic	no
O	O	data	no
O	O	have	no
O	O	been	no
O	O	collected	no
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	or	no
O	O	,	no
O	O	alternatively	no
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

O	O	While	no
O	O	the	no
O	O	recognition	no
O	O	of	yes
O	O	drug	yes
O	O	toxicity	no
O	O	resulting	no
O	O	from	no
O	O	interactions	no
O	O	is	yes
O	O	of	yes
O	O	importance	no
O	O	to	no
O	O	all	yes
B-group	O	physciains	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	especially	no
O	O	so	no
O	O	for	yes
O	O	the	no
O	O	clinician	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	welfare	no
O	O	of	yes
O	O	those	no
O	O	in	yes
O	O	the	no
O	O	aerospace	no
O	O	environment	no
O	O	.	no

O	O	The	no
O	O	serum	yes
O	O	estrogen	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	+	no
O	B-drug_n	endotoxin-treated	no
O	O	rats	no
O	O	decreased	no
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	,	no
O	O	while	no
O	O	those	no
O	O	of	yes
O	O	the	no
O	B-drug_n	endotoxin-treated	no
O	O	rats	no
O	O	increased	no
O	O	(	no
O	O	2-	no
O	O	to	no
O	O	5-fold	no
O	O	)	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	12	yes
O	O	normal	yes
O	O	subjects	no
O	O	,	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	decreased	no
B-drug	B-drug	ketoprofen	yes
O	O	protein	yes
O	O	binding	no
O	O	and	yes
O	O	increased	no
B-drug	B-drug	ketoprofen	yes
O	O	plasma	yes
O	O	clearance	no
O	O	from	no
O	O	0.07	no
O	O	L/kg/h	no
O	O	without	no
B-brand	B-brand	aspirin	yes
O	O	to	no
O	O	0.11	no
O	O	L/kg/h	no
O	O	with	yes
B-brand	B-brand	aspirin	yes
O	O	.	no

B-drug	B-drug	Everolimus	yes
O	O	dose-proportionality	no
O	O	and	yes
O	O	stability	no
O	O	over	no
O	O	time	no
O	O	were	no
O	O	assessed	no
O	O	in	yes
O	O	the	no
O	O	context	no
O	O	of	yes
O	O	linear	yes
O	O	regression	no
O	O	and	yes
O	O	ANOVA	no
O	O	models	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	,	no
B-drug	B-drug	des-ciclesonide	no
O	O	appears	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	inhibitory	yes
O	O	or	no
O	O	induction	no
O	O	potential	no
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	450	yes
O	O	enzymes	yes
O	O	.	no

B-group	B-group	Thiazides	no
O	O	:	no
B-group	B-group	Thiazides	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	hypercalcemia	no
O	O	by	no
O	O	the	no
O	O	reduction	yes
O	O	of	yes
B-drug	O	calcium	yes
O	O	excretion	no
O	O	in	yes
O	O	urine	no
O	O	.	no

O	O	Cssmax	no
O	O	of	yes
O	O	the	no
O	O	metabolite	yes
O	O	,	no
O	O	ucb	no
O	O	L057	no
O	O	,	no
O	O	was	no
O	O	approximately	no
O	O	doubled	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	while	no
O	O	the	no
O	O	fraction	yes
O	O	of	yes
O	O	drug	yes
O	O	excreted	no
O	O	unchanged	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	remained	no
O	O	the	no
O	O	same	yes
O	O	.	no

O	O	Severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	receiving	no
B-group	B-group	azole	no
I-group	I-group	antifungal	no
I-group	I-group	agents	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	chronic	no
O	O	high	yes
O	O	dose	no
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	adjust	no
B-group	B-group	salicylate	yes
O	O	dosage	no
O	O	accordingly	no
O	O	if	no
O	O	effect	no
O	O	is	yes
O	O	altered	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	TCAs	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRIs	no
O	O	and	yes
O	O	also	no
O	O	in	yes
O	O	switching	no
O	O	from	no
O	O	one	no
O	O	class	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	O	Chapter	no
O	O	2	yes
O	O	considers	no
O	O	the	no
O	O	mode	no
O	O	of	yes
O	O	action	no
O	O	,	no
O	O	including	no
O	O	ovulation	no
O	O	prevention	no
O	O	;	no

B-group	B-group	Diuretics	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	diuretics	no
O	O	,	no
O	O	especially	no
O	O	those	no
O	O	in	yes
O	O	whom	no
B-group	O	diuretic	no
O	O	therapy	no
O	O	was	no
O	O	recently	no
O	O	instituted	no
O	O	,	no
O	O	may	no
O	O	occasionally	no
O	O	experience	no
O	O	an	no
O	O	excessive	no
O	O	reduction	yes
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	Lotensin	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	adverse	no
O	O	reactions	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	been	no
O	O	taking	no
B-group	B-group	benzodiazepines	no
O	O	on	no
O	O	a	yes
O	O	regular	yes
O	O	basis	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	particularly	no
O	O	important	no
O	O	that	no
O	O	physicians	no
O	O	query	no
O	O	patients	no
O	O	or	no
O	O	their	no
O	O	guardians	no
O	O	carefully	no
O	O	about	no
B-group	B-group	benzodiazepine	yes
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	and	yes
B-group	B-group	sedative	no
O	O	use	no
O	O	as	yes
O	O	part	no
O	O	of	yes
O	O	the	no
O	O	history	no
O	O	prior	no
O	O	to	no
O	O	any	no
O	O	procedure	no
O	O	in	yes
O	O	which	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	ROMAZICON	yes
O	O	is	yes
O	O	planned	no
O	O	.	no

O	O	+15	no
O	O	%	no
O	O	+5	no
O	O	%	no
O	O	+15	no
O	O	%	no
O	O	+4	no
O	O	%	no

O	O	the	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	naloxone	yes
O	O	required	no
O	O	to	no
O	O	antagonize	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	were	no
O	O	more	no
O	O	than	no
O	O	100	yes
O	O	times	no
O	O	higher	no
O	O	than	no
O	O	those	no
O	O	required	no
O	O	to	no
O	O	antagonize	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	.	no

O	O	Among	no
B-brand	B-brand	aspirin	yes
O	O	or	no
B-group	B-group	NSAID	no
O	O	users	no
O	O	,	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	upper	no
O	O	gastrointestinal	no
O	O	adverse	no
O	O	events	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	ibandronate	yes
O	O	2.5	yes
O	O	mg	yes
O	O	daily	no
O	O	(	no
O	O	28.9	no
O	O	%	no
O	O	)	no
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	in	yes
O	O	placebo-treated	no
O	O	patients	no
O	O	(	no
O	O	30.7	no
O	O	%	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	celecoxib	yes
O	O	on	no
O	O	the	no
O	O	anti-coagulant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	a	yes
O	O	group	yes
O	O	of	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
O	O	daily	no
O	O	doses	no
O	O	of	yes
O	O	2-5	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	4	yes
O	O	.	no

O	O	Increased	no
O	O	anticoagulation	no
O	O	effects	no
O	O	due	no
O	O	to	no
O	O	interactions	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	with	yes
O	O	various	no
O	O	oral	yes
B-group	O	anticoagulents	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	pronounced	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	.	no

B-drug	B-drug	Colchicine	yes
O	O	may	no
O	O	increase	no
O	O	sensitivity	no
O	O	to	no
O	O	the	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	increases	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	busulfan	yes
O	O	by	no
O	O	15	yes
O	O	%	no
O	O	or	no
O	O	more	no
O	O	,	no
O	O	possibly	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	induction	no
O	O	of	yes
O	O	glutathione-S-transferase	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
B-drug	B-drug	doxazosin	yes
I-drug	I-drug	mesylate	yes
O	O	tablets	yes
O	O	have	no
O	O	been	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	on	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	concomitant	no
O	O	medications	no
O	O	;	no

O	O	The	no
O	O	evidence	no
O	O	for	yes
O	O	a	yes
O	O	role	no
O	O	for	yes
B-drug	O	norepinephrine	yes
O	O	and	yes
B-drug	O	dopamine	yes
O	O	and	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistaminics	no
O	O	on	no
O	O	them	no
O	O	are	no
O	O	less	no
O	O	well	no
O	O	established	no
O	O	.	no

B-group	B-group	H2	no
I-group	I-group	Blockers/Proton	no
I-group	I-group	Pump	no
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	Long-term	no
O	O	suppression	no
O	O	of	yes
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	by	no
B-group	B-group	H2	no
I-group	I-group	blockers	no
O	O	or	no
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	famotidine	yes
O	O	and	yes
B-drug	B-drug	omeprazole	yes
O	O	)	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	reduce	no
B-drug	B-drug	dasatinib	yes
O	O	exposure	yes
O	O	.	no

O	O	abnormal	no
O	O	vaginal	no
O	O	bleeding	no
O	O	;	no

O	O	Inhibitors	no
O	O	or	no
O	O	substrates	no
O	O	of	yes
O	O	CYP2D6	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	[	no
B-group	B-group	SSRIs	no
O	O	]	no
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	doxepin	yes
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	No	yes
O	O	volunteer	no
O	O	showed	no
O	O	hormonal	no
O	O	evidence	no
O	O	of	yes
O	O	ovulation	no
O	O	,	no
O	O	but	no
O	O	one	no
O	O	volunteer	no
O	O	reported	no
O	O	intermenstrual	no
O	O	bleeding	no
O	O	during	no
B-drug	B-drug	felbamate	yes
O	O	treatment	no
O	O	.	no

O	O	Paralytic	no
O	O	ileus	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressants	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-drug	anticholinergic-type	no
I-group	O	drugs	no
O	O	.	no

O	O	Repeat	no
O	O	Treatment	no
O	O	Studies	no
O	O	evaluating	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	repeated	no
O	O	courses	no
O	O	of	yes
O	B-brand	Zmax	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	The	no
O	O	extent	no
O	O	to	no
O	O	which	no
B-group	B-group	SSRI-TCA	no
O	O	interactions	no
O	O	may	no
O	O	pose	no
O	O	clinical	no
O	O	problems	no
O	O	will	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	and	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRI	no
O	O	involved	no
O	O	.	no

O	O	this	no
O	O	can	no
O	O	cause	no
O	O	headaches	no
O	O	and	yes
O	O	other	no
O	O	signs	no
O	O	of	yes
O	O	hypertensive	no
O	O	crisis	no
O	O	.	no

B-drug	B-drug	chloral	yes
O	O	hydrate*	no
O	O	;	no

B-drug	B-drug	Chlorpropamide	yes
O	O	:	no
B-group	B-drug	Chlorpropamides	no
O	O	plasma	yes
O	O	half-life	no
O	O	may	no
O	O	be	no
O	O	prolonged	no
O	O	by	no
B-drug	B-drug	allopurinol	yes
O	O	,	no
O	O	since	no
B-drug	B-drug	allopurinol	yes
O	O	and	yes
B-drug	B-drug	chlorpropamide	yes
O	O	may	no
O	O	compete	no
O	O	for	yes
O	O	excretion	no
O	O	in	yes
O	O	the	no
O	O	renal	no
O	O	tubule	no
O	O	.	no

O	O	This	no
O	O	is	yes
O	O	especially	no
O	O	true	yes
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	may	no
O	O	subject	no
O	O	themselves	no
O	O	to	no
O	O	an	no
O	O	overdosage	no
O	O	of	yes
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Colchicine	yes
I-drug	I-drug	para-aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
O	O	heavy	yes
B-drug	B-drug	alcohol	yes
O	O	intake	no
O	O	for	yes
O	O	longer	no
O	O	than	no
O	O	2	yes
O	O	weeks	no
O	O	may	no
O	O	produce	no
O	O	malabsorption	no
O	O	of	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B12	yes
O	O	.	no

O	O	When	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	receptor	yes
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	:	no
B-group	B-group	Anesthetics	no
O	O	,	no
O	O	general	no
O	O	:	no
O	O	exaggeration	no
O	O	of	yes
O	O	the	no
O	O	hypotension	no
O	O	induced	no
O	O	by	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	.	no

O	O	It	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
B-drug	B-drug	Itraconazole	yes
O	O	enhances	no
O	O	the	no
O	O	anticoagulant	no
O	O	effect	no
O	O	of	yes
B-group	B-group	coumarin-like	no
I-group	O	drugs	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	at	yes
O	O	400	yes
O	O	mg	yes
O	O	BID	no
O	O	(	no
O	O	the	no
O	O	usual	no
O	O	prescription	no
O	O	dose	no
O	O	)	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	(	no
O	O	500	yes
O	O	mcg	no
O	O	BID	no
O	O	)	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
B-drug	B-drug	dofetilide	yes
O	O	plasma	yes
O	O	levels	no
O	O	by	no
O	O	58	no
O	O	%	no
O	O	.	no

O	O	.	no

O	O	Integumentary	no

O	O	341	no
O	O	PI	no
O	O	affecting	no
O	O	197	yes
O	O	patients	no
O	O	(	no
O	O	31.5	no
O	O	%	no
O	O	,	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	3.6	no
O	O	)	no
O	O	were	no
O	O	identified	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	bupropion	yes
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	,	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	may	no
O	O	affect	no
O	O	its	no
O	O	clinical	no
O	O	activity	yes
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	Anti-Inflammatory	no
I-group	I-group	Drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	-A	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	with	yes
O	O	an	no
B-group	B-group	NSAID	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-group	B-group	Steroids	no
O	O	enhance	no
O	O	the	no
O	O	renal	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	edetate	no
I-drug	I-drug	calcium	yes
I-drug	I-drug	disodium	yes
O	O	in	yes
O	O	animals	no
O	O	.	no
O	O	7	yes
B-drug	B-drug	Edetate	no
I-drug	I-drug	calcium	yes
I-drug	I-drug	disodium	yes
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	zinc	yes
I-drug	I-drug	insulin	yes
O	O	preparations	no
O	O	by	no
O	O	chelating	no
O	O	the	no
B-drug	B-drug	zinc	yes
O	O	.	no
O	O	7	yes

O	O	These	no
O	O	effects	no
O	O	are	no
O	O	usually	no
O	O	reversible	no
O	O	.	no

B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	O	analogues	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	as	yes
O	O	this	no
O	O	could	no
O	O	create	no
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	and	yes
O	O	hypercalcemia	no
O	O	.	no

O	O	H1	no
O	O	and	yes
B-group	B-group	H2	no
I-group	I-group	Blockers	no
O	O	-	yes
O	O	Although	no
O	O	not	no
O	O	reported	no
O	O	,	no
B-drug	B-drug	L-histidine	yes
O	O	,	no
O	O	via	no
O	O	its	no
O	O	metabolism	no
O	O	to	no
O	O	histamine	yes
O	O	,	no
O	O	might	no
O	B-group	decrease	no
O	I-group	the	no
O	O	efficacy	no
O	O	of	yes
O	O	H1	no
O	O	and	yes
B-group	B-group	H2	no
I-group	I-group	blockers	no
O	O	.	no

O	O	Serious	no
O	O	toxicity	no
O	O	may	no
O	O	result	no
O	O	if	no
B-drug	B-drug	dextromethorphan	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	MAOIs	no
O	O	)	no
O	O	.	no

O	O	Human	yes
O	O	pharmacokinetic	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	markedly	no
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	mean	no
O	O	eight-fold	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

O	O	Growth	yes
O	O	of	yes
O	O	M	yes
O	O	.	no

B-group	B-group	Opiate	no
I-group	I-group	agonists	no

O	O	Maximum	no
O	O	calculated	no
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	ranged	no
O	O	from	no
O	O	2	yes
O	O	1/2	no
O	O	to	no
O	O	3	yes
O	O	1/2	no
O	O	times	no
O	O	baseline	no
O	O	.	no

O	O	Interactions	no
O	O	may	no
O	O	also	no
O	O	occur	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-group	B-group	anti-depressants/anti-anxiety	no
I-group	I-group	drugs	no
O	O	,	no
O	O	drugs	no
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	an	no
O	O	overactive	no
O	O	thyroid	yes
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	sparfloxacin	yes
O	O	,	no
B-drug	B-drug	grepafloxacin	yes
O	O	,	no
B-drug	B-drug	guanethidine	yes
O	O	,	no
B-drug	B-drug	guanadrel	yes
O	O	,	no
B-drug	B-drug	metrizamide	yes
O	O	,	no
B-drug	B-drug	cabergoline	yes
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
B-group	B-group	narcotic	no
O	O	pain	yes
O	O	medication	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	codeine	yes
O	O	)	no
O	O	,	no
O	O	drugs	no
O	O	used	no
O	O	to	no
O	O	aid	no
O	O	sleep	no
O	O	,	no
O	O	drowsiness-causing	no
B-group	B-group	antihistamines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	diphenhydramine	yes
O	O	)	no
O	O	,	no
O	O	any	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	may	no
O	O	make	no
O	O	you	no
O	O	drowsy	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	extensive	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	NSAIDs	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	and	yes
O	O	no	yes
O	O	differential	no
O	O	effect	no
O	O	was	no
O	O	observed	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	at	yes
O	O	lower	no
O	O	concentrations	no
O	O	only	no
B-drug	B-drug	zinc	yes
O	O	demonstrated	no
O	O	toxicity	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	DIABINESE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	decrease	no
B-drug	B-drug	dasatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	CYP3A4	no
O	O	Inducers	no
O	O	:	no
O	O	Drugs	no
O	O	that	no
O	O	induce	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	may	no
O	O	decrease	no
B-drug	B-drug	dasatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

B-drug	I-drug	Valproate	yes
O	O	**	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	precipitation	no
O	O	occurs	no
O	O	when	no
O	O	eye	yes
O	O	drops	no
O	O	containing	yes
B-drug	B-drug_n	thimerosal	yes
O	O	are	no
O	O	mixed	yes
O	O	with	yes
B-drug	B-drug	latanoprost	yes
O	O	.	no

O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	several	no
O	O	closely	no
O	O	related	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	methylphenidate	yes
O	O	or	no
O	O	hepatic	no
O	O	enzyme	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	)	no
O	O	and	yes
O	O	decreased	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	hepatic	no
O	O	enzyme	no
O	O	inducers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	such	no
O	O	an	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	anticipated	no
O	O	with	yes
O	B-drug	CMI	no
O	O	as	yes
O	O	well	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	interactions	no
O	O	could	no
O	O	occur	no
O	O	following	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	psychotropic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	B-group	analgesics	no
O	O	,	no
B-group	B-group	antiemetics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	)	no
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	clinical	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	to	no
O	O	date	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	,	no
O	O	cytochrome	no
O	O	p450	no
O	O	inhibitors	no
O	O	and	yes
O	O	inducers	no
O	O	are	no
O	O	unlikely	no
O	O	to	no
O	O	affect	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	clofarabine	yes
O	O	.	no

B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	:	no
O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	its	no

O	O	This	no
O	O	conference	no
O	O	reviews	no
O	O	recent	no
O	O	developments	no
O	O	in	yes
O	O	these	no
O	O	areas	no
O	O	,	no
O	O	examines	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	drug	yes
O	O	use	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	and	yes
O	O	implications	no
O	O	for	yes
O	O	management	no
O	O	,	no
O	O	and	yes
O	O	discusses	no
O	O	current	no
O	O	information	no
O	O	on	no
O	O	how	no
O	O	age	no
O	O	may	no
O	O	influence	no
O	O	the	no
O	O	response	no
O	O	of	yes
O	O	cancer	no
O	O	to	no
O	O	therapy	no
O	O	.	no

O	O	We	no
O	O	incorporate	no
O	O	the	no
O	O	principles	no
O	O	of	yes
O	O	recovery	no
O	O	and	yes
O	O	define	no
O	O	positive	no
O	O	and	yes
O	O	constructive	no
O	O	alternatives	no
O	O	in	yes
O	O	dealing	no
O	O	with	yes
B-drug	O	cocaine	yes
O	O	hunger	no
O	O	.	no

O	O	Although	no
O	O	a	yes
O	O	causal	no
O	O	mechanism	no
O	O	and	yes
O	O	a	yes
O	O	cause-and-effect	no
O	O	relationship	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	,	no
O	O	current	no
O	O	evidence	no
O	O	suggests	no
O	O	that	no
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	in	yes
O	O	patients	no
O	O	on	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	even	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	renal	no
O	O	failure	no
O	O	,	no
O	O	and	yes
O	O	dosage	no
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	even	no
O	O	more	no
O	O	conservatively	no
O	O	adjusted	yes
O	O	in	yes
O	O	those	no
O	O	patients	no
O	O	on	no
O	O	such	no
O	O	combined	no
O	O	therapy	no
O	O	if	no
O	O	diminished	no
O	O	renal	no
O	O	function	no
O	O	is	yes
O	O	detected..	no

O	O	These	no
O	O	effects	no
O	O	were	no
O	O	not	no
O	O	considered	no
O	O	clinically	no
O	O	important	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	peripheral	no
O	O	neuropathy	no
O	O	include	no
B-group	B-drug	antiretroviral	no
I-group	I-drug	nucleoside	yes
I-group	I-drug	analogues	no
O	O	,	no
B-drug	B-drug	chloramphenicol	yes
O	O	,	no
B-drug	B-drug	cisplatin	yes
O	O	,	no
B-drug	B-drug	dapsone	yes
O	O	,	no
B-drug	B-drug	disulfiram	yes
O	O	,	no
B-drug	B-drug	ethionamide	yes
O	O	,	no
B-drug	B-drug	glutethimide	yes
O	O	,	no
B-drug	B-drug	gold	yes
O	O	,	no
B-drug	B-drug	hydralazine	yes
O	O	,	no
B-drug	B-drug	iodoquinol	yes
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-drug	B-drug	metronidazole	yes
O	O	,	no
B-drug	B-drug	nitrofurantoin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	ribavirin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	vincristine	yes
O	O	.	no

O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	phenothiazines	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	anorectic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	diethylpropion	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	,	no
O	O	predominantly	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	other	no
O	O	agents	yes
O	O	that	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	In	yes
O	O	another	no
O	O	report	no
O	O	,	no
O	O	nine	no
O	O	patients	no
O	O	with	yes
O	O	breast	no
O	O	cancer	no
O	O	were	no
O	O	reported	no
O	O	to	no
O	O	have	no
O	O	decreased	no
O	O	symptoms	no
O	O	of	yes
B-drug	B-drug	methotrexate-related	no
O	O	toxicity	no
O	O	when	no
O	O	given	no
O	O	supplemental	no
B-drug	B-drug	L-glutamine	yes
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	0.5	yes
O	O	gram/kilogram/day	no
O	O	.	no

O	O	Other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	in	yes
O	O	some	no
O	O	studies	no
O	O	and	yes
O	O	with	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Both	no
O	O	groups	no
O	O	of	yes
O	O	agents	yes
O	O	lower	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Carmustine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-brand	BiCNU	yes
O	O	)	no
O	O	or	no

O	O	The	no
O	O	mechanism	no
O	O	of	yes
O	O	these	no
O	O	interactions	no
O	O	has	no
O	O	been	no
O	O	evaluated	no
O	O	in	yes
O	O	in	yes
O	O	vitro	no
O	O	,	no
O	O	in	yes
O	O	situ	no
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	animal	no
O	O	models	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	L-phenylalanine	yes
O	O	and	yes
B-group	B-group	non-selective	no
I-group	I-group	MAO	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	cause	no
O	O	hypertension	no
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	of	yes
O	O	such	no
O	O	concomitant	no
O	O	use	no
O	O	with	yes
B-brand	B-brand	Activase	yes
O	O	for	yes
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	acute	no
O	O	ischemic	no
O	O	stroke	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-group	B-group	Veratrum	no
I-group	I-group	alkaloids	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	inhibit	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	veratrum	no
I-group	I-group	alkaloids	yes
O	O	.	no

O	O	Rarely	no
B-group	B-group	salicylate	yes
O	O	toxicity	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	discontinue	no
O	B-group	steroids	no
O	O	after	no
O	O	concurrent	no
O	O	high-dose	no
B-brand	B-brand	aspirin	yes
O	O	therapy	no
O	O	.	no

O	O	Since	no
B-drug	B-drug	amiodarone	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	CYP3A4	no
O	O	and	yes
O	O	CYP2C8	no
O	O	,	no
O	O	drugs/substances	no
O	O	that	no
O	O	inhibit	no
O	O	these	no
O	O	isoenzymes	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	metabolism	no
O	O	and	yes
O	O	increase	no
O	O	serum	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	.	no

O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-brand	Prostigmin	no
O	O	may	no
O	O	have	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	accordingly	no
O	O	.	no

O	O	Accelerated	no
O	O	prothrombin	yes
O	O	time	no
O	O	,	no
O	O	partial	no
O	O	thromboplastin	no
O	O	time	no
O	O	,	no
O	O	and	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	time	no
O	O	;	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	doubled	no
O	O	the	no
O	O	AUC	no
O	O	for	yes
B-drug	B-drug	cefprozil	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	exists	no
O	O	for	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
O	O	any	no
O	O	agent	yes
O	O	that	no
O	O	induces	no
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	elevated	no
B-drug	B-drug	digoxin	yes
O	O	serum	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	on	no
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	,	no
O	O	but	no
O	O	cases	no
O	O	of	yes
O	O	increased	no
B-drug	B-drug	lithium	yes
O	O	plasma	yes
O	O	levels	no
O	O	during	no
B-brand	B-brand	TORADOL	yes
O	O	therapy	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	These	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	ketoconazole	yes
O	O	or	no
B-drug	B-drug	erythromycin	yes
O	O	co-administration	no
O	O	enhances	no
B-drug	B-drug	fexofenadine	yes
O	O	gastrointestinal	no
O	O	absorption	no
O	O	.	no

O	O	Because	no
O	O	prostaglandina	no
O	O	play	no
O	O	an	no
O	O	important	no
O	O	role	no
O	O	in	yes
O	O	hemostasis	no
O	O	and	yes
B-drug	B-drug	ketoprofen	yes
O	O	has	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	platelet	yes
O	O	function	no
O	O	as	yes
O	O	well	no
O	O	,	no
O	O	concurent	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	ketoprofen	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	requires	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	on	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Initial	no
O	O	doses	no
O	O	of	yes
B-group	B-group	adrenergic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dopamine	yes
O	O	or	no
B-drug	B-drug	epinephrine	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	and	yes
O	O	titrated	no
O	O	to	no
O	O	achieve	no
O	O	the	no
O	O	desired	no
O	O	response	no
O	O	.	no

O	O	But	no
O	O	it	no
O	O	is	yes
O	O	now	no
O	O	difficult	no
O	O	to	no
O	O	situate	no
O	O	the	no
O	O	exact	no
O	O	place	no
O	O	of	yes
O	O	the	no
O	O	pharmacological	no
O	O	indications	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	experiments	no
O	O	reported	no
O	O	here	no
O	O	,	no
O	O	we	no
O	O	examined	no
O	O	the	no
O	O	interactions	no
O	O	between	yes
B-drug_n	B-drug	1,25	no
I-drug_n	I-drug	(	no
I-drug_n	I-drug	OH	no
I-drug_n	I-drug	)	no
I-drug_n	I-drug	2D3	no
O	O	and	yes
O	O	the	no
B-drug_n	B-group	antiestrogen	no
B-drug_n	B-drug_n	4-hydroxytamoxifen	yes
O	O	(	no
B-drug_n	B-drug_n	TAM	no
O	O	)	no
O	O	,	no
O	O	which	no
O	O	also	no
O	O	induces	no
O	O	apoptosis	no
O	O	in	yes
O	O	MCF-7	no
O	O	cells	yes
O	O	.	no

B-group	B-group	Anti-HIV	no
I-group	I-group	protease	yes
I-group	I-group	inhibitors	no
O	O	:	no
B-drug	B-drug	Saquinavir/ritonavir	no
O	O	combination	yes

B-drug_n	B-drug_n	Diethyl	yes
I-drug_n	I-drug_n	pyrocarbonate	no
O	O	,	no
O	O	at	yes
O	O	pH	yes
O	O	7.0	no
O	O	,	no
O	O	was	no
O	O	used	no
O	O	to	no
O	O	chemically	no
O	O	modify	no
O	O	exposed	no
O	O	histidine	yes
O	O	residues	no
O	O	on	no
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	.	no

O	O	in	yes
O	O	vitro	no
O	O	data	no
O	O	on	no
O	O	metabolic	no
O	O	interactions	no
O	O	indicate	no
O	O	that	no
B-brand	B-brand	Keppra	yes
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	produce	no
O	O	,	no
O	O	or	no
O	O	be	no
O	O	subject	no
O	O	to	no
O	O	,	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	.	no

O	B-group	Estrogen	no
O	O	increased	no
O	O	levels	no
O	O	of	yes
O	O	corticosteroid-binding	no
O	O	globulin	yes
O	O	,	no
O	O	thereby	no
O	O	increasing	no
O	O	the	no
O	O	bound	no
O	O	(	no
O	O	inactive	no
O	O	)	no
O	O	fraction	yes
O	O	;	no

B-brand	B-brand	AMEVIVE	no
O	O	underwent	no
B-drug	O	trans-placental	no
O	O	passage	no
O	O	and	yes
O	O	produced	no
O	O	in	yes
O	O	utero	no
O	O	exposure	yes
O	O	in	yes
O	O	the	no
O	O	developing	no
O	O	monkeys	no
O	O	.	no

O	O	No	yes
O	O	special	yes
O	O	precautions	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	necessary	no
O	O	when	no
O	O	oral	yes
B-group	O	anticoagulant	no
O	O	therapy	no
O	O	is	yes
O	O	begun	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	already	no
O	O	stabilized	no
O	O	on	no
O	O	maintenance	no
O	O	thyroid	yes
O	O	replacement	no
O	O	therapy	no
O	O	.	no

O	O	Diagnostic	yes
O	O	,	no
O	O	treatment	no
O	O	and	yes
O	O	aftercare	no
O	O	approaches	no
O	O	to	no
B-drug	B-drug	cocaine	yes
O	O	abuse	no
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	drugs	no
O	O	:	no
O	O	(	no
O	O	oral	yes
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	)	no
O	O	-	yes
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	antidiabetic	no
I-group	I-group	drug	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Although	no
O	O	studies	no
O	O	designed	no
O	O	to	no
O	O	examine	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	done	no
O	O	,	no
O	O	it	no
O	O	was	no
O	O	noted	no
O	O	that	no
B-group	B-group	corticosteroid	no
O	O	or	no
B-group	B-drug	ACTH	yes
O	O	treatment	no
O	O	of	yes
O	O	relapses	no
O	O	for	yes
O	O	periods	no
O	O	of	yes
O	O	up	no
O	O	to	no
O	O	28	yes
O	O	days	no
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	(	no
O	O	N=180	no
O	O	)	no
O	O	receiving	no
B-brand	B-brand	Betaseron	yes
O	O	.	no

B-drug	I-drug	Indinavir	yes
O	O	and	yes
B-drug	B-drug	didanosine	yes
O	O	formulations	no
O	O	containing	yes
O	O	buffer	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	at	yes
O	O	least	no
O	O	one	no
O	O	hour	yes
O	O	apart	no
O	O	on	no
O	O	an	no
O	O	empty	no
O	O	stomach	no
O	O	.	no

O	O	OBJECTIVES	no
O	O	:	no
O	O	To	no
O	O	examine	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	acute	no
B-drug	B-drug	hydrocortisone	yes
O	O	pretreatment	no
O	O	on	no
O	O	the	no
O	O	subjective	no
O	O	and	yes
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	d-amphetamine	yes
O	O	.	no

B-drug	B-drug	Efavirenz	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	in	yes
O	O	vivo	no
O	O	to	no
O	O	induce	no
O	O	CYP3A4	no
O	O	.	no

O	O	The	no
B-group	B-group	beta-blocker	no
O	O	should	no
O	O	be	no
O	O	withdrawn	no
O	O	first	no
O	O	.	no

O	O	Although	no
O	O	this	no
O	O	interaction	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	reported	no
O	O	with	yes
B-drug	B-drug	cinoxacin	yes
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-drug	B-drug	cinoxacin	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	caffeine-containing	no
O	O	products	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	probable	no
O	O	that	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
O	O	given	no
O	O	as	yes
O	O	antiemetic	no
O	O	prophylaxis	no
O	O	,	no
O	O	contributed	no
O	O	to	no
O	O	hyperglycemia	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

O	O	[	no
O	O	Drug	yes
O	O	treatment	no
O	O	of	yes
O	O	erection	no
O	O	disorders	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	cardiovascular	no
O	O	disease	no
O	O	]	no
O	O	Erectile	no
O	O	dysfunction	no
O	O	is	yes
O	O	a	yes
O	O	frequent	no
O	O	condition	no
O	O	in	yes
O	O	cardiovascular	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Physostigmine	yes
O	O	briefly	no
O	O	reduced	yes
O	O	the	no
O	O	amplitude	no
O	O	of	yes
O	O	most	no
O	O	components	no
O	O	,	no
O	O	including	no
O	O	P2	no
O	O	.	no

O	O	No	yes
O	O	specific	no
O	O	studies	no
O	O	in	yes
O	O	humans	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	and	yes
O	O	caution	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Coadministered	no
O	O	Concentration	no
O	O	Concentration	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	celecoxib	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	ramipril	yes
O	O	,	no
B-drug	B-drug	valsartan	yes
O	O	,	no
B-drug	B-drug	metformin	yes
O	O	and	yes
B-drug	B-drug	amlodipine	yes
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	clinically	no
O	O	significant	no
O	O	increases	no
O	O	in	yes
B-drug	B-drug	aliskiren	yes
O	O	exposure	yes
O	O	.	no

O	O	During	no
O	O	administration	no
O	O	of	yes
O	O	multiple	no
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	to	no
O	O	healthy	no
O	O	subjects	no
O	O	stabilized	no
O	O	on	no
O	O	a	yes
O	O	maintenance	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	a	yes
O	O	13	yes
O	O	%	no
O	O	-19	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	occurred	no
O	O	at	yes
O	O	six	no
O	O	hours	no
O	O	postdose	no
O	O	.	no

O	O	Some	no
O	O	reports	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	thiazides	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	causes	no
O	O	hypercalcemia	no
O	O	.	no

O	O	This	no
O	O	report	no
O	O	describes	no
O	O	a	yes
O	O	recently	no
O	O	identified	no
O	O	case	no
O	O	of	yes
O	O	interference	no
O	O	of	yes
B-drug	B-drug	acetylcysteine	yes
O	O	with	yes
O	O	the	no
O	O	urine	no
O	O	test	yes
O	O	for	yes
O	O	ketones	no
O	O	and	yes
O	O	demonstrates	no
O	O	the	no
O	O	importance	no
O	O	of	yes
O	O	a	yes
O	O	thorough	no
O	O	medication	no
O	O	review	no
O	O	in	yes
O	O	evaluating	no
O	O	abnormal	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

B-group	B-group	Nondepolarizing	no
I-group	I-group	Muscle	no
I-group	I-group	Relaxants	no
O	O	:	no
O	O	In	yes
O	O	postmarketing	no
O	O	experience	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	a	yes
O	O	possible	no
O	O	interaction	no
O	O	between	yes
O	O	TORADOLIV/IM	no
O	O	and	yes
B-group	B-group	nondepolarizing	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	that	no
O	O	resulted	no
O	O	in	yes
O	O	apnea	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	;	no

O	O	faecalis	no
O	O	ATCC	no
O	O	51299	no
O	O	showed	no
O	O	the	no
O	O	flavonoids	no
O	O	alone	no
O	O	significantly	no
O	O	lowered	no
O	O	numbers	no
O	O	of	yes
O	O	colony	yes
O	O	forming	no
O	O	units	yes
O	O	(	no
O	O	CFUs	no
O	O	)	no
O	O	.	no

O	O	Catecholamine-depleting	no
O	O	drugs	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	)	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-group	B-group	beta-blocking	no
I-group	O	agents	yes
O	O	.	no

O	O	in	yes
O	O	vitro	no
O	O	,	no
O	B-brand	Gleevec	yes
O	O	inhibits	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzyme	no
O	O	CYP2D6	no
O	O	activity	yes
O	O	at	yes
O	O	similar	no
O	O	concentrations	no
O	O	that	no
O	O	affect	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	.	no

O	O	When	no
O	O	the	no
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	was	no
O	O	administered	no
O	O	30	yes
O	O	minutes	no
O	O	after	no
O	O	the	no
B-drug	B-drug	sumatriptan	yes
O	O	nasal	no
O	O	spray	no
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	increased	no
O	O	11	yes
O	O	%	no
O	O	and	yes
O	O	Cmax	no
O	O	decreased	no
O	O	18	yes
O	O	%	no
O	O	.	no

O	O	Dosage	no
O	O	adjustments	no
O	O	of	yes
B-brand	B-brand	BROVANA	yes
O	O	are	no
O	O	not	no
O	O	necessary	no
O	O	when	no
O	O	the	no
O	O	drug	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	potent	no
O	O	CYP2D6	no
O	O	inhibitors	no
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	Drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
O	O	other	no
O	O	medications	no
O	O	,	no
O	O	including	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	hexobarbital	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	alfentanil	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	bromocriptine	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	lovastatin	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interferences	no
O	O	:	no
B-drug	B-drug	Dicumarol	yes
O	O	and	yes
B-drug	B-group	indanedione	no
B-group	I-group	anticoagulants	no
O	O	,	no
O	O	including	no
B-drug	B-drug	anisindione	yes
O	O	,	no
O	O	or	no
O	O	their	no
O	O	metabolites	no
O	O	may	no
O	O	color	no
O	O	alkaline	yes
O	O	urine	no
O	O	red-orange	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	spectrophotometrically	no
O	O	determined	no
O	O	urinary	yes
O	O	laboratory	no
O	O	tests	no
O	O	.	no

O	O	.	no

O	O	An	no
O	O	individual	no
O	O	who	no
O	O	is	yes
O	O	stable	no
O	O	on	no
O	O	a	yes
O	O	given	no
O	O	dose	no
O	O	of	yes
B-group	B-group	TCA	no
O	O	may	no
O	O	become	no
O	O	abruptly	no
O	O	toxic	no
O	O	when	no
O	O	given	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	inhibiting	no
O	O	drugs	no
O	O	as	yes
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	study	no
O	O	(	no
O	O	n=6	no
O	O	)	no
O	O	,	no
O	O	ingestion	no
O	O	of	yes
O	O	an	no
B-group	B-group	antacid	no
O	O	containing	yes
O	O	1.7-gram	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
I-drug	I-drug	hydroxide	yes
O	O	with	yes
O	O	500-mg	no
O	O	of	yes
B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	increased	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	by	no
O	O	125	yes
O	O	%	no
O	O	and	yes
O	O	36	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no
O	O	A	yes
O	O	number	no
O	O	of	yes
O	O	compounds	no
O	O	are	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2C9	no
O	O	including	no
B-drug	B-drug	fluconazole	yes
O	O	,	no
B-drug	B-drug	lovastatin	yes
O	O	and	yes
B-drug	B-drug	trimethoprim	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	ouabain	yes
O	O	was	no
O	O	applied	no
O	O	to	no
O	O	the	no
O	O	muscle	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	phentolamine	yes
O	O	,	no
O	O	both	no
O	O	first	no
O	O	and	yes
O	O	second	no
O	O	contractile	no
O	O	responses	no
O	O	to	no
B-drug_n	B-drug_n	PTX	no
O	O	were	no
O	O	abolished	no
O	O	.	no

O	O	Studies	no
O	O	in	yes
O	O	rats	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	neomycin	yes
O	O	administration	no
O	O	attenuates	no
O	O	certain	no
O	O	types	no
O	O	of	yes
O	B-group	adrenocortical	no
O	I-group	steroid	no
O	O	dependent	no
O	O	hypertension	no
O	O	,	no
O	O	including	no
B-group	B-drug	ACTH	yes
O	O	hypertension	no
O	O	.	no

O	O	If	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	,	no
O	O	especially	no
O	O	when	no
B-drug	B-drug	diltiazem	yes
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	,	no
O	O	adjusted	yes
O	O	,	no
O	O	or	no
O	O	discontinued	no
O	O	.	no

O	O	We	no
O	O	conclude	no
O	O	that	no
B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	prevents	no
B-drug	B-drug	morphine-induced	no
O	O	increases	no
O	O	in	yes
O	O	gastrointestinal	no
O	O	transit	no
O	O	time	no
O	O	by	no
O	O	means	no
O	O	of	yes
B-group	O	selective	no
I-group	O	peripheral	no
I-group	O	opioid	no
I-group	O	anitagonism	no
O	O	without	no
O	O	affecting	no
O	O	central	no
B-group	O	opioid	no
O	O	analgesia	no
O	O	.	no

O	O	Dose	no
O	O	reduction	yes
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	to	no
O	O	600	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	taking	no
B-drug	B-drug	delavirdine	yes
O	O	400	yes
O	O	mg	yes
O	O	three	no
O	O	times	no
O	O	a	yes
O	O	day	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	block	yes
B-group	O	angiotensin	yes
I-group	O	II	yes
O	O	or	no
O	O	its	no
O	O	effects	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
B-drug	B-drug	amiloride	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	,	no
O	O	or	no
O	O	salt	yes
O	O	substitutes	no
O	O	containing	yes
B-drug	O	potassium	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	,	no
O	O	no	yes
O	O	significant	no
O	O	drug-drug	no
O	O	interaction	no
O	O	was	no
O	O	observed	no
O	O	when	no
B-brand	B-brand	Norpace	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	propranolol	yes
O	O	or	no
B-drug	B-drug	diazepam	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	and	yes
B-drug	B-drug	fluvoxamine	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	Interaction	no
O	O	of	yes
B-brand	B-brand	GABITRIL	yes
O	O	with	yes
O	O	Highly	no
O	O	Protein	yes
O	O	Bound	no
O	O	Drugs	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	showed	no
O	O	that	no
B-drug	B-drug	tiagabine	yes
O	O	is	yes
O	O	96	no
O	O	%	no
O	O	bound	no
O	O	to	no
O	O	human	yes
O	O	plasma	yes
O	O	protein	yes
O	O	and	yes
O	O	therefore	no
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	other	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	compounds	no
O	O	.	no

O	O	Alternate	no
O	O	treatments	no
O	O	lacking	no
O	O	CYP3A4	no
O	O	inducing	no
O	O	activity	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	In	yes
O	O	many	no
O	O	of	yes
O	O	these	no
O	O	cases	no
O	O	,	no
B-drug	B-drug	buprenorphine	yes
O	O	was	no
O	O	misused	no
O	O	by	no
O	O	self-injection	no
O	O	of	yes
O	O	crushed	no
B-brand	B-brand	SUBUTEX	yes
O	O	tablets	yes
O	O	.	no

B-drug	B-drug	Sildenafil	yes
I-drug	I-drug	citrate	yes
O	O	-	yes
O	O	Theoretically	no
O	O	,	no
B-drug	B-drug	L-arginine	yes
O	O	supplements	no
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	sildenafil	yes
I-drug	I-drug	citrate	yes
O	O	,	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	.	no

O	O	.	no

O	O	Agents	yes
O	O	Having	no
O	O	Vasodilator	no
O	O	Activity	yes
O	O	:	no
O	O	Data	no
O	O	on	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	B-group	vasodilators	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	captopril	yes
O	O	for	yes
O	O	heart	no
O	O	failure	no
O	O	are	no
O	O	not	no
O	O	available	no
O	O	;	no

O	O	The	no
O	O	coadministration	no
O	O	of	yes
O	O	a	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	enzyme	no
O	O	inducer	no
O	O	,	no
O	O	although	no
O	O	not	no
O	O	posing	no
O	O	a	yes
O	O	safety	no
O	O	concern	no
O	O	,	no
O	O	thus	no
O	O	could	no
O	O	lead	no
O	O	to	no
O	O	ineffectiveness	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	serum	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	when	no
O	O	initiating	no
O	O	or	no
O	O	changing	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	BEXTRA	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Five	no
O	O	,	no
O	O	10	yes
O	O	,	no
O	O	20	yes
O	O	,	no
O	O	or	no
O	O	50	yes
O	O	mg/kg	no
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	alone	no
O	O	or	no
O	O	20	yes
O	O	,	no
O	O	50	yes
O	O	,	no
O	O	or	no
O	O	100	yes
O	O	mg/kg	no
O	O	of	yes
O	O	metabolite	yes
O	O	I	yes
O	O	alone	no
O	O	produced	no
O	O	less	no
O	O	than	no
O	O	10	yes
O	O	minutes	no
O	O	of	yes
O	O	hypnosis	no
O	O	.	no

B-drug	B-drug	Fluoxetine	yes

B-drug	B-drug	Theophylline	yes
O	O	alone	no
O	O	caused	no
O	O	identical	no
B-drug	O	insulin	yes
O	O	and	yes
O	O	glucagon	yes
O	O	release	yes
O	O	in	yes
O	O	diabetics	no
O	O	and	yes
O	O	normals	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	be	no
O	O	used	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	neither	no
B-drug	B-drug	phenobarbital	yes
O	O	nor	yes
B-drug	B-drug	diazepam	yes
O	O	appears	no
O	O	to	no
O	O	affect	no
B-drug	B-brand	Dantrium	yes
O	O	metabolism	no
O	O	.	no

B-group	B-group	Bile	no
I-group	I-group	acid	yes
I-group	I-group	binding	no
I-group	I-group	resins	no
O	O	may	no
O	O	also	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	phosphate	yes
O	O	supplements	no
O	O	and	yes
B-drug	B-drug	hydrocortisone	yes
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Because	no
B-drug	B-drug	cyclosporine	yes
O	O	can	no
O	O	produce	no
O	O	nephrotoxicity	no
O	O	with	yes
O	O	decreases	no
O	O	in	yes
O	O	creatinine	yes
O	O	clearance	no
O	O	and	yes
O	O	rises	no
O	O	in	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	,	no
O	O	and	yes
O	O	because	no
O	O	renal	no
O	O	excretion	no
O	O	is	yes
O	O	the	no
O	O	primary	no
O	O	elimination	no
O	O	route	no
O	O	of	yes
B-group	B-group	fibrate	no
I-group	I-group	drugs	no
O	O	including	no
B-brand	B-brand	TRICOR	yes
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	risk	no
O	O	that	no
O	O	an	no
O	O	interaction	no
O	O	will	no
O	O	lead	no
O	O	to	no
O	O	deterioration	no
O	O	.	no

O	O	-	yes
B-group	B-group	Antithyroid	no
I-group	I-group	agents	yes
O	O	(	no
O	O	medicine	no
O	O	for	yes
O	O	overactive	no
O	O	thyroid	yes
O	O	)	no
O	O	or	no

O	O	In	yes
O	O	the	no
O	O	digitalized	no
O	O	patient	no
O	O	,	no
O	O	slow	yes
O	O	alterations	no
O	O	in	yes
O	O	serum	yes
O	O	levels	no
O	O	after	no
O	O	oral	yes
O	O	administration	no
O	O	appeared	no
O	O	well	no
O	O	correlated	no
O	O	with	yes
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	,	no
O	O	the	no
O	O	negative	no
O	O	chronotropic	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	.	no

O	O	Potential	no
O	O	for	yes
O	O	Other	no
O	O	Drugs	no
O	O	to	no
O	O	Affect	no
B-brand	B-brand	ABILIFY	yes
B-drug	I-brand	Aripiprazole	yes
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	of	yes
O	O	CYP1A1	no
O	O	,	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2A6	no
O	O	,	no
O	O	CYP2B6	no
O	O	,	no
O	O	CYP2C8	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	or	no
O	O	CYP2E1	no
O	O	enzymes	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	quinidine	yes
O	O	did	no
O	O	not	no
O	O	seem	no
O	O	to	no
O	O	change	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	esomeprazole	yes
O	O	.	no

O	O	DRUG/LABORATORY	no
O	O	TEST	yes
O	O	INTERACTIONS	no
O	O	1	yes
O	O	.	no

O	O	In	yes
O	O	several	no
O	O	well-controlled	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	guanfacine	yes
O	O	was	no
O	O	administered	no
O	O	together	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	with	yes
O	O	no	yes
O	O	drug	yes
O	O	interactions	no
O	O	reported	no
O	O	.	no

B-drug	B-drug	Spermine	yes
O	O	(	no
O	O	0.5-2	no
O	O	mM	yes
O	O	)	no
O	O	promoted	no
O	O	the	no
O	O	translocation	no
O	O	of	yes
O	O	phosphatidate	no
O	O	phosphohydrolase	no
O	O	from	no
O	O	the	no
O	O	soluble	no
O	O	to	no
O	O	the	no
O	O	microsomal	no
O	O	fraction	yes
O	O	in	yes
O	O	a	yes
O	O	cell-free	no
O	O	system	yes
O	O	derived	yes
O	O	from	no
O	O	rat	yes
O	O	liver	yes
O	O	.	no

B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
B-drug	B-drug	Norethindrone	yes

O	O	Due	no
O	O	to	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	additive	no
O	O	effects	no
O	O	,	no
O	O	caution	no
O	O	and	yes
O	O	careful	no
O	O	titration	yes
O	O	are	no
O	O	warranted	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	diltiazem	yes
I-drug	I-drug	hydrochloride	yes
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	agents	yes
O	O	known	no
O	O	to	no
O	O	affect	no
O	O	cardiac	no
O	O	contractility	no
O	O	and/or	no
O	O	conduction	no
O	O	.	no

O	O	laryngeal	no
O	O	edema	no

O	O	Since	no
B-brand	B-brand	Zarontin	yes
O	O	(	no
B-drug	B-drug	ethosuximide	yes
O	O	)	no
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	concurrently	no
O	O	administered	no
B-group	B-group	antiepileptic	no
I-group	I-group	drugs	no
O	O	,	no
O	O	periodic	no
O	O	serum	yes
O	O	level	no
O	O	determinations	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ethosuximide	yes
O	O	may	no
O	O	elevate	no
B-drug	B-drug	phenytoin	yes
O	O	serum	yes
O	O	levels	no
O	O	and	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	both	no
O	O	increase	no
O	O	and	yes
O	O	decrease	no
B-drug	B-drug	ethosuximide	yes
O	O	levels	no
O	O	)	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	B-group	Mixed	yes
B-group	I-group	Agonist/Antagonist	no
I-group	I-group	Opioid	no
I-group	I-group	Analgesics	no
O	O	:	no
B-group	B-group	Agonist/antagonist	no
I-group	I-group	analgesics	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	pentazocine	yes
O	O	,	no
B-drug	B-drug	nalbuphine	yes
O	O	,	no
B-drug	B-drug	butorphanol	yes
O	O	,	no
B-drug	B-drug	dezocine	yes
O	O	and	yes
B-drug	B-drug	buprenorphine	yes
O	O	)	no
O	O	should	no
O	O	NOT	no
O	O	be	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	who	no
O	O	has	no
O	O	received	no
O	O	or	no
O	O	is	yes
O	O	receiving	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
O	O	a	yes
O	B-group	pure	yes
B-group	I-group	agonist	no
I-group	I-group	opioid	no
I-group	I-group	analgesic	no
O	O	such	no
O	O	as	yes
B-brand	B-brand	Levo-Dromoran	yes
O	O	.	no

B-drug	B-drug	Amphotericin	yes
I-drug	I-drug	B	yes
O	O	or	no
B-group	B-group	Corticosteroids	no
O	O	or	no
B-drug	B-drug	Corticotropin	yes
O	O	(	no
B-drug	B-drug	ACTH	yes
O	O	)	no

O	O	If	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	are	no
O	O	also	no
O	O	being	no
O	O	given	no
O	O	,	no
O	O	compensatory	no
O	O	increases	no
O	O	in	yes
O	O	clotting	no
O	O	factor	yes
O	O	synthesis	no
O	O	are	no
O	O	impaired	no
O	O	.	no

O	O	Because	no
O	O	efficient	no
O	O	labeling	no
O	O	can	no
O	O	be	no
O	O	achieved	no
O	O	with	yes
O	O	0.1	no
O	O	%	no
O	O	biocytin	no
O	O	with	yes
O	O	whole-cell	no
O	O	recording	no
O	O	,	no
O	O	higher	no
O	O	concentrations	no
O	O	are	no
O	O	contraindicated	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	additive	no
O	O	negative	no
O	O	inotropic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	and	yes
B-drug	B-drug	flecainide	yes
O	O	should	no
O	O	be	no
O	O	recognized	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
B-brand	B-brand	ENABLEX	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	medications	no
O	O	that	no
O	O	are	no
O	O	predominantly	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	and	yes
O	O	which	no
O	O	have	no
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	window	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	flecainide	yes
O	O	,	no
B-drug	B-drug	thioridazine	yes
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
O	O	see	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	show	no
O	O	that	no
B-group	B-group	lung	yes
I-group	I-group	surfactant	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	of	yes
O	O	enhancing	no
O	O	the	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
O	O	dissolution	no
O	O	of	yes
O	O	drugs	no
O	O	administered	no
O	O	to	no
O	O	the	no
O	O	lung	yes
O	O	.	no

O	O	Inhibition	no
O	O	of	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	leading	no
O	O	to	no
O	O	increases	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	concentrations	no
O	O	has	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
O	O	low	yes
O	O	temperatures	no
O	O	on	no
O	O	microtubules	no
O	O	in	yes
O	O	the	no
O	O	non-myelinated	no
O	O	axons	no
O	O	of	yes
O	O	post-ganglionic	no
O	O	sympathetic	no
O	O	nerves	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	LDL-C	no
O	O	reduction	yes
O	O	was	no
O	O	greater	no
O	O	when	no
B-drug	B-drug	atorvastatin	yes
O	O	and	yes
B-drug	B-drug	colestipol	yes
O	O	were	no
O	O	coadministered	no
O	O	than	no
O	O	when	no
O	O	either	no
O	O	drug	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	therefore	no
O	O	,	no
B-brand	B-brand	VIRACEPT	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	Results	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	wshow	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	interaction	no
O	O	with	yes
O	O	either	no
O	O	single	yes
O	O	or	no
O	O	repeated	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	.	no

O	O	The	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	with	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	In	yes
O	O	general	no
O	O	,	no
O	O	most	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	dirithromycin	yes
O	O	who	no
O	O	are	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	theophylline	yes
O	O	therapy	no
O	O	may	no
O	O	not	no
O	O	require	no
O	O	empiric	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	dosage	no
O	O	or	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	and	yes
B-drug	B-drug	glutamate	yes
O	O	(	no
O	O	15	yes
O	O	mg/kg	no
O	O	e.w	no
O	O	.	no
O	O	)	no

O	O	Other	no
O	O	drugs	no
O	O	which	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
O	B-group	nondepolarizing	no
O	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-brand	B-brand	NIMBEX	yes
O	O	include	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-group	B-group	aminoglycosides	no
O	O	,	no
B-group	B-group	tetracyclines	no
O	O	,	no
B-drug	B-drug	bacitracin	yes
O	O	,	no
B-group	B-group	polymyxins	no
O	O	,	no
B-drug	B-drug	lincomycin	yes
O	O	,	no
B-drug	B-drug	clindamycin	yes
O	O	,	no
B-drug	B-drug	colistin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	colistemethate	no
O	O	)	no
O	O	,	no
B-drug	B-group	magnesium	yes
O	O	salts	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	diseases	no
O	O	of	yes
O	O	the	no
O	O	liver	yes
O	O	,	no
O	O	gallbladder	no
O	O	,	no
O	O	and	yes
O	O	bowel	yes
O	O	;	no

O	O	In	yes
O	O	in	yes
O	O	vivo	no
O	O	studies	no
O	O	,	no
O	O	10-	no
O	O	to	no
O	O	30-mg/day	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	metabolism	no
O	O	by	no
O	O	CYP2D6	no
O	O	(	no
B-drug	B-drug	dextromethorphan	yes
O	O	)	no
O	O	,	no
O	O	CYP2C9	no
O	O	(	no
B-drug	B-drug	warfarin	yes
O	O	)	no
O	O	,	no
O	O	CYP2C19	no
O	O	(	no
B-drug	B-drug	omeprazole	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	CYP3A4	no
O	O	(	no
B-drug	B-drug	dextromethorphan	yes
O	O	)	no
O	O	substrates	no
O	O	.	no

B-drug	B-drug	Lapatinib	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	inhibit	no
O	O	the	no
O	O	following	no
O	O	enzymes	yes
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	:	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2C19	no
O	O	,	no
O	O	and	yes
O	O	CYP2D6	no
O	O	or	no
O	O	UGT	no
O	O	enzymes	yes
O	O	in	yes
O	O	vitro	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	On	no
O	O	the	no
O	O	other	no
O	O	hand	no
O	O	,	no
O	O	the	no
O	O	enhanced	no
O	O	secretion	no
O	O	of	yes
O	O	colonic	no
O	O	fluid	no
O	O	by	no
B-drug_n	B-drug_n	dmPGE2	no
O	O	,	no
O	O	given	no
O	O	intraluminally	no
O	O	,	no
O	O	was	no
O	O	only	no
O	O	half	no
O	O	of	yes
O	O	that	no
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	,	no
O	O	whereas	no
O	O	the	no
O	O	colonic	no
O	O	transit-enhancing	no
O	O	effect	no
O	O	of	yes
B-drug_n	B-drug_n	dmPGE2	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	was	no
O	O	more	no
O	O	pronounced	no
O	O	than	no
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	at	yes
O	O	15	yes
O	O	but	no
O	O	not	no
O	O	at	yes
O	O	30	yes
O	O	min	no
O	O	after	no
O	O	its	no
O	O	administration	no
O	O	.	no

O	O	Increases	no
O	O	in	yes
O	O	INR	no
O	O	and	yes
O	O	prothrombin	yes
O	O	time	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	abnormal	no
O	O	bleeding	no
O	O	and	yes
O	O	even	no
O	O	death	no
O	O	.	no

O	O	A	yes
O	O	5-mg	no
B-drug	B-drug	Vardenafil	yes
O	O	dose	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	exceeded	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	200	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
B-drug	B-drug	ketoconazole	yes
O	O	.	no

B-drug	B-drug	Fluvoxamine	yes
O	O	increased	no
O	O	mean	no
B-drug	B-drug	alosetron	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	approximately	no
O	O	6-fold	no
O	O	and	yes
O	O	prolonged	no
O	O	the	no
O	O	half-life	no
O	O	by	no
O	O	approximately	no
O	O	3-fold	no
O	O	.	no

O	O	[	no
O	O	Stimulation	no
O	O	by	no
O	B-drug_n	cerulein	yes
O	O	--	no
O	O	an	no
O	O	analog	yes
O	O	of	yes
O	O	the	no
O	O	octapeptide	yes
O	O	cholecystokinin	yes
O	O	--	no
O	O	of	yes
O	B-drug_n	3H-spiroperidol	no
O	O	binding	no
O	O	after	no
O	O	the	no
O	O	long-term	no
O	O	administration	no
O	O	of	yes
B-group	B-group	neuroleptics	no
O	O	]	no
O	O	It	no
O	O	has	no
O	O	been	no
O	O	established	no
O	O	in	yes
O	O	experiments	no
O	O	on	no
O	O	white	yes
O	O	male	no
O	O	rats	no
O	O	that	no
O	O	prolonged	no
O	O	administration	no
O	O	(	no
O	O	twice	no
O	O	a	yes
O	O	day	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	haloperidol	yes
O	O	(	no
O	O	0.25	no
O	O	mg/kg	no
O	O	)	no
O	O	and	yes
B-drug	B-drug_n	pyreneperone	no
O	O	(	no
O	O	0.25	no
O	O	mg/kg	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	the	no
O	O	reduced	yes
O	O	interaction	no
O	O	between	yes
B-drug_n	B-drug_n	3H-spiroperidol	no
O	O	and	yes
O	O	low	yes
O	O	affinity	no
O	O	binding	no
O	O	sites	no
O	O	for	yes
B-drug	B-drug	apomorphine	yes
O	O	in	yes
O	O	subcortical	no
O	O	structures	no
O	O	,	no
O	O	whereas	no
O	B-drug_n	3H-spiroperidol	no
O	O	binding	no
O	O	with	yes
O	O	high	yes
O	O	affinity	no
O	O	binding	no
O	O	sites	no
O	O	for	yes
B-drug	B-drug	apomorphine	yes
O	O	increased	no
O	O	both	no
O	O	in	yes
O	O	the	no
O	O	frontal	no
O	O	cortex	no
O	O	and	yes
O	O	subcortical	no
O	O	structures	no
O	O	of	yes
O	O	the	no
O	O	forebrain	no
O	O	.	no

O	O	Pulmonary	no
O	O	granulomata	no
O	O	,	no
O	O	subacute	no
O	O	hepatitis	yes
O	O	and	yes
O	O	other	no
O	O	lesions	no
O	O	resulting	no
O	O	from	no
O	O	intravenous	yes
O	O	drug	yes
O	O	use	no
O	O	were	no
O	O	common	yes
O	O	findings	no
O	O	at	yes
O	O	autopsy	no
O	O	.	no

O	O	Blunting	no
O	O	of	yes
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	beta-adrenoceptor	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	by	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-drug	B-drug	heparin	yes
I-drug	I-drug	sodium	yes
O	O	is	yes
O	O	given	no
O	O	with	yes
B-drug	B-drug	dicumarol	yes
O	O	or	no
B-drug	B-drug	warfarin	yes
I-drug	I-drug	sodium	yes
O	O	,	no
O	O	a	yes
O	O	period	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	intravenous	yes
O	O	dose	no
O	O	or	no
O	O	24	yes
O	O	hours	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	subcutaneous	yes
O	O	dose	no
O	O	should	no
O	O	elapse	no
O	O	before	no
O	O	blood	yes
O	O	is	yes
O	O	drawn	no
O	O	if	no
O	O	a	yes
O	O	valid	no
O	O	prothrombin	yes
O	O	time	no
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	obtained	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	with	yes
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

O	O	When	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	INDOCIN	yes
O	O	are	no
O	O	made	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	carefully	no
O	O	and	yes
O	O	in	yes
O	O	small	no
O	O	increments	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	a	yes
O	B-drug	disulfiram-like	no
O	O	reaction	no
O	O	may	no
O	O	be	no
O	O	produced	no
O	O	by	no
O	O	the	no
O	O	ingestion	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	+12	no
O	O	%	no
O	O	+19	no
O	O	%	no
O	O	-11	no
O	O	%	no
O	O	-3	no
O	O	%	no

O	O	Because	no
O	O	both	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	have	no
O	O	negative	no
O	O	inotropic	no
O	O	properties	no
O	O	and	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	coadministration	no
O	O	with	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	are	no
O	O	unknown	no
O	O	,	no
O	O	neither	no
B-drug	B-drug	disopyramide	yes
O	O	nor	yes
B-drug	B-drug	verapamil	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	unless	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	judgment	no
O	O	of	yes
O	O	the	no
O	O	physician	no
O	O	,	no
O	O	the	no
O	O	benefits	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	outweigh	no
O	O	the	no
O	O	risks	no
O	O	.	no

O	O	The	no
O	O	20	yes
O	O	%	no
O	O	v/v	no
O	O	solution	yes
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	was	no
O	O	prepared	no
O	O	in	yes
O	O	water	yes
O	O	from	no
O	O	a	yes
O	O	stock	no
O	O	solution	yes
O	O	of	yes
O	O	95	no
O	O	%	no
B-drug	B-drug	ethanol	yes
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	in	yes
O	O	preterm	no
O	O	neonates	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Retrospective	no
O	O	analysis	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	showed	no
O	O	that	no
O	O	poor	no
O	O	2D6	no
O	O	metabolizers	no
O	O	had	no
O	O	a	yes
O	O	higher	no
O	O	rate	no
O	O	of	yes
O	O	dizziness	no
O	O	during	no
O	O	up-titration	no
O	O	,	no
O	O	presumably	no
O	O	resulting	no
O	O	from	no
O	O	vasodilating	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	higher	no
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	a-blocking	no
O	O	R	yes
O	O	(	no
O	O	+	no
O	O	)	no
O	O	enantiomer	no
O	O	.	no

O	O	asthma	no
O	O	drugs	no
O	O	and	yes
B-group	B-group	antipsychotics	no
O	O	.	no

O	O	bone	no
O	O	marrow	no
O	O	hypoplasia	no

O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	entecavir	yes
O	O	with	yes
B-drug	B-drug	lamivudine	yes
O	O	,	no
B-drug	B-drug	adefovir	yes
I-drug	I-drug	dipivoxil	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	tenofovir	yes
I-drug	I-drug	disoproxil	yes
I-drug	I-drug	fumarate	yes
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	drugs	no
O	O	that	no
O	O	may	no
O	O	depress	no
O	O	the	no
O	O	nervous	no
O	O	system	yes
O	O	,	no
B-drug	B-drug	ethanol	yes
O	O	or	no
B-drug	B-drug	triazolam	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	tiagabine	yes
O	O	.	no

B-drug	B-drug	Aminoglutethimide	yes
O	O	:	no
B-drug	B-drug	Aminoglutethimide	yes
O	O	may	no
O	O	diminish	no
O	O	adrenal	no
O	O	suppression	no
O	O	by	no
B-group	B-group	corticosteroids	no
O	O	.	no

B-drug	B-drug	Atropine	yes
O	O	,	no
O	O	either	no
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	produced	no
O	O	approximately	no
O	O	the	no
O	O	same	yes
O	O	degree	no
O	O	of	yes
O	O	enhancement	no
O	O	of	yes
O	O	component	yes
O	O	P2	no
O	O	.	no

O	O	Animals	no
O	O	studies	no
O	O	on	no
O	O	the	no
O	O	various	no
O	O	dual-memory	no
O	O	theories	no
O	O	have	no
O	O	been	no
O	O	carried	no
O	O	out	no
O	O	mainly	no
O	O	on	no
O	O	the	no
O	O	basis	no
O	O	of	yes
O	O	hippocampal	no
O	O	system	yes
O	O	function	no
O	O	.	no

B-drug	B-drug	Sertraline	yes

O	O	Potential	no
O	O	Drug	yes
O	O	Interactions	no
B-drug	B-drug	Dofetilide	yes
O	O	is	yes
O	O	eliminated	no
O	O	in	yes
O	O	the	no
O	O	kidney	yes
O	O	by	no
O	O	cationic	no
O	O	secretion	no
O	O	.	no

O	O	was	no
O	O	evaluated	no
O	O	as	yes
O	O	a	yes
O	O	possible	no
O	O	explanation	no
O	O	for	yes
O	O	the	no
O	O	association	no
O	O	of	yes
O	O	deep-seated	no
O	O	infection	no
O	O	with	yes
O	O	this	no
O	O	organism	no
O	O	and	yes
O	O	abuse	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	When	no
B-drug	B-drug	Vardenafil	yes
O	O	dosing	no
O	O	was	no
O	O	separated	no
O	O	from	no
B-drug	B-drug	terazosin	yes
O	O	10	yes
O	O	mg	yes
O	O	by	no
O	O	6	yes
O	O	hours	no
O	O	,	no
O	O	7	yes
O	O	of	yes
O	O	28	yes
O	O	subjects	no
O	O	who	no
O	O	received	no
O	O	20	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	experienced	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	standing	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	below	no
O	O	85	no
O	O	mm	yes
O	O	Hg	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	The	no
O	O	neurochemical	no
O	O	and	yes
O	O	functional	no
O	O	consequences	no
O	O	following	no
B-drug_n	B-drug_n	MPTP	no
O	O	administration	no
O	O	to	no
O	O	the	no
O	O	rat	yes
O	O	were	no
O	O	evaluated	no
O	O	and	yes
O	O	compared	no
O	O	to	no
O	O	similar	no
O	O	effects	no
O	O	following	no
B-drug	B-drug	methamphetamine	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Caffeine	yes
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	ketoprofen	yes
O	O	reduced	yes
O	O	the	no
O	O	urine	no
O	O	volume	no
O	O	in	yes
O	O	4	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
B-drug	B-drug	theophylline-related	no
O	O	side-effects	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	concomitant	no
O	B-drug	theophylline-quinolone	no
O	O	therapy	no
O	O	.	no

B-group	B-group	Non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	(	no
O	O	but	no
O	O	not	no
B-brand	B-brand	aspirin	yes
O	O	)	no
O	O	:	no
O	O	These	no
O	O	drugs	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	very	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	provoke	no
O	O	convulsions	no
O	O	in	yes
O	O	pre-clinical	no
O	O	studies	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	human	yes
O	O	liver	yes
O	O	microsome	no
O	O	studies	no
O	O	and	yes
O	O	an	no
O	O	in	yes
O	O	vivo	no
O	O	metabolic	no
O	O	probe	no
O	O	study	no
O	O	demonstrated	no
O	O	that	no
B-drug	B-drug	alosetron	yes
O	O	did	no
O	O	not	no
O	O	inhibit	no
O	O	CYP	no
O	O	enzymes	yes
O	O	2D6	no
O	O	,	no
O	O	3A4	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	or	no
O	O	2C19	no
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	to	no
O	O	its	no
O	O	enantiomer	no
O	O	,	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-NANM	no
O	O	failed	no
O	O	to	no
O	O	increase	no
O	O	FI	no
O	O	responding	no
O	O	significantly	no
O	O	in	yes
O	O	either	no
O	O	species	no
O	O	;	no

O	O	The	no
O	O	extent	no
O	O	to	no
O	O	which	no
B-group	B-group	SSRI-TCAinteractions	no
O	O	may	no
O	O	pose	no
O	O	clinical	no
O	O	problems	no
O	O	will	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	inhibition	no
O	O	and	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRI	no
O	O	involved	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	in	yes
O	O	addition	no
O	O	to	no
O	O	its	no
O	O	proposed	no
O	O	specific	no
O	O	information	no
O	O	processing	no
O	O	functions	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	relational	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	hippocampus	no
O	O	would	no
O	O	play	no
O	O	a	yes
O	O	role	no
O	O	in	yes
O	O	addressing	no
O	O	information	no
O	O	to	no
O	O	the	no
O	O	brain	yes
O	O	memory	no
O	O	system	yes
O	O	that	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	given	no
O	O	situation	no
O	O	,	no
O	O	has	no
O	O	the	no
O	O	best	no
O	O	adaptive	no
O	O	value	no
O	O	.	no
O	O	(	no
O	O	ABSTRACT	no
O	O	TRUNCATED	yes
O	O	AT	yes
O	O	250	yes
O	O	WORDS	no
O	O	)	no

O	O	When	no
B-brand	B-brand	INDOCIN	yes
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	probenecid	yes
O	O	,	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	are	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	.	no

B-group	B-group	Antihistamines	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	counteract	no
O	O	the	no
O	O	sedative	no
O	O	effect	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Mixing	no
O	O	of	yes
B-group	B-group	Insulins	no

O	O	There	no
O	O	was	no
O	O	not	no
O	O	a	yes
O	O	significant	no
O	O	difference	no
O	O	(	no
O	O	p	yes
O	O	>	no
O	O	0.05	no
O	O	)	no
O	O	in	yes
O	O	AUC	no
O	O	(	no
O	O	48.59	no
O	O	+/-	no
O	O	8.52	no
O	O	vs.	no
O	O	49.9	no
O	O	+/-	no
O	O	9.93	no
O	O	)	no
O	O	,	no
O	O	Cmax	no
O	O	(	no
O	O	7.73	no
O	O	+/-	no
O	O	2.6	no
O	O	vs.	no
O	O	6.6	no
O	O	+/-	no
O	O	2.0	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	tmax	no
O	O	(	no
O	O	1.1	no
O	O	+/-	no
O	O	0.6	no
O	O	vs.	no
O	O	1.6	no
O	O	+/-	no
O	O	1.1	no
O	O	)	no
O	O	for	yes
B-drug	B-drug	levofloxacin	yes
O	O	versus	no
B-drug	B-drug	levofloxacin/oxycodone	no
O	O	regimens	no
O	O	.	no

O	O	The	no
B-group	B-group	thiazolidinediones	no
O	O	(	no
B-drug	B-drug	rosiglitazone	yes
O	O	and	yes
B-drug	B-drug	pioglitazone	yes
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	new	no
O	O	class	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	are	no
O	O	"	no
O	O	insulin	yes
O	O	sensitizers	no
O	O	"	no

O	O	Although	no
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	in	yes
O	O	HIV-1	no
O	O	seropositive	no
O	O	subjects	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	for	yes
O	O	the	no
O	O	classes	no
O	O	of	yes
O	O	drugs	no
O	O	listed	no
O	O	in	yes
O	O	Table	no
O	O	4	yes
O	O	,	no
O	O	additional	no
O	O	clinical	no
O	O	monitoring	no
O	O	may	no
O	O	be	no
O	O	warranted	no
O	O	when	no
O	O	co-administering	no
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	situation	no
O	O	,	no
O	O	special	yes
O	O	patient	no
O	O	care	yes
O	O	and	yes
O	O	observation	no
O	O	are	no
O	O	appropriate	no
O	O	.	no

B-drug	B-drug	Labetalol	yes
I-drug	I-drug	HCl	yes
O	O	has	no
O	O	also	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	produce	no
O	O	a	yes
O	O	false	no
O	O	positive	no
O	O	test	yes
O	O	for	yes
B-drug	B-drug	amphetamine	yes
O	O	when	no
O	O	screening	no
O	O	urine	no
O	O	for	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	drugs	no
O	O	using	no
O	O	the	no
O	O	commercially	no
O	O	available	no
O	O	assay	no
O	O	methods	no
O	O	Toxi-Lab	no
O	O	A	yes
O	O	(	no
O	O	thin-layer	no
O	O	chromatographic	no
O	O	assay	no
O	O	)	no
O	O	and	yes
O	O	Emit-d.a.u	no
O	O	.	no
O	O	(	no
O	O	radioenzymatic	no
O	O	assay	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	is	yes
O	O	recommended	no
O	O	and	yes
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	dose	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	when	no
B-brand	B-brand	EULEXIN	yes
O	O	Capsules	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	The	no
O	O	data	no
O	O	inTables	no
O	O	1	yes
O	O	and	yes
O	O	3	yes
O	O	are	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	conducted	no
O	O	in	yes
O	O	HIV-1	no
O	O	seropositive	no
O	O	subjects	no
O	O	unless	no
O	O	otherwise	no
O	O	indicated	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	toxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	on	no
O	O	chronic	no
B-drug	B-drug	phenobarbital	yes
O	O	treatment	no
O	O	following	no
O	O	the	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Hydrochlorothiazide	yes
O	O	:	no
O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	healthy	no
O	O	volunteers	no
O	O	has	no
O	O	shown	no
O	O	that	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	DynaCirc	yes
O	O	(	no
B-drug	B-drug	isradipine	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	does	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	altered	no
O	O	pharmacoktnetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

B-brand	B-brand	CANCIDAS	yes
O	O	has	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
O	O	or	no
O	O	the	no
O	O	active	no
O	O	metabolite	yes
O	O	of	yes
B-drug	O	mycophenolate	yes
O	O	.	no

B-group	B-group	Antidepressants	no
O	O	(	no
B-group	B-group	tricyclic	no
O	O	)	no
O	O	,	no
B-drug	B-drug	atropine	yes
O	O	or	no
O	O	other	no
B-group	B-group	anticholinergic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	or	no
B-group	B-group	digitalis	yes
I-group	I-group	glycosides	yes
O	O	:	no
O	O	concurrent	no
O	O	use	no
O	O	with	yes
B-drug	B-drug	arbutamine	yes
O	O	may	no
O	O	produce	no
O	O	additive	no
O	O	inotropic	no
O	O	and/or	no
O	O	chronotropic	no
O	O	effects	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	clinically	no
O	O	significant	no
O	O	.	no

O	O	Since	no
O	O	bacteriostatic	yes
O	O	drugs	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	bactericidal	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	penicillin	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	advisable	no
O	O	to	no
O	O	avoid	no
O	O	giving	no
B-group	B-group	tetracyclines	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-drug	B-group	penicillin	yes
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	reduction	yes
O	O	of	yes
O	O	growth	yes
O	O	caused	no
O	O	by	no
O	O	the	no
O	O	drugs	no
O	O	was	no
O	O	1,000-fold	no
O	O	greater	no
O	O	for	yes
O	O	49	no
O	O	Pseudomonas	no
O	O	strains	no
O	O	from	no
O	O	normal	yes
O	O	subjects	no
O	O	than	no
O	O	for	yes
O	O	32	yes
O	O	strains	no
O	O	from	no
O	O	drug	yes
O	O	addicts	no
O	O	(	no
O	O	4.2	no
O	O	vs.	no
O	O	1.3	no
O	O	logs	no
O	O	of	yes
O	O	reduction	yes
O	O	at	yes
O	O	2	yes
O	O	hr	yes
O	O	,	no
O	O	P	yes
O	O	less	no
O	O	than	no
O	O	.0005	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Diazepam	yes
O	O	:	no
B-drug	B-drug	Diazepam	yes
O	O	(	no
B-brand	B-brand	Valium	yes
O	O	)	no
O	O	is	yes
O	O	a	yes
O	O	CYP	no
O	O	3A4	no
O	O	and	yes
O	O	CYP	no
O	O	2C19	no
O	O	substrate	yes
O	O	.	no

O	O	INCREASED	no
B-drug	B-drug	PHENYTOIN	yes
O	O	LEVELS	no
O	O	SHOULD	no
O	O	BE	no
O	O	TREATED	no
O	O	WITH	yes
O	O	APPROPRIATE	no
O	O	DOSAGE	no
O	O	ADJUSTMENT	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	because	no
O	O	of	yes
O	O	demonstrated	no
O	O	hypokalemia	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	with	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	Cytochrome	no
O	O	P4502D6	no
O	O	-	yes
O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	did	no
O	O	not	no
O	O	reveal	no
O	O	an	no
O	O	inhibitory	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	on	no
O	O	CYP2D6	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	and	yes
O	O	other	no
B-group	B-group	hydroxymethylglutaryl	no
I-group	I-group	coenzyme	yes
I-group	I-group	A	yes
I-group	I-group	(	no
I-group	I-group	HMG-CoA	no
I-group	I-group	)	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	have	no
O	O	resulted	no
O	O	in	yes
O	O	previous	no
O	O	reports	no
O	O	of	yes
O	O	rhabdomyolysis	no
O	O	.	no

O	O	The	no
O	O	pressor	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	ERGOMAR	yes
O	O	and	yes
O	O	other	no
B-group	B-group	vasoconstrictor	no
I-group	I-group	drugs	no
O	O	can	no
O	O	combine	no
O	O	to	no
O	O	cause	no
O	O	dangerous	no
O	O	hypertension	no
O	O	.	no

O	O	A	yes
O	O	causal	no
O	O	relationship	no
O	O	between	yes
O	O	these	no
O	O	events	no
O	O	and	yes
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	and	yes
B-brand	B-brand	HALDOL	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	;	no

O	O	Aortic	no
O	O	rings	no
O	O	with	yes
O	O	intact	no
O	O	endothelium	no
O	O	from	no
O	O	the	no
O	O	high-dose	no
O	O	(	no
O	O	4	yes
O	O	mg/kg/day	no
O	O	)	no
B-drug	B-drug	estradiol	yes
O	O	group	yes
O	O	were	no
O	O	supersensitive	no
O	O	to	no
B-drug	B-drug	noradrenaline	yes
O	O	compared	no
O	O	to	no
O	O	the	no
O	O	vehicle	no
O	O	or	no
O	O	low-dose	no
O	O	(	no
O	O	10	yes
O	O	microg/kg/day	no
O	O	)	no
B-drug	O	estradiol	yes
O	O	groups	no
O	O	(	no
O	O	pD2	no
O	O	values	no
O	O	=	no
O	O	7.86+/-0.09	no
O	O	,	no
O	O	7.30+/-0.11	no
O	O	and	yes
O	O	7.35+/-0.04	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	two	no
O	O	or	no
O	O	more	no
O	O	drugs	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	--	no
O	O	such	no
O	O	as	yes
O	O	an	no
B-group	B-group	antipsychotic	no
I-group	I-group	drug	yes
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	chlorpromazine	yes
O	O	)	no
O	O	,	no
O	O	an	no
O	B-group	antiparkinsonian	no
O	I-group	drug	yes
O	O	(	no
O	O	eg	no
O	O	,	no
O	B-drug	trihexyphenidyl	yes
O	O	)	no
O	O	,	no
O	O	and/or	no
O	O	a	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	amitriptyline	yes
O	O	)	no
O	O	--	no
O	O	commonly	no
O	O	results	no
O	O	in	yes
O	O	excessive	no
O	O	anticholinergic	no
O	O	effects	no
O	O	,	no
O	O	including	no
O	O	dry	no
O	O	mouth	no
O	O	and	yes
O	O	associated	no
O	O	dental	yes
O	O	complications	no
O	O	,	no
O	O	blurred	no
O	O	vision	no
O	O	,	no
O	O	and	yes
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	exposed	no
O	O	to	no
O	O	high	yes
O	O	temperature	no
O	O	and	yes
O	O	humidity	no
O	O	,	no
O	O	hyperpyrexia	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	pattern	no
O	O	of	yes
O	O	use	no
O	O	for	yes
O	O	oral	yes
B-drug	B-drug	allopurinol	yes
O	O	includes	no
O	O	longer	no
O	O	term	no
O	O	therapy	no
O	O	,	no
O	O	particularly	no
O	O	for	yes
O	O	gout	no
O	O	and	yes
O	O	renal	no
O	O	calculi	no
O	O	,	no
O	O	the	no
O	O	experience	no
O	O	gained	no
O	O	may	no
O	O	be	no
O	O	relevant	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	1-year	no
O	O	monthly	no
O	O	comparison	no
O	O	study	no
O	O	,	no
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	were	no
O	O	taken	no
O	O	by	no
O	O	39	no
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	1602	no
O	O	patients	no
O	O	.	no

O	O	These	no
O	O	factors	no
O	O	,	no
O	O	in	yes
O	O	concert	no
O	O	with	yes
O	O	age-dependent	no
O	O	alterations	no
O	O	in	yes
O	O	immune	yes
O	O	function	no
O	O	and	yes
O	O	host	no
O	O	defense	no
O	O	,	no
O	O	may	no
O	O	help	no
O	O	to	no
O	O	explain	no
O	O	the	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	malignant	no
O	O	disease	no
O	O	in	yes
O	O	aged	no
O	O	persons	no
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	slight	no
O	O	reduction	yes
O	O	in	yes
O	O	blood	yes
O	O	sugar	yes
O	O	concentrations	no
O	O	during	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	and	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	signs	no
O	O	or	no
O	O	symptoms	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Survival	no
O	O	of	yes
O	O	miracidia	no
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	increasing	no
O	O	metal	no
O	O	concentration	no
O	O	except	no
O	O	at	yes
O	O	concentrations	no
O	O	of	yes
O	O	10	yes
O	O	microg/l	no
O	O	for	yes
O	O	single	yes
O	O	metal	no
O	O	toxicity	no
O	O	where	no
O	O	survival	no
O	O	was	no
O	O	increased	no
O	O	above	no
O	O	the	no
O	O	control	no
O	O	.	no

O	O	-	yes
B-group	B-group	Antihypertensives	no
O	O	:	no
B-drug	B-drug	Bumetanide	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	various	no
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	,	no
O	O	necessitating	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	acetaminophen/theophylline	no
O	O	,	no
B-drug	B-drug	lidocaine/quinidine	no
O	O	,	no
B-drug	B-drug	phenobarbital/acetaminophen	no
O	O	,	no
B-drug	B-drug	phenobarbital/valproic	no
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	quinidine/lidocaine	no
O	O	,	no
B-drug	B-drug	theophylline/acetaminophen	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid/phenobarbital	no
O	O	.	no

O	O	-	yes
O	O	Increased	no
O	O	prothrombin	yes
O	O	and	yes
O	O	factors	no
O	O	VII	yes
O	O	,	no
O	O	VIII	yes
O	O	,	no
O	O	IX	yes
O	O	,	no
O	O	and	yes
O	O	X	yes
O	O	;	no

B-drug	B-drug	Enalapril	yes
O	O	IV	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	reactions	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
O	B-drug	CMI	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	if	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	eosinophilia	no

O	O	Presumably	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	acts	no
O	O	as	yes
O	O	a	yes
O	O	stimulator	no
O	O	of	yes
B-group	B-group	coumarin	yes
O	O	metabolism	no
O	O	and	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	decreased	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	and	yes
O	O	increased	no
B-drug	O	prothrombin-proconvertin	no
O	O	concentrations	no
O	O	.	no

O	O	Johns	yes
O	O	Wort	yes
O	O	)	no
O	O	may	no
O	O	significantly	no
O	O	reduce	no
O	O	exposure	yes
O	O	to	no
B-brand	B-brand	Gleevec	yes
O	O	.	no

O	O	(	no
O	O	Read	no
O	O	circulars	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparations	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	concomitant	no
O	O	therapy	no
O	O	.	no
O	O	)	no

O	O	The	no
O	O	results	no
O	O	indicate	no
O	O	that	no
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
O	O	readily	no
O	O	penetrates	no
O	O	both	no
O	O	the	no
O	O	mucosal	no
O	O	and	yes
O	O	serosal	no
O	O	surfaces	no
O	O	of	yes
O	O	the	no
O	O	epithelial	no
O	O	membrane	yes
O	O	.	no

B-drug	B-drug	Clarithromycin	yes

B-group	B-brand	Aspirin/Nonsteroidal	no
I-group	B-group	Antiinflammatory	no
I-group	O	Drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no

B-group	B-drug	thyroid	yes
I-group	O	medication	no
O	O	;	no

O	O	Pharmacokinetic	no
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	cetirizine	yes
O	O	in	yes
O	O	adults	no
O	O	were	no
O	O	conducted	no
O	O	with	yes
B-drug	B-drug	pseudoephedrine	yes
O	O	,	no
B-drug	B-drug	antipyrine	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	azithromycin	yes
O	O	.	no

O	O	When	no
O	O	given	no
O	O	i.p.	no
O	O	,	no
B-drug_n	B-drug_n	dmPGE2	no
O	O	(	no
O	O	0.3	yes
O	O	mg/kg	no
O	O	)	no
O	O	induced	no
O	O	a	yes
O	O	watery	no
O	O	stool	no
O	O	in	yes
O	O	cecectomized	no
O	O	and	yes
O	O	control	no
O	O	rats	no
O	O	with	yes
O	O	the	no
O	O	same	yes
O	O	efficacy	no
O	O	,	no
O	O	although	no
O	O	these	no
O	O	effects	no
O	O	were	no
O	O	short-lasting	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	oral	yes
O	O	administration	no
O	O	.	no

O	O	Prior	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	4-methylpyrazole	yes
O	O	(	no
O	O	90	yes
O	O	mg	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	was	no
O	O	shown	no
O	O	to	no
O	O	prevent	no
O	O	the	no
O	O	conversion	yes
O	O	of	yes
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	to	no
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	in	yes
O	O	vivo	no
O	O	and	yes
O	O	to	no
O	O	eliminate	no
O	O	the	no
B-drug	O	fluoride	yes
O	O	and	yes
O	O	citrate	yes
O	O	elevations	no
O	O	seen	no
O	O	in	yes
O	B-drug_n	1,3-difluoro-2-propanol-intoxicated	no
O	O	animals	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	lamivudine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	zalcitabine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no

B-drug	B-drug_n	Echistatin	no
O	O	alone	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	tyrosine	yes
O	O	phosphorylation	no
O	O	in	yes
O	O	T24	no
O	O	cells	yes
O	O	,	no
O	O	but	no
O	O	dose-dependently	no
O	O	inhibits	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	contortrostatin	no
O	O	when	no
O	O	both	no
O	O	are	no
O	O	added	no
O	O	simultaneously	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-group	B-group	diuretics	no
O	O	are	no
O	O	at	yes
O	O	a	yes
O	O	greater	no
O	O	risk	no
O	O	of	yes
O	O	developing	no
O	O	renal	no
O	O	failure	no
O	O	secondary	yes
O	O	to	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	renal	no
O	O	blood	yes
O	O	flow	no
O	O	caused	no
O	O	by	no
O	O	prostaglandin	yes
O	O	inhibition	no
O	O	.	no

B-drug	B-drug	Heparin	yes
O	O	,	no
O	O	other	no
B-group	B-group	anticoagulants	no
O	O	,	no
B-group	B-group	thrombolytics	no
O	O	,	no
O	O	and	yes
B-group	B-group	anti	yes
I-group	I-group	platelet	yes
I-group	I-group	agents	yes
O	O	are	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	bleeding	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Ethotoin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Peganone	yes
O	O	)	no
O	O	or	no

O	O	Further	no
O	O	,	no
O	O	they	no
O	O	bring	no
O	O	into	no
O	O	question	no
O	O	the	no
O	O	utility	no
O	O	of	yes
O	O	using	no
B-drug_n	B-drug_n	PCP	yes
O	O	combination	yes
O	O	procedures	no
O	O	in	yes
O	O	animals	no
O	O	to	no
O	O	screen	no
O	O	for	yes
O	O	antipsychotic	no
O	O	potential	no
O	O	.	no

B-drug	B-drug	chloral	yes
O	O	hydrate*	no
O	O	;	no

B-drug	B-drug	clofibrate	yes
O	O	;	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	in	yes
O	O	concurrent	no
O	O	or	no
O	O	serial	no
O	O	use	no
O	O	of	yes
O	O	other	no
O	O	neurotoxic	no
O	O	and/	no
O	O	or	no
O	O	nephrotoxic	no
O	O	drugs	no
O	O	because	no
O	O	of	yes
O	O	possible	no
O	O	enhancement	no
O	O	of	yes
O	O	the	no
O	O	nephrotoxicity	no
O	O	and/or	no
O	O	ototoxicity	no
O	O	of	yes
B-drug	B-drug	neomycin	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Ibuprofen	yes
O	O	produced	no
O	O	an	no
O	O	elevation	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	in	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	eleven	no
O	O	normal	yes
O	O	volunteers	no
O	O	.	no

B-drug	B-drug	fenoprofen	yes
O	O	;	no

O	O	The	no
O	O	genotypes	no
O	O	of	yes
O	B-drug	CYP2C9	no
O	O	and	yes
O	O	2C19	no
O	O	,	no
O	O	the	no
O	O	enzymes	yes
O	O	responsible	no
O	O	for	yes
B-drug	O	phenytoin	yes
O	O	metabolism	no
O	O	,	no
O	O	were	no
O	O	homozygous	no
O	O	for	yes
O	O	the	no
O	O	wild-type	no
O	O	alleles	no
O	O	(	no
O	B-drug	CYP2C9*1/*1	no
O	O	and	yes
O	O	2C19*1/	no
O	O	*1	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Gabapentin	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	naproxen	yes
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	.	no

O	O	Coadministration	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	dextromethorphan	yes
O	O	plasma	yes
O	O	levels	no
O	O	suggesting	no
O	O	that	no
O	O	,	no
O	O	at	yes
O	O	these	no
O	O	doses	no
O	O	,	no
B-drug	B-drug	valdecoxib	yes
O	O	is	yes
O	O	a	yes
O	O	weak	no
O	O	inhibitor	yes
O	O	of	yes
O	O	2D6	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Lofexidine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	anti-hypertensive	no
I-group	I-group	drug	yes
O	O	therapy	no

O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	The	no
O	O	central	no
O	B-group	anticholinergic	no
O	O	syndrome	no
O	O	can	no
O	O	occur	no
O	O	when	no
B-group	O	anticholinergic	no
I-group	O	agents	yes
O	O	such	no
O	O	as	yes
B-brand	B-brand	AKINETON	yes
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	have	no
O	O	secondary	yes
O	O	anticholinergic	no
O	O	actions	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
O	O	certain	no
B-group	B-group	narcotic	no
I-group	I-group	analgesics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	meperidine	yes
O	O	,	no
O	O	the	no
B-group	B-group	phenothiazines	no
O	O	and	yes
O	O	other	no
B-group	B-group	antipsychotics	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	certain	no
B-group	B-group	antiarrhythmics	no
O	O	such	no
O	O	as	yes
O	O	the	no
B-drug	B-drug	quinidine	yes
O	O	salts	no
O	O	,	no
O	O	and	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	unlike	no
B-drug_n	B-drug_n	ibogaine	no
O	O	,	no
B-drug_n	B-drug_n	18-MC	no
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	responding	no
O	O	for	yes
O	O	a	yes
O	O	nondrug	no
O	O	reinforcer	no
O	O	(	no
O	O	water	yes
O	O	)	no
O	O	.	no

O	B-brand	INOmax	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	tolazoline	yes
O	O	,	no
B-drug	B-drug	dopamine	yes
O	O	,	no
B-drug	B-drug	dobutamine	yes
O	O	,	no
B-group	B-group	steroids	no
O	O	,	no
B-group	B-drug	surfactant	yes
O	O	,	no
O	O	and	yes
O	O	high-frequency	no
O	O	ventilation	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	doxepin	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	.	no

O	O	in	yes
O	O	vitro	no
O	O	,	no
B-brand	B-brand	Gleevec	yes
O	O	inhibits	no
B-drug	O	acetaminophen	yes
O	O	O-glucuronidation	no
O	O	(	no
O	O	Ki	yes
O	O	value	no
O	O	of	yes
O	O	58.5	no
O	O	M	yes
O	O	)	no
O	O	at	yes
O	O	therapeutic	no
O	O	levels	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	several	no
O	O	factors	no
O	O	that	no
O	O	could	no
O	O	have	no
O	O	increased	no
O	O	his	yes
O	O	risk	no
O	O	for	yes
O	O	developing	no
O	O	rhabdomyolysis	no
O	O	,	no
O	O	including	no
O	O	chronic	no
O	O	renal	no
O	O	failure	no
O	O	.	no

O	O	These	no
O	O	small	no
O	O	changes	no
O	O	are	no
O	O	not	no
O	O	clinically	no
O	O	significant	no
O	O	and	yes
O	O	no	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	necessary	no
O	O	.	no

O	O	and	yes
B-group	B-group	diuretics	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

I-group	O	D	yes
O	O	.	no

B-brand	B-brand	NovoSeven	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	mixed	yes
O	O	with	yes
O	O	infusion	no
O	O	solutions	no
O	O	until	no
O	O	clinical	no
O	O	data	no
O	O	are	no
O	O	available	no
O	O	to	no
O	O	direct	no
O	O	this	no
O	O	use	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	with	yes
B-group	B-group	fibrates	no
O	O	should	no
O	O	generally	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	Gentamycin	no
O	O	reduced	yes
O	O	twitch	no
O	O	strength	yes
O	O	from	no
O	O	40	yes
O	O	+/-	no
O	O	1	yes
O	O	%	no
O	O	(	no
O	O	mean	no
O	O	+/-	no
O	O	sem	no
O	O	)	no
O	O	to	no
O	O	29	yes
O	O	+/-	no
O	O	4	yes
O	O	%	no
O	O	within	no
O	O	7.0	no
O	O	+/-	no
O	O	1.5	yes
O	O	min	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	0.02	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	isoenzyme	no
O	O	including	no
O	O	certain	no
B-group	B-group	antidepressants	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	nortriptyline	yes
O	O	,	no
B-drug	B-drug	imipramine	yes
O	O	,	no
B-drug	B-drug	desipramine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	)	no
O	O	,	no
B-group	B-group	antipsychotics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	haloperidol	yes
O	O	,	no
B-drug	B-drug	risperidone	yes
O	O	,	no
B-drug	B-drug	thioridazine	yes
O	O	)	no
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	metoprolol	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	Type	yes
I-group	I-group	1C	no
I-group	I-group	antiarrhythmics	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	propafenone	yes
O	O	,	no
B-drug	B-drug	flecainide	yes
O	O	)	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	initiated	no
O	O	at	yes
O	O	the	no
O	O	lower	no
O	O	end	no
O	O	of	yes
O	O	the	no
O	O	dose	no
O	O	range	no
O	O	of	yes
O	O	the	no
O	O	concomitant	no
O	O	medication	no
O	O	.	no

O	O	The	no
O	O	plasma	yes
O	O	and	yes
O	O	tumour	no
O	O	total	yes
B-drug	B-group	nitrosourea	yes
O	O	peak	no
O	O	concentrations	no
O	O	were	no
O	O	reduced	yes
O	O	by	no
O	O	1.5	yes
O	O	and	yes
O	O	1.7	no
O	O	fold	no
O	O	respectively	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	reduction	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	,	no
O	O	hence	no
B-drug	B-drug	zalcitabine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	to	no
O	O	be	no
O	O	ingested	no
O	O	simultaneously	no
O	O	with	yes
B-group	B-drug	magnesium/aluminum-containing	no
I-group	B-group	antacids	no
O	O	.	no

O	O	phophatase	no

O	O	Therefore	no
O	O	,	no
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	,	no
O	O	including	no
O	O	oral	yes
O	O	,	no
O	O	injectable	no
O	O	,	no
O	O	transdermal	no
O	O	,	no
O	O	and	yes
O	O	implantable	no
O	O	forms	no
O	O	,	no
O	O	may	no
O	O	not	no
O	O	be	no
O	O	reliable	no
O	O	when	no
B-brand	B-brand	TRACLEER	yes
O	O	is	yes
O	O	co-administered	no
O	O	.	no

B-drug	B-drug	Calcium	yes
O	O	Supplements	no
O	O	:	no
O	O	Uncontrolled	no
O	O	intake	no
O	O	of	yes
O	O	additional	no
O	B-drug	calcium-containing	no
O	O	preparations	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	reactions	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	Clinistix	no
O	O	or	no
O	O	Tes-Tape	no
O	O	)	no
O	O	be	no
O	O	used	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	:	no
O	O	A	yes
O	O	relationship	no
O	O	of	yes
O	O	functional	no
O	O	antagonism	no
O	O	exists	no
O	O	between	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	I-group	analogues	no
O	O	,	no
O	O	which	no
O	O	promote	no
O	O	calcium	yes
O	O	absorption	no
O	O	,	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	which	no
O	O	inhibit	no
O	O	calcium	yes
O	O	absorption	no
O	O	.	no

O	O	Infusion	no
O	O	requirements	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	in	yes
O	O	patients	no
O	O	administered	no
B-drug	B-drug	succinylcholine	yes
O	O	prior	no
O	O	to	no
O	O	infusions	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	were	no
O	O	comparable	no
O	O	to	no
O	O	or	no
O	O	slightly	no
O	O	greater	no
O	O	than	no
O	O	when	no
B-drug	B-drug	succinylcholine	yes
O	O	was	no
O	O	not	no
O	O	administered	no
O	O	.	no

O	O	The	no
O	O	potentiation	no
O	O	resulted	no
O	O	from	no
O	O	a	yes
O	O	CNS	no
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	;	no

O	O	Since	no
B-drug	B-drug	fondaparinux	yes
I-drug	I-drug	sodium	yes
O	O	does	no
O	O	not	no
O	O	bind	no
O	O	significantly	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	other	no
O	O	than	no
B-brand	O	ATIII	no
O	O	,	no
O	O	no	yes
O	O	drug	yes
O	O	interactions	no
O	O	by	no
O	O	protein-binding	no
O	O	displacement	no
O	O	are	no
O	O	expected	no
O	O	.	no

O	O	Adjustment	no
O	O	of	yes
O	O	dosage	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	because	no
O	O	bleeding	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-drug	B-drug	ibuprofen	yes
O	O	and	yes
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	have	no
O	O	been	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	on	no
B-group	B-group	coumarin-type	no
I-group	I-group	anticoagulants	no
O	O	,	no
O	O	the	no
O	O	physician	no
O	O	should	no
O	O	be	no
O	O	cautious	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	ibuprofen	yes
O	O	to	no
O	O	patients	no
O	O	on	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	itraconazole	yes
O	O	also	no
O	O	markedly	no
O	O	inhibits	no
O	O	the	no
O	O	biotransformation	no
O	O	system	yes
O	O	mainly	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	;	no

O	O	fecal	no
O	O	excretion	no
O	O	,	no
O	O	too	no
O	O	,	no
O	O	was	no
O	O	increased	no
O	O	by	no
O	O	supplementary	no
B-drug	B-drug	iron	yes
O	O	;	no

O	O	No	yes
O	O	statistically	no
O	O	significant	no
O	O	differences	no
O	O	between	yes
O	O	treatment	no
O	O	groups	no
O	O	were	no
O	O	observed	no
O	O	for	yes
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	calculated	no
B-drug	B-drug	digoxin	yes
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	.	no

O	O	Medications	no
O	O	can	no
O	O	cause	no
O	O	in	yes
O	O	vivo	no
O	O	effects	no
O	O	when	no
O	O	the	no
O	O	concentration	no
O	O	or	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	analyte	no
O	O	is	yes
O	O	altered	no
O	O	before	no
O	O	the	no
O	O	analysis	no
O	O	and	yes
O	O	therefore	no
O	O	the	no
O	O	assay	no
O	O	result	no
O	O	is	yes
O	O	true	yes
O	O	and	yes
O	O	accurate	no
O	O	.	no

B-drug	I-drug	tadalafil	yes
O	O	concentration	no

B-drug	B-drug	Neomycin	yes
O	O	has	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	blood	yes
O	O	pressure	no
O	O	or	no
O	O	metabolic	no
O	O	responses	no
O	O	to	no
B-drug	B-group	ACTH	yes
O	O	in	yes
O	O	sheep	yes
O	O	.	no

O	O	The	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	anticholinergics	no
O	O	with	yes
B-drug	B-drug	hydrocodone	yes
O	O	may	no
O	O	produce	no
O	O	paralytic	no
O	O	ileus	no
O	O	.	no

O	O	Modification	no
O	O	of	yes
O	O	surface	yes
O	O	histidine	yes
O	O	residues	no
O	O	abolishes	no
O	O	the	no
O	O	cytotoxic	yes
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	Clostridium	yes
I-drug_n	I-drug_n	difficile	no
I-drug_n	I-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	.	no

O	O	Induction	no
O	O	of	yes
O	O	apoptosis	no
O	O	in	yes
O	O	breast	no
O	O	cancer	no
O	O	cells	yes
O	O	in	yes
O	O	response	no
O	O	to	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	and	yes
B-group	B-group	antiestrogens	no
O	O	.	no

O	O	These	no
O	O	six	no
O	O	volunteers	no
O	O	received	no
B-drug	B-drug	terfenadine	yes
O	O	alone	no
O	O	(	no
O	O	60	no
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	for	yes
O	O	8	yes
O	O	days	no
O	O	,	no
O	O	followed	no
O	O	by	no
B-drug	B-drug	terfenadine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	dirithromycin	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	there	no
O	O	are	no
O	O	limited	no
O	O	in	yes
O	O	vivo	no
O	O	data	no
O	O	suggesting	no
O	O	a	yes
O	O	modest	no
O	O	CYP2D6	no
O	O	inhibitory	yes
O	O	effect	no
O	O	for	yes
B-drug	B-drug	escitalopram	yes
O	O	,	no
O	O	i.e.	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	escitalopram	yes
O	O	(	no
O	O	20	yes
O	O	mg/day	no
O	O	for	yes
O	O	21	yes
O	O	days	no
O	O	)	no
O	O	with	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
B-drug	B-drug	desipramine	yes
O	O	(	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	50	yes
O	O	mg	yes
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	CYP2D6	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	40	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	and	yes
O	O	a	yes
O	O	100	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	.	no

B-drug	B-drug	Ketoconazole/Itraconazole	no
O	O	,	no
B-group	B-group	Macrolides	no
O	O	,	no
O	O	Including	no
B-drug	B-drug	Erythromycin	yes

O	O	Transient	no
O	O	and	yes
O	O	minor	no
O	O	adverse	no
O	O	events	no
O	O	occurred	no
O	O	with	yes
O	O	similar	no
O	O	frequency	no
O	O	on	no
O	O	placebo	no
O	O	and	yes
B-drug	B-drug	rofecoxib	yes
O	O	treatments	no
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	treatment-related	no
O	O	pattern	no
O	O	was	no
O	O	apparent	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drug	yes
O	O	interactions	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	undergoing	no
O	O	treatment	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	allopurinol	yes
O	O	.	no

O	O	.	no

B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	each	no
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	.	no

B-group	B-group	Potassium-sparing	no
I-group	I-group	diuretics	no
O	O	(	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
B-drug	B-drug	amiloride	yes
O	O	,	no
B-drug	B-drug	triamterene	yes
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	)	no
O	O	or	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	can	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hyperkalemia	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	erlotinib	yes
O	O	exposure	yes
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	hepatic	no
O	O	dysfunction	no
O	O	.	no

O	O	alone	no
O	O	.	no

O	O	Pregnancy	no
O	O	Pregnancy	no
O	O	Category	no
O	O	D	yes
O	O	:	no
O	O	.	no

B-drug	B-drug	Nevirapine	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	be	no
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemics	no
O	O	,	no
O	O	regular	yes
O	O	monitoring	no
O	O	of	yes
O	O	blood	yes
B-drug	O	glucose	yes
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	be	no
O	O	determined	no
O	O	before	no
O	O	starting	no
B-drug	B-drug	lovastatin	yes
O	O	and	yes
O	O	frequently	no
O	O	enough	no
O	O	during	no
O	O	early	no
O	O	therapy	no
O	O	to	no
O	O	insure	no
O	O	that	no
O	O	no	yes
O	O	significant	no
O	O	alteration	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	occurs	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	currently	no
O	O	little	no
O	O	adequate	no
O	O	evidence	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	presence	no
O	O	or	no
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	serious	no
O	O	adverse	no
O	O	reactions	no
O	O	to	no
O	O	such	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	although	no
O	O	many	no
O	O	such	no
O	O	reactions	no
O	O	have	no
O	O	been	no
O	O	hypothesized	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	include	no
O	O	medications	no
O	O	such	no
O	O	as	yes
O	O	:	no
B-group	B-group	anticoagulants	no
O	O	,	no
B-group	B-group	platelet	yes
I-group	I-group	inhibitors	no
O	O	including	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	O	sali-cylates	no
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	(	no
O	O	including	no
B-drug	B-drug	ketorolac	yes
I-drug	I-drug	tromethamine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	dipyridamole	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	sulfinpyrazone	yes
O	O	.	no

O	O	Diminished	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	norfloxacin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	and	yes
B-drug	B-drug	norfloxacin	yes
O	O	.	no

O	O	Retention	no
O	O	was	no
O	O	calculated	no
O	O	by	no
O	O	the	no
O	O	balance	yes
O	O	technique	no
O	O	and	yes
O	O	by	no
O	O	the	no
O	O	comparative	no
O	O	slaughter	no
O	O	technique	no
O	O	.	no

O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	wort	yes
O	O	(	no
O	O	Hypericum	yes
O	O	perforatum	yes
O	O	)	no

O	O	Either	no
O	O	single	yes
O	O	(	no
O	O	170	yes
O	O	mg/kg	no
O	O	)	no
O	O	or	no
O	O	repeated	no
O	O	(	no
O	O	75	yes
O	O	mg/kg	no
O	O	per	no
O	O	day	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	)	no
O	O	oral	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cypermethrin	no
O	O	was	no
O	O	found	no
O	O	to	no
O	O	produce	no
O	O	significant	no
O	O	oxidative	no
O	O	stress	no
O	O	in	yes
O	O	cerebral	no
O	O	and	yes
O	O	hepatic	no
O	O	tissues	no
O	O	of	yes
O	O	rats	no
O	O	,	no
O	O	as	yes
O	O	was	no
O	O	evident	no
O	O	by	no
O	O	the	no
O	O	elevation	no
O	O	of	yes
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	thiobarbituric	no
O	O	acid	yes
O	O	reactive	yes
O	O	substances	no
O	O	(	no
O	O	TBARS	no
O	O	)	no
O	O	in	yes
O	O	both	no
O	O	tissues	no
O	O	,	no
O	O	either	no
O	O	4	yes
O	O	or	no
O	O	24	yes
O	O	h	yes
O	O	after	no
O	O	treatment	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	REGRANEX	yes
O	O	Gel	yes
O	O	with	yes
O	O	other	no
O	O	topical	yes
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

B-drug	O	Histidine	yes
O	O	modification	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	glucosyl	no
O	O	transferase	no
O	O	enzyme	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	.	no

O	O	Hypotension	no
O	O	,	no
O	O	AV	no
O	O	conduction	no
O	O	disturbances	no
O	O	,	no
O	O	and	yes
O	O	left	no
O	O	ventricular	no
O	O	failure	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	when	no
O	O	an	no
O	O	oral	yes
B-group	B-group	calcium	yes
I-group	I-group	antagonist	yes
O	O	was	no
O	O	added	no
O	O	to	no
O	O	the	no
O	O	treatment	no
O	O	regimen	no
O	O	.	no

O	O	When	no
O	O	a	yes
B-group	B-group	diuretic	no
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	the	no
O	O	therapy	no
O	O	of	yes
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	PRINIVIL	yes
O	O	,	no
O	O	an	no
O	O	additional	no
O	O	antihypertensive	no
O	O	effect	no
O	O	is	yes
O	O	usually	no
O	O	observed	no
O	O	.	no

O	O	METHODS	no
O	O	.	no

O	O	These	no
O	O	recommendations	no
O	O	are	no
O	O	based	no
O	O	on	no
O	O	either	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	or	no
O	O	predicted	no
O	O	interactions	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	expected	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	and	yes
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	events	no
O	O	or	no
O	O	loss	no
O	O	of	yes
O	O	efficacy	no
O	O	.	no

O	O	free	yes
O	O	T4	yes
O	O	concentration	no
O	O	is	yes
O	O	unaltered	no
O	O	:	no
O	O	impaired	no
O	O	glucose	yes
O	O	tolerance	no
O	O	;	no

O	O	The	no
O	O	inhibition	no
O	O	of	yes
O	O	CYP-2C19	no
O	O	by	no
B-drug	B-drug	OXC	no
O	O	and	yes
B-drug_n	B-drug_n	MHD	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	is	yes
O	O	clinically	no
O	O	relevant	no
O	O	.	no

B-group	B-group	anticholinergics	no
O	O	or	no
O	O	other	no
O	O	medications	no
O	O	with	yes
O	O	anticholinergic	no
O	O	activity	yes
O	O	-	yes
O	O	anticholinergic	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	when	no
O	O	these	no
O	O	medications	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	diphenidol	yes
O	O	;	no

B-drug	B-drug	Lopinavir/Ritonavir	no

O	O	Other	no
O	O	factors	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	this	no
O	O	drug	yes
O	O	interaction	no
O	O	,	no
O	O	including	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	other	no
O	O	medications	no
O	O	that	no
O	O	are	no
O	O	associated	no
O	O	with	yes
O	O	myopathy	no
O	O	,	no
O	O	underlying	no
O	O	renal	no
O	O	insufficiency	no
O	O	,	no
O	O	and	yes
O	O	administration	no
O	O	of	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	MICRONASE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	Other	no
O	O	Drug	yes
O	O	Interactions	no
O	O	Oral	yes
B-group	B-group	Contraceptives	no
B-brand	B-brand	Keppra	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	containing	yes
O	O	0.03	no
O	O	mg	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
O	O	0.15	yes
O	O	mg	yes
B-drug	B-drug	levonorgestrel	yes
O	O	,	no
O	O	or	no
O	O	of	yes
O	O	the	no
B-drug	O	luteinizing	yes
I-drug	O	hormone	yes
O	O	and	yes
B-drug	O	progesterone	yes
O	O	levels	no
O	O	,	no
O	O	indicating	no
O	O	that	no
O	O	impairment	no
O	O	of	yes
O	O	contraceptive	yes
O	O	efficacy	no
O	O	is	yes
O	O	unlikely	no
O	O	.	no

B-drug	B-drug	Amitriptyline	yes
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	25	yes
O	O	mg	yes
O	O	or	no
O	O	100	yes
O	O	mg	yes
B-drug	B-drug	cinacalcet	yes
O	O	with	yes
O	O	50	yes
O	O	mg	yes
B-drug	B-drug	amitriptyline	yes
O	O	increased	no
B-drug	B-drug	amitriptyline	yes
O	O	exposure	yes
O	O	and	yes
B-drug	B-drug_n	nortriptyline	yes
O	O	(	no
O	O	active	no
O	O	metabolite	yes
O	O	)	no
O	O	exposure	yes
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	in	yes
O	O	CYP2D6	no
O	O	extensive	no
O	O	metabolizers	no
O	O	.	no

O	O	When	no
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	labetalol	yes
O	O	have	no
O	O	a	yes
O	O	positive	no
O	O	urine	no
O	O	test	yes
O	O	for	yes
B-drug	B-drug	amphetamine	yes
O	O	using	no
O	O	these	no
O	O	techniques	no
O	O	confirmation	no
O	O	should	no
O	O	be	no
O	O	made	no
O	O	by	no
O	O	using	no
O	O	more	no
O	O	specific	no
O	O	methods	no
O	O	such	no
O	O	as	yes
O	O	a	yes
O	O	gas	yes
O	O	chromatographic-mass	no
O	O	spectrometer	no
O	O	technique	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	;	no

O	O	Since	no
B-drug	B-drug	indomethacin	yes
O	O	and	yes
B-group	B-group	potassium-sparing	no
I-group	I-group	diuretics	no
O	O	,	no
O	O	including	no
B-brand	B-brand	MIDAMOR	yes
O	O	,	no
O	O	may	no
O	O	each	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
O	O	serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	,	no
O	O	the	no
O	O	potential	no
O	O	effects	no
O	O	on	no
O	O	potassium	yes
O	O	kinetics	no
O	O	and	yes
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

O	O	Some	no
O	O	preliminary	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-group	B-group	calcium	yes
I-group	I-group	blockers	no
O	O	also	no
O	O	increase	no
O	O	generation	no
O	O	of	yes
O	O	vasodilator	no
O	O	and	yes
O	O	platelet	yes
O	O	antiaggregant	no
B-drug	O	prostacyclin	yes
O	O	,	no
O	O	which	no
O	O	could	no
O	O	contribute	no
O	O	to	no
O	O	decrease	no
O	O	in	yes
O	O	platelet	yes
O	O	function	no
O	O	.	no

O	O	Hypotension	no
O	O	Patients	no
O	O	on	no
O	B-group	Diuretic	no
O	O	Therapy	no
O	O	:	no
O	O	Patients	no
O	O	on	no
B-group	B-group	diuretics	no
O	O	and	yes
O	O	especially	no
O	O	those	no
O	O	in	yes
O	O	whom	no
B-group	B-group	diuretic	no
O	O	therapy	no
O	O	was	no
O	O	recently	no
O	O	instituted	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	those	no
O	O	on	no
O	O	severe	no
O	O	dietary	no
O	O	salt	yes
O	O	restriction	no
O	O	or	no
O	O	dialysis	no
O	O	,	no
O	O	may	no
O	O	occasionally	no
O	O	experience	no
O	O	a	yes
O	O	precipitous	no
O	O	reduction	yes
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	usually	no
O	O	within	no
O	O	the	no
O	O	first	no
O	O	hour	yes
O	O	after	no
O	O	receiving	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	captopril	yes
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	by	no
O	O	the	no
O	O	nonlinear	no
O	O	kinetic	no
O	O	characteristics	no
O	O	for	yes
B-drug	B-drug	verapamil	yes
O	O	and	yes
B-drug	B-drug	diltiazem	yes
O	O	(	no
O	O	and	yes
O	O	probably	no
O	O	for	yes
B-drug	B-drug	nifedipine	yes
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	)	no
O	O	and	yes
O	O	the	no
O	O	derivative	yes
O	O	implications	no
O	O	for	yes
O	O	decreased	no
O	O	dosing	no
O	O	frequency	no
O	O	requirements	no
O	O	;	no

O	O	In	yes
O	O	eight	no
O	O	HIV-infected	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	steady-state	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	was	no
O	O	decreased	no
O	O	an	no
O	O	average	no
O	O	of	yes
O	O	26	yes
O	O	%	no
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	=	no
O	O	14	yes
O	O	%	no
O	O	,	no
O	O	37	no
O	O	%	no
O	O	)	no
O	O	when	no
B-drug	B-drug	ciprofloxacin	yes
O	O	was	no
O	O	administered	no
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	a	yes
O	O	marketed	no
O	O	chewable/dispersible	no
O	O	tablet	no
O	O	formulation	no
O	O	of	yes
B-brand	B-brand	VIDEX	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	O	gly-buride	no
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	any	no
O	O	changes	no
O	O	in	yes
O	O	either	no
B-drug	B-drug	metformin	yes
O	O	pharmacokinetics	no
O	O	or	no
O	O	pharmaco-dynamics	no
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	begin	no
O	O	taking	no
B-drug	B-drug	diclofenac	yes
O	O	or	no
O	O	who	no
O	O	increase	no
O	O	their	no
B-drug	B-drug	diclofenac	yes
O	O	dose	no
O	O	or	no
O	O	any	no
O	O	other	no
B-group	B-group	NSAID	no
O	O	while	no
O	O	taking	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	cyclosporine	yes
O	O	may	no
O	O	develop	no
O	O	toxicity	no
O	O	characteristics	no
O	O	for	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Mercaptopurine/Azathioprine	no
O	O	:	no
B-drug	B-drug	Allopurinol	yes
O	O	inhibits	no
O	O	the	no
O	O	enzymatic	no
O	O	oxidation	no
O	O	of	yes
B-drug	B-drug	mercaptopurine	yes
O	O	and	yes
B-drug	B-drug	azathioprine	yes
O	O	to	no
B-drug_n	B-drug	6-thiouric	no
I-drug_n	I-drug	acid	yes
O	O	.	no

O	O	There	no
O	O	was	no
O	O	a	yes
O	O	small	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	capecitabine	yes
O	O	and	yes
O	O	one	no
O	O	metabolite	yes
O	O	(	no
O	B-drug_n	5-DFCR	no
O	O	)	no
O	O	;	no

O	O	Concomitant	no
O	O	oral	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	a	yes
O	O	known	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	activity	yes
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	intestinal	no
O	O	mucosa	no
O	O	)	no
O	O	caused	no
O	O	an	no
O	O	eight-fold	no
O	O	increase	no
O	O	of	yes
O	O	the	no
O	O	systemic	no
O	O	exposure	yes
O	O	to	no
O	O	oral	yes
B-drug	B-drug	budesonide	yes
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	or	no
B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	or	no
B-drug	B-drug	cimetidine	yes
O	O	decreases	no
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	,	no
O	O	most	no
O	O	likely	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	information	no
O	O	on	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	other	no
O	O	highly	no
O	O	plasma	yes
O	O	protein	yes
O	O	bound	no
O	O	drugs	no
O	O	on	no
B-drug	B-drug	doxazosin	yes
O	O	binding	no
O	O	.	no

O	O	sickle	no
O	O	cell	yes
O	O	disease	no
O	O	;	no

B-drug	B-drug	Buprenorphine	yes
O	O	is	yes
O	O	metabolized	no
O	O	to	no
B-drug	B-drug_n	norbuprenorphine	no
O	O	by	no
O	O	cytochrome	no
O	O	CYP	no
O	O	3A4	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	other	no
B-group	B-group	narcotic	no
I-group	I-group	analgesics	no
O	O	,	no
B-group	B-group	antipsychotics	no
O	O	,	no
B-group	B-group	antianxiety	no
I-group	I-group	agents	yes
O	O	,	no
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	)	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	hydrocodone	yes
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	tablets	yes
O	O	may	no
O	O	exhibit	no
O	O	an	no
O	O	additive	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	Depending	no
O	O	on	no
O	O	the	no
O	O	traction	no
O	O	of	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentration	no
O	O	may	no
O	O	be	no
O	O	small	no
O	O	,	no
O	O	or	no
O	O	quite	no
O	O	large	no
O	O	(	no
O	O	8	yes
O	O	fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	B-group	TCA	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Isoproterenol	yes
O	O	alone	no
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	2.7	no
O	O	mg/kg/day	no
O	O	(	no
O	O	approximately	no
O	O	7	yes
O	O	times	no
O	O	the	no
O	O	maximum	no
O	O	recommended	no
O	O	daily	no
O	O	inhalation	no
O	O	dose	no
O	O	in	yes
O	O	adults	no
O	O	on	no
O	O	a	yes
O	O	mg/m2	no
O	O	basis	no
O	O	)	no
O	O	increased	no
O	O	both	no
O	O	resorptions	no
O	O	and	yes
O	O	malformations	no
O	O	.	no

O	O	This	no
O	O	could	no
O	O	facilitate	no
O	O	the	no
O	O	action	no
O	O	of	yes
O	O	fatty	yes
O	O	acids	yes
O	O	and	yes
O	O	enable	no
O	O	cells	yes
O	O	to	no
O	O	increase	no
O	O	their	no
O	O	capacity	no
O	O	for	yes
O	O	triacylglycerol	no
O	O	synthesis	no
O	O	to	no
O	O	match	no
O	O	an	no
O	O	increased	no
O	O	availability	no
O	O	of	yes
O	O	fatty	yes
O	O	acids	yes
O	O	.	no

O	O	Formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	ORENCIA	yes
O	O	.	no

B-drug	B-drug	Benzylpenicillin	yes
O	O	,	no
B-drug	B-drug	ampicillin	yes
O	O	,	no
B-drug	B-drug	oxacillin	yes
O	O	,	no
B-drug	B-drug	chlortetracycline	yes
O	O	,	no
B-drug	B-drug	doxycycline	yes
O	O	,	no
B-drug	B-drug	cephalothin	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	sulfamethoxazole	yes
O	O	have	no
O	O	no	yes
O	O	influence	no
O	O	in	yes
O	O	vitro	no
O	O	on	no
O	O	the	no
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	in	yes
O	O	human	yes
O	O	serum	yes
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	,	no
B-drug	B-drug	hexobarbital	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	.	no

B-group	B-group	Anticholinergic	no
I-group	I-group	agents	yes
O	O	:	no
O	O	Although	no
B-drug	B-drug	ipratropium	yes
I-drug	I-drug	bromide	yes
O	O	is	yes
O	O	minimally	no
O	O	absorbed	no
O	O	into	no
O	O	the	no
O	O	systemic	no
O	O	circulation	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	some	no
O	O	potential	no
O	O	for	yes
O	O	an	no
O	O	additive	no
O	O	interaction	no
O	O	with	yes
O	O	concomitantly	no
O	O	used	no
B-group	B-group	anticholinergic	no
I-group	I-group	medications	no
O	O	.	no

O	O	Preliminary	no
O	O	animal	no
O	O	and	yes
O	O	human	yes
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	small	no
O	O	quantities	no
O	O	of	yes
O	O	systemically	no
O	O	administered	no
B-drug	B-drug	leucovorin	yes
O	O	enter	no
O	O	the	no
O	O	CSF	no
O	O	primarily	no
O	O	as	yes
O	O	5-methyltetrahydro-folate	no
O	O	and	yes
O	O	,	no
O	O	in	yes
O	O	humans	no
O	O	,	no
O	O	remain	no
O	O	1	yes
O	O	to	no
O	O	3	yes
O	O	orders	no
O	O	of	yes
O	O	magnitude	no
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	usual	no
B-drug	B-drug	methotrexate	yes
O	O	concentrations	no
O	O	following	no
O	O	intrathecal	no
O	O	administration	no
O	O	.	no

O	O	THE	no
O	O	POTENTIATING	no
O	O	ACTION	no
O	O	OF	yes
B-drug	B-drug	HYDROXYZINE	yes
O	O	MUST	no
O	O	BE	no
O	O	CONSIDERED	no
O	O	WHEN	no
O	O	THE	no
O	O	DRUG	yes
O	O	IS	yes
O	O	USED	no
O	O	IN	yes
O	O	CONJUNCTION	no
O	O	WITH	yes
B-group	B-group	CENTRAL	no
I-group	I-group	NERVOUS	no
I-group	I-group	SYSTEM	yes
I-group	I-group	DEPRESSANTS	no
O	O	SUCH	no
O	O	AS	yes
O	B-group	NARCOTICS	no
O	O	,	no
B-group	B-group	NON-NARCOTIC	no
I-group	I-group	ANALGESICS	no
O	O	AND	yes
B-group	B-group	BARBITURATES	no
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	increases	no
O	O	enterohepatic	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	and	yes
O	O	may	no
O	O	reduce	no
O	O	its	no
O	O	serum	yes
O	O	levels	no
O	O	and	yes
O	B-drug	t1/2	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	these	no
O	O	drugs	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	zalcitabine	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	toxicity	no
O	O	and	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	reduced	yes
O	O	if	no
O	O	warranted	no
O	O	.	no

O	O	.	no

B-group	B-group	Thiazides	no
O	O	:	no
B-group	B-group	Thiazides	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	hypercalcemia	no
O	O	by	no
O	O	the	no
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	calcium	yes
O	O	excretion	no
O	O	in	yes
O	O	urine	no
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	may	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	be	no
O	O	administered	no
O	O	alternately	no
O	O	provided	no
O	O	a	yes
O	O	proper	no
O	O	interval	no
O	O	has	no
O	O	elapsed	no
O	O	between	yes
O	O	doses	no
O	O	.	no

O	O	Data	no
O	O	suggest	no
O	O	that	no
O	O	coadministration	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	cisapride	yes
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
O	B-drug	CMI	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	haloperidol	yes
O	O	;	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	naproxen	yes
O	O	anion	yes
O	O	,	no
O	O	because	no
O	O	of	yes
O	O	its	no
O	O	affinity	no
O	O	for	yes
O	O	protein	yes
O	O	,	no
O	O	may	no
O	O	displace	no
O	O	from	no
O	O	their	no
O	O	binding	no
O	O	sites	no
O	O	other	no
O	O	drugs	no
O	O	which	no
O	O	are	no
O	O	also	no
O	O	albumin-bound	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	these	no
O	O	2	yes
O	O	agents	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	In	yes
O	O	the	no
O	O	case	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	.	no

B-drug	B-drug	Ranitidine	yes
O	O	150	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	did	no
O	O	not	no
O	O	interact	no
O	O	significantly	no
O	O	with	yes
B-drug	B-drug	nisoldipine	yes
O	O	(	no
O	O	AUC	no
O	O	was	no
O	O	decreased	no
O	O	by	no
O	O	15-20	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-brand	B-brand	VIOXX	yes
O	O	,	no
O	O	antiplatelet	no
O	O	therapies	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	discontinued	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	an	no
O	O	indication	no
O	O	for	yes
O	O	cardiovascular	no
O	O	prophylaxis	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	decreased	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	I-drug	A	yes
O	O	(	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	.	no

B-group	B-group	Diuretics	no
O	O	:	no
B-drug	B-drug	Diclofenac	yes
O	O	and	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-group	B-group	diuretics	no
O	O	.	no

O	O	Clinical	no
O	O	experience	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	pulmonary	no
O	O	arterial	no
O	O	hypertension	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	INR	no
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	dose	no
O	O	(	no
O	O	baseline	no
O	O	vs.	no
O	O	end	no
O	O	of	yes
O	O	the	no
O	O	clinical	no
O	O	studies	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	need	no
O	O	to	no
O	O	change	no
O	O	the	no
B-drug	B-drug	warfarin	yes
O	O	dose	no
O	O	during	no
O	O	the	no
O	O	trials	no
O	O	due	no
O	O	to	no
O	O	changes	no
O	O	in	yes
O	O	INR	no
O	O	or	no
O	O	due	no
O	O	to	no
O	O	adverse	no
O	O	events	no
O	O	was	no
O	O	similar	no
O	O	among	no
O	B-drug	bosentan-	no
O	O	and	yes
O	O	placebo-treated	no
O	O	patients	no
O	O	.	no

O	O	This	no
O	O	included	no
O	O	post	no
O	O	myocardial	no
O	O	infarction	no
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	receiving	no
O	O	intravenous	yes
O	O	or	no
O	O	transdermal	no
B-drug	B-drug	nitroglycerin	yes
O	O	.	no

O	O	Potentiation	no
O	O	of	yes
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-group	B-group	nitrates	no
O	O	for	yes
O	O	patients	no
O	O	with	yes
O	O	ischemic	no
O	O	heart	no
O	O	disease	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	,	no
O	O	and	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	and	yes
B-group	B-group	nitrates	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

B-drug	B-drug	sulindac	yes
O	O	;	no

O	O	.	no

O	O	No	yes
O	O	differences	no
O	O	in	yes
O	O	safety	no
O	O	or	no
O	O	efficacy	no
O	O	were	no
O	O	observed	no
O	O	between	yes
O	O	older	no
O	O	and	yes
O	O	younger	no
O	O	patients	no
O	O	,	no
O	O	but	no
O	O	there	no
O	O	were	no
O	O	not	no
O	O	sufficient	no
O	O	data	no
O	O	to	no
O	O	exclude	no
O	O	important	no
O	O	differences	no
O	O	.	no

O	O	Increased	no
O	O	thyroid-binding	no
O	O	globulin	yes
O	O	(	no
O	O	TBG	no
O	O	)	no
O	O	levels	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	circulating	no
O	O	total	yes
O	O	thyroid	yes
O	O	hormone	yes
O	O	levels	no
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	protein-bound	no
O	B-drug	iodine	yes
O	O	(	no
O	O	PBI	no
O	O	)	no
O	O	,	no
O	O	T4	yes
O	O	levels	no
O	O	(	no
O	O	by	no
O	O	column	no
O	O	or	no
O	O	by	no
O	O	radioimmunoassay	no
O	O	)	no
O	O	or	no
O	O	T3	yes
O	O	levels	no
O	O	by	no
O	O	radioimmunoassay	no
O	O	.	no

B-drug	B-drug	Bosentan	yes
O	O	is	yes
O	O	also	no
O	O	expected	no
O	O	to	no
O	O	reduce	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	that	no
O	O	are	no
O	O	predominantly	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2C9	no
O	O	or	no
O	O	CYP3A4	no
O	O	.	no

O	O	2	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
O	O	when	no
O	O	compared	no
O	O	to	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	has	no
O	O	a	yes
O	O	less	no
O	O	pronounced	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	biotransformation	no
O	O	system	yes
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	.	no

O	O	These	no
O	O	data	no
O	O	suggest	no
O	O	the	no
O	O	modified	yes
O	O	histidine	yes
O	O	residues	no
O	O	on	no
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	are	no
O	O	critical	no
O	O	to	no
O	O	its	no
O	O	cytotoxic	yes
O	O	activity	yes
O	O	.	no

B-drug	B-drug_n	Misonidazole	yes
O	O	has	no
O	O	a	yes
O	O	complex	yes
O	O	effect	no
O	O	on	no
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	Free	yes
O	O	T4	yes
O	O	and	yes
O	O	free	yes
O	O	T3	yes
O	O	concentrations	no
O	O	are	no
O	O	unaltered	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	:	no
O	O	It	no
O	O	should	no
O	O	be	no
O	O	borne	no
O	O	in	yes
O	O	mind	no
O	O	that	no
B-drug	B-drug	alcohol	yes
O	O	ingestion	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	danger	no
O	O	inherent	no
O	O	in	yes
O	O	any	no
O	O	intentional	no
O	O	or	no
O	O	unintentional	no
B-brand	B-brand	SINEQUAN	yes
O	O	overdosage	no
O	O	.	no

O	O	A	yes
O	O	similar	no
O	O	effect	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	with	yes
B-drug	B-drug	eszopiclone	yes
O	O	.	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	decreased	no
O	O	by	no
B-brand	B-brand	SUSTIVA	yes
O	O	;	no

O	O	The	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	mediated	no
O	O	by	no
O	O	the	no
O	O	known	no
O	O	inhibition	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	on	no
O	O	hepatic	no
O	O	cytochrome	no
O	O	P-450	no
O	O	,	no
O	O	the	no
O	O	enzyme	no
O	O	system	yes
O	O	probably	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	first-pass	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	nifedipine	yes
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug-interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	clinically	no
O	O	significant	no
O	O	interaction	no
O	O	with	yes
O	O	other	no
O	O	medications	no
O	O	used	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	hypoxic	no
O	O	respiratory	no
O	O	failure	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	excluded	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	available	no
O	O	data	no
O	O	.	no

O	O	unreliable	no
O	O	prothrombin	yes
O	O	time	no
O	O	determinations	no
O	O	;	no

O	O	Since	no
B-drug	B-drug	etodolac	yes
O	O	has	no
O	O	a	yes
O	O	well-defined	no
O	O	pharmacokinetic-pharmacodynamic	no
O	O	relationship	no
O	O	,	no
O	O	measurement	no
O	O	of	yes
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	is	yes
O	O	clinically	no
O	O	relevant	no
O	O	.	no

O	O	Core	yes
O	O	temperature	no
O	O	was	no
O	O	decreased	no
O	O	in	yes
O	O	rats	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	manner	no
O	O	when	no
B-drug	B-drug	ethanol	yes
O	O	was	no
O	O	administered	no
O	O	to	no
O	O	rats	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	disulfiram	yes
O	O	8	yes
O	O	hours	no
O	O	before	no
O	O	the	no
B-drug	B-drug	ethanol	yes
O	O	challenge	no
O	O	.	no

O	O	Other	no
O	O	drug	yes
O	O	interactions	no

O	O	These	no
O	O	drugs	no
O	O	include	no
O	O	the	no
B-group	B-group	thiazides	no
O	O	and	yes
O	O	other	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	O	thyroid	yes
I-group	O	products	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	B-group	sympathomimetics	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	When	no
O	O	you	no
O	O	are	no
O	O	using	no
B-drug	B-drug	idoxuridine	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	especially	no
O	O	important	no
O	O	that	no
O	O	your	no
O	O	health	no
O	O	care	yes
O	O	professional	no
O	O	know	no
O	O	if	no
O	O	you	no
O	O	are	no
O	O	using	no
O	O	the	no
O	O	following	no
O	O	:	no
O	O	Eye	yes
O	O	product	no
O	O	containing	yes
B-drug	B-drug	boric	no
I-drug	I-drug	acid	yes
O	O	.	no

B-drug	B-drug	Rifabutin	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
B-drug	B-drug	amprenavir	yes
O	O	's	no
O	O	pharmacokinetics	no
O	O	.	no

O	O	an	no
O	O	oral	yes
O	O	200	yes
O	O	mg	yes
O	O	dose	no
O	O	achieves	no
O	O	a	yes
O	O	highest	no
O	O	level	no
O	O	of	yes
O	O	approximately	no
O	O	5	yes
O	O	uM	no
O	O	in	yes
O	O	people	no
O	O	)	no
O	O	;	no

O	O	These	no
O	O	drugs	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	concomitantly	no
O	O	.	no

O	O	The	no
O	O	mechanisms	no
O	O	of	yes
O	O	metal	no
O	O	toxicity	no
O	O	to	no
O	O	miracidia	no
O	O	are	no
O	O	briefly	no
O	O	discussed	no
O	O	.	no

B-drug	B-drug	Dolasetron	yes
O	O	does	no
O	O	not	no
O	O	influence	no
O	O	anesthesia	yes
O	O	recovery	no
O	O	time	no
O	O	in	yes
O	O	patients	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	TIKOSYN	yes
O	O	with	yes
B-drug	B-drug	verapamil	yes
O	O	resulted	no
O	O	in	yes
O	O	increases	no
O	O	in	yes
B-drug	B-drug	dofetilide	yes
O	O	peak	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	42	no
O	O	%	no
O	O	,	no
O	O	although	no
O	O	overall	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	dofetilide	yes
O	O	was	no
O	O	not	no
O	O	significantly	no
O	O	increased	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	decreased	no
O	O	the	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	by	no
O	O	a	yes
O	O	net	no
O	O	change	no
O	O	of	yes
O	O	6.8	no
O	O	%	no
O	O	(	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	FDF	no
O	O	,	no
O	O	8.8	no
O	O	%	no
O	O	)	no
O	O	at	yes
O	O	277.5	no
O	O	micromol/L	no
O	O	;	no

O	O	This	no
O	O	small	no
O	O	decrease	no
O	O	in	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	gabapentin	yes
O	O	by	no
B-drug	B-drug	cimetidine	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	clinical	no
O	O	importance	no
O	O	.	no

O	O	The	no
O	O	average	no
O	O	infusion	no
O	O	rate	no
O	O	requirement	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	by	no
O	O	as	yes
O	O	much	no
O	O	as	yes
O	O	30	yes
O	O	%	no
O	O	to	no
O	O	40	yes
O	O	%	no
O	O	.	no

O	O	This	no
O	O	report	no
O	O	describes	no
O	O	two	no
O	O	cases	no
O	O	in	yes
O	O	which	no
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	accelerated	no
O	O	markedly	no
O	O	with	yes
O	O	concomitant	no
B-drug	B-drug	phenytoin	yes
O	O	administration	no
O	O	.	no

O	O	Minimum	no
O	O	inhibitory	yes
O	O	concentrations	no
O	O	(	no
O	O	MICs	no
O	O	)	no
O	O	and	yes
O	O	viable	no
O	O	counts	no
O	O	were	no
O	O	determined	no
O	O	in	yes
O	O	Iso-sensitest	no
O	O	broth	no
O	O	using	no
O	O	a	yes
O	O	microtitre	no
O	O	method	yes
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	if	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	REVIA	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	is	yes
O	O	required	no
O	O	.	no

O	O	Sinus	yes
O	O	bradycardia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	lidocaine	yes
O	O	(	no
O	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	given	no
O	O	for	yes
O	O	local	no
O	B-drug	anesthesia	yes
O	O	.	no

O	O	Need	no
O	O	for	yes
O	O	more	no
O	O	inhalations	no
O	O	than	no
O	O	usual	no
O	O	of	yes
O	B-group	short-acting	no
O	I-group	,	no
O	I-group	inhaled	no
B-group	I-group	beta2-agonists	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	changes	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	100	yes
O	O	mg	yes
O	O	BID	no
O	O	(	no
O	O	OTC	yes
O	O	dose	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	13	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	dofetilide	yes
O	O	plasma	yes
O	O	levels	no
O	O	(	no
O	O	500	yes
O	O	mcg	no
O	O	single	yes
O	O	dose	no
O	O	)	no
O	O	.	no

O	O	Blood	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug_n	hydrodolasetron	no
O	O	increased	no
O	O	24	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	dolasetron	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	nonselective	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P-450	no
O	O	)	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	,	no
O	O	and	yes
O	O	decreased	no
O	O	28	yes
O	O	%	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	(	no
O	O	potent	no
O	O	inducer	no
O	O	of	yes
O	O	cytochrome	no
O	O	P-450	no
O	O	)	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	.	no

B-drug	B-drug	Rifabutin	yes
O	O	,	no
O	O	another	no
B-drug	B-drug	rifamycin	yes
O	O	,	no
O	O	is	yes
O	O	structurally	no
O	O	similar	no
O	O	to	no
B-drug	B-drug	rifampin	yes
O	O	and	yes
O	O	may	no
O	O	possibly	no
O	O	have	no
O	O	some	no
O	O	of	yes
O	O	the	no
O	O	same	yes
O	O	drug	yes
O	O	interactions	no
O	O	as	yes
B-drug	B-drug	rifampin	yes
O	O	.	no

O	O	Binding	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	is	yes
O	O	reduced	yes
O	O	by	no
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	O	clotibrate	no
O	O	and	yes
O	O	increased	no
O	O	by	no
B-drug	B-drug	tolbutamide	yes
O	O	.	no

O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	Q12h	no
O	O	)	no

B-drug	B-drug	Cisapride	yes
O	O	is	yes
O	O	metabolized	no
O	O	mainly	no
O	O	via	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	enzyme	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	increased	no
O	O	bioavailability	no
O	O	and	yes
O	O	whether	no
O	O	similar	no
O	O	increases	no
O	O	will	no
O	O	occur	no
O	O	in	yes
O	O	patients	no
O	O	given	no
O	O	oral	yes
B-group	B-group	H2-antagonists	no
O	O	is	yes
O	O	unknown	no
O	O	;	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	;	no

O	O	Literature	no
O	O	reports	no
O	O	indicate	no
O	O	that	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	by	no
O	O	inhibiting	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	Drug	yes
O	O	regimens	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	cardiovascular	no
O	O	disease	no
O	O	are	no
O	O	frequently	no
O	O	complex	yes
O	O	and	yes
O	O	can	no
O	O	be	no
O	O	significantly	no
O	O	affected	no
O	O	by	no
O	O	alterations	no
O	O	in	yes
O	O	renal	no
O	O	function	no
O	O	.	no

B-brand	B-brand	SUBUTEX	yes
O	O	and	yes
B-brand	B-brand	SUBOXONE	yes
O	O	should	no
O	O	be	no
O	O	prescribed	no
O	O	with	yes
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	on	no
B-group	B-group	benzodiazepines	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	act	no
O	O	on	no
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	,	no
O	O	regardless	no
O	O	of	yes
O	O	whether	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	taken	no
O	O	on	no
O	O	the	no
O	O	advice	no
O	O	of	yes
O	O	a	yes
O	O	physician	no
O	O	or	no
O	O	are	no
O	O	taken	no
O	O	as	yes
O	O	drugs	no
O	O	of	yes
O	O	abuse	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	on	no
B-brand	B-brand	Exjade	yes
O	O	pharmacokinetics	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	antimicrobial	no
O	O	combinations	no
O	O	of	yes
B-drug_n	B-drug_n	GL	no
O	O	with	yes
O	O	four	no
B-group	B-group	antibiotics	no
O	O	resulted	no
O	O	in	yes
O	O	additive	no
O	O	effect	no
O	O	in	yes
O	O	most	no
O	O	instances	no
O	O	,	no
O	O	synergism	no
O	O	in	yes
O	O	two	no
O	O	instances	no
O	O	,	no
O	O	and	yes
O	O	antagonism	no
O	O	in	yes
O	O	two	no
O	O	instances	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	a	yes
O	O	1-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	administered	no
O	O	as	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	300	yes
O	O	mg	yes
O	O	QID	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	post-marketing	no
O	O	experience	no
O	O	,	no
O	O	bleeding	no
O	O	events	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	predominantly	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	,	no
O	O	in	yes
O	O	association	no
O	O	with	yes
O	O	increases	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	VIOXX	yes
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Interactions	no
O	O	between	yes
O	O	treatments	no
O	O	with	yes
O	B-drug_n	coumaphos	no
O	O	,	no
B-drug	B-drug	bishydroxycoumarin	no
O	O	(	no
O	O	an	no
B-group	B-group	anticoagulant	no
O	O	)	no
O	O	,	no
B-drug	B-drug_n	trichlorfon	no
O	O	(	no
O	O	an	no
O	B-group	organophosphorous	no
O	I-group	compound	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
I-drug	I-drug	sodium	yes
O	O	(	no
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	microsomal	no
O	O	enzymes	yes
O	O	)	no
O	O	were	no
O	O	investigated	no
O	O	in	yes
O	O	sheep	yes
O	O	.	no

O	O	Clinical	no
O	O	comments	no
O	O	about	no
O	O	possible	no
O	O	dosage	no
O	O	modifications	no
O	O	based	no
O	O	on	no
O	O	these	no
O	O	pharmacokinetic	no
O	O	changes	no
O	O	are	no
O	O	listed	no
O	O	in	yes
O	O	Table	no
O	O	3	yes
O	O	.	no

O	O	In	yes
O	O	contrast	no
O	O	,	no
O	O	in	yes
O	O	isolated	no
O	O	single	yes
O	O	pancreatic	yes
O	O	acinar	no
O	O	cells	yes
O	O	,	no
B-drug_n	B-drug_n	RR	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug_n	B-drug_n	InsP	no
O	I-drug_n	(	no
O	I-drug_n	3	yes
O	I-drug_n	)	no
O	O	-induced	no
O	O	responses	no
O	O	.	no

O	O	Other	no
O	O	No	yes
O	O	clinically	no
O	O	important	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	occurred	no
O	O	when	no
B-brand	B-brand	Lotensin	yes
O	O	was	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	chlorthalidone	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	,	no
B-drug	B-drug	naproxen	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	These	no
O	O	differences	no
O	O	were	no
O	O	reflected	no
O	O	in	yes
O	O	the	no
O	O	roughly	no
O	O	twofold	no
O	O	greater	no
O	O	antitumour	no
O	O	activity	yes
O	O	for	yes
O	O	the	no
O	O	oral	yes
O	O	route	no
O	O	.	no

B-brand	B-brand	ISUPREL	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	if	no
O	O	at	yes
O	O	all	yes
O	O	,	no
O	O	when	no
O	O	potent	no
O	O	inhalational	no
B-group	B-group	anesthetics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	halothane	yes
O	O	are	no
O	O	employed	no
O	O	because	no
O	O	of	yes
O	O	potential	no
O	O	to	no
O	O	sensitize	no
O	O	the	no
O	O	myocardium	no
O	O	to	no
O	O	effects	no
O	O	of	yes
B-group	B-group	sympathomimetic	no
I-group	I-group	amines	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	The	no
O	O	biochemical	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	metabolizing	no
O	O	isozyme	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	debrisoquin	yes
O	O	hydroxylase	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	caucasian	no
O	O	population	no
O	O	(	no
O	O	about	no
O	O	7	yes
O	O	to	no
O	O	10	yes
O	O	%	no
O	O	of	yes
O	O	caucasians	no
O	O	are	no
O	O	so	no
O	O	called	no
O	O	poor	no
O	O	metabolizers	no
O	O	)	no
O	O	;	no

O	O	Conversely	no
O	O	,	no
O	O	the	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	serum	yes
O	O	levels	no
O	O	and	yes
O	O	prolong	no
O	O	the	no
O	O	serum	yes
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	by	no
O	O	inhibiting	no
O	O	its	no
O	O	metabolism	no
O	O	.	no

O	O	Antinociception	no
O	O	was	no
O	O	measured	no
O	O	by	no
O	O	the	no
O	O	hot-plate	no
O	O	method	yes
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	worsened	no
O	O	glucose	yes
O	O	control	no
O	O	in	yes
O	O	patients	no
O	O	using	no
O	O	these	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	B-group	Catecholamine-depleting	no
O	I-group	drugs	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-group	B-group	beta-blocking	no
I-group	I-group	agents	yes
O	O	.	no

B-group	B-group	Antacids	no
O	O	or	no
B-group	B-group	H	yes
I-group	I-group	2	yes
I-group	I-group	-receptor	no
I-group	I-group	antagonists	no
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	increased	no
O	O	gastric	yes
O	O	pH	yes
O	O	on	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	ceftibuten	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	18	yes
O	O	healthy	no
O	O	adult	yes
O	O	volunteers	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	esomeprazole	yes
O	O	is	yes
O	O	not	no
O	O	likely	no
O	O	to	no
O	O	inhibit	no
O	O	CYPs	no
O	O	1A2	no
O	O	,	no
O	O	2A6	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	2E1	no
O	O	and	yes
O	O	3A4	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	place	no
O	O	of	yes
B-group	B-group	H2	no
I-group	I-group	blockers	no
O	O	or	no
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	SPRYCEL	yes
O	O	therapy	no
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	studies	no
O	O	of	yes
B-drug	B-drug	candesartan	yes
I-drug	I-drug	cilexetil	yes
O	O	given	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
O	O	and	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	or	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	enalapril	yes
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	heart	no
O	O	failure	no
O	O	(	no
O	O	NYHA	no
O	O	class	no
O	O	II	yes
O	O	and	yes
O	O	III	yes
O	O	)	no
O	O	.	no

O	O	Potential	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	were	no
O	O	assessed	no
O	O	in	yes
O	O	clinical	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	(	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	)	no
O	O	and	yes
O	O	through	no
O	O	pharmacokinetic	no
O	O	screening	no
O	O	in	yes
O	O	the	no
O	O	placebo-controlled	no
O	O	clinical	no
O	O	studies	no
O	O	in	yes
O	O	epilepsy	no
O	O	patients	no
O	O	.	no

O	O	N=13	no
O	O	)	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP2D6	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-group	B-group	NSAIDs	no
O	O	on	no
O	O	GI	no
O	O	bleeding	no
O	O	are	no
O	O	synergistic	no
O	O	,	no
O	O	such	no
O	O	that	no
O	O	users	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	together	no
O	O	have	no
O	O	a	yes
O	O	risk	no
O	O	of	yes
O	O	serious	no
O	O	GI	no
O	O	bleeding	no
O	O	higher	no
O	O	than	no
O	O	that	no
O	O	of	yes
O	O	users	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	alone	no
O	O	.	no

O	O	Systemic	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	acetaminophen	yes
O	O	is	yes
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	increased	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	Gleevec	yes
O	O	.	no

O	O	If	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	an	no
O	O	interval	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	minutes	no
O	O	between	yes
O	O	applications	no
O	O	.	no

O	O	Others	no
O	O	reported	no
O	O	:	no
O	O	Neuropsychiatric	no
O	O	:	no
O	O	Confusion	no
O	O	(	no
O	O	1-11	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	headache	no
O	O	(	no
O	O	4-8	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	insomnia	no
O	O	(	no
O	O	2-7	no
O	O	%	no
O	O	)	no
O	O	;	no

O	O	Effects	no
O	O	of	yes
B-group	B-group	sympathomimetics	no
O	O	are	no
O	O	increased	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	adrenergic	no
I-group	I-group	blockers	no
O	O	.	no

O	O	Other	no
O	O	Cardiovascular	no
O	O	Agents	yes
O	O	:	no
B-drug	B-drug	Enalapril	yes
O	O	and	yes
B-drug	B-drug	enalapril	yes
O	O	IV	yes
O	O	have	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	beta	yes
I-group	I-group	adrenergic-blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	methyldopa	yes
O	O	,	no
B-group	B-group	nitrates	no
O	O	,	no
B-group	B-group	calcium-blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-drug	B-drug	hydralazine	yes
O	O	,	no
B-drug	B-drug	prazosin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	The	no
O	O	co-administration	no
O	O	of	yes
B-brand	B-brand	Natrecor	yes
O	O	with	yes
O	O	IV	yes
B-group	B-group	vasodilators	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	nitroglycerin	yes
O	O	,	no
B-drug	B-drug	nitroprusside	yes
O	O	,	no
B-drug	B-drug	milrinone	yes
O	O	,	no
O	O	or	no
O	O	IV	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	(	no
O	O	these	no
O	O	drugs	no
O	O	were	no
O	O	not	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	Natrecor	yes
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes

O	O	The	no
O	O	contribution	no
O	O	of	yes
O	O	each	no
O	O	of	yes
O	O	the	no
O	O	treatments	no
O	O	to	no
O	O	this	no
O	O	adverse	no
O	O	reaction	no
O	O	is	yes
O	O	unknown	no
O	O	but	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	can	no
O	O	not	no
O	O	be	no
O	O	excluded	no
O	O	.	no

O	O	v.	no
O	O	Patients	no
O	O	should	no
O	O	be	no
O	O	cautioned	no
O	O	regarding	no
O	O	potential	no
O	O	adverse	no
O	O	cardiovascular	no
O	O	effects	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	palpitations	no
O	O	or	no
O	O	chest	no
O	O	pain	yes
O	O	.	no

O	O	Research	no
O	O	has	no
O	O	shown	no
O	O	that	no
O	O	herbal	no
O	O	remedy	no
O	O	use	no
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	acute	no
O	O	renal	no
O	O	failure	no
O	O	.	no

O	O	Because	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	toxic	no
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticonvulsant	no
O	O	may	no
O	O	occur	no
O	O	when	no
O	O	an	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Irinotecan	yes
O	O	concentrations	no
O	O	were	no
O	O	similar	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	bolus-IFL	no
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	AVASTIN	yes
O	O	.	no

O	O	Possible	no
O	O	drug	yes
O	O	interactions	no
O	O	of	yes
B-brand	B-brand	HUMORSOL	yes
O	O	with	yes
B-drug	B-drug	succinylcholine	yes
O	O	or	no
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinesterase	no
I-group	I-group	agents	yes
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	of	yes
B-brand	B-brand	Activase	yes
O	O	with	yes
O	O	other	no
O	O	cardioactive	no
O	O	or	no
O	O	cerebroactive	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	tetracyclines	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	may	no
O	O	render	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	less	no
O	O	effective	no
O	O	.	no

O	O	600-1800	no

B-drug	B-drug	Insulin	yes
O	O	:	no
O	O	A	yes
O	O	clinical	no
O	O	study	no
O	O	in	yes
O	O	6	yes
O	O	insulin-dependent	no
O	O	diabetic	no
O	O	patients	no
O	O	demonstrated	no
O	O	no	yes
O	O	effect	no
O	O	of	yes
B-brand	B-brand	EXTRANEAL	yes
O	O	on	no
B-drug	B-drug	insulin	yes
O	O	absorption	no
O	O	from	no
O	O	the	no
O	O	peritoneal	no
O	O	cavity	no
O	O	or	no
O	O	on	no
B-group	B-drug	insulins	no
O	O	ability	no
O	O	to	no
O	O	control	no
O	O	blood	yes
O	O	glucose	yes
O	O	when	no
B-drug	B-drug	insulin	yes
O	O	was	no
O	O	administered	no
O	O	intraperitoneally	no
O	O	with	yes
B-brand	B-brand	EXTRANEAL	yes
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

B-drug	B-drug	Imipramine	yes
O	O	(	no
O	O	5	yes
O	O	mg/kg	no
O	O	)	no
O	O	,	no
B-drug	B-drug	moclobemide	yes
O	O	(	no
O	O	30	yes
O	O	mg/kg	no
O	O	)	no
O	O	,	no
B-drug	B-drug	clonazepam	yes
O	O	(	no
O	O	0.25	no
O	O	mg/kg	no
O	O	)	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	(	no
O	O	20	yes
O	O	mg/kg	no
O	O	)	no
B-drug	B-drug	sertraline	yes
O	O	(	no
O	O	30	yes
O	O	mg/kg	no
O	O	)	no
O	O	or	no
O	O	vehicle	no
O	O	was	no
O	O	administered	no
O	O	.	no

O	O	The	no
O	O	LST	no
O	O	mice	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	any	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	Kd	no
O	O	and	yes
O	O	Bmax	no
O	O	in	yes
O	O	either	no
O	O	the	no
O	O	STR	no
O	O	or	no
O	O	the	no
O	O	NAC	yes
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	MICRONASE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	evidence	no
O	O	that	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	halofantrine	yes
O	O	after	no
O	O	Mefloquineuine	no
O	O	causes	no
O	O	a	yes
O	O	significant	no
O	O	lengthening	no
O	O	of	yes
O	O	the	no
O	O	QTc	no
O	O	interval	no
O	O	.	no

O	O	Systemic	no
B-drug	B-drug	clonidine	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	production	no
O	O	of	yes
O	O	catecholamines	no
O	O	in	yes
O	O	response	no
O	O	to	no
B-drug	O	insulin-induced	no
O	O	hypoglycemia	no
O	O	and	yes
O	O	mask	no
O	O	the	no
O	O	signs	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	should	no
O	O	also	no
O	O	be	no
O	O	monitored	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	Itraconazole	yes
O	O	.	no

O	O	While	no
B-drug_n	B-drug_n	18-MC	no
O	O	and	yes
B-drug_n	B-drug_n	ibogaine	no
O	O	have	no
O	O	similar	no
O	O	affinities	no
O	O	for	yes
O	O	kappa	yes
B-group	O	opioid	no
O	O	and	yes
O	O	possibly	no
O	O	nicotinic	yes
O	O	receptors	no
O	O	,	no
B-drug_n	B-drug_n	18-MC	no
O	O	has	no
O	O	much	no
O	O	lower	no
O	O	affinities	no
O	O	than	no
B-drug_n	B-drug_n	ibogaine	no
O	O	for	yes
O	O	NMDA	yes
O	O	and	yes
O	O	sigma-2	no
O	O	receptors	no
O	O	,	no
O	O	sodium	yes
O	O	channels	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	5-HT	no
O	O	transporter	no
O	O	.	no

O	O	The	no
O	O	specific	no
O	O	objectives	no
O	O	of	yes
O	O	this	no
O	O	study	no
O	O	were	no
O	O	to	no
O	O	elucidate	no
O	O	metal	no
O	O	toxicity	no
O	O	to	no
O	O	hatching	no
O	O	,	no
O	O	survival	no
O	O	and	yes
O	O	avoidance	no
O	O	behaviour	no
O	O	of	yes
O	O	Schistosoma	no
O	O	mansoni	no
O	O	miracidia	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	relevance	no
O	O	of	yes
O	O	these	no
O	O	reports	no
O	O	and	yes
O	O	any	no
O	O	mechanism	no
O	O	of	yes
O	O	coagulation	yes
O	O	alterations	no
O	O	is	yes
O	O	unclear	no
O	O	,	no
O	O	patients	no
O	O	on	no
B-drug	B-drug	warfarin	yes
O	O	should	no
O	O	have	no
O	O	their	no
O	O	prothrombin	yes
O	O	time	no
O	O	monitored	no
O	O	.	no

O	O	(	no
B-group	B-group	Thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	raise	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	blood	yes
O	O	uric	yes
O	O	acid	yes
O	O	;	no

O	O	A	yes
O	O	conservative	no
O	O	approach	no
O	O	to	no
O	O	dosing	no
B-drug	B-drug	felodipine	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	.	no

O	O	the	no
B-drug	B-drug	disulfiram	yes
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	if	no
O	O	such	no
O	O	signs	no
O	O	appear	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	increase	no
O	O	or	no
O	O	enhance	no
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	osteomalacia	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	receiving	no
O	O	chronic	no
B-drug	B-drug	phenytoin	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Glucose	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	exert	no
O	O	additive	no
O	O	ocular	no
O	O	and	yes
O	O	renal	no
O	O	vasodilator	no
O	O	effects	no
O	O	on	no
O	O	healthy	no
O	O	humans	no
O	O	.	no

O	O	The	no
O	O	rate	no
O	O	of	yes
O	O	metabolism	no
O	O	and	yes
O	O	the	no
O	O	leukopenic	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	cyclophosphamide	yes
O	O	reportedly	no
O	O	are	no
O	O	increased	no
O	O	by	no
O	O	chronic	no
O	O	administration	no
O	O	of	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	.	no

B-brand	B-brand	Exjade	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	combined	no
O	O	with	yes
O	O	other	no
B-drug	O	iron	yes
O	O	chelator	no
O	O	therapies	no
O	O	,	no
O	O	as	yes
O	O	safety	no
O	O	of	yes
O	O	such	no
O	O	combinations	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	the	no
O	O	remainder	no
O	O	were	no
O	O	of	yes
O	O	uncertain	no
O	O	cause	no
O	O	.	no

O	O	In	yes
O	O	occasional	no
O	O	susceptible	no
O	O	patients	no
O	O	or	no
O	O	in	yes
O	O	those	no
O	O	receiving	no
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	including	no
B-group	O	antiparkinsonism	no
I-group	O	agents	yes
O	O	)	no
O	O	in	yes
O	O	addition	no
O	O	,	no
O	O	the	no
O	O	atropine-like	no
O	O	effects	no
O	O	may	no
O	O	become	no
O	O	more	no
O	O	pronounced	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	paralytic	no
O	O	ileus	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Thioridazine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	single	yes
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	20	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	thioridazine	yes
O	O	50	yes
O	O	mg	yes
O	O	produced	no
O	O	additive	no
O	O	effects	no
O	O	on	no
O	O	decreased	no
O	O	alertness	no
O	O	and	yes
O	O	impaired	no
O	O	psychomotor	no
O	O	performance	no
O	O	for	yes
O	O	2	yes
O	O	to	no
O	O	4	yes
O	O	hours	no
O	O	after	no
O	O	administration	no
O	O	.	no

O	O	Pharmacology	no
O	O	and	yes
O	O	pharmacotherapy	no
O	O	of	yes
O	O	cardiovascular	no
O	O	drugs	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	chronic	no
O	O	renal	no
O	O	disease	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	identified	no
O	O	.	no

O	O	Motility	no
O	O	agents	yes

O	O	No	yes
O	O	Important	no
O	O	Interactions	no
O	O	To	no
O	O	Date	no
B-drug	B-drug	Levosimendan	yes
O	O	does	no
O	O	not	no
O	O	have	no
O	O	clinically	no
O	O	important	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	captopril	yes
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	,	no
B-drug	B-drug	felodipine	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	isosorbide	yes
I-drug	I-drug	mononitrate	yes
O	O	,	no
B-drug	B-drug	carvedilol	yes
O	O	,	no
B-drug	B-drug	ethanol	yes
O	O	or	no
B-drug	B-drug	itraconazole	yes
O	O	.	no

B-group	B-group	Selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	)	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	,	no
O	O	rarely	no
O	O	,	no
O	O	to	no
O	O	cause	no
O	O	weakness	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	and	yes
O	O	incoordination	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-group	O	5-HTv	no
I-group	O	agonists	no
O	O	.	no

O	O	1	yes
O	O	hour	yes
O	O	after	no
O	O	starting	no
O	O	the	no
B-drug	B-drug	oxycodone	yes
O	O	or	no
B-drug	B-drug	levofloxacin	yes
O	O	500	yes
O	O	mg	yes
O	O	p.o	no
O	O	.	no

B-drug	B-group	Vitamin	yes
I-drug	I-group	A	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	retinoids	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-group	vitamin	yes
O	I-group	A	yes
O	O	and/or	no
O	O	other	no
O	O	oral	yes
B-group	B-group	retinoids	no
O	O	with	yes
B-drug	B-drug	acitretin	yes
O	O	must	no
O	O	be	no
O	O	avoided	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	hypervitaminosis	no
O	O	A	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	can	no
O	O	cause	no
O	O	a	yes
O	O	significant	no
O	O	elevation	no
O	O	in	yes
O	O	plasma	yes
O	O	corticosteroid	no
O	O	levels	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	O	higher-than	no
O	O	expected	no
O	O	steady-state	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	when	no
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	in	yes
O	O	patients	no
O	O	already	no
O	O	taking	no
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	higher	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-brand	B-brand	AMICAR	yes
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	severe	no
O	O	renal	no
O	O	failure	no
O	O	.	no

O	O	During	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	ibuprofen	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	renal	no
O	O	failure	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	to	no
O	O	assure	no
O	B-group	diuretic	no
O	O	efficacy	no
O	O	.	no

B-group	B-group	Antifungal	no
I-group	I-group	Agents	yes

B-drug	B-drug	Cisapride	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	prolong	no
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	:	no
O	O	certain	no
B-group	B-group	antiarrhythmics	no
O	O	,	no
O	O	including	no
O	O	those	no
O	O	of	yes
O	O	Class	no
O	O	IA	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	and	yes
B-drug	B-drug	procainamide	yes
O	O	)	no
O	O	and	yes
B-drug	O	Class	no
I-drug	O	III	yes
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	sotalol	yes
O	O	)	no
O	O	;	no

O	O	therefore	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	strongly	no
O	O	induce	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	reduced	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	that	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	decreased	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-group	O	Anticoagulant	no
O	O	activity	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	the	no
O	O	first	no
O	O	few	no
O	O	days	no
O	O	after	no
O	O	initiating	no
O	O	or	no
O	O	changing	no
B-brand	B-brand	VIOXX	yes
O	O	therapy	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	similar	no
O	O	agents	yes
O	O	,	no
O	O	since	no
O	O	these	no
O	O	patients	no
O	O	are	no
O	O	at	yes
O	O	an	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	complications	no
O	O	.	no

O	O	Although	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blockers	no
O	O	or	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	may	no
O	O	be	no
O	O	useful	no
O	O	in	yes
O	O	combination	yes
O	O	to	no
O	O	control	no
O	O	atrial	no
O	O	fibrillation	no
O	O	,	no
O	O	their	no
O	O	additive	no
O	O	effects	no
O	O	on	no
O	O	AV	no
O	O	node	no
O	O	conduction	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	advanced	no
O	O	or	no
O	O	complete	yes
O	O	heart	no
O	O	block	yes
O	O	.	no

O	O	subjects	no
O	O	.	no

O	O	No	yes
O	O	specific	no
O	O	information	no
O	O	available	no

O	O	It	no
O	O	is	yes
O	O	proposed	no
O	O	that	no
O	O	the	no
O	O	phosphohydrolase	no
O	O	becomes	no
O	O	metabolically	no
O	O	active	no
O	O	when	no
O	O	it	no
O	O	combines	no
O	O	with	yes
O	O	membranes	no
O	O	and	yes
O	O	that	no
B-group	O	polyamines	no
O	O	might	no
O	O	help	no
O	O	to	no
O	O	regulate	no
O	O	this	no
O	O	interaction	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	both	no
B-drug	B-drug	dexamethasone	yes
O	O	and	yes
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	,	no
O	O	and	yes
O	O	possibly	no
O	O	other	no
B-group	B-group	glucocorticoids	no
O	O	and	yes
B-group	B-group	retinoids	no
O	O	,	no
O	O	may	no
O	O	regulate	no
O	O	the	no
O	O	proliferation	no
O	O	of	yes
O	O	prostate	no
O	O	epithelium	no
O	O	by	no
O	O	a	yes
O	O	dose-dependent	no
O	O	modification	no
O	O	of	yes
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	and	yes
B-drug_n	B-drug_n	EGF	no
O	O	.	no

O	O	Neurochemical	no
O	O	and	yes
O	O	functional	no
O	O	consequences	no
O	O	following	no
B-drug_n	B-drug_n	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	no
O	O	(	no
B-drug_n	B-drug_n	MPTP	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	methamphetamine	yes
O	O	.	no

O	O	There	no
O	O	are	no
O	O	few	no
O	O	data	no
O	O	regarding	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	radiation	no
O	O	therapy	no
O	O	and	yes
B-drug	B-drug	epirubicin	yes
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	epirubicin	yes
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	.	no

B-brand	B-brand	TRACRIUM	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	until	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	recovered	no
O	O	from	no
B-drug	B-drug	succinylcholine-induced	no
O	O	neuromuscular	no
O	O	block	yes
O	O	.	no

O	O	We	no
O	O	conclude	no
O	O	that	no
O	O	the	no
O	O	prophylactic	no
O	O	and	yes
O	O	antidotal	no
O	O	properties	no
O	O	of	yes
B-drug_n	B-drug	4-methylpyrazole	yes
O	O	seen	no
O	O	in	yes
O	O	animals	no
O	O	treated	no
O	O	with	yes
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	derive	no
O	O	from	no
O	O	its	no
O	O	capacity	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	NAD+-dependent	no
O	O	oxidation	no
O	O	responsible	no
O	O	for	yes
O	O	converting	no
B-drug_n	B-drug_n	1,3-difluoro-2-propanol	no
O	O	to	no
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	in	yes
O	O	the	no
O	O	committed	no
O	O	step	no
O	O	of	yes
O	O	the	no
O	O	toxic	no
O	O	pathway	no
O	O	.	no

O	O	No	yes
O	O	drugs	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	conversion	yes
O	O	of	yes
B-drug	B-drug	fosphenytoin	yes
O	O	to	no
B-drug	B-drug	phenytoin	yes
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	lovastatin	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	;	no

O	O	Combination	yes
O	O	Therapy	no
O	O	:	no
O	O	Any	no
O	O	form	yes
O	O	of	yes
O	O	therapy	no
O	O	which	no
O	O	adds	no
O	O	to	no
O	O	the	no
O	O	stress	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	,	no
O	O	interferes	no
O	O	with	yes
O	O	nutrition	no
O	O	or	no
O	O	depresses	no
O	O	bone	no
O	O	marrow	no
O	O	function	no
O	O	will	no
O	O	increase	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	Floxuridine	yes
O	O	.	no

O	O	The	no
O	O	1-year	no
O	O	risk	no
O	O	of	yes
O	O	relapse	no
O	O	(	no
O	O	rehospitalisation	no
O	O	)	no
O	O	was	no
O	O	significantly	no
O	O	lower	no
O	O	with	yes
B-drug	B-drug	olanzapine	yes
O	O	than	no
O	O	with	yes
B-drug	B-drug	haloperidol	yes
O	O	treatment	no
O	O	.	no

B-drug	B-group	Vitamin	yes
I-drug	I-group	A	yes
O	O	:	no
O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	relationship	no
O	O	of	yes
B-brand	B-brand	Accutane	yes
O	O	to	no
B-drug	B-group	vitamin	yes
O	I-group	A	yes
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	advised	no
O	O	against	yes
O	O	taking	no
B-drug	B-group	vitamin	yes
O	I-group	supplements	no
O	O	containing	yes
B-drug	B-group	vitamin	yes
O	I-group	A	yes
O	O	to	no
O	O	avoid	no
O	O	additive	no
O	O	toxic	no
O	O	effects	no

O	O	similar	no
O	O	events	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	drugs	no
O	O	or	no
O	O	even	no
B-drug	B-drug	Clozapine	yes
O	O	by	no
O	O	itself	no
O	O	.	no

O	O	In	yes
O	O	EM	no
O	O	individuals	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	paroxetine	yes
O	O	or	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	atomoxetine	yes
O	O	is	yes
O	O	approximately	no
O	O	6-	no
O	O	to	no
O	O	8-fold	no
O	O	and	yes
O	O	Css	no
O	O	,	no
O	O	max	no
O	O	is	yes
O	O	about	no
O	O	3-	no
O	O	to	no
O	O	4-fold	no
O	O	greater	no
O	O	than	no
B-drug	B-drug	atomoxetine	yes
O	O	alone	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	using	no
B-drug	B-drug	bromocriptine	yes
I-drug	I-drug	mesylate	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	systematically	no
O	O	evaluated	no
O	O	,	no
O	O	but	no
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	bromocriptine	yes
I-drug	I-drug	mesylate	yes
O	O	.	no

O	O	Fatalities	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	However	no
O	O	,	no
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	stimulated	no
O	O	,	no
O	O	but	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	inhibit	no
O	O	,	no
O	O	proliferation	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	which	no
O	O	the	no
O	O	2	yes
O	O	mg	yes
B-drug	B-drug	clonazepam	yes
O	O	orally	no
O	O	disintegrating	yes
O	O	tablet	no
O	O	was	no
O	O	administered	no
O	O	with	yes
O	O	and	yes
O	O	without	no
B-drug	B-drug	propantheline	yes
O	O	(	no
O	O	an	no
B-group	B-group	anticholinergic	no
I-group	I-group	agent	yes
O	O	with	yes
O	O	multiple	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	GI	no
O	O	tract	no
O	O	)	no
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	clonazepam	yes
O	O	was	no
O	O	10	yes
O	O	%	no
O	O	lower	no
O	O	and	yes
O	O	the	no
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	clonazepam	yes
O	O	was	no
O	O	20	yes
O	O	%	no
O	O	lower	no
O	O	when	no
O	O	the	no
O	O	orally	no
O	O	disintegrating	yes
O	O	tablet	no
O	O	was	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	propantheline	yes
O	O	compared	no
O	O	to	no
O	O	when	no
O	O	it	no
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	Agents	yes
O	O	Increasing	no
O	O	Serum	yes
O	O	Potassium	yes
O	O	:	no
B-drug	B-drug	Enalapril	yes
O	O	and	yes
B-drug	B-drug	enalapril	yes
O	O	IV	yes
O	O	attenuate	no
O	O	potassium	yes
O	O	loss	no
O	O	caused	no
O	O	by	no
B-group	B-group	thiazide-type	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	4	yes
O	O	.	no

B-group	B-group	Protease	yes
I-group	I-group	inhibitors	no
O	O	:	no
B-drug	B-drug	Amprenavir	yes
O	O	,	no
B-drug	B-drug	lopinavir	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	ritonavir	yes
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	decrease	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	;	no

O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
O	O	higher	no
B-drug	B-drug	ketoconazole	yes
O	O	dose	no
O	O	(	no
O	O	400	yes
O	O	mg/day	no
O	O	)	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Although	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	,	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	involvement	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P-450	no
O	O	3A	yes
O	O	family	yes
O	O	in	yes
B-drug	B-drug	clonazepam	yes
O	O	metabolism	no
O	O	,	no
O	O	inhibitors	no
O	O	of	yes
O	O	this	no
O	O	enzyme	no
O	O	system	yes
O	O	,	no
O	O	notably	no
O	O	oral	yes
B-group	B-group	antifungal	no
I-group	I-group	agents	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	clonazepam	yes
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	,	no
B-drug	B-drug	clonazepam	yes
O	O	,	no
B-drug	B-drug	ethosuximide	yes

O	O	As	yes
O	O	a	yes
O	O	result	no
O	O	,	no
O	O	when	no
O	O	giving	no
O	O	these	no
O	O	drugs	no
O	O	concomitantly	no
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	warfarin	yes
O	O	levels	no
O	O	may	no
O	O	change	no
O	O	with	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	increases	no
O	O	in	yes
O	O	coagulation	yes
O	O	time	no
O	O	.	no

B-drug	B-drug	Ritonavir	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	ritonavir	yes
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	152	no
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	AUC	no
O	O	and	yes
O	O	very	no
O	O	little	no
O	O	change	no
O	O	in	yes
B-drug	B-drug	ritonavir	yes
O	O	plasma	yes
O	O	A.C	no
O	O	.	no

O	O	These	no
O	O	usually	no
O	O	clear	no
O	O	within	no
O	O	a	yes
O	O	week	no
O	O	,	no
O	O	leaving	no
O	O	only	no
O	O	the	no
O	O	"	no
O	O	drug	yes
O	O	hunger	no
O	O	"	no

O	O	-	yes
O	O	Although	no
O	O	not	no
O	O	a	yes
O	O	true	yes
O	O	drug	yes
O	O	interaction	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	precipitate	no
O	O	seizures	no
O	O	in	yes
O	O	susceptible	no
O	O	patients	no
O	O	and	yes
B-brand	B-brand	Cerebyx	yes
O	O	dosage	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	adjusted	yes

B-group	B-group	Selective	no
I-group	I-group	Serotonin	yes
I-group	I-group	Reuptake	no
I-group	I-group	Inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	:	no
B-group	B-group	SSRIs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	)	no
O	O	have	no
O	O	been	no
O	O	rarely	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	weakness	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	and	yes
O	O	incoordination	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-group	B-group	5-HT1	no
I-group	I-group	agonists	no
O	O	.	no

B-drug	B-drug	Lamivudine	yes
O	O	is	yes
O	O	predominantly	no
O	O	eliminated	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	by	no
O	O	active	no
O	O	organic	no
O	O	cationic	no
O	O	secretion	no
O	O	.	no

O	O	Because	no
B-group	O	prostaglandins	no
O	O	play	no
O	O	an	no
O	O	important	no
O	O	role	no
O	O	in	yes
O	O	hemostasis	no
O	O	,	no
O	O	and	yes
B-group	B-group	NSAIDs	no
O	O	affect	no
O	O	platelet	yes
O	O	function	no
O	O	as	yes
O	O	well	no
O	O	,	no
O	O	concurrent	no
O	O	therapy	no
O	O	with	yes
O	O	all	yes
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	including	no
B-drug	B-drug	diclofenac	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	requires	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	to	no
O	O	be	no
O	O	certain	no
O	O	that	no
O	O	no	yes
O	O	change	no
O	O	in	yes
O	O	their	no
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	is	yes
O	O	required	no
O	O	.	no

B-drug	B-drug	Cytosine	yes
O	I-drug	arabinoside	yes
O	O	,	no
O	O	a	yes
O	B-group	cytostatic	no
O	I-group	agent	yes
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	inactivate	no
O	O	the	no
O	O	antifungal	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	flucytosine	yes
O	O	by	no
O	O	competitive	no
O	O	inhibition	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	3	yes
O	O	mg	yes
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	taking	no
O	O	another	no
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	highly	no
O	O	protein-bound	no
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	cause	no
O	O	an	no
O	O	alteration	no
O	O	in	yes
O	O	the	no
O	O	free	yes
O	O	concentration	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	.	no

B-drug	B-group	Pyrazolone	yes
I-drug	I-group	Derivatives	no
O	O	(	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	oxyphenbutazone	yes
O	O	,	no
O	O	and	yes
O	O	possibly	no
B-drug	B-drug	dipyrone	no
O	O	)	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	with	yes
B-brand	B-drug	aspirin	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	gastrointestinal	no
O	O	ulceration	no
O	O	.	no

B-drug_n	B-drug_n	18-MC	no
O	O	,	no
O	O	a	yes
O	O	novel	no
O	O	iboga	no
O	O	alkaloid	no
O	O	congener	yes
O	O	,	no
O	O	is	yes
O	O	being	no
O	O	developed	no
O	O	as	yes
O	O	a	yes
O	O	potential	no
O	O	treatment	no
O	O	for	yes
O	O	multiple	no
O	O	forms	no
O	O	of	yes
O	O	drug	yes
O	O	abuse	no
O	O	.	no

O	O	Drugs	no
O	O	With	yes
O	O	A	yes
O	O	Narrow	no
O	O	Therapeutic	no
O	O	Index	no
B-drug	B-drug	Digoxin	yes
O	O	A	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	3	yes
O	O	mg	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	measured	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	following	no
O	O	dosing	no
O	O	of	yes
O	O	0.5	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	one	no
O	O	day	no
O	O	and	yes
O	O	0.25	no
O	O	mg	yes
O	O	daily	no
O	O	for	yes
O	O	the	no
O	O	next	yes
O	O	6	yes
O	O	days	no
O	O	.	no

B-drug	B-drug_n	Mineral	no
O	O	Oil-Concomitant	no
O	O	intake	no
O	O	of	yes
O	B-drug_n	mineral	no
O	I-drug_n	oil	yes
O	O	and	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
I-drug	I-drug	carbonate	yes
O	O	:	no
O	O	The	no
O	O	anorectic	no
O	O	and	yes
O	O	stimulatory	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	may	no
O	O	be	no
O	O	inhibited	no
O	O	by	no
B-drug	B-drug	lithium	yes
I-drug	I-drug	carbonate	yes
O	O	.	no

O	O	400-2800	no

O	O	Studies	no
O	O	with	yes
B-drug	B-drug	famotidine	yes
O	O	in	yes
O	O	man	no
O	O	,	no
O	O	in	yes
O	O	animal	no
O	O	models	no
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	vitro	no
O	O	have	no
O	O	shown	no
O	O	no	yes
O	O	significant	no
O	O	interference	no
O	O	with	yes
O	O	the	no
O	O	disposition	no
O	O	of	yes
O	O	compounds	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	hepatic	no
O	O	microsomal	no
O	O	enzymes	yes
O	O	,	no
O	O	e.g.	no
O	O	,	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	.	no

O	O	Agents	yes
O	O	with	yes
O	O	Increased	no
O	O	Levels	no
O	O	in	yes
O	O	the	no
O	O	Presence	no
O	O	of	yes
B-drug	B-drug	Carbamazepine	yes
O	O	:	no
B-brand	B-brand	EQUETROTM	no
O	O	increases	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	agents	yes
O	O	:	no
B-drug	B-drug	Clomipramine	yes
I-drug	I-drug	HCl	yes
O	O	,	no
B-drug	B-drug	Phenytoin	yes
O	O	(	no
O	O	6	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	primidone	yes
O	O	Thus	no
O	O	,	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	stable	no
O	O	dosage	no
O	O	on	no
O	O	one	no
O	O	of	yes
O	O	the	no
O	O	agents	yes
O	O	in	yes
O	O	this	no
O	O	category	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	begins	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	the	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	EQUETROTM	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	reasonable	no
O	O	to	no
O	O	expect	no
O	O	that	no
O	O	a	yes
O	O	dose	no
O	O	decrease	no
O	O	for	yes
O	O	the	no
O	O	concomitant	no
O	O	agent	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	These	no
O	O	doses	no
O	O	were	no
O	O	6	yes
O	O	to	no
O	O	11	yes
O	O	times	no
O	O	(	no
O	O	mouse	yes
O	O	)	no
O	O	and	yes
O	O	8	yes
O	O	to	no
O	O	16	yes
O	O	times	no
O	O	(	no
O	O	rat	yes
O	O	)	no
O	O	the	no
O	O	human	yes
O	O	AUC	no
O	O	(	no
O	O	0-24	no
O	O	)	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	maximum	no
O	O	recommended	no
O	O	human	yes
O	O	dose	no
O	O	of	yes
O	O	80	yes
O	O	mg/day	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	the	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	and	yes
B-drug	B-drug	diflunisal	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	fatal	no
O	O	gastrointestinal	no
O	O	hemorrhage	no
O	O	.	no

B-brand	B-brand	FLUOTHANE	yes
O	O	may	no
O	O	augment	no
O	O	the	no
O	O	hypotension	no
O	O	caused	no
O	O	by	no
O	O	the	no
O	O	ganglionic-blocking	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	tubocurarine	yes
O	O	.	no

O	O	Specific	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	ibandronate	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	may	no
O	O	elevate	no
B-drug	B-drug	cyclosporine	yes
O	O	levels	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	of	yes
O	O	over	no
O	O	1600	no
O	O	patients	no
O	O	enrolled	no
O	O	in	yes
O	O	a	yes
O	O	study	no
O	O	comparing	no
B-drug	O	once-monthly	no
O	O	with	yes
O	O	daily	no
O	O	dosing	no
O	O	regimens	no
O	O	of	yes
B-drug	B-drug	ibandronate	yes
O	O	,	no
O	O	14	yes
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	used	no
O	O	anti-peptic	no
O	O	agents	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	prostaglandin	yes
I-drug	I-drug	F2alpha	yes
O	O	and	yes
B-drug	B-drug	oxytocin	yes
O	O	in	yes
O	O	placental	no
O	O	vessels	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	relatively	no
O	O	specific	no
O	O	blockade	no
O	O	of	yes
O	O	diverse	no
O	O	potassium	yes
O	O	channel	no
O	O	types	no
O	O	.	no

O	O	250-500	no

O	O	Patients	no
O	O	taking	no
O	O	both	no
B-drug	B-drug	flurbiprofen	yes
O	O	and	yes
O	O	a	yes
B-group	B-group	beta-blocker	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	to	no
O	O	ensure	no
O	O	that	no
O	O	a	yes
O	O	satisfactory	no
O	O	hypotensive	no
O	O	effect	no
O	O	is	yes
O	O	achieved	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	DIABINESE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	mercaptopurine	yes
O	O	(	no
B-drug	B-brand	Purinethol	yes
O	O	)	no
O	O	or	no
B-drug	B-drug	azathioprine	yes
O	O	(	no
B-brand	B-brand	Imuran	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	300-600	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	per	no
O	O	day	no
O	O	will	no
O	O	require	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	dose	no
O	O	to	no
O	O	approximately	no
O	O	one-third	no
O	O	to	no
O	O	one-fourth	no
O	O	of	yes
O	O	the	no
O	O	usual	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	mercaptopurine	yes
O	O	or	no
B-drug	B-drug	azathioprine	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	schizophrenic	no
O	O	patients	no
O	O	who	no
O	O	received	no
B-drug	B-drug	clozapine	yes
O	O	under	no
O	O	steady	no
O	O	state	no
O	O	conditions	no
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	or	no
B-drug	B-drug	paroxetine	yes
O	O	was	no
O	O	added	no
O	O	in	yes
O	O	16	yes
O	O	and	yes
O	O	14	yes
O	O	patients	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Longitudinal	no
O	O	assessment	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	in	yes
O	O	de	yes
O	O	novo	yes
O	O	renal	no
O	O	transplant	no
O	O	recipients	no
O	O	over	no
O	O	the	no
O	O	first	no
O	O	post-transplant	no
O	O	year	no
O	O	:	no
O	O	pharmacokinetics	no
O	O	,	no
O	O	exposure-response	no
O	O	relationships	no
O	O	,	no
O	O	and	yes
O	O	influence	no
O	O	on	no
B-drug	B-drug	cyclosporine	yes
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	with	yes
O	O	appropriate	no
O	O	adjustment	no
O	O	to	no
O	O	the	no
B-drug	B-drug	lithium	yes
O	O	dose	no
O	O	in	yes
O	O	accordance	no
O	O	with	yes
O	O	standard	yes
O	O	clinical	no
O	O	practice	no
O	O	.	no

O	O	Because	no
O	O	the	no
O	O	small	no
O	O	magnitude	no
O	O	and	yes
O	O	the	no
O	O	direction	no
O	O	of	yes
O	O	the	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	,	no
O	O	this	no
O	O	interaction	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	be	no
O	O	clinical	no
O	O	concern	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	MICRONASE	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	No	yes
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	in	yes
O	O	human	yes
O	O	subjects	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Depending	no
O	O	on	no
O	O	the	no
O	O	fraction	yes
O	O	of	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentration	no
O	O	may	no
O	O	be	no
O	O	small	no
O	O	,	no
O	O	or	no
O	O	quite	no
O	O	large	no
O	O	(	no
O	O	8-fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	B-group	TCA	no
O	O	)	no
O	O	.	no

O	O	With	yes
O	O	combined	no
O	O	use	no
O	O	,	no
O	O	clinicians	no
O	O	should	no
O	O	be	no
O	O	aware	no
O	O	,	no
O	O	when	no
B-drug	B-drug	phenytoin	yes
O	O	is	yes
O	O	added	no
O	O	,	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	reexacerbation	no
O	O	of	yes
O	O	pulmonary	no
O	O	symptomatology	no
O	O	due	no
O	O	to	no
O	O	lowered	no
O	O	serum	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	one	no
O	O	reported	no
O	O	case	no
O	O	of	yes
O	O	a	yes
O	O	patient	no
O	O	with	yes
O	O	acute	no
O	O	delirium	no
O	O	associated	no
O	O	with	yes
O	O	the	no
O	O	simultaneous	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	fluphenazine	yes
O	O	and	yes
O	O	oral	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Sublingual	no
B-drug	B-drug	nitroglycerin	yes
O	O	may	no
O	O	be	no
O	O	taken	no
O	O	if	no
O	O	necessary	no
O	O	for	yes
O	O	the	no
O	O	control	no
O	O	of	yes
O	O	acute	no
O	O	angina	no
O	O	attacks	no
O	O	during	no
B-drug	B-drug	Bepridil	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	(	no
O	O	200	yes
O	O	mg	yes
O	O	q12h	no
O	O	)	no
O	O	+307	no
O	O	%	no
O	O	+73	no
O	O	%	no

O	O	Studies	no
O	O	with	yes
O	O	other	no
O	O	oral	yes
O	O	or	no
O	O	implant	no
B-group	B-group	contraceptives	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
O	O	coadministered	no
O	O	drugs	no
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	on	no
O	O	the	no
O	O	binding	no
O	O	of	yes
O	O	therapeutic	no
O	O	drugs	no
O	O	to	no
O	O	human	yes
O	O	serum	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	A	yes
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	of	yes
B-brand	B-brand	FOSCAVIR	yes
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	has	no
O	O	been	no
O	O	described	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	also	no
O	O	be	no
O	O	taken	no
O	O	in	yes
O	O	concurrent	no
O	O	or	no
O	O	serial	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	B-group	aminoglycosides	no
O	O	and	yes
B-group	B-group	polymyxins	no
O	O	because	no
O	O	they	no
O	O	may	no
O	O	enhance	no
B-drug	O	neomycin	yes
O	O	s	yes
O	O	nephrotoxicity	no
O	O	and/or	no
O	O	ototoxicity	no
O	O	and	yes
O	O	potentiate	no
B-drug	B-drug	neomycin	yes
I-drug	I-drug	sulfate	yes
O	O	neuromuscular	no
O	O	blocking	no
O	O	effects	no
O	O	.	no

O	O	In	yes
O	O	nine	no
O	O	otherwise	no
O	O	healthy	no
O	O	subjects	no
O	O	with	yes
O	O	epilepsy	no
O	O	ingesting	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	the	no
O	O	steady-state	no
O	O	trough	no
O	O	(	no
O	O	Cmin	no
O	O	)	no
B-drug	B-drug	carbamazepine	yes
O	O	concentration	no
O	O	was	no
O	O	8	yes
O	O	2	yes
O	O	micrograms/mL	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	AUC	no
O	O	values	no
O	O	of	yes
O	O	EE	no
O	O	were	no
O	O	decreased	no
O	O	by	no
O	O	48	yes
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	22-65	no
O	O	]	no
O	O	in	yes
O	O	one	no
O	O	study	no
O	O	and	yes
O	O	52	no
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	38-52	no
O	O	]	no
O	O	in	yes
O	O	another	no
O	O	study	no
O	O	[	no
O	O	1,2	yes
O	O	]	no
O	O	.	no

B-group	B-group	Barbiturates	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	rifampin	yes
O	O	increased	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	fludrocortisone	yes
I-drug	I-drug	acetate	yes
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	induction	no
O	O	of	yes
O	O	hepatic	no
O	O	enzymes	yes
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	rare	no
O	O	reports	no
O	O	of	yes
O	O	reddish	no
O	O	stools	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	received	no
B-drug	B-drug	cefdinir	yes
O	O	in	yes
O	O	Japan	yes
O	O	.	no

B-group	B-group	Beta-blockers	no
O	O	,	no
B-drug	B-drug	clonidine	yes
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	salts	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	either	no
O	O	potentiate	no
O	O	or	no
O	O	weaken	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	When	no
B-brand	B-brand	Lodine	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	its	no
O	O	protein	yes
O	O	binding	no
O	O	is	yes
O	O	reduced	yes
O	O	,	no
O	O	although	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	free	yes
B-drug	B-drug	etodolac	yes
O	O	is	yes
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	The	no
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	two	no
O	O	drugs	no
O	O	differ	no
O	O	,	no
O	O	and	yes
O	O	they	no
O	O	do	no
O	O	not	no
O	O	act	no
O	O	on	no
O	O	the	no
O	O	same	yes
O	O	target	no
O	O	sites	no
O	O	in	yes
O	O	the	no
O	O	brain	yes
O	O	,	no
O	O	although	no
O	O	they	no
O	O	may	no
O	O	share	no
O	O	,	no
O	O	or	no
O	O	partly	no
O	O	share	no
O	O	,	no
O	O	certain	no
O	O	properties	no
O	O	.	no

O	O	The	no
O	O	extent	no
O	O	of	yes
O	O	plasma	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	atovaquone	yes
O	O	in	yes
O	O	human	yes
O	O	plasma	yes
O	O	is	yes
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	therapeutic	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	(	no
O	O	15	yes
O	O	mcg/	no
O	O	mL	no
O	O	)	no
O	O	,	no
O	O	nor	yes
O	O	is	yes
O	O	the	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	atovaquone	yes
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	renal	no
O	O	cationic	no
O	O	secretion	no
O	O	are	no
O	O	contraindicated	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	.	no

B-group	B-group	Nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	(	no
B-group	B-group	NSAIDS	no
O	O	)	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	(	no
O	O	or	no
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	antiinflammatory	no
I-group	I-group	agents	yes
O	O	)	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	increases	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	gastrointestinal	no
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	Consider	no
O	O	doubling	no
O	O	the	no
B-drug	B-drug	rifabutin	yes
O	O	dose	no
O	O	in	yes
O	O	regimens	no
O	O	where	no
B-drug	B-drug	rifabutin	yes
O	O	is	yes
O	O	given	no
O	O	2	yes
O	O	or	no
O	O	3	yes
O	O	times	no
O	O	a	yes
O	O	week	no
O	O	.	no

B-drug	B-drug	Diflunisal	yes
O	O	decreased	no
O	O	the	no
O	O	hyperuricemic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	are	no
O	O	concomitantly	no
O	O	receiving	no
B-brand	B-brand	VELCADE	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	inhibitors	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	for	yes
O	O	either	no
O	O	toxicities	no
O	O	or	no
O	O	reduced	yes
O	O	efficacy	no
O	O	.	no

B-drug	B-drug	Bosentan	yes
O	O	is	yes
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	CYP3A4	no
O	O	and	yes
O	O	CYP2C9	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	during	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	concomitant	no
B-drug	B-drug	phenytoin	yes
O	O	administration	no
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	quetiapine	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	unknown	no
O	O	whether	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	proton	no
I-group	I-group	pump	no
I-group	I-group	inhibitors	no
O	O	affects	no
B-drug	B-drug	duloxetine	yes
O	O	absorption	no
O	O	.	no

O	O	Routine	no
O	O	administration	no
O	O	of	yes
B-group	B-group	vaccines	no
O	O	or	no
B-group	O	toxoids	no
O	O	should	no
O	O	be	no
O	O	deferred	no
O	O	until	no
B-group	B-group	corticosteroid	no
O	O	therapy	no
O	O	is	yes
O	O	discontinued	no
O	O	if	no
O	O	possible	no
O	O	.	no

O	O	While	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	this	no
O	O	interaction	no
O	O	occurs	no
O	O	with	yes
B-group	B-group	fibrates	no
O	O	other	no
O	O	than	no
B-drug	B-drug	gemfibrozil	yes
O	O	,	no
O	O	myopathy	no
O	O	and	yes
O	O	rhabdomyolysis	no
O	O	have	no
O	O	occasionally	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-group	B-group	fibrates	no
O	O	alone	no
O	O	,	no
O	O	including	no
B-drug	B-drug	clofibrate	yes
O	O	.	no

B-drug	B-drug	Clarithromycin	yes

O	O	The	no
O	O	minimal	no
O	O	inhibitory	yes
O	O	concentration	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	minimal	no
O	O	bactericidal	no
O	O	concentration	no
O	O	of	yes
B-drug_n	B-drug_n	KRM-1648	no
O	O	against	yes
O	O	M	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
O	O	the	no
O	O	binding	no
O	O	is	yes
O	O	not	no
O	O	easily	no
O	O	removed	no
O	O	.	no

O	O	There	no
O	O	are	no
O	O	rare	no
O	O	reports	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	from	no
O	O	marketing	no
O	O	experiences	no
O	O	,	no
O	O	of	yes
O	O	changes	no
O	O	in	yes
O	O	effects	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	that	no
O	O	necessitated	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	doses	no
O	O	of	yes
O	O	such	no
O	O	agents	yes
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	which	no
O	O	are	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	anticoagulants	no
O	O	)	no
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	drug-drug	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	in	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
O	O	.	no

B-drug	B-drug	Calcium	yes
O	O	Supplements	no
O	O	:	no
O	O	Uncontrolled	no
O	O	intake	no
O	O	of	yes
O	O	additional	no
O	B-drug	calcium-containing	no
O	O	preparations	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-brand	B-brand	DOSTINEX	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-group	O	D2-antagonists	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	butyrophenones	no
O	O	,	no
B-group	B-group	thioxanthines	no
O	O	,	no
O	O	or	no
B-drug	B-drug	metoclopramide	yes
O	O	.	no

O	O	Interference	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug_n	phosphate	yes
O	O	supplements	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
O	O	another	no
B-group	O	positively-charged	no
I-group	O	bile	no
I-group	O	acid	yes
I-group	O	sequestrant	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	short-term	no
O	O	controlled	no
O	O	study	no
O	O	in	yes
O	O	14	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	ketoprofen	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	on	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Co-administration	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	with	yes
B-group	B-group	antiplatelet	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	thrombolytics	no
O	O	,	no
O	O	and	yes
O	O	other	no
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

O	O	Corresponding	no
O	O	values	no
O	O	for	yes
O	O	free	yes
B-drug	B-drug	valproate	yes
O	O	Cmin	no
O	O	concentrations	no
O	O	were	no
O	O	7	yes
O	O	3	yes
O	O	,	no
O	O	9	yes
O	O	4	yes
O	O	,	no
O	O	and	yes
O	O	11	yes
O	O	6	yes
O	O	micrograms/mL	no
O	O	for	yes
O	O	0	no
O	O	,	no
O	O	1200	no
O	O	,	no
O	O	and	yes
O	O	2400	no
O	O	mg/day	no
B-brand	B-brand	Felbatol	yes
O	O	,	no
O	O	respectively	no
O	O	.	no

B-drug	B-drug	Indinavir	yes
O	O	is	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoform	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Currently	no
O	O	,	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	data	no
O	O	available	no
O	O	from	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

O	O	structural	no
O	O	heart	no
O	O	disease	no
O	O	is	yes
O	O	a	yes
O	O	known	no
O	O	risk	no
O	O	factor	yes
O	O	for	yes
O	O	arrhythmia	no
O	O	.	no

B-group	B-group	Ergot	yes
I-group	I-group	alkaloids	yes

B-drug	B-drug	Magnesium/Aluminum-containing	no
B-group	B-group	Antacid	no
O	I-group	Products	no
O	O	:	no
O	O	Absorption	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	is	yes
O	O	moderately	no
O	O	reduced	yes
O	O	(	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	)	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	magnesium/aluminum-containing	no
B-group	B-group	antacid	no
O	I-group	products	no
O	O	.	no

O	O	This	no
O	O	increase	no
O	O	is	yes
O	O	greatest	no
O	O	in	yes
O	O	the	no
O	O	evening	no
O	O	.	no

O	O	Pressor	no
O	O	amines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	norepinephrine	yes
O	O	)	no
O	O	:	no
O	O	possible	no
O	O	decreased	no
O	O	response	no
O	O	to	no
O	O	pressor	no
O	O	amines	no
O	O	but	no
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	preclude	no
O	O	their	no
O	O	use	no
O	O	.	no

B-group	B-group	Antihistamines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-group	chlorpheniramine	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Ranitidine	yes
O	O	produced	no
O	O	smaller	no
O	O	,	no
O	O	non-significant	no
O	O	increases	no
O	O	.	no

O	O	Increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	cisapride	yes
O	O	cause	no
O	O	QT	no
O	O	prolongation	no
O	O	and	yes
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	torsades	no
O	O	de	yes
O	O	pointes-type	no
O	O	ventricular	no
O	O	tachycardia	no
O	O	,	no
O	O	sometimes	no
O	O	fatal	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Animal	no
O	O	studies	no
O	O	wshow	no
O	O	that	no
B-brand	B-brand	aspirin	yes
O	O	given	no
O	O	with	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	,	no
O	O	including	no
B-drug	B-drug	ibuprofen	yes
O	O	,	no
O	O	yields	no
O	O	a	yes
O	O	net	no
O	O	decrease	no
O	O	in	yes
O	O	anti-inflammatory	no
O	O	activity	yes
O	O	with	yes
O	O	lowered	no
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
B-group	O	non-aspirin	no
I-group	O	drug	yes
O	O	.	no

O	O	Furthermore	no
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	inducers	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	bexarotene	yes
O	O	concentrations	no
O	O	.	no

O	O	Reduced	yes
O	O	levels	no
O	O	(	no
O	O	up	no
O	O	to	no
O	O	20	yes
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	total	yes
B-drug	O	glutathione	yes
O	O	(	no
O	O	total	yes
O	O	GSH	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	elevation	no
O	O	of	yes
O	O	conjugated	yes
O	O	dienes	no
O	O	(	no
O	O	approximately	no
O	O	60	no
O	O	%	no
O	O	in	yes
O	O	liver	yes
O	O	by	no
O	O	single	yes
O	O	dose	no
O	O	at	yes
O	O	4	yes
O	O	h	yes
O	O	)	no
O	O	also	no
O	O	indicated	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	an	no
O	O	oxidative	no
O	O	insult	no
O	O	.	no

O	O	General	no
O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	demonstrated	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	cytochrome	no
O	O	P450-mediated	no
O	O	drug	yes
O	O	interactions	no
O	O	that	no
O	O	are	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	clinical	no
O	O	relevance	no
O	O	.	no

O	O	Correlative	no
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	,	no
O	O	which	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	using	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	pronounced	no
O	O	if	no
O	O	a	yes
O	O	300	yes
O	O	mg	yes
O	O	daily	no
O	O	dose	no
O	O	is	yes
O	O	co-administered	no
O	O	,	no
O	O	particularly	no
O	O	since	no
B-drug	B-drug	fluvoxamine	yes
O	O	exhibits	no
O	O	non-linear	no
O	O	pharmacokinetics	no
O	O	over	no
O	O	the	no
O	O	dosage	no
O	O	range	no
O	O	100-300	no
O	O	mg	yes
O	O	.	no
O	O	If	no
B-drug	B-drug	alprazolam	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	,	no
O	O	the	no
O	O	initial	no
B-drug	B-drug	alprazolam	yes
O	O	dosage	no
O	O	should	no
O	O	be	no
O	O	at	yes
O	O	least	no
O	O	halved	no
O	O	and	yes
O	O	titration	yes
O	O	to	no
O	O	the	no
O	O	lowest	no
O	O	effective	no
O	O	dose	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Both	no
O	O	of	yes
O	O	these	no
O	O	strategies	no
O	O	will	no
O	O	become	no
O	O	more	no
O	O	feasible	no
O	O	as	yes
O	O	specific	no
O	O	molecular	yes
O	O	differences	no
O	O	between	yes
O	O	tumor	yes
O	O	and	yes
O	O	normal	yes
O	O	cells	yes
O	O	are	no
O	O	being	no
O	O	rapidly	yes
O	O	identified	no
O	O	and	yes
O	O	new	no
O	O	combination	yes
O	O	therapies	no
O	O	that	no
O	O	take	no
O	O	advantage	no
O	O	of	yes
O	O	these	no
O	O	differences	no
O	O	are	no
O	O	being	no
O	O	designed	no
O	O	and	yes
O	O	tested	no
O	O	.	no

O	O	Hypothermia	no
O	O	as	yes
O	O	an	no
O	O	index	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	disulfiram-ethanol	no
O	O	reaction	no
O	O	in	yes
O	O	the	no
O	O	rat	yes
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	post-marketing	no
O	O	observations	no
O	O	,	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

O	O	In	yes
O	O	dogs	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	unchanged	no
O	O	the	no
O	O	secretion	no
O	O	of	yes
O	B-drug	cardiotrast	no
O	O	,	no
O	O	a	yes
O	O	test	yes
O	O	agent	yes
O	O	for	yes
O	O	anionic	no
O	O	transport	no
O	O	.	no

O	O	This	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	(	no
O	O	which	no
O	O	also	no
O	O	lowers	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	given	no
O	O	with	yes
O	O	it	no
O	O	)	no
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	(	no
O	O	n=	no
O	O	15	yes
O	O	)	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	normal	yes
O	O	volunteers	no
O	O	(	no
O	O	n=	no
O	O	16	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	extremely	no
O	O	acidic	no
O	O	conditions	no
O	O	,	no
B-drug	B-drug	Duloxetine	yes
O	O	,	no
O	O	unprotected	no
O	O	by	no
O	O	the	no
O	O	enteric	no
O	O	coating	no
O	O	,	no
O	O	may	no
O	O	undergo	no
O	O	hydrolysis	no
O	O	to	no
O	O	form	yes
B-drug	O	naphthol	no
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	inhibits	no
O	O	CYP3A4	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	increased	no
O	O	anticoagulant	no
O	O	effects	no
O	O	when	no
B-drug	B-drug	erythromycin	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	were	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	Oral	yes
B-drug	B-drug	neomycin	yes
I-drug	I-drug	sulfate	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	coumarin	yes
O	O	in	yes
B-group	B-group	anticoagulants	no
O	O	by	no
O	O	decreasing	no
B-group	O	vitamin	yes
I-group	O	K	yes
O	O	availability	no
O	O	.	no

O	O	The	no
O	O	physician	no
O	O	should	no
O	O	be	no
O	O	alert	no
O	O	for	yes
O	O	possible	no
O	O	combined	no
O	O	drug	yes
O	O	actions	no
O	O	,	no
O	O	desirable	no
O	O	or	no
O	O	undesirable	no
O	O	,	no
O	O	involving	no
B-drug	B-drug	cyclophosphamide	yes
O	O	even	no
O	O	though	no
B-drug	B-drug	cyclophosphamide	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	successfully	no
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	including	no
O	O	other	no
B-group	O	cytotoxic	yes
I-group	O	drugs	no
O	O	.	no

O	O	Among	no
O	O	fifteen	no
O	O	species	no
O	O	of	yes
O	O	bacteria	no
O	O	tested	no
O	O	,	no
O	O	the	no
O	O	antimicrobial	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	GL	no
O	O	was	no
O	O	the	no
O	O	most	no
O	O	potent	no
O	O	against	yes
O	O	Micrococcus	no
O	O	luteus	no
O	O	(	no
O	O	MIC	yes
O	O	,	no
O	O	0.75	yes
O	O	mg/ml	no
O	O	)	no
O	O	.	no

B-drug	I-drug	Aprepitant	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	CYP3A4	no
O	O	;	no

O	O	This	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	reduced	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
O	O	a	yes
O	O	prolongation	no
O	O	of	yes
O	O	its	no
O	O	plasma	yes
O	O	half-life	no
O	O	.	no

B-drug	B-drug	Aripiprazole	yes
O	O	also	no
O	O	does	no
O	O	not	no
O	O	undergo	no
O	O	direct	no
O	O	glucuronidation	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	,	no
O	O	in	yes
O	O	particular	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	found	no
O	O	to	no
O	O	exhibit	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	this	no
O	O	variety	no
O	O	.	no

B-drug	B-drug	Vitamin	yes
I-drug	I-drug	D3	yes
O	O	administration	no
O	O	to	no
O	O	rachitic	no
O	O	chicks	no
O	O	was	no
O	O	effective	no
O	O	in	yes
O	O	significantly	no
O	O	elevating	no
O	O	duodenal	no
O	B-drug_n	arsenate	no
O	O	absorption	no
O	O	,	no
O	O	acting	yes
O	O	primarily	no
O	O	to	no
O	O	enhance	no
O	O	serosal	no
O	O	transport	no
O	O	.	no

O	O	TBg	no
O	O	may	no
O	O	also	no
O	O	be	no
O	O	increased	no
O	O	during	no
O	O	infectious	no
O	O	hepatitis	yes
O	O	.	no

O	O	.	no

O	O	The	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	were	no
O	O	also	no
O	O	decreased	no
O	O	by	no
O	O	approximately	no
O	O	30	yes
O	O	%	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	induce	no
O	O	hepatic	no
O	O	enzymes	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	and	yes
O	O	may	no
O	O	require	no
O	O	increases	no
O	O	in	yes
B-group	B-group	corticosteroid	no
O	O	dose	no
O	O	to	no
O	O	achieve	no
O	O	the	no
O	O	desired	no
O	O	response	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	:	no
B-drug	B-drug	Amiodarone	yes
O	O	therapy	no
O	O	alone	no
O	O	can	no
O	O	cause	no
O	O	hypothyroidism	no
O	O	or	no
O	O	hyperthyroidism	no
O	O	.	no

O	O	Higher	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	(	no
O	O	10	yes
O	O	(	no
O	O	-8	no
O	O	)	no
O	O	-	yes
O	O	10	yes
O	O	(	no
O	O	-6	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	or	no
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	(	no
O	O	3	yes
O	O	X	yes
O	O	10	yes
O	O	(	no
O	O	-8	no
O	O	)	no
O	O	-	yes
O	O	10	yes
O	O	(	no
O	O	-7	no
O	O	)	no
O	O	M	yes
O	O	)	no
O	O	enhance	no
O	O	the	no
O	O	mitogenic	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	EGF	no
O	O	.	no

O	O	Certain	no
O	O	drugs	no
O	O	tend	no
O	O	to	no
O	O	produce	no
O	O	hyperglycemia	no
O	O	and	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	Recent	no
O	O	studies	no
O	O	and	yes
O	O	consensus	yes
O	O	reports	no
O	O	have	no
O	O	expanded	no
O	O	our	no
O	O	understanding	no
O	O	of	yes
O	O	its	no
O	O	efficacy	no
O	O	,	no
O	O	safety	no
O	O	,	no
O	O	contraindications	no
O	O	,	no
O	O	and	yes
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Inhibit	no
O	O	CYP3A4	no
O	O	(	no
B-drug	B-drug	Ketoconazole	yes
O	O	)	no
O	O	CYP3A4	no
O	O	is	yes
O	O	a	yes
O	O	major	no
O	O	metabolic	no
O	O	pathway	no
O	O	for	yes
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	.	no

O	O	A	yes
O	O	pharmacokinetic	no
O	O	study	no
O	O	evaluating	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	INSPRA	yes
O	O	100	yes
O	O	mg	yes
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	200	yes
O	O	mg	yes
O	O	BID	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	CYP3A4	no
O	O	pathway	no
O	O	,	no
O	O	showed	no
O	O	a	yes
O	O	1.7-fold	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	and	yes
O	O	a	yes
O	O	5.4-fold	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	eplerenone	yes
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	and	yes
O	O	dose	no
O	O	reduction	yes
O	O	of	yes
O	O	the	no
O	O	concomitant	no
O	O	substrate	yes
O	O	drug	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	dosing	no
B-drug	B-drug	lapatinib	yes
O	O	concurrently	no
O	O	with	yes
O	O	medications	no
O	O	with	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	windows	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	of	yes
O	O	CYP3A4	no
O	O	or	no
O	O	CYP2C8	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
O	B-group	agents	yes
O	I-group	with	yes
B-group	I-group	b-blocking	no
O	I-group	properties	no
O	O	,	no
O	O	if	no
B-brand	B-brand	COREG	yes
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	administered	no
O	O	orally	no
O	O	with	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	verapamil	yes
O	O	or	no
B-drug	B-drug	diltiazem	yes
O	O	type	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	ECG	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	be	no
O	O	monitored	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	assessments	no
O	O	of	yes
O	O	drug-drug	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	Vidaza	yes
O	O	and	yes
O	O	other	no
O	O	agents	yes
O	O	have	no
O	O	been	no
O	O	conducted	no

O	O	Pregnancies	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	by	no
O	O	users	no
O	O	of	yes
B-group	B-group	combined	no
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	who	no
O	O	also	no
O	O	used	no
O	O	some	no
O	O	form	yes
O	O	of	yes
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	.	no

B-drug	B-drug	Phenobarbital	yes

O	O	Specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	and	yes
B-group	B-group	NRTIs	no
O	O	other	no
O	O	than	no
B-drug	B-drug	lamivudine	yes
O	O	and	yes
B-drug	B-drug	zidovudine	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Norpace	yes
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	resulted	no
O	O	in	yes
O	O	slight	no
O	O	increases	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	disopyramide	yes
O	O	levels	no
O	O	and	yes
O	O	slight	no
O	O	decreases	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	quinidine	yes
O	O	levels	no
O	O	.	no

O	O	OBJECTIVE	no
O	O	:	no
O	O	To	no
O	O	report	no
O	O	a	yes
O	O	case	no
O	O	of	yes
O	O	rhabdomyolysis	no
O	O	resulting	no
O	O	from	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	clarithromycin	yes
O	O	and	yes
B-drug	B-drug	simvastatin	yes
O	O	.	no

O	O	Drugs	no
O	O	with	yes
O	O	a	yes
O	O	Narrow	no
O	O	Therapeutic	no
O	O	Index	no
B-drug	B-drug	Digoxin	yes
O	O	:	no
B-brand	B-brand	Sonata	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	profile	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	(	no
O	O	0.375	no
O	O	mg	yes
O	O	q24h	no
O	O	for	yes
O	O	8	yes
O	O	days	no
O	O	)	no
O	O	.	no

O	O	Coadministration	no
O	O	with	yes
O	O	compounds	no
O	O	that	no
O	O	are	no
O	O	potent	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	decreased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-group	B-group	Quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	enoxacin	yes
O	O	,	no
O	O	decrease	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	R-warfarin	no
O	O	,	no
O	O	the	no
O	O	less	no
O	O	active	no
O	O	isomer	no
O	O	of	yes
O	O	racemic	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
B-drug	B-drug	Phenytoin	yes
O	O	may	no
O	O	decrease	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	14	yes
O	O	.	no

O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	also	no
O	O	decrease	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	When	no
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	were	no
O	O	coadministered	no
O	O	,	no
O	O	steady-state	no
O	O	plasma	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	increased	no
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Oxcarbazepine	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	to	no
O	O	determine	no
O	O	its	no
O	O	capacity	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	major	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

O	O	In	yes
O	O	studies	no
O	O	with	yes
B-drug	B-drug	finasteride	yes
O	O	,	no
O	O	no	yes
O	O	clinically	no
O	O	meaningful	no
O	O	changes	no
O	O	in	yes
B-drug	O	luteinizing	yes
I-drug	O	hormone	yes
O	O	(	no
O	O	LH	yes
O	O	)	no
O	O	,	no
B-drug	O	follicle-stimulating	yes
I-drug	O	hormone	yes
O	O	(	no
B-drug	O	FSH	yes
O	O	)	no
O	O	or	no
B-drug	O	prolactin	no
O	O	were	no
O	O	detected	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes

B-drug	B-drug	Amiodarone	yes
O	O	caused	no
O	O	a	yes
O	O	three-	no
O	O	to	no
O	O	fivefold	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
O	O	reverse	no
O	O	triiodothyronine	yes
O	O	levels	no
O	O	,	no
O	O	but	no
O	O	changes	no
O	O	in	yes
O	O	thyroid	yes
O	O	function	no
O	O	were	no
O	O	not	no
O	O	quantitatively	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	changes	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	unknown	no
O	O	;	no

O	O	Additive	no
O	O	CNS	no
O	O	depression	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-group	B-group	antihistamines	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	including	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	This	no
O	O	article	no
O	O	looks	no
O	O	at	yes
O	O	five	no
O	O	commonly	no
O	O	used	no
B-group	B-group	immunosuppressive	no
I-group	I-group	drugs	no
O	O	in	yes
O	O	turn	no
O	O	(	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-drug	B-drug	cyclosporin	yes
O	O	,	no
B-drug	B-drug	azathioprine	yes
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
B-drug	B-drug	cyclophosphamide	yes
O	O	)	no
O	O	,	no
O	O	discussing	no
O	O	the	no
O	O	main	no
O	O	,	no
O	O	non-infection	no
O	O	,	no
O	O	unwanted	no
O	O	effects	no
O	O	,	no
O	O	ways	no
O	O	to	no
O	O	avoid	no
O	O	them	no
O	O	and	yes
O	O	what	no
O	O	to	no
O	O	do	no
O	O	if	no
O	O	problems	no
O	O	arise	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-group	B-group	TCAs	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRIs	no
O	O	and	yes
O	O	also	no
O	O	in	yes
O	O	switching	no
O	O	from	no
O	O	one	no
O	O	class	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	O	No	yes
O	O	pharmacokinetic-based	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	SYNAREL	yes
O	O	.	no

O	O	Prescribers	no
O	O	are	no
O	O	advised	no
O	O	to	no
O	O	consult	no
O	O	the	no
O	O	package	no
O	O	insert	no
O	O	of	yes
O	O	medication	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	,	no
O	O	since	no
O	O	some	no
O	O	medications	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
O	O	these	no
O	O	birth	no
O	O	control	no
O	O	products	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	anastrozole	yes
O	O	and	yes
B-drug	B-drug	tamoxifen	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	anastrozole	yes
O	O	plasma	yes
O	O	levels	no
O	O	by	no
O	O	27	yes
O	O	%	no
O	O	compared	no
O	O	with	yes
O	O	those	no
O	O	achieved	no
O	O	with	yes
B-drug	B-drug	anastrozole	yes
O	O	alone	no
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	of	yes
O	O	this	no
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-group	B-group	salicylates	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	furosemide	yes
O	O	,	no
O	O	as	yes
O	O	in	yes
O	O	rheumatic	no
O	O	disease	no
O	O	,	no
O	O	may	no
O	O	experience	no
B-group	B-group	salicylate	yes
O	O	toxicity	no
O	O	at	yes
O	O	lower	no
O	O	doses	no
O	O	because	no
O	O	of	yes
O	O	competitive	no
O	O	renal	no
O	O	excretory	no
O	O	sites	no
O	O	.	no

O	O	When	no
B-drug	B-drug	lansoprazole	yes
O	O	was	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP3A	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	minor	no
O	O	increase	no
O	O	(	no
O	O	10	yes
O	O	%	no
O	O	)	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	was	no
O	O	seen	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	in	yes
O	O	using	no
B-drug	B-drug	Duloxetine	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	conditions	no
O	O	that	no
O	O	may	no
O	O	slow	yes
O	O	gastric	yes
O	O	emptying	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	some	no
O	O	diabetics	no
O	O	)	no
O	O	.	no

B-group	B-group	Diuretic	no
I-group	I-group	agents	yes
O	O	reduce	no
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	These	no
O	O	cells	yes
O	O	express	no
O	O	the	no
B-group	O	vitamin	yes
I-group	O	D	yes
O	O	receptor	yes
O	O	and	yes
O	O	exhibit	no
O	O	doubling	no
O	O	times	no
O	O	comparable	no
O	O	to	no
O	O	the	no
O	O	parental	no
O	O	MCF-7	no
O	O	cells	yes
O	O	,	no
O	O	even	no
O	O	when	no
O	O	grown	no
O	O	in	yes
O	O	100	yes
O	O	mM	yes
B-drug	B-drug	1,25	no
I-drug	I-drug	(	no
I-drug	I-drug	OH	no
I-drug	I-drug	)	no
I-drug	I-drug	2D3	no
O	O	.	no

O	O	Some	no
O	O	reports	no
O	O	have	no
O	O	shown	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	thiazides	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	causes	no
O	O	hypercalcemia	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	uricosuric	no
I-group	I-group	agents	yes
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	excretion	no
O	O	of	yes
B-drug	O	oxypurines	no
O	O	(	no
B-drug	O	hypoxanthine	yes
O	O	and	yes
B-drug	O	xanthine	yes
O	O	)	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	urinary	yes
O	O	uric	yes
O	O	acid	yes
O	O	excretion	no
O	O	compared	no
O	O	with	yes
O	O	that	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	allopurinol	yes
O	O	alone	no
O	O	.	no

B-brand	B-brand	TAMBOCOR	yes
O	O	has	no
O	O	been	no
O	O	used	no
O	O	in	yes
O	O	a	yes
O	O	large	no
O	O	number	no
O	O	of	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	diuretics	no
O	O	without	no
O	O	apparent	no
O	O	interaction	no
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Inhibit	no
O	O	Aldehyde	yes
O	O	Oxidase	yes
O	O	The	no
O	O	aldehyde	yes
O	O	oxidase	yes
O	O	enzyme	no
O	O	system	yes
O	O	is	yes
O	O	less	no
O	O	well	no
O	O	studied	no
O	O	than	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	eight	no
O	O	healthy	no
O	O	volunteers	no
O	O	has	no
O	O	shown	no
O	O	a	yes
O	O	50	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	peak	no
B-drug	B-drug	nimodipine	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	a	yes
O	O	90	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	curve	no
O	O	,	no
O	O	after	no
O	O	a	yes
O	O	one	no
O	O	week	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	at	yes
O	O	1,000	yes
O	O	mg/day	no
O	O	and	yes
B-drug	B-drug	nimodipine	yes
O	O	at	yes
O	O	90	yes
O	O	mg/day	no
O	O	.	no

O	O	We	no
O	O	have	no
O	O	selected	no
O	O	a	yes
O	O	subclone	no
O	O	of	yes
O	O	MCF-7	no
O	O	cells	yes
O	O	resistant	no
O	O	to	no
B-drug	B-drug	1,25	no
I-drug	I-drug	(	no
I-drug	I-drug	OH	no
I-drug	I-drug	)	no
I-drug	I-drug	2D3	no
O	O	(	no
O	O	MCF-7D3Res	no
O	O	)	no
O	O	.	no

O	O	Antagonism	no
O	O	between	yes
B-drug	B-drug	lincomycin	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	in	yes
O	O	vitro	no
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	.	no

O	O	The	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	histidine	yes
O	O	residues	no
O	O	may	no
O	O	be	no
O	O	crucial	no
O	O	to	no
O	O	the	no
O	O	receptor-binding	no
O	O	activity	yes
O	O	of	yes
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	.	no

O	O	The	no
O	O	following	no
O	O	precautions	no
O	O	should	no
O	O	be	no
O	O	kept	no
O	O	in	yes
O	O	mind	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	anticholinesterase	no
O	O	poisoning	no
O	O	although	no
O	O	they	no
O	O	do	no
O	O	not	no
O	O	bear	no
O	O	directly	no
O	O	on	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	atropine	yes
O	O	and	yes
B-drug	B-drug	pralidoxime	yes
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	None	no
O	O	known	no
O	O	.	no

O	O	Other	no
O	O	Chemotherapy	no
O	O	Agents	yes
O	O	In	yes
O	O	a	yes
O	O	separate	no
O	O	study	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lapatinib	yes
O	O	with	yes
B-drug	B-drug	capecitabine	yes
O	O	did	no
O	O	not	no
O	O	meaningfully	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	(	no
O	O	or	no
O	O	the	no
O	O	metabolites	no
O	O	of	yes
B-drug	B-drug	capecitabine	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Labetalol	yes
I-drug	I-drug	HCl	yes
O	O	blunts	no
O	O	the	no
O	O	reflex	no
O	O	tachycardia	no
O	O	produced	no
O	O	by	no
B-drug	B-drug	nitroglycerin	yes
O	O	without	no
O	O	preventing	no
O	O	its	no
O	O	hypotensive	no
O	O	effect	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	advisable	no
O	O	to	no
O	O	check	no
O	O	coagulation	yes
O	O	time	no
O	O	within	no
O	O	the	no
O	O	first	no
O	O	few	no
O	O	days	no
O	O	after	no
O	O	the	no
O	O	start	no
O	O	and	yes
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	therapy	no
O	O	,	no
O	O	with	yes
O	O	an	no
O	O	appropriate	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	dose	no
O	O	,	no
O	O	if	no
O	O	necessary	no
O	O	.	no

O	O	This	no
O	O	is	yes
O	O	especially	no
O	O	important	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	may	no
O	O	use	no
B-drug	B-drug	alcohol	yes
O	O	excessively	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	likely	no
O	O	that	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	epirubicin	yes
O	O	with	yes
O	O	radiotherapy	no
O	O	may	no
O	O	sensitize	no
O	O	tissues	no
O	O	to	no
O	O	the	no
O	O	cytotoxic	yes
O	O	actions	no
O	O	of	yes
O	O	irradiation	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	overdose	no
O	O	recognized	no
O	O	by	no
O	O	a	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	assay	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	vasopressors	no
O	O	,	no
B-group	O	vasoconstricting	no
I-group	O	agents	yes
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ergonovine	yes
O	O	)	no
O	O	and	yes
O	O	some	no
B-group	B-group	oxytocic	no
I-group	I-group	drugs	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	severe	no
O	O	hypertension	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	with	yes
O	O	general	no
B-group	B-group	anesthetics	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	arrhythmias	no
O	O	.	no

B-group	B-group	Thrombolytic	no
I-group	I-group	agents	yes
O	O	:	no
O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	effectiveness	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	with	yes
B-group	B-group	thrombolytic	no
I-group	I-group	agents	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

B-group	B-group	Non-steroidal	no
I-group	I-group	Anti-inflammatory	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	compromised	no
O	O	renal	no
O	O	function	no
O	O	who	no
O	O	are	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	enalapril	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	further	no
O	O	deterioration	no
O	O	of	yes
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	This	no
O	O	indicates	no
O	O	that	no
B-drug	B-drug	tiagabine	yes
O	O	does	no
O	O	not	no
O	O	cause	no
O	O	induction	no
O	O	or	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	hepatic	no
O	O	microsomal	no
O	O	enzyme	no
O	O	systems	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	antipyrine	yes
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	Co-administration	no
O	O	with	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	[	no
O	O	800	no
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	]	no
O	O	increased	no
O	O	the	no
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	rofecoxib	yes
O	O	by	no
O	O	21	yes
O	O	%	no
O	O	,	no
O	O	the	no
O	O	AUC0-120hr	no
O	O	by	no
O	O	23	no
O	O	%	no
O	O	and	yes
O	O	the	no
O	O	t1/2	no
O	O	by	no
O	O	15	yes
O	O	%	no
O	O	.	no

O	O	Other	no
O	O	drug	yes
O	O	interactions	no
B-drug	B-drug	Cimetidine	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	dextropropoxyphene	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug_n	B-drug_n	MHD	no
O	O	.	no

O	O	Standard	yes
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	methotrexate-related	no
O	O	toxicity	no
O	O	should	no
O	O	be	no
O	O	continued	no
O	O	if	no
B-brand	B-brand	VIOXX	yes
O	O	and	yes
B-drug	B-drug	methotrexate	yes
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Risk	no
O	O	of	yes
O	O	Anaphylactic	no
O	O	Reaction	no
O	O	While	no
O	O	taking	no
B-group	B-group	beta-blockers	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	severe	no
O	O	anaphylactic	no
O	O	reaction	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	reactive	yes
O	O	to	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	either	no
O	O	accidental	no
O	O	,	no
O	O	diagnostic	yes
O	O	,	no
O	O	or	no
O	O	therapeutic	no
O	O	.	no

O	O	In	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	finasteride	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	response	no
O	O	of	yes
B-drug	O	LH	yes
O	O	and	yes
O	O	FSH	yes
O	O	to	no
O	O	gonadotropin-releasing	yes
O	O	hormone	yes
O	O	indicating	no
O	O	that	no
O	O	the	no
O	O	hypothalamic-pituitary-testicular	no
O	O	axis	no
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	.	no

B-drug	I-drug	Rifabutin	yes

O	O	The	no
O	O	prior	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	does	no
O	O	not	no
O	O	enhance	no
O	O	the	no
O	O	duration	no
O	O	,	no
O	O	but	no
O	O	quickens	no
O	O	the	no
O	O	onset	no
O	O	and	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	depth	no
O	O	,	no
O	O	of	yes
O	O	neuromuscular	no
O	O	block	yes
O	O	induced	no
O	O	by	no
B-brand	B-brand	TRACRIUM	yes
O	O	.	no

B-drug	B-drug	ranitidine*	no
O	O	;	no

O	O	The	no
O	O	appropriate	no
O	O	interval	no
O	O	between	yes
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	dexfenfluramine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	The	no
O	O	half-life	no
O	O	increased	no
O	O	from	no
O	O	4.0	no
O	O	to	no
O	O	4.8	no
O	O	hours	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	zaleplon	yes
O	O	and	yes
B-drug	B-drug	diphenhydramine	yes
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	and	yes
O	O	50	yes
O	O	mg	yes
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	of	yes
O	O	each	no
O	O	drug	yes
O	O	.	no

B-drug	I-drug	saquinavir	yes
O	O	concentration	no

O	O	The	no
O	O	adverse	no
O	O	experience	no
O	O	profile	no
O	O	seen	no
O	O	with	yes
B-brand	B-brand	KEMSTROTM	no
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	seen	no
O	O	with	yes
B-drug	B-drug	baclofen	yes
O	O	tablets	yes
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	are	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	that	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	,	no
O	O	or	no
O	O	are	no
O	O	expected	no
O	O	,	no
O	O	to	no
O	O	increase	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-brand	B-brand	EQUETROTM	no
O	O	are	no
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	Acetazolamide	yes
O	O	,	no
B-group	B-group	azole	no
I-group	I-group	antifungals	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	dalfopristin	yes
O	O	,	no
B-drug	B-drug	danazol	yes
O	O	,	no
B-drug	B-drug	delavirdine	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	grapefruit	no
O	O	juice	no
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	loratadine	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	niacinamide	yes
O	O	,	no
B-drug	B-drug	nicotinamide	yes
O	O	,	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	propoxyphene	yes
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	quinupristin	yes
O	O	,	no
B-drug	B-drug	troleandomycin	yes
O	O	,	no
B-drug	B-drug	valproate	yes
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	,	no
B-drug	B-drug	zileuton	yes
O	O	.	no

O	O	In	yes
O	O	three	no
O	O	separate	no
O	O	controlled	no
O	O	,	no
O	O	parallel	no
O	O	group	yes
O	O	clinical	no
O	O	pharmacology	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	desloratadine	yes
O	O	at	yes
O	O	the	no
O	O	clinical	no
O	O	dose	no
O	O	of	yes
O	O	5	yes
O	O	mg	yes
O	O	has	no
O	O	been	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	500	yes
O	O	mg	yes
O	O	followed	no
O	O	by	no
O	O	250	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	4	yes
O	O	days	no
O	O	(	no
O	O	n=18	no
O	O	)	no
O	O	or	no
O	O	with	yes
B-drug	B-drug	fluoxetine	yes
O	O	20	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	after	no
O	O	a	yes
O	O	23	no
O	O	day	no
O	O	pretreatment	no
O	O	period	no
O	O	with	yes
B-drug	B-drug	fluoxetine	yes
O	O	(	no
O	O	n=18	no
O	O	)	no
O	O	or	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	600	yes
O	O	mg	yes
O	O	every	no
O	O	12	yes
O	O	hours	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	(	no
O	O	n=18	no
O	O	)	no
O	O	under	no
O	O	steady	no
O	O	state	no
O	O	conditions	no
O	O	to	no
O	O	normal	yes
O	O	healthy	no
O	O	male	no
O	O	and	yes
O	O	female	no
O	O	volunteers	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-group	B-group	sympathomimetics	no
O	O	increases	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

B-drug	B-drug	Olanzapine	yes
O	O	is	yes
O	O	associated	no
O	O	with	yes
O	O	significantly	no
O	O	fewer	no
O	O	extrapyramidal	no
O	O	symptoms	no
O	O	than	no
B-drug	B-drug	haloperidol	yes
O	O	and	yes
B-drug	B-drug	risperidone	yes
O	O	.	no

B-drug	B-drug	lithium	yes
O	O	;	no

O	O	Drugs	no
O	O	which	no
O	O	impair	no
O	O	glomerular	no
O	O	filtration	no
O	O	may	no
O	O	prolong	no
O	O	the	no
O	O	biological	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	flucytosine	yes
O	O	.	no

B-drug	B-drug	Meperidine	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	potentiate	no
O	O	the	no
O	O	analgesic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	meperidine	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Dantrolene	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Dantrium	yes
O	O	)	no
O	O	or	no

O	O	Drug-Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	reported	no
O	O	drug-laboratory	no
O	O	test	yes
O	O	interactions	no
O	O	.	no

B-brand	B-brand	Lodine	yes
O	O	treatment	no
O	O	is	yes
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	small	no
O	O	decrease	no
O	O	in	yes
O	O	serum	yes
O	O	uric	yes
O	O	acid	yes
O	O	levels	no
O	O	.	no

O	O	Immediate	no
O	O	and	yes
O	O	Extended	yes
O	O	Release	yes
O	O	Tablets	yes
O	O	The	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-group	B-group	sulfonylureas	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	certain	no
O	O	drugs	no
O	O	including	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	,	no
O	O	some	no
O	B-group	azoles	no
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
B-drug	B-drug	chloramphenicol	yes
O	O	,	no
B-drug	B-drug	probenecid	yes
O	O	,	no
B-group	B-group	coumarins	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	CYP3A4	no
O	O	inducers	no
O	O	:	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	levels/effects	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	.	no

B-drug	I-drug	Aprepitant	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	as	yes
O	O	a	yes
O	O	regimen	no
O	O	of	yes
O	O	125	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	80	yes
O	O	mg/day	no
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	and	yes
O	O	3	yes
O	O	,	no
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	methylprednisolone	yes
O	O	,	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	,	no
O	O	by	no
O	O	1.34-fold	no
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	by	no
O	O	2.5-fold	no
O	O	on	no
O	O	Day	no
O	O	3	yes
O	O	,	no
O	O	when	no
B-drug	B-drug	methylprednisolone	yes
O	O	was	no
O	O	coadministered	no
O	O	intravenously	no
O	O	as	yes
O	O	125	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	orally	no
O	O	as	yes
O	O	40	yes
O	O	mg	yes
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	and	yes
O	O	3	yes
O	O	.	no

O	O	Catecholamine-depleting	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	)	no
O	O	:	no
O	O	additive	no
O	O	effect	no
O	O	;	no

B-drug	B-drug	Doxazosin	yes
I-drug	I-drug	mesylate	yes
O	O	tablets	yes
O	O	have	no
O	O	been	no
O	O	used	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	or	no
O	O	drug	yes
O	O	classes	no
O	O	:	no
O	O	1	yes
O	O	.	no

O	O	Because	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	theoretical	no
O	O	basis	no
O	O	that	no
O	O	these	no
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	additive	no
O	O	,	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ergotamine-containing	no
O	O	or	no
B-group	B-group	ergot-type	no
I-group	I-group	medications	no
O	O	(	no
O	O	like	yes
B-drug	B-drug	dihydroergotamine	yes
O	O	or	no
B-drug	B-drug	methysergide	yes
O	O	)	no
O	O	and	yes
B-brand	B-brand	AXERT	yes
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
O	O	each	no
O	O	other	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	Miracidia	no
O	O	demonstrated	no
O	O	a	yes
O	O	rapid	no
O	O	avoidance	no
O	O	behaviour	no
O	O	when	no
O	O	briefly	no
O	O	exposed	no
O	O	to	no
O	O	heavy	yes
O	O	metals	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes
O	O	:	no
O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
O	O	the	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	at	yes
O	O	100	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	and	yes
O	O	200	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	17	yes
O	O	days	no
O	O	,	no
O	O	systemic	no
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	to	no
B-drug	B-drug	lapatinib	yes
O	O	was	no
O	O	decreased	no
O	O	approximately	no
O	O	72	no
O	O	%	no
O	O	.	no

O	O	The	no
O	O	aim	yes
O	O	of	yes
O	O	this	no
O	O	paper	no
O	O	was	no
O	O	to	no
O	O	study	no
O	O	the	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug_n	neurotensin	no
O	O	and	yes
O	O	both	no
B-group	B-drug_n	enkephalins	no
O	O	or	no
O	O	its	no
O	O	synthetic	yes
O	O	analogue	yes
B-drug	B-drug_n	D-Ala2-metenkephalinamide	no
O	O	,	no
O	O	or	no
B-drug_n	B-drug_n	tuftsin	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	antinonciceptive	no
O	O	effect	no
O	O	of	yes
O	O	these	no
O	O	peptides	yes
O	O	in	yes
O	O	mice	no
O	O	after	no
O	O	intracisternal	no
O	O	injection	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
O	O	this	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	.	no

O	O	The	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	within	no
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	ranges	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Treatment	no
O	O	of	yes
B-drug_n	B-drug_n	toxin	yes
I-drug_n	I-drug_n	A	yes
O	O	with	yes
O	O	[	no
O	O	(	no
O	O	14	yes
O	O	)	no
O	O	C	yes
O	O	]	no
O	B-drug_n	-diethyl	no
O	I-drug_n	pyrocarbonate	no
O	O	revealed	no
O	O	concentration	no
O	O	dependent	no
O	O	labelling	no
O	O	of	yes
O	O	histidine	yes
O	O	residues	no
O	O	on	no
O	O	the	no
O	O	toxin	yes
O	O	molecules	no
O	O	.	no

O	O	Cross-reactions	no
O	O	with	yes
O	O	non-Aspergillus	no
B-group	O	polysaccharides	no
O	O	and	yes
B-group	O	polyfuranoses	no
O	O	with	yes
O	O	the	no
O	O	Bio-Rad	no
O	O	Laboratories	no
O	O	Platelia	no
O	O	Aspergillus	no
O	O	EIA	no
O	O	test	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	A	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	copper	yes
O	O	reduction	yes
O	O	tests	no
O	O	(	no
O	O	Benedict	no
O	O	s	yes
O	O	or	no
O	O	Fehling	no
O	O	s	yes
O	O	solution	yes
O	O	or	no
O	O	with	yes
O	O	Clinitest	no
O	O	tablets	yes
O	O	)	no
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	enzyme-based	no
O	O	tests	no
O	O	for	yes
O	O	glycosuria	no
O	O	.	no

O	O	Grapefruit	no
O	O	juice	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	oral	yes
B-drug	O	amiodarone	yes
O	O	.	no

O	O	monitor	no
B-drug	B-drug	cyclosporine	yes
O	O	levels	no
O	O	.	no

O	O	Table	no
O	O	3	yes
O	O	Established	no
O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
O	O	Alteration	no
O	O	in	yes
O	O	Dose	no
O	O	or	no
O	O	Regimen	no
O	O	May	no
O	O	Be	no
O	O	Recommended	no
O	O	Based	no
O	O	on	no
O	O	Drug	yes
O	O	Interaction	no
O	O	Studies	no

B-drug	B-drug	Anagrelide	yes
O	O	is	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cyclic	yes
O	O	AMP	yes
O	O	PDE	no
O	O	III	yes
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	nicardipine	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	levels	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	myopathy	no
O	O	and	yes
O	O	rhabdomyolysis	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	insufficiency	no
O	O	or	no
O	O	those	no
O	O	who	no
O	O	are	no
O	O	concurrently	no
O	O	taking	no
O	O	medications	no
O	O	associated	no
O	O	with	yes
O	O	myopathy	no
O	O	.	no

B-brand	B-brand	FLUOTHANE	yes
O	O	augments	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	non-depolarising	no
I-group	I-group	muscle	no
I-group	O	relaxants	no
O	O	and	yes
O	O	the	no
O	O	muscle	no
O	O	relaxant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	aminoglycosides	no
O	O	.	no

O	O	Twelve	no
O	O	strains	no
O	O	of	yes
O	O	Staphylococcus	no
O	O	aureus	no
O	O	(	no
O	O	a	yes
O	O	frequent	no
O	O	cause	no
O	O	of	yes
O	O	infection	no
O	O	in	yes
B-drug_n	B-drug_n	heroin	yes
O	O	,	no
O	O	but	no
O	O	not	no
O	O	in	yes
B-drug	B-drug	pentazocine	yes
O	O	and	yes
B-drug	B-drug	tripelennamine	yes
O	O	,	no
O	O	addicts	no
O	O	)	no
O	O	were	no
O	O	completely	no
O	O	inhibited	no
O	O	by	no
O	O	the	no
O	O	drug	yes
O	O	combination	yes
O	O	.	no

O	O	Recovery	no
O	O	programs	no
O	O	should	no
O	O	be	no
O	O	flexible	no
O	O	and	yes
O	O	involve	no
O	O	individual	no
O	O	and	yes
O	O	family	yes
O	O	education	no
O	O	on	no
O	O	recovery	no
O	O	and	yes
O	O	the	no
O	O	nature	no
O	O	of	yes
O	O	addictive	no
O	O	disease	no
O	O	.	no

O	O	-	yes
B-group	B-group	Skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
O	O	nondepolarizing	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	tubocurarine	yes
O	O	)	no
O	O	:	no
O	O	Possible	no
O	O	increased	no
O	O	responsiveness	no
O	O	to	no
O	O	the	no
B-group	B-group	muscle	no
I-group	I-group	relaxant	no

O	O	Continued	no
O	O	admistration	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	is	yes
O	O	required	no
O	O	to	no
O	O	maintain	no
O	O	barpress	no
O	O	response	no
O	O	in	yes
O	O	this	no
O	O	strain	no
O	O	of	yes
O	O	dogs	no
O	O	.	no

O	O	A	yes
O	O	dose	no
O	O	increase	no
O	O	of	yes
B-drug	B-drug	lopinavir/ritonavir	no
O	O	to	no
O	O	533/133	no
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	with	yes
O	O	food	no
O	O	isrecommended	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	either	no
O	O	inhibitors	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	.	no

O	O	Permanent	no
O	O	nerve	yes
O	O	damage	no
O	O	could	no
O	O	theoretically	no
O	O	occur	no
O	O	if	no
O	O	vitamin	yes
O	O	B12	yes
O	O	deficiency	no
O	O	is	yes
O	O	not	no
O	O	treated	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Carbamazepine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Tegretol	yes
O	O	)	no
O	O	or	no

B-drug	B-drug	Anagrelide	yes
O	O	is	yes
O	O	metabolized	no
O	O	at	yes
O	O	least	no
O	O	in	yes
O	O	part	no
O	O	by	no
O	O	CYP1A2	no
O	O	.	no

O	O	If	no
O	O	the	no
O	O	usual	no
O	O	amounts	no
O	O	of	yes
B-group	O	nondepolarizing	no
I-group	O	relaxants	no
O	O	are	no
O	O	given	no
O	O	,	no
O	O	the	no
O	O	time	no
O	O	for	yes
O	O	recovery	no
O	O	from	no
O	O	neuromuscular	no
O	O	blockade	no
O	O	will	no
O	O	be	no
O	O	longer	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	Enflurane	yes
O	O	than	no
O	O	when	no
B-drug	B-drug	halothane	yes
O	O	or	no
B-drug	B-drug	nitrous	yes
I-drug	I-drug	oxide	yes
O	O	with	yes
O	O	a	yes
O	O	balanced	yes
O	O	technique	no
O	O	are	no
O	O	used	no
O	O	.	no

O	O	Although	no
O	O	not	no
O	O	studied	no
O	O	systematically	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	no	yes
O	O	drug	yes
O	O	interactions	no
O	O	were	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	vecuronium	yes
O	O	,	no
B-drug	B-drug	pancuronium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	atracurium	yes
O	O	were	no
O	O	administered	no
O	O	following	no
O	O	varying	no
O	O	degrees	no
O	O	of	yes
O	O	recovery	no
O	O	from	no
O	O	single	yes
O	O	doses	no
O	O	or	no
O	O	infusions	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	.	no

O	O	Free	yes
O	O	T3	yes
O	O	resin	yes
O	O	uptake	no
O	O	is	yes
O	O	decreased	no
O	O	,	no
O	O	reflecting	no
O	O	the	no
O	O	elevated	no
O	O	TBG	no
O	O	;	no

O	O	In	yes
O	O	both	no
O	O	periods	no
O	O	,	no
O	O	blood	yes
O	O	and	yes
O	O	urine	no
O	O	were	no
O	O	sampled	no
O	O	at	yes
O	O	regular	yes
O	O	intervals	no
O	O	.	no

O	O	Interest	no
O	O	in	yes
O	O	administering	no
O	O	compounds	no
O	O	in	yes
O	O	combination	yes
O	O	lies	no
O	O	both	no
O	O	in	yes
O	O	enhancing	no
O	O	efficacious	no
O	O	effects	no
O	O	and	yes
O	O	in	yes
O	O	limiting	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
O	O	addictive	no
O	O	medications	no
O	O	,	no
O	O	especially	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	(	no
I-group	I-group	CNS	no
I-group	I-group	)	no
I-group	I-group	depressants	no
O	O	with	yes
O	O	habituating	no
O	O	potential	no
O	O	(	no
O	O	prolonged	no
O	O	concurrent	no
O	O	use	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	habituation	no
O	O	)	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	CNS	no
O	O	depression	no
O	O	producing	no
O	O	medications	no
O	O	(	no
O	O	concurrent	no
O	O	use	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	of	yes
O	O	either	no
O	O	these	no
O	O	medications	no
O	O	or	no
B-drug	B-drug	ethinamate	yes
O	O	)	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	significant	no
O	O	differences	no
O	O	among	no
O	O	the	no
O	O	pD2	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	noradrenaline	yes
O	O	in	yes
O	O	aortic	no
O	O	rings	no
O	O	without	no
O	O	endothelium	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	troleandomycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	Additional	no
O	O	animals	no
O	O	in	yes
O	O	both	no
O	O	dose	no
O	O	groups	no
O	O	developed	no
O	O	B-cell	no
O	O	hyperplasia	no
O	O	of	yes
O	O	the	no
O	O	spleen	no
O	O	and	yes
O	O	lymph	no
O	O	nodes	no
O	O	.	no

O	O	When	no
O	O	the	no
O	O	CYP2D6	no
O	O	inhibitor	yes
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	the	no
O	O	combination	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	then	no
O	O	be	no
O	O	increased	no
O	O	.	no

O	O	(	no
B-drug	B-drug	Indomethacin	yes
O	O	)	no
B-group	B-group	diuretics	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

O	O	Preliminary	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	dobutamine	yes
O	O	and	yes
B-drug	B-drug	nitroprusside	yes
O	O	results	no
O	O	in	yes
O	O	a	yes
O	O	higher	no
O	O	cardiac	no
O	O	output	no
O	O	and	yes
O	O	,	no
O	O	usually	no
O	O	,	no
O	O	a	yes
O	O	lower	no
O	O	pulmonary	no
O	O	wedge	no
O	O	pressure	no
O	O	than	no
O	O	when	no
O	O	either	no
O	O	drug	yes
O	O	is	yes
O	O	used	no
O	O	alone	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	use	no
O	O	the	no
O	O	pharmacological	no
O	O	properties	no
O	O	of	yes
O	O	induced	no
O	O	therapeutic	no
O	O	hypermagnesaemia	no
O	O	,	no
O	O	high	yes
O	O	oral	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	magnesium	yes
O	O	(	no
O	O	>	no
O	O	10	yes
O	O	mg/kg/day	no
O	O	)	no
O	O	are	no
O	O	advisable	no
O	O	for	yes
O	O	chronic	no
O	O	indications	no
O	O	and	yes
O	O	the	no
O	O	parenteral	no
O	O	route	no
O	O	is	yes
O	O	suitable	no
O	O	for	yes
O	O	acute	no
O	O	indications	no
O	O	.	no

B-drug	B-drug	insulin	yes
O	O	requirements	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	,	no
O	O	decreased	no
O	O	,	no
O	O	or	no
O	O	unchanged	no
O	O	.	no
O	O	)	no

O	O	The	no
O	O	CYP3A4	no
O	O	isoenzyme	no
O	O	is	yes
O	O	present	no
O	O	in	yes
O	O	both	no
O	O	the	no
O	O	liver	yes
O	O	and	yes
O	O	intestines	no
O	O	.	no

O	O	No	yes
O	O	information	no
O	O	available	no

B-brand	B-brand	DIDREX	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	stimulants	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	as	yes
O	O	with	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Lodine	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	not	no
O	O	generally	no
O	O	recommended	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	of	yes
O	O	increased	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-drug	B-drug	hydroflumethiazide	yes
O	O	and	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no
O	O	.	no
O	O	)	no

O	O	In	yes
O	O	such	no
O	O	cases	no
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	more	no
O	O	frequent	no
O	O	dosing	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	to	no
O	O	achieve	no
O	O	or	no
O	O	maintain	no
O	O	the	no
O	O	desired	no
O	O	hypotensive	no
O	O	response	no
O	O	.	no

B-drug	B-drug	Gabapentin	yes
O	O	is	yes
O	O	not	no
O	O	appreciably	no
O	O	metabolized	no
O	O	nor	yes
O	O	does	no
O	O	it	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	commonly	no
O	O	coadministered	no
B-group	B-group	antiepileptic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	Inhibit	no
O	O	or	no
O	O	Induce	no
O	O	Cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	Enzymes	yes
B-drug	B-drug	Lapatinib	yes
O	O	undergoes	no
O	O	extensive	no
O	O	metabolism	no
O	O	by	no
O	O	CYP3A4	no
O	O	,	no
O	O	and	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	strong	no
O	O	inhibitors	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	alter	no
B-drug	B-drug	lapatinib	yes
O	O	concentrations	no
O	O	significantly	no
O	O	.	no

O	O	When	no
O	O	initiating	no
O	O	a	yes
O	O	multi-day	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	maintained	no
O	O	on	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	the	no
B-drug	B-drug	theophylline	yes
O	O	maintenance	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	halved	no
O	O	for	yes
O	O	the	no
O	O	period	no
O	O	of	yes
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	and	yes
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	initiated	no
O	O	as	yes
O	O	a	yes
O	O	guide	no
O	O	to	no
O	O	further	no
O	O	dosage	no
O	O	adjustments	no
O	O	.	no

B-brand	B-brand	ZEBETA	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	care	yes
O	O	when	no
B-group	B-group	myocardial	no
I-group	I-group	depressants	no
O	O	or	no
O	O	inhibitors	no
O	O	of	yes
O	O	AV	no
O	O	conduction	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	certain	no
B-group	B-group	calcium	yes
I-group	I-group	antagonists	no
O	O	(	no
O	O	particularly	no
O	O	of	yes
O	O	the	no
B-drug	B-group	phenylalkylamine	no
O	O	[	no
B-drug	B-drug	verapamil	yes
O	O	]	no
O	O	and	yes
B-drug	B-group	benzothiazepine	no
O	O	[	no
B-drug	B-drug	diltiazem	yes
O	O	]	no
O	O	classes	no
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-group	antiarrhythmic	no
I-drug	I-group	agents	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	disopyramide	yes
O	O	,	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	.	no

O	O	Elevated	no
B-drug	B-drug	cyclosporine	yes
O	O	serum	yes
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	.	no

B-group	B-group	Cytotoxic	yes
I-group	I-group	Agents	yes
O	O	:	no
O	O	Enhanced	no
O	O	bone	no
O	O	marrow	no
O	O	suppression	no
O	O	by	no
B-drug	B-drug	cyclophosphamide	yes
O	O	and	yes
O	O	other	no
B-group	B-group	cytotoxic	yes
I-group	I-group	agents	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	among	no
O	O	patients	no
O	O	with	yes
O	O	neoplastic	no
O	O	disease	no
O	O	,	no
O	O	except	no
O	O	leukemia	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	.	no

O	O	100-150	no

O	O	Once	no
O	O	a	yes
O	O	stable	no
O	O	prothrombin	yes
O	O	time	no
O	O	has	no
O	O	been	no
O	O	documented	no
O	O	,	no
O	O	prothrombin	yes
O	O	times	no
O	O	can	no
O	O	be	no
O	O	monitored	no
O	O	at	yes
O	O	the	no
O	O	intervals	no
O	O	usually	no
O	O	recommended	no
O	O	for	yes
O	O	patients	no
O	O	on	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	if	no
B-drug	B-drug	enalapril	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	-	yes
B-group	B-group	Non-steroidal	no
I-group	I-group	Anti-inflammatory	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agent	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	O	diuretic	no
O	O	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
O	O	potassium-sparing	no
O	O	and	yes
B-group	B-drug	thiazide	no
I-group	I-drug	diuretics	no
O	O	.	no

O	O	The	no
O	O	reluctance	no
O	O	to	no
O	O	treat	no
O	O	aggressively	no
O	O	is	yes
O	O	understandable	no
O	O	because	no
O	O	the	no
O	O	geriatric	no
O	O	population	no
O	O	is	yes
O	O	susceptible	no
O	O	to	no
O	O	adverse	no
O	O	drug	yes
O	O	reactions	no
O	O	.	no

O	B-drug_n	Leukocyte	no
O	I-drug_n	transfusions	no
O	O	:	no
O	O	acute	no
O	O	pulmonary	no
O	O	toxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	intravenous	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	and	yes
O	B-drug_n	leukocyte	no
O	I-drug_n	transfusions	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	on	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	is	yes
O	O	variable	no
O	O	.	no

O	O	The	no
O	O	levorotatory	no
O	O	isomer	no
O	O	had	no
B-group	O	opioid-antagonist	no
O	O	and	yes
O	O	non-opioid	no
O	O	agonist	no
O	O	effects	no
O	O	in	yes
O	O	pigeons	no
O	O	and	yes
O	O	mixed	yes
O	O	opioid	no
O	O	agonist-antagonist	no
O	O	effects	no
O	O	in	yes
O	O	monkeys	no
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	is	yes
O	O	a	yes
O	O	consequence	no
O	O	of	yes
O	O	blocking	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	vardenafil	yes
O	O	by	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
O	O	a	yes
O	O	highly	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	,	no
O	O	which	no
O	O	also	no
O	O	inhibits	no
O	O	CYP2C9	no
O	O	.	no

O	O	Samples	no
O	O	for	yes
O	O	plasma	yes
O	O	and	yes
O	O	urine	no
O	O	immunoreactive	no
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	were	no
O	O	collected	no
O	O	through	no
O	O	120	no
O	O	hours	no
O	O	following	no
O	O	the	no
B-drug	B-drug	digoxin	yes
O	O	dose	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	irbesartan	yes
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	nifedipine	yes
O	O	or	no
B-drug	B-drug	hydrochlorothiazide	yes

B-drug	B-drug	griseofulvin	yes
O	O	;	no

B-drug	B-drug	Praziquantel	yes
O	O	:	no
O	O	In	yes
O	O	the	no
O	O	fed	no
O	O	state	no
O	O	,	no
B-drug	B-drug	praziquantel	yes
O	O	(	no
O	O	40	yes
O	O	mg/kg	no
O	O	)	no
O	O	increased	no
O	O	mean	no
O	O	maximum	no
O	O	plasma	yes
O	O	concentration	no
O	O	and	yes
O	O	area	no
O	O	under	no
O	O	the	no
O	O	curve	no
O	O	of	yes
B-drug	B-drug	albendazole	yes
I-drug	I-drug	sulfoxide	yes
O	O	by	no
O	O	about	no
O	O	50	yes
O	O	%	no
O	O	in	yes
O	O	healthy	no
O	O	subjects	no
O	O	(	no
O	O	n=10	no
O	O	)	no
O	O	compared	no
O	O	with	yes
O	O	a	yes
O	O	separate	no
O	O	group	yes
O	O	of	yes
O	O	subjects	no
O	O	(	no
O	O	n=6	no
O	O	)	no
O	O	given	no
B-drug	B-drug	albendazole	yes
O	O	alone	no
O	O	.	no

O	O	Such	no
O	O	individuals	no
O	O	are	no
O	O	referred	no
O	O	to	no
O	O	as	yes
O	O	poor	no
O	O	metabolizers	no
O	O	of	yes
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	debrisoquin	yes
O	O	,	no
B-drug	B-drug	dextromethorphan	yes
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	tests	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	.	no

O	O	-	yes
B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	Interaction	no
O	O	studies	no
O	O	in	yes
O	O	humans	no
O	O	have	no
O	O	shown	no
B-drug	B-drug	bumetanide	yes
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	warfarin	yes
O	O	metabolism	no
O	O	or	no
O	O	on	no
O	O	plasma	yes
O	O	prothrombin	yes
O	O	activity	yes
O	O	.	no

O	O	Both	no
O	O	studies	no
O	O	used	no
O	O	12	yes
O	O	subjects	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-group	B-group	Nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	steadystate	no
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	.	no

O	O	After	no
B-drug	B-drug	etofibrate	yes
O	O	treatment	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	decrease	no
O	O	of	yes
O	O	total	yes
B-drug	O	cholesterol	yes
O	O	and	yes
B-drug	O	triglyceride	yes
O	O	plasma	yes
O	O	levels	no
O	O	and	yes
O	O	a	yes
O	O	trend	no
O	O	to	no
O	O	increase	no
O	O	high-density	no
O	O	lipoprotein	yes
O	O	cholesterol	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	nc1,2	no
O	O	30	yes
O	O	%	no
O	O	decrease	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	3	yes
O	O	%	no
O	O	decrease	no
O	O	,	no
O	O	48	yes
O	O	%	no
O	O	decrease	no
O	O	]	no

O	O	Patients	no
O	O	receiving	no
B-group	B-group	hydantoins	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
O	O	or	no
B-group	B-group	sulfonylureas	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	for	yes
O	O	increased	no
O	O	activity	yes
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	and	yes
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	signs	no
O	O	of	yes
O	O	toxicity	no
O	O	from	no
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	drug	yes
O	O	metabolism	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-brand	B-brand	Starlix	yes
O	O	is	yes
O	O	predominantly	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isozyme	no
O	O	CYP2C9	no
O	O	(	no
O	O	70	yes
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	to	no
O	O	a	yes
O	O	lesser	no
O	O	extent	no
O	O	CYP3A4	no
O	O	(	no
O	O	30	yes
O	O	%	no
O	O	)	no
O	O	.	no

B-drug	B-drug	zaleplon	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	.	no

B-drug	B-drug	Dofetilide	yes
O	O	is	yes
O	O	not	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	nor	yes
O	O	of	yes
O	O	other	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzymes	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2D6	no
O	O	)	no
O	O	and	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	levels	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

O	O	Reductions	no
O	O	in	yes
O	O	serum	yes
O	O	endogenous	no
O	O	vitamin	yes
O	O	D	yes
O	O	concentrations	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	300	yes
O	O	mg/day	no
O	O	to	no
O	O	1200	no
O	O	mg/day	no
B-drug	B-drug	ketoconazole	yes
O	O	for	yes
O	O	a	yes
O	O	week	no
O	O	to	no
O	O	healthy	no
O	O	men	no
O	O	.	no

B-drug_n	O	n-Octyl	no
O	O	and	yes
O	O	n-cetyl	no
B-drug	O	gallate	yes
O	O	also	no
O	O	showed	no
O	O	good	no
O	O	inhibition	no
O	O	,	no
O	O	while	no
B-drug	O	gallic	no
I-drug	O	acid	yes
O	O	itself	no
O	O	was	no
O	O	not	no
O	O	so	no
O	O	active	no
O	O	,	no
O	O	suggesting	no
O	O	that	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	hydrophobic	no
O	O	side	no
O	O	chain	yes
O	O	is	yes
O	O	important	no
O	O	for	yes
O	O	the	no
O	O	suppressive	no
O	O	effect	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	Itraconazole	yes
O	O	.	no

B-drug_n	B-drug_n	18-Methoxycoronaridine	no
O	O	(	no
B-drug_n	B-drug_n	18-MC	no
O	O	)	no
O	O	and	yes
B-drug_n	B-drug_n	ibogaine	no
O	O	:	no
O	O	comparison	no
O	O	of	yes
O	O	antiaddictive	no
O	O	efficacy	no
O	O	,	no
O	O	toxicity	no
O	O	,	no
O	O	and	yes
O	O	mechanisms	no
O	O	of	yes
O	O	action	no
O	O	.	no

O	O	Conjugation	no
O	O	at	yes
B-drug_n	B-drug_n	NaCMC	no
O	O	with	yes
B-drug	B-drug	cysteine	yes
O	O	moieties	no
O	O	significantly	no
O	O	improves	no
O	O	the	no
O	O	intestinal	no
O	O	permeation	no
O	O	of	yes
O	O	the	no
O	O	hydrophilic	no
O	O	molecule	yes
B-drug	B-drug	NaFlu	no
O	O	and	yes
O	O	the	no
O	O	model	no
O	O	peptide	yes
O	O	drugs	no
B-drug	B-drug	bacitracin	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	in	yes
O	O	vitro	no
O	O	,	no
O	O	therefore	no
O	O	this	no
O	O	conjugated	yes
O	O	system	yes
O	O	maybe	no
O	O	useful	no
O	O	for	yes
O	O	peroral	no
O	O	administration	no
O	O	of	yes
B-group	O	peptide	yes
I-group	O	drugs	no
O	O	in	yes
O	O	the	no
O	O	future	no
O	O	.	no

O	O	Reproductive	no
O	O	toxicology	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	in	yes
O	O	cynomolgus	no
O	O	monkeys	no
O	O	at	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	5	yes
O	O	mg/kg/week	no
O	O	(	no
O	O	about	no
O	O	62	no
O	O	times	no
O	O	the	no
O	O	human	yes
O	O	dose	no
O	O	based	no
O	O	on	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	and	yes
O	O	have	no
O	O	revealed	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	impaired	no
O	O	fertility	no
O	O	or	no
O	O	harm	no
O	O	to	no
O	O	the	no
O	O	fetus	no
O	O	due	no
O	O	to	no
B-brand	B-brand	AMEVIVE	no
O	O	.	no

O	O	Since	no
O	O	both	no
B-drug	B-drug	alcohol	yes
O	O	and	yes
O	O	organoleads	no
O	O	are	no
O	O	present	no
O	O	in	yes
O	O	the	no
O	O	environment	no
O	O	and	yes
O	O	seem	no
O	O	to	no
O	O	influence	no
O	O	limbic	no
O	O	integration	no
O	O	,	no
O	O	the	no
O	O	interaction	no
O	O	of	yes
O	O	these	no
O	O	two	no
O	O	compounds	no
O	O	was	no
O	O	assessed	no
O	O	in	yes
O	O	the	no
O	O	present	no
O	O	experiment	no
O	O	.	no

O	O	Interactions	no
O	O	between	yes
O	O	theraputic	no
O	O	agents	yes
O	O	have	no
O	O	been	no
O	O	recognized	no
O	O	as	yes
O	O	increasingly	no
O	O	important	no
O	O	causes	no
O	O	of	yes
O	O	drug	yes
O	O	at	yes
O	O	their	no
O	O	usual	no
O	O	recommended	no
O	O	dose	no
O	O	may	no
O	O	,	no
O	O	under	no
O	O	certain	no
O	O	conditions	no
O	O	,	no
O	O	produce	no
O	O	toxicity	no
O	O	of	yes
O	O	life-endangering	no
O	O	proportions	no
O	O	.	no

O	O	We	no
O	O	examined	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	exogenous	no
B-drug	B-drug	estradiol	yes
O	O	on	no
O	O	the	no
O	O	changes	no
O	O	in	yes
O	O	serum	yes
O	O	steroid	no
O	O	hormone	yes
O	O	levels	no
O	O	induced	no
O	O	by	no
O	O	a	yes
O	O	nonlethal	no
O	O	dose	no
O	O	of	yes
O	O	Escherichia	yes
O	O	coli	yes
O	B-drug_n	endotoxin	no
O	O	in	yes
O	O	male	no
O	O	rats	no
O	O	and	yes
O	O	the	no
O	O	deaths	no
O	O	due	no
O	O	to	no
O	O	nonlethal	no
O	O	and	yes
O	O	lethal	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug_n	endotoxin	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	such	no
O	O	agents	yes
O	O	.	no

B-drug	B-drug	Meperidine	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	potentiate	no
O	O	the	no
O	O	analgesic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	meperidine	yes
O	O	.	no

O	O	A	yes
O	O	direct	no
O	O	causal	no
O	O	relationship	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	,	no
O	O	but	no
O	O	physicians	no
O	O	should	no
O	O	consider	no
O	O	the	no
O	O	possibility	no
O	O	that	no
B-drug	B-drug	diclofenac	yes
O	O	may	no
O	O	alter	no
O	O	a	yes
O	O	diabetic	no
O	O	patient	no
O	O	s	yes
O	O	response	no
O	O	to	no
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Both	no
B-drug_n	B-drug_n	ibogaine	no
O	O	and	yes
B-drug_n	B-drug_n	18-MC	no
O	O	decrease	no
O	O	extracellular	no
O	O	levels	no
O	O	of	yes
B-drug	O	dopamine	yes
O	O	in	yes
O	O	the	no
O	O	nucleus	no
O	O	accumbens	no
O	O	,	no
O	O	but	no
O	O	only	no
B-drug_n	B-drug_n	ibogaine	no
O	O	increases	no
O	O	extracellular	no
O	O	levels	no
O	O	of	yes
O	O	serotonin	yes
O	O	in	yes
O	O	the	no
O	O	nucleus	no
O	O	accumbens	no
O	O	.	no

O	O	Before	no
O	O	prescribing	no
O	O	a	yes
O	O	symptomatic	no
O	O	(	no
O	O	pharmaceutical	no
O	O	)	no
O	O	treatment	no
O	O	for	yes
O	O	patients	no
O	O	with	yes
O	O	an	no
O	O	erection	no
O	O	disorder	no
O	O	,	no
O	O	attention	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	tot	no
O	O	the	no
O	O	sexological	no
O	O	,	no
O	O	psychological	no
O	O	and	yes
O	O	medical	yes
O	O	backgrounds	no
O	O	of	yes
O	O	the	no
O	O	disorder	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	36	no
O	O	patients	no
O	O	with	yes
O	O	mild	yes
O	O	to	no
O	O	moderate	no
O	O	hypertension	no
O	O	where	no
O	O	the	no
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-brand	B-brand	PRINIVIL	yes
O	O	alone	no
O	O	were	no
O	O	compared	no
O	O	to	no
B-brand	B-brand	PRINIVIL	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	indomethacin	yes
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	reduced	yes
O	O	antihypertensive	no
O	O	effect	no
O	O	,	no
O	O	although	no
O	O	the	no
O	O	difference	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	regimens	no
O	O	was	no
O	O	not	no
O	O	significant	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	study	no
O	O	we	no
O	O	investigated	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug_n	B-drug_n	ginsenosides	no
O	O	on	no
O	O	high	yes
O	O	threshold	no
O	O	voltage-dependent	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	channel	no
O	O	subtypes	no
O	O	using	no
O	O	their	no
O	B-group	selective	no
O	I-group	Ca	no
O	I-group	(	no
O	I-group	2+	no
O	I-group	)	no
O	I-group	channel	no
O	I-group	blockers	no
B-drug	B-drug	nimodipine	yes
O	O	(	no
O	O	L-type	no
O	O	)	no
O	O	,	no
B-drug_n	B-drug_n	omega-conotoxin	no
I-drug_n	I-drug_n	GVIA	no
O	O	(	no
O	O	N-type	no
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-drug_n	omega-agatoxin	no
O	I-drug_n	IVA	no
O	O	(	no
O	O	P-type	no
O	O	)	no
O	O	in	yes
O	O	bovine	yes
O	O	chromaffin	no
O	O	cells	yes
O	O	.	no

O	O	Dose	no
O	O	reduction	yes
O	O	or	no
O	O	interruption	no
O	O	of	yes
B-brand	B-brand	TARCEVA	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	if	no
O	O	changes	no
O	O	in	yes
O	O	liver	yes
O	O	function	no
O	O	are	no
O	O	severe	no
O	O	.	no

B-drug	B-drug	Trimethoprim	yes
O	O	Alone	no
O	O	or	no
O	O	in	yes
O	O	Combination	yes
O	O	with	yes
B-drug	B-drug	Sulfamethoxazole	yes
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	trimethoprim	yes
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	sulfamethoxazole	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	This	no
O	O	paper	no
O	O	critically	no
O	O	reviews	no
O	O	the	no
O	O	suitability	no
O	O	of	yes
O	O	the	no
O	O	urinary	yes
O	O	thioether	no
O	O	assay	no
O	O	as	yes
O	O	a	yes
O	O	method	yes
O	O	for	yes
O	O	the	no
O	O	detection	no
O	O	of	yes
O	O	exposure	yes
O	O	to	no
O	O	electrophilic	no
O	O	agents	yes
O	O	or	no
O	O	their	no
O	O	precursors	no
O	O	.	no

O	O	clinical	no
O	O	implications	no
O	O	are	no
O	O	unclear	no
O	O	.	no

B-drug	B-drug	Nabilone	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	CNS	no
O	O	depressant	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
O	O	either	no
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-brand	secobarbitone	yes
I-drug	I-brand	sodium	yes
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	or	no
B-drug	B-drug	codeine	yes
O	O	.	no

O	O	The	no
O	O	interaction	no
O	O	may	no
O	O	be	no
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	inhibition	no
O	O	of	yes
O	O	both	no
O	B-drug	CYP2C9	no
O	O	and	yes
O	O	2C19	no
O	O	by	no
B-drug	B-drug	fluvoxamine	yes
O	O	.	no

O	O	Other	no
O	O	nephrotoxic	no
O	O	medications	no
O	O	:	no
O	O	agents	yes
O	O	such	no
O	O	as	yes
B-group	B-group	aminoglycosides	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	pentamidine	yes
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	drug-induced	no
O	O	renal	no
O	O	toxicity	no
O	O	,	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	only	no
O	O	with	yes
O	O	great	no
O	O	caution	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
O	O	An	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	hepatitis	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	result	no
O	O	from	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	and	yes
B-drug	B-drug	etretinate	yes
O	O	.	no

O	O	certain	no
B-group	B-group	antipsychotic	no
I-group	I-group	medications	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	B-drug	sertindole	yes
O	O	)	no
O	O	;	no

B-drug	B-drug	Phenytoin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	and	yes
B-drug	B-drug	carbamazepine	yes
O	O	are	no
O	O	ge	yes
O	O	nerally	no
O	O	classified	no
O	O	as	yes
O	O	enzyme	no
O	O	inducers	no
O	O	;	no

B-drug	B-drug	Sertraline	yes
O	O	neutralized	no
O	O	the	no
O	O	increase	no
O	O	of	yes
O	O	glycemia	no
O	O	induced	no
O	O	by	no
O	O	oral	yes
B-drug	B-drug	glucose	yes
O	O	overload	no
O	O	.	no

O	O	Drug/	no
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Certain	no
O	O	endocrine	no
O	O	and	yes
O	O	liver	yes
O	O	function	no
O	O	tests	no
O	O	may	no
O	O	be	no
O	O	affected	no
O	O	by	no
B-group	B-group	estrogen-containing	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Divalproex	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Depakote	yes
O	O	)	no
O	O	or	no

O	O	This	no
O	O	is	yes
O	O	especially	no
O	O	important	no
O	O	for	yes
O	O	drugs	no
O	O	associated	no
O	O	with	yes
O	O	serious	no
O	O	toxicity	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	other	no
B-group	B-group	antiarrhythmics	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	hypertensive	no
O	O	patients	no
O	O	,	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	isradipine	yes
O	O	to	no
O	O	existing	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	therapy	no
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	any	no
O	O	unexpected	no
O	O	adverse	no
O	O	effects	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	isradipine	yes
O	O	had	no
O	O	an	no
O	O	additional	no
O	O	antihypertensive	no
O	O	effect	no
O	O	.	no

B-drug	B-drug	Acarbose	yes
O	O	did	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	or	no
O	O	disposition	no
O	O	of	yes
O	O	the	no
B-group	B-drug	sulfonylurea	no
B-drug	I-drug	glyburide	yes
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	are	no
O	O	usually	no
O	O	reversible	no
O	O	.	no

O	O	Inhibitors	no
O	O	Of	yes
O	O	Endogenous	no
O	O	Prostaglandin	yes
O	O	Synthesis	no
O	O	It	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
B-drug	B-drug	indomethacin	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	captopril	yes
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	cases	no
O	O	of	yes
O	O	low	yes
O	O	renin	no
O	O	hypertension	no
O	O	.	no

O	O	Pregnancy	no
O	O	(	no
O	O	Category	no
B-drug	O	B	yes
O	O	)	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-brand	B-brand	INDOCIN	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	unless	no
O	O	otherwise	no
O	O	specified	yes
O	O	,	no
O	O	appropriate	no
O	O	dosage	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
O	O	Between	yes
B-brand	B-brand	Keppra	yes
O	O	And	yes
O	O	Other	no
B-group	B-group	Antiepileptic	no
I-group	I-group	Drugs	no
O	O	(	no
B-group	B-group	AEDs	no
O	O	)	no
B-drug	B-drug	Phenytoin	yes
B-brand	B-brand	Keppra	yes
O	O	(	no
O	O	3000	no
O	O	mg	yes
O	O	daily	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	disposition	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	refractory	no
O	O	epilepsy	no
O	O	.	no

O	O	The	no
O	O	benefits	no
O	O	of	yes
B-drug	B-drug	Mefloquine	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	weighed	no
O	O	against	yes
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	adverse	no
O	O	effects	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	cardiac	no
O	O	disease	no
O	O	.	no

O	O	Each	no
O	O	treatment	no
O	O	period	no
O	O	was	no
O	O	separated	no
O	O	by	no
O	O	14	yes
O	O	to	no
O	O	21	yes
O	O	days	no
O	O	.	no

B-drug	B-drug_n	Zimelidine	yes
I-drug	B-drug	etomidate	yes
O	O	antagonism	no

O	O	In	yes
O	O	these	no
O	O	cases	no
O	O	,	no
O	O	your	no
O	O	doctor	no
O	O	may	no
O	O	want	no
O	O	to	no
O	O	change	no
O	O	the	no
O	O	dose	no
O	O	,	no
O	O	or	no
O	O	other	no
O	O	precautions	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Other	no
O	O	significant	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	fluoxetine	yes
O	O	or	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	have	no
O	O	similar	no
O	O	effects	no
O	O	and	yes
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	accompanied	no
O	O	by	no
O	O	similar	no
O	O	dose	no
O	O	reductions	no
O	O	.	no

O	O	Patients	no
O	O	with	yes
O	O	major	no
O	O	psychotic	no
O	O	disorders	no
O	O	,	no
O	O	treated	no
O	O	with	yes
B-group	B-group	neuroleptics	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	treated	no
O	O	with	yes
B-group	B-group	dopamine	yes
I-group	I-group	agonists	no
O	O	only	no
O	O	if	no
O	O	the	no
O	O	potential	no
O	O	benefits	no
O	O	outweigh	no
O	O	the	no
O	O	risks	no
O	O	.	no

O	O	Nine	no
O	O	additional	no
O	O	patients	no
O	O	who	no
O	O	had	no
O	O	initial	no
O	O	positive	no
O	O	tests	no
O	O	were	no
O	O	negative	no
O	O	on	no
O	O	repeat	no
O	O	testing	no
O	O	.	no

B-group	B-group	Antiepileptic	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	Sporadic	no
O	O	cases	no
O	O	of	yes
O	O	seizures	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	and	yes
B-group	B-group	antiepileptic	no
I-group	I-group	drugs	no
O	O	(	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	)	no
O	O	.	no

O	O	Concomitant	no
O	O	Drug	yes

O	O	-	yes
B-drug	B-drug	Plicamycin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-brand	Mithracin	yes
O	O	)	no
O	O	or	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	When	no
B-brand	B-brand	Starlix	yes
O	O	120	no
O	O	mg	yes
O	O	before	no
O	O	meals	no
O	O	was	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	1-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	.	no

O	O	Additional	no
O	O	interactions	no

O	O	Therefore	no
O	O	,	no
O	O	inhibitors	no
O	O	of	yes
O	O	these	no
O	O	enzymes	yes
O	O	are	no
O	O	expected	no
O	O	to	no
O	O	reduce	no
B-drug	B-drug	vardenafil	yes
O	O	clearance	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	,	no
O	O	at	yes
O	O	200	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	,	no
O	O	systemic	no
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	to	no
B-drug	B-drug	lapatinib	yes
O	O	was	no
O	O	increased	no
O	O	to	no
O	O	approximately	no
O	O	3.6-fold	no
O	O	of	yes
O	O	control	no
O	O	and	yes
O	O	half-life	no
O	O	increased	no
O	O	to	no
O	O	1.7-fold	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	Guidelines	no
O	O	are	no
O	O	provided	no
O	O	to	no
O	O	assist	no
O	O	the	no
O	O	clinician	no
O	O	in	yes
O	O	his	yes
O	O	logical	no
O	O	approach	no
O	O	to	no
O	O	the	no
O	O	identification	no
O	O	of	yes
O	O	drug	yes
O	O	interactions	no
O	O	when	no
O	O	serious	no
O	O	drug	yes
O	O	toxicity	no
O	O	is	yes
O	O	encountered	no
O	O	in	yes
O	O	a	yes
O	O	pateint	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	B-drug	foscarnets	no
O	O	tendency	no
O	O	to	no
O	O	cause	no
O	O	renal	no
O	O	impairment	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	FOSCAVIR	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	potentially	no
O	O	nephrotoxic	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-group	B-group	aminoglycosides	no
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	unless	no
O	O	the	no
O	O	potential	no
O	O	benefits	no
O	O	outweigh	no
O	O	the	no
O	O	risks	no
O	O	to	no
O	O	the	no
O	O	patient	no
O	O	.	no

B-drug	B-drug	Epinephrine	yes
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	neuron	no
O	O	blockade	no
O	O	produced	no
O	O	by	no
B-drug	B-drug	guanethidine	yes
O	O	resulting	no
O	O	in	yes
O	O	decreased	no
O	O	antihypertensive	no
O	O	effect	no
O	O	and	yes
O	O	requiring	no
O	O	increased	no
O	O	dosage	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	.	no

O	O	Because	no
O	O	CYP	no
O	O	3A4	no
O	O	inhibitors	no
O	O	may	no
O	O	increase	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	buprenorphine	yes
O	O	,	no
O	O	patients	no
O	O	already	no
O	O	on	no
O	O	CYP	no
O	O	3A4	no
O	O	inhibitors	no
O	O	such	no
O	O	as	yes
B-group	B-group	azole	no
I-group	I-group	antifungals	no
O	O	(	no
O	O	e.g	no
O	O	.	no

O	O	With	yes
O	O	each	no
O	O	successive	no
O	O	generation	no
O	O	more	no
O	O	people	no
O	O	are	no
O	O	becoming	no
O	O	more	no
O	O	severely	no
O	O	depressed	no
O	O	at	yes
O	O	a	yes
O	O	younger	no
O	O	age	no
O	O	.	no

B-drug	I-drug	saquinavir	yes
O	O	concentration	no

O	O	Marked	no
O	O	symptomatic	no
O	O	orthostatic	no
O	O	hypotension	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	and	yes
O	B-group	organic	no
B-group	I-group	nitrates	no
O	O	were	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	.	no

O	O	Thus	no
O	O	no	yes
O	O	dosing	no
O	O	adjustments	no
O	O	are	no
O	O	necessary	no
O	O	during	no
O	O	concomitant	no
O	O	use	no
O	O	with	yes
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Sonata	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	800	no
O	O	mg	yes
O	O	)	no
O	O	produced	no
O	O	an	no
O	O	85	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	mean	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	.	no

O	O	This	no
O	O	antagonistic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	on	no
B-drug	B-drug	bumetanide	yes
O	O	natriuresis	no
O	O	is	yes
O	O	not	no
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	direct	no
O	O	action	no
O	O	on	no
O	O	sodium	yes
O	O	excretion	no
O	O	but	no
O	O	is	yes
O	O	probably	no
O	O	secondary	yes
O	O	to	no
O	O	its	no
O	O	inhibitory	yes
O	O	effect	no
O	O	on	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
B-drug	B-drug	bumetanide	yes
O	O	.	no

O	O	For	yes
O	O	information	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	Gemzar	yes
O	O	and	yes
B-drug	B-drug	cisplatin	yes
O	O	in	yes
O	O	combination	yes
O	O	,	no
O	O	see	no
O	O	Drug	yes
O	O	Interactions	no
O	O	under	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	section	no
O	O	.	no

O	B-drug	Caffeine-related	no
O	O	adverse	no
O	O	effects	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	patients	no
O	O	consuming	no
B-drug	B-drug	caffeine	yes
O	O	while	no
O	O	on	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	enoxacin	yes
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	Among	no
O	O	these	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	upper	no
O	O	gastrointestinal	no
O	O	adverse	no
O	O	experiences	no
O	O	in	yes
O	O	the	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	Ibandronate	yes
O	O	150	yes
O	O	mg	yes
O	O	once	no
O	O	monthly	no
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	Ibandronate	yes
O	O	2.5	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	.	no

B-drug	B-drug	Ampicillin	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	chloroquine	yes
O	O	significantly	no
O	O	reduced	yes
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	ampicillin	yes
O	O	.	no

O	O	Metal	no
O	O	mixtures	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	B-drug	egg	no
O	O	hatching	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	its	no
O	O	primary	no
O	O	CNS	no
O	O	effect	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
B-brand	B-brand	EQUETROTM	no
O	O	is	yes
O	O	taken	no
O	O	with	yes
O	O	other	no
O	B-group	centrally	no
O	I-group	acting	yes
O	I-group	drugs	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	including	no
B-drug	B-drug	lisinopril	yes
O	O	.	no

O	O	Thus	no
O	O	agents	yes
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	concomitantly	no
O	O	administered	no
O	O	with	yes
B-drug	B-brand	Chirocaine	yes
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isoenzyme	no
O	O	family	yes
O	O	may	no
O	O	potentially	no
O	O	interact	no
O	O	with	yes
B-drug	B-brand	Chirocaine	yes
O	O	.	no

O	O	These	no
O	O	individuals	no
O	O	may	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

O	O	In	yes
O	O	order	no
O	O	to	no
O	O	approximate	no
O	O	the	no
O	O	steady	no
O	O	state	no
O	O	level	no
O	O	,	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	drawn	no
O	O	either	no
O	O	before	no
O	O	or	no
O	O	at	yes
O	O	least	no
O	O	six	no
O	O	hours	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	an	no
O	O	oral	yes
O	O	tablet	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
O	O	herbal	no
O	O	remedies	no
O	O	is	yes
O	O	becoming	no
O	O	increasingly	no
O	O	popular	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	States	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	decrease	no
B-drug	B-drug	imatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	:	no
O	O	Substances	no
O	O	that	no
O	O	are	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	activity	yes
O	O	may	no
O	O	increase	no
O	O	metabolism	no
O	O	and	yes
O	O	decrease	no
B-drug	B-drug	imatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	This	no
O	O	inhibition	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	unexpectedly	no
O	O	high	yes
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	other	no
O	B-drug	drugs	no
O	O	which	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	those	no
O	O	CYP450	no
O	O	enzymes	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	diabetics	no
O	O	with	yes
O	O	microalbuminuria	no
B-brand	B-brand	INSPRA	yes
O	O	200	yes
O	O	mg	yes
O	O	combined	no
O	O	with	yes
O	O	the	no
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
B-drug	B-drug	enalapril	yes
O	O	10	yes
O	O	mg	yes
O	O	increased	no
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	hyperkalemia	no
O	O	(	no
O	O	serum	yes
O	O	potassium	yes
O	O	5.5	no
O	O	mEq/L	no
O	O	)	no
O	O	from	no
O	O	17	yes
O	O	%	no
O	O	on	no
B-drug	B-drug	enalapril	yes
O	O	alone	no
O	O	to	no
O	O	38	no
O	O	%	no
O	O	.	no

O	O	Tumor	yes
O	O	phenotype	no
O	O	and	yes
O	O	susceptibility	no
O	O	to	no
O	O	progression	no
O	O	as	yes
O	O	an	no
O	O	expression	no
O	O	of	yes
O	O	subpopulations	no
O	O	of	yes
O	O	initiated	no
O	O	murine	yes
O	O	cells	yes
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	:	no
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	.	no

O	O	When	no
B-group	B-group	catecholamines	no
O	O	are	no
O	O	administered	no
O	O	,	no
O	O	dilute	yes
O	O	solutions	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	and	yes
O	O	blood	yes
O	O	pressure	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	.	no

B-drug	B-drug	Iodine	yes
O	O	or	no
B-drug	B-drug	iodine	yes
O	O	excess	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	Carbimazole	yes
O	O	,	no
O	O	and	yes
O	O	an	no
O	B-drug	iodine	yes
O	O	deficiency	no
O	O	can	no
O	O	increase	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	Carbimazole	yes
O	O	.	no

O	O	Elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	some	no
B-group	B-group	quinolones	no
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	.	no

O	O	See	no
O	O	WARNINGS	no
O	O	,	no
O	O	Myopathy/Rhabdomyolysis	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	increases	no
B-drug	B-drug	lithium	yes
O	O	excretion	no
O	O	and	yes
O	O	the	no
B-drug	B-drug	lithium	yes
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	increase	no
B-drug	B-drug	dasatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	CYP3A4	no
O	O	Inhibitors	no
O	O	:	no
B-drug	B-drug	Dasatinib	yes
O	O	is	yes
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	.	no

O	O	No	yes
O	O	significant	no
O	O	interaction	no
O	O	has	no
O	O	been	no
O	O	found	no
O	O	with	yes
B-group	O	broad-spectrum	no
I-group	B-group	antibiotics	no
O	O	.	no

B-drug	B-drug	Magnesium	yes
O	O	:	no
B-drug	B-drug	Magnesium-containing	no
O	O	preparations	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-group	B-group	antacids	no
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	hypermagnesemia	no
O	O	and	yes
O	O	should	no
O	O	therefore	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	by	no
O	O	patients	no
O	O	on	no
O	O	chronic	no
O	O	renal	no
O	O	dialysis	no
O	O	.	no

O	O	Currently	no
O	O	,	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	data	no
O	O	available	no
O	O	from	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

O	O	Differential	no
O	O	regulation	no
O	O	of	yes
O	O	tyrosine	yes
O	O	phosphorylation	no
O	O	in	yes
O	O	tumor	yes
O	O	cells	yes
O	O	by	no
B-drug_n	B-drug_n	contortrostatin	no
O	O	,	no
O	O	a	yes
O	O	homodimeric	no
O	O	disintegrin	no
O	O	,	no
O	O	and	yes
O	O	monomeric	no
O	O	disintegrins	no
O	B-drug_n	echistatin	no
O	O	and	yes
O	B-drug_n	flavoridin	no
O	O	.	no

O	O	Usually	no
O	O	,	no
O	O	this	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	diabetes	no
O	O	mellitus	no
O	O	or	no
O	O	evidence	no
O	O	of	yes
O	O	glucose	yes
O	O	intolerance	no
O	O	prior	no
O	O	to	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	.	no

O	O	.	no

O	O	Salt	yes
O	O	substitutes	no
O	O	containing	yes
B-drug	B-drug	potassium	yes
O	O	should	no
O	O	also	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	.	no

O	O	In	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	receiving	no
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	concurrently	no
O	O	did	no
O	O	not	no
O	O	experience	no
O	O	an	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	.	no

B-group	B-group	Benzodiazepines	no
O	O	:	no
O	O	Combination	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	some	no
B-group	B-group	benzodiazepines	no
O	O	(	no
B-drug	B-drug	alprazolam	yes
O	O	,	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	)	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
O	O	others	no
O	O	(	no
B-drug	B-drug	lorazepam	yes
O	O	,	no
B-drug	B-drug	oxazepam	yes
O	O	,	no
B-drug	B-drug	temazepam	yes
O	O	)	no
O	O	.	no

O	O	All	yes
O	O	animals	no
O	O	in	yes
O	O	the	no
O	O	study	no
O	O	were	no
O	O	positive	no
O	O	for	yes
O	O	an	no
O	O	endemic	no
O	O	primate	no
O	O	gammaherpes	no
O	O	virus	yes
O	O	also	no
O	O	known	no
O	O	as	yes
O	O	lymphocryptovirus	no
O	O	(	no
O	O	LCV	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	-	yes
B-drug	B-drug	L-arginine	yes
O	O	may	no
O	O	counteract	no
O	O	the	no
O	O	antinaturetic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	cyclosporin	yes
O	O	.	no

O	O	Although	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	unknown	no
O	O	whether	no
O	O	this	no
O	O	could	no
O	O	result	no
O	O	in	yes
O	O	clinically	no
O	O	significant	no
O	O	effects	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	Cerebyx	yes
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	significantly	no
O	O	bind	no
O	O	to	no
O	O	serum	yes
O	O	albumin	yes
O	O	.	no

O	O	Coingestion	no
O	O	of	yes
B-drug	B-drug	acetaminophen	yes
O	O	with	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	with	yes
B-drug	B-drug	acetaminophen	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	with	yes
B-drug	B-drug	phenobarbital	yes
O	O	at	yes
O	O	high	yes
O	O	to	no
O	O	toxic	no
O	O	concentrations	no
O	O	decreases	no
O	O	the	no
O	O	binding	no
O	O	of	yes
O	O	the	no
O	O	target	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Alosetron	yes
O	O	does	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	induce	no
O	O	the	no
O	O	major	no
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	drug	yes
O	O	metabolizing	no
O	O	enzyme	no
O	O	3A	yes
O	O	.	no

O	O	3	yes
O	O	.	no

B-group	B-group	antacids	no
O	O	;	no

O	O	N=12	no
O	O	)	no
O	O	are	no
O	O	identical	no
O	O	whether	no
O	O	the	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	alone	no
O	O	or	no
O	O	together	no
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	(	no
O	O	500	yes
O	O	mg	yes
O	O	t.i.d	no
O	O	)	no
O	O	produced	no
O	O	a	yes
O	O	4-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	vardenafil	yes
O	O	AUC	no
O	O	and	yes
O	O	a	yes
O	O	3-fold	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Vardenafil	yes
O	O	5	yes
O	O	mg	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

B-group	B-group	HMG-CoA	no
I-group	I-group	Reductase	no
I-group	I-group	Inhibitor	yes
O	O	:	no
B-drug	B-drug	atorvastatin	yes

O	O	These	no
O	O	results	no
O	O	would	no
O	O	seem	no
O	O	to	no
O	O	dictate	no
O	O	against	yes
O	O	the	no
O	O	clinical	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	with	yes
B-brand	B-brand	ELSPAR	yes
O	O	,	no
O	O	or	no
O	O	during	no
O	O	the	no
O	O	period	no
O	O	following	no
B-brand	B-brand	ELSPAR	yes
O	O	therapy	no
O	O	when	no
O	O	plasma	yes
B-drug	O	asparagine	yes
O	O	levels	no
O	O	are	no
O	O	below	no
O	O	normal	yes
O	O	.	no

O	O	Gastrointestinal	no
O	O	transit	no
O	O	time	no
O	O	(	no
O	O	lactulose	yes
O	O	hydrogen	yes
O	O	breath	yes
O	O	test	yes
O	O	)	no
O	O	was	no
O	O	measured	no
O	O	in	yes
O	O	14	yes
O	O	volunteers	no
O	O	with	yes
O	O	oral	yes
O	O	and	yes
O	O	intravenous	yes
O	O	placebo	no
O	O	,	no
O	O	oral	yes
O	O	placebo	no
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	0.05	no
O	O	mg	yes
O	O	x	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	oral	yes
B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	(	no
O	O	4	yes
O	O	mg	yes
O	O	)	no
O	O	and	yes
O	O	intravenous	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	0.05	no
O	O	mg	yes
O	O	x	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	)	no
O	O	in	yes
O	O	a	yes
O	O	double	yes
O	O	blind	no
O	O	,	no
O	O	cross-over	no
O	O	study	no
O	O	.	no

O	O	Also	no
O	O	,	no
O	O	bleeding	no
O	O	and/or	no
O	O	increased	no
O	O	prothrombin	yes
O	O	time	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	a	yes
O	O	few	no
O	O	patients	no
O	O	taking	no
B-group	B-group	coumarin	yes
I-group	O	anticoagulants	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lovastatin	yes
O	O	.	no

O	O	The	no
O	O	acceleration	no
O	O	of	yes
O	O	gastric	yes
O	O	emptying	no
O	O	by	no
B-drug	B-drug	cisapride	yes
O	O	could	no
O	O	affect	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	absorption	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	15	yes
O	O	male	no
O	O	subjects	no
O	O	(	no
O	O	ages	no
O	O	19	yes
O	O	to	no
O	O	35	yes
O	O	years	no
O	O	)	no
O	O	who	no
O	O	were	no
O	O	extensive	no
O	O	metabolizers	no
O	O	of	yes
O	O	the	no
O	O	CYP2D6	no
O	O	isoenzyme	no
O	O	,	no
O	O	daily	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	given	no
O	O	as	yes
O	O	150	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	50	yes
O	O	mg	yes
B-drug	B-drug	desipramine	yes
O	O	increased	no
O	O	the	no
O	O	Cmax	no
O	O	,	no
O	O	AUC	no
O	O	,	no
O	O	and	yes
O	O	t1/2	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	by	no
O	O	an	no
O	O	average	no
O	O	of	yes
O	O	approximately	no
O	O	2-	no
O	O	,	no
O	O	5-	no
O	O	and	yes
O	O	2-fold	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-group	B-group	Quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	cinoxacin	yes
O	O	,	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	The	no
O	O	selection	no
O	O	of	yes
O	O	drugs	no
O	O	and	yes
O	O	their	no
O	O	dosages	no
O	O	may	no
O	O	be	no
O	O	improved	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	adverse	no
O	O	effects	no
O	O	reduced	yes
O	O	by	no
O	O	pharmacogenetic	no
O	O	investigations	no
O	O	.	no

B-drug	B-drug	Chlorthalidone	yes
O	O	and	yes
O	O	related	yes
O	O	drugs	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	tubocurarine	yes
O	O	.	no

O	O	Although	no
O	O	a	yes
O	O	3-day	no
O	O	regimen	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	,	no
O	O	alternative	no
O	O	or	no
O	O	back-up	no
O	O	methods	no
O	O	of	yes
O	O	contraception	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	.	no

B-drug	B-drug	Caffeine	yes
O	O	:	no
O	O	Two	no
O	O	hundred	no
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	(	no
O	O	equivalent	no
O	O	to	no
O	O	1	yes
O	O	to	no
O	O	3	yes
O	O	cups	no
O	O	of	yes
O	O	American	yes
O	O	coffee	no
O	O	)	no
O	O	was	no
O	O	administered	no
O	O	to	no
O	O	16	yes
O	O	normal	yes
O	O	,	no
O	O	healthy	no
O	O	volunteers	no
O	O	who	no
O	O	had	no
O	O	achieved	no
O	O	steady-state	no
O	O	blood	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	lomefloxacin	yes
O	O	after	no
O	O	being	no
O	O	dosed	no
O	O	at	yes
O	O	400	yes
O	O	mg	yes
O	O	qd	no
O	O	.	no

O	O	Their	no
O	O	concurrent	no
O	O	use	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	Metoclopramide	yes
O	O	:	no
O	O	When	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	MONUROL	yes
O	O	,	no
B-drug	B-drug	metoclopramide	yes
O	O	,	no
O	O	a	yes
O	O	drug	yes
O	O	which	no
O	O	increases	no
O	O	gastrointestinal	no
O	O	motility	no
O	O	,	no
O	O	lowers	no
O	O	the	no
O	O	serum	yes
O	O	concentration	no
O	O	and	yes
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	fosfomycin	yes
O	O	.	no

O	O	Dosage	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	may	no
O	O	require	no
O	O	reduction	yes
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	maintain	no
O	O	satisfactory	no
O	O	therapeutic	no
O	O	hypoprothrombinemia	no
O	O	.	no

O	O	Among	no
O	O	the	no
O	O	proteins	no
O	O	that	no
O	O	undergo	no
O	O	tyrosine	yes
O	O	phosphorylation	no
O	O	in	yes
O	O	response	no
O	O	to	no
O	B-drug_n	contortrostatin	no
O	O	treatment	no
O	O	is	yes
O	O	CAS	no
O	O	,	no
O	O	a	yes
O	O	130	no
O	O	kDa	no
O	O	adapter	no
O	O	protein	yes
O	O	involved	no
O	O	in	yes
O	O	integrin	yes
O	O	signaling	no
O	O	.	no

O	O	Careful	no
O	O	observation	no
O	O	is	yes
O	O	required	no
O	O	.	no

O	O	The	no
O	O	presence	no
O	O	of	yes
O	O	food	no
O	O	in	yes
O	O	the	no
O	O	stomach	no
O	O	does	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-brand	B-brand	PRINIVIL	yes
O	O	.	no

B-group	O	Epidural	no
B-drug	B-drug	clonidine	yes
O	O	may	no
O	O	prolong	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	pharmacologic	no
O	O	effects	no
O	O	of	yes
B-drug	O	epidural	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	,	no
O	O	including	no
O	O	both	no
O	O	sensory	no
O	O	and	yes
O	O	motor	no
O	O	blockade	no
O	O	.	no

B-drug	B-drug	Esomeprazole	yes
O	O	is	yes
O	O	extensively	no
O	O	metabolized	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	by	no
O	O	CYP2C19	no
O	O	and	yes
O	O	CYP3A4	no
O	O	.	no

O	O	also	no
O	O	induced	no
O	O	diarrhea	no
O	O	,	no
O	O	but	no
O	O	did	no
O	O	not	no
O	O	produce	no
O	O	a	yes
O	O	watery	no
O	O	stool	no
O	O	in	yes
O	O	cecectomized	no
O	O	rats	no
O	O	.	no

O	O	(	no
O	O	Concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	,	no
O	O	as	yes
O	O	they	no
O	O	may	no
O	O	provoke	no
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	because	no
O	O	of	yes
O	O	reduced	yes
O	O	renal	no
O	O	clearance	no
O	O	.	no
O	O	)	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	tablets	yes
O	O	is	yes
O	O	therefore	no
O	O	contraindicated	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	the	no
O	O	literature	no
O	O	reports	no
O	O	,	no
O	O	the	no
O	O	same	yes
O	O	effects	no
O	O	may	no
O	O	be	no
O	O	extrapolated	no
O	O	to	no
O	O	other	no
O	O	fruit	no
O	O	juices	no
O	O	such	no
O	O	as	yes
O	O	apple	no
O	O	juice	no
O	O	.	no

O	O	Drugs	no
O	O	possessing	no
O	O	beta-blocking	no
O	O	properties	no
O	O	can	no
O	O	blunt	no
O	O	the	no
O	O	bronchodilator	no
O	O	effect	no
O	O	of	yes
B-group	B-group	beta-receptor	no
I-group	I-group	agonist	no
I-group	I-group	drugs	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	bronchospasm	no
O	O	;	no

B-drug	B-drug	Ritonavir	yes

O	O	-	yes
B-drug	B-drug	Dapsone	yes
O	O	or	no

O	O	A	yes
O	O	study	no
O	O	in	yes
O	O	six	no
O	O	healthy	no
O	O	volunteers	no
O	O	has	no
O	O	shown	no
O	O	a	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	peak	no
B-drug	B-drug	diltiazem	yes
O	O	plasma	yes
O	O	levels	no
O	O	(	no
O	O	58	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	AUC	no
O	O	(	no
O	O	53	no
O	O	%	no
O	O	)	no
O	O	after	no
O	O	a	yes
O	O	1-week	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	1200	no
O	O	mg/day	no
O	O	and	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	60mg	no
O	O	.	no

O	O	The	no
O	O	pathophysiologic	no
O	O	consequences	no
O	O	could	no
O	O	be	no
O	O	an	no
O	O	increased	no
O	O	synaptic	no
O	O	concentration	no
O	O	of	yes
O	B-drug	norepinephrine	yes
O	O	predisposing	no
O	O	to	no
O	O	adenylyl	no
O	O	cyclase	no
O	O	desensitization	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	a	yes
O	O	significantly	no
O	O	higher	no
O	O	proportion	no
O	O	of	yes
O	O	neurons	no
O	O	fired	no
O	O	spontaneous	no
O	O	action	no
O	O	potentials	no
O	O	with	yes
O	O	either	no
O	O	0.05-0.2	no
O	O	or	no
O	O	1	yes
O	O	%	no
O	O	biocytin	no
O	O	compared	no
O	O	to	no
O	O	no	yes
O	O	biocytin	no
O	O	.	no

O	O	The	no
B-brand	B-brand	Factrel	yes
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	conducted	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	which	no
O	O	directly	no
O	O	affect	no
O	O	the	no
O	O	pituitary	no
O	O	secretion	no
O	O	of	yes
O	O	the	no
O	O	gonadotropins	no
O	O	.	no

B-drug	O	Cimetidine	yes
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	a	yes
O	O	non-specific	no
O	O	CYP-450	no
O	O	inhibitor	yes
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	of	yes
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	the	no
O	O	Cmax	no
O	O	,	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

B-drug	B-drug	triclofos	no
I-drug	I-drug	sodium	yes
O	O	;	no

O	O	Metal	no
O	O	mixture	no
O	O	toxicity	no
O	O	investigation	no
O	O	was	no
O	O	undertaken	no
O	O	with	yes
O	O	equal	no
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	metals	no
O	O	.	no

O	O	A	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	diltiazem	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	during	no
O	O	studies	no
O	O	involving	no
O	O	renal	no
O	O	and	yes
O	O	cardiac	no
O	O	transplant	no
O	O	patients	no
O	O	.	no

O	O	Reversal	no
O	O	of	yes
O	O	the	no
O	O	block	yes
O	O	with	yes
B-drug	B-drug	edrophonium	yes
O	O	and	yes
O	O	subsequent	no
O	O	recovery	no
O	O	of	yes
O	O	the	no
O	O	horses	no
O	O	from	no
O	O	anaesthesia	no
O	O	were	no
O	O	uneventful	no
O	O	.	no

O	O	Mean	no
O	O	number	no
O	O	of	yes
O	O	drugs	no
O	O	per	no
O	O	MAC	no
O	O	was	no
O	O	4	yes
O	O	(	no
O	O	95	no
O	O	%	no
O	O	CI	yes
O	O	,	no
O	O	+/-	no
O	O	0.2	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	minimum	no
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	increased	no
O	O	15	yes
O	O	%	no
O	O	and	yes
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	was	no
O	O	decreased	no
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	Patients	no
O	O	undergoing	no
O	O	systemic	no
O	O	anticholinesterase	no
O	O	treatment	no
O	O	should	no
O	O	be	no
O	O	warned	no
O	O	of	yes
O	O	the	no
O	O	possible	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	Phospholine	yes
I-drug	I-drug	Iodide	yes
O	O	.	no

O	O	The	no
O	O	presence	no
O	O	of	yes
O	O	the	no
O	B-group	radiopharmaceutical	no
O	O	in	yes
O	O	the	no
O	O	kidneys	no
O	O	,	no
O	O	along	no
O	O	with	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	renal	no
O	O	retention	no
O	O	,	no
O	O	tend	no
O	O	to	no
O	O	produce	no
O	O	scintigraphic	no
O	O	results	no
O	O	that	no
O	O	falsely	no
O	O	identify	no
O	O	characteristics	no
O	O	related	yes
O	O	to	no
O	O	diseases	no
O	O	such	no
O	O	as	yes
O	O	renal	no
O	O	vascular	no
O	O	,	no
O	O	or	no
O	O	urinary	yes
O	O	tract	no
O	O	obstruction	no
O	O	,	no
O	O	and	yes
O	O	even	no
O	O	renal	no
O	O	cancer	no
O	O	.	no

O	O	When	no
O	O	given	no
O	O	concurrently	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	with	yes
O	O	other	no
B-group	B-group	oxytocic	no
I-group	I-group	agents	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-group	B-group	Anticonvulsants	no
O	O	:	no
B-drug	B-drug	Phenytoin	yes
I-drug	I-drug	Phenobarbital	yes
I-drug	I-drug	Carbamazepine	yes

O	O	decreased	no
O	O	pharmacologic	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	.	no

O	O	The	no
O	O	inhibiting	no
O	O	effects	no
O	O	of	yes
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	on	no
O	O	gastric	yes
O	O	hydrochloric	no
O	O	acid	yes
O	O	secretion	no
O	O	are	no
O	O	antagonized	no
O	O	by	no
O	O	agents	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	achlorhydria	no
O	O	and	yes
O	O	those	no
O	O	used	no
O	O	to	no
O	O	test	yes
O	O	gastric	yes
O	O	secretion	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	administered	no
O	O	concurrently	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	,	no
O	O	particularly	no
O	O	when	no
O	O	their	no
O	O	main	no
O	O	route	no
O	O	of	yes
O	O	elimination	no
O	O	is	yes
O	O	active	no
O	O	renal	no
O	O	secretion	no
O	O	via	no
O	O	the	no
O	O	organic	no
O	O	cationic	no
O	O	transport	no
O	O	system	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	trimethoprim	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	information	no
O	O	was	no
O	O	obtained	no
O	O	from	no
O	O	the	no
O	O	literature	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	cerivastatin	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	antagonism	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	theophylline-induced	no
O	O	anxiogenic	no
O	O	effects	no
O	O	by	no
B-drug_n	B-drug_n	CGS21680	no
O	O	was	no
O	O	only	no
O	O	observed	no
O	O	in	yes
O	O	the	no
O	O	time	no
O	O	spent	no
O	O	in	yes
O	O	the	no
O	O	light	yes
O	O	zone	no
O	O	,	no
O	O	and	yes
B-drug_n	B-drug_n	DPCPX-induced	no
O	O	anxiogenic	no
O	O	effects	no
O	O	were	no
O	O	neither	no
O	O	reversed	no
O	O	by	no
B-drug_n	B-drug	CGS	no
I-drug_n	I-drug	21680	no
O	O	nor	yes
O	O	by	no
B-drug_n	B-drug_n	CPA	no
O	O	.	no

O	O	No	yes
O	O	clinical	no
O	O	or	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	was	no
O	O	conducted	no
O	O	with	yes
B-drug	B-drug	dolasetron	yes
O	O	.	no

O	O	Although	no
O	O	other	no
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	are	no
O	O	highly	no
O	O	effective	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	pregnancy	no
O	O	from	no
O	O	women	yes
O	O	who	no
O	O	have	no
O	O	used	no
O	B-group	combined	no
O	I-group	oral	yes
B-group	I-group	contraceptives	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	topical/injectable/implantable/insertable	no
O	O	hormonal	no
O	O	birth	no
O	O	control	no
O	O	products	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
B-drug	B-drug	Warfarin	yes

O	O	METHODS	no
O	O	:	no
O	O	The	no
O	O	study	no
O	O	was	no
O	O	carried	no
O	O	out	no
O	O	as	yes
O	O	an	no
O	O	open	yes
O	O	,	no
O	O	randomized	no
O	O	,	no
O	O	crossover	no
O	O	design	no
O	O	with	yes
O	O	14	yes
O	O	healthy	no
O	O	participants	no
O	O	.	no

O	O	7	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	single	yes
O	O	in	yes
O	O	vivo	no
O	O	rodent	no
O	O	study	no
O	B-drug	denileukin	yes
O	I-drug	diftitox	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	P450	no
O	O	levels	no
O	O	.	no

O	O	If	no
O	O	hypotension	no
O	O	occurs	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	placed	no
O	O	in	yes
O	O	a	yes
O	O	supine	no
O	O	position	no
O	O	and	yes
O	O	,	no
O	O	if	no
O	O	necessary	no
O	O	,	no
O	O	receive	no
O	O	an	no
O	O	intravenous	yes
O	O	infusion	no
O	O	of	yes
O	O	normal	yes
O	O	saline	yes
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	formal	no
O	O	studies	no
O	O	of	yes
O	O	the	no
O	O	interaction	no
O	O	of	yes
B-brand	B-brand	LEVULAN	yes
B-brand	I-brand	KERASTICK	no
O	O	for	yes
O	O	Topical	yes
O	O	Solution	yes
O	O	with	yes
O	O	any	no
O	O	other	no
O	O	drugs	no
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	drug-specific	no
O	O	interactions	no
O	O	were	no
O	O	noted	no
O	O	during	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	controlled	no
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	herbal	no
O	O	remedies	no
O	O	may	no
O	O	be	no
O	O	detrimental	no
O	O	for	yes
O	O	the	no
O	O	patient	no
O	O	with	yes
O	O	compromised	no
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
B-drug	B-drug	theophylline-related	no
O	O	adverse	no
O	O	reactions	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	estazolam	yes
O	O	(	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	)	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	during	no
O	O	multiple-dose	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	suggesting	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	.	no

O	O	Even	no
O	O	so	no
B-drug	B-drug	dextromethorphan	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	valdecoxib	yes
O	O	were	no
O	O	almost	no
O	O	5-fold	no
O	O	lower	no
O	O	than	no
O	O	those	no
O	O	seen	no
O	O	in	yes
O	O	CYP	no
O	O	2D6	no
O	O	poor	no
O	O	metabolizers	no
O	O	suggesting	no
O	O	that	no
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	not	no
O	O	necessary	no
O	O	.	no

O	O	CNS	no
O	O	Acting	yes
O	O	Drugs	no
O	O	:	no
O	O	Given	no
O	O	the	no
O	O	primary	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	Duloxetine	yes
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	taken	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	or	no
O	O	substituted	yes
O	O	for	yes
O	O	other	no
O	O	centrally	no
O	O	acting	yes
O	O	drugs	no
O	O	,	no
O	O	including	no
O	O	those	no
O	O	with	yes
O	O	a	yes
O	O	similar	no
O	O	mechanism	no
O	O	of	yes
O	O	action	no
O	O	.	no

O	O	Slow	yes
O	O	chylomicron	no
O	O	intravascular	no
O	O	catabolism	no
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	and	yes
O	O	screening	no
O	O	for	yes
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	speed-up	no
O	O	this	no
O	O	process	no
O	O	can	no
O	O	be	no
O	O	important	no
O	O	.	no

O	O	Pretreatment	no
O	O	of	yes
O	O	healthy	no
O	O	volunteers	no
O	O	with	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Gleevec	yes
O	O	,	no
O	O	increased	no
B-brand	B-brand	Gleevec	yes
O	O	oral-dose	no
O	O	clearance	no
O	O	by	no
O	O	3.8-fold	no
O	O	,	no
O	O	which	no
O	O	significantly	no
O	O	(	no
O	O	p	yes
O	O	0.05	no
O	O	)	no
O	O	decreased	no
O	O	mean	no
O	O	cmax	no
O	O	and	yes
O	O	AUC	no
O	O	(	no
O	O	0-8	no
O	O	)	no
O	O	.	no

B-drug	I-drug	sertraline	yes
O	O	concentration	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	almotriptan	yes
O	O	and	yes
O	O	the	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitor	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	q.d	no
O	O	.	no
O	O	for	yes
O	O	3	yes
O	O	days	no
O	O	)	no
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	approximately	no
O	O	60	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	plasma	yes
O	O	concentration-time	no
O	O	curve	no
O	O	and	yes
O	O	maximal	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	almotriptan	yes
O	O	.	no

B-drug	B-drug	Delavirdine	yes

O	O	Because	no
O	O	pregnancy	no
O	O	could	no
O	O	not	no
O	O	be	no
O	O	maintained	no
O	O	in	yes
O	O	the	no
O	O	rabbit	yes
O	O	following	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	fulvestrant	yes
O	O	of	yes
O	O	1	yes
O	O	mg/kg/day	no
O	O	and	yes
O	O	above	no
O	O	,	no
O	O	this	no
O	O	study	no
O	O	was	no
O	O	inadequate	no
O	O	to	no
O	O	fully	no
O	O	define	no
O	O	the	no
O	O	possible	no
O	O	adverse	no
O	O	effects	no
O	O	on	no
O	O	fetal	no
O	O	development	no
O	O	at	yes
O	O	clinically	no
O	O	relevant	no
O	O	exposures	no
O	O	.	no

B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	:	no
O	O	The	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	TRICOR	yes
O	O	and	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	unless	no
O	O	the	no
O	O	benefit	no
O	O	of	yes
O	O	further	no
O	O	alterations	no
O	O	in	yes
O	O	lipid	no
O	O	levels	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	outweigh	no
O	O	the	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	this	no
O	O	drug	yes
O	O	combination	yes
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	with	yes
B-drug	B-drug	rifampin	yes
O	O	or	no
O	O	any	no
O	O	known	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	when	no
O	O	possible	no
O	O	,	no
O	O	and	yes
O	O	alternative	no
O	O	therapy	no
O	O	considered	no
O	O	.	no

B-drug	O	Acellular	no
O	O	,	no
O	O	live	yes
O	O	and	yes
B-group	B-group	live-attenuated	no
I-group	I-group	vaccines	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	during	no
B-brand	B-brand	RAPTIVA	yes
O	O	treatment	no
O	O	.	no

O	O	Drugs	no
O	O	Highly	no
O	O	Bound	no
O	O	to	no
O	O	Plasma	yes
O	O	Protein	yes
B-drug	B-drug	Zaleplon	yes
O	O	is	yes
O	O	not	no
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	proteins	no
O	O	(	no
O	O	fraction	yes
O	O	bound	no
O	O	60	no
O	O	%	no
O	O	15	yes
O	O	%	no
O	O	)	no
O	O	;	no

O	O	The	no
O	O	administration	no
O	O	of	yes
O	O	local	no
B-group	B-group	anesthetic	no
I-group	I-group	solutions	no
O	O	containing	yes
B-drug	B-drug	epinephrine	yes
O	O	or	no
B-drug	B-drug	norepinephrine	yes
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	or	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	produce	no
O	O	severe	no
O	O	,	no
O	O	prolonged	no
O	O	hypertension	no
O	O	.	no

B-group	B-group	Skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	:	no
B-drug	B-drug	amphotericin	yes
O	O	B-induced	no
O	O	hypokalemia	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	curariform	no
O	O	effect	no
O	O	of	yes
B-group	B-group	skeletal	no
I-group	I-group	muscle	no
I-group	I-group	relaxants	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	tubocurarine	yes
O	O	)	no
O	O	.	no

O	O	[	no
O	O	2	yes
O	O	epidemics	no
O	O	of	yes
O	O	arsenical	no
O	O	encephalopathy	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	trypanosomiasis	no
O	O	,	no
O	O	Uganda	no
O	O	,	no
O	O	1992-1993	no
O	O	]	no
O	O	Since	no
O	O	1988	no
O	O	,	no
O	O	the	no
O	O	french	no
O	O	non-governmental	no
O	O	organisation	no
O	O	M	yes
O	O	decins	no
O	O	Sans	no
O	O	Fronti	no
O	O	res	no
O	O	is	yes
O	O	running	no
O	O	a	yes
O	O	control	no
O	O	program	no
O	O	of	yes
O	O	human	yes
O	O	african	no
O	O	trypanosomiasis	no
O	O	in	yes
O	O	the	no
O	O	district	no
O	O	of	yes
O	O	Moyo	no
O	O	,	no
B-drug_n	O	North-Uganda	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	increased	no
O	O	anticoagulant	no
O	O	effects	no
O	O	when	no
B-drug	B-drug	erythromycin	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	were	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	Verapamil	yes
O	O	also	no
O	O	significantly	no
O	O	decreased	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	lymphatic	no
O	O	invasion	no
O	O	of	yes
O	O	adenocarcinomas	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	enhanced	no
O	O	by	no
B-drug_n	B-drug_n	bombesin	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	high	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	leucovorin	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
O	O	intrathecally	no
O	O	administered	no
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	Other	no
O	O	factors	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	tolerance	no
O	O	and	yes
O	O	sensitization	no
O	O	to	no
O	O	the	no
O	O	drugs	no
O	O	'	no
O	O	actions	no
O	O	and	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	withdrawal	no
O	O	symptoms	no
O	O	,	no
O	O	may	no
O	O	also	no
O	O	contribute	no
O	O	to	no
O	O	dependence	no
O	O	.	no

O	O	epilepsy	no
O	O	;	no

B-drug	B-drug	Cisplatin	yes
O	O	was	no
O	O	administered	no
O	O	over	no
O	O	the	no
O	O	last	no
O	O	two	no
O	O	hours	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	thiosulfate	yes
O	O	infusion	no
O	O	.	no

O	O	Determinants	no
O	O	of	yes
O	O	cellular	no
O	O	sensitivity	no
O	O	to	no
O	B-group	topoisomerase-targeting	no
O	I-group	antitumor	no
O	I-group	drugs	no
O	O	.	no

O	O	Care	yes
O	O	should	no
O	O	be	no
O	O	given	no
O	O	when	no
O	O	administering	no
O	O	this	no
O	O	drug	yes
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	symptoms	no
O	O	of	yes
O	O	myasthenic	no
O	O	weakness	no
O	O	who	no
O	O	are	no
O	O	also	no
O	O	on	no
B-group	B-group	anticholinesterase	no
I-group	I-group	drugs	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Exjade	yes
O	O	and	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

O	O	it	no
O	O	was	no
O	O	independent	no
O	O	of	yes
O	O	the	no
O	O	influence	no
O	O	of	yes
O	O	the	no
O	O	nueronal	no
O	O	cell	yes
O	O	body	no
O	O	and	yes
O	O	of	yes
O	O	protein	yes
O	O	synthesis	no
O	O	within	no
O	O	the	no
O	O	axon	no
O	O	.	no

O	O	An	no
O	O	altered	no
O	O	biodistribution	no
O	O	may	no
O	O	provide	no
O	O	misleading	no
O	O	information	no
O	O	that	no
O	O	can	no
O	O	either	no
O	O	mask	no
O	O	or	no
O	O	mimic	no
O	O	certain	no
O	O	disease	no
O	O	symptoms	no
O	O	.	no

O	O	Such	no
O	O	data	no
O	O	are	no
O	O	discussed	no
O	O	herein	no
O	O	,	no
O	O	with	yes
O	O	emphasis	no
O	O	on	no
O	O	those	no
O	O	aspects	no
O	O	that	no
O	O	impact	no
O	O	on	no
O	O	the	no
O	O	clinical	no
O	O	use	no
O	O	of	yes
O	O	the	no
B-group	B-group	calcium-entry	no
I-group	I-group	antagonists	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	Ten	no
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	stabilized	no
O	O	on	no
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	were	no
O	O	given	no
B-drug	B-drug	guanfacine	yes
O	O	,	no
O	O	1-2	no
O	O	mg/day	no
O	O	,	no
O	O	for	yes
O	O	4	yes
O	O	weeks	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	with	yes
B-drug	B-drug	probenecid	yes
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	significantly	no
O	O	eliminated	no
O	O	by	no
O	O	active	no
O	O	renal	no
O	O	tubular	no
O	O	secretion	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	penciclovir	yes
O	O	.	no

B-drug	B-drug	Fenbufen	yes
O	O	is	yes
O	O	not	no
O	O	approved	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	States	no
O	O	at	yes
O	O	this	no
O	O	time	no
O	O	.	no

B-brand	B-brand	TAXOL	yes
O	O	contains	no
O	O	dehydrated	yes
B-drug	O	alcohol	yes
O	O	USP	yes
O	O	,	no
O	O	396	no
O	O	mg/mL	no
O	O	;	no

O	O	Another	no
O	O	oral	yes
B-group	B-group	azole	no
I-group	I-group	antifungal	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	elevated	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	astemizole	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
B-drug	B-drug_n	desmethylastermizole	no
O	O	which	no
O	O	may	no
O	O	prolong	no
O	O	QT	no
O	O	intervals	no
O	O	.	no

B-drug	B-drug	Lansoprazole	yes
O	O	has	no
O	O	also	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	amoxicillin	yes
O	O	.	no

O	O	Potential	no
O	O	drug	yes
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	Keppra	yes
O	O	and	yes
O	O	other	no
B-group	B-group	AEDs	no
O	O	(	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	gabapentin	yes
O	O	,	no
B-drug	B-drug	lamotrigine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	primidone	yes
O	O	and	yes
B-drug	B-drug	valproate	yes
O	O	)	no
O	O	were	no
O	O	also	no
O	O	assessed	no
O	O	by	no
O	O	evaluating	no
O	O	the	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	and	yes
O	O	these	no
B-group	B-group	AEDs	no
O	O	during	no
O	O	placebo-controlled	no
O	O	clinical	no
O	O	studies	no
O	O	.	no

O	O	These	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug_n	B-drug_n	ginsenosides	no
O	O	are	no
O	O	negatively	no
O	O	coupled	no
O	O	to	no
O	O	three	no
O	O	types	no
O	O	of	yes
O	O	calcium	yes
O	O	channels	no
O	O	in	yes
O	O	bovine	yes
O	O	chromaffin	no
O	O	cell	yes
O	O	,	no
O	O	including	no
O	O	an	no
B-drug_n	B-drug_n	omega-conotoxin	no
I-drug_n	O	GVIA-sensitive	no
O	O	(	no
O	O	N-type	no
O	O	)	no
O	O	channel	no
O	O	,	no
O	O	an	no
O	B-drug_n	omega-agatoxin	no
O	O	IVA-sensitive	no
O	O	(	no
O	O	P-type	no
O	O	)	no
O	O	channel	no
O	O	and	yes
O	B-drug	nimodipine/omega-conotoxin	no
O	B-drug_n	GVIA/omega-agatoxin	no
O	O	VIA-resistant	no
O	O	(	no
O	O	presumptive	no
O	O	Q-type	no
O	O	)	no
O	O	channel	no
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	with	yes
B-group	B-group	Beta-Blockers	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	fenoldopam	yes
O	O	with	yes
B-group	B-group	beta-blockers	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-drug	B-drug	Morphine	yes
O	O	prolonged	no
O	O	gastrointestinal	no
O	O	transit	no
O	O	time	no
O	O	from	no
O	O	69	no
O	O	to	no
O	O	103	no
O	O	minutes	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	.005	no
O	O	)	no
O	O	;	no
O	O	this	no
O	O	was	no
O	O	prevented	no
O	O	by	no
B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	.004	no
O	O	)	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	and	yes
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	increased	no
O	O	AUC	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	norethindrone	yes
O	O	and	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	by	no
O	O	approximately	no
O	O	30	yes
O	O	%	no
O	O	and	yes
O	O	20	yes
O	O	%	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
B-brand	B-brand	INDOCIN	yes
O	O	is	yes
O	O	administered	no
O	O	simultaneously	no
O	O	with	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	exfoliative	no
O	O	dermatitis	no

O	O	Therefore	no
O	O	,	no
O	O	it	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	that	no
O	O	a	yes
O	O	dosing	no
O	O	schedule	no
O	O	of	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	given	no
O	O	at	yes
O	O	bedtime	no
O	O	and	yes
B-drug	B-drug	cholestyramine	yes
O	O	given	no
O	O	before	no
O	O	the	no
O	O	evening	no
O	O	meal	no
O	O	would	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	significant	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	16	yes
O	O	%	no
O	O	and	yes
O	O	32	yes
O	O	%	no
O	O	increases	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	of	yes
O	O	the	no
O	O	combined	no
O	O	moieties	no
O	O	of	yes
O	B-drug_n	threohydrobupropion	no
O	O	and	yes
O	B-drug_n	erythrohydrobupropion	no
O	O	.	no

O	O	The	no
O	O	permeability	no
O	O	of	yes
O	O	the	no
O	O	cell	yes
O	O	membrane	yes
O	O	was	no
O	O	changed	no
O	O	as	yes
O	O	evidenced	no
O	O	by	no
O	O	the	no
O	O	leakage	no
O	O	of	yes
O	O	260-nm	no
O	O	absorbing	no
O	O	materials	no
O	O	,	no
O	O	amino	yes
O	O	acids	yes
O	O	,	no
O	O	proteins	no
O	O	,	no
O	O	and	yes
O	O	inorganic	yes
O	O	cations	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	nitazoxanide	yes
O	O	concurrently	no
O	O	with	yes
O	O	other	no
O	O	highly	no
O	O	plasma	yes
O	O	protein-bound	no
O	O	drugs	no
O	O	with	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	indices	no
O	O	,	no
O	O	as	yes
O	O	competition	no
O	O	for	yes
O	O	binding	no
O	O	sites	no
O	O	may	no
O	O	occur	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	plasma	yes
O	O	maximum	no
O	O	concentration	no
O	O	and	yes
O	O	area	no
O	O	under	no
O	O	the	no
O	O	plasma	yes
O	O	concentration-time	no
O	O	curve	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-drug	B-drug_n	desacetyldiltiazem	no
O	O	,	no
O	O	and	yes
B-drug	B-drug_n	desmethyldiltiazem	no
O	O	were	no
O	O	unchanged	no
O	O	after	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	potentiation	no
O	O	of	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	on	no
O	O	diastolic	no
O	O	or	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	or	no
O	O	on	no
O	O	the	no
O	O	electrocardiographic	no
O	O	parameters	no
O	O	was	no
O	O	seen	no
O	O	.	no

O	O	Prothrombin	yes
O	O	time	no
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	levetiracetam	yes
O	O	.	no

B-group	B-group	Noncardioselective	no
I-group	I-group	beta-blockers	no
O	O	(	no
B-drug	B-drug	nadolol	yes
O	O	,	no
B-drug	O	porpranolol	no
O	O	,	no
B-drug	B-drug	timolol	yes
O	O	)	no
O	O	may	no
O	O	exacerbate	no
O	O	rebound	no
O	O	hypertension	no
O	O	when	no
B-drug	B-drug	guanfacine	yes
O	O	is	yes
O	O	withdrawn	no
O	O	.	no

O	O	**No	no
O	O	significant	no
O	O	effect	no
O	O	.	no

O	O	Data	no
O	O	from	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	of	yes
B-group	B-group	benzodiazepines	no
O	O	other	no
O	O	than	no
B-drug	B-drug	alprazolam	yes
O	O	suggest	no
O	O	a	yes
O	O	possible	no
O	O	drug	yes
O	O	interaction	no
O	O	for	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	ergotamine	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-drug	B-drug	nicardipine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	nifedipine	yes
O	O	.	no

O	O	An	no
O	O	interacting	no
O	O	drug	yes
O	O	which	no
O	O	leads	no
O	O	to	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	necessitating	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	to	no
O	O	maintain	no
O	O	an	no
O	O	adequate	no
O	O	degree	no
O	O	of	yes
O	O	anticoagulation	no
O	O	may	no
O	O	,	no
O	O	if	no
O	O	abruptly	no
O	O	discontinued	no
O	O	,	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	subsequent	no
O	O	bleeding	no
O	O	.	no

O	O	Among	no
O	O	these	no
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	upper	no
O	O	gastrointestinal	no
O	O	adverse	no
O	O	experiences	no
O	O	in	yes
O	O	the	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	Ibandronate	yes
O	O	was	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	in	yes
O	O	placebo-treated	no
O	O	patients	no
O	O	.	no

B-group	B-group	Corticosteroids	no
O	O	,	no
B-group	B-group	Methylxanthines	no
O	O	and	yes
B-group	B-group	Diuretics	no
O	O	:	no
O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	xanthine	yes
I-group	I-group	derivatives	no
O	O	,	no
B-group	B-group	steroids	no
O	O	,	no
O	O	or	no
B-group	B-group	diuretics	no
O	O	may	no
O	O	potentiate	no
O	O	a	yes
O	O	possible	no
O	O	hypokalemic	no
O	O	effect	no
O	O	of	yes
B-group	B-group	beta2-agonists	no
O	I-group	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	The	no
O	O	presence	no
O	O	of	yes
B-drug	O	labetalol	yes
O	O	metabolites	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	falsely	no
O	O	elevated	no
O	O	levels	no
O	O	of	yes
O	O	urinary	yes
O	O	catecholamines	no
O	O	,	no
B-drug	O	metanephrine	no
O	O	,	no
B-drug	O	normetanephrine	no
O	O	and	yes
B-drug	O	vanillylmandelic	no
I-drug	O	acid	yes
O	O	when	no
O	O	measured	no
O	O	by	no
O	O	fluorimetric	no
O	O	or	no
O	O	photometric	no
O	O	methods	no
O	O	.	no

O	O	Eight	no
O	O	healthy	no
O	O	volunteers	no
O	O	were	no
O	O	randomized	no
O	O	in	yes
O	O	an	no
O	O	open-label	no
O	O	,	no
O	O	two-way	no
O	O	crossover	no
O	O	study	no
O	O	to	no
O	O	receive	no
B-drug	B-drug	oxycodone	yes
O	O	,	no
O	O	5	yes
O	O	mg	yes
O	O	p.o	no
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-group	B-group	coumarin-derivative	no
I-group	I-group	anticoagulants	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	capecitabine	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	regularly	no
O	O	for	yes
O	O	alterations	no
O	O	in	yes
O	O	their	no
O	O	coagulation	yes
O	O	parameters	no
O	O	(	no
O	O	PT	no
O	O	or	no
O	O	INR	no
O	O	)	no
O	O	.	no

O	B-group	Cytokines	no
O	O	(	no
B-drug	B-group	interferon	yes
O	O	,	no
O	B-group	interleukin	yes
O	O	)	no
O	O	:	no
B-group	B-group	Cytokines	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	induce	no
O	O	both	no
O	O	hyperthyroidism	no
O	O	and	yes
O	O	hypothyroidism	no
O	O	.	no

B-drug	B-drug	Corticotropin	yes
O	O	may	no
O	O	accentuate	no
O	O	the	no
O	O	electrolyte	yes
O	O	loss	no
O	O	associated	no
O	O	with	yes
B-group	B-drug	diuretic	no
O	O	therapy	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	low	yes
O	O	dietary	no
B-drug	B-drug	cobalt	yes
O	O	concentration	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	the	no
B-drug	B-drug	iron	yes
O	O	contents	no
O	O	of	yes
O	O	the	no
O	O	diets	no
O	O	,	no
O	O	no	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	cobalt	yes
O	O	on	no
B-drug	B-drug	iron	yes
O	O	absorption	no
O	O	and	yes
O	O	excretion	no
O	O	occurred	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	Antidepressants	no
O	O	:	no
O	O	Concurrent	no
O	O	use	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	therapeutic	no
O	O	and	yes
O	O	toxic	no
O	O	effects	no
O	O	of	yes
O	O	both	no
O	O	drugs	no
O	O	,	no
O	O	possibly	no
O	O	due	no
O	O	to	no
O	O	increased	no
O	O	catecholamine	no
O	O	sensitivity	no
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
O	O	:	no
O	O	The	no
O	O	pharmacokinetic	no
O	O	and	yes
O	O	pharmacodynamic	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	UROXATRAL	yes
O	O	and	yes
O	O	other	no
B-group	B-group	alpha-blockers	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	determined	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	SUPRAX	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	using	no
O	O	Clinitest	no
O	O	**	no
O	O	,	no
O	O	Benedict	no
O	O	s	yes
O	O	solution	yes
O	O	,	no
O	O	or	no
O	O	Fehling	no
O	O	s	yes
O	O	solution	yes
O	O	.	no

B-group	B-group	thyroid	yes
I-group	I-group	drugs	no
O	O	;	no

O	O	No	yes
O	O	formal	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	The	no
O	O	reduction	yes
O	O	in	yes
O	O	MAC	no
O	O	was	no
O	O	correlated	no
O	O	with	yes
O	O	brain	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	ketamine	yes
O	O	or	no
O	O	metabolite	yes
O	O	I	yes
O	O	,	no
O	O	suggesting	no
O	O	a	yes
B-drug	B-drug	ketamine	yes
O	O	:	no
O	O	metabolite	yes
O	O	I	yes
O	O	potency	no
O	O	ration	no
O	O	of	yes
O	O	3:1	no
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	demonstrated	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	incompatibility	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	with	yes
B-brand	B-brand	EXTRANEAL	yes
O	O	.	no

O	O	The	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	colchicine	yes
O	O	is	yes
O	O	potentiated	no
O	O	by	no
O	B-group	alkalinizing	no
O	I-group	agents	yes
O	O	.	no

O	O	In	yes
O	O	male	no
O	O	Sprague-Dawley	no
O	O	rats	no
O	O	fasted	no
O	O	for	yes
O	O	18	yes
O	O	h	yes
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	(	no
O	O	0.1	no
O	O	g/kg	no
O	O	,	no
O	O	i.p	no
O	O	.	no
O	O	)	no

O	O	If	no
O	O	combination	yes
O	O	therapy	no
O	O	is	yes
O	O	needed	no
O	O	,	no
O	O	careful	no
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	the	no
O	O	pharmacology	no
O	O	of	yes
O	O	all	yes
O	O	agents	yes
O	O	to	no
O	O	be	no
O	O	used	no
O	O	.	no

B-drug	B-drug	Zalcitabine	yes
O	O	inhibited	no
B-drug	B-drug	lamivudine	yes
O	O	phosphorylation	no
O	O	at	yes
O	O	high	yes
O	O	concentration	no
O	O	ratios	no
O	O	(	no
O	O	10	yes
O	O	and	yes
O	O	100	yes
O	O	)	no
O	O	;	no

B-drug	B-drug	Lithium	yes
O	O	generally	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	because	no
O	O	they	no
O	O	reduce	no
O	O	its	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

B-drug	B-drug	Valdecoxib	yes
O	O	caused	no
O	O	a	yes
O	O	statistically	no
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	exposures	no
O	O	of	yes
B-drug	B-drug	R-warfarin	no
O	O	and	yes
B-drug	B-drug	S-warfarin	no
O	O	(	no
O	O	12	yes
O	O	%	no
O	O	and	yes
O	O	15	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	pharmacodynamic	no
O	O	effects	no
O	O	(	no
O	O	prothrombin	yes
O	O	time	no
O	O	,	no
O	O	measured	no
O	O	as	yes
O	O	INR	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-group	B-group	NSAIDs	no
O	O	have	no
O	O	produced	no
O	O	an	no
O	O	elevation	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	.	no

O	O	Mutagenicity	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	;	no

O	O	The	no
O	O	relative	no
O	O	risk	no
O	O	of	yes
O	O	myocardial	no
O	O	infarction	no
O	O	during	no
O	O	sexual	no
O	O	activity	yes
O	O	is	yes
O	O	not	no
O	O	significantly	no
O	O	higher	no
O	O	than	no
O	O	for	yes
O	O	healthy	no
O	O	persons	no
O	O	.	no

O	O	Those	no
O	O	for	yes
O	O	which	no
O	O	effectiveness	no
O	O	is	yes
O	O	reported	no
O	O	includes	no
B-drug	B-drug	diphenhydramine	yes
O	O	,	no
B-drug	B-drug	hydroxyzine	yes
O	O	,	no
B-drug	B-drug	orphenadrine	yes
O	O	,	no
B-drug	B-drug	pyrilamine	yes
O	O	,	no
B-drug	B-drug_n	phenyltoloxamine	no
O	O	,	no
B-drug	B-drug	promethazine	yes
O	O	,	no
B-drug	B-drug	methdilazine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	tripelennamine	yes
O	O	.	no

O	O	Heart	no
O	O	rate	no
O	O	increased	no
O	O	initially	no
O	O	and	yes
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	40	yes
O	O	minutes	no
O	O	after	no
B-drug	B-drug	ethanol	yes
O	O	challenge	no
O	O	.	no

O	O	The	no
O	O	concentration	no
O	O	of	yes
B-brand	B-brand	AMICAR	yes
O	O	necessary	no
O	O	to	no
O	O	maintain	no
O	O	inhibition	no
O	O	of	yes
O	O	fibrinolysis	yes
O	O	is	yes
O	O	0.99	no
O	O	mMol/L	no
O	O	or	no
O	O	0.13	no
O	O	mg/mL	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	unless	no
O	O	otherwise	no
O	O	specified	yes
O	O	,	no
O	O	appropriate	no
O	O	dosage	no
O	O	adjustments	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	absorption	no
O	O	,	no
O	O	metabolism	no
O	O	,	no
O	O	and	yes
O	O	elimination	no
O	O	of	yes
O	O	each	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	unchanged	no
O	O	when	no
O	O	they	no
O	O	are	no
O	O	used	no
O	O	together	no
O	O	.	no

B-group	B-group	Short-Acting	no
I-group	I-group	beta2-agonists	no
O	O	:	no
O	O	Aerosol	no
B-group	B-group	bronchodilators	no
O	O	of	yes
O	O	the	no
B-group	O	short-acting	no
I-group	O	adrenergic	no
I-group	O	stimulant	no
I-group	O	type	yes
O	O	may	no
O	O	be	no
O	O	used	no
O	O	for	yes
O	O	relief	yes
O	O	of	yes
O	O	breakthrough	no
O	O	symptoms	no
O	O	while	no
O	O	using	no
B-drug	B-drug	formoterol	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	gabapentin	yes
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	following	no
B-brand	B-brand	Maalox	no
O	O	administration	no
O	O	.	no

B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	;	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	When	no
O	O	healthy	no
O	O	subjects	no
O	O	were	no
O	O	administered	no
B-brand	B-brand	Starlix	yes
O	O	120	no
O	O	mg	yes
O	O	three	no
O	O	times	no
O	O	daily	no
O	O	before	no
O	O	meals	no
O	O	for	yes
O	O	four	no
O	O	days	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	30	yes
O	O	mg	yes
O	O	on	no
O	O	day	no
O	O	2	yes
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	alterations	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	.	no

B-drug	B-brand	Cerubidine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	previously	no
O	O	received	no
O	O	the	no
O	O	recommended	no
O	O	maximum	no
O	O	cumulative	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	doxorubicin	yes
O	O	or	no
B-drug	B-brand	Cerubidine	yes
O	O	.	no

O	O	However	no
O	O	,	no
B-brand	B-drug_n	L-NAME	yes
O	O	(	no
O	O	100	yes
O	O	and	yes
O	O	300	yes
O	O	micromol/l	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-brand	B-drug_n	reseveratrol	no
O	O	on	no
O	O	arteries	no
O	O	from	no
O	O	dietary-obese	no
O	O	rats	no
O	O	,	no
O	O	giving	no
O	O	superimposed	no
O	O	concentration-responses	no
O	O	curves	no
O	O	.	no

O	O	-	yes
O	O	a	yes
O	O	sulfa-based	no
O	O	drug	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	sulfamethoxazole-trimethoprim	no
O	O	(	no
B-brand	B-brand	Bactrim	yes
O	O	,	no
B-brand	B-brand	Septra	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	sulfisoxazole	yes
O	O	(	no
B-brand	B-brand	Gantrisin	yes
O	O	)	no
O	O	,	no
O	O	or	no
B-drug	B-drug	sulfasalazine	yes
O	O	(	no
B-drug	B-brand	Azulfidine	yes
O	O	)	no
O	O	;	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	SPRYCEL	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	CYP3A4	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	atazanavir	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	,	no
B-drug	B-drug	telithromycin	yes
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	exposure	yes
O	O	to	no
B-drug	B-drug	dasatinib	yes
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	be	no
O	O	cautioned	no
O	O	against	yes
O	O	engaging	no
O	O	in	yes
O	O	hazardous	no
O	O	activities	no
O	O	requiring	no
O	O	complete	yes
O	O	mental	no
O	O	alertness	no
O	O	such	no
O	O	as	yes
O	O	operating	no
O	O	machinery	no
O	O	or	no
O	O	driving	no
O	O	a	yes
O	O	motor	no
O	O	vehicle	no
O	O	.	no

O	O	If	no
O	O	a	yes
B-group	B-group	diuretic	no
O	O	is	yes
O	O	also	no
O	O	used	no
O	O	,	no
O	O	the	no
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	.	no

B-drug	B-drug	Insulin	yes
O	O	or	no
O	O	Oral	yes
B-group	B-group	Hypoglycemics	no
O	O	:	no
O	B-group	Agents	yes
O	I-group	with	yes
B-group	I-group	b-blocking	no
O	I-group	properties	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	blood-sugar-reducing	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	insulin	yes
O	O	and	yes
O	O	oral	yes
B-group	B-group	hypoglycemics	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	drug	yes
O	O	interactions	no
O	O	were	no
O	O	studied	no
O	O	with	yes
B-drug	B-drug	ketoprofen	yes
O	O	doses	no
O	O	of	yes
O	O	200	yes
O	O	mg/day	no
O	O	.	no

O	O	The	no
O	O	gonadotropin	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	transiently	no
O	O	elevated	no
O	O	by	no
B-drug	B-drug	spironolactone	yes
O	O	,	no
O	O	minimally	no
O	O	elevated	no
O	O	by	no
B-drug	B-drug	levodopa	yes
O	O	,	no
O	O	and	yes
O	O	suppressed	no
O	O	by	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Careful	no
O	O	observations	no
O	O	on	no
O	O	hepatotoxicity	no
O	O	are	no
O	O	suggested	no
O	O	when	no
B-drug	B-drug	acetaminophen	yes
O	O	is	yes
O	O	prescribed	no
O	O	with	yes
B-drug	B-drug	caffeine	yes
O	O	.	no

O	O	Lipids	no
O	O	:	no
O	O	Pretreatment	no
O	O	and	yes
O	O	follow-up	no
O	O	blood	yes
O	O	lipids	no
O	O	should	no
O	O	be	no
O	O	obtained	no
O	O	under	no
O	O	fasting	no
O	O	conditions	no
O	O	.	no

O	O	This	no
O	O	effect	no
O	O	should	no
O	O	be	no
O	O	kept	no
O	O	in	yes
O	O	mind	no
O	O	when	no
O	O	bleeding	no
O	O	times	no
O	O	are	no
O	O	determined	no
O	O	.	no

B-brand	B-brand	Trecator	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	adverse	no
O	O	effects	no
O	O	of	yes
O	O	other	no
O	B-group	antituberculous	no
O	I-group	drugs	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Immunodeficiency-associated	no
O	O	lymphocyte	yes
O	O	disorders	no
O	O	(	no
O	O	plasmacytic	no
O	O	hyperplasia	no
O	O	,	no
O	O	polymorphic	no
O	O	proliferation	no
O	O	,	no
O	O	and	yes
O	O	B-cell	no
O	O	lymphomas	no
O	O	)	no
O	O	occur	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	congenital	no
O	O	or	no
O	O	acquired	no
O	O	immunodeficiencies	no
O	O	including	no
O	O	those	no
O	O	resulting	no
O	O	from	no
B-group	B-group	immunosuppressive	no
O	O	therapy	no
O	O	.	no

O	O	Prescribing	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Hydroxychloroquine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Plaquenil	yes
O	O	)	no
O	O	or	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	myopathy	no
O	O	is	yes
O	O	also	no
O	O	increased	no
O	O	by	no
O	O	the	no
O	O	following	no
O	O	lipid-lowering	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	potent	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	,	no
O	O	but	no
O	O	which	no
O	O	can	no
O	O	cause	no
O	O	myopathy	no
O	O	when	no
O	O	given	no
O	O	alone	no
O	O	.	no

B-drug	B-drug	Codeine	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	B-group	narcotic	no
I-group	I-group	analgesics	no
O	O	,	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	tranquilizers	no
O	O	,	no
B-group	B-group	sedative-hypnotics	no
O	O	,	no
O	O	or	no
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	(	no
O	O	including	no
B-drug	B-drug	alcohol	yes
O	O	)	no
O	O	has	no
O	O	additive	no
O	O	depressant	no
O	O	effects	no
O	O	.	no

O	O	Potential	no
O	O	for	yes
O	O	serious	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	risk	no
O	O	of	yes
O	O	myopathy	no
O	O	including	no
O	O	rhabdomyolysis	no
O	O	.	no

B-drug	B-drug	Heparin	yes
O	O	:	no
O	O	Since	no
B-drug	B-drug	heparin	yes
O	O	is	yes
O	O	contraindicated	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	B-drug	heparin-induced	no
O	O	thrombocytopenia	no
O	O	,	no
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	and	yes
B-drug	B-drug	heparin	yes
O	O	is	yes
O	O	unlikely	no
O	O	for	yes
O	O	this	no
O	O	indication	no
O	O	.	no

O	O	If	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	needed	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	before	no
B-drug	B-drug	cimetidine	yes
O	O	administration	no
O	O	.	no

B-drug	B-drug	Terfenadine	yes
O	O	:	no
O	O	Administration	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	with	yes
B-brand	B-brand	VIRACEPT	yes
O	O	resulted	no
O	O	in	yes
O	O	the	no
O	O	appearance	no
O	O	of	yes
O	O	unchanged	no
B-drug	B-drug	terfenadine	yes
O	O	in	yes
O	O	plasma	yes
O	O	;	no

O	O	increased	no
O	O	levels	no
O	O	of	yes
O	O	fibrinogen	yes
O	O	and	yes
O	O	fibrinogen	yes
O	O	activity	yes
O	O	;	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
B-drug	B-drug	Probenecid	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	metabolism	no
O	O	or	no
O	O	renal	no
O	O	tubular	no
O	O	excretion	no
O	O	of	yes
O	O	many	no
O	O	drugs	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	acetaminophen	yes
O	O	,	no
B-drug	B-drug	acyclovir	yes
O	O	,	no
B-group	B-group	angiotensin-converting	no
I-group	I-group	enzyme	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	,	no
B-drug	B-drug	bumetanide	yes
O	O	,	no
B-drug	B-drug	clofibrate	yes
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
B-drug	B-drug	famotidine	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	O	agents	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	zidovudine	yes
O	O	)	no
O	O	.	no

O	O	The	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug_n	B-drug_n	18-MC	no
O	O	has	no
O	O	a	yes
O	O	narrower	no
O	O	spectrum	no
O	O	of	yes
O	O	actions	no
O	O	and	yes
O	O	will	no
O	O	have	no
O	O	a	yes
O	O	substantially	no
O	O	greater	no
O	O	therapeutic	no
O	O	index	no
O	O	than	no
B-drug_n	B-drug_n	ibogaine	no
O	O	.	no

B-drug	B-drug	Cyclopentolate	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	anti-glaucoma	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	carbachol	yes
O	O	or	no
B-drug	B-drug	pilocarpine	yes
O	O	;	no

B-group	B-group	Anticonvulsants	no
O	O	(	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	felbamate	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	topiramate	yes
O	O	)	no
O	O	:	no
O	O	Increase	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and/or	no
O	O	some	no
B-group	B-group	progestins	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	possible	no
O	O	decrease	no
O	O	in	yes
O	O	contraceptive	yes
O	O	effectiveness	no
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	While	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	shown	no
B-drug	B-drug	diclofenac	yes
O	O	to	no
O	O	interact	no
O	O	with	yes
B-group	B-group	anticoagulants	no
O	I-group	of	yes
O	I-group	the	no
B-drug	I-group	warfarin	yes
O	I-group	type	yes
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	,	no
O	O	nonetheless	no
O	O	,	no
O	O	since	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	seen	no
O	O	with	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	.	no

B-drug	B-drug	Methenamine	yes
O	O	therapy	no
O	O	Urinary	yes
O	O	excretion	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	is	yes
O	O	increased	no
O	O	,	no
O	O	and	yes
O	O	efficacy	no
O	O	is	yes
O	O	reduced	yes
O	O	by	no
B-group	O	acidifying	no
I-group	O	agents	yes
O	O	used	no
O	O	in	yes
B-drug	B-drug	methenamine	yes
O	O	therapy	no
O	O	.	no

O	O	Dose	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	lapatinib	yes
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	for	yes
O	O	patients	no
O	O	who	no
O	O	must	no
O	O	receive	no
O	O	concomitant	no
O	O	strong	no
O	O	inhibitors	no
O	O	or	no
O	O	concomitant	no
O	O	strong	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	enzymes	yes
O	O	.	no

O	O	Short-term	no
O	O	controlled	no
O	O	studies	no
O	O	failed	no
O	O	to	no
O	O	show	no
O	O	that	no
O	O	taking	no
O	O	the	no
O	O	drug	yes
O	O	significantly	no
O	O	affects	no
O	O	prothrombin	yes
O	O	times	no
O	O	when	no
O	O	administered	no
O	O	to	no
O	O	individuals	no
O	O	on	no
B-group	B-group	coumarin-type	no
I-group	I-group	anticoagulants	no
O	O	.	no

O	O	Monitoring	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	may	no
O	O	be	no
O	O	helpful	no
O	O	when	no
O	O	possible	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	suspected	no
O	O	.	no

O	O	SUSTIVAhas	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	decrease	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	.	no

O	O	Interaction	no
O	O	of	yes
B-drug	B-drug	gentamycin	no
O	O	and	yes
B-drug	B-drug	atracurium	yes
O	O	in	yes
O	O	anaesthetised	no
O	O	horses	no
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	Although	no
O	O	not	no
O	O	observed	no
O	O	in	yes
O	O	this	no
O	O	study	no
O	O	,	no
O	O	adverse	no
O	O	effects	no
O	O	could	no
O	O	potentially	no
O	O	arise	no
O	O	from	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	cephalexin	yes
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	tubular	no
O	O	secretion	no
O	O	via	no
O	O	organic	no
O	O	cationic	no
O	O	transporter	no
O	O	systems	no
O	O	.	no

O	O	In	yes
O	O	bioavailability	no
O	O	studies	no
O	O	with	yes
O	O	normal	yes
O	O	subjects	no
O	O	,	no
O	O	the	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	at	yes
O	O	therapeutic	no
O	O	levels	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	influence	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-brand	B-brand	TRANXENE	yes
O	O	tablets	yes
O	O	.	no

B-drug	B-drug	Nitroglycerin	yes
O	O	:	no
B-drug	B-brand	DynaCirc	yes
O	O	(	no
B-drug	B-drug	isradipine	yes
O	O	)	no
O	O	has	no
O	O	been	no
O	O	safely	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	nitroglycerin	yes
O	O	.	no

O	O	Even	no
O	O	though	no
O	O	such	no
O	O	interactions	no
O	O	were	no
O	O	not	no
O	O	seen	no
O	O	during	no
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	volume	no
O	O	of	yes
O	O	circulating	no
O	O	fluids	no
O	O	might	no
O	O	be	no
O	O	required	no
O	O	if	no
O	O	such	no
O	O	an	no
O	O	interaction	no
O	O	were	no
O	O	to	no
O	O	occur	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
O	O	substrates	no
O	O	of	yes
O	O	C.P.A	no
O	O	.	no
O	O	were	no
O	O	not	no
O	O	excluded	no
O	O	from	no
O	O	clinical	no
O	O	trials	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
B-brand	B-brand	Keppra	yes
O	O	(	no
O	O	1000	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	)	no
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	R	yes
O	O	and	yes
B-drug	B-drug	S	yes
I-drug	I-drug	warfarin	yes
O	O	.	no

O	O	Hepatotoxic	no
O	O	Drugs	no
O	O	Increased	no
O	O	side	no
O	O	effects	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	leflunomide	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	hepatotoxic	no
O	O	substances	no
O	O	.	no

O	O	Physicians	no
O	O	needing	no
O	O	to	no
O	O	treatpatients	no
O	O	co-infected	no
O	O	with	yes
O	O	tuberculosis	yes
O	O	andusing	no
O	O	a	yes
B-drug	B-drug	nevirapine	yes
O	O	containing	yes
O	O	regimen	no
O	O	mayuse	no
B-drug	B-drug	rifabutin	yes
O	O	instead	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	study	no
O	O	,	no
O	O	38	no
O	O	healthy	no
O	O	female	no
O	O	subjects	no
O	O	received	no
B-drug	B-drug	ketoconazole	yes
O	O	200	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	,	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	alosetron	yes
O	O	1	yes
O	O	mg	yes
O	O	on	no
O	O	the	no
O	O	last	no
O	O	day	no
O	O	.	no

B-drug	B-drug	ketoconazole	yes
O	O	)	no
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	erythromycin	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	HIV	no
I-group	I-group	protease	yes
I-group	I-group	inhibitors	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	indinavir	yes
O	O	and	yes
B-drug	B-drug	saquinavir	yes
O	O	)	no
O	O	should	no
O	O	have	no
O	O	their	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	SUBUTEX	yes
O	O	or	no
B-brand	B-brand	SUBOXONE	yes
O	O	adjusted	yes
O	O	.	no

O	O	It	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	to	no
O	O	adjust	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	anticoagulants	no
O	O	upon	no
O	O	beginning	no
O	O	or	no
O	O	stopping	no
B-drug	B-drug	disulfiram	yes
O	O	.	no
O	O	since	no
B-drug	B-drug	disulfiram	yes
O	O	may	no
O	O	prolong	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	advised	no
O	O	nonetheless	no
O	O	,	no
O	O	since	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	seen	no
O	O	with	yes
O	O	other	no
B-group	O	nonsteroidal	no
I-group	O	agents	yes
O	O	of	yes
O	O	this	no
O	O	class	no
O	O	.	no

O	O	The	no
O	O	simplest	no
O	O	inference	no
O	O	is	yes
O	O	that	no
O	O	the	no
O	O	toxicity	no
O	O	and	yes
O	O	effectiveness	no
O	O	of	yes
B-group	O	polyenes	no
O	O	are	no
O	O	determined	no
O	O	by	no
O	O	their	no
O	O	relative	no
O	O	avidities	no
O	O	for	yes
O	O	the	no
O	O	predominant	no
O	O	sterol	no
O	O	in	yes
O	O	cell	yes
O	O	membranes	no
O	O	.	no

O	O	In	yes
O	O	Study	no
O	O	1	yes
O	O	,	no
O	O	patients	no
O	O	receiving	no
O	O	bolus-IFL	no
O	O	plus	yes
B-brand	B-brand	AVASTIN	yes
O	O	had	no
O	O	a	yes
O	O	higher	no
O	O	incidence	no
O	O	of	yes
O	O	Grade	no
O	O	3-4	no
O	O	diarrhea	no
O	O	and	yes
O	O	neutropenia	no
O	O	.	no

O	O	Plasma	yes
B-group	B-group	TCA	no
O	O	concentrations	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
B-group	B-group	TCA	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	reduced	yes
O	O	if	no
O	O	a	yes
B-group	B-group	TCA	no
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	Duloxetine	yes
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	is	yes
O	O	little	no
O	O	risk	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	contraceptive	yes
O	O	efficacy	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	increased	no
O	O	exposures	no
O	O	in	yes
O	O	terms	no
O	O	of	yes
O	O	safety	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Additional	no
O	O	clinical	no
O	O	experience	no
O	O	may	no
O	O	reveal	no
O	O	other	no
O	O	drugs	no
O	O	affected	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Tagamet	yes
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	Antidepressants	no
O	O	:	no
O	O	Use	no
O	O	of	yes
O	B-group	thyroid	yes
O	I-group	products	no
O	O	with	yes
B-drug	B-drug	imipramine	yes
O	O	and	yes
O	O	other	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	increase	no
O	O	receptor	yes
O	O	sensitivity	no
O	O	and	yes
O	O	enhance	no
O	O	antidepressant	no
O	O	activity	yes
O	O	transient	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	on	no
O	O	Low-Dose	no
O	B-group	Combination	yes
O	I-group	Oral	yes
B-group	I-group	Contraceptives	no
O	O	A	yes
O	O	group	yes
O	O	of	yes
O	O	24	yes
O	O	nonsmoking	no
O	O	,	no
O	O	healthy	no
O	O	white	yes
O	O	female	no
O	O	volunteers	no
O	O	established	no
O	O	on	no
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	regimen	no
O	O	containing	yes
O	O	30	yes
O	O	mg	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
O	O	75	yes
O	O	mg	yes
B-drug	B-drug	gestodene	yes
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	3	yes
O	O	months	no
O	O	received	no
O	O	2400	no
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	from	no
O	O	midcycle	no
O	O	(	no
O	O	day	no
O	O	15	yes
O	O	)	no
O	O	to	no
O	O	midcycle	no
O	O	(	no
O	O	day	no
O	O	14	yes
O	O	)	no
O	O	of	yes
O	O	two	no
O	O	consecutive	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	cycles	no
O	O	.	no

O	O	The	no
O	O	median	no
O	O	survival	no
O	O	for	yes
O	O	CHOP-HAART	no
O	O	patients	no
O	O	was	no
O	O	not	no
O	O	reached	no
O	O	,	no
O	O	whereas	no
O	O	the	no
O	O	medial	no
O	O	survival	no
O	O	of	yes
O	O	CHOP	no
O	O	patients	no
O	O	was	no
O	O	7	yes
O	O	months	no
O	O	(	no
O	O	P	yes
O	O	=	no
O	O	0.03	no
O	O	)	no
O	O	.	no

O	O	increased	no
O	O	platelet	yes
O	O	count	no
O	O	;	no

B-drug	B-drug	Tadalafil	yes

B-drug	B-drug	Cisapride	yes
O	O	was	no
O	O	well	no
O	O	tolerated	no
O	O	when	no
O	O	administered	no
O	O	alone	no
O	O	or	no
O	O	with	yes
B-drug	B-drug	fluoxetine	yes
O	O	.	no

B-group	B-group	H2	no
I-group	I-group	Blockers	no
O	O	and	yes
B-group	B-group	Proton	no
I-group	I-group	Pump	no
I-group	I-group	Inhibitors	no
O	O	(	no
B-group	B-group	PPIs	no
O	O	)	no

B-group	B-group	Antihistamines	no
O	O	may	no
O	O	partially	no
O	O	counteract	no
O	O	the	no
O	O	anticoagulation	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Since	no
B-brand	B-brand	FOSCAVIR	yes
O	O	decreases	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	ionized	no
O	O	calcium	yes
O	O	,	no
O	O	concurrent	no
O	O	treatment	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	influence	no
O	O	serum	yes
O	O	calcium	yes
O	O	concentrations	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	particular	no
O	O	caution	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	add	no
O	O	some	no
O	O	further	no
O	O	antihypertensive	no
O	O	effect	no
O	O	to	no
B-drug	B-drug	captopril	yes
O	O	,	no
O	O	but	no
O	O	the	no
O	O	overall	no
O	O	response	no
O	O	is	yes
O	O	less	no
O	O	than	no
O	O	additive	no
O	O	.	no

O	B-drug	chymotrypsin	no
O	O	;	no

O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	ertapenem	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	metabolism	no
O	O	mediated	no
O	O	by	no
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	six	no
O	O	cytochrome	no
O	O	p450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	isoforms	no
O	O	:	no
O	O	1A2	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	2E1	no
O	O	and	yes
O	O	3A4	no
O	O	.	no

O	O	These	no
O	O	events	no
O	O	required	no
O	O	medical	yes
O	O	intervention	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Interaction	no
O	O	studies	no
O	O	in	yes
O	O	humans	no
O	O	have	no
O	O	shown	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	digoxin	yes
O	O	blood	yes
O	O	levels	no
O	O	.	no

B-group	B-group	Potassium-depleting	no
I-group	I-group	diuretics	no
O	O	are	no
O	O	a	yes
O	O	major	no
O	O	contributing	no
O	O	factor	yes
O	O	to	no
B-group	B-group	digitalis	yes
O	O	toxicity	no
O	O	.	no

O	O	Rhabdomyolysis	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	administered	no
O	O	alone	no
O	O	(	no
O	O	at	yes
O	O	recommended	no
O	O	dosages	no
O	O	)	no
O	O	or	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	immunosuppressive	no
I-group	I-group	drugs	no
O	O	including	no
B-drug	B-drug	cyclosporine	yes
O	O	.	no

B-drug	B-drug	Magnesium	yes
O	O	and	yes
O	O	therapeutics	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	lipid-lowering	no
O	O	drugs	no
O	O	that	no
O	O	can	no
O	O	cause	no
O	O	myopathy	no
O	O	when	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	Geriatric	no
O	O	Use	no

B-drug	B-drug	Quetiapine	yes
I-drug	I-drug	fumarate	yes
O	O	(	no
B-brand	B-brand	'Seroquel	no
O	O	'	no
O	O	)	no
O	O	is	yes
O	O	a	yes
O	O	newly	no
O	O	introduced	no
B-group	B-group	atypical	no
I-group	I-group	antipsychotic	no
O	O	with	yes
O	O	demonstrated	no
O	O	efficacy	no
O	O	in	yes
O	O	the	no
O	O	treatment	no
O	O	of	yes
O	O	positive	no
O	O	and	yes
O	O	negative	no
O	O	symptoms	no
O	O	of	yes
O	O	schizophrenia	no
O	O	.	no

O	B-drug	glucagon	yes
O	O	;	no

O	O	In	yes
O	O	the	no
O	O	case	no
O	O	of	yes
O	O	severe	no
O	O	neutropenia	no
O	O	(	no
O	O	500	yes
O	O	cells/mm3	no
O	O	for	yes
O	O	seven	no
O	O	days	no
O	O	or	no
O	O	more	no
O	O	)	no
O	O	during	no
O	O	a	yes
O	O	course	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	therapy	no
O	O	,	no
O	O	a	yes
O	O	20	yes
O	O	%	no
O	O	reduction	yes
O	O	in	yes
O	O	dose	no
O	O	for	yes
O	O	subsequent	no
O	O	courses	no
O	O	of	yes
O	O	therapy	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	adult	yes
O	O	data	no
O	O	,	no
O	O	lower	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	may	no
O	O	be	no
O	O	needed	no
O	O	following	no
O	O	coadministration	no
O	O	of	yes
O	O	drugs	no
O	O	which	no
O	O	are	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
B-drug	B-drug	caffeine	yes
O	O	elimination	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	)	no
O	O	and	yes
O	O	higher	no
B-drug	B-drug	caffeine	yes
O	O	doses	no
O	O	may	no
O	O	be	no
O	O	needed	no
O	O	following	no
O	O	coadministration	no
O	O	of	yes
O	O	drugs	no
O	O	that	no
O	O	increase	no
B-drug	B-drug	caffeine	yes
O	O	elimination	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Disulfiram	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Antabuse	yes
O	O	)	no
O	O	or	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
B-brand	B-brand	MEPRON	yes
O	O	Suspension	yes
O	O	results	no
O	O	in	yes
O	O	a	yes
O	O	significant	no
O	O	decrease	no
O	O	in	yes
O	O	average	no
O	O	steady-	no
O	O	state	no
O	O	plasma	yes
B-drug	B-drug	atovaquone	yes
O	O	concentrations	no
O	O	.	no

O	O	When	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	were	no
O	O	concomitantly	no
O	O	administered	no
O	O	intravenously	no
O	O	to	no
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	a	yes
O	O	10-20	no
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	blood	yes
O	O	levels	no
O	O	at	yes
O	O	some	no
O	O	time	no
O	O	points	no
O	O	.	no

O	O	Grapefruit	no
O	O	juice	no
O	O	increases	no
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	concentrations	no
O	O	and	yes
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
B-drug	B-drug	progesterone	yes
O	O	serum	yes
O	O	levels	no
O	O	as	yes
O	O	well	no
O	O	;	no

B-drug	B-drug	Rifabutin	yes

B-drug	B-drug	Acetazolamide	yes
O	O	and	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	bicarbonate	yes
O	O	used	no
O	O	concurrently	no
O	O	increases	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	renal	no
O	O	calculus	no
O	O	formation	no
O	O	.	no

B-drug	I-drug	Efavirenz	yes

O	O	Moreover	no
O	O	,	no
O	O	the	no
O	O	basal	no
O	O	and	yes
B-drug_n	B-drug_n	dmPGE2-induced	no
I-drug_n	O	jejunal	no
O	O	net	no
O	O	fluid	no
O	O	transfers	no
O	O	were	no
O	O	the	no
O	O	same	yes
O	O	in	yes
O	O	cecectomized	no
O	O	and	yes
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	clinical	no
O	O	pharmacology	no
O	O	study	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
O	O	an	no
B-group	B-group	antacid	no
O	O	(	no
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydroxide	yes
O	O	,	no
B-drug	B-drug	magnesium	yes
I-drug	I-drug	hydroxide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	simethicone	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	fosinopril	yes
O	O	reduced	yes
O	O	serum	yes
O	O	levels	no
O	O	and	yes
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug_n	fosinoprilat	no
O	O	as	yes
O	O	compared	no
O	O	with	yes
B-drug	B-drug	fosinopril	yes
O	O	administered	no
O	O	alone	no
O	O	,	no
O	O	suggesting	no
O	O	that	no
B-group	B-group	antacids	no
O	O	may	no
O	O	impair	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	fosinopril	yes
O	O	.	no

O	O	The	no
O	O	renal	no
O	O	effects	no
O	O	of	yes
O	O	nephrotoxic	no
O	O	compounds	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-drug	B-drug	Carboplatin	yes
O	O	.	no

O	O	Further	no
O	O	,	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	PROSCAR	yes
O	O	(	no
B-drug	B-drug	finasteride	yes
O	O	,	no
O	O	5	yes
O	O	mg	yes
O	O	)	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	older	no
O	O	men	no
O	O	who	no
O	O	have	no
O	O	benign	no
O	O	prostatic	no
O	O	hyperplasia	no
O	O	(	no
O	O	BPH	no
O	O	)	no
O	O	,	no
O	O	PSA	no
O	O	levels	no
O	O	are	no
O	O	decreased	no
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	may	no
O	O	suppress	no
O	O	certain	no
O	O	CYP450	no
O	O	enzymes	yes
O	O	,	no
O	O	including	no
O	B-drug	CYP1A2	no
O	O	,	no
O	B-drug	CYP2C9	no
O	O	,	no
O	B-drug	CYP2D6	no
O	O	,	no
O	O	and	yes
O	B-drug	CYP3A4	no
O	O	.	no

O	O	Influence	no
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	and	yes
B-drug	B-drug	progesterone	yes
O	O	on	no
O	O	the	no
O	O	sensitivity	no
O	O	of	yes
O	O	rat	yes
O	O	thoracic	no
O	O	aorta	no
O	O	to	no
B-drug	B-drug	noradrenaline	yes
O	O	.	no

O	O	Use	no
O	O	of	yes
B-drug	B-brand	Cerubidine	yes
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	who	no
O	O	has	no
O	O	previously	no
O	O	received	no
B-drug	B-drug	doxorubicin	yes
O	O	increases	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	cardiotoxicity	no
O	O	.	no

O	O	Because	no
B-brand	B-brand	Anafranil	yes
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	serum	yes
O	O	protein	yes
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Anafranil	yes
O	O	to	no
O	O	patients	no
O	O	taking	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	protein	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	,	no
O	O	potentially	no
O	O	resulting	no
O	O	in	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Olanzapine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	3	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	olanzapine	yes
O	O	10	yes
O	O	mg	yes
O	O	produced	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	DSST	no
O	O	scores	no
O	O	.	no

O	O	METHOD	yes
O	O	:	no
O	O	This	no
O	O	study	no
O	O	was	no
O	O	a	yes
O	O	multicenter	no
O	O	randomized	no
O	O	double-blind	no
O	O	study	no
O	O	of	yes
O	O	101	yes
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	randomly	no
O	O	assigned	no
O	O	1:1:1	no
O	O	to	no
O	O	receive	no
B-drug	B-drug	everolimus	yes
O	O	tablets	yes
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	0.5	yes
O	O	mg	yes
O	O	,	no
O	O	1	yes
O	O	mg	yes
O	O	,	no
O	O	or	no
O	O	2	yes
O	O	mg	yes
O	O	twice	no
O	O	daily	no
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	and	yes
B-drug	B-drug	prednisone	yes
O	O	.	no

O	O	The	no
O	O	onset	no
O	O	of	yes
O	O	symptoms	no
O	O	usually	no
O	O	occurred	no
O	O	within	no
O	O	hours	no
O	O	(	no
O	O	most	no
O	O	commonly	no
O	O	1	yes
O	O	to	no
O	O	4	yes
O	O	hours	no
O	O	)	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	contrast	no
O	O	media	no
O	O	.	no

O	O	The	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	decreases	no
O	O	the	no
O	O	biologic	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	fenoprofen	yes
O	O	because	no
O	O	of	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	metabolic	no
O	O	clearance	no
O	O	that	no
O	O	results	no
O	O	in	yes
O	O	a	yes
O	O	greater	no
O	O	amount	no
O	O	of	yes
O	B-drug_n	hydroxylated	no
B-drug	I-drug_n	fenoprofen	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	.	no

O	O	If	no
B-brand	B-brand	NovoLog	yes
O	O	is	yes
O	O	mixed	yes
O	O	with	yes
B-drug	B-drug	NPH	yes
I-drug	I-drug	human	yes
I-drug	I-drug	insulin	yes
O	O	,	no
B-brand	B-brand	NovoLog	yes
O	O	should	no
O	O	be	no
O	O	drawn	no
O	O	into	no
O	O	the	no
O	O	syringe	yes
O	O	first	no
O	O	.	no

O	O	The	no
O	O	fraction	yes
O	O	of	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	absorbed	no
O	O	is	yes
O	O	unaffected	no
O	O	by	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nasal	no
I-group	I-group	vasoconstrictor	no
O	O	(	no
B-drug	B-drug	oxymetazoline	yes
O	O	)	no
O	O	,	no
O	O	but	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	absorption	no
O	O	is	yes
O	O	decreased	no
O	O	.	no

O	O	Minor	no
O	O	symptoms	no
O	O	such	no
O	O	as	yes
O	O	flushing	no
O	O	,	no
O	O	skin	yes
O	O	reactions	no
O	O	,	no
O	O	dyspnea	no
O	O	,	no
O	O	hypotension	no
O	O	,	no
O	O	or	no
O	O	tachycardia	no
O	O	do	no
O	O	not	no
O	O	require	no
O	O	interruption	no
O	O	of	yes
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Spermine	yes
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	a	yes
O	O	lesser	no
O	O	extent	no
O	O	,	no
B-drug	B-drug_n	spermidine	yes
O	O	,	no
O	O	enhanced	no
O	O	the	no
O	O	translocating	no
O	O	action	no
O	O	of	yes
O	O	oleate	yes
O	O	and	yes
O	O	increased	no
O	O	its	no
O	O	effectiveness	no
O	O	in	yes
O	O	transferring	no
O	O	the	no
O	O	phosphohydrolase	no
O	O	from	no
O	O	the	no
O	O	soluble	no
O	O	to	no
O	O	the	no
O	O	microsomal	no
O	O	fraction	yes
O	O	.	no

O	O	Carcinogenesis	no
O	O	,	no
O	O	Mutagenesis	no
O	O	and	yes
O	O	Impairment	no
O	O	of	yes
O	O	Fertility	no
O	O	A	yes
O	O	two-year	no
O	O	carcinogenesis	no
O	O	study	no
O	O	was	no
O	O	conducted	no
O	O	in	yes
O	O	female	no
O	O	and	yes
O	O	male	no
O	O	rats	no
O	O	,	no
O	O	at	yes
O	O	intramuscular	no
O	O	doses	no
O	O	of	yes
O	O	15	yes
O	O	mg/kg/30	no
O	O	days	no
O	O	,	no
O	O	10	yes
O	O	mg/rat/30	no
O	O	days	no
O	O	and	yes
O	O	10	yes
O	O	mg/rat/15	no
O	O	days	no
O	O	.	no

O	O	Although	no
O	O	in	yes
O	O	vivo	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	done	no
O	O	to	no
O	O	see	no
O	O	if	no
B-drug	B-drug	etodolac	yes
O	O	clearance	no
O	O	is	yes
O	O	changed	no
O	O	by	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	that	no
O	O	they	no
O	O	be	no
O	O	coadministered	no
O	O	.	no

O	O	Products	no
O	O	containing	yes
B-drug	B-drug	calcium	yes
O	O	and	yes
O	O	other	no
O	B-drug	multivalent	no
O	I-drug	cations	no
O	O	likely	no
O	O	will	no
O	O	interfere	no
O	O	with	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	alendronate	yes
O	O	.	no

B-drug	B-drug	Enoxaparin	yes
O	O	dosed	no
O	O	as	yes
O	O	a	yes
O	O	1.0	no
O	O	mg/kg	no
O	O	subcutaneous	yes
O	O	injection	yes
O	O	q12h	no
O	O	for	yes
O	O	four	no
O	O	doses	no
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	eptifibatide	yes
O	O	or	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	in	yes
O	O	healthy	no
O	O	adults	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	indicate	no
O	O	that	no
O	O	the	no
O	O	pancreatic	yes
O	O	alpha	yes
O	O	cell	yes
O	O	of	yes
O	O	the	no
O	O	diabetic	no
O	O	Chinese	yes
O	O	hamster	no
O	O	responds	no
O	O	excessively	no
O	O	to	no
B-drug	B-drug	arginine	yes
O	O	,	no
O	O	as	yes
O	O	is	yes
O	O	seen	no
O	O	in	yes
O	O	the	no
O	O	human	yes
O	O	diabetic	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	AUC	no
O	O	values	no
O	O	of	yes
O	O	LNG	no
O	O	were	no
O	O	decreased	no
O	O	by	no
O	O	32	yes
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	20-45	no
O	O	]	no
O	O	in	yes
O	O	one	no
O	O	study	no
O	O	and	yes
O	O	52	no
O	O	%	no
O	O	[	no
O	O	90	yes
O	O	%	no
O	O	CI	yes
O	O	:	no
O	O	42-52	no
O	O	]	no
O	O	in	yes
O	O	another	no
O	O	study	no
O	O	.	no

O	O	Cohort	no
O	O	1	yes
O	O	then	no
O	O	received	no
B-drug	B-drug	amprenavir	yes
O	O	plus	yes
B-drug	B-drug	rifabutin	yes
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	,	no
O	O	and	yes
O	O	cohort	no
O	O	2	yes
O	O	received	no
B-drug	B-drug	amprenavir	yes
O	O	plus	yes
B-drug	B-drug	rifampin	yes
O	O	for	yes
O	O	4	yes
O	O	days	no
O	O	.	no

B-group	B-group	Protease	yes
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	indinavir	yes
O	O	and	yes
B-drug	B-drug	ritonavir	yes
O	O	markedly	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	which	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	cisapride	yes
O	O	levels	no
O	O	and	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	Death	no
O	O	due	no
O	O	to	no
B-drug	O	fulminant	no
O	O	pancreatitis	no
O	O	possibly	no
O	O	related	yes
O	O	to	no
O	O	intravenous	yes
B-drug	B-drug	pentamidine	yes
O	O	and	yes
B-drug	B-drug	HIVID	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	These	no
O	O	findings	no
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	into	no
O	O	account	no
O	O	for	yes
O	O	proper	no
O	O	interpretation	no
O	O	of	yes
O	O	serum	yes
O	O	PSA	no
O	O	when	no
O	O	evaluating	no
O	O	men	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	finasteride	yes
O	O	.	no

O	O	The	no
O	O	dosage	no
O	O	of	yes
O	O	these	no
O	O	medications	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	changed	no
O	O	and	yes
O	O	they	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	stopped	no
O	O	without	no
O	O	consulting	no
O	O	the	no
O	O	physician	no
O	O	,	no
O	O	even	no
O	O	if	no
O	O	the	no
O	O	patient	no
O	O	feels	no
O	O	better	no
O	O	after	no
O	O	initiating	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	FORADIL	yes
O	O	.	no

B-group	B-group	Diuretic	no
I-group	I-group	agents	yes
O	O	reduce	no
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	and	yes
O	O	add	no
O	O	a	yes
O	O	high	yes
O	O	risk	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	action	no
O	O	of	yes
O	O	the	no
B-group	B-group	benzodiazepines	no
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
B-group	B-group	anticonvulsants	no
O	O	,	no
B-group	B-group	antihistamines	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	narcotics	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	psychotropic	no
I-group	I-group	medications	no
O	O	,	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	produce	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	Although	no
O	O	there	no
O	O	is	yes
O	O	no	yes
O	O	documentation	no
O	O	of	yes
O	O	such	no
O	O	,	no
O	O	a	yes
O	O	similar	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	ethotoin	yes
O	O	and	yes
O	O	the	no
B-group	B-group	coumarin	yes
I-group	I-group	anticoagulants	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	if	no
O	O	necessary	no
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	can	no
O	O	continue	no
O	O	to	no
O	O	be	no
O	O	used	no
O	O	after	no
O	O	insertion	no
O	O	of	yes
O	O	a	yes
O	O	pacemaker	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	severe	no
O	O	bradycardia	no
O	O	or	no
O	O	sinus	yes
O	O	arrest	no
O	O	.	no

O	O	Although	no
O	O	neither	no
B-drug	B-drug	dexamethasone	yes
O	O	nor	yes
B-drug	B-drug	retinyl	no
I-drug	I-drug	acetate	yes
O	O	affected	no
O	O	the	no
O	O	proliferation	no
O	O	of	yes
O	O	prostatic	no
O	O	epithelium	no
O	O	in	yes
O	O	RPMI1640	no
O	O	containing	yes
B-drug	B-drug_n	transferrin	no
O	O	alone	no
O	O	,	no
O	O	they	no
O	O	modify	no
O	O	the	no
O	O	mitogenic	no
O	O	effect	no
O	O	of	yes
B-drug_n	B-drug_n	EGF	no
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	.	no

B-group	B-group	Barbiturates	no
O	O	and	yes
B-drug	B-drug	glutethimide	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	coumarin	yes
I-group	I-group	drugs	no
O	O	.	no

O	O	If	no
O	O	pregnancy	no
O	O	occurs	no
O	O	while	no
O	O	taking	no
B-brand	B-brand	AMEVIVE	no
O	O	,	no
O	O	continued	no
O	O	use	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	should	no
O	O	be	no
O	O	assessed	no
O	O	.	no

O	O	drugs	no
O	O	affecting	no
O	O	blood	yes
O	O	elements	no
O	O	;	no

O	O	Electrolyte	yes
O	O	Disturbances	no
O	O	Patients	no
O	O	with	yes
O	O	hypokalemia	no
O	O	or	no
O	O	hypomagnesemia	no
O	O	should	no
O	O	have	no
O	O	the	no
O	O	condition	no
O	O	corrected	no
O	O	whenever	no
O	O	possible	no
O	O	before	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-brand	B-drug	Cordarone	yes
O	I-drug	I.V.	yes
O	O	,	no
O	O	as	yes
O	O	these	no
O	O	disorders	no
O	O	can	no
O	O	exaggerate	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	QTc	no
O	O	prolongation	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	TdP	no
O	O	.	no

O	O	Potentially	no
O	O	fatal	no
O	O	drug	yes
O	O	interactions	no
O	O	may	no
O	O	occur	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	as	yes
O	O	this	no
O	O	may	no
O	O	enhance	no
O	O	cardiovascular	no
O	O	depression	no
O	O	and	yes
O	O	bradyarrhythmias	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	O	Interacts	no
O	O	with	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes

O	O	Furthermore	no
O	O	,	no
B-drug	B-drug_n	arsenate	no
O	O	and	yes
B-drug	B-drug	phosphate	yes
O	O	do	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	share	no
O	O	a	yes
O	O	common	yes
O	O	transport	no
O	O	pathway	no
O	O	in	yes
O	O	the	no
O	O	duodenum	no
O	O	and	yes
O	O	no	yes
O	O	evidence	no
O	O	was	no
O	O	obtained	no
O	O	for	yes
O	O	any	no
O	O	interaction	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	at	yes
O	O	this	no
O	O	level	no
O	O	.	no

O	O	Ingestion	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	may	no
O	O	increase	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	methotrexate	yes
O	O	and	yes
O	O	increase	no
B-drug	B-drug	cyclosporine	yes
O	O	s	yes
O	O	nephrotoxicity	no
O	O	.	no

O	O	No	yes
O	O	dose	no
O	O	adjustment	no
O	O	is	yes
O	O	necessary	no
O	O	when	no
B-brand	B-brand	Simulect	yes
O	O	is	yes
O	O	added	no
O	O	to	no
O	O	triple-immunosuppression	no
O	O	regimens	no
O	O	including	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	and	yes
O	O	either	no
B-drug	B-drug	azathioprine	yes
O	O	or	no
B-drug	B-drug	mycophenolate	yes
I-drug	I-drug	mofetil	yes
O	O	.	no

O	O	Inhibition	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	isozymes	no
O	O	evaluated	no
O	O	(	no
O	O	CYPs	no
O	O	2A1	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	3A4	no
O	O	,	no
O	O	and	yes
O	O	3E1	no
O	O	)	no
O	O	was	no
O	O	0-16	no
O	O	%	no
O	O	.	no

O	O	Taken	no
O	O	together	no
O	O	,	no
O	O	these	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	site	no
O	O	of	yes
O	O	the	no
O	O	inhibitory	yes
O	O	action	no
O	O	of	yes
B-drug_n	B-drug_n	RR	no
O	O	is	yes
O	O	at	yes
O	O	the	no
B-drug_n	O	InsP	no
O	O	(	no
O	O	3	yes
O	O	)	no
O	O	receptor	yes
O	O	,	no
O	O	or	no
O	O	its	no
O	O	closely	no
O	O	associated	no
O	O	proteins	no
O	O	.	no

O	O	Iodometric	no
O	O	titration	yes
O	O	of	yes
O	O	the	no
O	O	polymer	yes
O	O	conjugates	no
O	O	was	no
O	O	used	no
O	O	to	no
O	O	determine	no
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	immobilised	no
B-drug	B-drug	cysteine	yes
O	O	.	no

O	O	The	no
O	O	duration	no
O	O	of	yes
O	O	the	no
O	O	period	no
O	O	following	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	AMEVIVE	no
O	O	before	no
O	O	one	no
O	O	should	no
O	O	consider	no
O	O	starting	no
O	O	other	no
B-group	B-group	immunosuppressive	no
O	O	therapy	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	.	no

O	O	Plasma	yes
O	O	membrane	yes
O	O	and	yes
O	O	intracellular	no
O	O	mobilization	no
O	O	of	yes
B-drug	O	calcium	yes
O	O	ions	no
O	O	are	no
O	O	intimately	no
O	O	related	yes
O	O	to	no
O	O	platelet	yes
O	O	activation	no
O	O	and	yes
O	O	release	yes
O	O	of	yes
O	O	platelet	yes
O	O	contents	no
O	O	.	no

O	O	Prior	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	neuromuscular	no
O	O	block	yes
O	O	following	no
O	O	initial	no
O	O	or	no
O	O	maintenance	no
O	O	bolus	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	.	no

O	O	-	yes
O	O	Increased	no
O	O	serum	yes
O	O	triglyceride	yes
O	O	and	yes
O	O	phospholipid	no
O	O	concentration	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-drug	B-drug	flurbiprofen	yes
O	O	and	yes
B-drug	B-drug	furosemide	yes
O	O	or	no
O	O	other	no
B-group	B-group	diuretics	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

B-group	B-group	Quinolones	no
O	O	,	no
O	O	including	no
B-drug	B-drug	nalidixic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	or	no
B-drug	B-drug	digoxin	yes
O	O	has	no
O	O	led	no
O	O	to	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	three	no
O	O	drugs	no
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
O	O	other	no
O	B-group	potassium-sparing	no
B-group	I-group	antihypertensives	no
O	O	with	yes
B-group	B-group	NSAIDs	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	and	yes
O	O	result	no
O	O	in	yes
O	O	severe	no
O	O	hyperkalemia	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	.	no

B-drug	B-drug	Anastrozole	yes
O	O	inhibited	no
O	O	in	yes
O	O	vitro	no
O	O	metabolic	no
O	O	reactions	no
O	O	catalyzed	no
O	O	by	no
O	O	cytochromes	no
O	O	P450	no
O	O	1A2	no
O	O	,	no
O	O	2C8/9	no
O	O	,	no
O	O	and	yes
O	O	3A4	no
O	O	but	no
O	O	only	no
O	O	at	yes
O	O	relatively	no
O	O	high	yes
O	O	concentrations	no
O	O	.	no

O	O	(	no
O	O	Effects	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	;	no

B-drug	B-drug	Chloral	yes
I-drug	I-drug	hydrate	yes
O	O	and	yes
B-drug	B-drug	methaqualone	yes
O	O	interact	no
O	O	pharmacologically	no
O	O	with	yes
O	O	orally	no
O	O	administered	no
B-group	B-group	anticoagulant	no
I-group	I-group	agents	yes
O	O	,	no
O	O	but	no
O	O	the	no
O	O	effect	no
O	O	is	yes
O	O	not	no
O	O	clinically	no
O	O	significant	no
O	O	.	no

O	O	Standard	yes
O	O	therapy	no
O	O	includes	no
B-group	B-group	antibiotics	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	penicillin	yes
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	;	no

O	O	This	no
O	O	effect	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

B-drug	B-drug	Leucovorin	yes
O	O	:	no
O	O	The	no
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	5-fluorouracil	yes
O	O	is	yes
O	O	increased	no
O	O	and	yes
O	O	its	no
O	O	toxicity	no
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
B-drug	B-drug	leucovorin	yes
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	warranted	no
O	O	and	yes
O	O	therapeutic	no
O	O	concentration	no
O	O	monitoring	no
O	O	is	yes
O	O	recommended	no
O	O	for	yes
B-group	B-group	antiarrhythmics	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	.	no

O	O	This	no
O	O	slowing	no
O	O	potentiates	no
B-group	B-group	amphetamines	no
O	O	,	no
O	O	increasing	no
O	O	their	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	release	yes
O	O	of	yes
B-drug	O	norepinephrine	yes
O	O	and	yes
O	O	other	no
O	O	monoamines	no
O	O	from	no
O	O	adrenergic	no
O	O	nerve	yes
O	O	endings	no
O	O	;	no

O	O	The	no
O	O	majority	no
O	O	of	yes
O	O	these	no
O	O	reports	no
O	O	concerned	no
O	O	variable	no
O	O	elevations	no
O	O	in	yes
O	O	prothrombin	yes
O	O	times	no
O	O	without	no
O	O	clinically	no
O	O	significant	no
O	O	sequelae	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-group	B-group	Antacids	no
O	O	on	no
B-brand	B-brand	Felbatol	yes
O	O	The	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	of	yes
O	O	a	yes
O	O	2400	no
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	as	yes
O	O	monotherapy	no
O	O	given	no
O	O	as	yes
O	O	tablets	yes
O	O	was	no
O	O	not	no
O	O	affected	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	.	no

O	O	There	no
O	O	has	no
O	O	been	no
O	O	too	no
O	O	little	no
O	O	experience	no
O	O	with	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	with	yes
B-drug	B-drug	nifedipine	yes
O	O	or	no
B-drug	B-drug	diltiazem	yes
O	O	to	no
O	O	recommend	no
O	O	concomitant	no
O	O	use	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	increased	no
O	O	exposure	yes
B-drug	B-drug	tonevirapine	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	inconcomitant	no
O	O	administration	no
O	O	,	no
O	O	and	yes
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	for	yes
B-drug	O	nevirapine-associated	no
O	O	adverse	no
O	O	events	no
O	O	.	no

B-group	B-group	Cardiac	no
I-group	I-group	Glycosides	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	of	yes
O	O	young	no
O	O	healthy	no
O	O	male	no
O	O	subjects	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	a	yes
O	O	direct	no
O	O	pharmacokinetic	no
O	B-drug	captopril-digoxin	no
O	O	interaction	no
O	O	could	no
O	O	be	no
O	O	found	no
O	O	.	no

O	O	Monitor	no
O	O	cardiovascular	no
O	O	status	no
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

B-drug	I-drug	methadone	yes
O	O	concentration	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	information	no
O	O	regarding	no
O	O	the	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	lamivudine	yes
O	O	pharmacokinetics	no
O	O	of	yes
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	TMP/SMX	no
O	O	such	no
O	O	as	yes
O	O	those	no
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	Pneumocystis	no
O	O	carinii	no
O	O	pneumonia	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	known	no
O	O	metabolic	no
O	O	profiles	no
O	O	,	no
O	O	clinically	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	not	no
O	O	expected	no
O	O	between	yes
B-brand	B-brand	VIRACEPT	yes
O	O	and	yes
B-drug	B-drug	dapsone	yes
O	O	,	no
B-drug	B-drug	trimethoprim/sulfamethoxazole	no
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	or	no
B-drug	B-drug	fluconazole	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	cyclosporin	yes
O	O	level	no
O	O	is	yes
O	O	recommended	no
O	O	and	yes
O	O	,	no
O	O	if	no
O	O	necessary	no
O	O	,	no
B-drug	B-drug	chloroquine	yes
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	.	no

B-drug	B-drug	Lapatinib	yes
O	O	inhibits	no
O	O	human	yes
O	O	P-glycoprotein	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	anticoagulants	no
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	hypoglycemic	no
O	O	action	no
O	O	of	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	and	yes
B-drug	B-drug	chlorpropamide	yes
O	O	,	no
O	O	by	no
O	O	inhibiting	no
O	O	their	no
O	O	metabolism	no
O	O	in	yes
O	O	the	no
O	O	liver	yes
O	O	.	no

O	O	The	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	include	no
O	O	some	no
O	O	that	no
O	O	are	no
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	enzyme	no
O	O	(	no
B-drug	B-drug	quinidine	yes
O	O	;	no

O	O	No	yes
O	O	formal	no
O	O	drug/drug	no
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	Plenaxis	yes
O	O	were	no
O	O	performed	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	levetiracetam	yes
O	O	.	no

O	O	All	yes
B-group	O	antagonists	no
O	O	decreased	no
O	O	the	no
O	O	time	no
O	O	spent	no
O	O	in	yes
O	O	the	no
O	O	light	yes
O	O	zone	no
O	O	in	yes
O	O	this	no
O	O	test	yes
O	O	,	no
O	O	which	no
O	O	suggested	no
O	O	that	no
O	O	these	no
O	O	compounds	no
O	O	have	no
O	O	anxiogenic	no
O	O	effects	no
O	O	.	no

O	O	iv	yes
O	O	.	no

B-group	O	Nucleoside	yes
O	O	Analogues	no
O	B-drug	Didanosine	yes
O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	COPEGUS	yes
O	O	and	yes
B-drug	B-drug	didanosine	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Glutathione-S-transferase	no
O	O	(	no
O	O	GST	no
O	O	)	no
O	O	activity	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	did	no
O	O	not	no
O	O	differ	no
O	O	from	no
O	O	control	no
O	O	values	no
O	O	for	yes
O	O	any	no
O	O	dose	no
O	O	or	no
O	O	at	yes
O	O	any	no
O	O	time	no
O	O	point	no
O	O	in	yes
O	O	cerebral	no
O	O	and	yes
O	O	hepatic	no
O	O	tissues	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	if	no
O	O	a	yes
O	O	patient	no
O	O	has	no
O	O	been	no
O	O	titrated	no
O	O	to	no
O	O	a	yes
O	O	stable	no
O	O	dosage	no
O	O	of	yes
B-brand	B-brand	EQUETROTM	no
O	O	,	no
O	O	and	yes
O	O	then	no
O	O	begins	no
O	O	a	yes
O	O	course	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	CYP3A4	no
O	O	or	no
O	O	epoxide	no
O	O	hydrolase	yes
O	O	inhibitors	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	reasonable	no
O	O	to	no
O	O	expect	no
O	O	that	no
O	O	a	yes
O	O	dose	no
O	O	reduction	yes
O	O	for	yes
B-brand	B-brand	EQUETROTM	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	ten-subject	no
O	O	study	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
O	O	(	no
O	O	120	no
O	O	mg	yes
O	O	bid	no
O	O	)	no
O	O	with	yes
B-drug	B-drug	lovastatin	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	3-4	no
O	O	times	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
B-drug	B-drug	lovastatin	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	vs.	no
B-drug	B-drug	lovastatin	yes
O	O	alone	no
O	O	;	no

O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	in	yes
O	O	patients	no
O	O	undergoing	no
O	O	PTCA/PCI	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-brand	B-brand	Angiomax	yes
O	O	with	yes
B-drug	B-drug	heparin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-group	B-group	thrombolytics	no
O	O	or	no
B-group	O	glycoprotein	no
I-group	O	IIb/IIIa	no
I-group	O	inhibitors	no
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	increased	no
O	O	risks	no
O	O	of	yes
O	O	major	no
O	O	bleeding	no
O	O	events	no
O	O	compared	no
O	O	to	no
O	O	patients	no
O	O	not	no
O	O	receiving	no
O	O	these	no
O	O	concomitant	no
O	O	medications	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	The	no
O	O	urine	no
O	O	of	yes
O	O	patients	no
O	O	who	no
O	O	take	no
B-brand	B-brand	Lodine	yes
O	O	can	no
O	O	give	no
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	urinary	yes
O	O	bilirubin	no
O	O	(	no
O	O	urobilin	no
O	O	)	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	phenolic	no
O	O	metabolites	no
O	O	of	yes
B-drug	B-drug	etodolac	yes
O	O	.	no

B-group	B-group	Hormonal	no
I-group	I-group	Contraceptives	no
O	O	:	no
O	O	It	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	if	no
O	O	there	no
O	O	is	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	acitretin	yes
O	O	and	yes
O	B-group	combined	no
O	I-group	oral	yes
B-group	I-group	contraceptives	no
O	O	.	no

B-group	B-group	Beta-blockers	no
O	O	not	no
O	O	only	no
O	O	block	yes
O	O	the	no
O	O	therapeutic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	beta-agonists	no
O	O	,	no
O	O	but	no
O	O	may	no
O	O	produce	no
O	O	severe	no
O	O	bronchospasm	no
O	O	in	yes
O	O	COPD	no
O	O	patients	no
O	O	.	no

O	O	A	yes
O	O	smaller	no
O	O	24-week	no
O	O	study	no
O	O	has	no
O	O	suggested	no
B-drug	B-drug	nevirapine	yes
O	O	may	no
O	O	be	no
O	O	superior	no
O	O	to	no
O	O	the	no
O	B-group	PI	no
B-drug	B-drug	nelfinavir	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	and	yes
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	adjusted	yes
O	O	as	yes
O	O	required	no
O	O	.	no

O	O	Tablets	yes
O	O	,	no
O	O	Injection	yes
O	O	,	no
O	O	and	yes
O	O	Oral	yes
O	O	Solution	yes
O	O	One	no
O	O	study	no
O	O	in	yes
O	O	six	no
O	O	subjects	no
O	O	demonstrated	no
O	O	that	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	temporarily	no
O	O	reduced	yes
O	O	creatinine	yes
O	O	clearance	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	chronic	no
O	O	renal	no
O	O	insufficiency	no
O	O	.	no

O	O	Because	no
O	O	the	no
O	O	potential	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	efavirenz	yes
O	O	with	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	fully	no
O	O	characterized	no
O	O	,	no
O	O	a	yes
O	O	reliable	no
O	O	method	yes
O	O	of	yes
O	O	barrier	no
O	O	contraception	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	addition	no
O	O	to	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	.	no

O	O	and	yes
O	O	exert	no
O	O	direct	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	mechanisms	no
O	O	of	yes
B-drug	O	insulin	yes
O	O	resistance	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	whenever	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	co-therapy	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
I-group	I-group	agent	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	Transfer	no
O	O	from	no
O	O	the	no
O	O	intestinal	no
O	O	lumen	no
O	O	to	no
O	O	the	no
O	O	mucosal	no
O	O	cells	yes
O	O	at	yes
O	O	low	yes
B-drug_n	B-drug_n	As	yes
I-drug_n	I-drug_n	(	no
I-drug_n	I-drug_n	V	yes
I-drug_n	I-drug_n	)	no
O	O	concentration	no
O	O	(	no
O	O	0.1	no
O	O	mM	yes
O	O	)	no
O	O	is	yes
O	O	rapid	no
O	O	,	no
O	O	while	no
O	O	transfer	no
O	O	from	no
O	O	the	no
O	O	mucosal	no
O	O	cells	yes
O	O	to	no
O	O	the	no
O	O	body	no
O	O	occurs	no
O	O	more	no
O	O	slowly	no
O	O	.	no

O	O	Increased	no
B-drug	B-drug	metoprolol	yes
O	O	plasma	yes
O	O	levels	no
O	O	have	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	decreased	no
O	O	cardioselectivity	no
O	O	.	no

B-group	B-group	Bacteriostatic	yes
I-group	I-group	Antibiotics	no
O	O	:	no
B-drug	B-drug	Chloramphenicol	yes
O	O	,	no
B-group	B-drug	erythromycins	no
O	O	,	no
B-group	B-group	sulfonamides	yes
O	O	,	no
O	O	or	no
B-group	B-group	tetracyclines	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	bactericidal	no
O	O	effect	no
O	O	of	yes
B-group	B-group	penicillins	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	possible	no
O	O	that	no
O	O	the	no
O	O	cardiovascular	no
O	O	action	no
O	O	of	yes
O	O	other	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	could	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-brand	B-brand	Nimotop	yes
O	O	.	no

O	O	Free	yes
O	O	T4	yes
O	O	and	yes
O	O	T3	yes
O	O	concentrations	no
O	O	are	no
O	O	unaltered	no
O	O	.	no

B-group	O	uterine	no
I-group	O	fibroids	no
O	O	;	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	tacrolimus	yes
O	O	and	yes
B-drug	B-drug	bosentan	yes
O	O	resulted	no
O	O	in	yes
O	O	markedly	no
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	in	yes
O	O	animals	no
O	O	.	no

B-drug	B-drug	sucralfate	yes
O	O	or	no
O	O	divalent	no
O	O	or	no
O	O	trivalent	no
O	O	cations	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	iron	yes
O	O	;	no

O	B-drug_n	Indocyanine	yes
O	I-drug_n	green	yes
O	O	as	yes
O	O	an	no
O	O	index	no
O	O	of	yes
O	O	hepatic	no
O	O	drug	yes
O	O	extraction	no
O	O	has	no
O	O	been	no
O	O	tested	no
O	O	and	yes
O	O	no	yes
O	O	significant	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	found	no
O	O	.	no

O	O	Tumors	no
O	O	of	yes
O	O	more	no
O	O	malignant	no
O	O	phenotype	no
O	O	were	no
O	O	demonstrated	no
O	O	only	no
O	O	in	yes
O	O	genetically	no
O	O	predisposed	no
O	O	mice	no
O	O	(	no
O	O	C57BL/6N	no
O	O	X	yes
O	O	C3H/HeN	no
O	O	F1	no
O	O	)	no
O	O	that	no
O	O	received	no
O	O	one	no
O	O	dose	no
O	O	of	yes
O	O	carcinogen	no
O	O	.	no

O	O	use	no
B-drug	B-drug	potassium	yes
O	O	supplements	no
O	O	if	no
O	O	necessary	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	when	no
B-drug	B-drug	ketoprofen	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

B-brand	B-brand	Tagamet	yes
O	O	,	no
O	O	apparently	no
O	O	through	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	certain	no
O	O	microsomal	no
O	O	enzyme	no
O	O	systems	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	warfarin-type	no
I-group	I-group	anticoagulants	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
B-drug	B-drug	diazepam	yes
O	O	,	no
O	O	certain	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	and	yes
B-drug	B-drug	metronidazole	yes
O	O	,	no
O	O	thereby	no
O	O	delaying	no
O	O	elimination	no
O	O	and	yes
O	O	increasing	no
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	A	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	ketones	no
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	tests	no
O	O	using	no
B-drug	B-drug	nitroprusside	yes
O	O	but	no
O	O	not	no
O	O	with	yes
O	O	those	no
O	O	using	no
B-drug	B-drug	nitroferricyanide	yes
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	adverse	no
O	O	reactions	no
O	O	from	no
O	O	the	no
O	O	drugs	no
O	O	in	yes
O	O	nursing	no
O	O	infants	no
O	O	,	no
O	O	a	yes
O	O	decision	no
O	O	must	no
O	O	be	no
O	O	made	no
O	O	whether	no
O	O	to	no
O	O	discontinue	no
O	O	nursing	no
O	O	or	no
O	O	discontinue	no
B-brand	B-brand	PEGASYS	yes
O	O	and	yes
B-brand	B-brand	COPEGUS	yes
O	O	treatment	no
O	O	.	no

O	O	Several	no
O	O	classes	no
O	O	of	yes
O	O	cardiovascular	no
O	O	drugs	no
O	O	are	no
O	O	also	no
O	O	discussed	no
O	O	in	yes
O	O	relationship	no
O	O	to	no
O	O	their	no
O	O	differential	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	management	no
O	O	and	yes
O	O	progression	no
O	O	of	yes
O	O	renal	no
O	O	disease	no
O	O	.	no

O	O	Exercise	no
O	O	that	no
O	O	produces	no
O	O	cardiopulmonary	no
O	O	stimulation	no
O	O	is	yes
O	O	a	yes
O	O	helpful	no
O	O	means	no
O	O	of	yes
O	O	reducing	no
O	O	drug	yes
O	O	hunger	no
O	O	and	yes
O	O	anxiety	no
O	O	during	no
O	O	recovery	no
O	O	therapy	no
O	O	.	no

O	O	There	no
O	O	has	no
O	O	been	no
O	O	little	no
O	O	experience	no
O	O	with	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	TAMBOCOR	yes
O	O	and	yes
O	O	either	no
B-drug	B-drug	disopyramide	yes
O	O	or	no
B-drug	B-drug	verapamil	yes
O	O	.	no

O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cefdinir	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	urine	no
O	O	using	no
O	O	Clinitest	no
O	O	,	no
O	O	Benedict	no
O	O	s	yes
O	O	solution	yes
O	O	,	no
O	O	or	no
O	O	Fehlings	no
O	O	solution	yes
O	O	.	no

O	O	Anaesthesia	no
O	O	and	yes
O	O	the	no
O	O	epileptic	no
O	O	pateint	no
O	O	.	no

O	O	.	no

O	O	therefore	no
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	(	no
O	O	with	yes
O	O	food	no
O	O	)	no
O	O	one	no
O	O	hour	yes
O	O	after	no
O	O	or	no
O	O	more	no
O	O	than	no
O	O	two	no
O	O	hours	no
O	O	before	no
B-drug	B-drug	didanosine	yes
O	O	.	no

O	O	Dose	no
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	to	no
O	O	half	no
O	O	the	no
O	O	standard	yes
O	O	dose	no
O	O	and	yes
O	O	a	yes
O	O	dose	no
O	O	increase	no
O	O	of	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	to	no
O	O	1000	yes
O	O	mg	yes
O	O	(	no
O	O	three	no
O	O	333-mg	no
O	O	capsules	no
O	O	)	no
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	are	no
O	O	recommended	no
O	O	when	no
B-drug	B-drug	rifabutin	yes
O	O	and	yes
B-brand	B-brand	CRIXIVAN	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

B-drug	B-drug	Succinylcholine	yes
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	sudden	no
O	O	extrusion	no
O	O	of	yes
O	O	potassium	yes
O	O	from	no
O	O	muscle	no
O	O	cells	yes
O	O	,	no
O	O	and	yes
O	O	may	no
O	O	thereby	no
O	O	cause	no
O	O	arrhythmias	no
O	O	in	yes
O	O	digitalized	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	dextrothyroxine	yes
O	O	;	no

O	O	Cardiac	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	dopamine	yes
O	O	are	no
O	O	antagonized	no
O	O	by	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	propranolol	yes
O	O	and	yes
B-drug	B-drug	metoprolol	yes
O	O	.	no

O	O	The	no
O	O	principal	no
O	O	drugs	no
O	O	given	no
O	O	(	no
O	O	number	no
O	O	of	yes
O	O	patients	no
O	O	in	yes
O	O	parentheses	no
O	O	)	no
O	O	were	no
O	O	:	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	(	no
O	O	115	no
O	O	)	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	and	yes
B-group	B-group	hypnotics	no
O	O	(	no
O	O	103	no
O	O	)	no
O	O	,	no
B-group	B-group	coronary	no
I-group	I-group	vasodilators	no
O	O	(	no
O	O	52	no
O	O	)	no
O	O	,	no
O	O	oral	yes
B-group	B-group	hypoglycemics	no
O	O	(	no
O	O	45	yes
O	O	)	no
O	O	,	no
O	O	cough	no
O	O	and	yes
O	O	cold	yes
O	O	preparations	no
O	O	(	no
O	O	45	yes
O	O	)	no
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	(	no
O	O	38	no
O	O	)	no
O	O	,	no
B-group	B-group	antihyperlipidemics	no
O	O	(	no
O	O	29	yes
O	O	)	no
O	O	,	no
B-group	B-group	antigout	no
I-group	I-group	drugs	no
O	O	(	no
O	O	24	yes
O	O	)	no
O	O	,	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	(	no
O	O	18	yes
O	O	)	no
O	O	,	no
B-group	B-group	bronchodilators	no
O	O	(	no
O	O	13	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	insulin	yes
O	O	(	no
O	O	10	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	(	no
O	O	10	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
O	O	Estimates	no
O	O	of	yes
O	O	steady-state	no
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	for	yes
B-drug	B-drug	phenobarbital	yes
O	O	or	no
B-drug	B-drug	gabapentin	yes
O	O	(	no
O	O	300	yes
O	O	mg	yes
O	O	TID	no
O	O	;	no

O	O	It	no
O	O	is	yes
O	O	concluded	no
O	O	that	no
B-drug	B-drug	chloral	yes
I-drug	I-drug	hydrate	yes
O	O	and	yes
B-drug	B-drug	methaqualone	yes
O	O	may	no
O	O	be	no
O	O	administered	no
O	O	safely	no
O	O	without	no
O	O	additional	no
O	O	caution	no
O	O	in	yes
O	O	prothrombin	yes
O	O	test	yes
O	O	monitoring	no
O	O	during	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	therapy	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	anecdotal	no
O	O	reports	no
O	O	,	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	an	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	buprenorphine	yes
O	O	and	yes
B-group	B-group	benzodiazepines	no
O	O	.	no

O	O	Unlike	no
O	O	nucleolin/C23	no
O	O	,	no
O	O	down-regulation	no
O	O	of	yes
O	O	nucleophosmin/B23	no
O	O	was	no
O	O	thus	no
O	O	not	no
O	O	proliferation-dependent	no
O	O	but	no
O	O	caspase-3-	no
O	O	and	yes
O	O	apoptosis-dependent	no
O	O	.	no

B-brand	B-drug_n	Buforin	no
O	I-drug_n	II	yes
O	O	showed	no
O	O	moderate	no
O	O	activity	yes
O	O	,	no
O	O	which	no
O	O	increased	no
O	O	with	yes
O	O	increasing	no
O	O	concentration	no
O	O	to	no
O	O	55.7	no
O	O	%	no
O	O	suppression	no
O	O	of	yes
O	O	growth	yes
O	O	at	yes
O	O	20	yes
O	O	microM	no
O	O	.	no

O	O	To	no
O	O	avoid	no
O	O	this	no
O	O	interaction	no
O	O	,	no
B-drug	B-drug	delavirdine	yes
O	O	or	no
B-drug	B-drug	indinavir	yes
O	O	should	no
O	O	be	no
O	O	given	no
O	O	1	yes
O	O	hour	yes
O	O	prior	no
O	O	to	no
O	O	dosing	no
O	O	with	yes
B-brand	B-brand	VIDEX	yes
O	O	.	no

O	O	Drug	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	clomiphene	yes
I-drug	I-drug	citrate	yes
O	O	tablets	yes
O	O	USP	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	documented	no
O	O	.	no

O	O	Drug	yes
O	O	Name	no

O	O	In	yes
O	O	the	no
O	O	general	no
O	O	population	no
O	O	,	no
B-drug	B-drug	sildenafil	yes
O	O	is	yes
O	O	considered	no
O	O	to	no
O	O	have	no
O	O	an	no
O	O	acceptable	no
O	O	tolerability	no
O	O	profile	no
O	O	;	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	cancer	no
O	O	increases	no
O	O	progressively	no
O	O	with	yes
O	O	age	no
O	O	.	no

O	O	Absorption	no
O	O	of	yes
B-drug	B-drug	tetracycline	yes
O	O	is	yes
O	O	impaired	no
O	O	by	no
B-drug	B-drug	bismuth	yes
I-drug	I-drug	subsalicylate	yes
O	O	.	no

O	O	increased	no
O	O	factors	no
O	O	II	yes
O	O	,	no
O	O	VII	yes
O	O	antigen	yes
O	O	,	no
O	O	VIII	yes
O	O	antigen	yes
O	O	,	no
O	O	VIII	yes
O	O	coagulant	yes
O	O	activity	yes
O	O	,	no
O	O	IX	yes
O	O	,	no
O	O	X	yes
O	O	,	no
O	O	XII	no
O	O	,	no
O	O	VII-X	no
O	O	complex	yes
O	O	,	no
O	O	II-VII-X	no
O	O	complex	yes
O	O	,	no
O	O	and	yes
B-drug_n	O	beta-thromboglobulin	no
O	O	;	no

O	O	If	no
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	is	yes
O	O	used	no
O	O	with	yes
B-drug	B-drug	nitroglycerin	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	angina	no
O	O	pectoris	no
O	O	,	no
O	O	additional	no
O	O	antihypertensive	no
O	O	effects	no
O	O	may	no
O	O	occur	no
O	O	.	no

B-drug	B-drug	Oxcarbazepine	yes
O	O	can	no
O	O	inhibit	no
O	O	CYP2C19	no
O	O	and	yes
O	O	induce	no
O	O	CYP3A4/5	no
O	O	with	yes
O	O	potentially	no
O	O	important	no
O	O	effects	no
O	O	on	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	results	no
O	O	of	yes
O	O	the	no
O	O	DST	no
O	O	should	no
O	O	be	no
O	O	interpreted	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

B-group	B-group	Broad-Spectrum	no
I-group	I-group	Antibiotics-Broad-spectrum	no
I-group	I-group	antibiotics	no
O	O	may	no
O	O	sterilize	no
O	O	the	no
O	O	bowel	yes
O	O	and	yes
O	O	decrease	no
O	O	the	no
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
O	O	contribution	no
O	O	to	no
O	O	the	no
O	O	body	no
O	O	by	no
O	O	the	no
O	O	intestinal	no
O	O	microflora	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	TORADOL	yes
O	O	on	no
B-drug	B-drug	methotrexate	yes
O	O	clearance	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Exaggerated	no
O	O	hypertensive	no
O	O	responses	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	from	no
O	O	the	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	antagonists	no
O	O	and	yes
B-group	B-group	alpha-adrenergic	no
I-group	I-group	stimulants	no
O	O	,	no
O	O	including	no
O	O	those	no
O	O	contained	no
O	O	in	yes
O	O	proprietary	no
O	O	cold	yes
O	O	remedies	no
O	O	and	yes
O	O	vasoconstrictive	no
O	O	nasal	no
O	O	drops	no
O	O	.	no

B-brand	B-brand	TAMBOCOR	yes
O	O	has	no
O	O	been	no
O	O	administered	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	digitalis	yes
I-group	I-group	preparations	no
O	O	or	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	without	no
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	Pharmacological	no
O	O	treatment	no
O	O	of	yes
O	O	depression	no
O	O	:	no
O	O	the	no
O	O	role	no
O	O	of	yes
B-drug	B-drug	paroxetine	yes
O	O	.	no

O	O	Anticoagulant	no
O	O	inhibition	no
O	O	was	no
O	O	observed	no
O	O	during	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	secobarbital	yes
O	O	and	yes
B-drug	B-drug	glutethimide	yes
O	O	;	no

O	O	Hypertensive	no
O	O	crises	no
O	O	have	no
O	O	resulted	no
O	O	when	no
B-group	B-group	sympathomimetic	no
I-group	I-group	amines	no
O	O	have	no
O	O	been	no
O	O	used	no
O	O	concomitantly	no
O	O	within14	no
O	O	days	no
O	O	following	no
O	O	use	no
O	O	of	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Systemic	no
O	O	exposure	yes
O	O	is	yes
O	O	limited	no
O	O	,	no
O	O	as	yes
B-drug	B-drug	fluvastatin	yes
O	O	is	yes
O	O	subject	no
O	O	to	no
O	O	first-pass	no
O	O	metabolism	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	plasma	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	is	yes
O	O	approximately	no
O	O	30	yes
O	O	minutes	no
O	O	.	no

O	O	In	yes
O	O	these	no
O	O	subjects	no
O	O	(	no
O	O	R=	no
O	O	B	yes
O	O	)	no
O	O	,	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	65	yes
O	O	%	no
O	O	and	yes
O	O	that	no
O	O	of	yes
B-drug_n	B-drug_n	N-desmethyldiazepam	no
O	O	to	no
O	O	a	yes
O	O	level	no
O	O	that	no
O	O	was	no
O	O	too	no
O	O	low	yes
O	O	to	no
O	O	measure	no
O	O	over	no
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	the	no
O	O	2	yes
O	O	week	no
O	O	long	yes
O	O	study	no
O	O	.	no

O	O	an	no
O	O	interval	no
O	O	of	yes
O	O	at	yes
O	O	least	no
O	O	4	yes
O	O	hours	no
O	O	between	yes
O	O	intake	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	chloroquine	yes
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	.	no

O	O	Following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	INAPSINE	yes
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

B-brand	B-brand	PROLEUKIN	yes
O	O	may	no
O	O	affect	no
O	O	central	no
O	O	nervous	no
O	O	function	no
O	O	.	no

O	O	In	yes
O	O	another	no
O	O	study	no
O	O	with	yes
O	O	intravenous	yes
O	O	administration	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	Aprepitant	yes
O	O	was	no
O	O	given	no
O	O	as	yes
O	O	125	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	80	yes
O	O	mg/day	no
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	and	yes
O	O	3	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	midazolam	yes
O	O	2	yes
O	O	mg	yes
O	O	IV	yes
O	O	was	no
O	O	given	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	the	no
O	O	3-day	no
O	O	regimen	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	and	yes
O	O	on	no
O	O	Days	no
O	O	4	yes
O	O	,	no
O	O	8	yes
O	O	,	no
O	O	and	yes
O	O	15	yes
O	O	.	no

O	O	The	no
O	O	impact	no
O	O	of	yes
O	O	the	no
O	O	combined	no
O	O	chemotherapy	no
O	O	plus	yes
O	O	HAART	no
O	O	treatment	no
O	O	on	no
O	O	patient	no
O	O	survival	no
O	O	needs	no
O	O	urgently	no
O	O	to	no
O	O	be	no
O	O	evaluated	no
O	O	in	yes
O	O	prospective	no
O	O	studies	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	caspofungin	yes
O	O	did	no
O	O	not	no
O	O	induce	no
O	O	the	no
O	O	CYP3A4	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Physostigmine	yes
O	O	pretreatment	no
O	O	augmented	no
O	O	the	no
O	O	depressant	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	on	no
O	O	the	no
O	O	early	no
O	O	components	no
O	O	P1	no
O	O	and	yes
O	O	N1	no
O	O	,	no
O	O	while	no
O	O	attenuating	no
B-drug	B-drug	alcohol	yes
O	O	's	no
O	O	influence	no
O	O	on	no
O	O	components	no
O	O	P2	no
O	O	and	yes
O	O	P3	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	with	yes
B-drug	B-group	iron	yes
O	O	supplements	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	the	no
O	O	reduced	yes
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	iron	yes
O	O	.	no

O	O	Skin	yes
O	O	tests	no
O	O	:	no
B-group	B-group	Corticosteroids	no
O	O	may	no
O	O	suppress	no
O	O	reactions	no
O	O	to	no
O	O	skin	yes
O	O	tests	no
O	O	.	no

O	O	If	no
B-group	B-drug	digitalis	yes
O	O	treatment	no
O	O	is	yes
O	O	continued	no
O	O	,	no
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	and	yes
O	O	patients	no
O	O	observed	no
O	O	for	yes
O	O	clinical	no
O	O	evidence	no
O	O	of	yes
O	O	toxicity	no
O	O	.	no

B-drug	B-drug	Dexamethasone	yes
O	O	is	yes
O	O	a	yes
O	O	moderate	no
O	O	inducer	no
O	O	of	yes
O	O	CYP	no
O	O	3A4	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-brand	B-brand	LODOSYN	yes
O	O	(	no
B-drug	B-drug	Carbidopa	yes
O	O	)	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	levodopa	yes
O	O	or	no
B-drug	B-drug	carbidopa-levodopa	no
O	O	combination	yes
O	O	products	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	with	yes
B-drug	B-drug	dofetilide	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	higher	no
O	O	occurrence	no
O	O	of	yes
O	O	torsade	no
O	O	de	yes
O	O	pointes	no
O	O	.	no

B-drug	B-drug	Chlorthalidone	yes
O	O	and	yes
O	O	related	yes
O	O	drugs	no
O	O	may	no
O	O	decrease	no
O	O	arterial	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	norepinephrine	yes
O	O	.	no

B-group	B-group	Anticholinergic	no
I-group	I-group	drugs	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	increased	no
O	O	intraocular	no
O	O	pressure	no
O	O	may	no
O	O	be	no
O	O	hazardous	no
O	O	when	no
O	O	taken	no
O	O	concurrently	no
O	O	with	yes
O	O	agents	yes
O	O	such	no
O	O	as	yes
O	O	corti	no
O	O	costeroids..	no

O	O	Although	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	decreased	no
B-drug	B-drug	zalcitabine	yes
O	O	activity	yes
O	O	because	no
O	O	of	yes
O	O	lessened	no
O	O	active	no
O	O	metabolite	yes
O	O	formation	no
O	O	,	no
O	O	the	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	these	no
O	O	in	yes
O	O	vitro	no
O	O	results	no
O	O	are	no
O	O	not	no
O	O	known	no
O	O	.	no

B-drug	B-drug	Phenytoin/Phenobarbital	no
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	phenobarbital	yes
O	O	will	no
O	O	not	no
O	O	affect	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	,	no
O	O	but	no
O	O	may	no
O	O	reduce	no
O	O	endogenous	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	by	no
O	O	accelerating	no
O	O	metabolism	no
O	O	.	no

O	O	Because	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	infections	no
O	O	and	yes
O	O	certain	no
O	O	malignancies	no
O	O	is	yes
O	O	higher	no
O	O	in	yes
O	O	the	no
O	O	elderly	no
O	O	population	no
O	O	,	no
O	O	in	yes
O	O	general	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	treating	no
O	O	the	no
O	O	elderly	no
O	O	.	no

O	O	An	no
O	O	increase	no
O	O	of	yes
O	O	63	no
O	O	%	no
O	O	in	yes
O	O	the	no
O	O	mean	no
O	O	AUC	no
O	O	and	yes
O	O	increases	no
O	O	of	yes
O	O	50	yes
O	O	%	no
O	O	and	yes
O	O	4	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	mean	no
O	O	T	yes
O	O	max	no
O	O	and	yes
O	O	mean	no
O	O	C	yes
O	O	max	no
O	O	were	no
O	O	noted	no
O	O	in	yes
O	O	1	yes
O	O	study	no
O	O	of	yes
O	O	6	yes
O	O	individuals	no
O	O	.	no

O	O	-	yes
B-group	B-group	Anticoagulants	no
O	O	(	no
B-group	B-group	blood	yes
I-group	O	thinners	no
O	O	)	no
O	O	or	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	in	yes
O	O	patients	no
O	O	concurrently	no
O	O	taking	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	may	no
O	O	be	no
O	O	associated	no
O	O	with	yes
O	O	elevations	no
O	O	in	yes
O	O	serum	yes
O	O	levels	no
O	O	of	yes
O	O	these	no
O	O	other	no
O	O	drugs	no
O	O	.	no

O	O	Results	no
O	O	demonstrate	no
O	O	that	no
B-drug	B-drug	oxcarbazepine	yes
O	O	and	yes
O	O	its	no
O	O	pharmacologically	no
O	O	active	no
O	O	10-monohydroxy	no
O	O	metabolite	yes
O	O	(	no
B-drug_n	B-drug_n	MHD	no
O	O	)	no
O	O	have	no
O	O	little	no
O	O	or	no
O	O	no	yes
O	O	capacity	no
O	O	to	no
O	O	function	no
O	O	as	yes
O	O	inhibitors	no
O	O	for	yes
O	O	most	no
O	O	of	yes
O	O	the	no
O	O	human	yes
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	evaluated	no
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	CYP2A6	no
O	O	,	no
O	O	CYP2C9	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	CYP4A9	no
O	O	and	yes
O	O	CYP4A11	no
O	O	)	no
O	O	with	yes
O	O	the	no
O	O	exception	no
O	O	of	yes
O	O	CYP2C19	no
O	O	and	yes
O	O	CYP3A4/5	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	codeine	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	additive	no
O	O	CNS	no
O	O	depressant	no
O	O	effects	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	antihistamines	no
O	O	,	no
B-group	B-group	psychotropics	no
O	O	or	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	produce	no
O	O	CNS	no
O	O	depression	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	Targretin	yes
O	O	capsules	no
O	O	and	yes
B-drug	B-drug	gemfibrozil	yes
O	O	resulted	no
O	O	in	yes
O	O	substantial	no
O	O	increases	no
O	O	in	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	bexarotene	yes
O	O	,	no
O	O	probably	no
O	O	at	yes
O	O	least	no
O	O	partially	no
O	O	related	yes
O	O	to	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	inhibition	no
O	O	by	no
B-drug	B-drug	gemfibrozil	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-group	O	GABA-positive	no
I-group	O	drugs	no
O	O	be	no
O	O	included	no
O	O	into	no
O	O	a	yes
O	O	complex	yes
O	O	of	yes
O	O	treatment	no
O	O	measures	no
O	O	for	yes
O	O	edema	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	coadministered	no
O	O	drugs	no
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	on	no
O	O	the	no
O	O	binding	no
O	O	of	yes
O	O	therapeutic	no
O	O	drugs	no
O	O	to	no
O	O	human	yes
O	O	serum	yes
O	O	in	yes
O	O	vitro	no
O	O	was	no
O	O	investigated	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
O	O	May	no
O	O	be	no
O	O	less	no
O	O	effective	no
O	O	and	yes
O	O	increased	no
O	O	breakthrough	no
O	O	bleeding	no
O	O	may	no
O	O	occur	no
O	O	.	no

B-drug	B-drug	rifampin	yes
O	O	;	no

O	O	Specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	ENBREL	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	patients	no
O	O	on	no
B-drug	B-drug	digoxin	yes
O	O	may	no
O	O	show	no
O	O	elevations	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	FLOLAN	yes
O	O	,	no
O	O	which	no
O	O	may	no
O	O	be	no
O	O	clinically	no
O	O	significant	no
O	O	in	yes
O	O	patients	no
O	O	prone	no
O	O	to	no
B-drug	B-drug	digoxin	yes
O	O	toxicity	no
O	O	.	no

O	O	A	yes
O	O	number	no
O	O	of	yes
O	O	substances	no
O	O	affect	no
O	O	glucose	yes
O	O	metabolism	no
O	O	and	yes
O	O	may	no
O	O	require	no
B-drug	B-drug	insulin	yes
O	O	dose	no
O	O	adjustment	no
O	O	and	yes
O	O	particularly	no
O	O	close	no
O	O	monitoring	no
O	O	.	no

O	O	While	no
O	O	no	yes
O	O	clinical	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	C.P.A	no
O	O	.	no

O	O	Alternatives	no
O	O	to	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	azithromycin	yes
O	O	,	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	raise	no
O	O	the	no
O	O	gastrointestinal	no
O	O	pH	yes
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	an	no
O	O	earlier	no
O	O	release	yes
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no
B-drug	B-drug	rifabutin	yes
O	O	concentration	no

B-group	B-group	Coumarin	yes
I-group	I-group	Anticoagulants	no
O	O	Altered	no
O	O	coagulation	yes
O	O	parameters	no
O	O	and/or	no
O	O	bleeding	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	capecitabine	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	coumarin-derivative	no
I-group	I-group	anticoagulants	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	phenprocoumon	yes
O	O	.	no

B-drug	B-drug	Fluconazole	yes
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	5-HT3	no
I-group	I-group	antiemetics	no
B-drug	B-drug	ondansetron	yes
O	O	(	no
B-brand	B-brand	Zofran	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	granisetron	yes
O	O	(	no
B-brand	B-brand	Kytril	yes
O	O	)	no
O	O	have	no
O	O	all	yes
O	O	been	no
O	O	used	no
O	O	with	yes
B-brand	B-brand	BUSULFEX	yes
O	O	.	no

O	O	Though	no
O	O	individual	no
B-drug	B-drug	theophylline	yes
O	O	levels	no
O	O	fluctuated	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	symptoms	no
O	O	of	yes
O	O	drug	yes
O	O	inter-action	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	whenever	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	other	no
O	O	drugs	no
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	co-therapy	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressant	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Serum	yes
O	O	potassium	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	deficiencies	no
O	O	corrected	no
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	were	no
O	O	not	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	Vardenafil	yes
O	O	20	yes
O	O	mg	yes
O	O	was	no
O	O	taken	no
O	O	24	yes
O	O	hours	no
O	O	before	no
O	O	the	no
O	B-drug	NTG	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
B-brand	B-brand	INDOCIN	yes
O	O	and	yes
B-group	B-group	anticoagulants	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	aluminum	yes
O	O	,	no
B-drug	B-drug	magnesium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	calcium	yes
O	O	,	no
O	O	with	yes
B-drug	B-drug	sucralfate	yes
O	O	,	no
O	O	with	yes
O	O	metal	no
O	O	cations	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	iron	yes
O	O	,	no
O	O	or	no
O	O	with	yes
B-group	B-group	multivitamins	no
O	O	containing	yes
B-drug	B-drug	iron	yes
O	O	or	no
B-drug	B-drug	zinc	yes
O	O	,	no
O	O	or	no
O	O	with	yes
O	O	formulations	no
O	O	containing	yes
O	O	divalent	no
O	O	and	yes
O	O	trivalent	no
O	O	cations	no
O	O	such	no
O	O	as	yes
B-brand	B-brand	VIDEX	yes
O	O	(	no
B-drug	B-drug	didanosine	yes
O	O	)	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	,	no
O	O	may	no
O	O	substantially	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	systemic	no
O	O	concentrations	no
O	O	considerably	no
O	O	lower	no
O	O	than	no
O	O	desired	no
O	O	.	no

O	O	Steady-state	no
O	O	serum	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	are	no
O	O	reported	no
O	O	to	no
O	O	fluctuate	no
O	O	significantly	no
O	O	when	no
B-drug	B-drug	cimetidine	yes
O	O	is	yes
O	O	either	no
O	O	added	no
O	O	or	no
O	O	deleted	no
O	O	from	no
O	O	the	no
O	O	drug	yes
O	O	regimen	no
O	O	.	no

O	O	Concurrent	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	bumetanide	yes
O	O	is	yes
O	O	thus	no
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Drug	yes
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	Prolongation	no
O	O	of	yes
O	O	the	no
O	O	template	no
O	O	bleeding	no
O	O	time	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	continuous	no
O	O	intravenous	yes
O	O	infusion	no
O	O	of	yes
B-brand	B-brand	AMICAR	yes
O	O	at	yes
O	O	dosages	no
O	O	exceeding	no
O	O	24	yes
O	O	g/day	no
O	O	.	no

B-drug	B-drug	Diazepam	yes
O	O	:	no
O	O	The	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	is	yes
O	O	generally	no
O	O	not	no
O	O	advisable	no
O	O	.	no

B-group	B-group	Anti-HIV	no
I-group	I-group	Protease	yes
I-group	I-group	Inhibitors	no

O	O	Although	no
B-drug	B-drug	verapamil	yes
O	O	administered	no
O	O	at	yes
O	O	either	no
O	O	dose	no
O	O	had	no
O	O	little	no
O	O	or	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	enhancement	no
O	O	of	yes
O	O	intestinal	no
O	O	carcinogenesis	no
O	O	by	no
B-drug_n	B-drug_n	bombesin	yes
O	O	or	no
O	O	on	no
O	O	the	no
O	O	location	no
O	O	,	no
O	O	histologic	no
O	O	type	yes
O	O	,	no
O	O	depth	no
O	O	of	yes
O	O	involvement	no
O	O	,	no
O	O	labeling	no
O	O	index	no
O	O	,	no
O	O	apoptotic	no
O	O	index	no
O	O	or	no
O	O	tumor	yes
O	O	vascularity	no
O	O	of	yes
O	O	intestinal	no
O	O	cancers	no
O	O	,	no
O	O	it	no
O	O	significantly	no
O	O	decreased	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	cancer	no
O	O	metastasis	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	are	no
O	O	examples	no
O	O	of	yes
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	related	yes
B-group	B-group	benzodiazepines	no
O	O	,	no
O	O	presumably	no
O	O	through	no
O	O	inhibition	no
O	O	of	yes
O	O	CYP3A	no
O	O	:	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
B-drug	B-drug	isoniazide	no
O	O	,	no
O	O	and	yes
O	O	some	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	.	no

O	O	There	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	formal	no
O	O	drug-interaction	no
O	O	studies	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	Mylotarg	yes
O	O	.	no

B-group	B-group	Vasoconstrictors	no
O	O	:	no
B-brand	B-brand	D.H.E	no
O	I-brand	.	no
B-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
B-group	B-group	peripheral	no
I-group	I-group	vasoconstrictors	no
O	O	because	no
O	O	the	no
O	O	combination	yes
O	O	may	no
O	O	cause	no
O	O	synergistic	no
O	O	elevation	no
O	O	of	yes
O	O	blood	yes
O	O	pressure	no
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	:	no
O	O	A	yes
O	O	recent	no
O	O	case	no
O	O	study	no
O	O	has	no
O	O	shown	no
O	O	a	yes
O	O	possible	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	plasma	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	valproate	yes
O	O	when	no
O	O	co	yes
O	O	administered	no
O	O	with	yes
B-drug	B-drug	isoniazid	yes
O	O	.	no

O	O	This	no
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	any	no
O	O	statistically	no
O	O	or	no
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	caffeine	yes
O	O	or	no
O	O	its	no
O	O	major	no
O	O	metabolite	yes
O	O	,	no
B-drug	B-drug_n	paraxanthine	no
O	O	.	no

O	O	Leukopenia	no
O	O	was	no
O	O	similar	no
O	O	between	yes
O	O	the	no
O	O	two	no
O	O	groups	no
O	O	,	no
O	O	but	no
O	O	colony	yes
O	O	stimulating	yes
O	O	factor	yes
O	O	support	no
O	O	was	no
O	O	significantly	no
O	O	greater	no
O	O	in	yes
O	O	the	no
O	O	CHOP-HAART	no
O	O	group	yes
O	O	than	no
O	O	in	yes
O	O	the	no
O	O	control	no
O	O	group	yes
O	O	(	no
O	O	92	no
O	O	%	no
O	O	vs.	no
O	O	66	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	;	no
O	O	P	yes
O	O	=	no
O	O	0.03	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	hypotensive	no
O	O	effects	no
O	O	with	yes
B-brand	B-brand	PRINIVIL	yes
O	O	can	no
O	O	be	no
O	O	minimized	no
O	O	by	no
O	O	either	no
O	O	discontinuing	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	or	no
O	O	increasing	no
O	O	the	no
O	O	salt	yes
O	O	intake	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	PRINIVIL	yes
O	O	.	no

O	O	When	no
O	O	other	no
B-group	B-group	antiplatelet	no
I-group	I-group	agents	yes
O	O	or	no
B-group	B-group	anticoagulants	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	there	no
O	O	is	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
B-brand	B-brand	FLOLAN	yes
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

O	O	Taking	no
O	O	a	yes
B-drug	B-group	rauwolfia	yes
I-drug	I-group	alkaloid	no
O	O	while	no
O	O	you	no
O	O	are	no
O	O	taking	no
O	O	or	no
O	O	within	no
O	O	2	yes
O	O	weeks	no
O	O	of	yes
O	O	taking	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	depression	no
O	O	or	no
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	severe	no
O	O	high	yes
O	O	blood	yes
O	O	pressure	no
O	O	reaction	no
O	O	.	no

O	O	No	yes
O	O	autoinduction	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	with	yes
B-brand	B-brand	Trileptal	yes
O	O	.	no

O	O	Latent	no
O	O	diabetes	no
O	O	mellitus	no
O	O	may	no
O	O	become	no
O	O	manifest	no
O	O	during	no
B-drug	B-drug	chlorthalidone	yes
O	O	administration	no
O	O	.	no

O	O	Repeated	no
O	O	oral	yes
O	O	administration	no
O	O	of	yes
B-drug_n	B-drug_n	coumaphos	no
O	O	in	yes
O	O	sheep	yes
O	O	:	no
O	O	interactions	no
O	O	of	yes
B-group	B-drug_n	coumaphos	no
O	O	with	yes
B-drug	B-drug	bishydroxycoumarin	no
O	O	,	no
B-drug	B-drug_n	trichlorfon	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	surgery	no
O	O	;	no

O	O	In	yes
O	O	another	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
O	O	orally	no
O	O	inhaled	no
B-drug	B-drug	ciclesonide	yes
O	O	and	yes
O	O	oral	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	,	no
O	O	increased	no
O	O	the	no
O	O	exposure	yes
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	des-ciclesonide	no
O	O	by	no
O	O	approximately	no
O	O	3.6-fold	no
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	,	no
O	O	while	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	ciclesonide	yes
O	O	remained	no
O	O	unchanged	no
O	O	.	no

B-drug	I-drug	rifabutin	yes
O	O	concentration	no

O	O	The	no
O	O	percentage	no
O	O	of	yes
O	O	neurons	no
O	O	hyperpolarized	no
O	O	by	no
O	B-group	mu-	no
O	O	,	no
O	O	delta	yes
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	-	yes
O	O	,	no
O	O	and	yes
O	B-group	kappa-selective	no
B-group	I-group	opioids	no
O	O	was	no
O	O	significantly	no
O	O	reduced	yes
O	O	when	no
O	O	1	yes
O	O	%	no
O	O	but	no
O	O	not	no
O	O	<	no

B-group	B-group	antacids	no
O	O	after	no
O	O	meals	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	lowered	no
O	O	the	no
B-drug	B-drug	diltiazem	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	to	no
O	O	undetectable	no
O	O	levels	no
O	O	.	no

O	O	Laboratory	no
O	O	Tests	no
O	O	:	no
O	O	The	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	Amprenavir	yes
O	O	and	yes
O	O	low-dose	no
B-drug	B-drug	ritonavir	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	elevations	no
O	O	of	yes
O	O	cholesterol	yes
O	O	and	yes
O	O	triglycerides	yes
O	O	,	no
O	O	SGOT	no
O	O	(	no
O	O	AST	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	SGPT	no
O	O	(	no
O	O	ALT	no
O	O	)	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	elimination	no
O	O	half	no
O	O	life	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	and	yes
B-drug	B-drug	triazolam	yes
O	O	also	no
O	O	increased	no
O	O	(	no
O	O	1.5-2.5	no
O	O	fold	no
O	O	)	no
O	O	during	no
O	O	coadministration	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

O	O	These	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	by	no
O	O	the	no
B-group	B-group	NSAID	no
O	O	.	no

O	O	If	no
O	O	possible	no
O	O	,	no
B-group	B-group	anticholinesterase	no
I-group	I-group	agents	yes
O	O	should	no
O	O	be	no
O	O	withdrawn	no
O	O	at	yes
O	O	least	no
O	O	24	yes
O	O	hours	no
O	O	before	no
O	O	initiating	no
B-group	B-group	corticosteroid	no
O	O	therapy	no
O	O	.	no

O	O	Potential	no
O	O	for	yes
O	O	Interaction	no
O	O	with	yes
B-group	B-group	Monoamine	no
I-group	I-group	Oxidase	yes
I-group	I-group	Inhibitors	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	ketoprofen	yes
O	O	and	yes
B-drug	B-drug	probenecid	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Eprosartan	yes
O	O	doses	no
O	O	of	yes
O	O	up	no
O	O	to	no
O	O	300	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	have	no
O	O	been	no
O	O	safely	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	O	sustained-release	no
I-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	(	no
O	O	sustained-release	no
B-drug	B-drug	nifedipine	yes
O	O	)	no
O	O	with	yes
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	there	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	3	yes
O	O	major	no
O	O	metabolites	no
O	O	(	no
O	B-drug_n	5-DFUR	no
O	O	,	no
O	B-drug_n	5-FU	yes
O	O	and	yes
O	B-drug_n	FBAL	no
O	O	)	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	ELLENCE	yes
O	O	with	yes
O	O	other	no
B-group	O	cardioactive	no
I-group	O	compounds	no
O	O	that	no
O	O	could	no
O	O	cause	no
O	O	heart	no
O	O	failure	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	)	no
O	O	,	no
O	O	requires	no
O	O	close	no
O	O	monitoring	no
O	O	of	yes
O	O	cardiac	no
O	O	function	no
O	O	throughout	no
O	O	treatment	no
O	O	.	no

O	O	Clearance	no
O	O	of	yes
B-drug	B-drug_n	hydrodolasetron	no
O	O	decreased	no
O	O	by	no
O	O	about	no
O	O	27	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	dolasetron	yes
I-drug	I-drug	mesylate	yes
O	O	was	no
O	O	administered	no
O	O	intravenously	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	atenolol	yes
O	O	.	no

O	O	The	no
O	O	blockade	no
O	O	of	yes
O	O	the	no
O	O	spinal	no
O	O	endorphinergic	no
O	O	system	yes
O	O	by	no
O	O	intrathecal	no
B-drug	B-drug	naloxone	yes
O	O	on	no
O	O	the	no
O	O	production	no
O	O	of	yes
O	O	tail-flick	no
O	O	inhibition	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
B-drug_n	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	was	no
O	O	then	no
O	O	studied	no
O	O	.	no

O	O	The	no
O	O	time	no
O	O	to	no
O	O	onset	no
O	O	of	yes
O	O	maximum	no
O	O	block	yes
O	O	following	no
B-brand	B-brand	NIMBEX	yes
O	O	is	yes
O	O	approximately	no
O	O	2	yes
O	O	minutes	no
O	O	faster	no
O	O	with	yes
O	O	prior	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	significant	no
O	O	change	no
O	O	in	yes
O	O	platelet	yes
O	O	count	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	,	no
O	O	partial	no
O	O	thromboplastin	no
O	O	time	no
O	O	,	no
O	O	or	no
O	O	thrombin	no
O	O	time	no
O	O	.	no

O	O	Serum	yes
O	O	transaminase	no
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	obtained	no
O	O	before	no
O	O	starting	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	Plenaxis	yes
O	O	and	yes
O	O	periodically	no
O	O	during	no
O	O	treatment	no
O	O	.	no

B-drug	B-drug	Benzthiazide	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	blood	yes
I-group	O	thinners	no
O	O	,	no
B-group	B-group	decongestant	no
I-group	I-group	drugs	no
O	O	(	no
O	O	allergy	yes
O	O	,	no
O	O	cold	yes
O	O	,	no
O	O	and	yes
O	O	sinus	yes
O	O	medicines	no
O	O	)	no
O	O	,	no
O	O	diabetic	no
O	O	drugs	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
B-drug	B-drug	norepinephrine	yes
O	O	,	no
B-group	B-group	NSAIDs	no
O	O	like	yes
B-brand	B-brand	Aleve	yes
O	O	or	no
B-drug	B-drug	Ibuprofen	yes
O	O	,	no
O	O	and	yes
O	O	high	yes
O	O	blood	yes
O	O	pressure	no
O	O	medications	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-group	O	prostaglandin	yes
I-group	O	synthase	no
I-group	O	inhibiting	no
I-group	O	drugs	no
O	O	,	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	indomethacin	yes
O	O	,	no
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	.	no

O	O	Therefore	no
O	O	when	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	hydroxyzine	yes
O	O	their	no
O	O	dosage	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	-	yes
O	O	The	no
O	O	persistence	no
O	O	of	yes
O	O	clinical	no
O	O	and	yes
O	O	laboratory	no
O	O	evidence	no
O	O	of	yes
O	O	hypothyroidism	no
O	O	in	yes
O	O	spite	no
O	O	of	yes
O	O	adequate	no
O	O	dosage	no
O	O	replacement	no
O	O	indicates	no
O	O	either	no
O	O	poor	no
O	O	patient	no
O	O	compliance	yes
O	O	,	no
O	O	poor	no
O	O	absorption	no
O	O	,	no
O	O	excessive	no
O	O	fecal	no
O	O	loss	no
O	O	,	no
O	O	or	no
O	O	inactivity	no
O	O	of	yes
O	O	the	no
O	O	preparation	no
O	O	.	no

O	O	.	no

B-drug	B-drug	Diclofenac	yes
O	O	:	no
O	O	Administration	no
O	O	of	yes
O	O	morning	no
O	O	and	yes
O	O	lunch	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	Starlix	yes
O	O	120	no
O	O	mg	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	75-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	diclofenac	yes
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	resulted	no
O	O	in	yes
O	O	no	yes
O	O	significant	no
O	O	changes	no
O	O	to	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	.	no

B-drug	B-drug	Loratadine	yes
O	O	(	no
O	O	10	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	has	no
O	O	been	no
O	O	coadministered	no
O	O	with	yes
O	O	therapeutic	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	in	yes
O	O	controlled	no
O	O	clinical	no
O	O	pharmacology	no
O	O	studies	no
O	O	in	yes
O	O	adult	yes
O	O	volunteers	no
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	on	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	circulating	no
O	O	catecholamines	no
O	O	after	no
B-brand	B-brand	ALPHAGAN	yes
O	I-brand	P	yes
O	O	administration	no
O	O	are	no
O	O	available	no
O	O	.	no

B-drug	B-drug	Amitriptyline	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	clonidine	yes
O	O	enhances	no
O	O	the	no
O	O	manifestation	no
O	O	of	yes
O	O	corneal	no
O	O	lesions	no
O	O	in	yes
O	O	rats	no
O	O	Epidural	no
O	O	Injection	yes
B-drug	B-drug	Clonidine	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	CNS-depressive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	or	no
O	O	other	no
B-group	B-group	sedating	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Other	no
O	O	substances	no
O	O	,	no
O	O	including	no
O	O	herbal	no
O	O	preparations	no
O	O	:	no
O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	Wort	yes
O	O	(	no
O	O	Hypericum	yes
O	O	perforatum	yes
O	O	)	no
O	O	induces	no
O	O	CYP3A4	no
O	O	.	no

O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	receiving	no
B-drug	B-drug	indomethacin	yes
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	decreased	no
O	O	the	no
O	O	renal	no
O	O	clearance	no
O	O	and	yes
O	O	significantly	no
O	O	increased	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	indomethacin	yes
O	O	.	no

B-drug	B-drug	Valproate	yes
O	O	:	no
B-brand	B-brand	Felbatol	yes
O	O	causes	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	steady-state	no
B-drug	B-drug	valproate	yes
O	O	concentrations	no
O	O	.	no

O	O	APRD00513_IN	no
O	O	,	no
O	O	txt	no

O	O	These	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	within	no
O	O	the	no
O	O	two	no
O	O	hour	yes
O	O	period	no
O	O	before	no
O	O	or	no
O	O	within	no
O	O	the	no
O	O	two-hour	no
O	O	period	no
O	O	after	no
B-drug	B-drug	nalidixic	yes
I-drug	I-drug	acid	yes
O	O	administration	no
O	O	.	no

O	O	Intrathecal	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	naloxone	yes
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	0.4	no
O	O	to	no
O	O	40	yes
O	O	micrograms	no
O	O	caused	no
O	O	a	yes
O	O	dose-related	no
O	O	blockade	no
O	O	of	yes
O	O	the	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	tail-flick	no
O	O	response	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
O	O	injection	yes
O	O	of	yes
B-drug_n	B-drug_n	beta-endorphin	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	high	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	naloxone	yes
O	O	(	no
O	O	40	yes
O	O	micrograms	no
O	O	)	no
O	O	completely	no
O	O	blocked	no
O	O	the	no
O	O	tail-flick	no
O	O	inhibition	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
B-drug_n	B-drug_n	beta-endorphin	no
O	O	(	no
O	O	16	yes
O	O	micrograms	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	one	no
O	O	survey	no
O	O	,	no
O	O	2.3	no
O	O	%	no
O	O	of	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	experienced	no
O	O	tremor	no
O	O	,	no
O	O	as	yes
O	O	compared	no
O	O	to	no
O	O	0.7	no
O	O	%	no
O	O	reported	no
O	O	to	no
O	O	occur	no
O	O	with	yes
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	alone	no
O	O	.	no

O	O	When	no
B-group	B-group	sympathomimetic	no
I-group	I-group	drugs	no
O	O	are	no
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	hypertensive	no
O	O	reactions	no
O	O	,	no
O	O	including	no
O	O	hypertensive	no
O	O	crises	no
O	O	,	no
O	O	may	no
O	O	occur	no
O	O	.	no

B-group	B-group	Resins	no
O	O	:	no
O	O	Since	no
B-group	B-group	bile	no
I-group	I-group	acid	yes
I-group	I-group	sequestrants	no
O	O	may	no
O	O	bind	no
O	O	other	no
O	O	drugs	no
O	O	given	no
O	O	concurrently	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	take	no
B-brand	B-brand	TRICOR	yes
O	O	at	yes
O	O	least	no
O	O	1	yes
O	O	hour	yes
O	O	before	no
O	O	or	no
O	O	4-6	no
O	O	hours	no
O	O	after	no
O	O	a	yes
B-group	B-group	bile	no
I-group	I-group	acid	yes
I-group	I-group	binding	no
I-group	I-group	resin	yes
O	O	to	no
O	O	avoid	no
O	O	impeding	no
O	O	its	no
O	O	absorption	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	.	no

O	O	In	yes
O	O	common	yes
O	O	with	yes
O	O	other	no
B-group	B-group	broad-spectrum	no
I-group	I-group	antibiotics	no
O	O	,	no
B-brand	B-brand	AUGMENTIN	yes
I-brand	I-brand	XR	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	efficacy	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptives	no

B-group	B-group	Antimycobacterial	no
I-group	I-group	Agents	yes

B-drug	B-drug	Valdecoxib	yes
O	O	steady	no
O	O	state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	significantly	no
O	O	with	yes
O	O	multiple	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	omeprazole	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	.	no

B-drug	I-drug	lopinavir	yes
O	O	concentration	no

O	O	3	yes
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	and	yes
B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	Increased	no
O	O	prothrombin	yes
O	O	time	no
O	O	,	no
O	O	with	yes
O	O	or	no
O	O	without	no
O	O	clinical	no
O	O	bleeding	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	when	no
B-drug	B-drug	cefixime	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	Lower	no
O	O	Seizure	no
O	O	Threshold	no
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	and	yes
O	O	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	antipsychotics	no
O	O	,	no
O	O	other	no
B-group	B-group	antidepressants	no
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-group	O	systemic	no
I-group	B-group	steroids	no
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	that	no
O	O	lower	no
O	O	seizure	no
O	O	threshold	no
O	O	should	no
O	O	be	no
O	O	undertaken	no
O	O	only	no
O	O	with	yes
O	O	extreme	no
O	O	caution	no
O	O	.	no

O	O	Drug	yes
O	O	Name	no

O	O	A	yes
O	O	single	yes
O	O	0.5	yes
O	O	mg	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	elixir	no
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	the	no
O	O	7th	no
O	O	day	no
O	O	of	yes
O	O	each	no
O	O	11-day	no
O	O	period	no
O	O	.	no

B-drug	B-drug	HCTZ	yes
O	O	50	yes
O	O	mg	yes
O	O	QD	no
O	O	or	no
B-drug	B-drug	HCTZ/triamterene	no
O	O	50/100	no
O	O	mg	yes
O	O	QD	no
O	O	was	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	(	no
O	O	500	yes
O	O	mcg	no
O	O	BID	no
O	O	)	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	(	no
O	O	following	no
O	O	2	yes
O	O	days	no
O	O	of	yes
B-group	B-group	diuretic	no
O	O	use	no
O	O	at	yes
O	O	half	no
O	O	dose	no
O	O	)	no
O	O	.	no

O	O	Results	no
O	O	from	no
O	O	existing	no
O	O	clinical	no
O	O	trials	no
O	O	suggest	no
O	O	no	yes
O	O	significant	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	COPAXONE	yes
O	O	and	yes
O	O	other	no
O	O	therapies	no
O	O	commonly	no
O	O	used	no
O	O	in	yes
O	O	MS	yes
O	O	patients	no
O	O	,	no
O	O	including	no
O	O	the	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	28	yes
O	O	days	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-brand	B-brand	LEVSIN	no
O	O	.	no

O	O	The	no
B-drug	B-drug	zidovudine	yes
O	O	study	no
O	O	dosed	no
O	O	subjects	no
O	O	with	yes
O	O	1200	no
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	7	yes
O	O	)	no
O	O	(	no
O	O	later	no
O	O	changed	no
O	O	to	no
O	O	600	yes
O	O	mg/day	no
O	O	[	no
O	O	n	yes
O	O	=	no
O	O	5	yes
O	O	]	no
O	O	)	no
O	O	for	yes
O	O	Days	no
O	O	8	yes
O	O	to	no
O	O	21	yes
O	O	of	yes
O	O	a	yes
O	O	21-day	yes
O	O	course	no
O	O	of	yes
O	O	100	yes
O	O	mg	yes
O	O	,	no
O	O	five	no
O	O	times/day	no
O	O	of	yes
B-drug	B-drug	zidovudine	yes
O	O	.	no

B-drug	B-drug	Sulindac	yes
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	sulindac	yes
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	resulted	no
O	O	in	yes
O	O	lowering	no
O	O	of	yes
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
O	O	active	no
B-drug	O	sulindac	yes
I-drug	O	sulfide	yes
O	O	metabolite	yes
O	O	by	no
O	O	approximately	no
O	O	one-third	no
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	enoxacin	yes
O	O	and	yes
B-drug	B-drug	bismuth	yes
I-drug	I-drug	subsalicylate	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-brand	B-brand	CRIXIVAN	yes
O	O	may	no
O	O	not	no
O	O	be	no
O	O	effective	no
O	O	due	no
O	O	to	no
O	O	decreased	no
B-drug	B-drug	indinavir	yes
O	O	concentrations	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	these	no
O	O	agents	yes
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	Nifedipine	yes
O	O	:	no
B-drug	B-drug	Vardenafil	yes
O	O	20	yes
O	O	mg	yes
O	O	,	no
O	O	when	no
O	O	co-administered	no
O	O	with	yes
O	O	slow-release	no
B-drug	B-drug	nifedipine	yes
O	O	30	yes
O	O	mg	yes
O	O	or	no
O	O	60	no
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	,	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	relative	no
O	O	bioavailability	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	or	no
O	O	maximum	no
O	O	concentration	no
O	O	(	no
O	O	Cmax	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	nifedipine	yes
O	O	,	no
O	O	a	yes
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	metabolized	no
O	O	via	no
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	Isoflurane	yes
O	O	,	no
B-drug	B-drug	enflurane	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	halothane	yes
O	O	decrease	no
O	O	the	no
O	O	ED50	no
O	O	of	yes
B-brand	B-brand	NUROMAX	yes
O	O	by	no
O	O	30	yes
O	O	%	no
O	O	to	no
O	O	45	yes
O	O	%	no
O	O	.	no

O	O	Since	no
O	O	photic	no
O	O	evoked	no
O	O	potential	no
O	O	components	no
O	O	are	no
O	O	representations	no
O	O	of	yes
O	O	neural	no
O	O	pathways	no
O	O	which	no
O	O	are	no
O	O	activated	yes
O	O	during	no
O	O	photic	no
O	O	stimulation	no
O	O	,	no
O	O	study	no
O	O	of	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	on	no
O	O	these	no
O	O	components	no
O	O	may	no
O	O	help	no
O	O	to	no
O	O	trace	no
O	O	pathways	no
O	O	which	no
O	O	are	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	While	no
O	O	all	yes
O	O	the	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	SSRIs	no
O	O	)	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	O	seriraline	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	inhibit	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	they	no
O	O	may	no
O	O	vary	no
O	O	in	yes
O	O	the	no
O	O	extent	no
O	O	of	yes
O	O	inhibition	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	study	no
O	O	,	no
O	O	we	no
O	O	investigated	no
O	O	the	no
O	O	mechanism	no
O	O	(	no
O	O	s	yes
O	O	)	no
O	O	of	yes
B-drug_n	B-drug_n	resveratrol-induced	no
O	O	vasorelaxation	no
O	O	in	yes
O	O	resistance	no
O	O	mesenteric	no
O	O	arteries	no
O	O	from	no
O	O	male	no
O	O	lean	no
O	O	and	yes
B-drug	O	dietary-induced	no
O	O	obese	no
O	O	rats	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	VIDEX	yes
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	cause	no
O	O	pancreatitis	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	this	no
O	O	toxicity	no
O	O	(	no
O	O	see	no
O	O	WARNINGS	no
O	O	)	no
O	O	and	yes
O	O	should	no
O	O	be	no
O	O	done	no
O	O	with	yes
O	O	extreme	no
O	O	caution	no
O	O	,	no
O	O	only	no
O	O	if	no
O	O	other	no
O	O	alternatives	no
O	O	are	no
O	O	not	no
O	O	available	no
O	O	,	no
O	O	and	yes
O	O	only	no
O	O	if	no
O	O	clearly	no
O	O	indicated	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	glipizide	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	hypoglycemia	no
O	O	.	no

O	O	The	no
O	O	in	yes
O	O	vitro	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	nevirapine	yes
O	O	and	yes
O	O	the	no
B-group	B-group	antithrombotic	no
I-group	I-group	agent	yes
B-drug	B-drug	warfarin	yes
O	O	is	yes
O	O	complex	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	is	yes
O	O	enhanced	no
O	O	by	no
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	like	yes
B-drug	B-drug	lidocaine	yes
O	O	,	no
B-drug	B-drug	procaine	yes
O	O	,	no
B-group	B-group	beta-blockers	no
O	O	,	no
B-drug	B-drug	metaclopramide	no
O	O	,	no
B-drug	B-drug	lithium	yes
I-drug	I-drug	carbonate	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	terbutaline	yes
O	O	.	no

O	O	The	no
O	O	optimal	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	when	no
O	O	given	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	efavirenz	yes
O	O	,	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Example	no
O	O	inducers	no
O	O	include	no
B-drug	B-drug	aminoglutethimide	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	nafcillin	yes
O	O	,	no
B-drug	B-drug	nevirapine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
B-group	B-group	rifamycins	no
O	O	.	no

B-drug	B-drug	Cobalt	yes
O	O	excretion	no
O	O	was	no
O	O	enhanced	no
O	O	by	no
O	O	supplementary	no
B-drug	B-drug	cobalt	yes
O	O	;	no

O	O	This	no
O	O	effect	no
O	O	is	yes
O	O	small	no
O	O	with	yes
O	O	occasional	no
O	O	doses	no
O	O	of	yes
B-group	B-group	antacids	no
O	O	,	no
O	O	but	no
O	O	may	no
O	O	be	no
O	O	clinically	no
O	O	significant	no
O	O	when	no
B-group	B-group	antacids	no
O	O	are	no
O	O	used	no
O	O	on	no
O	O	a	yes
O	O	continuous	no
O	O	schedule	no
O	O	.	no

O	O	Toxicologic	no
O	O	and	yes
O	O	toxicokinetic	no
O	O	studies	no
O	O	in	yes
O	O	rats	no
O	O	did	no
O	O	not	no
O	O	demonstrate	no
O	O	any	no
O	O	alterations	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	or	no
O	O	toxicologic	no
O	O	profile	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	methotrexate	yes
O	O	or	no
B-brand	B-brand	Kineret	yes
O	O	when	no
O	O	the	no
O	O	two	no
O	O	agents	yes
O	O	were	no
O	O	administered	no
O	O	together	no
O	O	.	no

O	O	Whether	no
O	O	this	no
O	O	interaction	no
O	O	also	no
O	O	occurs	no
O	O	with	yes
O	O	the	no
O	O	intravenous	yes
O	O	,	no
O	O	topical	yes
O	O	,	no
O	O	or	no
O	O	vaginal	no
O	O	preparations	no
O	O	of	yes
B-drug	B-drug	miconazole	yes
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	with	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	should	no
O	O	be	no
O	O	approached	no
O	O	cautiously	no
O	O	.	no

O	O	Dosage	no
O	O	adjustment	no
O	O	may	no
O	O	be	no
O	O	warranted	no
O	O	when	no
B-drug	B-drug	levobupivacaine	yes
O	O	is	yes
O	O	concurrently	no
O	O	administered	no
O	O	with	yes
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	and	yes
O	O	CYP1A2	no
O	O	inhibitors	no
O	O	as	yes
O	O	systemic	no
B-drug	B-drug	levobupivacaine	yes
O	O	levels	no
O	O	may	no
O	O	rise	no
O	O	resulting	no
O	O	in	yes
O	O	toxicity	no
O	O	.	no

O	O	Microdosed	no
B-drug	O	minipill	no
I-drug	B-drug	progestin	no
O	O	preparations	no
O	O	are	no
O	O	not	no
O	O	recommended	no
O	O	for	yes
O	O	use	no
O	O	with	yes
B-brand	B-drug	Soriatane	yes
O	O	.	no

O	O	An	no
O	O	in	yes
O	O	vivo	no
O	O	interaction	no
O	O	study	no
O	O	in	yes
O	O	humans	no
O	O	demonstrated	no
O	O	that	no
O	O	a	yes
O	O	single	yes
O	O	1mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	anagrelide	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	900	no
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	was	no
O	O	generally	no
O	O	well	no
O	O	tolerated	no
O	O	.	no

O	O	N=50	no
O	O	)	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	manner	no
O	O	relative	no
O	O	to	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	hydrocodone	yes
O	O	alone	no
O	O	;	no

B-brand	B-brand	INDOCIN	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	captopril	yes
O	O	and	yes
B-drug	B-drug	losartan	yes
O	O	.	no

O	O	The	no
O	O	general	no
O	O	public	no
O	O	feels	no
O	O	that	no
B-drug	B-drug	cocaine	yes
O	O	is	yes
O	O	not	no
O	O	particularly	no
O	O	dangerous	no
O	O	because	no
O	O	it	no
O	O	does	no
O	O	not	no
O	O	produce	no
O	O	a	yes
O	O	well	no
O	O	defined	no
O	O	physical	no
O	O	dependency	no
O	O	and	yes
O	O	abstinence	no
O	O	syndrome	no
O	O	.	no

O	O	It	no
O	O	should	no
O	O	also	no
O	O	be	no
O	O	avoided	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	blood	yes
O	O	,	no
O	O	liver	yes
O	O	or	no
O	O	kidney	yes
O	O	diseases	no
O	O	,	no
O	O	recent	no
O	O	radiation	no
O	O	treatment	no
O	O	,	no
O	O	or	no
O	O	uncontrolled	no
O	O	diabetes	no
O	O	.	no

O	O	A	yes
O	O	decrease	no
O	O	of	yes
O	O	the	no
O	O	dosage	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	when	no
O	O	patient	no
O	O	becomes	no
O	O	euthyroid	no
O	O	.	no

B-group	B-group	dihydropyridine	no
I-group	I-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	concentration	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	C.P.A	no
O	O	.	no
O	O	substrates	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Acute	no
B-drug	B-drug	hydrocortisone	yes
O	O	administration	no
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	subjective	no
O	O	responses	no
O	O	to	no
B-drug	B-drug	d-amphetamine	yes
O	O	in	yes
O	O	humans	no
O	O	.	no

B-drug	B-drug	Acetaminophen	yes
O	O	:	no
O	O	May	no
O	O	increase	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
B-group	B-group	synthetic	yes
I-group	I-group	estrogens	yes
O	O	,	no
O	O	possibly	no
O	O	by	no
O	O	inhibiting	no
O	O	conjugation	no
O	O	.	no

O	O	Concomitant	no
O	O	Crohn	no
O	O	s	yes
O	O	disease	no
O	O	medications	no
O	O	were	no
B-group	B-group	antibiotics	no
O	O	,	no
B-group	B-group	antivirals	no
O	O	,	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	B-drug	6-MP/AZA	no
O	O	and	yes
B-group	O	aminosalicylates	no
O	O	.	no

O	O	Serum	yes
O	O	concentrations	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	in	yes
O	O	patients	no
O	O	concurrently	no
O	O	receiving	no
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	Interaction	no
O	O	between	yes
B-drug	B-drug	oxytocin	yes
O	O	and	yes
B-group	O	antidiuretic	no
I-group	O	hormone	yes
O	O	and	yes
O	O	its	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	milk	yes
O	O	secretion	no
O	O	by	no
O	O	alveoli	no
O	O	of	yes
O	O	the	no
O	O	mammary	no
O	O	gland	no
O	O	of	yes
O	O	lactating	no
O	O	rats	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	eight	no
O	O	target	no
O	O	drug/added	no
O	O	drug	yes
O	O	combinations	no
O	O	were	no
O	O	studied	no
O	O	:	no
B-drug	B-drug	acetaminophen/phenobarbital	no
O	O	.	no

O	O	The	no
B-group	B-group	antifungal	no
I-group	I-group	drug	yes
O	O	,	no
B-drug	B-drug	miconazole	yes
I-drug	I-drug	nitrate	yes
O	O	,	no
O	O	inhibits	no
O	O	the	no
O	O	growth	yes
O	O	of	yes
O	O	several	no
O	O	species	no
O	O	of	yes
O	O	Candida	no
O	O	.	no

O	O	No	yes
O	O	dosage	no
O	O	adjustment	no
O	O	is	yes
O	O	required	no
O	O	for	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	.	no

B-group	B-drug	Fluoroquinolones	no
O	O	,	no
B-group	B-drug	macrolide	no
I-group	I-drug	antibiotics	no
O	O	,	no
O	O	and	yes
B-group	O	azoles	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	cause	no
O	O	QTc	no
O	O	prolongation	no
O	O	.	no

O	O	Concomitant	no
O	O	use	no
O	O	with	yes
O	O	other	no
B-group	B-drug	calcium-containing	no
I-group	O	medicines	no
O	O	(	no
O	O	including	no
B-group	B-group	antacids	no
O	O	)	no
O	O	may	no
O	O	cause	no
O	O	too	no
O	O	much	no
B-drug	B-drug	calcium	yes
O	O	in	yes
O	O	the	no
O	O	blood	yes
O	O	or	no
O	O	urine	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	These	no
O	O	individuals	no
O	O	may	no
O	O	develop	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	clozapine	yes
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

O	O	Other	no
O	O	reported	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	:	no
B-drug	B-drug	Fentanyl	yes
O	O	(	no
O	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	may	no
O	O	cause	no
O	O	hypotension	no
O	O	,	no
O	O	bradycardia	no
O	O	,	no
O	O	and	yes
O	O	decreased	no
O	O	cardiac	no
O	O	output	no
O	O	.	no

O	O	Finally	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	notable	no
O	O	that	no
O	O	xanthine-derived	no
O	O	adenosine	yes
O	O	antagonists	no
O	O	tested	no
O	O	here	no
O	O	commonly	no
O	O	showed	no
O	O	anxiogenic	no
O	O	effects	no
O	O	in	yes
O	O	the	no
O	O	light/dark	no
O	O	test	yes
O	O	in	yes
O	O	mice	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	(	no
B-drug	B-drug	aminophylline	yes
O	O	5.8	no
O	O	mg/kg	no
O	O	infused	no
O	O	over	no
O	O	20	yes
O	O	minutes	no
O	O	)	no
O	O	were	no
O	O	unchanged	no
O	O	following	no
O	O	a	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	albendazole	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	)	no
O	O	in	yes
O	O	6	yes
O	O	healthy	no
O	O	subjects	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Tests	no
O	O	Interactions	no
O	O	Because	no
O	O	false	no
O	O	positive	no
O	O	readings	no
O	O	were	no
O	O	reported	no
O	O	with	yes
O	O	the	no
O	O	Ames	no
O	O	N-Multistix	no
O	O	SG	no
O	O	dipstick	no
O	O	test	yes
O	O	for	yes
O	O	urinary	yes
O	O	protein	yes
O	O	when	no
B-drug	B-drug	gabapentin	yes
O	O	was	no
O	O	added	no
O	O	to	no
O	O	other	no
B-group	B-group	antiepileptic	no
I-group	I-group	drugs	no
O	O	,	no
O	O	the	no
O	O	more	no
O	O	specific	no
B-drug	O	sulfosalicylic	no
I-drug	O	acid	yes
O	O	precipitation	no
O	O	procedure	no
O	O	is	yes
O	O	recommended	no
O	O	to	no
O	O	determine	no
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	urine	no
O	O	protein	yes

O	O	Thus	no
O	O	,	no
O	O	certain	no
O	O	factors	no
O	O	,	no
O	O	such	no
O	O	as	yes
O	O	reinforcing	no
O	O	drug	yes
O	O	effects	no
O	O	,	no
O	O	conditioning	no
O	O	processes	no
O	O	,	no
O	O	automatic	no
O	O	behavior	no
O	O	,	no
O	O	and	yes
O	O	stress	no
O	O	,	no
O	O	may	no
O	O	influence	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	dependence	no
O	O	on	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	.	no

O	O	This	no
O	O	risk	no
O	O	is	yes
O	O	present	no
O	O	whether	no
O	O	the	no
O	O	drugs	no
O	O	are	no
O	O	administered	no
O	O	as	yes
O	O	oral	yes
O	O	,	no
O	O	parenteral	no
O	O	,	no
O	O	or	no
O	O	topical	yes
O	O	formulations	no
O	O	.	no

O	O	Successful	no
O	O	prophylaxis	no
O	O	of	yes
O	O	manic-depressive	no
O	O	disorder	no
O	O	requires	no
O	O	more	no
O	O	than	no
O	O	the	no
O	O	prescription	no
O	O	of	yes
B-drug	B-drug	lithium	yes
I-drug	I-drug	carbonate	yes
O	O	.	no

O	O	Dependent	no
O	O	measures	no
O	O	included	no
O	O	self-reported	no
O	O	mood	no
O	O	and	yes
O	O	subjective	no
O	O	effects	no
O	O	(	no
O	O	Addiction	no
O	O	Research	no
O	O	Center	no
O	O	inventory	no
O	O	,	no
O	O	the	no
O	O	profile	no
O	O	of	yes
O	O	mood	no
O	O	states	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	series	no
O	O	of	yes
O	O	visual	no
O	O	analogue	yes
O	O	scales	no
O	O	)	no
O	O	,	no
O	O	vital	no
O	O	signs	no
O	O	,	no
O	O	salivary	yes
O	O	cortisol	yes
O	O	,	no
O	O	and	yes
O	O	psychomotor	no
O	O	performance	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	,	no
O	O	prothrombin	yes
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	tests	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	Cyanokit	yes
O	O	.	no

B-drug	B-drug	vitamin	yes
I-drug	I-drug	C	yes
O	O	;	no

B-drug	B-drug	Meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	serum	yes
O	B-group	salicylate	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-group	B-group	NSAIDs	no
O	O	in	yes
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	receiving	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	potentiate	no
O	O	renal	no
O	O	disease	no
O	O	states	no
O	O	.	no

O	O	Therapeutic	no
O	O	drug	yes
O	O	monitoring	no
O	O	can	no
O	O	avoid	no
O	O	iatrogenic	no
O	O	alterations	no
O	O	caused	no
O	O	by	no
B-drug	B-drug	99mTc-methylene	no
I-drug	I-drug	diphosphonate	yes
O	O	(	no
B-drug	O	MDP	yes
O	O	)	no
B-drug	B-drug	-gentamicin	no
O	O	interaction	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	should	no
O	O	be	no
O	O	reassessed	no
O	O	periodically	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	increase	no
O	O	the	no
B-drug	B-drug	warfarin	yes
O	O	requirements	no
O	O	in	yes
O	O	human	yes
O	O	subjects	no
O	O	ingesting	no
O	O	these	no
O	O	agents	yes
O	O	simultaneously	no
O	O	.	no

O	O	This	no
O	O	appears	no
O	O	to	no
O	O	be	no
O	O	the	no
O	O	only	no
O	O	clinically	no
O	O	relevant	no
O	O	interaction	no
O	O	of	yes
O	O	this	no
O	O	kind	no
O	O	with	yes
B-drug	B-drug	Mefloquine	yes
O	O	,	no
O	O	although	no
O	O	theoretically	no
O	O	,	no
O	O	coadministration	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	alter	no
O	O	cardiac	no
O	O	conduction	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	B-drug	anti-arrhythmic	no
O	O	or	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	antihistamines	no
O	O	or	no
B-group	B-group	H1-blocking	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	and	yes
B-group	B-group	phenothiazines	no
O	O	)	no
O	O	might	no
O	O	also	no
O	O	contribute	no
O	O	to	no
O	O	a	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QTc	no
O	O	interval	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	was	no
O	O	present	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	7	yes
O	O	days	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	.	no

B-group	B-group	Barbiturates	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	decrease	no
O	O	the	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	doxycycline	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	nifedipine	yes
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	currently	no
O	O	receiving	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	cautious	no
O	O	titration	yes
O	O	is	yes
O	O	advised	no
O	O	.	no

O	O	During	no
O	O	concomitant	no
O	O	therapy	no
O	O	of	yes
B-brand	B-brand	Ponstel	yes
O	O	with	yes
B-drug	B-drug	furosemide	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	renal	no
O	O	failure	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	to	no
O	O	assure	no
O	O	diuretic	no
O	O	efficacy	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	appropriate	no
O	O	monitoring	no
O	O	of	yes
O	O	blood	yes
B-drug	O	glucose	yes
O	O	should	no
O	O	be	no
O	O	performed	no
O	O	when	no
O	O	initiating	no
B-brand	B-brand	EXTRANEAL	yes
O	O	in	yes
O	O	diabetic	no
O	O	patients	no
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	dosage	no
O	O	should	no
O	O	be	no
O	O	adjusted	yes
O	O	if	no
O	O	needed	no
O	O	.	no

O	O	Depending	no
O	O	on	no
O	O	the	no
O	O	fraction	yes
O	O	of	yes
O	O	drug	yes
O	O	metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	,	no
O	O	the	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentration	no
O	O	may	no
O	O	be	no
O	O	small	no
O	O	,	no
O	O	or	no
O	O	quite	no
O	O	large	no
O	O	(	no
O	O	8-fold	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	AUC	no
O	O	of	yes
O	O	the	no
B-group	B-group	TCA	no
O	O	)	no
O	O	.	no

O	O	An	no
O	O	alternative	no
O	O	non-CYP3A4	no
O	O	substrate	yes
O	B-group	hypnotic	no
O	I-group	agent	yes
O	O	may	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenobarbital	yes
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Disturbances	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	,	no
O	O	including	no
O	O	hyperglycemia	no
O	O	and	yes
O	O	hypoglycemia	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	quinolones	no
O	O	and	yes
O	O	an	no
B-group	B-group	antidiabetic	no
I-group	I-group	agent	yes
O	O	.	no

O	O	The	no
O	O	purpose	no
O	O	of	yes
O	O	this	no
O	O	study	no
O	O	was	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug_n	sodium	yes
I-drug	I-drug_n	carboxymethylcellulose	no
O	O	(	no
B-drug_n	B-drug_n	NaCMC	no
O	O	)	no
O	O	and	yes
B-drug_n	B-drug_n	carboxymethylcellulose-cysteine	no
O	O	(	no
B-drug_n	B-drug_n	CMC-Cys	no
O	O	)	no
O	O	conjugates	no
O	O	on	no
O	O	the	no
O	O	intestinal	no
O	O	permeation	no
O	O	of	yes
O	B-drug	sodium	yes
O	I-drug	fluorescein	yes
O	O	(	no
B-drug	B-drug	NaFlu	no
O	O	)	no
O	O	and	yes
O	O	model	no
O	O	peptide	yes
O	O	drugs	no
O	O	,	no
B-drug	B-drug	bacitracin	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	.	no

B-group	B-group	Uricosuric	no
I-group	I-group	Agents	yes
O	O	:	no
B-brand	B-brand	Aspirin	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	,	no
B-drug	B-drug	sulfinpyrazone	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	phenylbutazone	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	fulvestrant	yes
O	O	on	no
O	O	the	no
O	O	fertility	no
O	O	of	yes
O	O	female	no
O	O	rats	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	consistent	no
O	O	with	yes
O	O	its	no
O	O	anti-estrogenic	no
O	O	activity	yes
O	O	.	no

O	O	The	no
O	O	availability	no
O	O	of	yes
O	O	potent	no
B-group	B-group	non-nucleoside	no
I-group	I-group	reverse	no
I-group	I-group	transcriptase	no
I-group	I-group	inhibitor	yes
O	O	(	no
B-group	B-group	NNRTI	no
O	O	)	no
O	O	-based	no
O	O	regimens	no
O	O	for	yes
B-group	B-group	antiretroviral	no
O	O	therapy	no
O	O	and	yes
O	O	concerns	no
O	O	regarding	no
B-group	B-group	protease	yes
I-group	I-group	inhibitor	yes
O	O	(	no
O	B-group	PI	no
O	O	)	no
O	O	-related	no
O	O	metabolic	no
O	O	disturbances	no
O	O	have	no
O	O	led	no
O	O	to	no
O	O	significant	no
O	O	shifts	no
O	O	in	yes
O	O	treatment	no
O	O	practices	no
O	O	in	yes
O	O	HIV	no
O	O	infection	no
O	O	.	no

O	O	-	yes
B-group	B-group	Antidiabetic	no
I-group	I-group	drugs	no
O	O	:	no
O	O	(	no
O	O	Oral	yes
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	)	no
O	O	Dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	B-group	antidiabetic	no
I-group	I-group	drug	yes
O	O	may	no
O	O	be	no
O	O	required	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	certain	no
B-group	B-group	corticosteroids	no
O	O	by	no
O	O	up	no
O	O	to	no
O	O	60	no
O	O	%	no
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
B-group	B-group	corticosteroid	no
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	a	yes
O	O	See	no
O	O	Tables	no
O	O	1	yes
O	O	and	yes
O	O	2	yes
O	O	.	no

B-group	B-group	NSAIDs	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
O	O	and	yes
O	O	renal	no
O	O	function	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	.	no

O	O	Electrophilic	no
O	O	agents	yes
O	O	--	no
O	O	a	yes
O	O	class	no
O	O	of	yes
O	O	chemicals	no
O	O	that	no
O	O	includes	no
O	O	most	no
B-group	O	genotoxic	no
I-group	O	compounds	no
O	O	--	no
O	O	can	no
O	O	be	no
O	O	inactivated	yes
O	O	by	no
O	O	reaction	no
O	O	with	yes
B-drug	O	glutathione	yes
O	O	or	no
O	O	other	no
O	O	SH-bearing	no
O	O	molecules	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	In	yes
O	O	three	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	including	no
O	O	46	no
O	O	normal	yes
O	O	,	no
O	O	healthy	no
O	O	subjects	no
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	clearance	no
O	O	and	yes
O	O	concentration	no
O	O	were	no
O	O	not	no
O	O	significantly	no
O	O	altered	no
O	O	by	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	lomefloxacin	yes
O	O	.	no

O	O	Concurrent	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	ORENCIA	yes
O	O	and	yes
B-group	B-group	TNF	no
I-group	I-group	antagonists	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	can	no
O	O	inhibit	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	chloroquine	yes
O	O	,	no
O	O	increasing	no
O	O	its	no
O	O	plasma	yes
O	O	level	no
O	O	.	no

O	O	the	no
O	O	time	no
O	O	to	no
O	O	reach	no
O	O	maximum	no
O	O	concentration	no
O	O	was	no
O	O	delayed	no
O	O	approximately	no
O	O	30	yes
O	O	minutes	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	also	no
O	O	shown	no
O	O	that	no
O	O	after	no
O	O	14	yes
O	O	days	no
O	O	of	yes
O	O	daily	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	chlordiazepoxide	yes
O	O	,	no
O	O	withdrawal	no
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	not	no
O	O	only	no
O	O	re-results	no
O	O	in	yes
O	O	almost	no
O	O	complete	yes
O	O	loss	no
O	O	of	yes
O	O	bar-press	no
O	O	response	no
O	O	in	yes
O	O	the	no
O	O	E-strain	no
O	O	subjects	no
O	O	but	no
O	O	also	no
O	O	results	no
O	O	in	yes
O	O	a	yes
O	O	temporary	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	acquired	no
O	O	behavioral	no
O	O	response	no
O	O	of	yes
O	O	the	no
O	O	stable	no
O	O	A-strain	no
O	O	subjects	no
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-brand	B-brand	CELEBREX	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE-inhibitors	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-drug	B-drug	Lithium	yes
O	O	toxicity	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	lithium	yes
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	which	no
O	O	cause	no
O	O	elimination	no
O	O	of	yes
B-drug	O	sodium	yes
O	O	,	no
O	O	including	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Reciprocal	no
O	O	interactions	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Antizol	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	increase	no
O	O	or	no
O	O	inhibit	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	)	no
O	O	,	no
O	O	though	no
O	O	this	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no

B-drug	B-drug	Ranitidine	yes
O	O	also	no
O	O	has	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	eprosartan	yes
O	O	pharmacokinetics	no
O	O	.	no

B-group	B-group	multivitamins	no
O	O	containing	yes
B-drug	B-drug	zinc	yes
O	O	;	no

O	O	The	no
B-group	B-group	benzodiazepines	no
O	O	are	no
O	O	a	yes
O	O	family	yes
O	O	of	yes
B-group	B-group	anxiolytic	no
O	O	and	yes
B-group	B-group	hypnotic	no
I-group	I-group	drugs	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	aliskiren	yes
O	O	on	no
B-drug	B-drug	warfarin	yes
O	O	pharmacokinetics	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	evaluated	no
O	O	in	yes
O	O	a	yes
O	O	well-controlled	no
O	O	clinical	no
O	O	trial	no
O	O	.	no

B-drug	B-drug	Phenobarbital	yes
O	O	:	no
O	O	It	no
O	O	appears	no
O	O	that	no
B-drug	B-drug	phenobarbital	yes
O	O	may	no
O	O	reduce	no
O	O	plasma	yes
B-drug	B-drug	felbamate	yes
O	O	concentrations	no
O	O	.	no

O	O	False-negative	no
O	O	results	no
O	O	in	yes
O	O	the	no
O	O	dexamethasone	yes
O	O	suppression	no
O	O	test	yes
O	O	(	no
O	O	DST	no
O	O	)	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	INDOCIN	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	.	no

O	O	The	no
O	O	EC50	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	isoproterenol	yes
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	not	no
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
B-drug	B-drug	norepinephrine	yes
O	O	uptake-1	no
O	O	,	no
O	O	were	no
O	O	reduced	yes
O	O	in	yes
O	O	myocardium	no
O	O	in	yes
O	O	functional	no
O	O	classes	no
O	O	II	yes
O	O	to	no
O	O	III	yes
O	O	and	yes
O	O	IV	yes
O	O	compared	no
O	O	with	yes
O	O	those	no
O	O	in	yes
O	O	nonfailing	no
O	O	myocardium	no
O	O	.	no

B-group	B-group	HIV	no
I-group	I-group	Protease	yes
I-group	I-group	Inhibitors	no
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	amprenavir	yes
O	O	on	no
O	O	total	yes
O	O	drug	yes
O	O	concentrations	no
O	O	of	yes
O	O	other	no
B-group	B-group	HIV	no
I-group	I-group	protease	yes
I-group	I-group	inhibitors	no
O	O	in	yes
O	O	subjects	no
O	O	receiving	no
O	O	both	no
O	O	agents	yes
O	O	was	no
O	O	evaluated	no
O	O	using	no
O	O	comparisons	no
O	O	to	no
O	O	historical	no
O	O	data	no
O	O	.	no

O	O	A	yes
O	O	false-positive	no
O	O	direct	no
O	O	Coombs	no
O	O	test	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	other	no
B-group	B-group	cephalosporin	yes
I-group	I-group	antibiotics	no
O	O	;	no

O	O	Another	no
O	O	study	no
O	O	showed	no
O	O	that	no
B-drug	B-drug	alosetron	yes
O	O	had	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
I-group	I-group	agents	yes
B-drug	B-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	and	yes
B-drug	B-drug	levonorgestrel	yes
O	O	(	no
O	O	CYP3A4	no
O	O	substrates	no
O	O	)	no
O	O	.	no

B-drug	B-brand	Cytadren	yes
O	O	accelerates	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	dexamethasone	yes
O	O	;	no

O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	acute	no
O	O	ergot	yes
O	O	toxicity	no
O	O	characterized	no
O	O	by	no
O	O	peripheral	no
O	O	vasospasm	no
O	O	and	yes
O	O	ischemia	no
O	O	of	yes
O	O	the	no
O	O	extremities	no
O	O	and	yes
O	O	other	no
O	O	tissues	no
O	O	.	no

B-group	B-group	Anticholinergics	no
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
O	O	certain	no
B-group	B-group	anticholinergic	no
I-group	I-group	compounds	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-group	B-group	belladonna	no
I-group	I-group	alkaloids	yes
O	O	and	yes
B-drug	B-drug	dicyclomine	yes
O	O	,	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	compromise	no
O	O	the	no
O	O	beneficial	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

O	O	Use	no
O	O	of	yes
O	O	a	yes
B-group	B-group	nonhormonal	no
I-group	I-group	contraceptive	yes
I-group	I-group	product	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-drug	B-drug	Isoniazid	yes
O	O	may	no
O	O	increase	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	.	no

B-group	B-group	Non-nucleoside	no
I-group	I-group	reverse	no
I-group	I-group	transcriptase	no
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	NNRTIs	no
O	O	)	no
O	O	:	no
B-drug	B-drug	Nevirapine	yes
O	O	may	no
O	O	decrease	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	;	no

B-brand	B-brand	PEGASYS	yes
O	O	contains	no
B-drug	B-drug_n	benzyl	yes
I-drug	I-drug_n	alcohol	yes
O	O	.	no

O	O	because	no
O	O	of	yes
O	O	this	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	flecainide	yes
O	O	should	no
O	O	be	no
O	O	adjusted	yes
O	O	when	no
O	O	these	no
O	B-drug	drugs	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	hypotensive	no
O	O	effects	no
O	O	with	yes
B-brand	B-brand	Lotensin	yes
O	O	can	no
O	O	be	no
O	O	minimized	no
O	O	by	no
O	O	either	no
O	O	discontinuing	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	or	no
O	O	increasing	no
O	O	the	no
O	O	salt	yes
O	O	intake	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	Lotensin	yes
O	O	.	no

O	O	these	no
O	O	drugs	no
O	O	were	no
O	O	not	no
O	O	tested	no
O	O	to	no
O	O	determine	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	administration	no
O	O	one	no
O	O	hour	yes
O	O	before	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	along	no
O	O	with	yes
O	O	either	no
O	O	oral	yes
O	O	or	no
O	O	intravenous	yes
B-group	B-group	calcium	yes
I-group	I-group	antagonists	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	for	yes
O	O	possible	no
O	O	atrioventricular	no
O	O	conduction	no
O	O	disturbances	no
O	O	,	no
O	O	left	no
O	O	ventricular	no
O	O	failure	no
O	O	and	yes
O	O	hypotension	no
O	O	.	no

B-drug	B-drug	Nitrofurantoin	yes
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	therapeutic	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	nalidixic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	In	yes
O	O	vitro	no
O	O	,	no
O	O	at	yes
O	O	total	yes
O	O	drug	yes
O	O	concentrations	no
O	O	27-fold	no
O	O	higher	no
O	O	than	no
O	O	peak	no
O	O	plasma	yes
O	O	concentrations	no
O	O	observed	no
O	O	with	yes
O	O	the	no
O	O	1-mg	no
O	O	dosage	no
O	O	,	no
B-drug	B-drug	alosetron	yes
O	O	inhibited	no
O	O	CYP	no
O	O	enzymes	yes
O	O	1A2	no
O	O	(	no
O	O	60	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	2E1	no
O	O	(	no
O	O	50	yes
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Activity	yes
O	O	of	yes
B-drug_n	B-drug_n	buforin	no
I-drug_n	I-drug_n	II	yes
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	and	yes
B-drug	B-drug	minocycline	yes
O	O	against	yes
B-drug_n	O	Cryptosporidium	no
O	O	parvum	no
O	O	in	yes
O	O	cell	yes
O	O	culture	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	using	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	(	no
B-drug	B-drug	digoxin	yes
O	O	and	yes
O	O	others	no
O	O	)	no
O	O	,	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	O	calcium	yes
O	O	,	no
B-drug	O	potassium	yes
O	O	and	yes
B-drug	O	magnesium	yes
O	O	must	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	.	no

O	O	This	no
O	O	study	no
O	O	indicates	no
O	O	that	no
O	O	:	no
O	O	(	no
O	O	a	yes
O	O	)	no
O	O	the	no
O	O	maximal	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	resveratrol	yes
O	O	on	no
O	O	resistance	no
O	O	arteries	no
O	O	from	no
O	O	lean	no
O	O	and	yes
O	O	dietary-obese	no
O	O	rats	no
O	O	are	no
O	O	not	no
O	O	effected	no
O	O	by	no
O	O	endothelial	no
O	O	dysfunction	no
O	O	,	no
O	O	and	yes
O	O	(	no
O	O	b	yes
O	O	)	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	resveratrol	yes
O	O	in	yes
O	O	lean	no
O	O	animals	no
O	O	(	no
O	O	where	no
O	O	endothelial	no
O	O	function	no
O	O	is	yes
O	O	not	no
O	O	impaired	no
O	O	)	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	in	yes
O	O	dietary-obese	no
O	O	rats	no
O	O	,	no
O	O	are	no
O	O	mediated	no
O	O	via	no
O	O	NO	yes
O	O	.	no

O	O	In	yes
O	O	period	no
O	O	B	yes
O	O	,	no
O	O	the	no
O	O	volunteers	no
O	O	were	no
O	O	randomly	no
O	O	assigned	no
O	O	to	no
O	O	one	no
O	O	of	yes
O	O	two	no
O	O	groups	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	there	no
O	O	are	no
O	O	several	no
O	O	instances	no
O	O	in	yes
O	O	the	no
O	O	animal	no
O	O	literature	no
O	O	showing	no
O	O	that	no
O	O	hippocampal	no
O	O	lesions	no
O	O	actually	no
O	O	produced	no
O	O	enhanced	no
O	O	learning	no
O	O	and	yes
O	O	memory	no
O	O	function	no
O	O	.	no

O	O	This	no
O	O	secretory	no
O	O	diarrhea	no
O	O	model	no
O	O	is	yes
O	O	suitable	no
O	O	for	yes
O	O	evaluating	no
O	O	the	no
O	O	antidiarrheal	no
O	O	activity	yes
O	O	of	yes
O	O	drugs	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	cases	no
O	O	reported	no
O	O	in	yes
O	O	which	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	and	yes
B-drug	B-drug	hydrocortisone	yes
O	O	was	no
O	O	followed	no
O	O	by	no
O	O	cardiac	no
O	O	enlargement	no
O	O	and	yes
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Increased	no
O	O	activity	yes
O	O	of	yes
O	O	both	no
B-drug	B-drug	cyclosporine	yes
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	may	no
O	O	occur	no
O	O	when	no
O	O	the	no
O	O	two	no
O	O	are	no
O	O	used	no
O	O	concurrently	no
O	O	.	no

B-drug	B-drug	Phenytoin/Phenobarbital	no
O	O	:	no
O	O	The	no
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	phenobarbital	yes
O	O	will	no
O	O	not	no
O	O	affect	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	,	no
O	O	but	no
O	O	may	no
O	O	reduce	no
O	O	endogenous	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	calcitriol/ergocalcitriol	no
O	O	by	no
O	O	accelerating	no
O	O	metabolism	no
O	O	.	no

O	O	Clinical	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	show	no
O	O	that	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	CANCIDAS	yes
O	O	are	no
O	O	not	no
O	O	altered	no
O	O	by	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	,	no
B-drug	B-drug	mycophenolate	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	tacrolimus	yes
O	O	.	no

O	O	The	no
O	O	implications	no
O	O	of	yes
O	O	these	no
O	O	results	no
O	O	are	no
O	O	discussed	no
O	O	,	no
O	O	especially	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	observations	no
O	O	which	no
O	O	indicate	no
O	O	that	no
O	O	homocysteine	no
O	O	may	no
O	O	be	no
O	O	a	yes
O	O	precipitating	no
O	O	factor	yes
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	thrombosis	no
O	O	.	no

B-drug	B-drug	Calcium	yes
O	O	Supplements	no
O	O	:	no
O	O	Uncontrolled	no
O	O	intake	no
O	O	of	yes
O	O	additional	no
B-drug	B-drug	calcium-containing	no
O	O	preparations	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	Available	no
O	O	data	no
O	O	are	no
O	O	neither	no
O	O	sufficient	no
O	O	to	no
O	O	rule	no
O	O	out	no
O	O	possible	no
O	O	increases	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	with	yes
O	O	concomitant	no
O	O	treatment	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	nor	yes
O	O	other	no
O	O	possible	no
O	O	interactions	no
O	O	,	no
O	O	particularly	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	cardiac	no
O	O	conduction	no
O	O	abnormalities	no
O	O	(	no
O	O	Also	no
O	O	see	no
O	O	WARNINGS	no
O	O	Congestive	no
O	O	Heart	no
O	O	Failure	no
O	O	)	no
O	O	.	no

O	O	6	yes
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	studies	no
B-drug	B-drug	propofol	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	action	no
O	O	or	no
O	O	dosing	no
O	O	requirements	no
O	O	for	yes
B-brand	B-brand	NIMBEX	yes
O	O	.	no

O	O	The	no
O	O	pharmacodynamic	no
O	O	consequences	no
O	O	of	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	losartan	yes
O	O	and	yes
O	O	inhibitors	no
O	O	of	yes
O	O	P450	no
O	O	2C9	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	examined	no
O	O	.	no

O	O	this	no
O	O	was	no
O	O	seen	no
O	O	in	yes
O	O	studies	no
O	O	with	yes
B-drug	B-drug	estazolam	yes
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	cases	no
O	O	the	no
O	O	onset	no
O	O	of	yes
O	O	the	no
O	O	injection	yes
O	O	site	no
O	O	reaction	no
O	O	either	no
O	O	occurred	no
O	O	during	no
O	O	a	yes
O	O	prolonged	no
O	O	infusion	no
O	O	or	no
O	O	was	no
O	O	delayed	no
O	O	by	no
O	O	a	yes
O	O	week	no
O	O	to	no
O	O	ten	no
O	O	days	no
O	O	.	no

O	O	Free	yes
O	O	T3	yes
O	O	resin	yes
O	O	uptake	no
O	O	is	yes
O	O	decreased	no
O	O	,	no
O	O	reflecting	no
O	O	the	no
O	O	elevated	no
O	O	TBG	no
O	O	;	no

B-group	B-group	Anticonvulsants	no
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	pharmacokinetic	no
O	O	study	no
O	O	,	no
O	O	maximum	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	were	no
O	O	considerably	no
O	O	lower	no
O	O	in	yes
O	O	epileptic	no
O	O	patients	no
O	O	on	no
O	O	long-term	no
B-group	B-group	anticonvulsant	no
O	O	therapy	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	phenobarbital	yes
O	O	)	no
O	O	than	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	.	no

O	O	The	no
O	O	injection	yes
O	O	should	no
O	O	be	no
O	O	made	no
O	O	immediately	no
O	O	after	no
O	O	mixing	no
O	O	.	no

O	O	Patients	no
O	O	using	no
O	O	cardiovascular	no
O	O	drugs	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	IOPIDINE	yes
O	O	0.5	yes
O	O	%	no
O	O	Ophthalmic	no
O	O	Solution	yes
O	O	should	no
O	O	have	no
O	O	pulse	no
O	O	and	yes
O	O	blood	yes
O	O	pressures	no
O	O	frequently	no
O	O	monitored	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
B-brand	B-brand	ARAVA	yes
O	O	levels	no
O	O	to	no
O	O	continue	no
O	O	to	no
O	O	increase	no
O	O	with	yes
O	O	multiple	no
O	O	dosing	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	if	no
O	O	patients	no
O	O	are	no
O	O	to	no
O	O	be	no
O	O	receiving	no
O	O	both	no
B-brand	B-brand	ARAVA	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	.	no

O	O	Frequent	no
O	O	vital	no
O	O	sign	no
O	O	monitoring	no
O	O	,	no
O	O	particularly	no
O	O	during	no
O	O	the	no
O	O	first	no
O	O	hour	yes
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	infusion	no
O	O	,	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	amitriptyline	yes
O	O	)	no
O	O	;	no

O	O	Numerous	no
O	O	drug	yes
O	O	interactions	no
O	O	are	no
O	O	possible	no
O	O	with	yes
O	O	some	no
B-group	B-group	anticonvulsant	no
I-group	I-group	agents	yes
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenobarbitone	yes
O	O	and	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	which	no
O	O	affect	no
O	O	hepatic	no
O	O	microsomal	no
O	O	enzyme	no
O	O	systems	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	serum	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	and	yes
O	O	appropriate	no
B-drug	B-drug	cyclosporine	yes
O	O	dosage	no
O	O	adjustments	no
O	O	made	no
O	O	when	no
O	O	these	no
O	O	drugs	no
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	decreased	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	the	no
O	O	ERMBT	no
O	O	by	no
O	O	83	no
O	O	%	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	representative	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	2C9	no
O	O	,	no
O	O	CYP	no
O	O	2C19	no
O	O	,	no
O	O	CYP	no
O	O	2D6	no
O	O	or	no
O	O	CYP	no
O	O	3A4	no
O	O	.	no

O	B-group	Systemic	no
B-group	I-group	Corticosteroids	no
O	O	:	no
O	B-group	Systemic	no
B-group	I-group	corticosteroids	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	cause	no
O	O	osteoporosis	no
O	O	.	no

O	O	The	no
O	O	influence	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	on	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	morphine	yes
O	O	(	no
O	O	10	yes
O	O	mg/kg	no
O	O	)	no
O	O	,	no
B-drug	B-drug	metamizol	no
O	O	(	no
O	O	500	yes
O	O	mg/kg	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	indomethacin	yes
O	O	(	no
O	O	10	yes
O	O	mg/kg	no
O	O	)	no
O	O	was	no
O	O	investigated	no
O	O	in	yes
O	O	a	yes
O	O	mouse	yes
O	O	model	no
O	O	using	no
O	O	the	no
O	O	tail-flick	no
O	O	and	yes
O	O	hot-plate	no
O	O	tests	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	There	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	chemical	yes
O	O	or	no
O	O	laboratory	no
O	O	test	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	ceftibuten	yes
O	O	noted	no
O	O	to	no
O	O	date	no
O	O	.	no

O	O	incomplete	no
O	O	data	no
O	O	for	yes
B-drug	B-drug	efavirenz	yes
O	O	.	no

O	O	Preliminary	no
O	O	clinical	no
O	O	data	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	nephrolithiasis	no
O	O	is	yes
O	O	higher	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	indinavir	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ritonavir	yes
O	O	than	no
O	O	those	no
O	O	receiving	no
B-brand	B-brand	CRIXIVAN	yes
O	O	800	no
O	O	mg	yes
O	O	q8h	no
O	O	.	no

B-drug	B-drug	Propranolol	yes
O	O	:	no
O	O	In	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	pharmacokinetic	no
O	O	or	no
O	O	pharmacodynamic	no
O	O	interaction	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	single	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	and	yes
B-drug	B-drug	propranolol	yes
O	O	.	no

O	O	cases	no
O	O	,	no
O	O	occurred	no
O	O	between	yes
O	O	the	no
O	O	5th	no
O	O	and	yes
O	O	the	no
O	O	11th	no
O	O	day	no
O	O	of	yes
O	O	treatment	no
O	O	.	no

B-drug	B-drug	Arginine	yes
O	O	,	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	glucose	yes
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	,	no
O	O	caused	no
O	O	excessive	no
O	O	glucagon	yes
O	O	release	yes
O	O	but	no
O	O	nearly	no
O	O	normal	yes
O	O	insulin	yes
O	O	release	yes
O	O	in	yes
O	O	the	no
O	O	diabetics	no
O	O	.	no

O	O	A	yes
O	O	routine	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	zaleplon	yes
O	O	is	yes
O	O	not	no
O	O	considered	no
O	O	necessary	no
O	O	.	no

B-drug	B-drug	Sirolimus	yes
O	O	:	no
O	O	mammalian	no
O	O	target	no
O	O	of	yes
B-drug	B-drug	rapamycin	yes
I-drug	O	inhibitor	yes
O	O	to	no
O	O	prevent	no
O	O	kidney	yes
O	O	rejection	no
O	O	.	no

O	O	Serum	yes
B-drug	B-drug	theophylline	yes
O	O	concentrations	no
O	O	increase	no
O	O	when	no
B-drug	B-drug	grepafloxacin	yes
O	O	is	yes
O	O	initiated	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	maintained	no
O	O	on	no
B-drug	B-drug	theophylline	yes
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	is	yes
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	C.P.A	no
O	O	.	no
O	O	metabolism	no
O	O	and	yes
O	O	therefore	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
O	O	medications	no
O	O	with	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	windows	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

B-drug	B-drug	Colestipol	yes
O	O	:	no
O	O	Plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	decreased	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	when	no
B-drug	B-drug	colestipol	yes
O	O	and	yes
B-drug	B-drug	atorvastatin	yes
O	O	were	no
O	O	coadministered	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	clinical	no
O	O	significance	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	that	no
B-drug	B-drug	cefditoren	yes
I-drug	I-drug	pivoxil	yes
O	O	be	no
O	O	taken	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	.	no

B-drug	B-drug	Maprotiline	yes
O	O	:	no
O	O	Risk	no
O	O	of	yes
O	O	cardiac	no
O	O	arrhythmias	no
O	O	may	no
O	O	increase	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-drug	B-drug	Aliskiren	yes
O	O	on	no
O	O	Other	no
O	O	Drugs	no
B-drug	B-drug	Aliskiren	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	the	no
O	O	CYP450	no
O	O	isoenzymes	no
O	O	(	no
O	O	CYP1A2	no
O	O	,	no
O	O	2C8	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2D6	no
O	O	,	no
O	O	2E1	no
O	O	,	no
O	O	and	yes
O	O	CYP	no
O	O	3A	yes
O	O	)	no
O	O	or	no
O	O	induce	no
O	O	CYP	no
O	O	3A4	no
O	O	.	no

O	O	Clinical	no
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	indicated	no
O	O	that	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	Femara	yes
O	O	with	yes
O	O	these	no
O	O	drugs	no
O	O	does	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	clinically-	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	reduced	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
O	O	a	yes
O	O	prolongation	no
O	O	of	yes
O	O	its	no
O	O	serum	yes
O	O	half-life	no
O	O	.	no

B-drug	B-drug	Ganciclovir	yes
O	O	:	no
O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	foscarnet	yes
O	O	and	yes
B-drug	B-drug	ganciclovir	yes
O	O	were	no
O	O	not	no
O	O	altered	no
O	O	in	yes
O	O	13	yes
O	O	patients	no
O	O	receiving	no
O	O	either	no
O	O	concomitant	no
O	O	therapy	no
O	O	or	no
O	O	daily	no
O	O	alternating	no
O	O	therapy	no
O	O	for	yes
O	O	maintenance	no
O	O	of	yes
O	O	CMV	no
O	O	disease	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Tests	no
O	O	Interactions	no
O	O	No	yes
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	.	no

O	O	Pretreatment	no
O	O	with	yes
B-drug	B-drug	atropine	yes
O	O	likewise	no
O	O	further	no
O	O	reduced	yes
O	O	the	no
O	O	amplitudes	no
O	O	of	yes
O	O	components	no
O	O	P1	no
O	O	and	yes
O	O	N1	no
O	O	,	no
O	O	and	yes
O	O	produced	no
O	O	a	yes
O	O	similar	no
O	O	effect	no
O	O	on	no
O	O	component	yes
O	O	N3	no
O	O	.	no

B-drug	B-drug	naproxen	yes
O	O	;	no

O	O	Pharmacodynamic-related	no
O	O	Interactions	no
O	O	:	no
O	O	The	no
O	O	mechanism	no
O	O	of	yes
B-drug	B-drug	Clozapine	yes
O	O	induced	no
O	O	agranulocytosis	no
O	O	is	yes
O	O	unknown	no
O	O	;	no

O	O	Consequently	no
O	O	,	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	iron	yes
O	O	on	no
O	O	the	no
O	O	retention	no
O	O	of	yes
B-drug	B-drug	cobalt	yes
O	O	was	no
O	O	lower	no
O	O	than	no
O	O	on	no
O	O	absorption	no
O	O	.	no

B-drug	B-drug	Dextromethorphan	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	both	no
O	B-drug	CYP2D6	no
O	O	and	yes
O	B-drug	CYP3A4	no
O	O	.	no

O	O	The	no
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	metoprolol	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	were	no
O	O	increased	no
O	O	approximately	no
O	O	31	yes
O	O	and	yes
O	O	38	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-group	B-group	antihistamines	no
O	O	should	no
O	O	be	no
O	O	advised	no
O	O	against	yes
O	O	the	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	B-group	CNS	no
I-group	I-group	depressant	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Fourteen	no
O	O	days	no
O	O	later	no
O	O	,	no
O	O	all	yes
O	O	animals	no
O	O	were	no
O	O	challenged	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	hypnotic	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	(	no
O	O	3.5	no
O	O	g/kg	no
O	O	IP	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Quinidine	yes
O	O	at	yes
O	O	648	no
O	O	mg	yes
O	O	bid	no
O	O	decreased	no
O	O	the	no
O	O	bioavailability	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	nisoldipine	yes
O	O	by	no
O	O	26	yes
O	O	%	no
O	O	,	no
O	O	but	no
O	O	not	no
O	O	the	no
O	O	peak	no
O	O	concentration	no
O	O	.	no

B-group	B-group	Dopamine	yes
I-group	I-group	D2	yes
I-group	I-group	receptor	yes
I-group	I-group	antagonists	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-group	B-group	butyrophenones	no
O	O	,	no
B-drug	B-drug	risperidone	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	isoniazid	yes
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	therapeutic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	levodopa	yes
O	O	.	no

O	O	or	no
O	O	=0.2	no
O	O	%	no
O	O	biocytin	no
O	O	was	no
O	O	included	no
O	O	in	yes
O	O	the	no
O	O	recording	no
O	O	pipette	no
O	O	,	no
O	O	compared	no
O	O	with	yes
O	O	neurons	no
O	O	recorded	no
O	O	without	no
O	O	biocytin	no
O	O	.	no

O	O	Whenever	no
O	O	increased	no
O	O	thioether	no
O	O	excretion	no
O	O	is	yes
O	O	observed	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	exposure	yes
O	O	to	no
O	O	one	no
O	O	or	no
O	O	more	no
O	O	suspect	no
O	O	compounds	no
O	O	.	no

O	O	Two	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	in	yes
O	O	HIV-infected	no
O	O	subjects	no
O	O	to	no
O	O	assess	no
O	O	the	no
O	O	potential	no
O	O	for	yes
B-drug	B-drug	azithromycin	yes
O	O	to	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	zidovudine	yes
O	O	and	yes
B-drug	B-drug	dideoxyinosine	yes
O	O	.	no

O	O	Comparative	no
O	O	analysis	no
O	O	of	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	stimulation	no
O	O	and	yes
O	O	inhibition	no
O	O	of	yes
B-drug_n	O	cholino-	no
O	O	and	yes
B-drug_n	O	adrenoreceptors	no
O	O	on	no
O	O	this	no
O	O	inhibitory	yes
O	O	action	no
O	O	of	yes
B-group	B-drug_n	angiotensins	no
O	O	suggested	no
O	O	the	no
O	O	mediation	no
O	O	of	yes
B-drug_n	B-drug_n	angiotensin	yes
O	O	influence	no
O	O	through	no
O	O	the	no
O	O	modulation	no
O	O	of	yes
O	O	cholinergic	no
O	O	reactions	no
O	O	of	yes
O	O	parietal	no
O	O	cells	yes
O	O	in	yes
O	O	the	no
O	O	stomach	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	reduces	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-brand	B-brand	ALFENTA	yes
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	cause	no
O	O	significant	no
O	O	sustained	no
O	O	elevation	no
O	O	in	yes
O	O	gastric	yes
O	O	pH	yes
O	O	(	no
B-group	B-group	histamine	yes
I-group	I-group	H2-receptor	no
I-group	I-group	antagonists	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	ranitidine	yes
O	O	or	no
B-drug	B-drug	cimetidine	yes
O	O	)	no
O	O	may	no
O	O	reduce	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-brand	B-brand	IRESSA	yes
O	O	and	yes
O	O	therefore	no
O	O	potentially	no
O	O	may	no
O	O	reduce	no
O	O	efficacy	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	linezolid	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	interaction	no
O	O	with	yes
O	B-group	adrenergic	no
O	O	and	yes
B-group	B-group	serotonergic	no
I-group	I-group	agents	yes
O	O	.	no

B-drug_n	B-drug_n	Phencyclidine	yes
O	O	(	no
B-drug_n	B-drug_n	PCP	yes
O	O	)	no
O	O	produces	no
O	O	psychotomimetic	no
O	O	effects	no
O	O	in	yes
O	O	humans	no
O	O	that	no
O	O	resemble	no
O	O	schizophrenia	no
O	O	symptoms	no
O	O	.	no

B-drug	B-drug	Simvastatin	yes
O	O	and	yes
O	O	Other	no
B-group	B-group	Statins	no
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	bosentan	yes
O	O	decreased	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	simvastatin	yes
O	O	(	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	-hydroxy	no
O	O	acid	yes
O	O	metabolite	yes
O	O	,	no
O	O	by	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	.	no

O	O	After	no
O	O	prolonged	no
O	O	administration	no
O	O	of	yes
B-group	B-group	neuroleptics	no
O	O	the	no
O	O	displacing	no
O	O	effect	no
O	O	of	yes
O	B-drug_n	cerulein	yes
O	O	,	no
O	O	an	no
O	O	analog	yes
O	O	of	yes
O	O	cholecystokinin	yes
O	O	octapeptide	yes
O	O	,	no
O	O	was	no
O	O	replaced	no
O	O	by	no
O	O	the	no
O	O	stimulant	no
O	O	action	no
O	O	on	no
B-drug_n	B-drug_n	3H-spiroperidol	no
O	O	binding	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	EQUETROTM	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	taking	no
O	O	another	no
O	O	drug	yes
O	O	that	no
O	O	is	yes
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	should	no
O	O	not	no
O	O	cause	no
O	O	increased	no
O	O	free	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	.	no

O	O	Medication	no
O	O	such	no
O	O	as	yes
B-group	B-group	digitalis	yes
O	O	may	no
O	O	also	no
O	O	influence	no
O	O	serum	yes
O	O	electrolytes	yes
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	drug	yes
O	O	requirements	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	insulin	yes
O	O	)	no
O	O	may	no
O	O	be	no
O	O	altered	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	As	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	,	no
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	may	no
O	O	occur	no
O	O	.	no

O	B-group	Urinary	yes
O	I-group	acidifying	no
O	I-group	agents	yes
O	O	(	no
B-drug	B-drug	ammonium	yes
I-drug	I-drug	chloride	yes
O	O	,	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	acid	yes
I-drug	I-drug	phosphate	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	increase	no
O	O	the	no
O	O	concentration	no
O	O	of	yes
O	O	the	no
O	O	ionized	no
O	O	species	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	amphetamine	yes
O	O	molecule	yes
O	O	,	no
O	O	thereby	no
O	O	increasing	no
O	O	urinary	yes
O	O	excretion	no
O	O	.	no

O	O	Responses	no
O	O	to	no
B-drug	B-drug	arginine	yes
O	O	of	yes
O	O	the	no
O	O	perfused	no
O	O	pancreas	no
O	O	of	yes
O	O	the	no
O	O	genetically	no
O	O	diabetic	no
O	O	Chinese	yes
O	O	hamster	no
O	O	.	no

O	O	A	yes
O	O	two-way	no
O	O	interaction	no
O	O	between	yes
O	O	the	no
B-group	B-group	hydantoin	no
I-group	I-group	antiepileptic	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
O	O	the	no
B-group	B-group	coumarin	yes
I-group	O	anticoagulants	no
O	O	has	no
O	O	been	no
O	O	suggested	no
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	plus	yes
B-drug	B-drug	rifampin	yes
O	O	was	no
O	O	well	no
O	O	tolerated	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	because	no
O	O	of	yes
O	O	demonstrated	no
O	O	hypokalemia	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	with	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
O	O	Increased	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	lithium	yes
O	O	and	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
O	O	therapy	no
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	have	no
O	O	developed	no
O	O	severe	no
O	O	hypersensitivity	no
O	O	reactions	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	rechallenged	no
O	O	with	yes
B-brand	B-brand	TAXOL	yes
O	O	.	no

O	O	and	yes
O	O	,	no
O	O	rarely	no
O	O	,	no
O	O	enuresis	no
O	O	,	no
O	O	urinary	yes
O	O	retention	no
O	O	,	no
O	O	dysuria	no
O	O	,	no
O	O	impotence	no
O	O	,	no
O	O	inability	no
O	O	to	no
O	O	ejaculate	no
O	O	,	no
O	O	nocturia	no
O	O	,	no
O	O	hematuria	no
O	O	.	no

O	O	A	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	liquid	yes
B-group	B-group	antacid	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	C	yes
O	O	max	no
O	O	or	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	ceftibuten	yes
O	O	;	no

O	O	An	no
O	O	evaluation	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	and	yes
O	O	an	no
O	O	adjustment	no
O	O	of	yes
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	are	no
O	O	recommended	no

O	O	For	yes
O	O	this	no
O	O	reason	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
B-group	B-drug	anticoagulant	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	30	yes
O	O	-	yes
O	O	50	yes
O	O	%	no
O	O	at	yes
O	O	the	no
O	O	start	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	Bezalip	yes
O	O	or	no
B-brand	B-brand	Bezalip	yes
I-brand	O	retard	yes
O	O	and	yes
O	O	then	no
O	O	titrated	no
O	O	according	no
O	O	to	no
O	O	the	no
O	O	blood	yes
O	O	clotting	no
O	O	parameters	no

B-drug	B-drug	ibuprofen	yes
O	O	;	no

O	O	The	no
O	O	appropriate	no
O	O	dose	no
O	O	for	yes
B-drug	B-drug	nelfinavir	yes
O	O	incombination	no
O	O	with	yes
B-drug	B-drug	nevirapine	yes
O	O	,	no
O	O	with	yes
O	O	respectto	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	,	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fenofibrate	yes
O	O	(	no
O	O	equivalent	no
O	O	to	no
O	O	145mg	no
B-brand	B-brand	TRICOR	yes
O	O	)	no
O	O	with	yes
B-drug	B-drug	pravastatin	yes
O	O	(	no
O	O	40	yes
O	O	mg	yes
O	O	)	no
O	O	once	no
O	O	daily	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	mean	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	pravastatin	yes
O	O	by	no
O	O	36	no
O	O	%	no
O	O	(	no
O	O	range	no
O	O	from	no
O	O	69	no
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	321	no
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	and	yes
O	O	28	yes
O	O	%	no
O	O	(	no
O	O	range	no
O	O	from	no
O	O	54	no
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	128	no
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	and	yes
O	O	for	yes
O	O	3	yes
O	O	-hydroxy-iso-pravastatin	no
O	O	by	no
O	O	55	no
O	O	%	no
O	O	(	no
O	O	range	no
O	O	from	no
O	O	32	yes
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	314	no
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	and	yes
O	O	39	no
O	O	%	no
O	O	(	no
O	O	range	no
O	O	from	no
O	O	24	yes
O	O	%	no
O	O	decrease	no
O	O	to	no
O	O	261	no
O	O	%	no
O	O	increase	no
O	O	)	no
O	O	,	no
O	O	respectively	no
O	O	in	yes
O	O	23	no
O	O	healthy	no
O	O	adults	no
O	O	.	no

O	O	Data	no
O	O	from	no
O	O	several	no
O	O	studies	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	TIMI-II	no
O	O	,	no
O	O	ISIS-2	no
O	O	,	no
O	O	currently	no
O	O	do	no
O	O	not	no
O	O	suggest	no
O	O	any	no
O	O	clinical	no
O	O	interaction	no
O	O	between	yes
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	in	yes
O	O	the	no
O	O	acute	no
O	O	myocardial	no
O	O	infarction	no
O	O	setting	no
O	O	.	no

B-drug	B-drug	chlordiazepoxide	yes
O	O	;	no

O	O	Treatment	no
O	O	with	yes
O	O	daily	no
O	O	doses	no
O	O	of	yes
O	O	2	yes
O	O	mg	yes
O	O	of	yes
B-drug_n	B-drug_n	coumaphos/kg	no
O	O	for	yes
O	O	6	yes
O	O	days	no
O	O	did	no
O	O	not	no
O	O	modify	no
O	O	the	no
O	O	anticholinesterase	no
O	O	effect	no
O	O	of	yes
O	O	a	yes
O	O	2nd	no
O	O	series	no
O	O	of	yes
O	O	treatments	no
O	O	given	no
O	O	6	yes
O	O	weeks	no
O	O	later	no
O	O	.	no

O	O	Effects	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	on	no
O	O	other	no
O	O	drugs	no

B-drug	B-drug	Doxorubicin	yes
O	O	:	no
B-drug	B-drug	Doxorubicin	yes
O	O	caused	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	zalcitabine	yes
O	O	phosphorylation	no
O	O	(	no
O	O	50	yes
O	O	%	no
O	O	inhibition	no
O	O	of	yes
O	O	total	yes
O	O	phosphate	yes
O	O	formation	no
O	O	)	no
O	O	in	yes
O	O	U937/Molt	no
O	O	4	yes
O	O	cells	yes
O	O	.	no

O	O	it	no
O	O	is	yes
O	O	possible	no
O	O	that	no
O	O	larger	no
B-drug	B-drug	theophylline	yes
O	O	doses	no
O	O	could	no
O	O	have	no
O	O	a	yes
O	O	greater	no
O	O	effect	no
O	O	.	no

B-group	O	Progestin-only	no
O	O	oral	yes
O	O	contraception	no
O	O	:	no
O	O	a	yes
O	O	comprehensive	no
O	O	review	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	magnitude	no
O	O	of	yes
O	O	changes	no
O	O	in	yes
B-drug	B-drug	diazepam	yes
O	O	plasma	yes
O	O	exposure	yes
O	O	when	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	valdecoxib	yes
O	O	were	no
O	O	not	no
O	O	sufficient	no
O	O	to	no
O	O	warrant	no
O	O	dosage	no
O	O	adjustments	no
O	O	,	no
O	O	patients	no
O	O	may	no
O	O	experience	no
O	O	enhanced	no
B-group	O	sedative	no
O	O	side	no
O	O	effects	no
O	O	caused	no
O	O	by	no
O	O	increased	no
O	O	exposure	yes
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	under	no
O	O	this	no
O	O	circumstance	no
O	O	.	no

O	O	cardiovascular	no
O	O	effects	no
O	O	can	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	interactions	no
O	O	may	no
O	O	be	no
O	O	expected	no
O	O	,	no
O	O	and	yes
B-brand	B-brand	UROXATRAL	yes
O	O	should	no
O	O	NOT	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	B-group	alpha-blockers	no
O	O	.	no

O	O	The	no
O	O	addition	no
O	O	of	yes
O	O	540	no
O	O	mg/kg/day	no
O	O	of	yes
B-drug	B-drug	cromolyn	yes
I-drug	I-drug	sodium	yes
O	O	(	no
O	O	approximately	no
O	O	340	no
O	O	times	no
O	O	the	no
O	O	maximum	no
O	O	recommended	no
O	O	daily	no
O	O	inhalation	no
O	O	dose	no
O	O	in	yes
O	O	adults	no
O	O	on	no
O	O	a	yes
O	O	mg/m2	no
O	O	basis	no
O	O	)	no
O	O	to	no
O	O	2.7	no
O	O	mg/kg/day	no
O	O	of	yes
B-drug	B-drug	isoproterenol	yes
O	O	(	no
O	O	approximately	no
O	O	7	yes
O	O	times	no
O	O	the	no
O	O	maximum	no
O	O	recommended	no
O	O	daily	no
O	O	inhalation	no
O	O	dose	no
O	O	in	yes
O	O	adults	no
O	O	on	no
O	O	a	yes
O	O	mg/m2	no
O	O	basis	no
O	O	)	no
O	O	appears	no
O	O	to	no
O	O	have	no
O	O	increased	no
O	O	the	no
O	O	incidence	no
O	O	of	yes
O	O	both	no
O	O	resorptions	no
O	O	and	yes
O	O	malformations	no
O	O	.	no

O	O	Agents	yes
O	O	with	yes
O	O	Decreased	no
O	O	Levels	no
O	O	in	yes
O	O	the	no
O	O	Presence	no
O	O	of	yes
B-drug	B-drug	Carbamazepine	yes
O	O	due	no
O	O	to	no
O	O	Induction	no
O	O	of	yes
O	O	Cytochrome	no
O	O	P450	no
O	O	Enzymes	yes
B-drug	B-drug	Carbamazepine	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	CYP1A2	no
O	O	and	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-drug	penicillins	no
O	O	,	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	PIPRACIL	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	using	no
O	O	a	yes
O	O	copper-reduction	no
O	O	method	yes
O	O	.	no

O	O	The	no
O	O	total	yes
O	O	drug	yes
O	O	exposure	yes
O	O	for	yes
O	O	the	no
O	O	plasma	yes
O	O	was	no
O	O	approximately	no
O	O	twofold	no
O	O	at	yes
O	O	the	no
O	O	higher	no
B-drug	B-drug	cisplatin	yes
O	O	dose	no
O	O	.	no

O	O	The	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	informed	no
O	O	that	no
O	O	the	no
O	O	response	no
O	O	to	no
B-drug	B-drug	alcohol	yes
O	O	may	no
O	O	be	no
O	O	exaggerated	no
O	O	.	no

O	O	Drug	yes
O	O	Interaction	no
O	O	with	yes
B-drug	B-drug	Fluoxetine	yes
O	O	:	no
O	O	A	yes
O	O	multiple-dose	no
O	O	study	no
O	O	was	no
O	O	conducted	no
O	O	to	no
O	O	assess	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	20	yes
O	O	mg	yes
O	O	BID	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	estazolam	yes
O	O	2	yes
O	O	mg	yes
O	O	QHS	no
O	O	after	no
O	O	seven	no
O	O	days	no
O	O	.	no

O	O	Reductions	no
O	O	in	yes
O	O	serum	yes
O	O	endogenous	no
O	O	vitamin	yes
O	O	D	yes
O	O	concentrations	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	300	yes
O	O	mg/day	no
O	O	to	no
O	O	1200	no
O	O	mg/day	no
B-drug	B-drug	ketoconazole	yes
O	O	for	yes
O	O	a	yes
O	O	week	no
O	O	to	no
O	O	healthy	no
O	O	men	no
O	O	.	no

O	O	+45	no
O	O	%	no
O	O	+39	no
O	O	%	no
O	O	+43	no
O	O	%	no
O	O	+72	no
O	O	%	no

B-drug	B-brand	Geocillin	yes
O	O	(	no
B-drug	B-drug	carbenicillin	yes
I-drug	I-drug	indanyl	no
I-drug	I-drug	sodium	yes
O	O	)	no
O	O	blood	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	and	yes
O	O	prolonged	no
O	O	by	no
O	O	concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	.	no

O	O	It	no
O	O	may	no
O	O	increase	no
O	O	excretion	no
O	O	of	yes
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
O	O	and	yes
O	B-drug	ASA	yes
O	O	and	yes
O	O	may	no
O	O	also	no
O	O	increase	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-group	B-group	salicylates	no
O	O	.	no

O	O	Do	no
O	O	not	no
O	O	mix	yes
B-brand	B-brand	TORADOL	yes
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	in	yes
O	O	the	no
O	O	same	yes
O	O	syringe	yes
O	O	.	no

O	O	The	no
O	O	steady-state	no
O	O	Cmin	no
O	O	increased	no
O	O	to	no
O	O	21	yes
O	O	5	yes
O	O	micrograms/mL	no
O	O	when	no
O	O	1200	no
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	felbamate	yes
O	O	was	no
O	O	coadministered	no
O	O	.	no

B-drug	B-drug	Isoflurane	yes
O	O	or	no
B-drug	B-drug	enflurane	yes
O	O	administered	no
O	O	with	yes
B-group	B-drug	nitrous	yes
I-group	I-drug	oxide/oxygen	no
O	O	to	no
O	O	achieve	no
O	O	1.25	yes
O	O	MAC	no
O	O	[	no
O	O	Minimum	no
O	O	Alveolar	no
O	O	Concentration	no
O	O	]	no
O	O	may	no
O	O	prolong	no
O	O	the	no
O	O	clinically	no
O	O	effective	no
O	O	duration	no
O	O	of	yes
O	O	action	no
O	O	of	yes
O	O	initial	no
O	O	and	yes
O	O	maintenance	no
O	O	doses	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	and	yes
O	O	decrease	no
O	O	the	no
O	O	required	no
O	O	infusion	no
O	O	rate	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	,	no
O	O	therefore	no
O	O	,	no
O	O	advisable	no
O	O	to	no
O	O	monitor	no
B-drug	B-drug	digoxin	yes
O	O	concentrations	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	ketoconazole	yes
O	O	.	no

O	O	-	yes
B-group	B-group	Vitamin	yes
I-group	I-group	K	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	AquaMEPHYTON	yes
O	O	,	no
B-brand	B-brand	Synkayvite	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	sulfapyridine	yes
O	O	with	yes
O	O	these	no
O	O	medicines	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	blood	yes

O	O	No	yes
O	O	information	no
O	O	provided	no

O	O	Patients	no
O	O	receiving	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	concomitantly	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	.	no

O	O	Notably	no
O	O	,	no
O	O	systemic	no
O	O	exposure	yes
O	O	(	no
O	O	AUC0-12	no
O	O	)	no
O	O	of	yes
B-drug	B-drug_n	dapsone	yes
I-drug	I-drug_n	hydroxylamine	no
O	O	(	no
O	B-drug_n	DHA	yes
O	O	)	no
O	O	was	no
O	O	more	no
O	O	than	no
O	O	doubled	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	TMP/SMX	no
O	O	.	no

O	O	If	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	are	no
O	O	coadministered	no
O	O	,	no
O	O	the	no
B-group	B-group	beta	yes
I-group	I-group	blocker	no
O	O	should	no
O	O	be	no
O	O	withdrawn	no
O	O	several	no
O	O	days	no
O	O	before	no
O	O	the	no
O	O	gradual	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Therefore	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	tablets	yes
O	O	with	yes
B-drug	B-drug	cisapride	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	benign	no
O	O	breast	no
O	O	disease	no
O	O	;	no

B-drug	B-drug	Colchicine	yes
O	O	is	yes
O	O	inhibited	no
O	O	by	no
B-group	B-group	acidifying	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Co-administration	no
O	O	with	yes
B-drug	B-drug	efavirenz	yes
O	O	or	no
B-drug	B-drug	fluconazole	yes
O	O	had	no
O	O	a	yes
O	O	modest	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	azithromycin	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	Hypoglycemic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	In	yes
O	O	pharmacokinetic	no
O	O	studies	no
O	O	of	yes
B-brand	B-brand	MEVACOR	yes
O	O	in	yes
O	O	hypercholesterolemic	no
O	O	noninsulin	no
O	O	dependent	no
O	O	diabetic	no
O	O	patients	no
O	O	,	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	drug	yes
O	O	interaction	no
O	O	with	yes
B-drug	B-drug	glipizide	yes
O	O	or	no
O	O	with	yes
B-drug	B-drug	chlorpropamide	yes

O	O	Comparison	no
O	O	of	yes
B-drug	B-drug	cisplatin	yes
O	O	pharmacokinetics	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	202.5	no
O	O	mg/m2	no
O	O	plus	yes
B-drug	B-drug	thiosulfate	yes
O	O	to	no
O	O	those	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	100	yes
O	O	mg/m2	no
O	O	without	no
B-drug	B-drug	thiosulfate	yes
O	O	indicated	no
O	O	that	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	elimination	no
O	O	rate	no
O	O	constant	no
O	O	,	no
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	,	no
O	O	or	no
O	O	total	yes
O	O	body	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	cisplatin	yes
O	O	.	no

O	O	Dosage	no
O	O	adjustment	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	if	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	methylprednisolone	yes
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-brand	B-brand	NIZORAL	yes
O	O	Tablets	yes
O	O	.	no

O	O	No	yes
O	O	depressant	no
O	O	effect	no
O	O	on	no
O	O	blood	yes
O	O	levels	no
O	O	in	yes
O	O	humans	no
O	O	was	no
O	O	noted	no
O	O	when	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	was	no
O	O	administered	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	:	no
B-brand	B-brand	aspirin	yes
O	O	,	no
B-drug	B-brand	clindamycin	yes
O	O	,	no
B-drug	B-drug	clofibrate	yes
O	O	,	no
B-drug	B-drug	methyldopa	yes
O	O	,	no
B-drug	B-drug	nicotinic	yes
I-drug	I-drug	acid	yes
O	O	(	no
B-drug	B-drug	niacin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	phenytoin	yes
O	O	(	no
B-brand	B-brand	Dilantin	yes
O	O	)	no
O	O	;	no

O	O	Withdrawal	no
O	O	from	no
B-drug	B-drug	cocaine	yes
O	O	dependence	no
O	O	usually	no
O	O	involves	no
O	O	depression	no
O	O	,	no
O	O	anxiety	no
O	O	and	yes
O	O	lethargy	no
O	O	.	no

O	O	Therapeutic	no
O	O	drug	yes
O	O	monitoring	no
O	O	(	no
O	O	TDM	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	gentamicin	yes
O	O	therapy	no
O	O	,	no
O	O	and	yes
O	O	bone	no
O	O	scintigraphy	no
O	O	employing	no
B-drug	B-drug	99mTc-MDP	no
O	O	as	yes
O	O	the	no
O	B-group	radiopharmaceutical	no
O	O	was	no
O	O	carried	no
O	O	out	no
O	O	in	yes
O	O	22	no
O	O	patients	no
O	O	.	no

O	O	Refer	no
O	O	to	no
O	O	the	no
O	O	package	no
O	O	insert	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparations	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	preparations	no
O	O	with	yes
B-drug	B-drug	chlorothiazide	yes

O	O	Drug	yes
O	O	Interaction	no
O	O	with	yes
B-drug	B-drug	Erythromycin	yes
O	O	and	yes
B-drug	B-drug	Ketoconazole	yes
I-drug	I-drug	Fexofenadine	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	exhibit	no
O	O	minimal	no
O	O	(	no
O	O	ca	no
O	O	.	no
O	O	5	yes
O	O	%	no
O	O	)	no
O	O	metabolism	no
O	O	.	no

O	O	Because	no
B-drug	B-drug	eprosartan	yes
O	O	is	yes
O	O	not	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	system	yes
O	O	,	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP450	no
O	O	enzyme	no
O	O	would	no
O	O	not	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	affect	no
O	O	its	no
O	O	metabolism	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	fluconazole	yes
O	O	,	no
O	O	potent	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A	no
O	O	and	yes
O	O	2C9	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	have	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	have	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	eprosartan	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	intake	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	and	yes
B-drug	B-drug	Acamprosate	yes
O	O	does	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	alcohol	yes
O	O	or	no
B-drug	B-drug	acamprosate	yes
O	O	.	no

O	O	The	no
O	O	following	no
O	O	specific	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	:	no
B-drug	O	Itraconazole	yes
O	O	Co-administration	no
O	O	of	yes
O	O	another	no
O	O	extended	yes
O	O	release	yes
O	O	formulation	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	with	yes
B-drug	B-drug	itraconazole	yes
O	O	resulted	no
O	O	in	yes
O	O	approximately	no
O	O	8-fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	AUC	no
O	O	,	no
O	O	more	no
O	O	than	no
O	O	6-	no
O	O	fold	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	Cmax	no
O	O	,	no
O	O	and	yes
O	O	2-fold	no
O	O	prolongation	no
O	O	in	yes
O	O	the	no
O	O	half-	no
O	O	life	no
O	O	of	yes
B-drug	B-drug	felodipine	yes
O	O	.	no

B-drug	B-drug	Erythromycin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	significantly	no
O	O	alter	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	O	nonsedating	no
I-group	B-group	antihistamines	no
B-drug	B-drug	terfenadine	yes
O	O	and	yes
B-drug	B-drug	astemizole	yes
O	O	when	no
O	O	taken	no
O	O	concomitantly	no
O	O	.	no

O	O	Mixtures	no
O	O	of	yes
O	O	cadmium	no
O	O	and	yes
B-drug	B-drug	zinc	yes
O	O	had	no
O	O	a	yes
O	O	synergistic	no
O	O	effect	no
O	O	compared	no
O	O	with	yes
O	O	single	yes
O	O	metal	no
O	O	toxicity	no
O	O	but	no
O	O	only	no
O	O	at	yes
O	O	50000	no
O	O	microg/l	no
O	O	.	no

B-brand	B-brand	ALLEGRA	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	closely	no
O	O	in	yes
O	O	time	no
O	O	with	yes
B-drug	B-drug	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
O	O	containing	yes
B-group	B-group	antacids	no
O	O	.	no

O	O	No	yes
O	O	interaction	no
O	O	was	no
O	O	noted	no
O	O	with	yes
O	O	the	no
B-group	B-group	MAO-B	no
I-group	I-group	inhibitor	yes
B-drug	B-drug	selegiline	yes
O	O	in	yes
O	O	two	no
O	O	multiple-dose	no
O	O	interaction	no
O	O	studies	no
O	O	when	no
B-drug	B-drug	entacapone	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
O	O	a	yes
B-drug	B-drug	levodopa/dopa	no
B-group	B-group	decarboxylase	no
I-group	I-group	inhibitor	yes
O	O	(	no
O	O	n=29	no
O	O	)	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	convulsions	no
O	O	occurring	no
O	O	in	yes
O	O	susceptible	no
O	O	patients	no
O	O	following	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	the	no
O	O	new	no
B-group	B-group	anaesthetic	no
I-group	I-group	agents	yes
O	O	which	no
O	O	are	no
O	O	capable	no
O	O	of	yes
O	O	inducing	no
O	O	CNS	no
O	O	excitability	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
B-drug	B-drug	Hydrocortisone	yes
O	O	elevated	no
O	O	salivary	yes
O	O	cortisol	yes
O	O	levels	no
O	O	,	no
O	O	produced	no
O	O	modest	no
O	O	dysphoria	no
O	O	,	no
O	O	and	yes
O	O	reduced	yes
O	O	subjects	no
O	O	'	no
O	O	reports	no
O	O	of	yes
O	O	wanting	no
O	O	more	no
O	O	drug	yes
O	O	.	no

B-drug	I-drug	Clarithromycin	yes
O	O	14OH-	no
B-drug	O	clarithromycin	yes

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	during	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	adrenaline	yes
O	O	to	no
O	O	patients	no
O	O	anaesthetised	no
O	O	with	yes
B-brand	B-brand	FLUOTHANE	yes
O	O	as	yes
O	O	arrhythmias	no
O	O	may	no
O	O	be	no
O	O	precipitated	yes
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	:	no
O	O	The	no
O	O	oral	yes
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	before	no
O	O	intramuscular	no
O	O	injection	yes
O	O	of	yes
B-brand	B-brand	PIPRACIL	yes
O	O	produces	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	piperacillin	yes
O	O	peak	no
O	O	serum	yes
O	O	level	no
O	O	of	yes
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	.	no

O	O	A	yes
O	O	review	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	medicinal	yes
O	O	products	no
O	O	with	yes
O	O	similar	no
O	O	properties	no
O	O	such	no
O	O	as	yes
O	O	inotropes	no
B-drug	B-drug	milrinone	yes
O	O	,	no
B-drug	B-drug	enoximone	yes
O	O	,	no
B-drug	B-drug	amrinone	yes
O	O	,	no
B-drug	B-drug_n	olprinone	no
O	O	and	yes
B-drug	B-drug	cilostazol	yes
O	O	may	no
O	O	be	no
O	O	exacerbated	no
O	O	by	no
B-drug	B-drug	anagrelide	yes
O	O	.	no

O	O	Our	no
O	O	data	no
O	O	suggest	no
O	O	that	no
B-drug_n	B-drug_n	TAM	no
O	O	significantly	no
O	O	potentiates	no
O	O	the	no
O	O	reduction	yes
O	O	in	yes
O	O	cell	yes
O	O	number	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	1,25	no
I-drug	I-drug	(	no
I-drug	I-drug	OH	no
I-drug	I-drug	)	no
I-drug	I-drug	2D3	no
O	O	alone	no
O	O	.	no

O	O	Determinants	no
O	O	downstream	no
O	O	of	yes
O	O	cleavable	no
O	O	complex	yes
O	O	formation	no
O	O	that	no
O	O	affect	no
O	O	the	no
O	O	sensitivity	no
O	O	of	yes
O	O	tumor	yes
O	O	versus	no
O	O	normal	yes
O	O	cells	yes
O	O	to	no
O	O	topo	no
O	O	drugs	no
O	O	in	yes
O	O	particular	no
O	O	and	yes
O	O	DNA-damaging	no
O	O	agents	yes
O	O	in	yes
O	O	general	no
O	O	are	no
O	O	little	no
O	O	known	no
O	O	.	no

B-drug	B-drug	ethchlorvynol	yes
O	O	;	no

O	O	Injection	yes
O	O	of	yes
B-drug	B-drug	estradiol	yes
O	O	5	yes
O	O	min	no
O	O	before	no
O	O	a	yes
O	O	nonlethal	no
O	O	dose	no
O	O	of	yes
B-drug_n	B-drug_n	endotoxin	no
O	O	changed	no
O	O	the	no
O	O	serum	yes
O	O	sex	no
O	O	steroid	no
O	O	hormone	yes
O	O	response	no
O	O	of	yes
O	O	male	no
O	O	rats	no
O	O	to	no
B-drug_n	B-drug_n	endotoxin	no
O	O	.	no

O	O	Additive	no
O	O	depressant	no
O	O	effect	no
O	O	when	no
O	O	used	no
O	O	with	yes
O	O	general	no
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	antianxiety	no
I-group	I-group	drugs	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	,	no
B-drug	B-drug	alcohol	yes
O	O	,	no
O	O	and	yes
O	O	other	no
B-group	B-group	opiate	no
I-group	I-group	analgesics	no
O	O	.	no

O	O	Antagonism	no
O	O	has	no
O	O	been	no
O	O	demonstrated	no
O	O	between	yes
B-drug	B-drug	clindamycin	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	It	no
O	O	may	no
O	O	also	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	amantadine	yes
O	O	or	no
O	O	other	no
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	or	no
B-group	B-group	MAOIs	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	action	no
O	O	.	no

O	O	Oral	yes
B-group	B-group	Anticoagulants	no
O	O	:	no
O	O	In	yes
O	O	some	no
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	acenocoumarol	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	phenprocoumon	yes
O	O	resulted	no
O	O	in	yes
O	O	prolongation	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

B-drug	I-drug	Rifabutin	yes
O	O	and	yes
O	O	its	no
O	O	metabolite	yes
O	O	concentrationswere	no
O	O	moderately	no
O	O	increased	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	cephalothin	yes
O	O	and	yes
B-brand	B-brand	Coly-Mycin	yes
I-brand	I-brand	M	yes
O	O	Parenteral	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	for	yes
O	O	some	no
O	O	strains	no
O	O	combinations	no
O	O	were	no
O	O	synergistic	no
O	O	.	no

O	O	The	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	tetracycline	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	penicillin	yes
I-drug	I-drug	G	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	gemfibrozil	yes
O	O	was	no
O	O	significantly	no
O	O	decreased	no
O	O	when	no
O	O	given	no
O	O	simultaneously	no
O	O	with	yes
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	;	no

O	O	The	no
O	O	results	no
O	O	indicate	no
O	O	that	no
O	O	a	yes
O	O	spinal	no
O	B-drug	naloxone-sensitive	no
O	O	endorphinergic	no
O	O	system	yes
O	O	is	yes
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	production	no
O	O	of	yes
B-drug_n	B-drug_n	beta-endorphin	no
O	O	but	no
O	O	not	no
B-drug	B-drug	morphine-induced	no
O	O	tail-flick	no
O	O	inhibition	no
O	O	,	no
O	O	and	yes
O	O	suggest	no
O	O	that	no
O	O	intraventricular	no
B-drug_n	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	elicit	no
O	O	their	no
O	O	pharmacological	no
O	O	actions	no
O	O	via	no
O	O	the	no
O	O	activation	no
O	O	of	yes
O	O	different	no
O	O	descending	no
O	O	pain	yes
O	O	inhibitory	yes
O	O	systems	no
O	O	;	no

O	O	Effects	no
O	O	of	yes
O	O	Other	no
O	O	Drugs	no
O	O	on	no
B-drug	B-drug	Aliskiren	yes
O	O	Based	no
O	O	on	no
O	O	in-vitro	no
O	O	studies	no
O	O	,	no
B-drug	B-drug	aliskiren	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP	no
O	O	3A4	no
O	O	.	no

O	O	Combined	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	1,25	no
I-drug	I-drug	(	no
I-drug	I-drug	OH	no
I-drug	I-drug	)	no
I-drug	I-drug	2D3	no
O	O	and	yes
B-drug	B-drug_n	TAM	no
O	O	enhances	no
O	O	the	no
O	O	degree	no
O	O	of	yes
O	O	apoptosis	no
O	O	assessed	no
O	O	using	no
O	O	morphological	no
O	O	markers	no
O	O	that	no
O	O	identify	no
O	O	chromatin	no
O	O	and	yes
O	O	nuclear	no
O	O	matrix	no
O	O	protein	yes
O	O	condensation	no
O	O	.	no

O	O	At	yes
O	O	0.3	yes
O	O	mg/kg	no
O	O	,	no
O	O	the	no
O	O	diarrhea-inducing	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	dmPGE2	no
O	O	were	no
O	O	more	no
O	O	pronounced	no
O	O	in	yes
O	O	cecectomized	no
O	O	than	no
O	O	in	yes
O	O	control	no
O	O	rats	no
O	O	.	no

O	O	Tissue	yes
O	O	culture	no
O	O	and	yes
O	O	animal	no
O	O	studies	no
O	O	indicate	no
O	O	that	no
B-brand	B-brand	ELSPAR	yes
O	O	can	no
O	O	diminish	no
O	O	or	no
O	O	abolish	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	on	no
O	O	malignant	no
O	O	cells.14	no
O	O	This	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	methotrexate	yes
O	O	activity	yes
O	O	persists	no
O	O	as	yes
O	O	long	yes
O	O	as	yes
O	O	plasma	yes
B-drug	O	asparagine	yes
O	O	levels	no
O	O	are	no
O	O	suppressed	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	the	no
O	O	use	no
O	O	of	yes
O	O	genetic	no
O	O	data	no
O	O	in	yes
O	O	these	no
O	O	instances	no
O	O	has	no
O	O	to	no
O	O	be	no
O	O	regulated	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Quinine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Quinamm	no
O	O	)	no
O	O	or	no

O	O	Drug-drug	no
O	O	interactions	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	observed	no
O	O	between	yes
B-drug	B-drug	Argatroban	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	or	no
B-drug	B-drug	erythromycin	yes
O	O	.	no

B-drug	B-drug	Probenecid	yes
O	O	depresses	no
O	O	tubular	no
O	O	secretion	no
O	O	of	yes
O	O	certain	no
O	O	weak	no
O	O	acids	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	PAH	yes
O	O	.	no

O	O	Particular	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	with	yes
B-group	B-group	digitalis	yes
I-group	I-group	preparations	no
O	O	since	no
O	O	there	no
O	O	are	no
O	O	conflicting	no
O	O	results	no
O	O	for	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	on	no
O	O	the	no
O	O	availability	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	and	yes
B-drug	B-drug	digitoxin	yes
O	O	.	no

O	O	While	no
O	O	taking	no
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	,	no
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	severe	no
O	O	anaphylactic	no
O	O	reaction	no
O	O	to	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	allergens	no
O	O	may	no
O	O	be	no
O	O	more	no
O	O	reactive	yes
O	O	to	no
O	O	repeated	no
O	O	challenge	no
O	O	,	no
O	O	either	no
O	O	accidental	no
O	O	,	no
O	O	diagnostic	yes
O	O	,	no
O	O	or	no
O	O	therapeutic	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
O	O	When	no
O	O	a	yes
O	O	single	yes
O	O	375-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	Day9	no
O	O	of	yes
O	O	a	yes
O	O	14-day	no
O	O	regimen	no
O	O	of	yes
O	O	600	yes
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	a	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	decreased	no
O	O	approximately	no
O	O	11-fold	no
O	O	and	yes
O	O	the	no
O	O	mean	no
O	O	terminal	no
O	O	half-life	no
O	O	decreased	no
O	O	approximately	no
O	O	3-fold	no
O	O	.	no

O	O	For	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
O	O	see	no
O	O	CONTRAINDICATIONS	no
O	O	.	no

O	O	If	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	closely	no
O	O	monitor	no
O	O	serum	yes
O	O	electrolytes	yes
O	O	and	yes
O	O	cardiac	no
O	O	function	no
O	O	.	no

O	O	Interactions	no
O	O	with	yes
O	O	the	no
O	O	drugs	no
O	O	listed	no
O	O	below	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	;	no

B-drug	B-drug	Propranolol	yes
O	O	attenuated	yes
O	O	the	no
O	O	heart	no
O	O	rate	no
O	O	increase	no
O	O	following	no
O	O	administration	no
O	O	of	yes
O	O	immediate	no
O	O	release	yes
B-drug	B-drug	nisoldipine	yes
O	O	.	no

B-drug	B-drug	Ethinyl	yes
I-drug	I-drug	estradiol	yes

B-brand	B-brand	ELLENCE	yes
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	O	cytotoxic	yes
I-group	O	drugs	no
O	O	may	no
O	O	show	no
O	O	on-treatment	no
O	O	additive	no
O	O	toxicity	no
O	O	,	no
O	O	especially	no
O	O	hematologic	no
O	O	and	yes
O	O	gastrointestinal	no
O	O	effects	no
O	O	.	no

O	O	poor	no
O	O	metabolizers	no
O	O	of	yes
B-drug	B-drug	debrisoquin	yes
O	O	:	no
O	O	Interactions	no
O	O	of	yes
B-drug	B-drug	carvedilol	yes
O	O	with	yes
O	O	strong	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	propafenone	yes
O	O	)	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	,	no
O	O	but	no
O	O	these	no
O	O	drugs	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
O	O	R	yes
O	O	(	no
O	O	+	no
O	O	)	no
O	O	enantiomer	no
O	O	of	yes
B-drug	B-drug	carvedilol	yes
O	O	.	no

O	O	-	yes
B-drug	B-drug	Indomethacin	yes
O	O	:	no
B-drug	B-drug	Indomethacin	yes
O	O	blunts	no
O	O	the	no
O	O	increases	no
O	O	in	yes
O	O	urine	no
O	O	volume	no
O	O	and	yes
O	O	sodium	yes
O	O	excretion	no
O	O	seen	no
O	O	during	no
B-drug	B-drug	bumetanide	yes
O	O	treatment	no
O	O	and	yes
O	O	inhibits	no
O	O	the	no
B-drug	B-drug	bumetanide-induced	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	renin	no
O	O	activity	yes
O	O	.	no

O	O	anaphylaxis	no

O	O	It	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	that	no
O	O	results	no
O	O	of	yes
O	O	studies	no
O	O	in	yes
O	O	animals	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	dopamine-induced	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	during	no
O	O	anesthesia	yes
O	O	can	no
O	O	be	no
O	O	reversed	no
O	O	by	no
B-drug	B-drug	propranolol	yes
O	O	.	no

B-group	B-group	Calcium	yes
I-group	I-group	Channel	no
I-group	I-group	Blockers	no
O	O	:	no
O	O	Isolated	no
O	O	cases	no
O	O	of	yes
O	O	conduction	no
O	O	disturbance	no
O	O	(	no
O	O	rarely	no
O	O	with	yes
O	O	hemodynamic	no
O	O	compromise	no
O	O	)	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	when	no
B-brand	B-brand	COREG	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	.	no

B-drug	B-drug	Verapamil	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	almotriptan	yes
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	24	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	almotriptan	yes
O	O	.	no

O	O	The	no
O	O	elevated	no
O	O	plasma	yes
B-drug	B-drug	alprazolam	yes
O	O	concentrations	no
O	O	resulted	no
O	O	in	yes
O	O	decreased	no
O	O	psychomotor	no
O	O	performance	no
O	O	and	yes
O	O	memory	no
O	O	.	no

O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	binding	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	if	no
O	O	given	no
O	O	concomitantly	no
O	O	is	yes
O	O	present	no
O	O	.	no

O	O	Intraventricular	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	naloxone	yes
O	O	at	yes
O	O	doses	no
O	O	of	yes
O	O	1.2	no
O	O	to	no
O	O	12	yes
O	O	micrograms	no
O	O	equally	no
O	O	antagonized	no
O	O	in	yes
O	O	a	yes
O	O	dose-dependent	no
O	O	manner	no
O	O	the	no
O	O	tail-flick	no
O	O	inhibition	no
O	O	induced	no
O	O	by	no
O	O	intraventricular	no
B-drug	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	.	no

B-drug	B-drug	Lamivudine	yes
O	O	and	yes
B-drug	B-drug	zalcitabine	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	intracellular	no
O	O	phosphorylation	no
O	O	of	yes
O	O	one	no
O	O	another	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	fluoxetine	yes
O	O	significantly	no
O	O	decreased	no
B-drug	B-drug	cisapride	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	decreased	no
O	O	levels	no
O	O	of	yes
O	O	anti-factor	no
O	O	Xa	no
O	O	and	yes
B-drug	O	antithrombin	yes
I-drug	O	III	yes
O	O	,	no
O	O	decreased	no
O	O	antithrombin	yes
O	O	III	yes
O	O	activity	yes
O	O	;	no

O	O	Some	no
O	O	95	no
O	O	%	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	is	yes
O	O	excreted	no
O	O	via	no
O	O	the	no
O	O	biliary	no
O	O	route	no
O	O	,	no
O	O	with	yes
O	O	less	no
O	O	than	no
O	O	2	yes
O	O	%	no
O	O	of	yes
O	O	this	no
O	O	being	no
O	O	the	no
O	O	parent	no
O	O	compound	yes
O	O	.	no

O	O	.	no

O	O	higher	no
O	O	doses	no
O	O	decreased	no
O	O	FI	no
O	O	and	yes
O	O	FR	no
O	O	responding	no
O	O	in	yes
O	O	both	no
O	O	species	no
O	O	.	no

B-drug	B-drug	ERYTHROMYCIN	yes
O	O	:	no
O	O	In	yes
O	O	hypercholesterolemic	no
O	O	patients	no
O	O	,	no
O	O	steady-state	no
B-drug	B-drug	cerivastatin	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	increased	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	and	yes
O	O	24	yes
O	O	%	no
O	O	respectively	no
O	O	after	no
O	O	10	yes
O	O	days	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	,	no
O	O	a	yes
O	O	known	no
O	O	inhibitor	yes
O	O	of	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	As	yes
O	O	a	yes
O	O	false-negative	no
O	O	result	no
O	O	may	no
O	O	occur	no
O	O	in	yes
O	O	the	no
O	O	ferricyanide	no
O	O	test	yes
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	either	no
O	O	the	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	or	no
O	O	hexokinase	no
O	O	method	yes
O	O	be	no
O	O	used	no
O	O	to	no
O	O	determine	no
O	O	blood	yes
O	O	plasma	yes
O	O	glucose	yes
O	O	levels	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	cefuroxime	yes
O	O	.	no

B-brand	B-brand	Norpace	yes
O	O	does	no
O	O	not	no
O	O	increase	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	interactions	no
O	O	observed	no
O	O	in	yes
O	O	these	no
O	O	studies	no
O	O	do	no
O	O	not	no
O	O	appear	no
O	O	to	no
O	O	be	no
O	O	of	yes
O	O	major	no
O	O	clinical	no
O	O	importance	no
O	O	,	no
B-brand	B-brand	BREVIBLOC	yes
O	O	should	no
O	O	be	no
O	O	titrated	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	morphine	yes
O	O	,	no
B-drug	B-drug	succinylcholine	yes
O	O	or	no
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	Carcinogenesis	no
O	O	,	no
O	O	Mutagenesis	no
O	O	,	no
O	O	and	yes
O	O	Fertility	no

O	O	[	no
O	O	Dose-time	no
O	O	effects	no
O	O	of	yes
O	O	competitive	no
O	O	displacement	no
O	O	of	yes
B-drug	B-drug	radiopertechnetate	no
O	O	by	no
B-drug	B-drug_n	sodium	yes
I-drug	I-drug_n	perchlorate	yes
O	O	following	no
O	O	oral	yes
O	O	and	yes
O	O	intravenous	yes
O	O	administration	no
O	O	]	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	various	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug_n	sodium	yes
I-drug	I-drug_n	perchlorate	yes
O	O	in	yes
O	O	several	no
O	O	dose	no
O	O	fractions	no
O	O	on	no
O	O	the	no
O	O	extent	no
O	O	and	yes
O	O	the	no
O	O	time	no
O	O	scale	no
O	O	of	yes
O	O	displacement	no
O	O	of	yes
B-drug	B-drug	radiopertechnetate	no
O	O	,	no
O	O	in	yes
O	O	dependence	no
O	O	on	no
O	O	application	no
O	O	mode	no
O	O	,	no
O	O	was	no
O	O	studied	no
O	O	.	no

O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	;	no

O	O	CONCLUSIONS	no
O	O	:	no
O	O	Single-dose	no
B-drug	B-drug	diltiazem	yes
O	O	coadministration	no
O	O	leads	no
O	O	to	no
O	O	higher	no
B-drug	B-drug	sirolimus	yes
O	O	exposure	yes
O	O	,	no
O	O	presumably	no
O	O	by	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	first-pass	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	.	no

B-drug	B-drug	methylphenidate	yes
O	O	;	no

B-group	B-group	Diuretic	no
O	O	:	no
B-drug	B-drug	Hydrochlorothiazide	yes
O	O	,	no
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	ketoprofen	yes
O	O	,	no
O	O	produces	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	urinary	yes
O	O	potassium	yes
O	O	and	yes
B-drug	O	chloride	yes
O	O	excretion	no
O	O	compared	no
O	O	to	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	alone	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	Cytochrome	no
O	O	P450	no
O	O	Enzymes	yes
O	O	The	no
O	O	drug	yes
O	O	interaction	no
O	O	study	no
O	O	evaluating	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	grepafloxacin	yes
O	O	on	no
B-drug	B-drug	theophylline	yes
O	O	indicates	no
O	O	that	no
B-drug	B-drug	grepafloxacin	yes
O	O	inhibits	no
B-drug	B-drug	theophylline	yes
O	O	metabolism	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	mediated	no
O	O	by	no
O	O	CYP1A2	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	combined	no
O	O	therapy	no
O	O	is	yes
O	O	contemplated	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	Serum	yes
B-group	B-group	digitalis	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	in	yes
O	O	hyperthyroidism	no
O	O	or	no
O	O	when	no
O	O	a	yes
O	O	hypothyroid	no
O	O	patient	no
O	O	becomes	no
O	O	euthyroid	no
O	O	.	no

B-drug	B-drug	Nafazodone	no
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	consider	no
B-brand	B-brand	Xanax	yes
O	O	dose	no
O	O	reduction	yes
O	O	)	no
O	O	.	no

O	O	When	no
O	O	the	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	the	no
O	O	combination	yes
O	O	therapy	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	dose	no
O	O	should	no
O	O	then	no
O	O	be	no
O	O	increased	no
O	O	.	no

B-drug	B-drug	Sildenafil	yes
O	O	is	yes
O	O	contraindicated	no
O	O	in	yes
O	O	patients	no
O	O	using	no
B-group	B-group	long-acting	no
I-group	I-group	nitrates	no
O	O	or	no
O	O	who	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	use	no
B-group	B-group	short-acting	no
I-group	I-group	nitrates	no
O	O	,	no
O	O	because	no
O	O	the	no
O	O	combination	yes
O	O	may	no
O	O	cause	no
O	O	a	yes
O	O	sharp	no
O	O	fall	no
O	O	of	yes
O	O	the	no
O	O	blood	yes
O	O	pressure	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	with	yes
O	O	mild	yes
O	O	to	no
O	O	moderate	no
O	O	hypertension	no
O	O	,	no
O	O	administration	no
O	O	of	yes
O	O	25	yes
O	O	mg	yes
O	O	daily	no
O	O	of	yes
B-brand	B-brand	VIOXX	yes
O	O	with	yes
O	O	the	no
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
B-drug	B-drug	benazepril	yes
O	O	,	no
O	O	10	yes
O	O	to	no
O	O	40	yes
O	O	mg	yes
O	O	for	yes
O	O	4	yes
O	O	weeks	no
O	O	,	no
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	average	no
O	O	increase	no
O	O	in	yes
O	O	mean	no
O	O	arterial	no
O	O	pressure	no
O	O	of	yes
O	O	about	no
O	O	3	yes
O	O	mm	yes
O	O	Hg	yes
O	O	compared	no
O	O	to	no
B-group	B-group	ACE	no
I-group	I-group	inhibitor	yes
O	O	alone	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	seen	no
O	O	are	no
O	O	poorly	no
O	O	understood	no
O	O	and	yes
O	O	depend	no
O	O	upon	no
O	O	a	yes
O	O	variety	no
O	O	of	yes
O	O	factors	no
O	O	such	no
O	O	as	yes
O	O	dose	no
O	O	and	yes
O	O	type	yes
O	O	of	yes
O	B-group	thyroid	yes
O	I-group	preparations	no
O	O	and	yes
O	O	endocrine	no
O	O	status	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	.	no

B-drug	B-drug	Midazolam	yes
O	O	Synergism	no

O	O	Moreover	no
O	O	,	no
O	O	the	no
O	O	acquisition	no
O	O	of	yes
O	O	tasks	no
O	O	that	no
O	O	are	no
O	O	facilitated	no
O	O	by	no
O	O	hippocampal	no
O	O	lesions	no
O	O	(	no
O	O	or	no
O	O	dysfunction	no
O	O	)	no
O	O	is	yes
O	O	nevertheless	no
O	O	associated	no
O	O	,	no
O	O	in	yes
O	O	intact	no
O	O	subjects	no
O	O	,	no
O	O	with	yes
O	O	specific	no
O	O	neurobiological	no
O	O	alterations	no
O	O	in	yes
O	O	the	no
O	O	hippocampus	no
O	O	.	no

B-drug	B-drug	Tolazamide	yes
O	O	:	no
O	O	A	yes
O	O	case	no
O	O	of	yes
O	O	severe	no
O	O	hypoglycemia	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	a	yes
O	O	type	yes
O	O	II	yes
O	O	diabetic	no
O	O	patient	no
O	O	maintained	no
O	O	on	no
B-drug	B-drug	tolazamide	yes
O	O	(	no
O	O	1	yes
O	O	gm/day	no
O	O	)	no
O	O	11	yes
O	O	days	no
O	O	after	no
O	O	the	no
O	O	addition	no
O	O	of	yes
B-drug	B-drug	doxepin	yes
O	O	(	no
O	O	75	yes
O	O	mg/day	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	situations	no
O	O	when	no
O	O	concurrent	no
O	O	therapy	no
O	O	is	yes
O	O	necessary	no
O	O	,	no
O	O	careful	no
O	O	patient	no
O	O	monitoring	no
O	O	is	yes
O	O	essential	yes
O	O	.	no

O	O	Oral	yes
B-group	B-group	Anticoagulants	no
O	O	Interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	acenocoumarol	yes
O	O	failed	no
O	O	to	no
O	O	identify	no
O	O	any	no
O	O	clinically	no
O	O	important	no
O	O	effects	no
O	O	on	no
O	O	the	no
O	O	serum	yes
O	O	concentrations	no
O	O	or	no
O	O	clinical	no
O	O	effects	no
O	O	of	yes
O	O	these	no
B-group	B-group	anticoagulants	no
O	O	.	no

O	O	(	no
O	O	Cancer	no
O	O	Res.	no
O	O	,	no
O	O	38	no
O	O	:	no
O	O	2003-2010	no
O	O	,	no
O	O	1978	no
O	O	)	no
O	O	have	no
O	O	reported	no
O	O	that	no
O	O	a	yes
O	O	single	yes
O	O	,	no
O	O	small	no
O	O	pulse	no
O	O	of	yes
O	O	carcinogen	no
O	O	can	no
O	O	induce	no
O	O	early	no
O	O	and	yes
O	O	numerous	no
O	O	liver	yes
O	O	tumors	no
O	O	when	no
O	O	administered	no
O	O	neonatally	no
O	O	to	no
O	O	mice	no
O	O	with	yes
O	O	a	yes
O	O	genetic	no
O	O	predisposition	no
O	O	to	no
O	O	hepatotumorigenesis	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	most	no
B-group	O	psychoactive	no
I-group	O	medications	no
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	advised	no
O	O	to	no
O	O	avoid	no
B-drug	B-drug	alcohol	yes
O	O	while	no
O	O	taking	no
B-brand	B-brand	ABILIFY	yes

O	O	This	no
O	O	decrease	no
O	O	in	yes
O	O	absorption	no
O	O	results	no
O	O	in	yes
O	O	a	yes
O	O	36	no
O	O	%	no
O	O	and	yes
O	O	50	yes
O	O	%	no
O	O	lower	no
O	O	AUC	no
O	O	for	yes
B-drug	B-drug	trovafloxacin	yes
O	O	and	yes
B-drug	B-drug	ciprofloxacin	yes
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	which	no
O	O	could	no
O	O	cause	no
O	O	clinical	no
O	O	failures	no
O	O	.	no

O	O	A	yes
O	O	pregnancy	no
O	O	test	yes
O	O	must	no
O	O	be	no
O	O	repeated	no
O	O	each	no
O	O	month	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	female	no
O	O	patient	no
O	O	receiving	no
O	O	each	no
O	O	prescription	no

O	O	The	no
O	O	interaction	no
O	O	of	yes
B-brand	B-brand	Exjade	yes
O	O	with	yes
B-drug	B-drug	hydroxyurea	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	to	no
O	O	bleeding	no
O	O	associated	no
O	O	with	yes
B-drug	B-drug	heparin	yes
O	O	and	yes
B-group	B-group	vitamin	yes
I-group	I-group	K	yes
I-group	I-group	antagonists	no
O	O	,	no
O	O	drugs	no
O	O	that	no
O	O	alter	no
O	O	platelet	yes
O	O	function	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	dipyridamole	yes
O	O	and	yes
B-drug	B-drug	Abciximab	yes
O	O	)	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	if	no
O	O	administered	no
O	O	prior	no
O	O	to	no
O	O	,	no
O	O	during	no
O	O	,	no
O	O	or	no
O	O	after	no
B-brand	B-brand	Activase	yes
O	O	therapy	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	pressor	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	Desmopressin	yes
O	O	is	yes
O	O	very	no
O	O	low	yes
O	O	compared	no
O	O	to	no
O	O	its	no
O	O	antidiuretic	no
O	O	activity	yes
O	O	,	no
O	O	large	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	Desmopressin	yes
O	O	Tablets	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	other	no
B-group	O	pressor	no
I-group	O	agents	yes
O	O	only	no
O	O	with	yes
O	O	careful	no
O	O	patient	no
O	O	monitoring	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-group	B-group	anti-neoplastic	no
I-group	I-group	agents	yes
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	a	yes
O	O	P-glycoprotein	no
O	O	substrate	yes
O	O	,	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	conivaptan	yes
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	clearance	no
O	O	and	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	values	no
O	O	.	no

B-group	B-group	Cephalosporins-Cephalosporins	no
O	O	containing	yes
O	O	side	no
O	O	chains	no
O	O	of	yes
B-drug_n	O	N-methylthiotetrazole	no
O	O	(	no
B-drug	B-drug	cefmenoxime	yes
O	O	,	no
B-drug	B-drug	cefoperazone	yes
O	O	,	no
B-drug	B-drug	cefotetan	yes
O	O	,	no
B-drug	B-drug	cefamandole	yes
O	O	,	no
B-drug	B-drug	latamoxef	yes
O	O	)	no
O	O	or	no
B-drug	O	methylthiadiazole	no
O	O	(	no
B-drug	B-drug	cefazolin	yes
O	O	)	no
O	O	can	no
O	O	cause	no
B-group	O	vitamin	yes
I-group	O	K	yes
O	O	deficiency	no
O	O	and	yes
O	O	hypoprothrombinemia	no
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-drug	B-drug	cholestyramine	yes
O	O	,	no
B-drug	B-drug	colestipol	yes
O	O	(	no
O	O	use	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	prevent	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	from	no
O	O	working	no
O	O	properly	no
O	O	;	no

O	O	although	no
O	O	combinations	no
O	O	are	no
O	O	sometimes	no
O	O	used	no
O	O	for	yes
O	O	therapeutic	no
O	O	advantage	no
O	O	,	no
O	O	when	no
O	O	used	no
O	O	concurrently	no
O	O	,	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	concluded	no
O	O	that	no
B-drug_n	B-drug_n	neurotensin	no
O	O	modulates	no
O	O	in	yes
O	O	an	no
O	O	opposite	no
O	O	way	no
O	O	the	no
O	O	function	no
O	O	of	yes
O	O	the	no
O	O	enkephalinergic	no
O	O	neurons	no
O	O	and	yes
O	O	the	no
O	O	central	no
O	O	action	no
O	O	of	yes
B-drug_n	B-drug_n	tuftsin	no
O	O	.	no

O	O	Intensive	no
O	O	monitoring	no
O	O	of	yes
O	O	renal	no
O	O	function	no
O	O	is	yes
O	O	recommended	no
O	O	in	yes
O	O	patients	no
O	O	requiring	no
O	O	any	no
O	O	combination	yes
O	O	of	yes
O	O	nephrotoxic	no
O	O	medications	no
O	O	.	no

O	O	Thus	no
B-drug	B-drug	cimetidine	yes
O	O	appeared	no
O	O	to	no
O	O	alter	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	gabapentin	yes
O	O	and	yes
O	O	creatinine	yes
O	O	,	no
O	O	an	no
O	O	endogenous	no
O	O	marker	no
O	O	of	yes
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
O	O	other	no
O	O	creams	no
O	O	,	no
O	O	lotions	no
O	O	,	no
O	O	or	no
O	O	skin	yes
O	O	medicines	no
O	O	when	no
O	O	placed	no
O	O	on	no
O	O	the	no
O	O	same	yes
O	O	areas	no
O	O	of	yes
O	O	your	no
O	O	skin	yes
O	O	that	no
O	O	you	no
O	O	are	no
O	O	using	no
B-drug	B-drug_n	bentoquatam	yes
O	O	.	no

B-group	B-group	Neuroleptic	no
I-group	I-group	Drugs	no
O	O	-	yes
B-drug	B-drug	L-phenylalanine	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	tardive	no
O	O	dyskinesia	no
O	O	side	no
O	O	reactions	no
O	O	of	yes
B-group	B-group	neuroleptic	no
I-group	I-group	drugs	no
O	O	if	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
O	O	them	no
O	O	.	no

B-group	B-group	Beta	yes
I-group	I-group	blockers	no
O	O	may	no
O	O	exacerbate	no
O	O	the	no
O	O	rebound	no
O	O	hypertension	no
O	O	which	no
O	O	can	no
O	O	follow	no
O	O	the	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Other	no
O	B-group	5-HT1B/1D	no
O	I-group	Agonists	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
B-group	B-group	5-HT1B/1D	no
I-group	I-group	agonists	no
O	O	within	no
O	O	24	yes
O	O	hours	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	AXERT	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	agents	yes
O	O	may	no
O	O	increase	no
O	O	certain	no
O	O	actions	no
O	O	or	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	.	no
B-group	B-drug	amantadine	yes
I-group	B-group	antiarrhythmic	no
I-group	I-group	agents	yes
I-group	O	of	yes
I-group	O	class	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	quinidine	yes
O	O	)	no
O	O	,	no
B-group	B-group	antihistamines	no
I-group	I-group	antipsychotic	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.g	no
O	O	.	no
B-group	B-group	phenothiazines	no
O	O	)	no
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	.	no

O	O	Effect	no

O	O	The	no
O	O	utilization	no
O	O	of	yes
B-drug	B-drug	digitoxin	yes
O	O	for	yes
O	O	such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	considered	no
O	O	as	yes
O	O	an	no
O	O	alternative	no
O	O	.	no

O	O	Type	yes
O	O	2	yes
O	O	diabetes	no
O	O	mellitus	no
O	O	is	yes
O	O	a	yes
O	O	growing	no
O	O	problem	no
O	O	not	no
O	O	only	no
O	O	in	yes
O	O	the	no
O	O	United	no
O	O	States	no
O	O	but	no
O	O	also	no
O	O	across	no
O	O	the	no
O	O	world	no
O	O	.	no

O	O	No	yes
O	O	pharmacodynamic	no
O	O	effects	no
O	O	of	yes
O	O	either	no
B-group	B-group	histamine	yes
I-group	I-group	H2	no
I-group	I-group	receptor	yes
I-group	I-group	antagonist	yes
O	O	were	no
O	O	observed	no
O	O	.	no

O	O	BACKGROUND	no
O	O	.	no

O	B-group	Neuroleptic	no
O	O	:	no
B-drug	B-drug	pimozide	yes

O	O	These	no
O	O	results	no
O	O	indicate	no
O	O	that	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	quetiapine	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	when	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	are	no
O	O	given	no
O	O	concurrently	no
O	O	and	yes
O	O	that	no
O	O	caution	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	when	no
O	O	administering	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	or	no
O	O	induce	no
O	O	cytochromes	no
O	O	,	no
O	O	particularly	no
O	O	P450	no
O	O	3A4	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	because	no
O	O	of	yes
O	O	demonstrated	no
O	O	hypokalemia	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	and	yes
O	O	with	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
O	O	potassium	yes
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
B-drug	B-drug	Ketoprofen	yes
O	O	does	no
O	O	not	no
O	O	alter	no
B-brand	B-brand	aspirin	yes
O	O	absorption	no
O	O	;	no

O	O	Other	no
O	O	strong	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	,	no
B-drug	B-drug	nefazodone	yes
O	O	,	no
B-drug	B-drug	troleandomycin	yes
O	O	,	no
B-drug	B-drug	ritonavir	yes
O	O	,	no
B-drug	B-drug	nelfinavir	yes
O	O	)	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	behave	no
O	O	similarly	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	on	no
B-drug	B-drug	Vardenafil	yes

O	O	No	yes
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Because	no
O	O	of	yes
O	O	possible	no
O	O	clinical	no
O	O	significance	no
O	O	,	no
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	concurrently	no
O	O	.	no

O	O	These	no
O	O	agents	yes
O	O	may	no
O	O	also	no
O	O	prolong	no
O	O	the	no
O	O	clinically	no
O	O	effective	no
O	O	duration	no
O	O	of	yes
O	O	action	no
O	O	by	no
O	O	up	no
O	O	to	no
O	O	25	yes
O	O	%	no
O	O	.	no

O	O	Since	no
O	O	this	no
O	O	could	no
O	O	be	no
O	O	explained	no
O	O	either	no
O	O	by	no
O	O	enhanced	no
O	O	absorption	no
O	O	or	no
O	O	by	no
O	O	an	no
O	O	alteration	no
O	O	of	yes
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	,	no
O	O	special	yes
O	O	care	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	establishing	no
O	O	the	no
O	O	dose	no
O	O	required	no
O	O	for	yes
O	O	blood	yes
O	O	pressure	no
O	O	control	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	may	no
O	O	decrease	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	concentration	no
O	O	,	no
O	O	especially	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	dysfunction	no
O	O	,	no
O	O	by	no
O	O	increasing	no
O	O	the	no
O	O	non-renal	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	esomeprazole	yes
O	O	does	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	or	no
B-drug	B-drug	amoxicillin	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
O	O	concurrent	no
O	O	therapy	no
O	O	with	yes
B-drug	B-drug	clonidine	yes
O	O	,	no
O	O	if	no
O	O	therapy	no
O	O	is	yes
O	O	to	no
O	O	be	no
O	O	discontinued	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
B-brand	B-brand	ZEBETA	yes
O	O	be	no
O	O	discontinued	no
O	O	for	yes
O	O	several	no
O	O	days	no
O	O	before	no
O	O	the	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Both	no
O	O	groups	no
O	O	of	yes
O	O	agents	yes
O	O	lower	no
O	O	blood	yes
O	O	levels	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	.	no

O	O	METHODS	no
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	case	no
O	O	reports	no
O	O	,	no
O	O	and	yes
O	O	commentaries	no
O	O	and	yes
O	O	editorials	no
O	O	concerning	no
B-drug	B-drug	sildenafil	yes
O	O	published	no
O	O	in	yes
O	O	the	no
O	O	international	no
O	O	literature	no
O	O	between	yes
O	O	January	no
O	O	1999	no
O	O	and	yes
O	O	August	no
O	O	2000	yes
O	O	were	no
O	O	identified	no
O	O	through	no
O	O	searches	no
O	O	of	yes
B-brand	O	MEDLINE	no
O	O	,	no
B-brand	O	PREMEDLINE	no
O	O	,	no
O	O	and	yes
O	O	International	no
O	O	Pharmaceutical	no
O	O	Abstracts	no
O	O	,	no
O	O	using	no
O	O	the	no
O	O	terms	no
B-drug	B-drug	sildenafil	yes
O	O	,	no
B-brand	B-brand	Viagra	yes
O	O	,	no
O	O	and	yes
O	O	erectile	no
O	O	dysfunction	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
B-drug	B-drug	digoxin	yes
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-brand	B-brand	VAPRISOL	yes
O	O	,	no
O	O	the	no
O	O	clinician	no
O	O	should	no
O	O	be	no
O	O	alert	no
O	O	to	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
O	O	increases	no
O	O	in	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	.	no

O	O	While	no
O	O	no	yes
O	O	in	yes
O	O	vivo	no
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	conducted	no
O	O	between	yes
B-drug	B-drug	estazolam	yes
O	O	and	yes
O	O	inducers	no
O	O	of	yes
O	O	CYP3A	no
O	O	,	no
O	O	compounds	no
O	O	that	no
O	O	are	no
O	O	potent	no
O	O	CYP3A	no
O	O	inducers	no
O	O	(	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	and	yes
B-group	B-group	barbiturates	no
O	O	)	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	decrease	no
B-drug	B-drug	estazolam	yes
O	O	concentrations	no
O	O	.	no

O	O	Compounds	no
O	O	in	yes
O	O	these	no
O	O	categories	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	decreased	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	bromocriptine	yes
I-drug	I-drug	mesylate	yes
O	O	:	no
B-group	B-group	phenothiazines	no
O	O	,	no
B-drug	B-drug	haloperidol	yes
O	O	,	no
B-drug	B-drug	metoclopramide	yes
O	O	,	no
B-drug	B-drug	pimozide	yes
O	O	.	no

O	O	Both	no
O	O	the	no
O	O	sedative	no
O	O	and	yes
O	O	anticholinergic	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	B-group	major	no
B-group	I-group	tranquilizers	no
O	O	are	no
O	O	also	no
O	O	additive	no
O	O	to	no
O	O	those	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	.	no

O	O	The	no
O	O	intravenous	yes
O	O	application	no
O	O	of	yes
B-drug	B-drug_n	perchlorate	yes
O	O	offers	no
O	O	advantages	no
O	O	in	yes
O	O	clinical	no
O	O	use	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	the	no
O	O	disposition	no
O	O	of	yes
B-drug	B-drug	eszopiclone	yes
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	to	no
O	O	be	no
O	O	sensitive	no
O	O	to	no
O	O	alterations	no
O	O	in	yes
O	O	protein	yes
O	O	binding	no
O	O	.	no

O	O	Three	no
O	O	patients	no
O	O	met	yes
O	O	ACR	no
O	O	criteria	no
O	O	for	yes
O	O	liver	yes
O	O	biopsy	no
O	O	(	no
O	O	1	yes
O	O	:	no
B-brand	O	Roegnik	no
O	O	Grade	no
O	O	I	yes
O	O	,	no
O	O	2	yes
O	O	:	no
B-brand	O	Roegnik	no
O	O	Grade	no
O	O	IIIa	no
O	O	)	no
O	O	.	no

O	O	Nervous	no
O	O	System	yes
O	O	:	no
O	O	Although	no
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	peripheral	no
O	O	neuropathy	no
O	O	is	yes
O	O	frequent	no
O	O	,	no
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	severe	no
O	O	symptomatology	no
O	O	is	yes
O	O	unusual	no
O	O	and	yes
O	O	requires	no
O	O	a	yes
O	O	dose	no
O	O	reduction	yes
O	O	of	yes
O	O	20	yes
O	O	%	no
O	O	for	yes
O	O	all	yes
O	O	subsequentcourses	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug_n	B-drug_n	ginsenosides	no
O	O	on	no
O	O	voltage-dependent	no
O	O	Ca	no
O	O	(	no
O	O	2+	no
O	O	)	no
O	O	channel	no
O	O	subtypes	no
O	O	in	yes
O	O	bovine	yes
O	O	chromaffin	no
O	O	cells	yes
O	O	.	no

B-group	B-group	antiarrhythmic	no
I-group	I-group	agents	yes
O	O	concentration	no

O	O	Agents	yes
O	O	that	no
O	O	induce	no
O	O	CYP3A4	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	)	no
O	O	could	no
O	O	cause	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	aripiprazole	yes
O	O	clearance	no
O	O	and	yes
O	O	lower	no
O	O	blood	yes
O	O	levels	no
O	O	.	no

O	O	Do	no
O	O	not	no
O	O	take	no
O	O	this	no
O	O	medicine	no
O	O	with	yes
B-drug	O	thioridizine	no
O	O	,	no
O	O	or	no
O	O	within	no
O	O	5	yes
O	O	weeks	no
O	O	of	yes
O	O	taking	no
B-drug	B-drug	fluoxetine	yes
O	O	.	no

O	O	The	no
O	O	magnitude	no
O	O	of	yes
O	O	interaction	no
O	O	at	yes
O	O	other	no
O	O	doses	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	peak	no
O	O	plasma	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	metformin	yes
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	when	no
O	O	taking	no
B-drug	B-drug	Acarbose	yes
O	O	due	no
O	O	to	no
O	O	a	yes
O	O	slight	no
O	O	delay	no
O	O	in	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	metformin	yes
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Argatroban	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	5-7.5	no
O	O	mg	yes
O	O	initial	no
O	O	oral	yes
O	O	dose	no
O	O	followed	no
O	O	by	no
O	O	2.5-6	no
O	O	mg/day	no
O	O	orally	no
O	O	for	yes
O	O	6-10	no
O	O	days	no
O	O	)	no
O	O	results	no
O	O	in	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	(	no
O	O	PT	no
O	O	)	no
O	O	and	yes
O	O	International	no
O	O	Normalized	no
O	O	Ratio	no
O	O	(	no
O	O	INR	no
O	O	)	no
O	O	.	no

O	O	Little	no
O	O	has	no
O	O	been	no
O	O	studied	no
O	O	of	yes
O	O	the	no
O	O	adverse	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	exposure	yes
O	O	of	yes
O	O	the	no
O	O	liver	yes
O	O	to	no
O	O	the	no
O	O	interaction	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	with	yes
O	O	its	no
O	O	congeners	no
O	O	and	yes
B-drug_n	B-drug_n	acetaldehyde	yes
O	O	,	no
O	O	coexisting	no
O	O	in	yes
O	O	the	no
O	O	contents	no
O	O	of	yes
O	O	alcoholic	no
O	O	beverages	no
O	O	.	no

O	O	Other	no
O	O	Drugs	no
O	O	:	no
O	O	In	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	amlodipine	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	ranitidine	yes
O	O	,	no
B-drug	B-drug	omeprazole	yes
O	O	,	no
O	B-drug	hormone	yes
O	O	replacement	no
O	O	therapy	no
O	O	(	no
O	O	a	yes
O	O	combination	yes
O	O	of	yes
B-group	O	conjugated	yes
I-group	B-group	estrogens	yes
O	O	and	yes
B-drug	B-drug	medroxyprogesterone	yes
O	O	)	no
O	O	,	no
B-group	B-group	antacid	no
O	O	(	no
B-drug	O	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
I-drug	O	hydroxides	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	theophylline	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-brand	B-brand	TIKOSYN	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	,	no
O	O	oral	yes

O	O	Although	no
O	O	there	no
O	O	are	no
O	O	no	yes
O	O	study	no
O	O	data	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	possibility	no
O	O	,	no
B-group	B-group	nitric	yes
I-group	I-group	oxide	yes
I-group	I-group	donor	no
I-group	I-group	compounds	no
O	O	,	no
O	O	including	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	nitroprusside	yes
O	O	and	yes
B-drug	B-drug	nitroglycerin	yes
O	O	,	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	with	yes
B-brand	B-brand	INOmax	yes
O	O	on	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	developing	no
O	O	methemoglobinemia	no
O	O	.	no

O	B-drug	n-dodecyl	no
O	I-drug	gallate	yes
O	O	showed	no
O	O	the	no
O	O	most	no
O	O	potent	no
O	O	inhibition	no
O	O	(	no
O	O	66	no
O	O	%	no
O	O	inhibition	no
O	O	at	yes
O	O	10	yes
O	O	microM	no
O	O	)	no
O	O	,	no
O	O	which	no
O	O	was	no
O	O	far	no
O	O	more	no
O	O	potent	no
O	O	than	no
O	O	that	no
O	O	of	yes
O	O	crude	no
O	B-drug	tannic	yes
O	I-drug	acid	yes
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	this	no
O	O	isoenzyme	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	,	no
B-group	B-group	azole	no
I-group	I-group	antifungal	no
I-group	I-group	agents	yes
O	O	,	no
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	amiodarone	yes
O	O	,	no
B-group	B-group	cannabinoids	no
O	O	,	no
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	grapefruit	no
O	O	juice	no
O	O	,	no
B-drug	B-drug	nefazadone	no
O	O	,	no
B-drug	B-drug	norfloxacin	yes
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	zafirlukast	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	cautiously	no
O	O	coadministered	no
O	O	with	yes
B-brand	B-brand	TIKOSYN	yes
O	O	as	yes
O	O	they	no
O	O	can	no
O	O	potentially	no
O	O	increase	no
B-drug	B-drug	dofetilide	yes
O	O	levels	no
O	O	.	no

O	O	Electroconvulsive	no
O	O	Therapy	no
O	O	(	no
O	O	ECT	no
O	O	)	no
O	O	-	yes
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	clinical	no
O	O	studies	no
O	O	of	yes
O	O	the	no
O	O	combined	no
O	O	use	no
O	O	of	yes
O	O	ECT	no
O	O	and	yes
B-drug	B-drug	escitalopram	yes
O	O	.	no

B-drug	B-drug	Midazolam	yes
O	O	:	no
B-drug	B-drug	Aprepitant	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	,	no
O	O	a	yes
O	O	sensitive	no
O	O	CYP3A4	no
O	O	substrate	yes
O	O	,	no
O	O	by	no
O	O	2.3-fold	no
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	3.3-fold	no
O	O	on	no
O	O	Day	no
O	O	5	yes
O	O	,	no
O	O	when	no
O	O	a	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	midazolam	yes
O	O	2	yes
O	O	mg	yes
O	O	was	no
O	O	coadministered	no
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	Day	no
O	O	5	yes
O	O	of	yes
O	O	a	yes
O	O	regimen	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	125	yes
O	O	mg	yes
O	O	on	no
O	O	Day	no
O	O	1	yes
O	O	and	yes
O	O	80	yes
O	O	mg/day	no
O	O	on	no
O	O	Days	no
O	O	2	yes
O	O	through	no
O	O	5	yes
O	O	.	no

B-group	B-group	NNRTI-based	no
O	O	regimens	no
O	O	may	no
O	O	have	no
O	O	several	no
O	O	advantages	no
O	O	over	no
O	B-group	PI-based	no
O	O	therapy	no
O	O	for	yes
O	O	initial	no
O	O	or	no
O	O	prolonged	no
O	O	therapy	no
O	O	,	no
O	O	including	no
O	O	more	no
O	O	convenient	no
O	O	administration	no
O	O	regimens	no
O	O	,	no
O	O	lower	no
O	O	tablet	no
O	O	volume	no
O	O	,	no
O	O	fewer	no
O	O	drug	yes
O	O	interactions	no
O	O	,	no
O	O	and	yes
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	penetration	no
O	O	.	no

O	O	The	no
O	O	clearance	no
O	O	of	yes
B-group	B-group	salicylates	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	with	yes
O	O	concurrent	no
O	O	use	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	all	yes
O	O	drugs	no
O	O	,	no
O	O	care	yes
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	treating	no
O	O	patients	no
O	O	with	yes
O	O	multiple	no
O	O	medications	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	considering	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	BREVIBLOC	yes
O	O	and	yes
B-drug	B-drug	verapamil	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	depressed	no
O	O	myocardial	no
O	O	function	no
O	O	.	no

O	O	For	yes
O	O	a	yes
O	O	4-fold	no
O	O	range	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	doses	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	differential	no
O	O	effects	no
O	O	on	no
B-drug	B-drug	cyclosporine	yes
O	O	dosing	no
O	O	or	no
O	O	pharmacokinetics	no
O	O	.	no

O	O	An	no
O	O	increase	no
O	O	in	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	concentration	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	with	yes
B-brand	B-brand	ATACAND	yes
O	O	,	no
O	O	so	no
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	during	no
O	O	concomitant	no
O	O	use	no
O	O	.	no

O	O	Neuropathy	no
O	O	has	no
O	O	occurred	no
O	O	more	no
O	O	frequently	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	history	no
O	O	of	yes
O	O	neuropathy	no
O	O	or	no
O	O	neurotoxic	no
O	O	drug	yes
O	O	therapy	no
O	O	,	no
O	O	including	no
B-drug	B-drug	stavudine	yes
O	O	,	no
O	O	and	yes
O	O	these	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	at	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	neuropathy	no
O	O	during	no
B-brand	B-brand	VIDEX	yes
O	O	therapy	no
O	O	(	no
O	O	see	no
O	O	ADVERSE	no
O	O	REACTIONS	no
O	O	)	no
O	O	.	no

O	O	This	no
O	O	interference	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	apparent	no
O	O	factor	yes
O	O	concentration	no
O	O	that	no
O	O	is	yes
O	O	lower	no
O	O	than	no
O	O	the	no
O	O	true	yes
O	O	concentration	no
O	O	.	no

O	O	oral	yes
O	O	clearance	no
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	about	no
O	O	50	yes
O	O	%	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	containing	yes
B-drug	B-drug	magnesium	yes
I-drug	I-drug	trisilicate	yes
O	O	,	no
O	O	when	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	nitrofurantoin	yes
O	O	,	no
O	O	reduce	no
O	O	both	no
O	O	the	no
O	O	rate	no
O	O	and	yes
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	.	no

O	O	An	no
O	O	initial	no
O	O	dose	no
O	O	of	yes
O	O	5	yes
O	O	mg	yes
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	concomitantly	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	there	no
O	O	was	no
O	O	no	yes
O	O	significant	no
O	O	change	no
O	O	in	yes
O	O	prothrombin	yes
O	O	test	yes
O	O	results	no
O	O	during	no
O	O	the	no
O	O	trials	no
O	O	of	yes
B-drug	B-drug	chloral	yes
I-drug	I-drug	hydrate	yes
O	O	and	yes
B-drug	B-drug	methaqualone	yes
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	with	yes
O	O	a	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	receptor	yes
I-group	I-group	blocking	no
I-group	I-group	agent	yes
O	O	plus	yes
O	O	a	yes
B-group	O	catecholamine	no
I-group	O	depletor	no
O	O	should	no
O	O	therefore	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	evidence	no
O	O	of	yes
O	O	hypotension	no
O	O	or	no
O	O	marked	no
O	O	bradycardia	no
O	O	,	no
O	O	which	no
O	O	may	no
O	O	produce	no
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	,	no
O	O	or	no
O	O	postural	no
O	O	hypotension	no
O	O	.	no

B-group	B-group	Diuretics	no
O	O	:	no
O	O	Studies	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	flurbiprofen	yes
O	O	like	yes
O	O	other	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	,	no
O	O	can	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	.	no

O	O	Usually	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	the	no
B-group	B-group	anticoagulant	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	one-half	no
O	O	(	no
O	O	depending	no
O	O	on	no
O	O	the	no
O	O	individual	no
O	O	case	no
O	O	)	no
O	O	to	no
O	O	maintain	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	at	yes
O	O	the	no
O	O	desired	no
O	O	level	no
O	O	to	no
O	O	prevent	no
O	O	bleeding	no
O	O	complications	no
O	O	.	no

O	O	This	no
O	O	response	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	.	no

O	O	A	yes
O	O	1-month	no
O	O	washout	no
O	O	period	no
O	O	was	no
O	O	inserted	no
O	O	between	yes
O	O	the	no
O	O	treatment	no
O	O	periods	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	naltrexone	yes
O	O	and	yes
O	O	its	no
O	O	major	no
O	O	metabolite	yes
O	B-drug_n	6-beta-naltrexol	no
O	O	were	no
O	O	unaffected	no
O	O	following	no
O	O	co-administration	no
O	O	with	yes
B-drug	B-drug	Acamprosate	yes
O	O	.	no

B-drug	B-drug	cimetidine	yes
O	O	;	no

O	O	they	no
O	O	also	no
O	O	suggest	no
O	O	that	no
O	O	alcoholic	no
O	O	beverages	no
O	O	are	no
O	O	not	no
O	O	equivalent	no
O	O	in	yes
O	O	their	no
O	O	potential	no
O	O	to	no
O	O	cause	no
O	O	liver	yes
O	O	damage	no
O	O	.	no

O	O	Results	no
O	O	of	yes
O	O	preliminary	no
O	O	studies	no
O	O	in	yes
O	O	humans	no
O	O	and	yes
O	O	rats	no
O	O	suggest	no
O	O	that	no
O	O	nonabsorbable	no
B-group	B-group	antacids	no
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	lactulose	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	desired	no
B-drug	B-drug	lactulose-induced	no
O	O	drop	no
O	O	in	yes
O	O	colonic	no
O	O	pH	yes
O	O	.	no

B-group	B-group	Histamine	yes
I-group	I-group	H2	no
I-group	I-group	antagonists	no
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	inhibits	no
O	O	CYP3A4	no
O	O	and	yes
O	O	can	no
O	O	increase	no
O	O	serum	yes
B-drug	B-drug	amiodarone	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Modest	no
O	O	increases	no
O	O	in	yes
O	O	mean	no
O	O	trough	no
B-drug	B-drug	cyclosporine	yes
O	O	concentrations	no
O	O	were	no
O	O	observed	no
O	O	following	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	carvedilol	yes
O	O	treatment	no
O	O	in	yes
O	O	21	yes
O	O	renal	no
O	O	transplant	no
O	O	patients	no
O	O	suffering	no
O	O	from	no
O	O	chronic	no
O	O	vascular	no
O	O	rejection	no
O	O	.	no

O	O	.	no

O	O	These	no
O	O	reactions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	more	no
O	O	frequently	no
O	O	with	yes
O	O	the	no
O	O	24-hour	no
O	O	infusion	no
O	O	than	no
O	O	with	yes
O	O	the	no
O	O	3-hour	no
O	O	infusion	no
O	O	.	no

O	O	Altered	no
O	O	responsiveness	no
O	O	to	no
B-drug	B-drug	alcohol	yes
O	O	after	no
O	O	exposure	yes
O	O	to	no
O	O	organic	no
O	O	lead	no
O	O	.	no

O	O	At	yes
O	O	37	no
O	O	degrees	no
O	O	C	yes
O	O	the	no
O	O	non-myelinated	no
O	O	axons	no
O	O	contained	no
O	O	28.4	no
O	O	plus	yes
O	O	or	no
O	O	minus	no
O	O	0.8	no
O	O	S.E.M	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	alter	no
B-drug	B-drug	imatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	increase	no
B-drug	B-drug	imatinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	:	no
O	O	Caution	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	Gleevec	yes
O	O	with	yes
O	O	inhibitors	no
O	O	of	yes
O	O	the	no
O	O	CYP3A4	no
O	O	family	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	itraconazole	yes
O	O	,	no
B-drug	B-drug	erythromycin	yes
O	O	,	no
B-drug	B-drug	clarithromycin	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	Indinavir	yes
O	O	concentrations	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	nevirapine	yes
O	O	.	no

B-brand	B-brand	Trileptal	yes
O	O	dose	no
O	O	(	no
O	O	mg/day	no
O	O	)	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	these	no
O	O	tests	no
O	O	be	no
O	O	performed	no
O	O	at	yes
O	O	weekly	yes
O	O	or	no
O	O	biweekly	no
O	O	intervals	no
O	O	until	no
O	O	the	no
O	O	lipid	no
O	O	response	no
O	O	to	no
B-brand	B-brand	Accutane	yes
O	O	is	yes
O	O	established	no
O	O	.	no

O	O	Untreated	no
O	O	hypothyroidism	no
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	growth	yes
O	O	response	no
O	O	to	no
O	B-drug	somatrem	yes
O	O	or	no
B-drug	B-drug	somatropin	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
O	O	a	yes
O	O	potent	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	rifampicin	yes
O	O	or	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	a	yes
O	O	dose	no
O	O	increase	no
O	O	to	no
O	O	500	yes
O	O	mg	yes
O	O	daily	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	in	yes
O	O	the	no
O	O	absence	no
O	O	of	yes
O	O	severe	no
O	O	adverse	no
O	O	drug	yes
O	O	reaction	no
O	O	,	no
O	O	and	yes
O	O	clinical	no
O	O	response	no
O	O	and	yes
O	O	adverse	no
O	O	events	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	(	no
O	O	see	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY-Pharmacokinetics-Drug-Drug	no
O	O	Interactions	no
O	O	and	yes
O	O	DOSAGE	no
O	O	AND	yes
O	O	ADMINISTRATION-Dosage	no
O	O	Adjustment	no
O	O	sections	no
O	O	)	no
O	O	.	no

O	O	These	no
O	O	pharmacokinetic	no
O	O	effects	no
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	clinically	no
O	O	meaningful	no
O	O	changes	no
O	O	in	yes
O	O	ECG	no
O	O	,	no
O	O	heart	no
O	O	rate	no
O	O	or	no
O	O	blood	yes
O	O	pressure	no
O	O	beyond	no
O	O	those	no
O	O	changes	no
O	O	induced	no
O	O	by	no
B-drug	B-drug	diltiazem	yes
O	O	alone	no
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	Inhibit	no
O	O	Cytochrome	no
O	O	P450	no
O	O	Isoenzymes	no
O	O	and/or	no
O	O	Epoxide	no
O	O	Hydrolase	yes
B-drug	B-drug	Carbamazepine	yes
O	O	is	yes
O	O	metabolized	no
O	O	mainly	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	3A4	no
O	O	to	no
O	O	the	no
O	O	active	no
B-drug	B-drug	carbamazepine	yes
I-drug	I-drug	10,11-epoxide	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	further	no
O	O	metabolized	no
O	O	to	no
O	O	the	no
O	O	trans-diol	no
O	O	by	no
O	O	epoxide	no
O	O	hydrolase	yes
O	O	.	no

O	O	leukopenia	no

O	O	Drugs	no
O	O	That	no
O	O	Alter	no
O	O	Renal	no
O	O	Excretion	no
B-drug	B-drug	Ibuprofen	yes
O	O	:	no
B-drug	B-drug	Ibuprofen	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	affect	no
O	O	renal	no
O	O	function	no
O	O	and	yes
O	O	,	no
O	O	consequently	no
O	O	,	no
O	O	alter	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	.	no

B-drug_n	B-drug_n	Misonidazole	yes
O	O	also	no
O	O	reduced	yes
O	O	the	no
O	O	"	no
O	O	early	no
O	O	"	no

O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	any	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	ERBITUX	yes
O	O	and	yes
B-drug	B-drug	irinotecan	yes
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	possibility	no
O	O	of	yes
O	O	hypotensive	no
O	O	effects	no
O	O	with	yes
B-drug	B-drug	captopril	yes
O	O	can	no
O	O	be	no
O	O	minimized	no
O	O	by	no
O	O	either	no
O	O	discontinuing	no
O	O	the	no
B-group	B-group	diuretic	no
O	O	or	no
O	O	increasing	no
O	O	the	no
O	O	salt	yes
O	O	intake	no
O	O	approximately	no
O	O	one	no
O	O	week	no
O	O	prior	no
O	O	to	no
O	O	initiation	no
O	O	of	yes
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	captopril	yes
O	O	(	no
B-drug	B-drug	captopril	yes
O	O	tablets	yes
O	O	,	no
O	O	USP	yes
O	O	)	no
O	O	or	no
O	O	initiating	no
O	O	therapy	no
O	O	with	yes
O	O	small	no
O	O	doses	no
O	O	(	no
O	O	6.25	no
O	O	or	no
O	O	12.5	yes
O	O	mg	yes
O	O	)	no
O	O	.	no

O	O	Two	no
O	O	percent	no
O	O	of	yes
O	O	patients	no
O	O	treated	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	Kineret	yes
O	O	and	yes
B-drug	B-drug	etanercept	yes
O	O	developed	no
O	O	neutropenia	no
O	O	(	no
O	O	ANC	no
O	O	1	yes
O	O	x	yes
O	O	109/L	no
O	O	)	no
O	O	.	no

B-brand	B-brand	COPAXONE	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	evaluated	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	Interferon	yes
I-drug	I-drug	beta	yes
O	O	.	no

B-group	B-group	Estrogens	yes
O	O	,	no
O	O	including	no
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	:	no
B-group	B-group	Estrogens	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	hepatic	no
O	O	metabolism	no
O	O	of	yes
O	O	certain	no
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	thereby	no
O	O	increasing	no
O	O	their	no
O	O	effect	no
O	O	.	no

O	O	Potential	no
O	O	differences	no
O	O	in	yes
B-drug	B-drug	cyclosporine	yes
O	O	dosing	no
O	O	and	yes
O	O	pharmacokinetics	no
O	O	at	yes
O	O	different	no
O	O	levels	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	exposure	yes
O	O	were	no
O	O	assessed	no
O	O	in	yes
O	O	the	no
O	O	context	no
O	O	of	yes
O	O	ANOVA	no
O	O	.	no

O	O	Monitoring	no
O	O	of	yes
O	O	anticoagulation	no
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

O	O	These	no
O	O	data	no
O	O	emphasize	no
O	O	that	no
O	O	apoptosis	no
O	O	can	no
O	O	be	no
O	O	induced	no
O	O	in	yes
O	O	MCF-7	no
O	O	cells	yes
O	O	either	no
O	O	by	no
O	O	activation	no
O	O	of	yes
O	B-group	vitamin-D-mediated	no
O	O	signalling	no
O	O	or	no
O	O	disruption	no
O	O	of	yes
O	B-group	estrogen-dependent	no
O	O	signalling	no
O	O	.	no

B-group	B-group	Antithyroid	no
I-group	I-group	agents	yes
O	O	may	no
O	O	decrease	no
O	O	thyroidal	no
O	O	uptake	no
O	O	of	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	iodide	yes
O	I-drug	I131	no
O	O	,	no
O	O	a	yes
O	O	rebound	no
O	O	in	yes
O	O	uptake	no
O	O	may	no
O	O	occur	no
O	O	up	no
O	O	to	no
O	O	5	yes
O	O	days	no
O	O	after	no
O	O	sudden	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	Carbimazole	yes
O	O	.	no

B-group	B-group	5HT3	no
I-group	I-group	Antagonists	no
O	O	:	no
O	O	Based	no
O	O	on	no
O	O	reports	no
O	O	of	yes
O	O	profound	no
O	O	hypotension	no
O	O	and	yes
O	O	loss	no
O	O	of	yes
O	O	consciousness	no
O	O	when	no
B-drug	B-drug	apomorphine	yes
O	O	was	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	ondansetron	yes
O	O	,	no
O	O	the	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	apomorphine	yes
O	O	with	yes
O	O	drugs	no
O	O	of	yes
O	O	the	no
B-group	B-group	5HT3	no
I-group	I-group	antagonist	yes
I-group	I-group	class	no
O	O	(	no
O	O	including	no
O	O	,	no
O	O	for	yes
O	O	example	no
O	O	,	no
B-drug	B-drug	ondansetron	yes
O	O	,	no
B-drug	B-drug	granisetron	yes
O	O	,	no
B-drug	B-drug	dolasetron	yes
O	O	,	no
B-drug	B-drug	palonosetron	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	alosetron	yes
O	O	)	no
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	Severe	no
O	O	anemia	no
O	O	(	no
O	O	Grade	no
O	O	3-4	no
O	O	according	no
O	O	to	no
O	O	the	no
O	O	World	no
O	O	Health	no
O	O	Organization	no
O	O	criteria	no
O	O	)	no
O	O	was	no
O	O	significantly	no
O	O	greater	no
O	O	in	yes
O	O	the	no
O	O	patients	no
O	O	who	no
O	O	received	no
O	O	CHOP-HAART	no
O	O	compared	no
O	O	with	yes
O	O	the	no
O	O	patients	no
O	O	who	no
O	O	received	no
O	O	CHOP	no
O	O	alone	no
O	O	(	no
O	O	33	no
O	O	%	no
O	O	vs.	no
O	O	7	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	;	no
O	O	P	yes
O	O	=	no
O	O	0.001	no
O	O	)	no
O	O	.	no

B-drug	I-drug	atazanavir	yes

B-drug	B-drug	Magnesium	yes
O	O	infusions	no
O	O	can	no
O	O	only	no
O	O	be	no
O	O	envisaged	no
O	O	in	yes
O	O	intensive	no
O	O	care	yes
O	O	units	yes
O	O	with	yes
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	pulse	no
O	O	,	no
O	O	arterial	no
O	O	pressure	no
O	O	,	no
O	O	deep	no
O	O	tendon	no
O	O	reflexes	no
O	O	,	no
O	O	hourly	no
O	O	diuresis	no
O	O	,	no
O	O	electrocardiogram	no
O	O	and	yes
O	O	respiratory	no
O	O	recordings	no
O	O	.	no

O	O	As	yes
B-drug_n	B-drug_n	MHD	no
O	O	,	no
O	O	the	no
O	O	predominant	no
O	O	plasma	yes
O	O	substrate	yes
O	O	,	no
O	O	is	yes
O	O	only	no
O	O	a	yes
O	O	weak	no
O	O	inducer	no
O	O	of	yes
O	O	UDP-glucuronyl	no
O	O	transferase	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	have	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	mainly	no
O	O	eliminated	no
O	O	by	no
O	O	conjugation	no
O	O	through	no
O	O	UDP-glucuronyl	no
O	O	transferase	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	lamotrigine	yes
O	O	)	no
O	O	.	no

O	O	Other	no
O	O	concomitant	no
O	O	therapy	no
O	O	Although	no
O	O	specific	no
O	O	interaction	no
O	O	studies	no
O	O	were	no
O	O	not	no
O	O	performed	no
O	O	,	no
B-drug	B-drug	finasteride	yes
O	O	doses	no
O	O	of	yes
O	O	1	yes
O	O	mg	yes
O	O	or	no
O	O	more	no
O	O	were	no
O	O	concomitantly	no
O	O	used	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	acetaminophen	yes
O	O	,	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-group	O	a-blockers	no
O	O	,	no
B-group	B-group	analgesics	no
O	O	,	no
B-group	B-group	angiotensin-converting	no
I-group	I-group	enzyme	no
O	I-group	(	no
B-group	I-group	ACE	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	anticonvulsants	no
O	O	,	no
B-group	B-group	benzodiazepines	no
O	O	,	no
B-group	B-group	beta	yes
I-group	I-group	blockers	no
O	O	,	no
B-group	B-group	calcium-channel	no
I-group	I-group	blockers	no
O	O	,	no
B-group	O	cardiac	no
I-group	B-group	nitrates	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	H2	no
I-group	I-group	antagonists	no
O	O	,	no
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	prostaglandin	yes
I-group	I-group	synthetase	no
I-group	I-group	inhibitors	no
O	O	(	no
O	O	also	no
O	O	referred	no
O	O	to	no
O	O	as	yes
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	,	no
O	O	and	yes
B-group	B-group	quinolone	no
I-group	I-group	anti-infectives	no
O	O	without	no
O	O	evidence	no
O	O	of	yes
O	O	clinically	no
O	O	significant	no
O	O	adverse	no
O	O	interactions	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	if	no
O	O	other	no
B-group	B-group	phenothiazines	no
O	O	produce	no
O	O	a	yes
O	O	similar	no
O	O	response	no
O	O	.	no

O	O	Inhibition	no
O	O	of	yes
O	O	CYP3A4	no
O	O	metabolic	no
O	O	reactions	no
O	O	was	no
O	O	not	no
O	O	detected	no
O	O	in	yes
O	O	in	yes
O	O	vitro	no
O	O	experiments	no
O	O	.	no

O	O	Patients	no
O	O	should	no
O	O	take	no
O	O	other	no
O	O	drugs	no
O	O	at	yes
O	O	least	no
O	O	one	no
O	O	hour	yes
O	O	before	no
O	O	or	no
O	O	four	no
O	O	hours	no
O	O	after	no
B-brand	B-brand	COLESTID	yes
O	O	Tablets	yes
O	O	to	no
O	O	avoid	no
O	O	impeding	no
O	O	their	no
O	O	absorption	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	there	no
O	O	may	no
O	O	be	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	clinically	no
O	O	important	no
O	O	alterations	no
O	O	of	yes
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	coadministered	no
O	O	drugs	no
O	O	.	no

O	O	Injection	yes
O	O	There	no
O	O	is	yes
O	O	inadequate	no
O	O	systematic	no
O	O	experience	no
O	O	with	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	baclofen	yes
O	O	injection	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	O	medications	no
O	O	to	no
O	O	predict	no
O	O	specific	no
O	O	drug-drug	no
O	O	interactions	no
O	O	.	no

O	O	N=17	no
O	O	)	no
O	O	were	no
O	O	not	no
O	O	different	no
O	O	and	yes
O	O	neither	no
O	O	were	no
B-drug	B-drug	gabapentin	yes
O	O	pharmacokinetic	no
O	O	parameters	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	.	no

O	O	Other	no
B-group	O	depressasnts	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
O	O	and	yes
B-group	B-group	MAOIs	no
O	O	may	no
O	O	enhance	no
O	O	CNS	no
O	O	depression	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	ethchlorvynol	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	reduced	yes
O	O	serum	yes
O	O	folate	yes
O	O	concentration	no
O	O	;	no

O	O	One	no
O	O	animal	no
O	O	in	yes
O	O	the	no
O	O	high	yes
O	O	dose	no
O	O	group	yes
O	O	developed	no
O	O	a	yes
O	O	B-cell	no
O	O	lymphoma	no
O	O	that	no
O	O	was	no
O	O	detected	no
O	O	after	no
O	O	28	yes
O	O	weeks	no
O	O	of	yes
O	O	dosing	no
O	O	.	no

B-drug	B-drug	Clozapine	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihypertensive	no
I-group	I-group	drugs	no
O	O	and	yes
O	O	the	no
O	O	anticholinergic	no
O	O	effects	no
O	O	of	yes
B-group	B-drug	atropine-type	no
I-group	O	drugs	no
O	O	.	no

O	O	Drug	yes
O	O	Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Interactions	no
O	O	between	yes
B-drug	B-drug	darifenacin	yes
O	O	and	yes
O	O	laboratory	no
O	O	tests	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes

O	O	Increases	no
O	O	in	yes
O	O	serum	yes
O	O	creatinine	yes
O	O	have	no
O	O	occurred	no
O	O	when	no
B-brand	B-brand	CEFOTAN	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-drug	B-drug	chlorothiazide	yes
O	O	and	yes
B-group	B-group	non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no

O	O	Although	no
O	O	the	no
O	O	proposed	no
O	O	methodology	no
O	O	for	yes
O	O	deriving	no
O	O	experimental	no
O	O	designs	no
O	O	can	no
O	O	be	no
O	O	applied	no
O	O	to	no
O	O	any	no
O	O	nonlinear	no
O	O	regression	no
O	O	model	no
O	O	,	no
O	O	primary	no
O	O	focus	no
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	the	no
O	O	additive	no
O	O	and	yes
O	O	nonadditive	no
O	O	independent	no
O	O	joint	no
O	O	action	no
O	O	(	no
O	O	IJA	no
O	O	)	no
O	O	models	no
O	O	for	yes
O	O	individual	no
O	O	and	yes
O	O	combined	no
O	O	exposures	no
O	O	proposed	no
O	O	by	no
B-brand	O	Barton	no
O	O	,	no
O	O	Braunberg	no
O	O	,	no
O	O	and	yes
B-drug	O	Friedman	no
O	O	(	no
O	O	1	yes
O	O	)	no
O	O	.	no

B-drug	B-drug	diflunisal	yes
O	O	;	no

B-drug	B-drug	Potassium	yes
O	O	Supplements	no
O	O	and	yes
B-group	B-group	Potassium-Sparing	no
I-group	I-group	Diuretics	no
O	O	:	no
B-drug	B-drug	Fosinopril	yes
I-drug	I-drug	sodium	yes
O	O	can	no
O	O	attenuate	no
O	O	potassium	yes
O	O	loss	no
O	O	caused	no
O	O	by	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	the	no
O	O	usual	no
B-group	B-group	anticoagulant	no
O	O	dosage	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Delayed	no
O	O	Adverse	no
O	O	Reactions	no
O	O	to	no
O	B-group	Iodinated	no
O	I-group	Contrast	no
O	I-group	Media	no
O	O	:	no
O	O	A	yes
O	O	review	no
O	O	of	yes
O	O	the	no
O	O	literature	no
O	O	revealed	no
O	O	that	no
O	O	12.6	no
O	O	%	no
O	O	(	no
O	O	range	no
O	O	11-28	no
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	501	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	various	no
B-drug	B-drug	interleukin-2	yes
O	O	containing	yes
O	O	regimens	no
O	O	who	no
O	O	were	no
O	O	subsequently	no
O	O	administered	no
O	B-group	radiographic	no
B-drug	I-group	iodinated	no
O	I-group	contrast	no
O	I-group	media	no
O	O	experienced	no
O	O	acute	no
O	O	,	no
O	O	atypical	no
O	O	adverse	no
O	O	reactions	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	When	no
O	O	a	yes
O	O	single	yes
O	O	125-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Aprepitant	yes
O	O	was	no
O	O	administered	no
O	O	on	no
O	O	Day5	no
O	O	of	yes
O	O	a	yes
O	O	10-day	no
O	O	regimen	no
O	O	of	yes
O	O	400	yes
O	O	mg/day	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	,	no
O	O	a	yes
O	O	strong	no
O	O	CYP3A4	no
O	O	inhibitor	yes
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	increased	no
O	O	approximately	no
O	O	5-fold	no
O	O	and	yes
O	O	the	no
O	O	mean	no
O	O	terminal	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	increased	no
O	O	approximately	no
O	O	3-fold	no
O	O	.	no

O	O	At	yes
O	O	a	yes
O	O	low	yes
B-drug	B-drug	cocaine	yes
O	O	dose	no
O	O	and	yes
O	O	long	yes
O	O	withdrawal	no
O	O	period	no
O	O	(	no
O	O	10	yes
O	O	mg/kg	no
O	O	,	no
O	O	twice	no
O	O	a	yes
O	O	day	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	14-day	no
O	O	withdrawal	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	LST	no
O	O	mice	no
O	O	showed	no
O	O	tolerance	no
O	O	development	no
O	O	.	no

O	O	CONCLUSION	no
O	O	:	no
O	O	These	no
O	O	findings	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	verapamil	yes
O	O	inhibits	no
O	O	cancer	no
O	O	metastasis	no
O	O	through	no
O	O	actions	no
O	O	that	no
O	O	do	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	growth	yes
O	O	of	yes
O	O	intestinal	no
O	O	cancers	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	if	no
B-brand	B-brand	PRINIVIL	yes
O	O	is	yes
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	lithium	yes
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	on	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
B-drug	O	sodium	yes
O	O	plasma	yes
B-drug	B-drug	valproate	yes
O	O	concentrations	no
O	O	are	no
O	O	unpredictable	no

O	O	Potential	no
O	O	for	yes
O	O	Other	no
O	O	Drugs	no
O	O	to	no
O	O	Affect	no
B-drug	B-drug	Duloxetine	yes
O	O	:	no
O	O	Both	no
O	O	CYP1A2	no
O	O	and	yes
O	O	CYP2D6	no
O	O	are	no
O	O	responsible	no
O	O	for	yes
B-drug	B-drug	duloxetine	yes
O	O	metabolism	no
O	O	.	no

O	O	This	no
O	O	medication	no
O	O	should	no
O	O	not	no
O	O	be	no
O	O	taken	no
O	O	with	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Substances	no
O	O	that	no
O	O	are	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	activity	yes
O	O	increase	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	gefitinib	yes
O	O	and	yes
O	O	decrease	no
O	O	its	no
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	patients	no
O	O	taking	no
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	isozyme	no
O	O	,	no
O	O	which	no
O	O	metabolizes	no
B-drug	B-drug	sildenafil	yes
O	O	,	no
O	O	may	no
O	O	experience	no
O	O	increased	no
O	O	drug	yes
O	O	concentrations	no
O	O	and	yes
O	O	possible	no
O	O	toxicity	no
O	O	from	no
O	O	normal	yes
O	O	doses	no
O	O	of	yes
B-drug	B-drug	sildenafil	yes
O	O	.	no

B-group	B-group	Alpha-blockers	no
O	O	:	no
O	O	When	no
B-drug	B-drug	Vardenafil	yes
O	O	10	yes
O	O	or	no
O	O	20	yes
O	O	mg	yes
O	O	was	no
O	O	given	no
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	either	no
O	O	simultaneously	no
O	O	or	no
O	O	6	yes
O	O	hours	no
O	O	after	no
O	O	a	yes
O	O	10	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	terazosin	yes
O	O	,	no
O	O	significant	no
O	O	hypotension	no
O	O	developed	no
O	O	in	yes
O	O	a	yes
O	O	substantial	no
O	O	number	no
O	O	of	yes
O	O	subjects	no
O	O	.	no

O	O	Drug	yes
O	O	Interactions	no
O	O	:	no
B-drug	B-drug	Flupenthixol	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
O	O	some	no
O	O	drugs	no
O	O	,	no
O	O	like	yes
B-group	B-group	Monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	MAOI	no
O	O	)	no
O	O	:	no
B-group	B-group	MAOI	no
O	O	could	no
O	O	theoretically	no
O	O	affect	no
B-drug	B-drug	flupenthixol	yes
O	O	pharmacodynamics	no
O	O	-	yes
B-brand	B-drug_n	Arecoline	yes
O	O	-	yes
B-drug	O	Eproxindine	no
O	O	-	yes
B-drug	B-drug	Ethanol	yes
O	O	:	no
B-drug	B-drug	Flupenthixol	yes
O	O	and	yes
B-drug	B-drug	Ethanol	yes
O	O	cause	no
O	O	additive	no
O	O	CNS	no
O	O	depression	no
O	O	-	yes
B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	:	no
B-drug	B-drug	Flupenthixol	yes
O	O	increases	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no

O	O	Hepatic	no
O	O	Enzyme	no
O	O	Inducers	no
O	O	,	no
O	O	Inhibitors	no
O	O	and	yes
O	O	Substrates	no
O	O	:	no
O	O	Drugs	no
O	O	which	no
O	O	induce	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	(	no
O	O	CYP	no
O	O	3A4	no
O	O	)	no
O	O	enzyme	no
O	O	activity	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	)	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	and	yes
O	O	require	no
O	O	that	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	the	no
B-group	B-group	corticosteroid	no
O	O	be	no
O	O	increased	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	the	no
O	O	transfusion	no
O	O	practices	no
O	O	for	yes
O	O	such	no
O	O	patients	no
O	O	may	no
O	O	need	no
O	O	to	no
O	O	be	no
O	O	modified	yes
O	O	given	no
O	O	the	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

O	O	600-1800	no

O	O	See	no

O	O	If	no
O	O	this	no
O	O	is	yes
O	O	not	no
O	O	possible	no
O	O	,	no
O	O	the	no
O	O	starting	no
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	Until	no
O	O	data	no
O	O	on	no
O	O	possible	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	verapamil	yes
O	O	and	yes
B-drug	B-drug	disopyramide	yes
I-drug	I-drug	phosphate	yes
O	O	are	no
O	O	obtained	no
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	within	no
O	O	48	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	24	yes
O	O	hours	no
O	O	after	no
B-drug	B-drug	verapamil	yes
O	O	administration	no
O	O	.	no

O	O	Interaction	no
O	O	on	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	between	yes
B-drug	B-drug_n	neurotensin	no
O	O	and	yes
B-group	B-drug_n	enkephalins	no
O	O	or	no
B-drug_n	B-drug_n	tuftsin	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	these	no
O	O	tests	no
O	O	be	no
O	O	performed	no
O	O	weekly	yes
O	O	or	no
O	O	every	no
O	O	other	no
O	O	week	no
O	O	until	no
O	O	the	no
O	O	lipid	no
O	O	response	no
O	O	to	no
B-brand	B-brand	Soriatane	yes
O	O	has	no
O	O	stabilized	no
O	O	.	no

O	O	Decreased	no
O	O	core	yes
O	O	temperature	no
O	O	in	yes
O	O	female	no
O	O	rats	no
O	O	was	no
O	O	investigated	no
O	O	as	yes
O	O	one	no
O	O	possible	no
O	O	index	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	disulfiram-ethanol	no
O	O	reaction	no
O	O	(	no
O	O	DER	yes
O	O	)	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	transient	no
O	O	increases	no
O	O	in	yes
O	O	liver	yes
O	O	ALT	no
O	O	and	yes
O	O	AST	no
O	O	when	no
B-brand	B-brand	CANCIDAS	yes
O	O	and	yes
B-drug	B-drug	cyclosporine	yes
O	O	were	no
O	O	co-administered	no
O	O	.	no

O	O	Analyses	no
O	O	of	yes
O	O	this	no
O	O	sequence	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	usually	no
O	O	give	no
O	O	little	no
O	O	consideration	no
O	O	to	no
O	O	the	no
O	O	nature	no
O	O	of	yes
O	O	the	no
O	O	target	no
O	O	cell	yes
O	O	or	no
O	O	to	no
O	O	the	no
O	O	characteristics	no
O	O	of	yes
O	O	the	no
O	O	resultant	no
O	O	tumors	no
O	O	.	no

O	O	To	no
O	O	evaluate	no
O	O	the	no
O	O	impact	no
O	O	of	yes
O	O	chemotherapy	no
O	O	plus	yes
O	O	HAART	no
O	O	on	no
O	O	the	no
O	O	clinical	no
O	O	course	no
O	O	of	yes
O	O	patients	no
O	O	with	yes
O	O	HIV-related	no
O	O	,	no
O	O	systemic	no
O	O	,	no
O	O	non-Hodgkin	no
O	O	lymphoma	no
O	O	(	no
O	O	HIV-NHL	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	authors	no
O	O	compared	no
O	O	retrospectively	no
O	O	a	yes
O	O	group	yes
O	O	of	yes
O	O	24	yes
O	O	patients	no
O	O	with	yes
B-drug	O	HIV-NHL	no
O	O	who	no
O	O	were	no
O	O	treated	no
O	O	with	yes
O	O	the	no
B-drug	B-drug	cyclophosphamide	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	vincristine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	prednisone	yes
O	O	(	no
O	O	CHOP	no
O	O	)	no
O	O	chemotherapy	no
O	O	regimen	no
O	O	plus	yes
O	O	HAART	no
O	O	with	yes
O	O	a	yes
O	O	group	yes
O	O	of	yes
O	O	80	yes
O	O	patients	no
O	O	who	no
O	O	were	no
O	O	treated	no
O	O	with	yes
O	O	CHOP	no
O	O	chemotherapy	no
O	O	or	no
O	O	a	yes
O	O	CHOP-like	no
O	O	regimen	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	cyclophosphamide	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	teniposide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	prednisone	yes
O	O	with	yes
B-drug	B-drug	vincristine	yes
O	O	plus	yes
B-drug	B-drug	bleomycin	yes
O	O	)	no
O	O	without	no
O	O	receiving	no
B-group	B-group	antiretroviral	no
O	O	therapy	no
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

O	O	DRUG	yes
O	O	INTERACTIONS	no

O	O	Changes	no
O	O	in	yes
B-drug	B-drug	omeprazole	yes
O	O	pharmacokinetics	no
O	O	were	no
O	O	not	no
O	O	studied	no
O	O	.	no

O	O	In	yes
O	O	general	no
O	O	,	no
O	O	these	no
O	O	are	no
O	O	drugs	no
O	O	that	no
O	O	have	no
O	O	one	no
O	O	or	no
O	O	more	no
O	O	pharmacologic	no
O	O	activities	no
O	O	similar	no
O	O	to	no
B-drug	B-drug	bepridil	yes
I-drug	I-drug	hydrochloride	yes
O	O	,	no
O	O	including	no
B-group	B-group	anti-arrhythmic	no
I-group	I-group	agents	yes
O	O	such	no
O	O	as	yes
B-drug	B-drug	quinidine	yes
O	O	and	yes
B-drug	B-drug	procainamide	yes
O	O	,	no
B-group	B-group	cardiac	no
I-group	I-group	glycosides	yes
O	O	and	yes
B-group	B-group	tricyclic	no
I-group	I-group	anti-depressants	no
O	O	.	no

B-drug	B-drug	Ranitidine	yes
O	O	produced	no
O	O	smaller	no
O	O	,	no
O	O	nonsignificant	no
O	O	increases	no
O	O	.	no

B-group	B-group	Anesthetics/Sedatives/Hypnotics/Opioids	no
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	PRECEDEX	yes
O	O	with	yes
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	hypnotics	no
O	O	,	no
O	O	and	yes
B-group	B-group	opioids	no
O	O	is	yes
O	O	likely	no
O	O	to	no
O	O	lead	no
O	O	to	no
O	O	an	no
O	O	enhancement	no
O	O	of	yes
O	O	effects	no
O	O	.	no

O	O	Drug-Drug	no
O	O	Interactions	no
O	O	Given	no
O	O	the	no
O	O	primary	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
B-brand	B-brand	ABILIFY	yes
O	O	is	yes
O	O	taken	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
O	B-group	centrally	no
O	I-group	acting	yes
O	I-group	drugs	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	Rhabdomyolysis	no
O	O	secondary	yes
O	O	to	no
O	O	a	yes
O	O	drug	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	simvastatin	yes
O	O	and	yes
B-drug	B-drug	clarithromycin	yes
O	O	.	no

B-drug	B-drug	Phenytoin	yes
O	O	:	no
O	O	If	no
B-drug	B-drug	acitretin	yes
O	O	is	yes
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	the	no
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	A	yes
O	O	patient	no
O	O	had	no
B-drug	O	phenytoin	yes
O	O	intoxication	no
O	O	after	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	a	yes
B-group	O	selective	no
I-group	O	serotonin	yes
I-group	O	reuptake	no
I-group	O	inhibitor	yes
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	differences	no
O	O	between	yes
O	O	cecectomized	no
O	O	and	yes
O	O	control	no
O	O	rats	no
O	O	in	yes
O	O	basal	no
O	O	small	no
O	O	intestinal	no
O	O	transits	no
O	O	or	no
O	O	in	yes
B-drug_n	B-drug_n	dmPGE2	no
O	O	(	no
O	O	0.3	yes
O	O	mg/kg	no
O	O	,	no
O	O	p.o	no
O	O	.	no
O	O	)	no
O	O	-induced	no
O	O	enhancements	no
O	O	.	no

B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Agents	yes
O	O	Affecting	no
O	O	Sympathetic	no
O	O	Activity	yes
O	O	The	no
O	O	sympathetic	no
O	O	nervous	no
O	O	system	yes
O	O	may	no
O	O	be	no
O	O	especially	no
O	O	important	no
O	O	in	yes
O	O	supporting	no
O	O	blood	yes
O	O	pressure	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	captopril	yes
O	O	alone	no
O	O	or	no
O	O	with	yes
B-group	B-group	diuretics	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	flurbiprofen	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	therefore	no
O	O	not	no
O	O	recommended	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	VIRACEPT	yes
O	O	and	yes
O	O	drugs	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-group	B-group	dihydropyridine	no
I-group	I-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	other	no
O	O	drug	yes
O	O	that	no
O	O	could	no
O	O	increase	no
O	O	or	no
O	O	prolong	no
O	O	both	no
O	O	its	no
O	O	therapeutic	no
O	O	and	yes
O	O	adverse	no
O	O	effects	no
O	O	.	no

O	O	(	no
O	O	Note	no
O	O	:	no
O	O	All	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	theophylline	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	appropriately	no
O	O	,	no
O	O	regardless	no
O	O	of	yes
O	O	concomitant	no
O	O	drug	yes
O	O	therapy	no
O	O	.	no
O	O	)	no

B-drug	B-drug	valproate	yes
O	O	and	yes
B-drug	B-drug	gabapentin	yes
O	O	are	no
O	O	not	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	is	yes
O	O	given	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	to	no
O	O	prevent	no
O	O	excessive	no
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

B-drug	B-drug	Lithium	yes
O	O	:	no
B-group	B-group	NSAIDs	no
O	O	have	no
O	O	produced	no
O	O	an	no
O	O	elevation	no
O	O	of	yes
O	O	plasma	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	and	yes
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
O	O	renal	no
B-drug	B-drug	lithium	yes
O	O	clearance	no
O	O	.	no

O	O	65	yes
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	and	yes
O	O	13	yes
O	O	patients	no
O	O	were	no

O	O	The	no
O	O	minimal	no
O	O	inhibitory	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	and	yes
B-drug	B-drug	gentamicin	yes
O	O	alone	no
O	O	and	yes
O	O	in	yes
O	O	combinations	no
O	O	were	no
O	O	determined	no
O	O	by	no
O	O	a	yes
O	O	microdilution	no
O	O	method	yes
O	O	for	yes
O	O	163	no
O	O	aerobic	no
O	O	,	no
O	O	facultative	no
O	O	,	no
O	O	and	yes
O	O	anaerobic	no
O	O	clinical	no
O	O	isolates	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
O	B-group	dialysis	no
O	I-group	solutions	no
O	O	,	no
O	O	blood	yes
O	O	concentrations	no
O	O	of	yes
O	O	dialyzable	no
O	O	drugs	no
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	dialysis	no
O	O	.	no

O	O	therefore	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	Itraconazole	yes
O	O	with	yes
B-drug	B-drug	cisapride	yes
O	O	is	yes
O	O	contraindicated	no
O	O	.	no

O	O	Particular	no
O	O	caution	no
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	Gleevec	yes
O	O	with	yes
O	O	CYP3A4	no
O	O	substrates	no
O	O	that	no
O	O	have	no
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	window	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	or	no
B-drug	B-drug	pimozide	yes
O	O	)	no
O	O	.	no

B-group	O	Potassium	yes
I-group	O	sparing	no
I-group	O	agents	yes
O	O	should	no
O	O	generally	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	heart	no
O	O	failure	no
O	O	receiving	no
B-drug	B-drug	enalapril	yes
O	O	.	no

O	O	clinically	no
O	O	significant	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	through	no
O	O	competition	no
O	O	for	yes
O	O	protein	yes
O	O	binding	no
O	O	sites	no
O	O	are	no
O	O	therefore	no
O	O	unlikely	no
O	O	.	no

O	O	This	no
O	O	was	no
O	O	expected	no
O	O	because	no
B-drug	B-drug	zaleplon	yes
O	O	is	yes
O	O	primarily	no
O	O	metabolized	no
O	O	and	yes
O	O	renal	no
O	O	excretion	no
O	O	of	yes
O	O	unchanged	no
B-drug	B-drug	zaleplon	yes
O	O	accounts	no
O	O	for	yes
O	O	less	no
O	O	than	no
O	O	1	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	administered	no
O	O	dose	no
O	O	.	no

O	O	A	yes
O	O	muscle	no
O	O	biopsy	no
O	O	revealed	no
O	O	necrotizing	no
O	O	myopathy	no
O	O	secondary	yes
O	O	to	no
O	O	a	yes
O	O	toxin	yes
O	O	.	no

B-drug	B-drug	Cyclosporine	yes
O	O	:	no
O	O	Elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	with	yes
O	O	other	no
O	O	members	no
O	O	of	yes
O	O	the	no
B-group	B-group	quinolone	no
I-group	I-group	class	no
O	O	.	no

O	O	The	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	and	yes
B-drug	B-drug	ranitidine	yes
O	O	is	yes
O	O	accelerated	no
O	O	when	no
O	O	they	no
O	O	are	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	cisapride	yes
O	O	.	no

B-drug	B-drug	Amprenavir	yes
O	O	significantly	no
O	O	decreases	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	rifabutin	yes
O	O	and	yes
B-drug_n	B-drug_n	25-O-desacetylrifabutin	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	combination	yes
O	O	is	yes
O	O	poorly	no
O	O	tolerated	no
O	O	.	no

B-group	B-group	ACE-inhibitors	no
O	O	:	no
O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	ACE-inhibitors	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	CYP3A4	no
O	O	substrates	no
O	O	known	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	narrow	no
O	O	therapeutic	no
O	O	index	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	alfentanil	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	,	no
B-drug	B-drug	terfenadine	yes
O	O	,	no
B-drug	B-drug	cisapride	yes
O	O	,	no
B-drug	B-drug	cyclosporine	yes
O	O	,	no
B-drug	B-drug	fentanyl	yes
O	O	,	no
B-drug	B-drug	pimozide	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-drug	B-drug	sirolimus	yes
O	O	,	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
O	O	or	no
B-group	B-group	ergot	yes
I-group	I-group	alkaloids	yes
O	O	(	no
B-drug	B-drug	ergotamine	yes
O	O	,	no
B-drug	B-drug	dihydroergotamine	yes
O	O	)	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	SPRYCEL	yes
O	O	.	no

O	O	Thus	no
O	O	,	no
O	O	when	no
B-brand	B-brand	VIOXX	yes
O	O	and	yes
B-drug	B-drug	lithium	yes
O	O	are	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	subjects	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	carefully	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
B-drug	B-drug	lithium	yes
O	O	toxicity	no
O	O	.	no

B-drug	B-drug	aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	;	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Positive	no
O	O	direct	no
O	O	Coombs	no
O	O	tests	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
O	O	the	no
B-group	B-group	cephalosporin	yes
I-group	I-group	antibiotics	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	a	yes
O	O	one-week	no
O	O	course	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	at	yes
O	O	400	yes
O	O	mg	yes
O	O	b.i.d	no
O	O	.	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	5	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	isradipine	yes
O	O	on	no
O	O	the	no
O	O	sixth	no
O	O	day	no
O	O	showed	no
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	isradipine	yes
O	O	mean	no
O	O	peak	no
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	36	no
O	O	%	no
O	O	)	no
O	O	and	yes
O	O	significant	no
O	O	increase	no
O	O	in	yes
O	O	area	no
O	O	under	no
O	O	the	no
O	O	curve	no
O	O	(	no
O	O	50	yes
O	O	%	no
O	O	)	no
O	O	.	no

O	O	Synergism	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	between	yes
B-drug	B-drug	halothane	yes
O	O	anesthesia	yes
O	O	and	yes
O	O	intravenously	no
O	O	administered	no
B-drug	B-drug	labetalol	yes
I-drug	I-drug	HCl	yes
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
O	O	In	yes
O	O	an	no
O	O	interaction	no
O	O	study	no
O	O	of	yes
O	O	rheumatoid	no
O	O	arthritis	no
O	O	patients	no
O	O	taking	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
B-brand	B-brand	CELEBREX	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	a	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

O	O	Even	no
O	O	though	no
O	O	such	no
O	O	interactions	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	seen	no
O	O	in	yes
O	O	clinical	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	DynaCirc	yes
O	O	(	no
B-drug	B-drug	isradipine	yes
O	O	)	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	volume	no
O	O	of	yes
O	O	circulating	no
O	O	fluids	no
O	O	might	no
O	O	be	no
O	O	required	no
O	O	if	no
O	O	such	no
O	O	an	no
O	O	interaction	no
O	O	were	no
O	O	to	no
O	O	occur	no
O	O	.	no

B-drug	B-drug	Methadone	yes
O	O	levels	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	;	no
O	O	increased	no
O	O	dosages	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	to	no
O	O	prevent	no
O	O	symptoms	no
O	O	of	yes
B-group	B-group	opiate	no
O	O	withdrawal	no
O	O	.	no
B-drug	B-drug	Methadone	yes
O	O	maintained	no
O	O	patients	no
O	O	beginning	no
B-drug	B-drug	nevirapine	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	forevidence	no
O	O	of	yes
O	O	withdrawal	no
O	O	and	yes
B-drug	B-drug	methadone	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	adjusted	yes
O	O	accordingly	no
O	O	.	no

B-drug	I-drug	Diazoxide	yes
O	O	Hypotension	no

O	O	However	no
O	O	,	no
O	O	prudent	no
O	O	medical	yes
O	O	practice	no
O	O	dictates	no
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	all	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	azithromycin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	concomitantly	no
O	O	.	no

O	O	The	no
O	O	preceding	no
O	O	lists	no
O	O	of	yes
O	O	drugs	no
O	O	are	no
O	O	not	no
O	O	comprehensive	no
O	O	.	no

O	O	In	yes
O	O	an	no
O	O	in	yes
O	O	vitro	no
O	O	study	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	,	no
O	O	inhibition	no
O	O	of	yes
O	O	CYP2A6	no
O	O	hydroxylation	no
O	O	of	yes
B-drug_n	B-group	coumarin	yes
O	O	by	no
B-drug	B-drug	fondaparinux	yes
O	O	(	no
O	O	200	yes
O	O	m	yes
O	O	m	yes
O	O	M	yes
O	O	i.e.	no
O	O	,	no
O	O	350	yes
O	O	mg/L	no
O	O	)	no
O	O	was	no
O	O	17-28	no
O	O	%	no
O	O	.	no

B-drug	B-drug	Chlorpromazine	yes
O	O	:	no
B-drug	B-drug	Chlorpromazine	yes
O	O	blocks	no
B-drug	O	dopamine	yes
O	O	and	yes
B-drug	O	norepinephrine	yes
O	O	reuptake	no
O	O	,	no
O	O	thus	no
O	O	inhibiting	no
O	O	the	no
O	O	central	no
O	O	stimulant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	,	no
O	O	and	yes
O	O	can	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	treat	no
B-drug	B-group	amphetamine	yes
O	O	poisoning	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	study	no
O	O	,	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	etofibrate	yes
O	O	upon	no
B-drug	O	chylomicron	no
O	O	metabolism	no
O	O	was	no
O	O	tested	no
O	O	by	no
O	O	determination	no
O	O	of	yes
O	O	the	no
O	O	plasma	yes
O	O	kinetics	no
O	O	of	yes
O	O	a	yes
O	O	chylomicron-like	no
O	O	emulsion	no
O	O	model	no
O	O	in	yes
O	O	12	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	,	no
O	O	aged	no
O	O	59+/-11	no
O	O	years	no
O	O	,	no
O	O	(	no
O	O	total	yes
O	O	cholesterol	yes
O	O	:	no
O	O	240+/-41	no
O	O	mg/dl	no
O	O	;	no
O	O	triglycerides	yes
O	O	:	no
O	O	188+/-42	no
O	O	mg/dl	no
O	O	)	no
O	O	submitted	no
O	O	to	no
O	O	a	yes
O	O	randomized	no
O	O	,	no
O	O	crossover	no
O	O	,	no
O	O	double-blind	no
O	O	,	no
O	O	placebo-controlled	no
O	O	study	no
O	O	with	yes
O	O	administration	no
O	O	of	yes
O	O	1	yes
O	O	g	yes
O	O	per	no
O	O	day	no
B-drug	B-drug	etofibrate	yes
O	O	or	no
O	O	placebo	no
O	O	for	yes
O	O	1-month	no
O	O	.	no

O	O	When	no
B-drug	B-drug	indinavir	yes
O	O	at	yes
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	(	no
O	O	1000	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	)	no
O	O	was	no
O	O	given	no
O	O	with	yes
B-brand	B-brand	SUSTIVA	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	)	no
O	O	,	no
O	O	the	no
B-drug	B-drug	indinavir	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmin	no
O	O	were	no
O	O	decreased	no
O	O	on	no
O	O	average	no
O	O	by	no
O	O	33-46	no
O	O	%	no
O	O	and	yes
O	O	39-57	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	compared	no
O	O	to	no
O	O	when	no
B-drug	B-drug	indinavir	yes
O	O	(	no
O	O	800	no
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	)	no
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	.	no

O	O	Onset	no
O	O	of	yes
O	O	action	no
O	O	of	yes
B-group	B-group	tricyclics	no
O	O	may	no
O	O	be	no
O	O	accelerated	no
O	O	.	no

O	O	Fatal	no
O	O	cardiac	no
O	O	arrests	no
O	O	have	no
O	O	occurred	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	both	no
O	O	drugs	no
O	O	.	no

O	O	Drug-Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	:	no
O	O	There	no
O	O	are	no
O	O	no	yes
O	O	reported	no
O	O	drug-laboratory	no
O	O	test	yes
O	O	interactions	no
O	O	.	no

B-brand	B-brand	HEMABATE	yes
O	O	may	no
O	O	augment	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	other	no
B-group	B-group	oxytocic	no
I-group	I-group	agents	yes
O	O	.	no

B-drug	B-drug	Dexrazoxane	yes
O	O	was	no
O	O	not	no
O	O	mutagenic	no
O	O	in	yes
O	O	the	no
O	O	Ames	no
O	O	test	yes
O	O	but	no
O	O	was	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	clastogenic	no
O	O	to	no
O	O	human	yes
O	O	lymphocytes	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	to	no
O	O	mouse	yes
O	O	bone	no
O	O	marrow	no
O	O	erythrocytes	no
O	O	in	yes
O	O	vivo	no
O	O	(	no
O	O	micronucleus	no
O	O	test	yes
O	O	)	no
O	O	.	no

O	O	Special	yes
O	O	attention	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	electrolyte	yes
O	O	and	yes
O	O	acid-base	no
O	O	balance	yes
O	O	in	yes
O	O	patients	no
O	O	experiencing	no
O	O	severe	no
O	O	or	no
O	O	prolonged	no
O	O	diarrhea	no
O	O	or	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-group	B-drug	diuretics	no
O	O	.	no

O	O	Many	no
O	O	other	no
O	O	medicines	no
O	O	may	no
O	O	increase	no
O	O	or	no
O	O	decrease	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	glimepiride	yes
O	O	or	no
O	O	affect	no
O	O	your	no
O	O	condition	no
O	O	.	no

O	O	-	yes
O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	either	no
O	O	increase	no
O	O	or	no
O	O	decrease	no
O	O	plasma	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	include	no
O	O	:	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	O	vaiproic	no
I-drug	O	acid	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	valproate	yes
O	O	.	no

O	O	We	no
O	O	reviewed	no
O	O	the	no
O	O	clinical	no
O	O	data	no
O	O	relating	no
O	O	to	no
O	O	the	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	of	yes
O	O	pharmacologic	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ascorbic	yes
I-drug	I-drug	acid	yes
O	O	in	yes
O	O	the	no
O	O	prevention	no
O	O	and	yes
O	O	treatment	no
O	O	of	yes
O	O	the	no
O	O	common	yes
O	O	cold	yes
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	naproxen	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	because	no
B-drug	B-drug	naproxen	yes
O	O	is	yes
O	O	displaced	no
O	O	from	no
O	O	its	no
O	O	binding	no
O	O	sites	no
O	O	during	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	lower	no
O	O	plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	peak	no
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	Although	no
O	O	it	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	that	no
O	O	there	no
O	O	is	yes
O	O	an	no
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	Clozapine	yes
O	O	and	yes
B-group	B-group	benzodiazepines	no
O	O	or	no
O	O	other	no
B-group	B-group	psychotropics	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	advised	no
O	O	when	no
B-drug	B-drug	clozapine	yes
O	O	is	yes
O	O	initiated	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	a	yes
B-group	B-group	benzodiazepine	yes
O	O	or	no
O	O	any	no
O	O	other	no
B-group	B-group	psychotropic	no
I-group	I-group	drug	yes
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isozyme	no
O	O	and	yes
O	O	make	no
O	O	normal	yes
O	O	metabolizers	no
O	O	resemble	no
O	O	poor	no
O	O	metabolizers	no
O	O	.	no

B-drug	B-drug	Aprepitant	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	CYP3A4	no
O	O	;	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	NSAIDs	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE-inhibitors	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	assessments	no
O	O	of	yes
O	O	pharmacokinetic	no
O	O	drug-drug	no
O	O	interactions	no
O	O	between	yes
B-brand	B-brand	TRISENOX	yes
O	O	and	yes
O	O	other	no
O	O	agents	yes
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	Studies	no
O	O	on	no
O	O	two	no
O	O	strains	no
O	O	of	yes
O	O	pointer	no
O	O	dogs	no
O	O	have	no
O	O	demonstrated	no
O	O	that	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
B-group	B-group	benzodiazepine	yes
O	O	(	no
B-drug	B-drug	chlordiazepoxide	yes
O	O	)	no
O	O	facilitates	no
O	O	acquisition	no
O	O	of	yes
O	O	goal-directed	no
O	O	behavior	no
O	O	in	yes
O	O	"	no
O	O	genetically	no
O	O	nervous	no
O	O	"	no

O	O	+24	no
O	O	%	no
O	O	+14	no
O	O	%	no
O	O	+43	no
O	O	%	no
O	O	+40	no
O	O	%	no

B-group	B-group	Non-steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agents	yes
O	O	:	no
O	O	Seizures	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-drug	B-drug	enoxacin	yes
O	O	concomitantly	no
O	O	with	yes
O	O	the	no
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drug	yes
B-drug	B-drug	fenbufen	yes
O	O	.	no

O	O	In	yes
O	O	humans	no
O	O	,	no
O	O	two	no
O	O	inhibitors	no
O	O	of	yes
O	O	P450	no
O	O	3A4	no
O	O	have	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	it	no
O	O	may	no
O	O	be	no
O	O	important	no
O	O	also	no
O	O	in	yes
O	O	case	no
O	O	of	yes
O	O	medical	yes
O	O	examinations	no
O	O	for	yes
O	O	insurances	no
O	O	and	yes
O	O	job	no
O	O	appointments	no
O	O	,	no
O	O	since	no
O	O	some	no
O	O	patients	no
O	O	may	no
O	O	turn	no
O	O	out	no
O	O	to	no
O	O	need	no
O	O	expensive	no
O	O	drugs	no
O	O	or	no
O	O	to	no
O	O	be	no
O	O	susceptible	no
O	O	to	no
O	O	a	yes
O	O	certain	no
O	O	disease	no
O	O	.	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

B-drug	B-drug	Flurbiprofen	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	profile	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	mechanism	no
O	O	under	no
O	O	lying	no
O	O	the	no
O	O	interference	no
O	O	with	yes
B-drug	B-drug	propranolols	no
O	O	hypotensive	no
O	O	effect	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	MEASUREMENTS	no
O	O	AND	yes
O	O	MAIN	no
O	O	RESULTS	no
O	O	:	no
O	O	In	yes
O	O	December	no
O	O	1998	no
O	O	,	no
O	O	the	no
O	O	following	no
O	O	was	no
O	O	gathered	no
O	O	for	yes
O	O	every	no
O	O	MAC	no
O	O	with	yes
O	O	more	no
O	O	than	no
O	O	one	no
O	O	drug	yes
O	O	treatment	no
O	O	:	no
O	O	age	no
O	O	,	no
O	O	sex	no
O	O	,	no
O	O	number	no
O	O	of	yes
O	O	drugs	no
O	O	,	no
O	O	intrinsic	yes
O	O	value	no
O	O	,	no
O	O	drugs	no
O	O	prescribed	no
O	O	,	no
O	O	daily	no
O	O	dose	no
O	O	and	yes
O	O	pharmacological	no
O	O	interactions	no
O	O	(	no
O	O	PI	no
O	O	)	no
O	O	,	no
O	O	classified	no
O	O	(	no
O	O	using	no
O	O	the	no
O	O	scale	no
O	O	of	yes
B-brand	O	Hansten	no
O	O	1996	no
O	O	)	no
O	O	into	no
O	O	light	yes
O	O	and	yes
O	O	clinically	no
O	O	relevant	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450IID6	no
O	O	A	yes
O	O	subset	no
O	O	(	no
O	O	3	yes
O	O	%	no
O	O	to	no
O	O	10	yes
O	O	%	no
O	O	)	no
O	O	of	yes
O	O	the	no
O	O	population	no
O	O	has	no
O	O	reduced	yes
O	O	activity	yes
O	O	of	yes
O	O	certain	no
O	O	drug	yes
O	O	metabolizing	no
O	O	enzymes	yes
O	O	such	no
O	O	as	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	isoenzyme	no
O	O	P450IID6	no
O	O	.	no

O	O	(	no
O	O	Concurrent	no
O	O	use	no
O	O	with	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	possibility	no
O	O	of	yes
B-group	B-group	digitalis	yes
O	O	toxicity	no
O	O	associated	no
O	O	with	yes
O	O	hypokalemia	no
O	O	.	no
O	O	)	no

O	O	14	yes
O	O	%	no
O	O	increase	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	2	yes
O	O	%	no
O	O	increase	no
O	O	,	no
O	O	24	yes
O	O	%	no
O	O	increase	no
O	O	]	no
O	O	25	yes
O	O	%	no
O	O	decrease	no
O	O	[	no
O	O	CI	yes
O	O	:	no
O	O	12	yes
O	O	%	no
O	O	decrease	no
O	O	,	no
O	O	51	yes
O	O	%	no
O	O	decrease	no
O	O	]	no

O	O	Thus	no
O	O	,	no
O	O	results	no
O	O	of	yes
O	O	the	no
O	O	DST	no
O	O	should	no
O	O	be	no
O	O	interpreted	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	these	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	post-marketing	no
O	O	observations	no
O	O	,	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Folic	yes
I-drug	I-drug	acid	yes
O	O	in	yes
O	O	large	no
O	O	amounts	no
O	O	may	no
O	O	counteract	no
O	O	the	no
O	O	antiepileptic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	and	yes
B-drug	B-drug	primidone	yes
O	O	,	no
O	O	and	yes
O	O	increase	no
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	seizures	no
O	O	in	yes
O	O	susceptible	no
O	O	pediatric	yes
O	O	patients	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	important	no
O	O	that	no
O	O	health	no
O	O	care	yes
O	O	professionals	no
O	O	be	no
O	O	aware	no
O	O	of	yes
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	medications	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	clinical	no
O	O	laboratory	no
O	O	tests	no
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	Agents	yes
O	O	(	no
B-drug	B-drug	Insulin	yes
O	O	,	no
B-group	B-group	Sulfonylureas	no
O	O	)	no
O	O	:	no
O	O	Requirements	no
O	O	for	yes
B-drug	B-drug	insulin	yes
O	O	or	no
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	in	yes
O	O	hypothyroid	no
O	O	patients	no
O	O	with	yes
O	O	diabetes	no
O	O	mellitus	no
O	O	and	yes
O	O	may	no
O	O	subsequently	no
O	O	increase	no
O	O	with	yes
O	O	the	no
O	O	initiation	no
O	O	of	yes
B-group	O	thyroid	yes
I-group	O	hormone	yes
O	O	replacement	no
O	O	therapy	no
O	O	.	no

B-group	B-drug	Antihypertensives	no
O	O	:	no
B-drug	B-drug	Amiodarone	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	caution	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-drug	-receptor	no
I-group	O	blocking	no
I-group	O	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	a	yes
O	B-drug	CYP3A4	no
O	O	inhibitor	yes
O	O	)	no
O	O	or	no
B-group	B-drug	calcium	yes
I-group	I-drug	channel	no
I-group	O	antagonists	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	verapamil	yes
O	O	,	no
O	O	a	yes
O	B-drug	CYP3A4	no
O	O	substrate	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	diltiazem	yes
O	O	,	no
O	O	a	yes
O	B-drug	CYP3A4	no
O	O	inhibitor	yes
O	O	)	no
O	O	because	no
O	O	of	yes
O	O	the	no
O	O	possible	no
O	O	potentiation	no
O	O	of	yes
O	O	bradycardia	no
O	O	,	no
O	O	sinus	yes
O	O	arrest	no
O	O	,	no
O	O	and	yes
O	O	AV	no
O	O	block	yes
O	O	;	no

O	O	Carcinogenesis	no
O	O	,	no
O	O	Mutagenesis	no
O	O	,	no
O	O	Impairment	no
O	O	of	yes
O	O	Fertility	no
O	O	No	yes
O	O	long-term	no
O	O	carcinogenicity	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	carried	no
O	O	out	no
O	O	with	yes
B-drug	B-drug	dexrazoxane	yes
O	O	in	yes
O	O	animals	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	with	yes
B-brand	B-brand	Rebif	yes
O	O	.	no

O	O	Recurrence	no
O	O	of	yes
O	O	skin	yes
O	O	reactions	no
O	O	at	yes
O	O	a	yes
O	O	site	no
O	O	of	yes
O	O	previous	no
O	O	extravasation	no
O	O	following	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	TAXOL	yes
O	O	at	yes
O	O	a	yes
O	O	different	no
O	O	site	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	recall	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	rarely	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	studies	no
O	O	document	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	agents	yes
O	O	given	no
O	O	concomitantly	no
O	O	,	no
O	O	including	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	cimetidine	yes
O	O	.	no

O	O	When	no
O	O	therapeutic	no
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	dipyridamole	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	naproxen	yes
O	O	were	no
O	O	added	no
O	O	to	no
O	O	human	yes
O	O	plasma	yes
O	O	(	no
O	O	in	yes
O	O	vitro	no
O	O	)	no
O	O	,	no
O	O	the	no
O	O	plasma	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	Drugs	no
O	O	which	no
O	O	inhibit	no
O	O	CYP	no
O	O	3A4	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-group	B-group	macrolide	no
I-group	I-group	antibiotics	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	erythromycin	yes
O	O	)	no
O	O	have	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	No	yes
O	O	dosage	no
O	O	adjustment	no
O	O	is	yes
O	O	required	no
O	O	for	yes
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	.	no

B-group	B-group	Antimycobacterial	no
I-group	I-group	Agents	yes
O	O	:	no
B-drug	B-drug	rifampin	yes
O	O	CONTRAINDICATED	no
O	O	since	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	this	no
O	O	product	no
O	O	with	yes
B-drug	B-drug	saquinavir	yes
O	O	in	yes
O	O	an	no
B-group	B-group	antiretroviral	no
O	O	regimen	no
O	O	reduces	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	.	no

B-drug	B-drug	Ethyl	yes
I-drug	I-drug	alcohol	yes
O	O	is	yes
O	O	known	no
O	O	to	no
O	O	effect	no
O	O	the	no
O	O	functional	no
O	O	integrity	no
O	O	of	yes
O	O	the	no
O	O	limbic	no
O	O	system	yes
O	O	,	no
O	O	particularly	no
O	O	the	no
O	O	hippocampus	no
O	O	,	no
O	O	and	yes
O	O	to	no
O	O	alter	no
O	O	behaviors	no
O	O	which	no
O	O	are	no
O	O	thought	no
O	O	to	no
O	O	be	no
O	O	mediated	no
O	O	through	no
O	O	limbic	no
O	O	function	no
O	O	.	no

O	O	Prothrombin	yes
O	O	times	no
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
B-drug	B-drug	tiagabine	yes
O	O	.	no

O	O	The	no
O	O	specific	no
O	O	pharmacokinetic	no
O	O	changes	no
O	O	that	no
O	O	occur	no
O	O	with	yes
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	nevirapine	yes
O	O	and	yes
O	O	other	no
O	O	drugs	no
O	O	are	no
O	O	listed	no
O	O	in	yes
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	,	no
O	O	Table	no
O	O	1	yes
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	RAPTIVA	yes
O	O	.	no

O	O	The	no
O	O	disposition	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	by	no
O	O	concomitant	no
B-drug	B-drug	cetirizine	yes
O	O	administration	no
O	O	.	no

O	O	.	no

O	O	Toxicodynamic	no
O	O	interference	no
O	O	between	yes
B-group	O	solvents	no
O	O	can	no
O	O	give	no
O	O	rise	no
O	O	to	no
O	O	additive	no
O	O	,	no
O	O	potentiation	no
O	O	,	no
O	O	synergistic	no
O	O	,	no
O	O	antagonistic	no
O	O	effects	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
B-drug	B-drug	nateglinide	yes
O	O	had	no
O	O	no	yes
O	O	influence	no
O	O	on	no
O	O	the	no
O	O	serum	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	,	no
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	nicardipine	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	tolbutamide	yes
O	O	in	yes
O	O	vitro	no
O	O	.	no

B-drug	B-brand	Dantrium	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	liver	yes
O	O	,	no
O	O	and	yes
O	O	it	no
O	O	is	yes
O	O	theoretically	no
O	O	possible	no
O	O	that	no
O	O	its	no
O	O	metabolism	no
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	induce	no
O	O	hepatic	no
O	O	microsomal	no
O	O	enzymes	yes
O	O	.	no

O	O	Oral	yes
B-drug	B-drug	neomycin	yes
O	O	inhibits	no
O	O	the	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	penicillin	yes
I-drug	I-drug	V	yes
O	O	,	no
O	O	oral	yes
B-group	B-drug	vitamin	yes
I-group	I-drug	B-12	no
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	and	yes
B-drug	B-drug	5-fluorouracil	yes
O	O	.	no

O	O	If	no
O	O	concomitant	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	sumatriptan	yes
O	O	and	yes
O	O	an	no
B-group	B-group	SSRI	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
B-drug	B-drug	citalopram	yes
O	O	,	no
B-drug	B-drug	escitalopram	yes
O	O	)	no
O	O	is	yes
O	O	clinically	no
O	O	warranted	no
O	O	,	no
O	O	appropriate	no
O	O	observation	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	is	yes
O	O	advised	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	the	no
O	O	second	no
O	O	contraction	no
O	O	was	no
O	O	potentiated	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	co-administration	no
O	O	of	yes
B-group	O	TCA5	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRIs	no
O	O	and	yes
O	O	also	no
O	O	in	yes
O	O	switching	no
O	O	from	no
O	O	one	no
O	O	class	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	O	-	yes
O	O	a	yes
B-group	B-group	beta-blocker	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	propranolol	yes
O	O	(	no
B-brand	B-brand	Inderal	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	(	no
B-brand	B-brand	Tenormin	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	acebutolol	yes
O	O	(	no
B-brand	B-brand	Sectral	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	metoprolol	yes
O	O	(	no
B-brand	B-brand	Lopressor	yes
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	;	no

O	O	Caution	no
O	O	is	yes
O	O	recommended	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	hepatic	no
O	O	impairment	no
O	O	.	no

O	O	transaminases	no
O	O	(	no
O	O	AST	no

O	O	In	yes
O	O	this	no
O	O	study	no
O	O	there	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	a	yes
O	O	blunting	no
O	O	of	yes
O	O	the	no
O	O	antihypertensive	no
O	O	action	no
O	O	of	yes
B-brand	B-brand	VASOTEC	yes
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug_n	B-drug_n	DCG-IV	no
O	O	were	no
O	O	very	no
O	O	strong	no
O	O	and	yes
O	O	completely	no
O	O	depressed	no
O	O	the	no
B-drug_n	B-drug_n	PCP-induced	no
O	O	hyperlocomotion	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	glucose	yes
O	O	tests	no
O	O	based	no
O	O	on	no
O	O	enzymatic	no
O	O	glucose	yes
O	O	oxidase	yes
O	O	reactions	no
O	O	(	no
O	O	such	no
O	O	as	yes
O	O	Clinistix	no
O	O	**	no
O	O	or	no
O	O	Tes-Tape	no
O	O	**	no
O	O	)	no
O	O	be	no
O	O	used	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	ribavirin	yes
O	O	with	yes
O	O	either	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	No	yes
O	O	trials	no
O	O	specifically	no
O	O	examining	no
O	O	potential	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-brand	B-brand	Natrecor	yes
O	O	were	no
O	O	conducted	no
O	O	,	no
O	O	although	no
O	O	many	no
O	O	concomitant	no
O	O	drugs	no
O	O	were	no
O	O	used	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	A	yes
O	O	single	yes
O	O	10	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	at	yes
O	O	steady	no
O	O	state	no
O	O	.	no

B-drug	B-drug	Valproic	yes
I-drug	I-drug	acid	yes
O	O	diminished	no
O	O	binding	no
O	O	of	yes
B-drug	B-drug	phenobarbital	yes
O	O	by	no
O	O	a	yes
O	O	net	no
O	O	change	no
O	O	of	yes
O	O	9.9	no
O	O	%	no
O	O	(	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	FDF	no
O	O	,	no
O	O	21.2	no
O	O	%	no
O	O	)	no
O	O	at	yes
O	O	1732	no
O	O	micromol/L	no
O	O	.	no

B-drug_n	B-drug_n	Ibogaine	no
O	O	produces	no
O	O	whole	yes
O	O	body	no
O	O	tremors	no
O	O	and	yes
O	O	,	no
O	O	at	yes
O	O	high	yes
O	O	doses	no
O	O	(	no
O	O	>	no
O	O	or	no
O	O	=	no
O	O	100	yes
O	O	mg/kg	no
O	O	)	no
O	O	,	no
O	O	cerebellar	no
O	O	damage	no
O	O	;	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	before	no
B-drug	B-drug	succinylcholine	yes
O	O	to	no
O	O	attenuate	no
O	O	some	no
O	O	of	yes
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Additionally	no
O	O	,	no
B-drug	B-drug	saquinavir	yes
O	O	is	yes
O	O	a	yes
O	O	substrate	yes
O	O	for	yes
O	O	P-Glycoprotein	no
O	O	(	no
O	O	Pgp	no
O	O	)	no
O	O	.	no

O	O	[	no
O	O	The	no
O	O	GABA-ergic	no
O	O	system	yes
O	O	and	yes
O	O	brain	yes
O	O	edema	no
O	O	]	no
O	O	It	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	in	yes
O	O	rats	no
O	O	with	yes
O	O	experimental	no
O	O	toxic	no
O	O	and	yes
O	O	traumatic	no
O	O	edemas	no
O	O	that	no
B-drug_n	B-drug_n	picrotoxin	yes
O	O	(	no
O	O	1	yes
O	O	mg/kg	no
O	O	)	no
O	O	removes	no
O	O	the	no
O	O	antiedematous	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	diazepam	yes
O	O	,	no
B-drug	B-drug_n	phenazepam	no
O	O	,	no
B-drug_n	B-drug_n	phenibut	no
O	O	and	yes
O	B-drug_n	amizyl	no
O	O	and	yes
O	O	reduces	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	phentolamine	yes
O	O	.	no

O	O	Patients	no
O	O	on	no
B-group	B-group	warfarin-type	no
I-group	I-group	anticoagulant	no
O	O	therapy	no
O	O	may	no
O	O	require	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
O	O	the	no
B-group	O	anticoagulant	no
O	O	during	no
O	O	and	yes
O	O	after	no
B-drug	B-drug	griseofulvin	yes
O	O	therapy	no
O	O	.	no

O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	tablets	yes
O	O	reduces	no
O	O	the	no
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	the	no
O	O	latter	no
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	are	no
O	O	available	no
O	O	regarding	no
O	O	interactions	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	have	no
O	O	renal	no
O	O	clearance	no
O	O	mechanisms	no
O	O	similar	no
O	O	to	no
O	O	that	no
O	O	of	yes
B-drug	B-drug	lamivudine	yes
O	O	.	no

O	O	In	yes
O	O	13-day-old	no
O	O	embryos	no
O	O	,	no
B-drug	B-drug	glycine	yes
O	O	was	no
O	O	ineffective	no
O	O	in	yes
O	O	both	no
O	O	doses	no
O	O	.	no

B-drug	B-drug	Triazolam	yes
O	O	:	no
B-drug	B-drug	Erythromycin	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	decrease	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	triazolam	yes
O	O	and	yes
O	O	,	no
O	O	thus	no
O	O	,	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	pharmacologic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	triazolam	yes
O	O	.	no

O	O	(	no
B-group	B-group	Thiazide	no
I-group	I-group	diuretics	no
O	O	may	no
O	O	raise	no
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	;	no

O	O	Consequently	no
O	O	,	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	with	yes
B-drug	B-drug	acitretin	yes
O	O	is	yes
O	O	also	no
O	O	contraindicated	no
O	O	.	no

O	O	The	no
O	O	role	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	uptake-1	no
O	O	was	no
O	O	studied	no
O	O	in	yes
O	O	electrically	no
O	O	stimulated	no
O	O	(	no
O	O	1	yes
O	O	Hz	no
O	O	,	no
O	O	37	no
O	O	degrees	no
O	O	C	yes
O	O	)	no
O	O	human	yes
O	O	ventricular	no
O	O	cardiac	no
O	O	preparations	no
O	O	and	yes
O	O	isolated	no
O	O	myocardial	no
O	O	membranes	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	induce	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	lowered	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	indinavir	yes
O	O	.	no

B-drug	B-drug	Fluconazole	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	fluconazole	yes
O	O	at	yes
O	O	200	yes
O	O	mg	yes
O	O	QD	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	two-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	celecoxib	yes
O	O	plasma	yes
O	O	concentration	no
O	O	.	no

B-brand	B-brand	Starlix	yes
O	O	is	yes
O	O	a	yes
O	O	potential	no
O	O	inhibitor	yes
O	O	of	yes
O	O	the	no
O	O	CYP2C9	no
O	O	isoenzyme	no
O	O	in	yes
O	O	vivo	no
O	O	as	yes
O	O	indicated	no
O	O	by	no
O	O	its	no
O	O	ability	no
O	O	to	no
O	O	inhibit	no
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	.	no

O	O	Healthcare	no
O	O	prescribers	no
O	O	are	no
O	O	advised	no
O	O	to	no
O	O	consult	no
O	O	the	no
O	O	package	no
O	O	inserts	no
O	O	of	yes
O	O	medication	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	.	no

B-group	O	Catecholamine-depleting	no
I-group	O	Agents	yes
O	O	:	no
O	O	Patients	no
O	O	taking	no
O	O	both	no
O	B-group	agents	yes
O	I-group	with	yes
B-group	I-group	b-blocking	no
I-group	I-group	properties	no
O	O	and	yes
O	O	a	yes
O	O	drug	yes
O	O	that	no
O	O	can	no
O	O	deplete	no
O	O	catecholamines	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	and	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	signs	no
O	O	of	yes
O	O	hypotension	no
O	O	and/or	no
O	O	severe	no
O	O	bradycardia	no
O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	CYP3A	no
O	O	:	no
O	O	Results	no
O	O	of	yes
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	demonstrate	no
O	O	that	no
B-drug	B-drug	duloxetine	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	or	no
O	O	induce	no
O	O	CYP3A	no
O	O	activity	yes
O	O	.	no

B-drug	B-drug	astemizole	yes
O	O	,	no
B-drug	B-drug	bepridil	yes
O	O	,	no
B-drug	B-drug	sparfloxacin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	terodiline	no
O	O	.	no

O	O	for	yes
O	O	adult-onset	no
O	O	diabetics	no
O	O	,	no
O	O	dosage	no
O	O	adjustment	no
O	O	of	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	medications	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	during	no
O	O	and	yes
O	O	after	no
B-group	B-group	thiazide	no
I-group	I-group	diuretic	no
O	O	therapy	no
O	O	;	no

B-group	B-group	Beta	yes
I-group	I-group	Blockers	no
O	O	:	no
O	O	Although	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	a	yes
O	O	clinical	no
O	O	study	no
O	O	did	no
O	O	not	no
O	O	indicate	no
O	O	a	yes
O	O	safe	no
O	O	problem	no
O	O	associated	no
O	O	with	yes
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	D.H.E	no
O	I-brand	.	no
B-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	to	no
O	O	subjects	no
O	O	already	no
O	O	receiving	no
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	that	no
B-drug	B-drug	propranolol	yes
O	O	may	no
O	O	potentiate	no
O	O	the	no
O	O	vasoconstrictive	no
O	O	action	no
O	O	of	yes
B-drug	B-drug	ergotamine	yes
O	O	by	no
O	O	blocking	no
O	O	the	no
O	O	vasodilating	no
O	O	property	no
O	O	of	yes
B-drug	O	epinephrine	yes
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
O	O	skin	yes
O	O	products	no
O	O	or	no
O	O	shampoos	no
O	O	for	yes
O	O	dandruff	no
O	O	or	no
O	O	psoriasis	no
O	O	.	no

O	O	No	yes
O	O	data	no
O	O	are	no
O	O	available	no
O	O	for	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-brand	B-brand	INVIRASE/ritonavir	no
O	O	or	no
B-brand	B-brand	FORTOVASE/ritonavir	no
O	O	and	yes
O	O	garlic	no
O	O	capsules	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	evidence	no
O	O	of	yes
O	O	toxicity	no
O	O	.	no

B-brand	B-brand	BROVANA	yes
O	O	,	no
O	O	as	yes
O	O	with	yes
O	O	other	no
B-group	B-group	beta2-agonists	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	extreme	no
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	,	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
O	O	or	no
O	O	drugs	no
O	O	known	no
O	O	to	no
O	O	prolong	no
O	O	the	no
O	O	QTc	no
O	O	interval	no
O	O	because	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	adrenergic	no
I-group	I-group	agonists	no
O	O	on	no
O	O	the	no
O	O	cardiovascular	no
O	O	system	yes
O	O	may	no
O	O	be	no
O	O	potentiated	no
O	O	by	no
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	Drug	yes
O	O	laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	Serum	yes
B-group	O	Salicylate	yes
O	O	Assays	no
O	O	:	no
O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	interpreting	no
O	O	the	no
O	O	results	no
O	O	of	yes
O	O	serum	yes
O	O	salicylate	yes
O	O	assays	no
O	O	when	no
B-drug	B-drug	diflunisal	yes
O	O	is	yes
O	O	present	no
O	O	.	no

B-brand	B-brand	CANCIDAS	yes
O	O	did	no
O	O	not	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	.	no

B-drug	B-drug	Levetiracetam	yes
O	O	and	yes
O	O	its	no
O	O	major	no
O	O	metabolite	yes
O	O	,	no
O	O	at	yes
O	O	concentrations	no
O	O	well	no
O	O	above	no
O	O	cmax	no
O	O	levels	no
O	O	achieved	no
O	O	within	no
O	O	the	no
O	O	therapeutic	no
O	O	dose	no
O	O	range	no
O	O	,	no
O	O	are	no
O	O	neither	no
O	O	inhibitors	no
O	O	of	yes
O	O	nor	yes
O	O	high	yes
O	O	affinity	no
O	O	substrates	no
O	O	for	yes
O	O	human	yes
O	O	liver	yes
O	O	cytochrome	no
O	O	P450	no
O	O	isoforms	no
O	O	,	no
O	O	epoxide	no
O	O	hydrolase	yes
O	O	or	no
O	O	UDP-glucuronidation	no
O	O	enzymes	yes
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	did	no
O	O	not	no
O	O	have	no
O	O	any	no
O	O	effect	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	safety	no
O	O	or	no
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	ibutilide	yes
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	may	no
O	O	produce	no
O	O	a	yes
O	O	synergistic	no
O	O	anticonvulsant	no
O	O	action	no
O	O	.	no

O	O	whereas	no
O	O	urinary	yes
O	O	excretion	no
O	O	was	no
O	O	decreased	no
O	O	in	yes
O	O	both	no
O	O	cases	no
O	O	.	no

O	O	A	yes
O	O	drug-drug	no
O	O	interaction	no
O	O	study	no
O	O	evaluated	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	ACZONE	yes
O	O	Gel	yes
O	O	,	no
O	O	5	yes
O	O	%	no
O	O	,	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	double	yes
O	O	strength	yes
O	O	(	no
O	O	160	yes
O	O	mg/800	no
O	O	mg	yes
O	O	)	no
B-drug	B-drug	trimethoprim/sulfamethoxazole	no
O	O	(	no
B-drug	B-drug	TMP/SMX	no
O	O	)	no
O	O	.	no

O	O	An	no
O	O	intravenous	yes
O	O	dose	no
O	O	of	yes
O	O	50	yes
O	O	mg	yes
B-drug	B-drug_n	perchlorate	yes
O	O	was	no
O	O	in	yes
O	O	respect	no
O	O	of	yes
O	O	competitive	no
O	O	suppression	no
O	O	of	yes
O	O	organs	no
O	O	actively	no
O	O	concentrating	no
B-drug	B-drug	pertechnetate	yes
O	O	as	yes
O	O	effective	no
O	O	as	yes
O	O	intravenous	yes
O	O	1000	yes
O	O	mg	yes
O	O	ClO-4-	no
O	O	simultaneously	no
O	O	or	no
O	O	1000	yes
O	O	mg	yes
O	O	orally	no
O	O	30	yes
O	O	min	no
O	O	before	no
O	O	the	no
O	O	injection	yes
O	O	of	yes
B-drug	B-drug	radiopertechnetate	no
O	O	.	no

O	O	The	no
O	O	glucocorticoid-induced	no
O	O	gene	yes
O	O	transcription	no
O	O	was	no
O	O	strongly	no
O	O	suppressed	no
O	O	by	no
B-group	O	synthetic	yes
I-group	O	alkyl	no
I-group	O	esters	yes
O	O	;	no

O	O	Administration	no
O	O	of	yes
B-drug	B-drug	diltiazem	yes
I-drug	I-drug	hydrochloride	yes
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	propranolol	yes
O	O	in	yes
O	O	five	no
O	O	normal	yes
O	O	volunteers	no
O	O	resulted	no
O	O	in	yes
O	O	increased	no
B-drug	B-drug	propranolol	yes
O	O	levels	no
O	O	in	yes
O	O	all	yes
O	O	subjects	no
O	O	and	yes
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	propranolol	yes
O	O	was	no
O	O	increased	no
O	O	approximately	no
O	O	50	yes
O	O	%	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	in	yes
O	O	whom	no
O	O	CYP3A4	no
O	O	inducers	no
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	dexamethasone	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	rifampicin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	)	no
O	O	are	no
O	O	indicated	no
O	O	,	no
O	O	alternative	no
O	O	agents	yes
O	O	with	yes
O	O	less	no
O	O	enzyme	no
O	O	induction	no
O	O	potential	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	evidence	no
O	O	that	no
B-drug	B-drug	EPA	yes
O	O	supplements	no
O	O	have	no
O	O	detrimental	no
O	O	effects	no
O	O	on	no
B-drug	O	glucose	yes
O	O	tolerance	no
O	O	,	no
B-drug	O	insulin	yes
O	O	secretion	no
O	O	or	no
B-drug	O	insulin	yes
O	O	resistance	no
O	O	in	yes
O	O	non-diabetic	no
O	O	subjects	no
O	O	.	no

O	O	The	no
O	O	behavioral	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	stereoisomers	no
O	O	of	yes
B-drug_n	B-drug_n	N-allylnormetazocine	no
O	O	(	no
B-drug_n	B-drug_n	NANM	no
O	O	)	no
O	O	were	no
O	O	compared	no
O	O	with	yes
O	O	those	no
O	O	of	yes
B-drug_n	B-drug_n	phencyclidine	yes
O	O	(	no
B-drug_n	B-drug_n	PCP	yes
O	O	)	no
O	O	in	yes
O	O	pigeons	no
O	O	and	yes
O	O	squirrel	no
O	O	monkeys	no
O	O	responding	no
O	O	under	no
O	O	a	yes
O	O	multiple	no
O	O	fixed-interval	no
O	O	fixed-ratio	no
O	O	(	no
O	O	FI	no
O	O	FR	no
O	O	)	no
O	O	schedule	no
O	O	of	yes
O	O	food	no
O	O	presentation	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	and	yes
O	O	protein	yes
O	O	binding	no
O	O	of	yes
B-drug	B-drug	fosphenytoin	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	diazepam	yes
O	O	were	no
O	O	not	no
O	O	altered	no
O	O	when	no
B-drug	B-drug	diazepam	yes
O	O	and	yes
B-brand	B-brand	Cerebyx	yes
O	O	were	no
O	O	concurrently	no
O	O	administered	no
O	O	in	yes
O	O	single	yes
O	O	submaximal	no
O	O	doses	no
O	O	.	no

O	O	Since	no
O	O	higher	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	)	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	higher	no
O	O	increases	no
O	O	in	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	,	no
O	O	a	yes
O	O	single	yes
O	O	2.5	yes
O	O	mg	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	exceeded	no
O	O	in	yes
O	O	a	yes
O	O	24-hour	no
O	O	period	no
O	O	when	no
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	ketoconazole	yes
O	O	400	yes
O	O	mg	yes
O	O	daily	no
O	O	.	no

O	O	Also	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	with	yes
O	O	products	no
O	O	containing	yes
B-drug	B-drug	iron	yes
O	O	,	no
B-group	B-group	multivitamins	no
O	O	containing	yes
B-drug	B-drug	zinc	yes
O	O	,	no
O	O	or	no
B-brand	B-brand	Videx	yes
O	O	(	no
B-drug	B-drug	didanosine	yes
O	O	)	no
O	O	chewable/buffered	no
O	O	tablets	yes
O	O	or	no
O	O	the	no
O	O	pediatric	yes
O	O	powder	yes
O	O	for	yes
O	O	oral	yes
O	O	solution	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	low	yes
O	O	urine	no
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	risk	no
O	O	of	yes
O	O	this	no
O	O	interaction	no
O	O	may	no
O	O	be	no
O	O	reduced	yes
O	O	if	no
B-drug	B-drug	digoxin	yes
O	O	is	yes
O	O	given	no
O	O	as	yes
O	O	capsules	no
O	O	.	no

B-drug	B-drug	CHOLESTYRAMINE	yes
O	O	:	no
O	O	The	no
O	O	influence	no
O	O	of	yes
O	O	the	no
O	O	bile-acidsequestering	no
O	O	agent	yes
B-drug	B-drug	cholestyramine	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetits	no
O	O	of	yes
B-drug	B-drug	cerivastatin	yes
I-drug	I-drug	sodium	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	12	yes
O	O	healthy	no
O	O	males	no
O	O	in	yes
O	O	2	yes
O	O	separate	no
O	O	randomized	no
O	O	crossover	no
O	O	studies	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	increases	no
B-drug	B-drug	nicardipine	yes
I-drug	I-drug	HCl	yes
O	O	plasma	yes
O	O	levels	no
O	O	.	no

O	O	Catecholamine-depleting	no
O	O	drugs	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	reserpine	yes
O	O	,	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-group	B-group	beta	yes
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Higher	no
O	O	dosage	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	hypoglycemic	no
I-group	I-group	agents	yes
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	(	no
O	O	In	yes
O	O	some	no
O	O	patients	no
O	O	,	no
O	O	the	no
B-group	B-group	steroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	agent	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
B-group	O	diuretic	no
O	O	,	no
O	O	natriuretic	yes
O	O	,	no
O	O	and	yes
O	O	antihypertensive	no
O	O	effects	no
O	O	of	yes
O	O	loop	no
O	O	,	no
B-drug	O	potassium	yes
O	O	sparing	no
O	O	,	no
O	O	and	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	.	no

O	O	Care	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	if	no
B-drug	B-drug	labetalol	yes
O	O	is	yes
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	calcium	yes
I-group	O	antagonists	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	verapamil	yes
O	O	type	yes
O	O	.	no

O	O	There	no
O	O	are	no
O	O	reports	no
O	O	of	yes
O	O	enhanced	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	diminished	no
O	O	effects	no
O	O	of	yes
B-group	B-group	anticoagulants	no
O	O	when	no
O	O	given	no
O	O	concurrently	no
O	O	with	yes
B-group	B-group	corticosteroids	no
O	O	.	no

O	O	Effect	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	on	no
O	O	the	no
O	O	apparent	no
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	and	yes
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	cloxacillin	yes
O	O	.	no

O	O	They	no
O	O	may	no
O	O	be	no
O	O	administered	no
O	O	alternately	no
O	O	when	no
O	O	the	no
O	O	preceding	no
O	O	effect	no
O	O	of	yes
O	O	other	no
O	O	such	no
O	O	drug	yes
O	O	has	no
O	O	subsided	no
O	O	.	no

O	O	The	no
O	O	role	no
O	O	of	yes
B-brand	B-brand	AMEVIVE	no
O	O	in	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	the	no
O	O	lymphoid	no
O	O	malignancy	no
O	O	and	yes
O	O	the	no
O	O	hyperplasia	no
O	O	observed	no
O	O	in	yes
O	O	non-human	no
O	O	primates	no
O	O	and	yes
O	O	the	no
O	O	relevance	no
O	O	to	no
O	O	humans	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	Impaired	no
O	O	glucose	yes
O	O	tolerance	no
O	O	.	no

B-drug	I-drug	ethinyl	yes
I-drug	I-drug	estradiol	yes
O	O	concentration	no

O	O	There	no
O	O	was	no
O	O	a	yes
O	O	small	no
O	O	decrease	no
O	O	in	yes
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	cetirizine	yes
O	O	caused	no
O	O	by	no
O	O	a	yes
O	O	400-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	;	no

O	O	These	no
O	O	drugs	no
O	O	should	no
O	O	be	no
O	O	coadministered	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	and	yes
O	O	frequent	no
O	O	monitoring	no
O	O	of	yes
O	O	serum	yes
B-drug	B-drug	lithium	yes
O	O	levels	no
O	O	is	yes
O	O	recommended	no
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	(	no
O	O	increases	no
O	O	bioavailability	no
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	)	no
O	O	,	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	and	yes
B-group	O	valproates	no
O	O	.	no

O	O	Other	no
O	O	:	no
O	O	Instances	no
O	O	of	yes
O	O	rash	no
O	O	,	no
O	O	pruritus	no
O	O	,	no
O	O	ankle	no
O	O	edema	no
O	O	,	no
O	O	excessive	no
O	O	perspiration	no
O	O	,	no
O	O	weight	yes
O	O	gain	no
O	O	,	no
O	O	nasal	no
O	O	congestion	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	at	yes
O	O	least	no
O	O	two	no
O	O	weeks	no
O	O	prior	no
O	O	to	no
O	O	the	no
O	O	cautious	no
O	O	initiation	no
O	O	of	yes
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	SINEQUAN	yes
O	O	.	no

B-drug	B-drug	Cimetidine	yes

B-drug	B-drug	ADL	yes
I-drug	I-drug	8-2698	no
O	O	,	no
O	O	a	yes
O	O	trans-3,4-dimethyl-4-	no
O	O	(	no
B-drug	O	3-hydroxyphenyl	no
O	O	)	no
B-drug	O	piperidine	yes
O	O	,	no
O	O	prevents	no
O	O	gastrointestinal	no
O	O	effects	no
O	O	of	yes
O	O	intravenous	yes
B-drug	B-drug	morphine	yes
O	O	without	no
O	O	affecting	no
O	O	analgesia	no
O	O	.	no

O	O	The	no
O	O	change	no
O	O	in	yes
B-drug	B-drug	furosemide	yes
O	O	clearance	no
O	O	value	no
O	O	is	yes
O	O	not	no
O	O	likely	no
O	O	to	no
O	O	be	no
O	O	clinically	no
O	O	significant	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	-	yes
O	O	There	no
O	O	is	yes
O	O	one	no
O	O	report	no
O	O	that	no
B-drug	B-drug	methotrexate	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	possible	no
O	O	effectiveness	no
O	O	of	yes
O	O	supplemental	no
B-drug	B-drug	L-glutamine	yes
O	O	for	yes
O	O	chemotherapy-induced	no
O	O	mucositis	no
O	O	.	no

B-drug	B-drug	Methadone	yes

O	O	Plasma	yes
O	O	concentrations	no
O	O	and	yes
O	O	effects	no
O	O	potentially	no
O	O	increased	no
O	O	or	no
O	O	decreased	no
O	O	by	no
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

O	O	The	no
O	O	clearance	no
O	O	by	no
O	O	means	no
O	O	of	yes
B-drug_n	B-drug_n	4-hydroxytolbutamide	no
O	O	and	yes
B-drug_n	B-drug_n	carboxytolbutamide	no
O	O	was	no
O	O	significantly	no
O	O	reduced	yes
O	O	in	yes
O	O	both	no
O	O	groups	no
O	O	(	no
O	O	ie	no
O	O	,	no
O	O	from	no
O	O	901	no
O	O	mL/h	no
O	O	to	no
O	O	318	no
O	O	mL/h	no
O	O	in	yes
O	O	the	no
O	O	group	yes
O	O	that	no
O	O	received	no
O	O	150	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	per	no
O	O	day	no
O	O	and	yes
O	O	from	no
O	O	723	no
O	O	mL/h	no
O	O	to	no
O	O	457	no
O	O	mL/h	no
O	O	in	yes
O	O	the	no
O	O	group	yes
O	O	that	no
O	O	received	no
O	O	75	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	per	no
O	O	day	no
O	O	)	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-drug	B-drug	flurbiprofen	yes
O	O	resulted	no
O	O	in	yes
O	O	50	yes
O	O	%	no
O	O	lower	no
O	O	serum	yes
B-drug	B-drug	flurbiprofen	yes
O	O	concentrations	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	simultaneous	no
O	O	use	no
O	O	of	yes
O	O	creams	no
O	O	,	no
B-group	O	ointments	no
O	O	or	no
O	O	oils	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-brand	B-brand	Aspirin	yes
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	heparin	yes
O	O	,	no
B-group	B-group	NSAIDs	no

O	O	Approximately	no
O	O	2/3	no
O	O	of	yes
O	O	the	no
O	O	patients	no
O	O	in	yes
O	O	the	no
O	O	Phase	no
O	O	3	yes
O	O	study	no
O	O	received	no
O	O	either	no
O	O	prophylactic	no
O	O	low	yes
O	O	dose	no
B-drug	B-drug	heparin	yes
O	O	(	no
B-drug	B-drug	unfractionated	yes
I-drug	I-drug	heparin	yes
O	O	up	no
O	O	to	no
O	O	15,000	no
O	O	units/day	no
O	O	)	no
O	O	or	no
O	O	prophylactic	no
O	O	doses	no
O	O	of	yes
O	B-group	low	yes
O	I-group	molecular	yes
O	I-group	weight	yes
O	I-group	heparins	no
O	O	as	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	prescribing	no
O	O	information	no
O	O	for	yes
O	O	the	no
O	O	specific	no
O	O	products	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
B-brand	B-brand	SPRYCEL	yes
O	O	should	no
O	O	not	no
O	O	take	no
O	O	St.	yes
O	O	Johns	yes
O	O	wort	yes
O	O	.	no

O	O	Alternatively	no
O	O	,	no
O	O	provide	no
O	O	medical	yes
O	O	supervision	no
O	O	for	yes
O	O	at	yes
O	O	least	no
O	O	one	no
O	O	hour	yes
O	O	after	no
O	O	the	no
O	O	initial	no
O	O	dose	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-group	B-group	HMG-CoA	no
I-group	I-group	reductase	no
I-group	I-group	inhibitors	no
O	O	on	no
O	O	male	no
O	O	fertility	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	adequate	no
O	O	numbers	no
O	O	of	yes
O	O	patients	no
O	O	.	no

O	O	No	yes
O	O	drug	yes
O	O	,	no
O	O	nutritional	no
O	O	supplement	yes
O	O	,	no
O	O	food	no
O	O	or	no
O	O	herb	yes
O	O	interactions	no
O	O	are	no
O	O	known	no
O	O	.	no

O	O	In	yes
O	O	long	yes
O	O	surgical	yes
O	O	procedures	no
O	O	during	no
B-drug	B-drug	enflurane	yes
O	O	or	no
B-drug	B-drug	isoflurane	yes
O	O	anesthesia	yes
O	O	,	no
O	O	less	no
O	O	frequent	no
O	O	maintenance	no
O	O	dosing	no
O	O	,	no
O	O	lower	no
O	O	maintenance	no
O	O	doses	no
O	O	,	no
O	O	or	no
O	O	reduced	yes
O	O	infusion	no
O	O	rates	no
O	O	of	yes
B-brand	B-brand	NIMBEX	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	.	no

O	O	Other	no
O	O	substances	no
O	O	:	no
O	O	Grapefruit	no
O	O	juice	no
O	O	given	no
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	increased	no
B-drug	B-drug	amiodarone	yes
O	O	AUC	no
O	O	by	no
O	O	50	yes
O	O	%	no
O	O	and	yes
O	O	Cmax	no
O	O	by	no
O	O	84	no
O	O	%	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	increased	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

O	O	With	yes
O	O	simultaneous	no
O	O	dosing	no
O	O	of	yes
B-drug	B-drug	Vardenafil	yes
O	O	20	yes
O	O	mg	yes
O	O	and	yes
B-drug	B-drug	terazosin	yes
O	O	10	yes
O	O	mg	yes
O	O	,	no
O	O	2	yes
O	O	of	yes
O	O	9	yes
O	O	subjects	no
O	O	experienced	no
O	O	a	yes
O	O	standing	no
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	of	yes
O	O	less	no
O	O	than	no
O	O	85	no
O	O	mm	yes
O	O	Hg	yes
O	O	.	no

B-drug	B-drug	Auranofin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	together	no
O	O	with	yes
B-drug	B-drug	penicillamine	yes
O	O	(	no
B-brand	B-brand	Depen	yes
O	O	,	no
B-brand	B-brand	Cuprimine	yes
O	O	)	no
O	O	,	no
O	O	another	no
O	O	arthritis	no
O	O	medication	no
O	O	.	no

O	O	This	no
O	O	practice	no
O	O	resulted	no
O	O	in	yes
O	O	no	yes
O	O	apparent	no
O	O	increase	no
O	O	in	yes
O	O	local	no
O	O	breast	no
O	O	cancer	no
O	O	recurrence	no
O	O	relative	no
O	O	to	no
O	O	published	no
O	O	accounts	no
O	O	in	yes
O	O	the	no
O	O	literature	no
O	O	.	no

O	O	Continuous	no
O	O	cardiac	no
O	O	monitoring	no
O	O	is	yes
O	O	not	no
O	O	required	no
O	O	except	no
O	O	for	yes
O	O	patients	no
O	O	with	yes
O	O	serious	no
O	O	conduction	no
O	O	abnormalities	no
O	O	.	no

O	O	Agents	yes
O	O	Affecting	no
O	O	Cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	Isoenzyme	no
O	O	System	yes
B-drug	B-drug	Fentanyl	yes
O	O	is	yes
O	O	metabolized	no
O	O	mainly	no
O	O	via	no
O	O	the	no
O	O	human	yes
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	isoenzyme	no
O	O	system	yes
O	O	(	no
O	O	CYP3A4	no
O	O	)	no
O	O	,	no
O	O	therefore	no
O	O	potential	no
O	O	interactions	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-brand	B-brand	DURAGESIC	no
O	O	is	yes
O	O	given	no
O	O	concurrently	no
O	O	with	yes
O	O	agents	yes
O	O	that	no
O	O	affect	no
O	O	CYP3A4	no
O	O	activity	yes
O	O	.	no

B-drug_n	B-drug_n	Thiolated	no
I-drug_n	I-drug_n	carboxymethylcellulose	no
O	O	:	no
O	O	in	yes
O	O	vitro	no
O	O	evaluation	no
O	O	of	yes
O	O	its	no
O	O	permeation	no
O	O	enhancing	no
O	O	effect	no
O	O	on	no
B-group	O	peptide	yes
I-group	O	drugs	no
O	O	.	no

B-drug	B-drug	Ethoxzolamide	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	action	no
O	O	of	yes
B-group	B-group	tricyclics	no
O	O	,	no
B-group	B-group	amphetamines	no
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	General	no
O	O	:	no
O	O	Significant	no
O	O	interactions	no
O	O	may	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	celecoxib	yes
O	O	is	yes
O	O	administered	no
O	O	together	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	P450	no
O	O	2C9	no
O	O	.	no

O	O	Commonly	no
O	O	used	no
O	O	drugs	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	phenylpropanolamine	yes
O	O	and	yes
B-drug	B-drug	pseudoephedrine	yes
O	O	have	no
O	O	been	no
O	O	specifically	no
O	O	studied	no
O	O	.	no

O	O	May	no
O	O	interact	no
O	O	with	yes
O	O	the	no
O	O	following	no
O	O	:	no
B-group	B-group	beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	(	no
O	O	these	no
O	O	medicines	no
O	O	may	no
O	O	make	no
O	O	your	no
O	O	condition	no
O	O	worse	no
O	O	and	yes
O	O	prevent	no
O	O	the	no
B-group	B-group	adrenergic	no
I-group	I-group	bronchodilators	no
O	O	from	no
O	O	working	no
O	O	properly	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	quinidine	yes
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	procainamide	yes
O	O	(	no
O	O	these	no
O	O	medicines	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	heart	no
O	O	problems	no
O	O	)	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	in	yes
O	O	another	no
O	O	study	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	,	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	butorphanol	yes
O	O	were	no
O	O	significantly	no
O	O	altered	no
O	O	(	no
O	O	29	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	AUC	no
O	O	and	yes
O	O	38	no
O	O	%	no
O	O	decrease	no
O	O	in	yes
O	O	Cmax	no
O	O	)	no
O	O	when	no
O	O	a	yes
O	O	1-mg	no
O	O	dose	no
O	O	of	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	was	no
O	O	administered	no
O	O	1	yes
O	O	minute	no
O	O	after	no
O	O	a	yes
O	O	20-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	sumatriptan	yes
I-drug	O	nasal	no
O	O	spray	no
O	O	.	no

O	O	(	no
O	O	The	no
O	O	two	no
O	O	drugs	no
O	O	were	no
O	O	administered	no
O	O	in	yes
O	O	opposite	no
O	O	nostrils	no
O	O	.	no
O	O	)	no

O	O	Limited	no
O	O	data	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	known	no
O	O	enzyme	no
O	O	inducers	no
O	O	(	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	)	no
O	O	indicate	no
O	O	only	no
O	O	a	yes
O	O	30	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	rate	no
O	O	of	yes
B-drug	B-drug	flecainide	yes
O	O	elimination	no
O	O	.	no

O	O	Dosage	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	mentioned	no
O	O	above	no
O	O	and	yes
O	O	other	no
O	O	similarly	no
O	O	metabolized	no
O	O	drugs	no
O	O	,	no
O	O	particularly	no
O	O	those	no
O	O	of	yes
O	O	low	yes
O	O	therapeutic	no
O	O	ratio	no
O	O	or	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	and/or	no
O	O	hepatic	no
O	O	impairment	no
O	O	,	no
O	O	may	no
O	O	require	no
O	O	adjustment	no
O	O	when	no
O	O	starting	no
O	O	or	no
O	O	stopping	no
O	O	concomitantly	no
O	O	administered	no
B-brand	B-brand	Tagamet	yes
O	O	to	no
O	O	maintain	no
O	O	optimum	no
O	O	therapeutic	no
O	O	blood	yes
O	O	levels	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	because	no
O	O	some	no
B-group	B-group	quinolones	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	anticoagulation	no
O	O	test	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	if	no
O	O	a	yes
B-group	B-group	quinolone	no
I-group	I-group	antimicrobial	no
O	O	is	yes
O	O	administered	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	In	yes
O	O	five	no
O	O	men	no
O	O	,	no
B-drug	B-drug	terfenadine	yes
O	O	levels	no
O	O	were	no
O	O	undetectable	no
O	O	(	no
O	O	5	yes
O	O	ng/mL	no
O	O	)	no
O	O	throughout	no
O	O	the	no
O	O	study	no
O	O	;	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	chloroprocaine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	any	no
O	O	condition	no
O	O	in	yes
O	O	which	no
O	O	a	yes
B-group	B-group	sulfonamide	yes
I-group	I-group	drug	yes
O	O	is	yes
O	O	being	no
O	O	employed	no
O	O	.	no

B-brand	B-brand	Pletal	yes
O	O	does	no
O	O	not	no
O	O	,	no
O	O	however	no
O	O	,	no
O	O	appear	no
O	O	to	no
O	O	cause	no
O	O	increased	no
O	O	blood	yes
O	O	levels	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	,	no
O	O	as	yes
O	O	it	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	lovastatin	yes
O	O	,	no
O	O	a	yes
O	O	drug	yes
O	O	with	yes
O	O	metabolism	no
O	O	very	no
O	O	sensitive	no
O	O	to	no
O	O	C.P.A	no
O	O	.	no
O	O	inhibition	no
O	O	.	no

O	O	When	no
O	O	administering	no
O	O	other	no
O	O	drugs	no
O	O	for	yes
O	O	which	no
O	O	alterations	no
O	O	in	yes
O	O	blood	yes
O	O	levels	no
O	O	could	no
O	O	have	no
O	O	a	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	safety	no
O	O	or	no
O	O	efficacy	no
O	O	,	no
O	O	physicians	no
O	O	should	no
O	O	consider	no
O	O	monitoring	no
O	O	drug	yes
O	O	levels	no
O	O	or	no
O	O	effects	no
O	O	.	no

B-drug	O	Tacrolimus	yes
I-drug	B-drug	Felodipine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	blood	yes
O	O	concentration	no
O	O	of	yes
B-drug	B-drug	tacrolimus	yes
O	O	.	no

O	O	Drugs	no
O	O	That	no
O	O	Inhibit	no
B-drug	B-drug	Alprazolam	yes
O	O	Metabolism	no
O	O	Via	no
O	O	Cytochrome	no
O	O	P450	no
O	O	3A	yes
O	O	:	no
O	O	The	no
O	O	initial	no
O	O	step	no
O	O	in	yes
B-drug	B-drug	alprazolam	yes
O	O	metabolism	no
O	O	is	yes
O	O	hydroxylation	no
O	O	catalyzed	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A	yes
O	O	(	no
O	O	CYP	no
O	O	3A	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	who	no
O	O	have	no
O	O	received	no
B-group	B-group	muscle	no
I-group	I-group	relaxants	no
O	O	,	no
B-drug	B-drug	doxapram	yes
O	O	may	no
O	O	temporarily	no
O	O	mask	no
O	O	the	no
O	O	residual	no
O	O	effects	no
O	O	of	yes
B-group	B-group	muscle	no
I-group	I-group	relaxant	no
I-group	I-group	drugs	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	probenecid	yes
O	O	with	yes
B-drug	B-drug	acyclovir	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	mean	no
O	O	half-life	no
O	O	and	yes
O	O	the	no
O	O	area	no
O	O	under	no
O	O	the	no
O	O	concentration-time	no
O	O	curve	no
O	O	.	no

O	O	Pressor	no
O	O	agents	yes
O	O	-	yes
O	O	Because	no
O	O	of	yes
O	O	possible	no
O	O	effects	no
O	O	on	no
O	O	blood	yes
O	O	pressure	no
O	O	,	no
B-brand	B-brand	STRATTERA	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	with	yes
O	O	pressor	no
O	O	agents	yes
O	O	.	no

O	O	Increased	no
O	O	plasma	yes
O	O	HDL	no
O	O	and	yes
O	O	HDL2	no
O	O	cholesterol	yes
O	O	subfraction	no
O	O	concentrations	no
O	O	,	no
O	O	reduced	yes
O	O	LDL	no
O	O	cholesterol	yes
O	O	concentration	no
O	O	,	no
O	O	increased	no
O	O	triglyceride	yes
O	O	levels	no
O	O	.	no

B-drug	B-group	Iron	yes
O	I-group	Supplements	no
O	O	and	yes
O	O	Foods	no
O	O	Fortified	no
O	O	With	yes
B-drug	B-drug	Iron	yes
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cefdinir	yes
O	O	with	yes
O	O	a	yes
O	O	therapeutic	no
B-drug	B-group	iron	yes
O	I-group	supplement	yes
O	O	containing	yes
O	O	60	no
O	O	mg	yes
O	O	of	yes
O	O	elemental	yes
B-drug	B-drug	iron	yes
O	O	(	no
O	O	as	yes
B-brand	O	FeSO4	no
O	O	)	no
O	O	or	no
B-group	B-group	vitamins	no
O	O	supplemented	no
O	O	with	yes
O	O	10	yes
O	O	mg	yes
O	O	of	yes
O	O	elemental	yes
B-drug	B-drug	iron	yes
O	O	reduced	yes
O	O	extent	no
O	O	of	yes
O	O	absorption	no
O	O	by	no
O	O	80	yes
O	O	%	no
O	O	and	yes
O	O	31	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Use	no
O	O	in	yes
O	O	Conjunction	no
O	O	with	yes
O	O	Other	no
B-group	B-group	Antiepileptic	no
I-group	I-group	Drugs	no
O	O	:	no
O	O	The	no
O	O	addition	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	to	no
B-group	B-group	antiepileptic	no
I-group	I-group	drugs	no
O	O	(	no
B-group	B-group	AEDs	no
O	O	)	no
O	O	affects	no
O	O	the	no
O	O	steady-state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	AEDs	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	isoniazid	yes
O	O	(	no
B-brand	B-brand	Nydrazid	yes
O	O	)	no
O	O	;	no

O	O	Specific	no
O	O	Effects	no
O	O	of	yes
B-brand	B-brand	Felbatol	yes
O	O	on	no
O	O	Other	no
B-group	B-group	Antiepileptic	no
I-group	I-group	Drugs	no
B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-brand	B-brand	Felbatol	yes
O	O	causes	no
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	steady-state	no
B-drug	B-drug	phenytoin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	significant	no
O	O	effects	no
O	O	on	no
O	O	QTc	no
O	O	intervals	no
O	O	,	no
O	O	and	yes
O	O	no	yes
O	O	reports	no
O	O	of	yes
O	O	sedation	no
O	O	or	no
O	O	syncope	no
O	O	.	no

O	O	monitor	no
O	O	closely	no
O	O	for	yes
O	O	evidence	no
O	O	of	yes
O	O	hypotension	no
O	O	and/or	no
O	O	excessive	no
O	O	bradycardia	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	,	no
O	O	postural	no
O	O	hypotension	no
O	O	)	no
O	O	.	no

O	O	Unmodified	no
B-drug_n	B-drug_n	NaCMC	no
O	O	(	no
O	O	1	yes
O	O	%	no
O	O	m/v	no
O	O	)	no
O	O	significantly	no
O	O	improved	no
O	O	the	no
O	O	transport	no
O	O	ratio	no
O	O	(	no
O	O	R=	no
O	O	P	yes
O	O	(	no
O	O	app	no
O	O	)	no
O	O	polymer/	no
O	O	P	yes
O	O	(	no
O	O	app	no
O	O	)	no
O	O	control	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	NaFlu	no
O	O	to	no
O	O	1.3	no
O	O	and	yes
O	O	1	yes
O	O	%	no
O	O	(	no
O	O	m/v	no
O	O	)	no
O	B-drug_n	NaCMC	no
O	O	conjugated	yes
O	O	with	yes
B-drug	B-drug	cysteine	yes
O	O	further	no
O	O	enhanced	no
O	O	the	no
O	O	permeation	no
O	O	.	no

O	O	To	no
O	O	each	no
O	O	preparation	no
O	O	was	no
O	O	added	no
O	O	one	no
O	O	additional	no
O	O	drug	yes
O	O	at	yes
O	O	three	no
O	O	concentrations	no
O	O	ranging	no
O	O	from	no
O	O	therapeutic	no
O	O	to	no
O	O	toxic	no
O	O	.	no

O	O	To	no
O	O	investigate	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	disease	no
O	O	states	no
O	O	or	no
O	O	concomitant	no
O	O	drug	yes
O	O	administration	no
O	O	on	no
O	O	a	yes
O	O	patient	no
O	O	's	no
O	O	response	no
O	O	to	no
B-drug	B-drug	etodolac	yes
O	O	,	no
O	O	additional	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	were	no
O	O	carried	no
O	O	out	no
O	O	in	yes
O	O	special	yes
O	O	populations	no
O	O	.	no

O	O	No	yes
O	O	clinical	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	.	no

B-drug	B-drug	Ergotamine	yes
O	O	:	no
O	O	Concurrent	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	and	yes
B-drug	B-drug	ergotamine	yes
O	O	or	no
B-drug	B-drug	dihydroergotamine	yes
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	acute	no
O	O	ergot	yes
O	O	toxicity	no
O	O	characterized	no
O	O	by	no
O	O	severe	no
O	O	peripheral	no
O	O	vasospasm	no
O	O	and	yes
O	O	dysesthesia	no
O	O	.	no

O	O	Herbal	no
O	O	remedies	no
O	O	,	no
O	O	nephropathies	no
O	O	,	no
O	O	and	yes
O	O	renal	no
O	O	disease	no
O	O	.	no

B-drug	B-drug	Diclofenac	yes
O	O	is	yes
O	O	a	yes
B-group	O	prostaglandin	yes
I-group	O	synthetase	no
I-group	O	inhibitor	yes
O	O	,	no
O	O	however	no
O	O	,	no
O	O	and	yes
O	O	all	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	interfere	no
O	O	with	yes
O	O	platelet	yes
O	O	function	no
O	O	to	no
O	O	some	no
O	O	degree	no
O	O	;	no

O	O	nonetheless	no
O	O	,	no
O	O	the	no
O	O	possibility	no
O	O	that	no
O	O	causative	no
O	O	factors	no
O	O	may	no
O	O	interact	no
O	O	synergistically	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	and/or	no
O	O	severity	no
O	O	of	yes
O	O	bone	no
O	O	marrow	no
O	O	suppression	no
O	O	warrants	no
O	O	consideration	no
O	O	.	no

O	O	In	yes
O	O	studies	no
O	O	in	yes
O	O	female	no
O	O	rats	no
O	O	at	yes
O	O	doses	no
O	O	0.01	no
O	O	mg/kg/day	no
O	O	(	no
O	O	IM	yes
O	O	;	no

O	O	Mean	no
O	O	T	yes
O	O	max	no
O	O	and	yes
O	O	mean	no
O	O	plasma	yes
O	O	elimination	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	albendazole	yes
I-drug	I-drug	sulfoxide	yes
O	O	were	no
O	O	unchanged	no
O	O	.	no

B-drug	B-drug	Sildenafil	yes
O	O	dose	no
O	O	should	no
O	O	not	no
O	O	exceed	no
O	O	a	yes
O	O	maximum	no
O	O	of	yes
O	O	25	yes
O	O	mg	yes
O	O	in	yes
O	O	a	yes
O	O	48-	no
O	O	hour	yes
O	O	period	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-drug	B-drug	indinavir	yes
O	O	therapy	no
O	O	.	no

O	O	Herb/Nutraceutical	no
O	O	:	no
O	O	St	yes
O	O	Johns	yes
O	O	wort	yes
O	O	may	no
O	O	decrease	no
O	O	the	no
O	O	effectiveness	no
O	O	of	yes
B-group	B-group	combination	yes
I-group	I-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	by	no
O	O	inducing	no
O	O	hepatic	no
O	O	enzymes	yes
O	O	.	no

O	O	urticaria	no

O	B-brand	Caverject	yes
O	O	:	no
O	O	The	no
O	O	potential	no
O	O	for	yes
O	O	pharmacokinetic	no
O	O	drug-drug	no
O	O	interactions	no
O	O	between	yes
B-drug	B-drug	alprostadil	yes
O	O	and	yes
O	O	other	no
O	O	agents	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	formally	no
O	O	studied	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	recognized	no
O	O	that	no
O	O	a	yes
O	O	positive	no
O	O	Coombs	no
O	O	test	yes
O	O	may	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	.	no

O	O	Although	no
O	O	no	yes
O	O	drug-drug	no
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	conducted	no
O	O	in	yes
O	O	vivo	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	expected	no
O	O	that	no
O	O	no	yes
O	O	significant	no
O	O	interaction	no
O	O	would	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	nitazoxanide	yes
O	O	is	yes
O	O	co-administered	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	either	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	or	no
O	O	inhibit	no
O	O	cytochrome	no
O	O	P450	no
O	O	enzymes	yes
O	O	.	no

O	O	There	no
O	O	are	no
O	O	no	yes
O	O	clinical	no
O	O	data	no
O	O	on	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	NUROMAX	yes
O	O	and	yes
O	O	other	no
B-group	O	nondepolarizing	no
I-group	B-group	neuromuscular	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	to	no
O	O	hypoparathyroid	no
O	O	patients	no
O	O	who	no
O	O	are	no
O	O	concurrently	no
O	O	being	no
O	O	treated	no
O	O	with	yes
B-drug	B-drug	dihydrotachysterol	yes
O	O	may	no
O	O	cause	no
O	O	hypercalcemia	no
O	O	.	no

B-group	B-group	antibiotics	no
O	O	;	no

O	O	These	no
O	O	agents	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	NIZORAL	yes
O	O	Tablets	yes
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-drug	B-drug	lidocaine	yes

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	ethanol	yes
O	O	were	no
O	O	not	no
O	O	affected	no
O	O	by	no
O	O	multiple-dose	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	.	no

O	O	The	no
O	O	CNS	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	butalbital	yes
O	O	may	no
O	O	be	no
O	O	enhanced	no
O	O	by	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	.	no

B-drug	B-drug	Indinavir	yes
O	O	may	no
O	O	be	no
O	O	taken	no
O	O	with	yes
O	O	a	yes
O	O	light	yes
O	O	meal	no
O	O	1	yes
O	O	h	yes
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
O	O	400	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	didanosine	yes
O	O	.	no

B-group	B-group	Nitrates	no
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	Bepridil	yes
O	O	with	yes
B-group	O	long-	no
O	O	and	yes
B-group	O	short-acting	no
I-group	B-group	nitrates	no
O	O	has	no
O	O	been	no
O	O	safely	no
O	O	tolerated	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	stable	no
O	O	angina	no
O	O	pectoris	no
O	O	.	no

O	O	The	no
O	O	results	no
O	O	we	no
O	O	present	no
O	O	clearly	no
O	O	show	no
O	O	that	no
O	O	the	no
O	O	drug	yes
O	O	alters	no
O	O	the	no
O	O	cellular	no
O	O	permeability	no
O	O	,	no
O	O	and	yes
O	O	thus	no
O	O	the	no
O	O	exogenous	no
O	O	respiration	no
O	O	becomes	no
O	O	sensitive	no
O	O	to	no
O	O	the	no
O	O	drug	yes
O	O	.	no

B-drug	B-drug	Vardenafil	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	potentiate	no
O	O	the	no
O	O	hypotensive	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	during	no
O	O	the	no
O	O	4-hour	no
O	O	observation	no
O	O	period	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	when	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	alcohol	yes
O	O	(	no
O	O	0.5	yes
O	O	g/kg	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	to	no
O	O	this	no
O	O	pharmacological	no
O	O	interaction	no
O	O	,	no
O	O	this	no
O	O	report	no
O	O	describes	no
O	O	a	yes
O	O	novel	no
O	O	chemical	yes
O	O	reaction	no
O	O	between	yes
B-drug	B-drug	temazepam	yes
O	O	(	no
O	O	a	yes
B-group	B-group	benzodiazepine	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug	ethanol	yes
O	O	under	no
O	O	acidic	no
O	O	conditions	no
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	found	no
O	O	in	yes
O	O	vivo	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	3-ethoxylated	no
O	O	product	no
O	O	.	no

O	O	MEASUREMENTS	no
O	O	and	yes
O	O	MAIN	no
O	O	RESULTS	no
O	O	:	no
O	O	Blood	yes
O	O	samples	no
O	O	were	no
O	O	drawn	no
O	O	and	yes
O	O	12-lead	no
O	O	electrocardiograms	no
O	O	performed	no
O	O	at	yes
O	O	specified	yes
O	O	time	no
O	O	points	no
O	O	after	no
O	O	the	no
O	O	last	no
O	O	morning	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	in	yes
O	O	phases	no
O	O	1	yes
O	O	and	yes
O	O	3	yes
O	O	.	no

O	O	increased	no
O	O	liver	yes

O	O	Still	no
O	O	other	no
O	O	pathways	no
O	O	have	no
O	O	been	no
O	O	proposed	no
O	O	.	no

B-group	B-group	Sympathomimetic	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Possible	no
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	coronary	no
O	O	insufficiency	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	coronary	no
O	O	artery	no
O	O	disease	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	new	no
O	O	cases	no
O	O	of	yes
O	O	diabetes	no
O	O	have	no
O	O	been	no
O	O	diagnosed	no
O	O	during	no
B-brand	B-brand	Accutane	yes
O	O	therapy	no
O	O	,	no
O	O	although	no
O	O	no	yes
O	O	causal	no
O	O	relationship	no
O	O	has	no
O	O	been	no
O	O	established	no

O	O	This	no
O	O	may	no
O	O	potentiate	no
O	O	and	yes
O	O	prolong	no
O	O	hypnotic	no
O	O	and	yes
O	O	sedative	no
O	O	effects	no
O	O	,	no
O	O	especially	no
O	O	with	yes
O	O	repeated	no
O	O	dosing	no
O	O	or	no
O	O	chronic	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	.	no

O	O	Several	no
O	O	of	yes
O	O	the	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	cited	no
O	O	in	yes
O	O	these	no
O	O	reports	no
O	O	.	no

O	O	Bleeding	no
O	O	from	no
O	O	a	yes
O	O	number	no
O	O	of	yes
O	O	sites	no
O	O	may	no
O	O	be	no
O	O	a	yes
O	O	complication	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	treatment	no
O	O	and	yes
O	O	GI	no
O	O	bleeding	no
O	O	a	yes
O	O	complication	no
O	O	of	yes
B-drug	B-drug	ketoprofen	yes
O	O	treatment	no
O	O	.	no

O	O	.	no

O	O	Between	yes
O	O	1988	no
O	O	and	yes
O	O	1993	no
O	O	,	no
O	O	more	no
O	O	than	no
O	O	7,000	no
O	O	patients	no
O	O	were	no
O	O	diagnosed	no
O	O	and	yes
O	O	treated	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	monitoring	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	plasma	yes
O	O	levels	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	and	yes
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	adjusted	yes
O	O	,	no
O	O	as	yes
O	O	required	no
O	O	.	no

O	O	Both	no
O	O	CYP3A4	no
O	O	and	yes
O	O	CYP2D6	no
O	O	are	no
O	O	responsible	no
O	O	for	yes
B-drug	B-drug	aripiprazole	yes
O	O	metabolism	no
O	O	.	no

O	O	Separating	no
O	O	the	no
O	O	doses	no
O	O	of	yes
B-group	B-group	antacid	no
O	O	and	yes
B-drug	B-drug	lomefloxacin	yes
O	O	minimizes	no
O	O	this	no
O	O	decrease	no
O	O	in	yes
O	O	bioavailability	no
O	O	;	no

B-group	B-group	TCAs	no
O	O	decrease	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	guanfacine	yes
O	O	.	no

O	O	Poor	no
O	O	metabolizers	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-group	B-group	TCAs	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

B-group	B-group	Non-selective	no
I-group	I-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	-	yes
O	O	including	no
B-drug	B-drug	phenelzine	yes
I-drug	I-drug	sulfate	yes
O	O	,	no
B-drug	B-drug	tranylcypromine	yes
I-drug	I-drug	sulfate	yes
O	O	and	yes
B-drug	B-drug	pargyline	yes
O	O	HC1	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	this	no
O	O	sample	no
O	O	size	no
O	O	is	yes
O	O	too	no
O	O	small	no
O	O	to	no
O	O	allow	no
O	O	for	yes
O	O	any	no
O	O	conclusions	no
O	O	to	no
O	O	be	no
O	O	drawn	no
O	O	regarding	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	rashes	no
O	O	with	yes
O	O	concomitant	no
B-brand	B-brand	AUGMENTIN	yes
I-brand	I-brand	XR	yes
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	use	no
O	O	.	no

O	O	The	no
O	O	introductory	no
O	O	chapter	no
O	O	discusses	no
O	O	the	no
O	O	advantages	no
O	O	and	yes
O	O	disadvantages	no
O	O	of	yes
B-group	B-group	POCs	no
O	O	and	yes
O	O	the	no
O	O	magnitude	no
O	O	and	yes
O	O	prevalence	no
O	O	of	yes
O	O	their	no
O	O	use	no
O	O	.	no

B-drug	B-drug	Theophylline	yes
O	O	:	no
O	O	The	no
O	O	effect	no
O	O	of	yes
O	O	steady-state	no
B-drug	B-drug	fluvoxamine	yes
O	O	l50	no
O	O	mg	yes
O	O	bid	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	Theophylline	yes
O	O	(	no
O	O	375	yes
O	O	mg	yes
O	O	)	no
O	O	as	yes
O	O	442	no
O	O	mg	yes
B-drug	B-drug	aminophylline	yes
O	O	was	no
O	O	evaluated	no
O	O	in	yes
O	O	12	yes
O	O	healthy	no
O	O	non-smoking	no
O	O	,	no
O	O	male	no
O	O	volunteers	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	supplementary	no
O	O	oral	yes
B-drug	B-drug	cobalt	yes
O	O	and	yes
B-drug	B-drug	iron	yes
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	the	no
O	O	interaction	no
O	O	between	yes
O	O	both	no
O	O	at	yes
O	O	the	no
O	O	absorption	no
O	O	site	no
O	O	,	no
O	O	fecal	no
O	O	and	yes
O	O	urinary	yes
O	O	excretion	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	the	no
O	O	retention	no
O	O	of	yes
O	O	these	no
O	O	trace	no
O	O	elements	no
O	O	were	no
O	O	determined	no
O	O	by	no
O	O	using	no
O	O	four	no
O	O	diets	no
O	O	containing	yes
O	O	either	no
O	O	9	yes
O	O	or	no
O	O	63	no
O	O	micrograms/kg	no
O	O	of	yes
O	B-drug	Co	yes
O	O	and	yes
O	O	48	yes
O	O	or	no
O	O	446	no
O	O	mg/kg	no
O	O	of	yes
B-drug	B-drug	Fe	yes
O	O	over	no
O	O	a	yes
O	O	period	no
O	O	of	yes
O	O	19	yes
O	O	days	no
O	O	in	yes
O	O	a	yes
O	O	total	yes
O	O	of	yes
O	O	24	yes
O	O	rats	no
O	O	.	no

O	O	These	no
B-drug	B-drug	fulvestrant	yes
O	O	doses	no
O	O	correspond	no
O	O	to	no
O	O	approximately	no
O	O	2-	no
O	O	,	no
O	O	3-	no
O	O	,	no
O	O	and	yes
O	O	3-fold	no
O	O	the	no
O	O	systemic	no
O	O	exposure	yes
O	O	[	no
O	O	AUC0-30	no
O	O	days	no
O	O	]	no
O	O	achieved	no
O	O	in	yes
O	O	women	yes
O	O	.	no

O	O	This	no
O	O	review	no
O	O	discusses	no
O	O	the	no
O	O	actions	no
O	O	of	yes
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	on	no
O	O	certain	no
O	O	brain	yes
O	O	chemical	yes
O	O	(	no
O	O	i.e.	no
O	O	,	no
O	O	neurotransmitter	no
O	O	)	no
O	O	systems	no
O	O	and	yes
O	O	the	no
O	O	extent	no
O	O	to	no
O	O	which	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	two	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	.	no

B-drug	B-drug	Cholestyramine	yes
O	O	:	no
B-drug	B-drug	Cholestyramine	yes
O	O	binds	no
O	O	both	no
O	B-drug	T4	yes
O	O	and	yes
O	B-drug	T3	yes
O	O	in	yes
O	O	the	no
O	O	intestine	no
O	O	,	no
O	O	thus	no
O	O	impairing	no
O	O	absorption	no
O	O	of	yes
O	O	these	no
B-group	B-group	thyroid	yes
I-group	I-group	hormones	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Adenocard	yes
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	digitalis	yes
O	O	may	no
O	O	be	no
O	O	rarely	no
O	O	associated	no
O	O	with	yes
O	O	ventricular	no
O	O	fibrillation	no
O	O	.	no

B-drug	B-drug	Cisapride	yes

O	O	The	no
O	O	patient	no
O	O	was	no
O	O	also	no
O	O	chronically	no
O	O	receiving	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	levothyroxine	yes
I-drug	I-drug	sodium	yes
O	O	.	no

O	O	Pregnancy	no
O	O	:	no
O	O	Category	no
O	O	X	yes
O	O	:	no
O	O	Use	no
O	O	With	yes
B-drug	B-drug	Ribavirin	yes
O	O	(	no
O	O	see	no
O	O	CONTRAINDICATIONS	no
O	O	)	no
O	O	Significant	no
O	O	teratogenic	no
O	O	and/or	no
O	O	embryocidal	no
O	O	effects	no
O	O	have	no
O	O	been	no
O	O	demonstrated	no
O	O	in	yes
O	O	all	yes
O	O	animal	no
O	O	species	no
O	O	exposed	no
O	O	to	no
B-drug	B-drug	ribavirin	yes
O	O	.	no

O	O	When	no
B-drug	B-drug	Itraconazole	yes
O	O	was	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	or	no
B-group	O	H2antagonists	no
O	O	,	no
O	O	reduced	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	itraconazole	yes
O	O	were	no
O	O	reported	no
O	O	.	no

O	O	.	no

B-drug	B-drug	phenytoin	yes
O	O	;	no

B-drug	B-drug	Azithromycin	yes
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	impact	no
O	O	on	no
O	O	the	no
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	zidovudine	yes
O	O	,	no
O	O	although	no
O	O	it	no
O	O	significantly	no
O	O	decreased	no
O	O	the	no
B-drug	B-drug	zidovudine	yes
O	O	tmax	no
O	O	by	no
O	O	44	yes
O	O	%	no
O	O	and	yes
O	O	increased	no
O	O	the	no
O	O	intracellular	no
O	O	exposure	yes
O	O	to	no
O	O	phosphorylated	yes
B-drug	B-drug	zidovudine	yes
O	O	by	no
O	O	110	no
O	O	%	no
O	O	.	no

O	O	At	yes
O	O	similar	no
O	O	median	no
O	O	follow-up	no
O	O	,	no
O	O	opportunistic	no
O	O	infection	no
O	O	(	no
O	O	OI	no
O	O	)	no
O	O	rates	no
O	O	and	yes
O	O	mortality	no
O	O	were	no
O	O	significantly	no
O	O	lower	no
O	O	in	yes
O	O	the	no
O	O	CHOP-HAART	no
O	O	patients	no
O	O	than	no
O	O	in	yes
O	O	the	no
O	O	CHOP	no
O	O	patients	no
O	O	(	no
O	O	18	yes
O	O	%	no
O	O	vs.	no
O	O	52	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	;	no
O	O	P	yes
O	O	=	no
O	O	0.05	no
O	O	;	no
O	O	and	yes
O	O	38	no
O	O	%	no
O	O	vs.	no
O	O	85	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	;	no
O	O	P	yes
O	O	=	no
O	O	0.001	no
O	O	)	no
O	O	.	no

O	O	If	no
B-brand	B-brand	ProSom	yes
O	O	is	yes
O	O	given	no
O	O	concomitantly	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	acting	yes
O	O	on	no
O	O	the	no
O	O	central	no
O	O	nervous	no
O	O	system	yes
O	O	,	no
O	O	careful	no
O	O	consideration	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	to	no
O	O	the	no
O	O	pharmacology	no
O	O	of	yes
O	O	all	yes
O	O	agents	yes
O	O	.	no

O	O	Patients	no
O	O	taking	no
B-drug	B-drug	Acamprosate	yes
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	antidepressants	no
O	O	more	no
O	O	commonly	no
O	O	reported	no
O	O	both	no
O	O	weight	yes
O	O	gain	no
O	O	and	yes
O	O	weight	yes
O	O	loss	no
O	O	,	no
O	O	compared	no
O	O	with	yes
O	O	patients	no
O	O	taking	no
O	O	either	no
O	O	medication	no
O	O	alone	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	no	yes
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	to	no
O	O	evaluate	no
O	O	potential	no
O	O	drug-drug	no
O	O	interaction	no
O	O	.	no

O	O	No	yes
O	O	well-known	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	glutamic	yes
I-drug	I-drug	acid	yes

O	O	It	no
O	O	was	no
O	O	established	no
O	O	that	no
O	O	both	no
B-group	O	angiotensins	no
O	O	inhibited	no
O	O	gastric	yes
O	O	acid	yes
O	O	secretion	no
O	O	stimulated	no
O	O	by	no
B-drug	B-drug	pentagastrin	yes
O	O	but	no
O	O	not	no
O	O	by	no
B-drug	B-drug	histamine	yes
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
O	O	agents	yes
O	O	which	no
O	O	prolong	no
O	O	ECG	no
O	O	intervals	no
O	O	,	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	drugs	no
O	O	which	no
O	O	prolong	no
O	O	ECG	no
O	O	intervals	no
O	O	,	no
O	O	particularly	no
O	O	QTc	no
O	O	.	no

O	O	Other	no
O	O	interactions	no
O	O	:	no
B-drug	B-drug	Vardenafil	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	(	no
B-drug	O	glucose	yes
O	O	and	yes
B-drug	O	insulin	yes
O	O	concentrations	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	pharmacodynamic	no
O	O	parameters	no
O	O	)	no
O	O	.	no

O	O	Patients	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	TENORMIN	yes
O	O	plus	yes
O	O	a	yes
B-group	O	catecholamine	no
I-group	O	depletor	no
O	O	should	no
O	O	therefore	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	evidence	no
O	O	of	yes
O	O	hypotension	no
O	O	and/or	no
O	O	marked	no
O	O	bradycardia	no
O	O	which	no
O	O	may	no
O	O	produce	no
O	O	vertigo	no
O	O	,	no
O	O	syncope	no
O	O	,	no
O	O	or	no
O	O	postural	no
O	O	hypotension	no
O	O	.	no

B-drug	B-drug	diazoxide	yes
O	O	;	no

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	may	no
O	O	lower	no
B-drug	B-drug	meclofenamate	yes
I-drug	I-drug	sodium	yes
O	O	plasma	yes
O	O	levels	no
O	O	,	no
O	O	possibly	no
O	O	by	no
O	O	competing	no
O	O	for	yes
O	O	protein-binding	no
O	O	sites	no
O	O	.	no

B-drug	B-drug	Gentamicin	yes
O	O	is	yes
O	O	an	no
B-group	B-group	aminoglycoside	no
I-group	I-group	antibiotic	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	a	yes
O	O	wide	no
O	O	variety	no
O	O	of	yes
O	O	infections	no
O	O	caused	no
O	O	by	no
O	O	gram-negative	no
O	O	organisms	no
O	O	,	no
O	O	but	no
O	O	it	no
O	O	is	yes
O	O	potentially	no
O	O	toxic	no
O	O	to	no
O	O	the	no
O	O	kidneys	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	None	no
O	O	known	no
O	O	.	no

O	O	Interactions	no
O	O	attributed	no
O	O	to	no
O	O	the	no
O	O	combined	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	baclofen	yes
O	O	injection	yes
O	O	and	yes
O	O	epidural	no
B-drug	B-drug	morphine	yes
O	O	include	no
O	O	hypotension	no
O	O	and	yes
O	O	dyspnea	no
O	O	.	no

B-group	B-group	Antiarrhythmics	no

B-drug	B-drug	Isocarboxazid	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	to	no
O	O	patients	no
O	O	receiving	no
B-brand	B-brand	Antabuse	yes
O	O	(	no
B-drug	B-drug	disulfiram	yes
O	O	,	no
O	O	Wyeth-Ayerst	no
O	O	Laboratories	no
O	O	)	no
O	O	.	no

O	O	Since	no
B-drug	B-drug	acetaminophen	yes
O	O	in	yes
O	O	high	yes
O	O	doses	no
O	O	has	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	hepatotoxicity	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	acetaminophen	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	,	no
O	O	with	yes
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	patients	no
O	O	.	no

O	O	The	no
O	O	appropriate	no
O	O	doses	no
O	O	for	yes
O	O	this	no
O	O	combination	yes
O	O	,	no
O	O	with	yes
O	O	respect	no
O	O	to	no
O	O	efficacy	no
O	O	and	yes
O	O	safety	no
O	O	,	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	These	no
O	O	observations	no
O	O	are	no
O	O	discussed	no
O	O	in	yes
O	O	reference	no
O	O	to	no
O	O	possible	no
O	O	deleterious	no
O	O	effects	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	pargyline	yes
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	Parkinson	no
O	O	's	no
O	O	Disease	no
O	O	.	no

O	O	There	no
O	O	was	no
O	O	evidence	no
O	O	for	yes
O	O	longitudinal	no
O	O	stability	no
O	O	in	yes
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	everolimus	yes
O	O	during	no
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	the	no
O	O	study	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
O	O	the	no
O	O	combination	yes
O	O	of	yes
O	O	intravenous	yes
B-drug	B-drug	dantrolene	yes
I-drug	I-drug	sodium	yes
O	O	and	yes
B-group	B-group	calcium	yes
I-group	I-group	channel	no
I-group	I-group	blockers	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	verapamil	yes
O	O	,	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	together	no
O	O	during	no
O	O	the	no
O	O	management	no
O	O	of	yes
O	O	malignant	no
O	O	hyperthermia	no
O	O	crisis	no
O	O	until	no
O	O	the	no
O	O	relevance	no
O	O	of	yes
O	O	these	no
O	O	findings	no
O	O	to	no
O	O	humans	no
O	O	is	yes
O	O	established	no
O	O	.	no

B-drug	B-drug	L-glutamine	yes
O	O	has	no
O	O	orphan	no
O	O	drug	yes
O	O	status	no
O	O	for	yes
O	O	this	no
O	O	indication	no
O	O	.	no

O	O	BACKGROUND	no
O	O	:	no
O	O	The	no
O	O	feasibility	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
O	O	concomitant	no
O	O	chemotherapy	no
O	O	and	yes
B-group	B-group	highly	no
I-group	I-group	active	no
I-group	I-group	antiretroviral	no
O	O	therapy	no
O	O	(	no
O	O	HAART	no
O	O	)	no
O	O	is	yes
O	O	still	no
O	O	unknown	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	human	yes
O	O	immunodeficiency	no
O	O	virus	yes
O	O	(	no
O	O	HIV	no
O	O	)	no
O	O	-related	no
O	O	malignancies	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	SULAR	yes
O	O	with	yes
B-drug	B-drug	phenytoin	yes
O	O	or	no
O	O	any	no
O	O	known	no
O	O	CYP3A4	no
O	O	inducer	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	and	yes
O	O	alternative	no
B-group	B-group	antihypertensive	no
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	other	no
O	O	CYP3A4	no
O	O	inhibitors	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	diltiazem	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	with	yes
O	O	transdermal	no
B-drug	B-drug	fentanyl	yes
O	O	may	no
O	O	also	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	fentanyl	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	,	no
O	O	which	no
O	O	could	no
O	O	increase	no
O	O	or	no
O	O	prolong	no
O	O	adverse	no
O	O	drug	yes
O	O	effects	no
O	O	and	yes
O	O	may	no
O	O	cause	no
O	O	serious	no
O	O	respiratory	no
O	O	depression	no
O	O	.	no

O	O	This	no
O	O	information	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	when	no
O	O	changing	no
O	O	from	no
O	O	intravenous	yes
B-drug	B-drug	amiodarone	yes
O	O	to	no
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

B-drug	B-drug	Alcohol	yes
O	O	:	no
B-drug	B-drug	Alcohol	yes
O	O	(	no
O	O	0.5	yes
O	O	g/kg	no
O	O	body	no
O	O	weight	yes
O	O	:	no
O	O	approximately	no
O	O	40	yes
O	O	mL	no
O	O	of	yes
O	O	absolute	yes
B-drug	O	alcohol	yes
O	O	in	yes
O	O	a	yes
O	O	70	yes
O	O	kg	no
O	O	person	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	vardenafil	yes
O	O	plasma	yes
O	O	levels	no
O	O	were	no
O	O	not	no
O	O	altered	no
O	O	when	no
O	O	dosed	no
O	O	simultaneously	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	may	no
O	O	inhibit	no
O	O	both	no
O	O	synthetic	yes
O	O	and	yes
O	O	catabolic	no
O	O	enzymes	yes
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	mechanism	no
O	O	of	yes
O	O	interaction	no
O	O	between	yes
B-drug	B-drug	fenoprofen	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	is	yes
O	O	not	no
O	O	totally	no
O	O	known	no
O	O	,	no
O	O	enzyme	no
O	O	induction	no
O	O	and	yes
O	O	displacement	no
O	O	of	yes
B-drug	B-drug	fenoprofen	yes
O	O	from	no
O	O	plasma	yes
O	O	albumin	yes
O	O	binding	no
O	O	sites	no
O	O	are	no
O	O	possibilities	no
O	O	.	no

O	O	In	yes
O	O	evaluating	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	interactions	no
O	O	among	no
O	O	co-administered	no
O	O	antiepilepsy	no
O	O	drugs	no
O	O	(	no
B-group	B-group	AEDs	no
O	O	)	no
O	O	,	no
O	O	whether	no
O	O	or	no
O	O	not	no
O	O	an	no
B-group	B-group	AED	no
O	O	induces	no
O	O	or	no
O	O	does	no
O	O	not	no
O	O	induce	no
O	O	metabolic	no
O	O	enzymes	yes
O	O	is	yes
O	O	an	no
O	O	important	no
O	O	consideration	no
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	that	no
O	O	increase	no
O	O	gastrointestinal	no
O	O	motility	no
O	O	may	no
O	O	produce	no
O	O	similar	no
O	O	effects	no
O	O	.	no

B-drug	B-drug	Bromocriptine	yes
I-drug	I-drug	mesylate	yes
O	O	may	no
O	O	interact	no
O	O	with	yes
B-group	B-group	dopamine	yes
I-group	I-group	antagonists	no
O	O	,	no
B-group	B-group	butyrophenones	no
O	O	,	no
O	O	and	yes
O	O	certain	no
O	O	other	no
O	O	agents	yes
O	O	.	no

O	O	Inhibition	no
O	O	and	yes
O	O	stimulation	no
O	O	of	yes
O	O	the	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	oxytocin	yes
O	O	on	no
O	O	milk	yes
O	O	ejection	no
O	O	by	no
B-drug	O	vasopressin	yes
O	O	was	no
O	O	demonstrated	no
O	O	.	no

O	O	Accelerated	no
O	O	prothrombin	yes
O	O	time	no
O	O	,	no
O	O	partial	no
O	O	thromboplastin	no
O	O	time	no
O	O	,	no
O	O	and	yes
O	O	platelet	yes
O	O	aggregation	no
O	O	time	no
O	O	;	no

O	O	Care	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	when	no
O	O	using	no
O	O	immunoanalytical	no
O	O	methods	no
O	O	to	no
O	O	measure	no
O	O	plasma	yes
B-drug	B-drug	phenytoin	yes
O	O	concentrations	no
O	O	following	no
B-brand	B-brand	Cerebyx	yes
O	O	administration	no
O	O	.	no

O	O	Organometals	no
O	O	also	no
O	O	compromise	no
O	O	the	no
O	O	limbic	no
O	O	system	yes
O	O	and	yes
O	O	result	no
O	O	in	yes
O	O	deficits	no
O	O	in	yes
O	O	learning	no
O	O	and	yes
O	O	memory	no
O	O	.	no

O	O	Furthermore	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	proposed	no
O	O	that	no
B-drug	B-drug	isoniazid	yes
O	O	resulted	no
O	O	In	yes
O	O	induction	no
O	O	of	yes
O	O	P-450IIE1	no
O	O	in	yes
O	O	the	no
O	O	patients	no
O	O	liver	yes
O	O	which	no
O	O	,	no
O	O	in	yes
O	O	turn	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	greater	no
O	O	proportion	no
O	O	of	yes
O	O	the	no
O	O	ingested	no
B-drug	B-drug	acetaminophen	yes
O	O	being	no
O	O	converted	no
O	O	to	no
O	O	the	no
O	O	toxic	no
O	O	metabolites	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	the	no
O	O	above	no
O	O	data	no
O	O	from	no
O	O	in	yes
O	O	vitro	no
O	O	and	yes
O	O	in	yes
O	O	vivo	no
O	O	studies	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	unlikely	no
O	O	that	no
B-drug	B-drug	alosetron	yes
O	O	will	no
O	O	inhibit	no
O	O	the	no
O	O	hepatic	no
O	O	metabolic	no
O	O	clearance	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	the	no
O	O	major	no
O	O	CYP	no
O	O	enzyme	no
O	O	3A4	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	the	no
O	O	CYP	no
O	O	enzymes	yes
O	O	2D6	no
O	O	,	no
O	O	2C9	no
O	O	,	no
O	O	2C19	no
O	O	,	no
O	O	2E1	no
O	O	,	no
O	O	or	no
O	O	1A2	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	reduced	yes
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	caffeine	yes
O	O	and	yes
O	O	the	no
O	O	prolongation	no
O	O	of	yes
O	O	its	no
O	O	plasma	yes
O	O	half-life	no
O	O	.	no

B-drug	B-drug	Cimetidine	yes
O	O	-	yes
O	O	In	yes
O	O	subjects	no
O	O	who	no
O	O	had	no
O	O	received	no
O	O	21	yes
O	O	days	no
O	O	of	yes
O	O	40	yes
O	O	mg/day	no
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	,	no
O	O	combined	no
O	O	administration	no
O	O	of	yes
O	O	400	yes
O	O	mg/day	no
B-drug	B-drug	cimetidine	yes
O	O	for	yes
O	O	8	yes
O	O	days	no
O	O	resulted	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	citalopram	yes
O	O	AUC	no
O	O	and	yes
O	O	Cmax	no
O	O	of	yes
O	O	43	yes
O	O	%	no
O	O	and	yes
O	O	39	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Methotrexate	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Mexate	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	with	yes
B-drug	B-drug	sulfapyridine	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	affecting	no
O	O	the	no
O	O	liver	yes
O	O	and/or	no
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes

B-drug	B-drug	Norepinephrine	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	enhance	no
O	O	the	no
O	O	adrenergic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	.	no

O	O	A	yes
O	O	possible	no
O	O	interaction	no
O	O	has	no
O	O	been	no
O	O	suggested	no
O	O	with	yes
B-group	B-group	hormonal	no
I-group	I-group	contraceptives	no
O	O	and	yes
O	O	the	no
O	O	herbal	no
O	O	supplement	yes
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	based	no
O	O	on	no
O	O	some	no
O	O	reports	no
O	O	of	yes
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	users	no
O	O	experiencing	no
O	O	breakthrough	no
O	O	bleeding	no
O	O	shortly	no
O	O	after	no
O	O	starting	no
O	O	St.	yes
O	O	Johns	yes
O	O	Wort	yes
O	O	.	no

O	O	In	yes
O	O	an	no
O	O	emergency	yes
O	O	situation	no
O	O	when	no
B-group	O	opioid	no
I-group	O	analgesia	no
O	O	must	no
O	O	be	no
O	O	administered	no
O	O	to	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-brand	B-brand	REVIA	yes
O	O	,	no
O	O	the	no
O	O	amount	no
O	O	of	yes
B-group	B-group	opioid	no
O	O	required	no
O	O	may	no
O	O	be	no
O	O	greater	no
O	O	than	no
O	O	usual	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	resulting	no
O	O	respiratory	no
O	O	depression	no
O	O	may	no
O	O	be	no
O	O	deeper	no
O	O	and	yes
O	O	more	no
O	O	prolonged	no
O	O	.	no

O	O	The	no
O	O	net	no
O	O	effect	no
O	O	of	yes
O	O	these	no
O	O	interactions	no
O	O	is	yes
O	O	summarized	no
O	O	in	yes
O	O	the	no
O	O	following	no
O	O	table	no
O	O	:	no
B-group	B-group	AED	no
I-group	I-group	AED	no
B-brand	B-brand	Felbatol	yes

O	O	In	yes
O	O	these	no
O	O	patients	no
O	O	,	no
O	O	approximately	no
O	O	half	no
O	O	of	yes
O	O	the	no
O	O	CPK	no
O	O	elevations	no
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	within	no
O	O	2	yes
O	O	weeks	no
O	O	and	yes
O	O	half	no
O	O	returned	no
O	O	to	no
O	O	normal	yes
O	O	within	no
O	O	4	yes
O	O	weeks	no
O	O	.	no

O	O	Studies	no
O	O	on	no
O	O	the	no
O	O	mechanism	no
O	O	of	yes
O	O	action	no
O	O	of	yes
B-drug	B-drug	miconazole	yes
O	O	:	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	miconazole	yes
O	O	on	no
O	O	respiration	no
O	O	and	yes
O	O	cell	yes
O	O	permeability	no
O	O	of	yes
O	O	Candida	no
O	O	albicans	no
O	O	.	no

O	O	Concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	should	no
O	O	generally	no
O	O	be	no
O	O	avoided	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Mephenytoin	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Mesantoin	yes
O	O	)	no
O	O	Use	no
O	O	of	yes
B-drug	B-drug	sulfapyridine	yes
O	O	with	yes
O	O	these	no
O	O	medicines	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	of	yes
O	O	these	no
O	O	medicines	no

O	O	Such	no
O	O	patients	no
O	O	may	no
O	O	be	no
O	O	unresponsive	no
O	O	to	no
O	O	the	no
O	O	usual	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	epinephrine	yes
O	O	used	no
O	O	to	no
O	O	treat	no
O	O	allergic	no
O	O	reaction	no
O	O	.	no

O	O	1-	no
O	O	adrenergic	no
O	O	receptor	yes
O	O	antagonism	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	enhance	no
O	O	the	no
O	O	effect	no
O	O	of	yes
O	O	certain	no
B-group	B-group	antihypertensive	no
I-group	I-group	agents	yes
O	O	.	no

O	O	Nephrotoxicity	no
O	O	and	yes
O	O	ototoxicity	no
O	O	were	no
O	O	not	no
O	O	noted	no
O	O	when	no
B-drug	B-drug	ceftazidime	yes
O	O	was	no
O	O	given	no
O	O	alone	no
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	Median	no
O	O	gastric	yes
O	O	pH	yes
O	O	was	no
O	O	significantly	no
O	O	higher	no
O	O	when	no
B-drug	B-drug	indinavir	yes
O	O	was	no
O	O	taken	no
O	O	after	no
B-drug	B-drug	didanosine	yes
O	O	administration	no
O	O	;	no

B-drug	B-drug	carbamazepine	yes
O	O	;	no

O	O	Patients	no
O	O	taking	no
O	O	other	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	of	yes
O	O	CYP450	no
O	O	3A4	no
O	O	,	no
O	O	especially	no
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	and/or	no
O	O	hepatic	no
O	O	impairment	no
O	O	,	no
O	O	may	no
O	O	require	no
O	O	dosage	no
O	O	adjustment	no
O	O	when	no
O	O	starting	no
O	O	or	no
O	O	stopping	no
O	O	concomitantly	no
O	O	administered	no
B-drug	B-drug	diltiazem	yes
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	maintain	no
O	O	optimum	no
O	O	therapeutic	no
O	O	blood	yes
O	O	levels	no
O	O	.	no

O	O	The	no
O	O	initiated	no
O	O	cells	yes
O	O	that	no
O	O	result	no
O	O	from	no
O	O	this	no
O	O	hit	no
O	O	may	no
O	O	vary	no
O	O	from	no
O	O	those	no
O	O	that	no
O	O	demonstrate	no
O	O	very	no
O	O	little	no
O	O	progression	no
O	O	in	yes
O	O	cell	yes
O	O	type	yes
O	O	and	yes
O	O	may	no
O	O	or	no
O	O	may	no
O	O	not	no
O	O	require	no
O	O	exogenous	no
O	O	enhancement	no
O	O	of	yes
O	O	growth	yes
O	O	to	no
O	O	those	no
O	O	that	no
O	O	can	no
O	O	progress	no
O	O	very	no
O	O	rapidly	yes
O	O	to	no
O	O	fully	no
O	O	malignant	no
O	O	behavior	no
O	O	.	no

O	O	Exert	no
O	O	particular	no
O	O	caution	no
O	O	in	yes
O	O	combining	no
B-drug	B-drug	chlorprothixene	yes
O	O	with	yes
O	O	other	no
B-group	B-group	anticholinergic	no
I-group	I-group	drugs	no
O	O	(	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	and	yes
B-group	B-group	antiparkinsonian	no
I-group	I-group	agents	yes
O	O	)	no
O	O	:	no
O	O	Particularly	no
O	O	the	no
O	O	elderly	no
O	O	may	no
O	O	develop	no
O	O	delirium	no
O	O	,	no
O	O	high	yes
O	O	fever	no
O	O	,	no
O	O	severe	no
O	O	obstipation	no
O	O	,	no
O	O	even	no
O	O	ileus	no
O	O	and	yes
O	O	glaucoma	no
O	O	.	no

O	O	Poor	no
O	O	metabolizers	no
O	O	have	no
O	O	higher	no
O	O	than	no
O	O	expected	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	(	no
B-group	B-group	TCAs	no
O	O	)	no
O	O	when	no
O	O	given	no
O	O	usual	no
O	O	doses	no
O	O	.	no

O	O	14C-cholesterol	no
O	O	ester	yes
O	O	fractional	no
O	O	clearance	no
O	O	rate	no
O	O	was	no
O	O	260	no
O	O	%	no
O	O	greater	no
O	O	after	no
B-drug	B-drug	etofibrate	yes
O	O	than	no
O	O	after	no
O	O	placebo	no
O	O	.	no

O	O	The	no
O	O	mean	no
O	O	(	no
O	O	SD	yes
O	O	)	no
O	O	cumulative	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
O	O	immunoreactive	no
B-drug	B-drug	digoxin	yes
O	O	after	no
O	O	concurrent	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	rofecoxib	yes
O	O	or	no
O	O	placebo	no
O	O	was	no
O	O	228.2	no
O	O	(	no
O	O	+/-	no
O	O	30.8	no
O	O	)	no
O	O	and	yes
O	O	235.1	no
O	O	(	no
O	O	+/-	no
O	O	39.1	no
O	O	)	no
O	O	micrograms/120	no
O	O	hours	no
O	O	,	no
O	O	respectively	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	should	no
O	O	be	no
O	O	administered	no
O	O	with	yes
O	O	caution	no
O	O	with	yes
O	O	intranasal	no
B-drug	B-drug	ciclesonide	yes
O	O	.	no

O	O	Since	no
O	O	the	no
O	O	renal	no
O	O	excretion	no
O	O	of	yes
O	O	unchanged	no
B-drug	B-drug	dasatinib	yes
O	O	and	yes
O	O	its	no
O	O	metabolites	no
O	O	is	yes
O	O	4	yes
O	O	%	no
O	O	,	no
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	total	yes
O	O	body	no
O	O	clearance	no
O	O	is	yes
O	O	not	no
O	O	expected	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	renal	no
O	O	insufficiency	no
O	O	.	no

B-group	B-group	Estrogen	no
O	O	,	no
O	O	Oral	yes
B-group	B-group	Contraceptives	no
O	O	:	no
B-group	B-group	Estrogens	yes
O	O	tend	no
O	O	to	no
O	O	increase	no
O	O	serum	yes
O	O	thyroxine-binding	no
O	O	globulin	yes
O	O	(	no
O	O	TBg	no
O	O	)	no
O	O	.	no

O	O	Although	no
O	O	acid-base	no
O	O	and	yes
O	O	electrolyte	yes
O	O	disturbances	no
O	O	were	no
O	O	not	no
O	O	reported	no
O	O	in	yes
O	O	the	no
O	O	clinical	no
O	O	trials	no
O	O	with	yes
B-drug	B-drug	dorzolamide	yes
O	O	,	no
O	O	these	no
O	O	disturbances	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	oral	yes
B-group	B-group	carbonic	yes
I-group	I-group	anhydrase	no
I-group	I-group	inhibitors	no
O	O	and	yes
O	O	have	no
O	O	,	no
O	O	in	yes
O	O	some	no
O	O	instances	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	drug	yes
O	O	interactions	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	toxicity	no
O	O	associated	no
O	O	with	yes
O	O	high-dose	no
B-group	B-group	salicylate	yes
O	O	therapy	no
O	O	)	no
O	O	.	no

O	O	This	no
O	O	is	yes
O	O	also	no
O	O	to	no
O	O	be	no
O	O	considered	no
O	O	when	no
B-drug	B-drug	leflunomide	yes
O	O	treatment	no
O	O	is	yes
O	O	followed	no
O	O	by	no
O	O	such	no
O	O	drugs	no
O	O	without	no
O	O	a	yes
O	O	drug	yes
O	O	elimination	no
O	O	procedure	no
O	O	.	no

O	O	Consequently	no
O	O	,	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	two	no
O	O	isoenzymes	no
O	O	will	no
O	O	be	no
O	O	decreased	no
O	O	when	no
B-brand	B-brand	TRACLEER	yes
O	O	is	yes
O	O	co-administered	no
O	O	.	no

B-drug	B-drug	Heparin	yes
O	O	:	no
O	O	No	yes
O	O	human	yes
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	heparin	yes
O	O	were	no
O	O	conducted	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
O	O	mixing	no
B-brand	B-brand	NovoLog	yes
O	O	with	yes
O	B-group	insulins	no
O	O	of	yes
O	O	animal	no
O	O	source	no
O	O	or	no
B-drug	B-drug	insulin	yes
O	O	preparations	no
O	O	produced	no
O	O	by	no
O	O	other	no
O	O	manufacturers	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

B-drug	B-drug	astemizole	yes
I-drug	I-drug	midazolam	yes
O	O	,	no
B-drug	B-drug	triazolam	yes
I-drug	I-drug	cisapride	yes
I-drug	O	ergot	yes
I-drug	O	derivatives	no
I-drug	B-drug	voriconazole	yes

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	,	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	buspirone	yes
I-drug	I-drug	HCl	yes
O	O	and	yes
B-drug	B-drug	haloperidol	yes
O	O	resulted	no
O	O	in	yes
O	O	increased	no
O	O	serum	yes
B-drug	B-drug	haloperidol	yes
O	O	concentrations	no
O	O	.	no

O	O	The	no
O	O	inhibitory	yes
O	O	potential	no
O	O	of	yes
B-drug	B-drug	ciclesonide	yes
O	O	on	no
O	O	CYP450	no
O	O	isoenzymes	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	prolonged	no
O	O	hot	no
O	O	weather	no
O	O	;	no

O	O	Thus	no
O	O	,	no
O	O	smaller	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	adenosine	yes
O	O	may	no
O	O	be	no
O	O	effective	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
B-drug	B-drug	dipyridamole	yes
O	O	.	no

O	O	Drugs	no
O	O	Prolonging	no
O	O	the	no
O	O	QT/QTc	no
O	O	Interval	no
O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	prescribing	no
B-drug	B-drug	apomorphine	yes
O	O	concomitantly	no
O	O	with	yes
O	O	drugs	no
O	O	that	no
O	O	prolong	no
O	O	the	no
O	O	QT/QTc	no
O	O	interval	no
O	O	.	no

O	O	In	yes
O	O	healthy	no
O	O	subjects	no
O	O	receiving	no
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	1	yes
O	O	gm	no
O	O	daily	no
O	O	)	no
O	O	for	yes
O	O	one	no
O	O	week	no
O	O	,	no
O	O	plasma	yes
B-drug	B-drug	flecainide	yes
O	O	levels	no
O	O	increased	no
O	O	by	no
O	O	about	no
O	O	30	yes
O	O	%	no
O	O	and	yes
O	O	half-life	no
O	O	increased	no
O	O	by	no
O	O	about	no
O	O	10	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	effects	no
B-drug	B-drug	celecoxib	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	and/or	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	glyburide	yes
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-drug	B-drug	tolbutamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	have	no
O	O	been	no
O	O	studied	no
O	O	in	yes
O	O	vivo	no
O	O	and	yes
O	O	clinically	no
O	O	important	no
O	O	interactions	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	found	no
O	O	.	no

B-drug	B-drug	Albuterol	yes
O	O	,	no
B-group	B-group	Antihistamines	no
O	O	,	no
B-group	B-group	antidiabetic	no
I-group	I-group	drugs	no
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	digitalis	yes
O	O	.	no

O	O	Animal	no
O	O	data	no
O	O	indicated	no
O	O	that	no
B-drug	B-drug	bupropion	yes
O	O	may	no
O	O	be	no
O	O	an	no
O	O	inducer	no
O	O	of	yes
O	O	drug-metabolizing	no
O	O	enzymes	yes
O	O	in	yes
O	O	humans	no
O	O	.	no

O	O	600-1800	no

O	O	Age	no
O	O	(	no
O	O	range	no
O	O	,	no
O	O	17-69	no
O	O	years	no
O	O	)	no
O	O	,	no
O	O	weight	yes
O	O	(	no
O	O	range	no
O	O	,	no
O	O	49-106	no
O	O	kg	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	sex	no
O	O	(	no
O	O	65	yes
O	O	men	no
O	O	and	yes
O	O	36	no
O	O	women	yes
O	O	)	no
O	O	were	no
O	O	not	no
O	O	significant	no
O	O	contributors	no
O	O	to	no
O	O	variability	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	,	no
O	O	dosing	no
O	O	should	no
O	O	be	no
O	O	separated	no
O	O	by	no
O	O	2	yes
O	O	hours	no
O	O	.	no

O	O	No	yes
O	O	separate	no
O	O	information	no
O	O	available	no

O	O	Therefore	no
O	O	the	no
O	O	,	no
O	O	combination	yes
O	O	of	yes
B-drug	B-drug	anakinra	yes
O	O	with	yes
O	O	other	no
B-group	B-group	TNF-blocking	no
I-group	I-group	agents	yes
O	O	,	no
O	O	including	no
B-brand	B-brand	HUMIRA	yes
O	O	,	no
O	O	may	no
O	O	also	no
O	O	result	no
O	O	i	yes
O	O	n	yes
O	O	similar	no
O	O	toxicities	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	aliskiren	yes
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	lovastatin	yes
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	valsartan	yes
O	O	,	no
B-drug	B-drug	amlodipine	yes
O	O	,	no
B-drug	B-drug	metformin	yes
O	O	,	no
B-drug	B-drug	celecoxib	yes
O	O	,	no
B-drug	B-drug	atenolol	yes
O	O	,	no
B-drug	B-drug	atorvastatin	yes
O	O	,	no
B-drug	B-drug	ramipril	yes
O	O	or	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	The	no
O	O	onset	no
O	O	of	yes
O	O	neuromuscular	no
O	O	blockade	no
O	O	by	no
B-drug	B-drug	succinylcholine	yes
O	O	was	no
O	O	unaffected	no
O	O	by	no
B-brand	B-brand	BREVIBLOC	yes
O	O	,	no
O	O	but	no
O	O	the	no
O	O	duration	no
O	O	of	yes
O	O	neuromuscular	no
O	O	blockade	no
O	O	was	no
O	O	prolonged	no
O	O	from	no
O	O	5	yes
O	O	minutes	no
O	O	to	no
O	O	8	yes
O	O	minutes	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	concurrently	no
O	O	taking	no
B-group	O	antiseizure	no
I-group	O	medication	no
O	O	and	yes
B-drug	B-drug	Mefloquine	yes
O	O	should	no
O	O	have	no
O	O	the	no
O	O	blood	yes
O	O	level	no
O	O	of	yes
O	O	their	no
B-group	O	antiseizure	no
I-group	O	medication	no
O	O	monitored	no
O	O	and	yes
O	O	the	no
O	O	dosage	no
O	O	adjusted	yes
O	O	appropriately	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	drugs	no
O	O	that	no
O	O	affect	no
O	O	CYP3A4	no
O	O	and/or	no
O	O	Pgp	no
O	O	,	no
O	O	may	no
O	O	modify	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	.	no

O	O	There	no
O	O	is	yes
O	O	no	yes
O	O	clinical	no
O	O	experience	no
O	O	to	no
O	O	date	no
O	O	on	no
O	O	the	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	Femara	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	other	no
B-group	O	anticancer	no
I-group	O	agents	yes
O	O	.	no

O	O	Due	no
O	O	to	no
O	O	wide	no
O	O	interindividual	no
O	O	variability	no
O	O	in	yes
O	O	the	no
O	O	dose	no
O	O	adjustment	no
O	O	required	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	cyclosporine	yes
O	O	concentrations	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	after	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	carvedilol	yes
O	O	therapy	no
O	O	and	yes
O	O	that	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cyclosporine	yes
O	O	be	no
O	O	adjusted	yes
O	O	as	yes
O	O	appropriate	no
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	are	no
O	O	treated	no
O	O	with	yes
B-brand	B-brand	ZYVOX	yes
O	O	and	yes
O	O	concomitant	no
B-group	B-group	serotonergic	no
I-group	I-group	agents	yes
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	observed	no
O	O	for	yes
O	O	signs	no
O	O	and	yes
O	O	symptoms	no
O	O	of	yes
O	O	serotonin	yes
O	O	syndrome	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	cognitive	no
O	O	dysfunction	no
O	O	,	no
O	O	hyperpyrexia	no
O	O	,	no
O	O	hyperreflexia	no
O	O	,	no
O	O	incoordination	no
O	O	)	no
O	O	.	no

B-drug_n	B-drug_n	Misonidazole	yes
O	O	protects	no
O	O	mouse	yes
O	O	tumour	no
O	O	and	yes
O	O	normal	yes
O	O	tissues	no
O	O	from	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	CCNU	yes
O	O	.	no

O	O	Serial	no
O	O	pharmacokinetic	no
O	O	dosing	no
O	O	has	no
O	O	been	no
O	O	proposed	no
O	O	as	yes
O	O	a	yes
O	O	method	yes
O	O	to	no
O	O	accomplish	no
O	O	this	no
O	O	goal	no
O	O	.	no

B-drug	I-drug	clarithromycin	yes
O	O	concentration	no

O	O	Among	no
O	O	494	no
O	O	subjects	no
O	O	who	no
O	O	received	no
B-brand	B-brand	Angiomax	yes
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	and	yes
O	O	were	no
O	O	tested	no
O	O	for	yes
O	O	antibodies	no
O	O	,	no
O	O	2	yes
O	O	subjects	no
O	O	had	no
O	O	treatment-emergent	no
O	O	positive	no
O	B-drug	bivalirudin	yes
O	O	antibody	yes
O	O	tests	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	theophylline	yes
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	citalopram	yes
O	O	was	no
O	O	not	no
O	O	evaluated	no
O	O	.	no

O	O	Safety	no
O	O	and	yes
O	O	effectiveness	no
O	O	in	yes
O	O	children	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Except	no
O	O	in	yes
O	O	life-threatening	no
O	O	situations	no
O	O	,	no
O	O	avoid	no
O	O	this	no
O	O	combination	yes
O	O	.	no

O	O	Evoked	no
O	O	hind	no
O	O	limb	no
O	O	digital	no
O	O	extensor	no
O	O	tension	no
O	O	(	no
O	O	hoof	no
O	O	twitch	no
O	O	)	no
O	O	was	no
O	O	maintained	no
O	O	at	yes
O	O	40	yes
O	O	%	no
O	O	of	yes
O	O	baseline	no
O	O	for	yes
O	O	1	yes
O	O	h	yes
O	O	by	no
B-drug	B-drug	atracurium	yes
O	O	infusion	no
O	O	in	yes
O	O	7	yes
O	O	horses	no
O	O	anaesthetised	no
O	O	with	yes
B-drug	B-drug	halothane	yes
O	O	.	no

B-drug	B-drug	Ritonavir	yes
O	O	-	yes
O	O	Combined	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	ritonavir	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	)	no
O	O	,	no
O	O	both	no
O	O	a	yes
O	O	CYP3A4	no
O	O	substrate	yes
O	O	and	yes
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	escitalopram	yes
O	O	(	no
O	O	20	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	ritonavir	yes
O	O	or	no
B-drug	B-drug	escitalopram	yes
O	O	.	no

O	O	We	no
O	O	investigated	no
O	O	the	no
O	O	effects	no
O	O	of	yes
B-group	O	adenosine	yes
I-group	O	receptor	yes
I-group	O	antagonists	no
O	O	,	no
B-drug	B-drug	caffeine	yes
O	O	,	no
B-drug	B-drug	theophylline	yes
O	O	,	no
B-drug	B-drug_n	8-phenyltheophylline	no
O	O	,	no
O	O	and	yes
B-drug	B-drug_n	8-cyclopentyl-1,3-dipropylxanthine	yes
O	O	(	no
B-brand	B-drug_n	DPCPX	no
O	O	)	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	light/dark	no
O	O	test	yes
O	O	in	yes
O	O	mice	no
O	O	.	no

B-group	B-group	b-Adrenergic	no
I-group	I-group	Blocking	no
I-group	I-group	Agents	yes
O	O	:	no
O	O	Actions	no
O	O	of	yes
O	O	some	no
O	O	of	yes
B-group	B-group	beta-blocking	no
I-group	I-group	agents	yes
O	O	may	no
O	O	be	no
O	O	impaired	no
O	O	when	no
O	O	hypothyroid	no
O	O	patients	no
O	O	become	no
O	O	euthyroid	no
O	O	.	no

O	O	In	yes
O	O	these	no
O	O	trials	no
O	O	,	no
O	O	heart	no
O	O	rate	no
O	O	and	yes
O	O	systolic	no
O	O	blood	yes
O	O	pressure	no
O	O	were	no
O	O	approximately	no
O	O	2-3	no
O	O	bpm	no
O	O	and	yes
O	O	6-8	no
O	O	mm	yes
O	O	Hg	yes
O	O	higher	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	in	yes
O	O	subjects	no
O	O	on	no
O	O	concomitant	no
B-drug	B-drug	theophylline	yes
O	O	compared	no
O	O	with	yes
O	O	the	no
O	O	overall	no
O	O	population	no
O	O	.	no

O	O	(	no
O	O	Both	no
O	O	drugs	no
O	O	were	no
O	O	thus	no
O	O	dosed	no
O	O	to	no
O	O	steady	no
O	O	state	no
O	O	.	no
O	O	)	no

B-drug	B-drug	Efavirenz	yes

O	O	Concomitant	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	thrombolytics	no
O	O	(	no
O	O	eg	no
O	O	,	no
O	O	rt-PA	yes
O	O	or	no
O	B-drug	streptokinase	yes
O	O	)	no
O	O	may	no
O	O	:	no
O	O	-	yes
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	complications	no
O	O	-	yes
O	O	considerably	no
O	O	enhance	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	REFLUDAN	yes
O	O	on	no
O	O	aPTT	no
O	O	prolongation	no

O	O	When	no
B-drug	B-drug	duloxetine	yes
O	O	was	no
O	O	administered	no
O	O	(	no
O	O	at	yes
O	O	a	yes
O	O	dose	no
O	O	of	yes
O	O	60	no
O	O	mg	yes
O	O	BID	no
O	O	)	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
O	O	a	yes
O	O	single	yes
O	O	50-mg	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	,	no
O	O	a	yes
O	O	CYP2D6	no
O	O	substrate	yes
O	O	,	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	desipramine	yes
O	O	increased	no
O	O	3-fold	no
O	O	.	no

B-brand	B-drug	WARFARIN	yes
O	O	:	no
O	O	Co-	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
B-drug	B-drug	cerivastatin	yes
O	O	to	no
O	O	healthy	no
O	O	volunteers	no
O	O	did	no
O	O	not	no
O	O	result	no
O	O	in	yes
O	O	any	no
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	clotting	no
O	O	factor	yes
O	O	VII	yes
O	O	when	no
O	O	compared	no
O	O	to	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	and	yes
O	O	placebo	no
O	O	.	no

O	O	It	no
O	O	would	no
O	O	be	no
O	O	expected	no
O	O	that	no
O	B-group	laxative	no
O	O	use	no
O	O	during	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	would	no
O	O	worsen	no
O	O	the	no
O	O	incidence	no
O	O	or	no
O	O	severity	no
O	O	of	yes
O	O	diarrhea	no
O	O	,	no
O	O	but	no
O	O	this	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Pharmacokinetic	no
O	O	evaluation	no
O	O	of	yes
O	O	the	no
B-drug	B-drug	digoxin-amiodarone	no
O	O	interaction	no
O	O	.	no

O	O	Increasing	no
O	O	the	no
B-drug	B-drug	indinavir	yes
O	O	dose	no
O	O	to	no
O	O	1000	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	does	no
O	O	not	no
O	O	compensate	no
O	O	for	yes
O	O	the	no
O	O	increased	no
B-drug	B-drug	indinavir	yes
O	O	metabolism	no
O	O	due	no
O	O	to	no
B-brand	B-brand	SUSTIVA	yes
O	O	.	no

O	O	Convulsions	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	this	no
O	O	concurrent	no
O	O	use	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	desflurane	yes
O	O	on	no
O	O	the	no
O	O	disposition	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	determined	no
O	O	.	no

B-group	O	Hormonal	no
I-group	B-group	contraceptives	no
O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	Trileptal	yes
O	O	with	yes
O	O	an	no
O	O	oral	yes
B-group	B-group	contraceptive	yes
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	influence	no
O	O	the	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	two	no
O	O	hormonal	no
O	O	components	no
O	O	,	no
B-drug	B-drug	ethinylestradiol	yes
O	O	(	no
O	O	EE	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	levonorgestrel	yes
O	O	(	no
O	O	LNG	no
O	O	)	no
O	O	.	no

B-brand	B-brand	RAPTIVA	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	with	yes
O	O	other	no
B-group	B-group	immunosuppressive	no
I-group	I-group	drugs	no
O	O	.	no

O	O	In	yes
O	O	5	yes
O	O	other	no
O	O	schizophrenic	no
O	O	patients	no
O	O	treated	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	haloperidol	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	,	no
O	O	discontinuation	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	produced	no
O	O	a	yes
O	O	mean	no
O	O	3.3-fold	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	haloperidol	yes
O	O	concentrations	no
O	O	.	no

O	O	When	no
O	O	such	no
O	O	drugs	no
O	O	are	no
O	O	withdrawn	no
O	O	from	no
O	O	a	yes
O	O	patient	no
O	O	receiving	no
B-drug	B-drug	glipizide	yes
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	for	yes
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	.	no

O	O	This	no
O	O	may	no
O	O	be	no
O	O	due	no
O	O	to	no
O	O	an	no
O	O	improved	no
O	O	glucose	yes
O	O	utilization	no
O	O	with	yes
O	O	simultaneous	no
O	O	reduction	yes
O	O	in	yes
B-drug	B-drug	insulin	yes
O	O	requirement	no

B-drug	B-drug	Cyclopropane	no
O	O	or	no
B-group	B-group	halogenated	no
I-group	I-group	hydrocarbon	no
I-group	I-group	anesthetics	no
O	O	increase	no
O	O	cardiac	no
O	O	autonomic	no
O	O	irritability	no
O	O	and	yes
O	O	may	no
O	O	sensitize	no
O	O	the	no
O	O	myocardium	no
O	O	to	no
O	O	the	no
O	O	action	no
O	O	of	yes
O	O	certain	no
O	O	intravenously	no
O	O	administered	no
B-group	B-group	catecholamines	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	dopamine	yes
O	O	.	no

B-drug	B-drug	Esomeprazole	yes
O	O	may	no
O	O	potentially	no
O	O	interfere	no
O	O	with	yes
O	O	CYP2C19	no
O	O	,	no
O	O	the	no
O	O	major	no
B-drug	B-drug	esomeprazole	yes
O	O	metabolizing	no
O	O	enzyme	no
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
B-drug	B-drug	Ketoconazole	yes
O	O	may	no
O	O	inhibit	no
O	O	both	no
O	O	synthetic	yes
O	O	and	yes
O	O	catabolic	no
O	O	enzymes	yes
O	O	of	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	.	no

O	O	*	no
O	O	This	no
O	O	table	no
O	O	is	yes
O	O	not	no
O	O	all	yes
O	O	inclusive	no
O	O	**	no
B-brand	B-brand	VIRACEPT	yes
O	O	may	no
O	O	not	no
O	O	be	no
O	O	effective	no
O	O	due	no
O	O	to	no
O	O	decreased	no
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
O	O	these	no
O	O	agents	yes
O	O	concomitantly	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	allopurinol	yes
O	O	on	no
B-drug	B-drug	didanosine	yes
O	O	pharmacokinetics	no
O	O	in	yes
O	O	subjects	no
O	O	with	yes
O	O	normal	yes
O	O	renal	no
O	O	function	no
O	O	are	no
O	O	not	no
O	O	known	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
B-drug	B-drug	diphenoxylate	yes
O	O	has	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	prolong	no
O	O	the	no
O	O	biological	no
O	O	half-lives	no
O	O	of	yes
O	O	drugs	no
O	O	for	yes
O	O	which	no
O	O	the	no
O	O	rate	no
O	O	of	yes
O	O	elimination	no
O	O	is	yes
O	O	dependent	no
O	O	on	no
O	O	the	no
O	O	microsomal	no
O	O	drug	yes
O	O	metabolizing	no
O	O	enzyme	no
O	O	system	yes
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	-	yes
O	O	In	yes
O	O	subjects	no
O	O	who	no
O	O	had	no
O	O	received	no
O	O	21	yes
O	O	days	no
O	O	of	yes
O	O	40	yes
O	O	mg/day	no
O	O	racemic	yes
B-drug	B-drug	citalopram	yes
O	O	,	no
O	O	combined	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	citalopram	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	(	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
O	O	1	yes
O	O	mg	yes
O	O	)	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
B-drug	B-drug	citalopram	yes
O	O	or	no
B-drug	B-drug	digoxin	yes
O	O	.	no

B-drug	B-drug	Valproic	yes
I-drug	I-drug	Acid	yes
O	O	:	no
O	O	The	no
O	O	mean	no
O	O	steady-state	no
O	O	trough	no
O	O	serum	yes
B-drug	B-drug	valproic	yes
I-drug	I-drug	acid	yes
O	O	concentrations	no
O	O	prior	no
O	O	to	no
O	O	and	yes
O	O	during	no
O	O	concomitant	no
B-drug	B-drug	gabapentin	yes
O	O	administration	no
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	TID	no
O	O	;	no

B-group	B-group	Tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	blunt	no
O	O	the	no
O	O	hypotensive	no
O	O	effect	no
O	O	of	yes
O	O	systemic	no
O	B-drug	clonidine.It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
O	O	the	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	these	no
O	O	agents	yes
O	O	with	yes
B-brand	B-brand	ALPHAGAN	yes
O	I-brand	P	yes
O	O	in	yes
O	O	humans	no
O	O	can	no
O	O	lead	no
O	O	to	no
O	O	resulting	no
O	O	interference	no
O	O	with	yes
O	O	the	no
O	O	IOP	no
O	O	lowering	no
O	O	effect	no
O	O	.	no

O	O	DIAGNOSTIC	yes
O	O	INTERFERENCE	no
O	O	With	yes
O	O	expected	no
O	O	physiologic	no
O	O	effects	no
O	O	:	no
O	O	Blood	yes
O	O	and	yes
O	O	urine	no
O	O	glucose	yes
O	O	levels	no
O	O	(	no
O	O	usually	no
O	O	only	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	a	yes
O	O	predisposition	no
O	O	for	yes
O	O	glucose	yes
O	O	intolerance	no
O	O	)	no
O	O	and	yes
O	O	Serum	yes
O	O	bilirubin	no
O	O	levels	no
O	O	(	no
O	O	by	no
O	O	displacement	no
O	O	from	no
O	O	albumin	yes
O	O	binding	no
O	O	)	no
O	O	and	yes
O	O	Serum	yes
O	O	calcium	yes
O	O	levels	no
O	O	(	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	before	no
O	O	parathyroid-function	no
O	O	tests	no
O	O	are	no
O	O	carried	no
O	O	out	no
O	O	)	no
O	O	and	yes
O	O	Serum	yes
O	O	uric	yes
O	O	acid	yes
O	O	levels	no
O	O	(	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	)	no
O	O	Serum	yes
B-drug	O	magnesium	yes
O	O	,	no
O	O	potassium	yes
O	O	,	no
O	O	and	yes
O	O	sodium	yes
O	O	levels	no
O	O	(	no
O	O	may	no
O	O	be	no
O	O	decreased	no
O	O	;	no

B-drug	B-drug	Anastrozole	yes
O	O	did	no
O	O	not	no
O	O	inhibit	no
O	O	P450	no
O	O	2A6	no
O	O	or	no
O	O	the	no
O	O	polymorphic	no
O	O	P450	no
O	O	2D6	no
O	O	in	yes
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
B-drug	B-drug	oxcarbazepine	yes
O	O	and	yes
B-drug_n	B-drug_n	MHD	no
O	O	induce	no
O	O	a	yes
O	O	subgroup	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A	yes
O	O	family	yes
O	O	(	no
O	O	CYP3A4	no
O	O	and	yes
O	O	CYP3A5	no
O	O	)	no
O	O	responsible	no
O	O	for	yes
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-group	B-group	dihydropyridine	no
I-group	I-group	calcium	yes
I-group	I-group	antagonists	no
O	O	and	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	a	yes
O	O	lower	no
O	O	plasma	yes
O	O	concentration	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Gentamicin	yes
O	O	did	no
O	O	not	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	activity	yes
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	within	no
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	concentrations	no
O	O	tested	no
O	O	(	no
O	O	0.1	no
O	O	to	no
O	O	100	yes
O	O	mug/ml	no
O	O	)	no
O	O	;	no

O	O	Plasma	yes
O	O	concentrations	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	by	no
B-brand	B-brand	CRIXIVAN	yes
O	O	.	no

O	O	Intraventricular	no
O	O	injection	yes
O	O	of	yes
B-drug_n	B-drug_n	beta-endorphin	no
O	O	and	yes
B-drug	B-drug	morphine	yes
O	O	produced	no
O	O	an	no
O	O	inhibition	no
O	O	of	yes
O	O	the	no
O	O	tail-flick	no
O	O	response	no
O	O	to	no
O	O	the	no
O	O	heat	no
O	O	stimulus	no
O	O	in	yes
O	O	rats	no
O	O	.	no

O	O	Interaction	no
O	O	of	yes
B-brand	B-brand	GABITRIL	yes
O	O	with	yes
O	O	Other	no
O	O	Drugs	no
O	O	:	no
B-drug	B-drug	Cimetidine	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	(	no
O	O	800	no
O	O	mg/day	no
O	O	)	no
O	O	to	no
O	O	patients	no
O	O	taking	no
B-drug	B-drug	tiagabine	yes
O	O	chronically	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
B-drug	B-drug	tiagabine	yes
O	O	pharmacokinetics	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	are	no
O	O	examples	no
O	O	of	yes
O	O	substances	no
O	O	that	no
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	and	yes
O	O	susceptibility	no
O	O	to	no
O	O	hypoglycemia	no
O	O	:	no
O	O	oral	yes
B-group	B-group	antidiabetic	no
I-group	I-group	products	no
O	O	,	no
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	disopyramide	yes
O	O	,	no
B-group	B-group	fibrates	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	,	no
B-drug	B-drug	propoxyphene	yes
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-group	B-group	somatostatin	yes
I-group	I-group	analog	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	octreotide	yes
O	O	)	no
O	O	,	no
B-group	B-group	sulfonamide	yes
I-group	I-group	antibiotics	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	the	no
O	O	pharmacodynamic	no
O	O	effect	no
O	O	increased	no
O	O	by	no
O	O	190	yes
O	O	%	no
O	O	(	no
O	O	QTc	no
O	O	increase	no
O	O	over	no
O	O	time	no
O	O	)	no
O	O	and	yes
O	O	by	no
O	O	84	no
O	O	%	no
O	O	(	no
O	O	Maximum	no
O	O	QTc	no
O	O	increase	no
O	O	)	no
O	O	.	no

O	O	Mutagenesis	no
B-brand	B-brand	PEGASYS	yes
O	O	did	no
O	O	not	no
O	O	cause	no
O	O	DNA	yes
O	O	damage	no
O	O	when	no
O	O	tested	no
O	O	in	yes
O	O	the	no
O	O	Ames	no
O	O	bacterial	no
O	O	mutagenicity	no
O	O	assay	no
O	O	and	yes
O	O	in	yes
O	O	the	no
O	O	in	yes
O	O	vitro	no
O	O	chromosomal	no
O	O	aberration	no
O	O	assay	no
O	O	in	yes
O	O	human	yes
O	O	lymphocytes	no
O	O	,	no
O	O	either	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	or	no
O	O	absence	no
O	O	of	yes
O	O	metabolic	no
O	O	activation	no
O	O	.	no

B-drug	B-drug	Ganciclovir	yes
O	O	:	no
O	O	Administration	no
O	O	of	yes
B-brand	B-brand	VIDEX	yes
O	O	2	yes
O	O	hours	no
O	O	prior	no
O	O	to	no
O	O	or	no
O	O	concurrent	no
O	O	with	yes
O	O	oral	yes
B-drug	B-drug	ganciclovir	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	a	yes
O	O	111	yes
O	O	(	no
O	O	114	no
O	O	)	no
O	O	%	no
O	O	increase	no
O	O	in	yes
O	O	the	no
O	O	steady-state	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	didanosine	yes
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	12	yes
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	isoenzyme	no
O	O	,	no
O	O	including	no
O	O	many	no
B-group	B-group	antidepressants	no
O	O	(	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	,	no
B-group	B-group	selective	no
I-group	I-group	serotonin	yes
I-group	I-group	reuptake	no
I-group	I-group	inhibitors	no
O	O	,	no
O	O	and	yes
O	O	others	no
O	O	)	no
O	O	,	no
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	activity	yes
O	O	of	yes
O	O	this	no
O	O	isoenzyme	no
O	O	,	no
O	O	and	yes
O	O	thus	no
O	O	may	no
O	O	make	no
O	O	normal	yes
O	O	metab-olizers	no
O	O	resemble	no
O	O	poor	no
O	O	metabolizers	no
O	O	with	yes
O	O	regard	no
O	O	to	no
O	O	concomitant	no
O	O	therapy	no
O	O	with	yes
O	O	other	no
O	O	drugs	no
O	O	metabolized	no
O	O	by	no
O	O	this	no
O	O	enzyme	no
O	O	system	yes
O	O	,	no
O	O	leading	no
O	O	to	no
O	O	drug	yes
O	O	interactions	no
O	O	.	no

O	O	in	yes
O	O	one	no
O	O	man	no
O	O	,	no
O	O	the	no
O	O	C	yes
O	O	max	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	was	no
O	O	8.1	no
O	O	ng/mL	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	alone	no
O	O	and	yes
O	O	7.2	no
O	O	ng/mL	no
O	O	with	yes
B-drug	B-drug	terfenadine	yes
O	O	plus	yes
B-drug	B-drug	dirithromycin	yes
O	O	.	no

O	O	The	no
O	O	mechanism	no
O	O	(	no
O	O	s	yes
O	O	)	no
O	O	of	yes
O	O	altered	no
O	O	topo	no
O	O	I	yes
O	O	expression	no
O	O	in	yes
O	O	certain	no
O	O	tumor	yes
O	O	types	no
O	O	is	yes
O	O	unknown	no
O	O	,	no
O	O	but	no
O	O	may	no
O	O	be	no
O	O	related	yes
O	O	to	no
O	O	the	no
O	O	central	no
O	O	importance	no
O	O	of	yes
O	O	topoisomerases	no
O	O	in	yes
O	O	proliferating	no
O	O	cell	yes
O	O	functions	no
O	O	(	no
O	O	transcription	no
O	O	,	no
O	O	replication	no
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	aberrant	no
O	O	and	yes
O	O	chronic	no
O	O	activation	no
O	O	of	yes
O	O	these	no
O	O	functions	no
O	O	as	yes
O	O	a	yes
O	O	result	no
O	O	of	yes
O	O	specific	no
O	O	tumorigenic	no
O	O	alterations	no
O	O	.	no

O	O	All	yes
O	O	subjects	no
O	O	received	no
B-drug	B-drug	amprenavir	yes
O	O	(	no
O	O	1,200	no
O	O	mg	yes
O	O	twice	no
O	O	a	yes
O	O	day	no
O	O	)	no
O	O	for	yes
O	O	4	yes
O	O	days	no
O	O	,	no
O	O	followed	no
O	O	by	no
O	O	a	yes
O	O	7-day	no
O	O	washout	no
O	O	period	no
O	O	,	no
O	O	followed	no
O	O	by	no
O	O	either	no
B-drug	B-drug	rifabutin	yes
O	O	(	no
O	O	300	yes
O	O	mg	yes
O	O	once	no
O	O	a	yes
O	O	day	no
O	O	[	no
O	O	QD	no
O	O	]	no
O	O	)	no
O	O	(	no
O	O	cohort	no
O	O	1	yes
O	O	)	no
O	O	or	no
B-drug	B-drug	rifampin	yes
O	O	(	no
O	O	600	yes
O	O	mg	yes
O	O	QD	no
O	O	)	no
O	O	(	no
O	O	cohort	no
O	O	2	yes
O	O	)	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	.	no

O	O	Prospective	no
O	O	,	no
O	O	long-term	no
O	O	studies	no
O	O	on	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	VIOXX	yes
O	O	and	yes
B-brand	B-brand	aspirin	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	.	no

O	O	therefore	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	theoretically	no
O	O	possible	no
O	O	that	no
B-drug	B-drug	lansoprazole	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	drugs	no
O	O	where	no
O	O	gastric	yes
O	O	pH	yes
O	O	is	yes
O	O	an	no
O	O	important	no
O	O	determinant	no
O	O	of	yes
O	O	bioavailability	no
O	O	(	no
O	O	e.g	no
O	O	.	no
B-drug	B-drug	ketoconazole	yes
O	O	,	no
B-drug	B-drug	ampicillin	yes
I-drug	O	esters	yes
O	O	,	no
B-drug	B-drug	iron	yes
O	O	salts	no
O	O	,	no
B-drug	B-drug	digoxin	yes
O	O	)	no
O	O	.	no

O	O	Use	no
O	O	of	yes
B-group	B-group	MAO	no
I-group	I-group	inhibitors	no
O	O	may	no
O	O	cause	no
O	O	an	no
O	O	excessive	no
O	O	increase	no
O	O	in	yes
O	O	blood	yes
O	O	pressure	no
O	O	and	yes
O	O	heart	no
O	O	stimulation	no
O	O	.	no

O	O	Dosage	no
O	O	adjustment	no
O	O	of	yes
B-brand	B-brand	STRATTERA	yes
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	when	no
O	O	coadministered	no
O	O	with	yes
O	O	CYP2D6	no
O	O	inhibitors	no
O	O	,	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	Data	no
O	O	from	no
O	O	a	yes
O	O	randomized	no
O	O	trial	no
O	O	of	yes
B-brand	B-brand	HEXALEN	yes
O	O	and	yes
B-drug	B-drug	cisplatin	yes
O	O	plus	yes
O	O	or	no
O	O	minus	no
B-drug	B-drug	pyridoxine	yes
O	O	in	yes
O	O	ovarian	no
O	O	cancer	no
O	O	indicated	no
O	O	that	no
B-drug	B-drug	pyridoxine	yes
O	O	significantly	no
O	O	reduced	yes
O	O	neurotoxicity	no
O	O	;	no

O	O	May	no
O	O	lead	no
O	O	to	no
O	O	loss	no
O	O	of	yes
O	O	virologic	no
O	O	response	no
O	O	and	yes
O	O	possible	no
O	O	resistance	no
O	O	to	no
B-brand	B-brand	CRIXIVAN	yes
O	O	or	no
O	O	to	no
O	O	the	no
O	O	class	no
O	O	of	yes
B-group	B-group	protease	yes
I-group	I-group	inhibitors	no
O	O	.	no

B-group	B-group	Antineoplastic	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-drug	B-drug	nitrogen	yes
I-drug	I-drug	mustard	yes
O	O	,	no
O	O	etc	no
O	O	.	no
O	O	)	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	concomitantly	no
O	O	only	no
O	O	with	yes
O	O	great	no
O	O	caution	no
O	O	.	no

O	O	These	no
O	O	observations	no
O	O	suggest	no
O	O	that	no
O	O	exogenous	no
O	O	co-factors	no
O	O	could	no
O	O	be	no
O	O	involved	no
O	O	in	yes
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	ARE	no
O	O	.	no

B-group	B-drug	bromelains	no
O	O	;	no

B-group	B-group	Anticholinesterases	no
O	O	(	no
B-drug	O	neostgmine	no
O	O	,	no
B-drug	B-drug	physostigmine	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	lignocaine	yes
O	O	,	no
B-drug	B-drug	quinine	yes
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	can	no
O	O	enhance	no
O	O	toxicity	no
O	O	and	yes
O	O	cause	no
O	O	cardio	no
O	O	respiratory	no
O	O	depression	no
O	O	.	no

O	O	increased	no
O	O	norepinephrine-induced	no
O	O	platel	no
O	O	et	no
O	O	aggregation	no
O	O	;	no

B-drug	B-drug	Vardenafil	yes

O	O	Binding	no
O	O	to	no
O	O	Serum	yes
O	O	Proteins	no
O	O	:	no
O	O	The	no
O	O	following	no
O	O	agents	yes
O	O	may	no
O	O	either	no
O	O	inhibit	no
B-drug	B-drug	levothyroxine	yes
I-drug	I-drug	sodium	yes
O	O	binding	no
O	O	to	no
O	O	serum	yes
O	O	proteins	no
O	O	or	no
O	O	alter	no
O	O	the	no
O	O	concentrations	no
O	O	of	yes
O	O	serum	yes
O	O	binding	no
O	O	proteins	no
O	O	:	no
B-group	B-group	androgens	no
O	O	and	yes
O	O	related	yes
B-group	B-group	anabolic	no
I-group	I-group	hormones	no
O	O	,	no
O	B-drug	asparaginase	yes
O	O	,	no
B-drug	B-drug	clofibrate	yes
O	O	,	no
B-group	B-group	estrogens	yes
O	O	and	yes
B-group	B-group	estrogen-containing	no
I-group	I-group	compounds	no
O	O	,	no
B-drug	B-drug	5-fluorouracil	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-group	B-group	glucocorticoids	no
O	O	,	no
B-drug	B-drug	meclofenamic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	methadone	yes
O	O	,	no
B-drug	B-drug	perphenazine	yes
O	O	,	no
B-drug	B-drug	phenylbutazone	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	,	no
B-group	B-group	salicylates	no
O	O	,	no
B-drug	B-drug	tamoxifen	yes
O	O	.	no

B-drug	B-drug	Paroxetine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	once	no
O	O	daily	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	aprepitant	yes
O	O	,	no
O	O	as	yes
O	O	a	yes
O	O	tablet	no
O	O	formulation	no
O	O	comparable	no
O	O	to	no
O	O	85	no
O	O	mg	yes
O	O	or	no
O	O	170	yes
O	O	mg	yes
O	O	of	yes
O	O	the	no
O	O	capsule	yes
O	O	formulation	no
O	O	,	no
O	O	with	yes
B-drug	B-drug	paroxetine	yes
O	O	20	yes
O	O	mg	yes
O	O	once	no
O	O	daily	no
O	O	,	no
O	O	resulted	no
O	O	in	yes
O	O	a	yes
O	O	decrease	no
O	O	in	yes
O	O	AUC	no
O	O	by	no
O	O	approximately	no
O	O	25	yes
O	O	%	no
O	O	and	yes
O	O	Cmax	no
O	O	,	no
O	O	by	no
O	O	approximately	no
O	O	20	yes
O	O	%	no
O	O	of	yes
O	O	both	no
B-drug	B-drug	aprepitant	yes
O	O	and	yes
B-drug	B-drug	paroxetine	yes
O	O	.	no

B-drug	B-drug	Sumatriptan	yes
O	O	:	no
B-drug	B-drug	Sumatriptan	yes
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	coronary	no
O	O	artery	no
O	O	vasospasm	no
O	O	,	no
O	O	and	yes
O	O	its	no
O	O	effect	no
O	O	could	no
O	O	be	no
O	O	additive	no
O	O	with	yes
B-brand	B-brand	D.H.E	no
O	I-brand	.	no
B-brand	I-brand	45	yes
O	O	(	no
B-drug	B-drug	dihydroergotamine	yes
I-drug	I-drug	mesylate	yes
O	O	)	no
O	O	Injection	yes
O	O	,	no
O	O	USP	yes
O	O	.	no

O	O	It	no
O	O	was	no
O	O	shown	no
O	O	that	no
B-drug_n	B-drug_n	neurotensin	no
O	O	antagonized	no
O	O	evidently	no
O	O	the	no
O	O	antinociceptive	no
O	O	effect	no
O	O	of	yes
B-group	B-drug_n	enkephalins	no
O	O	and	yes
O	O	their	no
O	O	analogue	yes
O	O	.	no

O	O	If	no
O	O	signs	no
O	O	and	yes
O	O	symptoms	no
O	O	suggestive	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	toxicity	no
O	O	occur	no
O	O	when	no
B-drug	B-drug	enoxacin	yes
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	are	no
O	O	given	no
O	O	concomitantly	no
O	O	,	no
O	O	physicians	no
O	O	are	no
O	O	advised	no
O	O	to	no
O	O	obtain	no
O	O	serum	yes
B-drug	B-drug	digoxin	yes
O	O	levels	no
O	O	and	yes
O	O	adjust	no
B-drug	B-drug	digoxin	yes
O	O	doses	no
O	O	appropriately	no
O	O	.	no

B-group	B-group	Antidiabetic	no
I-group	I-group	drugs	no
O	O	(	no
O	O	oral	yes
O	O	agents	yes
O	O	and	yes
B-drug	B-drug	insulin	yes
O	O	)	no
O	O	:	no
O	O	hypoglycemia	no
O	O	or	no
O	O	hyperglycemia	no
O	O	;	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	on	no
O	O	the	no
B-drug	B-drug	warfarin	yes
O	O	requirement	no
O	O	of	yes
O	O	our	no
O	O	patient	no
O	O	appeared	no
O	O	to	no
O	O	be	no
O	O	maximal	no
O	O	5	yes
O	O	to	no
O	O	7	yes
O	O	days	no
O	O	after	no
O	O	the	no
O	O	initiation	no
O	O	of	yes
B-drug	B-drug	rifampin	yes
O	O	and	yes
O	O	extended	yes
O	O	a	yes
O	O	similar	no
O	O	length	no
O	O	of	yes
O	O	time	no
O	O	after	no
B-drug	B-drug	rifampin	yes
O	O	withdrawal	no
O	O	.	no

O	O	The	no
O	O	ratio	no
O	O	between	yes
O	O	the	no
O	O	liver	yes
O	O	weight	yes
O	O	and	yes
O	O	body	no
O	O	weight	yes
O	O	was	no
O	O	found	no
O	O	to	no
O	O	be	no
O	O	lower	no
O	O	in	yes
O	O	the	no
O	O	treated	no
O	O	animals	no
O	O	than	no
O	O	in	yes
O	O	the	no
O	O	control	no
O	O	group	yes
O	O	.	no

O	O	Other	no
O	O	Potentially	no
O	O	Clinically	no
O	O	Significant	no
O	O	Drug	yes
O	O	or	no
O	O	Herbal	no
O	O	Product	no
O	O	Interactions	no
O	O	With	yes
B-brand	O	SUSTIVAb	no

O	O	With	yes
O	O	oral	yes
B-drug	B-drug	dapsone	yes
O	O	treatment	no
O	O	,	no
B-group	B-group	folic	yes
I-group	I-group	acid	yes
I-group	I-group	antagonists	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	pyrimethamine	yes
O	O	have	no
O	O	been	no
O	O	noted	no
O	O	to	no
O	O	possibly	no
O	O	increase	no
O	O	the	no
O	O	likelihood	no
O	O	of	yes
O	O	hematologic	no
O	O	reactions	no

B-drug	B-drug	Ketoconazole	yes
O	O	increased	no
O	O	mean	no
B-drug	B-drug	alosetron	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	by	no
O	O	29	yes
O	O	%	no
O	O	.	no

O	O	Although	no
O	O	the	no
O	O	specific	no
O	O	drug	yes
O	O	interaction	no
O	O	was	no
O	O	not	no
O	O	studied	no
O	O	in	yes
O	O	a	yes
O	O	clinical	no
O	O	trial	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	more	no
O	O	than	no
O	O	50	yes
O	O	episodes	no
O	O	of	yes
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-group	O	antifibrinolytic	no
I-group	O	therapies	no
O	O	(	no
O	O	i.e.	no
O	O	,	no
B-drug	B-drug	tranexamic	yes
I-drug	I-drug	acid	yes
O	O	,	no
B-drug	B-drug	aminocaproic	yes
I-drug	I-drug	acid	yes
O	O	)	no
O	O	and	yes
B-brand	B-brand	NovoSeven	no
O	O	.	no

O	O	Urinary	yes
O	O	excretion	no
O	O	and	yes
O	O	renal	no
O	O	clearance	no
O	O	were	no
O	O	correspondingly	no
O	O	reduced	yes
O	O	.	no

O	O	During	no
O	O	transfer	no
O	O	to	no
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	levels	no
O	O	of	yes
O	O	previously	no
O	O	administered	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	30	yes
O	O	to	no
O	O	50	yes
O	O	%	no
O	O	several	no
O	O	days	no
O	O	after	no
O	O	the	no
O	O	addition	no
O	O	of	yes
O	O	oral	yes
B-drug	B-drug	amiodarone	yes
O	O	.	no

B-drug	B-drug	Ketoconazole	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	ketoconazole	yes
O	O	(	no
O	O	200	yes
O	O	mg/day	no
O	O	for	yes
O	O	14	yes
O	O	days	no
O	O	)	no
O	O	with	yes
O	O	a	yes
O	O	15-mg	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	and	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	by	no
O	O	63	no
O	O	%	no
O	O	and	yes
O	O	77	no
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	.	no

B-brand	B-brand	Survanta	yes
O	O	also	no
O	O	increased	no
O	O	rate	no
O	O	of	yes
O	O	dissolution	no
O	O	,	no
O	O	in	yes
O	O	a	yes
O	O	manner	no
O	O	similar	no
O	O	to	no
B-drug	B-drug_n	sodium	yes
I-drug	I-drug_n	dodecyl	yes
I-drug	I-drug_n	sulfate	yes
O	O	.	no

O	O	Since	no
O	O	drowsiness	no
O	O	may	no
O	O	occur	no
O	O	with	yes
O	O	use	no
O	O	of	yes
O	O	this	no
O	O	drug	yes
O	O	,	no
O	O	patients	no
O	O	should	no
O	O	be	no
O	O	warned	no
O	O	of	yes
O	O	this	no
O	O	possibility	no
O	O	and	yes
O	O	cautioned	no
O	O	against	yes
O	O	driving	no
O	O	a	yes
O	O	car	no
O	O	or	no
O	O	operating	no
O	O	dangerous	no
O	O	machinery	no
O	O	while	no
O	O	taking	no
B-brand	B-brand	Atarax	yes
O	O	.	no

B-drug	B-drug	Dolasetron	yes
I-drug	I-drug	mesylate	yes
O	O	did	no
O	O	not	no
O	O	inhibit	no
O	O	the	no
O	O	antitumor	no
O	O	activity	yes
O	O	of	yes
O	O	four	no
B-group	B-group	chemotherapeutic	no
I-group	I-group	agents	yes
O	O	(	no
B-drug	B-drug	cisplatin	yes
O	O	,	no
B-drug	B-drug	5-fluorouracil	yes
O	O	,	no
B-drug	B-drug	doxorubicin	yes
O	O	,	no
B-drug	B-drug	cyclophosphamide	yes
O	O	)	no
O	O	in	yes
O	O	four	no
O	O	murine	yes
O	O	models	no
O	O	.	no

B-group	B-group	Bisphosphonates	no
O	O	are	no
O	O	known	no
O	O	to	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	use	no
O	O	of	yes
B-group	O	bone-imaging	no
I-group	O	agents	yes
O	O	.	no

O	O	An	no
O	O	additive	no
O	O	hypotensive	no
O	O	effect	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	with	yes
O	O	the	no
O	O	combination	yes
O	O	of	yes
O	O	systemic	no
B-drug	B-drug	clonidine	yes
O	O	and	yes
O	B-group	neuroleptic	no
O	O	therapy	no
O	O	.	no

B-drug	B-drug	Nizatidine	yes
O	O	does	no
O	O	not	no
O	O	inhibit	no
O	O	the	no
O	O	cytochrome	no
O	O	P-450-linked	no
O	O	drug-metabolizing	no
O	O	enzyme	no
O	O	system	yes
O	O	;	no

B-brand	B-brand	Aspirin	yes
O	O	should	no
O	O	be	no
O	O	used	no
O	O	cautiously	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
B-group	B-group	cortico-steroids	no
O	O	in	yes
O	O	patients	no
O	O	suffering	no
O	O	from	no
O	O	hypopro-thrombinemia	no
O	O	.	no

O	O	RATIONALE	no
O	O	:	no
O	O	Stress	no
O	O	and	yes
B-group	B-group	glucocorticoids	no
O	O	facilitate	no
O	O	and	yes
O	O	reinstate	no
B-drug	O	psychostimulant	no
O	O	self-administration	no
O	O	in	yes
O	O	rodents	no
O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
B-group	B-group	NSAIDs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	competitively	no
O	O	inhibit	no
B-drug	B-drug	methotrexate	yes
O	O	accumulation	no
O	O	in	yes
O	O	rabbit	yes
O	O	kidney	yes
O	O	slices	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	Duloxetine	yes
O	O	with	yes
B-drug	B-drug	aluminum-	no
O	O	and	yes
B-drug	B-drug	magnesium-containing	no
B-group	B-group	antacids	no
O	O	(	no
O	O	51	yes
O	O	mEq	no
O	O	)	no
O	O	or	no
B-drug	B-drug	Duloxetine	yes
O	O	with	yes
B-drug	B-drug	famotidine	yes
O	O	,	no
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	rate	no
O	O	or	no
O	O	extent	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	absorption	no
O	O	after	no
O	O	administration	no
O	O	of	yes
O	O	a	yes
O	O	40-mg	no
O	O	oral	yes
O	O	dose	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	indicated	no
O	O	that	no
O	O	the	no
O	O	first	no
O	O	and	yes
O	O	second	no
O	O	contractile	no
O	O	responses	no
O	O	to	no
B-drug_n	B-drug_n	PTX	no
O	O	have	no
O	O	entirely	no
O	O	different	no
O	O	properties	no
O	O	.	no

B-drug	O	Dopamine	yes
O	O	(	no
O	O	DA	no
O	O	)	no
O	O	levels	no
O	O	did	no
O	O	not	no
O	O	differ	no
O	O	significantly	no
O	O	in	yes
O	O	either	no
O	O	striatum	no
O	O	(	no
O	O	STR	no
O	O	)	no
O	O	or	no
O	O	nucleus	no
O	O	accumbens	no
O	O	(	no
O	O	NAC	yes
O	O	)	no
O	O	for	yes
O	O	the	no
B-drug	B-drug	cocaine-treated	no
O	O	animals	no
O	O	to	no
O	O	their	no
O	O	corresponding	no
O	O	saline-treated	no
O	O	controls	no
O	O	.	no

O	O	Other	no
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	grapefruit	no
O	O	juice	no
O	O	with	yes
B-drug	B-drug	cisapride	yes
O	O	increases	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	and	yes
O	O	concomitant	no
O	O	use	no
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	.	no

B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	:	no
O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	Angiotensin	yes
I-group	I-group	Converting	no
I-group	I-group	Enzyme	no
I-group	I-group	(	no
I-group	I-group	ACE	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Similarly	no
O	O	,	no
O	O	the	no
O	O	acute	no
O	O	toxicity	no
O	O	was	no
O	O	also	no
O	O	diminished	no
O	O	by	no
O	O	a	yes
O	O	DMF	no
O	O	of	yes
O	O	0.74	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	careful	no
O	O	monitoring	no
O	O	of	yes
O	O	blood	yes
O	O	glucose	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	these	no
O	O	agents	yes
O	O	are	no
O	O	coadministered	no
O	O	.	no

O	O	Drug-drug	no
O	O	interactions	no
O	O	In	yes
O	O	vitro	no
O	O	studies	no
O	O	using	no
O	O	human	yes
O	O	liver	yes
O	O	microsomes	no
O	O	indicate	no
O	O	that	no
B-drug	B-drug	fenofibrate	yes
O	O	and	yes
B-drug	B-drug_n	fenofibric	yes
I-drug	I-drug_n	acid	yes
O	O	are	no
O	O	not	no
O	O	inhibitors	no
O	O	of	yes
O	O	cytochrome	no
O	O	(	no
O	O	CYP	no
O	O	)	no
O	O	P450	no
O	O	isoforms	no
O	O	CYP3A4	no
O	O	,	no
O	O	CYP2D6	no
O	O	,	no
O	O	CYP2E1	no
O	O	,	no
O	O	or	no
O	O	CYP1A2	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	may	no
O	O	have	no
O	O	their	no
O	O	plasma	yes
O	O	concentration	no
O	O	altered	no
O	O	by	no
B-drug	B-drug	dasatinib	yes
O	O	CYP3A4	no
O	O	Substrates	no
O	O	:	no
B-drug	B-drug	Dasatinib	yes
O	O	is	yes
O	O	a	yes
O	O	time-dependent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP3A4	no
O	O	.	no

O	O	Evidence	no
O	O	for	yes
O	O	reduction	yes
O	O	of	yes
B-drug	B-drug	norepinephrine	yes
O	O	uptake	no
O	O	sites	no
O	O	in	yes
O	O	the	no
O	O	failing	no
O	O	human	yes
O	O	heart	no
O	O	.	no

O	O	metabolizers	no
O	O	.	no

O	O	The	no
O	O	effects	no
O	O	of	yes
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	on	no
B-group	B-drug	clonidines	no
I-group	O	analgesic	no
O	O	actions	no
O	O	are	no
O	O	not	no
O	O	known	no
O	O	.	no

O	O	All	yes
O	O	subjects	no
O	O	received	no
B-drug	B-drug	glipizide	yes
O	O	alone	no
O	O	and	yes
O	O	following	no
O	O	treatment	no
O	O	with	yes
O	O	100	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	fluconazole	yes
O	O	as	yes
O	O	a	yes
O	O	single	yes
O	O	daily	no
O	O	oral	yes
O	O	dose	no
O	O	for	yes
O	O	seven	no
O	O	days	no
O	O	.	no

O	O	Therefore	no
B-brand	B-brand	FORADIL	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	given	no
O	O	together	no
O	O	with	yes
B-group	O	-adrenergic	no
I-group	O	blockers	no
O	O	(	no
O	O	including	no
O	O	eye	yes
O	O	drops	no
O	O	)	no
O	O	unless	no
O	O	there	no
O	O	are	no
O	O	compelling	no
O	O	reasons	no
O	O	for	yes
O	O	their	no
O	O	use	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	deaths	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	rarely	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	terfenadine	yes
O	O	and	yes
B-drug	B-drug	erythromycin	yes
O	O	.	no

O	O	It	no
O	O	reduced	yes
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	deaths	no
O	O	induced	no
O	O	by	no
O	O	nonlethal	no
O	O	(	no
O	O	2	yes
O	O	mg/kg	no
O	O	)	no
O	O	dose	no
O	O	of	yes
B-drug_n	B-drug_n	endotoxin	no
O	O	but	no
O	O	increased	no
O	O	the	no
O	O	number	no
O	O	of	yes
O	O	deaths	no
O	O	induced	no
O	O	by	no
O	O	a	yes
O	O	highly	no
O	O	lethal	no
O	O	dose	no
O	O	(	no
O	O	8	yes
O	O	mg/kg	no
O	O	)	no
O	O	.	no

O	O	and	yes
O	O	phase	no
O	O	3	yes
O	O	(	no
O	O	days	no
O	O	45-52	no
O	O	)	no
O	O	:	no
B-drug	B-drug	cisapride	yes
O	O	10	yes
O	O	mg	yes
O	O	4	yes
O	O	times/day	no
O	O	(	no
O	O	days	no
O	O	45-51	no
O	O	)	no
O	O	plus	yes
B-drug	B-drug	fluoxetine	yes
O	O	20	yes
O	O	mg/day	no
O	O	(	no
O	O	days	no
O	O	45-52	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Digoxin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	tiagabine	yes
O	O	did	no
O	O	not	no
O	O	affect	no
O	O	the	no
O	O	steady-state	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	or	no
O	O	the	no
O	O	mean	no
O	O	daily	no
O	O	trough	no
O	O	serum	yes
O	O	level	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	No	yes
O	O	dose	no
O	O	relationship	no
O	O	has	no
O	O	been	no
O	O	observed	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	may	no
O	O	prevent	no
O	O	the	no
O	O	urinary	yes
O	O	antiseptic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	methenamine	yes
O	O	.	no

O	O	When	no
O	O	administered	no
O	O	concurrently	no
O	O	,	no
O	O	the	no
O	O	following	no
O	O	drugs	no
O	O	may	no
O	O	interact	no
O	O	with	yes
B-drug	B-drug	amphotericin	yes
I-drug	I-drug	B	yes
O	O	:	no
B-group	B-group	Antineoplastic	no
I-group	I-group	agents	yes
O	O	:	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	renal	no
O	O	toxicity	no
O	O	,	no
O	O	bronchospasm	no
O	O	and	yes
O	O	hypotension	no
O	O	.	no

O	O	The	no
O	O	last	no
O	O	4	yes
O	O	chapters	no
O	O	cover	no
O	O	interactions	no
O	O	with	yes
O	O	drugs	no
O	O	and	yes
O	O	laboratory	no
O	O	tests	no
O	O	,	no
O	O	common	yes
O	O	side	no
O	O	effects	no
O	O	,	no
O	O	breast	no
O	O	feeding	no
O	O	,	no
O	O	and	yes
O	O	effective	no
O	O	use	no
O	O	of	yes
B-group	B-group	POCs	no
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	have	no
O	O	previously	no
O	O	received	no
O	O	pelvic/	no
O	O	abdominal	no
O	O	irradiation	no
O	O	are	no
O	O	at	yes
O	O	increased	no
O	O	risk	no
O	O	of	yes
O	O	severe	no
O	O	myelosuppression	no
O	O	following	no
O	O	the	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	CAMPTOSAR	yes
O	O	.	no

O	O	Five	no
O	O	days	no
O	O	of	yes
B-drug	B-drug	dofetilide	yes
O	O	treatment	no
O	O	did	no
O	O	not	no
O	O	significantly	no
O	O	affect	no
O	O	steady-state	no
O	O	pharmacokinetic	no
O	O	variables	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	compared	no
O	O	with	yes
O	O	placebo	no
O	O	;	no

O	O	For	yes
O	O	patients	no
O	O	with	yes
O	O	advanced	no
O	O	HIV	no
O	O	disease	no
O	O	and	yes
O	O	poor-risk	no
O	O	AIDS-related	no
O	O	Kaposi	no
O	O	s	yes
O	O	sarcoma	no
O	O	,	no
B-brand	B-brand	TAXOL	yes
O	O	,	no
O	O	at	yes
O	O	the	no
O	O	recommended	no
O	O	dose	no
O	O	for	yes
O	O	this	no
O	O	disease	no
O	O	,	no
O	O	can	no
O	O	be	no
O	O	initiated	no
O	O	and	yes
O	O	repeated	no
O	O	if	no
O	O	the	no
O	O	neutrophil	no
O	O	count	no
O	O	is	yes
O	O	at	yes
O	O	least	no
O	O	1000	yes
O	O	cells/mm3	no
O	O	.	no

O	O	If	no
O	O	co-administration	no
O	O	is	yes
O	O	essential	yes
O	O	,	no
O	O	close	no
O	O	monitoring	no
O	O	may	no
O	O	be	no
O	O	appropriate	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	the	no
O	O	analgesic	no
O	O	effect	no
O	O	of	yes
B-brand	B-brand	STADOL	yes
I-brand	I-brand	NS	no
O	O	may	no
O	O	be	no
O	O	diminished	no
O	O	when	no
O	O	it	no
O	O	is	yes
O	O	administered	no
O	O	shortly	no
O	O	after	no
B-drug	B-drug	sumatriptan	yes
I-drug	O	nasal	no
O	O	spray	no
O	O	,	no
O	O	but	no
O	O	by	no
O	O	30	yes
O	O	minutes	no
O	O	any	no
O	O	such	no
O	O	reduction	yes
O	O	in	yes
O	O	effect	no
O	O	should	no
O	O	be	no
O	O	minimal	no
O	O	.	no

O	O	Clinical	no
O	O	significance	no
O	O	of	yes
O	O	reduced	yes
B-drug	B-drug	efavirenz	yes
O	O	concentrations	no
O	O	unknown	no
O	O	.	no

B-drug	B-drug	Acetylsalicylic	yes
I-drug	I-drug	acid	yes
O	O	did	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	clearance	no
O	O	(	no
O	O	pharmacokinetics	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	iloprost	yes
O	O	.	no

B-group	B-group	Anticoagulants	no
O	O	predispose	no
O	O	a	yes
O	O	patient	no
O	O	to	no
O	O	bleeding	no
O	O	problems	no
O	O	.	no

O	O	Review	no
O	O	of	yes
O	O	these	no
O	O	case	no
O	O	reports	no
O	O	indicates	no
O	O	that	no
O	O	the	no
O	O	patients	no
O	O	were	no
O	O	mainly	no
O	O	receiving	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	for	yes
O	O	hypertension	no
O	O	and	yes
O	O	that	no
O	O	tests	no
O	O	to	no
O	O	rule	no
O	O	out	no
O	O	decreased	no
O	O	renal	no
O	O	function	no
O	O	secondary	yes
O	O	to	no
O	O	hypertensive	no
O	O	nephropathy	no
O	O	were	no
O	O	not	no
O	O	often	no
O	O	performed	no
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
O	O	CYP1A2	no
O	O	:	no
O	O	Concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	with	yes
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
O	O	an	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP1A2	no
O	O	,	no
O	O	results	no
O	O	in	yes
O	O	approximately	no
O	O	a	yes
O	O	6-fold	no
O	O	increase	no
O	O	in	yes
O	O	AUC	no
O	O	and	yes
O	O	about	no
O	O	a	yes
O	O	2.5-fold	no
O	O	increase	no
O	O	in	yes
O	O	Cmax	no
O	O	of	yes
B-drug	B-drug	duloxetine	yes
O	O	.	no

B-group	B-group	Benzodiazepines	no
O	O	were	no
O	O	administered	no
O	O	to	no
O	O	mice	no
O	O	30	yes
O	O	min	no
O	O	before	no
O	O	applying	no
O	O	the	no
B-group	B-group	analgesic	no
I-group	I-group	drugs	no
O	O	.	no

O	O	We	no
O	O	previously	no
O	O	reported	no
O	O	that	no
O	O	seeds	no
O	O	of	yes
O	O	Artocarpus	no
O	O	integrifolia	no
O	O	(	no
O	O	jackfruit	no
O	O	)	no
O	O	contain	no
O	O	a	yes
O	O	lectin	yes
O	O	,	no
O	O	which	no
O	O	we	no
O	O	call	no
B-drug_n	B-drug_n	jacalin	no
O	O	,	no
O	O	that	no
O	O	is	yes
O	O	both	no
O	O	a	yes
O	O	potent	no
O	O	T	yes
O	O	cell	yes
O	O	mitogen	no
O	O	and	yes
O	O	an	no
O	O	apparently	no
O	O	T	yes
O	O	cell-independent	no
O	O	activator	yes
O	O	of	yes
O	O	human	yes
O	O	B	yes
O	O	cells	yes
O	O	for	yes
O	O	the	no
O	O	secretion	no
O	O	of	yes
B-group	O	immunoglobulins	yes
O	O	.	no

O	O	Thus	no
O	O	in	yes
O	O	order	no
O	O	to	no
O	O	avoid	no
O	O	bleeding	no
O	O	,	no
O	O	reduced	yes
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	heparin	yes
O	O	is	yes
O	O	recommended	no
O	O	during	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	antithrombin	yes
I-drug	I-drug	III	yes
O	O	(	no
O	O	human	yes
O	O	)	no
O	O	.	no

O	O	Phosphate-Binding	no
O	O	Agents	yes
O	O	:	no
O	O	Since	no
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
O	O	also	no
O	O	has	no
O	O	an	no
O	O	effect	no
O	O	on	no
O	O	phosphate	yes
O	O	transport	no
O	O	in	yes
O	O	the	no
O	O	intestine	no
O	O	,	no
O	O	kidneys	no
O	O	and	yes
O	O	bones	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	phosphate-binding	no
O	O	agents	yes
O	O	must	no
O	O	be	no
O	O	adjusted	yes
O	O	in	yes
O	O	accordance	no
O	O	with	yes
O	O	the	no
O	O	serum	yes
O	O	phosphate	yes
O	O	concentration	no
O	O	.	no

O	O	Limited	no
O	O	clinical	no
O	O	experience	no
O	O	indicates	no
O	O	that	no
O	O	requirements	no
O	O	for	yes
O	B-group	volatile	no
O	I-group	inhalation	no
B-group	I-group	anesthetics	no
O	O	are	no
O	O	reduced	yes
O	O	by	no
O	O	30	yes
O	O	to	no
O	O	50	yes
O	O	%	no
O	O	for	yes
O	O	the	no
O	O	first	no
O	O	sixty	no
O	O	(	no
O	O	60	no
O	O	)	no
O	O	minutes	no
O	O	following	no
B-brand	B-brand	ALFENTA	yes
O	O	induction	no
O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	with	yes
B-brand	B-brand	ALFENTA	yes
O	O	can	no
O	O	significantly	no
O	O	inhibit	no
B-brand	B-brand	ALFENTA	yes
O	O	clearance	no
O	O	and	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	prolonged	no
O	O	or	no
O	O	delayed	no
O	O	respiratory	no
O	O	depression	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	this	no
O	O	finding	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	When	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP2D6	no
O	O	,	no
O	O	was	no
O	O	co-administered	no
O	O	with	yes
B-brand	B-brand	BROVANA	yes
O	O	at	yes
O	O	steady-state	no
O	O	,	no
O	O	exposure	yes
O	O	to	no
O	O	either	no
O	O	drug	yes
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	This	no
O	O	effect	no
O	O	has	no
O	O	been	no
O	O	attributed	no
O	O	to	no
O	O	inhibition	no
O	O	of	yes
O	O	renal	no
O	O	prostaglandin	yes
O	O	synthesis	no
O	O	by	no
B-drug	B-drug	ibuprofen	yes
O	O	.	no

O	O	While	no
O	O	additional	no
O	O	research	no
O	O	is	yes
O	O	needed	no
O	O	,	no
O	O	the	no
O	O	initial	no
O	O	clinical	no
O	O	data	no
O	O	in	yes
O	O	kidney	yes
O	O	recipients	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	sirolimus	yes
O	O	,	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	cyclosporine	yes
O	O	or	no
B-drug	B-drug	tacrolimus	yes
O	O	,	no
O	O	might	no
O	O	have	no
O	O	the	no
O	O	potential	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	frequency	no
O	O	of	yes
O	O	rejection	no
O	O	episodes	no
O	O	,	no
O	O	permit	no
O	O	reductions	no
O	O	in	yes
B-drug	B-drug	cyclosporine	yes
O	O	or	no
B-drug	B-drug	tacrolimus	yes
O	O	dosage	no
O	O	,	no
O	O	and	yes
O	O	permit	no
B-group	O	steroid	no
O	O	withdrawal	no
O	O	(	no
O	O	Kelly	no
O	O	,	no
O	O	1999	no
O	O	)	no
O	O	.	no

O	O	The	no
O	O	findings	no
O	O	of	yes
O	O	these	no
O	O	studies	no
O	O	are	no
O	O	summarized	no
O	O	in	yes
O	O	the	no
O	O	following	no
O	O	table	no
O	O	:	no
O	O	Effects	no
O	O	on	no
O	O	steady-state	no
B-drug	B-drug	fexofenadine	yes
O	O	pharmacokinetics	no
O	O	after	no
O	O	7	yes
O	O	days	no
O	O	of	yes
O	O	co-administration	no
O	O	with	yes
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	120	no
O	O	mg	yes
O	O	every	no
O	O	12	yes
O	O	hours	no
O	O	(	no
O	O	two	no
O	O	times	no
O	O	the	no
O	O	recommended	no
O	O	twice	no
O	O	daily	no
O	O	dose	no
O	O	)	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	(	no
O	O	n=24	no
O	O	)	no

B-drug	B-drug	Apraclonidine	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	used	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	MAO	no
I-group	O	inhibitors..	no

B-group	B-group	Corticosteroids	no
O	O	:	no
O	O	A	yes
O	O	relationship	no
O	O	of	yes
O	O	functional	no
O	O	antagonism	no
O	O	exists	no
O	O	between	yes
B-group	B-group	vitamin	yes
I-group	I-group	D	yes
I-group	O	analogues	no
O	O	,	no
O	O	which	no
O	O	promote	no
O	O	calcium	yes
O	O	absorption	no
O	O	,	no
O	O	and	yes
B-group	B-group	corticosteroids	no
O	O	,	no
O	O	which	no
O	O	inhibit	no
O	O	calcium	yes
O	O	absorption	no
O	O	.	no

O	O	No	yes
O	O	formal	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	been	no
O	O	performed	no
O	O	with	yes
B-brand	B-brand	ZEVALIN	yes
O	O	.	no

O	O	In	yes
O	O	patients	no
O	O	receiving	no
B-group	O	nonselective	no
I-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	(	no
B-group	B-group	MAOIs	no
O	O	)	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	selegiline	yes
I-drug	I-drug	hydrochloride	yes
O	O	)	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-group	B-group	serotoninergic	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
B-drug	B-drug	fluvoxamine	yes
O	O	,	no
B-drug	B-drug	paroxetine	yes
O	O	,	no
B-drug	B-drug	sertraline	yes
O	O	,	no
B-drug	B-drug	venlafaxine	yes
O	O	)	no
O	O	,	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	reports	no
O	O	of	yes
O	O	serious	no
O	O	,	no
O	O	sometimes	no
O	O	fatal	no
O	O	,	no
O	O	reactions	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	first	no
O	O	experiment	no
O	O	,	no
O	O	male	no
O	O	adult	yes
O	O	Wistar	no
O	O	rats	no
O	O	were	no
O	O	fasted	no
O	O	for	yes
O	O	12	yes
O	O	h	yes
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	study	no
O	O	with	yes
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-brand	B-brand	aspirin	yes
O	O	and	yes
B-drug	B-drug	fosinopril	yes
I-drug	I-drug	sodium	yes
O	O	,	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
O	O	unbound	no
B-drug	B-drug_n	fosinoprilat	no
O	O	was	no
O	O	not	no
O	O	altered	no
O	O	.	no

O	O	The	no
O	O	toxicity	no
O	O	of	yes
O	O	cadmium	no
O	O	,	no
B-drug	B-drug	zinc	yes
O	O	and	yes
O	O	cadmium/zinc	no
O	O	mixtures	no
O	O	at	yes
O	O	concentrations	no
O	O	ranging	no
O	O	from	no
O	O	1000	yes
O	O	to	no
O	O	50000	no
O	O	microg/l	no
O	O	were	no
O	O	investigated	no
O	O	against	yes
O	O	cercariae	no
O	O	and	yes
O	O	metacercariae	no
O	O	of	yes
O	O	Parorchis	no
O	O	acanthus	no
O	O	obtained	no
O	O	from	no
O	O	the	no
O	O	dog	no
O	O	whelk	no
O	O	Nucella	no
O	O	lapillus	no
O	O	.	no

O	O	The	no
O	O	emerging	no
O	O	roles	no
O	O	of	yes
B-group	B-group	non-nucleoside	no
I-group	I-group	reverse	no
I-group	I-group	transcriptase	no
I-group	I-group	inhibitors	no
O	O	in	yes
B-group	B-group	antiretroviral	no
O	O	therapy	no
O	O	.	no

O	O	The	no
O	O	safety	no
O	O	and	yes
O	O	efficacy	no
O	O	of	yes
B-drug	B-drug	anakinra	yes
O	O	used	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-brand	B-brand	HUMIRA	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Both	no
B-drug_n	B-drug_n	ibogaine	no
O	O	and	yes
B-drug_n	B-drug_n	18-MC	no
O	O	ameliorate	no
O	B-group	opioid	no
O	O	withdrawal	no
O	O	signs	no
O	O	.	no

B-drug	B-drug	Rofecoxib	yes
O	O	did	no
O	O	not	no
O	O	influence	no
O	O	the	no
O	O	plasma	yes
O	O	pharmacokinetics	no
O	O	or	no
O	O	renal	no
O	O	elimination	no
O	O	of	yes
O	O	a	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Resting	no
O	O	membrane	yes
O	O	potential	no
O	O	,	no
O	O	input	no
O	O	impedance	no
O	O	and	yes
O	O	the	no
O	O	proportion	no
O	O	of	yes
O	O	neurons	no
O	O	displaying	no
O	O	transient	no
O	O	outward	no
O	O	rectification	no
O	O	were	no
O	O	each	no
O	O	significantly	no
O	O	altered	no
O	O	for	yes
O	O	neurons	no
O	O	recorded	no
O	O	with	yes
O	O	1	yes
O	O	%	no
O	O	but	no
O	O	not	no
O	O	0.05-0.2	no
O	O	%	no
O	O	biocytin	no
O	O	.	no

B-group	B-group	Anticholinergic	no
I-group	I-group	drugs	no
O	O	may	no
O	O	antagonize	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	that	no
O	O	alter	no
O	O	gastrointestinal	no
O	O	motility	no
O	O	,	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	metoclopramide	yes
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
B-brand	B-brand	FLOLAN	yes
O	O	was	no
O	O	used	no
O	O	with	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	anticoagulants	no
O	O	,	no
O	O	oral	yes
B-group	B-group	vasodilators	no
O	O	,	no
O	O	and	yes
O	O	supplemental	no
B-drug	B-drug	oxygen.In	no
O	O	a	yes
O	O	pharmacokinetic	no
O	O	substudy	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	receiving	no
B-drug	B-drug	furosemide	yes
O	O	or	no
B-drug	B-drug	digoxin	yes
O	O	in	yes
O	O	whom	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	FLOLAN	yes
O	O	was	no
O	O	initiated	no
O	O	,	no
O	O	apparent	no
O	O	oral	yes
O	O	clearance	no
O	O	values	no
O	O	for	yes
B-drug	B-drug	furosemide	yes
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	23	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	digoxin	yes
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	30	yes
O	O	)	no
O	O	were	no
O	O	decreased	no
O	O	by	no
O	O	13	yes
O	O	%	no
O	O	and	yes
O	O	15	yes
O	O	%	no
O	O	,	no
O	O	respectively	no
O	O	,	no
O	O	on	no
O	O	the	no
O	O	second	no
O	O	day	no
O	O	of	yes
O	O	therapy	no
O	O	and	yes
O	O	had	no
O	O	returned	no
O	O	to	no
O	O	baseline	no
O	O	values	no
O	O	by	no
O	O	day	no
O	O	87	no
O	O	.	no

O	O	The	no
O	O	changes	no
O	O	in	yes
O	O	plasma	yes
O	O	levels	no
O	O	were	no
O	O	within	no
O	O	the	no
O	O	range	no
O	O	of	yes
O	O	plasma	yes
O	O	levels	no
O	O	achieved	no
O	O	in	yes
O	O	adequate	no
O	O	and	yes
O	O	well-controlled	no
O	O	clinical	no
O	O	trials	no
O	O	.	no

O	O	.	no

O	O	In	yes
O	O	an	no
O	O	uncontrolled	no
O	O	study	no
O	O	of	yes
O	O	over	no
O	O	200	yes
O	O	patients	no
O	O	with	yes
O	O	congestive	no
O	O	heart	no
O	O	failure	no
O	O	during	no
O	O	which	no
B-drug	B-drug	digoxin	yes
O	O	blood	yes
O	O	levels	no
O	O	were	no
O	O	not	no
O	O	measured	no
O	O	,	no
B-group	O	digitalis	yes
O	O	toxicity	no
O	O	was	no
O	O	not	no
O	O	observed	no
O	O	.	no

B-drug	B-drug	Cyclophosphamide	yes
O	O	used	no
O	O	concurrently	no
O	O	with	yes
B-brand	B-brand	Cerubidine	yes
O	O	may	no
O	O	also	no
O	O	result	no
O	O	in	yes
O	O	increased	no
O	O	cardiotoxicity	no
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	:	no
O	O	The	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	diflunisal	yes
O	O	and	yes
B-drug	B-drug	naproxen	yes
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	plasma	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	naproxen	yes
O	O	,	no
O	O	but	no
O	O	significantly	no
O	O	decreased	no
O	O	the	no
O	O	urinary	yes
O	O	excretion	no
O	O	of	yes
B-drug	B-drug	naproxen	yes
O	O	and	yes
O	O	its	no
B-drug	O	glucuronide	no
O	O	metabolite	yes
O	O	.	no

O	O	Drug	yes
O	O	Class	no
O	O	:	no
O	O	Drug	yes
O	O	Name	no
O	O	Clinical	no
O	O	Comment	no

B-drug	B-drug	phenobarbital	yes
O	O	reduced	yes
O	O	it	no
O	O	by	no
O	O	a	yes
O	O	net	no
O	O	change	no
O	O	of	yes
O	O	6.6	no
O	O	%	no
O	O	(	no
O	O	percentage	no
O	O	increase	no
O	O	in	yes
O	O	FDF	no
O	O	,	no
O	O	8.5	no
O	O	%	no
O	O	)	no
O	O	at	yes
O	O	431	no
O	O	micromol/L	no
O	O	.	no

O	O	No	yes
O	O	clinically	no
O	O	important	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	occurred	no
O	O	when	no
B-brand	B-brand	PRINIVIL	yes
O	O	was	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	propranolol	yes
O	O	or	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	.	no

O	O	Experience	no
O	O	with	yes
B-group	B-group	nonsteroidal	no
I-group	I-group	anti-inflammatory	no
I-group	I-group	drugs	no
O	O	(	no
B-group	B-group	NSAIDs	no
O	O	)	no
O	O	suggests	no
O	O	the	no
O	O	potential	no
O	O	for	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	Drug/Laboratory	no
O	O	Test	yes
O	O	Interactions	no
O	O	The	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	cefepime	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	false-positive	no
O	O	reaction	no
O	O	for	yes
O	O	glucose	yes
O	O	in	yes
O	O	the	no
O	O	urine	no
O	O	when	no
O	O	using	no
O	O	Clinitest	no
O	O	tablets	yes
O	O	.	no

B-drug	B-drug	Furosemide	yes
O	O	:	no
O	O	Clinical	no
O	O	studies	no
O	O	,	no
O	O	as	yes
O	O	well	no
O	O	as	yes
O	O	random	no
O	O	observations	no
O	O	,	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	ibuprofen	yes
O	O	can	no
O	O	reduce	no
O	O	the	no
O	O	natriuretic	yes
O	O	effect	no
O	O	of	yes
B-drug	B-drug	furosemide	yes
O	O	and	yes
B-group	B-group	thiazides	no
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Aminoglutethimide	yes
O	O	diminishes	no
O	O	the	no
O	O	effect	no
O	O	of	yes
B-group	B-group	coumarin	yes
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	effect	no
O	O	of	yes
B-brand	B-brand	ZEBETA	yes
O	O	on	no
O	O	prothrombin	yes
O	O	time	no
O	O	in	yes
O	O	patients	no
O	O	on	no
O	O	stable	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	.	no

O	O	To	no
O	O	avoid	no
O	O	potentiation	no
O	O	,	no
O	O	the	no
O	O	physician	no
O	O	wishing	no
O	O	to	no
O	O	terminate	no
O	O	treatment	no
O	O	with	yes
B-drug	B-drug	Isocarboxazid	yes
O	O	and	yes
O	O	begin	no
O	O	therapy	no
O	O	with	yes
O	O	another	no
O	O	agent	yes
O	O	should	no
O	O	allow	no
O	O	for	yes
O	O	an	no
O	O	interval	no
O	O	of	yes
O	O	10	yes
O	O	days	no
O	O	.	no

O	O	Studies	no
O	O	in	yes
O	O	healthy	no
O	O	volunteers	no
O	O	have	no
O	O	shown	no
O	O	that	no
B-drug	B-drug	Acarbose	yes
O	O	has	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	either	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	or	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	nifedipine	yes
O	O	,	no
B-drug	B-drug	propranolol	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	ranitidine	yes
O	O	.	no

O	O	CONCLUSIONS	no
O	O	:	no
B-drug	B-drug	Sildenafil	yes
O	O	is	yes
O	O	an	no
O	O	effective	no
O	O	first-line	no
O	O	therapy	no
O	O	for	yes
O	O	erectile	no
O	O	dysfunction	no
O	O	in	yes
O	O	men	no
O	O	.	no

B-group	B-group	Monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	such	no
O	O	as	yes
B-drug	B-drug	isocarboxazid	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Marplan	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	phenelzine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Nardil	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	procarbazine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Matulane	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	selegiline	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Eldepryl	yes
O	O	)	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	tranylcypromine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Parnate	yes
O	O	)	no
O	O	:	no
O	O	Using	no
O	O	these	no
O	O	medicines	no
O	O	with	yes
B-drug	B-drug	L-tryptophan	yes
O	O	may	no
O	O	increase	no
O	O	the	no
O	O	chance	no
O	O	of	yes
O	O	side	no
O	O	effects	no
O	O	.	no

O	O	Furthermore	no
O	O	,	no
O	O	whenever	no
O	O	one	no
O	O	of	yes
O	O	these	no
O	O	other	no
O	O	drugs	no
O	O	is	yes
O	O	withdrawn	no
O	O	from	no
O	O	co-therapy	no
O	O	,	no
O	O	an	no
O	O	increased	no
O	O	dose	no
O	O	of	yes
B-group	B-drug	tricyclic	no
I-group	I-drug	antidepressant	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	These	no
O	O	in	yes
O	O	vitro	no
O	O	studies	no
O	O	suggest	no
O	O	that	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	and	yes
B-drug	B-drug	lamivudine	yes
O	O	in	yes
O	O	humans	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	sub-therapeutic	no
O	O	concentrations	no
O	O	of	yes
O	O	active	no
O	O	phosphorylated	yes
B-drug	B-drug	zalcitabine	yes
O	O	,	no
O	O	which	no
O	O	may	no
O	O	lead	no
O	O	to	no
O	O	a	yes
O	O	decreased	no
O	B-group	antiretroviral	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	zalcitabine	yes
O	O	.	no

O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	reactions	no
O	O	such	no
O	O	as	yes
O	O	prolonged	no
O	O	or	no
O	O	increased	no
O	O	sedation	no
O	O	or	no
O	O	respiratory	no
O	O	depression	no
O	O	.	no

O	O	Pancreatic	yes
O	O	content	no
O	O	after	no
O	O	perfusion	no
O	O	did	no
O	O	not	no
O	O	correlate	no
O	O	with	yes
O	O	release	yes
O	O	during	no
O	O	perfusion	no
O	O	.	no

O	O	Patients/Guardians	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	the	no
O	O	following	no
O	O	information	no
O	O	:	no
O	O	i	yes
O	O	.	no

O	O	Epidemiological	no
O	O	studies	no
O	O	of	yes
O	O	the	no
O	O	case-control	no
O	O	and	yes
O	O	cohort	no
O	O	design	no
O	O	that	no
O	O	have	no
O	O	demonstrated	no
O	O	an	no
O	O	association	no
O	O	between	yes
O	O	use	no
O	O	of	yes
B-group	B-group	psychotropic	no
I-group	I-group	drugs	no
O	O	that	no
O	O	interfere	no
O	O	with	yes
O	O	serotonin	yes
O	O	reuptake	no
O	O	and	yes
O	O	the	no
O	O	occurrence	no
O	O	of	yes
O	O	upper	no
O	O	gastrointestinal	no
O	O	bleeding	no
O	O	have	no
O	O	also	no
O	O	shown	no
O	O	that	no
O	O	concurrent	no
O	O	use	no
O	O	of	yes
O	O	an	no
B-group	B-group	NSAID	no
O	O	or	no
B-brand	B-brand	aspirin	yes
O	O	potentiated	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	bleeding	no
O	O	.	no

B-drug	B-drug	Carbamazepine	yes

O	O	Plasma	yes
O	O	concentrations	no
O	O	(	no
O	O	AUC	no
O	O	0-24	no
O	O	hrs	no
O	O	)	no
O	O	of	yes
B-drug	B-drug	erythromycin	yes
O	O	decreased	no
O	O	15	yes
O	O	%	no
O	O	with	yes
O	O	coadministration	no
O	O	of	yes
B-drug	B-drug	loratadine	yes
O	O	relative	no
O	O	to	no
O	O	that	no
O	O	observed	no
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	alone	no
O	O	.	no

O	O	Relative	no
O	O	to	no
O	O	the	no
O	O	general	no
O	O	population	no
O	O	,	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	fluvastatin	yes
O	O	do	no
O	O	not	no
O	O	vary	no
O	O	as	yes
O	O	a	yes
O	O	function	no
O	O	of	yes
O	O	either	no
O	O	age	no
O	O	or	no
O	O	gender	no
O	O	.	no

O	O	Patients	no
O	O	who	no
O	O	are	no
O	O	applying	no
B-brand	B-brand	Panretin	yes
O	O	gel	yes
O	O	should	no
O	O	not	no
O	O	concurrently	no
O	O	use	no
O	O	products	no
O	O	that	no
O	O	contain	no
B-drug	B-drug	DEET	no
O	O	(	no
O	O	N	yes
O	O	,	no
B-drug_n	B-drug	N-diethyl-m-toluamide	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	common	yes
O	O	component	yes
O	O	of	yes
O	O	insect	no
O	O	repellent	no
O	O	products	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Alcohol	yes
O	O	,	no
B-group	B-group	barbiturates	no
O	O	,	no
O	O	or	no
B-group	B-group	narcotics	no
O	O	:	no
O	O	Potentiation	no
O	O	of	yes
O	O	otthostatic	no
O	O	hypotension	no
O	O	may	no
O	O	occur	no

O	O	The	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	or	no
O	O	other	no
B-group	B-group	central	no
I-group	I-group	nervous	no
I-group	I-group	system	yes
I-group	I-group	depressants	no
O	O	may	no
O	O	have	no
O	O	an	no
O	O	additive	no
O	O	effect	no
O	O	.	no

B-drug	B-drug	Fluconazole	yes

O	O	Therefore	no
O	O	,	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	in	yes
O	O	patients	no
O	O	to	no
O	O	avoid	no
O	O	drug	yes
O	O	toxicity	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	if	no
O	O	concomitant	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	agents	yes
O	O	is	yes
O	O	indicated	no
O	O	,	no
O	O	they	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	with	yes
O	O	caution	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	patients	no
O	O	serum	yes
O	O	potassium	yes
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	frequently	no
O	O	.	no

B-drug	B-drug	Nelfinavir	yes

O	O	The	no
O	O	results	no
O	O	generated	no
O	O	to	no
O	O	date	no
O	O	in	yes
O	O	clinical	no
O	O	pharmacokinetic	no
O	O	studies	no
O	O	with	yes
B-drug	B-drug	fluvastatin	yes
O	O	thus	no
O	O	support	no
O	O	its	no
O	O	use	no
O	O	in	yes
O	O	a	yes
O	O	broad	no
O	O	population	no
O	O	of	yes
O	O	hypercholesterolaemic	no
O	O	patients	no
O	O	.	no

B-drug	B-drug	Ritonavir	yes
O	O	significantly	no
O	O	prolonged	no
O	O	the	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	vardenafil	yes
O	O	to	no
O	O	26	yes
O	O	hours	no
O	O	.	no

O	O	In	yes
O	O	separate	no
O	O	studies	no
O	O	of	yes
O	O	patients	no
O	O	receiving	no
O	O	maintenance	no
O	O	doses	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	,	no
B-drug	B-drug	hydrochlorothiazide	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	digoxin	yes
O	O	,	no
B-drug	B-drug	irbesartan	yes
O	O	administration	no
O	O	for	yes
O	O	7	yes
O	O	days	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacodynamics	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	prothrombin	yes
O	O	time	no
O	O	)	no
O	O	or	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	oxyphenbutazone	yes
O	O	and	yes
B-group	B-group	androgens	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	elevated	no
O	O	serum	yes
O	O	levels	no
O	O	of	yes
B-drug	B-drug	oxyphenbutazone	yes
O	O	.	no

O	O	Potentiation	no
O	O	occurs	no
O	O	with	yes
B-drug	O	ganglionic	no
O	O	or	no
B-group	B-group	peripheral	no
I-group	I-group	adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	drugs	no
O	O	.	no

O	O	The	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	saquinavir	yes
O	O	is	yes
O	O	mediated	no
O	O	by	no
O	O	cytochrome	no
O	O	P450	no
O	O	,	no
O	O	with	yes
O	O	the	no
O	O	specific	no
O	O	isoenzyme	no
O	O	CYP3A4	no
O	O	responsible	no
O	O	for	yes
O	O	90	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	hepatic	no
O	O	metabolism	no
O	O	.	no

O	O	Inhibitors	no
O	O	of	yes
B-drug	B-drug	CYP3A4-Eplerenone	no
O	O	metabolism	no
O	O	is	yes
O	O	predominantly	no
O	O	mediated	no
O	O	via	no
O	O	CYP3A4	no
O	O	.	no

O	O	Like	yes
B-drug	B-drug	isoflurane	yes
O	O	,	no
B-drug	B-drug	desflurane	yes
O	O	does	no
O	O	not	no
O	O	predispose	no
O	O	to	no
O	O	premature	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	in	yes
O	O	the	no
O	O	presence	no
O	O	of	yes
O	O	exogenously	no
O	O	infused	no
B-drug	B-drug	epinephrine	yes
O	O	in	yes
O	O	swine	no
O	O	.	no

O	O	(	no
O	O	May	no
O	O	inhibit	no
O	O	gastrointestinal	no
O	O	absorption	no
O	O	of	yes
O	O	the	no
B-group	B-group	thiazide	no
I-group	I-group	diuretics	no
O	O	;	no

O	O	No	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
B-brand	B-brand	SUSTIVA	yes
O	O	is	yes
O	O	recommended	no
O	O	when	no
O	O	given	no
O	O	with	yes
B-drug	B-drug	clarithromycin	yes
O	O	.	no

O	O	By	no
O	O	contrast	no
O	O	,	no
B-drug	B-drug_n	spermidine	yes
O	O	(	no
O	O	1	yes
O	O	mM	yes
O	O	)	no
O	O	and	yes
B-drug	B-drug_n	putrescine	yes
O	O	(	no
O	O	1	yes
O	O	mM	yes
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	translocation	no
O	O	when	no
O	O	added	no
O	O	alone	no
O	O	.	no

B-group	B-group	Antidepressants	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	data	no
O	O	indicate	no
O	O	that	no
O	B-drug	nefazodone	yes
O	O	inhibits	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	cisapride	yes
O	O	,	no
O	O	which	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increase	no
O	O	in	yes
O	O	plasma	yes
B-drug	B-drug	cisapride	yes
O	O	levels	no
O	O	and	yes
O	O	prolongation	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	interval	no
O	O	on	no
O	O	the	no
O	O	ECG	no
O	O	.	no

O	O	In	yes
O	O	this	no
O	O	study	no
O	O	we	no
O	O	investigated	no
O	O	whether	no
O	O	also	no
B-drug	B-drug	glycine	yes
O	O	fulfils	no
O	O	the	no
O	O	function	no
O	O	as	yes
O	O	co-activator	no
O	O	in	yes
O	O	glutamatergic	no
O	O	activation	no
O	O	of	yes
O	O	NMDA	yes
O	O	receptors	no
O	O	in	yes
O	O	the	no
O	O	neuronal	no
O	O	apparatus	no
O	O	of	yes
O	O	spontaneous	no
O	O	motility	no
O	O	in	yes
O	O	chick	no
O	O	embryos	no
O	O	.	no

O	O	Treatment	no
O	O	of	yes
O	O	RAS-3T3	no
O	O	cells	yes
O	O	with	yes
O	O	nucleophosmin/B23	no
O	O	antisense	no
O	O	oligomer	no
O	O	significantly	no
O	O	potentiated	no
O	O	the	no
O	O	apoptosis	no
O	O	induced	no
O	O	by	no
O	O	serum	yes
O	O	deprivation	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	when	no
O	O	addiction	no
O	O	is	yes
O	O	defined	no
O	O	as	yes
O	O	compulsion	no
O	O	,	no
O	O	loss	no
O	O	of	yes
O	O	control	no
O	O	and	yes
O	O	continued	no
O	O	use	no
O	O	in	yes
O	O	spite	no
O	O	of	yes
O	O	adverse	no
O	O	consequences	no
O	O	,	no
B-drug	B-drug	cocaine	yes
O	O	drug	yes
O	O	hunger	no
O	O	can	no
O	O	be	no
O	O	seen	no
O	O	as	yes
O	O	an	no
O	O	agent	yes
O	O	of	yes
O	O	addictive	no
O	O	disease	no
O	O	.	no

O	O	Micro-dosed	no
B-drug	B-drug	Progesterone	yes
O	O	Preparations	no
O	O	:	no
O	O	Micro-dosed	no
B-drug	B-drug	progesterone	yes
O	O	preparations	no
O	O	(	no
O	O	minipills	no
O	O	that	no
O	O	do	no
O	O	not	no
O	O	contain	no
O	O	an	no
B-group	B-group	estrogen	no
O	O	)	no
O	O	may	no
O	O	be	no
O	O	an	no
O	O	inadequate	no
O	O	method	yes
O	O	of	yes
O	O	contraception	no
O	O	during	no
B-brand	B-brand	Accutane	yes
O	O	therapy	no
O	O	.	no

O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	NUROMAX	yes
O	O	before	no
B-drug	B-drug	succinylcholine	yes
O	O	to	no
O	O	attenuate	no
O	O	some	no
O	O	of	yes
O	O	the	no
O	O	side	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	succinylcholine	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	studied	no
O	O	.	no

O	O	Drug-drug	no
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	Mefloquine	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	explored	no
O	O	in	yes
O	O	detail	no
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no

B-drug	B-drug	Dopamine-induced	no
O	O	renal	no
O	O	and	yes
O	O	mesenteric	no
O	O	vasodilation	no
O	O	is	yes
O	O	not	no
O	O	antagonized	no
O	O	by	no
O	O	either	no
B-drug	O	alpha-	no
O	O	or	no
B-group	B-group	beta-adrenergic	no
I-group	B-drug	blocking	no
I-group	I-drug	agents	yes
O	O	.	no

O	O	These	no
O	O	results	no
O	O	suggest	no
O	O	that	no
O	O	acute	no
O	O	dosing	no
O	O	with	yes
B-drug	B-drug	clozapine	yes
O	O	would	no
O	O	not	no
O	O	affect	no
O	O	behaviors	no
O	O	most	no
O	O	closely	no
O	O	associated	no
O	O	with	yes
B-drug_n	B-drug_n	PCP	yes
O	O	intoxication	no
O	O	.	no

O	O	In	yes
O	O	clinical	no
O	O	trials	no
O	O	,	no
O	O	similar	no
O	O	changes	no
O	O	in	yes
B-drug	B-drug	carbamazepine	yes
O	O	and	yes
B-drug	B-drug_n	carbamazepine	yes
I-drug	I-drug_n	epoxide	no
O	O	were	no
O	O	seen	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	it	no
O	O	has	no
O	O	been	no
O	O	established	no
O	O	that	no
B-drug	B-drug	acitretin	yes
O	O	interferes	no
O	O	with	yes
O	O	the	no
O	O	contraceptive	yes
O	O	effect	no
O	O	of	yes
B-drug	O	microdosed	no
I-drug	B-drug	progestin	no
O	O	minipill	no
O	O	preparations	no
O	O	.	no

B-drug	B-drug	quinidine	yes
O	O	;	no

O	O	Statistically	no
O	O	significant	no
O	O	changes	no
O	O	in	yes
O	O	prothrombin	yes
O	O	and	yes
O	O	partial	no
O	O	thromboplastin	no
O	O	times	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	normal	yes
O	O	volunteers	no
O	O	.	no

O	O	Persons	no
O	O	taking	no
O	O	most	no
B-group	B-group	antibiotics	no
O	O	,	no
B-drug	B-drug	methotrexate	yes
O	O	and	yes
B-drug	B-drug	pyrimethamine	yes
O	O	invalidate	no
B-drug	B-drug	folic	yes
I-drug	I-drug	acid	yes
O	O	and	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B12	yes
O	O	diagnostic	yes
O	O	blood	yes
O	O	assays	no
O	O	.	no

O	O	Other	no
O	O	plasma	yes
O	O	proteins	no
O	O	may	no
O	O	be	no
O	O	increased	no
O	O	(	no
O	O	angiotensinogen/renin	no
O	O	substrate	yes
O	O	,	no
B-drug_n	O	alpha-1-antitrypsin	yes
O	O	,	no
B-drug	O	ceruloplasmin	no
O	O	)	no
O	O	.	no

O	O	use	no
O	O	caution	no
O	O	.	no

O	O	DRUG/LABORATORY	no
O	O	TEST	yes
O	O	INTERACTIONS	no
O	O	:	no
O	O	EFFECT	no
O	O	ON	no
O	O	BLOOD	yes
O	O	COAGULATION	yes
B-drug	B-drug	Ketoprofen	yes
O	O	decreases	no
O	O	platelet	yes
O	O	adhesion	yes
O	O	and	yes
O	O	aggregation	no
O	O	.	no

O	O	Even	no
O	O	when	no
O	O	an	no
B-group	B-group	aminoglycoside	no
O	O	and	yes
O	O	a	yes
B-group	B-group	penicillin-type	no
I-group	O	drug	yes
O	O	are	no
O	O	administered	no
O	O	separately	no
O	O	by	no
O	O	different	no
O	O	routes	no
O	O	,	no
O	O	a	yes
O	O	reduction	yes
O	O	in	yes
B-group	B-group	aminoglycoside	no
O	O	serum	yes
O	O	half-life	no
O	O	or	no
O	O	serum	yes
O	O	levels	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	impaired	no
O	O	renal	no
O	O	function	no
O	O	and	yes
O	O	in	yes
O	O	some	no
O	O	patients	no
O	O	with	yes
O	O	normal	yes
O	O	renal	no
O	O	function	no
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	administration	no
O	O	of	yes
B-group	B-group	quinolones	no
O	O	with	yes
B-group	B-group	antacids	no
O	O	containing	yes
B-drug	B-drug	calcium	yes
O	O	,	no
B-drug	B-drug	magnesium	yes
O	O	,	no
O	O	or	no
B-drug	B-drug	aluminum	yes
O	O	;	no

O	O	Substances	no
O	O	that	no
O	O	are	no
O	O	potent	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP3A4	no
O	O	activity	yes
O	O	(	no
O	O	eg	no
O	O	,	no
B-drug	B-drug	ketoconazole	yes
O	O	and	yes
B-drug	B-drug	itraconazole	yes
O	O	)	no
O	O	decrease	no
B-drug	B-drug	gefitinib	yes
O	O	metabolism	no
O	O	and	yes
O	O	increase	no
B-drug	B-drug	gefitinib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	:	no
O	O	concurrent	no
O	O	use	no
O	O	may	no
O	O	blunt	no
O	O	the	no
O	O	response	no
O	O	to	no
B-drug	B-drug	arbutamine	yes
O	O	.	no

O	O	2	yes
O	O	.	no

B-drug	B-drug	Rifampin	yes
O	O	:	no
O	O	Co-administration	no
O	O	of	yes
B-brand	B-brand	VIOXX	yes
O	O	with	yes
B-drug	B-drug	rifampin	yes
O	O	600	yes
O	O	mg	yes
O	O	daily	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inducer	no
O	O	of	yes
O	O	hepatic	no
O	O	metabolism	no
O	O	,	no
O	O	produced	no
O	O	an	no
O	O	approximate	no
O	O	50	yes
O	O	%	no
O	O	decrease	no
O	O	in	yes
B-drug	B-drug	rofecoxib	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	Certain	no
O	O	endocrine	no
O	O	and	yes
O	O	liver	yes
O	O	function	no
O	O	tests	no
O	O	may	no
O	O	be	no
O	O	affected	no
O	O	by	no
B-group	B-group	estrogen-containing	no
I-group	O	oral	yes
I-group	B-group	contraceptives	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	with	yes
O	O	simultaneous	no
O	O	use	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	and	yes
O	O	other	no
O	O	similar	no
O	O	pharmacologic	no
O	O	agents	yes

B-brand	B-brand	Aspirin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	low-dose	no
B-brand	B-brand	aspirin	yes
O	O	with	yes
B-brand	B-brand	VIOXX	yes
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	an	no
O	O	increased	no
O	O	rate	no
O	O	of	yes
O	O	GI	no
O	O	ulceration	no
O	O	or	no
O	O	other	no
O	O	complications	no
O	O	,	no
O	O	compared	no
O	O	to	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	VIOXX	yes
O	O	alone	no
O	O	.	no

O	O	Although	no
O	O	additional	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	have	no
O	O	not	no
O	O	been	no
O	O	conducted	no
O	O	,	no
O	O	the	no
O	O	most	no
O	O	common	yes
O	O	medications	no
O	O	used	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	anagrelide	yes
O	O	in	yes
O	O	clinical	no
O	O	trials	no
O	O	were	no
B-brand	B-brand	aspirin	yes
O	O	,	no
B-drug	B-drug	acetaminophen	yes
O	O	,	no
B-drug	B-drug	furosemide	yes
O	O	,	no
B-drug	B-drug	iron	yes
O	O	,	no
B-drug	B-drug	ranitidine	yes
O	O	,	no
B-drug	B-drug	hydroxyurea	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	allopurinol	yes
O	O	.	no

O	O	Drug	yes
O	O	Class	no
O	O	:	no
O	O	Drug	yes
O	O	Name	no
O	O	Clinical	no
O	O	Comment	no

B-brand	B-brand	VIRACEPT	yes
O	O	and	yes
B-drug	B-drug	rifampin	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	coadministered	no
O	O	.	no

O	O	Potential	no
B-drug	B-drug	Terfenadine	yes
O	O	,	no
B-drug	B-drug	Astemizole	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	Cisapride	yes
O	O	Interactions	no

O	O	The	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	praziquantel	yes
O	O	were	no
O	O	unchanged	no
O	O	following	no
O	O	coadministration	no
O	O	with	yes
B-drug	B-drug	albendazole	yes
O	O	(	no
O	O	400	yes
O	O	mg	yes
O	O	)	no
O	O	.	no

O	O	-	yes
O	O	Reduced	yes
O	O	serum	yes
O	O	folate	yes
O	O	concentration	no

O	O	Concurrent	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	dyphylline	yes
O	O	and	yes
B-drug	B-drug	probenecid	yes
O	O	,	no
O	O	which	no
O	O	competes	no
O	O	for	yes
O	O	tubular	no
O	O	secretion	no
O	O	,	no
O	O	has	no
O	O	been	no
O	O	shown	no
O	O	to	no
O	O	increase	no
O	O	the	no
O	O	plasma	yes
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	dyphylline	yes
O	O	.	no

B-group	O	H-2	no
I-group	O	Antagonists	no
O	O	:	no
O	O	In	yes
O	O	studies	no
O	O	with	yes
O	O	human	yes
O	O	volunteers	no
O	O	,	no
O	O	co-administration	no
O	O	of	yes
B-drug	B-drug	cimetidine	yes
O	O	or	no
B-drug	B-drug	ranitidine	yes
O	O	with	yes
B-drug	B-drug	ibuprofen	yes
O	O	had	no
O	O	no	yes
O	O	substantive	no
O	O	effect	no
O	O	on	no
B-drug	B-drug	ibuprofen	yes
O	O	serum	yes
O	O	concentrations	no
O	O	.	no

B-drug	B-drug	dextran	yes
O	O	;	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	administering	no
B-drug	B-drug	nabumetone	yes
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	since	no
O	O	interactions	no
O	O	have	no
O	O	been	no
O	O	seen	no
O	O	with	yes
O	O	other	no
B-group	B-group	NSAIDs	no
O	O	.	no

O	O	Drugs	no
O	O	that	no
O	O	reportedly	no
O	O	may	no
O	O	increase	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	response	no
O	O	,	no
O	O	ie	no
O	O	,	no
O	O	increased	no
O	O	prothrombin	yes
O	O	response	no
O	O	,	no
O	O	in	yes
O	O	man	no
O	O	include	no
O	O	:	no
B-drug	B-drug	alcohol*	no
O	O	;	no
B-drug	B-drug	allopurinol	yes
O	O	;	no
B-drug	B-drug	aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	;	no
B-drug	B-drug	amiodarone	yes
O	O	;	no
B-group	B-group	anabolic	no
I-group	I-group	steroids	no
O	O	;	no
B-group	B-group	antibiotics	no
O	O	;	no
B-group	B-drug	bromelains	no
O	O	;	no
B-drug	B-drug	chloral	yes
O	O	hydrate*	no
O	O	;	no
B-drug	B-drug	chlorpropamide	yes
O	O	;	no
B-drug	B-drug	chymotrypsin	no
O	O	;	no
B-drug	B-drug	cimetidine	yes
O	O	;	no
B-drug	B-drug	cinchophen	no
O	O	;	no
B-drug	B-drug	clofibrate	yes
O	O	;	no
B-drug	B-drug	dextran	yes
O	O	;	no
B-drug	B-drug	dextrothyroxine	yes
O	O	;	no
B-drug	B-drug	diazoxide	yes
O	O	;	no
O	O	dietary	no
O	O	deficiencies	no
O	O	;	no
B-drug	B-drug	diflunisal	yes
O	O	;	no
B-drug	B-drug	disulfiram	yes
O	O	;	no
O	O	drugs	no
O	O	affecting	no
O	O	blood	yes
O	O	elements	no
O	O	;	no
B-drug	B-drug	ethacrynic	yes
I-drug	I-drug	acid	yes
O	O	;	no
B-drug	B-drug	fenoprofen	yes
O	O	;	no
B-drug	B-drug	glucagon	yes
O	O	;	no
O	O	hepatotoxic	no
O	O	drugs	no
O	O	;	no
B-drug	B-drug	ibuprofen	yes
O	O	;	no
B-drug	B-drug	indomethacin	yes
O	O	;	no
B-group	B-group	influenza	no
I-group	I-group	virus	yes
I-group	I-group	vaccine	yes
O	O	;	no
O	O	inhalation	no
B-group	B-group	anesthetics	no
O	O	;	no
B-drug	B-drug	mefenamic	yes
I-drug	I-drug	acid	yes
O	O	;	no
B-drug	B-drug	methyldopa	yes
O	O	;	no
B-drug	B-drug	methylphenidate	yes
O	O	;	no
B-drug	B-drug	metronidazole	yes
O	O	;	no
B-drug	B-drug	miconazole	yes
O	O	;	no
B-group	B-group	monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	inhibitors	no
O	O	;	no
B-drug	B-drug	nalidixic	yes
I-drug	I-drug	acid	yes
O	O	;	no
B-drug	B-drug	naproxen	yes
O	O	;	no
B-drug	B-drug	oxolinic	no
I-drug	I-drug	acid	yes
O	O	;	no
B-drug	B-drug	oxyphenbutazone	yes
O	O	;	no
B-drug	B-drug	pentoxifylline	yes
O	O	;	no
B-drug	B-drug	phenylbutazone	yes
O	O	;	no
B-drug	B-drug_n	phenyramidol	no
O	O	;	no
B-drug	B-drug	phenytoin	yes
O	O	;	no
O	O	prolonged	no
O	O	hot	no
O	O	weather	no
O	O	;	no
B-group	B-group	prolonged	no
I-group	I-group	narcotics	no
O	O	;	no
B-group	B-group	pyrazolones	no
O	O	;	no
B-drug	B-drug	quinidine	yes
O	O	;	no
B-drug	B-drug	quinine	yes
O	O	;	no
B-drug	B-drug	ranitidine*	no
O	O	;	no
B-group	B-group	salicylates	no
O	O	;	no
B-drug	B-drug	sulfinpyrazone	yes
O	O	;	no
B-group	B-group	sulfonamides	yes
O	O	,	no
O	O	long	yes
O	O	acting	yes
O	O	;	no
B-drug	B-drug	sulindac	yes
O	O	;	no
B-group	B-group	thyroid	yes
I-group	I-group	drugs	no
O	O	;	no
B-drug	B-drug	tolbutamide	yes
O	O	;	no
B-drug	B-drug	triclofos	no
I-drug	I-drug	sodium	yes
O	O	;	no
B-drug	B-drug	trimethoprim/sulfamethoxazole	no
O	O	;	no
O	O	unreliable	no
O	O	prothrombin	yes
O	O	time	no
O	O	determinations	no
O	O	;	no
B-drug	B-drug	warfarin	yes
I-drug	I-drug	sodium	yes
O	O	overdosage	no
O	O	.	no

O	O	Nephrotoxicity	no
O	O	frequently	no
O	O	limits	no
O	O	the	no
O	O	dose	no
O	O	of	yes
B-drug	B-drug	cisplatin	yes
O	O	to	no
O	O	less	no
O	O	than	no
O	O	120	no
O	O	mg/m2	no
O	O	per	no
O	O	injection	yes
O	O	.	no

O	O	If	no
B-drug	B-drug	isradipine	yes
O	O	therapy	no
O	O	is	yes
O	O	initiated	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	currently	no
O	O	receiving	no
B-drug	B-drug	cimetidine	yes
O	O	careful	no
O	O	monitoring	no
O	O	for	yes
O	O	adverse	no
O	O	reactions	no
O	O	is	yes
O	O	advised	no
O	O	and	yes
O	O	downward	no
O	O	dose	no
O	O	adjustment	no
O	O	may	no
O	O	be	no
O	O	required	no
O	O	.	no

O	O	Long	yes
O	O	Acting	yes
B-group	B-group	Nitrates	no
O	O	:	no
B-drug	B-drug	Nifedipine	yes
O	O	may	no
O	O	be	no
O	O	safely	no
O	O	co-administered	no
O	O	with	yes
B-group	B-group	nitrates	no
O	O	,	no
O	O	but	no
O	O	there	no
O	O	have	no
O	O	been	no
O	O	no	yes
O	O	controlled	no
O	O	studies	no
O	O	to	no
O	O	evaluate	no
O	O	the	no
O	O	antianginal	no
O	O	effectiveness	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	.	no

O	O	These	no
O	O	steps	no
O	O	include	no
O	O	regular	yes
O	O	reevaluations	no
O	O	of	yes
O	O	dosages	no
O	O	and	yes
O	O	plasma	yes
O	O	drug	yes
O	O	concentrations	no
O	O	,	no
O	O	recognition	no
O	O	and	yes
O	O	understanding	no
O	O	of	yes
O	O	drug	yes
O	O	side	no
O	O	effects	no
O	O	,	no
O	O	and	yes
O	O	avoidance	no
O	O	of	yes
O	O	certain	no
O	O	agents	yes
O	O	.	no

O	O	This	no
O	O	interaction	no
O	O	should	no
O	O	be	no
O	O	given	no
O	O	consideration	no
O	O	in	yes
O	O	patients	no
O	O	taking	no
B-group	B-group	NSAIDs	no
O	O	concomitantly	no
O	O	with	yes
B-group	B-group	ACE	no
I-group	I-group	inhibitors	no
O	O	.	no

O	O	In	yes
O	O	addition	no
O	O	,	no
O	O	based	no
O	O	on	no
O	O	the	no
O	O	population	no
O	O	pharmacokinetics	no
O	O	analysis	no
O	O	of	yes
O	O	the	no
O	O	combined	no
O	O	data	no
O	O	from	no
O	O	grapefruit	no
O	O	and	yes
O	O	orange	no
O	O	juices	no
O	O	studies	no
O	O	with	yes
O	O	the	no
O	O	data	no
O	O	from	no
O	O	a	yes
O	O	bioequivalence	no
O	O	study	no
O	O	,	no
O	O	the	no
O	O	bioavailability	no
O	O	of	yes
B-drug	B-drug	fexofenadine	yes
O	O	was	no
O	O	reduced	yes
O	O	by	no
O	O	36	no
O	O	%	no
O	O	.	no

O	O	Agents	yes
O	O	that	no
O	O	Induce	no
O	O	Cytochrome	no
O	O	P450	no
O	O	Isoenzymes	no
B-drug	B-drug	Carbamazepine	yes
O	O	is	yes
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

O	O	All	yes
O	O	77	no
O	O	strains	no
O	O	of	yes
O	O	Staphylococcus	no
O	O	aureus	no
O	O	,	no
O	O	Diplococcus	no
O	O	pneumoniae	no
O	O	,	no
O	O	Streptococcus	no
O	O	pyogenes	no
O	O	,	no
O	O	and	yes
O	O	anaerobic	no
O	O	bacteria	no
O	O	(	no
O	O	except	no
O	O	for	yes
O	O	three	no
O	O	strains	no
O	O	of	yes
B-drug_n	O	Clostridium	yes
O	O	)	no
O	O	were	no
O	O	inhibited	no
O	O	by	no
O	O	1.6	no
O	O	mug	no
O	O	or	no
O	O	less	no
O	O	of	yes
B-drug	B-drug	clindamycin	yes
O	O	per	no
O	O	ml	no
O	O	.	no

O	O	Several	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	block	yes
O	O	the	no
O	O	pharmacologic	no
O	O	effects	no
O	O	of	yes
B-drug	B-drug	guanethidine	yes
O	O	,	no
B-drug	B-drug	clonidine	yes
O	O	,	no
O	O	or	no
O	O	similar	no
O	O	agents	yes
O	O	,	no
O	O	and	yes
O	O	such	no
O	O	an	no
O	O	effect	no
O	O	may	no
O	O	be	no
O	O	anticipated	no
O	O	with	yes
B-drug	B-drug	CMI	no
O	O	because	no
O	O	of	yes
O	O	its	no
O	O	structural	no
O	O	similarity	no
O	O	to	no
O	O	other	no
B-group	B-group	tricyclic	no
I-group	I-group	antidepressants	no
O	O	.	no

O	O	The	no
O	O	consumption	no
O	O	of	yes
B-drug	B-drug	alcohol	yes
O	O	during	no
O	O	treatment	no
O	O	with	yes
B-brand	B-brand	WELLBUTRIN	yes
O	O	should	no
O	O	be	no
O	O	minimized	no
O	O	or	no
O	O	avoided	no
O	O	(	no
O	O	also	no
O	O	see	no
O	O	a	yes
O	O	href=	no
O	O	bupropz_od.htm	no
O	O	#	no
O	O	CI	yes
O	O	CONTRAINDICATIONS	no
O	O	)	no

O	O	Intravenous	yes
O	O	infusion	no
O	O	of	yes
B-drug	B-drug	iloprost	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	digoxin	yes
O	O	.	no

B-drug	B-drug	Zalcitabine	yes
O	O	also	no
O	O	has	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	intracellular	no
O	O	phosphorylation	no
O	O	of	yes
B-drug_n	B-drug	ZDV	yes
O	O	,	no
O	O	as	yes
O	O	shown	no
O	O	in	yes
O	O	vitro	no
O	O	in	yes
O	O	peripheral	no
O	O	blood	yes
O	O	mononuclear	no
O	O	cells	yes
O	O	or	no
O	O	in	yes
O	O	two	no
O	O	other	no
O	O	cell	yes
O	O	lines	no
O	O	(	no
O	O	U937	no
O	O	and	yes
O	O	Molt-4	no
O	O	)	no
O	O	.	no

O	O	-	yes
B-drug	B-drug	Mercaptopurine	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-brand	B-brand	Purinethol	yes
O	O	)	no
O	O	or	no

O	O	Therefore	no
O	O	,	no
O	O	patients	no
O	O	under	no
B-drug	B-drug	methotrexate	yes
O	O	therapy	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	when	no
O	O	concomitant	no
B-drug	B-drug	ciprofloxacin	yes
O	O	therapy	no
O	O	is	yes
O	O	indicated	no
O	O	.	no

O	O	Additionally	no
O	O	,	no
B-drug	B-drug	aripiprazole	yes
O	O	and	yes
B-drug	B-drug_n	dehydroaripiprazole	no
O	O	did	no
O	O	not	no
O	O	show	no
O	O	potential	no
O	O	for	yes
O	O	altering	no
O	O	CYP1A2-mediated	no
O	O	metabolism	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	75	yes
O	O	years	no
O	O	of	yes
O	O	age	no
O	O	.	no

O	O	The	no
O	O	use	no
O	O	of	yes
B-brand	B-brand	FLUDARA	yes
O	O	FOR	yes
O	O	INJECTION	yes
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	pentostatin	yes
O	O	is	yes
O	O	not	no
O	O	recommended	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	risk	no
O	O	of	yes
O	O	severe	no
O	O	pulmonary	no
O	O	toxicity	no
O	O	.	no

O	O	The	no
O	O	homodimeric	no
O	O	disintegrin	no
B-drug_n	B-drug_n	contortrostatin	no
O	O	was	no
O	O	compared	no
O	O	directly	no
O	O	to	no
O	O	the	no
O	O	monomeric	no
O	O	disintegrins	no
B-drug_n	B-drug_n	echistatin	no
O	O	and	yes
B-drug_n	B-drug_n	flavoridin	no
O	O	for	yes
O	O	the	no
O	O	ability	no
O	O	to	no
O	O	affect	no
O	O	protein	yes
O	O	tyrosine	yes
O	O	phosphorylation	no
O	O	in	yes
O	O	tumor	yes
O	O	cells	yes
O	O	.	no

O	O	Extreme	no
O	O	caution	no
O	O	should	no
O	O	be	no
O	O	exercised	no
O	O	when	no
O	O	administering	no
B-brand	B-brand	TAXOL	yes
O	O	to	no
O	O	such	no
O	O	patients	no
O	O	,	no
O	O	with	yes
O	O	dose	no
O	O	reduction	yes
O	O	as	yes
O	O	recommended	no
O	O	in	yes
O	O	DOSAGE	no
O	O	AND	yes
O	O	ADMINISTRATION	no
O	O	,	no
O	O	Table	no
O	O	17	yes
O	O	.	no

O	O	The	no
O	O	carcinogenic	no
O	O	potential	no
O	O	of	yes
B-drug	B-drug	ribavirin	yes
O	O	has	no
O	O	not	no
O	O	been	no
O	O	fully	no
O	O	determined	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
B-group	B-group	Quinolones	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	the	no
O	O	oral	yes
B-group	B-group	anticoagulant	no
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	,	no
O	O	or	no
O	O	its	no
O	O	derivatives	no
O	O	.	no

O	O	however	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	considered	no
O	O	to	no
O	O	be	no
O	O	unlikely	no
O	O	that	no
O	O	this	no
O	O	decrease	no
O	O	of	yes
O	O	phosphorylated	yes
B-drug	B-drug	lamivudine	yes
O	O	concentration	no
O	O	is	yes
O	O	of	yes
O	O	clinical	no
O	O	significance	no
O	O	,	no
O	O	as	yes
B-drug	B-drug	lamivudine	yes
O	O	is	yes
O	O	a	yes
O	O	more	no
O	O	efficient	no
O	O	substrate	yes
O	O	for	yes
O	O	deoxycytidine	yes
O	O	kinase	yes
O	O	than	no
B-drug	B-drug	zalcitabine	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	when	no
B-brand	B-brand	EDECRIN	yes
O	O	and	yes
B-group	B-group	non-	no
I-group	I-group	steroidal	no
I-group	I-group	anti-	no
I-group	I-group	inflammatory	no
I-group	I-group	agents	yes
O	O	are	no
O	O	used	no
O	O	concomitantly	no
O	O	,	no
O	O	the	no
O	O	patient	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	closely	no
O	O	to	no
O	O	determine	no
O	O	if	no
O	O	the	no
O	O	desired	no
O	O	effect	no
O	O	of	yes
O	O	the	no
B-group	B-group	diuretic	no
O	O	is	yes
O	O	obtained	no
O	O	.	no

O	O	Cardiovascular	no
O	O	disease	no
O	O	is	yes
O	O	considered	no
O	O	in	yes
O	O	the	no
O	O	next	yes
O	O	chapter	no
O	O	,	no
O	O	and	yes
O	O	chapter	no
O	O	7	yes
O	O	presents	no
O	O	findings	no
O	O	on	no
O	O	endometrial	no
O	O	,	no
O	O	ovarian	no
O	O	,	no
O	O	cervical	no
O	O	,	no
O	O	breast	no
O	O	,	no
O	O	and	yes
O	O	other	no
O	O	cancers	no
O	O	.	no

O	O	aeruginosa	no
O	O	as	yes
O	O	common	yes
O	O	pathogens	no
O	O	of	yes
O	O	drug	yes
O	O	addicts	no
O	O	in	yes
O	O	areas	no
O	O	where	no
O	O	abuse	no
O	O	of	yes
O	O	this	no
O	O	combination	yes
O	O	of	yes
O	O	drugs	no
O	O	has	no
O	O	increased	no
O	O	.	no

B-group	B-group	Antihypertensive	no
I-group	O	Medications	no
O	O	and	yes
B-group	B-group	Vasodilators	no
O	O	:	no
O	O	The	no
O	O	following	no
O	O	adverse	no
O	O	events	no
O	O	were	no
O	O	experienced	no
O	O	more	no
O	O	commonly	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
O	O	concomitant	no
B-group	B-group	antihypertensive	no
I-group	I-group	medications	no
O	O	or	no
B-group	B-group	vasodilators	no
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	94	yes
O	O	)	no
O	O	compared	no
O	O	to	no
O	O	patients	no
O	O	not	no
O	O	receiving	no
O	O	these	no
O	O	concomitant	no
O	O	drugs	no
O	O	(	no
O	O	n	yes
O	O	=	no
O	O	456	no
O	O	)	no
O	O	:	no
O	O	hypotension	no
O	O	10	yes
O	O	%	no
O	O	vs	no
O	O	4	yes
O	O	%	no
O	O	,	no
O	O	myocardial	no
O	O	infarction	no
O	O	3	yes
O	O	%	no
O	O	vs	no
O	O	1	yes
O	O	%	no
O	O	,	no
O	O	serious	no
O	O	pneumonia	no
O	O	5	yes
O	O	%	no
O	O	vs	no
O	O	3	yes
O	O	%	no
O	O	,	no
O	O	serious	no
O	O	falls	no
O	O	9	yes
O	O	%	no
O	O	vs	no
O	O	3	yes
O	O	%	no
O	O	,	no
O	O	and	yes
O	O	bone	no
O	O	and	yes
O	O	joint	no
O	O	injuries	no
O	O	6	yes
O	O	%	no
O	O	vs	no
O	O	2	yes
O	O	%	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	(	no
B-drug	B-drug	aluminum-	no
O	O	or	no
B-drug	B-drug	magnesium-containing	no
O	O	)	no
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
O	O	300-mg	no
B-drug	B-drug	cefdinir	yes
O	O	capsules	no
O	O	with	yes
O	O	30	yes
O	O	mL	no
B-brand	B-brand	Maalox	no
I-brand	I-brand	TC	yes
O	O	suspension	yes
O	O	reduces	no
O	O	the	no
O	O	rate	no
O	O	(	no
O	O	Cmax	no
O	O	)	no
O	O	and	yes
O	O	extent	no
O	O	(	no
O	O	AUC	no
O	O	)	no
O	O	of	yes
O	O	absorption	no
O	O	by	no
O	O	approximately	no
O	O	40	yes
O	O	%	no
O	O	.	no

B-drug	B-drug	Acetazolamide	yes
O	O	may	no
O	O	increase	no
O	O	or	no
O	O	decrease	no
O	O	blood	yes
O	O	glucose	yes
O	O	levels	no
O	O	.	no

B-drug	B-drug	Etodolac	yes
O	O	is	yes
O	O	characterised	no
O	O	by	no
O	O	a	yes
O	O	high	yes
O	O	oral	yes
O	O	bioavailability	no
O	O	,	no
O	O	low	yes
O	O	clearance	no
O	O	,	no
O	O	a	yes
O	O	small	no
O	O	volume	no
O	O	of	yes
O	O	distribution	no
O	O	,	no
O	O	and	yes
O	O	a	yes
O	O	7-hour	no
O	O	half-life	no
O	O	.	no

B-group	B-group	Antacids	no
O	O	or	no
B-drug	B-drug	sucralfate	yes
O	O	substantially	no
O	O	interfere	no
O	O	with	yes
O	O	the	no
O	O	absorption	no
O	O	of	yes
O	O	some	no
B-group	B-group	quinolones	no
O	O	,	no
O	O	resulting	no
O	O	in	yes
O	O	low	yes
O	O	urine	no
O	O	levels	no
O	O	.	no

B-drug	B-drug	amiodarone	yes
O	O	;	no

O	O	Effects	no
O	O	of	yes
B-brand	B-brand	GABITRIL	yes
O	O	on	no
O	O	other	no
B-group	O	Antiepilepsy	no
I-group	O	Drugs	no
O	O	(	no
B-group	B-group	AEDs	no
O	O	)	no
O	O	:	no
B-drug	B-drug	Phenytoin	yes
O	O	:	no
B-drug	B-drug	Tiagabine	yes
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	steady-state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
B-drug	B-drug	phenytoin	yes
O	O	in	yes
O	O	patients	no
O	O	with	yes
O	O	epilepsy	no
O	O	.	no

O	O	It	no
O	O	is	yes
O	O	not	no
O	O	known	no
O	O	whether	no
B-brand	B-brand	AMEVIVE	no
O	O	is	yes
O	O	excreted	no
O	O	in	yes
O	O	human	yes
O	O	milk	yes
O	O	.	no

O	O	When	no
O	O	prescribing	no
O	O	for	yes
O	O	older	no
O	O	patients	no
O	O	,	no
O	O	some	no
O	O	physicians	no
O	O	are	no
O	O	overly	no
O	O	cautious	no
O	O	,	no
O	O	and	yes
O	O	this	no
O	O	strategy	no
O	O	can	no
O	O	result	no
O	O	in	yes
O	O	a	yes
O	O	less	no
O	O	than	no
O	O	optimal	no
O	O	treatment	no
O	O	outcome	no
O	O	.	no

O	O	Long-term	no
O	O	studies	no
O	O	are	no
O	O	needed	no
O	O	to	no
O	O	determine	no
O	O	whether	no
O	O	the	no
O	O	insulin-sensitizing	no
O	O	effects	no
O	O	of	yes
O	O	the	no
B-group	B-group	glitazones	no
O	O	can	no
O	O	prevent	no
O	O	or	no
O	O	delay	no
O	O	premature	no
O	O	atherosclerotic	no
O	O	cardiovascular	no
O	O	disease	no
O	O	,	no
O	O	morbidity	no
O	O	,	no
O	O	and	yes
O	O	death	no
O	O	.	no

O	O	.	no

O	O	Low	yes
O	O	initial	no
O	O	dosing	no
O	O	and	yes
O	O	small	no
O	O	gradual	no
O	O	dose	no
O	O	increases	no
O	O	should	no
O	O	be	no
O	O	employed	no
O	O	.	no

B-drug	B-drug	Etodolac	yes
O	O	is	yes
O	O	highly	no
O	O	protein	yes
O	O	bound	no
O	O	.	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	used	no
O	O	when	no
O	O	coadministering	no
O	O	medications	no
O	O	that	no
O	O	are	no
O	O	substrates	no
O	O	,	no
O	O	inhibitors	no
O	O	,	no
O	O	or	no
O	O	inducers	no
O	O	of	yes
O	O	CYP3A4	no
O	O	,	no
O	O	or	no
O	O	potentially	no
O	O	toxic	no
O	O	medications	no
O	O	that	no
O	O	are	no
O	O	metabolized	no
O	O	by	no
O	O	CYP3A4	no
O	O	.	no

O	O	Of	yes
O	O	particular	no
O	O	importance	no
O	O	,	no
O	O	sufficient	no
O	O	time	no
O	O	must	no
O	O	elapse	no
O	O	before	no
O	O	initiating	no
B-brand	B-group	TCAtreatment	no
O	O	in	yes
O	O	a	yes
O	O	patient	no
O	O	being	no
O	O	withdrawn	no
O	O	from	no
B-drug	B-drug	fluoxetine	yes
O	O	,	no
O	O	given	no
O	O	the	no
O	O	long	yes
O	O	half-life	no
O	O	of	yes
O	O	the	no
O	O	parent	no
O	O	and	yes
O	O	active	no
O	O	metabolite	yes
O	O	(	no
O	O	at	yes
O	O	least	no
O	O	5	yes
O	O	weeks	no
O	O	may	no
O	O	be	no
O	O	necessary	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	some	no
O	O	cases	no
O	O	where	no
O	O	serious	no
O	O	ventricular	no
O	O	arrhythmias	no
O	O	,	no
O	O	QT	no
O	O	prolongation	no
O	O	,	no
O	O	and	yes
O	O	torsades	no
O	O	de	yes
O	O	pointes	no
O	O	have	no
O	O	occurred	no
O	O	when	no
B-drug	B-drug	cisapride	yes
O	O	was	no
O	O	taken	no
O	O	in	yes
O	O	conjunction	no
O	O	with	yes
O	O	one	no
O	O	of	yes
O	O	the	no
O	O	cytochrome	no
O	O	P450	no
O	O	3A4	no
O	O	inhibitors	no
O	O	,	no
O	O	elevated	no
O	O	blood	yes
B-drug	B-drug	cisapride	yes
O	O	levels	no
O	O	were	no
O	O	noted	no
O	O	at	yes
O	O	the	no
O	O	time	no
O	O	of	yes
O	O	the	no
O	O	QT	no
O	O	prolongation	no
O	O	.	no

O	O	After	no
O	O	stopping	no
B-drug	B-drug	Fluvoxamine	yes
O	O	Tablets	yes
O	O	,	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	weeks	no
O	O	should	no
O	O	be	no
O	O	allowed	no
O	O	before	no
O	O	starting	no
O	O	a	yes
B-group	B-group	MAOI	no
O	O	.	no

O	O	cardiovascular	no
O	O	effects	no
O	O	can	no
O	O	be	no
O	O	potentiated	no
O	O	.	no

O	O	When	no
O	O	these	no
O	O	products	no
O	O	are	no
O	O	administered	no
O	O	concomitantly	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	or	no
O	O	other	no
O	O	suitable	no
O	O	coagulation	yes
O	O	tests	no
O	O	should	no
O	O	be	no
O	O	closely	no
O	O	monitored	no
O	O	.	no

O	O	These	no
O	O	results	no
O	O	,	no
O	O	together	no
O	O	with	yes
O	O	the	no
O	O	known	no
O	O	relationships	no
O	O	between	yes
B-group	B-group	estrogen	no
O	O	and	yes
O	O	the	no
O	O	immune	yes
O	O	response	no
O	O	,	no
O	O	suggest	no
O	O	that	no
B-group	B-group	estrogens	yes
O	O	affect	no
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	septic	no
O	O	shock	no
O	O	in	yes
O	O	a	yes
O	O	complex	yes
O	O	fashion	no
O	O	and	yes
O	O	may	no
O	O	have	no
O	O	either	no
O	O	protective	no
O	O	or	no
O	O	deleterious	no
O	O	effect	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	When	no
B-drug	B-drug	fluvoxamine	yes
I-drug	I-drug	maleate	yes
O	O	(	no
O	O	50	yes
O	O	mg	yes
O	O	tid	no
O	O	)	no
O	O	was	no
O	O	administered	no
O	O	concomitantly	no
O	O	with	yes
B-drug	B-drug	warfarin	yes
O	O	for	yes
O	O	two	no
O	O	weeks	no
O	O	,	no
B-drug	B-drug	warfarin	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	increased	no
O	O	by	no
O	O	98	no
O	O	%	no
O	O	and	yes
O	O	prothrombin	yes
O	O	times	no
O	O	were	no
O	O	prolonged	no
O	O	.	no

B-group	O	Nonketotic	no
O	O	,	no
O	O	genetically	no
O	O	diabetic	no
O	O	Cinese	no
O	O	hamsters	no
O	O	show	no
O	O	subnormal	no
O	O	pancreatic	yes
O	O	insulin	yes
O	O	release	yes
O	O	and	yes
O	O	impaired	no
O	O	suppression	no
O	O	of	yes
O	O	glucagon	yes
O	O	in	yes
O	O	response	no
O	O	to	no
B-drug	O	glucose	yes
O	O	.	no

O	O	If	no
O	O	a	yes
O	O	patient	no
O	O	requires	no
B-brand	B-brand	TIKOSYN	yes
O	O	and	yes
O	B-group	anti-ulcer	no
O	O	therapy	no
O	O	,	no
O	O	it	no
O	O	is	yes
O	O	suggested	no
O	O	that	no
B-drug	B-drug	omeprazole	yes
O	O	,	no
B-drug	B-drug	ranitidine	yes
O	O	,	no
O	B-drug	or	no
B-group	B-group	antacids	no
O	O	(	no
B-drug	O	aluminum	yes
O	O	and	yes
B-drug	B-drug	magnesium	yes
I-drug	O	hydroxides	no
O	O	)	no
O	O	be	no
O	O	used	no
O	O	as	yes
O	O	alternatives	no
O	O	to	no
B-drug	B-drug	cimetidine	yes
O	O	,	no
O	O	as	yes
O	O	these	no
O	O	agents	yes
O	O	have	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetic	no
O	O	profile	no
O	O	of	yes
B-brand	B-brand	TIKOSYN	yes
O	O	.	no

O	O	Altered	no
O	O	mental	no
O	O	status	no
O	O	in	yes
O	O	an	no
O	O	adolescent	no
O	O	presents	no
O	O	a	yes
O	O	diagnostic	yes
O	O	challenge	no
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	clinician	no
O	O	depends	no
O	O	on	no
O	O	clinical	no
O	O	evaluation	no
O	O	and	yes
O	O	laboratory	no
O	O	studies	no
O	O	to	no
O	O	determine	no
O	O	therapy	no
O	O	and	yes
O	O	prognosis	no
O	O	.	no

O	O	This	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	atherosclerotic	no
O	O	disease	no
O	O	is	yes
O	O	intricately	no
O	O	associated	no
O	O	with	yes
B-drug	O	insulin	yes
O	O	resistance	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	a	yes
O	O	major	no
O	O	pathophysiologic	no
O	O	abnormality	no
O	O	in	yes
O	O	type	yes
O	O	2	yes
O	O	diabetes	no
O	O	.	no

O	O	Twenty-four	no
O	O	h	yes
O	O	exposures	no
O	O	of	yes
O	O	fully	no
O	O	formed	no
O	O	cysts	no
O	O	had	no
O	O	no	yes
O	O	effect	no
O	O	on	no
O	O	excystment	no
O	O	in	yes
O	O	vitro	no
O	O	.	no

O	O	Co-administration	no
O	O	of	yes
B-drug	B-drug	atorvastatin	yes
O	O	resulted	no
O	O	in	yes
O	O	about	no
O	O	a	yes
O	O	50	yes
O	O	%	no
O	O	increase	no
O	O	in	yes
B-drug	B-drug	aliskiren	yes
O	O	Cmax	no
O	O	and	yes
O	O	AUC	no
O	O	after	no
O	O	multiple	no
O	O	dosing	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	relevance	no
O	O	of	yes
O	O	this	no
O	O	in	yes
O	O	vitro	no
O	O	finding	no
O	O	is	yes
O	O	unknown	no
O	O	.	no

O	O	As	yes
O	O	with	yes
O	O	other	no
B-group	B-group	antipsychotic	no
I-group	I-group	agents	yes
O	O	,	no
O	O	it	no
O	O	should	no
O	O	be	no
O	O	noted	no
O	O	that	no
B-brand	B-brand	HALDOL	yes
O	O	may	no
O	O	be	no
O	O	capable	no
O	O	of	yes
B-group	O	potentiating	no
I-group	B-group	CNS	no
I-group	I-group	depressants	no
O	O	such	no
O	O	as	yes
B-group	B-group	anesthetics	no
O	O	,	no
B-group	B-group	opiates	no
O	O	,	no
O	O	and	yes
B-drug	B-drug	alcohol	yes
O	O	.	no

O	O	Clinical	no
O	O	trials	no
O	O	of	yes
O	O	such	no
O	O	combinations	no
O	O	should	no
O	O	be	no
O	O	accompanied	no
O	O	by	no
O	O	detailed	no
O	O	pharmacokinetic	no
O	O	evaluation	no
O	O	.	no

B-group	B-group	Beta-adrenergic	no
I-group	I-group	blocking	no
I-group	I-group	agents	yes
O	O	should	no
O	O	be	no
O	O	withdrawn	no
O	O	at	yes
O	O	least	no
O	O	48	yes
O	O	hours	no
O	O	before	no
O	O	conducting	no
O	O	an	no
O	B-drug	arbutamine-mediated	no
O	O	stress	no
O	O	test	yes
O	O	.	no

O	O	Of	yes
O	O	the	no
O	O	remaining	no
O	O	cases	no
O	O	,	no
O	O	two	no
O	O	were	no
O	O	cardiac	no
O	O	,	no
O	O	two	no
O	O	hepatic	no
O	O	and	yes
O	O	the	no
O	O	rest	no
O	O	were	no
O	O	mixed	yes
O	O	drug	yes
O	O	overdose	no
O	O	.	no

B-group	B-group	Loop	no
I-group	I-group	Diuretics	no
O	O	:	no
B-drug	B-drug	Furosemide	yes
O	O	administered	no
O	O	concurrently	no
O	O	with	yes
B-drug	B-drug	captopril	yes
O	O	does	no
O	O	not	no
O	O	alter	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
B-drug	B-drug	captopril	yes
O	O	in	yes
O	O	renally	no
O	O	impaired	no
O	O	hypertensive	no
O	O	patients	no
O	O	.	no

O	O	Preliminary	no
O	O	data	no
O	O	which	no
O	O	suggest	no
O	O	that	no
B-drug	B-drug	dapsone	yes
O	O	may	no
O	O	inhibit	no
O	O	the	no
O	O	anti-inflammatory	no
O	O	activity	yes
O	O	of	yes
B-brand	B-brand	Lamprene	yes
O	O	have	no
O	O	not	no
O	O	been	no
O	O	confirmed	no
O	O	.	no

O	O	Other	no
O	O	drugs	no
O	O	which	no
O	O	may	no
O	O	enhance	no
O	O	the	no
O	O	neuromuscular	no
O	O	blocking	no
O	O	action	no
O	O	of	yes
B-group	O	nondepolarizing	no
I-group	O	agents	yes
O	O	such	no
O	O	as	yes
B-brand	B-brand	NUROMAX	yes
O	O	include	no
O	O	certain	no
B-group	B-group	antibiotics	no
O	O	(	no
O	O	e.	no
O	O	g.	no
O	O	,	no
B-group	B-group	aminoglycosides	no
O	O	,	no
B-group	B-group	tetracyclines	no
O	O	,	no
B-drug	B-group	bacitracin	yes
O	O	,	no
B-group	B-group	polymyxins	no
O	O	,	no
B-drug	B-drug	lincomycin	yes
O	O	,	no
B-drug	B-drug	clindamycin	yes
O	O	,	no
B-drug	B-drug	colistin	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	sodium	yes
I-drug	I-drug	colistimethate	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	magnesium	yes
O	O	salts	no
O	O	,	no
B-drug	B-drug	lithium	yes
O	O	,	no
O	O	local	no
B-group	B-group	anesthetics	no
O	O	,	no
B-drug	B-drug	procainamide	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	quinidine	yes
O	O	.	no

O	O	No	yes
O	O	differences	no
O	O	in	yes
O	O	adverse	no
O	O	events	no
O	O	or	no
O	O	QTc	no
O	O	interval	no
O	O	were	no
O	O	observed	no
O	O	when	no
O	O	subjects	no
O	O	were	no
O	O	administered	no
B-drug	B-drug	fexofenadine	yes
I-drug	I-drug	hydrochloride	yes
O	O	alone	no
O	O	or	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
O	O	either	no
B-drug	B-drug	erythromycin	yes
O	O	or	no
B-drug	B-drug	ketoconazole	yes
O	O	.	no

B-drug	B-drug	Ergotamine	yes

B-drug	B-drug	Aminosalicylic	yes
I-drug	I-drug	acid	yes
O	O	may	no
O	O	also	no
O	O	decrease	no
O	O	the	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	vitamin	yes
I-drug	I-drug	B12	yes
O	O	,	no
O	O	which	no
O	O	can	no
O	O	lead	no
O	O	to	no
O	O	a	yes
O	O	deficiency	no
O	O	.	no

O	O	Increasing	no
O	O	the	no
B-drug	B-drug	felbamate	yes
O	O	dose	no
O	O	to	no
O	O	2400	no
O	O	mg/day	no
O	O	increased	no
O	O	the	no
O	O	steadystate	no
B-drug	B-drug	valproate	yes
O	O	Cmin	no
O	O	to	no
O	O	96	no
O	O	25	yes
O	O	micrograms/mL	no
O	O	.	no

O	O	St.	yes
O	O	John	no
O	O	s	yes
O	O	Wort	yes
O	O	should	no
O	O	be	no
O	O	avoided	no
O	O	while	no
O	O	taking	no
O	O	this	no
O	O	medicine	no
O	O	due	no
O	O	to	no
O	O	the	no
O	O	additive	no
O	O	effects	no
O	O	of	yes
O	O	serotonin	yes
O	O	.	no

O	O	Accordingly	no
O	O	,	no
O	O	careful	no
O	O	patient	no
O	O	monitoring	no
O	O	and	yes
O	O	dose	no
O	O	adjustment	no
O	O	of	yes
B-drug	B-drug	metformin	yes
O	O	is	yes
O	O	recommended	no
O	O	in	yes
O	O	patients	no
O	O	concomitantly	no
O	O	taking	no
B-drug	B-drug	cephalexin	yes
O	O	and	yes
B-drug	B-drug	metformin	yes
O	O	.	no

O	O	Read	no
O	O	circulars	no
O	O	for	yes
B-drug	B-drug	lithium	yes
O	O	preparations	no
O	O	before	no
O	O	use	no
O	O	of	yes
O	O	such	no
O	O	concomitant	no
O	O	therapy	no
O	O	.	no

O	O	In	yes
O	O	two	no
O	O	controlled	no
O	O	crossover	no
O	O	clinical	no
O	O	pharmacology	no
O	O	studies	no
O	O	in	yes
O	O	healthy	no
O	O	male	no
O	O	(	no
O	O	n=12	no
O	O	in	yes
O	O	each	no
O	O	study	no
O	O	)	no
O	O	a	yes
O	O	nd	no
O	O	female	no
O	O	(	no
O	O	n=12	no
O	O	in	yes
O	O	each	no
O	O	study	no
O	O	)	no
O	O	volunteers	no
O	O	,	no
B-drug	B-drug	desloratadine	yes
O	O	7.5	yes
O	O	mg	yes
O	O	(	no
O	O	1.5	yes
O	O	times	no
O	O	the	no
O	O	daily	no
O	O	dose	no
O	O	)	no
O	O	once	no
O	O	daily	no
O	O	was	no
O	O	coadministered	no
O	O	with	yes
B-drug	B-drug	erythromycin	yes
O	O	500	yes
O	O	mg	yes
O	O	every	no
O	O	8	yes
O	O	hours	no
O	O	or	no
B-drug	B-drug	ketoconazole	yes
O	O	200	yes
O	O	mg	yes
O	O	every	no
O	O	12	yes
O	O	hours	no
O	O	for	yes
O	O	10	yes
O	O	days	no
O	O	.	no

O	O	reproductive	no
O	O	tract	no
O	O	infections	no
O	O	;	no

O	O	If	no
B-drug	B-group	iron	yes
O	I-group	supplements	no
O	O	are	no
O	O	required	no
O	O	during	no
B-brand	B-brand	OMNICEF	yes
O	O	therapy	no
O	O	,	no
B-brand	B-brand	OMNICEF	yes
O	O	should	no
O	O	be	no
O	O	taken	no
O	O	at	yes
O	O	least	no
O	O	2	yes
O	O	hours	no
O	O	before	no
O	O	or	no
O	O	after	no
O	O	the	no
O	O	supplement	yes
O	O	.	no

O	O	Women	yes
O	O	of	yes
O	O	childbearing	no
O	O	potential	no
O	O	make	no
O	O	up	no
O	O	a	yes
O	O	considerable	no
O	O	segment	no
O	O	of	yes
O	O	the	no
O	O	patient	no
O	O	population	no
O	O	affected	no
O	O	by	no
O	O	psoriasis	no
O	O	.	no

O	O	Generally	no
O	O	,	no
O	O	this	no
O	O	phenomenon	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	associated	no
O	O	with	yes
O	O	other	no
O	O	clinically	no
O	O	significant	no
O	O	events	no
O	O	.	no

O	O	.	no

B-drug	B-drug	Methotrexate	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	and	yes
O	O	some	no
B-group	B-group	NSAIDs	no
O	O	has	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	reduce	no
O	O	the	no
O	O	clearance	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	,	no
O	O	enhancing	no
O	O	the	no
O	O	toxicity	no
O	O	of	yes
B-drug	B-drug	methotrexate	yes
O	O	.	no

B-group	B-group	Digitalis	yes
O	O	:	no
B-group	B-group	Vitamin	yes
I-group	I-group	D	yes
O	O	dosage	no
O	O	must	no
O	O	be	no
O	O	determined	no
O	O	with	yes
O	O	care	yes
O	O	in	yes
O	O	patients	no
O	O	undergoing	no
O	O	treatment	no
O	O	with	yes
B-group	B-group	digitalis	yes
O	O	,	no
O	O	as	yes
O	O	hypercalcemia	no
O	O	in	yes
O	O	such	no
O	O	patients	no
O	O	may	no
O	O	precipitate	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

O	O	include	no
B-drug	B-drug	terfenadine	yes
O	O	,	no
B-drug	B-drug	astemizole	yes
O	O	,	no
B-drug	B-drug	cisapride	yes
O	O	,	no
B-drug	B-drug	midazolam	yes
O	O	,	no
O	O	and	yes
B-drug	B-drug	triazolam	yes
O	O	.	no

O	O	Stimulation	no
O	O	of	yes
O	O	the	no
O	O	glands	no
O	O	with	yes
B-drug	B-drug	carbachol	yes
O	O	synergistically	no
O	O	augmented	no
O	O	the	no
O	O	response	no
O	O	to	no
O	O	dibutyryl	no
O	O	cAMP	yes
O	O	.	no

O	O	There	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	significant	no
O	O	drug	yes
O	O	interactions	no
O	O	for	yes
O	O	any	no
O	O	of	yes
O	O	these	no
O	O	drugs	no

O	O	Caution	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	when	no
B-drug	B-drug	anileridine	yes
O	O	is	yes
O	O	coadministered	no
O	O	with	yes
O	O	other	no
B-group	B-group	opioids	no
O	O	,	no
B-group	B-group	sedatives	no
O	O	,	no
B-group	B-group	phenothiazines	no
O	O	,	no
O	O	or	no
B-group	B-group	anesthetics	no
O	O	,	no
O	O	as	yes
O	O	these	no
O	O	agents	yes
O	O	may	no
O	O	increase	no
O	O	respiratory	no
O	O	and	yes
O	O	circulatory	no
O	O	depression	no
O	O	.	no

O	O	However	no
O	O	,	no
O	O	no	yes
O	O	adverse	no
O	O	effects	no
O	O	on	no
O	O	fertility	no
O	O	were	no
O	O	observed	no
O	O	in	yes
O	O	male	no
O	O	Rhesus	no
O	O	monkeys	no
O	O	treated	no
O	O	with	yes
O	B-drug	non-pegylated	no
B-drug	I-drug	interferon	yes
I-drug	I-drug	alfa-2a	yes
O	O	for	yes
O	O	5	yes
O	O	months	no
O	O	at	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	25	yes
O	O	x	yes
O	O	106	no
O	O	IU/kg/day	no
O	O	.	no

O	O	The	no
O	O	most	no
O	O	potent	no
O	O	inhibitory	yes
O	O	activity	yes
O	O	was	no
O	O	observed	no
O	O	for	yes
B-drug	O	vardenafil	yes
O	O	metabolite	yes
O	O	M1	yes
O	O	,	no
O	O	which	no
O	O	had	no
O	O	a	yes
O	O	Ki	yes
O	O	of	yes
O	O	1.4	no
O	O	uM	no
O	O	toward	no
O	O	CYP3A4	no
O	O	,	no
O	O	which	no
O	O	is	yes
O	O	about	no
O	O	20	yes
O	O	times	no
O	O	higher	no
O	O	than	no
O	O	the	no
O	O	M1	yes
O	O	Cmax	no
O	O	values	no
O	O	after	no
O	O	an	no
O	O	80	yes
O	O	mg	yes
B-drug	B-drug	Vardenafil	yes
O	O	dose	no
O	O	.	no

O	O	This	no
O	O	effect	no
O	O	did	no
O	O	not	no
O	O	depend	no
O	O	on	no
O	O	the	no
O	O	order	no
O	O	of	yes
O	O	application	no
O	O	of	yes
O	O	the	no
O	O	drugs	no
O	O	.	no

B-drug	B-drug	Tizoxanide	no
O	O	is	yes
O	O	highly	no
O	O	bound	no
O	O	to	no
O	O	plasma	yes
O	O	protein	yes
O	O	(	no
O	O	99.9	no
O	O	%	no
O	O	)	no
O	O	.	no

O	O	combination	yes
O	O	therapy	no
O	O	is	yes
O	O	contemplated	no
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
O	O	one	no
O	O	or	no
O	O	both	no
O	O	agents	yes
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	.	no

O	O	There	no
O	O	was	no
O	O	no	yes
O	O	significant	no
O	O	difference	no
O	O	in	yes
O	O	the	no
O	O	pharmacodynamic	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	administered	no
O	O	alone	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	administered	no
O	O	with	yes
B-brand	B-brand	Lodine	yes
O	O	as	yes
O	O	measured	no
O	O	by	no
O	O	prothrombin	yes
O	O	time	no
O	O	.	no

O	O	Since	no
O	O	the	no
O	O	concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	warfarin	yes
O	O	with	yes
B-drug	B-drug	amiodarone	yes
O	O	increases	no
O	O	the	no
O	O	prothrombin	yes
O	O	time	no
O	O	by	no
O	O	100	yes
O	O	%	no
O	O	after	no
O	O	3	yes
O	O	to	no
O	O	4	yes
O	O	days	no
O	O	,	no
O	O	the	no
O	O	dose	no
O	O	of	yes
O	O	the	no
B-group	B-drug	anticoagulant	no
O	O	should	no
O	O	be	no
O	O	reduced	yes
O	O	by	no
O	O	one-third	no
O	O	to	no
O	O	one-half	no
O	O	,	no
O	O	and	yes
O	O	prothrombin	yes
O	O	times	no
O	O	should	no
O	O	be	no
O	O	monitored	no
O	O	closely	no
O	O	.	no

O	O	The	no
O	O	clinical	no
O	O	presentation	no
O	O	and	yes
O	O	natural	yes
O	O	history	no
O	O	of	yes
O	O	neoplasia	no
O	O	are	no
O	O	also	no
O	O	affected	no
O	O	by	no
O	O	aging	no
O	O	.	no

O	O	In	yes
O	O	period	no
O	O	A	yes
O	O	,	no
O	O	all	yes
O	O	volunteers	no
O	O	took	no
O	O	500	yes
O	O	mg	yes
O	O	of	yes
B-drug	B-drug	tolbutamide	yes
O	O	orally	no
O	O	.	no

B-drug	B-drug	Warfarin	yes
O	O	:	no
O	O	Concomitant	no
O	O	administration	no
O	O	of	yes
B-drug	B-drug	daptomycin	yes
O	O	(	no
O	O	6	yes
O	O	mg/kg	no
O	O	once	no
O	O	every	no
O	O	24	yes
O	O	hours	no
O	O	for	yes
O	O	5	yes
O	O	days	no
O	O	)	no
O	O	and	yes
B-drug	B-drug	warfarin	yes
O	O	(	no
O	O	25	yes
O	O	mg	yes
O	O	single	yes
O	O	oral	yes
O	O	dose	no
O	O	)	no
O	O	had	no
O	O	no	yes
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	drug	yes
O	O	,	no
O	O	and	yes
O	O	the	no
O	O	INR	no
O	O	was	no
O	O	not	no
O	O	significantly	no
O	O	altered	no
O	O	.	no

B-group	B-group	ACE-inhibitors	no
O	O	Reports	no
O	O	suggest	no
O	O	that	no
B-group	B-group	NSAIDs	no
O	O	may	no
O	O	diminish	no
O	O	the	no
O	O	antihypertensive	no
O	O	effect	no
O	O	of	yes
B-group	B-group	ACE-inhibitors	no
O	O	.	no

O	O	Caution	no
O	O	is	yes
O	O	recommended	no
O	O	during	no
O	O	the	no
O	O	coadministration	no
O	O	of	yes
O	O	any	no
O	O	of	yes
O	O	these	no
O	O	with	yes
B-drug	B-drug	alprazolam	yes
O	O	.	no

B-drug	B-drug	Metformin	yes
O	O	:	no
O	O	When	no
B-brand	B-brand	Starlix	yes
O	O	120	no
O	O	mg	yes
O	O	three	no
O	O	times	no
O	O	daily	no
O	O	before	no
O	O	meals	no
O	O	was	no
O	O	administered	no
O	O	in	yes
O	O	combination	yes
O	O	with	yes
B-drug	B-drug	metformin	yes
O	O	500	yes
O	O	mg	yes
O	O	three	no
O	O	times	no
O	O	daily	no
O	O	to	no
O	O	patients	no
O	O	with	yes
O	O	Type	yes
O	O	2	yes
O	O	diabetes	no
O	O	,	no
O	O	there	no
O	O	were	no
O	O	no	yes
O	O	clinically	no
O	O	relevant	no
O	O	changes	no
O	O	in	yes
O	O	the	no
O	O	pharmacokinetics	no
O	O	of	yes
O	O	either	no
O	O	agent	yes
O	O	.	no

O	O	.	no

O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	P450	no
O	O	2D6	no
O	O	:	no
O	O	The	no
O	O	biochemical	no
O	O	activity	yes
O	O	of	yes
O	O	the	no
O	O	drug	yes
O	O	metabolizing	no
O	O	isozyme	no
O	O	cytochrome	no
O	O	P450	no
O	O	2D6	no
O	O	(	no
O	O	debrisoquin	yes
O	O	hydroxylase	no
O	O	)	no
O	O	is	yes
O	O	reduced	yes
O	O	in	yes
O	O	a	yes
O	O	subset	no
O	O	of	yes
O	O	the	no
O	O	aucasian	no
O	O	population	no
O	O	(	no
O	O	about	no
O	O	7	yes
O	O	%	no
O	O	-10	no
O	O	%	no
O	O	of	yes
O	O	Caucasians	no
O	O	are	no
O	O	so-called	no
O	O	poor	no
O	O	metabolizers	no
O	O	)	no
O	O	;	no

O	O	The	no
O	O	clinical	no
O	O	significance	no
O	O	of	yes
O	O	these	no
O	O	findings	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	established	no
O	O	.	no

O	O	Administration	no
O	O	of	yes
B-drug_n	B-drug_n	1,3-difluoroacetone	no
O	O	(	no
O	O	100	yes
O	O	mg	yes
O	O	kg	no
O	O	(	no
O	O	-1	no
O	O	)	no
O	O	body	no
O	O	weight	yes
O	O	)	no
O	O	to	no
O	O	rats	no
O	O	in	yes
O	O	vivo	no
O	O	resulted	no
O	O	in	yes
B-drug_n	B-drug_n	(	no
I-drug_n	I-drug_n	-	yes
I-drug_n	I-drug_n	)	no
I-drug_n	I-drug_n	-erythro-fluorocitrate	no
O	O	synthesis	no
O	O	in	yes
O	O	the	no
O	O	kidney	yes
O	O	,	no
O	O	which	no
O	O	was	no
O	O	preceded	no
O	O	by	no
O	O	an	no
O	O	elevation	no
O	O	in	yes
O	O	fluoride	yes
O	O	levels	no
O	O	and	yes
O	O	followed	no
O	O	by	no
O	O	citrate	yes
O	O	accumulation	no
O	O	.	no

O	O	The	no
O	O	following	no
O	O	are	no
O	O	examples	no
O	O	of	yes
O	O	substances	no
O	O	that	no
O	O	may	no
O	O	reduce	no
O	O	the	no
O	O	blood-glucose-lowering	no
O	O	effect	no
O	O	:	no
B-group	B-group	corticosteroids	no
O	O	,	no
B-drug	B-drug	niacin	yes
O	O	,	no
B-drug	B-drug	danazol	yes
O	O	,	no
B-group	B-group	diuretics	no
O	O	,	no
B-group	B-group	sympathomimetic	no
I-group	I-group	agents	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	epinephrine	yes
O	O	,	no
B-drug	B-drug	salbutamol	yes
O	O	,	no
B-drug	B-drug	terbutaline	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	isoniazid	yes
O	O	,	no
B-group	B-group	phenothiazine	yes
I-group	I-group	derivatives	no
O	O	,	no
B-drug	B-drug	somatropin	yes
O	O	,	no
B-group	B-group	thyroid	yes
I-group	I-group	hormones	no
O	O	,	no
B-group	B-group	estrogens	yes
O	O	,	no
B-group	B-group	progestogens	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	in	yes
O	O	oral	yes
B-group	B-group	contraceptives	no
O	O	)	no
O	O	.	no

O	O	In	yes
O	O	EMs	no
O	O	,	no
O	O	selective	no
O	O	inhibitors	no
O	O	of	yes
O	O	CYP2D6	no
O	O	increase	no
B-drug	B-drug	atomoxetine	yes
O	O	steady-state	no
O	O	plasma	yes
O	O	concentrations	no
O	O	to	no
O	O	exposures	no
O	O	similar	no
O	O	to	no
O	O	those	no
O	O	observed	no
O	O	in	yes
O	O	PMs	no
O	O	.	no

O	O	If	no
O	O	these	no
O	O	preparations	no
O	O	have	no
O	O	been	no
O	O	used	no
O	O	it	no
O	O	is	yes
O	O	advisable	no
O	O	not	no
O	O	to	no
O	O	start	no
O	O	therapy	no
O	O	with	yes
B-brand	B-brand	DIFFERIN	yes
O	O	Gel	yes
O	O	until	no
O	O	the	no
O	O	effects	no
O	O	of	yes
O	O	such	no
O	O	preparations	no
O	O	in	yes
O	O	the	no
O	O	skin	yes
O	O	have	no
O	O	subsided	no
O	O	.	no

O	O	Based	no
O	O	on	no
O	O	clinical	no
O	O	and	yes
O	O	pharmacokinetic	no
O	O	results	no
O	O	from	no
O	O	the	no
O	O	ATAC	no
O	O	trial	no
O	O	,	no
B-drug	B-drug	tamoxifen	yes
O	O	should	no
O	O	not	no
O	O	be	no
O	O	administered	no
O	O	with	yes
B-drug	B-drug	anastrozole	yes
O	O	(	no
O	O	see	no
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	Drug	yes
O	O	Interactions	no
O	O	and	yes
O	O	CLINICAL	no
O	O	PHARMACOLOGY	no
O	O	-	yes
O	O	Clinical	no
O	O	Studies	no
O	O	-	yes
O	O	Adjuvant	no
O	O	Treatment	no
O	O	of	yes
O	O	Breast	no
O	O	Cancer	no
O	O	in	yes
O	O	Postmenopausal	no
O	O	Women	yes
O	O	subsections	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Naproxen	yes
O	O	may	no
O	O	interfere	no
O	O	with	yes
O	O	some	no
O	O	urinary	yes
O	O	assays	no
O	O	of	yes
O	O	5-hydroxy	yes
O	O	indoleacetic	no
O	O	acid	yes
O	O	(	no
O	O	5HIAA	no
O	O	)	no
O	O	.	no

B-drug	B-drug	Chlorpromazine	yes
O	O	:	no
B-drug	B-drug	Chlorpromazine	yes
O	O	blocks	no
B-drug	O	dopamine	yes
O	O	and	yes
B-drug	O	norepinephrine	yes
O	O	receptors	no
O	O	,	no
O	O	thus	no
O	O	inhibiting	no
O	O	the	no
O	O	central	no
O	O	stimulant	no
O	O	effects	no
O	O	of	yes
B-group	B-group	amphetamines	no
O	O	and	yes
O	O	can	no
O	O	be	no
O	O	used	no
O	O	to	no
O	O	treat	no
B-drug	B-group	amphetamine	yes
O	O	poisoning	no
O	O	.	no

O	O	The	no
O	O	pharmacokinetic	no
O	O	interactions	no
O	O	listed	no
O	O	below	no
O	O	are	no
O	O	potentially	no
O	O	clinically	no
O	O	important	no
O	O	.	no

B-drug	B-drug	Quinidine	yes
O	O	:	no
O	O	Coadministration	no
O	O	of	yes
O	O	a	yes
O	O	10-mg	no
O	O	single	yes
O	O	dose	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	with	yes
B-drug	B-drug	quinidine	yes
O	O	(	no
O	O	166	no
O	O	mg/day	no
O	O	for	yes
O	O	13	yes
O	O	days	no
O	O	)	no
O	O	,	no
O	O	a	yes
O	O	potent	no
O	O	inhibitor	yes
O	O	of	yes
O	O	CYP2D6	no
O	O	,	no
O	O	increased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
B-drug	B-drug	aripiprazole	yes
O	O	by	no
O	O	112	no
O	O	%	no
O	O	but	no
O	O	decreased	no
O	O	the	no
O	O	AUC	no
O	O	of	yes
O	O	its	no
O	O	active	no
O	O	metabolite	yes
O	O	,	no
B-drug_n	B-drug_n	dehydroaripiprazole	no
O	O	,	no
O	O	by	no
O	O	35	yes
O	O	%	no
O	O	.	no

O	O	The	no
O	O	effect	no
O	O	of	yes
B-drug	B-drug	clonazepam	yes
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	other	no
O	O	drugs	no
O	O	has	no
O	O	not	no
O	O	been	no
O	O	investigated	no
O	O	.	no

O	O	Patients	no
O	O	receiving	no
O	O	these	no
O	O	drugs	no
O	O	who	no
O	O	are	no
O	O	given	no
B-brand	B-brand	Lodine	yes
O	O	,	no
O	O	or	no
O	O	any	no
O	O	other	no
B-group	B-group	NSAID	no
O	O	,	no
O	O	and	yes
O	O	particularly	no
O	O	those	no
O	O	patients	no
O	O	with	yes
O	O	altered	no
O	O	renal	no
O	O	function	no
O	O	,	no
O	O	should	no
O	O	be	no
O	O	observed	no
O	O	for	yes
O	O	the	no
O	O	development	no
O	O	of	yes
O	O	the	no
O	O	specific	no
O	O	toxicities	no
O	O	of	yes
O	O	these	no
O	O	drugs	no
O	O	.	no

O	O	RESULTS	no
O	O	:	no
O	O	The	no
O	O	geometric	no
O	O	mean	no
O	O	(	no
O	O	90	yes
O	O	%	no
O	O	confidence	no
O	O	interval	no
O	O	)	no
O	O	whole	yes
O	O	blood	yes
B-drug	B-drug	sirolimus	yes
O	O	area	no
O	O	under	no
O	O	the	no
O	O	plasma	yes
O	O	concentration	no
O	O	time-curve	no
O	O	increased	no
O	O	60	no
O	O	%	no
O	O	(	no
O	O	35	yes
O	O	%	no
O	O	-90	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	from	no
O	O	736	no
O	O	to	no
O	O	1178	no
O	O	ng	yes
O	O	x	yes
O	O	h/mL	no
O	O	,	no
O	O	and	yes
O	O	maximum	no
O	O	concentration	no
O	O	increased	no
O	O	43	yes
O	O	%	no
O	O	(	no
O	O	14	yes
O	O	%	no
O	O	-81	no
O	O	%	no
O	O	)	no
O	O	,	no
O	O	from	no
O	O	67	yes
O	O	to	no
O	O	96	no
O	O	ng/mL	no
O	O	,	no
O	O	with	yes
B-drug	B-drug	diltiazem	yes
O	O	coadministration	no
O	O	,	no
O	O	whereas	no
O	O	the	no
O	O	mean	no
O	O	elimination	no
O	O	half-life	no
O	O	of	yes
B-drug	B-drug	sirolimus	yes
O	O	decreased	no
O	O	slightly	no
O	O	,	no
O	O	from	no
O	O	79	no
O	O	to	no
O	O	67	yes
O	O	hours	no
O	O	.	no

O	O	This	no
O	O	might	no
O	O	be	no
O	O	explained	no
O	O	by	no
O	O	a	yes
O	O	blockade	no
O	O	by	no
B-drug	B-drug	probenecid	yes
O	O	of	yes
O	O	the	no
O	O	elimination	no
O	O	of	yes
B-drug	B-drug	cloxacillin	yes
O	O	by	no
O	O	the	no
O	O	liver	yes
O	O	.	no

B-drug_n	O	*CBZ	no
I-drug_n	O	epoxide	no

B-drug	B-drug	Levothyroxine	yes
I-drug	I-drug	Sodium	yes
O	O	Absorption	no
O	O	:	no
O	O	The	no
O	O	following	no
O	O	agents	yes
O	O	may	no
O	O	bind	no
O	O	and	yes
O	O	decrease	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	levothyroxine	yes
I-drug	I-drug	sodium	yes
O	O	from	no
O	O	the	no
O	O	gastrointestinal	no
O	O	tract	no
O	O	:	no
B-drug	B-drug	aluminum	yes
I-drug	I-drug	hydoxide	no
O	O	,	no
B-drug	B-drug	cholestyramine	yes
I-drug	O	resin	yes
O	O	,	no
B-drug	B-drug	colestipol	yes
I-drug	I-drug	hydrochloride	yes
O	O	,	no
B-drug	B-drug	ferrous	yes
I-drug	I-drug	sulfate	yes
O	O	,	no
B-drug	B-drug	sodium	yes
I-drug	I-drug	polystyrene	yes
I-drug	I-drug	sulfonate	yes
O	O	,	no
O	O	soybean	yes
O	O	flour	no
O	O	(	no
O	O	e.g.	no
O	O	,	no
O	O	infant	no
O	O	formula	yes
O	O	)	no
O	O	,	no
B-drug	B-drug	sucralfate	yes
O	O	.	no

B-drug	B-drug	Fulvestrant	yes
O	O	was	no
O	O	associated	no
O	O	with	yes
O	O	an	no
O	O	increased	no
O	O	incidence	no
O	O	of	yes
O	O	fetal	no
O	O	variations	no
O	O	in	yes
O	O	rabbits	no
O	O	(	no
O	O	backwards	no
O	O	displacement	no
O	O	of	yes
O	O	the	no
O	O	pelvic	no
O	O	girdle	no
O	O	,	no
O	O	and	yes
O	O	27	yes
O	O	pre-sacral	no
O	O	vertebrae	no
O	O	at	yes
O	O	0.25	no
O	O	mg/kg/day	no
O	O	IM	yes
O	O	;	no

B-drug	B-drug	Didanosine	yes
O	O	:	no
O	O	It	no
O	O	is	yes
O	O	recommended	no
O	O	that	no
B-drug	B-drug	didanosine	yes
O	O	be	no
O	O	administered	no
O	O	on	no
O	O	an	no
O	O	empty	no
O	O	stomach	no
O	O	;	no

O	O	While	no
O	O	not	no
O	O	systematically	no
O	O	studied	no
O	O	,	no
O	O	certain	no
O	O	drugs	no
O	O	may	no
O	O	induce	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
B-drug	B-drug	bupropion	yes
O	O	(	no
O	O	e.g.	no
O	O	,	no
B-drug	B-drug	carbamazepine	yes
O	O	,	no
B-drug	B-drug	phenobarbital	yes
O	O	,	no
B-drug	B-drug	phenytoin	yes
O	O	)	no
O	O	.	no

O	O	Changes	no
O	O	in	yes
O	O	the	no
O	O	testes	no
O	O	and	yes
O	O	epididymides	no
O	O	had	no
O	O	not	no
O	O	recovered	no
O	O	20	yes
O	O	weeks	no
O	O	after	no
O	O	cessation	no
O	O	of	yes
O	O	dosing	no
O	O	.	no

O	O	The	no
O	O	incidence	no
O	O	of	yes
O	O	ARE	no
O	O	suddenly	no
O	O	exceeded	no
O	O	10	yes
O	O	%	no
O	O	of	yes
O	O	the	no
O	O	patients	no
O	O	treated	no
O	O	by	no
B-drug	B-drug	melarsoprol	yes
O	O	during	no
O	O	August	no
O	O	1992	no
O	O	and	yes
O	O	September	no
O	O	1993	no
O	O	.	no

B-group	B-group	Monoamine	no
I-group	I-group	oxidase	yes
I-group	I-group	(	no
I-group	I-group	MAO	no
I-group	I-group	)	no
I-group	I-group	inhibitors	no
O	O	prolong	no
O	O	and	yes
O	O	intensify	no
O	O	the	no
O	O	anticholinergic	no
O	O	effects	no
O	O	of	yes
B-group	B-group	antihistamines	no
O	O	.	no

O	O	Potential	no
O	O	for	yes
B-drug	B-drug	Duloxetine	yes
O	O	to	no
O	O	Affect	no
O	O	Other	no
O	O	Drugs	no
O	O	:	no
O	O	Drugs	no
O	O	Metabolized	no
O	O	by	no
O	O	CYP1A2	no
O	O	:	no
O	O	In	yes
O	O	vitro	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	demonstrate	no
O	O	that	no
B-drug	B-drug	duloxetine	yes
O	O	does	no
O	O	not	no
O	O	induce	no
O	O	CYP1A2	no
O	O	activity	yes
O	O	,	no
O	O	and	yes
O	O	it	no
O	O	is	yes
O	O	unlikely	no
O	O	to	no
O	O	have	no
O	O	a	yes
O	O	clinically	no
O	O	significant	no
O	O	effect	no
O	O	on	no
O	O	the	no
O	O	metabolism	no
O	O	of	yes
O	O	CYP1A2	no
O	O	substrates	no
O	O	.	no

O	O	In	yes
O	O	a	yes
O	O	comparison	no
O	O	of	yes
B-group	B-group	digitalis	yes
O	O	tolerance	no
O	O	in	yes
O	O	dogs	no
O	O	anesthetized	no
O	O	with	yes
B-drug	B-drug	ketamine	yes
O	O	,	no
B-brand	B-brand	Innovar	yes
O	I-brand	Vet	no
O	O	,	no
O	O	or	no
B-drug	B-drug	pentobarbital	yes
O	O	,	no
O	O	the	no
O	O	dosage	no
O	O	of	yes
B-drug	B-drug	ouabain	yes
O	O	needed	no
O	O	to	no
O	O	cause	no
O	O	ventricular	no
O	O	tachycardia	no
O	O	was	no
O	O	significantly	no
O	O	higher	no
O	O	,	no
O	O	as	yes
O	O	was	no
O	O	the	no
O	O	LD50	no
O	O	of	yes
B-drug	B-drug	ouabain	yes
O	O	,	no
O	O	with	yes
B-drug	B-drug	ketamine	yes
O	O	or	no
B-brand	B-brand	Innovar	yes
O	O	than	no
O	O	with	yes
B-drug	B-drug	pentobarbital	yes
O	O	.	no

O	O	Should	no
O	O	it	no
O	O	be	no
O	O	decided	no
O	O	to	no
O	O	discontinue	no
O	O	therapy	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-group	B-group	beta-blockers	no
O	O	and	yes
B-drug	B-drug	clonidine	yes
O	O	concurrently	no
O	O	,	no
O	O	the	no
B-group	B-group	beta-blocker	no
O	O	should	no
O	O	be	no
O	O	discontinued	no
O	O	slowly	no
O	O	over	no
O	O	several	no
O	O	days	no
O	O	before	no
O	O	the	no
O	O	gradual	no
O	O	withdrawal	no
O	O	of	yes
B-drug	B-drug	clonidine	yes
O	O	.	no

O	O	Therefore	no
O	O	,	no
O	O	prothrombin	yes
O	O	time	no
O	O	should	no
O	O	be	no
O	O	carefully	no
O	O	monitored	no
O	O	in	yes
O	O	patients	no
O	O	receiving	no
B-drug	B-drug	Itraconazole	yes
O	O	and	yes
B-group	B-group	coumarin-like	no
I-group	O	drugs	no
O	O	simultaneously	no
O	O	.	no

O	O	Few	no
O	O	data	no
O	O	exist	no
O	O	on	no
O	O	drug	yes
O	O	interactions	no
O	O	with	yes
B-drug	B-drug	caffeine	yes
O	O	in	yes
O	O	preterm	no
O	O	neonates	no
O	O	.	no

B-drug	B-drug	Ethosuximide	yes
O	O	:	no
B-group	B-group	Amphetamines	no
O	O	may	no
O	O	delay	no
O	O	intestinal	no
O	O	absorption	no
O	O	of	yes
B-drug	B-drug	ethosuximide	yes
O	O	.	no

O	O	Selective	no
O	O	survival	no
O	O	in	yes
B-drug	B-drug	pentazocine	yes
O	O	and	yes
B-drug	B-drug	tripelennamine	yes
O	O	of	yes
O	O	Pseudomonas	no
O	O	aeruginosa	no
O	O	serotype	no
O	O	O11	no
O	O	from	no
O	O	drug	yes
O	O	addicts	no
O	O	.	no

O	O	A	yes
O	O	reduced	yes
B-drug	B-drug	Clozapine	yes
O	O	dose	no
O	O	should	no
O	O	be	no
O	O	considered	no
O	O	.	no

O	O	Nevertheless	no
O	O	,	no
O	O	caution	no
O	O	is	yes
O	O	indicated	no
O	O	in	yes
O	O	the	no
O	O	coadministration	no
O	O	of	yes
B-group	B-group	TCAs	no
O	O	with	yes
O	O	any	no
O	O	of	yes
O	O	the	no
B-group	B-group	SSRIs	no
O	O	and	yes
O	O	also	no
O	O	in	yes
O	O	switching	no
O	O	from	no
O	O	one	no
O	O	class	no
O	O	to	no
O	O	the	no
O	O	other	no
O	O	.	no

O	B-group	Ergot-Containing	no
O	I-group	Drugs	no
O	O	:	no
O	O	These	no
O	O	drugs	no
O	O	have	no
O	O	been	no
O	O	reported	no
O	O	to	no
O	O	cause	no
O	O	prolonged	no
O	O	vasospastic	no
O	O	reactions	no
O	O	.	no

O	O	Observations	no
O	O	from	no
O	O	drug	yes
O	O	interaction	no
O	O	studies	no
O	O	with	yes
B-brand	B-brand	FORTOVASE	yes
O	O	may	no
O	O	not	no
O	O	be	no
O	O	predictive	no
O	O	for	yes
B-brand	B-brand	INVIRASE	yes
O	O	.	no

B-group	B-drug	Antihistamines	no
O	O	:	no
B-drug	B-drug	astemizole*	no
O	O	,	no
B-drug	B-drug	terfenadine*	no
O	O	CONTRAINDICATED	no
O	O	due	no
O	O	to	no
O	O	potential	no
O	O	for	yes
O	O	serious	no
O	O	and/or	no
O	O	life-threatening	no
O	O	cardiac	no
O	O	arrhythmias	no
O	O	.	no

B-drug	I-drug	indinavir	yes
O	O	concentration	no
B-drug	B-drug	ritonavir	yes
O	O	concentration	no

O	O	No	yes
O	O	data	no
O	O	on	no
O	O	the	no
O	O	level	no
O	O	of	yes
O	O	circulating	no
O	O	catecholamines	no
O	O	after	no
B-drug	B-drug	apraclonidine	yes
O	O	withdrawal	no
O	O	are	no
O	O	available	no
O	O	.	no

B-drug	B-drug	Amiodarone	yes
O	O	inhibits	no
O	B-drug	CYP2D6	no
O	O	.	no

O	O	No	yes
O	O	CNS	no
O	O	lesions	no
O	O	have	no
O	O	been	no
O	O	observed	no
O	O	in	yes
O	O	mice	no
O	O	after	no
O	O	chronic	no
O	O	treatment	no
O	O	for	yes
O	O	up	no
O	O	to	no
O	O	2	yes
O	O	years	no
O	O	at	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	400	yes
O	O	mg/kg/day	no
O	O	or	no
O	O	in	yes
O	O	rats	no
O	O	at	yes
O	O	doses	no
O	O	up	no
O	O	to	no
O	O	100	yes
O	O	mg/kg/day	no
O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-drug	B-drug	efavirenz	yes
O	O	with	yes
O	O	drugs	no
O	O	primarily	no
O	O	metabolized	no
O	O	by	no
O	O	these	no
O	O	isozymes	no
O	O	may	no
O	O	result	no
O	O	in	yes
O	O	altered	no
O	O	plasma	yes
O	O	concentrations	no
O	O	of	yes
O	O	the	no
O	O	coadministered	no
O	O	drug	yes
O	O	.	no

O	O	.	no

O	O	Coadministration	no
O	O	of	yes
B-brand	B-brand	VIRACEPT	yes
O	O	and	yes
O	O	drugs	no
O	O	that	no
O	O	inhibit	no
O	O	CYP3A	no
O	O	may	no
O	O	increase	no
B-drug	B-drug	nelfinavir	yes
O	O	plasma	yes
O	O	concentrations	no
O	O	.	no

O	O	Changes	no
O	O	in	yes
O	O	hepatic	no
O	O	function	no
O	O	induced	no
O	O	by	no
O	O	concomitant	no
O	O	therapies	no
O	O	may	no
O	O	affect	no
B-drug	B-drug	epirubicin	yes
O	O	metabolism	no
O	O	,	no
O	O	pharmacokinetics	no
O	O	,	no
O	O	therapeutic	no
O	O	efficacy	no
O	O	,	no
O	O	and/or	no
O	O	toxicity	no
O	O	.	no

O	O	Twitch	no
O	O	gradually	no
O	O	returned	no
O	O	to	no
O	B-drug	pre-gentamycin	no
O	O	strength	yes
O	O	over	no
O	O	the	no
O	O	course	no
O	O	of	yes
O	O	the	no
O	O	next	yes
O	O	hour	yes
O	O	.	no

